029,400,ADP,ATM,BACKGROUND,BRCA1,BRCA2,CHEK2,EVALUATION,FANCONI,LABEL,METHODS,OVERALL,RESULTS,SIXTEEN,SOLID,TREATMENT
000,ABOUT,ANATOMICAL,FAVORABLE,III,METABOLIC,PSA,THESE
ANALYSING,FINALLY
NIMBLEGEN,SNP,USING
001,114,243,BACKGROUND,BASED,COLORECTAL,CONCLUSION,COX,CXR,GOVERNMENT,HRS,INTERVIEW,LABEL,METHODS,OVARIAN,PRESS,PUBLISHED,RESULTS,SCREENING,TRIAL,UNIVERSITY
AGE,CURRENTLY,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THEIR
001,202,348,496,824,ACCORDING,CHINESE,CONCLUSION,EGGER,LABEL,LIBRARY,METHODS,OBJECTIVE,RESULTS,STATA,VIP,WANFANG
BPH,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,TRP,USING
177,1MM,300,307,356,3MM,4MM,5MM,6MM,726,8MM,931,963,ACCORDING,BMI,CTV,LABEL,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS
008,047,296,ASIAN,CAUCASIAN,HOWEVER,LABEL,METHODS,OBJECTIVE,OCTOBER,OVERALL,PURPOSE,RESULTS,SCIENCE,STRATIFIED,WEB
160,207,210,300,360,AFTER,AMICO,BETWEEN,CONTINENCE,LABEL,METHODS,OBJECTIVE,OVERALL,PATIENT,PURPOSE,RADICAL,RARPS,RESULTS,ROMANIA,VINCI
100,113,132,150,ADT,AFTER,ART,BETWEEN,DEPARTMENT,DISTANT,DSS,FIFTY,LABEL,LNI,LVI,MEIER,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SPLIT,UNIVERSITY
007,008,018,024,030,136,177,596,BASED,CEA,COLORECTAL,CONCLUSION,CRC,EMERGENCY,HOWEVER,LABEL,METHODS,MPV,NLR,OBJECTIVE,PURPOSE,RDW,RESULTS,THERE
EVALUATION,MAXIMAL,METASTASES
232,ABOUT,BACKGROUND,CASES,CONCLUSION,LABEL,LITTR,METHODS,PRIMARY,THERE
145,293,AFTER,CONCLUSION,FOXM1,GFP,LABEL,METHODS,MTT,OBJECTIVE,PCR,RESULTS,THREE,WESTERN,ZSGREEN
128,PATENTS,THESE,URINARY
ACE,BPH,GLEASON,INDICATORS,PCA
ANALYZING,C30,CURRENTLY,EORTC,QLQ
HOWEVER
169,COPYRIGHT,ECTOPIC,SCIENCE,SEQ,WNT,WNT5A
GLYCOMICS,THEREFORE
BASED,CALIFORNIA,INTERVIEW,PSA
280,AGREEMENT,BACKGROUND,END,LABEL,METHODS,PATHOLOGIC,RESULTS,TNM
169,COPYRIGHT,INC
001,003,006,009,022,169,32X10,35X10,467,591,72X10,BACKGROUND,CH12Q24,GECCO,INSTITUTE,LABEL,METHODS,NETWORK,PRESS,PUBLISHED,RESULTS,SH2B3,UNIVERSITY
169,COPYRIGHT,FORCE,INC,PREVENTIVE,PSA,WIDESPREAD
600,BACKGROUND,BASED,HOWEVER,INSTITUTE,LABEL,METHODS,MODEL,MUTATIONS,NETPHOS,REGARDING,RESULTS,SWISS
MEN
DESPITE,INTENSE
DRE,PSA
001,149,169,185,378,399,807,BACKGROUND,CD3,CONCLUSION,COX,FOXP3,HEIDELBERG,HOWEVER,HRS,IMMUNOCRIT,LABEL,LABORATORY,METHODS,PRESS,PUBLISHED,REGARDING,RESULTS,UNIVERSITY
044,100,101,954,AUC,CONCLUSION,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESPECTIVE,RESULTS,ROC,T3A,T3B
CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,SIX,STUDENT,THREE
078,299,517,563,956,APRIL,CHINESE,CIS,ENGLISH,HOWEVER,PCA,REMOVAL,RRS,STATA,STUDIES,WILEY
084,144,169,269,853,881,CAO,CONCLUSION,HOWEVER,LABEL,LIGHT,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SETTING
MALIGNANT,REGARDING,THERE
133,169,172,ACUTE,ADVERSE,COPYRIGHT,GRADE,INC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCORE,SYMPTOM,TOXICITIES
001,CGS,COMPARING,GLEASON,GRADE,GSS,HGS
160,193,523,CONCLUSION,HOWEVER,LABEL,LITERATURE,MARCH,METHODS,OBJECTIVE,RESULTS
2001AND,509,AFTER,COX,GLM,HISPANICS,HOWEVER,PATTERN,PROPENSITY
CONGENITAL,ECTOPIC,WHILE
AKT,CAP,LNCAP,MYC,SP1,STAT3,THESE
AMONG,BROAD,GENDICINE,THEREFORE
053,126,5ML,HOWEVER,PCR,SIMILAR,TRAIL
UNILATERAL
001,1940S,790,ADT,AFTER,BACKGROUND,INSTITUTE,LABEL,METHODS,RESULTS,SIX
BELONGING,FINALLY,HOWEVER
956,ADDITIONAL,HEP3B,STAT3
AMONG,DESPITE,DUE
BASED,HOWEVER,MAJOR,RADICAL
DIFERELIN
CIP2A,PROTEIN,SET
100,177,BACKGROUND,ECG,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PROLONGED,QTC,RESULTS,SEVERAL,UNLABELLED
169,COPYRIGHT,CURRENTLY,HOWEVER,IGF,IRELAND,LTD,PCA
215,219RN,223RA,DOSES,FDA,THESE,THREE,USING
GCS
CURRENT,WHETHER
169,705,COPYRIGHT,DU145,ERK,INC,NOTABLY,ROS,STAT3,THEREFORE,TYR
001,002,005,169,173,ADT,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,PFS,PSA,PUBLISHED,RESULTS,THERE
169,1MM,231,233,286,3MM,5MM,8MM,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS
001,CONCLUSION,CTS,DVH,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS
169,COPYRIGHT,DEFICIENCY,DESPITE,EDUCATION,ENDOCRINE,FOUNDATION,GUIDELINE,GUIDELINES,INC,JANUARY,MARCH,MEDICAL,MEN,PUBLISHED,SEVERAL,SOCIETY,SYNDROMES,THERAPY,USING
LOW,MEN,THERE,TRT
001,003,215,ADC,CONCLUSION,DIAGNOSIS,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,ROC
100,AMERICA,CLAVIEN,CONCLUSION,DINDO,FOCAL,FURTHER,GLEASON,LABEL,METHODS,MRI,NORTH,OBJECTIVE,ONCOLOGIC,PSA,QUALITY,RESULTS,UNDER
001,002,123,129,134,141,177,180,197,215,217,225,ADC,AUC,AWARENESS,CONCLUSION,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,ROC,ROI
ANOMALOUS,COLORECTAL,CONCLUSION,LABEL,OBJECTIVE,OVARIAN,SCREENING,TRIAL
008,542,BACKGROUND,INHIBITION,LABEL,METHODS,NOTCH,OBJECTIVE,RESULTS,SCS
001,142,165,183,190,198,325,488,956,FACTORS,WHILE
169,APMIS,HMWCK,LTD,P63,PSA,PUBLISHED,WILEY
169,AE1,AE3,COPYRIGHT,EMA,EPITHELIAL,INC,SUBSEQUENT
000,099,100,181,193,236,449,453,464,507,AMONG,CALIFORNIA,COHORTS,CRUDE,EXPOSURES,HODGKIN,IMPORTANCE,LABEL,METHODS,OBJECTIVE,PERMANENTE,RELEVANCE,RESULTS,SETTING,STUDIES
111,394,437,631,AFFAIRS,AMONG,BACKGROUND,BECAUSE,FSH,LABEL,METHODS,OBJECTIVE,PROMOTING,PROPORTION,RESULTS,SETTING
001,160,169,177,475,513,CONCLUSION,COPYRIGHT,CTV,D99,INC,LABEL,MATERIALS,METHODS,MLC,MULTILEAF,OBJECTIVE,PTV,PURPOSE,RESULTS,THESE,V65
112,160,169,AREAS,CONCLUSION,COPYRIGHT,ECE,GLEASON,INC,KETTERING,LABEL,METHODS,MRI,MSK,OBJECTIVE,PREDICTIVE,REGRESSION,RESULTS,SLOAN
100,956,AMP,AMPELOPSIN,ANNEXIN,CCK,FCM,WESTERN,WHETHER
CONCLUSION,FCH,FIRST,GLEASON,LABEL,PET,PSA,UNLABELLED
001,084,088,094,169,378,547,926,956,BMI,COPYRIGHT,FREQUENCY,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERWEIGHT,PATHOLOGY,PSA,RESULTS,SERUM,SOCIETY,WHILE
013,038,046,140,169,AFFILIATED,FIBULIN,HOWEVER,LABEL,METHODS,NANTONG,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY,WESTERN
169,ADT,AUTHORS,COPYRIGHT,HOWEVER,IRELAND,LTD,PUBLISHED
001,169,181,531,886,ACUTE,BACKGROUND,CHRONIC,CONCLUSION,INC,LABEL,METHODS,POISSON,PSA,REDUCTION,RESULTS,WILEY
160,169,BACKGROUND,COPYRIGHT,DOCETAXEL,HOWEVER,INC,LABEL,LNCAP,METHODS,MMP,MTS,PC3,RESULTS
001,030,061,138,164,177,280,307,606,825,ACCORDING,BCR,COX,JANUARY,MEIER,PSA,SERUM
123,145,169,916,936,945,BACKGROUND,BCL,BESIDES,INC,LABEL,METHODS,MITOTIC,PROTEIN,RESULTS,RHODAMINE,SEVERAL,WESTERN,WILEY
223,ADVERSE,III
001,169,200,821,AGE,BACKGROUND,DCA,GLEASON,INC,LABEL,METHODS,OVERALL,PCA,PSA,RESULTS,SIMILARLY,WILEY
112,169,BACKGROUND,FRESH,INC,LABEL,METHODS,PDX,PRIMARY,RESULTS,SELECTING,WILEY
000,169,239,370,AFTER,AUC,BACKGROUND,INC,INCLUSION,INITIALLY,LABEL,METHODS,POLYGENIC,RESULTS,SIX,WILEY
160,169,COPYRIGHT,FURTHER,INC
001,004,034,169,242,652,AMICO,BACKGROUND,COX,COXPH,GLEASON,INC,LABEL,MEIER,METHODS,OVERALL,PTPSA,RESULTS,STRATIFIED,WILEY
937,BACKGROUND,GADD45A,LABEL,METHODS,PSA,RESULTS,SERUM,THERE
945,GLUCOSE,GLUTS,PET,SGLT1,SGLT2,SGLTS,THREE
016,104,169,945,ADT,AIM,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SRD5A
001,006,169,AIM,CIS,COPYRIGHT,LABEL,LIBRARY,LTD,MEDLINE,MEETING,METHODS,OBJECTIVE,RESULTS,RRS
126,160,169,171,193,277,290,AFFAIRS,ANGELES,CONCLUSION,COPYRIGHT,FURTHER,GREATER,HEALTHCARE,INC,LABEL,LOS,METHODS,OBJECTIVE,PATIENT,RESULTS
001,238,946,AFTER,BETWEEN,CIS,COX,FURTHER,HOWEVER,INSURANCE,JANUARY
169,ACUTE,COPYRIGHT,INC,OPERATIVE
CEA,CURRENT,HOWEVER,TABLE
169,COPYRIGHT,GIVEN,LNCAP,SOCIETY,UDP,UGT,UGT2B15,UGT2B17
10878,169,754,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PC1,PURPOSE,RADAR,RESULTS,SUSTAINED,URINARY
215,809,951,A2780,ATM,DOWNSTREAM,I257V,L517P,N447S,ND5,PF6,ROS,SUPEROXIDE,WHOLE
169,945,946,AFTER,COPYRIGHT,HIF,HYPOXIA,INC,PC3,WHILE
169,AMONG,BIOLOGY,INC,MOLECULAR,SIAH2,SOCIETY
169,223,945,ARC,BIOLOGY,CK2,EGF,HOWEVER,INC,MOLECULAR,SER,SOCIETY,TAKEN
MRI,SINCE,STUMP

169,946,BIOLOGY,INC,MOLECULAR,SMAD7,SOCIETY,TGF,TIUL1
EGIST,MAZUR,THOSE
177,201,APRIL,BACKGROUND,EARLY,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SEPTEMBER,SPECT
100,100MG,169,177,212,AGE,ASA,AVERAGE,BHP,BPH,CONTROL,DEPARTMENT,GROUP,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SECONDARY,SELECTION,SIMILAR,UROLOGY
CONTROL,LOCALLY,T4A,THEIR,THEREFORE,TNM
00001,FURTHER,III,LABEL,LARGE,MATERIALS,METHODS,OBJECTIVE,RESULTS,SECONDARY,TEN,THESE
956,GLEASON,JANUARY,LABEL,MARCH,MEIER,METHODS,OBJECTIVE,PSA,RESULTS,SIX,T2C,T3A,T3B,THREE
000,CVD,FRUIT,INVERSE,ITALIAN,SIMILAR,SUGGESTIVE,SWISS
954,HOWEVER,IL6,RAPAMYCIN,REDUCED,TOR,TORC1
169,316,AFTERWARD,AMONG,CONCLUSION,COPYRIGHT,DOPPLER,GLEASON,INC,JANUARY,LABEL,METHODS,MRI,OBJECTIVE,PBX,PCA,RESULTS
169,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,USING
169,215,COPYRIGHT,INC,PUBLISHED,SOCIETY
000,093,100,161,169,231,889,982,ASR,KENYA,NAIROBI
001,169,536,BACKGROUND,BCR,COPYRIGHT,GLEASON,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,PSM,PURPOSE,RESULTS,SCORE,THESE,UROLOGY
CAUCASIANS,CHINESE,CIS,HAN,III,ORS,STRATIFIED
876,AGE,BASED,CRC,INSURANCE,SIR,SPM
003,004,005,019,021,023,025,026,160,169,ADC,AIM,AUC,COLLEGE,CONCLUSION,COPYRIGHT,DWI,FIFTY,GLEASON,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,REGIONS,RESULTS,ROYAL,THEREFORE
GENOMIC
139,169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,CRC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SMALL,TNM
104,169,AFTER,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS
000,169,378,470,582,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,CSS,INSTITUTE,LABEL,METHODS,NEC,OBJECTIVE,OVERALL,RESULTS,SCC,USING
169,197,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,HODGKIN,INSTITUTE,IRR,LABEL,MATERIALS,METHODS,RESULTS,SEVERAL,WHETHER,WORLDWIDE
007,169,AIM,ANTICANCER,BACKGROUND,BPH,CONCLUSION,COPYRIGHT,HOWEVER,INHIBITOR,INSTITUTE,KAZAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,RESULTS,SEVERAL,SNP
169,2D3,945,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,CYP27B1,INSTITUTE,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,OHASE,RESULTS,THERE
HORMONE,RESULTANT,SEX,THESE
AKT,MOLECULAR,THEREFORE
000,400,FOURIER,MEV,PCA,PRINCIPAL
000,230,ABOUT,ELEVATIONS,PCA,PSA
ESPECIALLY,GYNECOLOGY,UNIVERSITY,UROLOGY
100,EARLY
PCA
164,177,689,722,747,896,CD4,CONCLUSION,ELISA,FBG,FOXP3,IGF,III,LABEL,MEANWHILE,METHODS,OBJECTIVE,PBMCS,PCA,RESULTS,TNM,USING
001,002,027,391,BPH,CONCLUSION,FOXA1,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,TNM,USING
182,308,334,396,444,675,769,CONCLUSION,FIFTY,LABEL,METHODS,OBJECTIVE,PCR,PEARSON,RESULTS,TOTALLY,USING
169,INSURANCE,KOREA,PRESS,PUBLISHED,THROUGHOUT,UNIVERSITY
954,MICHAEL,STAT3,THESE,VERNOLIDE
007,169,200,282,389,941,946,AUTHORS,CORTACTIN,COX,HDAC6,HGPIN,HOWEVER,IA8,JOURNAL,PATHOLOGY,THEIR,THEREFORE
035,169,312,353,355,ACCORDING,ALLELIC,AMONG,ASIAN,BPH,COPYRIGHT,DUE,GENOTYPING,HRM,INC,MINOR,PCA,PCR,PSA,SERBIAN
001,169,177,AHX,APRIL,CONCLUSION,GLU,HISTOLOGIC,IMAGING,INC,JANUARY,LABEL,LYS,METHODS,MOLECULAR,NUCLEAR,PET,PSA,RESULTS,SOCIETY,THERE,UNLABELLED
100,229,470,ADVISER,BACKGROUND,LABEL,METHODS,MGRSS,MULTILOCUS,MULTIPLEX,NUCLEOTIDE,PCR,RESULTS,SENATOR,SNP,STUDIES,TAT,THESE,TURNAROUND,USING,WHILE
169,ADDITIONAL,HOWEVER,LIFESTYLE,PRESS,PROGRAMME,PUBLISHED,UNIVERSITY,WORLD
169,HOWEVER,PRESS,PUBLISHED,THESE,UNDER,UNIVERSITY
169,PRESS,PUBLISHED,THEREFORE,UNIVERSITY,WHEREAS
169,ACCORDING,COPYRIGHT,DMEAN,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OHS,PCA,PELVIMETRY,PURPOSE,RADIATION,REGARDING,RESULTS,SIX,THERAPY
169,256,287,310,326,ALONE,BECAUSE,BEM,COPYRIGHT,CTV,EVALUATION,GROUP,INC,JACCARD,LABEL,LOCALLY,MARSDEN,MATERIALS,METHODS,OBJECTIVE,PIVOTAL,PTV,PURPOSE,RADIATION,RESULTS,RMH,ROYAL,SEVEN,THERAPY
169,398,433,831,ACCORDING,COPYRIGHT,GLEASON,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIOR,PURPOSE,RADIATION,RESULTS,T1B,T2B,TAS,THERAPY
169,177,COPYRIGHT,CSS,CYBERKNIFE,DMEAN,ERASMUS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PLANS,PURPOSE,RESULTS,USING,V40GYEQ,V60GYEQ
BACKGROUND,HOWEVER,LABEL,METHODS,MMP,PCA,RESULTS,SC144,THERE,YM155
585,761,967,BACKGROUND,CAPRA,CCP,CCR,GLEASON,KINGDOM,LABEL,METHODS,PSA,RESULTS
001,122,132,153,285,AFTER,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS
004,317,954,AMONG,AUC,CONCLUSION,ECE,INITIAL,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,ROC
CONCLUSION,DWI,EPI,LABEL,METHODS,MRI,OBJECTIVE,RESULTS
041,CONCLUSION,LABEL,METHODS,MRI,MRL,NORMALIZED,OBJECTIVE,RESULTS,THREE
102,128,132,138,141,176,202,277,872,ANOVA,CANCERS,CONCLUSION,INCLUSION,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PERIPHERAL,PSA,RESULTS,THEREAFTER
003,155,169,379,383,BACKGROUND,CONCLUSION,COPYRIGHT,GIVEN,GLEASON,GROUP,INC,LABEL,LYMPHOCELE,METHODS,RESULTS,STRATEGIC,TECHNICAL
205,215,500,652,ASIAN,ATM,CANCERS,EUROPEANS,GASTRIC,MAF
423,431,854,BACKGROUND,CURRENTLY,FOUNDATION,HEART,LABEL,METHODS,RESULTS,ROUTINE,THERE
2PROPSA,PCA,PHI,RUSSIAN
MRI
001,ANOTHER,BFB,EMG,RPE,URINARY
160,169,COPYRIGHT,DU145,HGF,INC,MET,RABMABS,THROUGH
CAD,CTR,EWING,MC3T3,THESE
223,FINALLY,THERE
0CM,125,145,169,1CM,250,BACKGROUND,COPYRIGHT,CTV,DVH,GTV,IRELAND,LABEL,LDR,LTD,METHODS,MRI,MULTI,OBJECTIVE,PURPOSE,RESULTS,TRANS
169,AUTHORS,BACKGROUND,COPYRIGHT,HOWEVER,HRQOL,IRELAND,LABEL,LOWER,LTD,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS,THERE
INSTITUTE,JOINPOINT,OVERALL,PANAMANIAN,REGRESSION,STATISTICS
169,ADP,COPYRIGHT,INC,PARP1
169,177,CONCLUSION,FIRST,III,IMAGING,INC,INITIAL,LABEL,LNCAP,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SOCIETY,UNLABELLED
169,ACC,ADENOID,COPYRIGHT,HOPKINS,INC,JOHNS,MYB,PBCCS
180,199,240,311,33258,440,480,956,ACCORDING,ANNEXIN,BESIDES,BIC,CHINESE,CYTOMETRY,ELISA,HOECHST,LNCAP,MEANWHILE,MTT,PCR,PSA,R1881,WESTERN
ANATOMY,CONCLUSION,DEPARTMENT,LABEL,METHODS,OBJECTIVE,PSA,SETTING,SKENE
HOWEVER,OTHER,PLANT,REDUCTIONS
169,ACCORDING,BESIDES,HOWEVER,INCIDENCE,INDONESIA,INDONESIAN,NON,PRESS,PUBLISHED,RADICAL,THEREFORE,UNIVERSITY
003,004,731,909,ADIPOSITY,ALPHA,BLOOMBERG,COLORECTAL,GOVERNMENT,HOPKINS,INCIDENCE,JOHNS,NUTRITION,OVARIAN,OVERALL,PRESS,PREVENTION,PUBLISHED,SCREENING,SEX,THERE,TOCOPHEROL,TRIAL,UNIVERSITY
COMBINING,DAILY,HOWEVER,IDEALLY,OVERALL,TCP
ACCORDING,COX,FLAVONOIDS,THEIR
223,SAR,THESE
169,946,BIOLOGY,CONSISTENT,HCC,HOWEVER,INC,KNOCKDOWN,MOLECULAR,MYC,SOCIETY,SRC,STEROID,WNT
THESE
ALGORITHM,ASIAN,BACKGROUND,ENGLAND,GROUP,LABEL,METHODS,NAMES,RESULTS,SOUTH

169,459,461,816,AFTER,CONCLUSION,COX,DESPITE,HIV,HODGKIN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
001,019,112,169,477,BACKGROUND,BCR,COX,ESPECIALLY,FINALLY,INC,JANUARY,LABEL,MEIER,METHODS,MFS,OVERALL,RESULTS,THERE,THREE,UNI,WILEY
144,169,537,617,ASPIRIN,BACKGROUND,COX,FINNISH,GROWING,HOWEVER,INC,LABEL,METHODS,NSAID,PCA,RESULTS,SCREENING,TRIAL,WILEY
169,945,BACKGROUND,CTE9908,CTX,CXCR4,INC,LABEL,MEIER,METHODS,MMP,PC3,PCA,PLERIXAFOR,RESULTS,SDF,STROMAL,THEREFORE,WILEY
COMMITTEE,CONTROL,DESPITE,GLEASON,JOINT,PSA,STAGE,STAGING,TNM,UNION
PCA,PSA

AAI,EXPRESSION,GLEASON,TREATMENT,WHILE
APART,GLEASON,UNUSUAL
001,10878,169,177,BACKGROUND,COMPOSITE,CONCLUSION,COPYRIGHT,CRUDE,IRELAND,LABEL,LTD,MEN,METHODS,PSA,RADAR,RDE,RESULTS
169,CONSISTENT,HOWEVER
005,100,11E,15E,22RV1,DISSECTED,IBP,INHIBITION,INHIBITORS,PCA,RAP1A,THREE,WESTERN
000,006,169,223,306,475,681,990,CONCLUSION,FORTY,FTV10,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,OVERALL,PET,RESULTS,SECONDARY,SOCIETY,SRE,SUV,TLF10,UNLABELLED
004,169,961,CONCLUSION,DCFBC,GLEASON,HOWEVER,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SOCIETY,THERE,UNLABELLED
169,HOWEVER,LNCAP,NOTABLY,PREDICTIVE,STRIKINGLY
116,128,160,169,183,ABOUT,CONCLUSION,DCE,DEDICATED,DRG,DWI,GEORG,GERMANY,HDS,KEY,LABEL,MATERIALS,METHODS,MRI,MRP,MRS,OBJECTIVE,PPS,PURPOSE,RADIOLOGY,REPORTS,RESULTS,SOCIETY,STRUCTURED,STUTTGART
215,AFTER,BACKGROUND,BLOOD,BONFERRONI,LABEL,METHODS,PCA,PSA,RESULTS,SEVEN
101,169,AKT,BCL,COPYRIGHT,DU145,HOWEVER,INC,MTT,PC3,RAL,TAKEN,TEM
331,MEN
169,223,BECAUSE,COPYRIGHT,HOWEVER,LTD,UNTIL
BACKGROUND,COLLISION,CONCLUSION,LABEL,METHODS,THREE
141,AFTER,CONCLUSION,LABEL,LNCAP,METHODS,OBJECTIVE,PCR,RESULTS,UTR,WESTERN
169,COPYRIGHT,ERG,HIPPO,INC,THESE
140,145,916,BECAUSE,LEINAMYCIN,LNCAP,LNM,PREVIOUSLY,ROS
169,CONCLUSION,FORCE,INTERVIEW,LABEL,METHODS,OBJECTIVE,PREVENTIVE,PSA,PURPOSE,RESULTS,SCREENING,SOCIETY,THEREFORE
ACCURAY,ACUTE,CONCLUSION,CYBERKNIFE,GROUP,KNOWLEDGE,LABEL,METHODS,NADIR,OBJECTIVE,OCTOBER,PHOENIX,RADIATION,RESULTS,SUNNYVALE,THERAPY,TREATMENT
LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SWITCHING,THREE,UNIVARIATE
160,169,177,222,AUTHORS,COPYRIGHT,INC,INCREASED,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PERIRECTAL,PRE,PUBLISHED,PURPOSE,RESULTS,THERE,V70
145,169,COPYRIGHT,FAM,HENCE,IRELAND,LTD,R11,SSPEI
006,007,023,079,169,945,948,AAS,AFRICAN,BACKGROUND,CAP,CIS,DIETARY,EAS,INC,INVERSE,LABEL,METHODS,ORS,RESULTS,WILEY
ADVERSE,AES,APRIL,CBZ,CTCAE,DESPITE,HOWEVER,INSTITUTE,NCI,THEREFORE
127,169,302,369,425,5MG,623,730,858,ADT,ADVERSE,BACKGROUND,CENTRAL,COPYRIGHT,LABEL,LTD,METHODS,PRIMARY,PSA,RANDALL,RESULTS,TDP,THERE,WHITE
001,007,022,043,060,169,342,366,AUS,BETWEEN,COMPOSITE,CONCLUSION,COPYRIGHT,HRQOL,INC,INDEX,INVENTORY,IQR,JANUARY,LABEL,MEN,METHODS,OBJECTIVE,QOL,RESULTS,SHORT,UDI,URINARY,UROGENITAL
169,COPYRIGHT,HOWEVER,INC
169,ANDROLOGY,COPYRIGHT,FINALLY,INC,PUBLISHED,SOCIETY
169,172,674,848,881,946,BACKGROUND,CASES,CONCLUSION,GLEASON,IL1,IL2,IL4,IL6,IL8,INC,LABEL,METHODS,PREVENTION,PSA,RESULTS,SINCE,THESE,TRIAL,VARIATION,WILEY
054,055,169,AFRICAN,BACKGROUND,BLOCK,BRIEF,CONCLUSION,FREQUENCY,FURTHER,HUH,INC,LABEL,METHODS,PCA,RESULTS,THESE,UNIVERSITY,WILEY
169,BACKGROUND,C57BL,CAPSAICIN,CONCLUSION,INC,KIP,LABEL,METHODS,PC3,PIN,RESULTS,TRAMP,WILEY
001,003,074,117,125,162,AMERICANS,ART,BACKGROUND,EUROPEANS,FINALLY,FORTY,LABEL,LATIN,MAY,METHODS,OBJECTIVE,OVERALL,RESULTS
169,237,294,BACKGROUND,COPYRIGHT,EARLY,LABEL,LITHUANIA,LTD,METHODS,PSA,PUBLISHING,RESULTS
100,BMJ,CHK,GROUP,IHC,INCREASED,LABEL,LIMITED,MALIGNANT,METHODS,OBJECTIVE,PCR,PUBLISHED,PUBLISHING,RESULTS,THERE
CAR,CRLF2,FINALLY,SHORT,TSLPR
400,AIM,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE
169,AMYGDALIN,B17,SINCE
BMJ,CSC,EPITHELIAL,GROUP,HOLOCLONES,LABEL,LIMITED,LNCAP,METHODS,OBJECTIVE,PC3,PCA,PUBLISHED,PUBLISHING,RESULTS,TARGETING,TRANSITION
100,5YCSS,5YPRFSS,ADT,AMICO,FIFTY,GLEASON,PSA,THEIR,THERE,THESE
AFTER,CARIBBEAN,CONCLUSION,LABEL,METHODS,REGARDING,RESULTS,SAN,SECONDARY,UNLABELLED,VTE
125,145,D90,DHI,LDR,LSS,MRI,PRO,V90
125,162,229,239,539,678,901,ACCORDING,BETWEEN,FORTY,FURTHER,HDR,HUNGARIAN,HUNGARY,INCLUDING,INSTITUTE,JANUARY,MOC,MUNICIPIAL,NIO,THERE,TREATMENT,UNION
001,004,018,042,145,169,ADJUSTING,BACKGROUND,BMI,CAP,COX,CSM,INCREASING,LABEL,METHODS,RESULTS,SOCIETY,T1B
700
100,160,169,450,BLOOD,COPYRIGHT,HNSCC,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROCESSES,PURPOSE,RESULTS
017,111,143,151,169,183,206,207,ADT,AVENTIS,BACKGROUND,COPYRIGHT,DOCETAXEL,EARLY,FUNDING,GLEASON,IQR,LABEL,LIGUE,LOCAL,LTD,METHODS,NEITHER,RESULTS
169,231,233,CLINICIANS,COPYRIGHT,DENOSUMAB,DESPITE,PUBLISHED,SAS,SINCE,THESE
169,231,233,CASTRATION,COPYRIGHT,PUBLISHED,SAS
10878,133,140,169,200,756,945,946,BED,COPYRIGHT,DOSES,HDR,INCREASES,INCREASING,IRELAND,LABEL,LTD,MATERIALS,METHODS,MIXED,OBJECTIVE,PURPOSE,RESULTS
CAUSATION,CONTROLFOR,HPV,SEVERAL,THERE

100,BPH,CONCLUSION,EPCAM,LABEL,METHODS,OBJECTIVE,PCA,PIN,RESULTS
BPH,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PIN,RESULTS,USING
BASED,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
946,947,HLA,IFN,TGF,THESE,VACCINE
169,202,381,AFTERWARDS,AMONG,ANTICANCER,COPYRIGHT,COULTER,DEPARTMENT,ESPECIALLY,INSTITUTE,PCA,PSA
169,946,947,AIM,ANTICANCER,BETWEEN,CONCLUSION,COPYRIGHT,CSF,EGF,FIFTEEN,FURTHER,GRO,IFN,INSTITUTE,LABEL,MAY,METHODS,OBJECTIVE,PCA,RESULTS,SEVENTEEN,TGF
169,ANTICANCER,BACKGROUND,CD4,CD8,CONCLUSION,COPYRIGHT,DCS,H11,HYPER,INSTITUTE,LABEL,MATERIALS,METHODS,RESULTS,TRAMP,WHOLE
169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,CXC,CXCR2,HOWEVER,IL8,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,PROFILING,RESULTS
169,945,ANTICANCER,COPYRIGHT,EFFECTIVE,INSTITUTE,NATURAL,SANDALWOOD,SANTLOL,SKH
169,947,ADC,CARLO,CONCLUSION,COPYRIGHT,D02,D50,D95,INC,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,TCP
BACKGROUND,CONTEXT,LABEL,METHODS,OBJECTIVE,RESULTS,SHORT,SIPULEUCEL,SYNTHESIS,THEREFORE,TREATMENT
001,007,169,201,231,233,509,ARN,COPYRIGHT,ODM,PUBLISHED,SAS,SEVERAL,TAK,TOK
700,900,COHORTS,DLT,DURABLE,MTD
169,946,FURTHER,TMPRSS2
BPH,GLEASON,PCA,PSA,THEREFORE
22RV1,LABEL,LNCAP,METHODS,OBJECTIVE,PURPOSE,RESULTS,TMFOL,TRAMP
105,192,TREATMENT
205,4N0
100,104,115,189,D10,D90,HDR,THERE
427,616,CRR,GENERAL,THEREFORE
110
PASSING
BASIC,JOINING,ODS,PSA,SOD
169,946,ADT,BACKGROUND,CASTRATION,CHROMATIN,CLINICALLY,CONCLUSION,DHT,INC,INCREASED,KNOCKDOWN,LABEL,LUCIFERASE,METHODS,MTS,PCA,PCR,RESISTANT,RESULTS,THESE,WESTERN,WHILE,WILEY
100,103,169,215,244,BACKGROUND,CPG,DNASE,ENRICHMENT,ERG,FOXA1,GENOMIC,H3K27AC,H3K4ME1,H3K4ME2,H3K4ME3,HMS,HOWEVER,IIA,INC,LABEL,METHODS,NR3C1,PCA,POLYMERASE,RESULTS,SEQ,TFS,WILEY
169,ACADEMY,CROSS,FOURIER,METABOLIC,NOVEL,RAMAN,TECHNIQUES,THESE
001,003,008,028,169,205,ADT,ASSESSMENT,CONCLUSION,CTG,FUNCTIONAL,HRQOL,III,LABEL,METHODS,MRC,OBJECTIVE,PR3,PURPOSE,RESULTS,SOCIETY,THERAPY,TREATMENT
091,107,169,324,570,BACKGROUND,BETWEEN,COMMUNITY,CONFIDENCE,COX,GLEASON,INC,LABEL,METHODS,PSA,RATIO,RESULTS,TEN,WILEY
18F,BESIDES,HOWEVER,SINCE
27G,BULGARIAN,ERG,GSTP1,LABEL,METASTATIC,METHODS,OBJECTIVE,PCA,PCR,PURPOSE,RESULTS,TMPRSS2,TNM
160,177,CONCLUSION,CTCAE,FDA,FOLLOWING,LABEL,MEGESTROL,METHODS,NCI,OBJECTIVE,PURPOSE,RESULTS,THESE
100,177,956,CALLIANDRA,CAM,CONCLUSION,DETECTION,EFFECTS,HOWEVER,LABEL,LDH,LNCAP,METHODS,OBJECTIVE,PCA,PRECISELY,RESULTS,XTT
100,401,COMPARING,CONCLUSION,EPSTEIN,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,T1C
AFRICAN,BRAZILIAN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
125,227,233,429,830,CASES,EORTC,GLEASON,IOG,JOS,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,SEPTEMBER,THROUGH
029,130,148,278,CONCLUSION,INSERTION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
106,CONCLUSION,EMPIRICAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
001,042,177,272,292,390,421,642,743,910,CONTROL,GLEASON,INDEX,LABEL,LOW,LOWER,MATERIALS,MAY,MEN,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
004,177,229,633,AUC,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,THERE
CNA,GLEASON,MULTIFOCAL,THESE
169,COPYRIGHT,DIFFERENT,HOWEVER,INC,MICRORNAS,PCA,SINCE
145,150,177,956,CUR,DU145,ETOPOSIDE,ETP,PC3,WHILE
150,169,946,APC,ATM,BRCA1,BRCA2,COPYRIGHT,ETS,INC
100,169,BACKGROUND,BASEL,BRAIN,CONCLUSION,III,INTRADURAL,LABEL,METHODS,THESE,UNDER
BACKGROUND,LABEL,RESULTS,SET
002,123,158,169,233,297,AFTER,ALCOHOL,BACKGROUND,CONCLUSION,COX,HOWEVER,LABEL,METHODS,MIN,NUTRITION,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SOCIETY,SUPPL,VITAMINES
145,945,HDACI,HDACS,MCF,THESE
10A,10H,145,946,947,AKT,BIOLOGICAL,DDQ,FINALLY,HOWEVER
CONCLUSION,FRANKEL,JANUARY,KARNOFSKY,LABEL,LOG,METHODS,RESULTS,SCORE,SIXTY,SPINE,UNLABELLED,VERTEBRAL
AIDED,CAD,DCE,DEVELOPING,DIAGNOSIS,DIFFUSION,DWI,DYNAMIC,IMAGING,MRI,ULTRASOUND
169,BACKGROUND,COPYRIGHT,HRQOL,INDEX,IRELAND,KNOWLEDGE,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PCI,PURPOSE,QOL,RESULTS,SCORE,SHORT,SRT,SYMPTOM
004,169,215,383,740,803,827,AUC,BACKGROUND,ERG,GLEASON,HOWEVER,INC,LABEL,METHODS,PCA,RESULTS,ROC,TK1,TMPRSS2,TRANSCRIPT,WILEY
169,239,BACKGROUND,BDC,INC,LABEL,MET,METHODS,MIC,RANKL,RESULTS,WILEY
000,169,AFTER,BACKGROUND,DLT,LABEL,MDSCS,METHODS,PSA,RESULTS,SOCIETY,THERAPY,WBM
AFTER,THERE
956,COMPOUNDS,LNCAP,NMR,QUEENSLAND,SAR
ACADEMY,ACP,BACKGROUND,COLLEGE,FORCE,INSTITUTE,LABEL,METHODS,PHYSICIAN,PHYSICIANS,PREVENTIVE,QUERY,SCREENING,SOCIETY,UROLOGICAL
CLUSTER,CTC,EFFICIENT,USING
169,233,471,ALTOGETHER,ASE,COPYRIGHT,EXPRESSION,INC,OVERALL,PUBLISHED,SOCIETY,USING
073,169,178,ADULT,AFTER,ATP,BACKGROUND,III,INC,LABEL,METABOLIC,METHODS,PANEL,PFS,RESULTS,SIXTY,TREATMENT,WILEY
169,946,COPYRIGHT,INC,SD208,SMADS,TGF
001,003,037,169,244,BACKGROUND,CGEMS,COLORECTAL,DRE,INC,LABEL,MARKERS,METHODS,OVARIAN,PCA,PGS,PSA,RESULTS,SCREENING,TRIAL,WILEY
292,502,862,CSF,GRADEB3,RATES
HOWEVER
108,169,814,851,994,AMONG,BETWEEN,HOWEVER,JANUARY,LABEL,MEIER,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
169,206,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,PEARSON,PHASE,PRESS,PUBLISHED,RESULTS,SECONDARY,UNIVERSITY
169,CASTRATION,COPYRIGHT,HOWEVER,HSP27,LTD
001,169,400,AVERAGE,BCR,BOARD,CCI,COPYRIGHT,INTRA,JANUARY,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE
1ST,HODGKIN,MOUTH,MRI,MYELOMA,NON,PET,RAY,SINCE,THERE,VISIBLE

169,529,ADDITIONAL,AMONG,GLEASON,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
EFFECTIVE,FOLLOWING,RADICAL
007,111,169,310,CONCLUSION,IMAGING,INC,JVZ,LABEL,LNCAP,METHODS,MOLECULAR,NANOBODIES,NUCLEAR,PCA,RENAL,RESULTS,SCN,SOCIETY,SPECT,UNLABELLED,VHH
169,ERG,ETS,TMPRSS2
006,028,042,169,BACKGROUND,CONCLUSION,COPYRIGHT,DENOSUMAB,END,FEWER,HCM,III,LABEL,LTD,METHODS,PATIENT,RESULTS
135,141,186,BPH,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SHORT,STR,THERE
177,25OHD,ANOVA,BACKGROUND,BMI,BPH,BULGARIAN,FURTHER,GLEASON,KRUSKAL,LABEL,METHODS,OTHER,PCA,PSA,RESULTS
145,1522B,AG0,MCT,RIBES,SCT,THESE,UNDER
946,AMONG,BEL,IC50S,PC3,SAR,SGC
BACKGROUND,ISOPURE,LABEL,REPLACING,RESULTS
COMPOUNDS,HCT,NMR,THEIR,THREE,VALERIANA
169,ELISA,IL6,INC,KNOCK,LABEL,METHODS,MYC,OBJECTIVE,PCR,PSA,PURPOSE,RESULTS,STAT3,WESTERN,WILEY,WOUND
100,CONCLUSION,EPL,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,TPS
145,169,PRESS,PSA,PUBLISHED,THESE,TMPRSS2,UNIVERSITY
169,BIOLOGY,MICRORNAS,SOCIETY
169,BMS,COPYRIGHT,CYTOTOXIC,INC
169,250,750,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,PSA,REDUCED,RESULTS
100,158,169,174,177,ADT,AIM,ANTICANCER,BETWEEN,CONCLUSION,COPYRIGHT,EXCLUSION,GLEASON,INCLUSION,INSTITUTE,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SAMPLES,THERE
169,3DCRT,945,946,ACCORDING,AFTER,AIM,ANTICANCER,BACKGROUND,BASED,CONCLUSION,CONFORMAL,COPYRIGHT,EARLY,EORTC,INSTITUTE,LABEL,METHODS,NETWORK,OBJECTIVE,PCA,PHOENIX,RESULTS,TREATMENT
169,313,553,678,737,796,AIM,ANTICANCER,AUC,BCH,CONCLUSION,COPYRIGHT,INSTITUTE,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,ROC
169,468,946,ANTICANCER,APPARENTLY,BACKGROUND,CONCLUSION,COPYRIGHT,GAL,H1975,INSTITUTE,LABEL,MATERIALS,MDA,MEL28,METHODS,MULTIPLEX,NCI,PCR,PRIMARY,PROBE,RESULTS,SCGB2A2,SW962
169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,GBC,IL1,IL1RN,IL8,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,RESULTS,USING
021,077,156,169,233,294,619,935,AFRICAN,AIM,AMERICANS,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,DNASE,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,RESULTS,USING
169,AIM,ANTICANCER,APOPTOSIS,BACKGROUND,CONCLUSION,COPYRIGHT,GFP,H2B,HOWEVER,INDUCTION,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,RFP
169,ANTICANCER,CONCERNING,COPYRIGHT,HOWEVER,HPV,INSTITUTE
001,169,ADT,AGE,CONCLUSION,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
001,008,169,HODGKIN,INC,NHL,USING,WILEY
BECAUSE,CLASS,GRADE
169,ACT,BACKGROUND,COMPLEXING,HUVEC,INC,LABEL,METHODS,PSA,RESULTS,WILEY
001,003,014,015,100,169,220,248,BACKGROUND,DISCUSSION,EPE,GLEASON,IDC,INC,ITALY,LABEL,METHODS,RESULTS,RUSSIAN,SMALL,WILEY
135,169,174,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MASON,MATERIALS,MEN,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,PURPOSE,RESULTS,UNIVERSITY,UROLOGICAL,WELCH
045,125,169,303,723,774,BACKGROUND,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,WHEREAS
125,144,169,ADVERSE,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PURPOSE,RESULTS
ALKYL,BIS,FORTY,WADSWORTH
169,DESPITE,FINALLY,INC,SINCE,SOCIETY
001,169,318,ADT,AFTER,BACKGROUND,CLINICALLY,COX,GLEASON,HRS,LABEL,METHODS,PCA,PRESS,PROPENSITY,PSA,PUBLISHED,RESULTS,THESE,UNIVERSITY,USING
GLEASON,TNM
ACC,CONCLUSION,CONTOURED,CONTOURING,FOLLOWING,INTENSITY,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PARTICULAR,RESULTS,TECHNIQUES
169,COPYRIGHT,DIFFUSION,DWI,INC

III,THEREFORE
145,DU145,LNCAP,PC3,PCA,PNT1A
187,204,555,MACHINE,RESULTS,ROACH
176,CONCLUSION,D95,HOWEVER,INTER,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RBE,RESULTS,TOTAL
178,AFRICAN,ANY,BACKGROUND,CONCLUSION,EIGHT,LABEL,METHODS,RESULTS,SEVERAL
001,028,407,APRIL,CENTRAL,SIMILAR,SMD
169,COPYRIGHT,FINALLY,LTD,SILIBININ,SILYBUM,STAT3
169,BAHRAIN,COPYRIGHT,COUNCIL,DESPITE,HODGKIN,LTD,QATAR,SAUDI
100,160,169,946,956,ACC,AMP,ASPIRIN,AUTHORS,COA,LIMITED,MRC,PNT1A,PRE,PRESS,SALICYLATE
169,191,726,945,946,956,COPYRIGHT,HSC70,HSP90,INHIBITING,KU675,OVERALL,SOCIETY,WESTERN
000,001,003,007,052,150,169,BACKGROUND,BASED,BPH,CONCLUSION,DHEAS,DHT,HOWEVER,INC,LABEL,METHODS,PSA,RESULTS,WILEY
003,007,025,032,041,047,048,169,AMONG,BACKGROUND,DECREASED,ERG,INC,LABEL,LOG,METHODS,PSA,RESULTS,THERE,TMPRSS2,WILEY
001,009,112,169,189,406,612,AUTHORS,BACKGROUND,CONCLUSION,GLEASON,HEMIZYGOUS,INC,LABEL,METHODS,MICROARRAY,PSA,RESULTS,THERE,TMA,WILEY
104,208,BDE,BLOOMBERG,CASES,COLORECTAL,GOVERNMENT,HOPKINS,INCREASING,JOHNS,OVARIAN,PBDES,PRESS,PUBLISHED,SCREENING,TRIAL,UNIVERSITY
011,013,10877,10878,169,348,4GY,99A,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,169,COPYRIGHT,CTV,FIFTEEN,GTV,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PGI,PTV,PURPOSE,RESULTS,RGI,TCP
100,107,145,169,181,191,195,205,218,CARLO,COPYRIGHT,D10,D90,FOCAL,INC,ISA,LABEL,LDR,MATERIALS,METHODS,MONTE,MRI,OBJECTIVE,PURPOSE,RESULTS,TPM,TREATMENT
169,19A,COPYRIGHT,FEDERATION,MICRORNAS,PCA,PUBLISHED,SOCIETIES
169,CONCLUSION,COPYRIGHT,ELDERLY,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCALE,SIXTEEN,THERE,TREATMENT,VES,VULNERABLE
169,4CM,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SINCE,SIX,SIXTY,SUFFICIENT
169,ACIDS,FINALLY,HOWEVER,NUCLEIC,PCA,PRESS,PUBLISHED,THESE,UNIVERSITY
169,182,780,945,946,956,COPYRIGHT,ERE,ICI,LTD
MDV3100
BPH,CONCLUSION,LABEL,METHODS,OBJECTIVE,PBL,PCA,RESULTS
169,946,956,COPYRIGHT,GENISTEIN,HOWEVER,INHIBITORY,LNCAP,LTD,PCA,THEREFORE
169,BACKGROUND,END,ESOPHAGEAL,GISTS,HODGKIN,HOWEVER,LABEL,METHODS,OVARIAN,RESULTS,SIR,SOCIETY,SPR,THERE,THESE
CIS,FURTHER,INSURANCE,MDS,NHI,ORS,OVERALL,TAIWANESE
161,169,690,AFTER,BACKGROUND,BMI,CONCLUSION,COX,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS,WILEY
347,369,376,443,499,954,ADDITIONAL,AMONG,DESPITE,DIGITAL,GLEASON,GP5,HOWEVER,REMAINING,THESE
602,616,BACKGROUND,CONCLUSION,EPSTEIN,FIRST,GENERATION,LABEL,METHODS,MULTI,NPC,POISSON,RESULTS,RRS,SWEDISH
144,157,355,DRE,GLEASON,GROUP,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RESULTS,STUDENT
103,672,811,AMONG,CONTINUED,III,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PSM,PURPOSE,RESULTS
001,004,016,BACKGROUND,BPH,BRAZILIAN,GLEASON,IGF,IGFBP,LABEL,MATERIALS,METHODS,NON,OBJECTIVE,PCA,PSA,RESULTS,THERE
500,AFTER,CONCLUSION,EIGHT,FEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SIXTEEN,THERE
APRIL,COMPOSITE,HDR,HRQOL,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX,SIXTY,THERE
000,280,ADT,DUE,HOWEVER,PCA,PSA
169,366,608,ADT,AFTER,BACKGROUND,LABEL,METHODS,RESULTS,SOCIETY,THERE,TREATMENT
APOPTOSIS,BAX,BCL,CYTOCHROME,DESPITE,DETECTION,DOCETAXEL,DTX,ELISA,KIT,LABEL,METHODS,OBJECTIVE,OCT,OCTREOTIDE,PURPOSE,RESULTS,SSTR2,SSTR5,THESE,XTT
GCPII,III
122,ANOVA,BONFERRONI,BPH,CONCLUSION,III,IMAGE,LABEL,MEANS,METHODS,OBJECTIVE,PAC,PRO,PURPOSE,RESULTS,SMC,THERE
11WEEKS,29WEEKS,956,ALDH1A1,CPG,DECREASED,HYAL1,INC,INCREASED,NES,NTM,PUBLISHED,S100P
169,231,233,COPYRIGHT,MECHANISMS,PUBLISHED,SAS
128,169,HOWEVER,KNOCKDOWN,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
956,DU145,NTUB1,SOLANUM
ANTITUMOR,MCI,MTT,NYMPHOIDES,PC3,SCREENING
002,169,378,945,BACKGROUND,ESTRADIOL,GEOMETRIC,INC,LABEL,MEN,METHODS,NUTRITION,PSA,RESULTS,SERUM,WILEY
123,169,588,AIM,BACKGROUND,BRITISH,CONCLUSION,DESPITE,GENERAL,JOURNAL,LABEL,METHODS,OBJECTIVE,RANDOMISED,RESULTS,SETTING
135,195,230,239,272,281,292,314,329,375,65308,65309,LND,LYMPH,THERE,TOTAL
169,BAX,BCL,CHANGES,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PC3,RESULTS
058,079,101,169,286,781,ADJUSTING,COLORECTAL,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OVARIAN,PSA,RESULTS,RISKS,SCREENING,TRIAL
118,169,381,665,901,ASIAN,CONCLUSION,COPYRIGHT,COX,HEART,INC,JANUARY,KOREA,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
000,004,022,114,169,568,967,ADT,BACKGROUND,DETECTION,IDC,INC,LABEL,METHODS,PSA,PSADT,RESULTS,WILEY
029,100,169,177,300,500,BACKGROUND,BPH,CD3,CONCLUSION,ECS,INC,LABEL,METHODS,NIH,PIN,RESULTS,THERE,WILEY
001,169,688,794,AMONG,BACKGROUND,END,INSURANCE,LABEL,METHODS,PATIENT,RATES,RESULTS,SOCIETY,VARIATION
169,1COMPARED,BACKGROUND,DU145,GELATIN,HPADS,INC,LABEL,LNCAP,MCP,METHODS,MMP,MTT,OBESITY,RESULTS,WESTERN,WILEY

GASTRIC
169,AHR,BIC,ICT,KNOCKDOWN,MDV,PERSISTENT,PRESS,PSA,PUBLISHED,THEREFORE,UBE2C,UNIVERSITY
002,BACKGROUND,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,YAP
124,176,177,186,BACKGROUND,DAILY,LABEL,METHODS,OBJECTIVE,PTV,RESULTS,TREATMENT,VISICOILS
283,656,AHS,AMONG,BMJ,GROUP,LABEL,LIMITED,METHODS,NEWLY,NORTH,OBJECTIVE,POISSON,PUBLISHED,PUBLISHING,RESULTS,RRS
100,169,295,590,BACKGROUND,BETWEEN,CIS,COLORECTAL,CONCLUSION,DBP,FURTHER,LABEL,METHODS,NUTRITION,OBJECTIVE,ORS,OVARIAN,RESULTS,SOCIETY,VITAMIN
002,004,010,014,018,021,025,039,041,100,169,200,626,ALPHA,AUTHORS,DESPITE,INC,PREVENTION,PSA,PUBLISHED,SERUM,TOCOPHEROL,ULTRAHIGH,WILEY
169,LABORATORY,LIU,PRESS,PUBLISHED,SHAD1,SOCIETY,YB1
100,169,240,ADT,ADVERSE,BACKGROUND,BCR,EIGHT,INSTITUTE,LABEL,METHODS,PSA,RESULTS,SIXTEEN,SOCIETY,TREATMENT
125,13YEARS,169,208,60YEARS,630,ADULT,BACKGROUND,BMI,CHILDHOOD,CONCLUSION,COPENHAGEN,COPYRIGHT,COX,HRZ,LABEL,LINKAGE,LTD,METHODS,RECORDS,RESULTS,THEREFORE,THESE
001,177,AFTER,CCS,CONCLUSION,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,TEXTURE
000,250,300,HCT,HDL,PSA,SERUM,SEVERAL,TREATMENT,TRT,WHILE
AFTER,HOWEVER
HOWEVER,PCA,PSA
10878,BACKGROUND,CNV,CYP17A1,LABEL,MEIER,METHODS,PFS,PSA,RESULTS,SERUM
169,ADVANTAGES,ANEUPLOIDY,BACKGROUND,CHEMISTRY,HOWEVER,LABEL,METHODS,RESULTS,SCREENING,SEQ,SEQUENCING,THEREFORE
169,177,531,700,AMICO,COPYRIGHT,EDUCATION,INC,LABEL,LYMPH,MATERIALS,METASTASES,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SINCE,SUPER,THREE,UROLOGICAL
169,22RV1,BACKGROUND,CHROMATIN,INC,LABEL,LNCAP,METFORMIN,METHODS,MTT,PCR,PSA,RESULTS,WILEY
053,169,177,181,600,92A,956,AFTER,AGILENT,BACKGROUND,CONCLUSION,HGPIN,INC,LABEL,METHODS,PCA,PREVENTION,PSA,RAW,RESULTS,SAMPLES,TRIAL,VISIBLE,VITAMIN,WILEY
169,BACKGROUND,CONVERSELY,INC,LABEL,MEN,METHODS,PREVENTION,RESULTS,TELOMERES,THESE,TRIAL,WILEY
169,423,BACKGROUND,BASED,DISCUSSION,GLEASON,INC,LABEL,METHODS,PCA,RESULTS,TMA,WILEY
169,FOUNDATION,INC,OCTOBER,PCF,RETREAT,SCIENTIFIC,WILEY
001,145,169,945,946,AKT,BACKGROUND,CSC,DEPLETION,DISCUSION,DU145,FMISO,HIF,HOWEVER,ID1,INC,LABEL,LNCAP,METHODS,PDGFR,RESULTS,SUNITINIB,UNASSIGNED,WILEY
056,150MG,169,239,428,438,607,611,6YEAR,866,991,BACKGROUND,COPYRIGHT,COX,GROUP,HOWEVER,LABEL,LTD,MEIER,METHODS,OVERALL,PCA,PSA,RESULTS,THROUGHOUT,WORLD
160,169,250,956,AUTONOMIC,BACKGROUND,CONCLUSION,COPYRIGHT,DVF,EXCELLENT,FASCIAE,LABEL,LEEDS,LTD,METHODS,MILLERS,OPTIMAL,PROGRAMME,RESULTS,TME
169,ADC,COPYRIGHT,DIFFUSION,LTD,MRI
100,169,AEROBIC,BACKGROUND,CHANGES,EFFECTS,HRQOL,LABEL,METHODS,MODERATION,QOL,RESULTS,SOCIETY
013,037,169,177,ACUTE,COPYRIGHT,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,SERUM,THERAPY,VITAMIN
169,1YEAR,365,649,990,APRIL,BACKGROUND,CIS,COPYRIGHT,HRS,LABEL,LTD,METHODS,RESULTS,THOSE
145,146,169,4D4,956,ASSAY,CDR,COPYRIGHT,DUE,FAB,LYS,MAB,PSA
020,028,123,125,169,242,LABEL,METHODS,OBJECTIVE,OCTOBER,PHOENIX,PRESS,PUBLISHED,RESULTS,THEIR,UNIVERSITY
169,945,946,CD133,CXCR4,FASEB,INHIBITION,USING
068,106,135,160,169,181,183,218,220,224,225,257,278,309,327,360,603,610,623,705,769,790,803,812,826,845,872,ASSESSMENT,BACKGROUND,BPI,BRIEF,COPYRIGHT,FUNCTIONAL,FUNDING,HRQOL,INVENTORY,IQR,LABEL,LTD,MEDIVATION,METHODS,PREVAIL,RESULTS,SHORT,THERAPY
169,BACKGROUND,COPYRIGHT,DU145,INC,LABEL,MATERIALS,METHODS,PC3,RESULTS,USING
945,BACKGROUND,DEF,ERG,ERK,ETS,HOWEVER,LABEL,RAS,RESULTS,THEREFORE
169,AREAS,COPYRIGHT,INC,LUR,NO2,NOX,ORS,THESE
DIETARY
128,148,150,169,177,AFTER,CONCLUSION,EUK,EXM,FDG,IMAGING,INC,INJECTION,LABEL,MBQ,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SOCIETY,THERAPY,UNLABELLED,WHOLE
058,113,169,177,529,617,CONCLUSION,DESPITE,HOWEVER,IMAGING,INC,LABEL,LNCAP,METHODS,MOLECULAR,NUCLEAR,ORGAN,PET,RESULTS,SOCIETY,SPECT,SUBSEQUENT,THEREFORE,UNLABELLED
169,COPYRIGHT,HOWEVER,INC,TUR
169,CLINICIANS,CONCLUSION,COPYRIGHT,INC,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,SCORE,STUDIES,SYMPTOM,UROLOGICAL,WHETHER
160,169,BECLIN1,CONCLUSION,COPYRIGHT,EXPRESSION,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RESULTS,UNC
000,100,152,312,330,CDC,CENTRAL,CESSATION,LABEL,METHODS,POPULATION,RICAN,STATISTICS,UNLABELLED
002,010,150,169,AUSTRALIA,AUTHORS,BACKGROUND,COHEN,FURTHER,INC,LABEL,MELBOURNE,METHODS,RESULTS,SOCIETY,WILEY
169,22RV1,946,ADN,BACKGROUND,BPH,CHINESE,CONCLUSION,EMT,EPIGENETIC,EPITHELIAL,GLEASON,H3K4ME3,IHC,INC,LABEL,LNCAP,METHODS,MSP,MTS,PCA,PCR,PROSTATIC,RESULTS,SILENCING,TGF,TRANSITION,TSA,WESTERN,WILEY
169,AUTHORS,BRITAIN,FINALLY,GREAT,IRELAND,JOURNAL,LTD,MCT,METABOLIC,PATHOLOGY,PCA,SOCIETY,USING,WILEY
ACUTE,CONCLUSION,DOSIMETRIC,HOWEVER,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,V10
PSA,ULTIMATELY
LABEL,METHODS,OBJECTIVE,RESULTS,RUNNING,SENSE,YET
009,169,333,369,GLEASON,PRESS,PUBLISHED,RPS,TURPS,UNIVERSITY,USING
169,BASAL,COPYRIGHT,ERBB2,ERG,INC,KIT,TMPRSS2
ACCORDING
002,1RA,946,947,BACKGROUND,DOCETAXEL,EARLY,HOWEVER,IFN,LABEL,METHODS,PC3,PC3RX,PSA,RESULTS
150,ELISA,LOW,VITAMIN,WHITNEY
001,127,169,COPYRIGHT,DSC,FACTORS,INC,IPL,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PET,PURPOSE,RESULTS,SUV,SUV60,T2W
169,CONCLUSION,COPYRIGHT,INC,INTRINSIC,ISD,LABEL,METHODS,OBJECTIVE,RESULTS,SIXTY
001,0NG,119,133,169,428,617,634,651,704,716,719,734,738,761,802,820,838,AUC,BACKGROUND,GLEASON,LABEL,METHODS,PRESS,PSA,PUBLISHED,RESULTS,TESTING,TREATMENT,UNIVERSITY,USING
001,006,169,866,ADIPOR2,BMI,COX,GLEASON,HOWEVER,PHYSICIANS,PRESS,PSA,PUBLISHED,RESULTS,THESE,TUNEL,UNIVERSITY,USING
100MG,169,AEF,CONTRARILY,FEF,GLE,HENCE,HOWEVER,ISOLATION,PRESS,PUBLISHED,UNIVERSITY
169,ANTICANCER,BACKGROUND,CLINICIANS,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,RESULTS,SUBSEQUENT
108,169,179,428,793,796,975,AMONG,ANTICANCER,BACKGROUND,BPH,COMPARISON,CONCLUSION,COPYRIGHT,DRE,INSTITUTE,ITALIAN,LABEL,METHODS,PCA,PIN,PSA,RESULTS
001,005,169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,PCA,PFR,PSA,PVRUV,RESULTS
169,ANTICANCER,COPYRIGHT,ENGLISH,FDG,HISTOLOGIC,INSTITUTE,QUADRUPLE,SUBSEQUENT,SUV
015,169,956,ABCB1,ANTICANCER,ATP,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,LNCAP,MATERIALS,METHODS,RESISTANCE,RESULTS,STEROID
169,ANTICANCER,BACKGROUND,CD133,CELLS,CONCLUSION,COPYRIGHT,EXPRESSION,INSTITUTE,ITGA6,LABEL,MATERIALS,METHODS,PCR,RESULTS
169,ANTICANCER,COPYRIGHT,INHIBITION,INSTITUTE,KALLIKREIN,OSCCS,THEREFORE
145,169,AKT,ANTICANCER,COPYRIGHT,ERK,INSTITUTE,JUN,LNCAP,STATINS,THESE
001,140,169,CONSORTIUM,GRADE,LABEL,MEDICAL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,SAPPORO,THERE,UNIVERSITY
000,032,100,150,243,263,BACKGROUND,CRUDE,CUMULATIVE,LABEL,METHODS,OBJECTIVE,PERCENTAGE,RESULTS,RZESZ,THERE
160,169,AKT,AMP,BECAUSE,COPYRIGHT,HOWEVER,IGF,INC,METFORMIN
005,160,BLOOD,LABEL,MATE1,METHODS,MICROARRAY,OBJECTIVE,PCR,PURPOSE,RESULTS,SEVENTEEN,SLC47A1
147,148,CHILEAN,HOWEVER,NORTH
CAR,EFFECTIVE,HOWEVER,INCLUSION,OPTIMAL,OTHER,SCIENCE
169,231,233,COPYRIGHT,DESPITE,PUBLISHED,SAS,THROUGH
169,BMP,EPIGENETIC,IL6,PROSTATIC,SOSTDC1,SYNTHESIS,THESE,WNT
169,945,ALTERED,FUNCTIONAL,PCSCS,TAKEN
MANAGEMENT,PSA,SPOTLIGHT,SPR,VICKERS
169,BACKGROUND,COMPETING,CONCLUSION,COPYRIGHT,DUE,GROUP,HOWEVER,IRELAND,LABEL,LTD,METHODS,MFS,RESULTS,SOUTHWEST,TRIAL
COLORECTAL,ERSPC,GROUP,OVARIAN,PIVOT,PSA,RANDOMIZED,SCREENING,TRIAL
169,BIOLOGY,E131Q,EXPRESSION,GTPASES,HYAL1,HYALURONAN,INC,MOLECULAR,OVERALL,RAB,SOCIETY,USING,Y202F
169,CROSS
155,169,209,BACKGROUND,ELISA,FGF,FGF19,FIBROBLAST,GLEASON,INC,LABEL,LNCAP,METHODS,MTT,PC3,PCA,PSA,RESULTS,SERUM,UNDER,WESTERN,WILEY
169,563,BLOOMBERG,BMI,COMPARING,ERG,ETS,HOPKINS,JOHNS,PRESS,PUBLISHED,T2E,TMPRSS2,UNIVERSITY,WASHINGTON
781,CALCULATOR,CURRENT,DUTCH,ERSPC,PSA
169,1960S,COPYRIGHT,DESPITE,EDUCATION,EFFORTS,ENGLISH,GLEASON,INC,LABEL,LARGE,MATERIALS,MEMBERS,METHODS,OBJECTIVE,POPULATION,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE,THESE,UROLOGICAL,YOUNG
133,169,CONCLUSION,EPE,FEATURE,IMAGING,LABEL,LESIONS,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIOLOGY,REPORTING,RESULTS,SOCIETY,UROGENITAL,ZONAL
REDUCED
036,105,169,180,210,967,A12,CONCLUSION,CTC,IGF,IMC,LABEL,LOWER,METHODS,OBJECTIVE,PATIENT,PSA,PURPOSE,RESULTS,SECONDARY,SOCIETY
177,326,BESIDES,CLINICALLY,CONCERNING,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,RCP,RESULTS
169,505,551,577,595,763,BACKGROUND,CHANGES,CRT,DESPITE,FUNCTIONAL,GROUP,INDEX,LABEL,METHODS,RADIATION,RESULTS,SOCIETY,THERAPY,THERE
129,165,169,335,AIM,ASSESSMENT,BACKGROUND,INDEX,LABEL,METHODS,OBJECTIVE,ORDINAL,OUTCOME,PRIOR,RESULTS,SIX,SOCIETY
146,169,290,CONCLUSION,COPYRIGHT,CTV,DAILY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,RESULTS,THESE
160,169,219,CONVERTING,COPYRIGHT,DVH,GROUP,INC,KUTCHER,LABEL,LKB,LYMAN,MATERIALS,METHODS,NTCPS,OBJECTIVE,PTV,PURPOSE,RADIATION,REPLANNING,RESULTS,THERAPY
169,210,221,BIC,COPYRIGHT,DHT,HOWEVER,IRELAND,LNCAP,LTD,MIB,PCR,TREATMENT
169,COPYRIGHT,EDUCATION,HOWEVER,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,STRICTURES,SUCCESS,UROLOGICAL
169,AUC,BACKGROUND,DISCUSSION,FDA,HGPIN,INC,LABEL,MEN,METHODS,MULTIPLEX,PCA,PCR,PPV,RESULTS,UNI,USING,WILEY
169,744,810,890,ACIDS,KNOCK,MICRORNAS,NUCLEIC,PRESS,PUBLISHED,THESE,UNIVERSITY,XPC
001,015,016,044,169,280,APL,BACKGROUND,LABEL,METHODS,REPORTS,RESULTS,SOCIETY,TREATMENT
169,228,BACKGROUND,BEGINNING,COMPOSITE,DISEASE,HRQOL,INDEX,LABEL,MEDICAL,METHODS,PCA,RESULTS,SOCIETY,THESE
947,AFTER,CONVERSELY,LOCAL
002,ART,BACKGROUND,CONVERSELY,HIV,HODGKIN,IRR,JOINT,KAMPALA,LABEL,METHODS,NATIONS,POISSON,PROGRAM,RESULTS,SAHARAN,THESE
169,COPYRIGHT,EBV,EPSTEIN,HIV,HODGKIN,INC,NHL,OTHER,SCC,TRANSPLANT,VIRUS
024,169,ASIAN,C677T,COPYRIGHT,MTHFR,OVERALL,PCA,RECESSIVE,TAKEN
169,1980S,1990S,858,COPYRIGHT,END,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RADIATION,RESULTS,THESE
001,169,177,CONCLUSION,FDG,IMAGING,INC,LABEL,METHODS,MOLECULAR,NAF,NUCLEAR,PET,RESULTS,SOCIETY,SUV,UNLABELLED
169,177,947,AFTER,CLI,CONCLUSION,HOWEVER,IMAGING,INC,LABEL,MBQ,METHODS,MOLECULAR,NUCLEAR,OTHER,RESULTS,SOCIETY,UNLABELLED,USING
001,111,130,169,177,468,CLAUDIN,CONCLUSION,GST,IMAGING,INC,LABEL,MAMMARY,MDA,METHODS,MOLECULAR,NUCLEAR,OVERT,RESULTS,SOCIETY,SPECT,SQ20B,TAKEN,UNLABELLED
AFRICAN,CAUCASIAN,CONCLUSION,FDG,FIFTEEN,FIFTY,GLEASON,IMAGING,LABEL,METHODS,OBJECTIVE,PET,PSA,RESULTS,SUBJECT
BACKGROUND,BPH,GLEASON,LABEL,LOW,LTP,METHODS,RESULTS
004,223,262,FURTHER,LITERATURE,MANAGER,STATA
AUTOPSY,BMJ,BRCA2,GLEASON,GROUP,LIMITED,PUBLISHED,PUBLISHING
169,COPYRIGHT,ETHANOLIC,PSA,PUBLISHED,WCE,WEDELIA
1930S,1950S,PAP,SINCE
169,442,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
169,ASPECTS,COPYRIGHT,DESPITE,INC,ITALIAN,MEDICAL,PHYSICS,SEVERAL
ADDITIONAL,ANXIETY,AUTHORS,BACKGROUND,CENTRAL,COLLECTION,CONTROLLED,DEPRESSION,GROUP,ICTRP,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,RANDOMISED,REIKI,RESULTS,SELECTION,THERE,THESE,TREATMENTS,WORLD
017,035,042,499,571,BACKGROUND,CAUCASIANS,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,THR241MET,XRCC3
160,169,177,COPYRIGHT,FTP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,STP
100,102,103,108,160,169,177,ADAPTATION,COPYRIGHT,CORRECTION,CTV,DAILY,EUD,EVALUATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,THREE,TREATMENT
001,100,105,160,169,945,946,COPYRIGHT,IDL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PLAN100,PURPOSE,RESULTS,TCP,THERE
169,BASEL,FUNCTIONAL,TREATMENT
120,190,300,310,630,AIM,BACKGROUND,CONCERNING,CONCLUSION,LABEL,METHODS,OBJECTIVE,RADICAL,RESULTS,T3A,T3B,T4A
100,DQA,INCUBATION
COLLEGE,CONCLUSION,DOPPLER,IQBAL,JANUARY,LABEL,MEDICAL,METHODS,OBJECTIVE,POWER,RESULTS,SIX
001,169,993,ADL,AMERICA,ASSESSMENT,BACKGROUND,CGA,COLORECTAL,CONCLUSION,COX,EASTERN,GERIATRIC,GROUP,GUG,LABEL,METHODS,MORTALITY,PRESS,PUBLISHED,RESULTS,SOCIETY,UNIVERSITY
CANCEROUS,CIP2A,INHIBITOR,USING
169,367,945,BACKGROUND,CONCLUSION,FSP,GLEASON,HOWEVER,INC,LABEL,METHODS,RESULTS,SINCE,SMA,THESE,WILEY
169,BACKGROUND,DU145,INC,INTRA,LABEL,LPS,MAT,METHODS,PC3,PCA,RESULTS,TAKEN,ULTIMATELY,WILEY
160,169,223,226,921,945,947,COPYRIGHT,INC,RESULTS
11R,169,945,BACKGROUND,FINALLY,LABEL,LIMITED,METHODS,PREVIOUSLY,RECEPTORS,RESULTS,SOCIETY,THESE
BETWEEN,CYBERKNIFE,JANUARY,OCTOBER,PRESCRIBED
CANCERS,DARWINIAN,HOWEVER,INTEGRATED,LESIONS,METASTASIS,USING
22RV1,945,CROSSTALK,FKBP5,GIVEN,GOVERNMENT,HIF,LNCAP,SIMILARLY,TMPRSS2,TREATMENT
945,EP2,HIF,LNCAP,PC3,THESE
169,BACKGROUND,FNA,LABEL,MEDICAL,METHODS,PANCREATIC,RESULTS,SOCIETY,THERE
006,007,008,009,169,AFTER,AUTHORS,BJU,CONCLUSION,GAINS,GIVEN,LABEL,MAINTAINED,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,UNASSIGNED,YOUNGER
169,ALTOGETHER,COPYRIGHT,INITIALLY,NGS,WHOLE
169,400,COPYRIGHT,ERASMUS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SHORTER,WORST
22RV1,AFTER
MENIN,MLL,RESISTANCE,TAKEN,TREATMENT
945,INHIBITION
169,AUTHORS,GLEASON,INC,INCIDENTAL,MEDLINE,PUBLISHED,THERE,WILEY
169,COPYRIGHT,HDR,IRELAND,LTD
947,CONCLUSION,IGG,LABEL,METHODS,MTS,NCSHRNA,OBJECTIVE,PC3,PCR,RESULTS,WESTERN
945,947,BARRETT,DUOX1,DUOX2,KNOWLEDGE,NADPH,NOX,ROS
10878,169,BACKGROUND,BIOLOGICAL,CNV,CONCLUSION,COPYRIGHT,CROSS,FIFTY,GRADE,IRELAND,KUTCHER,LABEL,LKB,LTD,LYMAN,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTY,SNP
126,134,137,144,169,204,AROCLOR,COPYRIGHT,CPF,DU145,EDS,EMT,ENDOCRINE,EPITHELIAL,INC,MMP
169,194,210,241,267,333,385,916,C5B,COPYRIGHT,CRYSTAL,GPI,INC,MVS
001,160,169,876,AFTER,AMONG,CONCLUSION,COPYRIGHT,INC,LABEL,LNS,METHODS,OBJECTIVE,OVERALL,RESULTS,USING
BACKGROUND,DMQ,FINALLY,LABEL,MATERIALS,MEN,METHODS,REASONS,RESULTS
169,178,AIM,BMI,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,RESULTS
ADT,HOWEVER,HUGGINS,OPTIONS
100,169,250,53BP1,956,CAPSAICIN,COPYRIGHT,DU145
032,045,139,141,143,169,COCHRAN,CONCLUSION,COPYRIGHT,DBT,ENCOUNTER,GREATER,INC,LABEL,METHODS,MORNING,OAD,OBJECTIVE,PRN,PROFILE,RESULTS,SECONDARY,SEP,SPL,THESE
145,169,COPYRIGHT,HSP90,IRELAND,LNCAP,LTD,SEVERAL,TREATMENT
180,AMONG,SMALL,THERE,THREE
223,LOW,OSSEOUS
102,169,225,720,956,CONTROL,HYPOCCS,LABEL,METHODS,OBJECTIVE,RESULTS,SIR,SOCIETY,STUDIES,THERE,USING
169,458,AUSTRALIAN,BMI,COX,HARRELL,HIP,HOWEVER,INDEX,OBESITY,SHAPE,STRONGEST,WHR,ZEALAND
169,ADT,AGGREGATE,BACKGROUND,LABEL,MEDICAL,METHODS,MIXED,PREVIOUSLY,QOL,RESULTS,SHORT,SOCIETY,TIMED,TUG
COMPETING,GRAPHICAL,MRE,THEREFORE,UTR,VIA,WHILE
032,038,041,150,169,180,537,610,967,ADVERSE,BACKGROUND,CONCLUSION,GLEASON,INC,LABEL,METHODS,PSA,RESULTS,WILEY
017,121,169,AMONG,AUTHORS,BACKGROUND,CAUCASIAN,CHINESE,ERG,ETS,IHC,INC,INCIDENCE,INDIA,ISH,LABEL,METHODS,MOLECULAR,NORTH,PCA,RAF,RESULTS,WILEY
169,AUTHORS,INC,IRE,JOULE,NUMERICAL,WHERE,WHILE,WILEY
169,945,946,CSC,CXCR4,HOWEVER,TAKEN,TNC
169,BACKGROUND,ELL,FOXA1,GFP,HOWEVER,INC,LABEL,LNCAP,METHODS,PCR,RESULTS,THESE,USING,WILEY
169,969,975,AMACR,AUTHORS,BACKGROUND,CAP,CELLS,COMPARISON,CYTOCLEAR,DRE,ERG,ICC,INC,LABEL,LNCAP,METHODS,PANEL,PHI,PSA,RESULTS,TMPRSS2,URINE,WILEY
169,888,ABT,MAR,PC3,PCA
APC,CURRENTLY,ERG,FGFR3,GSTP1,PCA,PTGS2,RARB2,SFRP2,TMPRSS2,VHL
369,660,674,BPH,GLEASON,MMP
189
102,NADIR,PSA,RPE
MRI,MRS,THESE
945,HSP90,IMAGING,LABEL,METHODS,OBJECTIVE,RESULTS
000,100,300,BESIDES,PSA,SEVERAL
160,ARGENTINA,COLUMBIAN,CUEVA,DIFFERENT,JUJUY,NORTHWEST,SOUTH
169,875,AMONG,ANGELES,BETWEEN,CALIFORNIA,CONCLUSION,COPYRIGHT,IMPROVING,INC,JANUARY,LABEL,LOS,MARCH,METHODS,OBJECTIVE,OVERALL,PATIENT,RESULTS,UNIVERSITY,URINARY
169,AFTER,DESPITE,DISCUSSION,LABEL,METHODS,MEXICAN,NUTRITION,OBJECTIVE,PAP,POPULAR,RESULTS
BACKGROUND,CONCLUSION,LABEL,METHODS,SUPRAPUBIC
956,LNCAP,PLASMODIUM
169,COPYRIGHT,ECTOPIC,ERK,SOCIETY,SRC
ARCAP,AUGMENTED,CXCL1,CXCL2,CXCR2,INCREASED,PC3
001,147,169,295,772,AFFAIRS,BACKGROUND,CLINICALLY,COMPOSITE,INDEX,LABEL,MEDICAL,MET,METHODS,OBJECTIVE,OUTCOME,OVERALL,RESULTS,SOCIETY,THERE
001,034,169,250,301,711,ADDITIONAL,CONCLUSION,COU,CTC,EXAMINING,III,LABEL,LDH,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SOCIETY
BASED,XIX
PRESENTED
114,177,6TH,ART,PSA,START,TOTAL
110,122,ACCORDING,CURRENTLY,DEPARTMENT,DUE,FIRST,FOCAL,MARCH,MSMSU,PCA,SINCE,UROLOGY
2ND,6TH,AWARENESS
001,003,008,010,013,169,239,254,486,ADDED,ADT,AMICO,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PHOENIX,RESULTS
CTV,DAILY,DISCUSSION,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTEEN,TCP
100,109,169,430,920,AFTER,C5B,COPYRIGHT,INC,MVS,PC3,PKC,RHO,USING
016,017,058,074,091,169,471,945,COPYRIGHT,DHT,DIETARY,ENZYMES,HSD17B2,IGF,LNCAP,LOW,LTD,PCA,PSA,STEROID,THERE,WESTERN
PCSCS,THEREFORE
002,003,005,013,014,055,177,206,321,674,CONCLUSION,GLEASON,GSS,LABEL,METHODS,OBJECTIVE,RESULTS,THOSE
169,949,COPYRIGHT,IRELAND,LNCAP,LTD,NOTCH,PC3,PCA,PLC
169,COPYRIGHT,CTV,GTV,IRELAND,LABEL,LTD,MATERIALS,METHODS,MULTIFOCAL,OBJECTIVE,PURPOSE,RESULTS,SATELLITES,THERE,VOLUMES
005,007,100,169,355,COPYRIGHT,GLEASON,INCIDENTAL,IRELAND,LABEL,LTD,METHODS,MRI,NPV,OBJECTIVE,OBJECTIVES,PPV,PSA,RESULTS,ROUTINE,SEPTEMBER
169,400,COPYRIGHT,ERG,GLEASON,HDAC1,HDACS,HISTONE,INC,PSA,RESULTS,TMPRSS2
001,130,140,165,166,169,313,529,852,977,AMERICANS,ASIAN,BACKGROUND,BECAUSE,CHINESE,CSM,DESPITE,END,HAWAIIANS,KOREANS,LABEL,METHODS,PACIFIC,PAKISTANI,PRESS,PROGRAM,PUBLISHED,RESULTS,SOUTH,THESE,UNIVERSITY,VIETNAMESE
169,205,946,956,ABROGATION,ANTICANCER,COPYRIGHT,DIM,GRP78,IRELAND,LTD,MIAPACA,MMP,NGD16
10877,10878,169,ADT,BACKGROUND,CAPSURE,CONCLUSION,COPYRIGHT,ENDEAVOUR,GLEASON,LABEL,LTD,METHODS,PSA,RESULTS,STRATEGIC
CONCLUSION,LABEL,MRI,OBJECTIVE
072,074,079,084,085,091,099,103,108,111,119,AUC,CONCLUSION,DCE,DWI,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,ROC,SEPTEMBER
293,954,ASSESSMENT,BMJ,GROUP,JANUARY,LABEL,LIMITED,METHODS,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS
339,APM,COX,DATABASES,JANUARY,NETWORK,PROGRAM,USING
100,155,169,177,393,AHX,CONCLUSION,GLEASON,GLU,IMAGING,INC,LABEL,LYS,MBQ,METHODS,MOLECULAR,NUCLEAR,PET,PSA,RESULTS,SOCIETY,UNLABELLED,WHEREAS
000,830,BACKGROUND,BRITISH,CONCLUSION,INCIDENCE,KINGDOM,LABEL,METHODS,PSA,RESULTS,SUCCESSFUL,THERE
001,169,COPYRIGHT,DAILY,EDUCATION,FLASH,GROUP,HOT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RELATED,RESULTS,SCALE,SEVERAL,THREE,UROLOGICAL
001,002,045,BESIDES,BMI,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROBOT,SEPTEMBER,THERE,THESE
AMONG,BLOOD,DIETARY,PCA,PUFAS
169,956,BIOLOGY,INC,MOLECULAR,NMR,SOCIETY
169,956,BACKGROUND,BCL,CONCLUSION,DU145,HOWEVER,INC,KIT,LABEL,METHODS,MTS,PC3,PCR,RESULTS,WILEY
169,COPYRIGHT,GREAT,HOWEVER,LTD,WHILE
001,160,169,177,232,CONVERSELY,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,140,184,304,AIM,CHOLINE,LABEL,LESIONS,METHODS,OBJECTIVE,PET,PSA,RESULTS
169,BACKGROUND,CONCLUSION,ELISA,INC,LABEL,METHODS,PROSTATIC,RESULTS,THESE,WESTERN,WILEY
169,231,COPYRIGHT,IRELAND,LNCAP,LTD,MDA,PC3,PRDX4,THESE,USING
1ST,APRIL,ASIAN,CAUCASIAN,CIS,CRUDE,HCC,LABEL,MEANWHILE,METHODS,OBJECTIVE,ORS,PURPOSE,PVUII,RESULTS,T594T
947,ARETAIEION,CONCLUSION,DEVIATION,INTENSITY,JANUARY,LABEL,LINAC,MAY,MEDICAL,METHODS,MODULATED,OBJECTIVE,PRE,PURPOSE,RADIATION,RESULTS,SIEMENS,THERAPY,TREATMENT,UNIVERSITY
005,006,010,150,CONCLUSION,COX,DFS,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,WESTERN
001,002,004,169,AUC,BRIER,CAL,CONCLUSION,CONTINUOUS,COPYRIGHT,FP1,FP2,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RCS,RESULTS,SETTING
945,946,AMD,AMONG,CXCR4,MMP,MSC,STROMAL,WESTERN
001,BPH,PCA,PCR,QRT,SOX,SOX11
169,AMERICA,BECAUSE,NORTH,RESULTS,SOCIETY,TEAMS
169,COPYRIGHT,INC,LABEL,LHRHA,MATERIALS,METHODS,OBJECTIVE,OPTIMIZING,PCA,PSA,PURPOSE,RADIATION,RESULTS,SIXTEEN,THERE
169,231,8PN,946,ANOTHER,CHINESE,COPYRIGHT,DU145,HUVEC,IXN,JAK,MCF,MDA,PSA,SOPHORA,SW620,TGF
100,123,169,183,995,BACKGROUND,CONCLUSION,COPYRIGHT,FAILURE,HDR,IRELAND,LABEL,LTD,MEIER,METHODS,NADIR,OBJECTIVE,PSA,PURPOSE,RESULTS,ROC
001,10878,132,159,169,506,AIM,BACKGROUND,CONCLUSION,COPYRIGHT,EAU,END,GERMANY,IRELAND,LABEL,LTD,MATERIALS,METHODS,NAT,RESULTS,THEREOF,THROUGH,USA
169,ERG,ETS,GLEASON,LNCAP,PRP
000,169,CRE,DACH1,ENDOGENOUS,IL6,IL8,USING
DECREASES,PCR,SIMILARLY,TFO,THREE
PSA,ROS
000,100,120,151,160,180,350,359,368,407,CONCLUSION,LABEL,METHODS,OBJECTIVE,QALYS,RESULTS,ROBOTIC,WHILE,WTP
025,045,186,242,776,BASED,HUMANEXOME,ILLUMINAM,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,RESULTS,THESE
FURTHER,MAJOR,MEN,MRI,THERE
11C,CHOLINE,INSURANCE,MARCH,PET
MRI,MRS,PET
006,015,027,169,215,247,251,657,AFTER,BACKGROUND,BONFERRONI,COLORECTAL,LABEL,METHODS,NUTRITION,OBJECTIVE,OBJECTIVES,OVARIAN,PEARSON,RESULTS,SCREENING,SERUM,SOCIETY,TRIAL,USUAL
001,195,954,BMJ,END,FURTHER,GLEASON,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PUBLISHING,RESULTS,UNIVARIATE
ONGOING,WHILE
223,CONVERSELY,CTC,DAILY,FOLLOWING,GIVEN,HOWEVER,PSA
945,GRP78,PKRGFQD,SNTRVAP,THESE
006,160,169,177,511,AUTHORS,BMI,FOLLOWING,INC,IQR,MEN,PROTECT,PUBLISHED,SIMILARLY,TESTING,TREATMENT,WILEY
000,036,058,100,154,289,295,347,433,531,533,543,587,600,624,741,CRS,ESTIMATES,HODGKIN,ITALIAN,ITALY,LABEL,MATERIALS,MEN,METHODS,MORTALITY,OBJECTIVE,OBJECTIVES,PREVALENCE,REGISTRIES,RESULTS,VALIDATED
833,947,954,CHINA,EVALUATION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOLID
001,169,ADIPOSITY,ADULT,BACKGROUND,HRT,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,SEPTEMBER,UNIVERSITY,WHILE
126,AFTER,MARCH,MAY,PATHOLOGY,PSA
100,ADVERSE,ALP,CONCLUSION,DOC,FORTY,LABEL,METHODS,OBJECTIVE,OCTOBER,PSA,PURPOSE,RESULTS,SEPTEMBER
102,412,IDC,LABEL,MAPPING,MATERIALS,METHODS,OBJECTIVE,RESULTS,THERE
345,946,950,BACKGROUND,EMT,ENDOGENOUS,INCREASED,LABEL,METHODS,PAR,PAR6SER,RESULTS,RWPE1,TGF
CONCLUSION,FPS,HOWEVER,LABEL,MEDLINE,METHODS,NOMOGRAMS,OBJECTIVE,RESULTS,SELECTION,SOURCES,SYNTHESIS
COMMITTEE,CONCLUSION,DISEASE,FPS,GROUP,LABEL,METHODS,NETWORK,OBJECTIVE,ONTARIO,PRIMARY,PROVINCIAL,THESE,UNASSIGNED
APRIL,GIVEN,JANUARY,USA
169,171,AFRICAN,BACKGROUND,COX,HOWEVER,INITIATIVE,LABEL,METHODS,RESULTS,SOCIETY,THERE,THESE,WOMEN
00026,001,006,011,014,039,146,169,375,ANTIGEN,BPH,COX,DSS,ELISA,GLEASON,PCA,PCR
169,BACKGROUND,CASTRATION,ELISA,INC,LABEL,LNCAP,METHODS,RESULTS,RESURGENT,TUNEL,WILEY
169,275,406,642,BACKGROUND,GLEASON,HOWEVER,INC,LABEL,METHODS,PSA,RESULTS,THEREFORE,UNIVERSITY,WILEY
208,234,242,255,308,484,526,602,APRIL,EBL,GLEASON,HOWEVER,LABEL,LRP,MAY,METHODS,MINIMALLY,OBJECTIVE,OPERATION,ORP,PSA,RAL,RALRP,RESULTS,RPS,SHORTER,WHILE
169,ADP,BAX,BCL,COPYRIGHT,GBA,HOWEVER,LEWIS,LTD,MCL,MYELOID,NSCLC,OVERALL,TUNEL,WESTERN,WILEY
BEGINNING,PRE
179,195,208,244,507,BACKGROUND,CONCLUSION,GENERAL,LABEL,METHODS,PROFILE,RESULTS,SOCIETY
602,MIA,MMP,PAPILLARY,PTC,SIMILARLY,SV1,THYROID
169,946,AKT,ARRESTIN2,FOXO1,IGF,INC,WILEY
169,945,946,CONCLUSION,COPYRIGHT,CSC,DCC,DLQ,FITTING,GBM,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SLQ,SMALLER
001,169,CBCTS,CONCLUSION,COPYRIGHT,CTS,CTV,HOWEVER,INC,LABEL,MATERIALS,METHODS,NODAL,OBJECTIVE,PURPOSE,RESULTS,SIXTY,THESE
001,169,CONCLUSION,COPYRIGHT,COX,HOWEVER,INC,ITALIAN,LABEL,METHODS,OBJECTIVE,OUTCOME,PURPOSE,RADIATION,RATES,REGIONE,RESULTS,ROMAGNA
108,109,169,COPYRIGHT,DRE,INC,LABEL,LDR,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PHOENIX,RESULTS
001,002,009,169,215,260,COPYRIGHT,CRT,GROUP,HOWEVER,IDENTICAL,IMAGE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERAPY,THEREFORE,UNIVARIATE
169,177,ACUTE,ADVERSE,COPYRIGHT,GRADE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TOLERANCE
001,711,967,APRIL,EFFORTS,IMPORTANCE,LABEL,METHODS,OBJECTIVE,PEARSON,RELEVANCE,RESULTS,SETTING,SIMILAR
100,108,112,120,148,169,327,458,AIM,AMICO,ANTICANCER,CONCLUSION,COPYRIGHT,GLEASON,HDR,HOWEVER,INSTITUTE,LABEL,METHODS,OBJECTIVE,PSA,RECURRENCE,REGARDING,RESULTS,T1C,T2A,T2B,T2C,T3A,T3B,T3BN0M0,UNIVERSITY
100,169,200,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PIGMENT,PSA,RESULTS
169,AFRICAN,AIM,ANTICANCER,ASIAN,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,HAPLOTYPE,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SEVERAL,THESE,VDR
145,169,2YL,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,CWR,INSTITUTE,LABEL,LNCAP,MATERIALS,METHODS,MTT,OBJECTIVE,PC3,RESULTS,ROOTS,THESE
169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,MATERIALS,MCF,MEK,METHODS,MTT,OBJECTIVE,PCK3145,RESULTS,USING
001,CONCLUSION,DIFFUSION,KEP,KEY,LABEL,LDA,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS,ROC,TUMOURS
000,150,800,900,CORRECTED,COSTS,GAMMA,HODGKIN,LABEL,METHODS,OBJECTIVE,PER,RESULTS,ZEALAND
CURRENTLY,SIMILAR
145,169,COPYRIGHT,CPG,DNMTS,IRELAND,LTD,PC3,RESPONSES,UTR
021,103,151,209,236,339,564,599,938,AMONG,BIOMEDICAL,CONCLUSION,INNOVATION,INSTITUTE,JANUARY,LABEL,METHODS,NSCLC,OBJECTIVE,RESULTS,SMOKING,THYROID,UPPER
169,COPYRIGHT,DU145,IRELAND,LTD,PC3,THESE,TREFOIL
101,102,105,107,116,124,177,CONCLUSION,CRT,CTV,CYBERKNIFE,D95,D98,DIFFERENT,DOSES,DVH,FIELD,IMPORTANT,ITALIAN,LABEL,MATERIALS,MEDICAL,METHODS,OAR,OBJECTIVE,PHYSICS,PLANS,PTV,PURPOSE,REPLANNING,RESULTS,SIMILAR
163,169,281,COPYRIGHT,CURRENT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,SUSPICIOUS,UROLOGICAL
169,946,COPYRIGHT,DU145,EFFECTS,EMT,IPA,MOLECULAR,P21,P38,PC3,SELECTIVE,SNAIL,TGF,TRAF6
169,945,ACCORDING,COPYRIGHT,IGFBP,INC,RESULTS,SERUM,VARIATIONS
001,005,008,044,169,290,332,945,CONCLUSION,CONTINENCE,COPYRIGHT,H2O,HOWEVER,INC,LABEL,MAXIMAL,METHODS,OBJECTIVE,RESULTS,SHORT,SOCIETY
119,169,COPYRIGHT,GROUP,IRELAND,LTD,MRI,PHYSICISTS
169,227,781,ALZHEIMER,AMERICA,AMERICANS,BACKGROUND,CENTERS,CMS,DESPITE,FILES,LABEL,METHODS,PRESS,PUBLISHED,QUALITY,RESULTS,SEVEN,SOCIETY,SUMMARY,UNIVERSITY
166,169,204,CADMIUM,CDCL2,COPYRIGHT,ECC,HEPG2,HOWEVER,INSTEAD,IRELAND,LTD,MAPKS,MCF,MEK,RAF,SER,TYR
109,114,129,169,183,221,303,381,521,525,526,533,BACKGROUND,CELGENE,CLINICIANS,COPYRIGHT,EASTERN,FUNDING,FURTHER,GRADE,GROUP,IQR,JAN,LABEL,LTD,METHODS,NOV,OVERALL,RESULTS
FURTHER,HEAVY
000,CHIBA,CURRENTLY,DAV,HEAVY,HIMAC,HOWEVER,HSP90,INSTITUTE,PROJECT
215,233,ADC,BCG,CONCLUSION,DWI,GADOLINIUM,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
169,CASTRATION,COPYRIGHT,FURTHER,HOWEVER,IMPORTANCE,LABEL,MPE,OBJECTIVE,PRIMARY,SOCIETY,STAT1,THERE,THESE,UNLABELLED,VSV
169,947,950,AM1,CAR,CD3,COPYRIGHT,DAP12,FURTHER,HLA,IFN,INC,KIR,NOTABLY,YTS,ZAP
169,348,446,794,AFRICAN,AMERICANS,BACKGROUND,CAP,CAUCASIAN,DECISIONAL,INCREASED,LABEL,METHODS,POTENTIAL,RESULTS,SOCIETY,TREATMENT,YOUNGER
JOINT,MONOLIX,PSA,STOCHASTIC
ADC,CONCLUSION,DAILY,DIFFUSION,DWI,EPI,GERMANY,HEALTHCARE,HOWEVER,IMPORTANT,KNOWLEDGE,LABEL,LIVERPOOL,METHODS,OBJECTIVE,OVERALL,PHANTOM,RESOLVE,RESULTS,SIEMENS,THERAPY,THREE
169,BACKGROUND,BECAUSE,BLADDER,HIV,LABEL,METHODS,ORS,RESULTS,SOCIETY
185,NAF,PET
CIP2A,INHIBITOR,SGOL1,Y2H,YEAST
169,AFTER,APRIL,BACKGROUND,CONCLUSION,COPYRIGHT,DESPITE,EXTRACTION,FEW,HODGKIN,LABEL,LTD,MEDLINE,METHODS,NOMOGRAMS,OBJECTIVE,PURPOSE,RESULTS,SELECTION,SIX,SOURCES,STUDIES,SYNTHESIS,THREE
169,ABT,CSF1R,GROWING,INHIBITORS,TAM
113,169,313,BRUEL,KINGDOM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,RESULTS,SETTING,THERE,VAN,WOMEN
ADDITIONAL,BIOMARKERS,DISEASE,EARLY,PSA,TREATMENT
FDA,HOWEVER
ADT,BCR,BECAUSE,DEPENDING,INITIAL,LOCALIZED,MEN,THESE
003,007,020,034,037,057,065,136,139,166,191,199,213,216,219,297,298,302,323,505,508,521,554,583,594,630,788,821,890,942,987,AFRICAN,BACKGROUND,CAS,CIS,INPATIENT,LABEL,METHODS,NATIONWIDE,ORS,PROST,RADICAL,RESULTS,SMALL,UNI
145,AKT,ALTOGETHER,BAX,BCL,HUVEC,LOTUS,LUP,LUPINUS
HOWEVER,JAPAN,PCA,PSA
001,650,698,CONCLUSION,KNOWLEDGE,LABEL,METHODS,MLC,OBJECTIVE,RESULTS
BACKGROUND,ENGLAND,FURTHER,LABEL,METHODS,RESULTS,SERVICE,STAGE
BACKGROUND,GLEASON,HOWEVER,LABEL,METHODS,MMP,OBJECTIVE,PSA,RESULTS,SERUM
160,169,CONCLUSION,COPYRIGHT,CSAG2,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PAGE4,RESULTS,USING
169,CONCLUSION,COPYRIGHT,EIGHT,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,TEN,THREE
169,465,594,595,870,AMONG,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,ONTARIO,PROPENSITY,RESULTS,THESE
169,317,353,945,CONCLUSION,COPYRIGHT,DHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PREVENTION,RESULTS,SIMILAR,THERE,TRIAL
169,COPYRIGHT,CRITICS,INC,PSA,RANDOMIZED,SCREENING,SIMILARLY,ULTIMATELY
169,187,362,656,747,785,959,ADT,CONCLUSION,COX,CVD,LABEL,MEN,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SOCIETY,SWEDISH
015,169,CAD,CONCLUSION,COX,CSS,LABEL,LOW,MAXIMUM,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,THERE,THREE
002,169,264,496,518,945,BACKGROUND,CIS,CYP24A1,CYP27A1,CYP27B1,GENOTYPING,LABEL,METHODS,ORS,PCA,RESULTS,SNP,SOCIETY,THERE
003,100,103,1245A,1245C,169,946,ADT,BACKGROUND,CONCLUSION,DESPITE,DHT,FURTHER,GLEASON,INC,LABEL,METHODS,PSA,RESULTS,WILEY
003,024,032,125,130,293,HOWEVER,NSCLC,PCR
1269A,169,BACKGROUND,CONCLUSION,FUNCTIONAL,INC,LABEL,LNCAP,METHODS,PCR,RESULTS,SEVERAL,WESTERN,WILEY
ERG,MUTATIONS,SUBSETS
AAA,AIM,CONCLUSION,LABEL,METHODS,MUC18,OBJECTIVE,PCR,RESULTS,TEA,USING,WESTERN
474,AMONG,ENDOCRINE,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SOCIETY
145,169,22RV1,AMONG,BACKGROUND,CONCLUSION,ELISA,EMT,ERK,HOWEVER,INC,KNOCKDOWN,LABEL,LIPOCALIN,LNCAP,METASTASIS,METHODS,PC3,PCA,RESULTS,THEREFORE,U0126,WILEY
125B2,169,AFTER,APEX1,BACKGROUND,CONCLUSION,H3K4ME2,INC,KDM1A,LABEL,METHODS,OXIDATION,RESULTS,TMPRSS2,WILEY
169,196,ASIAN,BACKGROUND,GLEASON,INC,JAPAN,LABEL,MEDICAL,METHODS,PCS,RESULTS,UNIVERSITY,WILEY
169,22RV1,907,916,AKT,BACKGROUND,CONCLUSION,DU145,EXPRESSION,INC,LABEL,METHODS,PCR,RESULTS,SNAIL,WESTERN,WILEY
169,239,ADT,BACKGROUND,CIS,COX,ERG,GLEASON,HARBORING,HRS,INC,LABEL,METHODS,PHYSICIANS,RESULTS,ROUGHLY,THERE,TMPRSS2,WILEY
121,169,BCI,CRC,H3K4ME2,INC,SMYD3,THESE,WILEY
169,22RV1,946,BACKGROUND,E74,EMT,HOWEVER,INC,LABEL,LNCAP,METHODS,RESULTS,SMAD3,TGF,THESE,WILEY
169,185,574,667,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,LABEL,LTD,MEN,METHODS,PCA,PSA,RESULTS,STOCKHOLM,THERE
945,BPA,HOXC6,MLL,PUBLISHED,SPRAGUE
002,006,009,035,169,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
169,945,COPYRIGHT,EPHB4,GFP,INC,NLS,THESE
169,178,179,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,CRUCIALLY,EPHB4,INC,KLK,LABEL,METHODS,MOUSE,PSA,PUBLISHED,RESULTS,SDS,THESE,WESTERN
111,169,194,COPYRIGHT,ERG,GLEASON,INC,INTER,NBX,PCA,YET
001,003,028,063,169,200,252,452,CAUCASIANS,CHINESE,COX,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,POTENTIAL,PRESS,PUBLISHED,RESULTS,THERE,UNIVERSITY
EGF,EPIDERMAL,KNOWLEDGE,PUBLISHED,SEPW1
139,169,603,675,CAUCASIAN,CAUCASIANS,COX,FINALLY,GENOMIC,INFECTION,PCR,SINCE,SPAIN,SPANISH
AFTER,RADIATION,THREE
068,169,171,683,BACKGROUND,BASEL,DOCETAXEL,HOWEVER,LABEL,METHODS,RESULTS,THERE
169,CROSS,FEDERATION,GYNECOLOGY,NEOVAGINAS,OBSTETRICS,PATHOLOGY,SEX,SHORTENING,SOCIETIES
169,945,ATP,BIOLOGY,CH3,COA,GRP78,INC,MOLECULAR,SOCIETY
BACKGROUND,CELLSEARCH,CTC,LABEL,METHODS,OWING,PRIOR,RESULTS
001,191,954,ABORIGINAL,AFTER,CONCLUSION,CROSS,LABEL,MEASURE,METHODS,NSW,OBJECTIVE,OUTCOME,OVERALL,RESULTS,RRR,SETTING,SOUTH,WALES
19Q13,674,AFRICAN,AFTER,CASES,GLEASON,GROUP,NCI,PSA,SIMILAR,SNP,SPORE,WORKING
ACCORDING,AMONG,GLEASON,HOWEVER,PSA
002,011,013,054,106,177,636,ADC,CONCLUSION,DCE,DWI,MATERIALS,METHODS,MRI,OBJECTIVE,OTHER,RESULTS,THREE
001,003,012,042,215,800,ADC,ANOVA,AUC,CONCLUSION,DECREASING,GLEASON,LESIONS,METHODS,MRI,OBJECTIVE,RESULTS,ROC
169,INSTITUTE,JOURNAL,PRESS,PREVENTION,PUBLISHED,THESE,TRIAL,UNIVERSITY,VITAMIN
169,946,947,BRITAIN,CAP,COPYRIGHT,EMT,GREAT,IRELAND,LINEAGE,LTD,PREVIOUSLY,PUBLISHED,SOCIETY,WILEY
146,169,954,FOXP3,IRAK1,NOTABLY,TARGETING,TRAF6
169,ACIDS,E2F,ETS,EWING,EWS,NUCLEIC,PRESS,PUBLISHED,UNIVERSITY,USING
169,COPYRIGHT,INC
001,035,100,160,169,177,COPYRIGHT,EDUCATION,GLEASON,HAUSDORFF,IMAGING,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TESLA,THREE,UROLOGICAL
069,107,169,827,COMPETING,CONFORMAL,COPYRIGHT,COX,EDUCATION,INC,INTENSITY,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,PROPENSITY,PUBLISHED,PURPOSE,RADICAL,RESULTS,SHR,UROLOGICAL
169,COPYRIGHT,DESPITE,FINALLY,INC
160,169,CONCLUSION,COPYRIGHT,INC,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,THERE
001,002,004,005,009,051,122,CELLSEARCH,COMPARING,CTC,LABEL,METHODS,OBJECTIVE,PURPOSE,RADIOLOGIC,RESULTS
ADT,BASED,ONGOING
AKT,AMONG,BACKGROUND,CMS,LABEL,MOLECULAR,RESULTS,STN,TFS,THESE
MRI
PSA,SERUM,THERE
001,139,385,AMONG,BMI,CIS,CONCLUSION,DRE,LABEL,METHODS,OBJECTIVE,ORS,PSA,RESULTS
017,131,177,230,252,270,723,BPH,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PCR,PIN,RESULTS,USING
001,002,169,407,413,COMPARE,CONCLUSION,COPYRIGHT,COSTS,INC,IRELAND,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SETTING
001,005,115,169,180,340,AGE,AMONG,BACKGROUND,CHINA,CHINESE,CIS,GLEASON,INC,LABEL,METHODS,OVERALL,PCA,PSA,RESULTS,UCA,WILEY
169,A2A,A2B,ADENOSINE,BACKGROUND,CONCLUSION,INC,LABEL,LNCAP,METHODS,PCR,RESULTS,TAQ,THESE,TOTAL,WESTERN,WILEY
009,169,177,178,183,750,AFTER,BACKGROUND,BETWEEN,COPYRIGHT,DEC,FUNDING,GRADE,IQR,LABEL,LTD,METHODS,NETWORK,NOV,RESULTS,SPAIN,SPANISH,T1C,T3B
169,BACKGROUND,BASED,CARLO,CONCLUSION,COPYRIGHT,D10,D90,FMC,GROUP,IRELAND,LABEL,LTD,MATERIALS,MCW,METHODS,MONTE,OBJECTIVE,PHYSICISTS,PURPOSE,RESULTS,TG186
100,18F,AFTER,PET,PSA
000,100,180,195,217,239,AMONG,CONTINENTS,INCIDENCE,OVERALL,RESULTS,THERE,THYROID,USING
152,BACKGROUND,FINALLY,LABEL,MEASURING,METHODS,OBJECTIVE,PTG,REGARDING,RESULTS,SPIRITUAL,SUBJECTIVE,THESE,YOUNGER
160,169,ADV,COPYRIGHT,EPITOPE,INC
111,169,ABOUT,APA,CONCLUSION,CONSTRAST,COPYRIGHT,IEA,III,IPA,IRELAND,IVA,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,THERE
11152,169,COPYRIGHT,ERG,ETS,GLEASON,INC,SEC14L1,TMPRSS2,TMPSSR2
137,169,183,292,324,358,400,611,770,779,781,784,AFTER,AMERICA,BACKGROUND,COMPANY,COPYRIGHT,CYP,FUNDING,HOWEVER,INC,IQR,JAN,LABEL,LIMITED,LTD,METHODS,MILLENNIUM,NORTH,OCT,ORTERONEL,RESULTS,SERIOUS
169,COPYRIGHT,INC,TOOLS
956,BIOLOGICAL,CELLS,DMF,ELISA,LNCAP,PC3,THEIR,THREE
HGF,MET,SAR
166,169,210,COPYRIGHT,EDUCATION,ERSPC,INC,INITIAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROTTERDAM,RRS,TREATMENT,UROLOGICAL
100,10878,665,AMONG,BACKGROUND,FOLLOWING,GLEASON,LABEL,METHODS,RESULTS,T3A
ADT,AMONG,CLAVIEN,CONCLUSION,DINDO,LABEL,LND,MEIER,METHODS,NEWLY,PALLIATIVE,PSA,RESULTS,SEVENTEEN,THREE
362,BACKGROUND,DESPITE,GLEASON,HOPKINS,LABEL,MATERIALS,METHODS,MRI,PATIENT,PSA,RADICAL,RESULTS,T1C,UPGRADING,UPSTAGING,VLR
555,AFTER,AMONG,BACKGROUND,INVERSE,LABEL,MATERIALS,METHODS,OVERALL,PRUDENT,RESULTS
ADT,ANOTHER,BACKGROUND,CTCV3,IRB,LABEL,MATERIALS,METHODS,RESULTS,SURGERY,TREATMENT
100,AVERAGE,BACKGROUND,COMPOSITE,ENGLISH,INDEX,LABEL,MATERIALS,METHODS,RESULTS,SCREENING,SURGERY
169,ASCT2,AUTHORS,BRITAIN,E2F,GLUTAMINE,GREAT,IRELAND,JOURNAL,LNCAP,LTD,PATHOLOGY,SOCIETY,TCA,USING,WILEY
FUNCTIONAL,INCREASING,KEY,LABEL,MRI,OTHER,PET,PSA,UNLABELLED
018,023,103,185,18F,945,946,ANOTHER,CURRENTLY,FDG,FES,KETTERING,LOUIS,MBQ,PET,SEATTLE,SLOAN,SUV,UNIVERSITY,USING,WASHINGTON
ADT,EVENTUALLY,FURTHER,GPCRS,KETTERING,MEIER,PCA,SLOAN
GLEASON,PSA,SINCE,TNM
000,006,100,140,153,272,368,604,652,695,759,775,777,BACKGROUND,CZECH,LABEL,METHODS,REGARDING,RESULTS
INITIAL
001,003,129,239,BACKGROUND,COHEN,CONCLUSION,FURTHER,GLEASON,LABEL,METHODS,MRI,RESULTS,START,STD,TAR,THESE
001,169,199,465,589,602,603,956,ADT,CONCLUSION,COUNCIL,GLEASON,GROUP,INTERGROUP,LABEL,MEDICAL,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,SOCIETY,T94
003,005,007,008,015,043,052,141,192,209,225,228,BONFERRONI,DR4,GLEASON,NORTH,PCA,SIMILARLY,VARIANT
169,239,307,377,522,AFRICAN,AMONG,BACKGROUND,CIS,CLINICIANS,DISTANT,END,INCREASING,LABEL,METHODS,ORS,RESULTS,SOCIETY,SUICIDE,THERE
FINALLY
014,ENGLISH,FOCAL,HOWEVER,MEN
000,100,169,BACKGROUND,BAYES,COMPONENT,DENMARK,EMPIRICAL,ENGLAND,LABEL,METHODS,POINT,PRESS,PUBLISHED,RATIO,RESULTS,SYSTEMATIC,UNIVERSITY,VARIATION
947,AKT,ILK,PREVIOUSLY,VE5
028,035,101,163,169,215,898,AGE,AIM,BACKGROUND,CONCLUSION,COX,JANUARY,LABEL,LOG,METHODS,NSS,OBJECTIVE,OCTOBER,OUTCOME,REGRESSION,RESULTS,SCORE,SOCIETY,SUBJECTIVE
002,595,870,984,BACKGROUND,LABEL,MEN,METHODS,ONTARIO,RESULTS
GIOVANI,GROUP,HIGHLIGHTS,MEMBERS,WORKING,YOUNG
169,CONTROL,DCCPS,DCP,INSTITUTE,NCI,POPULATION,PRESS,PREVENTION,PUBLISHED,THREE,UNIVERSITY,VALIDATION
160,AREAS,BACKGROUND,COVERED,LABEL,MDV3100,METHODS,OPINION,PHASE,PREVAIL
160,169,289,923,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OPTIMAL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
780,BACKGROUND,LABEL,LNCAP,METHODS,OATP1B3,RESULTS,THERE
GIM
145,945,956,MECHANISM,NMR,TEXAS,THESE
BACKGROUND,CLEAR,FEW,LABEL,LITERATURE,METHODS,OBJECTIVE,RESULTS,THERE,UNASSIGNED,UROLOGISTS,VARIOUS
108,BILATERAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTY,VARIABLES
006,186,242,341,BASED,BCR,COX,EXOME,HUMANEXOME,INC,LABEL,LNI,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,THESE
SEVERAL,UROLOGISTS
HOWEVER
ENDOSCOPIC,PANCREATIC,VARIOUS
169,307,386,538,552,575,887,968,985,CALCULATOR,CONCLUSION,COPYRIGHT,INC,LABEL,LRS,METHODS,OBJECTIVE,OBJECTIVES,PREVENTION,RESULTS,SETTING,SNP,TRIAL
001,008,047,3DCRT,796,ACUTE,CONCLUSION,CURRENT,INTESTINAL,LABEL,MATERIALS,METHODS,NRI,OBJECTIVE,OVERALL,PURPOSE,RESULTS,TOMOSIB
019,034,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE
LN2,SEPARATOR,SMALLER,THESE,VAPOR
ADT,BECAUSE,EASTERN,END,GROUP,HOWEVER,OFF,RESULTS
145,169,945,946,BACKGROUND,INC,INSULIN,LABEL,LNCAP,METHODS,RESULTS,THESE,WESTERN,WILEY
169,449,455,ARTIFICIAL,BACKGROUND,DU145,INC,LABEL,METHODS,MIR200C,PC3,PCR,RESULTS,UTR,WILEY
160,169,426,507,AES,AUTHORS,BACKGROUND,CONCLUSION,EAP,FATIGUE,INC,LABEL,METHODS,RESULTS,SEIZURE,WILEY
169,BACKGROUND,BLOOD,FINNISH,INC,LABEL,METHODS,PCA,PSA,RESULTS,USING,WILEY
000,169,AGA,BACKGROUND,COLORECTAL,COPYRIGHT,CRC,GERMANY,INC,INSTITUTE,LABEL,METHODS,OBJECTIVE,OVARIAN,PUBLISHED,RESULTS,SCREENING,SIMILAR,TRIAL
169,ARTOCARPUS,CG901,COPYRIGHT,DU145,FOSBERG,INDONESIA,LTD,PARKINSON,STAT3,THESE,WILEY
169,1970S,956,COBAS,COPYRIGHT,DDE,DDT,DESPITE,HOWEVER,INHIBITORS,IRELAND,LNCAP,LTD,PCR,PSA,R1881,THESE
BPH,PC3,PCA,PCR,SILENCING
169,COPYRIGHT,INC
160,169,223,ALPHARADIN,AUTHORS,COPYRIGHT,INC,PUBLISHED
169,16Q23,BIOLOGY,DESPITE,SOCIETY
001,169,273,581,AOR,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,SIMILARLY,T2A,UROLOGICAL
169,AUTHORS,CONSISTENT,FINALLY,KNOCKDOWN,NADPH,PCA,PUBLISHED,ROS,THESE
169,AFTER,CMI,COPYRIGHT,D95,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,SMALL,WITHOUT
169,AMP,AUTHORS,COPYRIGHT,PDE4S,PKA,PUBLISHED
10Q,10Q23,AFFYMETRIX,CNV,FAS,PCA,PSA,SNP
CONCLUSION,END,KNOWLEDGE,LABEL,LOCAL,MAJOR,MARCH,METHODS,OBJECTIVE,PFS,RESULTS,SEPTEMBER,TOXICITIES
000,102MM,176,20MCG,2GR,800,8MG,956,99M,ADDITIONAL,ANOTHER,CRP,DUE,ESR,EXTENSIVE,MDP,MRI,SCJ,T10,WBC
001,007,458,AFTER,BACKGROUD,BCR,COX,LABEL,MEIER,METHODS,RESULTS,SNP,UNLABELLED,WNT
169,340,341,343,946,BIOLOGY,CUB,ECM,GFD,III,INC,MATRIPTASE,MOLECULAR,SOCIETY,THROUGH
110,169,177,302,BAY,CONCLUSION,DOSIMETRY,EXM,IMAGING,INC,LABEL,MBQ,METHODS,MOLECULAR,NUCLEAR,PCA,PET,RESULTS,SOCIETY,TEN,THREE,UNLABELLED
169,177,204,CHOLINE,CONCLUSION,FORTY,IMAGING,INC,LABEL,MBQ,METHODS,MODEL,MOLECULAR,NUCLEAR,PET,RESULTS,SOCIETY,SUV,UNLABELLED
18F,AMONG,BESIDES,FDG,PET
169,263,465,BACKGROUND,INDEX,ISI,LABEL,METHODS,RESULTS,SOCIETY
000,160,230
EARLY,OCT,OPTICAL,SEVERAL
SINCE,THERE,TREATMENT
ADT,HOWEVER,IAD,POTENTIAL,PSA
DECADES,THESE
WHILE
CER
PCA,THEIR
METASTATIC,SERUM,WHEREAS
FURTHER,SMALL,THERE
000,100,291,355,371,729,817,USA
123,151,185,211,233,286,289,440,AIM,AVERAGE,CONCLUSION,COSTS,ICD,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,THERE
99MTC,AHX,BRAIN,GLU,LYS,MDP,PET
18F,FCH,OWING,PET
18F,FDG,OWING,PET
000,233,BACKGROUND,LABEL
369,660,674,BPH,GLEASON,MMP
BPH,CONCURRENT,GLEASON
ACTIVATION,HOWEVER,MEANWHILE,SHH,SMO,THESE
COMPONENT,FIELD,PCA,PRINCIPAL
THEREFORE,URINE
AAA,ADDITIONAL,ANALYTICAL,AXB,CTV,D95,D98,DMEAN,PTV,THERE
181,377,378,421,475,532,651,AMONG,BACKGROUND,COX,HOWEVER,LABEL,METHODS,MORTALITY,OVERALL,RESULTS,SOCIETY,THESE
169,ACTIVATION,BIOLOGY,EMT,ERK,HSP90,INC,MEK,MOLECULAR,REMARKABLY,SNAIL,SOCIETY,TWIST
169,184,185,412,617,BACKGROUND,COPYRIGHT,FUNDING,HOWEVER,HRS,LABEL,LTD,METHODS,RESULTS,SWEDISH,UNIVERSITY,VASALOPPET
160,169,COPYRIGHT,GATA2,IGF1R,INC,THESE
160,169,COPYRIGHT,GATA2,INC,VIDAL
169,177,BASED,COPYRIGHT,HOWEVER,IRELAND,LTD,PUBLISHED,QOL,RUV,SCORE,SYMPTOM,TPV,ULTRASOUND
145,ANNEXIN,BAD,BASED,BAX,BCL,FINALLY,GLUCOSE,GRP78,GRP78KD,HOWEVER,MCL,MTT,THESE
102,139,153,292,GLEASON,NON,THESE
001,006,012,017,044,MRM,PAP,THESE,THREE,URINARY,USING,WESTERN
001,006,013,169,ADT,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,COX,INSTITUTE,LABEL,MANAGEMENT,MEIER,METHODS,OUTCOME,PSA,RESULTS
169,AIM,ANTICANCER,AUC,BACKGROUND,CONCLUSION,COPYRIGHT,DCA,GLEASON,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,RESULTS,ROC,SARCOSINE,SEVERAL,SUCCESSFUL
002,169,188,CONCLUSION,COX,HOWEVER,JEFFERSON,LABEL,METHODS,OBJECTIVE,PROGNOSTIC,PURPOSE,RESULTS,SOCIETY,THESE,UNIVERSITY
169,ACS,GUIDELINES,LABEL,MEASURE,METHODS,OBJECTIVE,PANEL,PSA,PURPOSE,REFER,RESULTS,SOCIETY
231,264,954,EXTENSIVE,FINALLY,MDA,MOUSE,QUE,RANKL,RAW,THEREFORE
ADT
DESPITE,OLDER
180,AMONG,APC,BACKGROUND,CPG,FIG,GSTP1,LABEL,METHODS,MSP,OBJECTIVE,OBJECTIVES,PCA,PCR,REF,RESULTS,TAB
252,GLEASON,HISTOLOGIC,SIMILARLY,THESE
945,GLUTAMINE,METABOLIC,NCOA2,SRC,SREBP,TCA
117,118,228,334,448,AFTER,BACKGROUND,BETWEEN,LABEL,MESORECTAL,METHODS,OBJECTIVE,POPULATION,RESULTS
169,HOWEVER,PRESS,PUBLISHED,UNIVERSITY
169,BACKGROUND,CRC,HUR,KNOCKDOWN,LABEL,MEIER,METHODS,MYC,MYCLO,PRESS,PUBLISHED,RESULTS,UNIVERSITY
169,1ST,2ND,ANY,BACKGROUND,CCP,CONCLUSION,INC,LABEL,METHODS,RESULTS,WILEY
169,AUTHORS,BACKGROUND,DEX,EPR,INC,LABEL,LIPOSOMAL,METHODS,RESULTS,WILEY
00E,169,AFFYMETRIX,ARRAY,AUTHORS,BACKGROUND,CD49F,EPCAM,FETAL,FUNCTIONAL,INC,INGENUITY,LABEL,METHODS,PATHWAY,PCR,RESULTS,STROMAL,SUITE,TIC,TOTAL,VERSION,WILEY
169,22RV1,945,946,ALTERED,BACKGROUND,BISULPHITE,CHANGES,CPG,FURTHER,HOWEVER,INC,ITGA2,LABEL,LNCAP,METHODS,PC3,PCR,RESULTS,TAKEN,WILEY
000,100,128,160,169,194,482,510,767,860,923,AMONG,BACKGROUND,COPYRIGHT,FACTORS,FOUNDATION,HISPANICS,HOWEVER,INC,LABEL,METHODS,PUBLISHED,RATES,RESULTS,SETTING,SIR,THESE
A11,A24,A26,A31,A33,CTL,HLA,IGG,KRM,TAA,TOTAL
008,103,157,169,192,209,212,248,646,AMONG,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SIMILAR,UROLOGICAL
GLI,PATCHED,SEVERAL,SMO
169,183,956,CHINA,COPYRIGHT,DU145,DYSOSMA,FLACK,PC3,PUBLISHED,TUBULIN,UNIVERSITY
114,169,592,862,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
1960S,1970S,1980S,1990S,BACKGROUND,CONCLUSION,DUE,LABEL,THEMATA,UNASSIGNED
212,237,253,269,280,375,ACCORDING,BACKGROUND,CHK,CHO,CONCLUSION,FIRST,KEY,KOC,LABEL,MAY,METHODS,NOV,OCTOBER,RESULTS,THERE,TME
MRI,PERINEURAL,PET,THEIR
215,BDC,HLA,PHASE
ABOUT,HOWEVER,LNCAP,SILENCING,THESE
169,945,COPYRIGHT,EBP,LTD,MOLECULAR,WHILE
027,169,COPYRIGHT,GLEASON,HOWEVER,INC,SMALL
169,COPYRIGHT,CURRENT,INC,SIMILARLY,TNM,ULTIMATELY
0MX,120,169,183,410,820,BACKGROUND,BETWEEN,COPYRIGHT,DEC,DUTCH,EORTC,FUNDING,GRADE,HYPRO,LABEL,LTD,MARCH,METHODS,NON,PATIENT,PSA,RESULTS,SOCIETY,T1B
169,177,CHX,CLI,CONCLUSION,FINALLY,FIRST,IMAGING,INC,LABEL,LNCAP,MBQ,METHODS,MOLECULAR,NUCLEAR,RESULTS,SOCIETY,SPECT,THROUGH,UNLABELLED
169,945,946,AKT,COPYRIGHT,DIETARY,ERE,ERK,ICI,INC,JNK,PS2,SERMS,TNF,TUNEL
BACKGROUND,CONCLUSION,DOCETAXEL,GENERALLY,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TREATMENT
1990S,480,AFRICAN,AMERICANS,BESIDES,GENERALLY,INCIDENCE,VARIOUS,WESTERN
D99,LABEL,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,SPORT,STATION
HEALTHCARE,INITIAL,LABEL,MEDICAL,METHODS,NUCLEAR,OBJECTIVE,OPTIMIZED,PHILIPS,PURPOSE,RESULTS,SUN,SYSTEMS,UIMAT
169,AMONG,AUTHORS,ELISA,LTD,PTY,PUBLISHING,SCIENCE,WILEY
169,BASED,OTHER,SOCIETY
001,ADA,ALT,AST,BACKGROUND,CRP,HDL,HOWEVER,IMA,LABEL,LDL,METHODS,PSA,RESULTS
003,008,169,BACKGROUND,GAMITRINIB,GBM,LABEL,MECHANISMS,METHODS,NOVEL,PI3KI,PRESS,PUBLISHED,RESULTS,SER,SER31,SMALL,THR,UNIVERSITY
145,169,22RV1,BACKGROUND,CONCLUSION,FIRST,INC,LABEL,LNCAP,METHODS,RESULTS,SINCE,WILEY
001,028,059,068,155,467,616,812,835,894,939,HGPCA,HOWEVER,PCA
000,169,900,BACKGROUND,BETWEEN,END,LABEL,METHODS,OVERALL,PREDICTING,RESULTS,SINCE,SOCIETY
169,176,625,798,880,995,COX,MEN,RRS
LBD
169,947,B16,CD4,CD8,COPYRIGHT,CPG,IFN,INC,ISCOMATRIX,OVA,TRAMP
129,169,BNSRP,COPYRIGHT,HOWEVER,INDEX,PUBLISHED,SEVERAL,TADALAFIL,THERE,TREATMENT
169,C81,COPYRIGHT,FINALLY,HIPPO,LNCAP,SOCIETY,YAP,YES
145,160,169,AUTHORS,FURTHER,LTD,PCA,PTY,PUBLISHING,SCIENCE,SENP1,TAKEN,WILEY
001,100,169,803,AFTER,CAUCASIAN,COPYRIGHT,END,GLEASON,GREATER,INC,LABEL,METHODS,OBJECTIVE,PROGRAM,PURPOSE,RESULTS,T1C
BASED,MEN,SERVICE
169,BPH,COPYRIGHT,INC,INSIGHT,RECIPROCAL
ADDITIONAL,AFTER,BACKGROUND,CELLS,FINAL,LABEL,PATIENT,PAZOPANIB,PEC,PSA,RESULTS,T1B,THERE,THEREFORE,THREE
CONCLUSION,CTV,GLEASON,IMAGE,LABEL,MAXIMUM,METHODS,OBJECTIVE,PCA,PSA,PTV,RESULTS,SCORE
168,BACKGROUND,CONCLUSION,DIAGNOSTIC,GLEASON,LABEL,MATERIALS,METHODS,PCA,PSA,RESULTS,T1C,TESLA
100,155,1ST,2ND,3RD,4TH,GLEASON,PCA,SMALL,THESE
THESE,VITAL
ELECTRONIC,ENGLISH,HOWEVER,JANUARY,LABEL,MEDLINE,METHODS,MRI,OBJECTIVE,PBX,PURPOSE,RESULTS,SATURATION,SINCE
100,AFTER,AIM,AUC,BACKGROUND,GLAND,GRADE,HGPIN,LABEL,MATERIALS,METHODS,NEOPLASIA,PCA,PPV,PROSTATIC,RESULTS,ROC,SMALL,THESE
835,CONCLUSION,GLEASON,JANUARY,LABEL,MATERIALS,METHODS,NEOPLASIA,OBJECTIVE,PIN,PROSTATIC,PSA,RESULTS,SMALL,THERE
001,022,037,038,108,127,162,177,591,756,846,APPARENTLY,BACKGROUND,CAP,DRE,LABEL,METHODS,PSA,RESULTS
100,BACKGROUND,BPH,CONCLUSION,FIRST,FOLEY,LABEL,METHODS,ROBOTIC
169,183,215,300,956,ACP,ALZHEIMER,BESIDES,CL2,COPYRIGHT,H2O,IRELAND,LTD,MET,MIC,NO3,SEVERAL
001,003,008,169,242,246,488,ASIAN,AUTHORS,BETWEEN,CENTERS,COPYRIGHT,GENERAL,GERIATRICS,HAWAI,JOURNAL,PACIFIC,PREVENTION,SOCIETY,TREATMENT
169,435,CAPSURE,COPYRIGHT,COX,EDUCATION,FACTORS,FURTHER,IMAGING,INC,LABEL,MANAGEMENT,MATERIALS,MEN,METHODS,OBJECTIVE,POISSON,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
124,BACKGROUND,BELLINI,HOTEL,LABEL,LEBANON,MATERIALS,METHODS,PATHOLOGY,RCC,RESULTS,SAINT,UNIVERSITY
695,AMONG,BACKGROUND,KERMANSHAH,LABEL,MATERIALS,MEDICAL,METHODS,RESULTS,UNIVERSITY
169,VCH,WILEY
001,054,10540,169,178,HCC,HIV,INC,INSURANCE,PWH,THERE,WILEY
169,175,279,BACKGROUND,E26,ERG,EXPRESSION,GLEASON,HENRI,KAZAL,LABEL,METHODS,PCA,POTENTIAL,PSA,RESULTS,SOCIETY
002,004,005,011,014,169,979,AKT,ARRYIPLEX,BACKGROUND,CHINESE,COPYRIGHT,EFEMP1AND,EGF,GBM,HAN,HOWEVER,LABEL,METHODS,NOTCH,RESULTS
169,COPYRIGHT,III,LTD,MDV3100,THERE
001,169,BACKGROUND,BASED,END,HODGKIN,HOWEVER,LABEL,LARGE,METHODS,PRESS,PUBLISHED,RESULTS,SEPARATELY,SMALLER,UNIVERSITY,YOUNGER
159,168,177,BECAUSE,FIFTY,MAY
169,1960S,1990S,DECREASES,FUKUI,HOWEVER,JAPAN,JOINPOINT,PRESS,PUBLISHED,UNIVERSITY
169,COPYRIGHT,CYDONIA,DYSURIA,IRANIAN,ITM,LTD,MALVACEAE,PORTULACA,THEREFORE
001,169,275,457,550,658,ADVERSE,AFTER,BECAUSE,COPYRIGHT,CRT,INC,LABEL,LYMAN,MATERIALS,METHODS,OBJECTIVE,PARAMETERS,PATIENT,PURPOSE,RESULTS,WHETHER
515,733,DESPITE,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,POISSON,PUBLISHED,PURPOSE,RADIATION,RATES,RESULTS,THERE
169,239,395,561,815,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHI,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL
169,178,187,281,320,828,COPYRIGHT,DETECTION,EARLY,EDUCATION,GLEASON,INC,INSTITUTE,LABEL,MATERIALS,METHODS,NCI,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SABOR,THESE,TREATMENT,UROLOGICAL,USING
169,400,AUC,CALCULATOR,CLEVELAND,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROTECT,PUBLISHED,PURPOSE,RESULTS,SABOR,TYROL,UROLOGICAL,USING
THERE
109,126,145,AKT,BETWEEN,BPH,CIP2A,MYC,PCA,PCR,SILENCING,WESTERN
946,AZA,CDK,HNSCC,METASTASES,NANOG,NR2F1,RAR
176,AFTER,CASPASE,DU145,H1299,HSP90,LABEL,MATERIALS,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS,U87MG,VIABILITY
AMONG,BOARD,CHECK,FORCE,HOWEVER,MEDICAL,PHE,PREVENTIVE,SERVICE,SINCE,SWISS,THEREFORE
CPG,SHP,THESE
056,100,169,ACRIN,CHANGES,COLLEGE,CONCLUSION,DYNAMIC,IMAGING,INC,LABEL,MEN,METHODS,MOLECULAR,NETWORK,NUCLEAR,OTHER,PET,PFS,RADIOLOGY,RESULTS,SOCIETY,SRC,SUVMAXAVG,UNLABELLED
169,BIOLOGY,HOWEVER,IAP,INC,MKN45,MOLECULAR,SOCIETY,TREATMENT,YM155
317,ALTOGETHER,BACKGROUND,CONCLUSION,HOWEVER,LABEL,METHODS,NEITHER,PSA,RESULTS,STILL
215,945,CHAIN,HCC,POLYMERASE,PTOV1
CLEARLY,MNK
169,BASED,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TESLA,UROLOGICAL
CHOWDHURY,COMMENT,ONCOTARGET
185,BRAIN,PET
DEVELOPING,ECM,HOWEVER,THEREFORE,USING
10877,10878,330,954,AFFYMETRIX,BACKGROUND,CHRONIC,EARLY,EGR,IL6,IL8,LABEL,METHODS,POTENTIAL,RESULTS,SILENCING
001,002,077,080,169,338,415,BLACK,COPYRIGHT,EDUCATION,FACILITIES,FEWER,HOWEVER,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
549,AMONG,COMPOUNDS,ESPECIALLY,THP,URSOLIC
ACP,ATP,LOD,MPA,QDS,THEREFORE,USING
CELLS,DOCETAXEL,FOLLOWING,GTP,GTPASES,OVERALL,RAS,RHO
COMPARISON,E26,ETS,HOWEVER,PCA,PIN,WHILE,YET
169,ANOVA,BIOLOGY,BPH,ELISA,HOWEVER,MOLECULAR,RANKL,UNION
169,239,BACKGROUND,CSA,FK506,GLEASON,INC,LABEL,METHODS,RESULTS,WILEY
169,ANDROGENS,BACKGROUND,FINALLY,HOWEVER,INC,LABEL,METHODS,PCA,PCR,RESULTS,WESTERN,WHETHER,WILEY
946,BACKGROUND,DU145,LABEL,PC3,RESULTS,RHO,THESE
100,116,205,549,956,HCT,MCF,METHANOLIC,NCI,SPP,SRB,THP
145,956,A1CL3,ALP,AMONG,ANTICANCER,CHLOROFORM,DRIED,FLAVONOID,IGR,MCF,OVI,PIPER,SRB,THP
285,789,ADULT,AGING,GENOMES,IMPUTATION,MEIER,PERMANENTE,PROGRAM,PROJECT,WHITE
EARLY,PDE,THESE
CUMULATIVE,GERIATRIC,GERIATRICS,ILLNESS,OLDER,PCA,SCORE
FOCAL,HOWEVER,LEADING
UNIVERSITY
001,103,122,170,173,213,258,461,469,690,AMONG,BACKGROUND,GLEASON,IDENTIFIER,IMPORTANCE,INSTITUTE,LABEL,METHODS,OBJECTIVE,PSA,RELEVANCE,RESULTS,SETTING,THERE,TRIAL

AGS,ANTIGEN,AUTOLOGOUS,DCS,HOWEVER,MHC,THESE
DESPITE,RESULTS,STRATEGIES
DESPITE,FURTHER,STS,THERE
001,088,169,CONCLUSION,HRS,LABEL,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS,SIMILAR,SOCIETY
001,062,099,128,169,190,400,653,700,739,760,885,886,ADVERSE,AMERICA,BRIEF,CONCLUSION,INVENTORY,KEY,LABEL,METHODS,NORTH,OBJECTIVE,ORTERONEL,PRIMARY,PSA,PSA50,PURPOSE,RESULTS,SHORT,SOCIETY,TAK
169,177,COPYRIGHT,DSC,FEM,MAD,MRI,THESE,TRE
002,032,116,169,BECAUSE,COPYRIGHT,EDUCATION,GLEASON,INC,IQR,LABEL,MARCH,MATERIALS,MAY,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,169,847,COPYRIGHT,COX,EDUCATION,GLEASON,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,THOSE,UROLOGICAL,USING
169,598,AFFAIRS,AFTER,ANGELES,BEACH,COPYRIGHT,EDUCATION,INC,LABEL,LOS,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
150,163,169,219,AFTER,AMONG,COPYRIGHT,COX,EDUCATION,GLEASON,INC,IQR,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,UPGRADE,UROLOGICAL
169,308,402,468,AAS,AFRICAN,AMERICANS,AUC,CALIFORNIA,CONCLUSION,COPYRIGHT,CURRENT,EPSTEIN,FRANCISCO,GLEASON,HOPKINS,HOWEVER,INC,JOHNS,KETTERING,LABEL,METHODS,MIAMI,NETWORK,OBJECTIVE,RESULTS,SAN,SLOAN,UNIVERSITY
001,004,169,185,CONCLUSION,COPYRIGHT,INC,LABEL,LPRES,METHODS,OBJECTIVE,RESULTS,STAGE,THESE,URINARY
002,015,111,118,169,603,CONCLUSION,COPYRIGHT,INC,JANUARY,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,SEPTEMBER,SEVENTEEN,THESE
001,169,AFRICAN,AMERICANS,CONCLUSION,COPYRIGHT,COX,EIGHT,HIV,III,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
001,150,160,169,ADT,BETWEEN,COMPOSITE,CONCLUSION,COPYRIGHT,DISEASE,INC,INDEX,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,URINARY,UROLOGY
169,AMONG,BLADDER,CONCLUSION,COPYRIGHT,ESTIMATED,FOUNDATION,GRADE,INC,INSTITUTE,LABEL,METHODS,NETWORK,OBJECTIVE,RESULTS,SOCIETY,TESTICULAR,UROLOGY,WEB
001,100,160,169,220,488,BETWEEN,COMPLEX,CONCLUSION,COPYRIGHT,DESPITE,INC,INCREASING,INPATIENT,LABEL,METHODS,NATIONWIDE,OBJECTIVE,RESULTS,THESE
169,603,616,676,681,945,BETWEEN,CLINICIANS,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
169,AQA,COPYRIGHT,DQD,E12,GLN,INC,NEOPLASIA,PRESS,PUBLISHED,SER,THR,TQS
169,CONCLUSION,COPYRIGHT,CROWN,IMAGE,LABEL,LAT,LTD,MATHWORKS,MEDICAL,METHODS,OBJECTIVE,ORGAN,PUBLISHED,PURPOSE,RESULTS,SYSTEMS,USA
223,AFTER
001,069,117,154,238,271,385,425,511,739,953,AFTER,LIBRARY,MEDLINE,PSA,SCHOLAR,SECONDARY
005,100,110,169,171,278,318,814,AGDER,BACKGROUND,COX,GLEASON,HENCE,INC,LABEL,METHODS,RESULTS,RSG,WILEY
169,22RV1,946,AKT,BACKGROUND,CONCLUSION,FURTHER,HOWEVER,INC,LABEL,LNCAP,METHODS,PCR,PSA,RESULTS,THERE,THESE,WILEY
HOWEVER,PCA,PET,PROSTATIC,TOMOGRAPHY
169,AFTER,COPYRIGHT,EFFECTIVE,ELECTRODE,INC,PLASMID
169,17A,231,945,946,956,AKR1C,COMPOUNDS,COPYRIGHT,HSD,LTD,MCF,MDA,PC3,SEVERAL,STRIKINGLY,SUPPORTING
169,ATR,COPYRIGHT,DHT,INC,MRN,USING
169,947,BACKGROUND,CAV,CONCLUSION,DU145,INC,LABEL,LNCAP,METHODS,MTT,PC3,PCR,RESULTS,THERE,THESE,WILEY
106,114,118,170,183,185,214,230,240,267,314,428,534,ARP,CONCLUSION,FBG,GENERAL,HAN,HOWEVER,HUI,JANUARY,LABEL,MEDICAL,METHODS,NINGXIA,OBJECTIVE,PSA,RESULTS,SEPTEMBER,UNIVERSITY
000,100,176,217,259,471,713,ASR,BACKGROUND,BLACK,BWIRR,CENTRAL,EAPCS,END,INC,LABEL,METHODS,PROGRAM,PUBLISHED,REGISTRIES,RESULTS,SOUTH,WESTERN,WHITE,WILEY
001,169,5KG,ADIPOSITY,ADULT,BACKGROUND,HRT,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,SEPTEMBER,UNIVERSITY,WHILE
169,786,945,AUC,BACKGROUND,BECAUSE,HOWEVER,LABEL,METHODS,MOTIVATION,PRESS,PUBLISHED,RESULTS,THEREFORE,UNIVERSITY
001,006,023,043,10878,169,261,BACKGROUND,COPYRIGHT,COX,CRP,CSS,DFS,GLEASON,LABEL,LTD,MEIER,METHODS,PSA,RESULTS,ROC
160,169,176,947,BLADDER,COLLIMATOR,COPYRIGHT,EUD,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROTATIONS,S78,SIMULATED
169,946,954,COPYRIGHT,EGF,EMT,HLA,LTD,SNAIL,TAKEN,TGF,THESE
CD11B,CTX,DLS,FURTHER,LEN,LIN,MDSCS,MTD,PSA,SIX
169,COPYRIGHT,IRELAND,LTD,NSCLC,PTP1B,THESE
BACKGROUND,BASED,DESPITE,HOWEVER,LABEL,OBJECTIVE,ORP,PURPOSE,REGARDING,RESULTS,ROBOT
000,160,169,542,570,880,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QALYS,RESULTS,TREATMENT,YEARS
ADP,AUSTRALIA,CHINA,EWING,III,JAPAN,KOREA,SOUTH,USA
169,BESIDES,CDK,COPYRIGHT,HOWEVER,INC,KNOCKDOWN,MG132,MMP,PLK,TAXANES,THESE,TUBULIN
8BR,AKT,AMP,CHROMATIN,CRE,CRTC2,EGF,EPIDERMAL,ERK,LNCAP,PUBLISHED,RAS,SILENCING
001,027,116,177,339,552,555,613,733,770,794,954,ADC,AUC,CONCLUSION,DWI,ECE,FIFTY,GLEASON,HOWEVER,IMAGING,MATERIALS,METHODS,MRI,OBJECTIVE,REPORTING,RESULTS,ROC,STUDENT,THERE
001,100,130,177,192,BRAZILIAN,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THERE
169,181,954,BACKGROUND,BASEL,CNS,CONCLUSION,EFFORTS,INSTITUTE,LABEL,METHODS,NCI,RESULTS,SCREENING,SRC,SRS06,STAT3,TRANSAM,WESTERN
130,169,BPH,COPYRIGHT,FACTORS,FINALLY,HEIDELBERG,HOWEVER,LTD,VITAMIN,WESTERN
125,169,99M,AFTER,BECAUSE,CONCLUSION,IMAGING,INC,LABEL,LNCAP,METHODS,MIP1095,MIP1404,MOLECULAR,NUCLEAR,RESULTS,SINCE,SOCIETY,THESE,UNLABELLED
10878,130MMHG,169,283,ADJUSTING,AMONG,BACKGROUND,BMI,CONTROL,COPYRIGHT,COX,GLEASON,LABEL,LTD,METHODS,RESULTS,SBP,VAT
100,169,381,442,HHV,INC,LOW,POISSON,SERUM,THERE,WILEY
474,EARLIER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
160,169,945,946,AUTHORS,LTD,PTY,PUBLISHING,SCIENCE,WILEY

145,169,200,AUTHORS,BCL,GINKGETIN,LTD,PTY,PUBLISHING,SCIENCE,STAT3,THEREFORE,WILEY
107,225,267,341,DU145,EMT,FIRST,FURTHER,PLB,PLUMBAGIN,SILAC,THESE,WESTERN
169,231,233,BIOLOGICAL,COPYRIGHT,CPMHS,CPMRC,HSMPC,MCRPC,PUBLISHED,SAS
160,169,231,233,BRCA1,BRCA2,COPYRIGHT,MENDELIAN,PUBLISHED,SAS,THESE
001,160,BACKGROUND,CDU,CONCLUSION,DOPPLER,FURTHER,LABEL,METHODS,PEARSON,POTENTIAL,RESULTS,ULTRASOUND
169,COPYRIGHT,RAMAN,SCIENCE,SERRS
274,459,CAUCASIANS,OVERALL,PRO187SER
006,008,019,023,BLOOD,DYNAMIC,FDG,FOV,GIVEN,HISTOLOGY,LABEL,METHODS,MRI,OBJECTIVE,PET,PURPOSE,REGIONS,RESULTS,THREE
956,GLEASON,PET,T3B
ACUTE,AICAR,AKI,ALCAR,OXIDATIVE,SIRT3,TREATMENT
219,228,ADVERSE,AMERICA,BACKGROUND,BMD,CONTEXT,FEWER,LABEL,MEN,METHODS,NORTH,OBJECTIVE,OUTCOME,RESULTS,SETTING,THESE
ACCORDING,AFTER,AIM,DRE,HGPIN,IHC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,RESULTS
945,STRUCTURAL,THESE
169,A20,UCHL1,USP22
100,177,500,AREAS,CONCLUSION,CRS,DIFFUSION,DWI,KNOWLEDGE,LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS,THESE
BACKGROUND,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,RESULTS,UPGRADING
197,ADT,BACKGROUND,COX,EIGHT,GLEASON,LABEL,MATERIALS,METHODS,PATHOLOGIC,RESULTS
000,2ND,5TH,900,BACKGROUND,IRANIAN,LABEL,METHODS,RESULTS,SMOKING
COMPETING,THERE
23A,23B,JAK,LNCAP,MICRORNAS,PC3,THESE
169,FURTHER,INCREASED,SIR,SWEDISH
THESE
MICRORNAS,NANOG,OCTAMER,POU,SEVERAL
102,104,145,163,223,282,517,595,643,722,BACKGROUND,CONCLUSION,COSTS,KINGDOM,LABEL,METHODS,NHS,PREDICTORS,RESULTS,SERVICE,TRUST
DIGITAL,JANUARY,MARCH,PSA,SINCE,T2CN0M0
SMALL
113,254,BMJ,DETERMINE,GROUP,LABEL,LIMITED,METHODS,NON,OBJECTIVE,OBJECTIVES,PUBLISHED,PUBLISHING,RESULTS,RHEUMATOID,RRS,THESE,ULCERATIVE
HT1,HT2,SEROTONIN,SERUM
145,169,238,302,354,365,387,435,540,542,546,741,773,BACKGROUND,COPRIMARY,COPYRIGHT,COU,EASTERN,FUNDING,IQR,JANSSEN,LABEL,LTD,METHODS,OVERALL,RESULTS,THESE
001,005,116,169,202,251,282,341,350,450,629,652,653,979,980,AUSTRALIA,AUTHORS,BJU,CONCLUSION,GLEASON,LABEL,MEN,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,OVERALL,PSA,RESULTS,THERE,VICTORIAN
ARF,NPM,THESE
169,ANTICANCER,AUC,COPYRIGHT,DU145,HUHS015,INSTITUTE,PCA
118,954,967,CONCLUSION,DRE,IMAGING,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PSA,PURPOSE,REPORTING,RESULTS,THERE,WHITNEY,YATES
100,169,184,AFTER,CONCLUSION,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,NPV,OBJECTIVE,PPV,PURPOSE,RESULTS,SWE
263,360,485,824,993,AFRICAN,ASIAN,DANES,EASTERNERS,EUROPEANS,HRS,IRANIAN,LOW,NORTH,ORDINAL,PANCREATIC,SOUTHEAST,SWEDISH,TURKISH,TURKS
001,177,180,599,779,BPH,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCORE,SYMPTOM,TARGETING,THERE,YANGPYEONG
004,173,272,AMONG,DHT,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,STEROID
ADDITIONAL,ADT,FAT
CURRENTLY,MRI,PCA
169,177,ABOVE,BACKGROUND,FEBRURARY,INC,LABEL,METHODS,PET,PSA,RESULTS,THEIR,THERE,WILEY
102,122,169,287,595,BACKGROUND,CHART,EPSTEIN,GLEASON,INC,LABEL,MARCH,METHODS,PCA,RESULTS,TEN,USING,WHILE,WILEY
001,004,007,169,213,215,562,599,645,815,AFTER,AUC,BACKGROUND,DENSITY,DRE,FR0348383,INC,LABEL,METHODS,PCA,PSA,RESULTS,ROC,WILEY
152,169,375,659,672,676,679,680,690,701,724,758,788,809,869,AMICO,AUC,BACKGROUND,DRE,INC,LABEL,METHODS,MRI,PCA,PRIAS,PSA,RESULTS,SMALL,THESE,WHILE,WILEY
126,169,221,222,486,AKT,BACKGROUND,BPH,CHINA,INC,LABEL,METHODS,PCA,PCR,RESULTS,WILEY
169,348,559,AUTHORS,BJU,BONFERRONI,C61,CONCLUSION,CURRENT,ICD10,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,OVERALL,PREVALENCE,QUESTIONS,RESULTS,SYMPTOM,WHILE,WILEY
MAY,PARTICULAR,RAF,WHILE
000,255,416,620,GPS,UROLOGISTS

AHT,CONCLUSION,ECT,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS
177,178,293,428,956,971,972,BPH,CONCLUSION,ELISA,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,USING
007,008,009,017,023,025,041,043,155,CHINESE,CONCLUSION,DNMT1,GLEASON,HOWEVER,LABEL,MASSARRAY,METHODS,OBJECTIVE,PCA,RESULTS,USING
H3K4ME3,JARID1B,K63,PCA,TAKEN,TRAF6,TRP53
945,946,HGF,MMP,MSC,SMA,STROMAL,TGF
169,500,ANTIBIOTIC,CIPROALONE,CIPROCEFT,CONCLUSION,COPYRIGHT,EIGHT,INC,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS
169,754,COPYRIGHT,CROWN,DERIVED,EFFECTS,INC,LABEL,MANAGEMENT,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADAR,RESULTS,SEPARATION,SUBJECTIVE,TISSUES,UNIVARIATE
001,004,007,169,254,388,400,470,500,687,COPYRIGHT,FINAL,HDR,INC,LABEL,LDR,MATERIALS,MEIER,METHODS,OBJECTIVE,PATIENT,PROCARS,PROPENSITY,PURPOSE,RESULTS
250,293,375,CAB,CTI,DSS,JAPIC,LTD,PFS,PSA,QOL
131,223,HODGKIN,III,STRONTIUM,THEREFORE,YTTRIUM,ZEVALIN
CTV,DVH,MRI,PTV
GUNMA,HEAVY,INSTITUTE,ION,JAPAN,MEDICAL,PRIMARY,SCIENCE,UNIVERSITY

ARS,DESPITE,TARGETING
000,SEVERAL
169,217,839,CONCLUSION,FIFTY,IMAGING,INC,LABEL,METHODS,MOLECULAR,NAF,NUCLEAR,OVERALL,PET,RESULTS,SOCIETY,UNLABELLED
169,BPH,CHRONIC,COPYRIGHT,HOWEVER,INC,THEREFORE
100,169,956,AKT,COPYRIGHT,IRELAND,LNCAP,LTD,OBACUNONE,TREATMENT
ADT
443,AVERAGE,BACKGROUND,CYTOSCAPE,DAVID,EXPRESSION,FGFR3,LABEL,LNCAP,LYN,METHODS,MULTI,OMNIBUS,ORTHOTOPIC,RESULTS,RMA,SEVERAL,TFS,THESE,USUALLY
13C,181,945,946,BAX,BCL,COMMIPHORA,CYCLOARTAN,MTT,PLANT,THESE,TUNEL,WESTERN
118,IMR,LNCAP,PAP,PCR,PROSTATIC,RENEWED,SELEX,SYSTEMATIC
001,124,945,946,CYP17,GALETERONE,III,PHASE,TOK
936,ACA,BOX,FINALLY
169,BIOLOGY,EXPRESSION,INC,MOLECULAR,PCR,SINCE,SOCIETY
100,160,553,ASTRO,CONCLUSION,CRT,DFS,DISEASE,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,RFS,SIB
100,169,675,ADT,AUSTRALIAN,BACKGROUND,COLLEGE,EIGHT,GRADE,HDR,LABEL,LDR,METHODS,MFS,MRI,PCASS,PREVALENCE,RESULTS,ROYAL,ZEALAND
BACKGROUND,BETWEEN,CONCLUSION,CURRENTLY,DESPITE,DIAGNOSTIC,GERMANY,LABEL,OBJECTIVE,OBJECTIVES,PRIMARY,RESULTS,SALVAGE
231,LNCAP,MCF,MDA,PCA,RAMAN
STEROID,THESE
128,483,AIM,BACKGROUND,CIS,ELISA,LABEL,METHODS,NMIBC,NMP22,RESULTS,UROVYSION
169,170,274,BACKGROUND,HOPKINS,JOHNS,LABEL,METHODS,RESULTS,SOCIETY,UTF
64257,730,BBN,GASTRIN,PC3,PET
001,169,CONCLUSION,COPYRIGHT,EPSTEIN,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PREDICTIVE,PSA,RESULTS
365,401,962,AMICO,ASSESSING,ATM,BMJ,ERG,GROUP,HISEQ,LABEL,LIMITED,METHODS,NCOR2,NGS,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS,TMPRRS2,USING
ADIPOR1,TAKEN
DESPITE,EARLY,HEPATOCYTE,III,PHASE
169,248,AFTER,BACKGROUND,DTC,DUE,GLEASON,INC,LABEL,M30,METHODS,PSA,RESULTS,WILEY
005,169,22RV1,BACKGROUND,CONCLUSION,CONVERSELY,CYP3A,DECREASED,DHT,INC,LABEL,LNCAP,METHODS,PSA,R1881,RESULTS,TMPRSS2,WILEY
169,BACKGROUND,EARLY,EBV,EIGHT,EPSTEIN,FRESH,INC,LABEL,METHODS,NOG,NSG,PDX,RESULTS,SIXTY,THERE,THEREFORE,WILEY
169,BACKGROUND,BASED,CONCLUSION,DU145,FINALLY,INC,LABEL,LNCAP,METHODS,RB1,RESULTS,USING,WESTERN,WILEY
169,COPYRIGHT,EDUCATION,INC,LABEL,LYMPHATIC,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THREE,UROLOGICAL
169,BRCA1,BRCA2
001,169,744,827,BACKGROUND,COPYRIGHT,COSTS,LABEL,METHODS,NETWORK,PROGRAM,RESULTS,TOXICITIES
006,169,460,468,CHEK2,I157T,MUTATIONS,THESE
100,125,145,164,169,638,700,AMICO,COPYRIGHT,FEW,INC,JANUARY,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OVERALL,PPB,PUBLISHED,PURPOSE,RESULTS,SOCIETY
119,125,BACKGROUND,BLOOD,GLEASON,LABEL,METHODS,MTT,NETWORK,PCA,PCT,PSA,RESULTS
001,023,150,169,177,193,266,488,BACKGROUND,FREQUENCY,HOWEVER,LABEL,LTD,METHODS,RESULTS,WILEY
12T,947,HOWEVER,LNCAP,LPB,NTSR1,SMALL,TAG
169,BACKGROUND,LABEL,METHODS,MIXED,OLDER,RESULTS,SIXTEEN,SOCIETY,THERE,THESE
169,ACS,ACT,AFFORDABLE,INTERVIEW,SOCIETY
007,009,013,015,020,043,DIETARY,WESTERN,ZEALAND
169,343,APPRAISAL,AUTHORS,BACKGROUND,CONCLUSION,COPYRIGHT,DUTCH,ENGLISH,FACTORS,FURTHER,HOWEVER,IMPORTANT,LABEL,LTD,MATERIALS,METHODS,MIXED,OLDER,PUBLISHED,RESULTS,SYSTEMATIC,TEN
946,AUSTRALIAN,EIGHT,LNCAP,NMR
104,105,181,183,211,AUC,FE3,HDACI,LABEL,LAQ,LIPOSOMAL,METHODS,OBJECTIVE,PEGYLATED,PURPOSE,RESULTS,SIMILARLY
160,181,BAX,BCL,CCK,FCM,FIRSTLY,KIT,PEPEROMIA,THESE,TUNEL,WESTERN
169,34B,946,COPYRIGHT,EMT,HOWEVER,INC,TCF
160,CONCLUSION,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PSA,PURPOSE,REPEATEDLY,RESULTS,TESLA
001,ADT,CSM,CSS,OVERALL,PCA
021,109,BAX,HSP70,P27,PCA,PREVIOUSLY,STUDIES,THREE
009,027,169,254,AIM,CME,COLLEGE,CONCLUSION,COPYRIGHT,DCE,DWI,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PARAMETRIC,PUBLISHED,RESULTS,ROYAL,THERE
PET
100,105,151,177,BMI,CONCLUSION,FIFTY,GLEASON,LABEL,METHODS,NPT,OBJECTIVE,PABFV,PBI,PCA,PSA,RESULTS,THERE,TVSSLRP
156,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SINCE
314,AKT,ARRAY,BRB,CONCLUSION,ECM,GEO,LABEL,METHODS,MOTIFSCAN,OBJECTIVE,PROTPARAM,RESULTS,SIGNALP,TMHMM,TOOLS,TOTALLY
CHINA,GIVEN,HIV,HPV,HSV,JOINT,NATIONS,PROGRAM,SHANG,WORLD
200
169,ACUTE,ADVERSE,COLLEGE,COMPOSITE,COPYRIGHT,FURTHER,GLEASON,INDEX,INITIAL,INSTITUTE,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,PUBLISHED,QUALITY,RESULTS,ROYAL,SIMILARLY
000,009,012,015,018,020,023,028,030,090,094,108,158,169,177,178,196,201,224,379,429,469,641,707,CAT,CAUCASIANS,COPYRIGHT,PCA,SEVERAL
169,223,945,EXTRACTION,FURTHER,LABEL,MAY,MEDICAL,MEDLINE,METHODS,OBJECTIVE,OCTOBER,PHASE,RESULTS,REVIEWS,SELECTION,SOC,SOURCES,SYNTHESIS
000,003,010,023,100,109,179,181,240,300,484,575,641,800,967,970,CSS,GLEASON,JANUARY,LABEL,MEIER,METHODS,OBJECTIVE,PERMANENT,PSA,RESULTS,T3A,THERE
946,DESPITE,FURTHER,LOW,PCA,WESTERN
125,956,AVA,BESIDES,BLOOD,CURRENT,FA01010,FBZ,FDG,GBQ,GRP,INFLUENCE,LABELED,NH2,PC3,PET,SAR,SFB,TLE,TYR
APOPTOSIS,ARRAYSCAN,CELLOMICS,FURTHER,MTT,PCR,VTI
223,945,CYP17,DESPITE,III,PHASE
174,BRISTOL,III,IPILIMUMAB,MYERS,PHASE,USA
GPS,ITALIAN,THEREFORE
946,947,AIM,CD3,CONCLUSION,DCS,IFN,LABEL,METHODS,OBJECTIVE,RESULTS,TGF,THESE
177,30MIN,313,AVERAGE,DUE,EIGHT,EVERY,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEIR
001,169,BACKGROUND,CONCLUSION,COPYRIGHT,EDUCATION,FOUNDATION,IDENTIFIER,INC,KRUSKAL,LABEL,MEDICAL,METHODS,OBJECTIVE,OCTOBER,PLIN2,PUBLISHED,RCC,RESULTS,THESE,TRIAL,URINE,WESTERN
002,169,251,557,AFTER,COPYRIGHT,COX,DUE,EDUCATION,FREEDOM,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
108,135,169,326,354,BACKGROUND,COMMITTEE,CONCLUSION,COPYRIGHT,END,INC,JOINT,LABEL,METHODS,RESULTS,STAGE,STAGING,T3AN0M0,T3BN0M0,TANYNANYM1,USING
001,131,229,CHINESE,CONCLUSION,HAN,HARDY,LABEL,METHODS,OBJECTIVE,PCA,PCR,RESULTS,UTR
177,321,336,341,361,378,399,423,457,500,771,916,942,ACCORDING,AMONG,CONCLUSION,III,JANUARY,LABEL,METHODS,OBJECTIVE,OCTOBER,OPERATIVE,RESULTS,THERE,THREE,TOKUHASHI,VAS
100,ADC,DCE,HENCE,HSC,MRI,ROI,SUPPORT,SVM,T2W
CONSENSUS,DSC,HOWEVER,INTER
CHALLENGE,DETECTION,GRAND,IMAGE,MRI,OPTIMAL,OSD,PROMISE,SURFACE,THESE
ACCORDING,BASED,DCE,MRI,PCA
DCE,MRI,SEVERAL
CURRENT,DIFFUSION,DWI,MRI
AAM,AUTOMATIC,SVM
100,109,187,200,280,295,350NM,550NM,956,HENCE,PARTIAL
1800S,PSA,SINCE,THERE
945,946,AKT,BISPHENOL,BPA,STAT3
480,PATIENT,SIX,SURGERY
169,ENGLISH,LABEL,METHODS,OBJECTIVE,RESULTS,SELECTING,SOURCES,STUDIES,SYSTEMATIC
946,AKT,CONSISTENT
169,946,BIOLOGY,DESPITE,DU145,IFN,INC,LNCAP,MOLECULAR,PC3,PCA,RIG,SOCIETY,SRC,STAT1,THEREFORE
169,945,946,AFTER,AMONG,BIOLOGY,INC,MOLECULAR,OVERALL,PC3,RECIPIENT,SOCIETY,TGF
169,BACKGROUND,CITUP,CONTACT,INTRA,LABEL,METHODS,MOTIVATION,PRESS,PUBLISHED,RESULTS,UNIVERSITY,USING
100,169,400,AFTER,BAT,CASTRATING,COPYRIGHT,HOWEVER,PSA,RESISTANCE,SCIENCE,TARGETING
101,112,116,122,185,GLEASON,LABEL,METHODS,OBJECTIVE,PATHOLOGY,RESULTS,UROLOGICAL,USING
100,160,945,956,MKN28,MKN45,NAFTOPIDIL,TNF
946,954,ACTIVATION,ATLAS,FUDAN,FUSCC,INCREASED,LDL,LNCAP,PCA,SERUM,STAT1,STAT3,UNIVERSITY
APRIL,BACKGROUND,CONCLUSION,LABEL,MALIGNANT,MARCH,METHODS,NIGERIA,PROSTATIC,RESULTS
100,169,416,BETWEEN,GLEASON,NNS,NPV,PCA,PRIMARY,PSA,THEREFORE
948,956,APTAMER,BECAUSE,BLOOD,CTC,LNCAP,SKBR3
419,CENTRAL,JANUARY,NORTH,PROCESS,RAPID,USING
DISCUSSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PFAAS,PSA,PURPOSE,RESULTS,THESE,USING
001,033,100,104,247,627,COX,MEIER,PCA,THERAPY
210,BASED,DMI,LABEL,METHODS,MLC,MUS,OBJECTIVE,PURPOSE,RESULTS,THESE,VALIDATION
120,176,AFTER,KIM,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEPTEMBER
EGO,IIP,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,120,CBCTS,GAMMA,GEOMETRIC,HOUNSFIELD,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROI,SIMILARLY,USING
177,DWI,HOWEVER,IMAGE,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
169,565,674,AFTER,AUA,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROVIDERS,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
922,935,BACKGROUND,CIS,CONCLUSION,GENOTYPING,GLEASON,LABEL,LTL,METHODS,OPENARRAY,ORS,PCR,RESULTS,SNP
72H,ACT,AGALYCHNIS,AMERICA,AMPHIBIAN,CENTRAL,GLN,GLU,GLY,LEU,LYS,MALDI,PHE,PRO,SOUTH,TOF,TPH,TRP,TYR
169,BCL,COPYRIGHT,DFO,DPC,DU145,MIAPACA,SOCIETY,SRC,STAT3,THESE
001,120,130,190,656,742,827,945,ANALYZING,ATLAS,AUC,AZGP1,CEA,CHINESE,ELISA,FIRST,LEAVE,PCR,ROC,THESE
010,029,115,160,169,189,422,AUTHORS,BJU,CONCLUSION,COX,GLEASON,HOWEVER,INDEX,LABEL,LTD,METHODS,OAD,OBJECTIVE,OBJECTIVES,PRN,PSA,PUBLISHED,RESULTS,THESE,WILEY
169,AUTHORS,BACKGROUND,CASTRATION,EMA,INC,LABEL,METHODS,PSA,RESULTS,SUCCESSFUL,TISSUES,WILEY,XENOGRAFTS
169,ALZHEIMER,ANTICANCER,BACKGROUND,BASED,CATALOGUE,CONCLUSION,CONSORTIUM,COPYRIGHT,CROHN,DELINASIOS,GWA,INSTITUTE,INTEGRATOR,LABEL,MATERIALS,METHODS,MUTATIONS,ORF,PANCREATIC,PHEGENI,PHENOME,RESULTS,SOMATIC,STUDIES,THESE
169,954,BACKGROUND,CGA,DU145,ELISA,ERK,FINALLY,HOWEVER,INC,INSTEAD,LABEL,LNCAP,METHODS,MMP,NED,PCR,PSA,RESULTS,WILEY
109,126,145,AKT,BETWEEN,BPH,CIP2A,MYC,PCA,PCR,SILENCING,WESTERN
169,464,COPYRIGHT,CYP17A1,DEFINITIVE,GALETERONE,INC,ORTERONEL,P450C17,PCA,PSA
169,945,946,BACKGROUND,ELISA,HOWEVER,INC,LABEL,LIVER,LNCAP,LXR,METHODS,PSA,RESULTS,TREATMENT,WILEY
169,312,620,AUTHORS,BACKGROUND,DUTCH,HPC,INC,LABEL,METHODS,ORS,RESULTS,ROC,SEVENTY,SPC,WILEY
169,954,AGING,BACKGROUND,CONCLUSION,HOWEVER,INC,LABEL,LNCAP,METHODS,MTT,RESULTS,SERUM,THESE,WESTERN,WILEY
169,ADT,CONCLUSION,LABEL,METHODS,OBJECTIVE,OLDER,PURPOSE,RCT,RESULTS,SOCIETY
120,156,169,177,251,954,ACT,CONCLUSION,DCE,IMAGING,INSURANCE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,REGIONS,REPORTING,RESULTS,THREE
169,FUNCTIONAL,GKIKA,HOWEVER,TCAF1,TCAF2,TCAFS,TRP,TRPM8
BACKGROUND,DISTORTION,EPE,FURTHER,LABEL,METHODS,MRI,PCA,RESULTS,RSI
EXPLORING,INSTITUTE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCP,SIXTEEN,SURVIVORS,THERE
945,946,AMONG,ANOTHER,LAP,OVERALL,RII,SMAD3,SMADS,TGF
001,024,AIM,BACKGROUND,BCR,CLOSE,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PSM,RESULTS
AFFILIATED,APRIL,AUC,CHINA,FURTHER,HOWEVER,JANUARY,PCR,PRISM,PSA,RELATIVITY,RESULTS,SERUM,THIRD,UNIVERSITY
100,169,1MM,956,COPYRIGHT,HOWEVER,INHIBITION,LNCAP,SEVERAL,THESE
169,BRITAIN,COPYRIGHT,FUNCTIONAL,GREAT,HOWEVER,IRELAND,LTD,NR2E1,OVERCOMING,PUBLISHED,RAS,SIRT1,SOCIETY,TLX,WILEY
001,162,239,328,ADT,AFTER
BACKGROUND,CONCLUSION,DOCKING,HIT,LABEL,LYTHRACEAE,MATERIALS,METHODS,NPACT,OBJECTIVE,OBJECTIVES,RESULTS,STUDIES
140,280,BACKGROUND,FAISALABAD,LABEL,MATERIALS,METHODS,PAKISTANI,RESULTS,THEREFORE
001,003,177,264,290,606,ACCORDING,BACKGROUND,HODGKIN,LABEL,MASHHAD,MATERIALS,METHODS,NON,OVERALL,RESULTS,SCREENING,THERE
1RNAI,AKT,BACKGROUND,BCL,CASPASE,CKK,ENDOTHELIN,LABEL,MATERIALS,METHODS,MMP,RESULTS,TRANSWELL,WESTERN
145,169,183,823,BGC,CHINA,COPYRIGHT,EDC,HCL,MTT,NMR,PUBLISHED,SEVERAL,THEIR,TREATMENT,UNIVERSITY
181,AS2O3,DYNAMIC,HIST1H2BD,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SYSTEMS,THESE
100,102,169,1C3,440,945,946,AKR1C,AMONG,BACCHARIN,BRAZILIAN,COPYRIGHT,IRELAND,LOW,LTD,STUDIES
223,946
169,AIM,COLLEGE,CONVERSELY,COPYRIGHT,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,SIGNS,STAGING,THESE
169,ACT,AIM,ARW,CCC,COLLEGE,CONCLUSION,COPYRIGHT,DISTANCES,ERC,FIFTY,INSURANCE,INTER,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PAC,PUBLISHED,RESULTS,ROYAL,SUM
169,946,ACA,AHHHHHH,COPYRIGHT,CSP,HADDOCK,LTD,NMR,RNP,SSD,STRUCTURES
ANTIBODIES,EXPERIENCE,FURTHER,IGE,IGG
643,DU145,EXPRESSION,PCA,TACSTD2,THESE,USING
AMONG,CIP,THESE
10A,123,169,231,AMONG,COPYRIGHT,COUMARINS,CYTOTOXIC,DOCETAXEL,ESTER,INC,MCF,MDA,MMP,MRC,PC3,RHODAMINE,THESE
AKT,BAX
BURKITT,PIM
AAL,ALEURIA,AMONG,BACKGROUND,CLINICALLY,GLEASON,LABEL,METHODS,PCA,PSA,RESULTS,ROC,SERUM,TIMP1
AMONG,ARRAY,BACKGROUND,BERBERINE,EMT,LABEL,MEIER,METHODS,NODAL,PCR,RESULTS,SNAIL,THESE
000,001,169,226,257,300,330,347,396,645,967,ANOVA,CONCLUSION,CONTINUOUS,GLEASON,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PCA,PET,PSA,RESULTS,SOCIETY,STUDENT,UNLABELLED
169,ACIDS,FOXA1,H3K4ME2,NUCLEIC,PIAS1,PRESS,PUBLISHED,SUMO2,TAKEN,UNIVERSITY
956,ADDITIONAL,AKT,BAX,BCL,CCM,CDK,LNCAP,OVERALL,PC3,PCA,TARGETING
ALTAI,FEDERAL,SFD,THERE

ASSESSMENT,CURRENT,PSA,PSADT
DISBALANCE,HODGKIN,OPG,RANKL
01105,LNCAP,NSK,WESTERN
110,160,BPH,GLEASON,HOWEVER,STE20,STK25
LNM,STRATIFIED,TMPRSS4,TNM
001,169,ANTICANCER,COPYRIGHT,COX,HGF,INSTITUTE,MET,OCTOBER,PSA
100,169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,DIAGNOSTIC,INSTITUTE,JANUARY,LABEL,METHODS,MULTI,OBJECTIVE,PCA,RESULTS,T1C,TESLA
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,CYP19,E10,ERE,GFP,INSTITUTE,LABEL,LNCAP,MATERIALS,MCF,METHODS,PCA,PCASC,PCR,RESULTS
169,ADP,AMERICA,ANTICANCER,BACKGROUND,BAX,CONCLUSION,COPYRIGHT,DU145,INSTITUTE,LABEL,LNCAP,MATERIALS,METHODS,NORTH,PC3,PETASIDES,PETASIN,RESULTS,T24,THESE,WESTERN
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,INSTITUTE,LABEL,LNCAP,MATERIALS,METHODS,RESULTS,YPSMA
945,AKT,BAX,BCL,DU145,ERK,IKB,LNCAP,MEANWHILE,SHARPIN
169,BIOLOGY,CONNEXINS,CXS,INC,MOLECULAR,SOCIETY
125,169,4A4,916,BASAL,COPYRIGHT,INC,PCA,TAP63
160,ABOUT,BACKGROUND,LABEL,METHODS
AKT,ETS,MOLECULAR,TMPRSS2
THERE,WHILE
169,COPYRIGHT,FOLFIRINOX,HOWEVER,PANCREATIC,PRESENTLY,PUBLISHED,STRATEGIES
4GLCNAC,946,BPH,IGG,PSA,THESE,WFA
000,160,169,SEVERAL,VCH,WILEY
169,373,BPH,INC,MMP,MT1,U87GM,UTR,WILEY
013,113,169,8OHDG,931,954,BACKGROUND,BAX,BCL,CONCLUSION,ELISA,GIVEN,INC,LABEL,METHODS,NUCLEAR,PSA,RESULTS,SECONDARY,TEA,THERE,TUNEL,WILEY
BACKGROUND,BASED,BCR,CIS,CONCLUSION,HOWEVER,LABEL,LABORATORY,MAY,METHODS,RESULTS
100,124,BACKGROUND,GLEASON,LABEL,METHODS,PSA,RESULTS,ROC,THOSE
CONCLUSION,DCE,GLEASON,LABEL,LDA,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PRINCIPAL,PSA,RESULTS,RFE,SVM,T2W,USING
040,041,045,128,148,CHINESE,CHROMATIN,CLINICALLY,COX,ERG,ETS,FUNCTIONAL,FURTHER,GLEASON,MMP,NOTABLY,OVERALL,PCA,SILENCING
169,213,5GY,BACKGROUND,COPYRIGHT,HDRBT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,STRICTURE,TEN
169,945,946,AKT,COPYRIGHT,HOWEVER,IGF1R,INC
008,042,100,202,433,517,598,956,BACKGROUND,CIS,HOWEVER,JANUARY,LABEL,LIBRARY,METHODS,OVERALL,RESULTS,STUDIES
INSTITUTE,INTENTION,LABEL,METHODS,NURSING,OBJECTIVE,OBJECTIVES,PURPOSE,RESULTS,SETTING,VARIABLES
AUSTRALIA,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PERTH,PURPOSE,RESULTS,SETTING
169,992,AMONG,COPYRIGHT,FURTHER,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,200,300,400,500,956,AGS,AKT,ANNEXIN,BAX,ECM,FLUOS,P53,PCR
ATLAS,MYC,NOTABLY,THESE,TTP,ZFP36
130,169,539,AHA,ATP,COPYRIGHT,COUNSELING,EDUCATION,IDF,III,INC,LABEL,MATERIALS,METHODS,NHLBI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WAIST
169,AMONG,BACKGROUND,CONCLUSION,DIFFUSION,DOCETAXEL,EFFORTS,END,FDA,III,LABEL,MAY,METHODS,PRESS,PROGRAM,PUBLISHED,RESULTS,UNIVERSITY
169,BIOLOGY,HOWEVER,INC,LOX,MK591,MOLECULAR,MYC,SOCIETY,THESE
BACKGROUND,COLORECTAL,CONCLUSION,INITIATIVE,KEY,LABEL,LARGE,OVARIAN,PREVENTION,RESULTS,SCREENING,TRIAL,USING,VITAMIN,WHILE,WOMEN
001,174,494,AMICO,ATM,BACKGROUND,BESIDES,ERCC1,ERCC2,GENOTYPIC,GLEASON,LABEL,METHODS,OPENARRAY,PSA,RESULTS,SNP,SNPATOR,SPANISH,XRCC1
001,AUSTRALIA,AUSTRALIAN,BACKGROUND,BMJ,COAST,COMMUNITY,GROUP,LABEL,LIMITED,METHODS,OBJECTIVE,OUTCOME,PSA,PUBLISHED,PUBLISHING,RESULTS,SETTING,TRIAL,ZEALAND
037,149,346,418,AIM,CONCLUSION,ECM,LABEL,MATERIALS,METHODS,MMP,OBJECTIVE,RESULTS,SIXTY,TIMPS,TURKISH,WESTERN
125,130,163,169,175,180,683,BETWEEN,COPYRIGHT,D90,GREATER,IMPLANT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RESULTS,ROC,THEREFORE
001,002,012,013,063,177,181,190,228,331,345,666,961,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PEARSON,PSA,RESULTS
100,225,239,CONCLUSION,LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS,SIMULATED,THREE
169,16Q23,BIOLOGY,DESPITE,SOCIETY
102,169,235,BACKGROUND,LABEL,METHODS,PATIENT,QOL,RESULTS,SOCIETY
169,BECAUSE,COPYRIGHT,NIR
104,119,120,145,162,163,174,179,233,BAK,BAX,BCL,ESPECIALLY,PLEUROTUS,THEIR,THESE
200,239,400,700,ACUTE,ADVERSE,AES,BID,CYCLE,DLT,FIFTEEN,GRADE,LABEL,METHODS,OBJECTIVE,ORTERONEL,PURPOSE,RESULTS,SERUM,TAK
116,145,169,174,180,231,3T3,A2780,ABCB1,ABCG2,COPYRIGHT,DARBY,HCT,HEPG2,IND,LTD,MADIN,MCF,MDAMB,NATURALLY,NIH,PC3,PXR,THESE
160,169,177,BASED,COPYRIGHT,FURTHER,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVEN,SOCIETY,THERE,THESE
009,100,110,239,250,308,343,AIM,AST,BMD,LABEL,LGNRH,MATERIALS,METHODS,OBJECTIVE,RESULTS,TOTAL,UNLABELLED
YET
AIM,BPH,CAG,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RANDOMIZED,RESULTS
169,945,946,CONSISTENT,DHT,FIRST,INC,LNCAP,MCF,MICROARRAY,PTHRP,R5020,THR,WILEY
BET,HOWEVER,JQ1,MEDICAL,THERE,UNIVERSITY
224,234,BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS,THERE
AFTER,ANOVA,BACKGROUND,DFA,GLEASON,LABEL,METHODS,OBVIOUSLY,PCA,PGR,PSA,RAR,RESULTS,THEREFORE,TUKEY
169,AUTHORS,FURTHER
BMJ,GROUP,LDR,LTD,PUBLISHING
10877,10878,266,AGE,BACKGROUND,CCI,COMPETING,CONCLUSION,CONVERSELY,CSM,LABEL,MEN,METHODS,OCM,OUTCOME,OVERALL,PCA,RESULTS,TEN
223,AREAS,BACKGROUND,COVERED,LABEL,MDV3100,MECHANISMS,METHODS,OPINION,P17
169,489,CONCLUSION,EXTENDING,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,THERE
169,AFTER,ARTIFICIAL,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,SIX,TOTAL,UROLOGICAL
000,169,254,BACKGROUND,CIS,COLORECTAL,COX,HOWEVER,INCIDENCE,INSTITUTE,LABEL,METHODS,NBP,OVARIAN,RESULTS,SCREENING,SOCIETY,SQX,TRIAL,WOMEN
INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS
001,003,027,169,224,COPYRIGHT,HOWEVER,INC,PCA,TAKEN
CW2,H2052,MKN45,NCI
HOWEVER,PERTUZUMAB
ENGLAND,FURTHER,JOURNAL,PSA
BIOLOGY,ETS,GIVEN,HOWEVER,THEIR,UTILIZING,WYATT
1950S,ANTICANCER,MCF,MYC,SF5,THEREFORE
001,003,005,169,659,BACKGROUND,CONCLUSION,CRP,LABEL,MEN,METHODS,MPC,RESULTS,SERUM
946,AIM,BPH,CD117,CD133,CONCLUSION,FZD,LABEL,METHODS,OBJECTIVE,RESULTS,WHILE,WNT,WNT7A
160,169,322,910,AUSTRALIA,AUSTRALIAN,AUTHORS,BACKGROUND,BASED,CENTRAL,COPYRIGHT,INCIDENCE,LABEL,LTD,METHODS,MODEL,NSW,PREVALENCE,PUBLISHED,RESULTS,SOUTH,THESE,VALIDATION,WALES
125,169,945,AFTER,CDS,COPYRIGHT,CUO,FIRSTLY,ITO,MEANWHILE,PEC,USING,ZNO
020,104,169,274,BLIND,CONCLUSION,COPYRIGHT,INC,INTERFACE,LABEL,METHODS,MHZ,OBJECTIVE,PERIPHERAL,PREVALENCE,RESULTS
169,323,670,86E,AMONG,AUC,CAUCASIAN,CONCLUSION,COPYRIGHT,GLEASON,INC,JANUARY,LABEL,METHODS,NET,OBJECTIVE,PCA,PERIPHERAL,PGS,PRIMARY,PSA,RESULTS,SEPTEMBER,THESE,TORONTO,UNIVERSITY
160,169,COMPOSITE,CONCLUSION,COPYRIGHT,INC,INDEX,LABEL,METHODS,MID,OBJECTIVE,RESULTS,SHORT,URINARY,USING
BACKGROUND,BECAUSE,CONCLUSION,ELISA,IGG,IGY,LABEL,METHODS,PSA
169,COPYRIGHT,INC,INCREASED,NAD,PARK2,PATHOLOGY,PROSTATIC,PUBLISHED,ROS,SIRT1,SOCIETY
177,186,243,322,99M,AIM,BACKGROUND,GLEASON,LABEL,MDP,METHODS,NUCLEAR,OBJECTIVE,PSA,RESULTS
036,041,045,046,060,169,AML,COPYRIGHT,GIVEN,HOWEVER,INC,INHBB,LABEL,LHCGR,METHODS,OBJECTIVE,OVARIAN,RESULTS,THERE,USING
169,789,885,BACKGROUND,CALCIUM,COX,LABEL,METHODS,NUTRITION,OBJECTIVE,PHOSPHORUS,RESULTS,SEVERAL,SOCIETY,THESE
138,169,213,217,435,582,825,AMONG,BACKGROUND,CIS,DIETARY,HOWEVER,HRS,LABEL,METHODS,NUTRITION,OBJECTIVE,RESULTS,SOCIETY,SOLUBLE,THESE,TOTAL
169,200,400,ANY,APRIL,BACKGROUND,CONTINUOUS,DAIRY,INTAKES,LABEL,METHODS,NUTRITION,OBJECTIVE,PROJECT,RESULTS,RRS,SOCIETY,SUMMARY,TOTAL
169,194,561,623,BACKGROUND,COX,FEW,HRS,LABEL,MET,METHODS,RESULTS
169,CXCR4,DU145,GUANINE,PC3,REX,THESE
169,AKT,BIOLOGY,CASTRATION,INC,MOLECULAR,SOCIETY,USING
000,121,160,BACKGROUND,FFF,LABEL,LINAC,METHODS,OBJECTIVE,PURPOSE,RESULTS
BACKGROUND,CONFRERES,COUPLES,DISTILLING,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,PCA,PCSGS,PURPOSE,RESULTS,THREE,WOMEN
BACKGROUND,CONCLUSION,CURRENT,HOWEVER,LABEL,LRP,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SINCE,THEREFORE
2D3,APART,BACKGROUND,CALCITRIOL,HOWEVER,KEY,LABEL,LANGERHANS,THESE,UNLABELLED,VITAMIN,WORDS
COX,THERE
AFTER,CYBERKNIFE,FORTY,GRADE,MAY,PFS,PRIMARY,PSA,THERE
394,AMONG,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,VETERAN,VHA
954
CHINESE,COX,GLEASON,HOWEVER,MEIER,PCR,PSA,SEVENTY
CLARITY,DEPARTMENT,HENCE,IMAGE,MAXIMUM
ABL,DU145,EXPRESSION,MMR,PCA,PWR,THESE,WESTERN
545,601,622,627,670,742,ACCORDING,AUC,HOWEVER,MALAT,PCA,PSA,ROC
100,174,400,MAY,MEETING,SCIENTIFIC,SOCIETY,SRS,USA
EARLY,RAMAN
CSPCA,MRI,PCA,PREBIOPSY,SEVERAL
AUC,CHALLENGES,FURTHER,MRI,PCA
AVERAGE,CONCLUSION,INDEX,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,USING
MRI,STAGING
GIVEN,MRI
129,BETWEEN,CONCLUSION,HIF1A,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,WHILE
169,FOUNDATION,INITIALLY,JOURNAL,SOCIETY,STICHTING
008,100,169,191,203,A1C,BECAUSE,COPYRIGHT,COX,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,808,AUTHORS,BJU,CANCERS,CENTRAL,CONFERENCE,CONTROLLED,GRADE,GROUP,LTD,MANAGER,MEDLINE,NON,PROSTATIC,PUBLISHED,SCIENCE,WEB,WILEY
ENTROPY,LIEBLER
169,AAS,AFRICAN,AMERICANS,BACKGROUND,EMOTIONAL,END,FURTHER,HISPANICS,HOWEVER,HRQOL,LABEL,MEDICAL,METHODS,MIXED,RESULTS,SHORT,SOCIETY,STRATIFIED,TRUST
169,604,COPYRIGHT,COX,INCIDENCE,INCREASED,OVERALL,RECIPIENTS,RESULTS,SIROLIMUS,SOCIETY,TRANSPLANT
100,110,CROSS,DESORPTION,LDA,PCA,RADICAL,RAPID,THESE
00016,013,141,30C,375,458,559,576,612,697,710,757,809,861,877,922,AUC,BPH,EXPRESSION,GLEASON,PSA,YAM
ASR,BACKGROUND,LABEL,MATERIALS,METHODS,MUSLIMS,NHL,OBJECTIVE,OBJECTIVES,POPULATION,RESULTS
BPH,FURTHER,LABEL,LDL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,WHITNEY
006,180,ABO,BACKGROUND,JANUARY,LABEL,MATERIALS,METHODS,RESULTS,SPC,TAIWANESE,THERE
156,191,207,347,946,AFTER,ANNOTATION,JAK,LNCAP,MAS,P53,TGF
000,100,HOWEVER,INCIDENCES,VIETNAM,WHILE
THERE,WORLDWIDE
946,HOWEVER,VARIOUS
162,ALLELIC,APA,BACKGROUND,FOK,HARDY,LABEL,MATERIALS,METHODS,PAKISTANI,PCA,PCR,RESULTS,SIMILARLY,TAQ,VDR,VITAMIN
169,BIOLOGY,INC,LIPIDOMIC,MOLECULAR,SOCIETY,WESTERN
015,575,ADAM7,ADT,BACKGROUND,BUB1B,CCNB1,CCNB2,ERG,ETS,LABEL,METHODS,MSKCC,ONCOGENOME,PCA,PROJECT,PUBLICALLY,RESULTS,SEQ,TMPRSS2,TRUSS,TTK,USING
BACKGROUND,HODGKIN,HOWEVER,JANUARY,LABEL,METHODS,REPORTS,RESULTS,THESE
AREAS,BACKGROUND,CHECKPOINT,COLORECTAL,COVERED,CRC,CURRENT,GIVEN,LABEL,METHODS,OPINION,SURGERY
223,DU145,HOWEVER,LNCAP,MICRORNAS,MIR,NOTABLY,PC3,PCA,SEPT6
BACKGROUND,BPH,EIA,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THESE,TOTAL,TUR
HENCE,HOPEFULLY,IGF,MEANWHILE,PCA
1990S,CSC,THEREFORE,THESE
ACCORDING,MICRORNAS
ETS,FOLLOWING,NGS,THOSE
THEREFORE
DUE,HOWEVER,PSA,WIDESPREAD
HOWEVER,JAPAN,PSA,QOL,THEREFORE,UROLOGICAL,WESTERN
BASED,CBZ,EZL,HOWEVER,JAPAN,THEREFORE,UNTIL
AKT,AMONG,HGF,KINASES,MET,PCA
223,JAPAN,THEREFORE
BECAUSE,IPILIMUMAB,SIPULEUCEL,SURGERY,THOSE
JAPAN,MANAGEMENT,TREATMENT
509,ARN,THESE
DHT,JAPAN,THEREFORE
DKK,OKAYAMA,PSA,TOKYO
HLA,PPV,SINCE
208,AE3,EP4,KUCAP,ONO,TARGETING,THESE
EXTREME
HOWEVER,OXIDATIVE,ROS,THEREFORE
ASC,HOWEVER,NOVEL
BECAUSE,ODN
LDL,THESE
239,III,JAPAN
ADT,REGARDING,THEREFORE
CYP,ERG,REGULATION,TMPRSS2
CASTRATION,TAKEN
954,ECM,EMT,MET,RANKL,THOSE
177,956,BACKGROUND,BIOLOGICAL,CIOCALTEU,CONCLUSION,COR,FOLIN,L23,LABEL,LPS,MCF,METHODS,MRC,OBJECTIVE,RESULTS,SRB,SXH,TOTAL,YET,YOD
177,956,BACKGROUND,CIOCALTEU,CONCLUSION,CYTOTOXIC,FOLIN,FRESH,GAE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SRB,TOTAL
BORDERLINE,ERG,PIN
215,HOWEVER,LABORATORY,PSA

HOWEVER
146,377,AIM,BACKGROUND,COMMANDER,FIFTY,LABEL,METHODS,OBJECTIVE,RESULTS,THOSE
169,COPYRIGHT,INC,PUBLISHED,SOCIETY
FET,PSA,TAKEN
ACCORDING,BACKGROUND,CIS,CONCLUSION,HOWEVER,LABEL,MANAGER,METHODS,QUALITY,RADICAL,RESULTS,URINARY,VERSION
264,699,DAKAR,LABEL,MATERIALS,METHODS,RESULTS,UNLABELLED
169,174,AUTHORS,CELLSEARCH,CELLSIEVE,CTC,EPCAM,HOWEVER,INC,PUBLISHED,THESE,USING,WILEY
145,AQP,AQUAPORINS,ERK,FINALLY,KNOCKDOWN,MMP,NOTABLY
SYAMS,THESE
169,916,945,956,COPYRIGHT,DHT,HOWEVER,IRELAND,LTD,P450C17,THESE,TREATMENT
001,003,006,169,CNR,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNR,WHOLE
062,109,119,122,136,139,142,164,301,309,336,445,536,557,633,694,774,880,BCR,LABEL,LOCATIONS,LRP,MATERIALS,MEIER,METHODS,OBJECTIVE,PSM,PURPOSE,RALRP,RESULTS,RPP,RRP,THERE
177,233,CENTRES,EARLY,EWING,HOWEVER,LABEL,LUTTE,MATERIALS,METHODS,NATIONALE,OBJECTIVE,PRIMARY,PURPOSE,RESULTS
AMONG,FOCAL,T1A
MYC,NADPH
169,819,844,993,AMONG,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SOCIETY,THERE
BACKGROUND,END,LABEL,METHODS,ORP,RESULTS,THERE
169,BACKGROUND,COPYRIGHT,HPV,ICAHN,INC,LABEL,LMICS,METHODS,MOUNT,OBJECTIVE,ORGANIZED,PUBLISHED,RESULTS,SCREENING,SINAI,VIA
000,100,169,ASIAN,ASR,BACKGROUND,BAHRAIN,CANCERS,COPYRIGHT,COUNTRIES,ICAHN,INC,IRANIAN,LABEL,LEBANON,METHODS,MOUNT,OBJECTIVE,OBJECTIVES,PUBLISHED,QATAR,RESULTS,SAUDI,SINAI,THEREFORE,THESE,TURKISH,WESTERN
BACKGROUND,BLADDER,LABEL,METHODS,THERE
DIGITAL,TOTAL
4TH,5TH,JAPAN,MUCOSAL,PCI,SINCE
215,RIGHT
135,65308,BASED,HOWEVER,NVB,UNIVARIATE
169,218,BASED,CLEARLY,COPYRIGHT,D52,INC,KNOCKDOWN,PC3,THESE,TPD52
BACKGROUND,LABEL,METABOLOME,NMR,QUANTUM,RESULTS,SIMILAR
001,012,450,CAUCASIANS,CONCLUSION,CONTEXT,FORTY,LABEL,MATERIALS,METHODS,NIGERIA,OBJECTIVE,RESULTS,SEVENTY,STUDIES,THERE
COLLEGE,PSA,RADIOLOGY,RATINGS
145,215,AFTER,BAX,BCL,CONCLUSION,LABEL,MATERIALS,METHODS,MTT,OBJECTIVE,PSA,PURPOSE,RESULTS
GLEASON,LABEL,MARCH,METHODS,OBJECTIVE,PCA,PHOENIX,PSA,RESULTS,SCS,THREE
AMONG,EMT,HOWEVER,PCA
12A,12B,13A,13B,15A,169,17A,17B,956,COPYRIGHT,DU145,SAS
DENDRITIC,DESPITE,FDA,FEDERAL
001,016,039,169,170,177,326,967,AZD1208,BACKGROUND,CAP,FINALLY,HOWEVER,HYPOXIA,IRRADIATED,LABEL,METHODS,MYC,PCS,PIM,PRESS,PUBLISHED,RECURRENT,RESULTS,STUDENT,UNIVERSITY,WHITNEY
169,73000,BACKGROUND,BASED,CONCLUSION,ERSPC,HOWEVER,LABEL,METHODS,PRESS,PSA,PUBLISHED,QALYS,RANDOMIZED,RESULTS,SCREENING,UNIVERSITY
001,139,140,169,226,267,762,956,965,BACKGROUND,CAUTION,CONCLUSION,COX,CRUDE,FEW,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,THERE,UNIVERSITY
169,BIOLOGY,FINALLY,INC,MOLECULAR,PCA,SOCIETY
100,169,ACELLULAR,ALREADY,BACKGROUND,CAUTION,DTM,ECM,EMBRYOLOGY,HOWEVER,KNOWN,LABEL,MATERIALS,METHODS,MTT,OBJECTIVE,PRESS,PUBLISHED,PXD001524,REASONS,RESULTS,RETENTION,SDS,SETTING,SOCIETY,SOLUBLE,SUMMARY,UNIVERSITY,WIDER
100,169,474,A2870,COPYRIGHT,FOLLOWING,HCC1806,LNCAP,LND,LTD,WILEY
ELK,ETS,PCA,SPAG9
000,022,027,18F,CONCLUSION,COX,EARLY,FCH,FORTY,LABEL,METHODS,OBJECTIVE,PATIENT,PET,PFS,PSA,RESULTS,THESE,UNIVARIATE
BACKGROUND,CHALLENGES,HOWEVER,LABEL,METHODS,RESULTS
246,250,782,850,CHAIR,GERMANY,MAX,THEREFORE,TUR,ULM,UNIVERSITY,UROLOGY
145,946,ADENOVIRAL,BASED,INFECTION,MET,PCA,WNT
001,006,242,456,GLEASON,HOWEVER,NIN,NOB,PCA,RFS,THESE
CLU,COMBINING,LC3,LIR
169,190,256,445,676,AIM,ANTICANCER,ARD,BMI,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS,UNIVARIATE
001,169,465,560,AIM,ANTICANCER,BETWEEN,CONCLUSION,COPYRIGHT,HOWEVER,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS
001,009,136,169,246,252,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PLCE1,RESULTS,USING
169,188,274,AIM,ANTICANCER,BPH,CONCLUSION,COPYRIGHT,DRE,INDEX,INSTITUTE,LABEL,METHODS,OBJECTIVE,PCA,PHI,PIN,PSA,RATIO,RESULTS,THREE
871,AUC,RWR
195,PKP,ROS,SRC,TYR
FIRST,SFRP4,WNT
100,33258,600,956,APOPTOSIS,ATP,CPT,FGC,GLYCOLYSIS,HEXOKINASE,HOECHST,HOWEVER,LNCAP,MMP,MTT,PC3,TREATMENT
160,380,LASS2,MCF,MMP,THEREFORE,TMSG1
892,ARG,ARG399GLN,CAUCASIAN,GLN,MONGOLOID,XRCC1
113,130,239,352,AFFILIATED,AMONG,CHINA,COX,FIRST,GUANGDONG,GUANGZHOU,HOWEVER,SEN,SHANTOU,SUN,UNIVERSITY,YAT
THEREFORE,WESTERN
125,169,CELLS,CONCLUSION,IGG,IMAGING,INC,IR700,LABEL,METHODS,MOLECULAR,NIR,NUCLEAR,PC3,RESULTS,SOCIETY,UNLABELLED
AMACR,CK5,HOWEVER,P504S,PIN,VARIOUS
001,003,008,127,169,627,754,BETWEEN,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,RFS,SOCIETY,THERE
169,468,47D,495,562,568,956,CNS,COPYRIGHT,HOP,INSTITUTE,MDA,MOTIVATED,RESULTS,SAS,SNB,USA
169,COPYRIGHT,HDR,INC,THERE,WHILE
005,032,169,343,BASED,COPYRIGHT,COX,INC,ISH,NEOPLASIA,PRESS,PUBLISHED,SCHLAP1
001,006,007,025,048,169,AZA,BORIS,COPYRIGHT,EPITHELIAL,GLEASON,HGPIN,INC,NEOPLASIA,PCA,PER,PRESS,PSA,PUBLISHED,THEIR,TREATMENT
169,293,330,945,ACCORDING,COPYRIGHT,DHT,FUNCTIONAL,FURTHER,HARDERIAN,HEK,HOWEVER,INC,PCR,THESE
169,196,417,532,CAPRA,COPYRIGHT,INC,IQR,JANUARY,LABEL,MATERIALS,MEIER,METASTASIS,METHODS,OBJECTIVE,PREDICTION,PUBLISHED,PURPOSE,RESULTS
000,100,102,169,AVERAGE,COPYRIGHT,EDUCATION,FILES,FURTHER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PUBLISHED,PURPOSE,RESULTS,RUCCS,RURAL,STATISTICS,UROLOGICAL,UROLOGIST
001,034,036,141,146,169,287,504,ASSOCIATES,COPYRIGHT,COX,LABEL,LTD,METHODS,OBJECTIVE,OCD,ORTHOTOPIC,PUBLISHED,PURPOSE,RESULTS,TOTAL
100,10A,143,145,15A,205,221,223,452,CONCLUSION,EXTRACTION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RNU,THERE
504,715,ANXIETY,INVENTORY,ITEMS,LABEL,METHODS,OBJECTIVE,PCA,PPB,RESULTS,RRP,SHORT,STATE,TRAIT
001,759,AUC,BACKGROUND,BETWEEN,DRE,GLEASON,HGPCA,LABEL,LGPCA,MATERIALS,METHODS,PCA,PSA,PVS,RESULTS,ROC,THERE
005,006,107,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PBX,PSA,RESULTS,SEVENTY
131,169,177,215,330,669,BBS,BECAUSE,COPYRIGHT,INC,LABEL,LYS,METHODS,RESULTS,TREATMENT,UNLABELLED
177,BACKGROUND,CT1,CT2,CT3,CTS,IMPLANT,LABEL,METHODS,MRD,RESULTS,THERE,THESE
KNOWLEDGE,THERE,THESE
CURRENT
160,169,AUTHORS,BJU,BWU,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHED,QOL,QUALITY,RANDOMISED,RESULTS,THERE,THREE,VALUE,WILEY
002,149,169,354,ADT,AIM,BACKGROUND,COX,END,LABEL,MEASURE,MEN,METHODS,OBJECTIVE,OUTCOME,OVERALL,RESULTS,SOCIETY,TRT,USING
001,008,BECAUSE,CA125II,COLORECTAL,OVARIAN,SCREENING,THESE,TRIAL
BACKGROUND,CONCLUSION,LABEL,RESULTS
175,APA,FOLLOWING,LOD
CD2N2,CH2N2,DAG,PC3,PTDINSP,TMS,USING
BACKGROUND,CONVERSELY,COX,GLEASON,LABEL,METHODS,NRI,ONTARIO,PATHOLOGY,RESULTS
004,052,551,BACKGROUND,BCR,BLACK,COX,ECE,GLEASON,LABEL,MEIER,METHODS,PSA,RESULTS,THERE
AKT,BACKGROUND,CASODEX,LABEL,METHODS,RESULTS,SORAFENIB,SUNITINIB,WHETHER
000,100,258,475,681,802,BACKGROUND,CONCLUSION,CZECH,LABEL,METHODS,POPULATION,RECORDS,RESULTS
ARGON,PROSTATIC
AUTHORS,ERSPC,HOWEVER,PSA,RANDOMISED,SCREENING
CALCULATOR,CARCINOMA,COLLEGE,DUTCH,GENERAL,MAJOR,PSA,SOCIETY,UROLOGY,USING
169,306,415,423,583,BACKGROUND,CIS,CONCLUSION,COX,END,FIRST,HRS,INC,LABEL,LIFESTYLE,METHODS,RESULTS,THEREFORE,VITAL,WASHINGTON,WILEY
001,003,169,202,900,ACCORDING,AMICO,BACKGROUND,BCR,COX,EQUAL,GLEASON,HOPKINS,JHH,JOHNS,LABEL,MEN,METHODS,NETWORK,NOS,PSA,RESULTS,SOCIETY,T2A,T2C,THESE,UROLOGICAL
100,169,24H,2GY,956,COPYRIGHT,HENCE,HOWEVER,ZNFE2O4
000,HDF,HOWEVER,NPS,PAH,PC3
AFTER,FINALLY,GMEB2,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,STMN3,UCKL1,ZNF512B
004,152,165,169,263,580,704,COMPOSITE,COPYRIGHT,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PROPENSITY,PURPOSE,RESULTS,SIMILARLY,STUDIES,THESE,TOBIT
169,891,COPYRIGHT,DU145,EPA,ERK,FAK,FAS,FURTHER,GPCRS,GPR40,HOWEVER,INITIAL,KNOCKDOWN,LPA,OMEGA,SOCIETY,TUG
120,139,145,177,1ST,BACKGROUND,BPH,CALABAR,CONCLUSION,EPI,HOWEVER,IMAGING,IUC,LABEL,LOWER,METHODS,RESONANCE,RESULTS,SEVENTY,THERE,TOMOGRAPHY,UNIVERSITY,URINARY
ATLAS,MOLECULAR,PROTEIN
CONVERSELY,GATA2
169,382,953,AUSTRALIAN,HODGKIN,LABEL,METHODS,OBJECTIVE,READERS,RESULTS
169,956,CCK,COMPOUNDS,COPYRIGHT,DU145,LNCAP,LTD,PUBLISHED,SAR
BACKGROUND,CHECK,EXECUTIVE,FORTY,HARYANA,INDIA,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PSA,RESULTS,SERUM
001,161,714,CONTROLLED,HOWEVER,HRS,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PFS,PSA,RESULTS,TTP,ZIBOTENTAN
169,945,AMONG,CDP,CHOLINE,RSM
001,008,10877,304,375,BACKGROUND,CONCLUSION,DEPENDING,GLEASON,LABEL,METHODS,OTHER,PSA,RESULTS
HOWEVER,METASTASES
162,BACKGROUND,COX,GLEASON,HOWEVER,LABEL,METHODS,MSP,PCR,PSA,RESULTS
ARF,PERIOSTIN,STRIKINGLY,THESE
183,1970S,1990S,2000S,AUTHORS,CURRENT,GEORG,RMS,STUTTGART,SURGERY,USING
AKT,ATP,BZATP,CLAUDIN,EMT,HOWEVER,MMP,SIMILAR,SNAIL,THESE
682,BAZ2A,CPG,EPIGENETIC,FINALLY
001,105,122,ANOVA,COMPARISON,DECREASED,GROUP,GSK,HTB41,INHIBITOR,KEULS,LABEL,METHODS,OBJECTIVE,PBS,PURPOSE,RESULTS,SCC,SGK
945,DESPITE,PKI,PRKAR2A,TAXOL
ADT,CONCLUSION,DESPITE,FURTHER,LOCAL,SALVAGE,SYNTHESIS,THERE
169,AUS,BACKGROUND,FIFTY,LABEL,MATERIALS,MEN,METHODS,REGARDLESS,RESULTS,THEIR,UDS
120,177,BACKGROUND,CONCLUSION,INCLUSION,IQR,JANUARY,LABEL,METHODS,PPI,RESULTS
230,349,362,AMICO,ASSESSMENT,BACKGROUND,CAPRA,LABEL,MATERIALS,METHODS,PSA,RESULTS,THERE,THESE,UNIVARIATE
ADDITIONAL,III,NSCLC,PHASE,TAA
174,AFTER,AMONG
THOSE,TPD52
5T4,CURRENTLY,DESPITE,MVA,THERE

NOVEL,THERE,VARIOUS
797,ACTIVATION,ATP,BESIDES,EGF,INCREASED,INHIBITION,MUTATIONAL
945,946,EMT,GSK,JUN,SER63,SMAD2,SMAD3,SMAD4,SMAD7,TGF,TRAF6
145,DU145,EPN,FINALLY,LIPOS,NPS,PC3,PEGYLATED,THESE,ZOL,ZOLEDRONIC
AXL,BMS777607,CRK,KNOCKDOWN,LYN,MPCD84111,SRC,TAKEN,THEREBY
169,946,COPYRIGHT,EGF,ELK,INC,MEK,RAS,SMAD3,TGF,U0126
169,COPYRIGHT,FURTHER,INC,TCA,THESE,TXNIP
169,231,AMONG,CHAETOMIUM,COPYRIGHT,ETOAC,HOWEVER,HSP90,LNCAP,LTD,MDA,NMR,RRL,THYMELAEA
169,945,COPYRIGHT,CYP17A1,ISSUE,LTD,PUBLISHED,SPECIAL,STEROID
103,120,125,131,169,195,COPYRIGHT,DEF,GBS,GNP,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
ALPHA,BACKGROUND,BPH,CPZ,DU145,IP3,LABEL,LNCAP,METHODS,MTT,PC3,PCA,PCR,PKC,PLC,RESULTS,SIGNALLING,THERE,THESE,TRPV1,WS433
169,177,826,876,917,CONCLUSION,COPYRIGHT,ICC,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SWE,THERE,YOUNG
001,003,012,025,169,408,563,601,914,AFTER,ARIMA,COPYRIGHT,EDUCATION,GLEASON,INC,IQR,LABEL,LOW,MATERIALS,METHODS,NETWORK,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,TORONTO,UNIVERSITY,UROLOGICAL
169,BIOLOGY,HOWEVER,INC,MOLECULAR,PC3,PICOMOLAR,SOCIETY,TRPM8,USING
169,293,ALONG,BIOLOGY,HEK,INC,MOLECULAR,SOCIETY,THESE,TRPM8,USING
PCR,SEQ,ULTRA
111,169,47D,BBN,COPYRIGHT,LNCAP,LTD,NLE,TYR
279,ANIMALS,BACKGROUND,CONCLUSION,E26,ERG,ETS,EXPRESSION,GLYATL2,INHIBITION,LABEL,LNCAP,METHODS,RESULTS,THEREFORE
169,177,FINALLY,PRESS,PUBLISHED,SFRP1,THESE,UNIVERSITY
001,169,688,ACM,AFTER,CCI,CONVERSELY,COPYRIGHT,CSM,LABEL,LTD,METHODS,MVA,OBJECTIVE,PURPOSE,RESULTS,SIMILAR,SUBGROUPS,USING
BACKGROUND,BASED,CONCLUSION,CONSENSUS,DESPITE,GLEASON,LABEL,METHODS,PSA,RESULTS
ACTIVATION,DHT,R1881,RAC,RAS,SER10,TEN
169,COPYRIGHT,ELISA,PSA
BACKGROUND,CURRENT,DESIRABLE,LABEL,OVERALL,RESULTS
169,COPYRIGHT,INC,NIX,UPR
ALA119SER,ASN453SER,CAUCASIANS,LEU432VAL
169,223,945,946,COPYRIGHT,INC,MAY,RACL2,SINCE,THESE
169,COPYRIGHT,INC
169,178,AIM,BACKGROUND,CNS,CONCLUSION,COPYRIGHT,DESPITE,IMPROVING,LABEL,LTD,METHODS,OBJECTIVE,OVERALL,PATIENT,RESULTS,THERE,THESE
OCCURRENCE,PATIENT,PCA,PIAS1
BACKGROUND,CARLO,CONCLUSION,FURTHER,LABEL,METHODS,MONTE,OBJECTIVE,OBJECTIVES,PCA,PREDICTED,RESULTS,SEVERAL,THEREFORE,TREATMENT,VALIDATION
001,085,169,327,389,AMONG,CUMULATIVE,END,LABEL,METHODS,OBJECTIVE,RESULTS,THESE,USING,VALIDATED
4PG,BACKGROUND,CPT,CSC,ENRICHMENT,HOWEVER,LABEL,LUC,METHODS,MTT,NEUTRAL,NUCLEAR,PC3,RED,RESULTS,THESE
139,15Q26,37E,454,749,89E,AFTER,AMONG,BLM,CHB,CHINESE,ERBB2IP,ERBB4,FRK,GEO,RPS6KA2
AVAILABLE,HOWEVER,PRESENT,PRL,STAT5
DCE,LABEL,METHODS,MRI,OBJECTIVE,PROMISING,PURPOSE,RESULTS,THESE
LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTY,THREE,VALIDATION
176,FURTHER,INSIGHTEC,LABEL,LNCAP,METHODS,MHZ,MRI,OBJECTIVE,PURPOSE,RESULTS,THERE
169,AKT,GDC,HEREGULIN,HOWEVER,THESE
001,171,177,221,392,ADDITIONAL,ADT,AMICO,BACKGROUND,BCR,COX,HDR,JANUARY,LABEL,MEIER,METHODS,OVERALL,PCA,PHYSICIANS,RESULTS
PIVOTAL
CANCERS,FRANCISCO,JANUARY,SAN,SOCIETY,SYMPOSIUM,USA
231,BAD,BAK,BAX,BCL,GAS,HEP,LNCAP,MDA,OVERALL,SOE,TREATMENT
DARWINIAN,FINALLY,HOWEVER,THROUGH
ANOTHER,BECAUSE,THESE
160,183,GEORG,STUTTGART,TEN,VALERIANA
848
956,ANNEXIN,DU145,FURTHER,MOLECULAR,STUDIES
000,169,183,279,AGAINST,AMERICA,ATLANTA,AUSTRALIA,BACKGROUND,BELFAST,CENTERS,CONTINUOUS,CONTROL,COPYRIGHT,DEC,DISEASE,ECUADOR,ESTIMATES,FOCUS,FUNDING,INDIVIDUAL,INSTITUTE,IRELAND,JAPAN,KOREA,LABEL,LEXINGTON,LIVER,LTD,METHODS,NORTH,PREVENTION,PUBLISHED,RESULTS,SOUTH,SWISS,TORONTO,UNIVERSITY,USA,WALES,WORLDWIDE
169,946,COPYRIGHT,LTD
169,497,AMERICA,AUSTRALIA,BACKGROUND,COMPARE,CONCLUSION,COPYRIGHT,DETERMINE,JANUARY,LABEL,LIBRARY,LTD,MEDLINE,METHODS,NORTH,OBJECTIVE,PSYCHINFO,RESULTS,SCIENCE,STUDIES,THERE,WEB
231,CD1,CD2,CU1,LNCAP,MDA,UBIQUITIN,UPS
10877,169,BACKGROUND,C30,CONCLUSION,COPYRIGHT,DIETARY,EFFECTS,FREQUENCY,HRQOL,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,QLQ,RESULTS,TREATMENT
169,COPYRIGHT
169,2B4,916,CAD11,EXPRESSION,FASEB,FURTHER,HEK293T,HIPPO,PC3,USING
BESIDES,HOWEVER
123,169,5FRACTIONS,5GY,CONCLUSION,COPYRIGHT,HDR,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,QOL,RESULTS,THERE,URINARY
169,ARB,BASED,COPYRIGHT,DESPITE,FDA,HOWEVER,IRELAND,LTD,PUBLISHED
169,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PLANS,PURPOSE,RESULTS
001,169,ADDITIONAL,BACKGROUND,BLACK,CONCLUSION,COPYRIGHT,DVD,FDR,FIRST,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SEVENTY,THERE,THESE,WHITE
100,169,731,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,LABEL,LTD,MATERIALS,METHODS,OVERALL,PATIENT,PCA,PRESCRIBED,RESULTS,SWEDISH,TIMELINESS
119,353,402,431,593,624,958,990,AUC,DOR,EBSCO,KNOWLEDGE,LIBRARY,MDP,MRI,TCM,WEB
169,CLU,COPYRIGHT,CPG,DU145,LYS27,PC3,PNT1A,START,TSA,TSS
169,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,516,549,550,551,558,648,654,658,661,698,707,708,AUC,AUSTRALIA,COPYRIGHT,EDUCATION,EPSTEIN,FDA,GLEASON,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PHI,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,251,322,570,634,776,806,879,880,COPYRIGHT,EDUCATION,FURTHER,INACCURATE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QALYS,RESULTS,UROLOGICAL
169,779,CIS,COPYRIGHT,COX,EDUCATION,HRS,INC,INCREASED,KINGDOM,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,REPOSITORY,RESULTS,THESE,UROLOGICAL,USING
100,169,247,ANY,COPYRIGHT,COX,EDUCATION,FIRST,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,269,324,391,COPYRIGHT,EDUCATION,GLEASON,INC,IQR,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL
001,010,016,169,190,247,CLINICIANS,COPYRIGHT,COX,EDUCATION,FURTHER,HOWEVER,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TREATMENT,UROLOGICAL
001,681,ACCORDING,AIM,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SERUM,THERE
169,COPYRIGHT,DETECTION,PEG,PSA
126,149,169,946,AFTER,COPYRIGHT,DU145,FUNCTIONAL,GAL,INC,LNCAP,MICRORNAS,MTS,NANOG,PC3,PCR,THESE
169,601,744,775,COPYRIGHT,DEPRESSION,DIFFERENT,FURTHER,HOWEVER,INSURANCE,KOREANS,MAJOR,REGARDING,SERVICE,THERE
100,160,169,200,COPYRIGHT,PUBLISHED,SAS,VORINOSTAT
145,160,169,956,AKT,AMONG,COPYRIGHT,FURTHER,HEPG2,HOECHST,MCF,PKB,SAS
169,945,COPYRIGHT,HIF,LNCAP,LTD,PC3,PGE,THEREFORE,THESE
956,DOCETAXEL,MBQ,METABOLITE,SEVEN,THESE
BACKGROUND,BCAS2,GST,HSP90,LABEL,LNCAP,METHODS,MTT,PCA,PROTEIN,RESULTS,THERE,THEREFORE
281,BACKGROUND,EXPRESSION,GLEASON,INDEX,LABEL,METHODS,RESULTS
001,100TH,143,184,255,291,327,452,711,754,963,BACKGROUND,COLORECTAL,CURRENTLY,CXR,EDITORS,FORCE,LABEL,METHODS,OVARIAN,PPV,PREVENTIVE,RESULTS,RISKS,SCREENING,SMOKERS,SUMMARY,TRIAL
169,200NG,3PG,963,AB1,AB2,COPYRIGHT,PSA,USING
169,BASED,COPYRIGHT,EN2,FAM,FINALLY,VARIOUS
169,1ML,COPYRIGHT,EPCAM,IFA,PBS,SEM,SPIKING,XPS
169,AUTHORS,COPYRIGHT,LTD,MRI,PUBLISHED
169,177,COPYRIGHT,DU145,LTD,MPA,WM115,WM266
947,ATM,CFS,COMPARING,FINALLY,HOWEVER
169,946,CD133,CD49F,COPYRIGHT,CXCR4,EPCAM,ISSUE,LTD,NOTCH,SPECIAL,TGF,VITAMIN,WNT
169,ADT,COPYRIGHT,CURRENTLY,IRELAND,LTD
BF3,BINDING,LNCAP,MR49F,PCA,PSA,THERE,THESE
111,177,20H,24H,255,321,945,946,AHX,ALA,ARG,ASP,BACKGROUND,ESI,GLN,GLU,GLY,INC,KNOWLEDGE,LABEL,LEU,METHODS,MICRO,NATURAL,NH2,PATIENT,PHE,PUBLISHED,RESULTS,RGD,RM2,STA,THESE,TRP,U87,VAL
169,632,657,669,705,ACCORDING,AUC,COPYRIGHT,NLR,PLR,PSA,PUBLISHED,ROC,SERUM,TEN,THERE
169,945,946,99M,COPYRIGHT,CURRENTLY,EC145,FOLIC,LTD,PHASE,THEREFORE,VINCA
169,176,177,1HR,BACKGROUND,COPYRIGHT,DSRED,ELISA,EPCAM,INC,LABEL,METHODS,PC3,RESULTS,SIMILAR
169,COPYRIGHT,FIFTY,GLEASON,HIGHEST,INC,MRI,PSA
169,960,AFTER,AGREEMENT,CONCLUSION,COPYRIGHT,ERC,ICC,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,LTD,THEIR
126,169,177,216,289,4HR,5HR,ALA,COPYRIGHT,GASTRIN,GLN,GLY,INC,LEU,NH2,STATINE,THESE,TRP,VAL
945,AFP,AFTER,ATP,BESIDES,BPE,ECL,ITO,NPS,PSA,TPA
012,128,169,ATLAS,BACKGROUND,CONCLUSION,COPYRIGHT,FTC,FVPTC,INC,LABEL,METHODS,NODAL,PTC,RESULTS
169,945,946,COPYRIGHT,EPR,ERP,TARGETING
III
00013,019,100,117,126,154,169,183,AUC,BACKGROUND,BIOMEDICAL,CAMBRIDGE,CHARITY,COPYRIGHT,DAD,ENRICHMENT,FOUNDATION,FOX,FUNDING,GENOMIC,HUTCHISON,INSTITUTE,KETTERING,LABEL,LALONDE,LIMITED,LTD,METHODS,MOTORCYCLE,MSKCC,ONTARIO,PMH,PROGRAM,PUBLISHED,RADIATION,RESULTS,SLOAN,SOCIETY,TERRY,TORONTO,UNIVERSITY,WHAMPOA
169,183,463,545,AFFYMETRIX,AMENDMENTS,BACKGROUND,CHARITABLE,COPYRIGHT,DEFENSE,DEPARTMENT,DETECTION,DORIS,EARLY,FOUNDATION,FUNDING,GLEASON,INSTITUTE,INSTITUTES,LABEL,LABORATORY,LTD,MEDICAL,METHODS,NETWORK,RESULTS,SCHLAP1,THEREFORE,VALIDATION
169,936,AUTHORS,JAPAN,LTD,MEN,OSAKA,PSA,PTY,PUBLISHING,SCIENCE,USING,WILEY
169,COPYRIGHT,FOURIER,LTD
945,ATLAS,EMT,GYLTY1B,PCR,REDUCTIONS,SNAIL
DISCOVERY,NRS,NUCLEAR,TFS,ULTIMATELY
125,169,COPYRIGHT,GRADE,INC,JAPAN,LDR,OUTCOME,PERMANENT,PUBLISHED,SCORE,SEVERAL,SOCIETY,SYMPTOM,URINARY
001,169,ACCORDING,BACKGROUND,CCI,COPYRIGHT,END,INDEX,LABEL,LTD,METHODS,MORTALITY,RESULTS,T4A
169,AMICO,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,LOW,MEDLINE,METHODS,MRI,NOVEL,RESULTS,SAS
169,946,COPYRIGHT,FEDERATION,FINALLY,IKB,IKK,LARGE,MCF,MLL,PC3,PKC,PUBLISHED,RAPID,SOCIETIES,SW620,TARGETING
169,945,946,ALLYL,ATE,BROMINATED,COPYRIGHT,HOWEVER,LAT,LTD,PSA,THESE,THREE,WESTERN
177,946,956,BASED,EG5,HR22C16,MCF,ME180,MOLECULAR,MTT,THESE
169,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,ORS,OVERALL,PCA,RESULTS,THESE
169,AKT,COPYRIGHT,EGFR1,ERB,LTD
169,2109A,22RV1,ANTIBODIES,CONCLUSION,CWR22PC,IMAGING,INC,LABEL,METHODS,MOLECULAR,MSTP2109A,NUCLEAR,PC3,PCA,PET,RESULTS,SOCIETY,THESE,UNLABELLED
169,611,BRAIN,CONCLUSION,FACBC,FDG,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,RESULTS,SIXTEEN,SOCIETY,UNLABELLED
002,011,058,169,526,BCR,CAUCASIAN,CONVERSELY,COX,GENOTYPES,HOWEVER,HRS,MEIER,PCA,SOCIETY,UGT1A10,UGT2B
103,169,AIM,ASSESSMENT,BACKGROUND,BRITISH,CONCLUSION,CURRENTLY,DRE,EVALUATION,GENERAL,IRISH,JOURNAL,LABEL,MAY,METHODS,OBJECTIVE,OCTOBER,PATIENT,PSA,RAPID,RESULTS,SETTING,SEVENTY
169,FVB,SFK,SRC
169,34S,COPYRIGHT,CRC,FURTHER,HCC,NPC,NSCLC,PCA,SCIENCE,THEREFORE,ULTIMATELY,WEB
160,169,COMMENTARY,COPYRIGHT,INC,PATHOLOGY,PUBLISHED,SANTE,SIRT1,SOCIETY
181,H1299,IND,INDANONES,INHIBITORY,MTT,NMR
001,121,169,AUC,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
100,169,AGREE,AUA,COPYRIGHT,EDUCATION,ENGLISH,HOWEVER,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
112,169,526,985,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OLDER,PROLONGED,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
111,112,125,137,169,230,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
119,150,169,231,233,626,BETWEEN,CONCLUSION,COPYRIGHT,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,THERE
169,177,183,231,233,BETWEEN,CONCLUSION,COPYRIGHT,HENRI,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,STUDIES
169,BRUCHOVSKY,COPYRIGHT,KUANG,LTD,PORTZ
1A1,4EBP1,946,CAP,CONSISTENT,INC,PDGFR,PIM,PUBLISHED,WESTERN
169,COPYRIGHT,PUBLISHED,SEVERAL
100,169,COPYRIGHT,DOX,LNCAP,THESE
169,231,945,CD49F,COPYRIGHT,DU145,FAK,ILK,INC,INHIBITION,ITGA6,MDA,PC3B1,TAKEN
019,AUC,CONCLUSION,DOR,FINALLY,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,SECTION,STATA,URINE
169,AUTHORS,COPYRIGHT,HOWEVER,INC,INITIAL,PUBLISHED,THESE
169,3LL,ALDH1A1,COPYRIGHT,CSC,ID1,INCREASED,IRELAND,LTD,NOTCH,OCT,PKH26,SCA,SOX,THROUGH,USING
169,945,946,AKT,COPYRIGHT,FURTHER,HGF,HOWEVER,IRELAND,LTD,MET,PC3,SILENCING,THESE,XL184
005,100,122,169,COPYRIGHT,GATA3,INC,INVUC,UCS,UROPLAKIN,UROPLAKINS
169,311,B3LYP,COPYRIGHT,DFT,MCF,MTT
CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,SIR,STUDIES
0NG,169,183,2PG,COPYRIGHT,FCA,INC,LOW,MCM48,NH2,PSA,UNDER
169,AFM,AMP,COPYRIGHT,HNP,STUDIES
169,178,185,ACETYLATED,AKT,COPYRIGHT,FINALLY,FURTHER,LYS,METASTASIS,TAKEN
169,COPYRIGHT,D90,DVH,EGO,GRAPHICAL,GRO,HOWEVER,IIP,INC,INVERSE,LABEL,MATERIALS,METHODS,OBJECTIVE,PDR,PUBLISHED,PURPOSE,RESULTS,SOCIETY,TREATMENT
169,BNI,COPYRIGHT,FAS,FOCAL,HGF,INC,INSTEAD,SUBSEQUENT
EARLY,FDA,HOWEVER,LICENSING,PET,PFS,PSA,SCREENING,SWISSMEDIC
279,387,902,948,COX,OPG,THERE
169,954,COPYRIGHT,COX,ERK,INC,LNCAP,PC3,PI3,PKA,RWPE1,VASOACTIVE,VIP
001,169,AKT,COMBINING,COPYRIGHT,EMT,FURTHER,HOWEVER,INC,MMP,PCA
169,307,388,AFTER,ARO,ART,COPYRIGHT,COX,FORTY,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,RESULTS,SRT
169,176,177,267,CONTINUOUS,COPYRIGHT,DOF,INC,KIM,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,VARIOUS
169,CONCLUSION,COPYRIGHT,CROWN,FIFTY,GRADE,HDPRT,LABEL,LOCAL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,THERE
120,169,BACKGROUND,BPH,CHINESE,CIS,COPYRIGHT,INC,LABEL,METHODS,ORS,PCA,PCR,RESULTS,STR
145,169,COPYRIGHT,DDC,GIVEN,MICRORNAS,MOTIVATED,OVERALL,PCR,PUBLISHED,WESTERN
169,200,956,AKT,APOPTOTIC,BCL,C18,COPYRIGHT,DESPITE,ERK,INC,KEY,LABEL,METHODS,MMP,MTT,OBJECTIVE,RESULTS,THESE,TUNEL,UNDERLYING,ZEA
169,177,945,954,956,COPYRIGHT,INC,KEY,LABEL,METHODS,MRP,MTX,OBJECTIVE,RES,RESULTS,TESTICULAR
164,169,174,582,ASA,COPYRIGHT,COX,DEFINITIVE,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,403,410,813,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,MUSIC,OBJECTIVE,PRACTICES,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,169,174,COPYRIGHT,CURRENTLY,HOWEVER,INC,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS
169,213,255,798,837,COPYRIGHT,EDUCATION,EPSTEIN,GIVEN,GLEASON,INC,INITIAL,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,174,945,COPYRIGHT,EDUCATION,HIF,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,THEREFORE,UROLOGICAL
120,169,181,AUC,COPYRIGHT,IRELAND,LTD,OCE,PCA
145,169,947,948,APPPI,COPYRIGHT,CYTOTOXIC,FURTHER,HOWEVER,IPP,IRELAND,LTD,U87MG,ZOL
169,223,303,APRIL,COPYRIGHT,EDUCATION,GIVEN,GUIDELINE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRINCIPLES,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,AUTHORS,BESIDES,FOUNDATION,IRF,JOURNAL,LNCAP,LTD,MOLECULAR,NOTABLY,PC3,PCA,THEREFORE,WILEY
169,COPYRIGHT,EVALUATION,INC,SHEAR,THERE
169,215,CONCLUSION,COPYRIGHT,GLEASON,HISTOLOGIC,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,RESULTS,UROSTATION
100,124,169,177,702,716,726,970,AUC,BXS,CAP,CONCLUSION,COPYRIGHT,HGPIN,INC,LABEL,MEANS,METHODS,OBJECTIVE,PSA,RESULTS
131,169,262,CONCLUSION,COPYRIGHT,DEPENDING,DESPITE,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,RESULTS,SVI,SVS
114,119,169,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PSA,RESULTS
169,CLAVIEN,CONCLUSION,COPYRIGHT,FUNCTIONAL,GLEASON,INC,KINGDOM,LABEL,METHODS,OBJECTIVE,RESULTS,THREE,WHOLE
023,028,115,117,118,169,175,176,233,CLAVIEN,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,MINIMUM,MINOR,OBJECTIVE,OCTOBER,OVERALL,RENAL,RESULTS,SERUM,SIMILARLY,VARIABLES
122,129,140,169,170,230,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SCORE,SYMPTOM,TEN
001,003,048,169,201,408,431,839,ASA,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MEN,METHODS,NSAID,OBJECTIVE,RESULTS
001,003,023,274,CONCLUSION,END,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PUBLISHED,RESULTS
169,323,426,AFFAIRS,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,POISSON,PSA,RESULTS,THESE
103,169,345,ACUTE,CONCLUSION,COPYRIGHT,FORTY,INC,LABEL,MARCH,MATERIALS,MAY,METHODS,OBJECTIVE,RESULTS,THESE
169,AFTER,CANONICAL,COPYRIGHT,DMA,HENCE,LTD,MULTI,PUBLISHED,RESULTS
169,286,843,ANGELES,CALIFORNIA,CAPSURE,COPYRIGHT,DESPITE,INC,INDEX,LABEL,LOS,METHODS,OBJECTIVE,PATIENT,RESULTS,UNIVERSITY
147,169,COPYRIGHT,COX,DEPRESSION,END,INC,LABEL,METHODS,NINTH,OBJECTIVE,POISSON,RESULTS,THESE
001,009,041,160,169,204,266,304,570,AUR,COLLEGE,COPYRIGHT,FORTY,HOWEVER,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PSA,PUBLISHED,RADIOLOGY,RATIONALE,RESULTS
169,247,316,563,929,945,946,947,AUC,BED,BETWEEN,COPYRIGHT,INC,LABEL,LIKELIHOOD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,169,177,CALCULATED,CONCLUSION,COPYRIGHT,CTS,D99,DRR,DSC,FURTHER,GAMMA,GENERATED,HOUNSFIELD,INC,LABEL,MAE,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIM
001,008,169,187,217,ADVERSE,AUTHORS,COPYRIGHT,DVH,GR1,GR2,GR3,GR4,GR5,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,POTENTIAL,PUBLISHED,PURPOSE,RESULTS,TECHNIQUES,THERE,TRANSIENT,UNIVARIATE,V75
500,ACCORDING,CALYPSO,CTS,CTV,D99,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TEN
169,250,954,AGREEMENT,CLEARER,CONCLUSION,COPYRIGHT,CTC,FORTY,GROUP,ICC,INC,INSTITUTE,JANUARY,LABEL,LOW,MATERIALS,METHODS,NCI,OBJECTIVE,PURPOSE,RADIATION,RESULTS,SEVENTY,THERAPY,USING,WEB
169,786,BAX,CASPASE,COPYRIGHT,FUNCTIONAL,HOWEVER,INC,ZFX
10878,169,BACKGROUND,CONCLUSION,COPYRIGHT,DVC,IMRTWHILE,IRELAND,LABEL,LRT,LTD,METHODS,R40,R50,R60,R65,R70,RESULTS,SIX,THERE
169,COPYRIGHT,HOWEVER,LTD,MULTI,SWEDISH,USING
169,376,425,BACKGROUND,COPYRIGHT,DECREASES,DEPARTMENT,INC,JOURNAL,LABEL,METHODS,MULTILEVEL,OBJECTIVE,PREVENTIVE,PUBLISHED,PURPOSE,RESULTS
100NM,169,COPYRIGHT,LOD,NHS,PCA,SOX
169,CLINICIANS,COLLEGE,COPYRIGHT,LTD,PUBLISHED,ROYAL,THESE,ULTIMATELY
001,003,169,842,CONCLUSION,COPYRIGHT,FORTY,INC,INVENTORY,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PEARSON,RADIATION,RESULTS
169,ADVERSE,CONCLUSION,COPYRIGHT,EPSTEIN,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,THERE
169,201,212,AFRICAN,AFTER,AMICO,CONCLUSION,COPYRIGHT,FACTORS,FORCE,GLEASON,INC,LABEL,MEN,METHODS,OBJECTIVE,PREVENTIVE,PSA,RESULTS
169,750,BCRFS,COMMITTEE,CONCLUSION,COPYRIGHT,COX,EPE,GLEASON,INC,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS
001,002,003,169,615,654,982,AAS,ADJUSTING,AFRICAN,CAUCASIAN,CAUCASIANS,CONCLUSION,COPYRIGHT,EXAMINING,GLEASON,HOPKINS,INC,INCLUDING,JOHNS,LABEL,METHODS,NETWORK,OBJECTIVE,PSA,RESULTS,THEREFORE,VLR
169,AFTER,CONCLUSION,COPYRIGHT,DU145,FINALLY,INC,KIT,LABEL,MATERIALS,METHODS,MMP,OBJECTIVE,PC3,RESULTS,USING,WESTERN
002,130,133,169,171,174,183,205,223,253,262,322,347,352,383,395,518,526,921,945,ASA,BACKGROUND,BAYER,COPYRIGHT,FEB,FUNDING,HEALTHCARE,LABEL,LTD,METHODS,PRIMARY,RESULTS
169,849,ACADEMY,ALLERGY,ATOPY,BACKGROUND,CIS,CONCLUSION,COPYRIGHT,COX,HOWEVER,IGE,IMMUNOLOGY,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,THERE
169,AFTER,COPYRIGHT,INC,THESE
029,100,121,149,169,3N0,COPYRIGHT,GLEASON,MARCH,NSM,PSM,PUBLISHED
001,117,197,379,475,AFFAIRS,BACKGROUND,CHARITABLE,CONCLUSION,DEPARTMENT,DORIS,FOUNDATION,FUNDING,GEOGRAPHIC,LABEL,LIMITATION,METHODS,MULTILEVEL,OBJECTIVE,OLDER,PER,PRIMARY,RESULTS,SETTING
945,DEPLETION,FINALLY,GLUT1,MYC,PCA,SIMILARLY,WHILE
100,116,169,539,549,956,CEM,CNS,COLON,COPYRIGHT,HCT,LTD,MALME,NCI,NON,NSC,OVARIAN,OVCAR,RENAL,SMALL
169,COPYRIGHT,EMT,FIRSTLY,HDAC1,HDAC2,INC,MEANWHILE,OVERALL,PC3,SW480,THESE,TSA
10Q,116,13Q,169,16Q,17P,18Q,21Q,546,662,AUTHORS,CNA,COPYRIGHT,ERG,INC,PREDICTED,PUBLISHED,TMPRSS2
006,061,169,231,376,382,428,839,983,A453G,CIS,COPYRIGHT,G119T,HENCE,IRELAND,LTD,ORS,PUBLISHED,REGARDING,STATA,THERE
10Q11,169,19Q13,200,215,554,754,COPYRIGHT,HOWEVER,PCA,PREVENTION,PSA,SLC45A3,SNP,THREE
BASIC,BRCA1,BRCA2,BRIP1,JAPAN,PALB2,PCR,RRM,THEREFORE
COMMITTEE,JOINT,STATINS
AFTER,BPH,COMPARISON,CONCLUSION,EVALUATION,EXPRESSION,INCREASED,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
THESE
169,1B1,945,946,956,AIM,BPH,COPYRIGHT,INC,KEY,LABEL,MALIGNANT,METHODS,OBJECTIVE,PCR,RESULTS,THESE
001,024,060,169,239,890,993,AFRICAN,BCR,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PATHOLOGIC,RESULTS,STUDIES
169,304,510,ASSESSMENT,CONCLUSION,COPYRIGHT,COX,INC,LABEL,MATERIALS,MEIER,METHODS,NADIA,OBJECTIVE,PROSVUE,RESULTS,SALVAGE
001,016,106,148,169,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,NVB,OBJECTIVE,RESULTS,THESE
ADT,HOWEVER,MDV3100,PCA,SINCE,WHILE
966,ERSPC,WHILE
169,COPYRIGHT,DENOSUMAB,DRUGS,LTD,PUBLISHED,STILL
169,ASC,BPH,COPYRIGHT,CURRENT,HOWEVER,INC,PATHOLOGY,PCA,PUBLISHED,SOCIETY
002,107,408,998,AMERICA,CIS,COLORECTAL,COX,GOVERNMENT,HRS,OVARIAN,PUBLISHED,RCC,SCREENING,TRIAL
169,309GG,331,501,532,717,749,830,AUTHORS,CONSISTENT,INC,PUBLISHED,SNP285C,SNP285G,SNP309T,WILEY
001,179,185,DU145,GLEASON,PC3,PCA,PET
956,AFTER,ANNEXIN,DU145,LNCAP,PC3,PLATYCODIN,THESE,WESTERN
150,177,195,1SD,BACKGROUND,LABEL,METHODS,RESULTS
176,947,CONCLUSION,DOSES,KNOWN,LABEL,METHODS,OAR,OBJECTIVE,PREVIOUSLY,PTV,PURPOSE,RESULTS
174,BOEHRINGER,COMMITTEE,INGELHEIM,IPF,MEDICINAL,MEDICINES,NINTEDANIB,OCTOBER,PHASE
241,544,574,641,668,900,ADC,CONCLUSION,DIFFERENCE,GLEASON,HISTOGRAM,KEY,LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS,ROC
160,169,204,ADDITIONAL,ASSESSMENT,AUTHORS,BJU,CENTRAL,CIS,CONTROLLED,EVALUATION,FINALLY,GHQOL,GRADE,GRADING,HOWEVER,LTD,MEDLINE,MEN,OCTOBER,OVERALL,PAIRS,PUBLISHED,QOL,RANDOMISED,SMD,THERE,WILEY
239,DCS,ENZ,FURTHER,HOWEVER,OVERALL,THESE
FETAL,SINCE
BPH,LOD,LOQ,MRM,PCA,PSA,SIL,SINCE
AFRICAN,AMERICANS,CARIBBEAN,FINALLY,GENOMIC,HIV,HOWEVER,INCLUSION
CORTACTIN,CXCR4,DENBINOBIN,DENDROBIUM,PC3,THESE,WHETHER
HOT,PUTTING
BACKGROUND,CONCLUSION,CRC,INDIVIDUAL,JAN,LABEL,MAR,METHODS,RESULTS,THERE
ADVERSE,BACKGROUND,CUTANEOUS,EARLY,IDENTIFIER,IMPORTANCE,INSTITUTE,INSTITUTES,LABEL,MET,METHODS,OBJECTIVE,OCTOBER,REACTIONS,RELEVANCE,RESULTS,RET,SETTING,TRIAL
CBG,OFF,PSA,USING
ATP,CSK,METABOLIC,THESE
549,BGLAP,LNCAP,NOTCH,RUNX2,SP7,TAKEN
177,244,471,ATLAS,CONSORTIUM,CUP,METASTATIC,SEQ
MYC
252,AKT,CREB1,ERK,HISTOLOGIC,HOMOZYGOUS,MYC,SP1,THESE
169,CONFIRMED,EASTERN,GRADE,GROUP,HOWEVER,JAPAN,LABEL,MEN,METHODS,OBJECTIVE,PHASE,PRESS,PRIMARY,PUBLISHED,RESULTS,SECONDARY,TRIAL,UNASSIGNED,UNIVERSITY
118,169,AMONG,CONCLUSION,D10,GRADE,GROUP,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RADIATION,RESULTS,THERAPY,TREATMENT,UNIVERSITY
155,BECAUSE,LIBRARY,MEDLINE,RANDOMIZED
946,956,BECAUSE,PC3,THESE
145,945,ADP,ATF,BIP,BORON,DIETARY,GRP78,LOW
ADVERSE,BACKGROUND,BPH,CHANGES,CLAVIEN,DESPITE,DISCUSSION,INSTITUTE,LABEL,METHODS,PAE,SCORE,SYMPTOM,TRIAL,TUR
145,177,99M,FURTHER,HOWEVER,IGF,MCF,RENAL
ARTISTE,BACKGROUND,FFF,LABEL,METHODS,PANTHER,PLANS,PROWESS,RESULTS,SCATTERED,SIEMENS,THERE,TREATMENT,WHILE
212,HIGHEST,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SUPPORTIVE,THEREFORE
169,181,213,394,ADVERSE,BACKGROUND,BLADDER,COX,LABEL,MAXIMUM,METHODS,PBT,PCA,RBE,RESULTS,SOCIETY
003,009,169,202,ADC,BLAND,CONCLUSION,DCE,FACTORS,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,VOLUMES,VT2
238,APPARENTLY,BACKGROUND,BESIDES,CODES,COX,DESPITE,FOLLOWING,LABEL,METHODS,PSA,RESULTS,THEIR,TREATMENT,UNIVARIATE
486,538,572,ALCOHOL,BACKGROUND,HEAVY,HODGKIN,LABEL,METHODS,NON,RESULTS,RRS,THERE
945,946,BECAUSE,LIGANDS,METHODS
080,AS1,BROWN,C20ORF166,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEQ,THREE
AKT,ASIAN,CHINA,MTT
0NG,117,183,207,4ML,559,BACKGROUND,CPC,DRE,LABEL,MATERIALS,MEN,METHODS,P504S,PRIMARY,PSA,RESULTS
000,100,150,218,AGE,BACKGROUND,DIGITAL,GLEASON,LABEL,MATERIALS,METHODS,PSA,RESULTS,T1C,THERE
169,946,BACKGROUND,HOWEVER,INC,LABEL,MC3T3,METHODS,RESULTS,SEMAPHORIN,WILEY
169,UROLOGICAL,VARIOUS
THERE,THEREFORE,THESE
DISCOVERY,PCA
SIMILARLY,ULTIMATELY,WHILE
BIOTECHNOL,NAT,THESE

CPG,EPIGENETIC,WESTERN
169,AMONG,CLEARER,COPYRIGHT,FEW,LABEL,LTD,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RESULTS,WILEY
13C,NMR
246,BACKGROUND,LABEL,METHODS,RESULTS,SEGMENTED,SPAIN
177,ACUTE,BPH,DYSURIA,FINALLY,OTHER,PCA,SIGNALMENT,TAKEN
DESPITE,ERG,FINALLY,TAXANES
000,100,221,891,BARANJA,C60,C63,CANCERS,CROATIA,INSTITUTE,OBC,OVERALL,THESE
948,956,HAX,HCLS1,MCL,MYC,PRKCD,PROTEIN,SCF
118,15A,19A,BACKGROUND,DESPITE,GO_BP,LABEL,RESULTS,SP1,TFS,TRAIT
FINALLY,GLEASON,HOWEVER,PATHOLOGY,SEVERAL,SOCIETY,UROLOGICAL
010,016,029,066,156,168,169,172,1ST,262,274,3RD,593,BACKGROUND,CASES,CONCLUSION,FIBER,INC,LABEL,METHODS,PSA,RESULTS,WILEY
169,90401,AGE,ATE,BACKGROUND,CALGB,COX,CYCLE,GROUP,LABEL,METHODS,RESULTS,SCANT,SOCIETY,VTE
001,003,005,169,454,AFRICAN,BACKGROUND,CAUCASIAN,GLEASON,INC,LABEL,LOW,METHODS,NEITHER,PSA,REMAINING,RESULTS,SEVENTY,T1C,T2A,THESE,WHILE,WILEY
181,316,690,CONCLUSION,CONTINUED,END,INDIANS,LABEL,METHODS,OBJECTIVE,RESULTS,WHILE,WHITE
266,CNS,FUNDING,LABEL,METHODS,OBJECTIVE,ONTARIO,PURPOSE,RESULTS,VALUE
169,990,BACKGROUND,CALCULATOR,CRC,END,FURTHER,INSTITUTE,LABEL,METHODS,PERMANENTE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
990,BACKGROUND,CALCULATOR,END,HMO,INSTITUTE,LABEL,METHODS,NOMOGRAMS,OPERATING,PERMANENTE,PRESS,PUBLISHED,RESULTS,THESE,UNIVERSITY
BACKGROUND,CONCLUSION,END,LABEL,METHODS,OBJECTIVE,PRESS,PROGRAM,PUBLISHED,RESULTS,UNIVERSITY,USING
169,API,ASIAN,BACKGROUND,DISCUSSION,END,LABEL,LOUISIANA,METHODS,PACIFIC,PRESS,PUBLISHED,RESULTS,SES,SIMILARLY,UNIVERSITY
169,BACKGROUND,CONCLUSION,END,INSTITUTE,JANUARY,LABEL,METHODS,PRESS,PROGRAM,PUBLISHED,RESULTS,SES,SLT,UNIVERSITY
125,147,160,200,457,600,BACKGROUND,DESPITE,FAIRE,LABEL,PROTEIN,RESULTS,SMS,STRUCTURAL,THESE

003,028,163,672,AMONG,BACKGROUND,CONCLUSION,LABEL,MARKERS,METHODS,RESULTS,THERE
946,FURTHER,RH2,TAKEN,TGF
281,STUDIES,SWEDISH
211,254,852,AFTERWARD,AUC,CONCLUSION,ECE,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,ROC,WHOLE
001,028,153,215,320,961,ADC,ADT,AFTER,CHANGES,CONCLUSION,DIFFUSION,DWI,FORTY,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,STUDENT
PROTONS
BECAUSE,PBT,THROUGH

FRESH
128,292,ACTIVATION,AUC,GEO,ONCOFINDER,PAS,PATHWAY,SIGNALING,THESE
945,AMONG,FINALLY,HOWEVER,NEAT1,USING
00067,139,154,ATM,ATR,DDR,DESPITE,GLEASON,NBN,PCA,PRKDC,PSA,RAD50
169,BACKGROUND,CONCLUSION,EMBRYOLOGY,ENGLISH,HOWEVER,LABEL,METHODS,OBESITY,PRESS,PUBLISHED,RELEVANTLY,RESULTS,SEVERAL,SOCIETY,UNIVERSITY
003,169,APRIL,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,THERE,V33,V60,V65,V70,V75,V80
169,CALYPSO,COPYRIGHT,INC,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,REGARDLESS,RESULTS,SOCIETY,SYSTEMS,THREE,UNILATERAL
169,AFTER,CHANGES,COPYRIGHT,CROWN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS
114,127,165,169,279,296,355,425,997,COPYRIGHT,GLEASON,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY
100,169,177,946,ALA,CIS,CONCLUSION,GASTRIN,GLN,GLY,IMAGING,INC,INHIBITORY,JMV4168,JMV5132,LABEL,LEU,MBQ,METHODS,MOLECULAR,NH2,NUCLEAR,PET,PHE,RESULTS,SMALL,SOCIETY,STA,THESE,TRP,UNLABELLED,VAL
112,259,BACKGROUND,CONCLUSION,GERMANY,HAROW,INDICATION,LABEL,MATERIALS,MEDICAL,METASTASES,METHODS,OPERATION,RESULTS
ANXIETY,DEPRESSION,FEMALES,FOP,GAD,HODGKIN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCALE,THERE,WHILE
001,116,172,177,ASA,BACKGROUND,JANUARY,LABEL,METHODS,RESULTS,SIX
169,283,400,578,591,6TH,7TH,BACKGROUND,COLLECTION,COMMITTEE,END,GLEASON,IIA,IIB,JOINT,LABEL,METHODS,PROGRAM,RESULTS,SOCIETY,STAGE,T3A,VERSION
956,ANNEXIN,CASTRATION,INSTEAD,MET,RIPK1,RIPK3,SEVERAL,SIM,TREATMENT,WARBURG
126,172,228,C57BL,CCL19,FIRST,ITGAX,MICROARRAY,QTL,TRAMP,TRAMPXNOD
169,200,215,300,BACKGROUND,BAX,BCL,BPH,CELLS,CONCLUSION,LABEL,METHODS,MTT,RESULTS,REVERSE,SEMINAL
100,116,122,177,319,416,901,ADT,AMONGST,CONCLUSION,GLEASON,GSC,HOWEVER,LABEL,METHODS,NPV,OBJECTIVE,PCA,PET,POTENTIAL,PPV,PSA,PURPOSE,RESULTS,SINCE
001,002,169,AFTER,BACKGROUND,GROUP,LABEL,METHODS,PSA,RADIATION,RADIOLOGY,RATES,RESULTS,SOCIETY,THERAPY,THESE
5MM,948,949,LNCAP,PC3,PKC,PROTEIN,RWPE1,THESE,TREATMENT
APOPTOSIS,BACKGROUND,DD1,DIF,EXPRESSION,FAST2,FASTKD1,FASTKD2,LABEL,LNCAP,METHODS,NRIF3,NUCLEAR,RESULTS,TAMOXIFEN,TUNEL
AFRICAN,ALA,CAP,FURTHER,LNCAP,R1881,T877A
BACKGROUND,LABEL,OBJECTIVE,RATIONALE,RESULTS
169,916,AGE,AUTHORS,BRITAIN,CD280,CLEC13E,CTLD2,ENDO180,EX2,GREAT,IRELAND,JOURNAL,LTD,PATHOLOGY,PEC,SOCIETY,THESE,WILEY
105,169,443,635,AUTHORS,BACKGROUND,FIRST,INC,LABEL,METHODS,PUBLISHED,RESULTS,RRS,THIRD,WILEY
169,360,369,BACKGROUND,EXOGENOUS,F10,HTRA2,INC,LABEL,METHODS,OMI,PC3,RESULTS,WESTERN,WILEY
169,946,BROMINE,NMR,VCH,WILEY
AREAS,CTV,GROUP,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RADIATION,RESULTS,TEN,THERAPY
FURTHER,THERE,THESE,WHILE
300,BELOW,ESTIMATED,FORTY,INCIDENTAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERUM,THERE
100,113,179,575,COX,FFM,IQR,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SRT,STEPHENSON,UNIVARIATE
180,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THESE,THREE
001,035,039,059,063,160,168,171,177,396,411,431,463,935,956,BIVARIATE,COX,DISEASE,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SIXTY,SRT
AFFAIRS,ASTRO,BOARD,DIRECTORS,DON,FOUNDATION,GOVERNMENT,LABEL,LITERATURE,MATERIALS,METHODS,OBJECTIVE,POTENTIAL,PURPOSE,QUALITY,RADIATION,RELATIONS,RESULTS,SOCIETY,THESE
AIM,CONCLUSION,LABEL,MATERIALS,METHODS,MNP,MRI,NOD,OBJECTIVE,RESULTS
BACKGROUND,FURTHER,HOWEVER,IKT,LABEL,MAY,METHODS,RESULTS,SEPTEMBER
17Q12,940,AMONG,BACKGROUND,LABEL,MET,METHODS,MICRORNAS,MIEN1,MIGRATION,RESULTS,THESE,UTR,WESTERN,WHILE
945,BELGIAN,BMJ,FGF23,GROUP,JANUARY,LTD,MARCH,MID,PUBLISHING,TRP
CONFIRMMDX,FINALLY,GENOMIC,LABEL,OBJECTIVE,PROMINENT,PURPOSE,RESULTS,SCORE,SUMMARY
ALONG,EARLY,FORCE,LABEL,OBJECTIVE,OTHER,PREVENTIVE,PURPOSE,RESULTS,SUMMARY,THESE,TMPRSS2,USING
ADDITIONAL,EPIGENETIC,LABEL,OBJECTIVE,OTHER,PCA,PURPOSE,RESULTS,SUMMARY,THERE
100,DESPITE,LABEL,OBJECTIVE,PSA,PURPOSE,RESULTS,SUMMARY,THERE
EARLY,MOLECULAR
007,008,083,306,425,469,658,713,740,891,955,GYEONGSANG,HOWEVER,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PREVENTIVE,PURPOSE,RESULTS,UNIVERSITY
102,107,351,354,798,AFTERWARD,GLEASON,HGPIN,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SIXTEEN
001,118,177,289,374,883,CANCERS,DAEGU,DRE,GLEASON,GYEONGBUK,LABEL,MATERIALS,METHODS,NUMBERS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
DUE,INDUCED
169,181,AMONG,RRS
III,MEN,REGARDLESS

033,037,064,205,BACKGROUND,BCR,COX,GLEASON,HOWEVER,JANUARY,LABEL,MARCH,MEIER,METHODS,PCA,RECIPIENTS,RESULTS,SEVEN,SEVENTY
003,120,BACKGROUND,GLEASON,LABEL,METHODS,NOTEWORTHY,PARTNER,PSA,RESULTS,TNM

001,169,196,AFRICAN,AFTER,ASIAN,CONCLUSION,LABEL,METHODS,OBJECTIVE,PACIFIC,PPC,PURPOSE,RESULTS,SOCIETY
FURTHER
005,AIM,CONCLUSION,EPB41L3,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PITX2,RESULTS,SPARC,WNT5A
104,127,169,194,208,234,ADT,AFTER,BASEL,CONCLUSION,COX,FIFTY,LABEL,MAORI,METHODS,MIDLAND,NETWORK,OBJECTIVE,OVERALL,PACIFIC,RESULTS,THERE,ZEALAND
100,104,175,239,386,526,ADVENTIST,AFRICAN,AMERICANS,AMONG,BLACK,BMI,COLORECTAL,COMMUNITY,COX,HRS,NIH,OBESITY,OVARIAN,PREVENTION,SCREENING,TRIAL,WOMEN
429,452,595,714,726,786,798,893,BPH,CGPCA,COMBINING,CONCLUSION,DCE,DWI,KAPPA,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,WHILE
169,EXPRESSION,OLFM4,VCH,WILEY
ACANTHOSIS,BACKGROUND,CAUCASIAN,CONCLUSION,CONCURRENT,LABEL,METHODS,UNDERLYING
169,408,954,AMONG,ANTITUMOR,DU145,LNCAP,PC3,RTA,SELECTIVE,THESE
169,946,948,956,AKT,AZD8186,CELLS,INHIBITORS,SCHEDULING
003,044,064,169,183,AFRICAN,AIM,AMERICANS,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,INSTITUTE,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,TANNING,VITAMIN,WASHINGTON
01105,956,AKT,ERK,LNCAP,MEK,NSK,RAF,WESTERN
BACKGROUND,BMJ,BOARD,COX,ETHICAL,GROUP,LABEL,LIMITED,METASTASIS,METHODS,PROCESS,PUBLISHED,PUBLISHING,QRESEARCH,REPORTING,SCIENTIFIC,STUDIES,UNIVERSITY,VGSCS,VOLTAGE
036,BACKGROUND,FEWER,HOWEVER,LABEL,METHODS,PCA,PREDICTION,RESULTS,SEVERAL
233,BCG,FDG,INCIDENTAL,PET
2MM,3MM,4MM,5MM,AMIDE,LOWER,PET,PHANTOM,SUVMEAN,TNM
000,226,578,859,885,NEUCH,REGISTRIES,SHN,SWISS,THESE
FDG,FINALLY,HOWEVER,PET
169,177,CANCEROUS,COPYRIGHT,GLEASON,HOWEVER,LTD,MRE,WILEY
100,BACKGROUND,DISCUSSION,ESTIMATES,IDENTIFIER,LABEL,METHODS,THESE,TRIAL,USUAL
004,028,224,HOWEVER,PCA
BERBERINE,CHINESE,EGF,FURTHER,HOWEVER,HUANGLIAN,LNCAP,WESTERN
169,7TH,8TH,BACKGROUND,FIFTY,HOWEVER,LABEL,METHODS,RESULTS,SOCIETY
HENCE,HOWEVER,LABEL,MARCH,OBJECTIVE,PSA,PURPOSE,RESULTS,SUMMARY
GENOMIC,LABEL,OBJECTIVE,PCA,PURPOSE,RESULTS,STRUCTURAL,SUMMARY,THESE
5ARIS,945,ALCOHOL,LABEL,MIRABEGRON,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SILODOSIN,SUMMARY,TADALAFIL
015,169,BACKGROUND,CHOLINE,DIAGNOSTIC,DWI,EUDRACT,HOWEVER,INC,LABEL,MAY,METHODS,MRI,PATIENT,PCA,RESULTS,SUMMARY,THESE,UNIVERSITY,WILEY
169,22RV1,BACKGROUND,CONCLUSION,INC,LABEL,LHR,LNCAP,METHODS,MTS,PKA,PSA,RESULTS,TREATED,TREATMENT,WILEY
169,CENDR,CRGDKGPDC,NRP,RGD,THESE
001,003,166,169,273,484,BACKGROUND,BMCC1,CONCLUSION,COPS2,EXPRESSION,LABEL,LNCRNAS,METHODS,PCR,RESULTS,SOX11,TEAD1,URINARY,WDR48
AFTER,DIGITAL,GRP,IMAGING,NSE,PRO,PROSTATIC,PSA
945,956,AKT,FAK,LABEL,METHODS,OBJECTIVE,REPORTS,RESULTS
169,947,AZ12253801,BO2,BRCA1,BRCA2,FINALLY,IGF,INHIBITION,RAD51,SIMILAR,THESE
169,945,946,NOTABLY,SYK
160,223,239,DISEASE,HOWEVER
001,170,232,442,469,984,999,AFTER,AMERICA,BACKGROUND,CASES,EST,FOLLOWING,LABEL,LATIN,METHODS,OBJECTIVE,RESIDENTS,RESULTS,SES,SITES,THERE
169,859,CONCLUSION,GIVEN,INSTITUTE,LABEL,METHODS,NPV,OBJECTIVE,PPV,PSA,PURPOSE,RESULTS,SOCIETY,THESE
16S,181,946,ATCC204508,ENDOPHYTIC,FDC83,INDOLES,KOCURIA,LGMB259,PC3,R5A,VINYL
115,146,224,AFTER,ATN,BACKGROUND,COX,GLEASON,LABEL,METHODS,PSA,RESULTS
001,006,BACKGROUND,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,PCA,RESULTS,SUMMARY
177,2FSTC,497,947,952,AFRICAN,BMI,DESPITE
001,133,169,177,321,674,889,AMONG,BACKGROUND,CAUCASIAN,COMPLIANCE,FURTHER,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY
100,169,181,600,800,ADC,AUC,COPYRIGHT,DWI,GAMMA,GLEASON,HOWEVER,LTD,MRE,MULTI,WILEY
BETWEEN,HAEMATURIA
PCA,SMALL,SRPK1,SRSF1,VEGF165
100,104,150,169,199,255,ASSESSMENT,CASES,JAPAN,LABEL,METHODS,OBJECTIVE,PRESS,PRIMARY,PUBLISHED,RESULTS,SUBTYPING,UNIVERSITY
001,169,177,786,945,ANGPTL4,BAY,DECLINE,FDG,FLT,FPP,LABEL,METHODS,OBJECTIVE,PC3,PET,PURPOSE,RESULTS,RGD
169,CNA,HOWEVER,MET,THESE
169,DU145,GLI,THESE,TIC
169,BPH,CONVERSELY,DU145,EGF,EPIDERMAL,FASEB,GOLGI,IGF,NVP,THESE
177,217,532,AUC,CHINESE,PCA,PSA,ROC,USING
956,AFRICAN,AGNPS,FOURIER,GEAGNPS,GRACILARIA,PC3,ZNO
CRITICALLY,DESPITE,SIMILAR
AMONG,C18,CLA,CONJUGATED,MOMORDICA
FURTHER,HOWEVER,PARTICULAR
169,AMONG,END,GERMANY,HODGKIN,RESULTS
169,19B,AKT,ARC,CONCLUSION,LABEL,LNCAP,METHODS,RESULTS,SCOPE,STAT3,THEIR,VCH,WILEY
746,AUTHORS,BACKGROUND,COLLECTION,CURRENTLY,ISSUE,LABEL,LIBRARY,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PRIMARY,QUALITY,REPORTING,RESULTS,SCIENCE,SELECTION,SURGERY,WEB,WHETHER
3T3,CYTOTOXIC,NIH
BAX,BCL,HOWEVER,KNOCKDOWN,LEUCINE,PCA,TAKEN,THESE
AKT,ETS,SEQ,USING
160,956,ACCORDING,MMP,WHEREAS
BASED,CNS,FIRST,HID28
169,215,895,925,ASIAN,ATLAS,CAUCASIAN,HAPLOTYPE,HNF1B,PRESS,PUBLISHED,SNP,THREE,UNIVERSITY
159,169,AMERICA,BACKGROUND,CHICAGO,CHINESE,CONCLUSION,ELDERLY,GREATER,HOWEVER,LABEL,METHODS,POPULATION,PRESS,PREVENTIVE,PUBLISHED,RESULTS,SOCIETY,UNIVERSITY
169,ABL,ACIDS,EPIDAURUS,FOXA1,GM12878,HEPG2,LNCAP,NUCLEIC,PRESS,PUBLISHED,UNIVERSITY
AKT,ARCAP,CANCEROUS,CIP2A,HOWEVER,PCA
26S,AUTOPHAGY,BORTEZOMIB,ERK,JNK,VELCADE
22RV1,CASTRATION,LNCAP,NOTABLY,PPD,RESURGENT
160,FIFTY,GRADE,III,LABEL,METHODS,MTD,OBJECTIVE,PURPOSE,RESULTS,SIX,THERE
133,BACKGROUND,CONCLUSION,INTERVIEWS,LABEL,MEN,METHODS,PRODIET,PSA,RESULTS,THESE
109,EVALUATION,FIFTY,GROSS,HOSPITALS,IBN,LABEL,MARCH,METHODS,OBJECTIVE,PURPOSE,RESULTS,STRUCTURED
BACKGROUND,LABEL,METHODS,PSA,RESULTS,SEVEN,THREE
103,177,DEPARTMENT,GLEASON,PSA,THEREFORE
411,700,BACKGROUND,CAUCASIANS,LABEL,MATERIALS,METHODS,RESULTS,SMOKING
008,012,033,047,1RN,511,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,STATA
078,106,127,132,18F,393,483,495,ADDITIONAL,DRE,FDG,GLEASON,HOWEVER,PET,PSA,SEPTEMBER,SERUM,THERE
160,BPH,HOWEVER,PCA
008,254,479,AMONG,ANTIGEN,BACKGROUND,COX,GLEASON,LABEL,METHODS,PSA,RESULTS,TEN
USING
SINCE,TAKEN,THESE,USING
AFFAIRS,BACKGROUND,COMPARE,COMPOSITE,LABEL,METHODS,OBJECTIVE,RESULTS
H2DCF,HCC,HEP3B,HOWEVER,LABEL,MET,METHODS,NH2,OBJECTIVE,PDGFR,PTP,PTP1B,PURPOSE,RESULTS,ROS,RTK,THERE,USING,WESTERN
AMONGST,PROSTATIC
DEV,FUKUI,INCREASING,JMJ,JUMONJI,KATOH,KONDO,SEVERAL
177,65292,AFTER,BCL,CONCLUSION,HOWEVER,IGFBP,IP6,LABEL,LNCAP,MEANWHILE,METHODS,MTT,OBJECTIVE,PCR,RESULTS,WESTERN
CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,PURTSCHER,RESULTS,SINCE
956,HOWEVER,THESE
110,AFTER,CTP,MTT,MVD
946,FIFTEEN,NELUMBO,THESE
197,AFTER,C34,CRM,GB5,GLOBO,HOWEVER,IGG,MCF,SSEA3,SSEA4
100,181,BACKGROUND,CONCLUSION,DU145,FLOWERS,LABEL,METHODS,MTT,PYROGALLOL,RESULTS
160,169,215,254,264,AFFYMETRIX,BACKGROUND,C2ORF43,FDR,ITGA6,LABEL,METHODS,PHYSICIANS,RESULTS,SNP,THESE
438,511,BACKGROUND,CONCLUSION,DEPARTMENT,FUNDING,FURTHER,LABEL,MAY,METHODS,RESULTS,THREE,TRIAL,UROLOGY
945,946,ANGPTL1,ANGPTL2,ANGPTL7,ANGPTLS,EMT,EXPRESSION,LNCAP,TARGETING
002,013,019,022,113,135,143,181,421,521,CHI,COX,GLEASON,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,PSA,RESULTS,STUDENT,THERAPY
916,BASED,DSC,EVALUATION,LABEL,MAD,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,THREE
LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
176,177,GRE,LABEL,METHODS,NORMALIZED,OBJECTIVE,PURPOSE,RESULTS,T1W
177,AFTER,HDR,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THESE,TRE
001,003,330,420,455,473,481,490,502,519,527,536,547,551,569,578,620,632,688,718,795,828,863,LABEL,LINAC,METHODS,MISPORT,MLC,OBJECTIVE,PURPOSE,RESULTS,TEXTURE,THERE,THESE
865,872,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
350,KIM,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TESTS
954,CLONOGENIC,NOTABLY
001,ABCB1,BPH,GSTP1,MSP,PCA,PCR,TEN
003,045,BACKGROUND,BRCA1,CANDIDATE,FANCG,FOLLOWING,INHIBITION,LABEL,LNCAP,METHODS,PCR,RAD51,RESULTS,THESE,USING,WHILE
001,026,697,794,892,ALP,AUC,HCC,HOWEVER,ROC,TAKEN
141,22RV1,DSN,MCF
DBP,HOWEVER,LNCAP,NED,PHTHALATE,TAKEN
095,169,224,549,BACKGROUND,COMPONENT,EMOTIONAL,END,HODGKIN,HRQOL,LABEL,MCS,METHODS,PCS,RESULTS,SCALE,SHORT,SOCIETY,SUMMARY,SURVIVORS
169,BACKGROUND,BCS,CALIFORNIA,CENTERS,COMMITTEE,CONTROL,DISEASE,GEORGIA,HOWEVER,JOINT,LABEL,LOUISIANA,METHODS,MINNESOTA,NETWORK,NORTH,POCBP,PREVENTION,PROGRAM,RADIATION,REGISTRIES,RESULTS,SIX,SOCIETY,WISCONSIN
069,106,110,169,285,913,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,PSA,PSAVS,RESULTS,THERE,UNIVARIATE
001,004,023,169,177,227,AIM,ALP,ANTICANCER,CELLS,CELLSEARCH,CONCLUSION,COPYRIGHT,CTC,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS
169,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,KIT,LABEL,MATERIALS,METHODS,NCOR2,OBJECTIVE,REGARDING,RESULTS
169,956,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,IGF,IGFBP,INSTITUTE,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PC3,RESULTS,WESTERN
169,ANTICANCER,COPYRIGHT,CYP17A1,HOWEVER,INSTITUTE,PERSISTENT
168,AFTER,PURPOSE,RETIREMENT,THEREFORE
000,169,CROSSROADS,IMMUNOLOGY,METASTATIC
169,EMT,LABEL,LUCAS,MET,SUMMARY,TMPRSS2
FOCAL,MEDLINE,RADICAL,RECTO,SALVAGE,THEREFORE
FURTHER,OBESITY,SATURATED,THERE
945,946,BASED,INSTEAD,MEANWHILE,THERE
RADIATION,SALVAGE,SOCIETY,UROLOGICAL
ANTICANCER,FRAME,PREVIOUSLY,SINCE,THERAPY,TRUST
HITEN,PATEL,PROFESSOR,ROBOTIC,SOCIETY,SURGERY,UROLOGY
160,HOWEVER,PSA
169,193,298,400,ADP,AES,BRCA1,BRCA2,CONCLUSION,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESPONSES,RESULTS,SOCIETY
169,ASTRO,AUA,GLEASON,LABEL,METHODS,OBJECTIVE,PHYSICIANS,PSA,PURPOSE,RADIATION,RESULTS,SOCIETY,THOSE,UROLOGICAL
AFRICAN,BACKGROUND,IIB,LABEL,METASTASES,METHODS,NORTH,SPLENIC
AREAS,BACKGROUND,COVERED,FDA,INNOVATIVE,LABEL,METHODS,OPINION,OTHER,SEVERAL,WHILE
AKT,DU145,HOWEVER,PC3,PKB,THESE
HOWEVER,LIMITED,LNCAP
169,COPYRIGHT,HOWEVER,LTD,MEIER,THESE,WILEY
169,AUTHORS,HOWEVER,LTD,PUBLISHED,SIMULATION,STATISTICS,WILEY
DU145,HENCE,PCR,RESULTS
160,ACCORDING,AMONG,BACKGROUND,CONCLUSION,GLEASON,HEMATURIA,LABEL,METHODS,REGARDING,RESULTS,SECONDARY,SPP,TCC,THEREFORE,URMIA
AKT,KEEPING,LNCAP,SOY,THESE
215,BLOOD
001,160,169,264,674,938,AFTER,ASSESSMENT,BACKGROUND,CDF,CONCLUSION,CUMULATIVE,DUE,FUNCTIONAL,LABEL,MEDICAL,METHODS,PMM,PRESS,PUBLISHED,RESULTS,SOCIETY,THERAPY,TRIAL,UNIVERSITY
037,048,COMPLEX,CONCLUSION,DVC,FORTY,LABEL,LRP,MATERIALS,METHODS,NARROWING,OBJECTIVE,OPERATIVE,PURPOSE,RADICAL,RESULTS
169,CYP17A1,GIVEN,PRESS
AFTER,BACKGROUND,CLINICIAN,DAC,FORTY,LABEL,METHODS,RESULTS,SDM,SEVENTY,USING
148,945,HIF,MHI,NIR,OATPS,PCA,PET
177,947,CLONOGENIC,HOWEVER,LNCAP,PNT1A,THERE,THESE
22RV1,ADT,AKT,AZD5363,BACKGROUND,CONCLUSION,HOWEVER,LABEL,LNCAP,LNCAP95,METHODS,PCA,PCR,RESULTS,WORTMANNIN
945,946,AKT,LNCAP,PIA,PIN,TNF
382,937,BACKGROUND,LABEL,METHODS,PCA,RESULTS,TLR,USING
110,128,150,924,HSP27,LABEL,LNCAP,METHODS,OBJECTIVE,OBVIOUSLY,PCR,PR1,QUERCETIN,RESULTS,TSU
ALTOGETHER,CXCR4,DTX,LIM,LIMK1,PCA
068,169,ADP,GLEASON,HSPBAP1,IHC,PCA,PSA,TMPRSS2
169,451,EVS,FASEB,LABEL,MOB,NMOBS,PC3,PROTEOMIC
144,169,AFTER,ERSPC,FINNISH,HOWEVER,MEN,NON,PCS,PSA,RANDOMIZED,SCREENING
169,AIM,BACKGROUND,COMPOSITE,COUPLES,FAITH,INDEX,INDUCTION,INTERVIEWS,LABEL,METHODS,NVIVO,OBJECTIVE,OUTCOME,RESULTS,SOCIETY
000,215,AMONG,CONCLUSION,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPAIN
169,1BB,950,CAR,CD137,CD3,FINALLY,IMMUNOL,P28BB,RES,TAKEN,TARGETING
169,ACADEMY,APPROACHES,BACKGROUND,CHECKPOINT,DISCUSSION,FOUNDATION,INC,JOLLA,LABEL,MEETING,METHODS,PCF,RESULTS,SPONSORED,TARGETING,WILEY
007,017,198,240,ADVERSE,CONCLUSION,INSTITUTE,ISR,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,VERSION
100,10MBQ,169,215,348,357,359,945,BACKGROUND,CONCLUSION,COS,DETECTING,DHT,FCH,FDG,GIVEN,IMAGING,INC,LABEL,METHODS,PET,PRESENTLY,RB390,RB448,RBA,RESULTS,STABILITY,T877A,WILEY
169,GIVEN,GLEASON,THESE,UROLOGICAL
001,010,011,020,025,169,181,BACKGROUND,BPH,FURTHER,GLEASON,INC,LABEL,METHODS,PCA,RESULTS,SERUM,UGM,VARIATIONS,WILEY
HOWEVER,OWING,STROMAL,STUMP
031,CPF,DHT,EMT,GLI,LABEL,LNCAP,METHODS,NPF,OBJECTIVE,PCA,PCR,PSA,RESULTS,SHH,SONIC,WHILE
945,BACKGROUND,CONCLUSION,HIF,LABEL,RESULTS,THEREFORE,TREATMENT
169,600,AMONG,BACKGROUND,CONCLUSION,HIV,LABEL,METHODS,PRESS,PSA,RESULTS,SIMON
008,169,761,AFRICAN,AMERICANS,AMONG,AUTHORS,CALIFORNIA,CONTROL,HISPANICS,HOWEVER,LTD,PCA,WILEY
169,AUTHORS,BASED,LTD,METASTASIS,OTHER,WILEY
347,C30,EFFECTS,EORTC,GOTHENBURG,HDRBT,HOWEVER,HRQOL,MEN,OCTOBER,PSA,QLQ
055,CONCLUSION,ECL,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
174,DOCETAXEL,LABEL,METHODS,NURSING,OBJECTIVE,OBJECTIVES,PURPOSE,RESULTS,REVIEWS,SOURCES,SYNTHESIS
ETS,METASTATIC
AMC,AMSTERDAM,BACKGROUND,BMJ,BOARD,CURRENT,GROUP,IRE,LABEL,LIMITED,MEDICAL,METHODS,MRI,PRIOR,PUBLISHED,PUBLISHING,TRIAL
145,148,160,783,946,DIFFERENT,LNCAP,MHI,NIR,OATP1,OATP1B1,OATP1B3
181,FOLLOWING,PC3,ROS,WESTERN
CENTRES,CONCLUSION,CTV,DVH,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PLANS,PTV,RESULTS,TCP,USING
DOCETAXEL
100,400,800,EXCLUDING,THEREFORE
223,ABIRATONE,THESE
B1R,B2R,BACKGROUND,CHAMBER,DU145,FURTHER,INCREASING,KKS,LABEL,METHODS,MTT,NEITHER,OBJECTIVE,OBJECTIVES,RESULTS,WHERE
000,169,BACKGROUND,CONCLUSION,ESTIMATES,HOWEVER,LABEL,METHODS,PSA,RESULTS,RRS,SNP
99A,DU145,FOLLOWING
169,464,ABI,CYP17A1,ENZ,FINALLY,HSD17B3,MR49C,MR49F,PCR,PSA,SIMILARLY,STEROID,THESE,WESTERN
169,ANDROGENS,SOCIETY
145,160,FCM,MTT,RUDITAPES,VENERIDAE
DECREASING,DU145,MTT,THESE
145,947,IFN,JANUS,JNK,P38,PUFAS,STAT1,THESE
160,CYTOTOXIC,DAU,DU145,III,THESE
160,429,IA8,MICRORNAS,MTT
DESPITE,FAS,INCREASED,RAMAN,SRS
532,AFTER,ANOVA,CONCLUSION,FURTHER,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,STUDENT,THESE
ASSESSMENT,CHRONIC,EORTC,FUNCTIONAL,ILLNESS,QLQ,QUALITY,THERAPY,TREATMENT
169,946,BIOLOGY,DAC,DNMT1,DNMTS,HAUSP,MSP,PC3,PCR,SOCIETY,T24,UHRF1,WESTERN,WIF,WNT,WST
169,PROSTATIC,SMALL,SOCIETY,USA
003,021,169,709,778,957,IGF,IGFBP,INSULIN
001,100,169,177,204,207,ASSESSMENT,AUC,BACKGROUND,CHEMISTRY,GENOMIC,GLEASON,LABEL,METHODS,RESULTS,ROC,SOLID,USING
002,071,406,484,AMONG,AOR,BACKGROUND,BLACK,COMPARE,LABEL,METHODS,RESULTS,THERE
10878,177,414,BACKGROUND,BPH,INCIDENCE,LABEL,METHODS,PRIMARY,PSA,RESULTS,SCORE,SECONDARY,SIMILARLY,TPV
169,BRITAIN,COPYRIGHT,CP1,GREAT,IRELAND,LTD,MULTIPLEX,MYC,PUBLISHED,SOCIETY,WILEY
142,ACUTE,CONFORMAL,DETAILS
480,956,CCAAT,COA,EXPRESSION,FLU,GAPDH,GRP78,HMG,HMOX1,MCF,NDRG1,VARIANT
AUS,OPTIONS,PERSISTENT,PLACEMENT,RTS
043,AFRICAN,ASIAN,AUTOPSY,CAUCASIAN,CAUCASIANS,EVALUATION,FIFTY,HOWEVER,LABEL,MATERIALS,METHODS,RESULTS,WHILE
AGE,BACKGROUND,BCR,BMI,BOARD,ECE,FINALLY,GLEASON,IDENTIFIED,IRB,LABEL,MARCH,MATERIALS,METHODS,PNI,PSA,PSM,RESULTS,SVI,TNM,UNIVARIATE,VARIABLES
125,ABOUT,ADDITIONAL,BACKGROUND,EIGHT,LABEL,MATERIALS,METHODS,OC125,RESULTS
225,BLI,DOSIMETRIC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,UNIFORMLY,VERNIER
AREAS,BACKGROUND,COVERED,DESPITE,III,LABEL,MET,METHODS,OPINION,PCA,PHASE,SEVERAL,SRC,TARGETS,THEREFORE,TKI,UNTIL,WESTERN
HEPG2,HIPERFECT,INTRA,PC3,THESE
OPG,RANKL,TNF
2PROPSA,INDEX,PSA
ADT,CTL,CURRENTLY,DESPITE,FAILURE,FUNCTIONAL
479,AKT,AMG,COMBINING,HOWEVER,IGF,INHIBITION,PHOSPHO,REDUCTION,THESE
945,946,GSK,TAKEN,THESE,WNT
078,145,898,BACKGROUND,FORTY,GLEASON,HOWEVER,JAPAN,LABEL,METHODS,MRI,PSA,SALVAGE,SIXTY,TEN
169,945,COFILIN,FIRST,LIM,LIMK1,LIMKI,THESE,TUBULIN
AUSTRALIA,BACKGROUND,CHRISTMAS,EASTERN,ENGLAND,HOWEVER,LABEL,METHODS,NORTH,RESULTS,SYMPTOM,WESTERN
001,476,ANXIETY,BACKGROUND,COMPOSITE,INDEX,INDIVIDUAL,INVENTORY,LABEL,LPC,MATERIALS,METHODS,OBJECTIVE,P3P,PATIENT,PROFILE,PURPOSE,RESULTS,STATE,THESE,TRAIT,TRIAL
000,250,500,595,649,AUC,BASED,CAUCASIAN,CIS,CONCLUSION,JAPAN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
2CC,320,ANOVA,BACKGROUND,BD2CC,CONCLUSION,IMAGE,LABEL,METHODS,OBJECTIVE,RESULTS,V40,V50,V60,V65
ADT,BACKGROUND,CONCLUSION,CSS,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
137,201,233,434,872,APRIL,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,VAN
002,045,100,174,211,385,ADDITIONAL,BACKGROUND,GLEASON,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE,THESE
100,810,THERE,UNIVERSITY
956,ANNEXIN,AURANOFIN,BCL,PC3,TREATMENT
2AC,AKT,CLUSTERIN,HOWEVER,PC3,PP2AC,TAKEN,TRANSIENT
009,010,023,031,169,230,361,ASPIRIN,BACKGROUND,COLORECTAL,LABEL,MEN,METHODS,OVARIAN,RESULTS,THESE,TRIAL
169,99M,BECAUSE,CONCLUSION,IMAGING,INC,LABEL,METHODS,MIP,MOLECULAR,NUCLEAR,PCA,RESULTS,SOCIETY,SPECT,UNDER,UNLABELLED,WHOLE
145,945,954,AKT,BACKGROUND,CONCLUSION,DU145,DUE,ELISA,HIF,INCREASING,LABEL,METHODS,MTS,NOBILETIN,PROTEIN,RESULTS,TAKEN
500,600,ADT,FOLLOWING
916,INCREASED,NUCLEAR,PCA,THESE
205,BCL,CONVERSELY,E2F,SIRNA
TEN
006,017,018,025,028,ECE,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,VISTA
HOWEVER,PCA,SIMILARLY,T3A
COA,FFA,HODGKIN,HOWEVER,OBESITY,WHETHER,WHILE
017,492,BACKGROUND,FTA,GLEASON,HOWEVER,LABEL,METHODS,MORBIDITY,PCA,POPULATION,PSM,RADICAL,RESULTS,URO
155,ANX,MICRO,MTT
BACKGROUND,CONCLUSION,LABEL,METHODS,PSA,RESULTS,TREATMENT
001,133,134,160,189,543,549,738,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS
110,125,145,160,192,230,312,CONCLUSION,D90,DSS,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,PSI,PURPOSE,RESULTS
002,007,169,784,COX,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
105,153,156,893,ASR,ASR12,ASR13,BACKGROUND,INCIDENCES,IRANIAN,KHUZESTAN,LABEL,MATERIALS,METHODS,RESULTS
140,222,335,347,793,864,AFRICAN,ASIAN,BACKGROUND,BLOOD,CAUCASIAN,CHINA,CHINESE,GLEASON,LABEL,MATERIALS,METHODS,NORTH,ORADJ,PCA,RESULTS,THESE
001,004,064,841,BACKGROUND,LABEL,MARCH,MATERIALS,METHODS,ORR,PFS,PSA,RESULTS,SCIENCE,SIMILARLY,SOCIETY,STUDENT,WEB
BIP,GLUCOSE,GRP78,HOWEVER
160,AMERICA,CRMP4,NORTH,PET,SMALL,TAKEN
ADT,GIVEN,HOWEVER,PCA,VITAMIN,WESTERN
ERSPC,NOW,PSA,RANDOMIZED,SCREENING
112,301,378,538,583,BACKGROUND,CONCLUSION,LABEL,MEN,METHODS,RESULTS,SWEDISH
005,011,028,117,249,415,AMONG,GLEASON,IQR,LNS,PATHOLOGIC,PGS
133,177,357,490,BPH,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,OPSAD,PSA,RESULTS,ROC
000,001,017,042,169,239,945,III,LABEL,LOQ,METHODS,OBJECTIVE,PFS,PSA,PURPOSE,RESULTS,SAMPLES,SIXTEEN
002,003,009,018,048,169,17Q11,17Q12,17Q21,215,272,ALTOGETHER,AUTHORS,EFCAB13,FINLAND,HDAC4,INC,PUBLISHED,WILEY
309,939,OVARIAN,THERE
001,872,BACKGROUND,CLINICIANS,CONCLUSION,CVD,FINAL,INCREASED,INSURANCE,IRR,LABEL,METHODS,NHI,RESULTS,TAIWANESE
181,22RV1,945,946,955,A2780,AURANOFIN,BASED,COMPLEXES,DTA,ESI,HL5,HLN,HOS,LPS,NMR,THP,TNF
620,954,BPH,CONSISTENT,ELISA,HOWEVER,OPG,PCA,PCR,RANKL,RWPE2,TRANSWELL
APART,EPIGENETIC,HOWEVER
945,CK2,PROTECTED,TBG
145,231,LIGHT,MDA,THERE,WHILE,XTT
100,181,FASUDIL,INHIBITION,PCA,RHO,THESE,WESTERN
215,AB1,AB2,BASED,HRP,MBS,NRS,PRIMARY,PSA
089,106,435,AFTER,AUSTRALIA,BACKGROUND,DESPITE,LABEL,METHODS,OBJECTIVE,OUTCOME,OVERALL,RESULTS,SCORE,SETTING,SOUTH,SYMPTOM,UNASSIGNED,WALES
001,002,003,144,ACS,COLLEGE,HIGHEST,LABEL,METHODS,NSQIP,OBJECTIVE,OBJECTIVES,ORP,PBT,POD,PROJECT,QUALITY,RADICAL,RESULTS
199,263,737,ABT,BCL,DOCETAXEL,DTX,DU145,HOWEVER,LNCAP,PC3,THESE
208,946,ALTOGETHER,BMP,DHT,LNCAP,MDV3100,PCA,PSA,TGF,TMPRSS2
AUTOPHAGY,FURTHER,THESE
100,III,JACCARD,RESULTS
679
BASED,MULTI,REGISTERED
118,169,301,427,441,ASPIRIN,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,NUTRITION,OBJECTIVE,PREVENTION,PURPOSE,RESULTS,SOCIETY
169,COPYRIGHT,ERK,ETS,JUN,MECHANISMS,RAS,SOCIETY
MTA
213,AMINOACIDS,BACKGROUND,CSC,CULTURE,ELISA,ISOTOPE,KNOCK,LABEL,METHODS,PCR,RESULTS,SILAC,SPARC,TRANSWELL
PPINS
145,169,176,AUNPS,BACKGROUND,BECAUSE,COPYRIGHT,LABEL,LTD,METHODS,RESULTS,SUCCESSFUL,WILEY
BACKGROUND,BASED,COX,GLEASON,LABEL,METHODS,OTHER,PSA,RESULTS,SCORE,SRT,TREATMENT
DRE,PSA,THESE,UROLOGICAL
177,400MG,500MG,BENIN,CONCLUSION,FEVER,INFECTIVE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNIVERSITY,URINE
BMJ,ENGLISH,GROUP,HOWEVER,LCNEC,LIMITED,LTD,PUBLISHING
139,169,AML,EVI,HEMATOLOGY,IKZF1,MECOM,MUTATIONS,MYCT1,PREX2,RAS,RESULTS,SF3B1,SOCIETY,U2AF1,VIP
FIRST,METABOLOME,WEB
001,011,10878,121,189,199,635,809,900,999,BACKGROUND,COX,GLEASON,LABEL,LVI,MEIER,METHODS,PSA,RESULTS,THESE
143,181,231,ASCIDIANS,MDA
ADJUSTMENT,BACKGROUND,CATALONIA,IRR,LABEL,MEDEA,METHODS,OBJECTIVE,POISSON,PRIMARY,RESULTS,SPAIN,SPANISH,THERE,THESE
EVALUATION,FOX,FOXA1,FOXP1,HOWEVER,TAKEN
169,292,302,APOPTOSIS,BACKGROUND,DECREASED,ENDOGENOUS,HOWEVER,INC,LABEL,LNCAP,METHODS,PCA,PRIMARY,RAF,RESULTS,THESE,TRAMP,WHILE,WILEY
169,176,332,335,AUTHORS,BACKGROUND,INC,IRE,JOULE,LABEL,METHODS,PUBLISHED,RESULTS,SIMULATION,WILEY
169,266,279,ADDITIONAL,BACKGROUND,DHT,DOCETAXEL,DU145,GTP,GTPASES,HOWEVER,IFN,INC,INCREASED,LABEL,LNCAP,METHODS,MMP13,MXA,MYXOVIRUS,PCA,RESULTS,STUDIES,THESE,TUBULIN,WILEY
169,954,BACKGROUND,CD3,CD4,CD8,EXPRESSION,GDF,IHC,INC,LABEL,METHODS,PC3,RESULTS,WILEY
169,ADC,BACKGROUND,BLISS,CELLS,INC,LABEL,LARGELY,LNCAP,METHODS,PHASE,POTENTIAL,RAPAMYCIN,RESULTS,SYNERGY,WILEY
ASN69,BECAUSE,GROUP,HOWEVER,PSA,THERE,THREE
004,031,169,200,252,452,ADT,AMI,AUTHORS,BJU,CHINESE,COX,EASTERN,GROUP,LABEL,LTD,MEIER,METHODS,OBJECTIVE,POTENTIAL,PUBLISHED,RESULTS,THERE,WILEY
954,ACTIVATION,AMONG,CHIR99021,CONSISTENT,CONVERSELY,EXPRESSION,FINALLY,GSK,HOWEVER,IKK,THESE
169,ADT,AUSTRALIAN,AUTHORS,BJU,LABEL,METHODS,OBJECTIVE,RANGING,RESULTS,THERE
001,007,018,137,169,183,AFTER,BACKGROUND,BCR,BETWEEN,CONCLUSION,COX,DES,GLEASON,HOWEVER,INC,INCREASING,LABEL,MEDICAL,METHODS,NSM,PSA,PSM,RESULTS,WILEY
169,BACKGROUND,GLEASON,INC,LABEL,METHODS,PSA,REGRESSION,RESULTS,UNI,WILEY
001,007,034,169,362,478,ADT,AMONGST,BACKGROUND,CASTRATION,GLEASON,INC,LABEL,METHODS,PSA,RESULTS,WILEY
001,138,169,ANTIGEN,AUC,BACKGROUND,DIAGNOSTIC,EPSTEIN,GLEASON,HOWEVER,INC,INDEX,LABEL,METHODS,PCA,PHI,PREDICTIVE,RESULTS,WILEY
121,122,142,ANN,CONCLUSION,INDEX,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS
001,023,104,239,602,EUROQOL,GAMMA,HRQOL,LABEL,METHODS,OBJECTIVE,OLS,PURPOSE,RESULTS,TOBIT,UNION,UTILITY
160,198,EGFR2,ERBB2,MBC,MUTATIONS,NEU
148,169,197,220,95E,95F,BIOLOGY,INC,KLK,MOLECULAR,SOCIETY,TAKEN
007,013,752,967,ASSESSMENT,BASED,CAB,CAP,CAPRA,CSS,GROUP,HOWEVER,JAPAN,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
APOPTOSIS,BACKGROUND,BID,CELLS,CK2,LABEL,LNCAP,LOW,METHODS,MTT,PC3,RESULTS,TAT,THEREFORE,TRAIL,WESTERN
157,ATTRITION,FUNCTIONAL,LABEL,METHODS,MISSING,OBJECTIVE,PURPOSE,RESULTS,SEM,T12,T13,T24
124,169,A11,LABEL,MDV,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS
160,359,ADDITIONAL,ART,BACKGROUND,CONCLUSION,LABEL,LND,LYMPHATIC,METHODS,NODAL,PCA,PSA,RESULTS,WHETHER
BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,PSA,THERE,UNASSIGNED,VIRTUAL
BACKGROUND,BESAG,BYM,GHR,HOWEVER,LABEL,METHODS,RESULTS
HORMONE,OTHER,PCA
DOX,FTS,PEG,PEG5K,PTX
035,053,250,500,AFTER,REGARDING,USING,UTI
004,011,014,024,035,195,250,ANG,BMI,CASES,CHUNG,FEBRILE,GROWING,HOWEVER,JANUARY,LABEL,MATERIALS,METHODS,NOVEL,OBJECTIVE,PURPOSE,QUINOLONE,RESULTS,UNIVERSITY,UTI
CURRENTLY,DESPITE,KOREA,OPTIMAL
169,956,BRAIN,CONCLUSION,IMAGING,INC,LABEL,MBQ,METHODS,MOLECULAR,NUCLEAR,PARKINSON,PERIPHERAL,PET,RADIATION,RESULTS,SOCIETY,UNLABELLED
154,169,379,409,CONCLUSION,EMT,HOWEVER,LABEL,METHODS,MICRORNAS,OBJECTIVE,PURPOSE,RESULTS
956,EHD,LOD,PSA
031,050,055,100,177,236,501,688,975,BPH,ELISA,EVALUATION,LABEL,METHODS,OBJECTIVE,PAI,PCA,PURPOSE,RESULTS
121,239,4N0M0,855,ADT,AMONG,BACKGROUND,COX,FURTHER,GLEASON,JAPAN,LABEL,METHODS,PSA,RESULTS,SECONDARY,THESE,ULTRA
160,ADC,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC
FORTY,HOWEVER,THERE
AGGRESSIVE
735,825,975,AFRICAN,CIS,CYP17,HOWEVER,ORS,OVERALL,PUBLISHED,RESULTS,SCIENCE,STRATIFIED,WEB
ELISA,PSA,RCA,THROUGH
169,BACKGROUND,CONTACT,LABEL,METHODS,MOTIVATION,PRESS,PUBLISHED,REGULATION,RESULTS,UNIVERSITY
169,AKT,GLEASON,MYC
945,948,PSA,TREATMENT
58T,AIF,BAX,BCL,DR5,OVERALL,ROS,TRAIL
CANONICAL,CAP,DCE,GNCCA,GROUP,MACHINE,MRI,SUPPORT,SVM,T2W,THESE
169,441,455,BALTIMORE,CAPSURE,CUMULATIVE,END,HOPKINS,JOHNS,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,STRATEGIC,TIMES,UNIVERSITY
169,239,253,GRADE,LABEL,MEN,METHODS,OBJECTIVE,PHASE,PRESS,PRIMARY,PUBLISHED,RESULTS,SECONDARY,TRIAL,UNASSIGNED,UNIVERSITY
169,DSF,FDA,GIVEN,HOWEVER,PREVIOUSLY,SIMILARLY
169,BECAUSE,BIOLOGY,FINALLY,INC,MAC,MOLECULAR,SIGLECS,SOCIETY,THESE
105,169,270,DCC,EPCAM,KRT14,KRT18,KRT19,KRT6A,PSA,PTPRC,TARGETING,THESE,USING
229,780,963,AGE,BPS,CONCLUSION,DEC,LABEL,MEIER,MEN,METHODS,OBJECTIVE,ONJ,RESULTS,SEP,SEQUENTIAL
GOLGI,HBP,METABOLIC,RTK
NUMERICAL
223,SINCE,SIPULEUCEL,STRATEGIES
001,054,066,112,160,207,236,505,556,593,598,610,774,966,AFTER,BACKGROUND,C00,C96,CANCERS,DETAILS,FEWER,ICD10,IRELAND,LABEL,METHODS,OVERALL,RESULTS,THESE
125,128,177,946,AFP,CEA,HCG,PSA,SCC,SERUM,VTE
169,HOWEVER,MRI,PSA,SEVERAL,WIDESPREAD
169,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,SDC,WESTERN
169,BACKGROUND,COPYRIGHT,DECREASING,FORTY,INC,INFECTIONS,LABEL,METHODS,RESULTS
BACKGROUND,EWING,GROUP,LABEL,LMS,MANAGEMENT,METHODS,RESULTS,RPS,TRANS,WORKING
169,CONCLUSION,FURTHER,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
THESE,VITAL
169,945,AKT,ATA,BOSWELLIA,COPYRIGHT,PRIOR,SOCIETY,THESE
006,032,151,169,178,279,798,946,952,BACKGROUND,BIOMARKERS,CAT,CONCLUSION,COX,EPIDEMIOL,FDR,HRS,III,INCREASED,LABEL,METHODS,OXIDATIVE,RESULTS,SEVEN
024,100,106,119,169,890,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,SECONDARY,UROLOGICAL
946,BMJ,FOLLOWING,GLEASON,GROUP,LTD,PUBLISHING
164,169,179,189,200,AURKB,BIRC5,CCNB2,CCNE2,EIGHT,EXPRESSION,FOXM1,MKI67,NANOSTRING,PXN,SYP,TEN,TRAMP
002,128167809,128393157,128498051,145,169,215,961,CAUCASIAN,CHROMOSOME,COLORECTAL,CPG,FDR,MYC,OVARIAN,POU5F1B,SCREENING,SNP,THESE,TRIAL
177,231,HMGN5,KNOCKDOWN,LC3,MDA,MMP,WESTERN
169,BACKGROUND,CONCLUSION,FORTY,GLEASON,LABEL,METHODS,RESULTS,SUSPICIOUS,USING
3AA,3BA,3CA,947,CISPLATIN,HILLMAN,MTT,THESE
METABOLIC,WARBURG
116,181,215,250,2YL,AGILENT,C18,COLON,DAD,EPIDERMOID,FINALLY,HCT,MTT,NCI,PRANGOS
10878,BACKGROUND,CYP17A1,DURABLE,LABEL,METHODS,PSA,RESULTS,STUDIES,TREATMENT
013,100,157,310,370,470,945,AIM,AMACR,COA,IHC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THESE
AIM,AKT,ANOVA,CAM,CONCLUSION,ECS,FGF,FURTHER,INCREASED,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SARCOSINE,STUDENT,THERE,THESE
150,BOARD,BRAIN,EVALUATION,HENCE,IDV,IMAGING,LABEL,LATERAL,MATERIALS,METHODS,OBI,OBJECTIVE,OPI,PURPOSE,RESULTS,SIMILARLY,THERE
177,400,CONCLUSION,CRT,CTV,LABEL,MATERIALS,METHODS,OBJECTIVE,ORGAN,PTV,RESULTS
169,31K,85K,ACERS,COPYRIGHT,COSTS,ICERS,NEITHER,NETWORK,NMB,PREDNISONE,WTP
C75,HOWEVER,INHIBITION,STRUCTURE,THESE,TRICLOSAN,YET
946,KNOCKDOWN,MSC,RUNX1,TARGETING,TGF,THESE
169,BACKGROUND,COLON,CXR,END,LABEL,METHODS,MPSTS,OVARIAN,RESULTS,SCREENING,TRIAL
169,BACKGROUND,C3F,COPYRIGHT,ESI,LABEL,MALDI,METHODS,PCA,PSA,RESULTS,SAMPLES
THERE
ATM,ATR,BRCA1,CDK12,FANCI
001,045,645,ACS,ASA,BACKGROUND,BPH,CLASS,COLLEGE,FURTHER,HOWEVER,LABEL,LVP,METHODS,NSQIP,OVERALL,PATIENT,PROGRAM,QUALITY,RESULTS,SOCIETY
10877,10878,113,190,1970S,AMONG,BACKGROUND,CAP,GLEASON,LABEL,METHODS,OVERALL,RESULTS,SIXTY,WESTERN,YET
001,292,347,610,AMONG,BACKGROUND,HOWEVER,LABEL,LOS,METHODS,ORP,OVERALL,RESULTS,THEREFORE,USING
116,HCT,HOWEVER,PAS,POLYAMINES,SW480,THEREFORE
001,169,916,ADT,AFTER,CONCLUSION,CYP17,INTENSIVE,LABEL,LHRHA,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SOCIETY
MMP,PCA,SPAG9,SPERM,TMA,TNM
AKT,MTT,PAC,SEX,WESTERN
196,260,266,456,945,967,ANDROGENS,CIS,GLEASON,HARDY,HOWEVER,ORS,POLYMERASE,PUBLISHED,THEREFORE
107,175,322,643,BIAGINI,BORIANI,JANUARY,KARNOFSKY,LABEL,LOG,MEIER,METHODS,OBJECTIVE,RESULTS,SCORE,WALKING,WEINSTEIN
DESPITE,GROWING,MICRORNAS,PCA,THEREFORE
946,CHINA,METHYLASE,RAR,SSS,THERE
169,AMONG,HOWEVER,INTENSITY,UROLOGICAL
000,006,011,020,031,035,158,169,177,225,232,278,499,886,945,AGAIN,ALP,BACKGROUND,CFS,COX,EASTERN,EPSTEIN,FURTHER,GLEASON,GROUP,HGB,HOWEVER,IDC,INC,LABEL,METHODS,PSA,RESULTS,TOTALLY,UNIVARIATE,WILEY
169,ALPHA,AMACR,BACKGROUND,COA,INC,LABEL,MEN,METHODS,PCA,PCR,RESULTS,SERUM,WILEY
169,AIM,CAP,CONCLUSION,COPYRIGHT,FINALLY,HOWEVER,LABEL,LNCAP,LTD,METHODS,NED,OBJECTIVE,PCA,RESULTS,USING
169,177,186,647,887,BACKGROUND,BECAUSE,HOPKINS,INC,JHH,JOHNS,LABEL,MDC,METHODS,MRI,OVERALL,PCA,RESULTS,USING,WILEY
001,002,010,025,111,122,136,169,233,374,AMONG,ANALYSING,AUTHORS,BJU,CHOLINE,CONCLUSION,DIFFERENT,DISEASE,GLEASON,LABEL,METHODS,OBJECTIVE,PET,PSA,PSADT,RESULTS,TRIGGER
169,ADT,AR3,BACKGROUND,CONCLUSION,DHT,DIM,EMT,INC,LABEL,METHODS,PCA,RESULTS,WILEY
001,100,169,181,954,ATHYMIC,BACKGROUND,CAPSAICIN,DISCUSSION,GIVEN,INC,LABEL,LNCAP,METHODS,PCA,RADIO,RESULTS,SENSITIZER,TRP,WESTERN,WILEY
001,003,108,125,169,AUTHORS,BACKGROUND,BCR,CD105,GLEASON,HOWEVER,INC,LABEL,METHODS,MVD,NHT,RESULTS,TSP,WILEY
123,169,BACKGROUND,BCL,DHR,DSB,DU145,EXPRESSION,FINALLY,FURTHER,GROUP,HMGN5,INC,LABEL,METHODS,MNSOD,PC3,PCR,RESULTS,ROS,WESTERN,WILEY
GLEASON,IT1,LNCAP,PC3,SPRY4,THERE
HOWEVER,PCA
135,198,257,340,700,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THREE,URINARY,USING,VINCI
CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
169,COPYRIGHT,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,STUDIES
169,COPYRIGHT,INC,INITIAL
169,COPYRIGHT,INC,ORP
169,COPYRIGHT,INC,ROBOTIC,RRP
169,COPYRIGHT,INC,ROBOT,TECHNICAL
169,945,946,COPYRIGHT,DEPARTMENT,GLEASON,INC,PATHOLOGY,PUBLISHED
169,500,800,956,BAPTA,CONVERSELY,COPYRIGHT,GF109203X,INHIBITION,PC3
169,APP,AUTHORS,COPYRIGHT,DU145,INC,PCA,PUBLISHED,TARGETING
169,ADDITIONAL,COPYRIGHT,LTD,MONITORING,NUTRITION,SEEKING,THROUGHOUT
169,945,COPYRIGHT,FURTHER,LTD,PROSTATIC,PTGS2,TNF,VDR
169,AUTHORS,COPYRIGHT,FACTORS,PUBLISHED,WHILE
058,123,141,169,CONCLUSION,COPYRIGHT,FLR,FUNCTIONAL,INC,KUTCHER,LABEL,LYMAN,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,V65GY
169,843,BACKGROUND,COX,EDUCATION,EQUAL,GIVEN,HDL,HOWEVER,HRPER,LABEL,LDL,METHODS,PROGRAM,RESULTS,THESE,WESTERN
001,014,100,103,125,130,154,169,174,449,478,520,620,697,753,927,ADVERSE,AUC,AUT,BLADDER,COPYRIGHT,COX,D20,D90,GRADE,INC,JANUARY,LABEL,LDR,LUT,MATERIALS,METHODS,OBJECTIVE,PALLADIUM,PURPOSE,RESULTS,ROC,STRUCTURES,THESE
169,233,COPYRIGHT,EORTC,INC,LABEL,MATERIALS,METHODS,NESTL,OBJECTIVE,PROCTITIS,PRT23,PURPOSE,QLQ,QUALITY,RESULTS,SYNBIOTICS,TREATMENT
169,COPYRIGHT,DOSIMETRIC,INC
00002,00004,00006,00008,00017,00030,169,800,ADC,BACKGROUND,CONCLUSION,COPYRIGHT,DIFFUSION,DWI,HEALTHY,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,THESE
152,156,169,308,ADT,COMPOSITE,COPYRIGHT,GLEASON,INC,INDEX,IRG,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PLANNED,PSA,PUBLISHED,RESULTS,SOCIETY,T1C,T2C
125,138,155,169,195,204,214,217,218,26A,30B,802,COPYRIGHT,INGENUITY,IPA,IRELAND,LTD,NGS,PATHWAY
100,146,169,471,520,ACUTE,ADVERSE,GRADE,IMAGE,JAPAN,MUS,OAR,PRESS,PTV,PUBLISHED,RADIATION,SOCIETY,THESE,UNIVERSITY
110,169,270,290,BACKGROUND,BECAUSE,BETWEEN,LABEL,METASTATIC,METHODS,RESULTS,SOCIETY,STUDIES
955,BACKGROUND,CONCLUSION,III,LABEL,METHODS,PHASE,RESULTS,THESE
169,176,202,945,A105L,ASN,BIOLOGY,CYP17A1,FIRST,INC,MOLECULAR,SOCIETY,THIRD
151,169,956,COPYRIGHT,DOCKING,EVALUATION,LNCAP,LTD,T877A,USING
ESL,KNOCK,MAP,PCA,RAS,SDF,THESE,USING
ADV,ADV_1,ADV_2,DTC,EPCAM,HOWEVER,NED,PCA
1000S,169,174,215,235PG,250NM,488,60MIN,916,ALEXA,ANNEXIN,BZATP,COPYRIGHT,CRYSTAL,FLUOR,INC,MVS,NTA,PC3,QCM,SAUERBREY,USING
004,048,116,169,1MONTHS,378,4MONTHS,7MONTHS,COPYRIGHT,HOWEVER,INC,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,TREATMENT
AKT,ASTRAGALUS,BACKGROUND,CONCLUSION,DU145,LABEL,MEANWHILE,METHODS,MTT,PCR,RESULTS,THEREFORE
001,100,125,165,169,177,BRITISH,COPYRIGHT,CTV,D90,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
HIV,POC,POINT
100,AFTER
106,11C,665,933,993,AUC,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SUV
945,946,BECAUSE,HIF,LNCAP,THESE
825,BACKGROUND,C30,C61,DISCUSSION,EORTC,HRQOL,ICD,KNOWLEDGE,LABEL,MATERIALS,METHODS,OTHER,PCA,PSM,QLQ,RESPONSES,RESULTS,TREATMENT
ADDITIONAL,AID,BACKGROUND,CHINESE,COCON,COMPETENCE,CONCLUSION,GERMANY,LABEL,METHODS,NETWORK,PSA,RESULTS,SOCIETY,UNASSIGNED
BASED,PCA,PUFAS
103,USING,VMY
AKT,CAMK2N1,CASODEX,CASTRATION,KNOCKDOWN,REDUCED,TAKEN
EFS,FYN,THEREFORE
001,002,005,363,372,523,RUSSIAN,SIX
145,EMT,FURTHER,GLEASON,PCA,PSA,THESE
145,231,435,549,946,HEPG2,HWE,MDA,OVCAR,THEIR,THREE,WADSWORTH
002,169,700,BACKGROUND,GLEASON,LABEL,METASTASIS,METHODS,PRESS,PUBLISHED,RESULTS,THOC1,UNIVERSITY
100,103,107,APOBEC3,BACKGROUND,LABEL,OBJECTIVE,RESULTS,THERE
000,100,231,241,262,311,AGE,ASRWS,AVERAGE,COLORECTAL,DCO,JOINPOINT,METHODS,OVERALL,RESULTS,SOFIA
BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,PCR,PREDICTING,RESULTS,SINCE,VGLL3
ADT,AKT,NCOA2,PCA,SRC,TAKEN,WHILE
0MG,666,CONCLUSION,DISEASE,FOUNDATION,GROUP,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,RENAL,RESULTS,WORKING
OTHER,THOSE
231,BASED,FACULTY,MERAM,SEL,UNIVERSITY
001,169,521,616,ADT,BIOMARKERS,CONCLUSION,COX,GLEASON,LABEL,LTADT,METHODS,OBJECTIVE,PURPOSE,RESULTS,STADT
LNCAP,PCA,PWR,R1881,SILIBININ,SREBP
954,KNOCKDOWN,L1CAM,MMP,THESE
169,AUTHORS,BJU,CONCLUSION,INC,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SANTA,USA
049,142,169,1ST,292,301,3RD,ALPHA,BACKGROUND,CLL,COLORECTAL,GREATER,HODGKIN,LABEL,METHODS,NHL,OVARIAN,PREVIOUSLY,RESULTS,SLL,THESE,TOCOPHEROL
169,ALPHA,BACKGROUND,BIOMARKERS,COLORECTAL,EPIDEMIOL,LABEL,MATERIALS,METHODS,ORS,OVARIAN,OVERALL,RESULTS,TOCOPHEROL,WOMEN
65291,ABDOMINAL,BECAUSE,GLEASON,HEMOGLOBIN,HOWEVER,INJECTING,VITAMIN
AFTER,ANOTHER,HOWEVER,RADICAL
233,AFTER,BCG,CIS,FINAL
ACCORDING,XTT
169,COPYRIGHT,HOWEVER,IGF,PROSTATIC,SOCIETY,USING
001,BACKGROUND,BOZOK,GLEASON,LABEL,MATERIALS,METHODS,PSA,RDW,RESULTS,UNIVERSITY,UROLOGY
625,652,ASIAN,BACKGROUND,CASP8,CIS,D302H,DESPITE,HOWEVER,LABEL,MATERIALS,METHODS,NON,ORS,PCA,RESULTS,THEREFORE
169,945,BPH,CCNB1,CCND1,CHINESE,COPYRIGHT,HOWEVER,IIA,LTD,TAN,TANSHINONE,THESE
169,643,AMONG,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,SEPTEMBER,STATEMENTS,SUCCESSFUL,SURGERY,UROLOGICAL
001,024,116,156,169,191,946,AFTER,CONCLUSION,COPYRIGHT,EBL,INC,LABEL,LPN,MATERIALS,METHODS,OBJECTIVE,RESULTS,RPLPN,USING
169,170,400,553,AMICO,CONCLUSION,COPYRIGHT,EPSTEIN,GLEASON,HGPIN,HOWEVER,INC,KETTERING,LABEL,METHODS,MSKCC,OBJECTIVE,RESULTS,SLOAN
APART,FURTHER,HOWEVER,HYDROXY,UNTIL
169,FDA,FINALLY,HOWEVER,INC
169,ACADEMY,BRITISH,CONFERENCE,COPYRIGHT,HOWEVER,JOURNAL,MEDICAL,PEDIATRICS,PREVENTING,THROUGH
123,169,232,ADDITIONAL,CASTRATION,EXPRESSION,FINALLY,GPER1,GPR30,HOWEVER,LNCAP,PCR,PCS,SOCIETY,USING
125,135,167,169,200,231,233,239,ACUTE,ADVERSE,AMICO,BETWEEN,CONCLUSION,COPYRIGHT,EORTC,GLEASON,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,T2A
001,008,135,CHINESE,COX,CRP,GLEASON,MEIER,THERE
111,177,BACKGROUND,DISCUSSION,GASTRIN,GRP,LABEL,METHODS,NEP,RESULTS,SWISS
160,169,231,233,COPYRIGHT,FINALLY,FIRST,IIA,III,MOL,SEVERAL,SFBBM,THERE
ALTAS,AMONG,L31,LNCAP,RPL31,THESE
001,104,120,160,169,50B11,964,BPH,COPYRIGHT,DU145,GLEASON,IHC,INC,LNCAP,NERVE,PATHOLOGY,PUBLISHED,SOCIETY,THESE
145,169,948,COPYRIGHT,INC,MCF
181,CD133,CD177,ISOLATING,NANOG,OVCA429,PROM1,SKOV3,SURVIVING,THEREFORE
200,2ND,945,946,956,AKT,EMT,FAK,GTPASES,MOLECULAR,PC3,PCA,PREVENTING,SILIBININ,SRC,TRANSWELL
492,AP4,FPN,INCREASING,INHIBITION,MYB,MZF,TARGETING,THESE
169,BACKGROUND,BAX,BCL,DU145,ELLAGIC,HOWEVER,INC,KIP,LABEL,LNCAP,METHODS,PFJ,RESULTS,THREE,WAF,WESTERN,WILEY
004,027,169,406,ABSENCE,AKT,BACKGROUND,CK5,CK8,COX,EXPRESSION,GLEASON,HOWEVER,INC,LABEL,MEIER,MET,METHODS,OVERALL,RESULTS,WILEY
251,330,AIM,BACKGROUND,CTX,DU145,KPT,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SELECTIVE,SELINEXOR,SIMILARLY,SINES
111,169,568,AMONG,BACKGROUND,CAT,COX,GLEASON,HOWEVER,INC,LABEL,METHODS,RESULTS,SEP15,SEPP1,THESE,WILEY
169,833,AUTHORS,CONCLUSION,COPYRIGHT,FIFTEEN,FORCE,GERIATRICS,JANUARY,JOURNAL,LABEL,MEN,METHODS,MIXED,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SETTING,SOCIETY
ARSENIC,HOWEVER,INORGANIC,KOREA,SOUTH,THERE,WHILE
009,141,169,310,829,BACKGROUND,BCR,CLINICIANS,COX,DESPITE,ESPECIALLY,GLEASON,INC,LABEL,MEIER,METHODS,PSA,RESULTS,TAKEN,WILEY
169,BACKGROUND,HOWEVER,INC,LABEL,METHODS,PCA,PHOENIX,RESULTS,SEVERAL,STUDIES,URINARY,WILEY
AFRICAN,AMERICANS,BECAUSE,CAUCASIAN,INC,PCA,PREVIOUSLY,PUBLISHED
102,165,432,BACKGROUND,CONCLUSION,DENMARK,DEPARTMENT,FUNDING,JANUARY,LABEL,METHODS,RESULTS,TRIAL,TUR,UROLOGY
155,160,169,946,AS2,AUTHORS,BRIEFLY,CURRENT,HENCE,HOWEVER,KNOCKDOWN,LNCAP,LTD,MIR,PTY,PUBLISHING,SCIENCE,SMAD2,TGF,THROUGH,UTR,WILEY
BACKGROUND,CIS,FURTHER,HOWEVER,LABEL,METHODS,NSAID,ORS,RESULTS,THEREFORE
169,COPYRIGHT,INC,NIR,THESE,VIS
169,454,666,AMONG,BECAUSE,CALIFORNIA,CHART,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PERMANENTE,PURPOSE,RESULTS,THESE
418,BRCA2,MUTATIONS,RAD51,THREE
ALGEBRAIC,CNR,FOLLOWING,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
CPCOP,CTVSV,D98,LABEL,METHODS,OBJECTIVE,PCA,PTV,PTVSV,PURPOSE,RESULTS,TCP,THESE
059,238,287,500,952,966,ASSOCIATED,BASED,CARLO,CTV,D90,DICOM,DIFFERENCE,ENGER,LABEL,MATERIALS,MED,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,STUDENT,TG186
CARLO,DIC,DMC_LOG,DMC_TPS,LABEL,LINAC,MCLOGQA,METHODS,MLC,MONTE,OBJECTIVE,PURPOSE,RESULTS,WHILE
192,233,ADDITIONAL,CURIETH,ESTRO,EUROP,GEC,GROUP,HOWEVER,PHYSICISTS,SOCIETY,THESE
169,240BP,CCAAT,COPYRIGHT,FOS,FURTHER,GIVEN,HOWEVER,LNCAP,PKC,PMA,PRMT5,PROTEIN
086,169,309,313,640,AFTER,BLADDER,CONTINENCE,COPYRIGHT,DRY,EDUCATION,ENCRYPTED,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,SECONDARY,THERE,UROLOGICAL
169,ERG,PRESS,PUBLISHED,THEREFORE,TMPRSS2,UNIVERSITY
082,169,215,291,307,694,972,986,PRESS,PUBLISHED,STAGE,THROUGH,UNIVERSITY
019,031,169,177,AGGRESSIVE,AGING,BLOOD,CONCLUSION,COPYRIGHT,DEFICIENCY,HEART,INC,INSTITUTE,LABEL,LOH,MATERIALS,METHODS,OBJECTIVE,PCA,RESULTS,THERE,THESE
169,945,COPYRIGHT,EARLY,LIFESTYLE,LTD,PSA,SEVERAL
150,169,174,181,215,255,287,289,291,317,373,461,500,529,945,ABSCIEX,ACQUITY,AUTHORS,C18,COPYRIGHT,DHT,FINALLY,HLB,KINETEX,OASIS,PROTONATED,PUBLISHED,QTRAP,VALIDATION
CLIC1,CONCLUSION,DU145,ERK,LABEL,MATERIALS,MEANWHILE,METHODS,MMP,MTT,RESULTS,THESE,TRANSWELL,UNLABELLED,USING
169,COPYRIGHT,DEK,SCIENCE
108,152,169,210,BLOOD,CONCLUSION,CTC,LABEL,METHODS,MTD,OBJECTIVE,PSA,PURPOSE,RESULTS,THESE,THREE
MRI
169,COPYRIGHT,CYTOTOXIC,LTD,MTT
169,BACKGROUND,CIS,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,ORS,PCA,PROTEUS,RESULTS
008,169,420,CONCLUSION,GIVEN,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS
AZD1152,LNCAP,TAKEN,TREATMENT
085,CONCLUSION,DESPITE,LABEL,LRP,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,RRP
956,DOX,DUE,ENHANCING,MTS,NDS,PC3,UTILIZING,VISIBLE
169,45S,ACTIVATION,BMH,FINALLY,FURTHER,NCI60,POL,TESTING,THESE,VIABILITY
169,AMONG,BASED,COPYRIGHT,EIGHT,GLEASON,INC,TEN
001,073,116,180,AUC,BACKGROUND,BCR,COX,GLEASON,HOWEVER,LABEL,METHODS,OVERALL,PREDICTIVE,PSA,PSM,RESULTS
956,ANIMALS,BACKGROUND,CASTRATION,CONCLUSION,LABEL,LUC,MET,METHODS,NOD,NSG,RESULTS,TREATMENT,VEGFR
169,226,427,BIOLOGY,HSP27,INC,MOLECULAR,OGX,PREVIOUSLY,RESULTS,SOCIETY,VALIDATION
145,22RV1,ATLAS,AZA,CPG,DAC,ENRICHMENT,EPIGENETIC,GLEASON,GS6,PCA,SET,THESE
126,216,945,946,CCN,CYR61,DU145,FAK,NOV,OSTEOBLAST,PC3,PCA,WNT
036,110,117,540,994,ANALYZING,EG5,GLEASON,NOVEL,NUCLEAR,PCA,SAMPLES
FOLLOWING
223,FDA,HOWEVER,III,VARIOUS
DUE,MICRORNAS,PSA,THESE
AKT,CAP,PI103,RAPAMYCIN
AHX,GLU,LYS,PET
124,169,954,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,INSTITUTE,LABEL,MATERIALS,METHODS,RESULTS,THEREFORE
105,112,169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,WORKING
1RA,414,548,946,BACKGROUND,CCL,CCL11,CCL17,COLORECTAL,CRP,CURRENT,EOTAXIN,LABEL,METHODS,ORS,OVARIAN,PRESS,PUBLISHED,RESULTS,SCREENING,SMOKING,THESE,TRIAL,UNIVERSITY
169,ADI,AKT,CXCR4,EMT,FAK,SINCE
003,169,19Q13,600,827,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THREE
169,AFTER,DUE,EPHB4,MFH,NVP,SEVERAL,SILENCING,STS,THEREFORE
001,144,169,235,702,723,756,866,ALTOGETHER,FINNISH,GLEASON,MEN,PSA,SCREENING,THERE,THEREFORE,TRIAL
169,HOWEVER,OVERALL,SOMATIC,SRC,USING
002,009,016,169,270,957,COX,MIXED,PCA,THESE,VALIDATION,VARIANT,XRCC1
160,786,ADP,AIF,AKT,BAX,BCL,CCRCC,CLL,FAS,HENCE,III,JNK,JUN,MAP,MMP,PC3,PREVIOUSLY,RIBOFLAVIN,SCHMIDT,SRC,TNF,TNFR1,TRADD,VEGFR
001,178,252,967,BACKGROUND,BDP,CONCLUSION,CONTROL,DEUTSCHER,DGP,GERMANY,GLEASON,LABEL,METHODS,PATHOLOGEN,PATHOLOGIE,PATHOLOGY,RESULTS,SOCIETY,UNION,WORLD
CONCLUSION,DIFFUSION,DWI,LABEL,MDC,METHODS,MRI,OBJECTIVE,RESULTS,TESLA
946,956,LIGIA,MTT,NMR,PC3
BRIEFLY,CADMIUM
134,169,322,CONCLUSION,CONTROL,IFS,LABEL,MATERIALS,MCNEMAR,METHODS,OBJECTIVE,PURPOSE,RATES,RESULTS

173,209,ENGLISH,LABEL,MEDICINES,METHODS,OBJECTIVE,PATHOLOGIC,PURPOSE,QOL,RADIATION,RESULTS,SCC,SRE,TREATMENT
ASCLEPIAS,C21,COMPOUNDS,DU145,ENZYMATIC,MOLECULAR,NMR,THEIR
001,029,152,160,ALTERED,EOC,HOWEVER,IHC,MEIER,PCR,PTOV1,RESULTS
509,946,AREAS,ARN,BACKGROUND,COVERED,LABEL,METHODS,NON,NOVEL,OPINION
160,169,177,966,ACADEMY,AGE,ANDROLOGY,BNR,CAVERNOUS,EFR,FEW,PHYSICIANS,SOCIETY,UNR
169,COMPOUNDS,COPYRIGHT,LTD,NMR,ROESY,THEIR
001,114,EPSTEIN,OHORI,SECTIONING
CF8,MK932,THEIR
700,FINLAND,METASTATIC,POPULATION,PSA
012,436,566,782,808,AFTER,AGE,DRE,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERE
591,BELIEFS,CBE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SCREENING
ALPHA,BPH,CURRENT,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THEIR,THERE,THESE
CD8,CONSISTENT,NKG2D,THESE,USING
160,169,183,223,ADT,ALPHA,CABAZITXEL,CYP17,GEORG,SIPULEUCEL,STUTTGART,WHILE
100,670,945,API,BACKGROUND,BECKMAN,CONTEXT,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,ROCHE,VALIDATION,WORLD
CHRONIC,LYMPHOMAS

181,ALKYLATION,CONSISTENT,CURRENT,CURRENTLY,HOWEVER,LBD,NTD
169,HOWEVER,THESE
946,HIF,HYPOXIA,TGF,TRAMP
169,AKT,ERK,IGF,IGF1R,INSULIN,IRS,LNCAP,NT157,PC3,THESE
169,NOVEL,OBESITY,PRESS,THESE
169,AFTER,EFFECTS,HOWEVER,HRS,IRR,POISSON,PSA,RISKS,SCREENING,SWEDISH
183,CVD,DENMARK,DESPITE,POTENTIAL,SEVEN
169,ADT,BPH,CAP,CPG,EPIGENETIC,GLEASON,H3K9ME3,LNCAP,LUCIFERASE,MAQMA,MECP2,POL,TAKEN,THREE,TMA,TRAMP,TSA
004,010,036,040,042,195,250,BONFERRONI,CHEMOKINES,GLEASON,HOWEVER,NORTH,PCA,PCR,SIMILARLY,VARIANT
169,DU145,INC,PEG,WILEY
1990S,HOWEVER,SINCE,VINCI
169,COPYRIGHT,ERG,ETS,FUSIONS,PRISM,PUBLISHED,SRM,STUDIES,THREE,TMPRSS2
145,252,BURKITT,CAL,DAUDI,HAH,HELIX,HIH,HLH,KLH,THEREFORE,THP
LNCAP,OBESITY,PACMETUT1,ROS
001,119,129,150,165,605,625,802,974,ADT,BACKGROUND,CENTRAL,CIS,CVD,CVM,LABEL,LIBRARY,MAY,MEDLINE,METHODS,PCA,RESULTS,THERE
956,DU145,INK4A,PC3,PROTEIN,WESTERN
100,169,362,540,COPYRIGHT,DEFENSE,DETECTION,EDUCATION,EXPLOSION,FURTHER,INC,ITALIAN,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,VETERINARY
001,132,169,322,381,703,COPYRIGHT,EDUCATION,INC,INITIALLY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SHEAR,UROLOGICAL,USING
029,062,086,134,169,174,610,742,AVERAGE,BASED,C30,COPYRIGHT,EDUCATION,EORTC,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QLQ,RESULTS,UROLOGICAL,UTILITY
002,006,169,944,BMI,DENMARK,OBESE,STAGE,THERE
100,169,181,2B6,2C8,2C9,2D6,3A4,AUC,COPYRIGHT,CYP,DDI,DRAFT,FDA,LTD,ORTERONEL,SIMULATION,THEREFORE,THESE,WILEY
169,COPYRIGHT,FOXA1,HOWEVER,INC,INK4A,RAS,THESE
169,ACTIVATION,ALTOGETHER,AUTHORS,COPYRIGHT,HOWEVER,INC,PUBLISHED,STAT3
ERG,INHIBITION,TMPRSS2
001,015,023,038,048,083,169,215,967,COPYRIGHT,FINALLY,HGPIN,IDC,INC,INTRACLASS,SIX,SOLID,THERE
169,5MM,643,716,CONFORMITY,COPYRIGHT,FOCAL,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTEEN,THERE,THESE,THREE
120,169,215,AAT,AMINO,BACKGROUND,COPYRIGHT,DU145,INC,LABEL,MB468,MDA,METHODS,PET,RESULTS,SIMILAR,SKOV3,THESE,U87
120,169,360,BACKGROUND,CGA,INC,LABEL,METHODS,PFS,PSA,RESULTS,UNV,WILEY
107,169,1A4,2G7,3E6,4E6,BACKGROUND,CONCLUSION,D2B,DUE,ELISA,FINALLY,GCP,GCPII,INC,LABEL,METHODS,RESULTS,SPR,USING,WESTERN,WILEY,YPSMA
169,COPYRIGHT,LTD
100MG,10878,133MG,169,1WEEK,BACKGROUND,COPYRIGHT,DOSES,HSP90,LABEL,LTD,METHODS,OVERALL,QOD,RESULTS,REVERSIBLE,SNX,THREE,USING
001,042,169,304,384,729,739,BACKGROUND,BMI,GLEASON,HOWEVER,LABEL,METHODS,OBESITY,OVERALL,PSA,RESULTS,STUDIES,THESE
100,169,945,956,COPYRIGHT,DHT,LTD
100,120,APRIL,AUS,AUTHORS,BACKGROUND,BPH,CENTRAL,CIS,COLLECTION,CONTROLLED,GROUP,HOWEVER,JANUARY,LABEL,MARCH,MEDLINE,MEN,METHODS,OBJECTIVE,OBJECTIVES,RANDOMISED,RESULTS,SELECTION,THERE
169,556,810,COPYRIGHT,COX,EDUCATION,FACTORS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
169,947,954,COPYRIGHT,INC,JNK
169,22RV1,945,COPYRIGHT,INC,LNCAP,MANGOSTIN,PCR,PRECS,SOUTHEAST,WESTERN
ASIAN,CAUCASIAN,CONCLUSION,K109R,LABEL,METHODS,OBJECTIVE,ORS,OVERALL,PURPOSE,RESULTS,SNP,THESE
AFTER,ASODN,CONCLUSION,DIFFERENT,KDR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,006,2N0,CONCLUSION,CRT,D50,EORTC,GLEASON,GRADE,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SIXTY,THERE,V70
125,169,400,700,945,AFP,AGE,ARCHITECT,BACKGROUND,C28,CA125,CA153,CALIPER,CEA,CHEMISTRY,HE4,HEALTHY,INITIATIVE,INTERVALS,LABEL,LABORATORY,METHODS,PEDIATRIC,PSA,REFERENCE,RESULTS,SCC
EGF,ERBB1,FTS,NUCLEOLIN,PREVIOUSLY,RAS,SALIRASIB,THESE,U87
DESPITE,PRIMARY,STAT3,STATTIC
221,332,630,AMONG,BETWEEN,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,TOTAL,TTV
169,COMPETING,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OLDER,RESULTS
169,COPYRIGHT,EDUCATION,FINALLY,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TOTAL,UROLOGICAL
142,169,934,AFTER,CONCLUSION,COPYRIGHT,COX,DUTCH,INC,KARNOFSKY,KPS,LABEL,MATERIALS,METASTASIS,METHODS,OBJECTIVE,PURPOSE,RESULTS,VAS,VRS
169,COPYRIGHT,INC
169,ARTICLE,AVAILABLE,COPYRIGHT,INC,ITEMS,OVERALL,PREFERRED,REPORTING,REVIEWS,SYSTEMATIC,WHETHER
ACUTE,BACKGROUND,FREEDOM,GRADE,LABEL,METHODS,OUTCOME,OVERALL,RESULTS,SIB
100,140,AFTER,HDR,LDR,MRI,PET,PSA
LOX,THEREFORE
3RD,CONFERENCE,CONSENSUS,MRI,PSM,SOCIETY,STAGING
223,III
DUE,HOWEVER,HUNGARY,MEDLINE,OVERALL,PSA,RCT
AFTER,AMONG,BASED,BETWEEN,LOCAL,MEDICAL,TEN,USA
HOWEVER,MINIMALLY,ROBOT,VINCI
BASIS,DISCOVERY,MEANWHILE
IPILIMUMAB,OTHER,USING
CHT,JANUARY
215,363,451,659,666,FLAIR,GRE,III,INCIDENTAL,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THERE,TSE
009,591,AMONG,ANALYZING,LABEL,METHODS,OBJECTIVE,OVERALL,POPULATION,RESULTS,RRS
169,198,361,AGE,ENGLAND,ENGLISH,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE,UROLOGICAL
169,COPYRIGHT,ISSUE,RAF,SPECIAL,UNTIL
160,169,ANEUPLOIDY,CONCLUSION,COPYRIGHT,DMR,H19,INC,INDIVIDUAL,ITGA6,KCNQ1OT,LABEL,MEASURE,METHODS,OBJECTIVE,OUTCOME,PATIENT,PEG,PUBLISHED,RESULTS,SETTING,SOCIETY,TESTICULAR,WHETHER
169,250,500,ALCOHOL,BIOMEDICAL,BOARD,CDC,CHINA,CHINESE,CONCLUSION,COPYRIGHT,EDITORIAL,GREEN,LABEL,METHODS,OBJECTIVE,PCA,PUBLISHED,REGULAR,RESULTS
169,233,242,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
108,145,160,BETWEEN,BPH,CCL19,PCA,PCR,SILENCING
SENSITIVE
001,002,041,196,330,BACKGROUND,DHT,GLEASON,LABEL,METHODS,RESULTS,THERE
146,169,215,760,AFTER,BLOOMBERG,CONSORTIUM,HOPKINS,INSTITUTE,JOHNS,PRESS,PUBLISHED,RAD51,RAD51L1,SNP,UNIVERSITY
001,169,947,ADVERSE,BACKGROUND,CD3,CD4,CD8,FOXP3,IHC,LABEL,METHODS,PHASE,PRESS,PUBLISHED,RESULTS,SIPULEUCEL,UNIVERSITY
169,600,ABSTRACTS,COPYRIGHT,INC,IRRITATIVE,LABEL,LITERATURE,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
148,169,175,237,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
686,ADJUSTMENT,BACKGROUND,CONCLUSION,GROUP,INSTITUTE,KARNOFSKY,KPS,LABEL,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,SAQ,THERAPY,WHITE
MSI,MUTATIONS
425,AFRICAN,ANN,ARBOR,BACKGROUND,BREAKFAST,COMMUNITY,CONTEXT,DESPITE,FELLOWSHIP,FIFTY,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,UNIVERSITY,YPSILANTI
032,043,169,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SURGERY,THESE,UROLOGICAL
660,745,ALTOGETHER,AURORAB,ETS,FOXM1,PCA,PLK,SAM,SPDEF,TOPO2ALPHA,TRANSGENIC,WHILE
169,GIVEN,LNCAP,PREVIOUSLY,THESE
169,ADC,LIV,LIV1A,SGN,SLC39A6,THESE
946,954,BESIDES,CPG,CRE,PCR
169,AKT,ASI,FINALLY,GIVEN,INHIBITION,NOTABLY,OVERALL,SREBP
111,169,177,AFTER,BECAUSE,HSG,IRDYE800CW,MBQ,MICROSPECT,PC3,RADICAL,SPECT
141,169,221,BACKGROUND,BASED,CASES,INC,LABEL,LOWER,METHODS,MICRORNAS,ORS,PCR,RESULTS,SEVERAL,TOTAL,WILEY
119,169,239,BACKGROUND,CONCLUSION,CONVERSELY,ERG,GLEASON,HOWEVER,INC,KAPPA,LABEL,METHODS,RESULTS,TMPRSS2,WILEY
001,140,169,435,653,680,744,AUC,AUTHORS,BJU,CDR,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THREE,USING
005,006,169,513,532,ADDITIONAL,AFRICAN,BACKGROUND,BARBADIAN,BLACK,CARIBBEAN,EMPIRICAL,INC,JAMAICA,LABEL,METHODS,POPULATION,RESULTS,RS2124036,SEVERAL,SNP,TEN,THESE,WILEY
001,009,013,033,286,430,448,726,858,LABEL,MATERIALS,METHODS,OBJECTIVE,PBX,PCA,PSA,PURPOSE,RESULTS
000,103,120,125,177,500,ADT,GROUP,III,JANUARY,LABEL,LDR,MATERIALS,METHODS,OBJECTIVE,PALLADIUM,PURPOSE,RADIATION,RESULTS,THERAPY,THERE
023,196,208,BRAZILIAN,CHAIN,CLEMENTINO,CONCLUSION,FEDERAL,FILHO,FRAGA,GENOTYPES,GSTA1,GSTM1,GSTP1,GSTT1,HMK,INSTITUTE,JANEIRO,LABEL,MARIO,MATERIALS,METHODS,OBJECTIVE,PCA,PCR,POLYMERASE,RESULTS,RIO,UNIVERSITY
182,BACKGROUND,BETWEEN,CONCLUSION,DISCUSSION,GLEASON,LABEL,MATERIALS,METHODS,PERINEURAL,PNI,RESULTS,SLIDE,THEIR
169,COPYRIGHT,ESSENTIAL,HOWEVER,ISSUE,LTD,METASTATIC,PSA,SPECIAL

MRI,PSA
169,ADT,HOWEVER,PCA,READERS,RESULTS,THESE
167,ANXIETY,FCS,HOWEVER,IL1,IL1R2,LABEL,METHODS,NFKB2,OBJECTIVE,PURPOSE,RESULTS,THEREFORE,THESE,USING,VARIATIONS
125,169,703,BACKGROUND,BMI,CCL13,CCL19,COLORECTAL,CRP,CXCL5,CXCL6,ENA,FDR,HOWEVER,LABEL,MARKERS,MCP,METHODS,MIP,ORS,OVARIAN,RESULTS,SCREENING,SDF,TRIAL
169,CONSISTENT,COPYRIGHT,GERIATRIC,INC,SOCIETY,TREATMENT,VULNERABLE
115,177,COELIAC,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SUV,SUVMEAN
602,DU145,HOWEVER,HPV,LNCAP,PC3,STEAP,SUBSEQUENT
AKT,BACKGROUND,BIRC5,CONCLUSION,COX,INHIBITION,LABEL,LNCAP,PKC,RESULTS,TAKEN,THESE,USING
BODP3,RELATED,SPECT
DUE,EARLY
004,025,424,CLINICIANS,FACTORS,INFECTIOUS,NEITHER
001,130,AFTER,ASSESSMENT,CALIFORNIA,CAPRA,COMPARING,COX,CPARA,FINALLY,FRANCISCO,MEIER,SAN,UNIVERSITY
ADM,HOWEVER,OSM,THESE
169,500,CD8,MHC,THESE
100,169,177,2NG,3NG,AMICO,BACKGROUND,CONCLUSION,COPYRIGHT,DUE,GROUP,HOWEVER,IIEF5,LABEL,LEVEL,MATERIALS,METHODS,PSA,RATES,RESULTS,ROBOTIC,SAS,SEVENTY
001,002,107,169,CONCLUSION,COX,CSM,GLEASON,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PLN,PURPOSE,REGRESSION,RESULTS,SOCIETY,THESE
JANUARY,OWING
BACKGROUND,BCR,FORTY,LABEL,LAPC3,LNCAP,MEN,METHODS,NON,PC3,PHC,PSA,RANDOMIZED,RESULTS,THERE
BFL,RGD,SV129
100,630,ARRHENIUS,CARLO,HEATING,LABEL,METHODS,MONTE,OBJECTIVE,OBJECTIVES,PARAMETRIC,RESULTS
DU145,FURTHER,HOWEVER,JANUS,OTHER,PC3,PTX,STAT3,ZERUMBONE
103,BACKGROUND,BETWEEN,CONCLUSION,CRT,GROUP,LABEL,METHODS,RADIATION,RESULTS,THERAPY
DWI,MRI
ACCORDING,FDA,PCA,PSA,SINCE,THESE
001,024,050,169,369,ABI,CAB,HOWEVER,MINOR,PFS,PRIMARY,PSA,SIXTY
169,BACKGROUND,CONCLUSION,COPYRIGHT,COX,EARLY,GLEASON,IAD,INC,LABEL,MEN,METHODS,PSA,RESULTS
009,168,169,218,638,ADDITIONAL,AMONG,CALCULATOR,COPYRIGHT,EDUCATION,INC,LABEL,LIKELIHOOD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SWEDISH,UROLOGICAL
001,169,543,621,671,876,AMONG,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL,USING
169,239,945,AFTER,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,MTT,OBJECTIVE,PERSISTENT,PUBLISHED,PURPOSE,RESULTS,TALALAY,THESE,UROLOGICAL
169,171,172,183,188,301,585,952,BACKGROUND,BETWEEN,COPYRIGHT,COU,FUNDING,IQR,JANSSEN,LABEL,LTD,METHODS,NOV,PSA,RESULTS
100,169,BASED,COMPARING,CONCLUSION,COPYRIGHT,CROWN,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PTV,PUBLISHED,RESULTS,SEVENTY
CELLS,GLEASON,HBP,KNOCKDOWN,TAKEN,UDP
145,DUSP6,FURTHER,LNCAP,TAKEN
108,169,8NG,AMONG,CONCLUSION,COPYRIGHT,CTCAE,EBR,FOCUSED,GLEASON,INTENSITY,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SAS,ULTRASOUND,URINARY
108,169,177,235,566,CONCLUSION,COPYRIGHT,DCE,DWI,GLEASON,IRELAND,LABEL,LESIONS,LTD,METHODS,MRI,NPV,OBJECTIVE,PCA,PSA,PSOVERALL,PSSUM,PURPOSE,RESULTS,TRANSITION,USING
CARNS,FINALLY,LINEAGE,ORGANOIDS
169,749,782,ADT,CONCLUSION,COPYRIGHT,COX,ELIXHAUSER,END,GIVEN,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OBJECTIVES,PARKINSON,RESULTS
001,013,033,169,201,BACKGROUND,BSI,COPYRIGHT,EXINIBONE,INC,LABEL,METHODS,RESULTS
082,125,169,AFTER,BRITISH,COPYRIGHT,COX,FURTHER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OLDER,PURPOSE,RADICAL,RESULTS,SIR
169,AMONG,COMPOUNDS,COPYRIGHT,NCI,SAS
001,034,169,239,500,558,999,COX,GLEASON,GROUP,JAPAN,LABEL,MEIER,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,SIMILAR,THERE,UNIVERSITY
169,AMERICA,CY5,CYS,GLU,HOWEVER,IRDY800,NIR,NORTH,RADICAL,SELECTIVE,THESE
100,125,160,169,923,952,CARLO,COPYRIGHT,D10,D30,D90,LTD,MCNPX,MONTE,PUBLISHED
001,215,AS1,ASSET,BRC,IFNW1,PRC,PRESS,PUBLISHED,RCC,RS10511729,SNP,TUSC1,UNIVERSITY
135,150,169,200,250,300,AKT,DUE,LABEL,METHODS,MRI,MTD,OBJECTIVE,PRP,PURPOSE,QOD,RESULTS,TREATMENT
169,ANN,CD147,CD9,CONCLUSION,COPYRIGHT,HLA,LABEL,METHODS,OBJECTIVE,RESULTS,ULTRA
169,916,COPYRIGHT,DETECTION,ERG,ERG72,ERG81,ETS,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,PCR,RESULTS,SOCIETY,TMPRSS2
169,200,CONCLUSION,COPYRIGHT,FOCAL,INC,LABEL,LOCAL,MATERIALS,METHODS,MRI,NEWER,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SOCIETY,WHOLE
169,946,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,UROSEPSIS,UTI
377,440,BACKGROUND,CONCLUSION,IDEAL,LABEL,LOWER,METHODS,RESULTS,SINCE,XVI
224,452,CCDC181,CURRENTLY,EPIGENETIC,GABRE,PITX2,SEVERAL,WESTERN
COMPOUNDS
INFLUENCE,LNCAP
IGFBP,NIDOGEN,PSA
AGRWT,PCA,PCR,PSA,ROC,USING
HENCE,RECURRENCE,TOP2A,TOP2AHIGH,USING
STROMAL
AFTER,AUA,DEPARTMENT,GUIDELINE,HOWEVER,KOREA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,UROLOGICAL,UROLOGY
169,571,899,AMONG,BACKGROUND,COPYRIGHT,HODGKIN,INC,ISPOR,LABEL,METHODS,NETWORK,NHL,OBJECTIVE,PRIMARY,PUBLISHED,RESULTS,SOCIETY,VHA
120,169,BACKGROUND,BRITISH,CO2,JOURNAL,LABEL,MEF50,METHODS,MIF50,PRESS,PUBLISHED,RESULTS,ROBOTIC,THEREFORE,UNIVERSITY
000,100,169,AFRICAN,ASR,EASTERN,PBCRS,REGISTERED,SAHARAN,THERE
169,509,ADDITIONAL,ARN,HOWEVER,SOCIETY
169,BACKGROUND,BETWEEN,COPYRIGHT,END,HOWEVER,INC,LABEL,MATERIALS,METHODS,PRIOR,PROCEDURES,RESULTS,THESE,USING
169,ALONE,RADIATION,SOCIETY
AREAS,BACKGROUND,BONES,COVERED,III,LABEL,MEDLINE,METHODS,OPINION,PCA,PHASE,PREVENTING
169,COPYRIGHT,CRPCS,GLEASON,LABEL,MICROARRAY,MIR,PATIENT,PCA,PRINCIPAL,PUBLISHED,REANALYSES,RESULTS,SCS,SUMMARY,UNLABELLED,UROLOGY
BACKGROUND,COS,DU145,GSH,LABEL,LNCAP,METHODS,NQM,OPH,PC3,PRODRUG,RESULTS,ROS,SIMILAR
HOWEVER,MULTIMODAL,WHILE
160,294,762,ASP148GLU,HOWEVER
INDEX,MEN,PCA,PCI,SHORT
ACQUIRING,BACKGROUND,DESPITE,HOWEVER,LABEL,MBC,METHODS,RESULTS,THESE
1990S,BACKGROUND,CONCLUSION,DRE,HOWEVER,LABEL,MALDI,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,SEPHAROSE,THEREFORE,TOF,URINARY
128,185,192,197,200,204,267,389,400,427,533,945,956,AFRICAN,BACKGROUND,ENDPOINTS,EYE,GROUP,HOWEVER,IDENTIFIER,IMPORTANCE,INDIVIDUAL,LABEL,METHODS,OBJECTIVE,PREVENTION,RELEVANCE,RESULTS,SETTING,SIMILAR,SOUTHWEST,THERE,THESE,TRIAL,VITAMIN
DESPITE,LABEL,LIFESTYLE,MEN,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE
10Q23,169,21Q22,COPYRIGHT,ERG,RESISTANT,SCIENCE
169,COPYRIGHT,SCIENCE
001,012,014,016,169,170,318,BACKGROUND,CONCLUSION,LABEL,MEDICAL,METHODS,PML,PRESS,PSA,PUBLISHED,RESULTS,SOCIETY,UNIVERSITY
169,945,ACTIVATION,BACKGROUND,COPYRIGHT,HOWEVER,HSA,INC,LABEL,METHODS,MSC,OBJECTIVE,PUBLISHED,RESULTS,SOCIETY,THERAPY,TNF,TRAIL,TSG
AKT,AMONG,EPHA3,GLEASON,HOWEVER,LNCAP,PCA,TAKEN
169,SEVERAL
APPROACHES,AUSTRALIA,AUSTRALIAN,BACKGROUND,BMJ,DIAGNOSTIC,GROUP,LABEL,LIMITED,METHODS,PUBLISHED,PUBLISHING,RESULTS,SECONDARY,TOTAL,TRIAL,UNIVERSITY,WESTERN,WHILE,ZEALAND
AVERAGE,VARIATIONS
169,BIOLOGY,CHE,EPIGENOMIC,FEDERATION,HENCE,PAR,SINCE,SP1
169,CONCLUSION,ENGLAND,GLEASON,KINGDOM,LABEL,LTD,METHODS,OBJECTIVE,PROTECT,PSA,RESULTS,THERE,WHILE,WILEY
BASED,FURTHER,HSP,HSP27
ANNEXIN,LC3,LNCAP,NEMOPILEMA,THESE,TREATMENT,VDT
REGUCALCIN
945,946,AMONGST,NMR,PC3,SCREENING
169,171NM,72H,CACO3,COPYRIGHT,HOWEVER,IBUPROFEN,THESE
DU145,MCF
160,AMONG,LOIRE,PAPILLOMA
169,CONSISTENT,CTBP2,NOTABLY,OVERALL
169,BECAUSE,COPYRIGHT,GLEASON,GP5,INC,NBX,PCA
946,BIOLOGICAL,INHIBITION,KEY,LABEL,MESSAGE,TGF,THEREFORE,THESE,TREGS,UNLABELLED
544,739,HOWEVER,JAPAN,PSA,SCORE,SYMPTOM,THERE,THESE
CERTAIN,HPV,HPV16,IRANIAN
APOPTOSIS,ARSENIC,PCR,PSA,RWPE1,WHILE,YET
001,008,160,174,ALTERED,BACKGROUND,CASES,CONCLUSION,COX,KRUSKAL,LABEL,METHODS,PCR,RESULTS,SIX,TRANSCRIPT
169,183,362,370,713,753,754,827,858,945,INC,KUDER,LABEL,METHODS,OBJECTIVE,RESULTS,RICHARDSON,WILEY
103,239,248,ADT,ASSESSMENT,CAPRA,CSS,HOWEVER,JAPAN,LABEL,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS,THEREFORE
160,AUC,CCL,COMPUTERS,GLEASON,IMAGING,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,REPORTING,RESULTS,ROC,TPM

001,111,150,177,215,CLINICALLY,HSG,LABEL,MBQ,METHODS,PC3,RESULTS,RIT,TROP2,UNLABELLED
956,CHINESE,PC3,TEN
181,22RV1,361,945,946,A2780,AURANOFIN,COMPLEXES,HLN,HOS,NMR,THP,TNF
176,177,CIDISTANCE,CIS,CONCLUSION,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,SDS,VRI
100,169,CONCLUSION,FEWER,LABEL,MET,METHODS,OBJECTIVE,OTHER,PURPOSE,RESULTS,SOCIETY,TAKEN,TREATMENT,XL184
070,138,169,571,ADJUSTMENT,CIS,COLORECTAL,CONCLUSION,COX,GLEASON,HOWEVER,HRS,III,LABEL,METHODS,OBJECTIVE,OTHER,OVARIAN,PURPOSE,RESULTS,SCREENING,SOCIETY,THEREFORE,TRIAL
001,012,018,032,034,123,169,CONCLUSION,COX,GLEASON,HRS,LABEL,MEDLINE,METHODS,NEPCS,OBJECTIVE,PCA,PURPOSE,RESULTS,SOCIETY,STUDIES,THERE,TREATMENT
145,DEPENDING,FOLLOWING,FORTY,THESE
105,COX,GROUP,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE,ZOLEDRONIC
006,1082C,10877,10878,49C,568,AFTER,AGE,BACKGROUND,BPH,CHRONIC,CIS,CRP,HOWEVER,IL6,IL8,INDEX,LABEL,LEP,METHODS,ORS,PPARG,RESULTS,SCORE,SYMPTOM,TNF,UROLOGICAL
090,10878,418,844,BACKGROUND,CHINESE,CIS,GENOTYPES,GLEASON,HAN,LABEL,METHODS,ORS,RESULTS,THESE
THEREFORE
946,CELLS,EGR,LNCAP,TGF
001,002,169,AMONG,BACKGROUND,BRCA1,BRCA2,LABEL,METHODS,NETWORK,RESULTS,SIR,SOCIETY
ADT,BACKGROUND,DISCUSSION,HOWEVER,LABEL,MDT,METASTASES,METHODS,MTD,PCA,PET,PSA,TRIAL
169,178,844,AMONG,BACKGROUND,CENTRAL,KOREA,LABEL,METHODS,RESULTS,SOCIETY,THYROID
FIRST,HOWEVER,PC3,RANKL,SIMILAR,THIRD,USING
001,177,967,CONCLUSION,EXCLUSION,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PCA,PURPOSE,RESULTS,THREE,TUKEY
005,025,101,149,169,ACCORDING,COX,GASC1,MYC,NANOG,PPARG,ROC,THEREFORE
169,BASED,COPYRIGHT,THESE
101,111,112,124,169,COPYRIGHT,ERG,ETS,FIFTY,MVD,THERE,WESTERN
169,COPYRIGHT,INC,LNCAP,NEOPLASIA,PACE4,PET,PRESS,PUBLISHED
954,ADT,ARV,HOWEVER,LBD,PCA,THESE
185,620,AFTER,AGE,CHINA,HOWEVER,JAPAN,KOREA,PSA,SERUM
CURRENT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,946,ACTIVATION,COPYRIGHT,ISSUE,LNCAP,MAP,MEDICAL,NDRG1,PROTEOMICS,PSGR1,SINCE,SPECIAL
001,009,169,215,263,BLOOD,CELLSEARCH,COX,CTC,III,JANSSEN,MEIER,NOTABLY,PSA,RECURSIVE,S0421,SAMPLES,THEREFORE
169,639,A1C,COPYRIGHT,EDUCATION,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TOTAL,UROLOGICAL
ANTIGEN,ASSESSMENT,BACKGROUND,CONCLUSION,EIGHT,GPS,LABEL,LAP,LEICESTER,METHODS,ONCOLOGIST,PACKAGE,PSA,RADIATION,RESULTS,SIX,THEREFORE
PAR
103,107,126,190,230,307,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX
169,956,APOPTOSIS,ASSESSING,BACKGROUND,COPYRIGHT,LABEL,METHODS,PBS,RESULTS,ROS,SPECIES
169,946,ALZHEIMER,AMYLOID,APP,COPYRIGHT,DU145,EMT,INC,LNCAP,NOTABLY,SNAI2,THESE,VIM
001,008,031,038,046,115,160,169,177,189,210,218,ASSOCIATES,BMI,COPYRIGHT,GLEASON,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,THERE
HRQOL,LABEL,METHODS,OBJECTIVE,PERHAPS,PURPOSE,RESULTS
169,AUTOMATED,BACKGROUND,CONCLUSION,COPYRIGHT,HIV,HPV,LABEL,MEDLINE,METHODS,RESULTS,SAS
215,303,737,AFRICAN,THESE
001,29321,BACKGROUND,CIS,COLORECTAL,CONCLUSION,COX,HRS,LABEL,METHODS,OVARIAN,PRESS,PUBLISHED,RESULTS,TVU,UNIVERSITY
169,PATIENT,PRESS,PUBLISHED,UNIVERSITY,YET
169,AMONG,COPYRIGHT,COX,CSM,END,LABEL,LOCAL,M1A,M1B,M1C,NLT,PATIENT,PUBLISHED,RESULTS,SUMMARY,THESE,UNLABELLED,UROLOGY
169,COPYRIGHT,PC3,SAS,THESE
001,042,BACKGROUND,LABEL,LNCAP,METHODS,MTT,RESULTS,THESE,TNM
169,ACUTE,ADVERSE,BED,COPYRIGHT,HOWEVER,INC,INSTITUTE,LABEL,LYMPH,MATERIALS,METHODS,NODES,OBJECTIVE,OVERALL,PRIAMOS,PURPOSE,RADIATION,RESULTS,SEPTEMBER,URINARY,WITHOUT
AKT,DECREASED,PHLPP,UAF,USP12,WDR20
001,005,100,133,300,500,ACCORDING,ANNEXIN,CD133,DU145,THEREFORE
916,946,CK5,CK8,CONVERSELY,CPG,DESPITE,ERG,GSTP1,THESE
737,ABT,BAD,BH3,CONSISTENT,CONVERSELY,CSC
AKT,BACKGROUND,ERBB2,GLEASON,LABEL,PRINCIPAL,RESULTS,THERE
123,99M,BACKGROUND,CONCLUSION,CONTEXT,FCH,FDG,LABEL,METHODS,PET,RESULTS
MRI
009,165,169,177,629,967,ANCTS,ANOVA,BPH,CHI,COPYRIGHT,IHC,NMIBC,PCR,STUDENT,TCC
125,145,169,945,946,AUGER,BACKGROUND,DU145,INC,INITIALLY,LABEL,LNCAP,METHODS,RADIOIODO,RESULTS,RISAD,WILEY
110,137,169,316,455,968,BACKGROUND,CARCINOMA,CONCLUSION,HEREDITARY,HOWEVER,III,LABEL,MATERIALS,METHODS,RESULTS
145,169,945,BACKGROUND,EBR,HOWEVER,INC,LABEL,LNCAP,PC3,RESULTS,ROS,THEREFORE,THESE,WILEY
BCL,ETS,LNCAP,PSA,WALNUTS
169,BACKGROUND,EFFECTS,INC,LABEL,METHODS,PCR,RESULTS,UTR,WILEY
169,181,BACKGROUND,DES,HOWEVER,INC,INK4A,JUN,LABEL,METHODS,RESULTS,ROS,WILEY
160,AMONG,ARG,HPV,PCR,PRO,PSA
131,169,367,BFD,COLLEGE,COPYRIGHT,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PUBLISHED,RESULTS,ROYAL,USING
169,ALIKE,BIOLOGY,COMMONS,HOWEVER,LICENSE,PACLITAXEL,SHARE,SOCIETY,TAXOL
160,240,360,956,BACKGROUND,BLOOD,CONCLUSION,LABEL,METHODS,RESULTS,THREE
AREAS,BACKGROUND,COVERED,DESPITE,FDA,LABEL,METHODS,OPINION,THERE
169,AFTER,COPYRIGHT,ERC,LINEWIDTH,LTD,WILEY
169,330,AFRICAN,BIOLOGY,BROADLY,EVOLUTION,KHOESAN,L0D,L0D2C,L0D2C1A,L0D2C1B,L0D2C1C,MOLECULAR,NAMIBIA,PRESS,PROVIDING,PUBLISHED,SAN,SOCIETY,UNIVERSITY
100,169,CONCLUSION,DEPARTMENT,FACULTY,HOWEVER,JAPAN,LABEL,METHODS,OBJECTIVE,RESULTS,SURGERY,TOTTORI,UNIVERSITY,UROLOGICAL,UROLOGY
032,129,169,APC,CRT,GRADE,JAPAN,PRESS,PUBLISHED,RADIATION,SOCIETY,THREE,UNIVARIATE,UNIVERSITY,V10,V65
177,435,585,633,638,HOWEVER,INTENSITY,LABEL,MATERIALS,METHODS,MFO,OBJECTIVE,PURPOSE,RESULTS,SFO,SIMILAR,THERE
169,NTD,VCH,WILEY
INCIDENTAL,IPC,LITERATURE,TUR
ACCORDING,AFTER,DEFINITIVE,QOL,SINCE,STRICTURES,TREATMENT,VUA,YAG
043,129,868,AFTER,BACKGROUND,CLAVIEN,DINDO,FISCHER,IRB,LABEL,LITERATURE,MAJOR,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,ROBOT,THERE
100,ALI,DESPITE,ECE,EMR,GLEASON,LABEL,METHODS,NATURAL,NLP,OBJECTIVE,PNI,POTENTIAL,RESULTS,SMS,SVI,TNM
001,160,169,ASSESSMENT,AUTHORS,EPIGENETIC,EXPRESSION,FOUNDATION,JOURNAL,LTD,MICROARRAY,MOLECULAR,MSP,NPT,PCA,PHENOTYPIC,WILEY
FAB,GHR,IGF,JANUS,LNCAP,SHORT,SIMILARLY,SOL,STAT5
177,956,DIADEMA,MYC,SNU,THESE,VIETNAMESE
001,003,006,022,043,169,BACKGROUND,CONCLUSION,INDIVIDUAL,LABEL,METHODS,PRESS,PRINCIPAL,PUBLISHED,RESULTS,STEARIC,THERE,UNIVERSITY
000,100,102,104,177,AGE,ASR,BACKGROUND,EXCEL,INCIDENCE,LABEL,METHODS,RESULTS
CSC,DU145,HEPG2
426,891,CIS,HYPOTHESIS,LABEL,LIBRARY,METHODS,OBJECTIVE,OVERALL,RESULTS,RRS,THERE
100,169,BAX,CONCLUSION,DOX,HOWEVER,KEY,LABEL,METHODS,OBJECTIVE,RESULTS,ROYAL,SOCIETY,THERE
002,013,134,164,169,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OTHERWISE,RESULTS,UROLOGICAL
169,99M,BECAUSE,GROWING,NAF,PET
013,040,285,328,893,AFTER,BACKGROUND,FEW,LABEL,METABOLIC,METHODS,PROJECT,RESULTS,RISKS
3MM,947,DVH,M3D,TPS
AAA,AXB,CARLO,ECLIPSE,HOUNSFIELD,MONTE,TPS,ULTIMATELY
ANY,BECAUSE,MLC,TPS
169,945,DESPITE,EMA,FDA,HLA,IDO,IFN,MEDICAL,NSCLC,PHD,SOCIETY,TMZ
60012,ECLIPSE,FINALLY,IBA,MLC,NUCLEAR,PTW,SUN,THESE,USING,VERSION
009,105,235,385,956,DEVIATIONS,GROUP
100,565,665,DLP,DLPCBCT,IMAGING,RESULTS,THESE
176,177,ACPDP,DELIVERED,DVH,MACHINE,OAR,PINNACLE3,PLANNED,PTV,SRS,TPS,TREATMENT,VIE
BIOLOGICAL,DVH,HOWEVER,MASTERPLAN,OAR,OMP,PTV,QUALITY,THREE,TPS
52427,62225,HODGKIN,HOWEVER,VDR
FURTHER
DIFFERENT,HOWEVER,OVERALL
LIPID
169,174,500,ADVERSE,COPYRIGHT,LTD,NEXRUTINE,THERE,TOXICITIES,WILEY
119,ADDITIONAL,BACKGROUND,CAP,LABEL,METHODS,RESULTS,SIMILARLY,SIR,THERE
015,160,215,523,AVERAGE,BACKGROUND,LABEL,METHODS,MRI,PSA,RESULTS
169,CLINICALLY,IMR,NOTABLY,SER10,THROUGH
THERE,THESE,WHILE
003,004,009,011,023,046,169,265,COPYRIGHT,COX,ERG,HENCE,LABEL,LOG,LTD,METHODS,OBJECTIVE,PCA,POZ,RESULTS,SPECKLE,T2E,TMPRSS2
169,1ST,715,APRIL,BACKGROUND,CIS,CONCLUSION,COPYRIGHT,COX,HRS,KINGDOM,LABEL,LTD,METHODS,OBJECTIVE,OCTOBER,RESULTS,SECONDARY,THERE
169,CRT,GRADE,HOWEVER,JAPAN,PRESS,PSA,PUBLISHED,QOL,RADIATION,SOCIETY,THOSE,UNIVERSITY
121,169,500,817,827,AMIGO,IMAGE,OPERATING,SOCIETY
000,006,008,009,014,239,240,297,301,302,359,400,550,620,627,ABSORPTION,BACKGROUND,BASED,COU,III,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,STUDIES
189,650,AUC,BCR,CANONICAL,CAP,FORTY,GLEASON,MEIER,MULTI,PEARSON
BPS,CURRENTLY,ZOLEDRONIC
AKT,AMINO,ANALYZING,ATRARIC,LNCAP,PCA,PP2,SRC,TAKEN,TREATMENT,USING
183,CONCLUSION,COX,GLEASON,IRELAND,LABEL,METHODS,OBJECTIVE,OLDER,PURPOSE,RESULTS
E26,ERG,ETS,FURTHER,HOWEVER,PCA
BNC,LABEL,MANAGEMENT,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SUMMARY
AFTER,BETWEEN,CONCLUSION,DIAGNOSTIC,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEPTEMBER
150,169,174,946,AFTER,AGING,ANTICANCER,BOD,BPH,CONCLUSION,COPYRIGHT,INSTITUTE,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,POD,RESULTS,RSH,TTG
169,ANTICANCER,CBX,COPYRIGHT,COX,INSTITUTE,LLW,MDA,PC3,PCA,STUDIES
002,013,034,169,946,COPYRIGHT,EMT,EPITHELIAL,FINALLY,INC,METFORMIN,NOTABLY,PCA,TGF
169,BPH,COPYRIGHT,SAS,WOMEN
160,169,COPYRIGHT,ERG,FOXA1,INC,TMPRSS2,USING,WHOLE
169,CK5,CK8,COPYRIGHT,INC,ORGANOIDS,THESE
000,001,100,10878,169,186,208,209,212,228,231,239,251,253,269,395,406,40YEARS,436,441,446,467,468,474,481,488,508,698,700,737,741,742,786,ASIAN,BACKGROUND,COPYRIGHT,COX,INSURANCE,LABEL,LTD,METFORMIN,METHODS,RESULTS,TAIWANESE,WHETHER
001,035,145,177,188,416,653,731,854,AMONG,BMI,CHI,CHINESE,CONCLUSION,GLEASON,LABEL,METHODS,OBESITY,OBJECTIVE,PARAMETERS,PSA,PURPOSE,RESULTS
169,22RV1,CASTRATION,COPYRIGHT,DHT,FORMATION,FURTHER,HOWEVER,LTD,MDV3100,UNDER
212,CSD,DU145,LIN28,MYC,PRIOR,TARGETSCAN,THEREFORE,THESE,ZNF
14YEARS,169,243,332,350,874,985,BACKGROUND,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,DILUTED,IRELAND,LDR,LTD,PEG
011,012,169,177,600,ADC,COPYRIGHT,DISTORTION,DWI,FIFTY,INC,KRUSKAL,MRI,STUDENT,SUM
169,676,AFTER,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PERSONS,POPULATION,RESULTS,THERE
145,EXPRESSION,LNCAP,MTT,PCA,PCR
021,125,169,976,AUTOPSY,CONCLUSION,COPYRIGHT,INC,JAPAN,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,SOCIETY
169,COPYRIGHT,CYP17,PUBLISHED,THESE

169,COPYRIGHT,FOCAL,III,INTENSITY,PUBLISHED,SAS,THESE
169,COPYRIGHT,DESPITE,LTD,TODAY
169,COPYRIGHT,FURTHER,IRELAND,LNCAP,LTD,METFORMIN,PSA,PUBLISHED,SMILE,SRC,TAKEN
169,223,LABEL,METHODS,OBJECTIVE,ONTARIO,PALLIATIVE,PURPOSE,QOL,RESULTS,SIPULEUCEL,SOCIETY,THERE
ADHERENCE,ADT,BACKGROUND,DISCUSSION,LABEL,METHODS,PILOT,TRIAL
001,160,326,HCC,HOWEVER,KNOCKDOWN,TAKEN,USING

ALTOGETHER,INITIATING
034,AIM,BACKGROUND,CCL18,DU145,EXPRESSION,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PCR,RESULTS
L122R,MYOD1,RMS,TUR
000,169,655,873,COPYRIGHT,EDUCATION,GLEASON,GREATER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,SURGEON,THERE,UROLOGICAL
001,007,169,499,AGE,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
110,169,642,752,COPYRIGHT,COX,EDUCATION,FURTHER,INC,IQR,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PROPENSITY,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
173,BACKGROUND,CONCLUSION,FURTHER,HOWEVER,KEY,LABEL,MDT,MEMBERS,METHODS,RESULTS,SPLITTING,THERE,UROLOGISTS
169,ADC,AUSTRALIAN,AVERAGE,BACKGROUND,CENTRAL,COLLEGE,DCE,FURTHER,GLEASON,KEP,LABEL,METHODS,MRI,MTD,NETWORK,PSA,RESULTS,ROYAL,ZEALAND
169,AUTHORS,EARLY,HOWEVER,LABEL,METHODS,NOTABLY,OBJECTIVE,PROTEOMICS,PSA,PUBLISHED,PURPOSE,RELEVANCE,RESULTS,VCH,WILEY
169,176,177,532,99M,AFTER,AUGER,AUNPS,COPYRIGHT,CYS,GLY,GRP,HIV,HYNIC,LTD,LYS,PC3,TAT,WILEY,YAG
169,221,AGE,COPYRIGHT,END,FORTY,FURTHER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PALLIATIVE,POISSON,PURPOSE,RATES,RECEIPT,RESULTS
169,945,COA,IMAGING,KIT,PRIMARY,UROLOGICAL,WORLD
SNP,WESTERN
159,170,268,379,428,430,515,525,577,619,695,734,870,922,943,ACCORDING,AUC,BASED,BPH,CONCLUSION,DOR,LABEL,LIBRARY,METHODS,OBJECTIVE,PHI,RESULTS,SERUM,THERE,TOTALLY,VIP
001,208,213,262,547,787,AE3,CONCLUSION,EP4,LABEL,LUC,METHODS,OBJECTIVE,ONO,PC3,RESULTS
THEREFORE
003,677,961,ANALYSING,HOWEVER,PSA
169,201,231,233,AFU,BETWEEN,COPYRIGHT,GLEASON,III,LOCAL,PSA,PUBLISHED,SALVAGE,SAS,SEVERAL,THREE,TUMEURS
169,192,231,233,COPYRIGHT,PUBLISHED,SAS,SINCE
169,231,233,COPYRIGHT,HOWEVER,MAJOR,MRI,PET,PUBLISHED,SAS
169,COPYRIGHT,CURRENT,FOCAL,HOWEVER,SAS,VTP,WST11
169,ABS_CAT,BACKGROUND,COPYRIGHT,GLOBALTEST,GLS,GSA,HOTELLING,LABEL,MED_CAT,METHODS,MMGSA,MRGSA,RESULTS,SET
169,COPYRIGHT,EMT,HOWEVER,INC,NOTABLY,PC3,RWPE1,UBIQUITIN,UCH,YET
016,018,027,032,169,215,ADT,COPYRIGHT,DISABILITY,INC,LABEL,MAXIMAL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,PCS,PUBLISHED,RANDOMIZED,RESULTS,RETENTION,SETTING
169,CK7,COPYRIGHT,MAC,NPH,P63,PAC,PSA,SAS,TCC
003,105,169,540,ACUTE,BOTHELL,BVI,BVS,COPYRIGHT,INC,LABEL,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,ORGAN,PUBLISHED,PURPOSE,QOL,RADIATION,RESULTS,SOCIETY,THERE
014,017,019,024,025,031,037,173,177,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PFA,PURPOSE,RATIO,RESULTS,RRP,SEVENTY
173,177,CONCLUSION,DIODE,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,PVR,RESULTS,SCORE,SYMPTOM,WHILE
181,1MG,956,CYP3A,EPR,HDAC4,IIA,P4503A4
576,906,C30,CONFIGURAL,EORTC,GIVEN,LABEL,METHODS,MULTI,OBJECTIVE,PURPOSE,QLQ,QUALITY,RESULTS
100,105,235,362,AFTER,AUSTRIA,BACKGROUND,HOWEVER,LABEL,METHODS,PREDICTION,RESULTS,STATISTICS,THEREFORE,TYROL
180,297,CONCLUSION,EASTERN,GLEASON,GRADE,GROUP,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TREATMENT
006,367,ASSESSMENT,BACKGROUND,BRITAIN,CCND2,CONCLUSION,COX,GLEASON,GREAT,HSPB1,LABEL,METHODS,PSA,RESULTS,UNIVARIATE
169,ADT,COPYRIGHT,INC,STUDIES
169,AMERICA,COLLEGE,CONCLUSION,COPYRIGHT,FIFTY,GROUP,III,LABEL,LTD,MATERIALS,METHODS,NORTH,OBJECTIVE,PUBLISHED,RADIATION,RESULTS,ROYAL,SYMPTOM,THERAPY
169,178,AC1,ACS,ATP,CLASS,COPYRIGHT,III,ISSUE,MAMMALIAN,SPECIAL
169,COPYRIGHT,LARGE,MRI,PET,PSA,PUBLISHED,SAS,SPECT,THESE,ULTIMATELY,WHILE
169,231,233,COPYRIGHT,PUBLISHED,SAS
ABC,ATP,HOWEVER,MDR,THESE,TKS
115,241,CAP67,DESPITE,GALXM,GXM,MPS,PC3,THESE
169,COPYRIGHT,DETECTION,EARLY,FDA,GUIDELINES,INDEX,NETWORK,OVERALL,THESE
177,234,278,DU145,GMO,HOWEVER,THEREFORE,THERMAL,TXR
169,407,ADULT,CONCLUSION,COPYRIGHT,DIF,GENERIC,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,QLACS,QUALITY,RASCH,RESULTS,SCORE,SURVIVORS
169,CCDC88A,CELLS,CLONOGENIC,CURRENTLY,FN1,GANIL,HOWEVER,JAPAN,PC3,PRESS,PUBLISHED,RADIATION,RBE,ROCK1,SOCIETY,UNIVERSITY
001,004,117,160,214,516,AMONG,BACKGROUND,BCR,LABEL,METHODS,PSA,PSM,RESULTS
100,118,126,334,AFTER,BACKGROUND,GLEASON,IDENTIFIED,INITIAL,IQR,LABEL,LNS,METHODS,PSA,RESULTS,SLN,SPIOS,USING
001,044,160,221,292,355,892,DRE,GLEASON,LUTSS,MIRNA,PSA
010,145,440,DOX,GROUP,IIA,IMMUNOBLOT,KNOCKDOWN,LNCAP,PCS,THESE
001,169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,RESULTS,VALIDATION
169,ANTICANCER,ANTISENSE,BCL,COPYRIGHT,INSTITUTE,LNCAP,STAT3,THESE,TREATED
001,016,100,102,114,119,169,170,211,5MM,954,ACCORDING,AGREEMENT,CONCLUSION,COPYRIGHT,GLEASON,IMAGING,INC,LABEL,MAXIMUM,METHODS,MRI,OBJECTIVE,PURPOSE,REPORTING,RESULTS
001,102,109,121,535,COX,CRIBRIFORM,FORTY,GLEASON,MARCH,PSA
128,252,375,CHO,GUO,HOWEVER,LARYNGEAL,LIANG,NON,PROJECT,THEIR,THEREFORE,THESE
000,001,017,024,039,240,352,421,650,794,BACKGROUND,LABEL,METHODS,RESULTS,SCORE,SYMPTOM
169,ADT,AMONG,CDK19,CPSF6,KDM3A,KDM4A,LABEL,MEN,NCOR1,NOTABLY,PCR,RASA1,RASGRP3,SETD5,SETD7,TP53BP1,UNLABELLED,USING
169,IMAGING,INC,MOLECULAR,NUCLEAR,RECEPTORS,SELECTIVE,SOCIETY
236,HSP75,HSP90,KARNOFSKY,KPS,THESE,TRAP1,WORLD
008,031,057,105,127,169,377,512,525,563,713,753,970,D9901,III,SIPULEUCEL
105,CHINESE,PCR,SLC45A3,THESE,USP9Y
001,867,956,BACKGROUND,CONCLUSION,DCE,LABEL,METHODS,MRI,OBJECTIVE,PCS,RCC,RESULTS,SIMILARLY,SUMMARY,WHITNEY
BMX,BTK,CTN06,DTX,ETK,KNOCKDOWN,PC3,RAF,SRC,TEC,TREATMENT,VEGFR,WHILE
EFFECTIVE,EXPRESSION,OVARIAN,PSP94,SIGNALING
25D,945,CONNEXIN32,FINALLY,GAP,LNCAP,THESE,VITAMIN
169,956,ACADEMY,BIOLOGICAL,BIOLOGY,CDK,CHINESE,EDITORIAL,INSTITUTE,INSTITUTES,MTT,PRESS,PUBLISHED,T24,UNIVERSITY
231,956,BACKGROUND,FC101,FURTHER,HACAT,HUC,LABEL,MCF,MDA,PC3,RESULTS,SCC
001,390,AMERICA,NORTH,SNP
100,116,169,APRIL,ASPIRIN,EXCLUSION,GROUP,INCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
001,151,160,227,BACKGROUND,BPH,CONCLUSION,GLEASON,INCREMENT,LABEL,METHODS,PCA,PLAC1,PSA,RESULTS
000,112,116,126,137,169,236,ACCORDING,AMICO,AUD,AUSTRALIAN,BACKGROUND,COLLEGE,CONCLUSION,DESPITE,JANUARY,LABEL,METHODS,RESULTS,ROYAL,THERE,ZEALAND
093,BASED,CHOLINE,CONCLUSION,GTV,LABEL,METHODS,OBJECTIVE,PARTIAL,PET,PURPOSE,RESULTS,SUVMEAN,TVP
EFFECTIVE,LABEL,METHODS,OBJECTIVE,PPB,PURPOSE,Q2D,Q2DVA,RESULTS,THESE,USING,WHILE
FINALLY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,THREE
176,177,AVERAGE,BASED,D95,DIR,DVF,FIFTY,LABEL,MAXIMUM,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,SVS,TEN
101,CTV,D95,D99,EVALUATION,LABEL,LINAC,METHODS,MLC,OBJECTIVE,PTV,PURPOSE,RESULTS,THESE,V65,WITHOUT
223,945,AREAS,BACKGROUND,COVERED,INITIAL,LABEL,METHODS,OPINION,PROSTATIC,UNTIL
006,009,068,100,415,BILIARY,HOWEVER,MEIER,WHILE
109,BACKGROUND,CURRENT,LABEL,RESULTS,SEVEN
169,COPYRIGHT,FGF,FGFR1,FGFRS,PCA,SCIENCE,THESE
169,COPYRIGHT,INC,PUBLISHED,SOCIETY
IMAGING,IMS,MALDI,OTHER
001,002,004,006,AMONG,BACKGROUND,DETECTION,FOUNDATION,LABEL,METHODS,PSA,RESULTS,SIMILARLY,THESE
BLM,DU145,DYE,THESE,WHILE
946,BPH,CONVERSION,GLEASON,HIGHEST,HSD,PSA,SAMPLES,TLC,USING
169,2000S,DESPITE,DIFFUSION,DWI,FOLLOWING,MRI,PHYSICS,RSI,USING
169,APRIL,AUTHORS,DIAGNOSIS,HOWEVER,LTD,MARCH,PROCEDURE,PTY,PUBLISHING,SCIENCE,WILEY
169,239,ADT,CAP,ENDOCRINE,HOWEVER,JAPAN,RELATED,SOCIETY,ZOL
570,726,844,952,BACKGROUND,BIOGRID,CYTOSCAPE,LABEL,METHODS,PPI,PROTEIN,RESULTS,SEQ,SUMO2,THERE,UBA52,YWHAQ
BME,WALES


109,150,177,252,ADT,BOLOGNA,CHANGES,CHOLINE,CONCLUSION,DISTANT,FURTHER,GLEASON,LABEL,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,TNM
160,BEAMNRC,CARLO,DOSXYZNRC,FRAME,MLC,MONTE,SYNERGY,THREE
007,400,BACKGROUND,CONCLUSION,DKK,HOWEVER,LABEL,METHODS,RESULTS,WNT
016,035,037,169,ADC,AIM,COLLEGE,CONCLUSION,COPYRIGHT,DWI,FORTY,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,SNR
DESIGNING,FDA,HCC,HEPATOCYTE,MEDULLARY,MET,MTC,RCC,THYROID,XL184
169,BAX,BID,CHINESE,COPYRIGHT,DU145,FAS,FLIPL,INC,INHIBITION,JUN,MMP,NH2,PC3,PWR,ROS,SER70,STEPHANIA
177,945,956,AAG,COMPOUNDS,DHT,EXPRESSION,GFP,GIVEN,HIV,IC50S,LIBRARY,LOPAC,LXXLL,NRS,PPI,REV,RFP,SMALL
BACKGROUND,HOWEVER,LABEL,LRIG1,LRIG2,LRIG3,METHODS,OPTIMAL,RESULTS,SEVERAL
169,COPYRIGHT,COX,EDUCATION,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SALVAGE,SIX,UROLOGICAL
COLLEGE,LABEL,METHODS,NUMERICAL,OBJECTIVE,PURPOSE,RADIOLOGY,RESULTS
AMONG,ANDROLOGY,COLLEGE,INCREASED,LABORATORY,NHS,SPERM,THESE,TRUNCATING,TRUST
BASED,BAYES,HOWEVER,NIM
125,AFTER,AMS,ART,GIVEN,GLEASON,IMAGING,PATHOLOGIC
BETWEEN,CASES,COLOSTOMY,SIX,THERE,WALLACE
169,COPYRIGHT,DCE,DYNAMIC,HOWEVER,LTD,MRI,THEREFORE
100,10878,150,AMONG,BACKGROUND,CAB,CONCLUSION,ITT,LABEL,METHODS,PARTIAL,PSA,RESULTS,SECONDARY,SIXTY
100,177,ADVERSE,AFTER,AMICO,BACKGROUND,FOCAL,FURTHER,IQR,IRE,LABEL,METHODS,MPMRI,MRI,NCI,OVERALL,PSA,RESULTS
169,BACKGROUND,BECAUSE,CONCLUSION,GUIDELINES,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
169,COPYRIGHT,GIVEN,HOWEVER,MEDLINE,PROGNOSTIC,PSA,PUBLISHED,SAS
001,003,169,195,1ST,945,BACKGROUND,CASES,COLORECTAL,GLEASON,III,INDIVIDUAL,LABEL,METHODS,OR4TH,ORS,OVARIAN,RESULTS,SCREENING,TRIAL
100,169,956,BACKGROUND,CHINA,COPYRIGHT,CUMULATIVE,IRELAND,KOREA,LABEL,LTD,MATERIALS,METHODS,RELEVANCE,RESULTS,SCE,SCHISANDRA
169,177,774,967,ANCTS,ANOVA,BLADDER,BPH,CEP55,CHI,COPYRIGHT,IHC,NMIBC,PCR,STUDENT,TCC,UNTIL
169,47D,AROMATASE,COPYRIGHT,HOWEVER,LTD,PSA,THESE,VARIANT
150,169,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,FIFTEEN,GADD45A,GRADE,INC,LABEL,METASTATIC,METHODS,RESULTS,SIX
003,100,CIS,EBL,FURTHER,LABEL,LIBRARY,LOS,MARCH,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OPERATING,ORS,OUTCOME,PSM,RESULTS,SCHOLAR,THERE,WMD
001,17Q12,535,726,946,AFRICAN,AFTER,AMERICANS,CAUCASIANS,CIS,ORA,ORS,POR
ALTERATION,BAK,BAX,BCL,BID,PCR,THERE,THOSE,VDAC1,VDAC2,VDAC3,VDACS
001,285,BPH,COX,III,LABEL,LOG,METHODS,OBJECTIVE,PCA,RESULTS
CONSISTENT,FATTY,INHIBITION
169,AUTHORS,COPYRIGHT,INC,MMP,MT1,PUBLISHED
APOPTOSIS,PROGRAMMED,TRAIL
169,582,AILNCAP,BACKGROUND,EFNB2,FUNCTIONAL,INC,LABEL,LNCAP,METHODS,MICRORNAS,MIR,PCR,RESULTS,UTR,WILEY
169,916,936,COMPOUNDS,COPYRIGHT,FURTHER,LTD,ROS,SEM,STOBBEL
001,002,100,124,169,1RECTUM,231,233,CONCLUSION,COPYRIGHT,CTV,D1URETHRA,D90,DHI,LABEL,MAY,METHODS,NUCLETRON,OBJECTIVE,PLATO,PUBLISHED,PURPOSE,RESULTS,SAS,STOCKHOLM
169,COPYRIGHT,DU145,LTD,MCF,PUBLISHED,UGI
169,362,457,636,800,AMONG,AUC,BACKGROUND,BECKMAN,CHINA,CHINESE,COULTER,CURVE,DCA,DXI,GLEASON,HOWEVER,INC,LABEL,METHODS,PCA,PHI,PSA,RESULTS,SCORE,SERUM,SIMILAR,WILEY
181,401,BASED,CTC,GFP,HOWEVER,OBP,SEVEN,THEREFORE
145,160,HOWEVER,HSP90,LNCAP,PC3,PCA,RTK,TREATMENT,TREATMENTS
013,073,089,107,169,239,AFTER,AMONG,BACKGROUND,COX,CROSS,INC,LABEL,METHODS,PFS,PSA,RESULTS,THESE,WILEY
001,169,BACKGROUND,BIOMARKERS,ERG,INC,LABEL,METHODS,OVERALL,RESULTS,THESE,TMPRSS2,USING,WILEY
169,239,967,BACKGROUND,CONCLUSION,INC,LABEL,METHODS,NOTABLY,PFS,PRIOR,PSA,QUESTIONS,RESULTS,THESE,TREATMENT,WILEY
ANNEXIN,BCL,CAP,HOWEVER,LNCAP,TREATMENT
169,BACKGROUND,CHROMATIN,INC,LABEL,LNCAP,METHODS,NANOG,NANOGP8,RESULTS,WILEY
169,APART,COPYRIGHT
169,ABCG2,BACKGROUND,INC,LABEL,METHODS,PCA,PCR,RECURRENT,RESULTS,STUDIES,WILEY
114,169,185,299,AFRICAN,BACKGROUND,CARIBBEANS,CAUCASIAN,CAUCASIANS,CLC,ERG,INC,LABEL,METHODS,PCA,PIN,RESULTS,TMPRSS2,WILEY
000,100,106,110,AGE,ALGERIA,APC,ASR,BACKGROUND,BETWEEN,INCIDENCE,INSTITUTE,LABEL,METHODS,RESULTS,SETIF,STATISTICS
169,1990S,COPYRIGHT,HOWEVER,PUBLISHED,SAS
169,231,233,COPYRIGHT,LOCAL,MRI,PET,PUBLISHED,RADICAL,SALVAGE,SAS
001,002,005,015,016,017,019,026,027,028,030,031,033,034,037,169,240,AUGMENTED,BCR,BFS,COPYRIGHT,EXPRESSION,GLEASON,INC,NRF,SAMPLES,THESE
125,160,166,169,172,COPYRIGHT,D90,LABEL,LTD,MEANS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,REGARDING,RESULTS,V90
160,DR5,HOWEVER,PCA,PIN,PSA,YIN,YY1
145,ADC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RCM,RESULTS,USING
106,10878,120,126,169,271,347,353,377,ADT,CONCLUSION,COPYRIGHT,CSS,HDR,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,T2C,THESE
169,946,ADP,EMT,FUNCTIONAL,IMPAIRING,PRESS,PUBLISHED,SMADS,TGF,TRAMP,UNIVERSITY,ZEB
001,169,COPYRIGHT,EDX,ELISA,FOURIER,ICP,LOD,PSA,TEM,UNDER
967,993,AUC,BOUTROS,SEQCONTROL,THESE,USING
160,HOWEVER,METASTATIC,NETWORK,USING
00001,822,CONCLUSION,CRT,GRADE,HOWEVER,INDEX,LABEL,LIBRARY,MANAGER,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCIENCE,SIX,STATA,WEB
ALK,CONSISTENT,CRIZOTINIB,IGF,IRS,SIMILAR,TKI
2000S,ANNEXIN,DESPITE,ORAI1,PCA,S100A11,TRANSIENT,TRPC1,TRPV6,XENOGRAFTS
169,185,CCL,COPYRIGHT,DU145,HTB,LTD
001,008,237,409,625,ANALOGOUS,EXPRESSION,FIFTY,FURTHER,PCR
HOWEVER
169,COPYRIGHT,CTC,INC,USING
UROLOGISTS
208,234,259,579,ADVERSE,BACKGROUND,BMI,CHI,CONCLUSION,CPT,CURRENT,FINAL,LABEL,M22,MATERIALS,METHODS,REASONS,RESULTS,ROBOTIC
100,ADVANCE,AUR,DESPITE,FINALLY,FURTHER,MRI,WHILE
00001,100,ADVANCE,AMS,BACKGROUND,CIC,LABEL,MATERIALS,METHODS,PPD,PPI,RESULTS,SIXTEEN,TOV,WHILE
9FY,CAP,ELISA,ERG,FURTHER,INCREASING,L57,MAB,P23,P27,P30,Q53,R50,THESE,TMPRSS2,W56
121,18F,444,47925,AIM,FDG,LABEL,METHODS,OBJECTIVE,OVERALL,PERIPHERIC,PET,PIU,RESULTS,SIX,SUV,THERE,THEREFORE
ALTERED,HOWEVER,III,LOX,MMP,NOTICEABLY
EMT,FAK,HOWEVER,MMP,PANCREATIC,SNAIL,SRC
005,013,163,303,BASEL,GLEASON,LABEL,METHODS,OBJECTIVE,PSM,RESULTS
002,005,007,548,945,946,BACKGROUND,BIOMARKERS,COLORECTAL,LABEL,METHODS,OVARIAN,PRESENTLY,RESULTS,THESE
141,CONCLUSION,GLEASON,ITGA5,KNOCKDOWN,LABEL,LNCAP,METHODS,OBJECTIVE,OPHN1,PC3,PCA,RESULTS,THESE
DU145,KNOCKDOWN,NIN
12Q21,169,18P11,20Q12,COPYRIGHT,GENOMIC,PROTEIN,PTPRM,PTPRQ,PTPRT,THEIR,THESE
100,169,COPYRIGHT,GLEASON,INC,LABEL,METHODS,MTT,OBJECTIVE,OBJECTIVES,PSA,RESULTS
169,264,330,350,540,657,AFTER,CAUCASIAN,CISD1,CLIC5,COPYRIGHT,CYP26B1,FIRST,GWASS,HOWEVER,LEU,MET,OVERALL,PCA,PSA,SER,THIRD,THR
439,AFTER,BMJ,GROUP,LTD,MARCH,MRI,OCTOBER,PSA,PUBLISHING,RETROGRADE
DESPITE,MALIGNANT,METFORMIN,THEREFORE
169,AFTER,AUTHORS,BETWEEN,BJU,COX,CSS,FURTHER,GLEASON,LABEL,LTD,MEIER,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,STAGE,T3A,T3B,THERE,WILEY
169,IMAGING,INC,MOLECULAR,NUCLEAR,SOCIETY
169,AVERAGE,CONCLUSION,COPYRIGHT,EIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS,TYPES
147,169,177,205,352,472,AMONG,CONCLUSION,COPYRIGHT,HOLEP,INC,LABEL,METHODS,NPI,OBJECTIVE,RESULTS
001,002,005,029,114,169,206,744,AMICO,ASSESSMENT,CAPRA,CONCLUSION,COPYRIGHT,COX,INC,LABEL,METHODS,OBJECTIVE,PHOENIX,RESULTS
027,169,ADULT,COMMITTEE,CONCLUSION,COPYRIGHT,COX,CSS,DIAGNOSIS,INC,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS,SURGERY,UNIVARIATE
169,BECAUSE,CLINICALLY,DRUGS,DVL,ERK,IGF,IGFIR,MEK,RAS,SHC,SOS,WNT
169,239,286,AUC,AUTHORS,BJU,CONCLUSION,GODOY,LABEL,LNI,LNS,LTD,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,THESE,WILEY
ANY,CONCLUSION,CRAWLEY,DSC,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OUTLINING,RESULTS,THERE
169,945,954,AKT,COPYRIGHT,LNCAP,MMP,THEREFORE,THESE,TIANEPTINE,TNF,TSS,USING
169,800,ADC,BACKGROUND,CONCLUSION,DIFFUSION,DWI,FORTY,FOUNDATION,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,TESLA,THEREFORE,WHEREAS
AMONG,CONCLUSION,FIRST,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,USING
155,AGA,AUSTRALIAN,BACKGROUND,IGG,IGM,LABEL,METHODS,MONOCLONAL,RESULTS
BASED,CHANGES,ULTRASOUND
223,AMONG,DISEASE,III,LABEL,OBJECTIVE,OSTEOCLAST,PHASE,PURPOSE,RESULTS,SUMMARY,THESE
169,22RV1,954,C42,CONVERSELY,LABEL,LAPC4,LNCAP,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
001,017,118,169,548,AFTER,AHR,BACKGROUND,BETWEEN,COPYRIGHT,DISCUSSION,DRE,GLEASON,INCREASING,LABEL,LTD,METHODS,PSA,RESULTS,T1C
177,BACKGROUND,GHANA,JANUARY,KORLE,LABEL,RESULTS,SAHARAN,SUB,THEIR
169,AMONG,BACKGROUND,BRAZILIAN,DISCUSSION,HODGKIN,INC,LABEL,METHODS,MOR,RESULTS,WILEY
169,466,806,GLEASON,INC,PCA,SEVERAL,THESE,TNM,WILEY
001,002,570,679,CYSTECTOMY,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PROMETRICS,PURPOSE,RADICAL,RESULTS,SOCIETY,THERE
100,169,183,228,247,337,429,444,538,545,553,956,966,ASSESSMENT,BACKGROUND,BETWEEN,CONSENTING,CONTROLLED,COPYRIGHT,FUNDING,GLEASON,INSTITUTE,JAN,LABEL,LTD,METHODS,OCT,PROGRAMME,PROTECT,PSA,PUBLISHED,RANDOMISED,RESULTS,T1C,TECHNOLOGY,TREATMENT,TRIAL
400,BACKGROUND,DISCUSSION,DUE,EVALUATION,JANUARY,LABEL,MATERIALS,METHODS,RESULTS,RPE
CONCLUSION,FURTHER,HOWEVER,LABEL,LIVER,METHODS,OBJECTIVE,PSA,RESULTS,TEN
136,143,177,236,383,400,800,956,BACKGROUND,CELLS,ELISA,HUVEC,LABEL,METHODS,MTT,RESULTS,TDT,THEREFORE,TUNEL,UMBILICAL
ALTOGETHER,BACKGROUND,CONCLUSION,DU145,III,LABEL,PC3,RESULTS
116,181,183,295,435,H358M,HCT,MDAMB,NCI,OVCAR,PC3
001,177,215,ADC,BASED,CONCLUSION,DWI,KNOWLEDGE,LABEL,METHODS,MRI,OBJECTIVE,PCS,RESULTS,ROC
947,THESE
169,ATLAS,AUC,BACKGROUND,CALLING,CONSORTIUM,LABEL,METHODS,MOTIVATION,PRESS,PUBLISHED,RESULTS,ROC,UNIVERSITY,USING,VARIANT,VCF
HODGKIN,INTERVIEWS,LABEL,METHODS,OBJECTIVE,PROVIDERS,PURPOSE,RESULTS,STRATEGIES,THERE
FNN,NETWORK,PSO
HEALTHCARE,HOWEVER,ITERATIVE,VISIONARY
100
005,682,954,AMONG,BACKGROUND,BECAUSE,FINALLY,HOWEVER,LABEL,METHODS,MUSIC,OBJECTIVE,OUTCOME,OVERALL,PATIENT,PSA,PUBLISHED,RESULTS,SETTING,SUMMARY,SURGERY,THERE,UROLOGICAL
000,169,252,946,AMH,BECKMAN,COLORECTAL,COULTER,CURRENT,DESPITE,DIFFERENT,ELISA,GEN,MEANWHILE,ORS,OVARIAN,PSA,SCREENING,TGF,TRIAL

AMONG,BACKGROUND,CONCLUSION,DESPITE,GIVEN,HODGKIN,LABEL,METHODS,THERE
168,AFTER,CALIFORNIA,FCS,GMM,IL1R2,KNOWLEDGE,LABEL,METHODS,NFKB2,NURSING,OBJECTIVE,OBJECTIVES,PURPOSE,QOL,RESULTS,SETTING,VARIABLES
CALIFORNIA,FATHERS,HOPEFUL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PURPOSE,RESULTS,SETTING,THEREFORE
DOX,LABEL,METHODS,OBJECTIVE,PAESE,PURPOSE,RESULTS,ROS,SSL,TREATMENT
009,100,172,ANY,BCR,COX,FIFTY,LABEL,LOG,MEIER,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,SIXTY,UNIVARIATE,WHITNEY
141,520,670
169,COPYRIGHT,FINALLY,GST,HOWEVER,INC,LNCAP,MEIS1,PSA,R1881,TAKEN
169,544,547,AMONG,COPYRIGHT,EDUCATION,FACTORS,GLEASON,INC,LABEL,LYMPH,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SECONDARY,UROLOGICAL
PSA,RESULTS,THERE
121,126,BACKGROUND,BIG,CELLS,CONCLUSION,CONVERSION,ENDOTHELIN,ET1,LABEL,METHODS,MICRO,RESULTS
008,149,945,CIS,COLORECTAL,CONCLUSION,CRP,INC,INCREASED,LABEL,LIMITED,METHODS,OBJECTIVE,ORS,OVARIAN,PRE,PRO,PUBLISHED,RESULTS,SCREENING,THESE,TNF,TRIAL
AFTER,AH2,IDEPT,PCA,THEREFORE
145,177,956,HISTOLOGY,IGF1R,INSULIN,LNCAP,MCF,PET,PROMINENT
100,169,GFP,METATARSAL,PC3
169,COPYRIGHT,KNOWLEDGE,LTD,SEVERAL
169,COPYRIGHT,LTD,OATPS,SLC,THEREFORE,VARIOUS,WILEY
127,145,150,169,AMONG,BASED,CBM,CHINA,CHINESE,COMMISSION,HELICAL,LABEL,LIBRARY,LTD,METHODS,OBJECTIVE,OBJECTIVES,PTY,PUBLISHING,RESULTS,SICHUAN,UNIVERSITY,VIP,WANFANG,WILEY
1RA,CD11B,CXC,CXCR2,IL1RA,STRIKINGLY,TAKEN,TARGETING,WHETHER
169,476,ADJUSTING,CIS,COLORECTAL,DBP,NEITHER,ORS,OVARIAN,SCREENING,TRIAL
001,005,333,400,415,427,AMICO,BACKGROUND,COX,GLEASON,HOWEVER,IQR,LABEL,MEIER,METHODS,NHT,RESULTS
001,002,213,BACKGROUND,COX,GLEASON,LABEL,MEIER,METHODS,PCA,PSA,RESULTS,THEREFORE,YWHAZ
000,100,169,AGE,APC,AUTHORS,BACKGROUND,BRAIN,CENTRAL,HODGKIN,INC,LABEL,METHODS,RESULTS,SOCIETY,STATISTICS,WILEY
169,ADT,CAP,FURTHER,HOWEVER,LOCAL,LTD,PTY,PUBLISHING,THERE,WILEY
169,945,CASTRATION,COPYRIGHT,CURRENT,FGF,FGF23,FGFR1,FGFRI,LTD,TIO,WHILE
120,169,BIOLOGICAL,COMPARE,COPYRIGHT,LTD,SAR
BACKGROUND,ETS,FINALLY,GENOMIC,LABEL,REMARKABLY,RESULTS,TEN
103,169,ADT,AFTER,BACKGROUND,COX,LABEL,MEIER,METHODS,PFS,RESULTS,SOCIETY,WHETHER
100,169,ACUTE,AUSTRALIAN,COLLEGE,CYBERKNIFE,ROYAL,TEN,THERE,THREE,ZEALAND
100,169,270,948,952,COM,COMAP,COPYRIGHT,D95,INC,LAM,MEDICAL,PUBLISHED
239,CONTINUED,ENGLAND,JOURNAL
169,258,286,ADT,BACKGROUND,EXPRESSION,FDA,INC,LABEL,METHODS,PCR,RESULTS,SERUM,THEREFORE,THESE,WILEY
001,150,177,215,297,380,ADC,ARTEFACTS,DISTORTION,DWI,EPI,FOV,FURTHER,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PTX,RESULTS
169,DUE,INC,PECHLIN,VON,WILEY
001,169,183,300,AMERICA,CARIBBEAN,GIVEN,HPT,LABEL,LATIN,LTD,MEMBERS,METHODS,OBJECTIVE,OCEANIA,RESULTS,THERE,THESE,WEB,WILEY
257,960,BACKGROUND,GPS,JANUARY,LABEL,LARGE,MEN,METHODS,MIDLAND,NETWORK,PSA,RESULTS,SCREENING,THERE,ZEALAND
895,ALZHEIMER,AUC,BASED
169,BASED,COPYRIGHT,LTD,THERE
001,169,389,856,BLACK,CONCLUSION,COPYRIGHT,END,INC,LABEL,MEN,METHODS,MHI,OBJECTIVE,OLDER,RESULTS
AKT,DESPITE,FUNCTIONAL,PCA
141,275,642,AUSTRALIA,AUSTRALIAN,OVERALL,POISSON,PSA,SOUTH,WALES
KLK,LNCAP,USING
006,018,030,034,050,378,COX,FINALLY,GLEASON,MEIER,PCA,PSA,REGARDING,THEREAFTER,TOTAL
378,FINALLY,GLEASON,KLK14,KLK15,MICRORNAS
ACCORDING,ASN,GOLGI,KLK,NOVEL,POTENTIAL,PSA,REMARKABLY,SEQUONS,SER,THESE,THR,XAA
KLK,PAR,PSA
231,947,COMPARISON,DEA,HNO,HSP70,INC,IPA,MDA,PUBLISHED,THESE
144,169,BGS,COPYRIGHT,FORTY,GLEASON,INC,OVERALL
FIFTH,FIRST,GERIATRIC,JAPAN,SIXTH,THIRD
100,125,169,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRE,PURPOSE,REGARDLESS,RESULTS,SOCIETY,USING
125,169,ACTUARIAL,CONCLUSION,COPYRIGHT,COX,CROWN,D90,GROUP,INC,LABEL,MATERIALS,MEIER,METHODS,NETWORK,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RADIATION,RESULTS,SCORE,SYMPTOM,THERAPY
169,200,4CM,CARLO,COPYRIGHT,LTD,MONTE
ALONG,BACKGROUND,CONCLUSION,FUNCTIONAL,LABEL,RESULTS,SEARCHING,USING
028,169,COPYRIGHT,CORES,EDUCATION,GLEASON,HOWEVER,INC,IQR,LABEL,MARCH,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,174,AFTER,COPYRIGHT,EDUCATION,FINALLY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,VINCI
015,111,169,685,821,839,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,UROLOGICAL
169,COPYRIGHT,EDUCATION,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS,SINCE,THREE,UROLOGICAL
CTCAE,DAILY,GRADE,INT,MAGIC,MEANWHILE,MEIER
003,006,007,169,268,945,946,947,BACKGROUND,CYTOKINES,GLEASON,IFN,IL1,IL12P70,IL6,IL8,LABEL,MEN,METHODS,ORS,OTHER,RESULTS,TH1,TNF,WHETHER
562,905,ALCOHOL,BLOOMBERG,COLORECTAL,COX,GOVERNMENT,HOPKINS,JOHNS,OVARIAN,PRESS,PUBLISHED,SCREENING,TRIAL,UNIVERSITY,WHETHER
169,AKT,COPYRIGHT,EGF,EMT,EPIDERMAL,EPITHELIAL,ERK,INC,QUERCETIN,SNAIL,TWIST,WESTERN
AAA,BACKGROUND,CAS,DISCUSSION,ENGLISH,FORCE,LABEL,METHODS,OVERALL,PREVENTIVE,RESULTS,SIXTY,SYSTEMATIC
001,13C,169,17OHP,6MONTHS,945,COPYRIGHT,CYP17A1,INC,OHP,PC3
169,818,902,BACKGROUND,CRS,HODGKIN,ITALIAN,LABEL,MEDICAL,METHODS,OVERALL,PERSONS,PRESS,PUBLISHED,RESULTS,SOCIETY,THEREFORE,UNIVERSITY
169,947,AKT,CONSISTENT,COPYRIGHT,DESPITE,DU145,ETOPOSIDE,INC,PCSCS
169,COPYRIGHT,INC,THERE
145,169,CHROMOSOME,CXORF36,FURTHER,GSDMC,HOWEVER,LNCAP,MYC,OTHER,PRESS,PUBLISHED,RRP12,SMIN3,UNIVERSITY,USP14,WNT
169,AMP,HOWEVER,LABEL,NVP,PDE4D,SHH,THESE,UNLABELLED
169,181,BACKGROUND,CONCLUSION,COPYRIGHT,COR,DIOSCOREA,HEPG2,IRELAND,L23,LABEL,LTD,MATERIALS,MCF,METHODS,MRC,PC3,RELEVANCE,RESULTS,SRB,TTM
169,945,956,BIOACTIVE,COPYRIGHT,DUE,LNCAP,LTD
00714,169,170,319,BONFERRONI,CONCLUSION,DESPITE,EQUATIONS,ESTIMATING,FOLLOWING,FURTHER,FVC,GEN,HEART,LABEL,METHODS,OBJECTIVE,PRE,PURPOSE,RESULTS,THEREFORE,VO2
MAXIMUM,SUB,WMAXC
CURRENTLY,HENCE,HOWEVER,PCA,THEREFORE,ULTIMATELY
100,300,700,967,975,979,981,989,990,993,994,ADC,BLAND,CONCLUSION,CVS,DWI,FORTY,ICC,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,STUDENT
ADC,APRIL,BETWEEN,CONCLUSION,DWI,ECE,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,WHOLE
ANDROGENS,ATP,CONTINUED,HOWEVER,PCA
002,035,040,054,169,308,831,AMONG,BACKGROUND,BMI,GLEASON,LABEL,METHODS,RESULTS,THESE,VFA
116,169,77301,HCT,LNCAP,REMARKABLY,RS4,SAR405838
169,AEG,PC3,PET,THROUGH
945,946,PDGFR
000,BASED
000,100,AIM,AUSTRALIA,AUSTRALIAN,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,SIMILAR,SUMMARISED,UNTIL,WORLD,ZEALAND,ZEALANDERS
000,100,183,350,441,GEORG,GERMANY,MRI,RFA,SEVERAL,STUTTGART
007,008,BACKGROUND,CPG,GSTP1,III,LABEL,METHODS,PCR,PCS,PHASE,PSA,RESULTS
ADT,INCREASING,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
001,102,120,123,169,AMONG,ANGELES,CALIFORNIA,INDEX,LABEL,LOS,METHODS,OBJECTIVE,OBJECTIVES,RESPONDERS,RESULTS,SCORE,SHORT,SYMPTOM,UNIVERSITY,UROLOGICAL
153,177,219,317,CONCLUSION,DOSIMETRIC,GIVEN,INITIAL,LABEL,LIVER,METHODS,OBJECTIVE,OPTIMAL,PET,PURPOSE,RESULTS,TEN,WHOLE
HORMONE,HOWEVER
115,3GALNAC,3GALT,3GLCNAC,4FUCT,4GLCNAC,945,946,A78,GAL,III,IIIGLYCANS,OVERALL,SIA,THESE
DPS,MLC,VOLUMETRIC
062,160,174,238,284,450,518,690,798,908,ADVERSE,AFTER,BACKGROUND,CYBERKNIFE,LABEL,METHODS,PSA,RESULTS,THERE,USING,V36GY
001,002,169,COMPETING,EARLY,END,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,UROLOGICAL
169,215,ANNEXIN,HEPG2,MTT,PC3,WILEY
264,665,929,ANESTHESIA,BACKGROUND,BCR,COX,GLEASON,KETTERING,LABEL,METHODS,PSA,RESULTS,SLOAN,THESE
BESIDES,DIAGNOSIS,THEIR
002,004,006,009,107,726,ACTIGRAPH,AFTER,CONCLUSION,LABEL,METHODS,NUTRITION,OBJECTIVE,PSA,PURPOSE,RESULTS,SOBEL,WBC
223,BASED,THESE
008,18F,BACKGROUND,BLINDED,CONCLUSION,FCH,IMAGING,LABEL,METHODS,MONITORING,MRI,PET,PSA,RESULTS,SERUM,SEVERAL,TIS
169,ANNEXIN,ANXA2,FINALLY,HSC,LABEL,SDF,UNLABELLED
169,AIM,COPYRIGHT,COX,EP1,INC,INCREASES,KEY,LABEL,METHODS,OBJECTIVE,RESULTS
828,945,946,947,954,ATP,BESIDES,CHS,HEPATITIS,HODGKIN,IKK,IMD,THROUGH
160,223,BASED,CURRENT,CURRENTLY,SEVERAL
690,BASEL,CONCLUSION,LABEL,LIBRARY,METHODS,OBJECTIVE,RESULTS,SIR,THERE
169,22RV1,945,954,ABCG2,AKT,BASEL,CONCLUSION,DU145,DUE,KNOCKDOWN,LABEL,LUCIFERASE,METHODS,OBJECTIVE,RESULTS,TREATMENT
001,002,017,028,043,169,240,554,929,937,941,AMONG,BMI,CONCLUSION,CURRENT,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,WHETHER
169,INC,UDS,WILEY
001,013,683,DUE,ECM,ELISA,EMMPRIN,PERIPHERAL,PSA,SERUM
AKT,CPP,PRUNE,USING
169,GEL,HOWEVER,PCA,PCR,PSA,USING
169,194,AUTHORS,BCR,BJU,CONCLUSION,COX,EPE,GLEASON,LABEL,LOG,LTD,MEIER,METHODS,OBJECTIVE,PATHOLOGY,PUBLISHED,RESULTS,SOCIETY,UROLOGICAL,WILEY
931,963,CONCLUSION,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,SDS
007,033,089,108,129,169,281,ANXIETY,CES,COPYRIGHT,DCS,DECISIONAL,DEPRESSION,DUTCH,INVENTORY,LABEL,LTD,MAX,METHODS,NTR1718,OBJECTIVE,OVERALL,QOL,REGISTERED,RESULTS,SCALE,STATE,STUDIES,THESE,TRAIT,WILEY
125,ASIAN,COUNTRIES,HOWEVER,METASTATIC,PAGET,RADIOLOGIC,WESTERN
945,946,ASGM1,COMPLEX,GM1,ST3GAL3,STS,THESE
BACKGROUND,CELLS,CHO,ETN,GF109203X,GPETN,IONOMYCIN,LABEL,LNCAP,MALIGNANCY,METHODS,PC3,PCA,PHORBOL,PKC,PLD,PNT1A,RESULTS,TPA
134,759,GREEK,PATIENT,SIMILAR,THEREFORE
AFTER,ASSESSMENT,CONCLUSION,EOS,FDG,FTP,HOWEVER,LABEL,MBQ,METHODS,OBJECTIVE,PET,RADIO,RESULTS,TLC
GBM,LDH,MYELOID,NATURAL,NKG2D
139,169,173,221,344,483,CONCLUSION,CSI,GROUP,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RELAPSE,RESULTS,SOCIETY,THESE,THREE
169,AUTHORS,CNS,COPYRIGHT,INC,PUBLISHED
169
PSA
ALTOGETHER,ARGONAUTE2,CCK,DICER,DU145,FIRST,GLEASON,IHC,LNCAP,PCA
BECAUSE,ENZ
002,160,AMONG,APOPTOSIS,ATLAS,GBM,PAR,SAC,SELECTIVE
BETWEEN,DESPITE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX,SURVIVORS
160,BACKGROUND,DR1,FURTHER,HOWEVER,LABEL,METHODS,PCR,RESULTS,TMED5
120,AMONG,BJF,CONCLUSION,DESPITE,IRB,LABEL,LOS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
001,100,102,177,3RD,455,BACKGROUND,BIPOLAR,BPE,CLAVIEN,DINDO,EVALUATED,EXCLUSION,GYRUS,HOWEVER,INCLUSION,INDEX,KINETIC,LABEL,METHODS,OBJECTIVE,OPERATION,PFR,PURPOSE,PVR,QOL,RESULTS,SCORE,SYMPTOM,USA
10877,120,157,684,961,ADT,AMONG,BACKGROUND,LABEL,MEN,METHODS,RESULTS
NOTCH,VARIOUS
AUTOPHAGY,HOWEVER,NOTABLY
956,CLA,CYTOTOXIC,MTT,OLA,PC3,TAX
M13,WHILE
012,033,036,107,125,128,133,276,342,523,966,991,ADHERENCE,AMONG,CONCLUSION,COX,CSS,LABEL,MAY,METHODS,MPR,NORTH,OBJECTIVE,OBJECTIVES,PVD,RESULTS,THOSE
000,PCR,THEREFORE,THESE,VARIOUS
404,IMPORTANCE,INTERVIEW,LABEL,METHODS,OBJECTIVE,RATES,RELEVANCE,RESULTS,ROUTINE,SETTING,THERE,THESE,USING
001,003,010,106,200,DIFFERENT,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,REGRESSION,RESULTS,TOTAL
001,169,300,945,946,ALPHA,AMACR,AMONG,AUTHORS,COA,LTD,PREVENTION,PRISTANIC,THERE,TOCOPHEROL,WILEY
169,200,201,BACKGROUND,INC,KINGDOM,LABEL,METHODS,ONJ,PCA,RESULTS,WILEY
169,897,AF5,BACKGROUND,CHROMATIN,CONCLUSION,CTD,GLI,GST,INC,LABEL,LNCAP,METHODS,MUTATIONS,PCA,PREVIOUSLY,RESULTS,THESE,WILEY,WXXLF
169,945,AMP,ATG,BAICALEIN,GFP,LC3,LC3WT,THESE,UNC,VPS34
AKT,BRCA1,DDR,MYC,P53,THESE
169,22RV1,ARV,CHROMATIN,COPYRIGHT,EDUCATION,INC,INTEGRATED,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SPLICED,UROLOGICAL
169,22RV1,CONSISTENT,THESE
169,AUSTRALIAN,LTD,POTASSIUM,POTENTIAL,PSA,PTY,PUBLISHING,QUESTIONS,WILEY
CURRENTLY,CYP17,HOWEVER,JAPAN,RHAGONISTS,WHILE
JAPAN
CSF,III
CYP17A1,III,JAPAN,QOL,WELFARE
160MG,199,239,717,ANOTHER,COMMITTEE,III,JAPAN,MAR,MAY,MEDICINES,MEDIVATION,MONITORING,PREVAIL,PSA,QOL,SRE,WELFARE
JAPAN,WESTERN,Y2014
000,CONCLUSION,GENERALLY,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,T3ANXM0,THEIR,THERE,THREE
100,110,150,230,242,750,956,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEPTEMBER
228,235,865,AMONG,CONCLUSION,GLEASON,IPCAS,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,PCA,RCP,RESULTS
169,FINALLY,INC,REPORTS,WILEY
012,021,024,169,183,215,267,268,956,AUG,AUSTRALIA,BACKGROUND,BETWEEN,CALVARY,COPYRIGHT,COUNCIL,CUMULATIVE,FUNDING,GLEASON,INSTITUTE,IQR,LABEL,LTD,MATER,MEDICAL,METHODS,NEITHER,NEWCASTLE,OCT,PSA,RADIATION,RESULTS,SHR,SOCIETY,STANDARDS,T2A,T2B,UNIVERSITY,ZEALAND
169,233,914,956,ALBERTA,BLACK,CALGARY,CONCLUSION,COPYRIGHT,FORTY,INC,JANUARY,LABEL,LABORATORY,METHODS,OBJECTIVE,OBJECTIVES,POISSON,PSA,PUBLISHED,RESULTS,SOCIETY,THERE,VISIBLE
145,AKT,HOWEVER,MMP,RCM,RUBUS,TIMPS
169,COPYRIGHT,TAM,THESE
001,007,142,169,383,440,965,AMONG,AUTHORS,BJU,BMI,CONCLUSION,GLEASON,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PHI,PROMETHEUS,PSA,RESULTS
PCA,PDE5I
001,619,715,754,755,ANN,AUC,BCR,GLEASON,HOWEVER,LRP,PSA,ROC,SCORE
169,COPYRIGHT,FURTHER,GLEASON,HH1,HISTONE,INC,INCREASED,SIMILARLY,SIXTY
142,169,654,946,AKT,EGF,EMT,HSP27,INCREASED,METASTASIS,PCA,THESE
004,100,169,215,375,BACKGROUND,CANDIDATE,COPYRIGHT,COX,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PATIENT,PUBLISHED,RESULTS,SETTING,SUMMARY,UROLOGY
169,ALA,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
100,ANNA1,INTRAVITAL
HOWEVER,ROBOTIC
070,665,933,BASEL,BCR,COX,CURRENTLY,GLEASON,IQR,MTD,PCA,PSA
00035,166,169,183,955,BACKGROUND,BHASKARAN,BMI,COPYRIGHT,COUNCIL,COX,FUNDING,INSTITUTE,LABEL,LTD,MEDICAL,METHODS,PUBLISHED,RESULTS,TRUST
152,160,439,821,BLADDER,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEVENTY,TREATMENT
ACS,ASIAN,CONSENSUS,NETWORK,STATEMENT
947,ACC,AMP,BACKGROUND,COA,CONCLUSION,GAMMA,LABEL,METHODS,PCA,PSP,RESULTS,SER
169,COPYRIGHT,DISULFIRAM,DSF
169,916,BIP,COPYRIGHT,ERK,GRP78,HOWEVER,INC,MEK,RAF,UNDER,V600E,WHILE
169,COPYRIGHT,FAK,HIF,INC,PCA,PTX,ROS,S13,SRC
100,145,160,169,231,293,956,AKT,COPYRIGHT,HEK,MCF,MDA,SAS,THREE,WHILE
169,COPYRIGHT,GLEASON,INC,THESE
084,169,961,ASSESSMENT,BACKGROUND,CONCLUSION,COPYRIGHT,FDG,INC,KINETIC,LABEL,MATERIALS,METHODS,NAF,PET,RESULTS,SUV
169,BRONJ,COPYRIGHT,CURRENTLY,LTD,PUBLISHED
015,033,039,169,172,215,AURKA,COPYRIGHT,GLEASON,INC,NED,THEREFORE
169,AMONG,COPYRIGHT,END,INC,ISPOR,LABEL,LARGE,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SOCIETY,VARIATION
000,160,169,ART,ASSESSMENT,CAPRA,COPYRIGHT,INC,ISPOR,LABEL,METHODS,NADIA,OBJECTIVE,OBJECTIVES,PROSVUE,PUBLISHED,QALYS,RESULTS,SOCIETY
000,125,169,818,COLORECTAL,CONCLUSION,CONTROLLED,COPYRIGHT,INC,INSTITUTE,LABEL,MENOPAUSAL,METHODS,NCI,OBJECTIVE,OVARIAN,RANDOMIZED,RESULTS,SCREENING,THERE,TRIAL,WOMEN
169,947,ANNEXIN,BRCA1,DSB,HDACI,HOWEVER,LABEL,PARPI,RAD51,SILENCING,SIMILARLY,THESE,UNLABELLED
BASED,CHROMATIN,COS,FOX,FOXA1,LNCAP,PSA,TAKEN
001,125,126,169,BETWEEN,COPYRIGHT,COX,FORTY,GLEASON,GRADE,INC,JAPAN,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,T1C
BROADER,CURRENT,HOWEVER,MRI,PCA,PSA
169,945,954,IKK,IL8,LABEL,NAD,NADPH,NOTABLY,THESE,TRAMP,UNASSIGNED,UNLABELLED
048,169,256,ADT,AFTER,AHR,AUTHORS,BJU,CHF,CONCLUSION,CSM,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,WILEY
BPH,COLLAGEOUS,ECM,LNCAP,PEC
1236C,150MG,169,2677G,3435C,34G,ABCB1,ABCG2,AFTER,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,METHODS,RESULTS
139,18A,18B,195,19A,20B,EIGHT,H19,HIPK3,HOWEVER,LINC00152,RB1,RP4,RUNX1,TARBASE,THESE,VEGFA
946,AKT,EGF,EMT,GSK,HOWEVER,PKC,SNAIL,TAKEN
100,252,BACKGROUND,CAM,CAUCASIAN,CD117,CK7,CLEAR,GLEASON,HMB,III,LABEL,METHODS,OTHER,PAX,PSA,RCC
169,257,529,AUTHORS,BJU,CAUSE,COLLECTION,CONCLUSION,COX,DESPITE,LABEL,MAY,MEIER,METHODS,MORTALITY,OBJECTIVE,RESULTS,ZEALAND
169,177,214,259,ABORIGINAL,AGE,AUTHORS,BJU,CONCLUSION,COX,LABEL,LTD,METHODS,NSW,OBJECTIVE,RESULTS,SOUTH,THERE,WALES,WILEY
160,169,263,395,461,684,AUTHORS,BJU,CONCLUSION,HOWEVER,III,LABEL,LTD,METHODS,NORTH,OBJECTIVE,PHASE,RESULTS,WILEY
946,AKT,EGF,EPIDERMAL,MMP,PGG,THEREFORE
169,945,946,956,CAP,COPYRIGHT,DIM,ERS,HOWEVER,INC,LNCAP
145,169,BCL,CONCLUSION,COPYRIGHT,ESCIN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,WESTERN
169,DECREASING,PCM,PSA,SCREENING,USING,WHILE
001,127,151,169,299,445,633,BACKGROUND,COLORECTAL,CONCLUSION,COPYRIGHT,CXR,IRELAND,LABEL,LTD,METHODS,OVARIAN,POTENTIAL,RESULTS,SCREENING,TRIAL
001,117,INITIAL,PCR,T24,TCC,URINE,UROTHELIAL
EMT,MCF,MTT,TAKEN,THERAPY,WESTERN,YET
233,AIM,BACKGROUND,BCG,COMMITTEE,GROUP,HYALURONIC,LABEL,METHODS,NMIBC,RESULTS,SCALE,SCORE,SYMPTOM,THESE,THREE,TOR,TRIAL,VAS,VERGATA
PSA
AUTOPHAGY,BECLIN1,FURTHER,HOWEVER,NUP98,ROS
169,HGF,LABEL,MET,THROUGH,TMPRSS2,UNLABELLED
BACKGROUND,BASED,CALCIUM,CONCLUSION,DISCUSSION,LABEL
169,946,AKT,CPT1A,HOWEVER,KNOCKDOWN,LNCAP,THESE,WESTERN
169,LNCAP,MCL,PACLITAXEL,PC3,PTTG1,THESE
169,172,175,250,2B3,2B4,308,350,473,485,491,500,872,945,956,AKT,COA,DOCETAXEL,HMG,NCR,SER,STUDIES,THR
005,100,181,945,ACUTE,AKT,CFU,CUR,DESPITE,DTX,HOWEVER,IHC,NFR,TARGETING,THEREFORE,TRIB3,TUNEL
16M,AMONG,BECAUSE,BIOLOGICAL,DESPITE
CPT11,CURRENT,HOWEVER,SUICIDE
100,CONCLUSION,EARLY,FCH,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,PET,PSA,PURPOSE,RESULTS
001,002,100,135,144,177,195,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,ROC
118,157,169,177,181,193,200,204,226,239,251,264,289,318,336,367,398,409,436,520,550,566,728,754,758,931,945,946,979,BHP,BPH,CON,GAL,HOWEVER,PCA,PNA,RLU,THESE,UEA
BNCTS,CONCLUSION,EMA,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THERE
AKT,BIOMARKERS,FURTHER,SIGNALLING,THEREFORE
173,272,GLEASON
956,CCK,COMPOUNDS,DU145,HOWEVER,LNCAP,SAR
BPH,CD4,CD8,FURTHER,PCA,TIM
CD117,DESPITE,MCS
005,028,973,AMONG,BACKGROUND,CONCLUSION,JANUARY,LABEL,MATERIALS,METHODS,RESULTS
BAK,BAX,BCL,DU145,FURTHER,HOWEVER,PC3,SILENCING
2D3,COX,DESPITE
C2C12,PC3
169,239,250,500,AUTHORS,LTD,PERSISTENT,PTY,PUBLISHING,SCIENCE,WILEY
177,COLON,IHC,LYNCH,MMR,MSI,ONTARIO,UNDER
003,160,169,564,ABOVE,BELOW,CLINICALLY,CONVERSELY,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE,UNIVARIATE,UROLOGICAL
169,COPYRIGHT,FEDERATION,HUVEC,INTEGRATED,NOTABLY,PUBLISHED,SOCIETIES,USING
169,954,BAX,BCL,COPYRIGHT,FINALLY,FIRSTLY,GNT,INC,LNCAP,PC3,PCA,SUMMARY
169,CNPY2,COPYRIGHT,DROSOPHILA,INC,MEP1A,MRGBP,THESE,USING
323,ASIAN,CIS,ORS,SEVERAL
THESE,YMB
001,002,169,597,AFTER,BACKGROUND,CHINA,CONCLUSION,COX,DIFFERENT,INSURANCE,LABEL,METHODS,PRESS,RESULTS
138,945,AKT,EMMPRIN,EMT,ERK,HOWEVER,MMP,RESULTS,SOLANUM,TAKEN,THESE
169,CONCLUSION,COPYRIGHT,LABEL,LTD,MEN,METHODS,OBJECTIVE,RESULTS,WILEY
169,195,251,863,AMACR,BESIDES,COPYRIGHT,FOAMY,GLEASON,INC,JANUARY,PERIPHERAL
BASEL,DECISIONS,LIMITED
1950S,647,690,ADDITIONAL,BACKGROUND,CAUSE,CIS,CONCLUSION,CORPS,CUMULATIVE,HRS,LABEL,LEJEUNE,METHODS,MORTALITY,NORTH,PARKINSON,PCE,PENDLETON,RESULTS
100,174,AIM,BACKGROUND,CERVARIXTM,CONCLUSION,CURRENTLY,CZECH,GENERALLY,HPV,LABEL,LARGE,OBJECTIVE,OVERALL,PERSISTENT,SILGARD,THERE,WHILE
001,169,AMICO,CONCLUSION,CURRENT,EXCELLENCE,INSTITUTE,JAPAN,LABEL,LOW,MEDICAL,MEIER,METHODS,NETWORK,OBJECTIVE,RESULTS,SOCIETY,STRATEGIC,UROLOGICAL,USING
C81,CHROMATIN,DNMT1,DU145,ENRICHMENT,HOWEVER,ID4,INCREASED,INHIBITOR,KNOCKDOWN,LNCAP
23B,27B,DU145,EXPRESSION,GOLM1,MEIER,PC3,PCA
124,CAM,CHICK,CTBP1,EXPRESSION,MIR,P4HA1,P4HAS,USING
169,316,658,CASES,COLORECTAL,GBV,HODGKIN,NHL,OVARIAN,SCREENING,TRIAL
ACCOUNTING,BACKGROUND,CONCLUSION,DETECTION,ENRICHMENT,ERG,ESC,GLEASON,LABEL,METHODS,MYC,PCA,RESULTS,SET
103,AUDIO,BACKGROUND,CONTROLLED,CONVERSELY,CURRENT,LABEL,METHODS,PROTECT,RCT,RECRUITERS,RESULTS,TREATMENT,TRIAL,WITHOUT
148,169,240,BACKGROUND,BRITISH,GROUP,KLEBSIELLA,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,SOCIETY,TRUBP,UNIVERSITY
169,COPYRIGHT,JAPAN,LTD
169,CONFORMITY,COPYRIGHT,HOWEVER,INC,MEDICAL,MUS,OVERALL,PUBLISHED
107,11C,160,ADVERSE,ART,BACKGROUND,C30,CONCLUSION,EORTC,HOWEVER,LABEL,LEADING,LND,METHODS,OVERALL,PCA,QLQ,RESULTS,VERSION
001,169,221,416,675,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,POISSON,PUBLISHED,PURPOSE,RESISTANCE,RESULTS,STUDENT,UROLOGICAL
003,007,010,026,032,037,046,169,535,BACKGROUND,CD3,CD4,CD8,INC,LABEL,METHODS,RESULTS,WILEY
169,BACKGROUND,CYP17,INC,LABEL,METHODS,PSA,RESULTS,SEVEN,WILEY
169,382,BACKGROUND,BRCA2,INC,LABEL,METHODS,PSA,RESULTS,VUS,WHILE,WILEY
000,169,174,270,650,BOZEC,CELLSEARCH,CTC,EUR,HNSCC,METASTATIC,THEREFORE,VALIDATED
169,947,BACKGROUND,CD8,DISCUSSION,HLA,IFN,INC,LABEL,METHODS,MOUSE,PSA,PSA65,RESULTS,TRAMP,TRANSGENIC,WILEY
AGC,ATP,PRK,PROTEIN,RHO
169,22RV1,AKT,ANNEXIN,BACKGROUND,BCL,CELLS,COMBINING,DU145,INC,LABEL,LNCAP,METHODS,PC3,PROPIDIUM,RESULTS,SILENCING,WESTERN,WILEY
169,176,BACKGROUND,BPH,CD3,FRESH,HOWEVER,INC,LABEL,METHODS,RESULTS,VARIOUS,WESTERN,WILEY
1154A,169,400,ABI,BACKGROUND,DOCETAXEL,ELISA,FORTY,GRADE,LABEL,METHODS,PCR,PFS,PRISM,RESULTS,SDS,SNP,SOCIETY
169,ALTOGETHER,AUTHORS,BACKGROUND,EVS,INC,LABEL,LNCAP,METHODS,PCA,PCR,RC92A,RESULTS,WILEY
052,169,856,ALA295THR,ARG283GLN,ARG441TER,BACKGROUND,BLM,CYP3A43,FORTY,FURTHER,GLN123ARG,HOWEVER,INC,KIF2B,LABEL,METHODS,OVERALL,PARP2,PCA,RESULTS,SIX,WILEY
169,946,BACKGROUND,DU145,FINALLY,HOWEVER,INC,ITGB1,LABEL,METHODS,MOUSE,MRAD9,PC3,PREVIOUSLY,RESULTS,THESE,WILEY
BETWEEN,COX,GRADE,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
945,COLORECTAL,CRC,HOWEVER,RESISTANCE,STUDIES
INITIAL,INSULIN,INSULINOMA
001PM,169,500,COPYRIGHT,ELISA,HOWEVER,PCR,PLA,PROXIMITY
156,177,263,431,875,945,BACKGROUND,DRE,ELISA,INDIA,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,ROC
001,280,555,BACKGROUND,BASED,CONCLUSION,LABEL,RESULTS
ARRESTIN2,EXPRESSION,FK506,PCA,THESE
169,183,490,781,AFTER,BACKGROUND,CONTROLLED,COPYRIGHT,CURRENT,DESPITE,ERSPC,FUNDING,LABEL,LTD,METHODS,PSA,RANDOMISED,RESULTS,SCREENING
169,1980S,1990S,2000S,BACKGROUND,CONCLUSION,COPYRIGHT,INC,INCIDENCE,LABEL,METHODS,RESULTS
169,425,APS,BACKGROUND,COPYRIGHT,CPS,CYBERKNIFE,IRELAND,LABEL,LTD,MATERIALS,METHODS,MULTIPLAN,OBJECTIVE,OVH,PTV,PURPOSE,RESULTS,ROBOTIC
169,COPYRIGHT,FREQUENCY,LTD,NUTRITION,PSA,PUFAS,SERUM
AFTER,CCK,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,TRANSWELL,WESTERN
001,055,169,338,412,522,COPYRIGHT,COX,EDUCATION,END,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,SIMILAR,UROLOGICAL
169,COPYRIGHT,LTD,MEN,SIXTY
169,239,COPYRIGHT,LTD
169,947,AAS,COPYRIGHT,IFN,IRELAND,LTD,STAT3,THESE
POLYMERASE
EFFECTIVE,OWING
100,101,169,272,CARCINOMA,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROSTATIC,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,169,237,257,465,591,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL
128,195,221,BACKGROUND,BKV,CHLAMYDIA,GLEASON,HPV,HSV,LABEL,METHODS,MYCOPLASMA,OVERALL,PCR,RESULTS,UREAPLASMA
160,CONCLUSION,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
002,012,023,174,231,945,946,ASSAY,BACKGROUND,CDK11,DFS,EXPRESSION,HOWEVER,LABEL,MDA,MEIER,METASTASIS,METHODS,PCR,RESULTS,SER,THESE,THR,TRANSWELL,WESTERN
000,140,AMERICANS,APRIL,BACKGROUND,DISCUSSION,EUROPEANS,FURTHER,LABEL,MEDLINE,METHODS,RESULTS
10878,DOCETAXEL,HOWEVER,IHC,PC3,PCA,PSA,TR4
BACKGROUND,BECAUSE,DISCUSSION,EFFORTS,LABEL,RESULTS,THEREFORE
AFTER,BACKGROUND,BRISTOL,CANCERS,CHI,CONCLUSION,EFFORTS,INDIA,KASHMIR,LABEL,MATERIALS,METHODS,PACKAGE,PEARSON,PRESENT,RESULTS,UNIVERSITY
101,160,169,174,183,248,259,275,399,625,652,800,BACKGROUND,BPI,BRIEF,COPYRIGHT,FUNDING,HRQOL,INVENTORY,LABEL,LTD,MEDIVATION,METHODS,OVERALL,RESULTS,SECONDARY,SHORT
BACKGROUND,CAUCASIAN,LABEL,METHODS,PAP,PSA
169,946,CHRONIC,FINALLY,INC,PCA,TAKEN,USING,WILEY
002,006,108,169,ADT,BACKGROUND,COPYRIGHT,COX,GLEASON,GROUP,HOWEVER,INC,LABEL,METHODS,OCCURRENCE,PSA,RADIATION,RESULTS,SIXTY,THERAPY
349,436,AUSTRALIAN,BACKGROUND,CONCLUSION,FINNISH,JOB,LABEL,METHODS,RESULTS,USING
001,006,011,012,063,200,939,GLEASON,HGPCA,HSC,NSC,PCA
BACKGROUND,LABEL,MASON,METHODS,OBJECTIVE,OUTCOME,RESULTS,SETTING,THERE,UNIVERSITY
100,177,188,BETWEEN,CONCLUSION,FURTHER,IBD,III,ILIAC,JANUARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
BACKGROUND,BRCA2,LABEL,MEN,METHODS,PSA,RESULTS,THESE
CALIFORNIA,EPSTEIN,FRANCISCO,HIV,HODGKIN,IAS,MARCH,MITSUYASU,MORTALITY,SAN,USA
001,002,200,343,592,GLEASON,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,PSA,RESULTS,SERUM,T1C,T2A,THERE,TTH
113,181,303,BACKGROUND,LABEL,METHODS,P504S,PRIMARY,PSA,RESULTS
001,017,021,028,044,086,129,182,317,351,396,524,734,860,887,BACKGROUND,EVALUATION,LABEL,METHODS,RESULTS,ROBOTIC,UNIVERSITY
202,608,897,ADJUSTMENT,AFFAIRS,AOR,BLACK,CRT,III,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,WHITE
001,304,AUC,COMBINING,CONCLUSION,DCE,DIAGNOSTIC,DWI,GLEASON,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PCA,PREDICTIVE,RESULTS,TESLA
001,017,375,HOWEVER,ICI,INCLUSION,INDEX,UNIVARIATE
AFTER,BECAUSE,MRI
080,169,725,956,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,TAIWANESE,UROLOGICAL
003,169,COX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PREZEON,RESULTS,UROLOGICAL
239,946,CASTRATION,MET,NANOG,PCA,RTK,SRY,TRP53
120,163,169,177,200,214,299,600,AMICO,APRIL,AUTHORS,BJU,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE,WHILE
169,AMICO,CONCLUSION,GROUP,JAPAN,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,T1C,UNIVERSITY
446,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS
CONDUCTION,PSA
AMERICANS,BACKGROUND,CURRENT,EDUCATION,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROUTINE,STUDIES
PCA,PCR,SEVERAL,XRCC4
001,004,169,416,AMONG,BASED,BECAUSE,CONCLUSION,COPYRIGHT,GLEASON,GUIDELINES,INC,LABEL,MARCH,MATERIALS,METHODS,NETWORK,OBJECTIVE,PSA,RESULTS,SURGERY,UROLOGICAL,UROLOGY,USING
169,HOWEVER,PCA,SOCIETY
169,ACTIVATED,ALCAM,PRESS,PUBLISHED,UNIVERSITY
CAG,SEVERAL
221,242,257,726,834,AFTER,AMONG,BACKGROUND,CONCLUSION,EPSTEIN,FDR,GLEASON,HUMANEXOME,ILLUMINAM,INC,LABEL,METHODS,PCA,PGU,PSA,RESULTS,SNP,T2A
010,015,24RGD,916,AD5,E1A,EVALUATION,IMPROVING,RGD
945,954,HOWEVER,MLN4924,TAKEN
123,GRADE,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
167,BACKGROUND,COLORECTAL,EAGLE,FINALLY,FUNCTIONAL,LABEL,OVARIAN,PRINCIPAL,RESULTS,SCREENING,SNP,TRIAL
BACKGROUND,CONSENSUS,CONTEXT,FORCE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PREVENTIVE,RESULTS,SYSTEMATIC,THESE,VITAL
LNCAP,THESE
145,ATOMISTIC,COMPLEXES,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TONPS
EARLY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SOCIETY,T1C,T2C,THERE
169,945,ARS,BUD31,COPYRIGHT,FEDERATION,FUNCTIONAL,FXX,LBD,PHAGE,PUBLISHED,SOCIETIES,STRUCTURAL,TREATMENT,TYR
169,210,CAF,COPYRIGHT,EMT,FEDERATION,HYPOXIC,PUBLISHED,SOCIETIES
169,323,428,751,AFTER,ASIAN,BMI,CASES,COPYRIGHT,GLEASON,LABEL,LTD,METHODS,OBESITY,OBJECTIVE,OBJECTIVES,OVERALL,PSA,PUBLISHED,RESULTS,THESE
100,101,111,112,114,116,169,177,181,ASIAN,BACKGROUND,BMI,COPYRIGHT,HBA1C,LABEL,METHODS,OBESITY,OBJECTIVE,PSA,RESULTS,TREATMENT,WAIST
BACKGROUND,BPH,EXPRESSION,LABEL,METHODS,PCA,RESULTS,SOX,SRY
10877,10878,BACKGROUND,IMAGING,LABEL,METHODS,OWING,PPC,RESULTS,SEVENTY,TEN,THERE
169,AUSTRALIAN,BACKGROUND,COLLEGE,CONCLUSION,GEELONG,LABEL,LOWER,METHODS,RESULTS,ROYAL,SOUTH,WESTERN,WHETHER,ZEALAND
152,BACKGROUND,BCR,COX,GLEASON,HOWEVER,LABEL,MEIER,METHODS,MSP,PCR,PSA,RESULTS
ABOUT,ADT,BLADDER,DEPENDING,LABEL,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SUMMARY,THERE,TUR
PET
946,IGF,TGF
169,945,AMONG,COPYRIGHT,ERE,GREB1,HOWEVER,INC,NAKAI,ROSMARINIC
169,3MM,COPYRIGHT,DVH,DYK,FURTHER,INC,MEDICAL,NUCLEAR,OAR,PDP,PEARSON,PTV,PUBLISHED,SUN,TPS,VAN
169,946,AKT,BACKGROUND,BASIC,COPYRIGHT,ECTOPIC,EMT,EPITHELIAL,GENERAL,GSK,HOWEVER,LABEL,METHODS,PCR,RESULTS,SNAIL,WESTERN,WOUND
169,AUTHORS,ERG,LNCAP,LTD,PTY,PUBLISHING,SCIENCE,SYNTHETIC,TARGETING,TMPRSS2,WILEY
169,236,COPYRIGHT,CSC,DEPENDING,LTD
116,169,205,549,956,COPYRIGHT,HCT,LTD,MTT
947,ATM,CONSISTENT,CONVERSELY,DDR,DU145,ECTOPIC,NLS,S15,T68,TAKEN
169,ALZHEIMER,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SCHOLAR,SCIENCE,SOCIETY,WEB
001,169,256,473,801,AFRICAN,ASSESSMENT,CAPRA,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,NETWORK,OBJECTIVE,PCA,PRESENTING,PURPOSE,RESULTS
001,003,169,765,770,BACKGROUND,CASTRATION,COPYRIGHT,INC,INSTITUTE,LABEL,MEN,METHODS,PSA,REPLACING,RESULTS,THERE
134,169,640,883,977,COPYRIGHT,END,HOWEVER,ICD,INC,INITIAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
169,283,792,952,COLORECTAL,COPYRIGHT,COX,INC,INSTITUTES,NIH,OVARIAN,SCREENING,SIMILAR,TRIAL,WOMEN
102,AIM,BACKGROUND,BETWEEN,LABEL,METHODS,NOVALIS,OAR,OBJECTIVE,RESULTS
034,169,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,MET,METHODS,PHASE,PROGRAM,RCC,RESULTS,SIX
169,3DCRT,COPYRIGHT,INC,INSTEAD,LARGE,MEDICAL,OAR,PTV,PUBLISHED,THESE,TREATMENT,V18,V30,V40,V45
005,124,169,277,366,AGE,BACKGROUND,BED,CONCLUSION,COPYRIGHT,COX,GLEASON,IRELAND,LABEL,LTD,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS
151,BACKGROUND,BCR,BPH,FRESH,GLEASON,LABEL,METHODS,MSP,PCR,PSA,RESULTS,SCORE
BEAMNRC,CARLO,DOSXYZNRC,III,LABEL,METHODS,MEV,MLC,MONTE,OBJECTIVE,PET,PTV,PURPOSE,RESULTS,SIEMENS,THESE,THREE,TPS
176,177,180,500,AFTER,EXTRACTED,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,RIS,SDI
177,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
COMPOSITE,DVH,LABEL,METHODS,OBJECTIVE,OTHERWISE,PURPOSE,RESULTS,THESE,VOXELWISE
138,ALA,APRIL,BACKGROUND,DRE,GLEASON,HOWEVER,LABEL,METHODS,PCA,PDD,PPD,PSA,RESULTS,URINE
169,945,946,C2GNT,FINALLY,GCNT1,GCNT3,GLEASON,GM130,GOLGI,GORASP1,GRASP65,IIA,LABEL,PDIA3,RAB6A,ST3GAL1,UNLABELLED
169,BIOLOGY,DBD,EVENTUALLY,FINALLY,INC,LBD,MOLECULAR,PCA,SOCIETY,TREATMENT
169,682,695,BACKGROUND,GLEASON,LABEL,METHODS,POLYTOMOUS,PREVENTION,PSA,RESULTS,THERE,THESE,TRIAL,VITAMIN
169,AFRICAN,OHD,PREVENTION,TRIAL,VITAMIN
107,112,169,357,508,611,CONCLUSION,CONTINENCE,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,PDE,POTENCY,RESULTS,RRP,SCP,SEPTEMBER
035,155,670,FAS,MAY,OVERALL,STUDIES,THEREFORE,WANFANG
BCL,BID,BIU,BLADDER,E1A,FAS,MTT,PSCAE,UROPLAKIN
160,169,CARLO,COPYRIGHT,D10,D90,FOCAL,INC,LABEL,MATERIALS,METHODS,MONTE,MRI,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS,SOCIETY,SYSTEMATIC
100,160,169,COMMENTARY,COPYRIGHT,GRADE,HDR,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
160,169,177,BRAGG,COPYRIGHT,HOWEVER,LABEL,LTD,MATERIALS,MED,METHODS,OAR,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS
FURTHER,HLA,INCREASED,MYELOID,TREGS
169,18F,ADVERSE,COPYRIGHT,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SEPTEMBER,TREATMENT
CELLS,CNV,CTC,HOWEVER,MYC,OVERALL,REMARKABLY,WHILE
22RV1,PAE,PLASMONIC,TAKEN
169,947,COPYRIGHT,ERMAS,INC,RESULTS,THESE,TZD,WARBURG
169,244,BECAUSE,COPYRIGHT,L1S,SCIENCE
169,AUSTRALIAN,BACKGROUND,BESIDES,COLLEGE,III,LABEL,LEVEL,METHODS,RADAR,RESULTS,ROYAL,USING,VARIATIONS,ZEALAND
10878,125,169,500,BFS,COPYRIGHT,D90,HORMONE,IRELAND,LABEL,LTD,MATERIALS,MEN,METHODS,OBJECTIVE,PSA,PURPOSE,RESTAGING,RESULTS,STI,WELLINGTON,ZEALAND
087,104,105,122,147,163,188,209,236,271,305,320,445,641,888,904,982,984,AGE,APC,ASIRC,ASIRW,CHINA,CHINESE,CONTROL,LABEL,METHODS,OBJECTIVE,OVERALL,PREVENTION,PROVINCIAL,RESULTS
CHENNAI,CONCLUSION,INDIA,LABEL,METHODS,OBJECTIVE,PREVALENCE,RESULTS
001,034,ACC,ERBB3,HCC,HOWEVER,L02,SERUM,UNIVARIATE,WESTERN
005,100,169,ACHIEVA,BACKGROUND,CONCLUSION,COPYRIGHT,DIAGNOSTIC,GLEASON,INC,LABEL,MARCH,METHODS,PCA,PHILIPS,PSA,RESULTS,T1C,TESLA
169,AUSTRALIAN,AUTHORS,COLLEGE,HORMONE,JOURNAL,PHYSICIANS,ROYAL,ZEALAND
946,EMT,NOTCH,NSCLC,TGF,WESTERN,ZEB
239,III,PREVAIL,PSA
169,BACKGROUND,CONCLUSION,CRC,EIGHT,EXTENSIVE,FURTHER,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
169,946,A2B,ADORA2B,ADP,AMP,ATP,GIVEN,ITGB1,LABEL,THESE,TREATMENT,UNLABELLED
169,APPL1,CURRENT,LABEL,MICROARRAY,THERE,THESE,UNLABELLED
ATLAS,BACKGROUND,EPIGENOME,H3K9ME3,LABEL,METHODS,RESULTS,SERVICE,SUZ12,WORKBENCH
AMONG,AREAS,BACKGROUND,COVERED,HBA1C,INJECTABLE,LABEL,MEDLINE,METHODS,OPINION,SIMILAR
CHINESE,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,650,BACKGROUND,COPYRIGHT,DISEASE,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE,WILEY
AMONG,BACKGROUND,DIFFERENT,EPIDERMAL,HPC,LABEL,METHODS,MYC,RESULTS,SP1
108,169,174,500,918,COPYRIGHT,COX,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PHOENIX,PRIMARY,PUBLISHED,PURPOSE,RESULTS,SB200,SB500,SECONDARY,SONABLATE,T1C,UROLOGICAL
108,150,169,186,294,COPYRIGHT,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MCNEMAR,METHODS,OBJECTIVE,OVERALL,PREDICTORS,PUBLISHED,PURPOSE,RESULTS,SYSTEMATIC,UROLOGICAL
154,ERG,GLEASON,PHI,PSA,TMPRSS2,UNIVARIATE
169,COPYRIGHT,GERIATRIC,LTD,SOCIETY
169,COPYRIGHT,LOG,SAS
150NM,169,AFM,BACKGROUND,CONCLUSION,COPYRIGHT,CSC,DSC,LABEL,METHODS,MTS,PDI,RESULTS,SEM,SPHERICAL
169,AKT,COPYRIGHT,EOC,HIPPO,HOWEVER,HYPOXIA,HYPOXIC,INC,LATS1,PDZ,S69,SKOV3,TAZ,YAP,YES
ALDH1L1,BAK,BAX,BCL,BH3,BID,JNK,JUN,T59,THR59
599,AFRICAN,EXTENSIVE,GENUINE,GLY,PAR,PCA,SER,SILENCING,THERE,THESE
181,BACKGROUND,CONCLUSION,DU145,HOWEVER,LABEL,METHODS,MIGRATORY,PC3,PNT,RESULTS,WST
125,145,ACUTE,ADVERSE,BACKGROUND,GRADE,LABEL,METHODS,OBJECTIVE,RESULTS,TOXICITIES,USING
ADT,APRIL,BACKGROUND,CASTRATION,CGA,CONCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEVERAL,THERAPY,TOTAL
223,946,THESE
035,118,160,170,946,954,COX,IFN,THERE
225,803,BACKGROUND,BELEM,BRAZILIAN,HIV,LABEL,METHODS,PAR,PCR,RESULTS,STATE,THERE,XENOTROPIC
004,005,026,040,100,169,205,AIM,ANTICANCER,CAB,CONCLUSION,COPYRIGHT,GLEASON,INSTITUTE,LABEL,METHODS,NTX,OBJECTIVE,PSA,RESULTS,ZOL
001,100,169,5X4,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,SIX,WBI
169,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEPTEMBER,SIB
169,203,560,ADT,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,MEIER,METHODS,OBJECTIVE,RESULTS,THERE
169,956,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,DEX,INSTITUTE,LABEL,LOWER,MATERIALS,METHODS,PC3,RESULTS
169,CONSISTENT,METADHERIN,RES,TRAMP
007,164,291,873,BACKGROUND,GLEASON,LABEL,MATERIALS,METHODS,PHOENIX,PPB,PSA,RESULTS,RRP,THREE,USING
HOWEVER,THEREFORE
169,946,AKT,BIOMEDICAL,BOARD,CDC,CHINA,CONCLUSION,COPYRIGHT,EDITORIAL,ELISA,HOWEVER,HVJ,IFN,JAK,JAPAN,JNK,LABEL,MAPKS,METHODS,MOI,MTT,OBJECTIVE,PC3,PUBLISHED,RESULTS
BACKGROUND,DESPITE,LABEL,MEN,METHODS,RECEIVING,RESULTS
169,COPYRIGHT,HOWEVER,INC,MOSBY,MRI,SCREENING
001,002,008,009,011,014,022,023,210,542,CAUCASIAN,DESPITE,GLN,GLU,GLU185GLN,OVERALL
145,956,ALGAL,CHLORELLA,INCREASED,THEREFORE
PREVAIL
159,160,946,956,MAX
169,COPYRIGHT,GIVEN,HOWEVER,INC,MEN,PCA,TST
169,AFTER,AUTHORS,BACKGROUND,COPYRIGHT,DISCUSSION,EARLY,FOCAL,GLEASON,IDEAL,INC,INCLUSION,IRE,LABEL,MAX,METHODS,MRI,PSA,PUBLISHED,TREATMENT
945,AKT,BACKGROUND,COCL2,FURTHER,HIF,INHIBITION,LABEL,MALIGNANT,METHODS,PC3,RESULTS,SURGERY
GRP78,HCC,LIVER,TGF
2011B,945,AKT,FURTHER,HOWEVER,ISA,KINOMESCAN,PC3,PIP5K,PNT1A
HOWEVER,PCA,PROVIDING,THEREFORE,TREATMENT
169,BECAUSE,ELDERLY,SOCIETY,THEREFORE,THESE
APOPTOSIS,BIRC6,IAP,INHIBITOR,TREATMENT
145,264,AGP,APOPTOSIS,BAX,BCL,BID,CDK,CONCLUSION,DU145,FMK,HOWEVER,INSTITUTE,LABEL,LNCAP,METHODS,MTT,NCI,OBJECTIVE,PURPOSE,RAW,RESULTS,SIMILAR,SRJ23,TAKEN
177,188,295,590,CONCLUSION,EDTMP,III,KARNOFSKY,KPS,LABEL,MBQ,METHODS,NONSERIOUS,OBJECTIVE,PURPOSE,RESULTS,THERE,VAS
169,260,AGE,ANXIETY,ASSESSMENT,AUTHORS,BJU,DEPRESSION,FUNCTIONAL,INVENTORY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,OVERALL,PEARSON,RESULTS,SCALE,STATE,THERAPY,TRAIT
160,ERK,EXTENSIVE,MEK,RAF,RAS,THERE,TREATMENT
107,120,169,AUSTRALIAN,AUTHORS,BJU,LABEL,MDM,METHODS,OBJECTIVE,OBJECTIVES,PRIMARY,RESULTS
150,200,DESPITE,HOWEVER,PSA,TST
160,945,AFTER,BAD,DU145,INHIBITION,TRANSWELL,UBIQUITIN,UPS,USING
178,AREAS,BACKGROUND,COVERED,INCREASED,LABEL,METHODS,OPINION,TRP,TRPM7
CARCINOMA,EMT,HOWEVER,LNCAP,LPS,PCA,THESE

2PROPSA,BESIDES,INDEX,PSA
195,956,A2780,ESI,HOS,LNCAP,NMR
169,BLADDER,COPYRIGHT,EDUCATION,HOWEVER,INC,INDEX,INVENTORY,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SECONDARY,THERE,URINARY,UROLOGICAL
169,179,314,833,COPYRIGHT,COX,EDUCATION,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCREENING,THOSE,UNIVARIATE,UROLOGICAL,WHITE
128,169,BACKGROUND,BECAUSE,CAB,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,PSA,RESULTS
169,AUTHORS,COPYRIGHT,DESPITE,EPIGENOME,INC,PUBLISHED
000,100,120,169,710,BACKGROUND,CONTINUED,CONTINUING,LABEL,METHODS,PSA,RESULTS,SOCIETY
HORMONE,MPA,OPG,RANKL,THESE

169,COPYRIGHT,H3K4ME3,H3K9ME1,INC,NSCLC
130,169,AFM,BACKGROUND,CRPCA,CSPCA,CTC,INC,LABEL,METHODS,PEAKFORCE,QNM,RESULTS,WILEY
169,ADENOVIRAL,ASSAY,BACKGROUND,CTC,E1A,HOWEVER,INC,LABEL,LUCIFERASE,METHODS,PBN,PCA,PSE,RESULTS,THEREFORE,VIRAL,WILEY
10878,135A2,AFTER,GLEASON,LNCAP,PCA,PCR,R1881,ROCK1,ROCK2,THEREFORE,THROUGH,USING
409,RAS,STRIKINGLY,THEREFORE
3758309,AKT,FURTHER,LYN,MEK,PC3
169,945,BRITAIN,COPYRIGHT,GREAT,HIF,HOWEVER,IRELAND,LTD,PUBLISHED,RACK1,SOCIETY,THESE,TRPM8,WILEY
160,177,904,962,BACKGROUND,CONCLUSION,GREATER,INTERVIEWS,LABEL,MEN,METHODS,ORS,PCA,RESULTS,SIMILAR,THESE
AGENT,OVERALL,VIETNAM,WAR
201,227,587,ARG194TRP,CAUCASIANS,HENCE,OVERALL,XRCC1
169,BACKGROUND,COMPLIANCE,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PRE,PURPOSE,RESULTS,WHILE
150MG,169,COPYRIGHT,DIETARY,IIB,INC,LC3,PIPER,ROS
001,003,004,007,100,169,459,BACKGROUND,CCI,CD4,CONCLUSION,EXCLUDING,FEWER,HIV,LABEL,METHODS,NETWORK,RADICAL,RESULTS,UNDER
001,002,015,169,718,APRIL,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,509,700,ARN,CASTRATION,CYP17,DHT,FINALLY,GALETERONE,HOWEVER,III,NEWLY,ORTERONEL,PERSISTENT,RESISTANT,TAK,THERE,TOK
008,015,169,177,265,963,AIM,COLLEGE,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,TEN,THERE,THESE
125,144,169,AUM,DUD90,DUP90,GRADE,JANUARY,JAPAN,PRESS,PUBLISHED,RADIATION,SOCIETY,UNIVARIATE,UNIVERSITY,URINARY
169,DICER,GIVEN,SOCIETY
150,174,HEM,LABEL,MEDICAL,METHODS,OBJECTIVE,PATIENT,RESULTS,RVF
DBD,FDA,FURTHER,PCA,THROUGH
HOWEVER,PRACTICAL
582,993,AAS,AFRICAN,AMERICANS,ANOTHER,CAS,CAUCASIAN,PCA,PCR,PRO,SER,SNP,THESE,UTR
116,169,205,431,923,936,956,COPYRIGHT,HCT,MTT,NCI,SAS
169,956,BESIDES,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,REGIONS,RESULTS
BTC,CONCLUSION,HIR,KNOWLEDGE,LABEL,METHODS,MRI,OBJECTIVE,RESULTS
100,150,169,PCA,PCSGS,RESULTS
AMONG,BACKGROUND,BASED,CONCLUSION,ECONLIT,EXCELLENCE,HTA,INSTITUTE,LABEL,LYS,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,OTHER,QALYS,REFERENCE,RESULTS,SIMILARLY,STUDIES,USA
169,COPYRIGHT,IMAGING,LTD,MSC,RESONANCE,SINCE,THESE,TRAMP
22RV1,A10,B10,C10,COMPOUNDS,CWR,DHT,E10,F10,LNCAP,SEVERAL
233,BACKGROUND,BESAG,CONCLUSION,LABEL,METHODS,MOLLI,RESULTS,SPAIN
169,699,AFTER,BACKGROUND,LABEL,MEN,METHODS,PSA,RESULTS,USING
169,221,AUTHORS,BJU,CCL,CONCLUSION,GLEASON,GROUP,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,OCD,PUBLISHED,RESULTS,UNIVARIATE,WILEY
100,117,150,160,169,197,436,449,AUTHORS,BJU,CONCLUSION,DISEASE,DISTANT,DSS,GLEASON,LABEL,LTD,MARCH,MEIER,METHODS,MFS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,WILEY
145,AKT,BACKGROUND,CONCLUSION,DOCETAXEL,ERK,HOWEVER,LABEL,MATERIALS,METHODS,RESULTS,THEREFORE
404,669,AUC,BETWEEN,BPH,CAP,DOR,FIFTY,HOWEVER,MICRORNAS,NLR,PLR,RESULTS,SEN,SPE,THEREFORE
947,AGILITY,COMPLIANCE,CONCLUSION,DMEAN,FURTHER,LABEL,METHODS,MLC,MLCI2,OAR,OBJECTIVE,PTV,PURPOSE,RESULTS,STOCKHOLM,USING
008,011,160,177,CONCLUSION,FAB,FDG,HSG,IMMUNOPET,LABEL,METHODS,OBJECTIVE,PC3,PROCEDURES,PURPOSE,RESULTS
169,CENTRAL,COLLEGE,CONCLUSION,COPYRIGHT,ENGLISH,HORMONE,LABEL,LIBRARY,LTD,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OPTIMAL,PREMEDLINE,PUBLISHED,RESULTS,ROYAL,SCI,SCIENCE,WEB
001,005,031,045,047,CEA,CK7,DAC,ERG,GLEASON,HMWCK,PAX,PSA,WHILE
169,288,ABSTRACTS,CONCLUSION,COPYRIGHT,CRD,DESPITE,ECONLIT,EED,HTA,IRELAND,LABEL,LTD,MEDLINE,METHODS,MRI,NHS,OBJECTIVE,PET,PRE,PSA,RESULTS,SIX
001,169,AMONG,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RATES,RESULTS,T1C,THESE
169,228,509,AIM,ART,BACKGROUND,DESPITE,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PDE5I,PRIOR,RESULTS,SOCIETY,THERE,UNTREATED,WHILE
169,946,ADJUSTMENT,ADT,APC,ASSESSMENT,BACKGROUND,COMPOSITE,DEPRESSION,FACTORS,FUNCTIONAL,GENERAL,GREATER,INDEX,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PEARSON,QOL,RESULTS,SCALE,SOCIETY,STUDIES,THERAPY
169,COPYRIGHT,ETS,LTD,POZ,SPECKLE
DISEASE,HOWEVER,IDR,SLIMS,THEREFORE
FINALLY,PATHWAY,THESE,THROUGH
169,AFTER,BIOLOGY,HOWEVER,INC,MOLECULAR,SOCIETY
100,147,196,EARLY,NSRRP,POTENCY
174,269,ALPHA,ASSOCIATED,BACKGROUND,CTCAE,CYBERKNIFE,GEORGETOWN,GRADE,HOWEVER,LABEL,METHODS,OVS,PATIENT,PRIOR,RESULTS,TRANSIENT,TREATMENT,UNIVERSITY
AD5,DETECTION,FOLLOWING,GLEASON,ID1,PSA,THESE
AUGMENTED,PC3,SMAD3,TAKEN
APRIL,CHINESE,CIS,HOWEVER,KNOWLEDGE,LIBRARY,ORS,SCIENCE,WEB
002,008,011,018,024,061,087,101,105,110,113,169,230,AAM,AFRICAN,CAM,CAUCASIAN,ERG,FURTHER,GLEASON,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,240,536,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL,USA
169,ADT,ENDOCRINE,SOCIETY

PRL
954,BETWEEN,CONCLUSION,GLEASON,INTERRATER,JANUARY,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PREBIOPSY,PSA,RESULTS
FINALLY,HOF,PREDICTIVE
100,BECAUSE,DETECTORS,HOWEVER
169,AFRICAN,AGE,GLYCATION
594,AFTER,AMONG,CIS,FURTHER,GSTP1,ORS,PCA,WANFANG
169,258,415,AMONG,CIS,COX,EHR,HRS,LABEL,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,PRESS,PUBLISHED,RESULTS,THESE,UNIVERSITY,USING,VANDERBILT
169,COPYRIGHT,DEGARELIX,LTD,PEPTIDE,SOCIETY,WILEY
169,BACKGROUND,CD3,CD4,CD8,HOWEVER,INC,LABEL,METHODS,RESULTS,SIMILAR,THERE,WILEY
169,BACKGROUND,INC,LABEL,METHODS,OVERALL,RESULTS,SIMILAR,TMS,WILEY
169,34A,598,AUTHORS,BACKGROUND,BCL,DOCETAXEL,FOLLOWING,INC,LABEL,METHODS,RESULTS,USING,WILEY
100,169,231,BACKGROUND,CONCLUSION,ERGETGP,FAP,FURTHER,INC,LABEL,LNCAP,MCF,MDA,METHODS,MICROMOLAR,RESULTS,THESE,WILEY
160,169,438,684,AUTHORS,BJU,GLEASON,INCREASING,LABEL,LTD,MEN,METHODS,NETWORK,OBJECTIVE,PSA,PUBLISHED,RESULTS,T1C,WILEY
169,257,502,BACKGROUND,INC,LABEL,METHODS,PFS,PRIOR,PSA,PSA30,PSA50,RESULTS,THERE,THEREFORE,TREATMENT,WILEY
169,177,BACKGROUND,DIETARY,INC,LABEL,METHODS,PIN,RESULTS,SIX,TRAMP,WESTERN,WILEY
169,916,946,ALTERED,BMP,FURTHER,HTY,NOTABLY,PC3,RUNX2,SMADS,TGF
776,790,946,947,DTH,IFN,TGF,THESE,USING
CONCLUSION,LABEL,METHODS,OBJECTIVE,PHASE,RESULTS
655,ASSESSMENT,ENCOUNTER,GAQ,HOWEVER,INDEX,NERVE,PCA,PROFILE,SEP,TEAES,THEREFORE,USING
100,169,956,CASTRATION,PC3,SOCIETY,WHETHER,ZOL
ARGON
169,COPYRIGHT,FINALLY,PUBLISHED,SAS
145,2GY,AAS,DU145,FOLLOWING,FURTHER,HOWEVER
160,BORTEZOMIB,E3S,PC3,UBIQUITIN
169,COPYRIGHT,DIETS,LTD,WHEREAS
169,AKT,AMD,AMN,AMONG,COPYRIGHT,DME,FURTHER,HENCE,IRELAND,LNCAP,LTD,METASTATIC,PCA,PHE
169,ADC,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,NPV,OBJECTIVE,PSA,RESULTS,SMALL
CURRENT,CURRENTLY,PCA,PSA
4TH,ACCORDING,GIVEN,GROSS,LABEL,METHODS,OBJECTIVE,RESULTS,THREE
145,169,486,687,956,AIM,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,DELINASIOS,INSTITUTE,LABEL,MATERIALS,METHODS,NCI,OBJECTIVE,PROGRAM,RESULTS,USPTO
AMONG,FDA,RESISTANCE,SEVERAL
001,061,406,572,BACKGROUND,DOCETAXEL,LABEL,PNP,RESULTS
009,169,220,AHS,BACKGROUND,EIGENSOFT,FARMING,IBD,INBREEDING,LABEL,METHODS,NORTH,PLINK,RESULTS,THESE,WHITE
169,231,945,954,COPYRIGHT,GOD,MDA,RANKL,SAS,THUNDER,TRIPTOLIDE
115,131,166,169,BETWEEN,COPYRIGHT,D90,FINALLY,INC,MEDICAL,PUBLISHED
559,718,BACKGROUND,CONCLUSION,INCREASED,LABEL,METHODS,PCA,RESULTS,SIR,THERE
169,750,ADT,AUSTRALIA,AUTHORS,BJU,CONCLUSION,COUNCIL,GROUP,LABEL,METHODS,OBJECTIVE,RADIATION,RESULTS,SOCIETY,TRANS,UROLOGICAL,USANZ,ZEALAND
BACKGROUND,BRCA1,BRCA2,DISCUSSION,FINALLY,HOWEVER,LABEL,METHODS,MRI,PRIOR,PSA,TRIAL
BACKGROUND,CYP17A1,DOC,FURTHER,LABEL,LAPC4,LNCAP,METHODS,PHASE,RESULTS
001,103,CONCLUSION,GLEASON,HOLEP,LABEL,MEN,METHODS,OBJECTIVE,OLDER,PSA,RESULTS,SEVENTY
140,160,169,COPYRIGHT,COX,DHH,EDUCATION,IHH,INC,LABEL,LIMITED,MATERIALS,METHODS,OBJECTIVE,PTCH1,PUBLISHED,PURPOSE,RESULTS,SHH,SMO,UROLOGICAL
III,IPILIMUMAB,PERHAPS,WHILE
169,COPYRIGHT,INNOVATIVE,LTD,SEVERAL
169,AUTHORS,BJU,HOWEVER,LTD,PATIENT,PUBLISHED,THERE,WILEY
001,007,025,115,154,169,500,AUTHORS,BJU,BRITISH,CONCLUSION,CONTINUOUS,EBL,JANUARY,LABEL,LRP,METHODS,OBJECTIVE,ORP,OVERALL,PEARSON,PSM,RESULTS,RPS,THERE,UNIVARIATE,UROLOGICAL,WHITNEY
169,APMIS,LTD,PUBLISHED,WILEY

169,AUTHORS,BJU,CONCLUSION,GROUP,LABEL,METHODS,OBJECTIVE,PNB,PPB,PSA,RESULTS,THERE,VAS
001,177,BETWEEN,CLAVIEN,CONCLUSION,DINDO,FATTY,III,LABEL,MAY,METHODS,OBJECTIVE,PURPOSE,QOL,QUALITY,RALPS,RESULTS,THERE
791,893,AGREEMENT,CONCLUSION,DETECTION,GLEASON,GOVERNMENT,LABEL,METHODS,MRI,OBJECTIVE,PER,PSA,PUBLISHED,RESULTS,USA
17P13,LOH,LOW,REN
018,188,268,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,PSA,PURPOSE,RESULTS,THEREFORE
115,FURTHER,INDEX,JANUARY,PCA,PHI,PSA,THESE
001,100,141,169,182,215,874,BACKGROUND,CONCLUSION,CS7,GS6,INC,LABEL,METHODS,MRI,NPV,RESULTS,SEVENTY,UPGRADING,WILEY
169,CONCLUSION,LABEL,METHODS,NETWORK,OVERALL,RESULTS,SCOPE,SFN,SP1,VCH,WILEY
169,COPYRIGHT,HODGKIN,LTD,WHEREAS,WILEY
169,17Q21,215,678,853,AFRICAN,ASIAN,FURTHER
160,169,186,AUROC,AUTHORS,BIOMARKERS,C1M,ECM,ELM,IMF,IPF,LTD,MMP,WILEY
169,VCH,WILEY
169,916,968,CELLS,CK2,FURTHER,INC,RESULTS,TBB,UTILIZING,WILEY
169,ACTIVATION,BACKGROUND,CONCLUSION,DHT,DU145,ENDOGENOUS,INC,LABEL,LNCAP,METHODS,PC3,PCR,RESULTS,RU486,SIMILARLY,STAT5,USING,WESTERN,WILEY
001,107,120,136,169,BACKGROUND,EXPRESSION,HGPIN,INC,LABEL,METHODS,MOUSE,PCA,PIA,RESULTS,THESE,WILEY
150,169,945,946,AFTER,ALA,ASP,BASED,COPYRIGHT,GDVO4,GLU,GLY,LTD,MRI,NSS,PAA,PET
100,169,BACKGROUND,BLOOD,ERG,INC,LABEL,METHODS,RESULTS,TMPRSS2,WILEY
169,201,231,COPYRIGHT,PUBLISHED,SAS
AKT,CD117,CSC,RAS,SIMILARLY
169,ANNEXIN,APOPTOSIS,AUTOPHAGY,BACKGROUND,CAP,HNK,HOWEVER,INC,LABEL,LC3,LNCAP,METHODS,MITOSOX,MYC,PEG,RESULTS,ROS,WILEY
100,110,169,300,BACKGROUND,ERG,HOWEVER,IHC,INC,LABEL,METHODS,PSA,RESULTS,THESE,TMA,WILEY
169,COPYRIGHT,IRELAND,LTD,WNT
169,945,946,BRITAIN,COPYRIGHT,CXCR4,GREAT,IRELAND,LTD,PCA,PUBLISHED,SOCIETY,THERE,WILEY
169,AIM,BACKGROUND,BRCA1,LABEL,METHODS,OBJECTIVE,RESULTS,SOCIETY,TRANS
169,AMONG,BACKGROUND,END,LABEL,METHODS,RESULTS,SOCIETY,SUBSTANCE
008,169,233,BPR,CONFERENCE,CONSENSUS,COPYRIGHT,COX,DEPARTMENT,EDUCATION,GLEASON,HOWEVER,PATHOLOGY,PSA,SOCIETY,THERE,UROLOGICAL
066,111,169,250,500,BACKGROUND,COPYRIGHT,CYP17,LABEL,LOW,LTD,MARCH,METHODS,OBJECTIVE,OUTCOME,PSA,RESULTS,THERE,THESE
032,049,169,AMONG,BACKGROUND,END,GLEASON,LABEL,MEN,METHODS,OVERALL,RESULTS,SOCIETY
006,014,169,194,249,349,741,967,AFTER,AMICO,COX,DESPITE,LABEL,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNIVERSITY,UROLOGICAL
103,124,169,177,201,AUTHORS,BJU,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,TESLA,TPSBS
001,002,003,012,013,023,028,045,047,048,056,097,108,135,136,159,170,203,204,228,261,269,278,281,338,346,356,414,447,474,562,566,661,768,789,892,APRIL,CHINA,EBSCO,G894T,INCREASED,KNOWLEDGE,OVERALL,SCHOLAR,THEREFORE
001,016,021,100,BACKGROUND,LABEL,MATERIALS,METHODS,PCA,REGRESSION,RESULTS
027,072,123,154,169,224,370,372,418,433,435,518,524,907,960,990,GENOMIC,LABEL,MET160VAL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE,TMPRSS2,UROLOGICAL
25D,945,THEREFORE,VDRES,VITAMIN
169,468,CHRONIC,COEXISTING,LTD,MPN,NORWEGIAN,PUBLISHED,QUALITY,SEVERAL,SPR,SWEDISH,WILEY
100,108,ADC,AMONG,BPH,FURTHER,GLEASON,HIGHEST,IRB,LABEL,MAPPING,MATERIALS,METHODS,MRI,NPV,OBJECTIVE,PPV,PURPOSE,RESULTS
CARCINOMA,METASTATIC,OTHER
036,154,897,COLORECTAL,CONSENT,COVARIATES,INC,LABEL,METHODS,NON,OBJECTIVE,ORS,OVARIAN,PUBLISHED,RESULTS,SCREENING,TRIAL,USING
147,EIGHT,LNS,LYMPH,MAY,WHILE
SEVERAL,THESE,URINARY,URODYNAMIC
036,043,179,215,917,CHINESE,ELISA,HAN,PCA
169,COPYRIGHT,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
000,169,COPYRIGHT,CURRENT,EARLY,FOCAL,INC
546,FINALLY,THESE
0325901,AZD6244,ERK,FINALLY,HOWEVER,IRINOTECAN,MAP,MDR,MEK,NOTABLY,PIONEERING,TOPOTECAN,USING
275,BASED,BLP,CROSS,FINALLY,HDAC1,INTEGRATED,LIBRARY,LINCS,NETWORK,PC3,SIGNATURES
11C,120,250,GLEASON,LABEL,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS
160,544,COX,HOWEVER,LABEL,MCNEMAR,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,REVISED,TOKUHASHI
001,004,136,169,339,APRIL,CHART,COPYRIGHT,GOC,HOSPICE,INC,INPATIENT,LABEL,MATERIALS,METHODS,OBJECTIVE,ONCOLOLOGY,PURPOSE,RADIATION,RATES,RECORDS,RESULTS,SOCIETY,THESE
001,169,898,BRITISH,COPYRIGHT,DESPITE,FURTHER,INC,KINGDOM,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
032,139,169,AMONG,AUTHORS,CONCLUSION,COPYRIGHT,COX,GENOMIC,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,STEPHENSON,STRATIFIED
169,261,AUC,COPYRIGHT,DVH,INC,KUTCHER,LABEL,LKB,LYMAN,MATERIALS,METHODS,OBJECTIVE,PARAMETERS,PREDICTIVE,PURPOSE,RESULTS
100,169,215,BECKMAN,COPYRIGHT,COULTER,CURRENTLY,INC,PCA,PHI,PSA
001,003,177,CONFIDENCE,FOLLOWING,GLEASON,HIPAA,INDEX,IRB,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,REFERENCE,RESULTS
169,COPYRIGHT,DIGITAL,FINALLY,INC
047,100,103,849,BACKGROUND,CAPTURE,CAUSE,CONCLUSION,LABEL,MEN,METHODS,PATIENT,PRESCRIBED,RESULTS,SWEDISH,TEN
160,B3LYP,CL3,III,LANL2DZ,MTT,NMR,PC3,SGC7901,THEIR,VIS
002,003,007,009,021,022,055,DCE,KEY,LABEL,LVA,LVD,LVP,METHODS,MRI,MVA,MVD,MVP,OBJECTIVE,OBJECTIVES,PARAMETERS,PERIPHERAL,RESULTS
CPG,DESPITE,LUNASIN,ROS,USING
160,BACKGROUND,CONVERSELY,GLEASON,KEY,LABEL,METHODS,RESULTS,TNM,USING
AMACR,P504S
ADT,EARLY,FURTHER,HOWEVER,ID1,LNCAP,PC3,PCR,WESTERN
000,132,169,ACIDS,FOLLOWING,NUCLEIC,PCR,PRESS,PUBLISHED,UNIVERSITY
JAPAN,THESE
169,HOWEVER,MEDLINE,METFORMIN
169,DHT,FINALLY,HOWEVER,LABEL,MCR,TAKEN,UNLABELLED
APC,DCS,FDA,HOWEVER,MHC,TAA
100,139,169,406,852,GLEASON,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,THESE,UNIVERSITY
100,200,ANNEXIN,CONCLUSION,INJECTION,LABEL,METHODS,MTT,OBJECTIVE,P53,RESULTS
103,130,233,252,255,422,667,677,CONCLUSION,GLEASON,GS3,LABEL,METHODS,OBJECTIVE,PATHOLOGY,RESULTS,SOCIETY,UROLOGICAL
124,AFTER,CONCLUSION,LABEL,LUCIFERASE,METHODS,MTT,OBJECTIVE,PC3,PCR,RESULTS,UTR,WESTERN
GLEASON,THESE
946,AMACR,CK5,E12,ERG,GATA3,GLEASON,HMWCK,IHC,P501S,PAP,PATHOLOGY,PCA,PSA,SOCIETY,UROLOGICAL
169,590,BACKGROUND,EOS,FINAL,LABEL,METHODS,MONITORING,PREVENTION,RESULTS,TRIAL
131,169,205,946,AKT,BCL,COPYRIGHT,CUR,FURTHER,LTD,MCL,MTS,NPS,PCR,STAT3,WESTERN
174,CELLSEARCH,CONCLUSION,CTC,GLEASON,LABEL,METHODS,NEWER,OBJECTIVE,OTHER,PSA,PURPOSE,RESULTS,SAMPLES
10877,128,225,AFTER,BACKGROUND,BIOMARKERS,HOWEVER,KNOWLEDGE,LABEL,METHODS,NADIA,PROSVUE,PSA,RESULTS,SELECTING
001,003,011,012,107,131,287,ADT,AFTER,AGE,BACKGROUND,CONCLUSION,COX,LABEL,LOCAL,MEIER,MEN,METHODS,RESULTS,SMALL,TREATMENTS,USING
233,BACKGROUND,FINALLY,LABEL,RESULTS
231,900,HOWEVER,HSPA2,K16,K29,K51,K73,PC3,SENPS,SENTRIN,SI2,SILAC,USING,USP39
005,169,ARTEMIS,COPYRIGHT,EIGEN,FURTHER,GLEASON,GRASS,INC,JANUARY,LABEL,MARCH,MATERIALS,METHODS,MONITORING,MRI,OBJECTIVE,OBJECTIVES,RESULTS,T1C
169,BOWEL,COLLEGE,COMPOSITE,CONCLUSION,COPYRIGHT,EFFECTS,HDR,INDEX,LABEL,LTD,MANAGEMENT,MARCH,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,RESULTS,ROYAL,SCORE,SUBJECTIVE,SYMPTOM,THERE,TISSUES
263,ABT,ADP,BAK,BAX,BCL,BH3,DU145,LENTIVIRUS,MCL,MLN2238,PC3,PROTEIN
219,434,556,932,CONCLUSION,HOWEVER,IATROGENIC,LABEL,LOS,METHODS,MIS,OBJECTIVE,RESULTS,USING
169,COPYRIGHT,INC
169,COPYRIGHT,INC,ORAI1
BF3,LNCAP,SEVERAL
OTHER,SEVEN,SIXTEEN,THREE
ARTICLE,IHC,MEMBERS,PATHOLOGY,SOCIETY,SPECIAL,UROLOGICAL
104,168,CNA,FEW,GLEASON,PREVIOUSLY,PRIMARY
169,BMP,EPIGENETIC,FN1,HOWEVER,LABORATORY,MASSIVELY,PRESS,PUBLISHED
169,CXCR4,ECS,PCA,PRESS,PUBLISHED,UNIVERSITY,USA
200,517,900,BETWEEN,CAP,EFFORTS,END,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATIENT,RESULTS,THERE,TREATMENT,USING
110,180,717,ADT,AMONG,END,IMPORTANCE,LABEL,METHODS,OBJECTIVE,PRIMARY,PROGRAM,RELEVANCE,RESULTS,SETTING
001,004,005,068,AFTER,END,IMPORTANCE,LABEL,MASTERFILE,MEDICAL,METHODS,MIXED,OBJECTIVE,PATIENT,PHYSICIAN,RATES,RELEVANCE,RESULTS,SETTING,TREATED
013,019,033,063,ASP148GLU,CAUCASIANS,CIS,ORS,OVERALL,WANFANG
114,169,192,2NG,COPYRIGHT,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE
BACKGROUND,CENTERS,CONCLUSION,CONTROL,DISEASE,ESTIMATES,FUNDING,HARMS,INSTITUTE,LABEL,LIMITATION,METHODS,OBJECTIVE,PREVENTION,PRIMARY,RESULTS,SCREENING,SETTING
DUE
WHETHER
OPERATIVE,PERFORMED,RADICAL
100,169,174,494,6TH,CALYPSO,CONCLUSION,COPYRIGHT,ERB,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,TOTAL
001,002,008,106,114,ABOUT,CLINICIANS,CRC,LABEL,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS,SURVIVORS
BACKGROUND,CRT,DUE,LABEL,METHODS,OBJECTIVE,PBT,QALYS,RESULTS,STUDIES,THERE
001,106,485,558,966,AIM,CONCLUSION,FIFTEEN,IDENTIFIED,LABEL,METHODS,OBJECTIVE,RESULTS
FURTHER,HOWEVER,HSP27,JNK,MITOGEN,MMP,ORTHOTOPIC,PCA,THESE
001,160,169,177,AUR,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS
160,169,215,AUR,COPYRIGHT,ETHICAL,EVALUATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS
169,947,948,COPYRIGHT,INC,THESE
115,169,ANTITUMOUR,BACKGROUND,BRITISH,CONFIRMED,COPYRIGHT,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PATIENT,PSA,PUBLISHED,RESULTS,SETTING,SUMMARY,THESE,UNIVARIATE,UROLOGY
169,COPYRIGHT,PUBLISHED,RANDOMIZED,SCREENING,UROLOGY
109,118,169,215,227,956,AES,BACKGROUND,CONCLUSION,COPYRIGHT,GRADE,HDR,IRELAND,LABEL,LTD,MEIER,METHODS,PHOENIX,PSA,RESULTS,SCORE,SYMPTOM,THESE
169,COPYRIGHT,PCA,RESULTS,TARGETING,UTR,WESTERN
160,231,26S,BAX,C15H11O2N2,C15H11O3N2,C15H9O4N2,C17H13O3N2,C19H14O3N3,LNCAP,MDA,STUDIES,UPS
MIXED
PRIMARY,PROGNOSIS
AFTER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,RRP,THESE
001,002,174,179,180,196,6TH,GROUP,LABEL,LOC,LRP,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS,UVA
108,118,137,211,AMICO,CHI,CONCLUSION,GLEASON,KLOTZ,LABEL,MATERIALS,METHODS,MISSTAGING,OBJECTIVE,PSA,RANDOMIZED,RESULTS,RRP,SOLOWAY,T2A,USA,WHITNEY
005,169,806,ADDITIONAL,ADHERENCE,BACKGROUND,GREATER,INSTITUTE,LABEL,MEETING,METHODS,PROTECT,PSA,RESULTS,THERE,WORLD
112,169,258,935,938,AFTER,APRIL,BACKGROUND,CONCLUSION,GIVEN,KINGDOM,LABEL,METHODS,OCTOBER,OVERALL,RESULTS
117,155,162,232,241,24H,357,387,403,483,500,752,AKI,AMONG,AVERAGE,BECAUSE
112,134,719,749,816,AUC,BACKGROUND,LABEL,LDH,METHODS,PSA,RESULTS,USING
010,169,177,AUNPS,BPH,COPYRIGHT,PCA,PSA,PUBLISHED,SPR
160,169,822,COPYRIGHT,CURRENTLY,EPIGENETIC,GLEASON,HISTONE,INC,KDM5C,PATHOLOGY,PUBLISHED,SOCIETY
169,COPYRIGHT,PUBLISHED
169,COPYRIGHT,CTC,DTC,FURTHER,IRELAND,LTD,PCA,THEIR,THESE
100,169,CK7,COPYRIGHT,ERG,GATA3,IHC,LABEL,METHODS,NOVEL,OBJECTIVE,OBJECTIVES,PATHOLOGY,PCA,PSA,RESULTS,S100P,SOCIETY,UCA
026,031,034,041,042,045,046,084,099,233,470,528,582,642,673,678,791,797,854,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,RESULTS
270,375,600,CONCLUSION,FORTY,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS,SCORE,SIX,SYMPTOM,THERE
100,APRIL,COHEN,CONCLUSION,KAPPA,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THEIR
137,195,332,AMONG,BETWEEN,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE
BAX,CONVERSELY,DR5,DU145,OVERALL,PCR,ROS,TANSHINONE,TRAIL,TUNEL
102,106,AD5,CMV,E1A,KU7,LUC,TAKEN
001,004,CUMULATIVE,INC,LABEL,MATERIALS,METHODS,MMC,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T10,THESE,WBC
OPTIMAL,PROGNOSTIC,SOCIETY
ATM,CDT,CYTOLETHAL,DOC,DSB,PCA,THESE
CANCEROUS,CIP2A,INHIBITOR,MYC
169,956,COPYRIGHT,DU145,GLN,INC,LABEL,LNCAP,UNASSIGNED,UNLABELLED
468,BAX,BCL,CASPASE,JNK,JUN,MDA,SLC39A9,THESE,TREATMENT
169,CADMIUM,COPYRIGHT,IRELAND,LNCAP,LTD,PSA,SENP1,SUMOYLATED
169,BACKGROUND,EMBRYOLOGY,LABEL,MEDLINE,METHODS,PRESS,PUBLISHED,RESULTS,SOCIETY,THERE,UNIVERSITY
000,100,169,239,956,AFTER,CONCLUSION,DLT,EIGHT,LABEL,METHODS,OBJECTIVE,PRIMARY,PSA,PURPOSE,RESULTS
169,744,ANDROGENS,BACKGROUND,BECAUSE,CAG,CONCLUSION,LABEL,MEN,METHODS,PSA,RESULTS,SERUM,SNP,USING
005,169,960,COPYRIGHT,FORTY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,V50,V80,V90
940,BACKGROUND,CB1,EGF,EGR,HOWEVER,INHIBITION,LABEL,MGL,RESULTS
057,139,161,162,169,250,289,592,604,6MONTHS,BACKGROUND,COPYRIGHT,IQR,IRELAND,LABEL,LTD,MARCH,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEPTEMBER,TRIAL
001,100,169,220,320,ASIAN,BPH,CAUCASIAN,COCHRAN,COPYRIGHT,HISTOLOGIC,JAPAN,LABEL,MEN,PATIENT,PUBLISHED,RESULTS,SUMMARY,TOKYO,UNLABELLED,UROLOGY
22RV1,AKT,CD133,DU145,ERK,LNCAP,MEK,NANOG,NOTABLY,NOTCH,OCT,SNAIL,THESE,WHILE
001,002,169,177,AFTER,BT474,CONCLUSION,DU145,FDG,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PET,PIVALIC,REGARDING,RESULTS,SOCIETY,U87,UNLABELLED
BACKGROUND,BSI,CONCLUSION,COX,HOWEVER,INDEX,LABEL,METHODS,RESULTS,SCAPULA,SPINE
BACKGROUND,CONSISTENT,DESPITE,LABEL,POLYMERASE,REPENRICH,REPETITIVE,RESULTS,THESE
104,AFTER,BASEL,GLEASON,MEN,RRP
001,013,177,264,775,CHINESE,DOPPLER,DVT,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,SEPTEMBER
062,169,320,647,739,942,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,ORS,PCA,RESULTS
001,162,BACKGROUND,CONCLUSION,ECLIPSE,HOWEVER,LABEL,METHODS,MUS,PLANS,RESULTS,THESE,TPS
615,BACKGROUND,DIFFERING,FINNISH,LABEL,METHODS,NSAID,RESULTS,SCREENING,TRIAL
183,404,BACKGROUND,BPH,COLORECTAL,LABEL,MEN,METHODS,OVARIAN,POISSON,RESULTS,SCREENING
ALZHEIMER,FINALLY,FULLY,HOWEVER,MRI,PET,POTENTIAL,PROMISING,SINCE,WHILE
822,LABEL,MARCH,METHODS,MRI,OBJECTIVE,OBJECTIVES,PCA,RESULTS,SVI,SVS,TESLA
108,117,136,244,ADT,AFTER,BCR,COX,CSS,GLEASON,LABEL,MATHERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RADICAL,RESULTS,SCORE,UNASSIGNED
118,127,129,GLEASON,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THOSE
001,005,022,100,161,228,BACKGROUND,BCR,CHI,CONCLUSION,COX,GLEASON,HOWEVER,LABEL,MARCH,MATERIALS,MEIER,METHODS,PSA,REGARDING,RESULTS,RRP,UNIVARIATE
006,195,261,ABOUT,EXPRESSION,GLEASON,IHC,OMNIBUS,PSA,SSTR2,THEREFORE,WHILE
169,BRACHYURY,LABEL,METHODS,MICROARRAY,OBJECTIVE,PIN,PURPOSE,RESULTS,SUCCESSFUL
169,COPYRIGHT,EBR,HOWEVER,THEREFORE
169,627,660,AMONG,AR3,COPYRIGHT,FOXA1,HOWEVER,INSTEAD,LBD,LNCAP,LTD,NTD,PCA
001,002,049,138,867,CONTINENCE,COX,ENDOPELVIC,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OCTOBER,PROGNOSTIC,RESULTS,URINARY
169,356,400,500,641,771,BACKGROUND,BEGINNING,CONCLUSION,LABEL,METHODS,NEITHER,NUTRITION,OBJECTIVE,PHYSICIANS,RESULTS,SOCIETY,THERE
001,031,694,ERG,IHC,MEIER,PCA,PCR,PSA,RECURRENT,THREE,TMA,TMPRSS2
BIOLOGICAL,ERG,ETS
APC,ARGON,BACKGROUND,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,V40,V60,V70
136,200,CONCLUSION,DRE,DWI,GLEASON,LABEL,MATERIALS,MCNEMAR,METHODS,MRI,MRS,OBJECTIVE,PSA,PURPOSE,RESULTS
169,ADDITIONAL,COMMITTEE,GROUP,INSTITUTE,MANAGEMENT,NCI,PRESS,PUBLISHED,QUALITY,RELATED,SYMPTOM,THESE,UNIVERSITY,WORKING
945,AKT,HORMONE,HOWEVER,HRMPC,SER2448,TAKEN,WESTERN
169,BACKGROUND,COMPOSITE,COPYRIGHT,INDEX,INITIAL,IQR,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PATIENT,PURPOSE,QOL,RESULTS,UNIVARIATE,URINARY,V20,V31,V35
223,945,946,AROMATASE,ELISA,ESTROGENS,GBM,III,PCR
031,113,145,185,187,198,233,258,405,422,435,688,708,716,728,747,944,9TH,BACKGROUND,CONCLUSION,COSTS,ICD,JANUARY,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PCA,PREMIER,RESULTS,SINCE,THERE
160,177,ADT,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
2013A,CTV,EUD,LABEL,MATERIALS,MCMAHON,METHODS,OBJECTIVE,PURPOSE,RESULTS,SMALL,TCP
174,CELGENE,EMA,OCTOBER,USA
RESISTANCE,STRATEGIES
181,200,22R,400,945,947,956,957,BAD,BAX,FURTHER,HOWEVER,MSA,OVERALL,PCA,PREVENTION,PSA,STUDIES,TRIAL,VITAMIN
132,152,410,AFRICAN,CAUCASIAN,DNMT1,ECTOPIC,EVALUATION,LNCAP,MDA,PCA,SEQUENCING,THERE,UTR
LABEL,MOLECULAR,MRI,OBJECTIVE,PCA,PET,PURPOSE,RESULTS,SEVERAL,SUMMARY,THESE
203,ACTIVATION,BIRC2,TKI
AKT,CAMK2N1,CONVERSELY,ERBB2,ERK,HOWEVER,IGF,MEK,REDUCED
BACKGROUND,LABEL,METHODS,RESULTS
BPH,EN2,GLEASON,PCA
215,DAMPS,DU145,ELISA,LNCAP,PC3,PCR,RADIATION,TOTAL
ACTIVATION,AMP,CONVERSELY,INSTEAD,METABOLIC,MODULATION,STRIKINGLY
4GALNACT3,4GALNACT4,4GALNACTS,4GLCNAC,946,LDN,THEREFORE
001,169,275,894,CONCLUSION,CONVERSELY,DEPRESSED,END,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
023,321,405,811,ADDITIONAL,AMONG,CIS,CONCLUSION,COX,GLEASON,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,VASECTOMY
169,FDA,III,PREVAIL
169,COPYRIGHT,EMT,METASTATIC,SOCIETY

169,COPYRIGHT,INC,MYC
CEA,CRC,ESTIMATING,HEART,HOWEVER,HRV,PSA,THESE
233,BCG,FEB,MAY,SEP,THEREFORE,TREATMENT
AFTER,BCG,CIS,III,PET
FAS,GRP78,PAR
107,114,143,148,153,201,ADVERSE,AES,BACKGROUND,BASED,EASTERN,FEBRILE,GRADE,GROUP,IQR,LABEL,METHODS,Q3W,RESULTS,SPANISH,THERE
AIM,TRP,TRPV2
ANTITUMOUR
132,EGF,JMR,PC3,PKA,SRC
177,345,AUA,BACKGROUND,BMI,BPH,CIS,INDEX,KNOWLEDGE,LABEL,LIFESTYLE,MEN,METHODS,ORS,RESULTS,SEVERAL,SHORT,SYMPTOM,UROLOGICAL
18F,FCH,PET
FDG,LABEL,METHODS,MRI,OBJECTIVE,PET,PURPOSE,RESULTS,SEVEN
945,946,PSA
103,169,BACKGROUND,CONCLUSION,COPYRIGHT,INC,ITALY,LABEL,METHODS,PFS,PSA,RESULTS,ROMAGNA
023,024,035,169,247,AMONG,BACKGROUND,COPYRIGHT,COX,INC,LABEL,METHODS,RESULTS,THESE,UNIVARIATE
160,169,AKT,ATP,COA,COPYRIGHT,HISTONE,INC
10878,144,169,ADVERSE,C30,CONCLUSION,COPYRIGHT,CTCAE,EARLY,EORTC,FOCAL,GRADE,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PHOENIX,PSA,PURPOSE,QOL,QUALITY,RESULTS,TREATMENT,WHOLE
147,169,COPYRIGHT,FINALLY,IRELAND,LTD,LUCAP
AREAS,BACKGROUND,COVERED,EXOGENOUS,GREB1,LABEL,METHODS,OPINION,STEROID
169,COPYRIGHT,INC,OCN
177,BACKGROUND,CARLO,HOUNSFIELD,LABEL,METHODS,MONTE,MRI,RESULTS
001,003,017,032,169,967,BACKGROUND,COMMITTEE,CONCLUSION,CONSISTENT,COPYRIGHT,EIGHT,ENGLISH,HAITIAN,INC,INCREASED,JOINT,LABEL,MARCH,METHODS,MORTALITY,OCTOBER,PATIENT,PEARSON,RESULTS,THERE
001,572,ADT,APRIL,BFR,FURTHER,HOWEVER,LIBRARY,STUDIES
169,231,945,946,COPYRIGHT,ERE,ERS,FURTHER,INC,MCF,MDA
99M,BSI,FIRST,INDEX,MDP,THERE,THESE,WHOLE
AES,DOCETAXEL,HOWEVER,LABEL,LOW,METHODS,NON,OBJECTIVE,PRE,PURPOSE,RESULTS
BASED,HOX,HOXA9
100,EXPRESSION,FURTHER,IDC,ILC,LABEL,METHODS,NUCLEAR,OBJECTIVE,RESULTS
282,APF,APRIL,BETWEEN,LABEL,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,THESE
145,160,169,231,COPYRIGHT,DU145,GASTRIC,HGC,MCF,MDAMB,MNK,SAS,SEVERAL,SIX,THESE,VILLSMEIER
169,215,239,BACKGROUND,COX,LABEL,LIVER,MARSDEN,METHODS,NLR,RESULTS,ROYAL,SOCIETY,THREE,ULN
001,127,169,326,880,COPYRIGHT,NETWORK,OVERALL,PATIENT,TEXAS,TRIAL,UNIVERSITY
THESE
AFRICAN,F102S,FURTHER,G111E,HOWEVER,I106I,PCA,POZ
103,INDEX,RPS
157,276,ALBERTA,CALGARY,CLS,JANUARY,LABORATORY,MARCH,PSA,SERUM
169,946,AICAR,AKT,EMT,FOXO3,IKK,OSU,OVERALL,PHENOTYPIC,THESE
169,DIFFERENT
CONVERSELY,LOCALIZED,TREATMENT
169,2ND,500,956,AFTER,AMACR,COA,COPYRIGHT,FINALLY,PCR,SELEX
108,145,AUTOPHAGY,DOX,GFP,LHRHR,LYS,MANAGEMENT,ROS
169,177,785,BACKGROUND,BASEL,CAUCASIAN,CONCLUSION,HOWEVER,LABEL,METHODS,RESULTS
160,ECM,NCK,SH3,SRC
001,002,003,006,007,014,029,030,034,035,AST,BACKGROUND,BMD,DISEASE,LABEL,METHODS,RESULTS,UNLABELLED
160,169,BESIDES,COPYRIGHT,CURRENT,INC,PUBLISHED,ROBOTIC,SOCIETY,VINCI
DIAGNOSIS,MEN,PERCEIVED,RAPID,THESE
028,030,038,042,045,058,ACUTE,COMPOSITE,CONCLUSION,CRANBERRY,FORTY,INDEX,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
CLEVELAND,ENHANCING,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SURVIVORS,UNIVERSITY
109,169,BASED,COPYRIGHT,FURTHER,HOWEVER,IES,INC,STROMAL,THESE
169,BOLUS,COPYRIGHT,THEREFORE,YM155
252,KI16425,LPA,TAKEN
MRI,TESLA
169,786,ACIDS,BCL,NUCLEIC,PRESS,PUBLISHED,SAM68,SIMILARLY,THESE,THREE,UNIVERSITY
HOWEVER,PAR,USING,WT1
205,ALTERED,BACKGROUND,EMT,EPCAM,EPITHELIAL,EXPRESSION,LABEL,MET,METHODS,OPPOSITELY,RESULTS
00056,012,021,046,169,BACKGROUND,COPYRIGHT,ELISA,FIFTY,GLEASON,III,LABEL,MEN,METHODS,NTX,PCA,PSA,RESULTS,SERUM,THESE
001,244,787,CONVERSELY,HODGKIN,MCC,QUEENSLAND,SIR,THESE
177,956,ACCORDING,BACKGROUND,CONCLUSION,FACBC,HOWEVER,LABEL,METHODS,MRI,PDT,PET,PROCEDURE,PSA,RESULTS,THERE
169,945,946,COPYRIGHT,IMPORTANCE,LABEL,OBJECTIVE,SINCE,SOCIETY,UNLABELLED,WHETHER,Y315F
DU145,GOVERNMENT,INHIBITION,PC3,WHEREAS
169,DDIT3,HOWEVER,INC,POZ,SER,STRIKINGLY,THR,WILEY
004,005,325,401,HEALTHCARE,IMPORTANCE,INDICATORS,INPATIENT,JANUARY,LABEL,METHODS,NATIONWIDE,OBJECTIVE,PATIENT,PSI,QUALITY,RAPID,RELEVANCE,RESULTS,SETTING,VINCI
ABCG2,ACCORDING,CD133,CK5,MOLECULAR,PCA,PSA
181,207,COBALAMIN,DCC,HCY,METHIONINE,THESE,THF
183,323,334,629,A392G,CAUCASIANS,MET235THR,OVERALL,PREVIOUSLY
145,169,900,AMG,AUTHORS,HISTONE,LNCAP,LTD,PC3,PCA,WHILE,WILEY
NMR
223,AMONG,ASSESSMENT,BACKGROUND,BPI,BRIEF,DIMENSIONS,EMA,EUROQOL,FDA,FUNCTIONAL,HRQOL,INTENSITY,INVENTORY,LABEL,MEDICINES,METASTATIC,METHODS,PRESENT,PRO,PRODUCT,REPORTS,RESULTS,SHORT,SUMMARIES,THERAPY
177,203,215,LABEL,METHODS,OBJECTIVE,PURPOSE,REGIONS,RESULTS,ROC,SVM,ULTRASOUND
FINALLY,GIVEN,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,OPTIMIZED,PURPOSE,RESULTS,RMS,THEREFORE,THESE
AAM,APPEARANCE,ASM,AUTOMATIC,DDD,FIRST,HOWEVER,LABEL,METHODS,MODEL,OBJECTIVE,PURPOSE,RATIO,RESULTS,SHAPE,THESE,THIRD
ANCOR,DSC,ELASTIC,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THESE,WHILE
174,2MM,500,800,BATCH,CARLO,CPU,DOSXYZNRC,DUE,GAMMA,GPU,INTEL,K20,K40,LABEL,M2090,METHODS,MONTE,OBJECTIVE,PATIENT,PSF,PTV,PURPOSE,RESULTS,USING
ART,GSI,HENCE,HOWEVER,LABEL,METHODS,OBJECTIVE,OPTIMIZING,PURPOSE,RESULTS,TPS,TRP
100,169,179,650,AUTHORS,BJU,COX,LABEL,MEIER,METHODS,NEITHER,OBJECTIVE,RADICAL,RESULTS,SATURATION
169,675,946,CURRENTLY,H19,M12,P69,PC3,TAKEN,TGFBI,UTR
169,265,AUTHORS,BJU,ITALIAN,LABEL,METHODS,NPP,OBJECTIVE,RESULTS
180,GLEASON,PCR,PROTEIN,WESTERN
169,239,945,APP,AUC,CANCEROUS,CRP,CSS,EXPRESSION,FOX,GLEASON,LABEL,METHODS,MYC,OBJECTIVE,OCT,PSA,PURPOSE,RESULTS
169,239,AKT,CASTRATION,DESPITE,OVERALL,PRESS,PUBLISHED,THEREFORE,THESE,UNIVERSITY
001,140,169,COPYRIGHT,DOSIMETRIC,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,CHLAMYDIA,COPYRIGHT,DESPITE,DUE,LTD,MEN,MYCOPLASMA,NEISSERIA,SIMPLEX,SRR,STI,TREPONEMA,UREAPLASMA,VIRUS
BACKGROUND,BRCA1,BRCA2,CHEK2,GENERATION,ITALIAN,LABEL,METHODS,SEQUENCING
8G4,EL2,HOWEVER,MSC,PC3,THEREFORE,THESE
116,169,181,224,294,BACKGROUND,C30,CLINICIANS,CONCLUSION,COPYRIGHT,LABEL,METHODS,NEEDS,PATIENT,PRO,QLQ,QUALITY,RESULTS,SHORT,SOCIETY,SUPPORTIVE,THESE,TREATMENT
169,239,COPYRIGHT,PUBLISHED,THERE,THROUGH,UROLOGY
169,946,ADT,AKT,COPYRIGHT,ERK,HOWEVER,IRELAND,JNK,LTD,TGF
119,967,BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS,UROLOGISTS
ACTIVATION,AKT,CAMK2N1,CAP,COMPARISON,FINALLY,FOXO1,FOXO3,FOXO4,INCREASED,KNOCKDOWN,LNCAP,PGC,PIP,PLA2G16,RUNX2
AVERAGE,BACKGROUND,FEMALES,HOWEVER,LABEL,METHODS,RESULTS,STATISTICS,YLL
946,947,954,BAY,ERK,FLIPL,IFN,JNK,LNCAP,PI3,REDUCED,UO126
045,087,169,648,AMONG,CD4,CONCLUSION,DLBCL,HIV,HODGKIN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,TEXAS
169,ACUTE,AIM,ANTICANCER,CONCLUSION,COPYRIGHT,GRADE,INSTITUTE,LABEL,MAY,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,SIB
169,174,ANTICANCER,COPYRIGHT,CTC,FIFTY,GLEASON,INSTITUTE
169,946,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,DUE,HSPB1,INSTITUTE,LABEL,MATERIALS,METHODS,PCA,RESULTS,TGFB1
169,182,956,ACCORDING,AKT,ANTICANCER,COPYRIGHT,INSTITUTE,NVP,TKI
169,AIM,ANTICANCER,BACKGROUND,CD9,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,RESULTS,SINCE
169,954,AIM,ANTICANCER,APOPTOSIS,BACKGROUND,CONCLUSION,COPYRIGHT,INSTITUTE,LABEL,LIPITOR,MATERIALS,METHODS,NUCLEAR,OBJECTIVE,ORTHOTOPIC,RESULTS
100,118,120,137,169,194,420,480,CONCLUSION,CONVERSELY,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,RESULTS,TPM
100,1C3,946,AFTER,ASP9521,BACKGROUND,HENCE,LABEL,LNCAP,METHODS,PSA,RESULTS
173,954,CISPLATIN,GGAAAGGAA,GGAAAGTCC,GGGCACC,LNCAP,PSA
169,ACIDS,EBP,FITTINGLY,FOXA1,K386R,K520R,NUCLEIC,PRESS,PUBLISHED,TAKEN,UNIVERSITY
100,155,169,228,303,374,529,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MODEL,OBJECTIVE,PREDICTORS,RESULTS,TARGETING
169,CHITINASE,EVALUATION,LNCAP,PCA,TREATMENT,YKL40
AFM,HOWEVER,THESE
169,177,956,IC50S,OBJECTIVE
038,061,174,284,458,539,829,DRE,HOLEP,HOLMIUM,HOWEVER,LABEL,METHODS,OBJECTIVE,PRIOR,PSA,PURPOSE,RESULTS,USING
203,CONVERSELY,HOWEVER,LASP1,LIM,LNCAP,PCA,PCR,PSA,SEVERAL,SH3,SUBSEQUENT,THESE
HEPATOCYTE,HOWEVER,RON,STAT3,THESE,TRAMP,WHILE
133,884,945,AIM,ANTITUMOR,CONCLUSION,DIM,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,RESULTS
000,023,169,350,COPYRIGHT,EAU,EDUCATION,INC,LABEL,MATERIALS,MAXIMUM,METHODS,NUMBERS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,177,187,234,843,945,COPYRIGHT,EDUCATION,HIF,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEMINAL,SERUM,UROLOGICAL
001,018,019,043,149,160,169,253,ASSESSMENT,COPYRIGHT,EDUCATION,GLEASON,GSTP1,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL
169,COPYRIGHT,GLEASON,LTD,WILEY
169,BACKGROUND,INT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SYSTEMATIC
001,203,ACA,ACT,AFFORDABLE,AMERICANS,AMONG,AOR,BACKGROUND,COX,END,INSURED,LABEL,METHODS,PROGRAM,RESULTS,UNINSURED

MEN
8TH,AFTER,DENTASCAN,EXTENSION,METASTATIC
169,AMERICA,AUTHORS,BIOLOGY,INC,IUBMB,MOLECULAR,PCA,UNION,UTR,WILEY
480,546,808,AUTHORS,BACKGROUND,CANCERS,CENTRAL,COLLECTION,CONFERENCE,CONTROLLED,CURRENTLY,FURTHER,GRADE,GROUP,HOWEVER,LABEL,MANAGER,MEDLINE,METHODS,NON,OBJECTIVE,OBJECTIVES,PREDEFINED,PROSTATIC,RESULTS,SCIENCE,SELECTION,WEB
001,002,134,174,AU1,BACKGROUND,CONTEXT,III,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,STUDIES,UROPLAKIN
102,118,169,215,220,748,762,775,802,815,956,ACCESS2,AUC,COPYRIGHT,INCLUDING,PCA,PSA,SERUM
002,521,AUC,BACKGROUND,DRE,JANUARY,LABEL,MATERIALS,METHODS,MODEL,PRE,PSA,RESULTS,ROC,THESE
524,AFRICAN,AMICO,BACKGROUND,CAUCASIAN,CAUCASIANS,CONCLUSION,CONVERSELY,GLAND,JANUARY,LABEL,MATERIALS,MEDICAL,METHODS,REFERRALS,RESULTS,WHOLE
001,012,123,154,164,BACKGROUND,CHI,CLOSE,CONTROL,EXACT,GLEASON,LABEL,MATERIALS,METHODS,OUTCOME,PSA,RESULTS,THESE
008,011,115,699,BACKGROUND,BCR,COX,GLEASON,HOWEVER,LABEL,MATERIALS,MEIER,METHODS,PSA,PSM,RESULTS
124,132,187,BACKGROUND,LABEL,LOCAL,MATERIALS,METHODS,MRI,PSA,RESULTS
BECAUSE,HISTOLOGY,HOWEVER,PET,THEREFORE
169,AMONG,COPYRIGHT,GDEPT,MSC,SAS
006,010,040,053,061,177,183,400,632,902,HOWEVER,IMMEDIATE,INCREASES,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TESTING
177,486,AFTER,BACKGROUND,JANUARY,LABEL,METHODS,RESULTS,SINCE,THERE
PTV
435,47D,562,CNS,HCT,INSTITUTE,MAXIMUM,MDA,NCI
COX,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PCA,PSA,RESULTS,THERE
110,160,169,ADT,AUTHORS,LTD,SIB,THERE,WILEY
128,169,COMPOSITE,CONCLUSION,INDEX,LABEL,METHODS,NERVE,OBJECTIVE,OBJECTIVES,RESULTS,THERE,THEREFORE,URINARY,UROLOGICAL
160,169,174,327,440,457,839,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS
169,613,ADT,AMERICA,ASSESSMENT,BMD,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,WORLD
031,032,053,169,CONCLUSION,COPYRIGHT,COX,GLEASON,INC,INDICES,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
001,169,845,CONCLUSION,COPYRIGHT,EPSTEIN,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PNI,RESULTS,VALIDATION
018,021,169,247,250,254,341,CONCLUSION,COPYRIGHT,FILLING,H2O,INC,LABEL,MCC,METHODS,NERVE,OBJECTIVE,RESULTS,ULR
BETWEEN,THESE,WHILE
169,203,221,361,463,950,AUC,BPH,DEPARTMENT,FURTHER,MIRNA,PCA,PCR,PSA,PSS,ROC,SINCE,STUDENT,UROLOGY
169,AFTER,FORCE,PREVENTIVE,PRUDENT,SOCIETY
169,2ND,CONCLUSION,COPYRIGHT,FIRST,HOWEVER,III,LABEL,LITERATURE,MATERIALS,METHODS,OBJECTIVE,OTHER,PROMISING,PSA,RESULTS,SAS,STUDIES
169,968,COPYRIGHT,ECE,GLEASON,LABEL,LEVEL,METHODS,OBJECTIVE,OHORI,PSA,RESULTS,SAS,STEUBER
169,BACKGROUND,BPH,COPYRIGHT,HBP,LABEL,LEVEL,MEN,METHODS,PCA,PSA,RESULTS,SAS,SNIIRAM
169,518,ASSESSMENT,BOWEL,COLORECTAL,COMPOSITE,CONCLUSION,COPYRIGHT,FUNCTIONAL,INC,INDEX,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,OVARIAN,PEARSON,PUBLISHED,QOL,RESULTS,SCREENING,SHORT,THERAPY,THESE,TREATMENT,TRIAL,WHITE
001,128,160,169,189,490,AAS,AFRICAN,AFTER,AMERICANS,AOR,CONCLUSION,COPYRIGHT,END,FACTORS,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,T2B,THERE
133,206,HDAC4,HOWEVER,SFR,WHILE
169,CHROMATIN,FINALLY,GLEASON,LUCIFERASE,MECHANISM,PCA,TESTICULAR,TR4
001,169,724,AUTHORS,CBP,CSC,FOLLOWING,ICG,LTD,PRI,PTY,PUBLISHING,SCIENCE,SSC,THROUGHOUT,WILEY
169,CSF,HOWEVER
001,004,123,169,COMPARISON,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,UROLOGICAL
215,368,633,741,AMERICA,HOWEVER,NORTH,PCOMBINED,SPANISH,TANC1,THERE,THESE
169,1CM,5MM,COPYRIGHT,INC,USING
000,004,105,169,BACKGROUND,BLACK,CONCLUSION,LABEL,METHODS,PSA,RESULTS,THERE,THESE
169,BACKGROUND,CAP,COPYRIGHT,ENGLISH,HOWEVER,INC,LABEL,MEDLINE,METHODS,PAPERCHASE,PSA,RESULTS
110,124,169,200,201,400,600,APRIL,BACKGROUND,COPYRIGHT,CPY17,EASTERN,FUNDING,GROUP,INC,LABEL,LTD,MARCH,MEN,METHODS,ODM,ORION,PSA,RESULTS,THESE,USA
169,BAX,BCL,BID,COPYRIGHT,CORDYCEPIN,CORDYCEPS,FAS,LC3,LNCAP,SEVERAL,THESE,VAD
125,169,985,COPYRIGHT,FAM,HOWEVER,PSA,USING
160,169,BI2S3,COPYRIGHT,LTD,MEANWHILE
947,CANDIDATE,CYTOTOXIC,EFFICIENT,ELISPOT,EWING,EWS,IFN,PRAME,STRATEGIES,TCR,XAGE1
160,169,177,AFFAIRS,BACKGROUND,CHRONIC,CONCLUSION,COPYRIGHT,CRP,CURRENT,ENDOSCOPIC,ENDOSCOPY,FLORIDA,FURTHER,HEALTHCARE,IQR,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS,RFA,RTD,SECONDARY,SETTING,SOCIETY,TREATMENT
169,956,AUSTRALIAN,COMPOUNDS,COPYRIGHT,DFT,HYRTIOS,LNCAP,LTD,NMR,STRUCTURAL
26A,ALTOGETHER,MICRORNAS,WESTERN,WNT5A
160,177,200,235,566,AUC,CONCLUSION,DCE,DWI,GLEASON,HISTOLOGY,IMAGING,KEY,LABEL,METHODS,MRI,OBJECTIVE,PCA,PSA,PURPOSE,RADIOLOGY,REGARDING,REPORTING,RESULTS,SOCIETY,UROGENITAL
177,BACKGROUND,CONCLUSION,FRAMELESS,LABEL,METHODS,PROCEDURE,RESULTS,TAMIS,TME
002,004,109,169,177,ADDITIONAL,CAP,DESPITE,GLEASON,MEN,PSA,RFS,SOCIETY
001,005,033,169,177,AFTER,BACKGROUND,BLS,COPYRIGHT,DFS,FGS,GREEN,INC,LABEL,MATERIALS,METHODS,RESULTS,SIX,ZOL
945,954,HIF,HYPOXIA,LNCAP,MST,SIMILARLY,STAT3
169,AUTHORS,COPYRIGHT,DCE,IMAGING,MRI,PUBLISHED,RESONANCE,TOFTS,TYPICALLY
032,057,096,125,152,160,25E,312,AKT,ERG,GLEASON,HOWEVER,PCA,SWEDISH,WNT
630,EMBRYONIC,GAK,GLEASON,SER,TAKEN,THR
002,100,AFTER,BACKGROUND,COX,INCIDENCE,INDEX,INSURANCE,LABEL,METHODS,RESULTS
169,177,386,416,422,946,955,956,COPYRIGHT,CYP17A1,DOCKING,INC,INHIBITORY,THESE
183,H3K9ME3,JMJD2,JUMONJI,K36,KDM4A,KDM4B,KDM4D,KDM4S
008,021,177,745,ADT,AMG,BACKGROUND,CONCLUSION,CONTEXT,LABEL,LBM,METHODS,MYOSTATIN,OBJECTIVE,RATES,RESULTS
CONSISTENT,FURTHER,GTPASES,HEPG2,HOWEVER,INHIBITORS,PC3,RAS,TREATMENT
ADT,DIFFERENT,GLEASON,III,PHASE,PSA,SEVERAL
947,ADP,CLONOGENIC,NIRAPARIB,RAD51,TAKEN,THESE
AUTOCRINE,CAP,CXCL8,CXCR1,CXCR2,CXCR4,PC3,THP
446,DU145,FYN,INITIAL,TYR,WHILE
169,946,954,CONSISTENT,IKK,TNF,TNFRSF12A
GISTS
169,COPYRIGHT,INC
124,945,DU145,EMT,HOWEVER,TGF
169,215,BASEL,SNP,THERE
169,COPYRIGHT,THREE
CLU,FINALLY,GDF,HOWEVER,MIC
126,CRK,HOWEVER,MIR,SGC
APC,HEALTHCARE,INTERVIEWS,LABEL,METHODS,OBJECTIVE,OBJECTIVES,ONTARIO,PURPOSE,RESULTS,SETTING,SUPPORTIVE
CANTRIL,CONTROL,ILLNESS,LABEL,MEN,METHODS,MONITORING,NURSING,OBJECTIVE,OBJECTIVES,PROFILE,PSA,PURPOSE,RESULTS,SCALE,SETTING,THREE,UNIVERSITY,UROLOGY,VARIABLES
ENGLISH,PRIMARY,THERE
PDE5I,TADALAFIL
HOWEVER,LARGE,POZ
ANOTHER,REMARKABLY,WARBURG
100,CONTINENCE,FOLLOWING,FORTY,GROUP,MRI,OCTOBER,PATIENT,PCA,PSM
006,008,009,222,AFRICAN,ANALYZING,CAUCASIAN,CAUCASIANS,COX,HOWEVER,LABEL,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,UNIVARIATE
169,COPYRIGHT,EXPRESSION,FUNCTIONAL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PC3,PCA,RESULTS,WESTERN
MICRORNAS,TFS
169,885,AGE,COMMUNITY,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PAF,PUBLISHED,RESULTS,STATISTICS,THOUSANDS,WHERE
231,AZA,BECAUSE,GPAT2,MDA,OVERALL,USING
145,AFTER,FIRST,PCA,PCR,PEARSON,STUDENT,THEREFORE,TOTAL
231,293,33258,474,956,CAUCASIAN,CHINESE,CHO,HEK,HOECHST,MDA,MTS,OVERALL
JANUARY,LIBRARY,MEDLINE,MRI,PCA,PUBLISHED
PALPATION,SINCE
BILATERAL,EMERGENCY,PLEURAL,SHORTLY
141,901,GLEASON,HGPIN,HOWEVER,IDC,REGULAR
ENDOGENOUS,LENTIVIRUS,NATURAL,PC3,PROTEIN,UTR
002,008,026,177,241,292,570,862,AGE,AIM,CONCLUSION,DEPARTMENT,LABEL,MEDICAL,METHODS,OBJECTIVE,POMERANIAN,RESULTS,UNIVERSITY
169,FGF,FGFR1,HNSCC,LABEL,MALIGNANT,MPM,PREVIOUSLY,THESE,TKI,UNLABELLED
169,AUSTRALIAN,BACKGROUND,CAPITAL,COLLEGE,CONCLUSION,LABEL,MARCH,METHODS,NCS,OCTOBER,RESULTS,ROYAL,SERVICE,SEVEN,ZEALAND
204,ACCURAY,AVERAGE,BETWEEN,COMPOSITE,CYBERKNIFE,GEORGETOWN,INDEX,LABEL,METHODS,OBJECTIVE,OCTOBER,PURPOSE,RESULTS,THREE,UNIVERSITY,URINARY
169,ALTOGETHER,COPYRIGHT,DENDRIMERS,DICER,FURTHER,INC,LABEL,SIMILAR,SMALL,UNASSIGNED,UNLABELLED
169,300,700,945,ADVERSE,LABEL,MEIER,METHODS,OBJECTIVE,ORTERONEL,PSA,PURPOSE,RESULTS,SECONDARY,TAK
PSA
169,574,AUSTRALIA,BACKGROUND,EASTERN,FDA,HOWEVER,KINGDOM,LABEL,METHODS,PATIENT,PCA,RESULTS,SEVENTEEN,SIX,SOCIETY,THERE,THESE
150MG,945,BCL,DOCETAXEL,INCREASED,METASTATIC
107,169,700,922,APPLIED,BACKGROUND,COX,EQUIPMENT,FOLLOWING,FURTHER,HRS,INC,LABEL,METHODS,NATURAL,OPERATORS,RESULTS,TRANSPORT,WBV,WILEY
FOCAL,SHORT
169,HCC,INC,PHC,PRIMARY,WILEY
100,169,197,236,262,964,AFTER,BETWEEN,CONCLUSION,DRE,HGPIN,IMPRINT,INC,LABEL,MALIGNANT,MAY,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,SAMPLES,SEVEN,THESE,WILEY
001,210,255,449,486,548,561,584,613,766,BETWEEN,CONCLUSION,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,PSA,RESULTS,SIRIRAJ
001,015,100,130,169,CLAVIEN,DINDO,LABEL,LYMPHOCELE,METHODS,MINIMALLY,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
169,AVASCULAR,CONVERSELY,FURTHER,HOWEVER,THESE,UROLOGICAL
169,409,CONCLUSION,EMT,GLEASON,LABEL,METHODS,OBJECTIVE,ORTHOTOPIC,PURPOSE,RESULTS
160,169,CONCLUSION,COPYRIGHT,COX,INC,LABEL,LEE,METHODS,OBJECTIVE,OVERALL,PRACTICAL,RESULTS
001,0CM,106CM,169,176,191,3CM,5CM,6CM,9CM,COLLECTED,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,635,AFRICAN,AMONG,BACKGROUND,COMMITTEE,FACTORS,III,JOINT,LABEL,METHODS,POISSON,RESULTS,SOCIETY,USA
169,BIOLOGY,INC,MOLECULAR,QUERCETIN,SOCIETY
169,693,BACKGROUND,COMPOSITE,HOWEVER,INDEX,INSTRUMENT,LABEL,METHODS,RESULTS,SERIOUS,SHORT,SOCIETY
231,945,946,DU145,HEPG2,MCF,MCP,MDA,MIP,PSO,TAKEN,TNF
ANTIGEN,DHT,LNCAP,MTS,PSA
169,ENDOCRINE,GRP78,OVERALL,SUPPORTING,THEREFORE,TRIB1
007,070,169,334,339,532,676,769,BACKGROUND,CONCLUSION,DRE,EXTREME,GLEASON,INC,LABEL,METHODS,PCA,PSA,RESULTS,THREE,WILEY
007,169,BACKGROUND,GLEASON,GOLDENGATE,GSTM2,HTR1B,INC,LABEL,METHODS,PANEL,RESULTS,WILEY
001,005,169,211,533,746,945,947,GLEASON,INCIDENCE,MEN,PREVENTION,TRIAL,VITAMIN
006,014,056,064,079,169,246,558,855,BACKGROUND,COX,HOWEVER,INC,LABEL,METHODS,PCA,RESULTS,T2D,VARIATION,WILEY
946,AJS,PCA,ROS,THESE
115,BPH,ERG,ETS,PCA,PCR,PIN,THESE,TMPRSS2
THESE
CSC,DU145,EPI,IM7,LNCAP,PCI,PDT,RIP,ROS
002,006,309,AMONG,ARD,BACKGROUND,CHANGES,ENDOSCOPIC,LABEL,METHODS,RECTOSCOPY,RESULTS,SCORE,VRS
101,118,169,194,219,233,343,444,BLADDER,COPYRIGHT,EDUCATION,INC,LABEL,MALIGNANT,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RECURRENCE,RESULTS,THREE,UROLOGICAL
171,DENMARK,DISEASE
169,DNAPK,ETS,EWING,HDAC1,PARP1,THESE
169,ACUTE,AMICO,COPYRIGHT,HOWEVER,III,PUBLISHED,SAS,URINARY
125,160,169,COPYRIGHT,DIL,HDR,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PHASE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,TREATMENT
033,160,169,174,ASSESSMENT,BCR,CONCLUSION,COPYRIGHT,COX,HOWEVER,INC,INCREASED,LABEL,METHODS,OBJECTIVE,RECORDS,RESULTS,THERE
000,169,200,369,399,400,489,AUTHORS,BJU,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,RPS,THERE,USA
169,AUTHORS,BASED,BJU,ITEMS,JANUARY,LITERATURE,PREFERRED,PSA,REPORTING,REVIEWS,SYSTEMATIC
TARGETING
169,181,326,COPYRIGHT,INC,INCIDENCE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RATES,RESULTS,SIR,THERE
169,CYBERKNIFE,HDR,HOWEVER,JAPAN,PRESS,PTV,PUBLISHED,RADIATION,SOCIETY,THESE,UNIVERSITY,V40,WHILE
143,183,223,600,ART,BACKGROUND,CBCTS,CONCLUSION,DAILY,LABEL,METHODS,PTV,RESULTS,SMALL,UNLABELLED
BACKGROUND,CONCLUSION,DIR,DVH,DYNAMIC,FINALLY,INITIALLY,LABEL,METHODS,RADIATION,RESULTS,THERAPY
240,241,BACKGROUND,CONCLUSION,GLEASON,GRADE,GROUP,IRELAND,LABEL,METHODS,PSA,RESOLUTION,RESULTS
038,089,170,579,616,737,755,819,985,BACKGROUND,COX,D9901,DISEASE,HOWEVER,III,LABEL,MEIER,METHODS,RESULTS,SIPULEUCEL,TREATMENT
PSA,SEVERAL,THEREFORE
CURRENTLY,DESPITE,PATIENT,RADICAL,RPE,THEIR
263,GLEASON,HOPKINS,JOHNS,MARSDEN,REGARDLESS,RMH,ROYAL
15F,160,169,549,956,COPYRIGHT,SAS,WHEREAS
169,181,2B4,AMD3100,CAP,CXCR4,MINERAL,NW1,PC3,SOCIETY,VYBRANT,WHEREAS
BPH,CURRENTLY,MORBIDITY,PCA,PROSTATIC,SELEX
ALONG,APATONE,DAMAGED,DU145,ROS,THESE,VK3
047,100,177,AE105,ELISA,FINALLY,PET
131,177,C12,DU145,DUE,INCREASED,PG1,PG2,SPECT
000,139,169,600,BACKGROUND,CALIFORNIA,FARMERS,INC,LABEL,METHODS,NHW,RESULTS,STAGE,THESE,UFW,WILEY,WORKERS
946,ELISA,FOLLOWING,FURTHER,INHIBITION,LC3II,TREATMENT
007,124,168,169,172,565,BACKGROUND,BMI,COPYRIGHT,COX,FURTHER,GLEASON,HOWEVER,LABEL,MEIER,MEN,METHODS,OBESITY,OBJECTIVE,OUTCOME,PATHOLOGIC,PATIENT,PCA,PUBLISHED,RESULTS,SETTING,SUMMARY,UROLOGY
112,168,169,191,213,240MG,392,ADVERSE,BACKGROUND,COPYRIGHT,GLEASON,GUIDELINES,IAD,INDUCTION,LABEL,METHODS,OBJECTIVE,OFF,OUTCOME,PATIENT,PSA,PUBLISHED,QOL,RESULTS,SECONDARY,SETTING,SUMMARY,TREATMENT,TRIAL
13A12,169,174,176,1NG,5C5,ANNEXIN,ANXA3,COPYRIGHT,DRE,INC,INTERASSAY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PUBLISHED,RESULTS,SOCIETY,TGC44,THESE,UNTIL,VIDAS
169,COPYRIGHT,GCPII,GLUTAMATE,HOWEVER,LOW,LTD,SAR,STRUCTURE
A9G,HOWEVER,TREATMENT
160,169,COPYRIGHT,INC,ORAI1,ORAI3,THESE
001,026,045,200GY,429,967,CONCLUSION,COX,D90,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PEARSON,PSI,PUBLISHED,PURPOSE,RESULTS,WHITNEY
169,947,AUTHORS,COPYRIGHT,DZNEP,IFN,INC,JAK,MYC,PUBLISHED,STAT1
169,965,AIM,COPYRIGHT,GENERATION,JANUARY,LABEL,LTD,METHODS,MULTI,OBJECTIVE,RESULTS,SIR,SWEDISH
169,177,185,AUSTRALIAN,BACKGROUND,BLAND,CBCTS,CLINICALLY,COLLEGE,COMPARISON,FMS,INTER,LABEL,LOA,LOAMEAN,METHODS,RESULTS,ROYAL,RTS,SIX,ZEALAND
169,224,COPYRIGHT,INC,PIM,PUBLISHED,SGI
160,169,180,231,453,COPYRIGHT,MCF,MDA,MTT,SAS,SIX
169,ADT,COPYRIGHT,CSC,EMT,IRELAND,LTD,NED
160,169,COPYRIGHT,CSC,HOWEVER,LTD,THEREFORE
169,AFTER,AGE,AUTHORS,BECAUSE,BJU,GLEASON,LABEL,METHODS,NORTH,OBJECTIVE,PSA,RESULTS,SNP,T2C,UNASSIGNED
169,859,AUC,BACKGROUND,BPH,CONCLUSION,COPYRIGHT,DCA,ELISA,FURTHER,LABEL,METHODS,PCA,PSA,PSP94,RESULTS,SERUM,UTILITY
169,CLDN3,CLDN4,COPYRIGHT,CPE,IRELAND,LTD,PSA
549,BLK,CNS,CURRENTLY,DISCOVERY,DU145,HDF,HSP70,IHC,LNCAP,NG108,PC3,SHOCK,TDF,THESE,USING,WESTERN
108,109,160,177,213,217,CONCLUSION,CURRENTLY,EVALUATION,FUROSEMIDE,LABEL,MAXIMUM,METHODS,OBJECTIVE,OVERALL,PATIENT,PCA,PET,PURPOSE,RESULTS,SUV,THEREFORE
A10,MTT,PCR,THESE
169,AMONG,LABEL,METHODS,OBJECTIVE,ONCOLOGIC,PRESS,PUBLISHED,RESULTS,UNIVARIATE,UNIVERSITY,WESTERN
005,169,177,492,BACKGROUND,CONCLUSION,DESPITE,FOUNDATION,LABEL,METHODS,MYLAB,OBJECTIVE,PURPOSE,RESULTS,SCC,SINCE,SUBPLEURAL,TUS,TWICE,UNDER
169,308,416,569,BACKGROUND,BASED,CONCLUSION,END,ESTIMATES,GIVEN,LABEL,METHODS,PHYSICIANS,POC,PRESS,PROGRAM,QUALITY,REGISTRIES,RESULTS,THESE
ADC,AVERAGE,CONCLUSION,DIFFUSION,DWI,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,THERE
10878,169,262,343,372,AUC,BACKGROUND,COPYRIGHT,CTV,EMLASSO,IRELAND,LABEL,LTD,MATERIALS,METHODS,MODEL,OBJECTIVE,PCA,PREDICTOR,PURPOSE,RESULTS,VARIABLES
169,BPH,CRP,PENTRAXIN,PSA,ROC
169,COPYRIGHT,SAS
BPE,PSA
027,101,117,177,315,AUSTRALIA,CONCLUSION,CONTEXT,EVERY,FOLLOWING,FURTHER,LABEL,LOWER,METHODS,OBJECTIVE,OUTCOME,PERTH,RESULTS,SETTING,SHR,WESTERN
169,509,945,ANDROGENS,ARN,CASTRATION,COPYRIGHT,CYP17A1,HSD17B6,INC,MDV3100,PATHOLOGY,PCA,PSA,PUBLISHED,SERUM,SOCIETY,TAKEN
100,200,597,AAS,AFRICAN,AMERICANS,CAS,CAUCASIAN,DUE,GLEASON,GLY,HOWEVER,PCA,SER,SILENCING,SNP,SOMATIC,THESE
916,MYC,PSA,SKP,THESE,TRANSGENIC
267,534,CAP,SFK,SRC,THERE
ANDROGENS,FOX,FOXA1,FOXO1,FOXO3,INCREASING,PCA,THEREFORE
945,ADT,AED,DHT,DOC,GIVEN,HOWEVER,PCA,SRD5A,WHILE
ADT,CAP
000,ADT,DOCETAXEL,EMT,HOWEVER,HUGGINS,INITIALLY,RESISTANCE,SINCE
ADT,CAP,CURRENT
129,169,240,ALTOGETHER,BACKGROUND,JANUARY,LABEL,METHODS,NEURO,PCNSL,PRESS,PRIMARY,PUBLISHED,RESULTS,SMS,SOCIETY,TEN,THEREFORE,UNIVERSITY
III
169,COPYRIGHT,LTD,MMP,MT1
001,003,005,169,BACKGROUND,COX,HOWEVER,LABEL,METHODS,PCR,PTOV1,RESULTS,UNIVARIATE
001,169,223,270,AUTHORS,BJU,DOCETAXEL,HOWEVER,LABEL,METHODS,OBJECTIVE,PFI,POTENTIAL,PSA,RESULTS,THERE
000,14284,200,20202,486,BACKGROUND,BLADDER,BRAIN,CANCERS,CONTEXT,EASTERN,ESOPHAGUS,LABEL,METHODS,OBJECTIVE,ORGAN,OROPHARYNX,OVARY,RAJASTHAN,RESULTS,THERE,WESTERN
129,169,198,BETWEEN,COPYRIGHT,GLEASON,INC,INCREASED,LABEL,MATERIALS,METHODS,OBJECTIVE,P21,PSMB4,PURPOSE,RESULTS
001,142,160,382,AUA,CAP,END,GLEASON,GUIDELINES,LABEL,MEN,METHODS,NODAL,OBJECTIVE,OCTOBER,PSA,PURPOSE,RESULTS,SCREENING,THOSE,UNSCREENED,UROLOGICAL,YOUNG
169,945,BERBERINE,COPYRIGHT,CSA,CYP,INC,INHIBITION,LNCAP,MMP,NAC,P53,PFT,ROS,SFA
233,252,ANTOINE,CAS,CHANGES,CHOLERA,FECAL,LAVOISIER,PETTERS,SALMONELLA,VIL,WILHELM
ADT,BACKGROUND,CONVEYING,CQP,DESPITE,HOWEVER,LABEL,METHODS,OVERALL,PROCESS,RCT,RESULTS,SALVAGE,SPC
303,310,315,COMMERCIAL,CONCLUSION,COX,FACTORS,INCLUSION,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS
160,169,1MG,300MG,420,ACADEMY,BACKGROUND,CONCLUSION,CONTEXT,COPYRIGHT,GIVEN,HOSPICE,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PALLIATIVE,PUBLISHED,REMARKABLY,RESULTS,STUDIES,USING
169,186,BACKGROUND,BUMELIA,COPYRIGHT,CYRTOMIUM,CYTOTOXIC,FRACTIONS,IRELAND,LABEL,LNCAP,LTD,METHODS,RELEVANCE,RESULTS,TRICHILIA
169,ERG,MOLECULAR
100,169,BLOOD,LTD,PUBLISHED,THESE,WILEY
169,HOWEVER,LTD,PUBLISHED,WILEY
001,137,169,ADT,CON,FIFTY,HRMAX,LBM,LTD,PCA,PUBLISHED,SECONDARY,WILEY
169,946,COPYRIGHT,FINALLY,HOWEVER,INC,RII,SMAD2,TGF,THESE,WDR77
BACKGROUND,CAV,CHAIN,GAPDH,LABEL,MATERIALS,MCF,METFORMIN,METHODS,PAR,PCR,POLYMERASE,RESULTS,SGK,UPR
169,AMONG,AUSTRALIAN,PRESS,PUBLISHED,THREE,UNIVERSITY,USA,WHILE
4F2,945,ANDROGENS,ASCT2,DHT,DU145,EXPRESSION,FACBC,LABEL,LNCAP,METHODS,OBJECTIVE,PROCEDURES,PURPOSE,RESULTS,SNAT5
BRAIN,CTV,DEVICES,INCREASES,JAPAN,MEDICAL,MRI,TAKEN
169,181,FMS,TGI,VCH,WILEY
160,169,COPYRIGHT,FINALLY,LNCAP,LTD,M12,SYNTHETIC,THESE
611,614,947,CSE,H2S,LNCAP,PSA,THESE,TMPRSS2
BCL,DU145,FAK,FOCAL,FOCUSSING,FOS,POD,THESE
100,169,181,200,ANNEXIN,BIOLOGY,FEDERATION,LNCAP,PROTEIN,ROS
160,AIM,CONCLUSION,LABEL,METHODS,NHA,OBJECTIVE,PSA,RESULTS,UNIVARIATE
169,174,177,252,351,967,BACKGROUND,BASEL,GLEASON,JANUARY,LABEL,LUCERNE,MATERIALS,METHODS,POISSON,RESULTS,SINCE,VINCI
BACKGROUND,CONCLUSION,CURRENTLY,FOCAL,GERMANY,HOWEVER,LABEL,METHODS,MRI,PCA,RESULTS
AMP,CAPSAICIN,STATS
114,22737,BACKGROUND,CENTRAL,CONCLUSION,CURRENT,DECREASED,LABEL,MEDLINE,METHODS,NEWCASTLE,OBJECTIVE,OBJECTIVES,RESULTS,SCIENCE,WEB
160,169,183,948,CCC,GEORG,STUTTGART
945,CHINESE,PCA,ROS,SCHIFFN,STEPH
BLOOD,DCT,NPS,PDLLA
169,24H,CBP,COPYRIGHT,GCPII,GLUTAMATE,INC,MG132,SIMILARLY,TAKEN,TREATMENT,U87MG,VPA
169,HOWEVER,MALIGNANT,METASTASIS,PRESS,PUBLISHED,UNIVERSITY,WHILE
169,946,COPYRIGHT,CXCR4,DOC,FINALLY,FURTHER,IGF,IL6,PC3,PROTEOMICS,ROS,STAT3
127,169,200,285,945,956,COMPLIANCE,GSH,OVERALL,PRIMARY,PSA,RESULTS,SECONDARY,SEMET,THESE
25S,945,946,956,COMPOUNDS,ETOAC,GBM,NMR,NSCLC,THEIR
0043132,215,BCR,BPH,COX,HOXD3,LABEL,METHODS,OBJECTIVE,PCA,PCR,PITX2,PURPOSE,RESULTS,TDRD1,UNI
286,ECM,NH2,PROGNOSCAN,SPARC
169,633,946,EXPRESSION,LOC,MED12,MET,PCA,SMAD3,SOCIETY,TGF,THEREFORE,WNT
001,007,10521,169,365,BACKGROUND,LABEL,METHODS,NAVIGATION,PATIENT,PRESS,PROGRAM,PUBLISHED,RESULTS,THERE,THESE,UNIVERSITY
628,ANTIGEN,BACKGROUND,CONFIDENCE,FRAILTY,INTERVALS,IRISH,LABEL,LIKELIHOOD,MEN,METHODS,PSA,RESULTS,THESE,TILDA
378,405,430,441,470,524,954,AREAS,CONCLUSION,GLEASON,IMAGING,LABEL,MATERIALS,METHODS,MLS,OBJECTIVE,PURPOSE,REPORTING,RESULTS
227,854,899,AMACR,APC,BACKGROUND,BPH,HOXC6,LABEL,METHODS,MICROARRAY,PCA,RESULTS,TACC2
001,120,BACKGROUND,CONCLUSION,FFF,FLATTENING,LABEL,METHODS,RESULTS,STD
169,COPYRIGHT,H4K20,HISTONE,INC,PSA,THEREFORE
169,COPYRIGHT,EPH,INC,MEMBERS,PICK1,THESE
AFTER,AMONG,BACKGROUND,BCC,COX,HAMPSHIRE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCC,SEVERAL
100,13A,14A,169,COPYRIGHT,FINALLY,HCT,MCF,SAS
CAP,DESPITE,DU145,ERBB2,LNCAP,MYC,PC3,RAS
THERE
159,160,CIS,GRADE,KUTCHER,LKB,LYMAN,VOLUMES
ANALOGIES,PARTICULAR
034,200,792,821,867,AFTER,ANTIGEN,BCR,CALCULATOR,COX,FINALLY,GLEASON,KOREA,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,T3A,THESE
125,169,174,ASA,CLAVIEN,COPYRIGHT,CYSTECTOMY,EDUCATION,III,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,UROLOGICAL
001,049,060,111,134,157,160,169,287,360,376,398,418,509,670,692,720,913,916,AFTER,CLAVIEN,COPYRIGHT,DESPITE,EDUCATION,INC,INPATIENT,LABEL,MATERIALS,METHODS,NATIONWIDE,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,YEARS
139,150,174,177,220,234,397,AMERICA,BACKGROUND,BPH,CLAVIEN,CYBERTM,FORTY,III,LABEL,MATERIALS,METHODS,NORTH,OCTOBER,PVR,QOL,RESULTS,SCORE,SIX,SYMPTOM,THERE,THULIUM,THUVP
148,169,172,177,605,625,677,ADT,AUC,CONCLUSION,GLEASON,IMAGING,INC,LABEL,METHODS,MOLECULAR,NUCLEAR,PCA,PET,PSA,PSADT,RESULTS,SEVENTEEN,SOCIETY,UNLABELLED
169,68936,BACKGROUND,BECAUSE,COMPARING,HODGKIN,HOWEVER,LABEL,MEDLINE,METHODS,PRESS,PROLONGED,PUBLISHED,RESULTS,RRS,SCISEARCH,SEDENTARY,UNIVERSITY
103,600,AFTERWARD,CONCLUSION,HISTOLOGIC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS,THERE,USING
169,BACKGROUND,CASTRATION,CONCLUSION,INC,LABEL,METHODS,PUBLISHED,RESULTS
100,343,363,417,865,FAHAD,GLEASON,JANUARY,LABEL,MADINAH,MATERIALS,METHODS,OBJECTIVE,PROSTATIC,PSA,RESULTS,SAUDI,SEVENTY,THERE
169,400,800,ADC,AUSTRALIAN,BACKGROUND,COLLEGE,CONCLUSION,DWI,GLEASON,KEP,LABEL,METHODS,MRI,PER,PERFUSION,RESULTS,ROYAL,THERE,ZEALAND
169,1940S,231,233,COPYRIGHT,PUBLISHED,SAS,SNFMI
005,125,199,507,BACKGROUND,DU145,ELISA,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,SERUM,SIX,SONOVUE,SPECIMENS,TREATMENT,ULTRASOUND,WESTERN
061,651,FURTHER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROUTINE,THEREAFTER
169,946,COPYRIGHT,DEPLETION,INC,NEDD4,PUBLISHED,TGF,THESE
231,COMBINING,INCREASING,LNCAP,MDA,METHODS,MPA,PC3,PRINCIPAL,R1881,RAMAN,USING
169,AKT,COPYRIGHT,LTD,NOTCH
169,CIS,COPYRIGHT,CTV,D95,D99,GROUP,INC,MEDICAL,PRO,PTV,PUBLISHED,RADIATION,RESULTS,THERAPY
001,169,531,720,ASP312ASN,COPYRIGHT,HAPLOTYPE,NER,PUBLISHED,SNP,XPA,XPD,XPG
100,169,954,956,AKT,ANNEXIN,COPYRIGHT,ELISA,GREEK,JNK,MIC,MTT
DOCKING,GLUCOSE,GLUT1,GLUT4,GLUTS,LNCAP,RESULTS,WESTERN
169,174,403,634,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
145,169,946,CREB1,JUN,MYC,SP1,TGF,THESE
169,COPYRIGHT,GENOMIC,IMPORTANT,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,AMACR,BRITAIN,COPYRIGHT,ERG,FURTHER,GREAT,IRELAND,LTD,PUBLISHED,SOCIETY,TMPRSS2,WILEY
169,FINALLY,INC,PCA,THESE
GLEASON,PCA,TRPM2
028,137,169,549,GUIDELINES,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,UROLOGICAL
169,COPYRIGHT,INC,MRI
010,029,041,059,163,169,724,AUTHORS,AVAILABLE,BJU,CONCLUSION,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,PSA,REDUCTION,RESULTS,WHILE
132,340,945,D131G,INDUCTION,PAR,TAKEN,TNF
018,031,040,169,ACCORDING,ADVERSE,KETTERING,MAY,SLOAN,UROLOGICAL
169,174,ABLATHERM,AFTER,AUTHORS,BCR,BETWEEN,BJU,CONCLUSION,CONTINENCE,DISEASE,EORTC,HSH,ICS,IMAGING,INCLUSION,INDEX,INTEGRATED,LABEL,METHODS,OBJECTIVE,PHOENIX,PSA,QLC,QLQ,RESULTS,SOCIETY,TREATMENT
169,946,COPYRIGHT,ESI,GUTTIFERAE,HYPERICUM,LTD,NMR,THEIR
160,169,AFTER,AGREEMENT,CONCLUSION,COPYRIGHT,FORCE,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PREVENTIVE,RESULTS
160,169,656,705,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MEN,METHODS,OBJECTIVE,PCA,RESULTS,THERE
011,165,347,547,APV,CONCLUSION,DISEASE,INC,LABEL,MATERIALS,METHODS,MULTI,OBJECTIVE,OBJECTIVES,PSA,PSADT,PUBLISHED,RAPID,RESULTS,THESE
169,3DCRT,AUSTRALIAN,BACKGROUND,COPYRIGHT,COSTS,INTENSITY,IRELAND,LABEL,LTD,METHODS,QALYS,RESULTS
AIM,CHALLENGES,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,ZEALAND,ZEALANDERS
160,169,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
001,002,003,006,012,019,020,031,032,047,170,535,AFTER,BACKGROUND,GLEASON,LABEL,MEIER,METHODS,NORWEGIAN,PCD,PCDFS,PNI,PSA,PSM,RESULTS,SCORE,STAGE
003,010,169,CAUTION,CONCLUSION,COPYRIGHT,GRADE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THRESHOLD
001,034,036,047,64257,AN3CA,BACKGROUND,ELISA,KNOCKDOWN,LABEL,METHODS,MTT,PCR,RESULTS,THEREFORE,TRANSWELL,WESTERN
169,ANN,COPYRIGHT,DARBY,MADIN
169,AKT,EGF,HOWEVER,LIPID,RES,YET
169,AMONG,FURTHER,MTA,PRESS,SIXTY
BASED,JUMONJI,KDM4C
AMONG,ARRAY,BACKGROUND,BASED,ESPECIALLY,LABEL,METHODS,OPN,OVCAR,OVERALL,PATHWAY,PCR,RESULTS,VEGFA
169,400,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,DLT,HOWEVER,LABEL,LTD,METHODS,QUESTIONS,REANALYSIS,RESULTS,THEREFORE
ACTIVATION,BACKGROUND,BCL,BIM,EBP,GAMITRINIB,HSP90,JUN,LABEL,METHODS,MTT,RESULTS
160,169,177,192,CARLO,CATHETERS,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,MONTE,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,STAINLESS
460,734,ADVERSE,AMONG,BACKGROUND,LABEL,METHODS,PCA,RESULTS,SNIIRAM,THESE
000,071,102,104,105,193,232,373,3RD,416,428,624,770,BACKGROUND,CARLO,CONFIDENCE,LABEL,LHRHA,MEN,METHODS,MONTE,PCA,RESULTS
AFTER,DRUGS,EMERGENCE,STEROID
BACKGROUND,DIRICHLET,ESTIMATING,LABEL,METHODS,RESULTS,STUDENT
001,002,005,22RV1,945,954,BAX,BCL,CFLAR,HOWEVER,MTT,PNT1A,THEREFORE,ZNT
145,946,CD133,CSC,ITG,MICROARRAY,MMP14,MMP16,TGF,THBS1,THESE,TIMP1
ALZHEIMER,KALLIKREIN,KLK,KLK15,PARTICULAR,PSA
231,946,BRK,COMPOUNDS,FAK,GFP,MDA,MET,NOVEL,PMH,SAR,WESTERN
HOWEVER,PC3,ROS,THESE,TRP
25D,945,ARTIFICIAL,BECAUSE,CYP24A1,ETS,LNCAP,PCA,TMPRSS2,VDR
AXL,MER,NSCLC,RTK,TAKEN,TAM,THESE
001,717,967,BACKGROUND,LABEL,METHODS,OBJECTIVE,OVERALL,PEARSON,RADIATION,RELEVANCE,RESULTS
169,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,PSA,RESULTS,SOCIETY
085,160,169,231,280,325,930,AMONG,CALIFORNIA,CONCLUSION,COPYRIGHT,FRANCISCO,INC,LABEL,METHODS,MODIFYING,NETWORK,OBJECTIVE,PCA,PRIAS,RESULTS,SAN,THEREFORE,UNIVERSITY,USING
147,169,221,291,BACKGROUND,CAG,ERG,LABEL,MEN,METHODS,ORS,RESULTS,THESE,TMPRSS2
169,945,954,AFTER,BACKGROUND,BAY,CONCLUSION,DECREASES,HOWEVER,LABEL,METHODS,MTS,NUCLEAR,PCA,RESULTS,SHANK,SHARPIN,SOCIETY,TRANSWELL
169,ABC,ATP,BACKGROUND,DU145,EXPRESSION,INC,LABEL,LNCAP,METHODS,MTT,PACLITAXEL,PCA,PCR,RESULTS,SHH,SONIC,WILEY
169,945,COPYRIGHT,ESSENTIAL,FDA,ISSUE,LTD,MDV,SPECIAL,WHILE
169,AMONG,COPYRIGHT,GATA3,INC,INTENSITY,NUCLEAR
169,177,CONCLUSION,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,WILEY
115,119,169,177,COPYRIGHT,GLEASON,PUBLISHED,THERE
001,051,169,177,ADC,BPH,CONCLUSION,DIFFUSION,DKI,DWI,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROC,WILEY
169,A10,COPYRIGHT,EPH,HOWEVER,INC,SCREENING,THEREFORE
169,177,190,720,CONCLUSION,HISTOLOGY,INC,LABEL,MATERIALS,METASTASIS,METHODS,MRI,OBJECTIVE,PURPOSE,REGIONS,RESULTS,WILEY
169,COPYRIGHT,PUBLISHED,ROBOTIC,VINCI
100,169,215,239,ADC,BAYES,CONCLUSION,EIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,WILEY
CONTINENCE,FORTY,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PERMANENT,PURPOSE,RESULTS,THESE
000,140,169,CANCERS,FIRST,INDIANS,NATIONS,ONTARIANS,ONTARIO
185,HOWEVER,LNCAP,MDA,PCA
160,169,267,378,777,BACKGROUND,COLORECTAL,COPYRIGHT,LABEL,LTD,METHODS,RCC,RESULTS,RISKS,SIR,SWEDISH
004,052,100,109,112,126,169,319,AIM,AMICO,ANTICANCER,CONCLUSION,COPYRIGHT,HDR,INDEX,INSTITUTE,LABEL,METHODS,NETWORK,OBJECTIVE,RESULTS,SEATTLE
169,AKT,ANTICANCER,CACO2,COPYRIGHT,FINALLY,FOCUSSING,INSTITUTE,MTT,POD,PROTEIN,THESE,TREATMENT
007,015,016,022,026,109,154,169,209,234,437,545,ANTICANCER,BPH,COPYRIGHT,EXPRESSION,GLEASON,INSTITUTE,KNOCKDOWN,LNCAP,MEIER,PCA,PPM1D,PROTEIN
169,ANTICANCER,BACKGROUND,CONCLUSION,COPYRIGHT,GSH,INSTITUTE,LABEL,MATERIALS,METHODS,RESULTS,SINCE
169,AFTER,ANTICANCER,COPYRIGHT,INSTITUTE
PCA,PSA
945,ESIPT,THESE
HOWEVER,ID4,LNCAP,PCA,WESTERN
AMACR,CK903,NAS,PIN,SIXTY
METHODS,ROC
159,160,BACKGROUND,CONCLUSION,HOPKINS,JOHNS,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,USING
100,2ND,3RD,ADT,ADVERSE,CONCLUSION,III,LABEL,METHODS,NON,OBJECTIVE,PCA,PFS,PSA,PURPOSE,RESULTS,SECONDARY,TEN
000,169,500,FRUIT,NUTRITION,SOCIETY,THERE
BASED,CONCLUSION,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,THEREFORE
169,COPYRIGHT,ECM,METASTASIS,SIMILAR,VCH,WILEY
215,283,303,413,ASIAN,AUC,BACKGROUND,BMJ,CHINESE,GROUP,HOWEVER,LABEL,LIMITED,METHODS,PCA,PSA,PUBLISHED,PUBLISHING,RESULTS,RS16856139,SLC45A3
945,946,GST,HOWEVER,LOCALIZED,NOTABLY,THESE,TRIP230,USING
COPYRIGHT,PROUS,SCIENCE,STOCKHOLM,UROLOGY
AMONG,APPROACHES,BACKGROUND,DELAY,HOWEVER,LABEL,METHODS,OVERALL,RESULTS,URINARY
LEUPROLIDE,OFUJI
053,458,798,BACKGROUND,COX,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRIOR,RESULTS
130,169,681,BACKGROUND,LABEL,METHODS,OLDER,RADIATION,RESULTS,SOCIETY,UROLOGICAL,USING
027,164,383,CAMBRIDGE,COMPARING,CONCLUSION,FISCHER,GLEASON,HEIDELBERG,KRUSKAL,LABEL,LOW,MDA,METHODS,MRI,OBJECTIVE,PATIENT,PURPOSE,RESULTS,STP,THERE
113,169,175,592,676,703,751,754,769,812,834,869,AGE,BACKGROUND,CAP,DRE,LABEL,MEN,METHODS,MRI,PREVENTION,PSA,RESULTS,SOCIETY,TESLA,THREE,TRIAL
AFTER,BECAUSE,CPT,HOWEVER,XELOX
144,207,5MG,JAPAN,TAP
FORCE,INSTITUTE,JAPAN,PREVENTIVE,PSA,USA
246,ERSPC,HOWEVER,JAPAN,PSA,QOL,RANDOMIZED,SCREENING,THEREFORE,UROLOGICAL
6TH,JAPAN,THERE
169,CPG,FINALLY,LABORATORY,NDR,PRESS,PUBLISHED,REMARKABLY,TFS
169,BASED,SOCIETY,THESE,WHILE
111,150,160,169,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PCA,REDUCTION,RESULTS
NHS
ADEQUATELY,BACKGROUND,BARRETT,CHRONIC,CRP,LABEL,METHODS,RESULTS,RFA,ULTRA
99M,BLOOD,DB4,DEMOBESIN,LABEL,METHODS,OBJECTIVE,PROCEDURES,PURPOSE,RESULTS,SPECT
169,COPYRIGHT,LTD,THROUGH
001,169,205,551,ADVANCING,COMPETING,CONVERSELY,COPYRIGHT,CSM,END,GLEASON,HOWEVER,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OVERALL,PCA,RESULTS
100,228,CGA,FIFTEEN,GASTRIC,GCDFP15,HMB45,LABEL,LYMPH,METASTASES,METASTATIC,METHODS,MOLECULAR,MPNST,OBJECTIVE,OVARIAN,P504S,PANCREATIC,PSA,RESULTS,SEVEN,SYN,TTF,WT1
132,145,169,945,946,947,COPYRIGHT,HDAC1,HDAC6,HRMPC,INC,RPA32,ULTIMATELY,VORINOSTAT,WJ35435
169,296,COPYRIGHT,HOWEVER,PUBLISHED,UTR
169,215,COLLIMATOR,DELTA,DYNAMIC,INTENSITY,JAPAN,MODULATED,MULTILEAF,PRESS,PUBLISHED,RADIATION,SOCIETY,THERAPY,UNIVERSITY
169,ACIDS,EXPRESSION,LIGHT,MT1,NUCLEIC,PRESS,PUBLISHED,UNIVERSITY
169,215,510,BACKGROUND,FDG,HOWEVER,INC,INCLUSION,LABEL,METHODS,PCA,PET,RESULTS,STRATIFIED,WILEY
169,946,AKT,BACKGROUND,DISCUSSION,FOXP3,INC,LABEL,LENTIVIRAL,METHODS,MYC,NUCLEAR,PGF,PRECS,RESULTS,TCF,WILEY,WNT
001,010,023,138,156,BCR,FIRST,GLEASON,PSA,REGARDING,USING
1B1,881,890,937,942,996,997,ARTICLE,ASIAN,BACKGROUND,CAUCASIAN,CYTOCHROME,HOWEVER,L432V,LABEL,METHODS,RESULTS,STATA,THEREFORE,UNASSIGNED,VIRTUAL
169,940,AT1,AUTHORS,BACKGROUND,CB1,ERBB2,FURTHER,INC,LABEL,RESULTS,WILEY
124,169,AUTHORS,BACKGROUND,BPH,CLINICALLY,DU145,INC,LABEL,METHODS,MIR,PACE4,PCA,PCR,RESULTS,UTR,WILEY
954,AKT,BACKGROUND,CONCLUSION,LABEL,METHODS,PCA,PCR,PROMOTION,RESULTS,WESTERN
100,125,149,160,169,185,CARLO,COPYRIGHT,D10,D90,DVH,FORMULA,GROUP,HOWEVER,INC,ISA,LABEL,MATERIALS,METHODS,MONTE,OBJECTIVE,PERIPHERAL,PUBLISHED,PURPOSE,RESULTS,SOCIETY
177,BACKGROUND,BLS,BURKITT,CONCLUSION,EBNA1,EBV,EPSTEIN,JID,LABEL,METHODS,MUTUI,PCR,PLAC1,RESULTS
157,167,169,225,551,708,GLEASON,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OPERATIVE,RESULTS,ROBOT,SEPTEMBER,THERE,UROLOGICAL
169,COPYRIGHT,CYTOSCAPE,HOWEVER,LTD,PROTEOMICS,THERE
CENTROSOME,ILK,INHIBITION,QLT,RB1,THESE,Y79
945,AIM,CONCLUSION,DU145,GIVEN,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THESE,TNF
169,AIM,CAP,CONCLUSION,COPYRIGHT,DU145,EXPRESSION,LABEL,LNCAP,LTD,METHODS,OBJECTIVE,OREXINS,OXA,RESULTS
169,192,ARF,COPYRIGHT,EMT,FEDERATION,MECHANISMS,PUBLISHED,SOCIETIES,THESE,TRP53
169,231,233,COPYRIGHT,PUBLISHED,SALVAGE,SAS
12A,145,169,945,946,AMONGST,COMPOUNDS,COPYRIGHT,INC,LNCAP,WHILE
005,160,169,232,ANALYZING,AUSTRALIAN,AUTHORS,AZGP1,BECAUSE,DIAGNOSTIC,EXPRESSION,GLEASON,IHC,LTD,MEN,MRR,POISSON,USING,WILEY
104,169,AGE,ASIAN,BACKGROUND,CAP,ERG,ETS,FILIPINOS,GENERAL,GLEASON,INC,LABEL,MAB,MEN,METHODS,OVERALL,PGH,PHILIPPINE,RESULTS,TMPRSS2,TRUSP,UNIVERSITY,WESTERN,WILEY
AIS,ANDROGENS,DBD,EARLY,HOWEVER,LBD,SEVERAL
100,508,784,842,AGE,CAB,CASTRATION,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
145,CONCLUSION,ERS,GPR30,LABEL,METHODS,OBJECTIVE,PCR,RESULTS
CXCL8,HMGB1,INCREASED,SDS
BINDING,CXCL8,CXCR2,GTP,HOWEVER,KNOWLEDGE
ACCORDING,ELECTRONIC,ENGLISH,HOWEVER,JANUARY,LABEL,MEDLINE,METHODS,MRI,OBJECTIVE,PBX,PSA,PURPOSE,RESULTS
AGE,BACKGROUND,COLORECTAL,CRC,KATHMANDU,LABEL,MAXIMUM,METHODS,NEPAL,RESULTS
145,169,COPYRIGHT,INC,KIC,LEU,MRS,THESE,TRAMP,USING
169,BECAUSE,COPYRIGHT,FATTY,FINALLY,GLEASON,INC,LNCAP,PATHOLOGY,PUBLISHED,SOCIETY
000,100,169,1970S,AMERICA,BACKGROUND,BETWEEN,COSTA,HOWEVER,LABEL,LATIN,MEDICAL,METHODS,PRESS,PUBLISHED,RESULTS,SOCIETY,TOBACCO,UNIVERSITY,USA,VENEZUELA,WORLD
169,BLOOMBERG,CAUCASIANS,GSTT1,HOPKINS,HOWEVER,JOHNS,LIBRARY,MARCH,PRESS,PUBLISHED,UNIVERSITY
149,169,ATLAS,EXPRESSION,LARGE,PRESS,PUBLISHED,UNIVERSITY
ACUTE,END,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,URINARY
169,945,GLEASON,LNCAP,PC3,PCA,PRESS,PUBLISHED,THREE,UNIVERSITY,USING
254,350,823,ADDITIONAL,COX,FEW,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERUM,SUA,VLAGTWEDDE
120,169,AUTHORS,BJU,FURTHER,LABEL,METHODS,OBJECTIVE,PATIENT,PSA,RESULTS
169,AKT,CAO,CHINESE,COPYRIGHT,DTT,DU145,ERK,FURTHER,HOWEVER,JNK,JUN,METASTASIS,MMP,ROS
169,946,INC,WILEY,WNT
098,169,199,303,368,IRR,KNOWLEDGE,MEN,POISSON,PSA,THESE
169,177,956,ABC294640,ACADEMY,BACKGROUND,COPYRIGHT,ENDOGENOUS,INSTITUTE,INTRINSIC,LABEL,LNCAP,METHODS,PARTNER,PUBLISHED,RESULTS,SPHK2,URBAN
169,202,AUTHORS,BJU,FURTHER,HOPKINS,JHH,JOHNS,LABEL,METHODS,OBJECTIVE,PRIAS,PSA,PSADT,RESULTS,SINCE,THERE
10A,169,COPYRIGHT,CPT,DOX,DU145,GENERALLY,HCT,MCF,PIPERAZINE,SAS,SEVERAL,TAKEN
000,003,156,169,334,425,454,465,991,AFRICAN,AMERICANS,HAWAIIANS,HOWEVER,LATINOS,MAF,ROCHE,SNP,THREE
122,ASSURANCE,BACKGROUND,DIFFERENT,GERMANY,GLEASON,GROUP,LABEL,MATERIALS,MAY,METHODS,NEWER,OBJECTIVE,OBJECTIVES,ODM,PSA,QUALITY,RESULTS,URO
ANGLO,BACKGROUND,CURRENTLY,ENGLISH,EVALUATION,LABEL,MATERIALS,METHODS,RESULTS,SAXON,THEREFORE,THESE
017,019,026,169,BACKGROUND,CONCLUSION,JANUARY,LABEL,MAY,METHODS,POTENTIAL,RESULTS
107,109,169,670,746,791,954,ACCORDING,AUTHORS,BJU,CONCLUSION,GLEASON,HOWEVER,KAPPA,LABEL,METHODS,OBJECTIVE,PATHOLOGY,RESULTS,SOCIETY,THREE,TREATMENT,UNWEIGHTED,UROLOGICAL
169,ACTIVATION,BACKGROUND,BRITISH,CLOFOCTOL,CONCLUSION,FINDING,HOPKINS,JOHNS,KEY,LABEL,LIBRARY,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
128,169,BMI,CSC,NANOG,USING
001,007,009,164,169,221,BACKGROUND,ECE,HISTORY,INDEX,LABEL,METHODS,NVB,OBJECTIVE,OHORI,OPTIMAL,OUTCOME,PDE5I,RESULTS,RRP,SIXTY,SNG,SOCIETY,THERE
177,235,273,307,856,C30,CLAVIEN,DINDO,EORTC,LABEL,METHODS,OBJECTIVE,PURPOSE,QLQ,QUALITY,RADICAL,RESULTS,WHILE
BRCA2,ECM,HOWEVER,INDUCTION,PCD,ROS,TAKEN,TREATMENT,USING
AFTER,BACKGROUND,CONCLUSION,EGIST,LABEL,METHODS,PRIMARY
34BETAE12,CHRONIC,CONCLUSION,ERG,LABEL,LUMINAL,MET,METHODS,OBJECTIVE,RESULTS
COA,OTHER,PCA,USING,WHILE
128,169,183,ACCORDING,AMONG,BACKGROUND,CONCLUSION,DRE,EAU,ESPECIALLY,GEORG,GLEASON,JANUARY,LABEL,LOW,METHODS,MRI,PCA,PRIOR,PSA,RESULTS,STUTTGART,TESLA,UROLOGY
150,AFTER,AFTERWARDS,GLEASON,SCORE,THEREFORE,THROUGH,USING,WEB
AUSTRALIAN,NFF,PC3,PIPESTELA,STRUCTURE,THEIR,THESE
115,180,BACKGROUND,CONTENT,DCR,DIGITAL,DISSECTION,LABEL,LOCAL,METHODS,OBJECTIVE,OUTCOME,RESULTS,SETTING,THERE,VIDEO
BNC,DESPITE,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE
010,100,132,173,323,BOO,BPH,CONCLUSION,FIFTY,HOLEP,LABEL,METHODS,OBJECTIVE,RESULTS,SCORE,SYMPTOM,VAS
22RV1,CCT,EMT,PC3,PCA
032,154,169,AUTHORS,BJU,CIS,COX,LABEL,MEIER,MEN,METHODS,OBJECTIVE,ORS,PCA,RESULTS,STUDENT,TOTAL
616,620,SPANISH,TAKEN
169,283,AMONG,BACKGROUND,BCR,FURTHER,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THEIR,WILEY
169,264,484,805,820,COX,LABEL,METHODS,OBJECTIVE,READERS,RESULTS
ACCORDING,ETS,MMP,PC3
AWARENESS,BACKGROUND,DISCUSSION,INCORRECT,LABEL,OBJECTIVE
CASTRATION,CLINICALLY,THESE
CHOLINE,MRS
124,160,177,231,549,956,ACCORDING,HOWEVER,MCF,MDA,MRC,MTT
414,CONCLUSION,DESMOGLEIN,FURTHER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
000,169,215,285,376,AFTER,CONSORTIUM,FINALLY,INSTITUTE,ORS,PRESS,PUBLISHED,TNM,UNIVERSITY
169,CIOCALTEU,COPYRIGHT,FOLIN,LTD,TOTAL,WILEY
DESPITE,PCA,UTR
001,002,010,156,160,229,385,635,658,COX,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,UCB
169,BAYES,COPYRIGHT,LTD,WILEY
102,ANP,B16,C57BL,ECTOPIC,NH2,NPR,THESE
169,946,AMERICA,AUTHORS,BJU,CONCLUSION,ERTAPENEM,LABEL,METHODS,OBJECTIVE,RESULTS,SIX,SOUTH
169,ANXIETY,AUSTRALIAN,AUTHORS,BJU,CONCLUSION,INDEX,LABEL,MAX,METHODS,OBJECTIVE,RESULTS,SCALE,SCORE,SYMPTOM,THERE,THREE,UAS
169,AUTHORS,BJU,GASTRIN,GRP
169,AUTHORS,BJU,INSERTION,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SPACERS
169,177,258,470,ANZUP,ART,AUSTRALIA,AUSTRALIAN,AUTHORS,BJU,CONCLUSION,COUNCIL,EARLY,GROUP,III,INSTITUTE,LABEL,LOCAL,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,PSA,RADIATION,RAVES,RESULTS,SALVAGE,SMS,SOCIETY,SRT,SURGERY,TRANS,TRIAL,UROGENITAL,UROLOGICAL,USANZ,ZEALAND
003,169,254,278,447,676,BACKGROUND,BONFERRONI,COLORECTAL,LABEL,METHODS,OVARIAN,OVERALL,RESULTS,SCREENING,SERUM,SOCIETY,TRIAL,USING
169,JAPAN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SLEEP,UROLOGICAL
CURRENT,ECS,HOWEVER,INITIAL,METASTASIS,THEREFORE
011,016,045,117,135,169,228,450,676,777,811,866,882,COX,PREVENTION,SIMILARLY,TRIAL,VITAMIN
001,021,026,100,103,ACUTE,ENI,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,V70
169,208,725,AUC,BACKGROUND,COPYRIGHT,GLEASON,GLS,INC,INDEX,LABEL,MATERIALS,METHODS,PCA,PSA,RESULTS
330,LIP,RESULTS,SEVERAL
19A,345,CAPRA,GLEASON,HOWEVER,PSA,SERUM
120,169,240,954,CIS,COHEN,CONCLUSION,IMAGE,LABEL,MATERIALS,METASTASES,METHODS,OBJECTIVE,PURPOSE,RESULTS,SHORT,WRITTEN
150,APRIL,BACKGROUND,CONCLUSION,DESPITE,LABEL,LRP,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEPTEMBER,THERE,TREATMENT
361,EFFECTIVE,EPCAM,MCF,MDA,PAMAM,PCA,PSA,THESE
221,222,AFTER,CELLS,LNCAP,MIR,SIRT1,STUDIES,THEIR,THERE,THESE
945,946,BSA,CAM,FUNCTIONAL,LNCAP,PCA,PNI,SCN2B,VOLTAGE
BACKGROUND,BAX,BP1,DCA,INCREASED,LABEL,METHODS,NAD,PC3,REDUCED,RESULTS,ROS
177,AFTER,ANOTHER,INSTITUTE,NCI,PHYSICS,RIGID,RPC,SOLID,SR4,SUBSTITUTE,TLD,TPS
CGE,ECLIPSE,EUD,PTV,TPS,XIO
219,518,555,609,BETWEEN,COX,HOWEVER,LABEL,METHODS,OBJECTIVE,PALATINATE,RESULTS,RHINELAND
EPHA2,GNR,LBL,OVERALL,TARGETING,YSA
013,032,100,169,215,AFRICAN,AMERICANS,BIOMARKER,EVALUATION,EVALUATORS,GENOMIC,METASTATIC,OVERALL,PPV,UNDER
169,COPYRIGHT,EVENT,IES,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,REVISED,SCALE,WILEY
APOPTOSIS,AREAS,BACKGROUND,COVERED,LABEL,METHODS,OPINION,PAR
169,AUTHORS,LTD,NOTABLY,PTY,PUBLISHING,SCIENCE,SEVEN,SEVENTY,THESE,WILEY
169,AUTHORS,HERVS,HOWEVER,INC,PUBLISHED,WHETHER,WILEY
169,AMERICANS,END,INSTITUTE,JANUARY,RESULTS,SOCIETY,THERE
169,ACUTE,ADVERSE,BETWEEN,COPYRIGHT,HOWEVER,INC,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,THERE
169,448,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,SRT,THESE,TNPSA,UNIVARIATE
AREAS,BACKGROUND,COVERED,CYP17A1,HOWEVER,LABEL,METHODS,OPINION,THERE
000,003,BACKGROUND,BLOOD,CONCLUSION,LABEL,METHODS,PSA,RESULTS,THREE
001,11C,215,785,832,ADC,AUC,CONCLUSION,DWI,KEY,LABEL,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,ROC,SUV
FGFR1,HPT,HRPT2,IHC,MUTATIONS,PCR,SIXTEEN,TOTAL,WELCH
EMT,INC,PUBLISHED
169,672,BACKGROUND,COX,GROUP,INC,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SARCOMA,SSG,WILEY
169,COPYRIGHT,INC
002,015,169,BACKGROUND,GAY,GMPCA,HOWEVER,HRQOL,INDEX,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,RESULTS,SOCIETY,WHERE
916,BACKGROUND,BIOLOGICAL,CONCLUSION,DUE,EXPRESSION,FIDAS,LABEL,LBD,METHODS,NUCLEAR,PCR,Q640X,REPRESSION,RESULTS,RSV,SUCCESSFUL,WESTERN
058,289,448,456,5ARIS,803,945,AFTER,BECAUSE,COX,EXPOSURES,GLEASON,IMPORTANCE,INCREASED,LABEL,METHODS,OBJECTIVE,REDUCTASE,RELEVANCE,RESULTS,SETTING,THERE,WHILE
946,ANDROGENS,CAS,FILTERING,GAPDH,GATA2,MECOM,MYBL1,MYBL2,NFKB1,NFKB2,NFY,REL,THESE
APRIL,BACKGROUND,DISCUSSION,GIVEN,IDENTIFIER,LABEL,MAY,MEN,METHODS,SIXTY,SPECIALIST,THESE,TRIAL
AFTER,BACKGROUND,HOWEVER,LABEL,METHODS,ROUTINE,SUBSEQUENT,THEREAFTER,THEREFORE
145,945,BACKGROUND,BERBERINE,HIF,LABEL,LNCAP,METHODS,RESULTS,UNASSIGNED,VIRTUAL,WESTERN
BACKGROUND,FOCUS,HOWEVER,INTERVIEWS,LABEL,MEN,METHODS,PROVISION,PSA,RESULTS,THERE
BASED,BIOLOGICAL,EAR,EFFECTS,ERR,HCC,LABEL,LAR,METHODS,OBJECTIVE,OED,PURPOSE,RADIATION,RESULTS,TREATMENTS,VII
ADP,ARTD8,ARTD9,BACKGROUND,BAL,DLBCL,DTX,DTX3L,DU145,EFFECTS,HPE,IL4,LABEL,LNCAP,METHODS,PARP9,PC3,PCA,PCR,RESULTS,RWPE1,STAT1,STAT3,STAT6,WESTERN
160,480,BACKGROUND,LABEL,METHODS,PCA,RESULTS,REVERSE,THESE,TISSUES,WARBURG
170,BACKGROUND,FAVORABLE,GLEASON,LABEL,LARGE,METHODS,MRI,PATHOLOGIC,PCA,RESULTS
156,216,280,878,ADT,BACKGROUND,LABEL,METHODS,PCA,PROPENSITY,RESULTS,THEREFORE
048,180,327,570,994,BACKGROUND,BCR,BED,COX,GY2,LABEL,LDR,METHODS,PHOENIX,PSA,RESULTS,SEPTEMBER
BACKGROUND,CDX,CK7,CONCLUSION,LABEL,METHODS,MUCIN,PATHOLOGY,PSA,THESE,TURBT
001,128,177,ADC,AUC,BACKGROUND,GLEASON,LABEL,METHODS,MRI,PCA,RESULTS
001,947,BACKGROUND,GCOM1,HOWEVER,LABEL,LTR,METHODS,MEX3D,PCA,PCR,RESULTS,RVS,TRPM4,TYPICALLY
1CM,215,ACCORDING,BACKGROUND,CAUCASIAN,CLINICIANS,GLEASON,LABEL,METHODS,SIX,SMALL,THERE
433,444,954,AZA,BACKGROUND,BSP,CDR,COBRA,CONCLUSION,CPG,DNMTS,IRS,LABEL,LNCAP,MEANWHILE,METHODS,MIR,MTS,NOTABLY,PC3,PCR,RESULTS,THEREFORE
946,BACKGROUND,DU145,EPCAM,ITGB4,LABEL,LN4,METASTASIS,METHODS,MICROARRAY,RESULTS,SIRNA,THESE,UK122,USING
001,120,ADT,AFTER,BACKGROUND,BETWEEN,COX,CTCAE,HDR,INSTITUTE,LABEL,MEIER,METHODS,PHOENIX,PREDICTORS,RESULTS
004,012,013,049,145,227,945,946,ACUTE,ADT,ADVERSE,AFTER,BED,BETWEEN,COX,CTCV3,HDR,LABEL,LDR,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,UNIVARIATE
384,945,AKT,BACKGROUND,BASED,CONCLUSION,EGF,ELISA,ERK,GIVEN,IL6,JNK,LABEL,LNCAP,MDA,METHODS,MTT,NORMALIZED,PC3,PCA,RESULTS,TNF
001,127,AGE,BACKGROUND,BMI,GLEASON,LABEL,MEDICAL,METHODS,MHZ,MRI,PBX,PSA,RESULTS,SUSPICIOUS
ACI,AUSTRALIA,AUSTRALIAN,BACKGROUND,CLINICIANS,DISCUSSION,INNOVATION,LABEL,METHODS,NETWORK,NSW,OUTCOME,PHASE,PROCESS,SOUTH,THERE,TRIAL,UROLOGY,WALES,ZEALAND
100,110,AES,BACKGROUND,CTV,D95,LABEL,MARGINS,METHODS,PTV,RESULTS,THREE,V70
GLEASON,PCSCS,WHILE
BACKGROUND,LABEL,MDL,NED,RESULTS,TAKEN
000,100,AGE,AMONG,BACKGROUND,CONCLUSION,EPI,EXCEL,GHANA,HISTOLOGY,HOUSING,KOMFO,LABEL,LABORATORY,LIVER,METHODS,MICROSOFT,OVARY,PATHOLOGY,POPULATION,REGISTRIES,RESULTS,SOUTH,STOMACH,VERSION
160,AFM,AKR1B10,ALDH3A1,BACKGROUND,BESIDES,CLDN2,DU145,HCT,INCIDENCES,LABEL,METASTASIS,METHODS,PCR,RESULTS,ROS,SEQUENCING,SW480
SINCE,THESE
ADT,FOLLOWING,REMARKABLY,THESE
018,160MG,BACKGROUND,BENEFIT,CYP17,E26,ERG,FOLLOWING,LABEL,LIMITED,MAXIMAL,MET,METHODS,OBJECTIVE,OUTCOME,PATIENT,PERSISTENT,PSA,PUBLISHED,RESULTS,SETTING,SRC,SUMMARY,TRIAL
945,946,B16,CYTOKINES,KNOCKDOWN,LAL,LEWIS,LYSOSOMAL,MDSCS,MYELOID,THEREFORE
ATM,BECAUSE,DU145,FINALLY,LOX,LYSYL,MRE11,PC3,THESE
001,686,DESPITE,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,OVERALL,RER,RESULTS,SETTING,SOUTH,THERE,URBAN,WALES
CURRENT,WHILE
177,ACCORDING,MRI,PSA,TESLA,THESE
001,160,532,540,626,BACKGROUND,FATIGUE,LABEL,MEDIVATION,METHODS,PREVAIL,PSA,RESULTS
004,031,139,177,181,220,293,BMI
BRCA2,CARIBBEAN,GLEASON,OTHER,PSA,WESTERN
10878,169,936,AFTER,ASSESSMENT,BACKGROUND,CONCLUSION,COPYRIGHT,CTCAEV3,DLT,EARLY,EORTC,FIFTEEN,GROUP,LABEL,LTD,METHODS,RDI,RESULTS,TARGETT,TREATMENT
169,AUTHORS,BACKGROUND,COPYRIGHT,FDE,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PET,PUBLISHED,PURPOSE,RESULTS
048,125,169,7MM,9MM,BACKGROUND,COMPOSITE,CONCLUSION,COPYRIGHT,FURTHER,GRADE,INC,INDEX,LABEL,MATERIALS,METHODS,PUBLISHED,QOL,RESULTS,SALVAGE,SOCIETY,SPACING,THERE
169,COPYRIGHT,ENDOCRINE,LTD
169,DU145,ERK,GLP,LNCAP,P504S,PC3,READERS,THESE
125,956,BMJ,GROUP,IMMEDIATE,LDR,LTD,PUBLISHING
480,803,956,CCNE2,HEPG2,MAX,MGC,PC3,PCR
001,006,139,245,254,499,887,ADDITIONAL,AFFAIRS,BLACK,CONCLUSION,GLEASON,LABEL,MEDICAL,METHODS,OBJECTIVE,POPULATION,PSA,PURPOSE,RESULTS,RRR
169,174,AGENDIA,COLOPRINT,COLORECTAL,CRC,CTC,EMT,EPCAM,NGS,TNM,TODAY
244,494,BIO,CLC,EXOME,HOWEVER,LIBRARIES,NGS,PEARSON,SEQ,WORKBENCH
ALTOGETHER,BIOMARKERS,DUE,MOLECULAR,SPECIAL

169,AMONG,COPYRIGHT,THESE
3DPCM,BACKGROUND,CONTEXT,GLEASON,GROUP,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RADIATION,RESULTS,SEVENTEEN,THERAPY
003,007,017,024,177,400,947,IVD,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
916,BASED,BEV,CTV,INTENSITY,LABEL,METHODS,MUS,OBJECTIVE,PURPOSE,RESULTS,TCP
ART,DVH,GPU,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
187,3N0M0,606,BASED,COX,LABEL,MEDICAL,METHODS,OBJECTIVE,RESULTS,TOKYO,UNIVERSITY
115,141,229,234,242,946,DESPITE,GLEASON,KOREANS,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,TESLA
022,027,132,COX,ELISA,GLEASON,PAI,PCA,PCR
PSA,THEREFORE
3BETA,8BETA,ADIOL,AMONG,DPN,VE2
ADC,CHOLINE,CONCLUSION,DRS,IMAGING,LABEL,METHODS,MRI,NPV,OBJECTIVE,PET,PURPOSE,REGARDING,RESULTS,SUV
213,AIM,ASR,BEIDA,CONCLUSION,EASTERN,LABEL,LIBYA,METHODS,NORTH,OBJECTIVE,POTENTIAL,RESULTS
100,169,215,BACKGROUND,BECAUSE,BPR,CHROMOSOME,LABEL,METHODS,MOTIVATION,NGS,PRESS,PUBLISHED,RESULTS,SLIDESORT,UNIVERSITY
000,169,190,420,538,809,875,AFTER,CKD,COPYRIGHT,NEPHROLOGY,SOCIETY
001,004,005,009,012,148,GLEASON,MEIER,PCA,THESE
FOXA1,TAKEN
013,257,293,RESULTS,THERE
169,ADT,CONCLUSION,COPYRIGHT,GREATER,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SERUM,SWEDISH
000,BCR,CGA,FORMULA,GLEASON
945,HIF,HIF1A,LNCAP,TAKEN
169,ARS,CYP17A1,EFFECTS,FINALLY,FURTHER,GALETERONE,LABEL,LNCAP,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS,SIMILAR,T878A
ADRENERGIC,CLINICALLY
186,240,273,AUR,BPH,CONCLUSION,LABEL,METHODS,MFR,OBJECTIVE,PCA,RESULTS,THERE,TOTALLY
CONCLUSION,LABEL,METHODS,OBJECTIVE,QUANTITIES,RESULTS,UNDER
13C,NMR,PANCRATIUM,THEIR
169,ADT,CROSS,FAT,SOCIETY,UNTIL
169,SOCIETY,STROMAL
100,225,BACKGROUND,CONCLUSION,CYSTECTOMY,CYSTOSCOPY,DIGITAL,GIANT,HOWEVER,LABEL,LOBES,METHODS,OBJECTIVE,PATIENT,RESULTS,THERE,TREATMENT,URINARY,URINE,UROGRAPHY
169,1990S,COPYRIGHT,DENDRITIC,HOWEVER,LTD,SINCE
ARGENTINA,MULTILEVEL,SPATIAL,TOBACCO
169,FINALLY,NUTRITION,PCA,SOCIETY,THEREFORE
188,198,AUC,HAMBURG,LABEL,MARTINI,METHODS,NPV,OBJECTIVE,OVERALL,PPV,PURPOSE,RESULTS
169,946,COPYRIGHT,CYTOTOXIC,OVERALL,SCIENCE,TCR,THESE,WHEREAS
160,347,54T,ASIAN,HOWEVER,RESULTS,UTR
001,102,CAB,CUMULATIVE,ENGLISH,INCLUDING,PSA,REGARDING
015,017,027,042,MAY,WBC
BACKGROUND,CENTRAL,KOREA,KRW,LABEL,MATERIALS,METHODS,OFF,PROGRAM,PSA,RESULTS,SCREENING,SEVERAL,THEREFORE,TRADE,UNDER
490,BACKGROUND,CRP,CSS,FURTHER,JAN,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,RCC,RESULTS,RFS,SEP,STUDIES
660,943,CHINESE,HOWEVER,OVERALL,STATA,WANFANG
91R,BECAUSE,IGG2B
169,BRITAIN,COPYRIGHT,ERG,GREAT,IRELAND,ITH,LTD,PCA,PUBLISHED,SOCIETY,TAKEN,TMPRSS2,WILEY
CONCLUSION,INSTITUTE,LABEL,OBJECTIVE,PRIMARY,RESULTS,SUGGESTED,WORLD
CCNE1,CXCL2,DU145,EXPRESSION,IL8,LNCAP,P16,PC3,PCR,THESE
GROUP,SUBGROUPS
169,954,ARS,CONCURRENT,DRUGS,HENCE,HINGE,HSP90
BACKGROUND,BMI,CASES,COPENHAGEN,COX,ESTIMATES,HOWEVER,LABEL,METHODS,OVERALL,RECORDS,RESULTS,THESE
DESPITE,EFFORTS,THESE
114,198,221,271,302,929,AMONG,BACKGROUND,CAP,CLUSTER,CONTROL,ENGLAND,LABEL,METHODS,PSA,RESULTS,SCREENING,SEVEN,THERE,WALES
100,169,CONCLUSION,COPYRIGHT,COX,DOC,FIFTY,GLEASON,INC,LABEL,LOG,MATERIALS,METHODS,OBJECTIVE,PROTEIN,PURPOSE,REDUCTION,RESULTS,STRATIFIED,T3A
AIM,BACKGROUND,CAND1,FURTHER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SEQ,SEQUENCING,THESE
PCA,RADICAL,SEVERAL

128,132,160,169,177,239,AFTER,COMBINING,COPYRIGHT,EDUCATION,GLEASON,HOWEVER,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TESLA,UROLOGICAL
HOWEVER,THEREFORE
169,AKT,LABEL,TRP53,UNLABELLED
100,235,BRESSON,HOWEVER,T2W
945,CLINICALLY,CONCLUSION,KEY,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS,SEVENTEEN,T2W,TESLA,THREE,VISIBILITY
ASSESSMENT,AUC,DIAGNOSTIC,DWI,GENERAL,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PATIENT,PCA,QUALITY,RESULTS,STUDIES,THERE
BPH,OVERALL
103,150,AFTER,CTV,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RADIATION,RESULTS
110,169,510,CAUCASIAN,GLEASON,HORMONE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL,USING
945,AKT,DESPITE,EMT,FOXO1,KNOCKDOWN,PCA,ROS,THESE
169,945,956,COPYRIGHT,DU145,HYPOXIA,INDONESIAN,INDUCIBLE,LTD
AIM,HENCE,HOWEVER
001,100,ACUTE,AIM,FIFTY,GRADE,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,TOTAL
104,BPH,DEPLETION,GPX,HOWEVER,NIGERIA,PCA,ROS,SOD,SOUTH
AKT,ANNEXIN,ANXA7,HOWEVER,INGENUITY,LNCAP,PATHWAY,PCD,USING
17P12,20Q13,ACCORDING,BRCA1,BRCA2,CYP17,HOWEVER,HPC,HPC20,THERE,THROUGH
169,CONCLUSION,COPYRIGHT,ENRICHMENT,HLA,ID4,INC,ITGA6,LABEL,MEASURE,METHODS,OBJECTIVE,OUTCOME,PATIENT,PUBLISHED,RESULTS,SETTING,SOCIETY,UCHL1
236,457,BIOMEDICAL,CBM,CHINESE,DLR,HOWEVER,KNOWLEDGE,MAY,OVERALL,PCA,PLR,SIXTEEN,STATA,URINE,VIP,WAN
169,177,1NM,263,BIO,COPYRIGHT,DSC,DU145,HOWEVER,SILIBININ,SURFACE,TEM,VARIOUS
001,ADC,CONCLUSION,CTP,DWI,KEY,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PERFUSION,RESULTS,THERE,TUMOURS
169,COPYRIGHT,LTD
001,169,474,713,978,AFRICAN,AFTER,AMERICANS,BACKGROUND,END,LABEL,METHODS,RESULTS,SOCIETY,THESE
005,168,BASEL,EVALUATING,LABEL,METHODS,MRI,OBJECTIVE,PSM,PURPOSE,RESULTS,SEPTEMBER
169,AFTER,COPYRIGHT,ECE,GLEASON,INC,LABEL,MATERIALS,METHODS,NPV,OBJECTIVE,OBJECTIVES,OVERALL,PPV,RESULTS
169,AMP,LTD,METFORMIN,PUBLISHED,THESE,WILEY
169,231,B16,COPYRIGHT,F10,FURTHER,HOWEVER,INC,MDA,NEOPLASIA,PRESS,PUBLISHED,THESE
169,254,942,AFRICAN,ANTONIO,BIOMARKERS,CONCLUSION,COPYRIGHT,DETECTION,EARLY,GLEASON,GROUP,INC,LABEL,METHODS,NETWORK,OBJECTIVE,PERCENT,PREVENTION,PSA,RESULTS,SAN,TRIAL
001,169,BIVARIATE,CONCLUSION,COPYRIGHT,END,EXCEPTIONS,INC,LABEL,LPN,LRN,METHODS,OBJECTIVE,OPN,RESULTS,SIMILARLY,THESE,USING
126,169,390,944,AIM,AMONG,BACKGROUND,CONCLUSION,DESPITE,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,USING
131,139,169,531,626,AMONG,COX,NUTRITION,THERE
169,INC,STEROID
001,169,644,674,795,879,AFRICAN,AMONG,CAP,CONCLUSION,COPYRIGHT,END,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PROGRAM,PSA,PURPOSE,RESULTS
003,032,034,045,169,209,258,315,792,AFRICAN,AFTER,AHR,AMONG,BACKGROUND,CAP,CONCLUSION,COPYRIGHT,END,FURTHER,GLEASON,INC,LABEL,MEN,METHODS,RESULTS,T2A
169,181,215,250,C18,CONFERENCE,COPYRIGHT,LTD,NILUTAMIDE,Q1A,WILEY
005,047,169,253,321,CONCLUSION,COPYRIGHT,GLEASON,GRADE,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PUBLISHED,RESULTS,SAS,SIXTY,THREE
120,120DAYS,169,816,BETWEEN,CONCERNING,COPYRIGHT,DATES,INSTITUTE,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,SAS,STATISTICS,STUDIES,THEREFORE
169,ASL,BACKGROUND,CONCLUSION,COPYRIGHT,DIFFUSION,DWI,IMAGING,LABEL,MATERIALS,METHODS,MRI,PET,RESULTS,SAS,THEREFORE
001,4EBP1,500,ACC,BACKGROUND,FORTY,LABEL,MEN,METFORMIN,METHODS,PRE,PSA,RESULTS,SCORE,THERE,TREATMENT

169,17G,945,ADT,AFTER,COPYRIGHT,DHT,ESSENTIAL,FINALLY,LTD,THESE,UDP,UGT,UGT2B15,UGT2B17
001,020,031,169,177,180,BACKGROUND,CONCLUSION,ENDOSCOPIC,FORCE,JANUARY,JAPAN,LABEL,LOC,LTD,METHODS,OCTOBER,PTY,PUBLISHING,RESULTS,SOCIETY,SURGERY,UBS,USING,VUA,WILEY
464,BPH,DFS70,ELISA,PCA,PSA,TAA,WESTERN
169,PCA,SOCIETY,THESE
169,PELP1,PROLINE,SOCIETY,SRS
2HF,AKT,BAX,BCL,DU145,HOWEVER,MCL,OVERALL,PCA,STAT3
008,157,193,417,ADT,KNOWLEDGE,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PRIOR,PURPOSE,RESULTS,SCIENCE,THESE,WEB
128,945,DEPLETION,HIF,HOWEVER,LUCIFERASE,PCA,PCR,RPS6KB1,SNAIL,USING
002,004,005,006,008,016,177,462,478,665,703,707,826,847,CAUCASIANS,HOWEVER,SCHOLAR,THESE,WANFANG
145,FLAVONOIDS,MTT
136,160,169,566,AFTER,COPYRIGHT,EDUCATION,GLEASON,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVEN,UROLOGICAL
160,222,CONSUMERS,FORCE,PREVENTIVE,PSA
169,COPYRIGHT,COX,EPCAM,INC,NON
169,945,ALA,BASED,COPYRIGHT,DHA,EPA,LINOLENIC,LTD
100,169,226,5MG,COPYRIGHT,EBL,LOD,PBS,POC,PSA,RIU,THESE
223,ADVANTAGE,EIGHT,EVALUATION,EVITA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SLE
001,003,004,036,042,833,BACKGROUND,CIS,JANUARY,LABEL,MATERIALS,METHODS,RESULTS,RRS,SUMMARY
005,100,169,AUNPS,BASED,COPYRIGHT,EPADS,GOX,PSA,PWE,TMB
001,008,012,017,ALP,AMONG,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
160,200,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SVN
13C,169,COPYRIGHT,DTG,ESR,H3L,H874Y,MOLECULAR,NMR,TGA,VIS
740,99M,ANN,AREAS,ARTIFICIAL,AUC,BSI,HOWEVER,LABEL,MBQ,METHODS,OBJECTIVE,OBJECTIVES,PIXON,RESULTS,WHOLE
EXPRESSION,MLC,THESE,VEGFR
100,169,176,1NM,200NM,956,AFTER,COPYRIGHT,ESI
182,780,945,946,ARS,DBP,ERS,ICI,LNCAP,MTT,PCR,TGF,THESE
135,294,947,AFRICAN,COMBINING,EXAMINING,MEN,PCR,PRESS,PSA,PUBLISHED,UNIVERSITY
001,007,177,236,668,8NG,ABOUT,DRE,GROUP,PSA
145,CAHPV,HEPATOCYTE,HGF,HOWEVER,PZHPV,THESE,TIGHT,TJS,WPE
ATP6AP2,ATPASES,CL1,DSRED,EXPRESS,LNCAP,PCR,PIGMENT,PROTEIN,THESE
CLINICIANS,III,LARGE,SUPPLEMENT,VITAMIN
DEVELOPING,FIRST,GROUP,NOW,PCWG2,THIRD,WORKING
ADDITIONAL,ASSAY,CELLSEARCH,CTC,FDA,III,VERIDEX
223,ALPHARADIN,IIA,III
223,AFTER,III,PHASE,THERE
169,194,BACKGROUND,BLADDER,CIS,CONCLUSION,COPYRIGHT,COX,HAMPSHIRE,INC,JANUARY,LABEL,METHODS,ORS,PATHOLOGY,RESULTS,SIMILARLY,SOCIETY,STATE,TNM,UROLOGICAL,WORLD
AMP,MCF,OLEANOLIC,TARGETING
017,370,371,427NG,725,AUA,BMI,BPH,FURTHER,LABEL,MATERIALS,MEDICAL,METHODS,OBESITY,OBJECTIVE,PAULO,PURPOSE,RESULTS,SAO,UNIVERSITY,UROLOGICAL,VARIABLES
227,AUC,BRIER,GLEASON,LABEL,LOESS,MATERIALS,METHODS,NOMOGRAMS,OBJECTIVE,OCD,PAULO,PSA,RESULTS,ROC,SVI,UNIVERSITY,USP,VARIABLES
167,CONCLUSION,FIFTY,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,PSA,RESULTS,RPS,T1C,T2A,THEREFORE
236,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THREE
483,CONCLUSION,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RECURRENCE,RESULTS,THERE
169,COPYRIGHT,INC,OLDER,STUDIES
AGA,CAG,GGN,PFS
341,945,DESPITE,IKB,LNCAP,LOW,PC3,THEREFORE,TSA,VELCADE,WESTERN,WST
169,BACKGROUND,ELISA,GCNT1,INC,LABEL,LEWIS,METHODS,PAP,PCR,PROTEIN,PSA,RESULTS,WILEY
169,BACKGROUND,BPH,CAP,COMPLEX,DETECTION,EARLY,FURTHER,HGPIN,INC,LABEL,LGPIN,METHODS,PIN,PSA,RESULTS,TELOMERASE,WILEY
946,CHINA,MENELLA,NOESY,SEA,SOUTH
145,169,BACKGROUND,BAD,BAX,CONCLUSION,COPYRIGHT,IHC,INC,LABEL,METHODS,PCR,REDUCTION,RESULTS,WESTERN
169,COPYRIGHT,DOCETAXEL,LTD,NOVEL,SEVERAL
169,847,ALPHA,COLORECTAL,FINLAND,LEUKOCYTE,ORS,OVARIAN,PREVENTION,SCREENING,TOCOPHEROL,TRIAL,WOMEN
169,CDR,IAD,PSA
169,COPYRIGHT,DESPITE,DOCETAXEL,DTX,PC3,THESE
169,CONFERENCE,COPYRIGHT,NETWORK
169,CARROLL,CONFERENCE,COPYRIGHT,DETECTION,EARLY,FEW,GUIDELINES,NETWORK,PETER,PSA,VICKERS
100,145,945,BACKGROUND,CELLS,CHANGES,CURRENT,HIF,LABEL,LNCAP,METHODS,PCR,RESULTS,SCR,SRF,STAT3,TARGETING,THREE
ACUTE,ADVERSE,BACKGROUND,BLADDER,CTCAE,LABEL,METHODS,OABSS,OBJECTIVE,OVERACTIVE,RESULTS,SCORE,SYMPTOM,V20
169,COPYRIGHT,INC,MRI,XGP
042,AUC,GLEASON,PCA,PHI,PSA
III,PHASE
030,160,164,169,177,956,COMPOUNDS,COPYRIGHT,FINALLY,HEPG2,MCF,NMR,SAS,THREE
169,COPYRIGHT,ULTRASOUND
000,017,018,116,119,177,181,235,431,665,705,881,BACKGROUND,BASEL,BLOOD,FURTHER,LABEL,MATERIALS,METHODS,RADICAL,RESULTS,RRP,TEA
169,BACKGROUND,BASEL,CDK,DU145,LABEL,METHODS,OBJECTIVE,RESULTS
AZA,CLASSIC,DDS,DECITABINE,DU145,EMHVS,EPIGENETIC,ERYTHRO,LNCAP,MAGNETO,THESE,VIROSOMES
066,074,177,215,284,315,517,867,914,ADC,BPH,CONCLUSION,DWI,LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS,THEIR
CONCLUSION,DETECTION,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,SERUM,USING
044,120,125,142,164,195,210,230,245,264,400,402,550,BLADDER,BNP,CONCLUSION,JANUARY,LABEL,LRP,METHODS,OBJECTIVE,RESULTS,THERE
AKT,GAC,THEREFORE
007,088,BPH,GLEASON,HOWEVER,PCA,PIN,PSA,SERUM
120,1A1,BPH,COMPARING,CYTOCHROME,GIVEN,GLEASON,PCA,PCR,REGARDING
169,740,LABEL,LNCAP,METHODS,OBJECTIVE,PAI,PC3,PURPOSE,RESULTS
036,169,947,ELISPOT,IFN,LABEL,METHODS,OBJECTIVE,PAP,PSA,PURPOSE,REPETITIVE,RESULTS,SIX,SIXTEEN,TH1
116,131,169,286,309,453,643,644,683,704,749,961,980,ADC,ADCMEAN,AREAS,AUC,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,UNIVARIATE,VOLUMEADC
822,ALZHEIMER,ROC,RWRLNCD
945,CHALLENGES,DIETARY,HOWEVER,THEREFORE,THESE
002,150,250,AES,NINTEDANIB,PSA
100,181,ANNEXIN,BHQ,BIFONAZOLE,CONVERSELY,GF109203X,INHIBITION,PC3
160,169,956,AMONG,AMPICILLIN,COPYRIGHT,DU145,HOWEVER,NMR,SAS,SKOV3
293,945,AFTER,ANNEXIN,E1A,LNCAP,NOVEL,PPT
FIRST,NOTABLY,THESE,THROUGH,USING,WAVE2
ANIMALS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROS,THERE,TOXICOLOGY
145,428,APC,STUDIES
001,1000S,169,177,300,4NG,600,ADC,ALTOGETHER,CONCLUSION,COPYRIGHT,DKI,GLEASON,INC,KAX,KMEAN,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,ROI,THERE
177,CASODEX,COMPOSITE,INDEX,QOL,TOTAL,ZOLADEX
BACKGROUND,INSTITUTE,LABEL,LOGISTICAL,METHODS,NAVIGATION,PATIENT,PROGRAM,RESULTS,SCALE
169,INSTITUTE,NUTRITION,SOCIETY,THERE,WORLD
CPG,CURRENTLY,EARLY,FDA,PSA
DTC,ERK
129,135,176,188,945,AFRICAN,AMERICANS,BACKGROUND,C18,CAP,CAUCASIAN,CONCLUSION,DHT,FINALLY,LABEL,LNCAP,METHODS,QTRAP,RESULTS,SAMPLES,SCIEX,UNLABELLED
008,013,031,035,BACKGROUND,CHI,GLEASON,HOXD3,LABEL,MAY,METHODS,MOLECULAR,OCTOBER,PCR,PMR,RESULTS
169,ADP,ATR,AZD7762,BRCA1,COPYRIGHT,DDR,MICROARRAY,MYB,PCA,SCIENCE
ACCORDING,EPIGENETIC,MEANWHILE
145,HOWEVER,NOTABLY,PC3,THESE
001,006,169,277,AFRICAN,AOR,CAP,COPYRIGHT,END,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PROGRAM,RESULTS,THERE
169,AMERICANS,BACKGROUND,BLADDER,COPYRIGHT,HOWEVER,INC,KINCAID,LABEL,METHODS,PATHOLOGY,REPORTS,RESULTS
114,16063,MICRORNAS,THESE
SEVERAL,SHORT,THESE
BESIDES,LNCAP,PCA,PSA
139,404,945,BPH,CONCLUSION,HOWEVER,LABEL,METHODS,MYC,NANOG,OBJECTIVE,OCT4A,PCA,PCR,RESULTS
180,ADVERSE,HOWEVER,LABEL,MEN,METHODS,RAD,RESULTS,UNLABELLED
AGAINST,AUA,FORCE,HOWEVER,OPTIMIZING,PREVENTIVE,PSA,UROLOGICAL,WHILE
947,AKT,THROUGH
177,246,AT1,HOWEVER,R3327
001,169,264,286,BACKGROUND,CONCLUSION,CRP,INC,LABEL,METHODS,PHYSICIANS,RESULTS,SNP,WILEY
160,CONVERSELY,FOXA1,IHC,KDM5B,LNCAP,NOVEL
000,029,169,446,454,CONCLUSION,COPYRIGHT,COSTS,FEE,FFS,HMO,HODGKIN,IMAGING,LABEL,MATERIALS,METHODS,MRI,NETWORK,NHL,OBJECTIVE,PET,PURPOSE,RATES,RESULTS,SOCIETY,THERE
152,509,ARN,BASED,CYP17
001,003,006,008,296,599,653,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIOR,RESULTS,ROI,SEVEN,SHEAR,SWE
AKT,BCL,BECAUSE,ERK,HUMIF,INFECTIONS,MIF,TVMIF
169,823,CONTROL,CTBP1,ENRICHMENT,HENCE,HFD,LABEL,METABOLIC,METHODS,NAD,OBJECTIVE,PC3,PURPOSE,RESULTS,SET
169,441,504,BACKGROUND,CONVERSELY,END,LABEL,MEN,METHODS,PROGRAM,RESULTS,SIR,SIRBLADDER,SIRRECTAL,SOCIETY,THERE
169,241,243,CIRUJANOS,COPYRIGHT,IMAGING,INDICATION,PUBLISHED,RESONANCE
160,947,AKT,CXCR4,HOWEVER,OVERALL,PCA,RSG,THEREFORE
160,945,946,D50,FORMULA,LEM,SEVERAL,TCP,THEIR,TPS
00016,023,025,155,169,436,901,ACL,CASES,COPYRIGHT,GLEASON,HGPIN,IDC,INC,USING
2B4,BAL,CONCLUSION,EIGHT,LABEL,LASS2,LYMPH,METHODS,MMP,MTT,NUCLEAR,OBJECTIVE,RESULTS,SILENCING,TMSG1
022,029,118,ERG,GLEASON,LABEL,METHODS,OBJECTIVE,PROSTATIC,RESULTS
360,HOPKINS,JOHNS,LIBRARY,MTS,PC3,SCREENING,VALIDATION
BASED,DONOR
HOWEVER,PRIMARILY,THEREFORE
044,075,215,529,611,685,756,762,893,ADC,AUC,CONCLUSION,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,PARAMETRIC,PET,PETMR,PURPOSE,RESULTS,ROC,SUV,WHILE
HEAVY,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,URINARY
HOWEVER,IATROGENIC,LABEL,OBJECTIVE,PURPOSE,RESULTS,RUF,SUMMARY
001,002,125,160,168,251,BACKGROUND,COMPETING,CSM,CUMULATIVE,GLEASON,INITIAL,LABEL,METHODS,NETWORK,PROPENSITY,PSA,RESULTS,T3A,THERE,THEREAFTER
001,002,003,008,154,703,BACKGROUND,BCR,BMI,COX,GLEASON,GREATER,ITV,LABEL,METHODS,PCA,PSA,RESULTS
AUC,DOR,MRI,PET,PUBLISHED,SIXTEEN,SPECT,SUMMARY
DEVELOPING,DISEASE,GENERAL,HRQOL,QUALITY,SEVERAL
169,255,863,866,ACT,ADT,AFTER,COPYRIGHT,END,INC,LABEL,MASTERFILE,MATERIALS,MEDICAL,METHODS,NON,OBJECTIVE,OBJECTIVES,OVERALL,PHYSICIAN,RESULTS
169,HOWEVER
100,169,AAS,C18,COPYRIGHT,LOQ,SPE,TURBOFLOW
001,169,AIM,ASSESSMENT,AUC,BACKGROUND,CONCLUSION,CONVERGENT,EHS,GAQ,HOWEVER,INDEX,JANUARY,LABEL,METHODS,NPS,NUMERIC,OBJECTIVE,OUTCOME,RESULTS,ROC,SCALE,SCORE,SOCIETY
HOWEVER,HUGGINS
HOWEVER
MRI,PSA,THEREFORE
3R2IIIB,EXPRESSION,FGFR2,FGFR2IIIB,FIBROBLAST,INDUCED,MTT,THESE,VIABILITY
108,169,CAF,COPYRIGHT,FEDERATION,FURTHER,NCF,PUBLISHED,SOCIETIES,THESE,WNT
BACKGROUND,BPH,CPG,EXTRACTED,GENOMIC,GLEASON,GSTP1,LABEL,METHODS,PCA,PCR,PSA,RESULTS,ROC,WESTERN
223,HEMATURIA
EARLY,MOLECULAR,SEVERAL,THEREFORE,URINE
014,021,040,053,337,419,717,763,794,913,C609T,CAUCASIANS,FURTHER,HOWEVER,LIBRARY,PUBLISHED,STATA
169,AKT,BAX,DEPLETION,LABEL,THESE,UNLABELLED
001,004,014,017,042,160,629,870,941,LABEL,MEDLINE,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,TERMS,USA
PSA
109,ADT,BACKGROUND,BETWEEN,CONCLUSION,CTV,GRADE,HDR,LABEL,MAXIMAL,METHODS,NETWORK,OBJECTIVE,OSAKA,PTV,PURPOSE,RESULTS
THESE
169,COMBINING,COPYRIGHT,FFF,FORTY,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS,SECONDARY,THERE
169,ARRB1,AUTHORS,HIF1A,HYPOXIA,PUBLISHED
169,FOLLOWING,HOWEVER,PRESS,PUBLISHED,SIX,THERE,UNIVERSITY
169,464,70807,BACKGROUND,CALGB,CONCLUSION,COPYRIGHT,HOWEVER,III,INC,LABEL,MEN,METHODS,PSA,SECONDARY
182,250,765,780,946,HMGA1,ICI,THESE
THEREFORE
ADT,HOWEVER
112,169,175,464,530,639,AIM,CAT,FEW,LABEL,LTD,METHODS,OBJECTIVE,PTY,PUBLISHING,RESULTS,THERE,WILEY,WOMEN
100,AFRICAN
169,AKT,COPYRIGHT,INC,KIT,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PC3,RESULTS,WESTERN
168,169,177,COPYRIGHT,DFO,HCC,HEP3B,HEPG2,IMAGING,LTD,PC3,PET
949,BLACK,CARLO,FINALLY,FORMULA,MONTE
169,945,AIM,BACKGROUND,DESPITE,DHT,LABEL,LITERATURE,MEDICAL,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,THREE
169,COPYRIGHT,LTD,PCAT1,PUBLISHED,SEVERAL
00037,116,169,183,202,223,233,307,614,921,945,BACKGROUND,BAYER,BETWEEN,COPYRIGHT,FEB,FUNDING,HEALTHCARE,LABEL,LTD,METHODS,RESULTS
169,COPYRIGHT,PUBLISHED,UROLOGY
001,003,005,167,169,198,288,395,441,732,ASSESSMENT,BACKGROUND,COPYRIGHT,COX,FURTHER,GENOMIC,GLEASON,GPS,LABEL,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,PUBLISHED,RESULTS,SCORE,SETTING,SUMMARY,UNASSIGNED,UROLOGY
169,185,CCL,COPYRIGHT,DU145,HTB,LTD,MBC,PROMISING,SHARPLESS
169,COPYRIGHT,CTBP2,GLEASON,HOWEVER,HSPC111,MYC,PC3,PSA,TAKEN

002,006,008,176,204,929,935,938,940,941,943,975,978,980,BACKGROUND,COLORECTAL,CONFIDENCE,LABEL,METHODS,RATIO,RESULTS,THESE
169,368,889,CLUSTERING,CRMP5,IGG,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIGNATURE
169,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,CTV,INTRA,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PLANS,PURPOSE,RESULTS,SCANNED
169,176,177,1CM,377,COPYRIGHT,INC,MEDICAL,POTENTIAL,PUBLISHED,USING,VARIATIONS
169,174,945,AUTHORS,COPYRIGHT,HSPG2,MMP,OTHER,PCA,PUBLISHED,TRANSWELL,WHILE
001,006,009,041,124,129,795,946,AMACR,COA,COMMITTEE,DSS,ENDOGENOUS,GIVEN,HONE1,III,JOINT,NPC,PCR,THOSE,THROUGH,WESTERN
BMJ,CIS,COX,GROUP,HRS,INDEX,INDUSTRIAL,LABEL,LIMITED,METHODS,MINNESOTA,MORTALITY,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS,SIMILARLY,WISCONSIN
LOH,OTHER,PIN,PSA,TRT
107,256,G7MINIGP4,GLEASON,GP4,GS6,GS7,GS7MINIGP4,HOWEVER,PATHOLOGY,SOCIETY,TEN,UROLOGICAL
005,169,ANTIBODIES,CSF,ELISA,HASHIMOTO,NOTABLY,TGABS,USING
169,213,215,3KB,BONFERRONI,CONSORTIUM,POPULATION,PRESS,PUBLISHED,SNP,UNIVERSITY,USING
053,101,169,183,393,396,399,400,799,BACKGROUND,BRISTOL,COPYRIGHT,EASTERN,FEB,FUNDING,GROUP,HOWEVER,IPILIMUMAB,LABEL,LTD,MAY,METHODS,MYERS,NON,RESULTS
169,511,AKT,COPYRIGHT,DU145,IRELAND,LTD,NOTABLY,PC3,THESE,USING
169,185,BACKGROUND,CASES,COPYRIGHT,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,RESULTS,THERE
169,COPYRIGHT,LABEL,LPC,LTD,MEN,METHODS,OBJECTIVE,RADICAL,REGULARLY,RESULTS,TREATMENT,WILEY
PCA,PSA
017,033,250,BCR,GLEASON,GROUP,NVB,PSM,THERE
PCA,THESE
COMMERCIAL,HOPKINS,JANUARY,JHH,JOHNS,MARCH,MARKETSCAN,POPULATION,REUTERS,THOMSON
169,ACT,AFFORDABLE,COPYRIGHT,INC,PATIENT,PCA,PHYSICIANS,PROTECTION,UNIVERSAL
947,HHD,HLA,HSPCS,NOD,NSG,USING
ADT,DEPRESSION,EORTC,LABEL,LOM,METHODS,OBJECTIVE,OBJECTIVES,PCA,QLQ,RADAR,RESULTS,SCORE,SYMPTOM,URINARY,UROLOGICAL
169,BECAUSE,DRUGS,OPTIMAL,SOCIETY,USA
169,946,APC,AXIN1,BIOLOGISTS,CK1,COMPANY,DU145,EMT,FRAT1,HOWEVER,LTD,NDRG1,PUBLISHED,SER33,TGF,THR41,WNT
169,INC,PROSTATIC,SOCIETY
169,BIOLOGY,FINALLY,INC,MOLECULAR,SOCIETY
231,234,AMONG,B02,DEBIO0719,EGF,ELISA,HOWEVER,KI16425,LPA,MCF,MDA,PC3,THEREFORE
001,005,724,802,887,967,ATP,BMI,HDL,III,LABEL,METHODS,OBJECTIVE,RESULTS,SIX
GLEASON,THREE
AFTER,AMONG,CAH,EXPOSURES,HOWEVER,IMPORTANCE,INPATIENT,LABEL,METHODS,NATIONWIDE,OBJECTIVE,RELEVANCE,RESULTS,SETTING,THERE,THESE
169,BRITAIN,COPYRIGHT,DEPLETION,GREAT,IRELAND,LTD,PCR,PIN,PUBLISHED,SOCIETY,TAKEN,THESE,WILEY
105,169,247,269,659,668,727,777,782,793,796,869,880,921,BIOLOGY,INC,MOLECULAR,PKC,PRKCE,SER,SOCIETY,SP1,STAT1
169,392,451,946,ADT,CYP24A1,ECTOPIC,HIC,LABEL,LNCAP,SIMILARLY,TGF,THEREFORE,UNLABELLED,VDR
169,945,CAB,SOCIETY
329,AFTER,ANXIETY,C30,DEPRESSION,EORTC,FATIGUE,HOWEVER,INVENTORY,LABEL,METHODS,OBJECTIVE,PURPOSE,QLQ,RADICAL,RESULTS,SCALE
001,169,518,APART,AUTHORS,BJU,CONCLUSION,GLEASON,INCIDENCES,JANUARY,LABEL,METASTASIS,METHODS,OBJECTIVE,OVERALL,RCP,RESULTS,TNM
PCA,PSA,WESTERN
001,010,177,HRS,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THEREFORE
001,004,007,009,169,262,AMICO,AUTHORS,BJU,CONCLUSION,LABEL,MAY,MELBOURNE,METHODS,NEITHER,OBJECTIVE,OLDER,PSA,RESULTS,ROCCO,SEPTEMBER,THERE
017,169,230,234,584,633,696,784,HOWEVER,LABEL,MARCH,METHODS,OBESITY,OBJECTIVE,OBJECTIVES,RESULTS,SEPTEMBER,THERE,UROLOGICAL
001,169,207,209,269,AUSTRALIAN,AUTHORS,BJU,CLAVIEN,CONCLUSION,DESPITE,FELLOWSHIP,LABEL,LRP,METHODS,OBJECTIVE,OPERATIVE,OVERALL,RESULTS,THERE
AMERICANS,CALIFORNIA,DETROIT,END,HISPANICS,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,POPULATION,PROGRAM,RESULTS
169,909,BACKGROUND,COPYRIGHT,ESTIMATES,LABEL,LTD,MEIER,METHODS,RESULTS
169,AFTER,THERE,UROLOGICAL
563,BACKGROUND,CHF,INSTITUTE,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,TREATMENT
140,169,553,AMONG,BACKGROUND,END,LABEL,MEN,METHODS,PROPENSITY,RESULTS,SOCIETY
ADT,DESPITE,PSA
DEPENDING,METASTASES,RESECTION,THERE,UROLOGICAL
001,169,232,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,RESULTS
160,169,789,796,831,862,869,876,882,885,ASSESSMENT,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS
195,CAG,CONCLUSION,ETS,INC,LABEL,METHODS,OBJECTIVE,PREVENTION,PUBLISHED,RESULTS,THERE,TMPRSS2,TRIAL
001,003,313,530,704,AMONG,BACKGROUND,CONSORTIUM,COX,HRHIGHEST,HRS,IGF,INSTITUTE,LABEL,METHODS,PCA,RESULTS,SNP,SSTR2
169,969,EPA,GLEASON,HOWEVER,RBC,THESE
916,946,BACKGROUND,BINDING,CONCLUSION,CONSISTENT,ECTOPIC,HNRNPA2B1,LABEL,METHODS,NUCLEAR,PCA,RESULTS,RGG,UTR
587,BACKGROUND,CETUXIMAB,DIFFERENT,HNSCC,LABEL,METHODS,PKI,RESULTS,TREATMENT
169,CENPF,COPYRIGHT,CROSS,FOXM1,INC
120,145,183,197,24H2O,335,894,CUTLM,LNCAP,RAMAN,SEVERAL
2ND,9TH,BLADDER,CYSTECTOMY,HOWEVER
125,OVERALL,PERMANENT
ANTIGEN,DIFFERENT,PSA,THERE
526,AUSTRALIA,AUSTRALIAN,LABEL,METHODS,OBJECTIVE,PERTH,PURPOSE,RESULTS,WESTERN
169,967,ACCORDING,ANOVA,BPX,CONCLUSION,COPYRIGHT,GLEASON,LABEL,MEANS,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,PURPOSE,RESULTS,SAS
169,941,CONCLUSION,COPYRIGHT,IHT,LABEL,LEVEL,METHODS,OBJECTIVE,PROOF,PSA,RESULTS,SAS,UROLOGY
169,AMICO,ANTIGEN,CONCLUSION,COPYRIGHT,HOWEVER,LABEL,LITERATURE,METHODS,MRI,OBJECTIVE,PSA,PSM,QUALITY,RESULTS,SALVAGE,SAS
046,141,169,ADJUVANTS,CARIBBEAN,CONCLUSION,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,ROC,SAS
000,100,124,145,160,169,188,206,ASR,AUTHORS,DESPITE,LTD,NCR,POPULATION,RATES,SIMILARLY,STATE,SUDAN,WILEY,WORLD
CTC
FAVOURABLE,GLEASON,LOW,PSA,SCORE
223,ADT,ANOTHER,BMD,DESPITE,FINALLY
AMONG,CURRENT,HOWEVER,RADICAL
169,ASP,EDMAN,GLN,ILE,LITORIA,LYS,MET,PHE,PHT,PRO,TRP,TYR,WILEY
169,BELGIUM,COMPLETED,COPYRIGHT,EORTC,HRQOL,III,ITALY,KINGDOM,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,TREATMENT
001,101,158,3845G,ADENINE,BACKGROUND,CAG,GLEASON,GUANINE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRE,PSA,RESULTS
BACKGROUND,CONCLUSION,ENGLAND,HOWEVER,LABEL,METHODS,NHS,PSA,RESULTS,THERE
001,361,387,AARAU,CHISM,CONCLUSION,CONVERSELY,DEPARTMENT,HAROW,KSA,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RADIATION,RESULTS,UROLOGY
000,001,008,100,102,131,182,424,799,BACKGROUND,CALIFORNIA,DECREASED,HIV,JANUARY,LABEL,METHODS,PERMANENTE,POISSON,PSA,RESULTS
100,169,JAPAN,PRESS,PTV,PUBLISHED,RADIATION,SET,SOCIETY,THESE,UNIVERSITY,WHILE
177,AMONG,GLEASON,PERINEURAL,PSA
AREAS,BACKGROUND,COVERED,FDA,HOWEVER,LABEL,METHODS,OPINION,PCA
29A,29S,947,DU145,LAMC1,LUCIFERASE,PC3,PCA,SILENCING
177,400,611,ACHIEVA,ANNEXIN,ION,LNCAP,MHZ,MRI,NMR,PHILIPS,RHODAMINE
INTERPLAY
169,BACKGROUND,ENOLASE,EXPRESSION,HAUSP,HOWEVER,INC,LABEL,LNCAP,METHODS,NED,NSE,PARACRINE,RE1,RESULTS,THESE,WILEY
169,380,435,570,653,781,814,AFTER,CONCLUSION,FOM,IMAGING,INC,LABEL,METHODS,MOLECULAR,NAF,NUCLEAR,ONCOLOGIC,OVERALL,PET,POM,RESULTS,SOCIETY,UNLABELLED
100,BACKGROUND,CHRONIC,GROUP,INDEX,LABEL,METHODS,NIH,OVERALL,RESULTS,SYMPTOM
161,322,AMONG,BACKGROUND,CAPSURE,INGENIX,LABEL,METHODS,MRI,RESULTS,SINCE,STRATEGIC,THERE,THESE
146,232,336,781,782,CAUCASIAN,CIS,CONNECT,CURRENT,DIETARY,FURTHER,MEDLINE,OCTOBER,ORS,REMOVAL,THERE,THESE
169,AUC,BACKGROUND,CONCLUSION,DCE,DWI,FOUNDATION,IMAGING,INTER,IRB,LABEL,METHODS,NPV,OBJECTIVE,OBSERVERS,PPV,PSA,PURPOSE,RADIOLOGY,REPORTING,RESULTS,ROC,SOCIETY,T2W,THREE,UROGENITAL
160,169,ACADEMY,BACKGROUND,CONCLUSION,CONTEXT,COPYRIGHT,COX,END,HOSPICE,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PALLIATIVE,PUBLISHED,RANDOMIZED,RESULTS
001,044,AMICO,BETWEEN,DESPITE,DIEGO,FUNCTIONAL,GLEASON,GROUP,HEALTHCARE,INSTRUCTOR,INVENTORY,KRUSKAL,LABEL,MEN,METHODS,OBJECTIVE,OCTOBER,PATIENT,PEARSON,PHASE,PROCTORED,PURPOSE,RALPS,RESULTS,SAN,WHITNEY
CURRENT,EARLY,FIRSTLY,USA
THESE
ADT,HOWEVER

000,200,214,220,494,700,ALZHEIMER,AMERICANS,AVERAGE,BETWEEN,TODAY,TOTAL
CD117,DOG,EGIST,IMAGING
169,BECAUSE,EXPRESSION,GENOMIC,HOWEVER,LYN,SRC
017,028,288,592,634,880,AMICO,ASIAN,BCR,BMI,COX,GLEASON,LABEL,METHODS,OBESE,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,THESE
ADP,BESIDES,CISPLATIN,CUSN2,FURTHER,HEPG2,MCF,MTT,TRP
THERE,THESE
CONCLUSION,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RESULTS,T2A,VARIATION
003,281,395,OVERALL,SMOKERS
000,001,003,169,AFRICAN,BACKGROUND,DECISIONAL,DECREASED,FEW,FURTHER,LABEL,METHODS,PERCEIVED,RESULTS,SCALE,SOCIETY
169,AUTHORS,COLLEGE,HOWEVER,JOURNAL,PHYSICIANS,POPULATION,PSA,ROYAL
169,COPYRIGHT,MODEL,THESE
160,169,218,AUTHORS,DU145,LASP1,LIM,LTD,LUCIFERASE,PC3,PCA,PTY,PUBLISHING,SCIENCE,SH3,WILEY
003,006,042,046,048,749,AMONG,BEIJING,CHINA,CHINESE,CONCLUSION,EUROPEANS,HAN,HRM,LABEL,METHODS,OBJECTIVE,ORDOMINANT,PCA,RESULTS,SIX,TIANJIN
100,ALTOGETHER,CHINESE,EASTERN,ERG,GLEASON,NEITHER,PSA,THERE,TMPRSS2,TNM,WHILE
103,128,149,151,209,4NG,AMONG,DRE,EIGHT,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
144,169,COLLEGE,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS
145,169,176,AMONG,COPYRIGHT,DNASE,HEPG2,INC,MCF,PUMPKIN,RNASE,SECONDARY,THESE
138,169,176,314,8A6,945,BACKGROUND,COPYRIGHT,INC,LABEL,MAGPLEX,METHODS,MFI,PCA,PSA,RESULTS,SERUM
169,AUGER,CARLO,COPYRIGHT,LTD,MB231,MCNPX,MDA,MONTE,PC3
169,CALCIUM,CLINICALLY,COPYRIGHT,HOWEVER,INC
177,AFTER,BACKGROUND,CONCLUSION,GIVEN,HAART,HIV,LABEL,METHODS,NON,RESULTS,THERE,VIRUS
169,AFTER,AMONG,BASED,CHOLINE,COPYRIGHT,FDG,IRELAND,LTD,PET,PSA
111,160,169,239,649,891,AMICO,COPYRIGHT,EDUCATION,GLEASON,HRS,INC,LABEL,MATERIALS,MEIER,METHODS,MINIMUM,NADIR,OBJECTIVE,PHOENIX,PHREG,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,VARIABLES
160,169,321,COPYRIGHT,EDUCATION,INC,LABEL,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS,SWEDISH,UROLOGICAL
EGF,EGFRS,HOWEVER,NUCLEAR,REGARDING,THEREFORE
ADT,CERTAIN,GLEASON,GROUP,HOWEVER,III,INSTITUTE,PSA,SOUTHWEST
CLINICALLY,HOWEVER,MYC,ONGOING,THESE
GUIDELINES,PANEL
BPH,DU145,LNCAP,PC3,PCA,THESE
001,CHEMICALLY,HOWEVER,PC3,THEREFORE
054,169,680,AMONG,BACKGROUND,LABEL,METHODS,RESULTS
169,COMPLEX,COPYRIGHT,LTD
169,BACKGROUND,CONCLUSION,DU145,ERK,HEPACAM,HOWEVER,INC,LABEL,LNCAP,MEANWHILE,METHODS,PC3,PCR,RESULTS,THEREFORE,WESTERN,WILEY,WST
AMIDA,AUTOMATED,DYNAMIC,GLANDULAR,IMAGE,RAC,THESE
134,214,376,450,639,BMI,CIS,COX,HRS,LABEL,METHODS,OBESE,OBJECTIVE,PURPOSE,RESULTS
169,183,BPH,CAP,EXPRESSION,GEORG,HSD17B2,HSD17B3,STUTTGART,THESE
CASP3,CASP8,CCAAT,CEBPD,CLINICALLY,INCREASES,SUZ12
001,177,CL1,CTX,CXCR1,DTX,IL8,IL8RA,INVERSELY,LNCAP,METASTASES,NT3,PC3,SIMILARLY,THERE,USING
TMA
000,115,116,146,190,220,224,250,GLEASON,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS
DIFFERENT
CAP,HOWEVER,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,VARIOUS
LABEL,OBJECTIVE,PURPOSE,RESULTS,SALVAGE,STRICTURE,SUMMARY
100,102,114,169,177,402,407,422,424,548,595,604,605,666,671,698,713,ASL,COPYRIGHT,DCE,FORTY,LTD,MRI,PERFUSION,THESE,WILEY
APART,DU145,IGF1R,INSRA,INSRB,LNCAP,PC3,PCA
GIVEN,KLK,PSA
153,177,CONCLUSION,GLEASON,INDEX,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SMALL,THESE
169,COPYRIGHT,IDLES,LTD,SCREENING,THEREFORE
001,002,253,COMMITTEE,CONCLUSION,COX,CSS,GFR,GIVEN,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RFS,RNU
404,880,936,ABOUT,AMONG,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,UROLOGISTS
001,009,012,041,169,AMICO,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,SMALL,THERE,UROLOGICAL

BACKGROUND,BASED,DESPITE,DUE,HOWEVER,LABEL,OBJECTIVE,OBJECTIVES,RESULTS,TUR
246,AFTER,HODGKIN,INCREASED,LABEL,LIMITED,METHODS,OBJECTIVE,RESULTS
002,005,009,012,169,BACKGROUND,CONCLUSION,COPYRIGHT,FCH,INC,LABEL,METHODS,PET,RESULTS,ROI,SUV,THESE,VOI
001,031,049,074,075,169,289,584,703,715,784,BACKGROUND,CONCLUSION,COPYRIGHT,COX,III,INC,LABEL,LDH,MEIER,METHODS,NLR,PSA,RESULTS,SUN,THESE
017,100,109,149,169,186,200,215,232,239,298,313,322,805,824,ADT,AGE,AUTHORS,BJU,CONCLUSION,ERG,GLEASON,III,LABEL,METHODS,OBJECTIVE,OTHER,PHASE,PSA,RESULTS,THESE,TMPRSS2,TRIPTOCARE,URINARY
100,133,169,183,205,305,BACKGROUND,CONCLUSION,GEORG,LABEL,METHODS,PCA,RESULTS,STUTTGART,THEREAFTER
001,009,177,180,GLEASON,MMP,PAR,PCA,THESE
231,946,AKT,HOWEVER,MDA,PD98059,RESULTS,TGF,THESE
400,650,950,CCD,DUE,LIGHT,NIR,OPTICAL
100,160,34A,ARGONAUTE,DU145,EMT,HOWEVER,MYC,NOTABLY,TAKEN
803,CONVERSELY,H3K27,MGC
BMI,FURTHER,GLEASON,HOWEVER,PSA,SCORE
142,164,166,169,330,354,CSS,CYP19,CYP19A1,DU145,HAPLOTYPE,PC3,SNP,THESE
146,DCS,DECISIONAL,LABEL,METHODS,OBJECTIVE,OVERALL,PHYSICIANS,RESULTS,SCALE,TREATMENT
122,169,587,697,804,956,AUC,BACKGROUND,COPYRIGHT,GLEASON,LABEL,METHODS,PCA,PCR,PSA,RESULTS,ROC
169,AUTHORS,BOWEL,CTC,DOSIMETRIC,GRADE,LTD,PATIENT,QOL,THREE,V40,V65,V70,WILEY
008,166,169,967,CONCLUSION,COPYRIGHT,ENDOSCOPY,INC,LABEL,MATERIALS,METHODS,NABUREN,OBJECTIVE,PURPOSE,RESULTS,THERE
DIGITAL
231,CA2,CALCIUM,FUNCTIONAL,MCU,MDA,MICU1,THESE
169,AFTER,BACKGROUND,COPYRIGHT,END,HRS,LABEL,LTD,METHODS,RESULTS,SIMILAR,THESE
112,169,205,AUTHORS,BJU,BXT,CONCLUSION,LABEL,LDR,METHODS,OBJECTIVE,PVR,QOL,RESULTS,SCORE,SELECTION,SYMPTOM
169,557,558,561,588,689,753,AUC,BACKGROUND,CONCLUSION,ELISA,FUC,GLEASON,GSS,HPT,INC,LABEL,METHODS,PCR,PSA,RESULTS,SERUM,WESTERN,WILEY
169,AAM,AFRICAN,AGE,BACKGROUND,CONCLUSION,EAM,END,LABEL,METHODS,PSA,RESULTS,THERE,UROLOGICAL
001,215,602,645,961,ADC,GLEASON,LABEL,LCS,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,TNR
120,159,161,169,177,180,200,302,330,446,APRIL,AUTHORS,BJU,CONCLUSION,GLEASON,LABEL,LRP,METHODS,NVB,OBJECTIVE,PSA,PSM,RESULTS
169,22RV1,BACKGROUND,CDC20,COX,EP1,EP2,EP3,EP4,HOWEVER,INC,KNOCKDOWN,LABEL,LNCAP,METHODS,MTT,NDC80,PC3,PCR,RESULTS,SC51322,TREATMENT,WILEY,ZWINT
169,585,850,AUTHORS,BJU,CEE,CENTRAL,CONCLUSION,EASTERN,EAU,GLEASON,GROUP,LABEL,MATERIALS,METHODS,OBJECTIVE,PARTY,PCA,PRE,PSA,RESULTS,SEPTEMBER,THERE,THESE,UROLOGISTS,UROLOGY,WESTERN,WORKING,YOUNG
169,BASEL
169,AFTER,AUTHORS,BJU,CONCLUSION,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PSA,RESULTS
945,DU145,HIF,HOWEVER,HYPOXIA,LNCAP,PC3
246,FOX,FOXA1,LNCAP,NFI,THESE,VALIDATION
036,215,228,AFRICAN,AMONG,JAZF1,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
16GAS,656,661,CONCLUSION,DEL,GLYCINE,HAPLOTYPES,HOWEVER,INS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STRP1,TAIWANESE
DEFINITIVE,HYALURONIC
113,AIM,BLOOD,CONCLUSION,LABEL,LOWER,LYMPHOCYTE,METHODS,OBJECTIVE,RESULTS,WHOLE
700,CYP17A1,EARLY,ELM,HOWEVER,III,ORTERONEL,PC5,PHASE,TAK,TREATMENT
169,ALONGSIDE,BRCA2,HOWEVER,INHIBITION,OVERALL,PCA
100,177,609,CONCLUSION,FINALLY,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PCR,RESULTS,SONOVUE,UNDER,USING,WESTERN
FINALLY,RESISTANCE
HSP27,INCREASED,MMP,MORTALITY,PCA,THESE
960,AMONG,BASED,GLEASON,GS6,LYMPH,OLDER,PSA,REVISED
MOLECULAR,PRE
169,215,CONCLUSION,DESPITE,EIGHT,LABEL,LTD,METHODS,OBJECTIVE,PSA,RATIONALE,RESULTS,TREATMENT,WILEY
10A,10B,122,PATHOLOGY,PSA,THERE
ASSESSMENT,CTC,DETECTION,INDIVIDUAL,PROGNOSIS
100,BEAMNRC,CARLO,CTV,DOSXYZNRC,ECLIPSE,MEDICAL,MONTE,PTV,SYSTEMS,TPS
000,169,BACKGROUND,INC,LABEL,METHODS,RESULTS,USING,WILEY
169,17Q21,202,BACKGROUND,BROAD,BTB,ERG,HOPKINS,INC,JOHNS,LABEL,METHODS,N296I,POZ,PROJECT,RESULTS,SPECKLE,TAKEN,TRAMTRACK,UNIVERSITY,WILEY
EGF,EPIDERMAL,KINASES,LNCAP,REGULATED,YET
007,022,071,118,121,CONCLUSION,ERG,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,NOTABLY,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,THERE
278,CONCERNING,ENGLISH,FEW,INCLUSION,LABEL,MEDLINE,METHODS,NATURAL,NEPCS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SERUM,TERMS
113,189,AFTER,AUGMENTED,COA,HIBCH,PCR,PSA,USING
001,033,139,169,16Q21,215,946,998,BACKGROUND,COLORECTAL,CSNK2A2,HEART,INC,LABEL,METHODS,OVARIAN,RESULTS,SCREENING,SIKHS,SOUTH,TRIAL,UKCVD
169,CSC,FOLLOWING,FOXM1,JUN,MECHANISM
ACS,COX,HEENT,HOWEVER,INSURANCE,LABEL,MATERIALS,METHODS,NHI,OBJECTIVE,RESULTS
118,169,COPYRIGHT,LQB,LTD,MYC,PACLITAXEL,THESE
145,169,960,COMPOUNDS,COPYRIGHT,EXPRESSION,LTD,MATRIPTASE,THESE
169,945,COPYRIGHT,DAG,HOWEVER,LTD,PKC,RAS,THESE
169,BACKGROUND,BRASILEIRA,CO2,COPYRIGHT,EDITORA,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PET,PUBLISHED,RESULTS,ROBOTIC,SIXTEEN,SOCIEDADE,THERE
001,003,115,169,270,AFTER,COPYRIGHT,GLEASON,INC,LABEL,LOG,LOG10,MATERIALS,METHODS,NGF,OBJECTIVE,OBJECTIVES,PATHOLOGIC,PATIENT,PCA,PERINEURAL,RESULTS,TOTAL,URINARY
GIVEN,TAKEN
169,946,956,COPYRIGHT,DU145,FURTHER,MTT,SAS
2B4,946,EXPRESSING,HOWEVER,MM2,PC3,PCA,S425A,S425D,USING
169,COPYRIGHT,FINALLY,H3K4ME3,HOWEVER,INC,MLL,USING
250,BASED,CYP,III,PFS,PSA
ADIPOR1,ADIPOR2,ELISA,MTT,OBESITY,PCR
169,AFTER,BACKGROUND,CD133,CONCLUSION,COPYRIGHT,CSPCS,FINALLY,LABEL,METHODS,OVARIAN,PA1,PUBLISHED,RESULTS
160,169,COPYRIGHT,EDUCATION,FINAL,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
169,COPYRIGHT,HOWEVER,PUBLISHED,SAS
169,COPYRIGHT,LTD,PEARSON,PUBLISHED,QUALITY,THI
001,002,003,014,169,BACKGROUND,COPYRIGHT,CTV,D50,D95,D98,EUD,LABEL,LTD,MATERIALS,METHODS,OAR,PTV,PUBLISHED,RESULTS,TEN
169,COPYRIGHT,INC
MEYER,RES,THESE,WESTERN
LABEL,OBJECTIVE,PURPOSE,RESULTS,SIMILAR,SUMMARY,THERE,THESE
169,COPYRIGHT,INC,PUBLISHED,SOCIETY
APRIL,CLINICALLY,CONCLUSION,DEDICATED,GYRUS,KETTERING,LABEL,METHODS,OBJECTIVE,RESULTS,SLOAN,THERE,ULTIMATELY
169,COPYRIGHT,ESPECIALLY,FIRSTLY,HCC,INC,KNOCKDOWN,THEREFORE
215,945,946,AD5,ADENOVIRUS,PCA,RFC,RIIFC,SEVEN
744,962,APRIL,AUC,BACKGROUND,CONCLUSION,LABEL,MEDLINE,METHODS,PCA,PSA,RESULTS,SCIENCE,WEB
105,107,169,BOWEL,COMPOSITE,CONCLUSION,INDEX,ITEMS,JANUARY,LABEL,MEDICAL,METHODS,OBJECTIVE,OCTOBER,OUTCOME,PRESS,PUBLISHED,RESULTS,SCORE,SHORT,SYMPTOM,UNIVERSITY,URINARY
123,136,147,153,180,239,BACKGROUND,DXA,LABEL,METHODS,OBJECTIVE,OSTEOPENIA,PRIMARY,QUALIFIED,RESULTS
100,145,205,549,620,AMONG,CNS,FURTHER,H23,HEP,HOLARRHENA,HOWEVER,IMR,MCF,NCI,NIH,OVCAR,SRB
FAD,LNCAP,MC3T3,NAC,ROS
169,204,248,APART,BACKGROUND,HRS,LABEL,METHODS,RESULTS
480,COMPOSITE,INDEX,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS,SCALE,SPANISH,UTILITY
156,169,AUSTRALIA,CONCLUSION,COPYRIGHT,GAD,HOWEVER,LABEL,LTD,MDD,METHODS,OBJECTIVE,PCA,RESULTS,THESE,WILEY
160,177,CBDIV17,CBIDV17,CMC,CONCLUSION,IHC,LABEL,LNCAP,METHODS,OBJECTIVE,PEG,PSA,PURPOSE,RESULTS,THERE,THESE
169
152,169,761,BACKGROUND,ERG,ESO,GLEASON,INC,LABEL,METHODS,PSA,RESULTS,THERE,WILEY
003,006,008,169,667,AFRICAN,AMONG,CHICAGO,GLEASON,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERUM,THERE
169,PSA,RES,VITAMIN
140,169,BACKGROUND,GLEASON,INC,LABEL,LNCAP,METHODS,PCR,RESULTS,TUNEL,WILEY
200,API,BACKGROUND,BIOGRID,CYTOSCAPE,GUIDE,LABEL,LINUX,MODULEROLE,NON,PAJEK,PPI,RAPIDLY,UNLABELLED,USERS,WINDOWS
100,ACTIVATION,ASSESSMENT,BACKGROUND,BAP,BTM,CEDIRANIB,CTX,DOCETAXEL,FUNCTIONAL,GROUP,INTENSITY,LABEL,METHODS,PATIENT,PCWG2,PFS,PHASE,PPI,PRESENT,PRIMARY,RESULTS,SRC,THERAPY,VEGFR,WORKING
PIN,PSA
001,169,297,300,APRIL,COPYRIGHT,GLEASON,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SIR,TECHNICAL
100,169,NOTABLY,RANKL
160,947,AKT,RSG,THESE
160,169,BACKGROUND,CONCLUSION,COPYRIGHT,DOCETAXEL,III,INC,LABEL,METHODS,PSA,RESULTS,SUBSEQUENT
001,004,100,169,354,AFTER,ART,BACKGROUND,CONCLUSION,COPYRIGHT,COX,ESTIMATES,GLEASON,INC,LABEL,MEN,METHODS,MTD,PSA,RESULTS,SEPTEMBER,T1C
B23,FOS,GST,MYC,NPM,P53,THESE
169,946,COPYRIGHT,DISCOIDIN,KNOCKDOWN,MOLECULAR,PTHRP,RTK,RUNX2,TGF
169,COPYRIGHT,INC
169,ADULT,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,GRAPHICAL,HRQOL,INC,INCLUSION,LABEL,METHODS,MOSBY,PRIMARY,PROVIDERS,RAPID,RESULTS,SCALE,SUBJECTIVE,YET
INHIBITION,JUN,NOTCH,PREVIOUSLY,THESE,USING
160,169,215,945,AKT,FOXN1NU,HIF,LNCAP,LTD,MELATONIN,PUBLISHED,THESE,WILEY
000,169,200,BACKGROUND,CVD,DARLING,ENRICHMENT,FDR,GWA,HDL,HNF1B,HOWEVER,LABEL,LDL,METHODS,PCA,PRESS,PUBLISHED,RESULTS,T2D,THESE,UNIVERSITY
177,946,ARRAY,BCS1L,CONCLUSION,FATIGUE,FURTHER,INC,LABEL,METHODS,MIXED,OBJECTIVE,OBJECTIVES,PATIENT,PCR,PUBLISHED,RESULTS,RT2
169,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,PUBLISHED,RESULTS,SIMILAR,STATISTICS,THERE
001,081,LABEL,LOS,MATERIALS,METHODS,MIS,NON,OBJECTIVE,OPERATIVE,PROGRAM,QUALITY,RESULTS,USING
504,AFTER,BACKGROUND,CIS,COLORECTAL,COX,HRS,LABEL,METHODS,OVARIAN,RESULTS,SCREENING,TRIAL,USING
120,ABO,DISEASE,EMR,IKZF1,SIMILARITY,SIMILARLY,VARIMED
946,AIM,CONCLUSION,DIFFERENT,FURTHER,LABEL,LNCAP,METHODS,NH2,OBJECTIVE,PCR,RESULTS
EN2,ENGRAILED,HEK293T,HOWEVER,IHC,MAB2600,RESULTS,TAKEN
169,ACP,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MAXWELL,METHODS,MRI,NETWORK,OBJECTIVE,RESULTS,THERE
164,169,215,355,516,633,862,BACKGROUND,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SNP,STRONGEST
400,GENERALLY,PET
169,508,773,841,BIOLOGY,COPYRIGHT,FEDERATION,INC,LIBRARY,MEDLINE,PUBLISHED,RTE,ULTRASOUND,WORLD
177,178,185,BASED,DSA,EVERY,LABEL,METHODS,NRS,OBJECTIVE,RESULTS,TPS,UNDER
169,BIKDD,HOWEVER,R1881,THEREFORE,UNDER
116,184,BNSRP,OVERALL,THESE
004,169,AMICO,AUTHORS,BJU,BRCA2,CONCLUSION,CSS,GENOTYPING,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHED,RESULTS,WILEY
001,107,110,118,122,130,145,169,193,276,303,530,ART,AUTHORS,BJU,KNOWLEDGE,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PATIENT,RESULTS,RPS,THESE,TREATMENT,WILEY,WITHOUT
174,BOT,DESPITE,HT1,HT2,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,RSS
100,153,154,1CC,535,651,956,CARLO,GBQ,HDR,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,TREATMENT
029,103,177,538,ADDITIONAL,BLOCKED,CARLO,LABEL,LAR,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,TESTICULAR
125,BOYER,FOURIER,ISODOSE,LABEL,METHODS,MOK,OBJECTIVE,PURPOSE,RESULTS
RAMAN
AFTERWARD,ARB,FIBEROPTIC,ICU
225,AIM,BACKGROUND,CONCLUSION,ELISA,FURTHER,HIV,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,SEQUENCES,WATER
050,128,250,285,300,768,801,838,AFRICAN,AFTER,AMERICANS,BACKGROUND,BASED,BECAUSE,CLL,GHANA,HOPKINS,JOHNS,LABEL,METHODS,MYC,PROJECT,RESULTS,UNIVERSITY,USING
116,149,177,BPH,CRP,HCT,HGB,INR,LOX,PAI,PLT,PSA,RBC,TGB,WBC
181,AFTER,GIVEN,THESE,TUNEL
1RN,511,AMERICA,FURTHER,GASTRIC,LATIN,OTHER
169,FINALLY,FIRST,MEDICAL,PRESS,PUBLISHED,SOCIETY,THERE,THROUGH,UNIVERSITY
169,447,ADDRESSING,AUSTRALIA,CONCLUSION,COPYRIGHT,GEOGRAPHIC,LABEL,LTD,MEN,METHODS,OBJECTIVE,RESULTS,THESE,WILEY
138,199,973,CONCLUSION,LABEL,METASTATIC,METHODS,OBJECTIVE,RESULTS
ABCC1,CHROMATIN,FINALLY,INHIBITION,LNCAP,PC3,PCR,PCSCS,PROTEIN,SHRNA
410,ADT,CSS,GLEASON,HAKULINEN,HOWEVER,MEANWHILE,PFS,THEIR
169,636,AMERICANS,CHI,CIS,INTERVIEW,NATIONS,ORS,PSA,THERE,WHITE
169,40S,50S,60S,DESPITE,HOWEVER,MASCULINE,STRUCTURED,THESE
169,FINALLY,JNK,LNCAP,MDV3100,PHORBOL,PKC,PMA,SOCIETY,TAKEN,THEREFORE
169,946,BMP,CAF,ECTOPIC,FURTHER,GDF15,MIC,NOTABLY,TGF
169,COPYRIGHT,PUBLISHED
020,10878,169,BACKGROUND,CONCLUSION,COPYRIGHT,CTV,CTVRTOG,FCH,IRELAND,LABEL,LTD,MATERIALS,METHODS,PET,RESULTS,TOMOGRAPHY
169,177,246,584,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,PEG,PEG12,RESULTS,THERE
169,AMONG,COPYRIGHT,ELDERLY,END,GREATER,INC,LABEL,METHODS,OBJECTIVE,PCA,POISSON,RESULTS,SNF,THERE
169,C35,COPYRIGHT,LTD,PUBLISHED,THEIR,THESE
100,126,21OHD,230,250,254,345,664,764,945,BACKGROUND,CHRONIC,CONCLUSION,CONTEXT,CYP17A1,LABEL,MEASURE,METHODS,OBJECTIVE,OUTCOME,RESULTS,SECONDARY,SERUM,SETTING
946,BACKGROUND,CONCLUSION,DRUGS,HOWEVER,INHIBITION,LABEL,METHODS,PCR,PDGFR,RESULTS,WESTERN
177,CH3,CYS,ENGINEERED,IMAGING,KDS,PET
145,169,AKT,AUTHORS,FOUNDATION,HDAC1,IGF,INVERSELY,JOURNAL,LTD,MOLECULAR,RAPAMYCIN,STILL,VPA,WILEY
013,023,033,037,039,044,286,288,574,859,907,ACCORDING,BACKGROUND,BEIJING,BLOOD,CHINA,CHINESE,LABEL,METHODS,RESULTS,SIX,TAC,THREE,TIANJIN
160,CONVERSELY,MRI,THESE,ULTIMATELY,WHILE
002,DUE,SIEMENS
104,169,349,BECAUSE,III,PSA,TH1
215,III,KALLIKREIN,KLK3E,PSA
177,AIM,ASSESSMENT,BACKGROUND,CAPRA,CCP,COMBINING,CONCLUSION,EIGHT,GLEASON,INITIAL,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS
122,400,AIM,BACKGROUND,BETWEEN,BOLOGNA,CONCLUSION,LABEL,LRP,MARCH,METHODS,OBJECTIVE,RESULTS,UNIVERSITY,UROLOGICAL,YEARS
169,MDSCS,TAM,THESE
001,169,ERG,INC,SIXTY,SMALL,TMPRSS2,WILEY
ARTISTE,BACKGROUND,DEPENDING,DOSIMETRIC,LABEL,METHODS,PANTHER,PATIENT,PROWESS,RESULTS,SIEMENS,TREATMENT
945
001,104,144,226,BASEL,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS
945,946,BAX,BCL,CRH,CRHR1,CRHR2,CRHRS,IL1,PERIPHERAL,PREVIOUSLY,SILENCING,UROCORTIN
BACKGROUND,CLINICALLY,DESPITE,LABEL,MATERIALS,MEDLINE,METHODS,RESULTS
223,BACKGROUND,DOCETAXEL,FINALLY,III,LABEL,MATERIALS,MEDLINE,METHODS,RAPID,RESULTS
ADT,BACKGROUND,CONCLUSION,CTIBL,LABEL,MATERIALS,MEDLINE,METHODS,RESULTS
BACKGROUND,DOCETAXEL,EIGHT,FDA,FRONT,GIVEN,LABEL,MATERIALS,METHODS,RESULTS
223,BACKGROUND,CONCLUSION,CYP,FURTHER,III,LABEL,METHODS,RESULTS,THERE
223,258,ABSTRACTS,BACKGROUND,CONCLUSION,LABEL,MATERIALS,MDV3100,MEDLINE,METHODS,ONGOING,PSA,RESULTS,SINCE,SOCIETY
BACKGROUND,III,LABEL,MATERIALS,METHODS,RESULTS,WHILE
BACKGROUND,FDA,III,LABEL,MATERIALS,MECHANISMS,METHODS,OTHER,PSA,RESULTS,WHILE
99M,BACKGROUND,CONCLUSION,DUE,LABEL,MATERIALS,MEDLINE,METHODS,MRI,OSSEOUS,RESULTS
BACKGROUND,BASED,CASTRATION,HOWEVER,LABEL,MATERIALS,METHODS,PSA,RESULTS,THERE
ADT,BACKGROUND,CENTRAL,CONTROLLED,HOWEVER,HRQOL,III,LABEL,MATERIALS,MEDLINE,METHODS,PUBLISHED,RESULTS
ADT,BACKGROUND,CAD,DUE,FDA,LABEL,LITERATURE,MATERIALS,METHODS,RESULTS
ADT,BACKGROUND,FSH,LABEL,MATERIALS,METHODS,NEWER,NORTH,RESULTS,THERE
ADT,BACKGROUND,DESPITE,FURTHER,LABEL,MATERIALS,METHODS,OLDER,RESULTS,THEREFORE
223,239,BACKGROUND,JOURNAL,KEY,LABEL,MATERIALS,METHODS,NEWER,PET,RESULTS,UROLOGY,WHILE
MEDICAL
115,182,234,BACKGROUND,INTRA,LABEL,MATERIALS,METHODS,NPV,PPV,RESULTS,TUR,UNIVERSITY
140,226,402,AUA,BACKGROUND,CONCLUSION,DRE,GLEASON,GSS,LABEL,MATERIALS,METHODS,OVERALL,PSA,RESULTS,THERE,UROLOGICAL
1ST,2ND,ALBERTSEN,ALLEN,ANGER,ANN,ANTHONY,BELLA,BURNETT,CHAIR,DRS,GOMELLA,GORMLEY,HOPKINS,JACKSON,JHS,JIM,KIM,LEONARD,MARSHAL,MICHAEL,MOREY,OLIVIER,PANEL,PETER,PRESIDENT,PROGRAM,RALPH,STOLLER,USA,WYOMING
151,945,ELISA,ETP,FINALLY,HIF,PCR,SEVERAL,THEREFORE,THESE,VEGFA
169,464,945,COPYRIGHT,CYP17,CYP17A1,LTD,MES,PHASE,USING
169,AIM,BACKGROUND,CONCLUSION,CROSS,DUE,GUIDELINES,HOWEVER,LABEL,METHODS,OBJECTIVE,OLDER,OUTCOME,RESULTS,RISKS,SOCIETY
006,008,023,099,137,174,221,271,332,362,408,517,757,813,861,889,BACKGROUND,COX,GLEASON,GROUP,LABEL,LOWER,METHODS,NADIR,PRIMARY,PSA,RESULTS,URO
1ST,6TH,BACKGROUND,BECAUSE,CONCLUSION,CONTEXT,DISCUSSION,EXPRESSION,FORTY,HLA,IGG,LABEL,METHODS,MST,PHASE,PPV,RESULTS
524,663,765,AIM,LABEL,METHODS,OBJECTIVE,RESULTS
112,125,165,176,634,AMACR,AVERAGE,LOCAL,MINIMUM,RECURRENCE

169,DESPITE,EARLY,LOCATED,REALIZING,THESE
169,AMONG,ATLAS,FGFR1,GCN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCC,TKI
169,239,945,CHANGES,CONSISTENT,FRESHLY,LABEL,METHODS,OBJECTIVE,PURPOSE,REDUCTION,RESULTS
169,FINALLY,GLEASON,INHIBITION,LABEL,METHODS,MYC,NOTABLY,OBJECTIVE,PURPOSE,RESULTS,XENOGRAFT
INTENSITY
169,945,ADT,ANDROGENS,CAP,CYP17A1,DHT,EARLY,PSA,SOCIETY,SRD5A,THERE
946,ASP9521,BACKGROUND,GIVEN,HOWEVER,LABEL,METHODS,RESULTS
268,380,468,BACKGROUND,GLEASON,GROUP,HOWEVER,LABEL,METHODS,MICHINOKU,PCA,PSA,RESULTS,UROLOGICAL
282,289,744,DIAGNOSTIC,END,FACTORS,HRQOL,INTERVIEW,LABEL,MDD,METHODS,OBJECTIVE,POR,PROGRAM,PURPOSE,RESULTS,SURVIVORS,UNASSIGNED
165,182,347,MRI,RESULTS,THEREFORE
181,946,AKT,CALCULATED,CSD,EGF,EMT,EPITHELIAL,FISETIN,PCA,PLASMON,RESONANCE,SILENCING,SURFACE
002,BMI,DRE,HEALTHCARE,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SCREENING,THOSE
ADT,AREAS,BMD,COMPARISON,HOWEVER,SEVERAL
162,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,ONTARIO,RESULTS
BRIEFLY,PSA,THERE,TOTAL
169,946,COPYRIGHT,FERMENTED,FPP
169,AKT,ALTOGETHER,CONSISTENT,COPYRIGHT,ERK,PUBLISHED,TRPM7,WHEREAS
IRELAND,LTD,PUBLISHED
001,002,003,028,033,040,152,160,169,356,ACTUARIAL,BETWEEN,COPYRIGHT,COVARIATES,COX,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,NOTABLY,OBESE,OBESITY,OBJECTIVE,PREDICTORS,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
160,169,174,AMONG,COPYRIGHT,EDUCATION,IMAGING,INC,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OCTOBER,OPTIMAL,PUBLISHED,PURPOSE,REPORTING,RESULTS,TECHNIQUES,UROLOGICAL
001,160,169,452,946,AFTER,APC,CCND2,COPYRIGHT,EDUCATION,GREATER,GSTP1,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RAR,RECURRENCE,RECURRENT,RESULTS,SSBP2,STAGING,TIMP3,UROLOGICAL
045,160,169,174,ADG,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,ONTARIO,PUBLISHED,PURPOSE,RADICAL,RESULTS,UROLOGICAL
169,224,COPYRIGHT,FEDERATION,PCA,PUBLISHED,SILENCING,SOCIETIES,TPD52
169,BIOLOGICAL,COPYRIGHT,DB1,DJ1,ESI,FTL,GDP,HSP27,LABEL,PROTEOMICS,PSME1,REMARKABLY,RHO,SH3BGRL,THERE,UBE2N,UNASSIGNED,UNLABELLED
000,169,579,640,954,961,AKT,COPYRIGHT,GSK,HOWEVER,INC,INCREASED,MYC,PERINEURAL,THESE
169,945,946,AKT,AMONG,COPYRIGHT,COUMESTROL,GSK,HIF,LTD,OVERALL,PUBLISHED,ROS,SKI,SPHK1
169,177,BACKGROUND,BECAUSE,COPYRIGHT,ERK,FURTHER,GFP,INC,LABEL,LNCAP,MATERIALS,METHODS,MLK,PCR,PD98059,PSA,RESULTS,TRANSCRIPT,TREATMENT,WESTERN
169,BECAUSE,CAP,COPYRIGHT,FEDERATION,MC3T3,PUBLISHED,RUNX2,S1P,SOCIETIES,SPHK1,SPNS2,STRATEGIES
001,169,172,173,214,215,268,269,405,647,957,966,AFTER,CONCLUSION,COPYRIGHT,END,INC,INCREASING,LABEL,MATERIALS,METHODS,OBJECTIVE,QUARTILES,RESULTS
169,AMONG,COPYRIGHT,IHC,INC,MEANWHILE,THERE
001,019,035,169,173,BAF250A,CASES,COPYRIGHT,EPSTEIN,INC,OVERALL,THESE,TORONTO,VANCOUVER
169,COPYRIGHT,HOPEFULLY,LTD,SEVERAL
106,169,640,945,954,961,AIB,COPYRIGHT,COX,DAX,GSK,INC,INCREASED,MYC,NERVE,PCA,PGP,PIM,PROTEIN,SKP,SRC,SRF
114,169,226,COPYRIGHT,E318K,INC,V320I
169,491,BACKGROUND,COPYRIGHT,FUNCTIONAL,HOWEVER,INC,INSTITUTE,LABEL,METHODS,RESULTS,SIMILARLY
015,048,169,280,359,ASIAN,BACKGROUND,BESIDES,BETWEEN,CLAVIEN,CONCLUSION,COPYRIGHT,DINDO,HOWEVER,III,JANUARY,LABEL,METHODS,MINIMALLY,PUBLISHED,RADICAL,RESULTS,THERE,WESTERN
169,653,956,963,COPYRIGHT,HRP,NPS,PCA,TMB,UNDER
001,169,ACT,COMPOSITE,DIEGO,ENGLISH,FORTY,GROUP,INC,INDEX,INSTITUTE,INSURANCE,LABEL,MATERIALS,METHODS,MISSING,OBJECTIVE,OPTIMAL,PUBLISHED,PURPOSE,QOL,RADIATION,RESULTS,SAN,THERAPY,VISIONTREE
RESULTS
169,CHANGED,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SIX,SUPPORTING,WILEY
100,169,181,300,COPYRIGHT,LTD,MRE,MRI,RESULTS,WILEY
111,168,169,177,COPYRIGHT,D2B,FAB,IGG,LNCAP,LTD,MAXIMUM,PC3,WILEY
150,170,200,888,ABT,ADP,AES,BIOMARKER,GRADE,PSA,TMZ,VELIPARIB
143,145,946,SEVERAL,TGF
945,AARRR,ASP,ATP,DFG,HENCE,HOWEVER,K88,MARK4,PAR,SER,THESE,THR,WNT
128,169,AFTER,FEC,GLEASON,HENCE,LABEL,METHODS,MRI,OBJECTIVE,PET,PURPOSE,RESULTS
HDAC6,HMOX1,JQ1,KEAP1,KNOCK,ROS,SEQ,SESN3,SP1,WITHOUT
AKT,ALTOGETHER,FURTHER,STIM1
ALDH1A1,ALDH3A1,ALDH7A1,BACKGROUND,DU145,LABEL,METHODS,PCSCS,PIN,RESULTS,WHEREAS,XENOGRAFT
123,189,ERG,TMPRSS2
BACKGROUND,CONCLUSION,CSC,HOWEVER,LABEL,MATERIALS,METHODS,RESULTS
181,533,5MM,683,CONCLUSION,DAILY,HOWEVER,LABEL,LEVEL,MATERIALS,METHODS,NAL,OBJECTIVE,OFFLINE,PTV,PURPOSE,RESULTS,USING
169,MYC
448,BACKGROUND,CONTINUOUS,DEPOT,HEALTHY,KISSPEPTIN,LABEL,METHODS,OBJECTIVE,RESULTS,TAK
SLCO1B1,SLCO1B3,SLCO2B1,SLCOS,THEREFORE
174,III,PHASE
956,LAT,LEUCINE,LNCAP,QUEENSLAND,USING,XENOPUS
145,33258,BAX,BCL,HOECHST,MTT,RASD1,WESTERN
572,639,BACKGROUND,CIS,EQUOL,LABEL,MATERIALS,METHODS,NATTS,ORS,RESULTS,SERUM,SLACKIA
BACKGROUND,LABEL,MATERIALS,METHODS,RESULTS,THESE,TRACE
177,AGE,DRE,GLEASON,HBA1C,HISTOLOGIC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
956,CONVENIENT,HOWEVER,MUA,PSA,QDS,UNDER
000,100,228,425,449,488,492,515,994,998,ADDITIONAL,ADHERENCE,ANALYTICS,BACKGROUND,DATASET,LABEL,MARCH,MARKETSCAN,METHODS,MPR,OBJECTIVE,POPULATION,RESULTS,SIMILAR,SOLUTIONS,THESE
3BETA,APOPTOSIS,BAX,BCL,CASPASE,CONCLUSION,HOECHST,LABEL,METHODS,MYRRH,OBJECTIVE,PC3,RESULTS,THESE,TREATMENT,WESTERN
001,002,004,012,034,036,057,116,221,222,GLEASON,LNCAP,MICRORNAS,PC3,THESE
176,500,CONCLUSION,HOWEVER,LABEL,MAGNESIUM,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THEREFORE
464,945,CYP17,HOWEVER,III,INHIBITION,REGULATORY

FDA
ADT
ADT,AKT,CASTRATION,PCA
000,100,138,169,250,323,500,581,600,742,BACKGROUND,FIGURES,GERMANY,ITALY,LABEL,MEDICAL,METHODS,NOTABLE,PANCREATIC,POPULATION,PRESS,PROJECTED,PUBLISHED,RESULTS,SOCIETY,SPAIN,UNION,UNIVERSITY,WORLD
BET,DESPITE,ERG,JQ1,MDV3100,MEN,TAKEN,TMPRSS2
002,024,047,282,AFTER,CONCLUSION,COX,DCE,DWI,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,RESULTS,UNIVARIATE
041,117,215,ADC,AMICO,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,RESULTS,ROC,THEIR
1980S,AGE,BACKGROUND,CLAYTON,CONCLUSION,FURTHER,HOWEVER,LABEL,MARTINIQUE,METHODS,RESULTS,SCHIFFLERS,WORLD
BACKGROUND,CONCLUSION,EORTC,FIFTY,GRADE,LABEL,METHODS,PEG,RADIATION,RECTOSCOPY,RESULTS,SCALE,SEVENTY,THERE,VRS

CURRENTLY,LIBRARY,MEDLINE,MRI,PCA,PET,PSA,PUBLISHED
174,BCC,EMA,FDA,GDC,JANUARY,MEDICINES,SMO,VISMODEGIB
HODGKIN,NOTABLE,NPI,PROTEOSOME
FDA,HEREDITARY,III,KIT,MEN,MET,MTC,NSCLC,RET,THEREFORE,VEGFR
411,792,CAUCASIAN,GLU298ASP,LIBRARY,SEPTEMBER,STATA,SUMMARY
FINALLY,SHORTLY,TRANSIENT,TRP,TRPM8
157,378,681,ACG,AFRICAN,APPARENTLY,AUG,CAT,ECAC2,FIXEMER,STAJICH,TROST,TRP,TRPV5,TRPV6,VOETS,WISSENBACH
160,174,240,DEGARELIX,GONAX,III,INJECTION,JAPAN,PSA
COMPOUNDS,TOUCH
100,BACKGROUND,HOWEVER,LABEL,REGULATORY,UNASSIGNED
001,169,488,AMONG,CONCLUSION,COPYRIGHT,COSTS,END,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,STUDIES,TEXAS,THOSE
940,980,AFTER,AIM,CONCLUSION,DAILY,ENDORECTAL,LABEL,METHODS,OBJECTIVE,PTV,RESULTS,SIB
001,062,22092,26089,29233,ADDITIONAL,BACKGROUND,CEC,CEP,CHEMONAIVE,CONCLUSION,EUDRACT,HOWEVER,LABEL,METHODS,MTD,PFS,PSA,REGISTERY,RESULTS,SUNITINIB,THESE,TRIAL,UNASSIGNED
AHR,BACKGROUND,BASAL,DISTANT,DU145,LABEL,LNCAP,METHODS,PC3,PCR,RESULTS,SEVERAL
169,GRK,INHIBITION,T66,TAKEN
169,367,468,542,BIOLOGY,CYS,DU145,HOWEVER,INC,MOLECULAR,SEPHAROSE,SOCIETY,STAT3
108,242,BMI,CHINESE,LABEL,METHODS,MGB,OBJECTIVE,PCA,PROBE,RESULTS,TECHNOLOGY,UNASSIGNED,UNIVARIATE,VDR,VIRTUAL,WHILE
100,158,678,786,890,CONCLUSION,LABEL,METHODS,MRI,MTD,OBJECTIVE,PEARSON,RESULTS,THREE,TVP
ANS,CHSDA,IHS,INCIDENCE,INDIANS,LABEL,METHODS,NATIVES,OBJECTIVE,OBJECTIVES,RESULTS,SERVICE,WHITE
AFRICAN,CONFERENCE
215,HEPG2,LIVER
169,180,AIM,BACKGROUND,CER,CONCLUSION,DCE,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,PATIENT,QUALITY,RESULTS,SOCIETY,SUM,THESE
MEN,NURSE


10Q11,146,169,17Q24,19Q13,437,804,854,BACKGROUND,LABEL,METHODS,PROTECT,PSA,RESULTS,THESE
169,PC3,RAD51,RESISTANCE,TREATMENT
169,945,ACIDS,ERG,ETS,EXPRESSION,NUCLEIC,PRESS,PUBLISHED,UNIVERSITY
169,BACKGROUND,CERTAIN,COPYRIGHT,GMO,LABEL,LTD,M21,METHODS,RESULTS,WILEY
169,BIOLOGY,FK506,HOWEVER,HSP,HSP70,HSP90,INC,MOLECULAR,SMALL,SOCIETY,STEROID,TAKEN
107,169,267B1,4GLCNAC,732,737,945,946,BIOLOGY,CARROLL,F77,FUC,GCNT1,GCNT2,GCNT3,INC,LAL,LLERA,MOLECULAR,PCR,RWPE1,SCI,SOCIETY,THESE,ZHANG
169,BIOLOGY,F77,INC,MOLECULAR,MONOCLONAL,PC3,SOCIETY
DESPITE,LABEL,METHODS,OBJECTIVE,PARTNER,PURPOSE,RESULTS,SEPTEMBER,STUDIES,SURVIVORS
169,946,AFRICAN,AMERICANS,CAP,CAUCASIAN,CAUCASIANS,DOCK1,EMPLOYING,EPIGENETIC,HOWEVER,RAC,ROBO1,SH2,SH3,USING,WHILE
SIGNALING
001,116,181,397,415,437,945,CONIFER,GREEK,HONEY,MCF,TNF
995,CTC,FIFTY,POWER
001,002,967,ANY,CONCLUSION,IMPAIRMENT,LABEL,MEASURE,METHODS,OBJECTIVE,RESULTS,SCALE,TOKUHASHI
COMPOSITE,CONSENSUS,GLEASON,GROUP,PSA,RCT,THESE
169,47D,COPYRIGHT,EAC,EHRLICH,GSH,HEP,HEPG2,IRELAND,LTD,MCF,PC3,SUNITINIB,SWISS,TAKEN,THESE
169,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
003,131,160,169,AUTHORS,BJU,CONCLUSION,FURTHER,GLEASON,JANUARY,LABEL,LTD,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,THERE,THEREFORE,THOSE,WILEY
169,233,LTD,PRIOR,PTY,PUBLISHING,TODAY,WILEY
154,177,794,BACKGROUND,BMI,LABEL,METHODS,NUTRITION,OBJECTIVE,OVERALL,RESULTS
100,ANGELES,ATTRIBUTE,CALIFORNIA,COMPOSITE,CURRENT,EIGHT,EMPRO,EVALUATING,INDEX,INSTRUMENT,LABEL,LOS,METHODS,OBJECTIVE,PATIENT,PCI,PURPOSE,QOL,QUALITY,RESULTS,SCALE,THESE,UNIVERSITY,UTILITY
946,CXCR4,GLEASON,LABEL,LOW,METHODS,OBJECTIVE,PCR,RESULTS,SDF
169,191,209,BACKGROUND,CHRONIC,CONCLUSION,GLEASON,LABEL,MEN,METHODS,PREVENTION,PSA,RESULTS,THESE,TRIAL
000,100,200,642,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PCASS,PSA,PURPOSE,REGARDLESS,RESULTS,THERE
169,BECAUSE,HORSE,PSA,THEREFORE
169,252,390,AVERAGE,BACKGROUND,COMPARISON,CONCLUSION,COPYRIGHT,DISCUSSION,INC,LABEL,MATERIALS,MEDICAL,METHODS,MODEL,OBJECTIVES,ODM,OVERALL,RESULTS,SEVERAL,SYSTEMATIC,THERE,THESE,UROLOGY
169,AML,COPYRIGHT,DESPITE,DNR,EME,LIPOSOMES,MOLECULES,MTX,PEGYLATED,USING
169,COPYRIGHT,DESPITE,PCA,PIP,PTP,TSG
160,169,350,APC,CONFIRMING,COPYRIGHT,DUE,EDUCATION,GSTP1,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
125,BACKGROUND,CEA,CEACAM1,COLORECTAL,CYFRA,HOWEVER,LABEL,METHODS,NSE,OPG,OPN,OVARIAN,PRL,RESULTS,SCREENING,SEVERAL,SIXTY,TRIAL
835,925,AUC,BPH,CCL,CSF,FAS,HOWEVER,IGFBP,PCA,ROC,SERUM,TNFRSF6
169,COPYRIGHT,DESPITE,HCC,ICC,INC,ROC,SINCE
169,231,945,946,CHROMATIN,COPYRIGHT,EXPRESSION,HIC,MCF,MDA,PC3,THROUGH,TXA,WILMS,WT1
037,154,160,166,169,272,307,352,ACCRA,AFRICAN,COPYRIGHT,EDUCATION,FURTHER,GHANA,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
002,160,169,258,902,AFTER,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PREVENTION,PUBLISHED,PURPOSE,RESULTS,TRIAL,UROLOGICAL,VITAMIN
102,169,956,COPYRIGHT,IMR,INC,LTR,STUDIES
169,201,231,COPYRIGHT,PUBLISHED,SAS,THERE
169,285,AFRICAN,COLLEGE,COPYRIGHT,EIGHT,FIFTEEN,LABEL,LOCALLY,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROYAL
169,450,750,CONCLUSION,COPYRIGHT,ELSSS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
001,002,169,237,742,979,AMICO,AMONG,BCR,CONCLUSION,COPYRIGHT,EXCLUSION,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,ORP,PATHOLOGIC,RESULTS,THERE
169,606,AVERAGE,BACKGROUND,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SPANISH,TOTAL,USING
001,100,169,177,200,2MM,4MM,5ML,APRIL,BACKGROUND,BETWEEN,BMI,COPYRIGHT,GEL,HDR,IRELAND,LABEL,LTD,MANSFIELD,MATERIALS,METHODS,OBJECTIVE,PEG,PURPOSE,RESULTS,SEALANT,THERE
169,231,233,COPYRIGHT,PUBLISHED,SAS,V70
115,169,539,BCR,CONCLUSION,COPYRIGHT,COX,DIAGNOSIS,GLEASON,INC,LABEL,MEN,METHODS,OBJECTIVE,PROJECT,RESULTS,RRP,UNIVERSITY
169,BECAUSE,COPYRIGHT,HOWEVER,IAC,PSA,RSD
169,BACKGROUND,COPYRIGHT,DISCHARGE,DISCUSSION,HOWEVER,LABEL,LTD,METHODS,RESULTS
169,3E6,AIM,BPH,COPYRIGHT,GLEASON,LABEL,METHODS,MONOCLONAL,OBJECTIVE,PR8,PSA,PUBLISHED,RESULTS,SAS,SERUM
ACUTE,AFTER,AIM,AVERAGE,EORTC,HELICAL,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
GLEASON,INTER,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PRE,RESULTS,TARGETING,THERE,TTP
001,008,023,026,168,239,ACTUARIAL,BETWEEN,CSS,EFFECTIVE,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SRT
208,AE3,EP4,LNCAP,ONO,PC3,THEIR
104,946,DACH1,DACHSHUND,ED2,KYSE150,KYSE510,NETWORK,PCR,RETINAL,TGF
135,169,253,496,BCL,HNSCC,OVERALL,PRESS,PUBLISHED,SCC,SINCE,TARGETING,UNIVERSITY
123,181,ACCORDING,HOWEVER,NRS,THEREFORE,THESE
181,AGA,DISSECTING,LBD,LNCAP,MINOXIDIL,THESE
ANNEXIN,JNK,MAPKS,PARP1,TREATMENT
002,169,392,COPYRIGHT,COX,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PREDICTORS,PUBLISHED,PURPOSE,RESULTS,TRANSITION,UROLOGICAL
945,954,BACKGROUND,HOWEVER,LABEL,METHODS,RESULTS
001,133,797,ARC,ARMSTRONG,BACKGROUND,CASTRATION,CTR,DTX,LABEL,MEDICAL,METHODS,NETWORK,PSA,RESULTS,SEVENTY,TRIAL,UNIVERSITY
ADT,AFTER,DIFFERENT,EMT,HOWEVER,MDR,TAXANES,UTR
393,BACKGROUND,CHANGES,END,INSTITUTE,LABEL,METHODS,RESULTS,SIR,THERE
AFTER
001,291,945,BACKGROUND,BPH,COX,GLEASON,GNAS1,HOWEVER,LABEL,METHODS,PCA,PSA,RESULTS,T393C
169,220,BIOLOGY,INC,MOLECULAR,PCA,SOCIETY,SWATH
120,360,CGA,DECLINE,PFS,PSA,UNV
169,BACKGROUND,HOWEVER,INC,LABEL,LNCAP,METHODS,PCR,PREVIOUSLY,RESULTS,RSK,TAKEN,WESTERN,WILEY
001,004,005,169,320,526,AFTER,ASIAN,BCR,CAUCASIAN,COX,MEIER,RESULTS
169,AKT,DU145,FABP4,FATTY,SEVERAL,THESE
001,003,160,CIS,COX,DWI,GLEASON,HARRELL,HIPPA,IRB,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SIXTY,THERE,THESE
169,DESPITE,DISCOIDIN,H1299,JM2,TAKEN
169,945,ACTIVATION,BCS,CYP17,SOCIETY
DU145,GLEASON,HOWEVER,MTT,SPAG9,SPERM,THERE
120,169,DESPITE,FDA,LABEL,LIBRARY,METHODS,OBJECTIVE,PRESTWICK,PSA,PURPOSE,RESULTS
093,169,215,312,398,412,502,BACKGROUND,BONFERRONI,COLORECTAL,DIETARY,GIVEN,INTRACLASS,LABEL,LARGE,METHODS,NUTRITION,OBJECTIVE,OBJECTIVES,OTHER,OVARIAN,PEARSON,RESULTS,SCREENING,SOCIETY,TRIAL,USUAL
11P15,215,NOVEL,TAKEN,THERE
160,169,BACKGROUND,COPYRIGHT,EASTERN,GROUP,LABEL,LTD,MEN,METHODS,PSA,RESULTS,THESE
AKT,ANTITUMOR,BACKGROUND,BAX,BCL,CONVERSELY,ERK,JNK,LABEL,MCL,METHODS,NH2,RESULTS,THESE,TUNEL,WESTERN,WHARTON
169,945,ANIMALS,CD49F,ITGA6,J8H,LAMININ,MEIER,THESE
00001,100,CONTINENCE,COX,LABEL,MEN,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,USING
BACKGROUND,CONCLUSION,CZECH,LABEL,METHODS,RESULTS,USING
945,946,DEPLETION,DHT,LNCAP,SER,THR
237,460,BRAZILIAN,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,PORTO,RESULTS
169,ALTOGETHER,AUTHORS,HOWEVER,JOURNAL,OCT4A,PATHOLOGY,THESE

129,343,ACCORDING,APRIL,BASED,BETWEEN,C49,CONCLUSION,DRE,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERE
114,144,CONCLUSION,LABEL,MAB,METHODS,OBJECTIVE,PCA,PSA,RESULTS,UNIVARIATE
BAX,BCL,CASPASE,CONCLUSION,GFP,HOWEVER,INHIBITION,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,STIM1,WESTERN
ANNEXIN,BORTEZOMIB,CCK,CONCLUSION,DU145,LABEL,LNCAP,METHODS,OBJECTIVE,PCA,RESULTS
33258,CONCLUSION,HOECHST,LABEL,LNCAP,METHODS,MTT,OBJECTIVE,PCR,RESULTS
008,009,024,026,052,056,065,072,076,081,087,146,163,215,256,498,502,589,CONCLUSION,LABEL,METHODS,MTT,OBJECTIVE,PCR,PTIEN,RESULTS,WESTERN
150,PC3,SLN,SOLID,THERE,THESE
DESPITE,HOWEVER,STUDIES
ABOVE,ACCORDING,BACKGROUND,BCR,CONCLUSION,ECE,LABEL,MEIER,METHODS,PATIENT,RESULTS
063,121,169,AMONG,CONCLUSION,COPYRIGHT,COX,ESA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIMILARLY,SINCE,SOCIETY
E2F,MYC
169,198,224,281,293,452,AUC,AVAILABLE,CONCLUSION,COX,DIAGNOSTIC,DU145,FINALLY,FUNCTIONAL,GABRE,LABEL,MEIER,METHODS,METHYLIGHT,OBJECTIVE,PC3,PURPOSE,RESULTS,ROC
104,105,130,164,169,186,215,361,474,514,946,BACKGROUND,CHALLENGE,COPYRIGHT,LABEL,LTD,MEMBERS,METHODS,PTG,RESILIENCE,RESULTS,WILEY
169,547,719,789,941,AFTER,BACKGROUND,EXCLUDING,LABEL,METHODS,NETWORK,RESULTS,SOCIETY
145,786,FOLLOWING,MMP,MTT,RCC,THESE
169,AKT,BACKGROUND,DU145,INC,KLF,KRUPPEL,LABEL,LNCAP,METHODS,PC3,PCA,PCR,RESULTS,TET,THESE,WESTERN,WILEY
169,BACKGROUND,BASED,DISCUSSION,HOWEVER,INC,INCREASED,JAGGED2,LABEL,METHODS,NOTCH,RESULTS,WILEY
169,ANTIBODIES,BIOLOGY,CDRH3,CDRL1,INC,MOLECULAR,SOCIETY,THESE
169,ETS,EWING,MEMBERS,THESE
160,64257,APOPTOSIS,HSC70,HSP70,HSP72,HSP90,KIT,PCR,THESE
160,BUPLEURUM,DU145,FURTHER,HOWEVER,SSD,THEREFORE,TREATMENT
APART,BACKGROUND,LABEL,METHODS,PSA,RESULTS
100,270,518,BACKGROUND,CLINICALLY,GEMOX,LABEL,METHODS,NCT,PSA,RESULTS,TALALAY,THERE
169,176,ALBUMIN,BIOLOGY,GIVEN,INC,METHIONINE,MOLECULAR,SAMPLES,SOCIETY
CELLSEARCH,FDA,OTHER,THEIR
10YEARS,147,169,17YEARS,ADT,AIM,CASTRATION,CONCLUSION,COPYRIGHT,ESTIMATED,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,TOTALLY
169,COPYRIGHT,HOWEVER,LTD,PTB,SH2

AKT,HOWEVER
169,AFRICAN,CHINESE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
THERE,TREATMENT
120,COLLOIDAL,DU145,EPR,MDR,THESE
300,DLS,FINALLY,NPS,OVERALL,SEM,SILYMARIN,TGA,XRD
100,181,462,700,780,ARNEBIA,GAE,LPO,TPC
008,015,100,3GALNAC,945,946,EARLY,III,QUADRAMET,STUDIES,THESE
001,439,476,915,CONCLUSION,FINALLY,GIVEN,HOWEVER,LABEL,METHODS,OBJECTIVE,OCTOBER,ORP,OVERALL,PURPOSE,RESULTS
LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS
GLEASON,MRI
001,039,046,205,216,223,275,64257,AUC,BASEL,GLEASON,INDEX,LABEL,METHODS,OBJECTIVE,PCA,PHI,PSA,RESULTS,UNIVARIATE
008,010,016,037,092,165,169,181,203,250,436,504,731,823,AFRICAN,AMONG,BACKGROUND,BIOMARKERS,COX,EPIDEMIOL,GLEASON,HRS,LABEL,METHODS,PREVENTION,RESULTS,THERE,TRIAL,VITAMIN
HPETE,MYC,NHP,PC3,PCA,PIN,TRANSGENIC
EOC,PATHWAY
001,003,015,022,ACS,BACKGROUND,COLLEGE,COMPARISON,DESPITE,LABEL,LARGE,METHODS,NSQIP,OPERATIVE,PGY,PROGRAM,PVP,QUALITY,REGRESSION,RESULTS,THERE,USING
100,160,174,177,200,DOSIMETRY,LABORATORY,OARTRAC,PSD,SOLID,TEXAS,THESE,UNIVERSITY,WATER
150,160,177,215,CARLO,MEV,MONTE,PGS,SINCE,USING
215,754,BASEL,IMAGING,LABEL,METHODS,MRI,OBJECTIVE,RESULTS

CELLSEARCH,INC,PUBLISHED,SEVENTY,TREATMENT,USING
169,COPYRIGHT,PUBLISHED,THESE,UROLOGY
169,325,COMMITTEE,COPYRIGHT,COX,GLEASON,III,INC,JOINT,LABEL,METHODS,NUTRITION,OBJECTIVE,OBS,OXIDATIVE,PREVENTION,PURPOSE,RESULTS
001,004,008,046,117,140,160,213,245,BMI,CONCLUSION,FAT,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,GCPII,LTD,THESE
CHEMOKINE,LTD,PREVIOUSLY,PUBLISHED
016,018,122,126,160,169,800,AMS,AUS,AUTHORS,BETWEEN,BJU,CONCLUSION,EARLY,EROSION,FINALLY,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS
105,BACKGROUND,CHINA,CHINESE,COX,EARLY,INDEX,JIADING,KARNOFSKY,LABEL,METHODS,PUTUO,RECORDS,RESULTS,SCALE,STAGING
169,174,185,210,348,3D14PBX,463,503,AGE,AUTHORS,BETWEEN,BJU,DRE,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RECURSIVE,RESULTS
001,169,183,608,AMICO,AUTHORS,BCR,BJU,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,PCA,PIH,PII,PSA,RESULTS,T2A,THESE
001,130,918,AFTER,BACKGROUND,BLOOD,BMI,CONTEXT,DECREASED,EPO,ESTRADIOL,FRACTURES,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,RESULTS,SETTING
100,10Z,11Z,160,200,946,RED,SEA,TME
145,954,CRGDK,GSH,NPS,NRP
APLASIA,FGF,FGF10,FGFR2,THESE
CURRENT,LABEL,MEDLINE,METHODS,OBJECTIVE,RESULTS,THERAPY
ABOVE,CGA,CONCLUSION,CSS,FORTY,HOWEVER,LABEL,METHODS,NED,OBJECTIVE,PSA,RESULTS,SERUM
126,12669,12676,442,453,500,ANKER,BESIDES,LABEL,MATER,NAT,SOC,SPR
NPS,THERE
200,ALBUMIN,INHIBITION
109,169,490,789,APRIL,INTENSITY,JAPAN,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
126,169,177,BBN,COPYRIGHT,DYNAMIC,FDG,LTD,PARTITION,PET,WILEY
169,ATLAS,FURTHER,INC,OVERALL,THROUGH,WILEY
169,ACTIVATED,BACKGROUND,ERK,HOWEVER,INC,LABEL,METHODS,NATURAL,RAF,RESULTS,RSK,TAKEN,TAXANES,TAXUS,WESTERN,WILEY
116,956,ANNEXIN,CAM,H2DCFDA,HCT,MTT,R24,ROS
112,119,124,161,300,372,381,675,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,PATIENT,RESULTS,THERE,TOM,TRIAL
169,946,BACKGROUND,CAS,CRK,EMT,GLEASON,IHC,INC,KNOCKDOWN,LABEL,LNCAP,METHODS,NEDD9,PCA,PSA,RESULTS,TGF,WHILE,WILEY
160,BACKGROUND,CONCLUSION,GIVEN,HOWEVER,INTERVIEW,LABEL,MEN,METHODS,NVIVO,OBJECTIVE,PARTNER,PURPOSE,RESULTS,SIX,TEN
126,160,347,9371A,ASN3124ILE,BRCA1,BRCA2,GERMANY,SOUTH,VUS
945,946,948,ADP,APC,CATENIN,ECTOPIC,HIF,LEF,MUTATIONS,MYC,THEREFORE,WNT
230,AMONG,HOWEVER,INCRNAS,THROUGH
169,228,402,AFTER,COPYRIGHT,INSURANCE,KBV,LTD,MORAN,PAP,PHYSICIANS,SPATIAL,STATUTORY
160,169,956,COPYRIGHT,OVERALL,SAS,THESE
169,COPYRIGHT,ELL,FINALLY,FURTHER,GFP,INC,LIN,LNCAP,RAS,RBBP4,WHILE
169,COPYRIGHT,ERG,ETS,FDA,HOWEVER,INDEX,OTHER,PCA,PSA,PUBLISHED,THERE,TMPRSS2
100,BASED,EPCAM,THEREFORE
169,BECAUSE,THEREFORE,THESE
169,CHO,COPYRIGHT,ECD_FGFR1A,ECD_FGFR1B,ECD_FGFR2A,ECD_FGFR2B,ECD_FGFR3A,ECD_FGFR3B,ECD_FGFR4A,ECD_FGFR4B,FGFRS,FIBROBLAST,INC,WESTERN
160,169,735,844,ADVERSE,COPYRIGHT,EDUCATION,ELLISON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCI,PREDICTORS,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,CCNA2,COPYRIGHT,DU145,HIPPO,INC,LNCAP,THESE
169,609DAYS,COPYRIGHT,END,HRS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,RESULTS,SCC,SRE,USING
169,64328,BACKGROUND,COPYRIGHT,DCI,ECR,ESTONIA,HODGKIN,LABEL,LTD,METHODS,RESULTS,RSR
169,APRIL,ASSESSMENT,COMPLIANCE,CONCLUSION,COPYRIGHT,GENERAL,INC,JANUARY,LABEL,METHODS,MODEL,OBJECTIVE,OCTOBER,PHYSICIANS,RESULTS,SCORE
169,260,358,946,COPYRIGHT,COX,GLEASON,LABEL,LOW,LTD,METHODS,OBJECTIVE,PDGFR,PURPOSE,RESULTS
169,215,956,ARCHITECT,COPYRIGHT,CVI,FOLLOWING,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OPTIONS,PASSING,PSA,PUBLISHED,RESULTS,ROCHE,SOCIETY,THESE,WORLD
169,CLAVIEN,CONCLUSION,COPYRIGHT,FIFTY,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PATHOLOGIC,RESULTS,THERE
169,956,AFTER,COPYRIGHT,LNCAP,LTD,T877A,USING
160,169,COPYRIGHT,CYBERKNIFE,GROUP,LABEL,LTD,METHODS,MONITOR,MUS,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS
124,145,149,169,237,AFTER,CONCLUSION,COPYRIGHT,GIVEN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PBX,PSA,RESULTS
00002,001,118,169,ADT,AGE,BMI,CONCLUSION,COPYRIGHT,DESPITE,INC,INCREASING,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,RESULTS,THREE
119,169,ANXIETY,C30,CLOSE,COPYRIGHT,DEPRESSION,DISCUSSION,EMOTIONAL,INC,LABEL,LOWER,METHODS,OBJECTIVE,PHYSICIAN,QUALITY,RESULTS,REVISED,SCALE,THESE,TREATMENT,TRUST
115,169,AUTHORS,BJU,CONCLUSION,GLEASON,HOWEVER,KETTERING,LABEL,METHODS,OBJECTIVE,RESULTS,SEVERAL,SLOAN,WHILE
169,755,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,OVERALL,PURPOSE,RESULTS,USING
169,COPYRIGHT,GLEASON,INC,LOGICAL,SEVERAL
169,COPYRIGHT,INC,PSA,REPEATING,VARIOUS
169,COPYRIGHT,INC,MRI
169,COPYRIGHT,HEMATURIA,INC
169,COPYRIGHT,INC,THERE
169,COPYRIGHT,INC,THERE
INC,PUBLISHED
FORCE,INC,PREVENTIVE,PSA,PUBLISHED,WHEREAS
169,BECAUSE,COPYRIGHT,INC
169,COPYRIGHT,ENTHUSIASM,INC
169,COPYRIGHT,FORCE,INC,PREVENTIVE,PSA
006,015,10878,125,169,BACKGROUND,COLLECTION,CONCLUSION,COPYRIGHT,DEPENDING,LABEL,LTD,MEIER,METHODS,OVERALL,PFS,PSA,PUBLISHED,RESULTS,THESE
24H,AFTER,COLO205,CONJUGATE,LNCAP,PC3
945,CK2,CONSISTENT,HOWEVER
177,BACKGROUND,BETWEEN,COLOR,CONCLUSION,DOPPLER,EARLY,INSTITUTES,LABEL,METHODS,RESULTS,SEPTEMBER,THYROID,TKI
169,487,COMPOSITE,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,URINARY,UROLOGICAL
150,250,500,800,COPOLYMER,DTA,EPIDERMOID,F68,GLYCOLIDE,LACTIDE,NMR,PC3,PENTABLOCK,PEO,PPO,SOLVENT,VESICULAR
000,169,181,ADJUSTING,AFRICAN,AMERICANS,AUTHORS,BACKGROUND,BLACK,CONCLUSION,GLEASON,HOWEVER,INC,LABEL,METHODS,PCA,PSA,RESULTS,SAPCS,SOUTH,USING,WHITE,WILEY
169,902,AIM,COX,INSURANCE,LABEL,METHODS,NHI,OBJECTIVE,PHYSICIANS,PRESS,PUBLISHED,RESULTS,UNIVERSITY
177,504,CHINESE,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,RCP,RESULTS,SPARING,THERE,WHOLE
AIM,BAX,DU145,PC3,THESE
ATG12,AUTOPHAGY,BCL,LC3,MAP1S,UNDER
143,415,848,AMICO,BACKGROUND,COMPARISON,DETECTION,ENGLISH,GLEASON,LABEL,METHODS,OCTOBER,PSA,RESULTS,TOOLS
10878,ADVERSE,BACKGROUND,BEGINNING,FORTY,GYE,LABEL,MAY,METHODS,PHOENIX,RESULTS,T1B,T3BN0M0
101,BACKGROUND,BIOMARKERS,CONCLUSION,III,INCLUSION,LABEL,LOW,METHODS,PSA,RESULTS,SHT,TLS

ERG,GLEASON,HISTOLOGIC,MOLECULAR,PSA,THESE
BCG,CIS,CLOSE,COMPARING,INCIDENCE,JANUARY,MEDLINE,PAPILLARY,PSA,RCC,REPORTS,TCC,UPPER,UUT
FINALLY,HOWEVER,PARTICULAR,ROBOTIC
169,231,AKT,COPYRIGHT,COUMARINS,HOWEVER,LNCAP,LTD,MCF,MDA,MTT,NMR,REDUCED,THESE
169,956,AMONG,COPYRIGHT,FURTHER,HOECHST,LTD,OVERALL
954,AKT,CAM,FAK,FINALLY,HOWEVER,NOV,PCA,PCACM
169,177,COPYRIGHT,DSC,EFFICIENT,T2W
100,169,199,228,317,333,AFTER,AMICO,GLEASON,LABEL,METHODS,OBJECTIVE,PRESS,PUBLISHED,RESULTS,UNIVERSITY
001,002,003,134,169,356,666,AOR,BACKGROUND,COMBOGS,CONCLUSION,COPYRIGHT,DIFFERING,GSS,INC,LABEL,METHODS,RESULTS,THEREFORE,WHETHER
160,420,883,BACKGROUND,CARLO,CONCLUSION,GROUP,HOWEVER,LABEL,METHODS,MONTE,QALYS,RESULTS,THERE,TREEAGE,UTILITY
14035,169,270,351,38581,762,AUSTRALIA,CENTRES,COLLEGE,COPYRIGHT,FRIESLAND,LABEL,LEEUWARDEN,LIVERPOOL,LTD,MACARTHUR,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,QUEENSLAND,RESULTS,RIF,ROYAL,SOUTH,THERAPY,WALES,WOMEN
169,COPYRIGHT,INC,LNCAP,MLV,XENOTROPIC
145,177,181,185,945,946,FDG,FEC,PCA,PET,RGD,RGDFV,THEREFORE,THESE
946,AKT,CAP,CSC,NOTCH,THERE,THEREFORE,WNT
001,002,177,ADT,AFTER,CONCLUSION,GROUP,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SERUM,THEREAFTER
169,FOUNDATION,INC,OCTOBER,PCA,PCF,RETREAT,SCIENTIFIC,WILEY
HMGB1
111IN,160,177,CORRECT,LNCAP,MAXIMUM,PC3,PET
AOA,ASP,DAU,GLP,GLY,III,LYS,NH2,PRO,TRP
104,169,215,407,ABHD9,ADHB9,AVERAGE,BACKGROUND,CPG,END,HOXD3,LABEL,METHODS,RECURRENCE,RESULTS,THESE
169,283,544,COLORECTAL,IGE,IMMUNOCAP,ORS,OTHER,OVARIAN,OVERALL,SCREENING,THERE,TRIAL,USING
BASED,GLEASON,IMAGING,MRI,SUBSEQUENT
169,239,ADT,ANDROGENS,COPYRIGHT,CYP17A1,ESSENTIAL,HOWEVER,ISSUE,LTD,PCA,PSA,SPECIAL,TAD,TOTAL
276,295,956,BACKGROUND,BRITISH,CONCLUSION,LABEL,METHODS,WHITE
ANOVA,BACKGROUND,DDW,LABEL,MATERIALS,METHODS,MTT,PACLITAXEL,RESULTS,TREATMENT
102,105,109,112,128,156,177,ABOUT,AIM,BACKGROUND,COLON,LABEL,MATERIALS,METHODS,NEPHROLOGY,OBJECTIVE,PSA,RESULTS,THERE,TODAY
AMONG,BACKGROUND,CIS,HEALTHY,IRANIAN,LABEL,MATERIALS,METHODS,ORS,PRIOR,RESULTS,WESTERN
DIFFERENT,THERE,VARIOUS
001,004,009,180,BACKGROUND,CONCLUSION,COX,GLEASON,LABEL,MEIER,METHODS,RABEX,RESULTS,WHILE
DESPITE,SCARAMANGA
155,169,GTPASES,PRESS,RAB1A,RAB1B,RAS
002,040,123,160,303,397,623,GAD,HOWEVER,PCA,PERCEIVED,PHQ,QSC,R10,SIMILARLY
169,946,AIM,BACKGROUND,CLONOGENIC,DSB,GSK,HOWEVER,INC,LABEL,METHODS,RAD51,RESULTS,SIX,TORC1,TORC2,TTP,WILEY
10001,333,MEDICAL,PUBLISHERS,SEVENTH,SEVERAL,SPECT,USA
10001,333,MEDICAL,OSSEOUS,PATIENT,PET,PUBLISHERS,SEVENTH,USA
231,CRYSTAL,LNCAP,MDA,NMR,THREE
167,174,203,283,773,BRAZILIAN,CROSS,LABEL,METHODS,OBJECTIVE,RESULTS,SCROTAL,SETTING,TINEA
MORTALITY,NORTHEAST,PRAIS,WINSTEN
PC3,PCA,PEI,SMALL,TAKEN,TARGETING
001,169,EXPRESSION,LABEL,MEMBRANOUS,METHODS,NSCLC,OBJECTIVE,PURPOSE,RCC,RES,RESULTS,THESE
200,20A,ARRAY,BACKGROUND,COX,DOCETAXEL,HOWEVER,LABEL,METHODS,NON,PSA,RESULTS,WHITNEY
001,003,007,BACKGROUND,DESPITE,DU145,GLEASON,HYPOXIA,LABEL,METHODS,PC3,PSA,RESULTS,SILENCING
153,223,AMONGST,HOWEVER,III,THESE
010,030,039,211,FUDAN,LDH,PFS,PRIMARY,SCC,SERUM,UNIVERSITY
DEFECTS,PCA
APRIL,HGPIN,HOWEVER,MEDLINE,ORS,PCA,PSA,SCIENCE,THEREFORE,USING,WEB
169,ANALYTICS,WEB,YOUTUBE
100,106,140,169,GLEASON,OVERALL,SIRT1,SIXTEEN,VALIDATION
169,BECAUSE,COPYRIGHT,INC,PATHOLOGY,PUBLISHED,SOCIETY
MRI,SUSPICIOUS
169,COPYRIGHT,INC
001,169,349,354,363,964,AFRICAN,AUTHORS,BJU,CAUCASIAN,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PSA,RESULTS,SNP,THERE,THESE
169,273,AUC,AUTHORS,BJU,LABEL,MATERIALS,METHODS,NAKANISHI,OBJECTIVE,RESULTS,STEYERBERG
000,169,177,BACKGROUND,BMI,CONCLUSION,FINALLY,HBA1C,HDL,LABEL,LDL,LOH,MEN,METHODS,OBJECTIVE,OUTCOME,PARAMETERS,RESTORING,RESULTS,SOCIETY
169,337,ACTUARIAL,ADT,AUTHORS,BETWEEN,BJU,C30,CONCLUSION,DEPARTMENT,INDEX,JANUARY,LABEL,METHODS,MISSING,OBJECTIVE,QLQ,QUALITY,RESULTS,SCORE,SCP,SYMPTOM,TREATMENT
001,112,121,162,169,241,499,AUTHORS,BJU,CONCLUSION,FGB,FORTY,GLEASON,LABEL,LENGTHS,METHODS,MRI,OBJECTIVE,PCA,PSA,RESULTS,SIX,SIXTY
169,FURTHER,HOWEVER,LTD,PUBLISHED,TREGS,WILEY
103,107,110,146,169,373,519,599,762,AMONG,COPYRIGHT,MONITORING,RECIPIENTS,SCIENTIFIC,SOCIETY,THERE,TRANSPLANT
100,22RV1,945,AKT,AMACR,BACKGROUND,BPH,COA,LABEL,LNCAP,MATERIALS,METHODS,METHYLACYL,PC3,PCA,RESULTS
001,002,025,169,204,338,ALASKAN,ANS,BACKGROUND,DISEASE,EFFORTS,END,FEWER,INDIANS,LABEL,METHODS,NATIONALLY,NATIVES,NONRECEIPT,RATES,RESULTS,SOCIETY,TREATMENT
DBNRR,LCNRR,NRR
178,DVH,DYNALOG,ECLIPSE,MILLENNIUM,MLC
176,177,4PT,ANATOMY,DELTA,ECLIPSE,GAFCHROMIC,GAI,ISOCENTER,PTV,SCANDIDOS,TPS
177,COMPASS,D10,D20,D80,D90,D95,DVH,MATRIXX,OAR
DICOM,DVH,MLC,TREATMENT,USING
DAO,GFO,MLC,PLANUNC
176,177,313,438,546,933,OVERALL,PTV,ROTATIONAL
169,945,CAF,INDUCTION,SIGNALS
100,144,177,BLOOD,CONCLUSION,CTP,FURTHER,GLEASON,LABEL,METHODS,MTT,MVD,OBJECTIVE,OBJECTIVES,RESULTS
177,CCMFM,GPU,T2W
215,284,ADC,CHANGES,DWI,MRF,MRI,RESPONDING,WBDWI,WHITNEY
FAVORABLE,FOCAL,GLEASON,LABEL,LOW,OBJECTIVE,PURPOSE,RADICAL,RESULTS,SUMMARY
BIOMARKERS,ERG,INDEX,LABEL,OBJECTIVE,PSA,PURPOSE,RESULTS,SUCCESSFUL,SUMMARY,TMPRSS2
ADDITIONAL,DIFFERENT,FOCAL,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
HOWEVER,LABEL,OBJECTIVE,PCA,PURPOSE,RESULTS,SUMMARY,THESE,THREE
001,112,240,417,482,704,768,786,811,AGE,AUC,CALCULATOR,ERSPC,LABEL,MAY,METHODS,OBJECTIVE,OBJECTIVES,PREVENTION,RANDOMIZED,RESULTS,SCREENING,SEOUL,SNUPC,TRIAL,UNIVERSITY,WESTERN
BIOMARKERS,MOLECULAR,POTENTIAL,SEMINAL,STRATEGIES,THESE
BACKGROUND,BRAIN,CONCLUSION,CXORF66,LABEL,MATERIALS,METHODS,ORF,RESULTS
160,169,CNT,COPYRIGHT,LTD,PEI
001,100,169,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THESE
145,169,223,CD49F,COPYRIGHT,INC,KNOCKDOWN,LUNATIC,NEOPLASIA,NOTCH,PRESS,TAKEN
169,177,AUR,COPYRIGHT,CORRECTION,DISTORTION,DWI,FORTY,GEOMETRIC,IMAGE,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PHANTOM,PUBLISHED,RATIONALE,RESULTS,STRATEGIES,THERE
000,ADVENTIST,AFRICAN,AHS,BACKGROUND,BLACK,LABEL,LESSONS,METHODS,PROMOTIONS,RESULTS
001,063,082,163,AMONG,ART,ASTRO,AUA,BACKGROUND,BCR,COX,LABEL,METHODS,PSA,RADIATION,RESULTS,SOCIETY,SRT,THEREFORE,THESE,UROLOGICAL
160,BACKGROUND,CCND1,HOXC6,LABEL,METHODS,MKI67,PCA,PREDICTIVE,PROGNOSTIC,RESULTS,SIAH2,SMAD4
BACKGROUND,DISCUSSION,LABEL,METASTATIC,METHODS,RESULTS
HOWEVER,PCA,PSA,SEVERAL,THERE
169,177,192,198,212,945,AMP,COPYRIGHT,LTD,MCF,MEK,METABOLIC,MRS,PC3,U0126,WILEY
000,002,004,041,042,048,052,160,514,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SURVIVORS,WHILE,WOMEN
145,EPCAM,LNCAP,PROTEIN,PSA,SHORT
100,AGE,BACKGROUND,ECE,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS,SVI
BACKGROUND,LABEL,METHODS,PSA,RESULTS,THESE,TREATMENT
CONCLUSION,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PITUITARY,PURPOSE,RESULTS,WHILE
CALCITRIOL,VITAMIN
231,945,DEGENERATE,LXXLL,MCF,MDA,SRC,SRC1LXXLL,THEREFORE,THESE
222,AUC,EXPRESSION,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,USING,VALIDATION
CARCINOID,FOUNDATION,LARGE,MIXED,SMALL,USUAL
113,129,945,AMACR,COA,ERG,SIXTY
169,CALCIUM,COPYRIGHT,DU145,HOWEVER,INC,LNCAP,THESE,TRPV6
169,185,515,840,BLADDER,CONCLUSION,COPYRIGHT,CYSTOSCOPY,DETECTION,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,RESULTS
110,169,AUTHORS,COPYRIGHT,III,LTD,PUBLISHED,ULTIMATELY
130,169,246,BACKGROUND,CIS,CONCLUSION,COPYRIGHT,COX,CROWN,GLEASON,HRS,IDC,LABEL,LTD,MEIER,METHODS,PATHOLOGY,PUBLISHED,RESULTS,SOCIETY,UROLOGICAL
169,302,853,947,AUR,AUTOMATIC,BETWEEN,COPYRIGHT,FORTY,HOWEVER,INC,INTRA,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS,TODAY
169,698,AUR,COPYRIGHT,DIFFUSION,DOR,DWI,FURTHER,INC,JANUARY,LABEL,LIBRARY,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,OCTOBER,PSA,PUBLISHED,RATIONALE,RESULTS,SUMMARY
169,954,ACT,ADC,AUR,CENTRAL,COPYRIGHT,INC,INSURANCE,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS
100,169,183,953,AUR,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS,SIMAX,USING
169,AMERICA,COLLEGE,COPYRIGHT,INDIVIDUAL,LTD,NORTH,PUBLISHED,REQUITE,ROYAL,SIMILAR,THESE,ULTIMATELY
954,ADP,CDK,D52,FINALLY,FURTHER,G2M,LNCAP,MOZ,MYST1,N1A,NOTABLY,PC3,PCA,TAKEN,TIP60,TPD52
947,CLEAR,NR2C2,TESTICULAR,TR4
CHALLENGES,PCA,PSA,SEVERAL
BECAUSE,PCA,SNP,WHILE
111,168,169,177,956,CONCLUSION,D2B,IMAGING,INC,IRDYE800CW,ITC,LABEL,LNCAP,MBQ,METHODS,MOLECULAR,NUCLEAR,PC3,RESULTS,SOCIETY,SPECT,THESE,UNLABELLED
169,99M,BINDING,COPYRIGHT,ELISA,LNCAP,LTD,NANOBODIES,PC3,PSMA6,SPECT,WILEY
169,191,BACKGROUND,CONCLUSION,COPYRIGHT,DEPRESSION,DEPRESSIVE,DIFFERENT,GOTLAND,HOWEVER,LABEL,LTD,MAJOR,MDD,METHODS,PATIENT,RESULTS,SCALE,THEREFORE,WILEY
169,AKT,EMT,EUPAFOLIN,INC,OVERALL,PI3,PROTEIN,RAS,WILEY
169,BASED,GIVEN,HENCE,III,MRI,PET,RGD,THESE,VCH,WILEY
169,945,946,954,HSPG2,INC,SMAD3,STUDIES,TGF,THESE,TNF,TREATMENT,WILEY
169,CYTOMETRY,EDU,MONITORING,SOCIETY
HOWEVER,MOLECULAR,SELECTION,THERE
ESPECIALLY,HOWEVER,MRI,PET,SINCE
317,392,600,BETWEEN,DESPITE,IQ1,IQ2,IQ3,IQ4,IQ5,IQ6,KNOWLEDGE,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PCA,PRIMARY,PSA,RESULTS,SIX,UNTIL,WHILE
169,183,GEORG,MRI,STUTTGART
946,ASF1A,ATR,FINALLY,THEREFORE
AML,CAR,ECARS,PCA,PRIOR,TAG
038,068,177,780,844,FIRST,LPQ,SVM
956,PINUS,PLANT,SCOTS,THESE,TRAIL,WESTERN
ARCAP,BAX,CAMALEXIN,EPITHELIAL,LNCAP,LYSOSOMES,MTS,PCA,ROS,SPECIES,THEREFORE
156,178,945,ACUTE,EB719,INTESTINAL,NLD
CSC
001,005,009,013,017,030,032,040,041,160,169,174,669,898,CAUSE,COPYRIGHT,COX,EDUCATION,HORMONE,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TREATMENTS,UROLOGICAL
HELLEBORUS
AMONG,COMPELLING,CONTROL,CONVERSELY,HUR,SEVERAL,TTP
000,GPI,HGF,MATRIPTASE,MCOTI,MOMORDICA,THESE,USING
001,005,007,015,148,160,177,CHANGES,DXA,LABEL,MCNEMAR,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
169,490,BACKGROUND,CALIFORNIA,CONCLUSION,COPYRIGHT,LABEL,METHODS,PCP,RESULTS,SOCIETY,SURVIVORS
C3D,C4D,C57BL,IPILIMUMAB,NOTABLY,PITUITARY,SJL
4EBP1,AKT,FURTHER,HOWEVER,S6K,THEREFORE
006,100,177,215,661,852,935,ADC,DIFFUSION,DWI,ICC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
150,204,354,723,732,AUC,BACKGROUND,GLEASON,LABEL,METHODS,PCA,RESULTS,SIMILARLY,USING
177,183,729,ADT,APART,BRUCE,LABEL,MAXIMAL,METHODS,O2MAX,OBJECTIVE,PURPOSE,RESULTS,SIXTY,UNLABELLED
AFRICAN,CAP,CAUCASIAN,CPG,NEDD4,PCR,REDUCED

956,AKT,BAX,BCL,CAP,CASPASE,DU145,KHC,THEREFORE,TUNEL
117,CAR,CD3ZETA,COMPARING,DESPITE,HA1,WHILE
144,41BBL,947,AFTER,CD152,CD274,CD275,CHANGES,CONVERSELY,CTL,DU145,ELISPOT,EPITHELIAL,FINALLY,ICOSL,IFN,LNCAP,OX40L,PC3,PCA,THESE
007,100,109,ADVERSE,AIM,CONCLUSION,CTCAE,EARLY,GROUP,HDR,LABEL,MATERIALS,METHODS,OBJECTIVE,OSAKA,RADIATION,RESULTS,THERAPY
029,124,AIM,CAB,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS
001,AIM,BACKGROUND,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,ROSMARINIC
954,BACKGROUND,CONCLUSION,HEPG2,IIA,III,LABEL,MATERIALS,METHODS,RESULTS,SILIBININ,SP1
956,AIM,BACKGROUND,CONCLUSION,DTS,HEN,LABEL,MATERIALS,METHODS,OBJECTIVE,PETIVERIA,RESULTS,WST
123,231,BACKGROUND,COMPOUNDS,CONCLUSION,EFFECTS,LABEL,MATERIALS,MDA,METHODS,PC3,RESULTS,THESE
174,EPIDERMAL,HOWEVER,III,PERJETA,PERTUZUMAB
169,FOLLOWING
169,AUTHORS,CSF,GIVEN,LTD,RAPID,SIMILARLY,WILEY
138,169,723,NERVOUS,OVERALL,SIR,SWEDISH
025,911,ACE,ALU,CIS,CQVIP,MANAGER,ORS,OVERALL,STATA,WANFANG
001,134,AKT,EXPRESSION,FDR,HOWEVER,KNOCKDOWN,LINC00963,LNCAP,MTT,PCA,PCR,WHOLE
945,946,PHG
440,495,503,BACKGROUND,EWS,GERMANY,LABEL,METHODS,OHLMANN,PSA,RESULTS,WORLD
121,221,ADJUSTMENT,AMONG,BACKGROUND,IDENTIFIER,IMPORTANCE,INDEX,LABEL,LOCKE,MARCH,MARITAL,METHODS,OBJECTIVE,OBJECTIVES,PRIMARY,RELEVANCE,RESULTS,SECONDARY,SETTING,STRATIFIED,TADALAFIL,THESE,TRIAL
HOWEVER,LABEL,LOW,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING,VIP
169,945,954,BAX,DESPITE,DU145,HMVP2,LNCAP,OVERALL,PC3,SHO,SHOGAOL,STAT3,TNF
BACKGROUND,DCE,DYNAMIC,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,TOFTS
001,007,AFTER,BACKGROUND,BIS,COX,FURTHER,JANUARY,LABEL,MBD,METHODS,RESULTS
001,153,216,GLEASON,IMC,LABEL,LRP,METHODS,OBJECTIVE,OBJECTIVES,PSA,RALRP,RESULTS,THERE
169,488,956,ALEXA,ANNEXIN,ATP,CASPASE,COPYRIGHT,CUB,FLUOR,HOWEVER,IRELAND,LNCAP,LTD,STRIKINGLY,SUB,USING
004,006,106,169,265,274,425,BCL,BPH,COPYRIGHT,GLEASON,HGPIN,REGARDING
001,002,115,169,AUSTRALIAN,BACKGROUND,COLLEGE,LABEL,METHODS,MRI,RESULTS,ROYAL,SEMINAL,SEPTEMBER,ZEALAND
132,140,145,FINALLY,HOWEVER,PC3,RAL,SEVERAL,SMA
001,176,177,184,204,CAPSAICIN,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,TRPV1
145,169,BAX,DU145,FURTHER,THESE
169,427,879,AKT,ERG,GLEASON,LABEL,METHODS,OBJECTIVE,PHYSICIANS,PROTEIN,PURPOSE,RESULTS,SEVENTY,THERE,TMPRSS2
APRIL,CIS,ELECTRONIC,JANUARY,LABEL,LIBRARY,METHODS,OBJECTIVE,PURPOSE,REGULAR,RESULTS,RRS,SEVERAL,THEREFORE
001,002,003,004,006,BACKGROUND,CCA,DCA,GLEASON,KEY,LABEL,MATERIALS,METHODS,MRI,PROSTATIC,RESULTS,SIR,THERE
CONCLUSION,LABEL,MRI,OBJECTIVE
100,195,203,99M,CONCLUSION,DETECTION,FINALLY,HISTOLOGIC,LABEL,LYMPH,MBQ,METHODS,RESULTS,SLN,UNILATERAL,UNLABELLED
118,BACKGROUND,CAD,HRS,IAD,LABEL,METHODS,RESULTS,THERE
BACKGROUND,EXCLUSION,FORTY,INSTEAD,LABEL,METHODS,MIDSTREAM,PBS,PCA,RESULTS,URINE
FOCUSED,INTENSITY,LOW,MALIGNANT,MULTIMODAL,TREATMENT,ULTRASOUND
100,169,1980S,HYGIENE,SOCIETY
CSC,HLA,HOWEVER
169,945,954,HOWEVER,MYC,THEREFORE,USING
015,026,035,044,053,085,127,171,215,288,289,313,327,485,602,700,BACKGROUND,CHINESE,CONCLUSION,EUROPEANS,HRM,LABEL,METHODS,PCA,RESULTS,SNP,THADA
BACKGROUND,CAUCASIANS,CHINA,CHINESE,CONCLUSION,DISEASE,EIGHT,JANUARY,LABEL,MARCH,MEDICAL,METHODS,MMS,OBJECTIVE,PAGET,RESULTS,THREE
110,115,125,140,169,5CC,945,946,AUTHORS,COPYRIGHT,D50,DIL,INC,KUTCHER,LABEL,LYMAN,MARSDEN,MATERIALS,METHODS,OBJECTIVE,POISSON,PTV,PUBLISHED,PURPOSE,RESULTS,TCP,TEN
169,BOARD,CBCTS,COPYRIGHT,DIR,HOUNSFIELD,INC,LABEL,MATERIALS,METHODS,MLT,OBJECTIVE,PCT,PURPOSE,RESULTS,STUDENT
001,042,169,301,AUC,COPYRIGHT,COU,PUBLISHED,THESE,UROLOGY
169,COLLEGE,CONCLUSION,COPYRIGHT,FIFTEEN,GROUP,HOWEVER,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RADIATION,RAVES,RESULTS,ROYAL,SCREENING,TRANS
001,006,009,169,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPECIALTY
BACKGROUND,BEIGE,CONVERSELY,DROSOPHILA,ENDOGENOUS,EXCEL,EXOGENOUS,HACAT,KNOCKDOWN,LABEL,METHODS,NOTCH,PCR,PROTEIN,PTOV1,RESULTS,UNDER,WESTERN
001,169,232,523,AMICO,AUC,AUTHORS,BCR,BJU,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,PCA,PSA,RESULTS,ROC,T2B
169,211,247,AUTHORS,BJU,CONCLUSION,LABEL,MEN,METHODS,OBJECTIVE,PATIENT,RESULTS,TEXAS,THERE,UROLOGY
054,100,144,155,169,300,AUTHORS,BJU,CONCLUSION,DISEASE,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
AUTOPSY,BECAUSE,GLEASON,THERE,WHETHER
000,100,110,183,698,743,ASSESSMENT,AUTHORS,BACKGROUND,CANCERLIT,CCMED,CENTRAL,COLLECTION,CONTROLLED,DENNERT,HOWEVER,ISSUE,LABEL,MEDLINE,METHODS,NEWCASTLE,OBJECTIVE,OBJECTIVES,PREVENTION,QUALITY,RCT,RESULTS,REVIEWS,SCALE,SELECTION,SYSTEMATIC,THESE,TRIAL,VITAMIN
150,300,335,956,99M,CONCLUSION,LABEL,METHODS,NODAL,OBJECTIVE,PURPOSE,RESULTS,SLN,USING,WITHOUT
054,102,108,176,236,AIM,CENTERS,FIFTY,LABEL,METHODS,OBJECTIVE,RESULTS,SIXTY,SPAIN,VIRTUAL
001,025,038,074,114,745,CNS,HET,LABEL,METHODS,NCI,OBJECTIVE,PURPOSE,RADIATION,RESULTS,SIR
169,213,526,ACCORDING,CONCLUSION,CYP3A43,HSD17B2,LABEL,METHODS,OBJECTIVE,PURPOSE,REMARKABLY,RES,RESULTS,SNP,SULT2A1,SULT2B1
000,246,767,AMONG,CONTINUING,GENERAL,GOTHENBURG,INCIDENCE,LABEL,METHODS,OBJECTIVE,OUTCOME,POPULATION,PREVENTIVE,PROJECT,PSA,RESULTS,SCREENING,SETTING
001,109,327,714,958,DENMARK,FURTHER,ICELAND,INCREASED,MEN,MRR,POISSON,WOMEN
105,BACKGROUND,BPE,DESPITE,FURTHER,HOWEVER,LABEL,METHODS,PSA,RESULTS,UROLOGISTS
169,474,549,945,946,956,CHO,COPYRIGHT,DU145,GAELS,GAL,GLC,NH2,PC3,SAS,TAKEN
947,ANTIGEN,CD4,CD8,CODON,HLA,KASEKIFYV,PBL,PERIPHERAL,TCR
ALTOGETHER,DEPLETING,ETS,LNCAP,NLR,PCA,PROTEOMIC,SRY
946,GTPASES,RAC,RHO,SIMILARLY,THESE,WHILE
CDH11,COX,THESE
27R,CD11C,CD4,CD8,COX,DU145,FLT,FRAGILE,PC3,PCA,PTGS1,THESE,TIMP3
043,050,169,BASED,COPYRIGHT,COX,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
109,115,136,169,174,300,AMONG,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
153,169,177,277,99M,BACKGROUND,COPYRIGHT,DEPARTMENT,EDTMP,INC,INSTITUTE,INSTITUTO,LABEL,MBQ,MDP,METHODS,MEXICAN,NUCLEAR,NUCLEARES,OBJECTIVE,PUBLISHED,RESULTS,VAS,VRS
169,945,946,954,COPYRIGHT,FINALLY,HOWEVER,IKB,IL1,IL6,IRELAND,LPS,LTD,MAR,MARCHANTIN,PBMCS,PCA,SINCE,STAT3,TNF
169,BACKGROUND,CONCLUSION,COPYRIGHT,COX,GLEASON,HOWEVER,INC,JANUARY,LABEL,MEN,METHODS,OVERALL,RESULTS,THERE,THESE
169,COPYRIGHT,HOWEVER,INC,THEREFORE
169,946,ADIPOSE,ADSCS,CONSISTENT,COPYRIGHT,HOWEVER,INC,LNCAP,NHDFS,PC3,PCA,SINCE,TGF
045,100,169,176,CONCLUSION,CONTINENCE,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,USING
100,117,169,410,AAS,AFRICAN,AMONG,CANCERS,CAUCASIAN,CAUCASIANS,CONCLUSION,COPYRIGHT,EPSTEIN,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SIX,T1C
169,491,581,AFTER,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,MUSIC,OBJECTIVE,RESULTS,SURGERY,TNM,UROLOGICAL
001,008,048,169,480,561,AMICO,APRIL,CONCLUSION,COPYRIGHT,EPSTEIN,INC,LABEL,MARCH,MATERIALS,MEN,METHODS,OBJECTIVE,PCA,RESULTS,THESE
111,113,148,159,169,307,388,AFTER,ARO,ART,BACKGROUND,COPYRIGHT,COX,HOWEVER,LABEL,LOCAL,METHODS,NEITHER,OBJECTIVE,OUTCOME,PATIENT,PCA,PFS,PUBLISHED,RESULTS,SETTING,SUMMARY,THREE,UROLOGY
000,169,350,COPYRIGHT,HODGKIN,IRELAND,LTD,PUBLISHED,SOCIETY,SPM,THESE
102,169,626,CONCLUSION,GROUP,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PUBLISHED,RADIATION,RESULTS,THERAPY,UNIVARIATE,USING
123,153,169,3DCRT,BACKGROUND,CHANGES,CLINICALLY,INC,LABEL,METHODS,PBT,PUBLISHED,QOL,RESULTS
001,169,183,198,232,233,311,502,503,945,956,BACKGROUND,CHARITABLE,COMIT,EORTC,FUNDING,INC,LABEL,LIGUE,METHODS,NATIONALE,PUBLISHED,RESULTS,TREATMENT,TRUST
001,554,852,ADT,CAD,IAD,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
005,956,CALOTROPIS,CISPLATIN,EGYPT,NMR,THEIR
AGE,ASA,BACKGROUND,COMPETING,CONCLUSION,COX,GLEASON,LABEL,MEIER,METHODS,RESULTS,SEVENTY,SOCIETY
ASPIRIN,BACKGROUND,CIS,GENERALLY,LABEL,METHODS,NSAID,PCA,RESULTS,THEREFORE
169,176,CONCLUSION,INC,KNOWLEDGE,LABEL,METHODS,NOE,NUCLEAR,OBJECTIVE,OVERHAUSER,PURPOSE,REMARKABLY,RESULTS,WILEY
169,BACKGROUND,CONCLUSION,COPYRIGHT,DOCTORS,INTERVIEW,LABEL,LTD,MEN,METHODS,NAVIGATED,NAVIGATION,OBJECTIVE,RESULTS,SIX,WILEY
221,ELECTRONIC,FURTHER,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,RESULTS
946,BPH,EMT,FOXM1,HOWEVER,METFORMIN,PCA,TGF,THESE
CONCLUSION,DEFECTIVE,EARLY,EL4,LABEL,METHODS,UNLABELLED
169,215,225,543,688,CONCLUSION,COX,IMAGING,INC,LABEL,MEIER,METASTATIC,METHODS,MOLECULAR,NET,NUCLEAR,PEARSON,PET,RESULTS,SOCIETY,SURVIVORS,SUV,TLA,UNLABELLED
246,AGE,AMONG,ASIAN,ASSESSMENT,CAPRA,GROUP,JAPAN,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PEARSON,PFS,PRIMARY,RESULTS,THERE,USA
034,295,HOWEVER,HPV,KOREANS,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,P16,RESULTS
223,DESPITE,FRONT,III,SIX
945,946,BLOOD,FURTHER,GAL,HOWEVER,SRC,THOMSEN,WESTERN
ABOUT,METASTATIC
001,ACTUARIAL,AMICO,BACKGROUND,HOWEVER,ITALIAN,LABEL,METHODS,OBJECTIVE,RESULTS
BACKGROUND,BLADDER,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
169,945,AMACR,COA,COPYRIGHT,HENCE,INC,METHYLACYL,SPN,THEREFORE
BACKGROUND,HBA1C,LABEL,METHODS,RESULTS,THESE
ADT,AIS,HORMONE,HOWEVER
946,DESPITE,LNCAP,OVERALL,PC3,TREATMENT
169,BACKGROUND,CASTRATION,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,METRONOMIC,PSA,RESULTS,SIX
946,947,954,AFTER,AZD3514,BACKGROUND,COHEN,CONTENT,CTC,ELISA,HOWEVER,IHC,ISR,KAPPA,LABEL,METHODS,POM,RESULTS,THESE
169,CONCLUSION,COPYRIGHT,FUR,LABEL,MASON,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SAS,SEVENTEEN
102,169,177,1ST,660,812,AIM,CONCLUSION,COPYRIGHT,DAKAR,DEPARTMENT,DRE,GENERAL,GLEASON,GRAND,JANUARY,LABEL,MAY,METHODS,OBJECTIVE,RESULTS,SAS,THERE,UNLABELLED,UROLOGY
169,CONCLUSION,COPYRIGHT,JANUARY,LABEL,LOCAL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PATHOLOGY,PSA,RESULTS,SALVAGE,SAS,SINCE
140,BACKGROUND,CONFERENCE,CONTINUING,EDUCATION,LABEL,MEDICAL,METHODS,PCA,PCSGS,PPS,RESULTS,WHILE
128,143,169,ADC,AGREEMENT,AMONG,AUTHORS,BJU,BLAND,CONCLUSION,DCE,DWI,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,THESE
462,AMONG,CORRECT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
019,239,300,ARM,CONCLUSION,FURTHER,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TREATMENT,VEGFR
DETECTION
CTC,PSA
HOWEVER,MOLECULAR
PSIP1,PULMONARY,RB1,SNF,SWI,THESE
FOCAL,FURTHER,IMAGE,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,STUDIES,SUMMARY
CURRENT,HOWEVER,LABEL,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,SEVERAL,SUMMARY
457,AFTER,BACKGROUND,COPYRIGHT,EDICIONES,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS
BACKGROUND,BETWEEN,CONCLUSION,DESPITE,FOLLOWING,HODGKIN,IMPROVING,LABEL,LITHUANIA,LITHUANIAN,METHODS,RAPID,RESULTS,WESTERN

169,26S,564,945,AUTHORS,COCL2,HIF,HYPOXIA,LO1,LTD,PRO,WILEY
122,169,945,946,ADT,BACKGROUND,CHEMOKINES,CONCLUSION,COX,INC,LABEL,MCP,METHODS,PSA,RESULTS,THERE,TNF,WILEY
169,AFTER,BACKGROUND,GLEASON,GS7,HYAL1,HYAL4,HYALURONAN,LABEL,METHODS,PCA,RESULTS,SOCIETY,SPAM1
169,HOWEVER,POTENTIAL,THERE,VCH,WILEY
000,008,370,945,947,BACKGROUND,BLOOD,CIS,LABEL,METHODS,OCTOBER,RESULTS,RRS
036,049,169,177,4N0M0,945,946,BETWEEN,COLLEGE,COPYRIGHT,GLEASON,GROUP,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RADIATION,RESULTS,ROACH,ROYAL,THERAPY
140,169,398,AFRICAN,COPYRIGHT,GIVEN,LABEL,LATINOS,LTD,MEN,METHODS,MEXICAN,OBJECTIVE,PSA,PURPOSE,RESULTS
126,142,169,223,BACKGROUND,COPYRIGHT,JANUARY,LABEL,MEN,METHODS,MRI,OBJECTIVE,OUTCOME,PATIENT,PCA,PUBLISHED,RESULTS,SECONDARY,SETTING,SUMMARY,UROLOGY
14C,160,956,BACKGROUND,CASTRATION,CONCLUSION,ELISA,HMGCR,HOWEVER,LABEL,LNCAP,METHODS,PSA,RESULTS
004,013,026,047,085,093,137,145,477,531,757,945,967,BACKGROUND,BIOMEDICAL,CBM,CHINA,CHINESE,KNOWLEDGE,LABEL,LIBRARY,LITERATURE,METHODS,RESULTS,THERE,TNF,UNASSIGNED,VIRTUAL
AKT,BAX,BCL,CHINA,RWPE1,THESE,TRIFOLIUM,WESTERN
BBC,LYNCH,NURSE
160,169,195,309,ACADEMY,AGA,BACKGROUND,BPH,CAP,LABEL,METHODS,NORWOOD,OBJECTIVE,OVERALL,PCR,PSA,RESULTS,SNP,THERE,VII
169,ADDITIONAL,AFFAIRS,BACKGROUND,CENTRAL,COX,EPIGENETIC,LABEL,METHODS,RESULTS,SAS,SOCIETY,VPA
CONCLUSION,GLEASON,LABEL,LNS,LYMPH,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
BACKGROUND,DECREASED,ELISA,HOWEVER,LABEL,METHODS,PCR,RECIPROCAL,RESULTS,SDF,USING
945,954,CELASTROL,CHINESE,ELISA,IKK,IMMUNOBLOT,KNOCKDOWN,PMA,RESULTS,TNF
156,314,ELISA,FURTHER,LABEL,METHODS,NEITHER,OBJECTIVE,ORS,PSA,PURPOSE,RESULTS
AZA,BACKGROUND,CONCLUSION,EMT,EPIGENETIC,FINALLY,FUNCTIONAL,LABEL,MEIER,METHODS,MICROARRAY,NGS,PCA,PCR,RESULTS,TAKEN,WESTERN,WHILE
103,170,COX,END,III,INSTITUTE,LABEL,METHODS,OBJECTIVE,RATIO,RESULTS,SECONDARY,WHILE
954,SEVERAL
232,730,763,767,945,946,947,ALTOGETHER,BURKINA,EOS,ESSENTIAL,EUCALYPTUS,LNCAP,MAJOR,MTT
005,792,AMP,ATG,AUTOPHAGY,CAP,CMI,MACRO,MDV,USING
AKT,KNOCKDOWN,SER1416,SMALL,TAKEN
ERBB3,NEDD4,SHORT,TAKEN,USING
CONSENSUS,MELBOURNE
CURRENTLY
BASED,HISTOLOGY,PET
169,293,294,556,COPYRIGHT,DHT,GFP,HOWEVER,HSP90,LBD,LTD,NTD,SINCE,THESE
002,023,100,166,169,ADVERSE,CHI,COPYRIGHT,COX,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PREEMPTIVE,PROACTIVE,PRW,PURPOSE,RECURRENT,RESULTS,SEPTEMBER,TGC,WHITNEY
169,CARLO,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS
169,176,180,360,548,COPYRIGHT,CTV,CYBERKNIFE,FIXED,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PLANNED,PURPOSE,RESULTS
016,101,102,169,6GY,CIMRT,COPYRIGHT,GROUP,HIMRT,INC,LABEL,MATERIALS,MEN,METHODS,MINIMIZING,OBJECTIVE,R64,RADIATION,RESULTS,THERAPY,THERE
001,169,4N1M0,796,AMONG,COPYRIGHT,COX,END,INC,LABEL,LOCAL,MATERIALS,MEIER,METHODS,NLT,OBJECTIVE,PSA,PURPOSE,RESULTS
014,022,048,169,177,198,214,CD4,CD8,COPYRIGHT,COX,FINALLY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PERIPHERAL,PURPOSE,RESULTS,V65
169,200,AFTER,AUTHORS,BETWEEN,BJU,DESPITE,FEWER,FORCE,LABEL,LTD,MATERIALS,MAY,METHODS,OBJECTIVE,OCTOBER,PREVENTIVE,PSA,PUBLISHED,RESULTS,THERE,TWITTER,USING,WILEY
169,329,ADJUSTMENT,ANXIETY,CHRONIC,DEPRESSION,HOWEVER,ILLNESS,LTD,PERCEIVED,PERSISTENT,SCALE,THESE,WILEY
002,019,125,126,160,169,240,ADVERSE,CONCLUSION,COPYRIGHT,DEGARELIX,III,INC,LABEL,METHODS,OBJECTIVE,RESULTS
COMMITTEE,DIEGO,DRUGS,FDA,INC,INVITED,MAY,ONCOLOGIC,PRODUCT,PUBLISHED,SAN,SUMMARY,UROLOGICAL
001,076,169,175,580,592,648,651,876,BETWEEN,COMPETING,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROBOT,UROLOGICAL
CAP,FINALLY,GSG,HORMONE,NMR,RELEASING
001,160,169,183,COX,DISCUSSION,HRS,INSURANCE,JANUARY,KNOWN,LABEL,LTD,METHODS,NHI,OBJECTIVE,PRIOR,RESULTS,TZD,USING,WILEY
169,379,758,ALLOGENEIC,BACKGROUND,GLEASON,LABEL,METHODS,PRIMARY,RESULTS,STRATIFIED
AREAS,BACKGROUND,COVERED,LABEL,METHODS,OPINION
001,609,AFTER,BACKGROUND,BNSRP,INDEX,JANUARY,LABEL,METHODS,ORP,PCA,RESULTS,SIMILARLY,URINARY
001,456,828,900,ADC,CONCLUSION,DWI,ECE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SEVENTY
3A4,AREAS,BACKGROUND,COVERED,CYP,DIAGNOSTIC,GRANTED,INHIBITORS,LABEL,METHODS,OPINION
954,DOCETAXEL,EMT,EXPRESSION,INCREASED,MOLECULAR,REVERSION,VIM
200,400,500,900,AIM,BACKGROUND,DESPITE,FIFTEEN,JANUARY,LABEL,MEDLINE,METHODS,OBJECTIVE,OCTOBER,RESULTS,USA
001,AGE,C00,C96,DISEASE,LABEL,METHODS,NON,OBJECTIVE,PURPOSE,RESULTS,TREND
BPH,CONCLUSION,DFS,GLEASON,HAI,HEPATOCYTE,IHC,LABEL,METHODS,OBJECTIVE,PCA,PCR,PURPOSE,RESULTS
145,APC,CD133,CONCLUSION,FRAT1,FZD,HOWEVER,LABEL,METHODS,OBJECTIVE,PCR,PPARD,PURPOSE,RESULTS,WNT
ECM,KLK,KLK15,PSA
THESE
954,ATP,GLUT1,LNCAP,ME1,PPP,TARGETING,THESE
ERG,ETS,FINALLY,TMPRSS2,TMRPSS2
001,002,012,028,029,140,177,418,674,760,ELISA,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PCR,PURPOSE,RESULTS,THESE,WESTERN
558,CHINESE,PSA,ROC,SIMILARLY,WESTERN
001,048,207,297,364,373,546,792,945,BLOOD,BPH,FIFTY,FURTHER,GLEASON,OMENTIN,PCA,PSA,THERE,THEREFORE
184,637,836,898,ASH,CONCLUSION,CURRENT,DEPENDENT,INSURANCE,LABEL,METHODS,OBJECTIVE,PURPOSE,RECEIPT,RESULTS,SCM
001,101,169,201,223,509,ARN,AZD,DESPITE,EPI,FINALLY,MEDICAL,MET,NOVEL,ODM,PRESS,PROMISING,PUBLISHED,SARDS,SOCIETY,SRC,TOK,UNIVERSITY
176,177,CELLS,CMV,GFP,HSP70,PC3,RFP,THESE,THREE
145,E2F,PEGYLATED,PEP,TREATMENT
136,147,148,192,214,460,691,947,CONCLUSION,DEGRO,DUE,EVALUATION,HOWEVER,LABEL,MAJOR,METHODS,OBJECTIVE,OVERALL,PURPOSE,QUIRO,RESULTS,THEREFORE
175,BACKGROUND,EVENTUALLY,HBD,HSC,INDUCTION,LABEL,METHODS,MMP,OVERALL,RESULTS,ROC,SCC,UM1
003,008,032,039,ACS,ASPIRIN,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
231,CONVERSELY,DU145,MDA,MKC,MTI,PC3,PREVIOUSLY,RAF,SRC,STAT3
ARRAY,BNIPI,DU145,GADD45A,HRK,IL6,IL8,INCREASED,PCR,TAKEN,TNFSF10,TP53BP2,TRAIL
HEPIN,HPN,THESE,WHILE
169,CONCURRENT,COPYRIGHT,DCP,HOWEVER,INC,LPA,LPAR1,NADPH,PROTEIN,PTP1B,THESE
160,169,382,590,956,CEM,COPYRIGHT,L1210,MOLT4,NOVEL,SAS,SEVERAL,THESE
169,COPYRIGHT,DISULFIRAM,HOWEVER,INC,INHIBITION,MTT,NON,NSCLC,PCR
169,COPYRIGHT,ECM,INC,PERIOSTIN
125,160,169,217,296,946,ATM,COPYRIGHT,CROWN,ERCC2,GENOMIC,GRADE,GSTA1,GSTP1,HOWEVER,INC,LABEL,MATERIALS,METHODS,NOS,OBJECTIVE,PUBLISHED,PURPOSE,RAD51,RESULTS,SCORE,SYMPTOM,TGF,XRCC1,XRCC3
013,083,105,169,609,ADT,CONCLUSION,COX,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS
169,954,BASED,COPYRIGHT,HOWEVER,LTD,TG2,THESE
145,169,COPYRIGHT,HOWEVER,LTD,VPA
BACKGROUND,LABEL,RESULTS,WHOLE
169,233,AUTHORS,BJU,BLACK,CIS,CONCLUSION,FURTHER,LABEL,LTD,METHODS,MONTR,OBJECTIVE,OBJECTIVES,ORS,PROTEUS,RESULTS,WILEY
APO2L,BACKGROUND,BECN1,CASPASE,DU145,GFP,INHIBITION,LABEL,LAMP2,LC3,LNCAP,METHODS,PC3,PCA,RESULTS,TRAIL
169,279,556,735,AFTER,CONCLUSION,COPYRIGHT,GLEASON,HOPKINS,INC,JOHNS,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PNI,RESULTS
BACKGROUND,CELASTROL,CONCLUSION,CONTEXT,DISCUSSION,FORMATION,LABEL,LIPOSOMAL,MATERIALS,METHODS,OBJECTIVE,PEGYLATED,RESULTS
107,121,169,183,353,BRITISH,CARCINOMA,ELISA,EN2,ENGRAILED,ESO,ESOPHAGEAL,IGG,IMMUNOLOGY,SOCIETY,SUN,WHILE
CURRENTLY,DETAILS,SEVEN
AKT,BASED,DU145,LC3,NVP,PC3
026,168,170,173,192,198,200,215,226,959,967,BACKGROUND,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERE,UROLOGISTS
001,010,028,100,113,119,174,849,855,ACCORDING,BACKGROUND,BCR,COX,GLEASON,LABEL,METHODS,PSA,RESULTS
004,046,047,100,105,107,109,129,177,192,BACKGROUND,BMI,CONCLUSION,FURTHER,LABEL,METHODS,MINIMUM,OPERATIVE,RESULTS,ROBOTIC,THERE
180,BACKGROUND,BCR,BPH,COX,GLEASON,HOWEVER,LABEL,LAPTM4B,MEIER,METHODS,PCA,PSA,RESULTS
NUCLEOTIDE,ROC,SNP,STUDIES,THROUGH
BMI,CELLS,LABEL,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SUMMARY,THESE
100,APC,HOXD3,METHYLIGHT,PCA,TGFB2,THESE
ADP,DU145,HENCE,NAD,SF295
169,COPYRIGHT,LTD
169,444,537,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,LTD,METHODS,NSCLC,RESULTS
001,169,952,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,UROLOGICAL
003,028,048,116,125,169,APRIL,BETWEEN,CONCLUSION,LABEL,MARCH,METHODS,OBJECTIVE,REGRESSION,RESULTS,UROLOGICAL
E1A,GIANT,HOWEVER,ONCOLYTIC,PPT,THESE,WESTERN
CLINICALLY,EPIGENETIC,REVERSIBLE
CURRENTLY,PCA,T1C

1ST,400,ANOTHER,SAFOCID
254,255,BIOMARKERS,COLORECTAL,OVARIAN,PRESS,PUBLISHED,UNIVERSITY
169,CHANGES,HOWEVER,OVERALL,RUNX2,SNAI2,SNAIL,THESE
169,AP1,CHIPSEQ,JMD2C,JUMONJI,KDM4C,REDUCED,SRC,THROUGH
641,946,ATTENDANCE,BACKGROUND,DIETARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SESSION,TELEPHONE
169,956,ASSAY,BACKGROUND,BINDING,GAUSSIA,INC,INHIBITOR,LABEL,LBD,LUCIFERASE,METHODS,PCA,PLA,PREVIOUSLY,PROXIMITY,RESULTS,ROS,SPERMIDINE,WILEY
131,169,193,206,527,611,ADT,AFTER,BACKGROUND,BCR,FAVORABLE,GLEASON,HOWEVER,LABEL,METHODS,OVERALL,PSA,RESULTS,SOCIETY
169,2G7,ANOTHER,BACKGROUND,CONCLUSION,GCPII,GLUTAMATE,INC,LABEL,METHODS,RESULTS,USING,WILEY
160,169,174,231,233,ARC,ARTPELVIS,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RAPID,REGARDING,RESULTS,SAS
181,22RV1,954,AFTER,COMPOUNDS,CWR,FIG
169,302,5MG,945,ADVERSE,APRIL,BACKGROUND,BRIEN,CIS,COPYRIGHT,COU,COX,EASTERN,FLEMING,GROUP,HRS,LABEL,LAN,MEIER,METHODS,OBJECTIVE,OUTCOME,PATIENT,PUBLISHED,RESULTS,SETTING,SUMMARY,TREATMENT,TRIAL,UROLOGY,WHILE
003,152,173,298,391,HOPKINS,IPP,JANUARY,JOHNS,SEVEN,THERE
BACKGROUND,LABEL,RESULTS,SHH,VALIDATION
231,950,BACKGROUND,CONCLUSION,DGK,GTPASES,KNOCKDOWN,LABEL,MDA,METHODS,PAK,RESULTS,RHO,SIMILARLY,SW480,SW620,THERE,THESE,TRANSWELL,UNRAVELING
450,750,CONCLUSION,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PTV,RESULTS,THERE,V95,V99
HOWEVER,MRI,THEREFORE
006,114,160,169,183,AMONG,CALCULATED,DHT,ELDERLY,FURTHER,ISCHAEMIC,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,TOTAL,WILEY
069,130,620,BACKGROUND,CMM,FACTORS,FURTHER,LABEL,METHODS,NORWEGIAN,RATES,RESULTS,SCC,SIR
ADDITIONAL,AFRICAN,AMONG,BACKGROUND,CONCLUSION,HRQOL,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PCA,RESULTS,ROUTINE
TEN
169,494,ARTIFICIAL,BACKGROUND,CXCR4,DU145,HOWEVER,INC,LABEL,LNCAP,MATERIALS,METHODS,MIR,MTT,RESULTS,SDF,TUNEL,UTR,WILEY
439,DENMARK,INDIVIDUAL,LABEL,METHODS,OBJECTIVE,OCTOBER,PURPOSE,RESULTS,SEPTEMBER,STRATIFIED
ANOTHER,APRIL,AVAILABLE,BASED,COLORECTAL,CONTROLLED,ERSPC,HARMS,HEART,IMPORTANCE,JANUARY,LABEL,MEDLINE,METHODS,OBJECTIVE,OTHER,OVARIAN,PSA,RANDOMIZED,RELEVANCE,RESULTS,SCORING,SCREENING
001,169,ACE,ADULT,COPYRIGHT,DISEASE,EVALUATION,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS,SOCIETY,STRATIFIED
184,240,LABEL,METHODS,OBJECTIVE,RESULTS,WHILE
497,FIRST,FLORIDA
CURRENTLY,SIX
009,144,165,189,BASEL,CONCLUSION,DUE,LABEL,METHODS,NOMINAL,OBJECTIVE,PURPOSE,RESULTS,WHITNEY
002,020,022,037,042,044,049,BACKGROUND,BAX,BEL7402,CHILD,HCC,HEPG2,HUH,IRT,LABEL,MEIER,METHODS,MMP,OBJECTIVE,PROGNOSTIC,PURPOSE,RESULTS,UNIVARIATE,ZRT
115,AFTER,BACKGROUND,BASEL,LABEL,METHODS,PSA,RESULTS,SHORTER
177,231,945,956,GELATIN,HOWEVER,MCF,MDA,NOS,NOSCAPINE
169,916,936,BASEL,CASPASE,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,TED
945,946,954,AKT,BACKGROUND,EMERGENCE,EMT,LABEL,METHODS,PCA,PREVIOUSLY,RESULTS
34A,CRC,EMT,MEMBERS,REPRESSION,SNAIL,STAT3
169,EQUALLY,PPI,PROTEIN,VARIOUS
AKT,BACKGROUND,ERK,ETS,LABEL,OFTEN,RAF,RAS,RESULTS
172,ADT,CAD,ENGLISH,IAD,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SEVEN,TEN
001,255,278,533,ADDITIONAL,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PCA,PSA,RESULTS,USING
111,160,169,954,COPYRIGHT,DIFFUSION,EDUCATION,FINAL,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PRIMARY,PUBLISHED,PURPOSE,RESULTS,SECONDARY,TESLA,THREE,UROLOGICAL
160,169,COPYRIGHT,EDUCATION,GIVEN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCREENING,UROLOGICAL,USING
160,169,COPYRIGHT,EDUCATION,GLEASON,INC,INVENTORY,IQR,LABEL,LOW,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
945,946,BACKGROUND,CTC,DISCUSSION,DUE,IDENTIFIER,III,IPI,LABEL,METHODS,NCI,PFS,PRIMARY,PSA,QOL,RADIATION,SECONDARY,TRIAL
240,AUSTRALIAN,BACKGROUND,DESPITE,DISCUSSION,LABEL,METHODS,THERE,THEREFORE,TRIAL,USUAL,ZEALAND
110,145,946,956,LNCAP,MAJOR,SOY,THREE
ICT2588,MMP,PRODRUG,VDA,WILLEBRAND
001,019,024,025,031,184,BACKGROUND,BMI,CONCLUSION,CRP,LABEL,METHODS,MRI,PEARSON,RESULTS,RRP
120,177,BACKGROUND,EPITHELIA,HOWEVER,III,IMAGE,LABEL,METHODS,PONCEAU,PRO,RESULTS,THERE
100,315,410,BACKGROUND,FOLLOWING,GLEASON,LABEL,LOW,MATERIALS,METHODS,PCA,PSA,RESULTS,VARIOUS
001,161,APRIL,BACKGROUND,CONCLUSION,HOWEVER,JANUARY,LABEL,MARCH,MEIER,METHODS,RESULTS,SEVERAL
CTC,FDA,SINCE
169,ANOTHER,DESPITE,PCA,SOCIETY
001,104,111,145,177,179,191,208,536,CONCLUSION,CUCL2,LABEL,LENTI,METHODS,OVERALL,PET,RESULTS,SCR,UNLABELLED,WESTERN
169,AUTHORS,DCA,FOLLOWING,LACTATE,LDH,LN3,LNCAP,LTD,METABOLITE,NMR,WILEY
112,113,160,194,371,560,910,BACKGROUND,BRT,CONCLUSION,ESCHWEILER,HDR,LABEL,LDR,METHODS,OFFENBACH,RADIATION,RESULTS,SOCIETY,WORKING
170,CONCLUSION,COX,GIVEN,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PRIMARY,PURPOSE,RESULTS
AFTER,BCG
301,347,546,BACKGROUND,COU,HOWEVER,LABEL,METHODS,PSA,REDUCTION,RESULTS,SERUM
130,5F3,BACKGROUND,COX,DISIALOSYL,DSGB5,FURTHER,HOWEVER,JANUARY,LABEL,MEIER,METHODS,PSA,RCC,RESULTS,THESE
LABEL,MEN,OBJECTIVE,PCA,PREDICTIVE,PURPOSE,QOL,RESULTS,SUMMARY
FOCAL,III,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE,THESE
FOCAL,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,STATE,SUMMARY,THERE,ULTRASOUND
EARLY,FOCAL,LABEL,OBJECTIVE,PARTIAL,PCA,PURPOSE,RESULTS,SUMMARY
169,878,945,AML,APL,CONVERSELY,LABEL,LINC00478,MOL,PML,RAR,RARES,RES,RESPONSIVE,THEREFORE,THESE,UNLABELLED
169,CARLO,COPYRIGHT,DCE,HOWEVER,INC,MONTE,MRI
117,162,169,236,718,ASSESSMENT,COPYRIGHT,EUROQOL,FUNCTIONAL,HRQOL,INC,ISPOR,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SOCIETY,THERAPY
027,103,702,ADDITIONAL,BACKGROUND,CIS,CONCLUSION,FORTY,HOWEVER,LABEL,METHODS,OURRESULTS,RESULTS,RRS
001,048,177,215,485,556,99M,ADC,BACKGROUND,E26,ERG,LABEL,MDP,METHODS,NOD,RESULTS,WHITNEY
BPH,CAP,GENOTYPING,PCR
145,AFTER,CELLIGENCE,PCR,WESTERN
THESE,USING
FOXO1,INHIBITION,LNCAP,PC3,PCR
102,120,124,177,956,ALA,ARG,ASN,ASP,ATBBN,BBN,GBQ,GLN,GLY,HOWEVER,LEU,PARTITION,PET,PHE,THERE,TRP,VAL,VARIOUS
231,300,BACKGROUND,CONCLUSION,LABEL,MATERIALS,MDA,METHODS,RESULTS,SIXTEEN,THESE,WHILE
ABCB1,CASP3,CASP9,DTX,DU145,INDUCTION,MTT,OCT,PCA,PCR,THERE,THESE,VEGFA
169,5CL,BN52021,COPYRIGHT,INC,MCF,NMR,PAF,PC3,WEB2170
169,22RV1,945,946,CONVERSELY,COPYRIGHT,HOWEVER,RESULTS,TRAMP
169,945,946,956,COPYRIGHT,INC,LNCAP,OXIME
125,169,34BETAE12,COA,COPYRIGHT,GATA3,P501S,PUBLISHED,SVS,UROLOGY
169,COPYRIGHT,GLEASON,INC,PATHOLOGY,PCA,PUBLISHED,REVEALING,SOCIETY,SURGERY,THEREFORE
169,2MM,CONCLUSION,COPYRIGHT,GROUP,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PROBE,PURPOSE,RESULTS,THEREFORE
10878,169,3MM,4MM,5MM,6MM,9CM,BACKGROUND,CONCLUSION,COPYRIGHT,CSA,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS
10878,116,131,169,247,2GY,5CC,5GY,7GY,AUC,BACKGROUND,COPYRIGHT,DSH,DUE01,DVH,IRELAND,LABEL,LTD,MATERIALS,METHODS,MVA,OBJECTIVE,PURPOSE,RESULTS,SCORE,SIMILAR
001,017,072,121,169,212,249,262,373,382,AMICO,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,TESLA,UROLOGICAL
169,ASSESSMENT,COPYRIGHT,DESPITE,INC,MEDICAL,PUBLISHED
047,117,169,177,ACCEPTABLE,COPYRIGHT,DOSIMETRIC,INC,MCO,MEDICAL,MINIMIZING,NAVIGATED,NUCLETRON,PUBLISHED,RAYSEARCH,RAYSTATION
169,309,ARD,COPYRIGHT,IRELAND,ITEMS,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROC,THERE
103,124,127,134,139,140,146,169,170,177,198,218,AFTER,CONCLUSION,COPYRIGHT,DTI,FIFTY,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,169,198,239,AFTER,AMONG,CONCLUSION,COPYRIGHT,FDG,INC,LABEL,METHODS,OBJECTIVE,RESULTS
169,ALA,BACKGROUND,CONCLUSION,COPYRIGHT,HVJ,JAPAN,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PDT,PORPHYRUS,PUBLISHED,RESULTS
067,119,126,169,257,782,ADT,BRITISH,COPYRIGHT,EXCLUSION,INC,LABEL,LST,MATERIALS,METHODS,OBJECTIVE,PHOENIX,RADIATION,RESULTS
001,169,654,COPYRIGHT,END,GLEASON,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
143,169,COPYRIGHT,EIGHT,GLEASON,NSI,PGI,PSA
138,169,BACKGROUND,CCL20,CHRONIC,CONCLUSION,COPYRIGHT,LABEL,METHODS,PANCREATIC,PCA,RESULTS
160,169,CFS,COPYRIGHT,HERVS,INC,XENOTROPIC
169,946,AUTHORS,FOUNDATION,JOURNAL,LTD,MOLECULAR,PROTEIN,TGF,WILEY
169,AUTHORS,BJU,MEN,SINCE
BACKGROUND,CANCERS,CONCLUSION,DUE,ENGLISH,EPSCC,ESPCC,HOWEVER,LABEL,METHODS,OCTOBER,PCI,RESULTS,SCC,SCOPE,SMALL,SOCIETY,THEREFORE
946,FAK,THESE
181,DU145,HOWEVER,PC3
AFRICAN,AMERICA,CAUCASIAN,LIMITED
1990S,450,CYP,DME,GST,HENCE,HOWEVER,LEBANON,NAT,PHASE,THERE
167,17Q12,17Q24,CHILEAN,CONCLUSION,HOWEVER,IBM,LABEL,METHODS,OBJECTIVE,PCA,PCR,PSA,PURPOSE,RESULTS
946,INCREASED,PC3,PTTG1,SHRNA,SINCE,SMAD3,TAKEN,TGF,WHEREAS
ADP,COMBINING,CPT,PC3,RAD51,THESE
HOWEVER,RUNX2,USING
001,005,105,BPH,CHANGES,HNRNP,LNCAP,PCA,PSA,THESE
CGP,HOWEVER,INDUCTION,LNCAP,M30,MYC,PCR,THEREFORE,THESE,TREATMENT
169,AFTER,CGA,COPYRIGHT,DNR,LOD,NIR,QDS
001,169,500,CNT,COPYRIGHT,ECL,PSA,ZNO
954,ALDH1,APOPTOSIS,CSC,CXCR4,DU145,JAGGED1,NANOG,NOTCH,NOVEL,PC3,SOX,THESE,TRAIL
LABEL,OBJECTIVE,PURPOSE,RESULTS,SIPULEUCEL,SUMMARY
AMENDMENT,BECKMAN,COULTER,FDA,GEN,INC,INDEX,LABEL,LABORATORY,OBJECTIVE,PCA,PROBE,PURPOSE,RESULTS,SEVERAL,SUMMARY,THESE
838,CONSISTENT,LABEL,OBJECTIVE,PREVALENCE,PURPOSE,RESULTS,SRE,SUMMARY,THERE,TRIAL
177,180,AFTER,FORTY,PSA,THEREFORE
001,853,BETWEEN,CHINA,CHINESE,DRE,FUDAN,FURTHER,HUASHAN,PCA,PSA,UNIVERSITY
GRS,HOWEVER
HIGGINS,OVERALL,SRR,THERE
CARLO,CHINESE,MONTE,OAR,RBM,RED,YBM
169,CMT,CONFORMAL,ENDORECTAL,GERIATRIC,INTENSITY,LEVEL,MEDICAL,NSCLC,PATIENT,PRESS,PUBLISHED,SHORT,SHORTER,SOCIETY,UNIVERSITY,WHERE
946,BASED,ETS,GIVEN,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,TGF,TMPRSS2
FOCAL,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
GROWING,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
CANDIDATES,GLEASON,HOWEVER,LABEL,MRI,OBJECTIVE,ORIGINALLY,PURPOSE,RESULTS,SINCE,SUMMARY,TODAY
BECAUSE,FLA,FOCAL,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
215,CARLO,CONVERSELY,LABEL,MATERIALS,METHODS,MONTE,OAR,OBJECTIVE,PHILIPS,PTV,PURPOSE,RESULTS,THERE
CHANGES
023,135,141,161,169,184,276,278,583,782,861,BACKGROUND,CONCLUSION,INSURANCE,JANUARY,LABEL,MALIGNANCY,MATERIALS,METHODS,PHYSICIANS,PRESS,PUBLISHED,RESULTS,SPM,UNIVERSITY
11Q23,12P24,259,483,542,945,ANOTHER,APOA5,BUD13,CIS,ORS,SNP,VITAMIN
112,132,181,CHO,DU145,IAP,INHIBITOR,LEU,M14,MIMICKING,OVERALL,TOP
169,947,FIRST,HOWEVER,NR1C3,NR2C2,NRS,PCA,PEROXISOME,SOCIETY,THESE,THIRD,TR4,TZD
177,99M,BINDING,BT474,IMAGING,ISOLINK,LABEL,MEMBRANOUS,METHODS,OBJECTIVE,PURPOSE,RESULTS
BACKGROUND,DELTA,JAK,LABEL,METHODS,PRL,PRLRS,PROLACTIN,RESULTS,WESTERN
116,344,ADDITIONAL,AFTER,AIP,COX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
160,MREIT,RES,SINCE,WITHOUT
169,FESEM,NPS,PLA
169,ART,CONCORD,COPYRIGHT,CTS,HEALTHCARE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OPT,PROWESS,PUBLISHED,PURPOSE,RADIATION,REALART,RESULTS,SIEMENS,SOCIETY,THREE,VARIOUS
100,169,COPYRIGHT,ECLIPSE,INC,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PLANS,PTV,PUBLISHED,PURPOSE,RADIATION,RESULTS,SIXTY,SOCIETY,STUDIES,SYSTEMS,THERE
100,169,COPYRIGHT,CROWN,HOWEVER,INC,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SYSTEMS,TEN
122,200,ADVERSE,DOSIMETRY,DVH,GROUP,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RADIATION,RESULTS,THERAPY,THERE,V100PTV,V80BLADDER,V80RECTUM
ADDITIONAL,AREAS,BACKGROUND,COVERED,FDA,LABEL,METHODS,OPINION,SIPULEUCEL,THESE
025,169,200,211,22RV1,BACKGROUND,CHINESE,CLINICALLY,CONNECTIVE,EMT,EPITHELIAL,ERG,ERK,ETS,HOWEVER,INC,KAZAL,KNOCKDOWN,LABEL,MEK,METHODS,PCA,PCR,RESULTS,THESE,WESTERN,WILEY
HOWEVER
565,577,BEUKEMA,FOWLPOX,FPV,PAP,REV,THESE,VACCINE
DENDRITIC,HOWEVER,PHASE
176,201,DNS,EPE,GLEASON,HOWEVER,INSTEAD,NON,PCA
NANOSIZED
AAG,ATRASENTAN,CONCLUSION,DOCETAXEL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
DU145,ERK,PCA
DESPITE,KNOWLEDGE,MMC,NMIBC,STRATEGIES
160,174,CALYPSO,CYBERKNIFE,INITIAL,TRANS
009,027,046,ACUTE,APRIL,BACKGROUND,BETWEEN,BOWEL,CONCLUSION,FAMOTIDINE,GRADE,III,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
ADT,HRPCA,NOS,PCA,SEQUENCING
AES,ASSESSMENT,BNSRP,EIGHT,ENCOUNTER,GAQ,HOWEVER,INDEX,PROFILE,RADICAL,SEP
418,GLEASON,HGPIN,HOPKINS,JANUARY,JOHNS,PATHOLOGY,PCA,PERINEURAL,PNI,SERVICE
100,AB1,AB2,THEREFORE
CASTRATION,EMT,NOTABLY,REVERSE,THESE
648,ALTERED,AMONG,BACKGROUND,FURTHER,HOWEVER,LABEL,METHODS,MICRORNAS,PCA,PCR,RESULTS,THESE,USING
160,ARCAP,BACKGROUND,DHE,DISMUTASE,EMT,LABEL,LNCAP,METHODS,MIGRATION,MITOSOX,MTS,MUSCADINE,RESULTS,ROS,SNAIL,SOD,SPECIES,SUPEROXIDE,THEREFORE
008,120,NON,PRIMARY
AFTER,BLI,NMIBC
139,171,255,716,759,803,AMONG,HOWEVER,JANUARY,MARCH,PATIENT,PCA,PSA,ROC,THEREFORE
DIFFUSION,HOWEVER,MRI,WHILE
FDA,HOWEVER,SEVERAL
169,AGING,CONCLUSION,LABEL,METHODS,OBJECTIVE,PRE,RESULTS,SOCIETY,STUDIES,WHY
001,009,023,335,645,670,BECAUSE,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STUDIES
CELLSEARCH,CONCLUSION,COX,CTC,IDI,III,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,REGRESSION,RESULTS,ROC,S0421,THESE
169,239,945,946,CAF,CCM,INC,PC3,PCA,PRSCS,SILIBININ,SMA,TGF,WILEY
169,177,916,ARG,BACKGROUND,CPD,G129R,IHC,INC,LABEL,METHODS,PRL,RESULTS,SEM,TMA,WILEY
169,BACKGROUND,CONCLUSION,CYS,GLU,INC,LABEL,METHODS,PC3,PIP,PLACEMENT,PREVAILING,RESULTS,SMALL,THROUGH,USING,WILEY
169,946,AKT,BACKGROUND,CAP,DU145,EMT,EXPRESSION,INC,KNOCK,LABEL,LNCAP,METHODS,PCR,RESULTS,WESTERN,WILEY,WNT
MOLECULAR
22RV1,BECAUSE,CWR,DESPITE,DUSP1,GSK650394,INCREASED,LAPC4,MAP,MDV3100,NR3C1,PSA,R1881,THEREFORE
169,1960S,HIV,HODGKIN,INCIDENCE,KAMPALA,NHL,OTHER,THERE
169,BRITAIN,COPYRIGHT,GREAT,HUNTINGTON,IRELAND,JOURNAL,LTD,PATHOLOGY,PUBLISHED,SOCIETY,VELASCO,WILEY,YESTE,ZDHHC
174,MAPISAL,PREDICTIVE,RADIATION,RRD
101,108,109,129,132,138,163,169,183,200,ALB,CARLO,CRP,CTRLS,EARLY,MONTE,SAMPLES
001,036,101,124,169,BPH,HOWEVER,PCS,SERUM,THEREFORE
229,238,384,CHINA,CHINESE,CSB,GENOTYPING,MASSARRAY,NER,XPC,XPG
AFTER,DENOSUMAB,GROUP
161,241,554,BACKGROUND,EVENTUALLY,LABEL,METHODS,OVERALL,PSA,RESULTS
014,115,199,967,BACKGROUND,CIS,FSG,GLEASON,LABEL,METHODS,POLYPHENOL,PSA,RESULTS,THERE
AFTER,ASSESSMENT,BACKGROUND,BCR,CAPRA,CAPSURE,LABEL,METHODS,PPV,PSA,RESULTS,STRATEGIC,THESE,THREE
LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE,THESE
LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
001,169,945,946,954,CHLAMYDIA,COPYRIGHT,LTD,MYD88,PCR,SEVERAL,TLR,TNF
169,COPYRIGHT,GLEASON,HOWEVER,PROSTATIC,THERE,THESE
169,BACKGROUND,COPYRIGHT,COX,LABEL,LTD,MEIER,METHODS,OVERALL,REGARDING,RESULTS
169,COPYRIGHT,LTD,PCA
001,028,100,125,160,169,COPYRIGHT,D90,EMULATING,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PLACING,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE
169,COPYRIGHT,HOWEVER,IRELAND,LTD
000,148,169,233,355,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,INCIDENCE,LABEL,METHODS,MORTALITY,RESULTS,SAS
160,169,5GY,AFTER,COPYRIGHT,CTV,D90,INC,IPS,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SOCIETY
739,AP1,BACKGROUND,BASED,EPITHELIAL,INDUCED,LABEL,MET,MYC,NFKB1,OVOLS,REFLECTING,RESULTS,STAT1,STAT3,TFS,THESE,TRANSITION
169,BMI,CONCLUSION,COPYRIGHT,DISCUSSION,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,SAS
CANCERS,CUTANEOUS
001,002,169,ACCORDING,AUTHORS,BCR,BJU,COX,GLEASON,LABEL,METHODS,NETWORK,OBJECTIVE,PCA,RESULTS
111,169,245,AUTHORS,BJU,EPWORTH,HEALTHCARE,HOWEVER,LABEL,MACCALLUM,MELBOURNE,METHODS,OBJECTIVE,PETER,RESULTS
100,169,190,ANGELES,CALIFORNIA,CONTINENCE,INDEX,LABEL,LOS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNIVERSITY,URINE,UROLOGICAL
001,140,169,239,474,ADT,AFTER,AMI,AUTHORS,BJU,CAD,COMPETING,END,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,SCD,USA
169,581,AUTHORS,BJU,CONSOLE,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PROPENSITY,RESULTS,RETZIUS,THERE
120,228,BETWEEN,GLEASON,LABEL,LOW,METHODS,OBJECTIVE,PSA,RESULTS,T1C,USING
000,100,120,240,308,AIM,BESIDES,CALPHAP,CROATIA,EASTERN,GLEASON,INSTRUMENT,PCR,PHD,ROCHE,SNP,THERE,THESE,TNF,V50
CONDITIONS,FEDERAL,ICD,PROGRAM,RELATED,SEPTEMBER,THROUGH,TRADE,WORLD,WTC
169,945,946,BECAUSE,BIOLOGISTS,COMPANY,FAK,LTD,PUBLISHED,THESE
2471373,4528134,878,985,BACKGROUND,INCIDENCE,LABEL,METHODS,PSA,RESULTS,THERE
133BM,169,178,CCK,COX,LABEL,LNCAP,METHODS,OBJECTIVE,PCR,RESULTS,WESTERN
169,HOWEVER,INC,WILEY
174,223,ALPHARADIN,III
945,HIF,HOWEVER,HYPOXIA,MMP,PC3,SNAIL,TNF
169,181,BACKGROUND,CYP17A1,ESPECIALLY,H295R,HOWEVER,INC,INHIBITION,LABEL,METHODS,PIC,RESULTS,RSV,RSVDA,RSVTA,RSVTM,SECRETION,STEROID,SULT1E1,TREATMENT,WILEY
1ST,2ND,344,392,3RD,4TH,736,COMPARISON,GENOTYPING,GSTP1,MNSOD,PCA,PCR,PSA,RUSSIAN,SNP
145,169,BACKGROUND,CH2,CH3,CONCLUSION,F11,INC,LABEL,METHODS,MONOCLONAL,OTHER,PET,RESULTS,SINCE,WILEY
BRCA2
001,029,169,945,ADDITIONAL,ATTITUDES,BACKGROUND,BANKS,BIOBANKING,CONTENT,ENGLISH,INTENTION,ITEMS,KNOWLEDGE,LABEL,METHODS,RESULTS,SPANISH
001,015,100,200,BLACK,CONCLUSION,HRQOL,LABEL,METHODS,OBJECTIVE,OVERALL,PATIENT,PURPOSE,RESULTS,SCALE,THESE,UTILITY,WHITE
100,110,398,407,805,COX,GLEASON,LABEL,LRP,MATERIALS,METHODS,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RESULTS,RFS,RRP,THERE
FURTHER,TEPHROSIA
169,221,947,IFN,JAK,SOCS3,STAT1,STAT3
169,231,47D,946,956,ACTIVATION,AMP,COPYRIGHT,DU145,FINALLY,INC,MDA,WNT
10A,10D,10H,10K,12A,160,169,205,549,945,946,COPYRIGHT,MTT,NMR,SAS
169,954,COPYRIGHT,FEDERATION,PUBLISHED,RAS,RASSF,SOCIETIES
100,169,27632,956,COPYRIGHT,EMD638683,FEDERATION,GSK650349,NHE,PUBLISHED,RHO,SOCIETIES,TAC
150NM,169,176,24H,500,956,COPYRIGHT,FINALLY,FURTHER,PAC,PC3,R11
022,038,215,ASSESSING,ERG,FUNCTIONAL,GLEASON,KETTERING,MSKCC,PCA,RESULTS,SLOAN,SWEDISH
169,AKT,ALTERED,COPYRIGHT,DEPLETION,ENABLED,INC,RAMAN,THESE
169,AKT,COPYRIGHT,INC,YUE
ALTOGETHER,ATPASES,THEREFORE,THESE
ID1,INHIBITOR,PC3,SIMILAR
000,001,100,ASR,BACKGROUND,BLADDER,EDUCATION,LABEL,MATERIALS,MEDICAL,METHODS,RESULTS,UROLOGICAL
283,301,302,343,940,ASSESSMENT,BACKGROUND,BASED,CONCLUTIOS,COU,EVALUATION,GRADE,GRADING,HRS,LABEL,LIBRARY,LITERATURE,METHODS,PSA,QUALITY,RCT,RESULTS,SCIENCE,STATA,SUMMARY,TEN,THEREFORE,WEB
APOPTOSIS,HSC70,HSP70,HSP72,HSP90,PCA,THESE,WESTERN
945,BACKGROUND,BPH,CYP17,LABEL,MATERIALS,METHODS,PCR,RESULTS,TAQ,VDR

177,215,945,956,BCH,CONCLUSION,ICP,LABEL,MATERIALS,METHODS,MTS,OBJECTIVE,PURPOSE,RESULTS
13527,19191,32718,ARMED,COMPARISON,CONCLUSION,DEPARTMENT,INSTITUTE,LABEL,METHODS,OBJECTIVE,PATHOLOGY,RAWALPINDI,RESULTS,TUMOURS
117,459,AMICO,EIGHT,FIFTY,FIRST,GLEASON,LABEL,LYMPH,METHODS,OBJECTIVE,RESULTS
169,GLEASON,INC,JAGGED1,LNCAP,PC3,PSA,SPRY1,THESE,WILEY
127,169,197,206,AFTER,AST,BACKGROUND,GLEASON,LABEL,METHODS,RESULTS,SOCIETY,THERE
177,187,383,BBN,GGG,GSG,IR800,LABEL,METHODS,NH2,OBJECTIVE,PROCEDURES,PURPOSE,RESULTS
174,223,BECAUSE,EMA,FDA,MEDICINES
145,CCL11,CCR,CHEMOKINES,ELISA,EOTAXIN,ERK,KNOCKDOWN,MEK,MMP,PCR,U0126
001,015,BACKGROUND,CONCLUSION,CONVERSELY,DRE,DSM,ESI,FURTHER,LABEL,METHODS,PCA,PSA,RESULTS,STUDIES,THEREFORE,USING
001,002,392,600,BASED,BASEL,BETWEEN,GERMANY,GPS,ISS,LABEL,MAY,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS
169,184,425,921,CHARLOTTE,COPYRIGHT,EDUCATION,EFFORTS,INC,LABEL,MATERIALS,METHODS,NORTH,OBJECTIVE,PREMIER,PUBLISHED,PURPOSE,RESULTS,SURGERY,UROLOGICAL
018,024,027,033,043,045,049,160,169,172,174,279,COPYRIGHT,DAILY,EDUCATION,INC,LABEL,MATERIALS,MEDICATION,METHODS,OBJECTIVE,PSS,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
160,169,233,COPYRIGHT,EARLY,EDUCATION,INC,IQR,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
001,006,466,BASEL,CONTROLLED,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PCA,RESULTS,SCORE,SMD,SYMPTOM,THREE
169,ADT,BACKGROUND,COPYRIGHT,END,LABEL,METHODS,OBJECTIVE,ORP,OUTCOME,PATIENT,PROPENSITY,PUBLISHED,RESULTS,ROBOT,SETTING,SUMMARY,UROLOGY
001,169,177,325,729,828,956,ADC,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PEARSON,PURPOSE,RESULTS,THERE
001,122,280,647,679,836,979,BACKGROUND,BCR,LABEL,METHODS,ONCOLOGIC,POTENCY,PSA,QUALITY,RESULTS,THERE
006,169,258,680,752,BACKGROUND,BETWEEN,CONCLUSION,COX,CSS,LABEL,MEIER,METHODS,NOTABLY,POTENTIAL,RESULTS
001,177,AREAS,CONCLUSION,DIL,INTENSITY,KNOWLEDGE,LABEL,METHODS,MRI,NTCPS,OBJECTIVE,RESULTS,TCP
947,AKT,BASED,CD8,IFN,NAIVE,RADIATION,TCR,TH1,THESE,WHEREAS
190,214,946,AKT,PHLPP,TGF
003,169,368,725,736,EGGER,INCLUSION,JANUARY,LITERATURE,MANAGER,MEDLINE,RRS
187,220,365,AFTER,CHOLINE,CONCLUSION,CT0,CT1,DOSES,GRADE,GROUP,HTT,LABEL,LNS,METHODS,OBJECTIVE,PCA,PET,PSA,PURPOSE,RADIATION,RESULTS,SIB,THERAPY
009,036,047,052,587,BACKGROUND,LABEL,METABOLIC,METHODS,RESULTS
169,HOWEVER
002,005,ALLOCATION,BACKGROUND,CENTRAL,CONCLUSION,CONTROLLED,HOWEVER,INCREASED,LABEL,MEDLINE,METHODS,RESULTS
806,945,CLU,HIF,HOWEVER,HRE,LNCAP,PCR,PRO,USING
013,113,183,215,441,BACKGROUND,BIOVU,CLL,CONCLUSION,DLBCL,HODGKIN,INITIATIVE,LABEL,METHODS,NHL,OBJECTIVE,POPULATION,RESULTS,SLL,WOMEN
22RV1,GADD153,LNCAP,MTT,TAKEN,THESE,UNION,USING,WESTERN
004,113,ASSIGNING,AUC,DCE,DWI,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
001,131,178,293,AFTER,BACKGROUND,CAB,KATTANS,LABEL,LYMPH,METHODS,MRI,PATHOLOGIC,PRIMARY,PSA,RESULTS,SECONDARY,WHILE
101,200,502,506,EMT,EPITHELIAL,FURTHER,MET,MIRNA
AIM,G2M,LABEL,METHODS,MSC,MTT,OBJECTIVE,RESULTS
FOCAL,MEDICAL,PATHOLOGY,RADIATION,RADIOLOGY,SYMPOSIUM,TREATMENT,UROLOGY
AMP,BACKGROUND,HIF,LABEL,METHODS,PCA,RESULTS,THEREFORE,TPE
001,200,247,347,348,695,BACKGROUND,BETWEEN,GROUP,HOWEVER,LABEL,METHODS,RADICAL,RESULTS,SECONDARY,SOCIETY,SWEDISH
133,169,199,253,AUSTRALIAN,BACKGROUND,BVI3000,BVI9400,COLLEGE,LABEL,METHODS,RESULTS,ROYAL,TREATMENT,ZEALAND
169,370,BACKGROUND,BRITISH,EPH,EPHA2,KEY,LABEL,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS,SOCIETY,TRP
RELEASE,THESE
114,221,268,ANTIGEN,BACKGROUND,HOWEVER,LABEL,METHODS,OBJECTIVE,OCTOBER,PSA,RESULTS,THESE
100,AIM,CONCLUSION,FOXA1,LABEL,MATERIALS,METHODS,OBJECTIVE,PGR,PSA,RESULTS,THEREFORE
005,126,1ST,213,2ND,BACKGROUND,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,REMISSION,RESULTS,SEPTEMBER
ACS,ACT,ACUTE,CAD,CARDIAC,CONCLUSION,GENSINI,GRACE,INFARCTION,LABEL,MACES,MATERIALS,METHODS,MYOCARDIAL,OBJECTIVE,PSA,PURPOSE,RESULTS,SERUM,SIXTY,STEMI,THERE,WHILE
001,177,190,COMPOSITE,CONCLUSION,HOLMIUM,INDEX,LABEL,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS,SCORE,SYMPTOM
HOWEVER,INFECTIOUS,PATHOGENIC
ACTIVATING,CHINESE,DELETIONS,GLEASON,IHC,L858R,MUTATIONS,PCA,THERE
177,18F,215,ADC,ADCMEAN,CONCLUSION,DIFFUSION,FIFTY,FURTHER,LABEL,METHODS,MRI,OBJECTIVE,PET,RESULTS,SUVMEAN,THERE
ASIAN,CONVERSELY,PSA,WESTERN,WESTERNERS
145,BACKGROUND,CAP,FUNCTIONS,GFP,INHIBITION,LABEL,METHODS,PC3,RESULTS,RHO,ROCK1,ROCK2,SELECTIVE,SIM,TEM
012,100,181,22RV1,BPA,LNCAP,NPREC,PSA,THESE
001,ART,DESPITE,NAF,NEITHER,PET,SIXTEEN,SKELETONS,TEN,THREE,TRT
117,150,168,177,191,ATLAS,DESPITE,HAUSDORFF,PET,SIXTEEN,SKELETONS,THEREFORE
116,FINALLY,RESULTS
NSE,THEREFORE
COMPOSITE,INDEX,JAPAN,QOL,SWITCHING
177,227,705,946,BMJ,BRITISH,GROUP,HOWEVER,IFN,LABEL,LIMITED,METHODS,OBJECTIVE,PUBLISHED,PUBLISHING,RESULTS,STATISTICS,THERE,USING,VITAL
001,005,127,169,268,333,ADT,AFTER,BACKGROUND,COMBOGS,CONCLUSION,COPYRIGHT,GPC,INC,INCREASING,LABEL,MEN,METHODS,RESULTS,WHETHER
0000001,068,081,169,474,615,639,AFRICAN,AMERICANS,CAUCASIAN,COPYRIGHT,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RECORDS,REPRINT,RESULTS,STUDENT
100,160,169,176,500,946,AMP,COPYRIGHT,GROUP,INFECTION,INFECTIOUS,JANUARY,LTD,NOTABLY,PUBLISHED,SIMILARLY,SOCIETY,TRACT,URINARY
019,169,859,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
DIGITAL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,VARIOUS,YOUNG
176,215,ARRAY,DISCOVERY,FOCUSED,INSIGHTEC,ISATA,LABEL,LTD,METHODS,MHZ,NUMERICAL,OBJECTIVE,PURPOSE,RESULTS,TREATABLE
100,120,140,165,241,274,947,BASED,CTDIVOL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,177,ART,CTS,CTV,DSC,LABEL,LARGE,METHODS,OAR,OBJECTIVE,PTV,PURPOSE,RESULTS,SIEMENS,THREE,V45GY,V60GY
003,AUC,CAD,CONCLUSION,DIAGNOSTIC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROC,SEPTEMBER,SEVEN
EBP,INSTITUTE
CNB,ECM
LAM,PIVOTAL,THESE,TSC
ERG,TMPRSS2,TREATMENT,USP9X
169,ADT,CURRENT,SOCIETY
114,194,GLEASON,GRAND,JOURNAL,LABORATORY,PSA
299,470,645,680,AFTER,CONCLUSION,EARLY,III,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PRIMARY,PURPOSE,RATES,RESULTS,SRE,ZOLEDRONIC
266,661,CHRONIC,FAT,NETWORK,PERINEURAL,REPORTING,TOTAL,WHILE
169,916,HSC70,MYC
148,169,737,PAF,SWEDISH
DESPITE,LATINAS,THEIR
165,239,BACKGROUND,DRE,GLEASON,LABEL,METHODS,PSA,RESULTS,TPTPB
129,475,670,AGE,BACKGROUND,BED,CONCLUSION,COX,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,VARIABLES
169,COPYRIGHT,DU145,GPNMB,HOWEVER,INC,MMP,NON,PC3,PCA
BMI,CIS,COX,FOLLOWING,HOWEVER,HRS,LITHUANIAN,SMOKING
292,300,786,794,CTL,EF292,EF786,HLA,HNSCC,HODGKIN,IGG,KNOCKDOWN,NHL,PBMCS,THESE
CHINESE
00001,002,007,169,967,BACKGROUND,BETWEEN,CENTRAL,CONCLUSION,CONTROLLED,COPYRIGHT,EGGER,FIXED,INC,LABEL,MATERIALS,MEDLINE,METHODS,OVERALL,RADICAL,RESULTS,SCIENCE,SEVENTEEN,SURGERY,WEB
497,CRP,CSS,HOWEVER,PCA,PFS,RELATED,SEVERAL
ADP,ETS,PARP1
CXCR2,IL8,P53,PSA,THERE
METASTASIS,METASTATIC,VARIOUS
DCE,DWI,MRI,WORLD
001,169,238,511,549,557,704,AUC,AUTHORS,BECKMAN,BJU,CONCLUSION,COULTER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PHI,PRO,PROMETHEUS,PSA,RESULTS
001,169,561,AUTHORS,BJU,INDIVIDUAL,LABEL,METHODS,OBJECTIVE,PFS,RESULTS
169,697,ABOUT,AFTER,AUTHORS,BJU,DISEASE,INDEX,LABEL,METHODS,OBJECTIVE,REGRESSION,RESULTS
001,004,169,384,AFTER,AUTHORS,BCR,BJU,CONCLUSION,COX,EQUAL,GIVEN,LABEL,METHODS,OBJECTIVE,RESULTS,WHETHER
CAP,CONTROL,CURRENT,GLEASON,THESE,TNM,UNION,WESTERN
STUDIES
169,BCR,BRITAIN,COPYRIGHT,FGFR1,FGFR2,FGFR3,GREAT,IRELAND,LTD,PUBLISHED,SOCIETY,WILEY
GASTRIC,HOWEVER
954,BACKGROUND,LABEL,METHODS,NUCLEAR,PAL,RESULTS,THESE
500,AMONG,IMS,MALDI,OCT,PAS,PES,PIS,THESE
246,400,457,ECM,EXOME,LNCAP,THESE
945,946,AGR,CASPASE,FAILURE,PC3,PROTEIN,THESE,TRAIL
DU145,HOWEVER,THESE
181,215,CALCITRIOL,HOWEVER,MWF,OVERALL,THEREFORE,TRAMP
228,947,FINNISH,POISSON,SIMILAR,THESE
034,287,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS
945,CPT,DOX,GGAGTCC,GGCAGAGCCC,GGGAAAGTCC,IMMUNOBLOT,LNCAP,PSA,TRANSIENT
181,DEPENDING,NEURITE,RGD,SCLCS,SMALL
002,005,020,022,664,702,CHINESE,IGF,IGFBP,INSULIN,PCA
ALZHEIMER,CANCERS,CENTRAL,CNS,COLORECTAL,NERVOUS,P53,PARKINSON,THERE,THESE,WNT
001,044,108,125,143,158,210,251,270,426,ASSESSMENT,BACKGROUND,GLEASON,JAPAN,LABEL,METHODS,RESULTS
169,BCL,CURRENT,INC,RU486,WILEY
AFTER,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
169,272,BACKGROUND,GLEASON,LABEL,METHODS,NEITHER,NUTRITION,OBESITY,PREVENTION,RESULTS,THESE
BACKGROUND,BMI,BPH,FINALLY,INDEX,KEY,LABEL,RDA,RESULTS,WHR
123,455,461,909,CIS,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,ORS,PURPOSE,RESULTS,SYSTEMATIC
181,AKT,APOPTOSIS,BAX,BCL,DIAMIDINO,DU145,JUN
134,351,397,884,945,BIOLOGY,CAUCASIANS,CBM,CHINA,CIS,HOWEVER,ORS,PVUII,RESULTS
001,012,015,DU145,HBXAP,HOWEVER,PSA,RSF,THERE
003,007,008,015,031,100,165,190,254,518,967,CRS,DBS,DIFFUSION,DWI,FORTY,GBS,GLEASON,GSS,HGG,MCNEMAR,MRI,MRS,PCA
169,ATM,MECHANISM,PCA,PRESS,PUBLISHED,RWPE1,TESTICULAR,TR4,UNIVERSITY,USING
2AX,DU145,GLIONITRIN,SER1778,TAKEN
103,222,CAP,CPG,MICROARRAY,PCR,PREDICTION,PSA,THESE
169,COPYRIGHT,DPV,OVERALL,PPY,PSA,SEM
130,AMD3100,ANOIKIS,CXCR4,HOWEVER,MFE,SDF,SKBR3
169,COPYRIGHT,E2F,FOXM1,INDIRECTLY,PCA,THESE,THROUGH,USING
169,BIP,COPYRIGHT,GLUCOSE,GRP78,HCC,HEPG2,INC,PCR,SORAFENIB,WESTERN
116,169,18B,969,COPYRIGHT,EARLY,HCT,PC3,SAS,THESE
001,134,169,ACCORDING,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,PATHOLOGY,PSA,RESULTS,SOCIETY,UROLOGICAL,USING
INC,LNCAP,NAP,PUBLISHED,SET,THESE,VARIOUS
169,806,CAPSURE,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCI,PROVIDERS,PUBLISHED,PURPOSE,RESULTS,SECONDARY,URINARY,UROLOGICAL,WHILE,YOUNGER
015,169,793,COPYRIGHT,EDUCATION,INC,LABEL,MARCH,MATERIALS,MEN,METHODS,MUSIC,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,THESE,UROLOGICAL,WHILE
100,169,174,AUC,CHEMPRO,COPYRIGHT,EDUCATION,INC,LABEL,LEAVE,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
001,101,123,160,169,294,627,683,850,AFTER,ASIAN,CONCLUSION,COPYRIGHT,COX,EDUCATION,END,FOUNDATION,HISPANICS,INC,JANUARY,LABEL,MEDICAL,METHODS,OBJECTIVE,OVERALL,PUBLISHED,RESULTS,THESE,TREATMENT
169,ADC,ASSESSMENT,COLLEGE,COPYRIGHT,DIFFUSION,DWI,LTD,MRI,PREDICTION,PUBLISHED,RCC,ROYAL
118,169,170,183,190,221,236,391,421,422,843,862,AUG,BACKGROUND,BASED,BETWEEN,COPYRIGHT,COUNCIL,DEARNALEY,DEC,FUNDING,IQR,JAN,LABEL,LTD,MEDICAL,METHODS,NEITHER,OVERALL,PUBLISHED,RESULTS,T1B,T3A,THESE,TREATMENT
169,COPYRIGHT,INC,POU5F1B,PUBLISHED,SEVERAL,SOCIETY
COLOR,DOPPLER,INC,PUBLISHED
169,177,946,BAX,BCL,COPYRIGHT,PAS,PCA,TAKEN
160,169,193,ADL,CLINICIANS,CONCLUSION,COPYRIGHT,INC,LABEL,MEDICAL,METHODS,OBJECTIVE,PANEL,QOL,RESULTS,USING
001,008,061,088,100,160,169,341,440,543,CONCLUSION,COPYRIGHT,END,HOWEVER,INC,LABEL,MEN,METHODS,OBJECTIVE,PROPENSITY,RESULTS,SCT,SRP,THERE
160,169,BACKGROUND,CONCLUSION,COPYRIGHT,FIFTY,FURTHER,INC,LABEL,METHODS,PEARSON,POSTERIOR,ROCCO,SCORE,SHORT,SUPPORT,SYMPTOM,TECHNICAL
005,017,160,169,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THOSE
100,160,169,CONCLUSION,COPYRIGHT,DUTCH,FINDING,GLEASON,INC,LABEL,LINKAGE,MEN,METHODS,MRI,OBJECTIVE,PCS,RESULTS,T1C
169,COPYRIGHT,GIVEN,INC,PSA
038,160,169,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SCORE
001,169,AUSTRALIAN,BACKGROUND,COLLEGE,CONCLUSION,D95,GRADE,LABEL,METHODS,MRI,RESULTS,ROYAL,SECONDARY,TEN,TREATMENT,V30,V40,V65,V70,V75,V80,ZEALAND
169,BACKGROUND,FOCUS,LABEL,LTD,MEN,METHODS,OBJECTIVE,OBJECTIVES,PREDICTORS,RELEVANCE,RESULTS,THERE,UNIVARIATE,WILEY,WIVES
014,108,135,184,232,CONCLUSION,CONTINENCE,ESI,INDEX,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SCP,USING
CONFORMAL
BACKGROUND,BESIDES,CONCLUSION,FIG,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTPATIENT,PCA,PSA,PTH,REF,RESULTS,SERUM,TAB,UROLOGY,YET
145,5MM,ACUTE,AFTER,BACKGROUND,BPH,CONCLUSION,CONSISTED,JANUARY,LABEL,LAGOS,METHODS,NIGERIA,NIGERIANS,OBJECTIVE,RESULTS,THERE,WHOLE
ANOTHER,CROHN,DESPITE,HOWEVER,RESULTS
AFRICAN,BACKGROUND,CONCLUSION,CUTANEOUS,ENGLISH,LABEL,MANAGEMENT,NIGERIA

349,CTS,DSC,IMAGE,VALIDATED
LABEL,METHODS,RESULTS,ROC,UNLABELLED
HOWEVER,IMAGE,ISA
DUE,LAPLACIAN,PCA,PSA
T2W
CURRENT
SEVERAL
ALA,CONCLUSION,GLEASON,GLN,GLY,LABEL,LEUNH,METHODS,PEG,PET,PHE,RESULTS,STA,T1C,T2B,THREE,TRP,UNLABELLED,VAL
100,169,COPYRIGHT,GATA3,INC,WILEY
110,169,176,BACKGROUND,BLOOD,HOWEVER,INC,INDEX,LABEL,METHODS,PRO,PSA,RESULTS,WHOLE,WILEY
024,510,997,AFTER,CONCLUSION,FDG,FOM,LABEL,MEN,METHODS,NAF,ONCOLOGIC,PET,POM,REFERRING,RESULTS,UNDER,UNLABELLED
095,107,116,125,366,661,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SURVIVORS,UNASSIGNED
102,174,LABEL,MEDICAL,METHODS,MOS,NURSING,OBJECTIVE,OBJECTIVES,PROGRAM,PURPOSE,RESULTS,SETTING,SURVIVORS,VARIABLES
124,131,300,BACKGROUND,BASED,CONCLUSION,DOSIMETRY,EXM,GBQ,LABEL,MBQ,METHODS,MIP,PCA,PET,PSA,RESULTS,SINCE,SIXTEEN,VOLUMES
AZD1480,HOWEVER,JAK,METASTATIC,STAT3
206,880,ASP,EUROPEANS,GLU,GLU298ASP
001,007,10924,BACKGROUND,CLEVELAND,COMPETING,LABEL,MDS,METHODS,OVERALL,RESULTS
169,BACKGROUND,COLORECTAL,FINAL,HOWEVER,IMPUTATION,INITIALLY,LABEL,LCS,METHODS,OVARIAN,RESULTS,SCREENING,SOCIETY,TRIAL
151,AFTER,BACKGROUND,CONCLUSION,COX,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,PARAMETERS,PSA,PSADT,PURPOSE,RESULTS,SRT,UNIVARIATE
001,011,023,029,177,C30,GLEASON,HRQOL,QLQ,TREATMENT
00001,945,BESIDES,HIF,P582S,STUDIES,THERE
103,108,141,164,305,BASED,CCP,CLINICIANS,CONCLUSION,CONVERSELY,LABEL,METHODS,OBJECTIVE,OVERALL,PHYSICIANS,PRE,RESULTS,THERE,TREATMENT
BACKGROUND,DOG,HOWEVER,LABEL,METHODS,OVERALL,RESULTS,STAGE,TESTS,THREE
223,III,SELECTION,TEN,TODAY
118,169,218,ADT,AKT,DU145,HOWEVER,JAGGED1,LABEL,LAPC4,LNCAP,NOTCH,PC3,THESE,THROUGH,UNLABELLED
515,533,982,AMONG,COMPETING,CUMULATIVE,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS,SETTING,SEVERAL,YOUNGER
109,153,406,ANN,CAD,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,NPV,OBJECTIVE,PPV,RESULTS,ROC,THERE
22RV1,CAO,CHINESE,HOWEVER,LNCAP,PSA

ACCORDING,DCE,DWI,FUNCTIONAL,GLEASON,MRI,MRS
BASED,PSA,THESE,WHOLE
ANCTS,CCK,ERK,FIRST,HOWEVER,IHC,LOX,LYSYL,MMP,SIMILARLY
15R,945,ANIMALS,CD8,INHIBITION,TRAMP
150,AFTER,AUSTRALIA,BACKGROUND,COMPLETION,EDUCATION,FACTORS,GPS,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,PHASE,RESULTS,THERE,THESE
AFTER,AKT,BACKGROUND,BESIDES,CCK,HOWEVER,LABEL,LNCAP,METHODS,RESULTS,TAKEN,TRANSWELL,WESTERN
174,APART,AREAS,BACKGROUND,CAP,COVERED,III,KLK,LABEL,METHODS,NOVEL,OPINION,PHASE,SYNTHETIC,TARGETING
011,025,036,1C3,377,396,AKR,BACKGROUND,BPH,CONCLUSION,GLEASON,LABEL,LNCAP,LOW,METHODS,PCA,PIN,PSA,RESULTS,SIXTY,UNASSIGNED,VIRTUAL
169,BASED,BPH,CAJAL,LABEL,LTD,METHODS,OBJECTIVE,PCA,RESULTS,WILEY
001,104,169,417,492,842,AUTHORS,BJU,CONCLUSION,GLEASON,GROUP,HOWEVER,LABEL,LRP,LTD,METASTASIS,METHODS,NERVE,OBJECTIVE,PSM,PUBLISHED,RESULTS,THERE,TNM,WILEY
AFM,BINDING,RIBOFLAVIN
ADIPOSE,BACKGROUND,CONSISTENT,EXPLANT,GLEASON,HOWEVER,LABEL,METHODS,OBESITY,PCA,PPA,RESULTS,SQA,THEREFORE,THESE,TISSUES
004,035,546,BACKGROUND,CONCLUSION,GLEASON,LABEL,MEN,METHODS,RCT,REFERRALS,RESULTS
000,100,ASR,BACKGROUND,CANCERS,CASABLANCA,CONCLUSION,FEW,HODGKIN,LABEL,METHODS,MOROCCO,RESULTS,STAGE,THESE,TUMOURS
231,453,ARV,ATT,CE3,CE9,EXPRESSION,GTT,HEPG2,ILE,LNCAP,MCF,MDA,SEQUENCING,VAL
007,100,177,385,BETWEEN,CONCLUSION,EASTERN,FACTORS,GROUP,LABEL,METHODS,OBJECTIVE,PLANNED,PURPOSE,RESULTS,THEREFORE
1C2,1C4,AKR1C,AML,BACKGROUND,HOWEVER,LABEL,METHODS,MPA,NCI,RESULTS,SCREENS
001,002,003,169,494,BACKGROUND,COPYRIGHT,GLEASON,HOWEVER,LABEL,METABOLIC,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,PUBLISHED,RESULTS,SETTING,SUMMARY,TESTS,THERE,TORONTO,UROLOGY
10Q23,BACKGROUND,BPH,CEP10,IDENTIFIER,LABEL,LOCUS,LPL,LSI,METHODS,MYC,RESULTS
113,ANOTHER,BACKGROUND,FOLLOWING,GLEASON,HOWEVER,IRANIAN,LABEL,MATERIALS,MEIER,METHODS,PATHOLOGY,RESULTS,SCORING,SEVERAL,THERE,THEREFORE,UNIVERSITY
946,CATENIN,CRUDE,HOWEVER,IRANIAN,LAMIACEAE,SW480,THESE
AAR,AMONG,BACKGROUND,BANGALORE,CHENNAI,DELHI,INDIA,LABEL,SIMILARLY
BACKGROUND,LABEL,MATERIALS,METHODS,RESULTS,THESE
ADIPOSITY,THERE
100,125,956,AIM,CHICAGO,DEPARTMENT,EPI,EXCEL,INC,KATHMANDU,LABEL,MATERIALS,METHODS,NEPAL,OBJECTIVE,OCTOBER,PACKAGE,PCA,PSA,RESULTS,USA,VERSION,WINDOWS
000,ACCORDING,ESSENTIAL,EXCELLENCE,HOWEVER,INSTITUTE
785,LNCAP,NIR
000,163,AWMSG,CONCLUSION,CS21A,DEGARELIX,III,ITT,LABEL,METHODS,OBJECTIVE,PAS,PHASE,PSA,RESULTS,SERVICE,TREATMENT
008,012,085,169,554,ATP,FINALLY,HSP,LABEL,NSCLC,THESE,TNF,TRAP1,UNLABELLED
ABL,BCR,BTK,HOWEVER,PROTEIN,SELECTIVE
ADDITIONAL,SHH,SONIC,TESTICULAR,THESE
268,362,567,974,COX,FEW
DCE,DWI,FINALLY,GIVEN,MRI,PSA
001,061,139,187,189,18F,325,456,ADT,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,SIMILARLY,WHITNEY
169,183,AGAIN,BACKGROUND,BASED,GEORG,GERMANY,HOWEVER,INSTEAD,LABEL,METHODS,NATIONWIDE,POMERANIA,RESULTS,STUTTGART,USING,WESTERN
001,BACKGROUND,GIVEN,GLEASON,LABEL,METHODS,PEARSON,PSA,QOL,RADIATION,RESULTS
18F,PET
FDG,PET
HONEY,THESE
001,005,778,BACKGROUND,COX,III,INCREASING,LABEL,MARKERS,METHODS,PRIOR,RESULTS,S0421,SERUM
169,COPYRIGHT,F876L,FL425,FL442,IRELAND,LNCAP,LTD,NOTABLY,THESE
169,AFTER,BACKGROUND,BCH,COPYRIGHT,HGPIN,LABEL,METHODS,OBJECTIVE,OTHER,PRODUCTION,PSA,RESULTS
169,22RV1,916,956,CASTRATION,COPYRIGHT,DHT,LNCAP,LTD,OVERALL,PCA,POM,PSA,WESTERN
169,22RV1,453,945,COPYRIGHT,DHT,DU145,HENCE,HOWEVER,LNCAP,LTD,MDA,PC3,PCA,SARMS,THEREFORE,THESE
BACKGROUND,GIVEN,LABEL,METHODS,RESULTS
145,946,954,BACKGROUND,CXCR4,EGR,EMT,IHC,LABEL,METHODS,MTT,PC3,PCA,RANKL,RESULTS,RUNX2,SMALL,SNAI1,SRC,WESTERN
ASSOCIATED,BACKGROUND,LABEL,METHODS,MHC,MMP11,RESULTS,THESE
BACKGROUND,CONCLUSION,DESPITE,DEVELOPING,KNOWN,LABEL,RESULTS,THESE,THREE
205,BACKGROUND,CREB1,HOWEVER,IGF,LABEL,PCA,RESULTS,SNP,SP1,TRAIT


100,8TH,DESPITE,MELAN,MFH,PSA,UPS
NMIBC,NON,PROSTATIC,PSA,RENAL,TLCNOMO,TURBT
241,643,AMONG,DTX,EIGHT,HAMAMATSU,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SALVAGE,SIX,TRANSITORY,UNIVERSITY
200,AMERICA,APOPTAG,CARIBBEAN,JAMAICA,LABEL,METHODS,OBJECTIVE,RESULTS,SOUTH,THERE,TILLANDSIA
720,AFRICAN,ASIAN,BACKGROUND,CAUCASIAN,CONCLUSION,ERG,HOWEVER,HRM,LABEL,METHODS,OBJECTIVE,OVERALL,POZ,PROTEIN,RECURRENT,RESULTS,SETTING,SPECKLE,SPOPMUT,THERE
007,008,111,489,BACKGROUND,CIS,COX,GLEASON,HRS,LABEL,MEN,METHODS,PCA,PREVENTION,RESULTS,THERE,TOENAIL,TRIAL,VITAMIN
005,817,COX,III,LOWER,PCA,SEPP1,THREE,TOENAIL
CAP,FINALLY,FURTHER,NUCLEAR
00001,AVAILABLE,CELLSEARCH,DFS,FORREST,HRS
138,586,DIFFICULTY
BAX,BCL,DU145,HDAC1,THESE,TREATMENT
001,003,004,099,162,464,746,916,COX,LABEL,MEIER,METHODS,NMIUC,OBJECTIVE,PCR,PRIMARY,PURPOSE,RESULTS
BACKGROUND,DISCUSSION,GERMANY,LABEL,METHODS,PSA,QUESTIONS,RESULTS,THERE,UNASSIGNED
321,594,THERE
ALONG,APART,PSA,USA,WESTERN
169,FURTHER,PC3,PCAI1,PRESS,PUBLISHED,ROS,SILENCING,THERE,THESE,UNIVERSITY
AMP,DESPITE,DEVELOPING,ZADRA
001,064,142,483,AFTER,BACKGROUND,COMPETING,CONVERSELY,CSM,EIGHT,END,LABEL,METHODS,NNT,OVERALL,PCA,RESULTS
100,178,179,185,200,223,956,MBQ,RADIATION,REMOVAL,SUBSEQUENT,TEN
PET
18F,FEC,HOWEVER,PET,USING
169,COPYRIGHT,FURTHER,HOWEVER,INC,THROUGH
WHOLE
145,169,231,COPYRIGHT,INC,MDA,NMR,PF6
169,BPH,COPYRIGHT,INC,PCA,PUBLISHED,SOCIETY
169,1WEEK,6GY,945,946,BACKGROUND,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,TREATMENTS
169,AFRICAN,BETWEEN,COPYRIGHT,COX,GLEASON,IRELAND,LABEL,LTD,MATERIALS,MEN,METHODS,OBJECTIVE,PSA,RESULTS,THERE
169,177,1CM,377,BACKGROUND,BLADDER,COPYRIGHT,CTV,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,THESE,VARIATIONS
169,1CM,267,3MM,490,4MM,BMI,CONCLUSION,COPYRIGHT,DAILY,IRELAND,LABEL,LEVEL,LTD,METHODS,OBJECTIVE,PCA,PTV,PURPOSE,RCS,RESULTS,THESE,WITHOUT
015,100,125,144GY,169,281,384,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,CTCAE,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,QUADRELLA,RESULTS,URINARY
169,188,COPYRIGHT,GMP,RHENIUM
169,AIF,COMPARING,COMPARISON,COPYRIGHT,DCE,DYNAMIC,FIRST,IMAGING,INC,INTRA,MRI,MULTI,PCA,RESONANCE,ROI,THESE
001,160,169,250,279,500,BETWEEN,CONCLUSION,COPYRIGHT,HOWEVER,LABEL,LRP,METHODS,OBJECTIVE,OPERATIVE,ORP,PSA,PUBLISHED,RESULTS,SAS,T1C,THERE
169,224,CARIBBEAN,CASES,CONCLUSION,COPYRIGHT,GUADELOUPE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PITRE,RESULTS,SAS
169,ACUTE,ARU,COPYRIGHT,PUBLISHED,SAS,SEVERAL
169,AUTHORS,COPYRIGHT,DIAGNOSTIC,SAS
124,169,1CM,ADC,COPYRIGHT,DCE,DWI,ECE,ESTIMATION,LABEL,METHODS,MRI,NPV,OBJECTIVE,PPV,RESULTS,SAS,T2W,THREE,VPN
220,269,789,CHINESE,GLEASON
001,100,114,125,160,169,177,AVERAGE,COPYRIGHT,D90,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
160,FIRST,FURTHER,PRESUMABLY
124,4T1,AIM,CONCLUSION,F11,JAA,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THESE,THOMSEN
FDA,III,OVERALL,PHASE
154,163,BIOCHIM,BIOPHYS,HIPK1,JUN,PAGE4,REGARDLESS,T51,THESE
243,AMERICA,ARGENTINA,BACKGROUND,BEVERAGES,COMPONENTS,CONCLUSION,COPYRIGHT,CRC,EDICIONES,FEEDING,LABEL,LATIN,METHODS,OBJECTIVE,PATTERN,PRINCIPAL,PRUDENT,PUBLISHED,RESULTS,RURAL,SOUTH,STARCHY,SWEET,TYPICAL

945,954,CCCTC,DECREASED,GENOMIC,H19,HDAC1,ICR,INSULIN,LOI
083,100,160,177,341,345,956,BEHNKEN,BOX,CONCLUSION,EQUAL,LABEL,METHODS,NPS,OBJECTIVE,OXIDATION,PC3,PURPOSE,RESULTS,ROS
FINALLY,MRI,THEREFORE
100,160,169,183,222,CONCLUSION,ECE,ENDORECTAL,GEORG,KEY,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,STUTTGART,SVI
AFRICAN,AMERICANS,OLDER,THERE,YOUNGER
177,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
160,174,177,277,550,CONCLUSION,D30,D50,D60,HOWEVER,LABEL,MATERIALS,MEDICAL,METHODS,MUS,OAR,OBJECTIVE,PTV,PURPOSE,REGARDING,RESULTS,SMALL,SYSTEMS,TREATMENT,USA
175,AKT,BASEL,EXPRESSION,HGPIN,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
BPH,IHC,PCA,PCR,SILENCING
169,LUCAP23,LUCAP86,TAXANES
BOARD,CARLO,GPU,IMAGING,MONTE,OBI,RADIATION
00164,191,AGILENT,ANNOVAR,BACKGROUND,BWA,LABEL,LOF,METHODS,RESULTS,THESE,TOOLKIT
169,COPYRIGHT,DCA,DPA,PCA,THESE,THREE
000,001,041,043,054,177,195,540,ASIAN,BACKGROUND,COX,LABEL,METHODS,PRIOR,RESULTS,THERE,TOTAL,TPE,UNASSIGNED,VIRTUAL
BACKGROUND,CBP,CHINESE,EXPRESSION,KNOCKDOWN,LABEL,METHODS,RESULTS,ZYFLAMEND
945,963,ACCOUNT,III,INITIAL,IRIDIUM,NAD,OCTAHEDRAL,THEIR,THESE
001,015,032,167,771,ADC,AUC,CONCLUSION,DWI,ECE,FURTHER,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,UNIVARIATE
AFTER,CONCLUSION,DETECTION,DWI,GLEASON,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,RTE,VOLUMETRIC
001,215,664,723,753,818,915,916,989,ADC,BPH,CONCLUSION,DTI,LABEL,MATERIALS,MCNEMAR,METHODS,OBJECTIVE,RESULTS,ROC
001,200,ADC,AUC,CONCLUSION,DWI,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS
177,CONCLUSION,DWI,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS
240,BACKGROUND,CAUCASIAN,FOLLOWING,GLEASON,HEM,LABEL,METHODS,T1C,THERE
AFTER,BACKGROUND,BASED,COMPARISON,LABEL,MICROARRAY,MICRORNAS,ORT,RESULTS
13C,205,ALPINIA,COMPOUNDS,DCM,NCI,NMR,SHARPLESS
031,077,16ALPHA,3BETA,ESI,ICH,LYSIMACHIA,NMR
DESPITE,OVERALL,ROBOTIC
169,183,GEORG,GIVEN,HNC,QOL,STUTTGART,THERE
823,945,946,BAX,BCL,BGC,CPS,DU145,HEMSL,JNK,LYSIMACHIA,P38,PC3,RESULTS,THEREFORE
BACKGROUND,DFS,GIVEN,LABEL,METHODS,RESULTS,SDC,SINCE,WHILE
001,233,COX,MAX,MIN,SUPPL,VITAMINES
001,104,113,217,361,65308,65309,AMICO,BMI,COLLEGE,GLEASON,KHR,MAY,PSA,PSM,SEPTEMBER,THERE,UNIVERSITY
206,640,FINALLY
BRAFV600E,PRE,PREDICTIVE
CHINESE,DIF,EORTC,HRQOL,LABEL,METHODS,OBJECTIVE,QLQ,RASCH,RESULTS
BISPHENOL,BPA,PND,PND35,TMT
169,533,AUTHORS,BJU,GLEASON,LABEL,LTD,METHODS,OBJECTIVE,ORGAN,PBX,PUBLISHED,RESULTS,WILEY,XML
233,BACKGROUND,DESPITE,DISCUSSION,LABEL,METHODS,TAKEN,WESTERN
001,152,169,AUTHORS,BJU,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,UROSTATION,V10
123,169,AFTER,AUTHORS,BCR,BECAUSE,BJU,CHT,GLEASON,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,WILEY
001,168,169,AFTER,AMONG,AUTHORS,BJU,GLEASON,GRADING,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,PSA,RESULTS,SOCIETY,THERE,UROLOGICAL
783,CTC,EPCAM,ISOLATION,NIR,PBMCS,PERIPHERAL,STAINED
ATLAS,CONSISTENT,THESE,USING
CGA,FURTHER,INCREASING,INHIBITION,KNOCKDOWN,LC3,LNCAP,NED,PCA,SIMILAR,THESE,TREATMENT
139,174,NGS,PCR,SHORT,SNP,STR
177,181,AMONG,BCL,EXCESSIVE,FURTHER,LNCAP,MMP,NAUCLEA,NMR,OVERALL,ROS,SUBDITINE,WESTERN
17Q21,215,440,469,700,ADDITIONAL,PRACTICAL
CAMLS,CTC,THESE,USING
032,169,944,BACKGROUND,HOWEVER,III,LABEL,METHODS,OVERALL,PATIENT,PET,PREDICTORS,RESULTS,ROUTINE,SEEKING,THESE,YET
169,BRITAIN,CD133,COPYRIGHT,FINALLY,GREAT,HOLOCLONES,INCREASING,IRELAND,LTD,NADPH,NOX,OGT2115,PC3,PUBLISHED,SOCIETY,TAKEN,THESE,TRAMP,WILEY
169,ANDROGENIC,COPYRIGHT,DHT,LTD,PGD,THEREFORE
105,ADT,BLOOD,CONCLUSION,DXA,FIFTY,FURTHER,GLEASON,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,SMOKING,THERE,TREATMENT
167,252,294,384,549,THP
102,169,199,204,239,945,946,ARM,CONCLUSION,IGF,LABEL,METHODS,OBJECTIVE,PFS,PSA,PURPOSE,RESULTS
004,169,370,401,CIS,COLORECTAL,DIETARY,HOWEVER,OVARIAN,PRESS,PUBLISHED,SCREENING,SEVERAL,TRIAL,UNIVERSITY
169,2D3,945,CYP24A1,CYP27B1,HPV,INC,THESE,VDR,WILEY
169,KLK,RAPIDLY,SUBSTRATES,VCH,WILEY
ADT,AURKA,DESPITE,ERG,HOWEVER,PSA,SCC
EXCESSIVE,ILLICIT,USA
232,684,CAUCASIANS,JANUARY,REVMAN4,STATA10,WANFANG,XRCC7
487,945,CA2,DAG,IL3,IP3,MYB,PKC,PLC,PROGNOSCAN
169,COPYRIGHT,CROWN,LTD,MICRO,PC3,PUBLISHED
100,169,406,473,623,AGREEMENT,COPYRIGHT,DISCUSSION,ESPECIALLY,HEINZ,ICD,LABEL,LTD,METHODS,NIXDORF,OBJECTIVE,RESULTS,VERSION
119,177,265,ADC,AUC,CONCLUSION,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROI
OXO,PC3,PET,PIP
169,EPS,INC,MGS,THERE,WILEY
RLESS,THEREFORE
001,008,009,022,025,031,041,121,177,308,336,540,656,681,775,857,907,CCI,CONCLUSION,COX,GLEASON,INDEX,IQR,LABEL,MATERIALS,METHODS,NON,OBJECTIVE,PCA,PCASS,PRE,PSA,PURPOSE,RESULTS,TEN
AES,ASIAN,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE
006,146,169,ACTIVITIES,AMONG,ASSESSMENT,BARTHEL,BATTERY,BRODY,CONCLUSION,COPYRIGHT,DAILY,FRONTAL,FUNCTIONAL,GENERAL,INDEX,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,THERAPY,THESE,WILEY
169,191,COPYRIGHT,DEPRESSION,EQUATIONS,IBI,ILLNESS,INDEX,INDICES,INDIVIDUAL,LABEL,LTD,METHODS,OBJECTIVE,PATIENT,RESPONSES,RESULTS,THESE,WILEY
001,012,014,027,136,160,952,966,975,BRIEF,BSI,INVENTORY,LABEL,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS,ROC,SECONDARY,SYMPTOM,USING
EDUCATING,PRIOR,PROVIDING,SUGGESTED
082,259,609,816,BEHAVIORAL,BMI,HOWEVER,LABEL,METHODS,OBJECTIVE,ONGOING,PURPOSE,RESULTS,SHORT,SURVIVORS
LEVEL,MANAGEMENT,MEN,PIVOT,PSA,RESULTS,TRIAL
AKT,BIOMARKERS,ERG,RESULTS,TMPRSS2
CCP,GLEASON,PSA,RESULTS,THESE
DESPITE,INSTITUTE,PSA
FAVORABLE,GLEASON,IIA,IIB,THESE
BPH,EARLY,SIMILARLY
FLAVONOIDS,MIGRATION,PRIMARY,THERE,THEREFORE,THESE
210,ASPIRIN,HOWEVER,INFERENCE
945,EFFECTIVE,LOE,SERMS
ANOTHER,HOWEVER
BASED,COLORECTAL,ERSPC,OVARIAN,RANDOMIZED,SCREENING
COLON,DETAILS,ERSPC,HOWEVER,OVARY,PSA,RANDOMIZED,SCREENING,USA
000,1990S,COLORECTAL,DRE,OVARIAN,PSA,SCREENING,TRIAL
ANTIGEN,ERSPC,GLEASON,PCA,PSA,RANDOMIZED,SCREENING
000,150,1990S,IGF,NUTRITION,THERE
DIFFERENT,HOWEVER,PCA,THEREFORE
EARLY,SINCE,THEIR,THESE
AMACR,DESPITE,HOWEVER,HPN,IGF,INSULIN,MYC,PSA,WHILE
169,COPYRIGHT,H1299,INC,NCI,RV1
10A,145,231,390,AMONG,MCF,MDA,PUBLISHED,SAS,TAKEN
792,956,AFTER,ARIZONA,BACKGROUND,CADMIUM,HEART,HRS,INDIANS,LABEL,LOW,METHODS,NORTH,OBJECTIVE,RESULTS,SOUTH
169,945,947,ASTRAGALUS,ATF,COPYRIGHT,COSCINIUM,EGR,INC,LAMIACEAE,NAG,NATURAL,NSAID,PLANT,SEVERAL,SP1
169,946,COPYRIGHT,CROWN,INC,LNCAP,MICROARRAY,PCA,PUBLISHED,R1881,TAKEN,TEB
169,22RV1,600,945,946,COPYRIGHT,MCF,PUBLISHED,RGDFK
169,945,COPYRIGHT,LABEL,NAD,PC3,SILENCING,TOCOPHERYL,UNASSIGNED,UNLABELLED,WHILE
024,169,193,8NMOL,AUC,COPYRIGHT,INC,INDEX,KRUSKAL,LABEL,METHODS,OBJECTIVE,PCA,PHI,PSA,PUBLISHED,RESULTS,ROC,SOCIETY,TOTAL,WHITNEY
169,945,956,COPYRIGHT,LAPACHONE,LTD,V79
169,945,946,COLLEGE,CONCLUSION,COPYRIGHT,CURRENT,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROYAL
169,CDC42,FINALLY,GROUP,GTPASES,INC,PAK,RAC,RHO
169,COPYRIGHT,ERASMUS,FULLY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,TPS,V95,VMATMAN
169,COPYRIGHT,LTD
COPYRIGHT,PATIENT,QOL,QUALITY,SLACK,THEREFORE
169,237,AUC,AUTHORS,BJU,INSTITUTO,IVO,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OCD,ONCOLOG,RESULTS,ROC,THEIR,VALENCIANO,VICKERS
001,002,169,238,AUTHORS,BJU,COX,LABEL,MEIER,MEN,METHODS,NLR,OBJECTIVE,RECORDS,RESULTS,THESE
001,009,103,125,169,177,AUSTRALIAN,AUTHORS,BACKGROUND,COLLEGE,IMAGING,JOURNAL,LABEL,MEDICAL,METHODS,OPERATIVE,RADIATION,RESULTS,ROYAL,ZEALAND
169,AUSTRALIA,AUSTRALIAN,AUTHORS,BACKGROUND,COLLEGE,CONCLUSION,GROUP,HDR,IMAGING,JOURNAL,LABEL,MEDICAL,METHODS,RADIATION,RESULTS,ROYAL,THERE,TOTAL,WESTERN,ZEALAND
HOWEVER,LEIOMYOMAS,MRI
BACKGROUND,COULD,CTC,DESPITE,FOLLOWING,HOWEVER,LABEL,LNCAP,MAXIMAL,METHODS,NBD,RESULTS,RWPE1,THESE
948,ANOVA,BACKGROUND,CSC,INHIBITION,LABEL,METHODS,NOVEL,PKC,RAS,RESULTS,SMALL,STUDENT,THESE
ASIAN,CONCLUSION,ESTIMATES,FURTHER,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,STRATIFIED,TEA
493,BACKGROUND,CONCLUSION,CONTEXT,LABEL,METHODS,MMP40,OBJECTIVE,OBJECTIVES,RESULTS,RPP40
160,169,183,901,FINLAND,HODGKIN,LTD,NHL,POISSON,RRS,WILEY
000,001,173,ANTITUMOR,BACKGROUND,EASTERN,GROUP,JANUARY,LABEL,METHODS,PATIENT,RESULTS,SOLID
AIM,III,LABEL,METHODS,MEXICAN,NUTRITION,OBJECTIVE,RESULTS,SDPPSU6,UDPSI,UNDER,WTPFEX6
LDR,MDR,SEARO
242,476,484,541,730,763,BPH,CONCLUSION,CXS,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS
397,BMI,CONCLUSION,FANGCHENG,GUANGXI,INCREASED,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEPTEMBER,THERE
TMPRSS2
169,CONCLUSION,HPA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
DIAGNOSTIC
100,CYSTECTOMY,RADIATION
IMAGE,INTENSITY,RADIATION,THERAPY,TREATMENT
AFTER,C30,CHINESE,CONTROL,IIA,LABORATORY,PSA,PSS,QLQ,ROUTINE
002,118,CONCLUSION,LABEL,MATERIALS,METHODS,NLR,OBJECTIVE,PFS,PSA,PURPOSE,RESULTS
169,170,365,481,669,751,BETWEEN,BMI,COX,HRS,NIH,SEDENTARY,SIMILAR,THERE
001,007,075,68366,ENGLISH,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIR,SLE,STATA,SUMMARY
TAXANES
6E3,EXPRESSION,HOWEVER,NANOG,SALL4,WILMS
193,232,298,BCR,HRS,PCA
CHEK1,DOCETAXEL,HOWEVER,IGR,INHIBITION,KNOCKDOWN,LZTS1,NSC663284
169,3KINASE,AKT,COPYRIGHT,CXCR4,DU145,HOWEVER,INC,TAKEN
169,AMONG,BACKGROUND,COMPOSITE,CONCLUSION,COPYRIGHT,FIFTY,GLEASON,INC,INDEX,LABEL,LARGE,METHODS,NORWEGIAN,PCA,RAD,RESULTS,SPAIN,SPANISH,USING
169,CAS,COPYRIGHT,IAS,LTD,PSA
169,BSA,DOX,FINALLY,MTT,NPS,WILEY
967,BACKGROUND,EDI,INDEX,LABEL,METHODS,PAF,POISSON,POPULATION,RESULTS
AKT,ANNEXIN,BASED,BCL,CSC,ERK,GLIOMAS,GRP,KNOCK,MUSASHI,PAR,SECRETORY,TAM,UCN
049,186,215,CONSORTIUM,DESPITE,INSTITUTE
945,BAG,CONVERSELY,FXXLF,HOWEVER,LBD,LXXLL,SEVERAL,THESE
152,169,DESPITE,IHC,NUCLEAR,PSA,THESE
169,BACKGROUND,FEW,GREATER,HRR,HSA,LABEL,METHODS,REPORTING,RESULTS,SOCIETY,STATE,WASHINGTON
120,169,BACKGROUND,INTERVIEW,LABEL,MEN,METHODS,PSA,RESULTS,SCREENING,SOCIETY,SURVEYS,TWICE
169,AMERICA,AMONG,BACKGROUND,BRCA1,BRCA2,CARIBBEAN,FACTORS,LABEL,LARGE,LATIN,METHODS,RESULTS,SEVERAL,SOCIETY
133,169,BACKGROUND,CONCLUSION,COX,INC,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,PSA,PSM,RESULTS,WILEY
AGE,HOWEVER,PPI
KINASES,KNOWLEDGE,SFK,SRC,THESE
112,181,182,969,AIM,BACKGROUND,LABEL,MCF,METHODS,MTS,NEITHER,OBJECTIVE,PERIPHERAL,PMS,RESULTS,THEIR,THESE,TREATMENT
163,451,736,958,983,ASSESSMENT,CAPRA,COX,DISEASE,GROUP,JAPAN,LABEL,MEIER,METHODS,NADIR,OBJECTIVE,PFS,PSA,PURPOSE,RESULTS,TTN,UNIVARIATE
100,110,169,177,280,357,365,469,963,ARC,CDR,JAPAN,MUS,PHILIPS,PRESS,PUBLISHED,RADIATION,SMART,SOCIETY,UNIVERSITY,VOLUMETRIC
AMPLE,CTC,EVERY,THESE
007,039,467,ACUTE,ANZDATA,AUSTRALIAN,BACKGROUND,CONCLUSION,COX,LABEL,METHODS,RECIPIENTS,RESULTS,THERE,TRANSPLANT,USING,ZEALAND
NOVEL
125,145,169,192,BLADDER,CONCLUSION,COPYRIGHT,DESPITE,HDR,INC,LABEL,LDR,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RBE,RESULTS,TEN
169,211,ACTUARIAL,ADVERSE,CGE,COMPOSITE,COPYRIGHT,CTCAE,FURTHER,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SYMPTOM,THERE,TOXICITIES
CELLSEARCH,FDA,STUDIES,WHETHER
106,184,291,339,435,511,762,814,849,ACEIS,ARB,BACKGROUND,HOWEVER,LABEL,METHODS,OVERALL,POPULATION,RESULTS,STATISTICS,THERE,THESE
HAACK,MEIER,SMALL,SYNTHESIS,THEREFORE,THESE
007,023,112,248,690,AMICO,BETWEEN,COX,EIGHT,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,RESULTS
485,709,767,BASED,BPH,CAG,CONCLUSION,EGGER,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SHORTER,THERE
160,34BETAE12,CONCLUSION,LABEL,METHODS,OBJECTIVE,P504S,P63,PSA,RESULTS
029,034,288,297,BPH,CONCLUSION,GLEASON,LABEL,OBJECTIVE,PCA,PSA
AKT,CURRENTLY,DASATINIB,FYN,GSK,INHIBITION,PC3,SRC,TREATMENT,Y216GSK,YES
001,LOC728606,METASTATIC,PCA,PES,THESE
001,019,169,634,AFTER,AUTHORS,CHI,COX,CRT,END,FIRST,INTENSITY,LTD,PROPENSITY,RESULTS,WILEY
100,169,177,233,AUTHORS,HOWEVER,LTD,METABOLITE,NMR,OUTER,QUEST,RAO,TES,WILEY
000,804,BECAUSE,CHINESE,CIS,CONCLUSION,EGGER,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCIENCE,THERE,WEB
003,004,009,1MMOL,233,514,557,APOA1,BIOMARKERS,COX,HDL,HOWEVER,MIN,SUPPL,VITAMINES
204,562,580,956,DISCOVERY,DU145,FINALLY,FORTY,INHIBITORS,MV4,PIM,SPECS,THEIR,THESE,THREE
110,111,122,160,169,209,238,278,393,498,681,CHOLINE,COPYRIGHT,DIAGNOSTIC,EDUCATION,IMAGING,INC,LABEL,LYMPH,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SALVAGE,UROLOGICAL
169,174,795,ACT,AFFORDABLE,ASA,COPYRIGHT,EDUCATION,GIVEN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OUTPATIENT,PATIENT,PROGRAM,PROTECTION,PUBLISHED,PURPOSE,QUALITY,READMITTED,RESULTS,UROLOGICAL,USING
001,003,026,043,125,169,174,182,187,189,273,711,ANOTHER,ARRAY,AUC,COPYRIGHT,EDUCATION,ERG,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TMPRSS2,TOTAL,UROLOGICAL
001,169,192,347,AFTER,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
001,169,170,936,AUC,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHI,PUBLISHED,PURPOSE,RESULTS,ROC,UROLOGICAL
001,169,226,260,396,COPYRIGHT,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL
160,169,786,945,947,CHIBA,COCL2,COPYRIGHT,CXCR3,EDUCATION,FINALLY,HIF,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RENAL,RESULTS,UNIVERSITY,UROLOGICAL
169,192,457,574,COPYRIGHT,COX,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PREVENTION,PUBLISHED,PURPOSE,RESULTS,THESE,TRIAL,UROLOGICAL,WHETHER
001,002,038,100,150,165,166,169,626,810,913,954,AGGREGATE,AUC,CHI,COPYRIGHT,EDUCATION,IMAGING,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADICAL,REPORTING,RESULTS,TESLA,UROLOGICAL

174,294,414,711,ADVERSE,AIM,BAP,CONCLUSION,LABEL,MATERIALS,METHODS,NTX,OBJECTIVE,OPG,RESULTS,SERUM,TAIWANESE,THERE,TRACP5B
CLINICALLY,HSP90
158,946,954,BACKGROUND,BMP,CAP,CONSISTENT,FURTHER,HOWEVER,LABEL,METHODS,RESULTS,SMAD5,THESE,WNT5A
BACKGROUND,DISRUPTION,LABEL,METHODS,PART1,PC3,PDE,RESULTS,WESTERN
BACKGROUND,CELECOXIB,COX,EP2,HOWEVER,LABEL,LNCAP,METHODS,NON,PC3,PCR,RESULTS,WESTERN
BLOOD,PSA
138,154,162,26E,50E,COMPARING,ERG,NDRG1,SLC45A3,THESE,TMPRSS2
150,AHEAD,APRIL,AUSTRALIA,AUSTRALIAN,BACKGROUND,CBT,DISCUSSION,FEB,IDENTIFIER,LABEL,METHODS,RCT,THERE,TRIAL,ZEALAND
BASED,INHIBITORS,SAR,SERCA,SIXTEEN
101,107,138,186,224,26A,26B,410,551,660,AMACR,BACKGROUND,BPH,LABEL,METHODS,MIR,PCA,PCR,RESULTS,TRPM8,USING,WESTERN
001,126,ACS,BACKGROUND,BPH,CAUCASIAN,CAUCASIANS,COLLEGE,LABEL,LEP,LVP,MEN,METHODS,NSQIP,OBJECTIVE,OVERALL,PROGRAM,PURPOSE,QUALITY,RELYING,RESULTS
946,956
176,300,FURTHER,HOWEVER,OVERALL,THESE,ULTIMATELY
308,945,AKT,FIRST,PDK,SILENCING,STUDIES,THR
022,038,173,176,178,190,224,CHINESE,ERG,ETS,GLEASON,NOTABLY,OVERALL,PCA,PSA,TUR,USING
161,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,USING
ABOUT,HOWEVER
169,945,946,AKT,AUTHORS,HIF,LTD,REDD1,WILEY
001,169,297,AUDIT,AUTHORS,DIAGNOSIS,ENGLISH,INC,IQR,PRIMARY,PUBLISHED,ROUTINELY,THESE,USING,WILEY
001,165,400,ABOUT,CONCLUSION,FEDERATION,GENERALLY,HRQOL,LABEL,MAY,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SWEDISH,THOSE,VAS
177,ADVERSE,CAUTIONARY,CONTROL,CTCAE,ELECTRONIC,EPR,LABEL,MAY,METHODS,OBJECTIVE,OSCIR,PATIENT,RESULTS,SUNNYBROOK,SYMPTOM,USING
125,145,BACKGROUND,BCR,CONCURRENT,COX,ERG,IHC,LABEL,METHODS,RESULTS
294,451,ACIDS,CIS,FATTY,FIBER,ITALIAN,LABEL,METHODS,OBJECTIVE,ORS,PURPOSE,RESULTS,VEGETABLE
002,004,005,010,015,239,CD4EM,CD8,NEG,PERIPHERAL,PHASE,PSA,THERE,THESE,TIM,TREGS
AMERICA,ETHANOL,MYRTACEAE,NFKB1,SOUTH
169,PAI
169,COPYRIGHT,INC,ORGANIZING
308,BACKGROUND,DRE,LABEL,METHODS,OVERALL,PCA,RESULTS,RIGHT
DMR,EPIGENETIC,EXPRESSION,H19,HOXC6,IGN,NDN,PCR,PPP1R9A,THEREFORE
036,169,215,461,BACKGROUND,CONCLUSION,COPYRIGHT,COX,GLEASON,LABEL,METHODS,RESULTS,SEVENTY,T2C
169,845,ASIAN,CALIFORNIA,CHINESE,COPYRIGHT,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,ORS,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL,USING,VIETNAMESE
169,COPYRIGHT,INC
001,006,100,113,169,COPYRIGHT,EDUCATION,EPSTEIN,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEN,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,REPORTING,RESULTS,STANDARDS,START,STUDIES,TARGETS,UROLOGICAL
057,169,305,AMONG,BACKGROUND,CIS,COPYRIGHT,COX,HOWEVER,INC,JOURNAL,LABEL,METHODS,OBJECTIVE,PREVENTION,PREVENTIVE,PUBLISHED,PURPOSE,RESULTS,RRS,SHORT,STUDIES,THERE,THESE
126,228,239,ACCURAY,AUA,BACKGROUND,BETWEEN,BOWEL,COMPOSITE,CYBERKNIFE,HOWEVER,INDEX,LABEL,LARGE,METHODS,QUALITY,RESULTS,SCORE,SYMPTOM,TRANSIENT,TREATMENT,URINARY,UROLOGICAL
E2C,EMT,HOWEVER,MTT,TRANSWELL,UBE2C,UBIQUITIN
162,197,577,BACKGROUND,END,ESTIMATES,LABEL,METHODS,PSA,RESULTS,SWEDISH
132,169,177,215,222,239,AUTHORS,BETWEEN,BJU,BMD,CONCLUSION,LABEL,METHODS,OBJECTIVE,OSTEOPENIA,RESULTS,SUBSIDIARY,THEIR,TREATMENT,ZDA
121,ANOTHER,AUROC,B2M,BPH,CONCLUSION,ERG,GAPDH,GLEASON,HSPD1,LABEL,OBJECTIVE,PATIENT,PCA,PSA,RESULTS,TMPRSS2
145,945,BACKGROUND,COS,DU145,ESTERASES,LABEL,LNCAP,METHODS,OPH,PC3,RESULTS,THESE,WESTERN
371,ANDROLOGY,PREDICTORS,PRESENT,TRADITIONS
169,439,ACE,ADULT,AUTHORS,CONCLUSION,COPYRIGHT,CROSS,EVALUATION,GERIATRICS,GUIDELINE,III,INDEX,JOURNAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OLDER,PROGRAM,RESULTS,SETTING,SOCIETY
100,ACETATE,AERVA,ALEAF,CHLOROFORM,ETHYL,SRB,THERE
AMONG,MOLECULAR,MRI,NEWER,PET,RADIATION,USING
500,600,ANTIGEN,BACKGROUND,CONCLUSION,DISEASE,KARNOFSKY,LABEL,METHODS,PRIMARY,RESULTS,REVIA,TEN,THESE,THIOCTACID
100,155,AIM,CONCLUSION,CSS,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RADICAL,RESULTS,RRP
AIM,CONCLUSION,EXPRESSION,FGF,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,RESULTS,TISSUES
133,141,170,26A,AFTER,AIM,BACKGROUND,CENTRES,CONCLUSION,GLEASON,HOWEVER,INCREASED,LABEL,METHODS,OBJECTIVE,PCA,PCR,PRE,RESULTS,SCORE,SERUM,SNORD43
152,169,ERG,GLEASON,KPNA2,TMPRSS2
HIV,HOWEVER,NOW,WHILE
ELECTRO
045,169,953,CAUCASIAN,CHINESE,EASTERN,INC,PCA,PKC,PRKCI,WILEY
422,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SIR,THERE
169,ADC,COPYRIGHT,CURRENT,DIFFUSION,FUNCTIONAL,INC,MRI,RARER,SUCCESSFUL,THESE,WILEY
001,169,AFTER,BACKGROUND,INDEX,LABEL,METHODS,RADIATION,RESULTS,SOCIETY,SURGERY,UNADJUSTED
160,AAZTA,III,MRI
CARLO,CONCLUSION,LABEL,MATERIALS,METHODS,MONTE,MUS,OAR,OBJECTIVE,PURPOSE,RESULTS
100,215,956,ECLIPSE,ENDOGENOUS
379,CAP,GLEASON,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,RRP
LABORATORY,POTENTIAL,RAMAN,THERE
003,006,132,174,445,GLEASON,INCLUDING,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS
CIA,ELISA,INTRA,METHODS,PSA,RESULTS
169,946,CFL,COFILIN,CONVERSELY,FURTHER,NOTABLY,TGF
004,336,751,855,AGE,CONCLUSION,FORTY,GLEASON,INCLUSION,LABEL,MARCH,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,TEN
205,400,945,BCR,ERG,GLEASON,LOW,THESE
123,169,176,215,283,582,AFFAIRS,COPYRIGHT,EDUCATION,HEALTHCARE,HOWEVER,INC,LABEL,MARTINI,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL
122,150,169,317,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
169,COPYRIGHT,PIPER,SAS
140,169,6NM,916,945,ABI,COPYRIGHT,CYP17A1,INHIBITION,LTD,P450C17
160,169,AUTHORS,COPYRIGHT,INC,PUBLISHED,SER,THR
169,260,CHILEAN,COPYRIGHT,COX,GSTM1,GSTM1NULL,GSTT1,GSTT1NULL,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PROGNOSTIC,RESULTS
18H,949,AHX,AVA,BBN,CUCL2,ESI,GASTRIN,INC,LABEL,LNCAP,METHODS,NH2,PET,PUBLISHED,RESULTS,UNLABELLED,WHOLE
125,169,170,487,COLLEGE,COPYRIGHT,LABEL,LIMITED,LTD,MATERIALS,METHODS,MORTALITY,OBJECTIVE,OVERALL,PUBLISHED,RESULTS,ROYAL,SERVICE,SIR,SPC,YORKSHIRE
DVH,IRELAND,LABEL,LOW,LTD,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,QOL,QUANTEC,RESULTS,SEGMENTAL,V25,V40,V50,V60,V70,V80
169,177,CAG,COLLEGE,COMPARING,COPYRIGHT,DEPARTMENT,FEB,HAN,LABEL,MEDICAL,METHODS,OBJECTIVE,PCR,PUBLISHED,RESULTS,SIXTY,SURGERY,THERE,URINARY
169,839,ACCORDING,AEU,CONTROLLED,COPYRIGHT,HOWEVER,LABEL,MEDLINE,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,SEVEN
116,169,177,236,BECAUSE,BLADDER,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,RCC,RESULTS,SIXTEEN,TCC,THERE,TREATMENTS
001,151,168,171,435,872,BACKGROUND,BASED,FEW,FUNCTIONAL,HOWEVER,LABEL,LRP,METHODS,OVERALL,RESULTS,RRP,SURGEON
103,125,126,131,144,160,198,4RS,945,946,BED,DIFFERENT,HOWEVER,INCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
004,DSH,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPATIAL
EFFORTS,EXCESSIVE,FINALLY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
177,AFTER,CBCTS,CONCURRENT,D95,LABEL,MAP,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX
CALYPSO,LABEL,METHODS,MLC,OBJECTIVE,PURPOSE,RESULTS,V60
169,189,236,425,BACKGROUND,LTD,PCA,RESILIENCE,RESULTS,THESE,WILEY
169,ADDITIONAL,AIM,BACKGROUND,CONVERSELY,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,VED
001,004,027,029,042,043,363,AMSTERDAM,AVL,C30,EORTC,INDEX,LABEL,METHODS,NCI,OBJECTIVE,QLQ,QOL,QUALITY,RESULTS,SHORT,TREATMENT
400,AIM,GLEASON,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RADICAL,RESULTS
EPITHELIAL,INDIVIDUAL,LAYER,LUMEN,RATIO
BCR,CAP,ENTROPY,FIRSTLY,RANDOMIZED,THIRDLY,TMA
DSC,MAD,TRE
INCREASED,MET,TAKEN
946,BASED,ERG,EXPRESSION,GLEASON,NOVEL,PDGFR,TMPRSS2
000,163,274,CONCLUSION,HOWEVER,LABEL,METHODS,PSA,RESULTS,SINCE,UNASSIGNED
100,174,300,ADAM9,DU145,HSP70,ITIH4,L1CAM,LDH,LYSATES,MET,MFG,NOTCH,SEVERAL,SOMAMER,THESE,WESTERN
002,225,354,CONCLUSION,DYNAMIC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
BPH,PCA,THESE,YOUNG
163,197,230,ALK,ERG,ESRRA,III,PCR,SALZMAN,TMPRSS2
169,215,ADC,AUC,BACKGROUND,CCC,CONCLUSION,FOUNDATION,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTING,RESULTS,USING
945,HIF,HOWEVER,HYPOXIA,MAMMALIAN,MRV,MRVINFECTS,PAS,PCA,RACK1,THESE,VIRUS
LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THESE
1260B,AFTER,BACKGROUND,GENISTEIN,INITIALLY,LABEL,METHODS,MIR,RESULTS,SMAD4,TCF,UTR,WESTERN
421,835,843,AUSTRALIA,BACKGROUND,BRITISH,HOUSEHOLD,LABEL,METHODS,MIDLIFE,MODEL,PANEL,RESULTS,RETIREMENT,SIBLING,THESE,WISCONSIN
181,233,ACC,BELGIAN,FN1,GRAND,NUCLEAR,PC3,SEVERAL
GEM,HOWEVER,KSI,MYC,THESE
AKT,AML,CHEK1,ERG,ETS,ITGB3,ITGB5,NILOTINIB,PKC,SUZ12,TMPRSS2,WNT
18F,236,FDG,INCIDENTAL,JAPAN,PET,PSA,UNIVERSITY
125,GROUP,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RADIATION,RESULTS,THERAPY,THREE
120,BACKGROUND,GIOVANI,HIGHLIGHTS,ITALIAN,ITALY,LABEL,MAY,METHODS,OBJECTIVE,RADIATION,RESULTS,YOUNG
CK903,GATA3,GLEASON,PSA,THREE
945,946,954,CLAUDIN,DISRUPTION,EMT,PAR,PROLONGED,SMAD2,SMAD4,SNAIL,TGF
145,169,2_FI2,946,FUNCTIONAL,INCOMPLETE,MAT,PRESS,PUBLISHED,SNAIL,THESE,UNIVERSITY
169,223,COPYRIGHT,IRELAND,LTD,SIPULEUCEL
LNCAP,LTD,PUBLISHED,SEVERAL
DPC,HIPPOPHAE,MDA,PCO,SBT,THESE
000,100,119,200,500,C57BL,POLYPHENON,THEREFORE,TRAMP
183,ATTENTION,GEORG,STUTTGART
169,FND,HOWEVER,NDS,PEG,VCH,WILEY
946,969,MOUSE
002,017,019,020,048,169,215,260,26S,343,637,646,ADDITIONAL,BACKGROUND,BLACK,FURTHER,GLEASON,INC,INORGANIC,IOR,LABEL,METHODS,RESULTS,USING,WILEY
THERE
BAY,EQUAL,FLORIDA,INSTITUTE,LEE,MEDICALLY,MOFFITT,SOUTH,TAMPA,UNIVERSITY
183,ADT,AMONG,BACKGROUND,BMD,CONCLUSION,LABEL,METHODS,PCS,POWIR,PREVENT,RESISTANCE,RESULTS,RETENTION,THERE
18F,ACCORDING,CLINICALLY,CUP,FDG,IMAGING,ISSUE,LABEL,METHODICAL,METHODS,MODALITIES,MRI,OBJECTIVE,PET,PRACTICAL,RESULTS,SUBSEQUENT,WHOLE
595,ADDITIONAL,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PCA3D,PSA,PURPOSE,RESULTS,SERUM,SIMILAR,USING
DESPITE,DETECTION
169,413,531,712,COPYRIGHT,IRELAND,IRR,LTD,THERE
26A,CPG,H3K4ME3,HIPPO,HOWEVER,MYC,PCR,REDUCTION,THESE
000,002,007,035,095,141,413,419,618,750,BMI,GLEASON,JANUARY,LABEL,MARCH,METHODS,MRI,OBJECTIVE,PSA,RESULTS,STUDENT,T3A,T3B
017,BACKGROUND,CONTROL,DISEASE,GLEASON,INTENSITY,LABEL,MEDICAL,METHODS,NON,PREVENTION,PSA,RESULTS,THOSE,UNIVARIATE
100,169,200,223,946,DDR,GIVEN,LNCRNAS,LTD,MODULATION,PREVIOUSLY,PUBLISHED,THESE,UVB,VDR,VDRES,VDS,VITAMIN,WHILE,WILEY,WNT
001,002,512,706,806,BACKGROUND,DESPITE,END,FOLLOWING,LABEL,METHODS,ORP,OVERALL,PCA,PROPENSITY,RESULTS,THESE
BACKGROUND,CONCLUSION,DU145,HOX,LABEL,LNCAP,METHODS,PBX,PC3,PCR,RESULTS,TARGETING
268,631,963,HENCE,OVERALL
200,BIP,CAR,CONCLUSION,DKK,GRP78,JNK,JUN,LABEL,MATERIALS,METHODS,MOI,NSCLC,OBJECTIVE,OBJECTIVES,RESULTS,THESE,TKI
145,174,945,DOXAZOSIN,ECM,IGFBP,ILK,TSP
ABOLITION,APA,ECE,ENDOTHELIN,UTR
727,H3K27,JAZF1,LNCAP,RS4907792,SNP
169,945,METABOLIC,MYC,PCA,SOCIETY,THESE
AMP,FINALLY,HOWEVER,MDV3100,PCA
160,169,183,CONCLUSION,GEORG,IRB,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PCA,RESULTS,STUTTGART
181,183,ANDROGENS,FIRST,GEORG,LNCAP,STUTTGART,THESE,THIRD
146,169,303,390,839,BACKGROUND,CAPSURE,GLEASON,LABEL,METHODS,PATIENT,PEARSON,PRIMARY,RESULTS,SALVAGE,SOCIETY,STRATEGIC,THERE
956,BAX,BCL,DIOSCIN,LNCAP,THESE,WESTERN
174,177,DTX,LNCAP,PCL,PEG,PMS,PSA,TWEEN
000,100,388,493,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
001,011,115,386,388,3DCRT,503,BACKGROUND,CONCLUSION,IMAGE,LABEL,METHODS,PCA,PTV,RESULTS
007,169,327,335,AMONG,COPYRIGHT,DPQ1W,DPQ3W,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,TAX,THERE
001,008,016,025,169,967,976,AFTER,CLASS,CONTROL,COPYRIGHT,FIRST,INC,INCENTIVE,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,CURRENTLY,ERG,INC,INITIALLY,PCA,PROMISING,PSA,TMPRSS2,WHILE,YET
147,182,285,309,ANGELES,BACKGROUND,CIS,LABEL,LOS,METHODS,ORS,RESULTS,THERE
178,956,BAPTA,BHQ,CA2,INHIBITION,PC3
DENDRIMERS,G4ARG,PAMAM,SUCCESSFUL,TEA
169,312,ACD,AUSDIAB,AUSTRALIA,AUSTRALIAN,AUTHORS,COHEN,LABEL,LIFESTYLE,METHODS,OBESITY,OBJECTIVE,RESULTS,SIMILARLY,YEARS
169,482,AFFAIRS,AUSTRALIA,AUSTRALIAN,CONCLUSION,DEPARTMENT,DVA,FEMALES,GOVERNMENT,LABEL,METHODS,NSW,OBJECTIVE,RESULTS,SIR,SMR,SOUTH,THESE,WALES


223,CASTRATION,OTHER,THESE
FURTHER,THESE,WHILE
REGULATION,THROUGHOUT,VGSCS
CURRENT,FATOSTATIN,FURTHER,LNCAP,PSA,SREBP
169,BACKGROUND,CONVERSELY,COPYRIGHT,COUPLES,FINALLY,HOWEVER,LABEL,LTD,METHODS,QOL,RESULTS,THESE,WILEY
001,300,BACKGROUND,BCRFS,GLEASON,LABEL,METHODS,RESULTS,THESE,WESTERN
301,374,407,824,990,ARG,ARG194TRP,CAUCASIANS,CHINA,KNOWLEDGE,OVERALL,TRP,XRCC1
177,181,AKT,ERK,FURTHER,SNU,USING,VIETNAMESE
HOWEVER,PIN,STRIKINGLY,TAKEN
173,272,BACKGROUND,BPH,CYP24A1,GLEASON,HOWEVER,LABEL,METHODS,PSA,RESULTS,THEREFORE,VITAMIN
946,GLEASON,RAR,USUALLY
111,169,APL,CD8,COPYRIGHT,HENCE,HLA,HOWEVER,LTD,PLASMID,TH1,THESE
145,231,956,DU145,EPE,MDA,MMP,PNT1A,THERE
169,CBP,CONVERSELY,DESPITE,K27
BASED,III,MDV3100,OTHER,PREVAIL
169,361,BCL,CASTRATION,COPYRIGHT,INC,PCA,STAT6,THEREFORE
169,CLU,CLUSTERIN,COPYRIGHT,HOWEVER,IGF,INVERSELY,IRELAND,LTD,STAT3
169,787,BACKGROUND,CONTEXT,COPYRIGHT,CURRENT,GLEASON,IMAGING,ITEMS,LABEL,METHODS,MRI,OBJECTIVE,PATIENT,PCA,PREFERRED,PUBLISHED,REPORTING,RESULTS,REVIEWS,SEVERAL,STUDIES,SUMMARY,SYNTHESIS,SYSTEMATIC,THESE,UROLOGY
002,003,008,119,169,239,BACKGROUND,COPYRIGHT,CROSS,LABEL,MAY,MEN,METHODS,OBJECTIVE,OUTCOME,PATIENT,PFS,PSA,PUBLISHED,RESULTS,SETTING,SUMMARY,TAXANES,UROLOGY
169,COPYRIGHT,HOWEVER,LTD
BACKGROUND,CONCLUSION,D35,D99,LABEL,MAR,METHODS,PTV,RESULTS,TREATMENT
001,00279,945,BACKGROUND,ERK,EXPRESSION,GEO,HIF,HOWEVER,LABEL,METHODS,MICROARRAY,MSC,PCR,RAF,RAS,RESULTS,THEREFORE,VEGFA
159,CEM,CHRONIC,DLBCL,PBSCT,RELAPSE
223,AREAS,BACKGROUND,COVERED,FIRST,HOWEVER,III,LABEL,METHODS,OPINION,PHASE,TARGETING,THERE
431,956,HYGROCINS,MDA,NMR,PC3,SIX
250,COMBI40,COMBI70,CONCLUSION,LABEL,METHODS,NINTEDANIB,OBJECTIVE,PSA,RESULTS
CLINICALLY,CROATIA,GLEASON,LOCALLY,METASTATIC,PSA,TNM,TREATMENT
107,184,CONCLUSION,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,STATISTIC,TESLA,THREE
283,665,BRCA1,BRCA2,COX
134,168,169,188,223,30D,376,544,939,940,FUNCTIONAL,HOWEVER,INGENUITY,IPA,MIR,NORMFINDER,PATHWAY,RNU6B,SEVEN
102,242,AMONG,DRE,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RCP,RESULTS
009,017,039,371,854,ARG,CAUCASIAN,CAUCASIANS,CHINA,CIS,FIXED,GALBRAITH,GLEASON,HARDY,HOWEVER,KNOWLEDGE,LIBRARY,OCTOBER,PCA,PRO,SYSTEMATIC,THEREFORE
246,ACADEMY,HOWEVER,IDM,NETWORK,PCS,PHYSICIAN,PHYSICIANS
169,ATR,COPYRIGHT,NATURALLY,THERE,VCH,WILEY
113,116,177,AES,CAUCASIAN,CYCLE,DLT,LABEL,METHODS,MTD,OBJECTIVE,PURPOSE,RESULTS,SEVENTEEN
106,192,387,674,ARHGEF3,C8ORF38,CORRECTING,ERG,EXCLUSION,OVERALL,PCA,PCR,TMPRSS2,USING
SURGERY,TREATMENT,UNIVERSITY
DRE,GLEASON,INTER,MYC,PSA
947,RESULTS,SEVERAL,TUNEL
169,180,231,453,956,COPYRIGHT,MCF,MDA,MTT,NMR,SAS,SIX,THEIR
000,600,LOCAL
169,954,CAF,CAV,COPYRIGHT,HOWEVER,LTD,ROS,THESE
100,169,2D3,945,956,COPYRIGHT,FORMATION,HEPATIC,LTD,NADPH,RESULTS,RG1,RH2,SIMILAR
169,AUC,BACKGROUND,COPYRIGHT,COX,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,OVERALL,PCA,PSA,PUBLISHED,RESULTS,RETROPUBIC,SETTING,UROLOGY
001,169,451,892,AFTER,BETWEEN,CONCLUSION,COPYRIGHT,COX,EDUCATION,FOUNDATION,GIVEN,GLEASON,INC,JANUARY,LABEL,MEDICAL,METHODS,MIB,OBJECTIVE,PREDICTIVE,PUBLISHED,RESULTS
169,416,BACKGROUND,COPYRIGHT,END,FOLLOWING,HBT,LABEL,LOS,METHODS,OBJECTIVE,OUTCOME,OVERALL,PATIENT,PUBLISHED,RELYING,RESULTS,SETTING,SUMMARY,THESE,UROLOGY
007,108,169,465,890,CONCLUSION,COPYRIGHT,DISEASE,IMPORTANT,INC,LABEL,METHODS,OBJECTIVE,RESULTS
169,BECAUSE,COPYRIGHT,DFU,LTD
169,477,4MM,BECAUSE,CBCTS,CONCLUSION,COPYRIGHT,CROWN,CTV,FIFTY,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PTV,PTV10,PUBLISHED,PURPOSE,RESULTS
169,220,290,AUTHORS,COPYRIGHT,IRELAND,LTD,PCA,PUBLISHED,SPC,THERE
145,169,180,421,746,BACKGROUND,CONCLUSION,COPYRIGHT,CSF,CUP,EAP,LABEL,LTD,METHODS,RESULTS
102,169,AFTER,CAMEY,CONCLUSION,COPYRIGHT,EARLY,ICP,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SEVEN,SIXTY,SSC
106,112,113,118,169,BACKGROUND,COPYRIGHT,IRELAND,JANUARY,LABEL,LTD,MEDICAL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SAMSUNG,THERE
169,946,BASAL,COPYRIGHT,E12,TRIPARTITE
169,BACKGROUND,CCAFU,CONCLUSION,COPYRIGHT,GLEASON,GUIDELINES,INDIVIDUAL,ISP,LABEL,MEDLINE,METHODS,PSA,RESULTS,RMN,SAS
169,317,416,549,781,792,841,CANCERS,CONCLUSION,COPYRIGHT,FRANCIM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRESENT,RESULTS,SAS,TESTICULAR,THERE
169,CONCLUSION,COPYRIGHT,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RESULTS,SAS,SCORE,SECONDARY,SEPTEMBER,SIXTY,SYMPTOM,TURIS
00001,001,169,303,APRIL,BMI,CLAVIEN,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,LABEL,LRP,METHODS,OBJECTIVE,PSA,RADICAL,RESULTS,SAS,THERE
169,AVS,BACKGROUND,BETWEEN,CONCLUSION,COPYRIGHT,LABEL,MARRAKESH,METHODS,RESULTS,SAS,THERE
169,AMICO,CONCLUSION,COPYRIGHT,DIFFUSION,LABEL,METHODS,MRI,NPV,OBJECTIVE,PPV,PSA,PUBLISHED,RESULTS,SAS,TNM
169,ANG,AT1,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,METHODS,RAS,RESULTS,SAS,SEVERAL
160,169,CHRONIC,COPYRIGHT,CXCL1,FEDERATION,FINALLY,PUBLISHED,SOCIETIES,TAKEN,USING,UTR
239,945,BACKGROUND,HOWEVER,INHIBITION,LABEL,METFORMIN,METHODS,PCR,RESULTS,THESE,WESTERN
116,169,549,956,AMONG,COPYRIGHT,HCT,HUISGEN,LTD,MCF,MICHAEL
169,178,185,945,DFO,EVALUATION,FDG,INC,OTHER,PET,RENAL,THERE
169,311,AMONG,BACKGROUND,BASED,COX,LABEL,METHODS,PERIPHERAL,RESULTS
001,108,113,169,518,ACTIVITIES,ADL,ASSESSMENT,BACKGROUND,CGA,CONCLUSION,CROSS,CUMULATIVE,DAILY,DEPRESSION,GERIATRIC,GERIATRICS,ILLNESS,LABEL,MATERIALS,METHODS,OBJECTIVE,PARIS,PREVALENCE,REFERENCE,RESULTS,SCALE,SETTING,STATE,THESE,TIMED
005,BACKGROUND,CALIFORNIA,CONCLUSION,FRANCISCO,HOWEVER,LABEL,MATERIALS,METHODS,PHOENIX,PSA,RESULTS,SAN,SIMILARLY,UNIVERSITY
162,169,199,428,531,731,791,BACKGROUND,BRCA1,BRCA2,COPYRIGHT,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,PPV,PSA,RESULTS,SETTING,SUMMARY,TARGETING,THESE,UROLOGY
16913,20005,20359,25910,46269,AGE,AMONG,BACKGROUND,CHANGES,FEDERAL,HODGKIN,LABEL,METHODS,RESULTS
169,688,696,ACADEMY,BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS
450,CONCLUSION,FINALLY,GLEASON,HOLEP,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERE,THOSE
956,BUFALIN,COMPOUNDS,THEIR
100,CANCERS,CIS,CONCLUSION,DETECTION,DIAGNOSTIC,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
277,491,718,762,AFTER,BACKGROUND,FACILITIES,FDG,HOWEVER,JAPAN,LABEL,METHODS,OSAKA,PET,PREFECTURE,RESULTS,SCREENING,WHOLE
001,169,COPYRIGHT,LABEL,LTD,MARITAL,METHODS,NEITHER,OBJECTIVE,RESULTS,SURVIVORS,WHILE,WILEY
10001,1960S,1970S,333,ADDITIONAL,CURRENTLY,FURTHER,HOWEVER,MEDICAL,PUBLISHERS,RANDOMIZED,SCREENING,SEVENTH,TRAIL,USA
104,169,206,BACKGROUND,CSS,EPE,FORTY,GLEASON,IDC,INC,LABEL,METHODS,PFS,PSA,RESULTS,SVI,WILEY
954,956,CHINESE,ERK,MOLECULAR,RANKL
954,AIM,AMONG,AP4,BBX,CONSORTIUM,FOXO4,GENOMES,GEO,HODGKIN,KYOTO,MBNL1,MFAP2,MYELOMA,SNAIL,SP1,TPD52,USING,YY1
AKT,CSC,H1975,NSCLC,OVERALL,REGULATION,SRY
596,600,BACKGROUND,CONCLUSION,CRPCA,HNPCA,LABEL,METHODS,RESULTS,SMALL,THEIR,TMA
001,146,147,APPLIED,BCR,BMI,FURTHER,GLEASON,GSC,KOREA,MEIER,NAFLD
123,CLOSO,LNCAP,THERE
HOWEVER,ORBITAL
256,770,837,847,858,875,AUC,BASEL,BULGARIAN,DESPITE,KETTERING,LNI,MSKCC,PCA,PREDICTED,SLOAN
169,1ST,5TH,ACCORDING,BASEL,HUNGARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROMAN
ATP,AUGMENTED,CTL,HMGB1,RADIATION,THESE
169,COPYRIGHT,HOWEVER,INC,THEREFORE
169,SER81,TAKEN,THESE
160,169,BECAUSE,COMPASS,COPYRIGHT,DICOM,DVH,INSTEAD,LTD,OAR,PEARSON,PUBLISHED
169,AIM,BACKGROUND,BECAUSE,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SURGERY
169,177,2MM,3MM,CONTROL,COPYRIGHT,GAMMA,INC,LINAC,MEDICAL,MELBOURNE,MONITOR,NUCLEAR,OVERALL,PATIENT,POINT,PUBLISHED,SNC,SUN
125,169,177,24H,518,945,946,AHX,ALA,ARG,ASP,BACKGROUND,BBN,COPYRIGHT,ECHISTATIN,ESI,GLN,GLU,GLY,INC,LABEL,LEU,METHODS,MICRO,NH2,PHE,RESULTS,RGD,RM2,STA,TRP,TYR,U87,VAL
001,028,031,102,111,169,AMONG,APMIS,CLDN1,CLDN7,FURTHER,LTD,PUBLISHED,SNP,THESE,TIGHT,TNM,WILEY
ANNEXIN,ANX,AREAS,BACKGROUND,CCC,COVERED,LABEL,METHODS,OPINION
177,956,ANNEXIN,CELLS,GIVEN,PC3,RAMOS,RED
169,17Q21,485,ATLAS,BECLIN1,BECN1,BRCA1,LABEL,LARGE,MCR,MOL,RES,UNLABELLED
001,004,ADVERSE,AES,BACKGROUND,III,LABEL,METHODS,PSA,RESULTS,STATISTICS
945,954,ABROGATING,AP4,FOXA2,LNCAP,MAX,MET,MYC,NANOG,PCA,RANKL,RUNX2,TFS,THESE
169,427,BACKGROUND,BLOCK,CALIFORNIA,COX,DESPITE,HISPANICS,LABEL,METHODS,RESULTS,SOCIETY,STAGE

001,101,628,AFRICAN,CANDIDATE,CAUCASIAN,PCA,PCR,USA
CURRENT,III,SINCE,WHILE
000,152,160,218,281,380,BIOMARKERS,CLDN3,COA,GLEASON,PSA,SPECIAL,THOSE
AMONG,CTIBL,LABEL,METHODS,OBJECTIVE,PHYSICIANS,PURPOSE,RESULTS,THERE,YET
153,172,222,HOWEVER,JADAD,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX
001,003,006,013,027,030,128,155,BACKGROUND,COX,GLEASON,IMMEDIATE,LABEL,MEIER,METHODS,RADICAL,RESULTS
ADT,BACKGROUND,CONCLUSION,CUP,DIGITAL,LABEL,METHODS,PSA,TEN
001,019,151,579,AMICO,BACKGROUND,HOWEVER,IHC,LABEL,METHODS,PCA,RESULTS
116,131,692,704,723,758,961,ADC,CLINICALLY,CONCLUSION,FORTY,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,009,021,025,026,051,078,082,092,109,867,881,946,CONCLUSION,COX,FDG,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS
001,177,20MIN,BPH,CONCLUSION,FACBC,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,WHOLE
DEF,DU145,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS
001,004,010,017,221,942,BACKGROUND,CIS,FURTHER,HCC,HRS,LABEL,METHODS,RESULTS,RFS,SCIENCE,WEB
104,NANOG,NEITHER,PACLITAXEL,SCG10,USING
178,945,TRANSIENT
ALTOGETHER,KNOCK,MMP,RUNX3,STRIKINGLY,TMA,TNM
031,061,119,437,MUTATIONS
011,048,427,ASSOCIATED,BACKGROUND,BRITISH,COMPLEX,CONCLUSION,END,GENERAL,LABEL,METHODS,OVERALL,PRS,RESULTS,SHIPMAN,THESE,WORLD
169,ANTIGEN,LABEL,MOS,VCH,WILEY
AFTER,CANCERS,IRELAND,OTHER,RISKS,VARIATIONS
176,AIM,BACKGROUND,GLEASON,LABEL,MATERIALS,MEIER,METHODS,PSA,RADICAL,RESULTS
115,D90,HOWEVER,LABEL,LOCAL,MAY,METASTATIC,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,RRP,SOCIETY
11C,18F,PET,PSA
AMERICA,CD4,CD8,DIGITAL,FEW,GOVERNMENT,HOWEVER,IHC,PBMCS,PSA,PUBLISHED,THERE,THESE,TREGS
HOWEVER,SOAKING,SOY,SYSTEMATIC
SNP
169,BRCA2,DSB,HOWEVER,IMPAIRMENT,PARP1,THESE,UTR
145,1522B,AGO,CATCHESIDE,CLINICALLY,CONCLUSION,KNOWLEDGE,LABEL,LEA,METHODS,OBJECTIVE,RESULTS,SINCE,THERE,THESE
956,BACKGROUND,CXCR4,HENCE,LABEL,METHODS,RESULTS,THESE
001,169,276,331,360,945,AUTHORS,BJU,BPH,CONCLUSION,DRE,FURTHER,ITALIAN,LABEL,METHODS,OBJECTIVE,PIN,PSA,RESULTS,THERE,THREE
520,AIM,DISCUSSION,III,LABEL,MATERIALS,METHODS,OBJECTIVE,PC3,RESULTS
001,009,015,169,461,536,603,AXIAL,CONCLUSION,INTERRATER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNR,STUDENT,THERE
043,215,250,299,ASSESSING,BACKGROUND,BASED,CONCLUSION,COX,FRANKEL,HARRELL,KARNOFSKY,LABEL,MEDICAL,MEIER,METHODS,PREDICTIVE,RESULTS,SBM
GTPASES,RHO,SEVERAL
BRONJ,INTER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,003,010,036,100,AFFAIRS,AGENT,BACKGROUND,FIFTY,FURTHER,HOWEVER,JANUARY,LABEL,LEVEL,METHODS,RESULTS,WASHINGTON
102,946,AKT,ECTOPIC,EGF,ERBB2,ERBB3,III,LABEL,UNLABELLED
114,117,AIM,BACKGROUND,ERG,ETS,LABEL,METHODS,PCS,PSA,REMARKABLY,RESULTS,THESE,TMA,TMPRSS2
687,803,822,BACKGROUND,COX,GLEASON,INCREASING,IQR,LABEL,MEANWHILE,MEIER,METHODS,PATIENT,PSA,RESULTS
BMD,CURIOUSLY,DENOSUMAB,LABEL,OBJECTIVE,OTHER,PURPOSE,REGARDLESS,RESULTS,SUMMARY
169,174,CONCLUSION,COPYRIGHT,ERG,EXPRESSION,HBP,INC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SIMILAR,TMPRSS2
001,006,115,169,CLINICIANS,CONCLUSION,COPYRIGHT,EPSTEIN,GLEASON,INC,LABEL,METHODS,MRI,NPV,OBJECTIVE,PPV,RESULTS
160,169,ASSESSMENT,CD44S,CD44V10,COPYRIGHT,EXPRESSION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNIVARIATE
COLLECTED,FIRST,MAP,MAXIMUM,NMF,NON,THIRD
001,004,008,015,019,022,026,028,042,045,169,ADT,AUTHORS,BJU,COMMENCING,CONCLUSION,CONCURRENT,LABEL,METHODS,OBJECTIVE,OTHER,RESULTS,SIXTY,THERE
001,169,AUTHORS,BJU,COMPETING,CONVERSELY,CSM,END,GLEASON,LABEL,METHODS,NNT,OBJECTIVE,OVERALL,PCA,RESULTS,T3A,T3B
185,NMR,PACLITAXEL,PTX,THESE
169,DAC,LABEL,LTD,METHODS,OBJECTIVE,PAPILLARY,PIN,RESULTS,WILEY
FINALLY,HOWEVER,TARGETING,USA
181,AEA,BACKGROUND,CACO2,CYP17,FATTY,HEPG2,LABEL,PRINCIPAL,RESULTS
ADT,CONVERSELY,DESPITE,DHT,LNCAP,PCA,PCR,PSA,SUBSEQUENT,THEREFORE,TMPRSS2
DIM,EPIGENETIC,HOWEVER,LNCAP,OVERALL,PC3,RESULTS,SFN
BASED,CHINESE,CHO,LNCAP,NEOPLASTIC,THEREFORE,WHILE,XENOPUS
141,145,173,EMT,INCREASED,PTHRP,SNAIL
CCP,FEW
153,155,EUCLIDEAN,PFS,PHASE
004,027,039,144,177,299,336,383,498,701,877,988,AGE,EFFICIENT,HOLEP,HOLMIUM,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,RESULTS,USING
EPCAM,EPICD,LABEL,MEMBRANOUS,METHODS,MOC,OBJECTIVE,REGULATED,RESULTS,TMA
169,607,ANNEXIN,ANXA1,CAF,CD49F,FURTHER,LABEL,MOL,NPF,RES,SCA,THESE,UNLABELLED
169,945,ADT,AUTHORS,DIGOXIN,EXPRESSION,GLEASON,HIF,LTD,PSA,WILEY
BASED,CURCUMA,DOCKING,EGF,FURTHER,GST,PDGFA,PRESENT,VARIOUS
169,20A,ABL,ASO,DU145,GLEASON,INC,KNOCKDOWN,WILEY
169,217,946,BAX,COLON,EMT,INC,PROTEIN,WILEY,WNT,WNT5A
SVM
169,177,AHX,BACKGROUND,GLU,INC,LABEL,LYS,METHODS,PET,RESULTS,SINCE,WILEY
169,ANOTHER,BACKGROUND,INC,METHODS,PSP94,RESULTS,SNP,VARIANT,WILEY
CAP,CPG,GSTP1,THESE
THEIR
COMBINING,DUE,HOWEVER,NPS,PC3,PEG,PEG2K,PEGYLATION,THESE
009,49898,967,AMONG,BACKGROUND,BECAUSE,CIS,COMPARING,COX,DIETARY,HRS,JANUARY,LABEL,METHODS,RESULTS
ENDOGENOUS,LABEL,OBJECTIVE,PAR,SAC
11A,12B,13A,14B,169,956,COPYRIGHT,INC,MCF,STRUCTURAL
169,COPYRIGHT,IRELAND,LTD,WNT
169,COPYRIGHT,DEVELOPED,LTD,PCA
111,169,BACKGROUND,CONCLUSION,COPYRIGHT,DU145,IMAGING,INC,LABEL,LOCALIZED,METHODS,RADIOLABEL,RESULTS,SPECT
169,231,233,COPYRIGHT,HOWEVER,INTENSITY,PUBLISHED,SAS
169,AFTER,COPYRIGHT,DU145,HUHS015,LTD,PCA
046,169,817,APRIL,BASED,CONCLUSION,COPYRIGHT,EGGER,EXTRACTION,LABEL,LTD,METHODS,MOOSE,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,RRS,SIR,SMR,SOCIETY
169,COPYRIGHT,GERIATRIC,LTD,NURSING,SOCIETY
169,COPYRIGHT,LTD,THESE
169,END,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PRINCIPAL,RESULTS,SETTING,SOURCES,TRUST,UROLOGIST
III,OXIDATIVE,SKQT1,UNDER
DU145,OXIDATIVE,SEM,TEM,THESE,VK3
177,ADDITIONAL,BACKGROUND,BFE,CARLO,CHAIN,FFE,HAUSDORFF,LABEL,MAD,METHODS,MONTE,RESULTS
419,BACKGROUND,CAD,CENTRAL,CONCLUSION,CONFIDENCE,CSS,IAD,INTERVALS,LABEL,MEDLINE,METHODS,OVERALL,QOL,RATIO,RESULTS,SEVERAL,TTP,USA,WESTERN
000,100,801,ASR,BACKGROUND,BASED,CHICAGO,ICD,KHUZESTAN,LABEL,MATERIALS,METHODS,RESULTS,THERE
215,BACKGROUND,CONCLUSION,DVH,GIVEN,HDR,LABEL,METHODS,OAR,RESULTS
ANALYZING,CHINA,DEC,EBSCOHOST,EVENTUALLY,JAN,LIBRARY,MEDLINE,MYSQL,PHP,WILEY
DHA
169,BACKGROUND,BPH,COPYRIGHT,EMG,EUS,INC,LABEL,METHODS,MOTOR,MUP,PCA,RESULTS,SIXTY,THERE,WILEY
160,ENGLISH,EXTRACTION,LABEL,MDV3100,METHODS,OBJECTIVE,PSA,RESULTS,SELECTION,SOURCES,SYNTHESIS
001,ASC,BMI
003,007,108,245,BACKGROUND,LABEL,MARCH,MARSDEN,METHODS,NHS,NLR,POTENTIAL,PSA,RESULTS,ROYAL
BASED,HISTOLOGIC,PET
013,229,577,ALS,ALZHEIMER,BACKGROUND,CNS,CONCLUSION,HUNTINGTON,INCREASED,ISI,KNOWLEDGE,LABEL,MARCH,MEDLINE,METHODS,PARKINSON,RESULTS,SCZ,SOURCES,THERE,WEB
CK2,FINALLY,HOWEVER,PAR
ARI,BPH,DHT,PCA
SEX,SIMILARLY
169,602,880,ASIAN,BASEL,CIS,FURTHER,HENCE,HOWEVER,IGFBP,LABEL,METHODS,OBJECTIVE,ORS,PCA,RESULTS,THESE
001,002,100,119,169,6H2,925,AUTHORS,CONTROLLED,COPYRIGHT,HOWEVER,IHC,INC,PATTERN,PUBLISHED
5ARIS,ARS,BPH,CELLS,ELISA,GROUP,LABEL,LNCAP,MARCH,MATERIALS,METHODS,MTT,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THESE,WESTERN
106,125,156,172,249,AMONG,ANALYZING,EPE,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RADICAL,RESULTS,SCORE,SVI
000,003,009,011,014,015,016,027,037,051,052,074,078,092,095,098,120,137,193,258,384,391,519,584,740,ACCORDING,AGE,BETWEEN,BINDING,BMI,DRE,HORMONE,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SERUM,SEX
400,COX,GLEASON,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,YOUNG
002,007,024,034,100,BACKGROUND,CONTINENCE,LABEL,LRP,METHODS,OBJECTIVE,PVR,RESULTS,SCORE,SEVERAL,SYMPTOM,THREE,URINARY
169,CLINICALLY,COUPLED,DISTANT,FEW,LTD,PUBLISHED,REVIEWING,WILEY
ASTRO,COX,GLEASON,GUROC,MEIER,PROCARS,RADIATION,SOCIETY
000,001,169,471,753,AMONG,BACKGROUND,BCR,EARLY,GLEASON,INC,LABEL,MEN,METHODS,NETWORK,PCA,RESULTS,THEREFORE,THESE,WILEY
169,2B4,HOWEVER,INC,LASS2,MMP,PCA,SILENCING,THESE,TMSG1,WILEY
002,041,053,064,073,154,1B1,238,432,504,783,853,942,981,EGGER,HOWEVER,LEU,LEU432VAL,VAL
160,200,COMMITTEE,CONSORTIUM,GEM,INSTITUTES,MOUSE,MYC,PCA,TODAY,TRAMP,WHICH
160,223,SINCE,STRATEGIES


009,016,023,034,30C,EXPRESSION,GLEASON,HOWEVER,MEIER,MIR,PCA,PCR
946,ATLAS,MICRORNAS,NGS,PC3,TGF,THEREFORE,WNT
160,169,183,GEORG,MRI,STUTTGART
001,002,270,AMU,BPW,EUS,FOV,FUNCTIONAL,LABEL,METHODS,MRI,MUL,OBJECTIVE,PURPOSE,RESULTS
169,183,20S,4DMSO,CL3,COPYRIGHT,CRL2221,H2O,III,INC,NO3,PUBLISHED,RESULTS,SPECIES
169,AKT,ATP,EHBP1,EMPLOYING,MEVALONATE,PRESS,PUBLISHED,STATINS,THESE,UNIVERSITY
003,FURTHER,HGPIN,HOWEVER,PROSTATIC,PSA,SINCE
HOWEVER,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
215,526,ASSESSMENT,CENTRAL,CONCLUSION,CONTROLLED,DCE,DIAGNOSTIC,DWI,LABEL,MATERIALS,MEDLINE,METHODS,MRI,OBJECTIVE,QUALITY,RESULTS,SEVEN,STUDIES
177,AIM,CONCLUSION,DOTATOC,LABEL,METHODS,NET,OBJECTIVE,PET,RESULTS,SIXTY
174,BASED,GEOGRAPHIC,TILEPRO,VINCI
169,CYP17A1,HOWEVER,LABEL,MECHANISMS,METHODS,OBJECTIVE,PURPOSE,RESULTS
AKT,BASIC,ERBB3,JAK,JANUS,MEK,TKI
177,AFTER,HOWEVER,RCF,SEVERAL
001,050,90401,CALGB,CONCLUSION,EASTERN,GROUP,III,LABEL,METHODS,OBJECTIVE,PROGNOSTIC,PURPOSE,RESULTS
047,127,415,490,COLORECTAL,EARLIER,HRS,OLDER,OVARIAN,SCREENING,TRIAL,USING
CARLO,MONTE,MRI
EFFECTIVE,GATA2,INGENUITY,LNCAP,LTL,REGULATOR,SIX
169,COPYRIGHT,DU145,LTD,P53,PCA,PMP53,THESE
BACKGROUND,CTV,FORTY,LABEL,METHODS,PTV,RESULTS,SEVEN,TVE
143,215,AUC,DRE,GOVERNMENT,LABEL,MEN,METHODS,MRI,OBJECTIVE,OBJECTIVES,PATIENT,PSA,PUBLISHED,RESULTS,SPL,USA
001,169,199,413,492,954,AUTHORS,BJU,CONCLUSION,HTS,HTV,LABEL,METHODS,MRI,MRTVS,OBJECTIVE,RESULTS,T2W,TVS,WHOLE
100,169,729,756,781,AVERAGE,BIOMEDICAL,CIS,COPYRIGHT,ICT,INTER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,QUESTIONS,RESULTS
126,BCL,BPH,EASTERN,GLEASON,GROUP,LABEL,LNCAP,METHODS,MMP,MTT,OBJECTIVE,PCA,PSA,RESULTS,TNM,TRANSWELL,WESTERN
100,169,177,949,956,COPYRIGHT,DOX,ECM,LNCAP,LRP,LTD,MDR,NPS,OVERALL,PCA,PCL,PEG,SEPARATELY,THREE
485,512,BACKGROUND,CPG,CURRENTLY,HOWEVER,LABEL,RESULTS
001,140,169,260,400,470,870,AUTHORS,BETWEEN,BJU,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,RFS,WHILE
AKT,LNCAP,P21CIP1,P53,RESULTS,SER15,THESE
100,169,HOWEVER,UROLOGICAL
DCG,MICROARRAY,REGULATORY,TFS,THESE
140,164,AFRICAN,AMERICANS,CAUCASIAN,CAUCASIANS,PCR,PGA,SERUM,SINCE
001,177,CONCLUSION,LABEL,MATERIALS,METHODS,MTV,OBJECTIVE,PET,PIN,PURPOSE,RESULTS
00001,113,BACKGROUND,BESIDES,CONTROLLED,FIXED,LABEL,MEDLINE,METHODS,PSA,RESPECTIVE,RESULTS,TRT,UROLOGISTS

AKT,CAP,EMT,LOCAL,RADIATION
946,AKT,AMONG,DU145,HOWEVER,IMMUNOBLOT,STAT3
001,003,005,015,039,061,846,967,HCC,LABEL,LITERATURE,METHODS,OBJECTIVE,PITUITARY,PURPOSE,RESULTS
LABEL,LDN,LND,LYMPH,OBJECTIVE,PURPOSE,RESULTS,ROUTINE,SUMMARY,THERE
001,005,006,008,017,122,504,CONVERSELY,COX,LABEL,MEIER,METHODS,NSM,OBJECTIVE,PSM,PURPOSE,RESULTS
169,COPYRIGHT,ERG,ETS,INC,TMPRSS2
000,169,COPYRIGHT,EARLY,ERG,ETS,INC,PCA,REMARKABLE,SRS,TMPRSS2,WHEREAS
074,155,169,211,215,272,CONSORTIUM,COPYRIGHT,INC,PRACTICAL,THESE
169,COPYRIGHT,CRPCS,INC,NCOR1,NOTABLY,SIAH2
10000,169,400,40000,BACKGROUND,CONTEXT,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PTH,RESULTS,SETTING,THESE,TORONTO,VITAMIN
001,002,052,169,243,413,897,AMONG,BETWEEN,INC,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RADIATION,RESULTS,SMS,THERAPY,UNLABELLED,USING
001,169,969,ADD,AFTER,AHR,CONCLUSION,END,GLEASON,INC,KNOWN,LABEL,MEN,METHODS,OBJECTIVE,PENDING,PIVOT,PSA,PUBLISHED,RESULTS,SUBJECT,T1C,TRIAL,UNLABELLED,WHETHER
160,169,660,BACKGROUND,C30,CONCLUSION,COPYRIGHT,DESPITE,EORTC,HRQOL,INC,LABEL,MARCH,METHODS,QLQ,QUALITY,RESULTS,TREATMENT
001,100,160,169,COPYRIGHT,EARLY,LTD,MAXILLO,PUBLISHED,SURGERY
AKT,GEM,JQ1,MYC,TAKEN,USING
160,169,226,COPYRIGHT,ETOPOSIDE,GRADE,PSA,PUBLISHED,SIXTEEN,TREATMENT
169,231,BACKGROUND,COPYRIGHT,GNP,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,MDA,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
169,4MM,5MM,COPYRIGHT,DEFORMABLE,ENDORECTAL,EXPANDING,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,ACCORDING,BACKGROUND,COPYRIGHT,FOCAL,GLEASON,INCLUSION,LABEL,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,RESULTS,SETTING,SUMMARY,T1C,T2A,UROLOGY
001,149,169,354,AIM,BACKGROUND,END,FOLLOWING,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,THESE,USING
169,300,588,AFTER,BRITISH,LYG,PLAUSIBLE,PSA,QALYS,RANDOMIZED,SCREENING
768,AMONG,CHINESE,HOWEVER,IDENTIFIED,MALAY,MALAYSIAN,THERE
160,BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS
119,169,177,284,927,BACKGROUND,CLINICALLY,INC,IRE,LABEL,LESIONS,METHODS,NUMERICAL,PROSTATES,RESULTS,THESE,WILEY
GBM,GFP,PCR,TGIFX,U87,U87MG
CCR2B,ERK,PC3,TAKEN,THP
RITUXIMAB
946,ACTIVATION,TGF
HOWEVER,KNOCKDOWN,LNCAP,PCA
ATP,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,SIX,WESTERN
DDM,DIR,ICE,PEARSON,THEREFORE
169,COPYRIGHT,FOLLOWING,HIC,IRELAND,LTD,PUBLISHED,TGFB1I1,THERE,THESE
169,183,465,BACKGROUND,CHAIR,COPYRIGHT,FUNDING,HOWEVER,LABEL,LTD,METHODS,OLDER,ONTARIO,RESULTS,STUDIES,THESE
169,BASED,BLOCK,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,129,169,260,261,353,AFTER,AMICO,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROBOTIC,UROLOGICAL
037,169,956,ACETATE,BACKGROUND,COPYRIGHT,DU145,EAGLE,FDG,FFA,INC,LABEL,LNCAP,MBQ,METHODS,PC3,PCA,RESULTS
000,100,135,160,169,177,335,720,CONCLUSION,COPYRIGHT,CURRENTLY,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SEVENTY,SURGEON,THERE,WORLD
AUTOPSY,BACKGROUND,BECAUSE,CAREFUL,CENTRAL,CONTEXT,CONTROLLED,ELECTRONIC,FACTORS,LABEL,METHODS,OBJECTIVE,PATIENT,PCA,PUBLISHED,RESULTS,SCREENING,SUMMARY,SYNTHESIS
100,169,AUR,COPYRIGHT,DOT,HCM,INC,PRIOR,PUBLISHED
002,110,169,BACKGROUND,COPYRIGHT,EXCLUSIVE,LABEL,METHODS,PUBLISHED,RESULTS,SEPAR
169,583,BACKGROUND,COPYRIGHT,LABEL,METHODS,NOTTINGHAM,OVERALL,PROFILE,PUBLISHED,QUALITY,RESULTS,SPAIN,SPANISH,SURVIVORS
169,BACKGROUND,BONFERRONI,CONCLUSION,COPYRIGHT,COX,FURTHER,HASHIMOTO,HOWEVER,INSURANCE,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SEVERAL,SOCIETY,TAIWANESE
100CM,125,169,COPYRIGHT,INC,JAPAN,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,TOKYO
001,160,169,284,327,AFFAIRS,AGE,AMONG,BASED,COMBINING,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PSA,RAISING,RESULTS
169,946,AUTHORS,CALU3,EXPRESSION,H23,KNOCKDOWN,LTD,NCI,NOD,PTY,PUBLISHING,SB208,SCIENCE,SMAD2,TGF,THESE,WILEY
786,ADR,ANTICANCER,EHRLICH,ERS,MODULATORS,NCI,OVCAR,PSIDIUM,RECEPTORS,RES,SELECTIVE,SERMS,SOLID
BACKGROUND,HOWEVER,KNOCK,LABEL,METHODS,MV3,RESULTS,STRIKINGLY,THEREFORE
947,950,BACKGROUND,CAR,CD3,IFN,LABEL,LOG,MEIER,METHODS,RESULTS,STUDENT
CRE,CRTC2,IGF,LNCAP,METFORMIN,SIMILARLY,SRC,THESE
10726,CONSORTIUM,G10398A,GIVEN,GPX,LEU198LEU,MNSOD,ND3,OVERALL,PRO198LEU,ROS
145,169,177,220,956,BIASING,COPYRIGHT,MCF,VCH,WHEREAS,WILEY
169,BACKGROUND,BIRTHPLACE,END,HISPANICS,LABEL,MEIER,METHODS,RESULTS,SOCIETY
150,515,983,AMONG,BACKGROUND,EASTERN,GROUP,INVENTORY,LABEL,METHODS,RATINGS,REGRESSION,RESULTS,SYMPTOM
160,ADP,BACKGROUND,BPH,CHINESE,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PAR,PCA,PSA,RESULTS
169,946,BACKGROUND,CLINICALLY,CONCLUSION,EMT,ERG,H3K4ME3,HOWEVER,INC,LABEL,METHODS,PCA,PCR,RESULTS,SILENCING,TGF,TSA,WESTERN,WILEY
164,169,194,BACKGROUND,CRP,INC,LABEL,MARKERS,METHODS,NEUTROPHIL,NLR,NUTRITION,PLR,PSA,RESULTS,SERUM,WILEY
169,222,BACKGROUND,HETES,INC,LABEL,MEIER,METHODS,PCA,PSA,RESULTS,UHPLC,WILEY
003,004,006,009,1498C,160,1612G,2489C,2578C,496,ATTGC,ATTGT,BACKGROUND,CCCCC,CCCGC,CONCLUSION,GENOTYPES,HAPLOTYPE,HAPLOVIEW,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
145,169,22RV1,BACKGROUND,CAHPV10,HPV,INC,LABEL,LNCAP,METHODS,PCR,PNT1A,RESULTS,THERE,WESTERN,WHILE,WILEY
169,945,BACKGROUND,CONVERSELY,EGF,EMT,EPIDERMAL,FURTHER,HIF,HOWEVER,HYPOXIA,INC,LABEL,METHODS,NAC,PCR,RESULTS,ROS,SILENCING,STAT3,WILEY
032,169,337,569,906,ALTOGETHER,ANNOTATION,APPLIED,BACKGROUND,BIOSYSTEMS,DISCOVERY,HOWEVER,INC,INTEGRATED,LABEL,METHODS,NS1,PCR,RESULTS,SOLID,WHILE,WHOLE,WILEY
947,INTENSITY,PCR,RAD17,USING
067,131,160,169,264,308,472,496,501,537,649,653,662,684,696,730,761,793,837,868,928,933,AFRICAN,BACKGROUND,CONCLUSION,END,HEALTHCARE,INDEX,LABEL,METASTATIC,METHODS,OBJECTIVE,PRICE,RESULTS,SRE,THERE
AKT,DU145,OST,OST3P,PC3,TUSC3
001,100,105,118,123,125,127,12M,177,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SILODOSIN,URINARY
012,FIFTY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
1940S,CHARLES,HOWEVER,HUGGINS,III,PHASE,THESE,UNTIL
954,DENOSUMAB,MEN
III,PSA,WHILE
DOT1L,PCAT8
142,160,BOARD,OVERALL
188,CONCLUSION,END,LABEL,LYNCH,METHODS,OBJECTIVE,PURPOSE,RESULTS,STATE,UNIVERSITY
169,CASCADE,CENTERS,COMMUNITY,CONTROL,COPYRIGHT,DISEASE,INC,LYNCH,MOSBY,NVIVO,PREVENTION,SIXTY,UNIVERSITY
946,BECAUSE,TAKEN
AKT,BACKGROUND,LABEL,METHODS,RESULTS,USING
169,16MOL,24H,63MOL,BINDING,COPYRIGHT,CRPPR,FINALLY,FVB,LIPOSOMES,LPP,NRP,PPC,PRIOR,TAKEN,THESE,USING
100,115,761,812,898,909,927,952,AMONG,CONCLUSION,DOCUMENTED,LABEL,METHODS,PATIENT,PET,RESULTS,UNLABELLED
169,947,ATM,COPYRIGHT,CPT,DDR,DSB,E2F,LNCAP,LTD,OVERALL,RAD50,S1981,THEREFORE
105,169,24H,250NG,293,3485NGH,532,5NM,946,AUC,C17,COPYRIGHT,HEK,HOWEVER,HSD17B3,LTD,NADPH,SINCE,TREATMENT
001,002,007,169,3DCRT,COPYRIGHT,INC,MEDICAL,MLC,MODULATOR,OAR,PUBLISHED,V50,V60,V65,V70
169,COPYRIGHT,PUBLISHED,SUCCESSFUL
169,ADT,AUTHORS,BJU,FURTHER,HOWEVER,III
916,946,947,ACTIVATED,CHROMATIN,CPD,GAS,LUCIFERASE,MCF,PRL,R1881,STAT5
177,975,AFFAIRS,CENTERS,HIV,IHD,LABEL,METHODS,OBJECTIVE,RESULTS

CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
124,912,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
22RV1,CONCLUSION,DU145,LABEL,METHODS,OBJECTIVE,PC3,PCR,RESULTS,UNC5B,WESTERN
22RV1,AFTER,AKT,CONCLUSION,LABEL,METHODS,MTT,OBJECTIVE,RESULTS,TORC2,WESTERN
10G,169,HOWEVER,ISOLATING,MIX,PRESS,PUBLISHED,THESE,UNIVERSITY
134,138,143,155,205,34C,373,AKT,BCL,CSC,ERK,INORGANIC,MICRORNAS,RAN,RAS,REDUCED,WPE
003,ELISA,FATTY,INCREASED,THESE
MRI
KNOWLEDGE,MRI,MRL,NODAL
MRI,MULTI,PSA
107,177,359,711,800,BACKGROUND,LABEL,MESCC,METHODS,OLDER,RESULTS,THOSE
CIS,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,SIR,SLE
127,169,FORTY,GLEASON,LABEL,LTD,METHODS,OBJECTIVE,PSA,PSM,RESULTS,WHILE,WILEY
300,400,9TH,BACKGROUND,BECAUSE,CONCLUSION,DISEASE,INPATIENT,LABEL,LOS,METHODS,NATIONWIDE,OBJECTIVE,PURPOSE,RESULTS
169,177,183,BMI,BUSSELTON,CVD,DHT,FURTHER,LABEL,LOWER,LTD,MEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SERUM,TOTAL,WILEY
DRAWING,THESE
437,696,BETWEEN,CONCLUSION,GLEASON,LABEL,LRP,MAXIMAL,METHODS,OBJECTIVE,OCTOBER,PATIENT,PSA,RESULTS
AFTER,BPE,BSA,CK5,CK8,EGF,EXPRESSION,F12,HOWEVER,LIF,LNCAP,NOD,PPRCC,PRCSC,PRIMARY,SCF,SFE
215,ADHERENCE,AFTER,DE3,ELISA,FOLLOWING,LNCAP,M13,PC3,VHH
PCA,USA,WHILE
169,LYNCH,MMR
169,945,ADAPTATION,BRITAIN,COPYRIGHT,ERR,GREAT,HIF,IRELAND,LTD,OESTROGEN,PUBLISHED,SOCIETY,THESE,WARBURG,WILEY
449,ADP,AKT,BAX,BCL,ERK,FOXO1,HOWEVER,LNCAP,MHY,PC3,PD98059,PREVIOUSLY,TAKEN,THEREFORE
100,101,160,CD9,DEVELOPING,EARLY,LNCAP,MVB,THEREFORE,TSG,USING
160,BPH,CONVERSELY,EMT,GLEASON,LNCAP,PC3,RESULTS,SEVERAL,SNAIL,TMA
010,039,1377G,160,171,175,404,585,607,844TT,878,956,AFTER,BACKGROUND,EORTC,FAS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,UNIVARIATE
CONCLUSION,HOUNSFIELD,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,THEREFORE
169,FINALLY,GREATER,HOWEVER,SOCIETY
105,160,BACKGROUND,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,ADIPOSE,ASC,BACKGROUND,CCM,COPYRIGHT,DU145,EPITECT,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PC3,PUBLISHED,RAS,RESULTS,SOCIETY,THERAPY,THESE
165,169,220,385,ADT,AMGEN,ASTRA,AVENTIS,BACKGROUND,COPYRIGHT,FUNDING,III,INSTITUTE,KAPPA,LABEL,LTD,METHODS,PHYSICIANS,RESULTS
100,200,250,946,956,AKT,BPA,CONTINUOUS,ERK,FURTHER,SIMILAR
160MG,427,AFTER,AMONG,CAB,CENTRAL,DISTANT,M1B,NODAL,PCA,PSA,RADICAL,T1C,TREATMENT
FINALLY,FOXA1,GATA2,THESE
177,916,947,D95,DHR,DMEAN,DSR,DVH,NUCLEAR,OAR,PDP,PTV,ROI,SUN
COMPARISON,PROTECTION,SCREENING,STATE,THEREFORE
956,DU145,EGF,LNCAP,WHETHER
AFTER,BACKGROUND,CASTRATION,CHANGES,CONFERRING,LABEL,METHODS,PSA,RESULTS
ACTUARIAL,ACUTE,ADVERSE,BACKGROUND,III,LABEL,MEIER,METHODS,PRIMARY,RESULTS,SECONDARY
011,048,164,169,177,184,286,BACKGROUND,CONCLUSION,ENDOSCOPIC,FORCE,JAPAN,LABEL,LTD,METHODS,NHT,PTY,PUBLISHING,RESULTS,SOCIETY,SURGERY,WILEY
001,180,967,BACKGROUND,BCR,BPH,COX,GLEASON,LABEL,MEIER,METHODS,NUCB2,PCA,PSA,RESULTS,THEREFORE,THROUGH
945,946,956,AMONG,DUNAL,MCF,MTT,NMR,NOW,WRL
AFTER,BACKGROUND,LABEL,METHODS,OVERALL,PSA,RESULTS,WHILE
231,549,956,ACCORDING,DYSIDEA,MCF,MDA,MRC
VON
026,169,171,17Q12,261,BPH,INC,PCA,PCR,SERBIAN,SNP,WILEY
ADULT,ANTIGEN,IMAGING,PROSTATIC
COMMENTARY,ERM,INCREASING,MEMBERS,SIMILARLY
145,331,954,BLADDER,BNP,CONCLUSION,CONTINENCE,ECT,LABEL,MAY,METHODS,MRI,OBJECTIVE,RESULTS,SOCIETY,T2C,THERE,TLB,URINARY
015,019,126,HOWEVER,NSCLC,PCR,RAF,TNM
781,AMONG,AUC,BIOPLEX,BMI,CSF,FIFTY,FURTHER,HGF,PECAM,PIN,PSA,ROC
FORCE,GLEASON,HOWEVER,PCA,PSA,RADICAL,T1C,T2A
000,118,ADULT,ENGLAND,ENGLISH,EPISODE,HODGKIN,INCIDENCE,JANUARY,KINGDOM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,STATISTICS,STRATEGIES,THERE
BETWEEN,CONCLUSION,CVD,END,FALLING,LABEL,MEASURING,METHODS,OBJECTIVE,OTHER,PURPOSE,RESULTS
HOWEVER,TSG
012,022,110,136,ARTIFACTS,MRI,TESLA
001,002,008,011,137,214,301,380,ADT,AMONG,BACKGROUND,BCR,EQUAL,LABEL,METHODS,PSA,PSADT,REGRESSION,RESULTS,THEREFORE
001,003,021,038,1E8,2B4,967,AFTER,BACKGROUND,BPH,COX,DU145,EXPRESSION,GLEASON,KNOCKDOWN,LABEL,LNCAP,MEIER,METHODS,PCA,PCR,PEARSON,PSA,RAS,RASGRP3,RESULTS,THERE,THESE
13C,MRI,PET,THESE
169,223,COPYRIGHT,CROWN,DESPITE,INITIAL,LTD,PUBLISHED,THERE,WESTERN
100,169,239,300,400,600,700,956,DECREASES,FIFTY,LABEL,LYASE,METHODS,OBJECTIVE,ORTERONEL,PSA,PURPOSE,RESULTS,TAK
100,169,ALGORITHMS,COPYRIGHT,ESPECIALLY,EVALUATION,IMAGE,IMORPHICS,MICCAI2012,MRI,OVERALL,PROMISE12
177,BACKGROUND,CONCLUSION,FEZ,GENERAL,GPS,LABEL,METHODS,MONITORING,MOROCCO,PREFECTURE,QUESTIONS,RESULTS
BACKGROUND,CHROMATIN,DEFECTS,ERG,GENOMATIX,LABEL,METHODS,PCR,QRT,RESULTS,THESE,TMPRSS2
123,169,ADT,AUSTRALIAN,BACKGROUND,BEPREPARED,COLLEGE,CONCLUSION,HENCE,LABEL,METHODS,P1NPS,RADAR,RESULTS,ROYAL,THERE,ZEALAND
169,946,956,COLLEGE,COPYRIGHT,LABEL,MEDICAL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,TGF,TWIST
169,AMONG,CALCIUM,COLLEGE,COPYRIGHT,DU145,FOUNDATION,LABEL,LNCAP,MEDICAL,METHODS,MMP,OBJECTIVE,OCCURRENCE,PC3,PCR,PUBLISHED,RESULTS,SABLE,TPRC6,TRANSWELL,TRPC6,WESTERN
945,CK2,CONCLUSION,LABEL,LNCAP,LUC,METHODS,OBJECTIVE,PCR,PSA,R1881,RESULTS
144,289,CONCLUSION,GLEASON,LABEL,MAB,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THEIR,UNIVARIATE
160,169,956,COPYRIGHT,HOWEVER,LOW,LTD,ROUTINE
100,ENDORECTAL,HOWEVER,MRI,SINCE

946,CSF,ERBB2,FUNCTIONAL,HUR,MYC,NCOA3,PTH,RAF,RAS,SEVERAL,TGF
015,384,631,APRIL,BORDERLINE,CENTRAL,DESPITE,EGGER,HOWEVER,THEREFORE,WEB,WHILE
174,CELLSEARCH,CTC,THESE
946,947,FINALLY,LNCAP,NSG,OLFACTORY,ORS,PCR,PI3,USING
169,946,ADAMTS3,CRT,ERP57,HEC,HSP27,HSPA9,INC,JAR,MALDI,PDI,TAPASIN,TOF,WILEY
AAA,AT2,HSF,LUCIFER
013,HOWEVER,IMMUNOBLOT,MEIER,NSCLC,RING1,TNM
FURTHER,ORN,RCC,WHEREAS,WHILE
009,010,945,CAUCASIANS,CIS,FURTHER,HOWEVER,ORS,PCA,PVUII,RESULTS
231,CAMELID,CORTACTIN,HENCE,MDA,MMP,NOTABLY,SH3,USING,WIP
HOWEVER,MSC
IGF,WHILE
000,DESPITE,USA

CRITERION,LNCAP,MDA,PC3,PCA,THESE,UTILIZING
169,491,503,946,CK1,GLEASON,KIF3A,LABEL,MOL,OTHER,RES,THESE,UNLABELLED,WNT
954,AKIP1,AP2,HENCE,HOWEVER,SP1
169,946,948,AKT,APART,COPYRIGHT,FGR,FYN,HOWEVER,LYN,SRC,TAKEN,TYR,Y1073,Y1112,Y1176
169,COPYRIGHT,ERSPC,PCA,PSA,PUBLISHED,RANDOMIZED,SCREENING,UROLOGY
169,BACKGROUND,COPYRIGHT,FORTY,LABEL,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,PFS,PSA,PUBLISHED,RESULTS,SETTING,SIMON,SUMMARY,SWISS,THERE,TREATMENT,TRIAL,UNASSIGNED,UROLOGY
121,169,177,418,7CM,BOOLEAN,CBCTS,DVH,MEDICAL,OVERALL,PRV,PUBLISHED
102,169,BACKGROUND,COPYRIGHT,ENDOSCOPIC,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,PRD,RESULTS,ROUTINE
169,BACKGROUND,COPYRIGHT,HOWEVER,IRELAND,LABEL,LNCAP,LTD,METHODS,NAD,NAMPT,PC3,RESULTS
001,122,169,BACKGROUND,COPYRIGHT,DESPITE,EAU,FINALLY,LABEL,LNI,METHODS,OBJECTIVE,OUTCOME,PATIENT,PUBLISHED,RESULTS,SETTING,SEVERAL,SUMMARY,THEREFORE,THESE,UROLOGY
169,COPYRIGHT,PSA,PUBLISHED,UROLOGY
169,427,ADP,AKT,BACKGROUND,COPYRIGHT,HSP,HSP27,HSP90,INDUCIBLE,KRUSKAL,LABEL,LNCAP,MEIER,METHODS,OBJECTIVE,OGX,OUTCOME,OVERALL,PATIENT,RESULTS,SETTING,SUMMARY,THESE,UROLOGY
169,239,ANTITUMOR,BACKGROUND,CHANGES,COPYRIGHT,EVALUATION,LABEL,METHODS,OBJECTIVE,OUTCOME,PATIENT,PSA,PUBLISHED,RADIOLOGIC,RESULTS,SETTING,SOLID,SUMMARY,THESE,UROLOGY
001,169,484,946,AFRICAN,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PUBLISHED,RESULTS,SES,UNIVARIATE
169,BACKGROUND,COMPARISON,CONCLUSION,CURRENT,FLA,HOWEVER,INC,LABEL,MATERIALS,METHODS,PCA,PDT,PROSTATIC,PUBLISHED,RESULTS,SEVERAL,THERE
001,169,BACKGROUND,COPYRIGHT,EFFORTS,END,LABEL,LTD,METHODS,ORP,OVERALL,PCA,RELYING,RESULTS,STRATIFIED,UNI
002,160,169,215,COPYRIGHT,CT1,CT2,CTS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PLANA,PLANB,PUBLISHED,PURPOSE,RESULTS,THERE,V90
137,160,169,945,946,ALGEBRA,CARLO,COPYRIGHT,EQUIVALENT,GROUP,INC,LABEL,LARGE,MATERIALS,METHODS,MONTE,OBJECTIVE,PHYSICISTS,PURPOSE,RESULTS
001,003,005,006,009,160,169,268,AFTER,COPYRIGHT,COX,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,REDUCTION,RESULTS,SCORE,SEVENTY,SYMPTOM,UNIVARIATE,V90
001,169,AMONG,COPYRIGHT,END,GUIDELINE,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PURPOSE,RESULTS,THERE
169,AMONG,COPYRIGHT,CURRENT,HOWEVER,IRELAND,LTD,SIX,SUNITINIB
169,BAX,BCL,CIT,COPYRIGHT,FCM,GFP,LTD,PAH,PEI,PROPIDIUM,WESTERN
024,169,487,AMONG,BACKGROUND,C2ORF43,COPYRIGHT,COX,EIGHT,JAZF1,LABEL,LMTK2,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,RESULTS,RS11672691,SCREENING,SETTING,SNP,STUDIES,SUMMARY,UROLOGY
169,177,204,220,224,246,253,265,AFTER,BACKGROUND,BLOOD,COPYRIGHT,DVP,LABEL,METHODS,NEUROSAFE,OBJECTIVE,OUTCOME,PATIENT,PROCEDURE,PSM,PUBLISHED,RESULTS,SETTING,SUMMARY,THERE,UROLOGY,VINCI
169,227,ADVERSE,C30,CONCLUSION,COPYRIGHT,EORTC,HRQOL,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PREVENTION,PURPOSE,QLQ,QUALITY,RESULTS,TREATMENT,URINARY
169,COPYRIGHT,INC
169,176,945,946,AMC,APLAN,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,T10,T50,T90
169,947,COPYRIGHT,DSB,INC,INDUCTION,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,RAD51,RESULTS
238,761,853,ACCORDING,AGE,BACKGROUND,CHINESE,DRE,GLEASON,LABEL,METHODS,PSA,RESULTS,WESTERN
215,BACKGROUND,CTV,EXTREME,III,LABEL,METHODS,MRI,PTV,RESULTS,THERE
000,060,119,120,260,338,361,399,518,536,553,635,699,754,807,813,880,881,979,AMONG,CONFIDENCE,DISCUSSION,EAR,FIRST,HODGKIN,HOWEVER,ICD,INCIDENCE,INCREASED,ISLANDS,ITALIAN,LABEL,LIFESTYLE,METHODS,MPS,NON,NORTH,OBJECTIVE,OBJECTIVES,OVERALL,RATIO,RESULTS,SIR,SOUTH,WOMEN
174,ALPHARADIN,METASTRON,QUADRAMET
947,EWING,INJECTION,NSG,OVERALL,TUMOURS
002,009,010,037,195,967,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,PCA,PET,RESULTS,SEVERAL,UNLABELLED
169,ACT,AFFORDABLE,CME,CNE,INC,INTERVIEW,PATIENT,PROTECTION,SOCIETY
ASIAN,CAUCASIAN,FINALLY,HOWEVER,MEANWHILE,THEREFORE,VDR
169,AUTHORS,BRITAIN,CORRECTED,FINALLY,GENOMIC,GREAT,IRELAND,JOURNAL,LTD,PATHOLOGY,SNP,SOCIETY,WILEY,ZDHHC14
SEVERAL,WESTERN
ADEQUATELY,CVD,DHT,HOWEVER,STUDIES,THERE
001,177,184,707,MRI,THESE
945,ANDROGENS,HOWEVER,KNOWING,WHETHER
100,ERG,TMPRSS2
169,APOPTOSIS,COPYRIGHT,E2F,HOWEVER,LNCAP,P53,PCR,TFDP3
169,1RA,946,COPYRIGHT,INCUBATION,LEUPROLIDE,LNCAP,SAS,WHILE
ALTOGETHER,MTT,PCA,PCR,TRANSWELL,TUNEL,WESTERN
169,454,ERG,GLEASON,RPS,TMPRSS2
169,223,5MG,CMCTS,COPYRIGHT,DERIVED,FAK,FGFR3,FIBROBLAST,FOCAL,INTESTINAL,IRELAND,KIT,LCK,LTD,LYMPHOCYTE,LYN,MASITINIB,MCS,STROMAL,YES
231,946,AGILENT,BACKGROUND,CHANGES,DAVID,ELISA,FAK,GENESPRING,IL1,LABEL,MAPKK,MDA,METHODS,NCI,PCR,PD98059,RESULTS,TGF
48H,ATP,DOC,DU145,HOWEVER,HSP70,LABEL,METHODS,MTT,OBJECTIVE,PC3,RESULTS,WESTERN
145,250,ABCG2,ALDEFLUOR,ALDH1A1,ATP,BACKGROUND,CELLS,CWR,INHIBITION,LABEL,LOW,METHODS,PSA,RESULTS
BACKGROUND,CONCLUSION,D98,DVH,HOWEVER,LABEL,METHODS,MRI,PTV,RESULTS
007,169,GROUP,JAPAN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THEIR,THESE,UROLOGICAL,YOUNG
110,114,160,177,ASSESSMENT,BUFFERING,COMPOSITE,COUPLES,DAS,EXPERIENCE,INDEX,INTERVIEWS,MEN,PBS,POTENTIAL,PROTECTIVE,SCALE,THESE
CMV,HOWEVER,SEVERAL
001,945,BACKGROUND,CONCLUSION,LABEL,METHODS,NON,RESULTS,STEROID,TSH
2C9,MOUSE,PBMCS,THESE,USING
BPS,CONCLUSION,FINALLY,LABEL,MATERIALS,MEDLINE,METHODS,RESULTS,UNLABELLED
169,AUTHORS,CAP,CASTRATION,CWR22,CWR22PC,LTD,RECURRENCE,SRC,TAKEN,WILEY
169,AUTHORS,GERMANY,HODGKIN,LTD,SPC,SWEDISH,WILEY
160,169,AUTHORS,BPH,DU145,GLEASON,LNCAP,LTD,PC3,PCR,PEARSON,PSA,TNM,WILEY
169,946,956,AUTHORS,FRIZZLE,LTD,MEMBERS,PCA,THESE,WHILE,WILEY
001,002,055,327,954,AGREEMENT,BASED,GLEASON,INTER,LABEL,METHODS,OBJECTIVE,PATHOLOGY,RESULTS,SOCIETY,UROLOGICAL
169,COPYRIGHT,REPRINT,VITAMIN
004,052,169,226,253,AUTHORS,DYNAMIN,GLEASON,INHIBITION,LTD,PCA,WILEY
AKT,HGF,IGF,MET,SRC,TREATMENTS
25OHD,AMERICA,NORTH,RTC,SINCE,UVB
160,AG490,IGF,MSM,RECURRENCE,STAT3,THEREFORE,THESE
ADDITIONAL,III,LABEL,OPINION,PAP,PSA,SEVERAL,SIPULEUCEL,STATEMENT,THESE,UNASSIGNED,WHEREAS
169,ERA,ERB,SOCIETY
125,206,ADT,BACKGROUND,BETWEEN,GLEASON,LABEL,METHODS,PHOENIX,RESULTS,STAGE,THERE
ABDOMINAL,AFTER,BAKER,FACES,LABEL,METHODS,MSE,OBJECTIVE,PURPOSE,RESULTS,THERE,WHILE
143,219,BACKGROUND,CONTINENCE,GLEASON,LABEL,MAY,METHODS,RESULTS,ROBOTIC
188,CONCLUSION,LABEL,METHODS,NETWORK,OBJECTIVE,PURPOSE,RESULTS,SPECIALIST
BACKGROUND,CHANCES,END,GLEASON,LABEL,METHODS,PSA,RESULTS
945,946,956,ADP,BACKGROUND,BAX,BCL,CAM,DU145,LABEL,LNCAP,MCL,METHODS,RESULTS,THESE,URSOLIC,WNT,WNT3A
100,108,115,159,212,247,254,267,405,506,879,BACKGROUND,COX,END,LABEL,MEIER,METHODS,PRISM,RESULTS,THERE
129,130,945,946,947,DBZ,ICD,NOTCH,PRESENILIN,PS1,TGF,THESE,TNF,TRAF6
160,BAX,BCL,CASPASE,HOWEVER,KANK1
19620,BPH,COX,IRS,ITALIAN,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PCA,PROPENSITY,RESULTS
173,LABEL,MALIZIA,MATERIALS,METHODS,OBJECTIVE,RESULTS
100,AIM,BPH,HEALTHY,IVD,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,RESULTS,ROUTINELY
160,CPT,ERLOTINIB,THEIR,THEREFORE,THESE,WHILE
MET,RANKL,THESE
H2A,NONCODING
ADIPOCYTES,AGE,COX,INCREASED,SPECIAL
RECURRENT
002,003,230,252,468,504,CIS,COLORECTAL,ORS,OVARIAN,PCR,RCC,RESULTS,SCREENING,THESE,TRIAL
001,002,006,008,028,BACKGROUND,FIFTY,HRPCA,ICI,LABEL,MARCH,MCT,METHODS,MOT,OBJECTIVE,OBJECTIVES,OCTOBER,PDR,PERCENTAGE,QOL,RESULTS
169,174,956,CASODEX,COPYRIGHT,DRP,IRELAND,LNCAP,LTD,THESE
121,122,123,124,125,134,135,138,169,1B7,APC,CD4,COPYRIGHT,EBV,ESO,LTD,MINIMAL,PBMCS,TCR,USING
BACKGROUND,CAM,DU145,GIVEN,HCC1143,HCC1937,LABEL,METHODS,MISTLETOE,NCI,RESULTS,VAE
001,131,177,190,BLOOD,CATEGORIC,LABEL,METHODS,OBJECTIVE,OCTOBER,PURPOSE,RESULTS,STUDENT
100,106,200,396,BIOLOGICAL,DESPITE,EXPRESSION,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RB1,RESULTS,USING
143,APRIL,AUC,BECAUSE,CONCLUSION,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,OCTOBER,PURPOSE,REGARDING,RESULTS,TESLA
MIA
METASTASIS,TNF,TRAIL
22RV1,602,606,690,ADT,BECAUSE,LNCAP,MIA,SV1
121,169,206,ADT,BACKGROUND,CONCLUSION,COX,DISTANT,INC,LABEL,MDT,METHODS,PCA,PSA,RESULTS,WILEY
PUFAS,THERE
ADT,AFTER,CONTINUOUS,HOWEVER,INT,KEY,LABEL,MEDICAL,NOVEL,OPINION,STATEMENT,UNASSIGNED
001,189,641,BACKGROUND,COX,ESC,LABEL,MEIER,METHODS,PCA,RESULTS,SWEDISH,UNIVARIATE,VGLL3
250,CYP17,JANUARY,PSA
000,300,350,500,750,FINALLY,HAI,INITIALLY,RFA,THEREFORE,THREE
OTHER,SIMILARLY,TREATMENT
125,33258,956,997,ABOUT,AFTER,APOPTOSIS,BACKGROUND,CASPASE,CONCLUSION,CONTEXT,DIELS,DISCUSSION,HOECHST,LABEL,MATERIALS,MCF,METHODS,MTT,OBJECTIVE,PREVIOUSLY,PROTEIN,RESULTS,SGC,WESTERN
AKT,PHLPP,PLECKSTRIN,PRECISE
945,GLA,LNCAP,MTX,NAALADASE,PAMAM,PC3,SIMILAR
CHINA,FINALLY,ITALY,LABEL,MAY,METHODS,OBJECTIVE,ORS,RESULTS,SELECTION,SYNTHESIS
198,1A1,ADDITIONAL,ASIAN,BACKGROUND,CAUCASIANS,CIS,CYTOCHROME,FURTHER,ILE462VAL,LABEL,METHODS,OVERALL,RESULTS
HOWEVER,MICRORNAS,RAS,RESULTS,SHANNON,SMAD4,THESE,USING
33342,FIRST,HOECHST,HOWEVER,SMA,THEREFORE
200
100,169,216,233,248,AFTER,AMT,BACKGROUND,CANDIDATE,CURRENT,LABEL,LTQ,MATERIALS,METHODS,PCA,PDCD6IP,PROTEOMIC,PSA,RESULTS,THEREFORE,VALIDATION,WESTERN
AFRICAN,HOWEVER,LINDL,SEVERAL
112,169,AUTOPHAGY,BACKGROUND,BPH,CHINA,GREATER,GUANGZHOU,LABEL,METHODS,PCA,RESULTS,SOCIETY
CHANGES,HOWEVER,PCA,THESE
223,680,CAUCASIANS,HOWEVER,USING
FILAMIN,GLEASON,MMP,PSA,WESTERN
109,181,COMPOUNDS,IVA,IVB,IVD,NCI,SORAFENIB,TGI
EFFORTS,SUCCESSFUL,TARGETS
160,AFTER,AMONG,III
160,927,BASED,BCR,BMI,DIFFERENT,MEDLINE,OBESITY,PCA,THERE,USA
FINALLY,HOWEVER,SNP
CK7,CRIBRIFORM,MOLECULAR
120,177,252,946,956,CONCLUSION,DYNAMIC,FAVORABLE,FSH,GBQ,HEART,LABEL,MAL,METHODS,MOLECULAR,OBJECTIVE,PC3,PET,PROCEDURES,PURPOSE,RESULTS
193,332,400,461,AMONG,INITIATION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SRE,USING
169,COPYRIGHT,DESPITE,EMT,OVERALL,PCA
005,641,BASIC,EXTREMITY,LABEL,LOWER,METHODS,OBJECTIVE,PURPOSE,RESULTS,UNLABELLED,WHILE
169,549,BECAUSE,COPYRIGHT,GPX,MCF,SAS
169,945,946,AZA,BPH,COPYRIGHT,CPG,DUCAP,FINALLY,HEX,LNCAP,PC3,RESULTS,SAS
169,AKT,BIOLOGY,COPYRIGHT,DECORIN,IGF,IGF1R,MET,NOTABLY,PUBLISHED,SOCIETY,USING,WHETHER
RECURRENT,THEREFORE
ADC
BRCA1,BRCA2,PCA,THEREFORE
169,ABDOMINAL,COLLEGE,COPYRIGHT,INC,LABEL,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS,SOCIETY,TEXAS,THERE
169,COPYRIGHT,DMM,GOX,LOD,PSA,UNDER
169,COPYRIGHT,HOWEVER,STAT3,STATS,THERE
14Q31,169,AFFYMETRIX,COPYRIGHT,FEDERATION,FINALLY,HCC,HOWEVER,NOTABLY,PCR,PUBLISHED,SNP,SOCIETIES,THESE
169,COPYRIGHT,FEDERATION,LTL,NOD,OMN54,PHASE,PSA,SOCIETIES,TRIAL
001,002,006,035,160,169,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,QOL,RESULTS,TEN
001,160,169,APRIL,BLADDER,COMPOSITE,CONCLUSION,COPYRIGHT,FIFTY,INC,INDEX,LABEL,METHODS,OBJECTIVE,RESULTS,SCORE,SHORT,SYMPTOM
125,169,174,177,600,CATPHAN,CONCLUSION,COPYRIGHT,FOV,IMAGE,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,XVI
169,177,956,COMPOUNDS,COPYRIGHT,LTD,NSAID,PC3,PCA
ANNEXIN,APOPTOSIS,BACKGROUND,CFLAR,CONCLUSION,DDIT3,DR5,EIF2A,HOWEVER,HSPA5,KNOCKDOWN,LABEL,METHODS,MTT,NSCLC,PTL,RESULTS,SILENCING,SRB,TNFRSF10B,WESTERN
100,135,150,200,250,AKT,AUC,BACKGROUND,CONCLUSION,INHIBITION,LABEL,MAD,METHODS,MTD,NSCLC,PRS,Q3W,QOD,RESULTS,SIX

CARLO,FLA,HOWEVER,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,USING
176,360,CARLO,HOUNSFIELD,HUS,LABEL,METHODS,MONTE,MRI,OBJECTIVE,PURPOSE,RESULTS,RTP,VOXEL
100,ADT,BACKGROUND,CASODEX,CDX,LABEL,MICRORNAS,RESULTS,THERAPIES,THESE,VALIDATION
169,ALI,APART,BLACKWELL,PCA,TDS,THEREFORE,TONGKAT,TRT
221,222,MICRORNAS
LNCRNAS
001,032,143,CAD,CONCLUSION,IAD,LABEL,MAB,MEIER,METHODS,OBJECTIVE,PSA,RESULTS
198,204,CONCLUSION,LABEL,LNCAP,METHODS,OBJECTIVE,RESULTS,THESE,TRUNCATED
016,488,CTC,HOWEVER,LEWIS,PCA,SEVERAL
181,ARI,BACKGROUND,DU145,FDA,LABEL,LNCAP,MATERIALS,METHODS,PC3,RESULTS
500,ANTIBODIES,HINT1,NDRG1,OPERATING,PROTEIN
018,020,022,248,HOWEVER,NORWEGIAN,OTHER,OVCAR,PFS,SEX,UNIVERSITY,WESTERN
001,017,018,019,026,069,167,284,BETWEEN,EPE,GLEASON,JAPAN,PSA,RATES,SVI
169,945,946,ANOTHER,GIVEN,HOWEVER,INCREASED,OVERALL,PTHRP,TGF
169,946,ALCAM,PC3,PREVENTION,TGF,THROUGH
002,009,028,038,039,AMONG,HOWEVER,INCREASED,METAL,SMOKERS,THESE
UROLOGISTS
ARS,EXPRESSION,NOVEL,THERE
132,605,792,920,APRIL,CIS,COX,KINGDOM,LABEL,METHODS,OBJECTIVE,OCTOBER,PURPOSE,REPOSITORY,RESULTS,STATISTICS
160,169,COPYRIGHT,EDUCATION,ERECTIONS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PADUA,PUBLISHED,PURPOSE,RESULTS,SURVIVORS,THEREFORE,UROLOGICAL
456,504,507,538,569,574,590,598,620,621,650,651,665,679,690,705,708,715,BACKGROUND,BASED,CONCLUSION,END,ICD,LABEL,METHODS,PCA,PPV,RESULTS
017,025,047,169,194,AMACR,BACKGROUND,COA,E277K,FURTHER,GGCGG,KOREANS,LABEL,MATERIALS,METHODS,RESULTS
169,BACKGROUND,DOC,EASTERN,ENZ,GROUP,IQR,LABEL,METHODS,PSA,RESULTS,SIXTY,SOCIETY
169,204,ASSESSMENT,AUTHORS,BACKGROUND,COMPOSITE,HOWEVER,INC,INDEX,INDIVIDUAL,LABEL,METHODS,PROSTQA,QOL,QUALITY,RESULTS,SOCIETY,THERE,THESE,TREATMENT,WILEY
169,224,HOWEVER,PCA,PSA,TRIB1
001,BACKGROUND,COMPOSITE,FURTHER,GRADE,INDEX,LABEL,METHODS,OVERALL,PSA,QUALITY,RESULTS,THERAPY
232,313,AFTER,CLL,EPM,FURTHER,HOWEVER,INTENSIVE,OVERALL,SIR,SPM
152,169,BACKGROUND,CONCLUSION,COPYRIGHT,E26,ERG,GLEASON,LABEL,LTD,METHODS,PSA,RESULTS,THERE
20Q13,CAR,HPC20,LABEL,THESE,UNLABELLED
246,DUE
150,ASIAN,BETWEEN,GRADE,LABEL,MARCH,MEIER,METHODS,OBJECTIVE,RESULTS,SALVAGE,T1C,THERE,THREE
000,100,177,190,426,497,550,575,576,862,910,BACKGROUND,COLORECTAL,CONCLUSION,END,FUNDING,GENERATOR,HARMS,HISTORY,HORIZON,INSTITUTE,LABEL,METHODS,OBJECTIVE,OUTCOME,OVARIAN,POPULATION,PRIMARY,RESULTS,SCENARIOS,SCREENING,SMOKING,SOURCES,TRIAL,UNASSIGNED
100,116,145,160,172,181,231,2OS,500,549,786,872,A2058,CA2,ECM,FBS,HCC,HCT,HEP,MCF,MDA,MIA,MMP,PMA
001,004,140,181,351,522,ACUTE,ASSESSMENT,BCG,LABEL,LOW,METHODS,OBJECTIVE,PURPOSE,RESULTS,URINARY,UROTHELIAL
BELLA,D2R,DISEASE,FURTHER,LABEL,MATERIALS,METHODS,OBJECTIVE,PAC,PARTIAL,RESULTS,STAGE,TAKEN
169,ACUTE,ADT,BACKGROUND,CONCLUSION,COPYRIGHT,DLT,GNRHA,INC,LABEL,MEN,METHODS,MTD,RESULTS
177,181,DUE,KLAKLAK,LABEL,LARGE,METHODS,OBJECTIVE,PBS,RESULTS,TMTP1,TUNEL,WHITE
169,HOWEVER,INC,REGULATION
169,323,BACKGROUND,COPYRIGHT,DESPITE,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,PATIENT,PCA,PUBLISHED,QALYS,QOL,QUALITY,RESULTS,SETTING,SUMMARY,THRESHOLD,TOTAL,UROLOGY
ATP,PROTEIN,RELATED,SINCE
100,163,BACKGROUND,HOWEVER,IRANIAN,LABEL,MATERIALS,METHODS,PCR,RESULTS
021,159,177,502,50S,657,ACCORDING,AFRICAN,AMERICA,AMERICANS,BACKGROUND,BMI,CAUCASIANS,GLEASON,KOREA,KOREANS,LABEL,MATERIALS,METHODS,PSA,RESULTS,THESE
231,916,945,946,947,BASED,MCF,MDA
005,011,042,049,288,289,577,BLOOD,CHINA,CHINESE,EIGHT,HAPLOTYPE,PCA,THREE
947,DCM,DSK,HEPG2,KK6,LNCAP,METHANOLIC,MTP,MTT,NAN,PAYAO,PIGMENTED,PRE,PYO,ROS
040,057,090,0MG,177,286,351,479,871,945,BACKGROUND,CONTINUOUS,DICLOFENAC,FOLEY,GLEASON,HOWEVER,JANUARY,LABEL,LRP,MATERIALS,METHODS,PSA,RESULTS,THERE,WHILE
100,CANCERS,FAS,HOWEVER,PCA,RSV,THEREFORE,XRT
178,ABOUT,CONCLUSION,DOPPLER,DVT,LABEL,MARCH,METHODS,NIGERIA,OBJECTIVE,PROSTATIC,RESULTS,THERE,VTE
945,946,LNCAP,PACLITAXEL,PHB,PROHIBITIN,THESE
007,119,130,177,292,2AM,5AM,BMI,COLORECTAL,MELATONIN,OVARIAN,PEARSON,SCREENING,SERUM,TRIAL
120,14627,174,17438,196,BACKGROUND,CAUCASIANS,FURTHER,HOWEVER,LABEL,PRINCIPLE,RESULTS,SOUTH
100,169,200,DUE,LOD,SARCOSINE,VCH,WILEY
169,22RV1,BACKGROUND,CAV,DU145,INC,LABEL,LNCAP,METHODS,PC3,PCA,PROTEIN,RESULTS,RWPE1,THESE,WILEY
039,100,169,177,99M,AUC,BACKGROUND,BVC,INC,LABEL,METHODS,MRI,PCA,RESULTS,ROC,TNM,TXR,WHOLE,WILEY
001,140,149,169,289,CGA,CSS,GLEASON,INC,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEN,WILEY
006,169,713,BACKGROUND,DUE,ETS,INC,LABEL,METHODS,RESULTS,SAM,SPDEF,WILEY
954,AKT,CSC,GROWING,HENCE,PCA,SEVERAL,THEREFORE
169,481,945,BACKGROUND,CD117,CD133,EXPRESSION,GLEASON,INC,LABEL,METHODS,PSA,RESULTS,VARIOUS,WILEY
169,CSC,EMT,ESC,INSIGHT,NANOG
177,BHP,BILLERICA,ELISA,HOWEVER,MDA,MILLIPORE,ROS,THESE,USA
169,718,946,DHT,IHC,LOC,MED15,MET,PCA,SMAD3,TAKEN,TGF
169,177,22RV1,945,CAF,CHROMATIN,DISSECTION,PCA,PRESS,PUBLISHED,THBS2,UNIVERSITY
169,BACKGROUND,COPYRIGHT,HOT,HOWEVER,IGF,IRELAND,LABEL,LTD,MAP,METHODS,OBJECTIVE,OCTOBER,PI3,RESULTS,ROS,THERE
002,005,100,169,AFTER,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SIMILAR,UROLOGICAL
001,009,130,169,359,COPYRIGHT,EDUCATION,INC,KINGDOM,LABEL,MATERIALS,METHODS,METICULOUS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,VALIDATED
ASIAN,HOWEVER,LTD,PCA,PUBLISHED,SOY,THERE,THESE
197,BACKGROUND,CONCLUSION,DEBAKEY,DESPITE,INC,LABEL,MEDICAL,MEIER,METHODS,MICHAEL,NOTABLE,PUBLISHED,RESULTS,THEREFORE
160,169,195GY,7MM,CHANGES,COPYRIGHT,FOLEY,INC,LABEL,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,SPATIAL
160,169,192,CAUSE,COPYRIGHT,FORTY,GRADE,HDR,INC,LABEL,METHODS,OBJECTIVE,PHASE,PUBLISHED,PURPOSE,RESULTS,SALVAGE,SOCIETY,THREE
315,522,837,AFRICAN,BACKGROUND,BLACK,DESPITE,LABEL,METHODS,PILOT,PSA,RESULTS,SAPCS,SOUTH,WHILE
169,BACKGROUND,CONTEXT,COPYRIGHT,ENGLISH,GENOMIC,INCREASED,LABEL,LNCRNAS,MEDICAL,METHODS,OBJECTIVE,PATIENT,PUBLISHED,RESULTS,SUBJECT,SUMMARY,SYNTHESIS,UROLOGY
001,004,018,160,BACKGROUND,EVALUATION,FURTHER,HLA,HOWEVER,IGG,LABEL,METHODS,PEPTIDE,PPV,PSA,PSADT,RESULTS,SEVERAL,SOLID,TRIAL,WORLD
160,169,175,291,493,679,ADJUSTING,IMPAIRMENT,LABEL,LTD,METHODS,MUI,OAB,OBJECTIVE,OUTCOME,QUESTIONS,RESULTS,THESE,UUI,WILEY
169,653,CUMULATIVE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
125,169,616,BETWEEN,JAPAN,JIKEI,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OPTIMAL,RESULTS,SALVAGE,THESE,TOKYO,UNIVERSITY,UROLOGICAL
169,AIM,ASPC1,BACKGROUND,BXPC3,DKK,FOUNDATION,HEPATOLOGY,JOURNAL,LABEL,LTD,METHODS,OBJECTIVE,PANC1,PTY,PUBLISHING,RESULTS,WILEY
114,160,169,DAN,DYSURIA,FINLAND,HOWEVER,LABEL,LTD,MATERIALS,MEN,METHODS,OBJECTIVE,PSS,RESULTS,SEVENTY,TAMPERE,THESE,WILEY
SMOKING,TOBACCO
CUSHING,EXTENSIVE
001,169,ASIAN,CONCLUSION,HCV,HEPATITIS,HIV,IBHPC,LABEL,METHODS,OBJECTIVE,OCTOBER,RESULTS,THERE,VIRUS,WHITE
000,100,AMONG
PRESENTED
CONTINENT
111,148,150,242,868,AVERAGE,BACKGROUND,BILATERAL,BLADDER,CLEVELAND,CONCLUSION,DENMARK,LABEL,METHODS,NEPHRON,NSS,RADICAL,RCC,RENAL,RESULTS,SAD,SURGERY,THERE,UROLOGY,USA,VHL
ADVANCE,ARGUS,ASSESSMENT,BACKGROUND,CONCLUSION,LABEL,OBJECTIVE,PAD,PRPUI,RESULTS,SUI,UNASSIGNED
169,INC
BACKGROUND,CONCLUSION,COPYRIGHT,COUNTRIES,EDICIONES,FURTHER,HOWEVER,LABEL,METHODS,OBJECTIVE,OLIVE,PUBLISHED,RESULTS,SCIENCE,THERE,WEB
PCA
954,ADDITIONAL,BASED,CONSISTENT,IFN,INHIBITION,INTRINSIC,PC3,VESICULAR,VSV
115,BACKGROUND,COMPOSITE,INDEX,LABEL,LRP,MEDICAL,METHODS,MIE,QOL,RESULTS,SHORT,THERE
169,205,COMPELLING,COPYRIGHT,INC,LAMP3,OVERALL,THESE
239,264,946,954,BACKGROUND,HOWEVER,INHIBITION,LABEL,METHODS,OPG,RANKL,RAW,RESULTS,SOLUBLE,TGF
CONCLUSION,LABEL,MRI,OBJECTIVE,ULTIMATELY
CONCLUSION,LABEL,MRI,OBJECTIVE,STRATEGIES
00001,914,ADDITIONAL,BCR,EPLND,HOWEVER,LABEL,LIBRARY,LNS,METHODS,OBJECTIVE,OPERATING,PCA,PURPOSE,REGARDLESS,RESULTS,WMD
FIFTEEN,FORTY,GLEASON,IQR,LRP,NBD,QOL,QUALITY,RRP,SCORE,SYMPTOM,VAS
337,434,506,916,ADDITIONAL,ADT,AUTHORS,BACKGROUND,CENTRAL,CIS,COLLECTION,CONTROLLED,FINALLY,GHQOL,GRADE,HOWEVER,INDIVIDUAL,LABEL,MEDLINE,MEN,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,OVERALL,PAIRS,QOL,RANDOMISED,RESULTS,SELECTION,SMD
300,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PET,RESULTS,SIX,THREE,WHOLE
169,COLLEGE,COPYRIGHT,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS,THREE
ADDRESSING,ADT,CHANGES,LABEL,METHODS,NURSING,OBJECTIVE,OBJECTIVES,PURPOSE,RESULTS,SETTING,URBAN,VARIABLES
AFRICAN,BECAUSE,FORCE,III,PREVENTIVE,PSA,YET
100,956,ADENOSINE,ATP,DU145,HENCE,MMP,MNSOD,PEG,ROS,SOD
22RV1,LNCAP,MANGOSTEEN,MFE,MTT,PRECS,WESTERN
BASED,PREDICTING,TSP
BPH,IGM,PCA,PSA
ADULT,CHRONIC,CP9,CREER,K14,PREVIOUSLY
106,761,CONCLUSION,INADEQUATE,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
LNCAP,PCA,PCR,PNT1A,THESE
147,CUFFLINKS,FUNCTIONAL,GENOMES,IPA,KYOTO,REGULATORY,SRA
001,150,160,181,22RV1,BAX,BCL,MTT,PCR,PNT1A,THESE
946,BACKGROUND,COX,FINALLY,HOWEVER,LABEL,LNCAP,MEIER,METHODS,OGT,OVERALL,RESULTS,THESE
BACKGROUND,BRCA2,LABEL,METHODS,PCA,RESULTS
024,030,177,BACKGROUND,BLADDER,INDEX,LABEL,METHODS,PROSTATIC,RESULTS,SCORE,SYMPTOM,URINARY
169,3MONTHS,AN1,CONCLUSION,COPYRIGHT,CURIE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,QOL,RESULTS,SAS,SCORE,SYMPTOM,THERE,THREE,URINARY
169,COPYRIGHT,DRE,EIGHT,FFOCT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SAS,SIX,SIXTEEN
169,BLADDER,COPYRIGHT,FUROSEMIDE,PET,PSA,SAS,TEP,THERE
COMPARING
DYSMORPHIC,HOWEVER,UROLOGICAL
001,003,874,897,BCR,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,T3A
KNOWLEDGE,PSA,QUITE
BACKGROUND,CAUCASIAN,CONCLUSION,CONVERSELY,HOWEVER,LABEL,LOWER,METHODS,NSGCT,PROSTATIC,RPLND,TCGTS,TGCTS
007,022,036,057,APRIL,COX,MAY,METHODS,RESULTS,UNIVERSITY
USING
169,CONVERSELY,ERBB2,FATTY,HNSCC,MMP,OTSCC,SCC,THESE,VEGFA165B,ZSGREEN
169,COPYRIGHT,CTC,DETECTION,EMT,GENOMIC,INC,SIMILARLY
169,215,365,833,883,BACKGROUND,CAUCASIAN,COPYRIGHT,DCA,FINALLY,INDEX,LABEL,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,PHI,PUBLISHED,RESULTS,SETTING,SUMMARY,THESE,TOTAL,UROLOGY
135,169,193,261,308,328,341,359,BACKGROUND,CONCLUSION,COPYRIGHT,INC,KAPPA,LABEL,MATERIALS,METHODS,PATHOLOGY,RESULTS,SOCIETY,UPGRADING,UROLOGICAL
169,COPYRIGHT,INC,POSTERIOR,SIMILARLY,TREATMENT,UROLUME
169,956,COPYRIGHT,EVALUATION,LTD
169,DVH,MCO,MEDICAL,PUBLISHED,RAYSEARCH,RAYSTATION,STOCKHOLM,WEIGHTS
116,117,122,160,169,945,946,ACCORDING,CONFORMAL,COPYRIGHT,FIRST,HDR,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PHOENIX,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS,SOCIETY,THESE
169,285,COPYRIGHT,INC,INPATIENT,LABEL,LOCAL,LTD,MATERIALS,METHODS,NATIONWIDE,NINTH,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SIMILAR
164,169,CONCLUSION,COX,EXPRESSION,GLEASON,INC,LABEL,MATERIALS,MEDICAL,MEIER,METHODS,OBJECTIVE,PCA,PUBLISHED,PURPOSE,RAF,RAS,RESULTS,UNIVERSITY
LNCAP,LTD,NAD,PUBLISHED,SAR,TOP
169,241,COPYRIGHT,CPG,PCR,PORTUGUESA,PUBLISHED,SOCIEDADE,TNM
145,169,CAP,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,THEREFORE,USING
155,160,169,177,374,CONCLUSION,COPYRIGHT,FORTY,INC,LABEL,METHODS,OBJECTIVE,RESULTS
BACKGROUND,BAX,BCL,BESIDES,BIP,J82,LABEL,METHODS,PEE,RESULTS,T24,TAIWANESE
520,APPRAISAL,BACKGROUND,BRITISH,FURTHER,HODGKIN,LABEL,METHODS,MINIMISING,NHS,PROGRAMME,RESULTS,SEVEN,SIX,THERE,ZEALAND
150,184,DESPITE,METABOLIC,OCM,PSA,THESE,UDP,UGT
BACKGROUND,DIRECTIONS,HOWEVER,LABEL,QSOX1,RESULTS,SEVERAL
ANOTHER,BACKGROUND,CONCLUSION,CTC,CTV,LABEL,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,URINARY
ALA,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PDD,RESULTS,TILEPRO,VINCI
GSTP1,THESE
544,CENTRAL,ELIZABETH,JANUARY,PERFORMING,QUEEN,THERE,WITHOUT
001,945,946,BACKGROUND,CAHPV,CLAUDIN,CONCLUSION,CURRENTLY,DU145,HOWEVER,LABEL,LNCAP,METHODS,OBJECTIVE,RESULTS,THESE
169,HOWEVER,INC,WILEY
169,CONCLUSION,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE,WILEY
086,252,447,578,AOK,BACKGROUND,DETMOLD,DISCUSSION,DISEASE,LABEL,MANAGEMENT,METHODS,PROGRAM,RESULTS,SIR,T2D
300,CAB,EMP,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,UFT
ASPIRIN,BACKGROUND,CIS,CONSISTENT,GENERAL,HRS,III,IRISH,LABEL,MEDICAL,MEN,METHODS,RESULTS,THESE
000,100,ACTRN,AUSTRALIAN,BACKGROUND,BEP,BLEOMYCIN,CONCLUSION,LABEL,METHODS,PRIMARY,RESULTS,ZEALAND
CHANGES,EFFORTS,GIVEN,STRATEGIES,VALIDATION
ERBB2,HIPPO,HOWEVER,ILK,INHIBITION,LATS1,MYPT1,PDZ,PP1,TAZ,YAP,YES
169,FURTHER,PROLONGED,XENOGRAFTS
169,COPYRIGHT,MALDI,PSA
001,181,584,592,623,BACKGROUND,BASEL,BETWEEN,EUR,GLEASON,LABEL,MATERIALS,METHODS,PCA,PSA,RESULTS
300,BACKGROUND,COX,DENMARK,FURTHER,LABEL,MEIER,METHODS,PCA,PHD,PRESENTLY,PSA,PSM,RESULTS,RPS,SINCE,THEREFORE
AMICO,BACKGROUND,CASES,CENTRAL,CONCLUSION,DENMARK,FOUNDATION,FUNDING,LABEL,METHODS,PHOENIX,PSA,RECURRENT,RESULTS,SOCIETY,STRATIFIED,THERE,THREE,TRIAL,UNIVERSITY
169,BACKGROUND,CONCLUSION,EDUCATION,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,RELEVANCE,RESULTS,VARIOUS,WILEY
000,007,018,142,158,161,307,817,BACKGROUND,BLINDED,COMBINING,HEREDITARY,HHT,IQR,LABEL,METHODS,OVERALL,RESULTS,THESE
169,AVM,BRAGG,JAMES,LINDA,MEDICAL,TREATMENT,UNIVERSITY,WHILE
100,169,DDA,DELIVERED,FITCHBURG,LYMAN,PHILIPS,PINNACLE3,RADIADYNE,RADIATION,SINCE,SYSTEMS,USA
BECAUSE,DBD,NRS,PYRVINIUM,USING

107
ECT,FDG,HOWEVER,MRI,PET,REGARDING,SPECT
AKT,IGF,INHIBITION,LABEL,LUCAP23,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
001,019,026,042,639,CPG,GLEASON,HENCE,HOWEVER,OVERALL,PCA,PSA,RAS,RASSF1A
209,233,LABEL,OVERALL,THERE,UNASSIGNED,UNLABELLED
CONCLUSION,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PCA,PET,PURPOSE,RESULTS,SUVMEAN
003,008,010,023,047,049,118,134,ACCORDING,BETWEEN,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
185,HOWEVER,RFS,TAKEN
169,22RV1,LABEL,LNCAP,METHODS,OBJECTIVE,PKC,PURPOSE,RESULTS,SIMILARLY,TAKEN
106,169,643,AKT,ERC,ERG,FORTY,HOWEVER,IHC,INDIVIDUAL,LABEL,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
946,DU145,FURTHER,HGF
145,181,268,ATTEMPTING,HCT,MCF,N13,SGF,SIF
PCA
178,ANSELIN,ARABIAN,EASTERN,GWR,HODGKIN,MORAN,NHL,OLS,POPULATION,SAUDI,THESE
034,038,045,047,121,123,AHT,AMICO,AMONG,BETWEEN,CRT,FURTHER,HDR,MAY,NHT,PSA
169,374,390,BCR,COPYRIGHT,COVARIATES,COX,EARLY,GIVEN,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RESULTS,UNI
141,169,177,ABDOMINAL,COPYRIGHT,DESPITE,EVERY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TUKEY
000,100,961,ANY,BACKGROUND,COSTS,EXCEL,HOWEVER,III,LABEL,METHODS,PCA,RESULTS,SPAIN,SPANISH,STAGE,THESE,USING
LEU,MULTI,NLE,PACE4
CONCLUSION,FURTHER,LABEL,OBJECTIVE,PURPOSE,THERE
300,312,BACKGROUND,CHARLOTTE,INC,INPATIENT,LABEL,MATERIALS,METHODS,ORP,PREMIER,RESULTS
001,003,006,126,128,177,BCR,CONCLUSION,COX,HOWEVER,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PCR,PSA,RESULTS,THESE,UNASSIGNED,VIRTUAL
000,100,185,265,455,INCIDENCE,JANUARY,KOREA,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SIR,VIETNAM,WAR
100,150,CAP,CCNB1,GLEASON,HENCE,HYPOXIA,OVERALL,PSA,SINCE
104,145,811,AKT,BCL,ERK,HOWEVER,LNCAP,MYC,P53,PACLITAXEL,PSA,SRC
632,FORMULA,FORWARD,HOWEVER,KMSFS,SELECTION,SEQUENTIAL,SUPPORT,SVM
183,215,807,815,ALA,ALPHA,BACKGROUND,BLOOD,DHA,EPA,IDENTIFIER,LABEL,METHODS,OMEGA,PSA,RESULTS,THEREFORE,TRIAL,UNASSIGNED,URL
001,945,946,CONCERNING,D50,EORTC,HOWEVER,LABEL,MATERIALS,METHODS,NIEMIERKO,OBJECTIVE,PURPOSE,RESULTS,V60
169,BACKGROUND,DESPITE,INC,K847R,LABEL,METHODS,NVP,PCA,PSA,RESULTS,TARGETING,WESTERN,WILEY
PCR,THESE,WHILE
160,169,239,945,946,AKT,ANNEXIN,CAF,EXO,HSP70,HSP90,HYPOXIC,IL6,INC,LNCAP,PC3,PCA,SMA,TGF,THESE,WILEY
001,004,043,112,119,231,BACKGROUND,CONCLUSION,COX,CSS,GLEASON,LABEL,LOCAL,MEIER,METHODS,PCA,RESULTS,T3B
123,140,CHOLINE,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,SUV
008,047,091,169,AFTER,BACKGROUND,BRITISH,GLEASON,JOURNAL,LABEL,MEDICAL,MEIER,METHODS,PRESS,PUBLISHED,RESULTS,UNIVERSITY
945,946,DETECTION,ELISA,HOWEVER,OVERALL,PSA,TNF
169,472,BACKGROUND,BCR,COPYRIGHT,COX,EARLY,GLEASON,HARRELL,LABEL,METHODS,OBJECTIVE,OUTCOME,OVERALL,PATIENT,PSA,PUBLISHED,REGRESSION,RESULTS,SALVAGE,SETTING,SUMMARY,THESE,UNASSIGNED,UNI,UROLOGY,USING
169,AUA,COPYRIGHT,EDUCATION,INC,INFECTION,LABEL,MARCH,MATERIALS,METHODS,MUSIC,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TRAINED,UROLOGICAL,USING,WHILE
10Q26,169,19Q13,321,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,PSA,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UNIVARIATE,UROLOGICAL
169,AUSTRALIAN,COLLEGE,RESPONSES,ROYAL,ZEALAND
169,AMONG,BRITISH,HOWEVER,SOCIETY,TRP,TRPA1
BRB,NECTARS,TEXTURE
121,ATP,BACKGROUND,BPH,CONCLUSION,CONVERSELY,DAC,H3K4ME2,H3K4ME3,HGPIN,HOWEVER,LABEL,MULTIDRUG,NPT,PCA,PCR,RESULTS,TSA
AFRICAN,BACKGROUND,CONCLUSION,LABEL,METHODS,PSA
HOWEVER,PCA,PSA,SEXTANT
946,CLINICALLY,FAS,HFD,LFD,LNCAP,PCA
AMONG,CONCLUSION,JANUARY,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,ONGOING,PURPOSE,RESULTS,TEN
39351,3RD,CANCERS,CHILDHOOD,CONCLUSION,DEC,EDITION,GENERAL,HACETTEPE,HOSPITALS,JAN,LABEL,MEDICAL,METHODS,OBJECTIVE,PEDIATRICS,PURPOSE,RADIATION,RESULTS,SURGERY,UNIVERSITY,UROLOGY
023,127,242,709,823,838,905,990,995,CAUCASIAN,CAUCASIANS,CONCLUSION,CONVERSELY,FIXED,FURTHER,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STRATIFIED,THEREFORE,VDR,VITAMIN
003,182,CONCLUSION,FACULTY,GLEASON,LABEL,MEDICAL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,UROLOGY
128,ADT,BETWEEN,CONCLUSION,LABEL,MARCH,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
CURRENT,FDA,SEVERAL
153,223,945,946,EDTMP,METASTATIC,THESE,TREATMENT
177,314,CONCLUSION,KOREA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THOSE,UNIVERSITY
164,AUSTRALIA,CONCLUSION,DEPRESSION,DSM,LABEL,MDD,METHODS,OBJECTIVE,PCA,QUEENSLAND,RESULTS,SCALE,THERE,THESE,TREATMENT
096,206,EGGER,EXCLUSION,HOWEVER,TEN
145,174,956,ADP,AUTOPHAGY,BH3,ERS,GADD153,INCREASING,PC3,PCA,PNT1A,POLYPHENON,THEREAFTER,UPR
169,ACS,AMONG,BACKGROUND,CDC,CENTERS,CENTRAL,CONTROL,DISEASE,END,ESTIMATES,INSTITUTE,LABEL,METHODS,NCI,NORTH,OVERALL,PREVENTION,REGISTRIES,RESULTS,SOCIETY,THROUGH
169,3MM,CONFORMITY,DOSIMETRIC,HOWEVER,INTENSITY,MASTERPLAN,MEDICAL,MUS,PRECISE,PUBLISHED,SIB
160,169,498,COPYRIGHT,EDUCATION,FORCE,FURTHER,HOSPITALS,INC,JANUARY,LABEL,MARCH,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PREVENTIVE,PUBLISHED,PURPOSE,RESULTS,SIMILAR,UNIVERSITY,UROLOGICAL
004,101,169,196,ADT,AMICO,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MEIER,METHODS,RESULTS
169,COPYRIGHT,DHH,FURTHER,HHS,IHH,IRELAND,LNCAP,LTD,SHH,SONIC,THESE
014,453,585,APRIL,DAN,HOWEVER,INDEX,LABEL,MAY,METHODS,OBJECTIVE,OVERALL,PATIENT,POTENCY,PSS,RESULTS,RRP,SCORE,SYMPTOM,THERE
001,132,178,185,ADT,BACKGROUND,BED,BIOLOGICAL,COX,FAILURE,FOLLOWING,GLEASON,IOP,LABEL,MEN,METHODS,PHOENIX,PSA,RESULTS,T1C,T2B
ANATOMICAL,CONCLUSION,LABEL,METHODS,OBJECTIVE,PAX,RESULTS,SPECIMENS,THESE
450,492,942,CBM,CHINESE,CONCLUSION,JOURNAL,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,RESULTS,SMD,WANFANG
AMONG,ANOTHER,BPH,CONCLUSION,DIAGNOSTIC,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SYMPTOM,THEREFORE
APC,CENTRAL,JANUARY,JOINTPOINT,LABEL,METHODS,OBJECTIVE,PROGRAM,PURPOSE,REGRESSION,RESULTS,ROMEDER,SUMMARY,VERSION
AZA,CROHN,IBD,TNF
ATP,FINALLY,FTS,MITOGEN,PCA,USING
AKT,FURTHER,HOWEVER,PCA,TAKEN,THESE
BAD,BASED,MCL,PKA,THESE
100,114,197,CAP,GLEASON,OVERALL,PATHOLOGIC,PSA,TUR,VARIABLES
169,C18,C19,CHINESE,COPYRIGHT,EARLIER,TRIPTOLIDE,VCH,WILEY
169,COPYRIGHT,MCF,NOSCAPINE,PAPAVER,PC3,VCH,WILEY
156,AMONG,CONCLUSION,FORTY,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,T1A,T1B,THERE,THESE
169,AFTER,COPYRIGHT,HACAT,LNCAP,SHG,VCH,WILEY
169,946,954,BACKGROUND,CXCL8,ELISA,ERK,HOWEVER,INC,INCUBATION,LABEL,MAP,METHODS,PCR,RESULTS,ROS,THP,WESTERN,WILEY
023,043,140,162,169,BACKGROUND,COX,CYP,GLEASON,HOWEVER,INC,KEIZMAN,LABEL,METHODS,ONCOLOGIST,PFS,PSA,RECORDS,RESULTS,WILEY
169,ANNEXIN,APOPTOSIS,BACKGROUND,HNK,HOWEVER,INC,LABEL,LNCAP,METHODS,NUCLEAR,PSA,R1881,RESULTS,REVERSE,TRAMP,WILEY
169,945,954,BACKGROUND,ELISA,ERK,FINALLY,HSP90,INC,LABEL,MEK,METHODS,MMP,PRSFS,RESULTS,STAT3,TME,WILEY
EMP,GLEASON,PSA,VEGFC,WESTERN
114,128,169,174,230,244,299,313,947,C57BL,CD4,CD8,DR1,FDA,HHDII,IFN,IMMUNOBODY,PAP,PROSTATIC,TREATMENT,VCH,WILEY
133,169,321,563,686,881,945,946,ALPHA,FINNISH,NEITHER,PREVENTION,TOCOPHEROL
169,302,947,ATHYMIC,BIOMARKERS,DIOC7,EF5,MCF
001,002,009,011,026,GLEASON,PCA,PSA,WESTERN
ATP,FACTORS,HOWEVER,IGF,INHIBITORS,INSULIN,IRA,OTHER,THESE
001,003,006,160,BETWEEN,BOWEL,COMPOSITE,CONCLUSION,HOWEVER,HRQOL,INDEX,LABEL,MCS,MEDICAL,METHODS,OBJECTIVE,PCA,PCS,PURPOSE,RESULTS,SHORT,THESE,URINARY
174,177,190,225,307,BACKGROUND,FOLEY,IMA,LABEL,LCA,METHODS,RESULTS,SCORE,SYMPTOM,VINCI
BACKGROUND,CONCLUSION,FORMULA,LABEL,MATERIALS,METHODS,MRI,OPTICAL,RESULTS
AMONG,LABEL,METHODS,OBJECTIVE,OVERALL,PCS,PREDICTOR,PURPOSE,RESULTS,SYMPTOM,THESE
200,ASSESSING,AUC,BASED,DOCETAXEL,EVALUABLE,FATIGUE,HOWEVER,INVENTORY,LABEL,MDASI,METHODS,MODAFINIL,MSADI,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SYMPTOM,THERE,TP1,TP2
AIM,BACKGROUND,LABEL,MATERIALS,METHODS,MTT,OBJECTIVE,PCR,PLNCRNA,RESULTS
000,100,120,177,240,300,500,956,99M,B12,CONCLUSION,DYNAMIC,LABEL,MBQ,METHODS,PREDOSING,RENAL,RESULTS,SIX,SPECT,TARGETING,TEN,UNLABELLED
107,177,215,225,945,956,A10,CONCLUSION,HUVEC,LABEL,LNCAP,MAT,MATLU,METHODS,PEGYLATED,RESULTS,THESE,UNLABELLED
119,122,BACKGROUND,BETWEEN,CONCLUSION,GLEASON,JANUARY,LABEL,METHODS,PSA,RESULTS,TPTPB
231,ALTOGETHER,MCF,MDA,VGSCS,VOLTAGE
143,145,15A,20A,375,AKT,LABEL,MICRORNAS,MIR,PCR,THESE,UNLABELLED
127,191,AIM,BACKGROUND,CHARING,CONCLUSION,CROSS,DESPITE,DETAILS,LABEL,MALIGNANT,MATERIALS,METHODS,OBJECTIVE,ONGOING,RESULTS,TREATMENT
CONCLUSION,GLEASON,LABEL,MESSAGE,METHODS,OBJECTIVE,PSA,QUALITY,RESULTS,TREATMENT
CUS,NPS,PSA,THROUGHOUT
648,BACKGROUND,CENTRAL,CONCLUSION,CONTROLLED,DESPITE,EXPECTING,HOWEVER,LABEL,MEDLINE,METHODS,PEDRO,RESULTS,SMD
AAC,AFRICAN,AIM,AMONG,CARIBBEAN,CAUCASIAN,FURTHER,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,UNLABELLED
GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PHOSPHORUS,RESULTS,SIGNALS
CHELATABLE,TPP,ZP1
223,GUIDELINES,III,PANEL
181,231,474,946,DU145,HEXADECYL,MDA,PC3
012,014,BLOOD,CEC,CEP,CONCLUSION,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T28,T56,T84,TEN,THESE,ZOL
FINGUIMOD,MOLECULAR,THESE
BASEL,FACBC,PET,SALVAGE
001,002,006,220,956,AGE,BACKGROUND,BASEL,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS
170,177,222,2ND,474,4TH,BASEL,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCA,RESULTS
160,MLC,THREE
169,COMPOUNDS,COPYRIGHT,NCI,PALLADIUM,SAS,THESE
013,100MG,169,385,COPYRIGHT,GONADAL,TAK,TWICE
005,169,AGREEMENT,COPYRIGHT,EDUCATION,FINALLY,GLEASON,HISTOLOGY,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESIDUALS,RESULTS,TESLA,UROLOGICAL
105,153,169,COPYRIGHT,EDUCATION,GIVEN,III,INC,INSTITUTES,LABEL,LESIONS,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TESLA,UROLOGICAL
005,169,204,AFTER,ASSESSMENT,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROVIDING,PUBLISHED,PURPOSE,QUALITY,RESULTS,SCALE,SERVICE,SOURCES,THERAPY,UROLOGICAL,VARIOUS
001,013,169,AMONG,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,PURPOSE,RESULTS,SUCCESSFUL,UROLOGICAL
169,COPYRIGHT,DIH,GPCRS,INC,MEANWHILE,PLC,ROS,S1P,XBP
001,073,169,341,599,679,682,697,702,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RECORDS,RESULTS,ROC,THESE,UROLOGICAL,USING
001,003,091,169,COPYRIGHT,COX,EDUCATION,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,YOUNGER
001,102,135,153,168,169,239,AIM,AUC,COLLEGE,CONCLUSION,COPYRIGHT,GLEASON,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PUBLISHED,RESULTS,ROC,ROYAL,SSS,USING
106,169,231,233,AMONG,CONCLUSION,COPYRIGHT,FIFTY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESIDENTS,RESULTS,SAS,SEVENTY,SFJRO
169,COPYRIGHT,HOWEVER,INC,JANUARY,METASTATIC
120,169,AFTER,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PUBLISHED,RECEIVING,RESULTS,THERE
169,831,969,COMPETING,DEPARTMENT,DRESDEN,GERMANY,HAMBURG,INC,LABEL,MARTINI,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATES,RESULTS,TECHNOLOGY,THREE,UNIVERSITY,UROLOGY
001,169,371,471,795,BMI,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERWEIGHT,PUBLISHED,RESULTS
169,758,BCR,COX,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,RPE,UNIVERSITY
169,INC,PUBLISHED
169,434,946,AFTER,CLC,CRC,CTBP2,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PIN,PROTEIN,PUBLISHED,RESULTS,THESE
169,BASED,CLS,CONFIDENCE,DQA,DVH,MEDICAL,PTV,PUBLISHED
169,COPYRIGHT,OUTCOME,PUBLISHED,UROLOGY
169,176,177,466,6MM,BACKGROUND,CBCTS,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PBM,PTV,PURPOSE,RESULTS
169,176,1FA,1PA,210,360,6MM,8MM,AGILITY,ARC,AUTHORS,BACKGROUND,COPYRIGHT,CTV,INCLUDING,IRELAND,LABEL,LTD,MATERIALS,METHODS,MLC,MODULATED,OAR,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS,SEVEN,THERAPY,USING,VOLUMETRIC
015,016,169,515,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,V40,V75
169,215,AFTER,AMONG,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,169,585,BETWEEN,COPYRIGHT,DFS,EIGHT,FAILURE,INC,LABEL,LDR,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
169,177,BACKGROUND,CHO,CONCLUSION,COPYRIGHT,INC,INCLUSION,LABEL,METHODS,PET,RESULTS,TREATMENT
112,118,122,126,132,244,BACKGROUND,DELAYED,DVC,ESTIMATED,LABEL,MATERIALS,METHODS,OPERATIVE,RESULTS,THERE,UNIVERSITY
037,ARS,BACKGROUND,ENGLAND,LABEL,MATERIALS,METHODS,MID,QUESTIONS,RESULTS,UROLOGICAL
017,125,350,445,607,714,926,BACKGROUND,FACTORS,GLEASON,IQR,LABEL,MATERIALS,METHODS,PSA,RESULTS
001,003,270,BACKGROUND,DEPENDING,DISCERN,LABEL,MATERIALS,METHODS,RESULTS
367,BACKGROUND,DEPARTMENT,EDS,EMERGENCY,INCREASING,JANUARY,LABEL,MATERIALS,METHODS,NATIONWIDE,NORTHEAST,RESULTS
BACKGROUND,BCSCS,GENISTEIN,LABEL,MCF,METHODS,PATHWAY,PCR,RESULTS,SIGNALING,THESE
169,INC,PUBLISHED,QOL,SURVIVORS,THEREFORE
160,BACKGROUND,CONCLUSION,IGG,LABEL,LNCAP,METHODS,RESULTS
BACKGROUND,BAX,CBP,CONVERSELY,DU145,ECTOPIC,HLH,ID4,LABEL,LNCAP,METHODS,P223L,RESULTS,TAKEN,V274F
160,ADT,ADVERSE,AFTER,BACKGROUND,COPENHAGEN,DISCUSSION,LABEL,METHODS,SECONDARY,TRIAL,UNIVERSITY,USING
160,ADT,ADVERSE,BACKGROUND,EARLY,EVALUATION,LABEL,METHODS,PROGRAM,RESULTS,SEVENTEEN,THERAPY,TREATMENT,VERSION
160,169,AIM,BRITAIN,COLORECTAL,CONCLUSION,DISEASE,GREAT,IRELAND,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,VINCI
169,502,940,FEW,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,WILEY
151,160,169,173,177,303,AMSTERDAM,BLACKWELL,HOWEVER,MEDICAL,PCA,PSA
GREEN
181,BACKGROUND,CONCLUSION,ESI,FDA,LABEL,LLE,RESULTS
227,374,475,AMICO,BASED,CLAVIEN,FEW,LABEL,METHODS,OBJECTIVE,RESULTS,ROBOT,UNIVERSITY
169,BASED,BIOMETRIC,SOCIETY,THESE
808,918,AIM,ANXIETY,BACKGROUND,C30,CONCLUSION,FORTY,HOWEVER,LABEL,LRP,METHODS,MINIMALLY,OBJECTIVE,PREVALENCE,QLQ,QOL,RESULTS,THERE
946,AKT,CONVERSELY,DU145,ELISA,EMT,MMP,OVERALL,PCR,SNAIL,TGF,TWIST
100,604,AFRICAN,BACKGROUND,CONCLUSION,LABEL,METHODS,PCP,PHYSICIANS,PRACTICES,PRIMARY,PSA,REGARDING,RESULTS,SCREENING
169,BBN,COPYRIGHT,LTD,NLE,THESE,WILEY
169,700,760,888,994,998,ALEXA,CELLSEARCH,CTC,CYTOMETRY,EMT,EPCAM,EXCELLENT,FLUOR,HOWEVER,SOCIETY,SPIKE,TAKEN
120,177,240,956,AFTER,BESIDES,DU145,GSTP1,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,SIMILARLY,THREE,WESTERN
006,007,012,019,036,044,BACKGROUND,III,LABEL,METHODS,MMP,PCR,RESULTS
BACKGROUND,BETWEEN,LABEL,LOW,MARCH,METHODS,OBJECTIVE,PRIOR,RESULTS
100,150,200,250,550,CONCLUSION,EERPE,EXCLUDING,LABEL,LRP,METHODS,OBJECTIVE,PSM,PURPOSE,RESULTS
ADR,DOX,NCS,PC3,PGP,THESE
169,COPYRIGHT,DESPITE,IHC,IRELAND,LNCAP,LTD,PCA,PIN
ASSESSMENT,BACKGROUND,CEA,CGS,COUNCIL,DES,ESTIMATES,EXCELLENCE,FUNDING,FURTHER,HOWEVER,INSTITUTE,LABEL,LIBRARY,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,PROGRAMME,RESULTS,SOURCES,TECHNOLOGY,THERE,VOL,WHERE
AMONG,JMJD2,KDM,LNCAP
005,CURRENTLY,DXR,FIRST,RPA,RPARPAR,TPP
SUPPORTED
JUSTINE,NHS,NOW,SIX
001,BACKGROUND,HOWEVER,JAPAN,LABEL,MEDICAL,METHODS,RESULTS,UNIVERSITY
169,ACCORDING,CHINA,CHINESE,CONCLUSION,DESPITE,LABEL,LTD,MEN,METHODS,OBJECTIVE,OBJECTIVES,PTY,PUBLISHING,RESULTS,SICHUAN,THESE,UNIVERSITY,WILEY
044,133,160,566,ADHERENCE,ADULT,AMONG,COX,DIETARY,HOWEVER,MEN,RELATIONS,SCORE,THERE,UPPSALA
100,169,SEVEN
027,100,124,150,274,782,793,800,806,844,887,953,966,ADC,AUC,CHO,CIT,CONCLUSION,DWI,LABEL,METHODS,MRS,OBJECTIVE,OOP,RESULTS,ROC,ROI
104,106,142,143,ACCORDING,BPH,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,THERE
BACKGROUND,DISCUSSION,EFFECTIVE,FOCUS,GPS,LABEL,MEN,METHODS,RESULTS
DESPITE,MCS
003,006,032,071,16250,16273,227,784,ATM,GROUP,PCR,RADIATION,THERAPY,THESE
177,370,740,AIM,CONCLUSION,INTRA,LABEL,METHODS,OBJECTIVE,PTV,RESULTS
164,216,346,AIM,BACKGROUND,CONCLUSION,COX,DESPITE,INSTEAD,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,RESULTS,UNIVARIATE
270,AIM,AMH,BASED,CONCLUSION,IGA,IVU,LABEL,LOW,METHODS,NEWLY,OBJECTIVE,RESULTS,THREE,UUT
117,ADVERSE,AIM,CONCLUSION,CTV,LABEL,METHODS,OBJECTIVE,PTV,RESULTS,THEREFORE
765GC,765GG,AIM,AMONG,BLADDER,CONCLUSION,COX,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,RESULTS,SIX
31G,57G,BACKGROUND,CENTRAL,CONCLUSION,HOWEVER,LABEL,MATERIALS,MEANWHILE,METHODS,NON,RESULTS,XRCC6
231,954,ADP,AIM,BACKGROUND,CONCLUSION,DU145,ELISA,LABEL,MATERIALS,MDA,METHODS,OBJECTIVE,PARP1,PIPER,RESULTS,ROS,SOUTHEAST
023,024,027,100,APC,BACKGROUND,CONCLUSION,CPG,GLEASON,GSTP1,LABEL,METHODS,PCA,PCR,PSA,PTGS2,RAR,RARBETA,RESULTS,SCORE
BACKGROUND,CONCLUSION,EXPRESSION,HPRT1,LABEL,MATERIALS,METHODS,PCR,RESULTS,TEN,TPB
150,169,IHC,LABEL,METHODS,OBJECTIVE,PURPOSE,RB1,RESULTS,SMALL
051,094,171,174,208,469,973,977,ARCHITECT,BACKGROUND,CVS,FREND,INC,KOREA,LABEL,LINEARITY,LOD,METHODS,NANOENTEK,PSA,RESULTS,SEOUL,TOTAL
001,012,169,892,900,ACUTE,BACKGROUND,LABEL,METHODS,PCA,REDUCTION,RESULTS,SOCIETY
176,319,330,AFTER,CO2,MOL,PC3,RES,ZHANG
109,301,BPH,CALIFORNIA,DIEGO,LEVEL,LOS,OSP,ROBOTIC,SAN,THESE,UNIVERSITY
001,097,168,289,584,591,725,762,873,890,914,AES,AFTER,CONCLUSION,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PFS,PURPOSE,RESULTS
001,945,CONCLUSION,DHT,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,TMPRSS2,ZBD
792,ASSESSMENT,BACKGROUND,CROSS,LABEL,MEDICAL,METHODS,PANEL,PLANS,PREVENTIVE,PRIOR,RESULTS
GLEASON
946,BRCA1,INDUCTION,INK4A,LABEL,LOW,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,RICCARDIN
000,169,300,AMICO,COPYRIGHT,COSTS,END,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,THERE
11C,169,223,ADT,COPYRIGHT,EAU,ENDORECTAL,LABEL,METHODS,OBJECTIVE,PATIENT,PCA,PET,PSA,PUBLISHED,RELAPSE,RESULTS,SRP,SRT,SUMMARY,SYNTHESIS,THERAPY,THESE,TREATMENT,UROLOGY,ZOLEDRONIC
120,169,CONCLUSION,DOD,DRE,ENGLISH,LABEL,MEDLINE,METHODS,OBJECTIVE,PSA,RESULTS,SUSPECT,THERE
001,002,020,025,038,042,100,169,419,544,963,ART,BRE,CONCLUSION,EARLY,END,HOWEVER,INC,INITIATING,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,UTILIZING
169,GENOMIC,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,WHILE
169,CONSENSUS,DESPITE,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SEVERAL,SINCE,SIXTY
215,320,BACKGROUND,DESPITE,LABEL,METHODS,PSA,QUESTIONS,RESULTS,RISKS,SIXTY,THESE
002,294,CCP,FIFTEEN,LABEL,METHODS,OBJECTIVE,PHYSICIANS,RESULTS,T3B,UROLOGISTS

100,160,180,233,BACKGROUND,CONCLUSION,GLEASON,INTENSITY,LABEL,METHODS,PSA,RESULTS,SEVENTY,SIB,TREATMENT
233,BACKROUND,CONCLUSION,FORTY,GRADE,INTENSITY,LABEL,METHODS,PRESCRIBED,RESULTS,UNASSIGNED
117,DSC,INTER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SLICE
BASED,HENCE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIMILARLY,TREATMENT,TYPICALLY
176,946,CARLO,COMPARING,FINALLY,HOWEVER,LABEL,METHODS,MONTE,OBJECTIVE,PCC,PEARSON,PET,PURPOSE,REGARDING,RESULTS,ROTATIONAL,SETUP
ART,DDT,GPS,LABEL,LOW,METHODS,OBJECTIVE,PERFORMING,PURPOSE,RESULTS
100,AFTER,BECAUSE,CENTROIDAL,CVT,D90,EIGHT,FINALLY,GROUP,HDR,HOWEVER,LABEL,METHODS,OBJECTIVE,PLANS,PURPOSE,RADIATION,RESULTS,THERAPY,TREATMENT,ULTIMATELY,VORONOI
001,947,BEV,LABEL,METHODS,MLC,OBJECTIVE,PEARSON,PURPOSE,RESULTS
177,CTS,CTV,D99,DAILY,DSC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEVEN,THESE
001,100,DECREASED,HDMLC,INTENSITY,LABEL,METHODS,MILLENNIUM,MLC,OBJECTIVE,PURPOSE,RESULTS
FACTORS,HOWEVER,LABEL,LEM,LOCAL,METHODS,MODEL,OBJECTIVE,PURPOSE,RBE,RESULTS,SPECIAL
DVH,HOWEVER,LABEL,METHODS,MLC,OBJECTIVE,PTV,PURPOSE,RESULTS,THERE,TOLERANCES
100,2CC,DVH,HOWEVER,LABEL,METHODS,OAR,OBJECTIVE,OPTIONS,PATIENT,PURPOSE,RESULTS,SELECTING,SIMULATED,V50,V70GY,V76GY
200,255,CARLO,FAN,LABEL,MCNPX,METHODS,MEV,MONTE,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SEVERAL,TREATMENT
CARLO,CONCLUSION,KNOWLEDGE,LABEL,LOWER,METHODS,MONTE,MRI,MUS,OBJECTIVE,PTV,PTV78,PTV86,RESULTS,SIB,V30,V50,V60,V80
169,BACKGROUND,CELLS,DISCUSSION,HOWEVER,INC,LABEL,METHODS,NANOG,NANOGP8,RESULTS,THEREFORE,WILEY
169,380,546,942,AMONG,CONCLUSION,DIGOXIN,GIVEN,INC,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,THESE,WASHINGTON,WILEY
ACHIEVING,DU145,HDV,MTT,PACE4,XTT
160,293,C30,CONCLUSION,EORTC,GERMANY,HOWEVER,LABEL,METHODS,OBJECTIVE,PROCASP,PURPOSE,QLQ,QOL,RESULTS,SEXUALITY
26S,946,948,CKI,CURRENTLY,METASTASIS,MTSS1,NOTABLY,S322A,SCF,THEREFORE,TRCP1
001,028,049,150,509,COLLEGE,CONCLUSION,GLTEQ,GODIN,HRQOL,INDEX,LABEL,LEISURE,MEN,METHODS,OBJECTIVE,PATIENT,PRIOR,PURPOSE,QUALITY,RADICAL,RESULTS,SCALE,SCORE,SURVIVORS,SYMPTOM,UTILITY
900,D52,PCR,STRONGEST,THESE,TPD52
USING
BURGEONING,HOWEVER,HSPC111,MYC,PC3,RHO,ROCK1,THEREFORE
177,BACKGROUND,COLOGNE,CONCLUSION,EXTENSIBLE,FINALLY,FIRST,HOWEVER,LABEL,MATERIALS,METHODS,RESULTS,TEN,THEREFORE,XML
BMI,MOLONEY,P16,PCA,THESE
044,160,176,346,ADVERSE,BETWEEN,CONCLUSION,CTCAE,GRADE,HDR,IHT,LABEL,MARCH,MEIER,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,SEPTEMBER
AFTER,ASA,BACKGROUND,BELGIUM,CONCLUSION,CONTENT,DCR,DIGITAL,DOUGLAS,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS,SETTING,THERE,TRANSANAL,VIDEO
945,AFTER,EMT,HIF,PCA,STRATEGIES,THESE
215,299,391,580,676,778,AFTER,ALPHA,CIS,COLORECTAL,FINNISH,LINE1,ORS,OVARIAN,PREVENTION,SCREENING,THESE,TOCOPHEROL,TRIAL
169,CA125,COLORECTAL,COPYRIGHT,INC,KINGDOM,OVARIAN,PUBLISHED,ROC,SCREENING,TRIAL,UKCTOCS
145,169,COPYRIGHT,EDUCATION,FURTHER,HORMONE,HOWEVER,INC,JNK,JUN,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVERAL,UROLOGICAL
059,160,169,534,COPYRIGHT,EDUCATION,GLEASON,HOPKINS,HOWEVER,INC,JOHNS,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
BACKGROUND,CONCLUSION,LABEL,MEDICAL,METHODS,UROLOGY
169,BACKGROUND,COPYRIGHT,CZECH,HOWEVER,LABEL,LTD,METHODS,RESULTS
169,AEU,ALTERATION,CONCLUSION,CONTEXT,COPYRIGHT,DETERMINE,EVIDENCES,HLA,LABEL,OBJECTIVE,PUBLISHED,SYNTHESIS,THERE,THOSE,UNASSIGNED
100,169,406,BACKGROUND,COPYRIGHT,FMD,INDEX,LABEL,PUBLISHED,SECONDARY,THERE,TRIAL,UNLABELLED,UROLOGY,VO2PEAK
169,COPYRIGHT,IRELAND,LTD
002,005,169,AMICO,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MEN,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,SIXTY
160,169,267,BECKMAN,BPH,COMPARING,CONCLUSION,COPYRIGHT,COULTER,INC,INDEX,LABEL,METHODS,OBJECTIVE,PCA,PHI,PSA,RESULTS
013,015,CONCLUSION,INC,LABEL,METHODS,OBJECTIVE,PHOENIX,PUBLISHED,RESULTS,THESE
169,412,999,CLEVELAND,CONCLUSION,COPYRIGHT,FOLLOWING,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PVP,RESULTS,SIXTY
169,ACUTE,COPYRIGHT,INC,THESE
169,233,241,243,400,COPYRIGHT,PUBLICADO,WILMS
169,BACKGROUND,CONCLUSION,COPYRIGHT,CYP17A1,INHIBITION,LABEL,MEDLINE,METHODS,REGARDLESS,RESULTS,SAS,SIMILARLY,STROMAL
169,BACKGROUND,CONCLUSION,COPYRIGHT,DOCETAXEL,ERG,GLEASON,LABEL,METHODS,NORTH,PROMISING,PSA,RESULTS,SAS,SEVERAL,WHILE
169,174,509,BACKGROUND,CONCLUSION,COPYRIGHT,CYP17,ENGLISH,FINALLY,HENCE,LABEL,MATERIALS,MEDLINE,METHODS,RESULTS,SAS
169,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,III,LABEL,MEDLINE,METHODS,PSA,RESULTS,SAS
169,BACKGROUND,CONCLUSION,COPYRIGHT,CYP17A1,HOWEVER,LABEL,METHODS,RESULTS,SAS
169,239,ALTERNATE,BACKGROUND,CASTRATION,CONCLUSION,COPYRIGHT,DESPITE,ENGLISH,LABEL,MAJOR,MEDLINE,METHODS,RESULTS,SAS,SEPTEMBER,STERO
107,169,2000S,BACKGROUND,CARIPLO,COMMISSION,COMPAGNIA,COPYRIGHT,FOUNDATION,FUNDING,FURTHER,HODGKIN,IRELAND,ITALIAN,LABEL,LTD,MAJOR,METHODS,PAOLO,RESULTS,SAN,UNIFORM,VARIATIONS
169,GIVEN,INC,RADIATION
001,003,024,039,169,344,408,446,498,AMONG,ASIAN,AUTHORS,BJU,BMI,DRE,GLEASON,LABEL,METHODS,OBESE,OBESITY,OBJECTIVE,PSA,RESULTS
140,ACTUARIAL,APRIL,BACKGROUND,CLINICALLY,CONCLUSION,CTCAE,DISTANT,LABEL,METHODS,NCI,PSA,PTV,RESULTS,SEPTEMBER,STAGE,TOXICITIES
156,169,332,AUSTRALIAN,COLLEGE,CONCLUSION,GAS,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROYAL,ZEALAND
163,169,18F,239,363,526,99M,AUTHORS,BJU,FCH,GLEASON,LABEL,MARCH,MAY,MDP,METHODS,MRI,NAF,OBJECTIVE,PET,PSA,RESULTS,SCANS,THEIR,WBS
169,175,179,AUTHORS,BCR,BJU,CLAVIEN,GRADE,III,LABEL,MEIER,METHODS,OBJECTIVE,PFS,POTENCY,PSA,RESULTS,SALVAGE
169,KARNOFSKY,KPS,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,UNIVERSITY,WILEY
111,125,159,177,181,ALA,ALF,BBN,EXPRESSION,GBQ,GLN,GLY,LEU,NH2,PET,PHE,STA,STABILITY,TRP,TYR,VAL
001,169,251,ACAT1,AMERICA,BACKGROUND,DISCUSSION,ERG,GLEASON,GS7,HOWEVER,INC,LABEL,METHODS,NORTH,PREVIOUSLY,PSA,RESULTS,TAKEN,USING,WHILE,WILEY
043,160,278,CONVERSELY,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,OCTOBER,RESULTS
BACKGROUND,DUE,LABEL,METHODS,PCA,PET,PSA,PSADT,RESULTS
000,013,030,039,103,105,191,197,224,300,332,376,413,441,719,744,776,809,831,832,834,844,849,862,882,893,902,958,959,962,968,ASIAN,HOWEVER,IGFBP,INSULIN
160,649,AFRICAN,PREVALENCE,WHILE
001,160,184,531,ADJUSTMENT,AFTER,ASPIRIN,CONCLUSION,LABEL,METHODS,OBJECTIVE,ORS,PURPOSE,RESULTS,THERE
005,163,264,AVERAGE,BRCA1,COLORECTAL,CONSORTIUM,END,MAMMOGRAM,MRI,NUTRITION,OVARIAN,PREVENTION,RESULTS,SCREENING,THESE,TRIAL
169,AMP,BACKGROUND,COPYRIGHT,EGF,EPCAM,EPITHELIAL,HOWEVER,INC,LABEL,METHODS,RESULTS
169,AKT,COPYRIGHT,LTD
000,ITALY

169,600,831,ENDOSCOPIC,FORCE,JAPAN,LTD,PTY,PUBLISHING,SOCIETY,SURGERY,T4BN0M0,TOTAL,TPE,WILEY
183,CHD,CVD,ESTIMATES,FFQ,HOWEVER,SFA
120,147,174,BPH,CAP,CROATIA,EASTERN,FURTHER,SNP
169,AG490,ELISA,EXPRESSION,HOWEVER,IL6,INC,LABEL,METHODS,MYC,OBJECTIVE,PCR,PSA,PURPOSE,RESULTS,STAT3,WESTERN,WILEY
056,272,593,CAUCASIANS,HENCE,INDIANS,OVERALL
100,125,CARLO,DEF,FE2O3,HOWEVER,MAXIMUM,MCNPX,MONTE,PROSTASEED,WHILE
001,002,BACKGROUND,JAMES,LABEL,METHODS,OBJECTIVES,QUESTIONS,RESULTS,ROCHESTER,SCP,SURVIVORS,TSS,UNIVERSITY
169,COPYRIGHT,LTD,NUMERICAL,REQUIRING,WILEY
117,125,BLADDER,CONCLUSION,DUE,INDEX,LABEL,METHODS,OBJECTIVE,OCTOBER,PURPOSE,RESULTS,SCORE,SYMPTOM,TME,WJD
001,505,795,873,961,965,975,BPH,COMPARING,COMPARISON,ICC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SVM,THREE
215,946,CAT,FGFR1,GLEASON,JOCK1,PRO,TGF,THEREFORE,UBI,USING,WNT
001,169,EPI,HSP90,THESE
169,AUSTRALIAN,AUTHORS,COLLEGE,HOWEVER,IMAGING,JOURNAL,LTD,MEDICAL,PTY,PUBLISHING,RADIATION,RESPONSES,ROYAL,WILEY,ZEALAND
HOWEVER,METASTATIC,USING
178,BACKGROUND,BIACORE,LABEL,MEIER,METHODS,RESULTS,SEC61,SEC62,TARGETING,TFP,THEREFORE,TREATMENT,USING
115,161,APO10,BACKGROUND,BIOMARKERS,EXPRESSION,FURTHER,LABEL,METHODS,RESULTS,TKTL1,WARBURG
100,160,169,APMIS,FURTHER,HOWEVER,LTD,PUBLISHED,WILEY
FINALLY,KLF,MYC,NANOG,OCT,SOX
AMONG,ERS,HOWEVER
231,239,FINALLY,HCC1954,MCF,MDA,OTHER,TREATMENT,USING,ZEBRAFISH
BIOLOGICAL,DUE,FIFTY,LABEL,MATERIALS,METHODS,PCA,RESULTS,SIMILARLY,SUPPORTED,UNLABELLED
BACKGROUND,ELASTIC,LABEL,MICRORNAS,RESULTS,USING
BACKGROUND,FUZZY,HOWEVER,LABEL,RESULTS
NAD
152,19A,19B,26A,30C,AFTER,ANNOTATION,FUNCTIONAL,SET,SIMILARITY,STUDENT,THEREFORE,THESE
001,169,215,244,658,BACKGROUND,CAPSURE,LABEL,MEN,METHODS,RESULTS,SOCIETY,STRATEGIC,T3CN0M0
169,CURRENT,SPANISH,THEREFORE,THESE,VCH,WILEY
179,424,BACKGROUND,CIS,HCC,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,RRS,SCIENCE,THEREFORE,WEB
150,159,192,194,212,284,669,693,EPE,GLEASON,PATHOLOGY,PSA,SEMINAL,SOCIETY,SPECIMENS,THESE,TUMOURS,UROLOGICAL
ADC,APC,BASED,CONCLUSION,FALLING,HIV,HODGKIN,LABEL,MATCH,METHODS,NADCS,NHL,OBJECTIVE,POISSON,POPULATION,RESULTS
AFFYMETRIX,HERVS,PSA
118,177,180,ACCORDING,BETWEEN,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,VAS
000,002,169,177,264,ADT,AMONG,BACKGROUND,BED,CONCLUSION,COPYRIGHT,CSS,EARLY,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
169,215,699,741,756,946,COPYRIGHT,DSC,LTD,NMR,ROESY,TEL,THESE
169,AIM,BRITAIN,COLORECTAL,CONCLUSION,DISEASE,GREAT,GROUP,IRELAND,LABEL,METHODS,OBJECTIVE,RADIATION,RESULTS,SEVEN,SIX,SPE,THERAPY,TREATMENT
001,042,BETWEEN,CONCLUSION,GPS,LABEL,METHODS,OBJECTIVE,OUTCOME,PRIMARY,RESULTS,SETTING
169,AUTHORS,BJU,MRI,PCA
001,101,169,221,873,964,AUTHORS,BJU,COX,GROUP,III,KENDALL,LABEL,METHODS,OBJECTIVE,REMOVAL,RESULTS,SUB,WORKING
OVERALL,SEVERAL,THESE
014,143,410,461,590,CLINICIANS,CONCLUSION,ERG,G300104,GLEASON,GTX,HGPIN,III,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
110,956,DU145,ROS,STUDIES
LNCAP,THEREFORE
012,AUC,BETWEEN,CONCLUSION,DWI,IMAGING,LABEL,LNS,MAY,METHODS,NEITHER,OBJECTIVE,OVERALL,PATIENT,PCA,PET,PURPOSE,RESULTS
946,AR3,AR3TG,CK5,CK8,TGF

CULTURING,LNCAP,TREATMENT
376,BASEL,DEPICTION,GLEASON,IIA,IIB,III,LABEL,METHODS,OBJECTIVE,OHORI,PCA,RESULTS,SVI,THERE,WHEELER
300,956,AFTER,FEW,FURTHER,OPTIMIZED,PCA,TSC
177,223,365,AIANS,ALASKAN,AMONG,BACKGROUND,BECAUSE,CALIFORNIA,COMPARING,CONCLUSION,IHSCS,INDIANS,LABEL,METHODS,NATIVES,REGISTRIES,RESULTS,SERVICE,STATE,USING,WASHINGTON
228,239,AMONG,BACKGROUND,BMI,CONCLUSION,GLEASON,HMW,LABEL,LMW,METHODS,RESULTS,TOTAL
155,BACKGROUND,DESPITE,FEWER,GLEASON,LABEL,MEIER,METHODS,PSA,RESULTS,SPECIMENS,THERE,TOTAL
CURRENTLY,EVALUATING,HOWEVER,WORLDWIDE
169,BACKGROUND,BASEL,GLEASON,LABEL,LRP,METHODS,PERITONEAL,PSA,RESULTS,SIX,THREE
100,169,946,956,BACKGROUND,BASEL,CA2,ERYPTOSIS,FLUO3,HALLMARKS,LABEL,METHODS,RESULTS
169,945,947,COPYRIGHT,EGF,GEFITINIB,HOWEVER,INCLUSION,IRELAND,LNCAP,LTD,PCA,SIMILARLY,SPATIAL,SRC,THESE,USING
001,100,103,169,CHRONIC,COPYRIGHT,GRADE,INC,INCLUDING,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SIXTY,SOCIETY,TOTAL
160,169,384,ACTUARIAL,ADVERSE,COPYRIGHT,GLEASON,GRADE,HDR,INC,LABEL,LOW,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RATES,RESULTS,SOCIETY,THERE
001,169,359,COPYRIGHT,METASTATIC,PUBLISHED,UROLOGY
0B1,945,946,ERB,FUNCTIONAL,NR0B2,NR1D1,NR2C1,NR2C2,NR2E1,NR2E3,NR2F1,NR2F2,NR2F6,NR4A1,NR4A2,NR4A3,NR6A1,NUR77,NURR1,PNR,RESULTS,REV,TFI,THESE
4GY,ERK,GATA3,ID2,PC3,PCR,THROUGH
218,AIM,CONCLUSION,III,ITALIAN,LABEL,METHODS,OBJECTIVE,PHASE,RESULTS,THESE
169,600,956,AFTER,CONCLUSION,COPYRIGHT,CROWN,HOWEVER,INC,LABEL,LNCAP,LOX,MEIER,METHODS,OBJECTIVE,PUBLISHED,RESULTS,TEN,TRAMP,WESTERN
ANOTHER,COA,FURTHER,HMG,RAC,RAS,REGARDING,RHO,STATINS
PARKINSON
262,AMONG,INCIDENCE,KNOWLEDGE,VIRGINIANS
AKT,AURKA,DU145,HDAC1,HISTONE,HOWEVER,INGENUITY,IPA,KAT2B,KAT6B,PATHWAY,PCA,SUBSEQUENT,THEREFORE
BET,MYC,POLII,SMALL
CCNG2,GLEASON,MTT,PCR,PSA,REVERSE,WESTERN
169,945,946,HOWEVER,RSD,SARCOSINE,VCH,WILEY
122,143,145,HOWEVER,LUCIFERASE,TRAIL
028,945,CASTRATION,DHT,FOXA1,LNCAP,WNT
ABCB1,APPARENTLY,ATP,BACKGROUND,CONCLUSION,LABEL,MATERIALS,MDR,METHODS,MTT,PC3,RESULTS,TAP
001,002,BCR,FIFTY,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PCR,PLN,PSA,RESULTS,UNDER,WITHOUT
2B4,673,811,ALTOGETHER,BMD,CASTRATION,LNCAP,MC3T3,OSTEOBLAST,OSTEOGENIC,THERE
001,119,AMONG,BACKGROUND,BMI,CIS,COX,ERG,LABEL,METHODS,PHYSICIANS,RESULTS,THESE,TMPRSS2
ASSESSMENT,FUNCTIONAL,GENERAL,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,QOL,QUALITY,RESULTS,SCALE,SURVEYS,SYMPTOM,THERAPY,WHILE
114,145,185,244,245,438,465,591,709,720,945,CONCLUSION,DESPITE,DVT,FOLLOWING,ICD,LABEL,MEN,METHODS,OBJECTIVE,ORP,PURPOSE,RESULTS,VTE
169,COPYRIGHT,DISCUSSION,IMAGING,INC,LABEL,MAPPING,MEN,METHODS,MRI,OBJECTIVE,PHS,PICTURE,RESONANCE,THOSE,TPM
169,24H,AMONG,ARSENIC,COPYRIGHT,FURTHER,H2A,HOWEVER,THESE,USING
169,184,390,COPYRIGHT,CYBERKNIFE,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,OFTEN,PTV,PUBLISHED,PURPOSE,RESULTS,TPS
169,393,AUSTRALIA,BACKGROUND,CLASSIC,COPYRIGHT,CRUDE,GLEASON,JANUARY,LABEL,LOWER,METHODS,OBJECTIVE,OCTOBER,OUTCOME,PATIENT,PCA,PSM,PUBLISHED,RESULTS,SETTING,SUMMARY,UNASSIGNED,UROLOGY
001,129,169,245,BACKGROUND,COMMITTEE,COPYRIGHT,CSM,DEFINITIVE,DSS,END,FACTORS,FEW,JOINT,LABEL,LOCAL,M1A,MEIER,MEN,METHODS,NSR,OBJECTIVE,OUTCOME,PATIENT,PCA,PUBLISHED,RESULTS,SETTING,SIMILAR,SUMMARY,THEREFORE,THESE,UNDERGOING,UROLOGY
169,231,ATP,COPYRIGHT,FURTHER,HOWEVER,III,LTD,MDA,PC3
169,531,6MONTHS,CFA,CONCLUSION,DIF,GIVEN,ILLNESS,IPQ,LABEL,METHODS,OBJECTIVE,PERCEPTION,RASCH,RESULTS
100,169,AFTER,BACKGROUND,COPYRIGHT,FERRP,FIFTY,ICG,LABEL,LYMPHATIC,METHODS,OBJECTIVE,OUTCOME,PARAMETERS,PILOT,PRIOR,PROCEDURE,PUBLISHED,RESULTS,RETZIUS,SETTING,TEN
169,COPYRIGHT,IRELAND,LTD
104,194,645,DRE,GLEASON,HEALTHY,HOWEVER,PCA,PSA,QOL,THERE,THESE,TURKISH
174,384,AIM,CSB,LABEL,MASSARRAY,METHODS,NER,OBJECTIVE,RESULTS,XPA,XPC,XPD,XPG
ADRB2,PCA,TRIPTOLIDE
169,206,215,EXPRESSION,LTD,MIR,PUBLISHED,THESE,UTR,WESTERN,WILEY
ADDITIONAL,AREAS,BACKGROUND,BMD,COVERED,DENOSUMAB,LABEL,METHODS,OPINION
001,002,160,181,608,726,ARMBAND,BACKGROUND,LABEL,METHODS,NOR,PRIMARY,RESULTS,SENSEWEAR,SHORT,THERE,URINARY
141,5TH,ELISA,PCR,PSA,THESE
001,002,034,150,GLEASON,HPV,MEIER,PCA
FUNCTIONAL,HMG,SOX,SRY
AKT,GIVEN
145,181,MCF,THREE
378,468,680,908,ASHAMAS,BENIN,CONCLUSION,DIAGNOSTIC,FOUNDATION,HOWEVER,LABEL,MATERIALS,METHODS,NIGERIA,NODULAR,NPH,OBJECTIVE,OBJECTIVES,PROSTATIC,RESULTS,SIX,SOUTH
ABDOMINAL,AFTER,BASEL,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,VAS
128,282,295,319,329,398,954,AC1,AGREEMENT,FINALLY,GPS,IQR,KAPPA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
108,169,182,200,300,600,609,686,700,800,861ST,866,866TH,AUSTRALIAN,BACKGROUND,COMPOSITE,COPYRIGHT,EARLY,INDEX,LABEL,METHODS,OBJECTIVE,ORP,OUTCOME,PSM,PUBLISHED,QOL,RARPS,RESULTS,SETTING,UROLOGY
169,946,COPYRIGHT,DIANA,LTD,PRODUCTION,TARGETSCAN,TGF,THEREFORE,THESE,WNT
110,116,120,169,177,4N0,COPYRIGHT,EDUCATION,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,214,AAM,AFRICAN,BETWEEN,CONCLUSION,COPYRIGHT,DISEASE,FAILURE,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RESULTS
120,160,177,224,596,BACKGROUND,LABEL,METHODS,PVP,RESULTS,RUV,SCORING,SYMPTOM,THERE
125,168,1ST,ANOTHER,CSF,LABEL,METHODS,MRI,NEITHER,OBJECTIVE,RESULTS,SDH,THEIR
ACCORDING,BAX,BCL,HEPG2,HOECHST,HOWEVER,PLANT
MEDLINE,MOLECULAR,PCA,THERE
004,021,023,052,169,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PVS,RESULTS,SMALL,WILEY
945,954,AKT,BCL,CONSISTENT,COX,DIAMIDINO,DU145,HOWEVER,MTT,RURTHER,TUNEL,WESTERN
177,181,730,AKT,CELLS,CHINESE,DU145,ERK,JNK,JUN,PC3
169,BACKGROUND,CRITICALLY,FURTHER,HOPKINS,HOWEVER,HPC,INC,JOHNS,LABEL,MEN,METHODS,PCR,RESULTS,TELOMERES,WILEY
BELOW,DIAGNOSIS,PNE,RADIATION
GTPASES,LNCAP,RHO
143,145,DU145,GOLGI,GOLM1,PC3,PCA,SILENCING
CELLS,CTC,DIFFERENT
169,ALA,BACKGROUND,CONCLUSION,COPYRIGHT,INHIBITION,LABEL,METHODS,NOC,PDT,RESULTS
169,MET,TREATMENT
043,AMONG,BACKGROUND,CONCLUSION,ENGLAND,EPISODE,LABEL,METHODS,RESULTS,STATISTICS,THERE,USING
BIOACTIVE,BMP,EPIGENETIC,THREE,TREGS
177,954,BACKGROUND,CONTEXT,GLEASON,LABEL,METHODS,OBJECTIVE,PATHOLOGY,REDUCTION,RESULTS,SOCIETY,UROLOGICAL
ANTIBODIES
169,AUTHORS,L505H,LTD,PIGMENT,PLX4032,PLX8394,PUBLISHED,V600K,WILEY
169,176,377,AUSTRALIAN,BACKGROUND,COLLEGE,LABEL,METHODS,RESULTS,ROYAL,THERE,ZEALAND
053,205,523,BACKGROUND,CENTRAL,CIS,FIXED,FURTHER,HOWEVER,INSULIN,JANUARY,LABEL,LIBRARY,METHODS,PCA,RESULTS,THERE
CTB,GLUCOSE,GRP78,PAR
AKT,LENTIVIRAL,MYC,THESE
946,BMP,EMT,ENDOGENOUS,GOOSECOID,SMAD4,SNAIL,TGF,TWIST,WNT
BASEL,PCA
945,EARLY,OTHER
130,188,AGE,BACKGROUND,BASEL,ECE,GLEASON,JANUARY,LABEL,MATERIALS,METHODS,PATHOLOGIC,PSA,RESULTS,ROC
160,FINALLY,HUVEC,PVA
ENDOCRINE,THEREFORE
CAM,DECREASED,GLEASON,IGF,PCA,PROTEIN,SOCS2,SUPPRESSOR
160,BETWEEN,EVALUATION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SRT,WHILE
DU145,HCA,HTS,PC3,PCA,SCREENING,THREE,THROUGHPUT,TOWARDS,UTILISING
149,196A2,27A,499,CRUDE,FINALLY,FURTHER,HOWEVER,MICRORNAS,SCCHN
125,169,CCL16,CD11B,CHEMR23,CMKLR,CMTM3,GLEASON,III,ILK,LABEL,LEC,LIGHT,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,THESE,TNFSF14
169,17G,945,946,FURTHER,LABEL,METHODS,OBJECTIVE,PURPOSE,REMARKABLY,RESULTS,SIMILARLY,SRD5A
223,HOWEVER,SELECTION
223,UNION,UNTIL,USA

464,945,946,BESIDES,C17,CYP,CYP11B1,CYP17,HOWEVER,UNDER
BACKGROUND,EIGHT,GLEASON,LABEL,MATERIALS,MEDLINE,METHODS,PCA,RESULTS,STUDIES,TNM
160,169,CLINICALLY,CONCLUSION,COPYRIGHT,INC,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,THESE
169,212,384,400,480,CONCLUSION,COPYRIGHT,DENMARK,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,ORA,ORS,OVERALL,PCA,PURPOSE,RESULTS,THEREFORE
169,619,638,AGE,AIM,ASR,AUSSIEDLER,COPYRIGHT,DISCUSSION,GERMANY,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SIR,STOMACH,UNION
169,COPYRIGHT,LOCAL,SAS
169,177,APRIL,BACKGROUND,COPYRIGHT,DISCUSSION,FIFTY,FINALLY,LABEL,LITERATURE,METHODS,MRI,NPV,PPV,PSA,PUBLISHED,RESULTS,SAS
169,456,BACKGROUND,CONCLUSION,COPYRIGHT,FIFTY,LABEL,METHODS,PSA,RESULTS,SAS
001,946,APA,AUSTRALIAN,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,PSA,RESULTS,STAGE,UNAFFECTED
006,047,055,101,169,234,244,345,ASSESSMENT,AUTHORS,BJU,CALIFORNIA,CAPRA,CONCLUSION,COX,FRANCISCO,GLEASON,LABEL,LDR,METHODS,OBJECTIVE,PHOENIX,PSA,RESULTS,SAN,THERE,UNIVERSITY
ADDITIONAL,AREAS,BACKGROUND,COVERED,FDA,LABEL,METHODS,OPINION,PHYSICIANS
INCREASED,MYC,SEVERAL
183,PC3,PT1
169,INC,POSITIVITY,PSA,THEREFORE,WILEY
169,AT6,BACKGROUND,CONCLUSION,ELL,INC,LABEL,LNCAP,METHODS,PC3,PIRIN,RESULTS,THROUGH,U19,WILEY
001,107,PCA,ROBO1,ROBO2,SEVERAL,TSG
22RV1,954,ARRAY,BPH,DU145,LIMITED,LNCAP,METHODS,OBESITY,PCR,SIMILAR,WESTERN,ZFP91
CTZ,KTZ,RUTHENIUM
189,279,ALP,BACKGROUND,CONCLUSION,CRP,DTX,LABEL,METHODS,PROGNOSTIC,PSA,RESULTS
BECAUSE,THESE
18Q21,946,GLEASON,HOWEVER,MEIER,PSA,SMAD4
174,945,C17,CYP,CYP17,GIVEN,III,UNION
ATP,CHANGES,PURINERGIC,THERE
160,ADC,HOUNSFIELD,HOWEVER,INCREASING,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,RESULTS,SIXTEEN
001,002,006,030,036,ADT,FAILURE,GLEASON,LABEL,METHODS,OBJECTIVE,PRE,PSA,PURPOSE,RESULTS,SRT
039,148,AFTER,AMICO,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PURPOSE,RESULTS,TVP
001,033,132,171,174,177,251,389,472,527,820,AMICO,COX,DISEASE,FIFTY,LABEL,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,SONABLATE,STUTTGART
001,007,015,303,BACKGROUND,KRUSKAL,LABEL,LEUKOCYTE,LOW,METHODS,PSA,RESULTS,SNP,THREE
059,079,215,265,786,810,DCE,DWI,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,THERE
BLINDED,LABEL,METHODS,MRI,OBJECTIVE,RESULTS
169,COPYRIGHT,FURTHER,NDRG1
169,APS,CYS,CYS32,CYS35,CYS62,CYS69,FURTHER,GLEASON,INC,KNOWLEDGE,LYSATES,MNSOD,PCA,REDOX,RESULTS,SO3,THESE,WESTERN
001,169,734,AIM,BACKGROUND,COPYRIGHT,LABEL,METHODS,NPV,PCA,RESULTS,UROLOGISTS
100,10MIN,169,176,2D3,3A4,945,956,COPYRIGHT,CYP17A1,FORMATION,ISSUE,LTD,NADPH,PUBLISHED,SIMILAR,SPECIAL,VITAMIN
169,COPYRIGHT,SAFFRON,TAKEN,TH1,TH2
001,002,169,502,582,AFTER,BMD,BMI,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
046,104,160,169,210,972,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS
160,169,177,192,950,ADVERSE,BETWEEN,COPYRIGHT,GRADE,HDR,INC,LABEL,MATERIALS,MAY,METHODS,MRI,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,THERE,TOXICITIES
160,169,231,233,COPYRIGHT,HOWEVER,PUBLISHED,SAS,THESE
169,AFTER,BMI,COPYRIGHT,DT2,SAS
169,BRCA2,COPYRIGHT,FEDERATION,GEMMS,KNUDSON,PUBLISHED,SOCIETIES,THESE
0CC,160,169,COPYRIGHT,D90,DELIVERED,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS,SOCIETY
233,342,AFRICAN,AFTER,BACKGROUND,BMI,CAUCASIAN,FIFTEEN,GLEASON,LABEL,METHODS,NOVEL,REGRESSION,RESULTS,SNP,THESE,UGT2B,UGT2B15,UGT2B17
169,AIM,BACKGROUND,DAYTIME,LABEL,MEANWHILE,MEASURE,MEDLINE,METHODS,NERVE,OAI,OAP,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,SPARING,THESE,WEB
3CELL,APOPTOSIS,BACKGROUND,BCL,BUFALIN,CASPASE,CHINA,HOWEVER,LABEL,METHODS,PCR,RESULTS,WESTERN
169,COPYRIGHT,INC,MICRORNAS,MODULATING,THESE,VARIATIONS
005,131,140,405,AGE,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SCORE,THESE,VAS
DIFFERENT,HYPOTHESIS,LABEL,MALIGNANCY,RESULTS,SIMILAR
AMONG,FURTHER,JANUARY,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PCA,PCR,PGC,PURPOSE,RESULTS
140,152,153,445,AMONG,CONCLUSION,GLEASON,HRCAP,IRB,JANUARY,LABEL,LRP,MARCH,MATERIALS,METHODS,OBJECTIVE,PSA,PSM,RESULTS,RRP,T3A
ELISA,EN2,EXTENSIVE
CEC,CURRENTLY,GIVEN,HOWEVER,PCA,SIMILARLY,WHILE
HOWEVER,NUCLEIC,PSA
ERG,TMPRSS2
COMBINING,IDEALLY,PBX,PCA,PSA
AIM,CONCLUSION,ELISA,LABEL,METHODS,OBJECTIVE,OPN,PCA,PSA,RESULTS,RETRIEVAL,SERUM,URINARY,WHITNEY
LABEL,MATERIALS,MCMAHON,METHODS,OBJECTIVE,POISSON,PURPOSE,RESULTS,SCENARIOS,TCP,UNDER
HOWEVER,LABEL,LND,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SCORE,SYMPTOM,URINARY,URINE
AD4BP,BCAPT10,BPH,FINALLY,NOTABLY,NR5A1,SF1,THEREFORE,THESE
169,COPYRIGHT,DWI,INC,MRI,TREATMENT,WILEY
001,015,035,155,169,191,403,770,781,AFTER,ALLELIC,AREAS,AUC,BACKGROUND,IDI,INC,INTEGRATED,LABEL,METHODS,NET,NRI,PCA,PREDICTIVE,PSA,RESULTS,ROC,THREE,WILEY
AKT,DU145,LABEL,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS,SAMD4,SMAD4,VPA,WESTERN
169,FINALLY,GPR39,HOWEVER,HSY,INC,MAP,PC3,PI3,SILENCING,WILEY,ZNR
ACTA2,DU145,ERBB2,FAS,HOWEVER,IFNA1,IFNB1,IL6,IL8,ITGA1,ITGB3,LNCAP,PC3,PDGFB,TAGLN,TEK,TNF
177,BRAZILIANS,MINAS,POISSON,PSA
177,400,689,956,ADDITIONAL,AU400,AU640,BACKGROUND,BECKMAN,COULTER,DOCETAXEL,DTX,INSTITUTE,LABEL,LABORATORY,LINEARITY,METHODS,RESULTS,STANDARDS,TESTING
666,AMONG,CHA,FOCUS,HEALTHCARE,LABEL,METHODS,MODEL,OBJECTIVE,PURPOSE,RESULTS,SURVIVORS
169,246,ANTIGEN,BSA,COPYRIGHT,CTA,DISRUPTING,HOWEVER,JUN,PAGE4,PCA
AMONG,BACKGROUND,INC,LABEL,METHODS,MORTALITY,PUBLISHED,REPORTS,RESULTS,STUDIES
160,169,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
160,169,COPYRIGHT,DUE,MEDICAL,PUBLISHED,SAS
169,956,COPYRIGHT,FURTHER,MIAPACA,NCI,SAS,SIMILARLY,THESE
125,169,172,AMONG,ARTEMIS,BACKGROUND,COPYRIGHT,GLEASON,INCREASING,LABEL,MARCH,MCNEMAR,METHODS,MRI,NAV,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,TARGETS,UROLOGY
945,AKT,ATP,BACKGROUND,CONCLUSION,DISCOVERY,ERK,FAK,HOWEVER,HUVEC,LABEL,LNCAP,METHODS,MOLECULAR,RESULTS,SRC,WESTERN
152,412,BACKGROUND,ERG,GLEASON,LABEL,METHODS,MTC02,PSA,RESULTS,TMA
MASSIVE,SERUM,THESE
CONCLUSION,LABEL,MRI,OBJECTIVE
CA125,CEA,CK7,FDG,MRI,PET,PRIMALY,PSA,SERUM
ACUTE,AMICO,CONCLUSION,CTCAE,LABEL,METHODS,NCI,OBJECTIVE,PSA,RESULTS
002,294,ABC,AKT,HOWEVER,MDR,PROCESSING,THESE
DU145,FOXO1,LNCAP,THEREFORE,UTR
028,160,1772C,1790G,945,BACKGROUND,CAUCASIANS,HIF,LABEL,PRINCIPAL,RESULTS
AG490,ARTEMISIA,BCL,CHINESE,CONSISTENT,DU145,MYC,PCR,SCOPARONE,SH2,SOCS3,SRC,STAT3,TRANSIENT,WESTERN
DOC,DOCETAXEL,GIVEN,JNK,KLK,LNCAP,PAC,PSA,THERE
129P2,C57BL,ELL,FVB,OLA,PIN,POL,STROMAL,THESE
AFTER,CURRENT,EXTRACTION,FDA,HOWEVER,INTRANASAL,JANUARY,LABEL,MEDICINES,MEDLINE,METHODS,OBJECTIVE,RESULTS,SCT,SELECTION,SEPTEMBER,SOURCES,SYNTHESIS
169,176,225,245,CONCLUSION,FOLLOWING,IMAGE,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SNR,TESLA,WILEY
00001,003,159,169,211,ANOTHER,BACKGROUND,CONCLUSION,GLEASON,INC,JAPAN,LABEL,METHODS,PSA,RESULTS,THREE,WILEY
100,110,158,169,185,956,AE1,AE3
231,947,HOWEVER,IIA,MCF,MDA,PLATELETS,SUPPORTING,SYK,TCIPS
001,169,336,BACKGROUND,CALIFORNIA,COX,HOWEVER,LABEL,MEIER,MEN,METHODS,OVERALL,PSA,RESULTS,SOCIETY,THERE,THESE
CONTINUED,MURRAYA,SER
100,127,131,258,366,422,463,BACKGROUND,CONTINUOUS,CPA,EORTC,LABEL,METHODS,PRIMARY,PSA,QLQ,QOL,RESULTS,SYMPTOM,THERE
LABEL,OBJECTIVE,PCA,PURPOSE,RESULTS,ROBOTIC,SUMMARY
4MM,BASED,DIR,DMP,DVF,FEM,FOURIER,PATIENT,REGIONS,SINUSOIDAL
ACCORDING,HOWEVER,SEVERAL
169,LTD,PUBLISHED,THESE,WILEY
001,002,003,005,008,019,169,283,290,397,641,763,839,DESPITE,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PERCENT,RESULTS,T3A,T3B,UROLOGICAL
001,004,006,008,010,045,100,169,174,219,260,361,604,BETWEEN,GLEASON,GY2,JAPAN,JIKEI,LABEL,LOW,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,TOKYO,UNIVERSITY,UROLOGICAL
DES
160,FISCHER,FORTY,HOWEVER,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,WHITNEY
103,916,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,PSA,PSADT,RESULTS,ROC,TOTAL
000,001,046,100,341,410,438,BACKGROUND,CAP,CONCLUSION,DRE,FORTY,GLEASON,LABEL,LAGOS,METHODS,NIGERIA,PSA,RESULTS,THOSE
001,034,039,111,134,136,169,BIOMARKER,BIOTECH,FORTY,LABEL,LDH,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS,TOXICITIES
001,026,047,169,956,BPH,HOWEVER,PCA,PSA,THEREFORE,THESE,THROUGH,VCH,WILEY
131,AIM,DOMINANCE,EXPRESSION,GEO,LABEL,MATERIALS,MENDELIAN,METHODS,OBJECTIVE,OMNIBUS,PENNCNV,RESULTS,SNP,WHOLE
177,BACKGROUND,BETWEEN,DRE,GROUP,LABEL,LEVATORES,METHODS,OWING,PSA,RESULTS,VAS,VSA
169,183,AIM,CARDIOLOGY,CONCLUSION,GEORG,LABEL,METHODS,OBJECTIVE,RESULTS,SOCIETY,STUTTGART,WHILE
001,005,009,012,018,023,040,067,SPILLOVER,USING
ACHIEVING,AFRICAN,AMERICA,ASIAN,CURRENT,HOWEVER,IRISH,NORTH,SOCIO,SOUTH,THESE
CAMBRIDGE,THESE,UNIVERSITY
160,229,APRIL,BACKGROUND,CONCLUSION,CTC,LABEL,MARCH,METHODS,RESULTS,SIX,THREE,UNIVERSITY
038,169,CHEMOKINES,COPYRIGHT,CXCL1,FURTHER,GLEASON,HOWEVER,INCREASED,STUDIES,UTILIZING
026,100,130,956,ELISA,LARGE,LOQ,PRISM,PSA,SRM
223,945,954,FCS,HOOGSTEEN,HOWEVER,IFN,PC3,PPRHS,REGARDING,THESE,TNF,USAGE
1RA,526,592,BACKGROUND,BCA,CCL17,CCL22,COLORECTAL,CONTROL,COX,CRP,CXCL5,CXCL9,DESPITE,ENA,LABEL,LUMINEX,MDC,METHODS,MIG,ORS,OVARIAN,RESULTS,SAA,SCREENING,SERUM,TGF,TRIAL
488,AMONG,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,RPP,RRP
121,122,169,CONTINENCE,FLOOR,INC,KHQ,LABEL,MATERIALS,METHODS,OBJECTIVE,QOL,RESULTS,SCORE,SUI,SYMPTOM,THERE,VALIDATED,WILEY
169,APPROACHES,BACKGROUND,DEPENDENT,DISCUSSION,INC,INSTITUTE,LABEL,MEETING,METASTATIC,METHODS,ORGAN,PATHWAY,PERSISTENT,RESULTS,SYSTEMS,THESE,WILEY
005,029,151,169,824,BACKGROUND,CASTRATION,CONCLUSION,HOWEVER,INC,LABEL,METHODS,PCA,RESULTS,SRF,THESE,TURPS,WILEY
ALK,ETS,EVALUATION,MAPK1,RET,SRC,WHETHER
001,005,007,014,016,019,023,025,030,049,118,126,167,187,198,203,209,320,361,492,501,566,714,778,779,911,946,BACKGROUND,ILLNESS,LABEL,METHODS,PERCEPTION,QUALITY,RESULTS,SCALE,THEREFORE,TREATMENT
038,177,956,BPE,CONCLUSION,ELISA,HOWEVER,LABEL,METHODS,ONFFN,RESULTS,TCC,UNLABELLED,URINE
DES,DISEASE,DURABLE,FORTY,HOWEVER,MEIER,PATIENT,PCWG2,PSA,SIXTY,TDP,THERE
129,239,AIM,CONCLUSION,DIAGNOSTIC,LABEL,METHODS,OBJECTIVE,PRIMARY,PROSTATIC,RESULTS,TUR
169,945,A2780,BACKGROUND,BASEL,CLOFIBRATE,CONCLUSION,DU145,LABEL,METHODS,OBJECTIVE,PPRES,RESULTS
FINALLY,GPS,HOWEVER,PRIMARY,SEVERAL
110,169,664,956,ASTRO,BCF,CONCLUSION,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PCD,PHOENIX,PRIMARY,PSA,PURPOSE,RADIOLOGY,RESULTS,SECONDARY,SOCIETY,T1B
154,169,755,838,ASSESSMENT,BPI,BRIEF,CASTRATION,COPYRIGHT,FUNCTIONAL,INVENTORY,LY2181308,PFS,PSA,PUBLISHED,SECONDARY,THERAPY,UROLOGY
169,CONCLUSION,COPYRIGHT,FINLAND,INC,INCIDENCE,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PIRKANMAA,PROSTATIC,REMISSION,RESULTS,SCORE,SYMPTOM
160,169,291,AMONG,BPH,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS,SCORE,SYMPTOM
169,ADT,GROUP,MPS,PCA,SEVEN,TEG,THESE,WHILE,WHOLE
169,186,201,GLEASON,ORS,PFAAS,PFHXS,PSA
005,012,034,160,169,200,447,945,AFTER,BPH,COX,HOWEVER,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,PVR,RESULTS,SCORE,SYMPTOM,TREATMENT,WILEY
ADT,APA,DEPRESSION,DESPITE,DUE,INCLUSION,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PCA,QOL,RESULTS,REVIEWS,SYSTEMATIC

HILIC,HOWEVER,METAL,PC3,THESE
002,003,004,008,015,021,038,046,562,BACKGROUND,CONCLUSION,COX,LABEL,MEIER,METHODS,RESULTS,USING
424,503,SRC,THESE
AKT,GRP78,HOWEVER
145,176,956,AMONG,CIP,HOWEVER,HSP,HSP70,KNOCKDOWN,LNCAP,MYC,PFT,QUERCETIN,THESE
FINANCIAL,IRELAND,THESE
239,BACKGROUND,CYP11A1,CYP17A1,HSD17B6,INDUCED,INTRA,LABEL,NON,PCR,PRINCIPAL,RESULTS,SUB,TRANSCRIPT,UNTREATED
100,123,154,163,169,351,437,BASED,CONCLUSION,COU,FURTHER,LABEL,METHODS,OBJECTIVE,RESULTS,USD
169,BOARD,CONCLUSION,COPYRIGHT,DWI,INC,LABEL,LESIONS,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,T2W,TESLA,WHILE,WILEY
169,BACKGROUND,COPYRIGHT,GETTING,GROWING,LABEL,LTD,MEN,METHODS,RATIONALES,RESULTS,SLOWING,WILEY
005,19S,946,HOWEVER,KRT18,SIMILARLY,TBLR1,TRANSDUCIN
169,956,BCL,PC3,TEN,VCH,WILEY
169,949,968,ANN,AUC,AUTOMATIC,BOARD,CONCLUSION,HIPAA,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,THESE,WILEY
002,025,033,035,ADT,CA9,PDGFR
AFRICAN,CONDUCTING,LAGOS,NIGERIA,PRE,STATE,UNIVERSITY
PEG,USING,VIRAL
169,663,CASTRATION,GLEASON,INC,LNCAP,TNM,WILEY
169,945,946,ADT,BACKGROUND,CYP3A,CYP3A43,HSD17B2,INC,INHIBITION,LABEL,LNCAP,METHODS,PCR,QRT,RESULTS,THESE,UGT2B15,VDR,WILEY
BECAUSE,BTC,HCO,LUCAP,MC3T3,PAP,PCA,THESE
AMP,EXPRESSION,GRADE,IHC,NAALAD1,SPON2,USING
231,946,CONVERSELY,DU145,FURTHER,MDA,PC3,PRH
C4S,EGF,THESE
741,BCS,CRC,INVARIANCE,LABEL,METHODS,OBJECTIVE,OVERALL,PBC,PCS,PURPOSE,RESULTS,STRUCTURAL,THESE,TPB,TREATMENT
945,946,947,DDT,GAMMA,GAS,GST,GSTM1,GSTT1,HCH,OCP,PCR,THESE,UBC,URINARY
007,172,249,BACKGROUND,LABEL,METHODS,MEXICAN,OBJECTIVE,PCA,RATIO,RESULTS
001,098,111,160,177,314,467,787,AUC,BACKGROUND,IGM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OTHER,PCA,PSA,RESULTS
176,748,CURRENT,ICP
001,101,127,158,280,381,404,609,661,938,967,CHOLINE,PET,PSA,SEPTEMBER,THESE
945,CA2,DHT,DU145,FIRST,HOWEVER,LNCAP,ORAI1,ORAI3,PSA,THIRD,THREE
946,947,FABP4,INCIDENCE
APART,INDICATOR
169,ADP,AKT,COPYRIGHT,EGF,FOXO1,INC,PARP1,PC3
000,001,094,100,169,182,215,ASIRS,BACKGROUND,CIR,CONCLUSION,COPYRIGHT,FURTHER,IRR,JANUARY,JIZAN,LABEL,METHODS,PACKAGE,POISSON,PUBLISHED,RESULTS,SAUDI,SCR,SPECIALIST,THERE,YEARS
169,COPYRIGHT,FURTHER,INC,WHILE
169,COPYRIGHT,HIV,HOWEVER,RETINOIDS,THERE
169,COPYRIGHT,INC,THEREFORE,THESE
169,ARTEMIS,COPYRIGHT,CURRENTLY,EIGEN,GEOSCAN,HITACHI,INC,MRI,PHILIPS,RVS,UROSTATION
169,COPYRIGHT,ETS,INC,LABEL,LESIONS,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE
169,AFTER,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PCWG2,PSA,RESULTS,STEIN,VALIDATION,WHITNEY
169,BACKGROUND,BPH,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,PIN,REGARDING,RESULTS,SEVERAL,SIX,THEREFORE
169,401,COPYRIGHT,FURTHER,INC,INCIDENCE,INSURANCE,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SCI
103,169,300,COPYRIGHT,DOSES,EDS,EFFECTIVE,EQUIVALENT,FIFTY,HTS,LABEL,LTD,MBQ,METHODS,OBJECTIVE,PET,PUBLISHED,PURPOSE,RESULTS,ROI
169,919,BACKGROUND,CONCLUSION,COPYRIGHT,ENDPOINTS,GLEASON,GRADE,INC,LABEL,METHODS,PSA,RESULTS,SERIOUS
160,169,207,895,AMONG,CONCLUSION,COPYRIGHT,COX,INC,LABEL,MEIER,METHODS,NORWEGIAN,OBJECTIVE,RESULTS
169,COPYRIGHT,HOWEVER,IMAGE,INC
169,176,APPLIED,AUTHORS,BJU,ICE,LABEL,MARGARITA,MEDICAL,METHODS,OBJECTIVE,RESULTS,SANTA,USA
509,572,601,603,622,647,AUC,BACKGROUND,CONSORTIUM,ECE,HOWEVER,IRISH,LABEL,METHODS,PREDICTION,RESULTS,T1C,T2A,THERE
001,BACKGROUND,CONCLUSION,CPG,FDR,LABEL,METHODS,MICROARRAY,POL,RCC,RESULTS,SAMPLES
169,212,BASED,BIOLOGY,HYBRIDOMAS,ICC,IHC,INC,MOLECULAR,PLAC1,REACTIVITY,UNION,WESTERN
AGE,AIM,CONCLUSION,DIVERSE,HEALTHCARE,HTE,INCLUSION,LABEL,MEDLINE,METHODS,OBJECTIVE,QUALITY,RESULTS,ULTIMATELY
GIVEN,HOWEVER
BACKGROUND,CONCLUSION,LABEL,METHODS,RADIATION,RESULTS,SURGERY,USA,WHILE
USA
ACHIEVA,HEALTHCARE,HOWEVER,MRI,PHILIPS,SINCE
AFTER,BIC,CPA,LNCAP,PCA,PHOSPHATE,PSA,THESE,WESTERN
945,FURTHER,KNOCK,ZNF

956,BACKGROUND,CONCLUSION,HISTOLOGIC,LABEL,METHODS,MTT,NLC,RESULTS,TUNEL
RFS,VOI
177,980,CY3,LNCAP,MOUSE,NAYF4,NIR
200,PORTUGUESE,PSA,THERE
176,CHINESE,CRITERION,RELATIVELY,SEVERAL,THESE
DEPARTMENT,HSP
100,169,BOOST,COPYRIGHT,FREEDOM,GROUP,HDR,LDR,LTD,RADIATION,STUDIES,THERAPY,WHILE
LABEL,OBJECTIVE,ONGOING,PURPOSE,RESULTS,SUMMARY
169,BAX,BID,COPYRIGHT,DR5,HOWEVER,INC,KEY,LABEL,METHODS,OBJECTIVE,RESULTS,TAKEN,TRAIL
101,198,1ST,BACKGROUND,COLORECTAL,HEALTHY,LABEL,LTD,MATERIALS,METHODS,OVARIAN,PCR,PUBLISHED,RESULTS,RTEL1,RTL,SCREENING,THERE,THEREFORE,TRIAL
115,165,169,215,AES,BACKGROUND,CONCLUSION,COPYRIGHT,EARLY,GRADE,HDR,HOWEVER,IRELAND,LABEL,LTD,METHODS,RESULTS,SCORE,SYMPTOM
10877,10878,169,AUC,BACKGROUND,COPYRIGHT,GLEASON,GUROC,INDEX,IRELAND,LABEL,LTD,METHODS,NET,PROCARS,PSA,RADIATION,RECURSIVE,RESULTS,RPA,T1T2A,T2B
001,100,139,145,167,169,177,BACKGROUND,COPYRIGHT,D90,IRELAND,LABEL,LTD,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SEVENTY,THERE,VCF,VOLUMETRIC
159,232,ACCOUNTING,BACKGROUND,CONCLUSION,EQUALLY,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QUANTEC,RESULTS,SIX
169,COPYRIGHT,INC,PIRH2
PRIMARY,RCC
GRADE,IHC,III,NOTABLY,RMP,THERE,TMA,URI
117,132,145,AMONG,BACKGROUND,HOWEVER,JNK,LABEL,METHODS,PATHWAY,PCA,RESULTS,SIGNALING,THESE,WESTERN
008,043,068,118,129,146,174,336,490,574,579,585,594,601,947,BACKGROUND,END,LABEL,MARKETS,METHODS,OBJECTIVE,RESULTS
001,274,630,GUIDELINES
003,034,GLEASON,HOWEVER,PATHOLOGY,RPS,SOCIETY,UROLOGICAL
ALK,ANTIBODIES,ERG,ETS,HMG,LANGERHANS,SALL4,SCHWANN,SOX10,SOX11,SRY,TREPENOMA
169,954,AKT,BRADYKININ,COPYRIGHT,INC,TAKEN
821,BACKGROUND,COMMONS,CURRENT,CURRENTLY,LABEL,LICENSE,RESULTS
ADP,BRCA1,MUT,PARPI,SEVERAL
III,KEY,PHASE,THERE
000,104,132,283,536,ACCOUNTING,SIPULEUCEL,THRESHOLD
096,100,105,169,AUTHORS,BELGIUM,BJU,LABEL,LESIONS,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,PEARSON,PHS,RESULTS,THESE,TTB

024,034,037,169,ARG462GLN,ASP541GLU,AUTHORS,CHILEAN,FOUNDATION,JOURNAL,LTD,MINITAB,MOLECULAR,PCA,PCR,PSA,REGARDING,THERE,WILEY
HEM,HOWEVER,NUCLEAR,PC3,PC3HO,PCA,THESE,USING
001,002,104,GLEASON,LABEL,MAJOR,METHODS,OBJECTIVE,OVERALL,PURPOSE,RADIATION,RESPONDENT,RESULTS,SINCE,THERE,UROLOGISTS
CHINESE,CONSORTIUM,DEALING,ERBB2,ERK,GENEVAR,HOWEVER,PCA,PROJECT,RTK
001,174,430,530,786,947,975,AUC,BACKGROUND,CD3,IFN,LABEL,METHODS,NATURAL,NKA,PBMCS,PCA,PROMOCA,REDUCTION,RESULTS,THESE
ABELSON,ABL,CPG,EXPRESSION,FURTHER,HOWEVER,LOW
946,BACKGROUND,CATHEPSIN,LABEL,MYCOPLASMA,NLRP3,PRINCIPAL,RESULTS,ROS
100,178,192,ADT,AFTER,GRADE,GROUP,HDR,NETWORK,RADIATION,THERAPY,VHR
001,002,003,006,206,AIM,CONCLUSION,GLEASON,LABEL,METHODS,NDRG2,NDRG3,OBJECTIVE,PCA,RESULTS,RFS
22RV1,BACKGROUND,CONCLUSION,HSPB1,LABEL,MATERIALS,METHODS,NOTABLY,PCA,RESULTS,SHORTENED
218,580,AIM,C521A,CONCLUSION,G14713A,G21985A,G32124A,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,RESULTS,T28608A,T29107A,TAIWANESE,UPPER,WESTERN
945,CERTAIN,FDA,RESULTS,THESE
016,246,817,BACKGROUND,FURTHER,LABEL,METABOLITE,METHODS,ORS,RESULTS,SWEDISH,WHOLE
1INTEGRIN,945,946,AFTER,BACKGROUND,CD133,CFE,FINALLY,LABEL,METHODS,PRIMARY,RESULTS,SCS
224,253,GLEASON,THESE
100,CSR,GGP,GLEASON,IMAGING,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,REPORTING,RESULTS
945,946,CD151,CLUSTERING,HOWEVER,PKC
DUTCH,HODGKIN,THESE
BACKGROUND,BECAUSE,LABEL,LOW,PEGYLATED,PEGYLATION,RESULTS
AMONG,BESIDES,DIETARY,SINCE,SOUTH,VARIOUS
FUKUI,HOWEVER,JAPAN,LABEL,METHODS,OBJECTIVE,RESULTS,SEVEN,THREE
AAV,ADDITIONAL,CBA,CD11C,DCS,DENDRITIC,LNCAP,MODCS,S663V,T492V,TAKEN
169,BACKGROUND,BASEL,CLUSTERIN,CONCLUSION,LABEL,METHODS,PCR,RESULTS,SIMILAR,WESTERN
169,BASEL,COPYRIGHT,WHILE
FDG,MALIGNANT,PET,SERUM
DIFFUSE,HDP,MYOCARDIAL
154,212,635,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,PCA,PSA,RESULTS,SETTING,THEIR,THESE
ACCORDING,DESPITE,DOCETAXEL,PATIENT,UNTIL
169,172,945,BASEL,C30,EORTC,KNOWN,LABEL,METHODS,MULTITRAIT,OBJECTIVE,QLQ,QOL,RESULTS,TREATMENT
169,COPYRIGHT,LTD,PEGYLATED,THESE
169,COPYRIGHT,CROWN,OCTOBER,PUBLISHED
169,302,ACTIVATION,COPYRIGHT,HENCE,PUBLISHED,RB1,UROLOGY
169,AMERICA,AUTHORS,BJU,CONSENSUS,LABEL,METHODS,MRI,NORTH,OBJECTIVE,RESULTS,STATE,STRUCTURED,UROLOGICAL
COMPARISON,NPS
ANY,BACKGROUND,COMPARISON,FEW,INCREASED,INSULIN,LABEL,LIBRARY,METHODS,NON,OBJECTIVE,OUTCOME,PICOS,POPULATION,RESULTS,SCIENCE,SOURCES,SYSTEMATIC,USERS,WEB
169,945,954,AUTHORS,BJU,CD4,EXPANSION,IKK,PCA
BURNS,EDUCATING,MCDONNELL,PREVENTION,PROGRAM,UNIVERSITY,UROLOGY
ACTIVITIES,ADVOCATES,AUDIO,BECAUSE,FINALLY,GIVEN,INCLUDING,INSTITUTE,LABEL,METHODS,OBJECTIVE,PURPOSE,RELATED,RESULTS,SURVIVORS
499,BACKGROUND,CLINICIANS,CONCLUSION,CONTEXT,EVALUATING,INDEX,LABEL,LINKING,METHODS,OBJECTIVE,OUTCOME,PERSISTENT,PSA,RESULTS,SETTING,SURVIVORS,YET
169,ADT,AFTER,BMD,COLLEGE,DENOSUMAB,INCREASES,PMO,THEREFORE
CAR,HOWEVER

HOWEVER,PC3,THESE
231,297,945,946,ARG,ASN,ASP,GLY,MAGNEVIST,MDA,MRI,NGR,RGD
223RA,945,MEDICAL,PARTICLES
169,BACKGROUND,BECAUSE,CHEMISTRY,CONTENT,LABEL,LARGE,SEVERAL,SUMMARY
169,COPYRIGHT,INC,PARAMETERS
169,231,945,946,COPYRIGHT,DISRUPTION,EAJ,INC,INDUCTION,KEY,LABEL,MDA,METHODS,NAC,OBJECTIVE,PMA,PREVIOUSLY,RESULTS,ROS,SEVERAL,TEM,TREATMENT
169,AFTER,COLO205,COPYRIGHT,EXPRESSION,PC3
169,916,956,COPYRIGHT,IRELAND,LNCAP,LTD,MOLECULAR,PC3
169,215,CMC,COPYRIGHT,INC,LTD,MATERIALIA,PUBLISHED,QDS
169,ANALYTICAL,BIOMARKER,COPYRIGHT,DIGITAL,EDUCATION,ERG,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,STUDENT,TMPRSS2,URINARY,URINE,UROLOGICAL
169,CVS,DLS,EDX,ELISA,HRTEM,INTRA,LOD,PEI,PSA,PUBLISHED,SEM,SPR,THEREAFTER,UNDER
145,169,23120,23206,23244,23704,23926,BIM,COPYRIGHT,IRELAND,LNCAP,LTD,PCA,SST,THESE
169,201,231,COPYRIGHT,DCE,DWI,HOWEVER,MRI,PUBLISHED,SAS
100,169,183,186,760,762,914,956,APRIL,BACKGROUND,BETWEEN,BRISTOL,COPYRIGHT,DASATINIB,EASTERN,FUNDING,GROUP,IQR,LABEL,LTD,METHODS,MYERS,OCT,RESULTS,SRC
169,BACKGROUND,BYM,CLASSIC,CONCLUSION,COPYRIGHT,DIC,ISERE,LABEL,MAPPING,METHODS,MORAN,POISSON,RESULTS,SAS
001,169,500,ACUTE,AUR,BRITISH,COPYRIGHT,CROWN,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RADIATION,RESULTS,THERAPY
169,177,288,947,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,TRANSIT
071,169,BACKGROUND,CONTEXT,COPYRIGHT,INCLUDING,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,PATIENT,PCA,PRO,PUBLISHED,QUALITY,RESULTS,SIXTY,SOCIETY,STUDIES,SUMMARY,SYNTHESIS
002,169,239,642,ACTIVITIES,ADT,AMONG,BACKGROUND,COPYRIGHT,DICTIONARY,EASTERN,EVENT,GROUP,LABEL,MEDICAL,MEIER,MEN,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,REGULATORY,RESULTS,SETTING,SINCE,TREATMENT
001,100MG,169,CONCLUSION,COPYRIGHT,INC,LABEL,MET,METHODS,OBJECTIVE,PFS,PRIMARY,PURPOSE,RESULTS,SERUM,SEVENTY,THOSE,XL184
001,003,169,765,770,BACKGROUND,CASTRATION,COPYRIGHT,INC,LABEL,MEN,METHODS,PSA,REPLACING,RESULTS,THERE
001,169,5MG,BACKGROUND,COPYRIGHT,GRADE,INC,LABEL,METHODS,RESULTS
169,192,193,ADT,AFTER,BACKGROUND,BELGIUM,BETWEEN,COPYRIGHT,DEC,DOCETAXEL,EARLY,GLASS,INC,IQR,KARNOFSKY,LABEL,METHODS,OCT,RESULTS
169,ATM,CEC,COPYRIGHT,DPS,FURTHER,GADD45A,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SHORTLY
001,003,016,207,993,AMICO,ANTIGEN,BACKGROUND,CSS,GLEASON,JANUARY,LABEL,MARCH,METHODS,MOC,OVERALL,PCA,PSA,RESULTS,THERE,TREATMENT
169,ADT,BACKGROUND,CONTEXT,COPYRIGHT,CURRENT,DIAGNOSIS,EAU,KNOWLEDGE,LABEL,METHODS,NERVE,OBJECTIVE,PATIENT,PCA,PSA,PUBLISHED,RADIATION,RADICAL,RESULTS,SCREENING,SUMMARY,SYNTHESIS,SYSTEMATIC,THESE,TREATMENT,UROLOGY
000,001,048,144,169,220,239,291,377,BACKGROUND,COPYRIGHT,FOCAL,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,UROLOGY
160,228,252,ADAPTATION,BACKGROUND,BASED,BEV,BOOST,CONCLUSION,CTV,EYE,IMITATION,INTEGRATED,LABEL,METHODS,MLC,MONITOR,PTV,RESULTS,UKW,UNITS,UNIVERSIT
001,129,169,AIM,BACKGROUND,CONCLUSION,COPYRIGHT,DESPITE,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PRODUCTION,RESULTS,THERE
001,113,158,169,928,AEU,CONCLUSION,COPYRIGHT,ERG,FDR,FORTY,HOXC6,LABEL,MAY,METHODS,OBJECTIVE,PCA,PCR,PPM,PUBLISHED,RESULTS,TEN,TMPRSS2
157,160,191,348,ADELPHI,BACKGROUND,DISEASE,DSP,GERMANY,ITALY,LABEL,MAY,METHODS,OVERALL,PROGRAMME,RESULTS,SPAIN,WHILE,WORLD
AREAS,BACKGROUND,COVERED,DUE,LABEL,METHODS,OPINION,WHILE
169,AUTHORS,BJU,MELBOURNE,VARIOUS,WORLD
LUCAP,MET,PCA,USING
110,208,BACKGROUND,CURRENT,FFL,FURTHER,LABEL,PRINCIPAL,RESULTS,STAT3,TFS,THEREFORE
PCR,PRIMERS,SPLICED,THERE,THESE
177,947,ADP,COMET,DU145,ERG,ETS,EWING,NEUTRAL,PARP1,PC3,SEM,THEREFORE,THESE,USING
BAD,BCL,BT549,LNCAP,MCL,PC3,PE38QQR,RESULTS,THESE,ZSTK474
518,BACKGROUND,CONSISTENT,ECONOMISTS,EMPIRICAL,HBM,INSURANCE,LABEL,MEDICAL,METHODS,MODEL,PANEL,PREVENTIVE,RESULTS,SURVEYS
169,SUCCESSFUL,THESE
014,028,134,967,GLEASON,PEARSON,PSA
223,MET
001,CAD,CHOLINE,CONCLUSION,KIMOD,LABEL,MATERIALS,METHODS,NAD,OBJECTIVE,OBJECTIVES,PEARSON,PET,PSA,RESULTS,SUV60,TEN,THERE,TMR60
AFTER
888,EPS,LNCAP,MICRORNAS,PC3,SMAD4,THESE
BOWEL,DCR,NON,OAR,RESULTS,V50,V60
100,RESULTS
169,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,RESULTS,SINCE,TREATMENT
HOWEVER,KDM4B,KDM5A,KDM6A,KMT2A,PCA,PRMT6,REMARKABLY,SMYD3,SUV39H2
001,002,004,031,081,094,155,169,173,177,178,208,245,459,779,800,803,850,906,936,ADC,AUR,BPH,CONCLUSION,COPYRIGHT,FORTY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PEARSON,PUBLISHED,RATIONALE,RESULTS
051,169,613,892,994,A1C,BMI,CHD,CLEVELAND,COMPARISON,COX,GFR,HDL,LABEL,LDL,LTD,METHODS,OBJECTIVE,RESULTS,WILEY
ALONG,FE3O4,HEK,HOWEVER,NPS,PARTICULAR,ROS
ARG,ASN,CYS,FINALLY,GLY,ILE,LEU,PHE
160,169,200,215,BACKGROUND,CALIPER,COPYRIGHT,DU145,GFP,HOWEVER,INC,LABEL,METHODS,MIXED,OBJECTIVE,PC3,PUBLISHED,RESULTS,SOCIETY,TAKEN,THERAPY
493,941,CIS,HOWEVER,ORS,PCA,STATA
INCREASING,MYC,NOTABLY,TAKEN,USP22
BACKGROUND,FDG,IMAGING,LABEL,METASTATIC,PCA,PET,PSA,RESULTS,ROUTINE
FOLLOWING,FRIENDS,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
128,445,IMAGING,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PCA,RADIOLOGY,REPORTING,RESULTS,ROC,SOCIETY,SUSPICIOUS,UROGENITAL,WHITNEY
109,150,ACUTE,CONCLUSION,CONFORMAL,CTCAE,FAVORABLE,INTENSITY,LABEL,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RESULTS,SIB,SINCE,TREATMENT
264,BACKGROUND,COMPOSITE,HRQOL,INDEX,LABEL,MEDICAL,METHODS,PCA,RESULTS,URINARY
100,141,200
945,FDA,HOWEVER,PEG,TNF,TRAIL
001,007,011,028,046,946,BESIDES,CAP,ERG,GLEASON,THERE,TMPRSS2,TOP2B
100,BASED,GROUP,HDR,LDR
ERSPC,FORCE,PREVENTIVE,PSA,RESULTS,SCIENTIFIC,SCREENING
157,160,177,BIOBANK,GLEASON,HOSPITALS,INTEGRITY,PROCURE,PSA,RIN,T3A,T3B,THESE,UNIVERSITY
AZT,GJICS,PANNEXIN1,PANX1,TAKEN
AKT,DOCETAXEL,DU145,FAK,HOWEVER,PC3,THESE,TKI,TREATMENT,USING
CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,VALUE,VOI
110,945,946,EXPRESSION,PCR
141,200,424,DU145,ECTOPIC,EMT,EPCAM,LN1,LN4,MET,USING
003,004,177,601,617,623,961,FDG,GLEASON,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PET,RESULTS,TESTS,THESE
AIR,EASTERN,GOF,GWR,HOWEVER,NO2,OVERALL,SAUDI,THESE
011,248,931,AMONG,SWEDISH,USING
009,520,540,BACKGROUND,COX,END,HEREDITARY,HHT,LABEL,MEIER,METHODS,RESULTS,THERE
19A,205,220,221,222,23B,BACKGROUND,CHINESE,LABEL,PCR,RESULTS
954,AP1,GSE,ISOLATING,PCA,STAT3
BMCHF,HOLOPTELEA,PLANT,THESE
223,945,BAYER,BC1,FDA,HEALTHCARE,INC,MAY,SSE
169,INC,WILEY,WNT
146,ASTRO,CNS,FIRST,MEDLINE,QOL,THERE
CTC,EARLY,FDA,GIVEN,HOWEVER,MEETING,NOVEL
571,945,ABL,ANNEXIN,CELLS,DEVDASE,EARLY,EGR,LNCAP,MTT,STI,TNF
005,006,181,194,239,247,COX,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TUR,VARIATIONS
109,110,705,BMI,CONCLUSION,CONCORD,LABEL,MEN,METHODS,OBJECTIVE,PROJECT,PSA,PURPOSE,RESULTS,THERE
002,372,539,603,995,BIENNIALLY,CONCLUSION,DIAGNOSIS,LABEL,METHODS,OBJECTIVE,PCA,PHS,PHYSICIANS,PURPOSE,RESULTS,STEROID,THESE
499,772,791,APRIL,CIS,CONCLUSION,COX,HOWEVER,HRS,KINGDOM,LABEL,METHODS,OBJECTIVE,OCTOBER,OVERALL,PURPOSE,RESULTS,THESE
001,753,AMONG,BACKGROUND,CURRENT,GLEASON,HOPKINS,JOHNS,LABEL,MEN,METHODS,NETWORK,PCA,PSA,RESULTS,THESE,VHR
024,CANCER1,COMPLETED,ENOBOSARM,GTX,III,LABEL,LGD,MAY,OBJECTIVE,PHASE,PREVENTION,PURPOSE,RESULTS,SARMS,SUMMARY,WASTING
005,946,947,948,BPH,GLEASON,PPARS,STUDENT,WHILE
AFTER,BACKGROUND,CLINICIANS,CONCLUSION,DESPITE,E2Z02,EASTERN,GROUP,LABEL,METHODS,QOL,RESULTS,SOAPP,SYMPTOM,THESE,UNIVARIATE
169,916,946,AKR1C,ALTERED,C17,C20,COPYRIGHT,GABAA,INC,MUTATIONS,NADPH,THESE
136,500,945,ADT,IRONICALLY,PSA
LARGE,OTHER,PREVENTION,REDUCTION,THEIR,TRIAL,VITAMIN
169,COPYRIGHT,INC,NOVEL,OPTIMIZING
169,223,945,COPYRIGHT,CROWN,CYP,INC,MEN,PUBLISHED,STRATEGIES,THESE
169,COPYRIGHT,DESPITE,INC,TARGETING
169,COPYRIGHT,INC
INC,PUBLISHED
169,COPYRIGHT,IMAGING,INC
169,COPYRIGHT,CROWN,HOWEVER,INC,PUBLISHED,THESE
169,COPYRIGHT,INC,SURGERY
169,COPYRIGHT,INC,PSA
615,BACKGROUND,EAU,HOWEVER,LABEL,LNI,LNS,MATERIALS,METHODS,RESULTS,SIMILARLY,UROLOGY
160,APRIL,CONCLUSION,CONTINENCE,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,RRP,WHITE
946,ALZHEIMER,CROHN,EXCESSIVE,HOWEVER,III,NSCLC,ORGAN,TGF,THERE
945,AMP,ATP,PGC,TAKEN,USING
10877,22RV1,947,AZ12253801,DSB,DU145,FINALLY,IGF,INHIBITION,IRRADIATED,LN3,LNCAP,MUTATED,PC3,THESE
EMT,ERG,ETS,PCA,SEQ,THEREFORE,THROUGH,TMPRSS2
ERCC1,PCK3145,PROSTATIC,PSP94
169,264,BMP,DTR,INC,LNCAP,METHODS,PREVIOUSLY,RAW,RESULTS,SMAD1,THP,TRAMP,WILEY
ALANINE,EXTENSIVE,PROTEIN,PTD,TAKEN,THESE
10P14,160,29E,360,458,474,543F8,66E,95E,AFRICAN,AGE,ASIAN,CONSORTIUM,FURTHER,GATA3,GHANA,GLEASON,HUMANOMNI,SNP
AFRICAN,AMERICANS,PHASE,WHILE
000NM,12MIN,169,ACCAD,ACPUT,ACSPD,ACSPM,C18,CAD,COPYRIGHT,DAP,DEUTERIUM,DIACCAD,DIACPUT,DIACSPD,DIACSPM,DILUTED,ESI,HOWEVER,IONIZATION,POLYAMINES,SPD,SPM
100,169,946,ALA,BBN,CHA,COPYRIGHT,DMPTACN,EXPLOITING,GLU,NLE,PET,SAS,SMALL
169,ATG4B,COPYRIGHT,DEVELOPING,HOWEVER,INC
068,169,174,AMONG,ASSESSMENT,CAPRA,CAPSURE,COPYRIGHT,EDUCATION,EMOTIONAL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QUALITY,RESULTS,STRATEGIC,SUBSCALES,TREATMENT,UROLOGICAL,WHILE
169,300,688,800,AGE,CONDITIONS,COPYRIGHT,EDUCATION,HOWEVER,INC,KRIMPEN,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,COPYRIGHT,LTD
169,COPYRIGHT,HOWEVER,LTD,MRI,NON,THESE
169,182,780,945,946,ADIOL,BECAUSE,COPYRIGHT,DU145,ICI,LTD,NOTABLY,PC3,PCS,THESE
147,169,4MM,750,BCR,COPYRIGHT,FINALLY,GLEASON,INC,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRIAS,RESULTS,T1C
169,COMPLEX,COPYRIGHT,H3K27,LTD,REPRESSIVE,THESE,ZESTE
007,104,125,169,663,9MONTHS,ASTRO,BETWEEN,CONCLUSION,COPYRIGHT,COX,CSS,D90,EARLY,GLEASON,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RADIOLOGY,RESULTS,SOCIETY,THERE
169,3MM,4MM,5MM,BACKGROUND,COPYRIGHT,CTS,CTV,D99,DVH,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,TREATMENT
012,169,240,242,245,267,295,577,773,904,AUSTRALIA,BACKGROUND,COPYRIGHT,HODGKIN,LABEL,LTD,METHODS,OTHER,RESULTS,THERE
169,CONCLUSION,CONVERSELY,ESI,GALLIUM,LABEL,METHODS,RESULTS,UHPLC,UNLABELLED
036,114,169,185,BPH,COPYRIGHT,GLEASON,GRADE,HGPIN,IRANIAN,NEOPLASIAS,PCA,PROSTATIC
001,002,003,013,055,169,229,BCR,BETWEEN,CALIFORNIA,COPYRIGHT,COX,GLEASON,INC,LABEL,LOG,MATERIALS,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGIC,PSA,PUBLISHED,RESULTS,UNIVERSITY
169,223,AIM,CONCLUSION,COPYRIGHT,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,RESULTS,SAS,UROLOGIST
169,AIM,CONCLUSION,COPYRIGHT,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,RESULTS,SAS
169,3PUFA,969,CVD,DHA,EPA,GIVEN,LTD,PUBLISHED,WHILE
169,176,360,COPYRIGHT,FFF,IRELAND,LABEL,LTD,MATERIALS,METHODS,MUS,OAR,OBJECTIVE,PURPOSE,RESULTS
169,BACKGROUND,BLOOD,CONCLUSION,COPYRIGHT,GSI,HEAVY,HEIDELBERG,HELMHOLTZ,ION,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,UNIVERSITY
144,162,169,243,270,945,946,BED,COPYRIGHT,FURTHER,GRADE,HDR,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THREE
169,COPYRIGHT,DISCUSSION,DOPPLER,INC
169,COPYRIGHT,INC,UROLOGISTS
169,CAREFUL,COPYRIGHT,GRAYSCALE,INC
153,186,188,223,PHOSPHORUS,RHENIUM,STRONTIUM
DESPITE,DIETARY,EVALUATION,HISTORY,INSTITUTE,NCI,PROGRAM,SERUM,THERAPY
169,3RD,AUTHORS,BJU,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,THREE
169,AUTHORS,BJU,CONCLUSION,FEW,LABEL,METHODS,MTX,OBJECTIVE,PALLIATIVE,RESULTS
169,AUTHORS,BJU,CONSENSUS,DISCUSSION,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS
100,160,216,239,ACCURAY,ADT,AVERAGE,BACKGROUND,BETWEEN,COMPOSITE,CYBERKNIFE,GEORGETOWN,GIVEN,HOWEVER,INDEX,INVENTORY,LABEL,MARCH,MEDICATION,MEN,METHODS,OVERALL,POTENCY,PRIOR,PSA,RESULTS,UNIVERSITY
945,BACKGROUND,CONCLUSION,ESL,FOLLOWING,FT3,FT6,FT7,FTS,INHIBITION,LABEL,METHODS,PCA,RESULTS
001,044,459,5A2,AKT,BACKGROUND,CONCLUSION,COX,CUTANEOUS,EUKARYOTIC,FURTHER,LABEL,METHODS,MMP,PCR,PMS,RESULTS,STRIKINGLY
339,585,664,768,786,HOWEVER,HYBRITECH,IPP,IRPPS,OCTOBER,PCA,PSA,ROC,TPV,TZV,USING
114,15D,C30,DEPARTMENT,EORTC,FATIGUE,HRQOL,LABEL,METHODS,OBJECTIVE,PURPOSE,QLQ,RESULTS,UNIVERSITY,UTILITY,VAS
COMMUNITY,END,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SES
001,160,ALA,ANOVA,COLON,FATTY,GLA,LABEL,METHODS,OBJECTIVE,PUFAS,PURPOSE,RESULTS,SDA,SNK,THESE
002,003,015,023,034,042,140,168,169,240,262,269,404,421,424,453,464,576,596,684,750,762,768,769,820,829,834,835,837,843,852,855,863,874,898,904,908,912,915,916,955,958,994,ACCORDING,CAUCASIANS,CHINESE,CONSORTIUM,COPYRIGHT,CROWN,ERK,HOWEVER,PCA,RTK,SNP
169,1990S,COMBINING,ERG,HOWEVER,PCA,PSA,SINCE,TMPRSS2
169,CSC,HOWEVER,STAT3
169,945,946,956,CD133,COA,COPYRIGHT,FAK,FURTHER,H1152,HMG,INC,MYPT1,RHO,ROCK1,THESE,WESTERN
169,AFFAIRS,BACKGROUND,CD4,CONCLUSION,COPYRIGHT,DEPARTMENT,HIV,INC,LABEL,MATERIALS,MEIER,METHODS,RESULTS,THERE
169,ASIAN,BANGKOK,COPYRIGHT,LTD,PACIFIC
169,BULKING,COPYRIGHT,SAS
169,174,BLADDER,CIS,COPYRIGHT,DUE,MUSCULARIS,NMIBC,PROPRIA,SAS,TURBT
136,AUSTRALIA,AUSTRALIAN,DRE,GENERAL,GPS,PCA
0MG,5MG,BACKGROUND,CAT,CYTOTOXIC,DU145,GPX,GSR,LABEL,MATERIALS,MDA,METHODS,MTT,PC3,PCR,PROTEIN,RESULTS,SOD,TBARS
275,506,588,EXPRESSION,GSE3824,ITGA2,ITGAV,ITGB1,ITGB3,ITGB6,LABEL,LIMMA,MATERIALS,METHODS,MIR,OBJECTIVE,OMNIBUS,PURPOSE,RESULTS,SP1
17000,177,358,478,99M,BACKGROUND,CIPTO,GLEASON,LABEL,MATERIALS,METHODS,PSA,RESULTS,THERE
ENGLISH
197
122,CONCLUSION,CRP,FSH,GLU,GROUP,HCY,HDL,III,LABEL,LDL,METHODS,OBJECTIVE,PRL,RESULTS,SEX,THERE
001,BACKGROUND,DEPLETION,HOWEVER,LABEL,METHODS,RESULTS,SMYD3,SP1,STUDENT,WESTERN,WHITNEY
003,175,397,CONTROL,JAPAN,LABEL,METHODS,OBJECTIVE,RESULTS,SEVENTEEN,SEVENTY,SMALL,THERE
ROC
169,1ST,2ND,947,BACKGROUND,CAR,IFN,IGCD28TCR,IGTCR,IL2,INC,LABEL,METHODS,RESULTS,WILEY
169,184,557,619,BACKGROUND,GLEASON,INC,LABEL,LNCAP,METHODS,REMARKABLY,RESULTS,SRC,WILEY
ADT,PCA,WHILE
145,CD151,LNCAP,LVD,MVD,THESE
240,AFRICAN,AGE,AMERICANS,CONTINUED,PATIENT,THERE
375,AZA,DNMTS,PCA,TAKEN
205,HRPCA,OVERALL,PCA,THESE
110,149,166,177,188,228,239,476,987,CHO,CIT,CONCLUSION,LABEL,LCMODEL,METABOLITE,METHODS,MRS,OBJECTIVE,PURPOSE,RELAXATION,RESULTS,SPECTRA
ADC,COMBINING,CONCLUSION,DCE,DWI,LABEL,MATERIALS,METHODS,OBJECTIVE,PPV,PURPOSE,RESULTS,SIXTY,T1W,T2W
AFTER,APRIL,AUXILIARY
CURRENT,LARGE
100,160,APRIL,BACKGROUND,LABEL,METHODS,OCTOBER,PCA,PSA,RESULTS,SEQUENTIAL
160,AFTER,ANOTHER,DEFORMABLE,DIR,FURTHER,HOWEVER,JAC,ORGAN,REDUNDANT,SEMINAL,THREE
001,002,BACKGROUND,DNASE,GENOMIC,HOWEVER,LABEL,METHODS,PARKINSON,RESULTS,THERE
125,185,252,945,AFP,AUC,CEA,HCG,INCREASED,NSE,PSAFREE,ROC
PSA
100,418,757,AMONG,CALIFORNIA,COX,LABEL,METHODS,NPH,OBJECTIVE,PERMANENTE,RESULTS
150,ANXIETY,ASSESSMENT,BRIEF,BSI,CHRONIC,CTCAEV4,FACIT,FATIGUE,FORTY,FUNCTIONAL,ILLNESS,INDEX,INVENTORY,LABEL,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RESULTS,STRETCHING,SURVIVORS,SYMPTOM,THERAPY
003,040,048,112,169,946,ADT,BLOOD,BMD,FITNESS,LABEL,MEN,MET,METHODS,NURSE,OBJECTIVE,PURPOSE,REGRESSION,SOURCES
129,149,299,575,931,AFTER,AMONG,GLEASON,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RCP,RESULTS
169,BACKGROUND,COPYRIGHT,EARLY,FEM,LABEL,LTD,MATERIALS,METHODS,PPV,RESULTS,THESE,WILEY
001,125,382,665,BACKGROUND,BETWEEN,LABEL,METHODS,MOUNT,MSEFS,PATIENT,POTENCY,RESULTS,SCORE,SINAI,UNIVARIATE
169,CCP,ELISA,FURTHER,IGF,PCR,SERUM,WESTERN
001,160,D95,DOI,ERB,FLEXI,HOWEVER,PTV,SEVENTY,T1CN0M0
100,169,COPYRIGHT,FURTHER,INC,MEANWHILE,TODAY
142,169,400,BACKGROUND,CONCLUSION,COPYRIGHT,EVALUATION,GLEASON,GRADE,INC,LABEL,METHODS,PSA,RESULTS,SECONDARY,SOLID,SORAFENIB,TEN,TTP
038,043,169,177,COPYRIGHT,DISEASE
AFTER,ALT,AST,BACKGROUND,CONCLUSION,DLT,EZN,FIBONACCI,LABEL,METHODS,PHASE,RESULTS
002,011,018,023,161,BACKGROUND,COHEN,COMPONENT,COMPOSITE,CONCLUSION,DENMARK,INDEX,INTENSION,LABEL,METHODS,PCA,PRIMARY,QOL,RESULTS,SCALE,SHORT,SUMMARY
041,043,143,224,471,ALPHA,BACKGROUND,CONCLUSION,COX,JAPAN,LABEL,METHODS,RESULTS,VEGETABLE
169,215,BACKGROUND,COPYRIGHT,D10,D25,LABEL,LTD,METHODS,MRI,PUBLISHED,RESULTS,SIMILAR,THEREBY
734,BACKGROUND,CENTRAL,EFFORTS,EXCLUDING,LABEL,MEASURING,METHODS,NORTH,OBJECTIVE,RESULTS,USING,WORKFORCE
016,019,032,139,141,143,169,1MM,5MG,675,704,916,BACKGROUND,COPYRIGHT,DFW,EDT,ENCOUNTER,GLEASON,INDEX,LABEL,METHODS,OBJECTIVE,OUTCOME,PROFILE,PUBLISHED,RANDOMISED,RESULTS,SECONDARY,SEP,SETTING,TADALAFIL,TREATMENT,TRIAL,UNASSISTED
174,292,DOPPLER,DSW,EDV,LABEL,METHODS,NVB,OBJECTIVE,OBJECTIVES,OVERALL,PSA,PSV,RESULTS,THERE,THESE
ABOUT,AIM,DECREMENT,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SURFACTANT,THERE,TNM,WESTERN
618,BACKGROUND,CONTEXT,DIAGNOSES,ECPBS,GLEASON,GUIDELINES,IHC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
100,150,200,945,956,ALA,DHA,EPA,GLA,HENCE,PCA,PUFAS,THESE,TNF
300,BIOLOGICAL,BMA,DLS,FLU,LNCAP,TEM
169,AMONG,BETWEEN,CALIFORNIA,CURRENTLY,FRANCISCO,GLEASON,HOPKINS,JANUARY,JOHNS,KETTERING,KOREA,LABEL,MEDICAL,METHODS,MIAMI,OBJECTIVE,OBJECTIVES,RESULTS,SAMSUNG,SAN,SEOUL,SLOAN,TORONTO,UNIVERSITY,UROLOGICAL
946,DU145,ELISA,FINALLY,IMMUNOBLOT,LC3II,MTT,PC3,SCREENING
THERE
181,GENISTEIN,H874Y,HOWEVER,LNCAP,PCA,SIMILAR,T877A,THESE,THR877ALA,W741C
001,205,214,221,99B,AFRICAN,CAUCASIAN,MICRORNAS,MIR,PCA,PCR,ROC,WHILE
169,LABEL,METHODS,MTC,OBJECTIVE,PURPOSE,RESULTS,SRE,STUDIES,ZOLEDRONIC
000,169,AUC,CROHN,EMPIRICAL,GWASS,HOWEVER,INC,PHASE,SNP,WILEY
113,EASTERN,ERG,EUROPEANS,GLEASON,MOLECULAR,PROSTATIC,WESTERN
169,BACKGROUND,CXC,CXCL3,CXCL5,CXCL6,CXCL8,DISCUSSION,INC,LABEL,METHODS,PC3,RESULTS,WILEY
14Q32,154,299,377,381,485,495,654,FINALLY,GLEASON,PCA,PSA
169,500,598,780,BACKGROUND,BECAUSE,CURRENT,INC,KALLIKREIN,LABEL,LITERATURE,METHODS,PANEL,RESULTS,WILEY
203,BECAUSE,CINPT,DAVINCI,GLEASON,JANUARY,LABEL,METHODS,MONTSOURIS,NVB,OBJECTIVE,PSM,PURPOSE,RESULTS,SEPTEMBER
ADT,ATRIGEL,GLEASON,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PRIMARY,PSA,PURPOSE,RESULTS,SECONDARY,T2A
001,008,109,110,169,180,260,270,275,290,521,BACKGROUND,DIAGNOSTIC,JANUARY,LABEL,MARCH,METHODS,NAVIGATION,NAVIGATORS,PATIENT,PROGRAM,RESULTS,SOCIETY,THERE
001,003,010,031,169,AMBULATORY,BACKGROUND,CURRENT,FACTORS,FORCE,GUIDELINES,LABEL,MEDICAL,METHODS,PREVALENCE,PREVENTIVE,RESULTS,SOCIETY,WHITE
DOCETAXEL,III,WHILE
169,390,800,CAM,CELLSEARCH,EMT,ICC,VITATEX,WHOLE
160,277,320,AMONG,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
SCHLAP1,SNF,SWI
001,173,208,381,ALREADY,BACKGROUND,BECKMAN,COULTER,GLEASON,GS6,GS8,GSS,INCLUSION,LABEL,METHODS,NOC,PCA,RESULTS,SCORE
946,LNCAP,THESE
001,669,ACS,BACKGROUND,COLLEGE,COMPARISON,HOWEVER,LABEL,LRP,METHODS,NSQIP,OPERATIVE,ORP,OVERALL,PGY,PROGRAM,QUALITY,RESULTS,TRAINEE,USING
169,ASPECTS,AUSTRALIA,AUTHORS,BACKGROUND,BJU,FURTHER,GLEASON,IMAGE,LABEL,MRI,PSA,SCREENING,SELECTION,TECHNICAL,TESLA,THERE,TREATMENT,UNASSIGNED,USANZ
1ST,329,3RD,6TH,HOWEVER,IIQ,LABEL,METHODS,OBJECTIVE,PURPOSE,REGARDING,RESULTS,SIMILAR,THERE,WITHOUT
CURRENT,ERG,GUIDELINES,PCA,POTENTIAL,PRO,PSA,THERE,THESE,TMPRSS2
611,AKT,ATM,ERK,FURTHER,HDACI,HDACS,INCREASED,OVERALL,PAN,PC3,PCA,THESE
946,CHROMATIN,GLEASON,MDV3100
10Q11,11Q13,160,17Q12,17Q24,283,368,506,560,946,CONSORTIUM,GENIE,HOWEVER,ICPCG
120,597,776,ADVERSE,DENOSUMAB,ENDPOINTS,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SRE
000,200,EXPRESSION,PCA,PCR,PITX2,THESE,WNT,WNT5A
001,100,102,108,125,148,154,234,305,329,344,361,414,419,442,490,541,597,624,631,636,798,BACKGROUND,LABEL,METHODS,OBJECTIVE,OLDER,OUTCOME,PATIENT,PROMS,REMINDERS,RESULTS,ROUTINE,SURVIVORS
ADDITIONAL,HEALTHCARE,KNOWLEDGE,LABEL,LYMPHEDEMA,METHODS,NURSING,OBJECTIVE,OBJECTIVES,PURPOSE,QOL,RESULTS,SETTING,SPOUSES,SUPPORTING,TELEPHONE,VARIABLES
141,169,177,5FU,CIS,COPYRIGHT,HT3,INC,KUTCHER,LABEL,LSS,LYMAN,MATERIALS,METHODS,MMC,OBJECTIVE,PBM,PURPOSE,RESULTS,TREATMENT
BACKGROUND,CONCLUSION,FAK,LABEL,METHODS,RESULTS,TGASE
947,BIS,CD2SU,CD2UR,DIAMIDE,FINALLY,OVERALL
ANTIGEN,CHAIN,DOCETAXEL,DTX,FOLLOWING,REVERSIBLE,SHORT
BACKGROUND,DOSIMETRIC,HELICAL,LABEL,METHODS,MODULATION,OAR,RESULTS,TEN
CON,EVANS,LECTINS,TISSUES
MALIGNANT,THEIR
171,187,CALCIUM,DENOSUMAB,HOWEVER,III,NON,OBJECTIVE,SRE,THERE,TREATMENT
177,207,248,530,945,AFTER,BESIDES,CONCLUSION,FEDERATION,INSTITUTE,LABEL,MEASURING,METHODS,OBJECTIVE,RESULTS,THESE,THOSE,UNLABELLED,WAITING
10B,946,BASED,FM4,PC3,WNT,WNT11
185
FINALLY,INCIDENCE,ITALIAN,ITALY,MORTALITY
1990S,BACKGROUND,CONCLUSION,ITALIAN,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,THESE
000,100,106,140,167,180,201,205,295,300,493,512,BACKGROUND,CONCLUSION,ESTIMATES,LABEL,METHODS,OBJECTIVE,RESULTS,SASSARI
000,100,500,ACCORDING,BACKGROUND,CONCLUSION,ESTIMATES,ITALIAN,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS
2000S,BACKGROUND,BASILICATA,CATANZARO,CONCLUSION,ITALY,LABEL,METHODS,OBJECTIVE,RESULTS,THESE
BACKGROUND,CONCLUSION,ITALIAN,LABEL,METHODS,OBJECTIVE,PREVALENCE,RESULTS,SINCE
000,100,629,675,969,BACKGROUND,CONCLUSION,ITALIAN,LABEL,METHODS,OBJECTIVE,PREVALENCE,RESULTS,SALERNO
200,2000S,300,341,394,698,ABRUZZO,BACKGROUND,CONCLUSION,INCIDENCE,ITALY,LABEL,METHODS,OBJECTIVE,PREVALENCE,RESULTS
000,100,1980S,239,315,529,617,759,934,BACKGROUND,CONCLUSION,INCIDENCE,ITALIAN,LABEL,LAZIO,METHODS,OBJECTIVE,PREVALENCE,RESULTS,SINCE,THESE
098,191,1980S,215,224,228,269,539,563,844,AGE,BACKGROUND,COLORECTAL,CONCLUSION,ITALIAN,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS
000,2010S,615,729,900,970,AGING,BACKGROUND,CONCLUSION,ESTIMATED,EVALUATION,FAVORABLE,ITALIAN,ITALY,LABEL,METHODS,MODEL,OBJECTIVE,PUBLISHED,RESULTS
000,082,092,188,ACCORDING,BACKGROUND,CONCLUSION,ITALIAN,LABEL,METHODS,OBJECTIVE,PREVALENCE,RESULTS,THESE,TUSCANY
000,100,1980S,400,700,AFTER,AMONG,BACKGROUND,CONCLUSION,ITALY,LABEL,METHODS,MORTALITY,OBJECTIVE,RESULTS,ROMAGNA
000,100,130,700,800,BACKGROUND,CONCLUSION,INSTITUTE,ITALIAN,ITALY,LABEL,METHODS,OBJECTIVE,RESULTS,STATISTICS,THESE,VENEZIA
000,390,677,729,760,BACKGROUND,CONCLUSION,ITALIAN,LABEL,METHODS,OBJECTIVE,PREVALENCE,RESULTS
100,2000S,ADIGE,BACKGROUND,BOLZANO,INCIDENCE,ISTAT,ITALIAN,LABEL,LIFESTYLE,METHODS,MORTALITY,OBJECTIVE,RESULTS
118,208,400,500,839,BACKGROUND,CONCLUSION,GENOA,ITALIAN,LABEL,LIGURIA,METHODS,MORTALITY,OBJECTIVE,RESULTS
000,116,200,500,700,900,BACKGROUND,CONCLUSION,HOWEVER,INCIDENCE,ITALIAN,LABEL,METHODS,MORTALITY,OBJECTIVE,PREVALENCE,PUBLISHED,RESULTS
000,1990S,300,700,900,AOSTA,BACKGROUND,COLORECTAL,INCIDENCE,ITALIAN,LABEL,METHODS,MONITORING,MORTALITY,OBJECTIVE,PREVALENCE,PUBLISHED,RESULTS,TURIN
153,BACKGROUND,BESIDES,CONCLUSION,EDTMP,LABEL,MATERIALS,MBQ,MEIER,METHODS,OBJECTIVE,PRIOR,RESULTS
231,ACTIN,INCREASED,MDA,RHO,TREATMENT
BPS,FINALLY,III,PCA,ZOL
AMP,ATP,FINALLY,MYC,NADPH,NCI60,SOG,TAKEN
3RR,AKT,CAP,CSC,DU145RR,EMT,LNCAPRR,PCR
APART,CRP,LABEL,OBJECTIVE,OVERALL,PURPOSE,RESULTS,STUDIES,SUMMARY,THERE
169,956,ATROPHY,GLEASON,HGPIN,THESE,WHETHER
100,AREAS,BACKGROUND,COVERED,FDA,HOWEVER,III,LABEL,METHODS,OPINION,OWING,PHASE,SEVERAL,WESTERN
000,BACKGROUND,FDA,III,LABEL,METHODS,OBJECTIVE,PREVALENCE,RESULTS,TREATMENT
174,323,BACKGROUND,GREENLIGHT,LABEL,METHODS,PSA,RESULTS,SERUM
CERTAIN,HOWEVER,TMA
001,005,114,885,BACKGROUND,HOWEVER,LABEL,MEDLINE,METHODS,RESULTS,URO,WHILE
100,CLU,CUSTIRSEN,DPC,ESTIMATED,LOWERED,MEN,MPC,PHASE,PSA,SUBJECT,THESE
398,922,BASED,COX,DOCETAXEL,MMP,PCA,THESE
133,169,649,BACKGROUND,BETWEEN,CONCLUSION,COX,INC,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PSA,PSM,RESULTS,SEVERAL,WILEY
169,945,946,AMACR,BACKGROUND,CONCLUSION,DU145,ERG,INC,LABEL,METHODS,PC3,PCA,PSA,RESULTS,THESE,TIC,TMPRSS2,WILEY,ZEBRAFISH
326,586,912,946,AFTER,CCND2,EXPRESSION,GEO,OMNIBUS,PPI,PROTEIN,REFERENCE,SRF,TGF,TGFB2,TGFB3,THEREFORE,THESE
ACCORDING,CONNECTING,CURRENT,STATISTICS
184,BPH,DU145,FCM,GLEASON,PC3,QKI,THESE,TNM,TUNEL,USING
BECAUSE,CANCERS,CURRENT,FDG,FDOPA,NAF,PET,WHILE
EPH,EPHA2,PC3,STRUCTURE,THESE
FDG,PET,PRIMARY,SERUM
PET
RESULTS,USING,WHILE
001,AMONG,BACKGROUND,LABEL,METHODS,NETWORK,RADIATION,RESULTS,SOCIETY,UROLOGISTS,USING
001,350,BASED,INDICATIVE,MODEL,OWING,P53
185,PET,PRIMARY,THERE,ULTRASOUND
169,954,BACKGROUND,ELISA,EXPRESSION,INC,LABEL,LUCIFERASE,METHODS,MMP,RESULTS,WESTERN,WILEY
169,BACKGROUND,EFFECTS,KEY,LABEL,METHODS,PREDICTORS,RESULTS,SOCIETY
169,AKT,INCREASING,THEREFORE,TREATMENT
169,945,BACKGROUND,CAP,CHO,CONCLUSION,CURRENTLY,CWR22,DHT,INC,LABEL,METHODS,PROTEIN,REDUCED,RESULTS,WILEY
005,115,169,178,185,946,BACKGROUND,E12,GRP,HOWEVER,INC,LABEL,METHODS,MIB,PIN,RESULTS,ROD,THERE,TYR,WILEY
PC3,TAKEN,TTP,UTR
037,263,267,923,931,CONCLUSION,GPS,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE,ZEALAND
DRS,KIT,LABEL,LIF,LNCAP,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,THESE,USING,VEGFA
169,239,302,542,546,APRIL,BIOTECH,BRIEN,COU,FLEMING,INC,JANSSEN
277,346,CHANGES,LABEL,LOW,MEDLINE,METHODS,MUCOSAL,OBJECTIVE,PURPOSE,RECTOSCOPY,RESULTS,SCORE,THREE
BESIDES,EVS,HOWEVER,OTHER
ALGORITHMS,BECAUSE,DETECTION,ERG,ETS,FINALLY,HLA,IDEAL,PCA,TMPRSS2
100,AZA,COLORECTAL,CRC,DACH1,LEF,MYC,SILENCING,TCF,THESE,WNT
169,195,268,CAP,CONCLUSION,CONVERSELY,COPYRIGHT,GLEASON,INC,LABEL,MEN,METHODS,OBJECTIVE,OLMSTED,PSA,RESULTS,SINCE
105,116,169,177,431,549,946,956,ARTEMISIA,BASED,COLON,COPYRIGHT,CRL,DAD,DECNE,EXCELLENT,FINALLY,HCT,LEUKAEMIA,MTT,THP
169,945,AROMATASE,BASED,COMPOUNDS,COPYRIGHT,CYP17A1,LTD,PC3,VIRTUAL
001,006,128,169,AUTHORS,BJU,FURTHER,GLEASON,HOPKINS,LABEL,METHODS,OBJECTIVE,RESULTS,UNIVERSITY
BACKGROUND,CLAVIEN,DINDO,DONAT,JANUARY,LABEL,METHODS,OBJECTIVE,PROGRAM,PURPOSE,QUALITY,RESULTS,THREE
100,CONCLUSION,HOLEP,III,LABEL,MEDIANS,METHODS,OBJECTIVE,PCA,QOL,RESULTS,SCORE,SYMPTOM,TREATMENT
CONCLUSION,ESTIMATES,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PEARSON,PSA,RESULTS
00001,961,CENTRAL,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PEARSON,PSA,RESULTS,THESE
000,177,200,AFTER,DSC,PCG,SIMILARITY,THEREFORE
270,ATG,BACKGROUND,CBM,DESPITE,FURTHER,LABEL,LEP,MEDLINE,METHODS,OVERALL,Q223R,RESULTS,SCIENCE,SNP,THEREFORE,WEB
CHANGES,HIV,MICHAELIS,PROTEASES,PSA,SDS
060,134,160,197,262,290,ADT,BACKGROUND,DXA,FEWER,FURTHER,LABEL,MEN,METHODS,RESULTS,TEXAS,THOSE,VARIATION
123,756,820,CAUCASIANS,MEANWHILE,OVERALL,SINCE

177,637,671,714,717,733,ASIAN,BECAUSE,CAUCASIAN,JANUARY,LABEL,MEDICAL,METHODS,OBJECTIVE,OVERALL,RESULTS,SIMILARLY,STEPHENSON,TOKYO,UNIVERSITY,USING
100,CK7,FORTY,PSA,THESE,THREE
IOF,TREATMENT,USA
145,22RV1,954,ARS,CURRENT,F876L,H874Y,HOWEVER,SC245,T877A,W741C
011,036,121,123,151,160,185,336,795,CCI,CSM,CUMULATIVE,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OCM,PSA,PURPOSE,RESULTS,THERE,VARIABLES
CTC,HOWEVER
CTV,D95,DOSIMETRIC,EMT,OAR,PDF,PTV
100,460,823,AMONG,GATA3,GCDFP,L50,LEICA
003,006,165,241,GLEASON,THESE
001,003,BACKGROUND,BCR,CAPRA,COX,DUE,GLEASON,LABEL,METHODS,PSA,PSADT,RESULTS,ROC,STEPHENSON,WHILE
100,THESE
200,LEADING
CONSISTENT,FINALLY,PC3,RADIATION,S1P,SGPP1,USING
001,016,020,090,144,147,471,ANXIETY,CONCLUSION,DEPRESSION,EFFECTS,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SCALE,TESTING,TREATMENT
169,945,INC,MICROARRAY,MITOVES,TRP
132,916,COMPARISON,FINALLY,KINETIC,T325A,T325D,THESE,UDP
169,AKT,CISPLATIN,COPYRIGHT,ECTOPIC,EMT,HOWEVER,INHIBITION,IRELAND,LTD,PAR,THEREFORE,TREATMENT
169,AMONG,COPYRIGHT,LTD,NMR,SINULARIA,STRUCTURES
111,169,174,COPYRIGHT,EDUCATION,FACBC,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,REFERENCE,RESULTS,UROLOGICAL
001,169,614,661,ADHERENCE,AREAS,CONSORTIUM,COPYRIGHT,DESPITE,EDUCATION,END,FORUM,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHYSICIAN,PUBLISHED,PURPOSE,QUALITY,RESULTS,SERVICE,UROLOGICAL
110,169,233,BACKGROUND,BCG,COPYRIGHT,COX,LABEL,METHODS,NMIBC,OBJECTIVE,OUTCOME,PATTERN,PREDICTORS,PRIMARY,PUBLISHED,RESULTS,SECONDARY,SETTING,TIS,UUT,VARIOUS
956,AKT,ASIAN,COMPOUNDS,NMR,SNU,THESE,TREATMENT
CAF,HOWEVER,TREATMENT
ASSESSMENT,DIAGNOSTIC,ERG,HOWEVER,OVERALL,PCR,QUALITY,STUDIES,TMPRSS2,WEB
112,117,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PER,PET,PURPOSE,RESULTS
001,108,152,524,AUR,CONCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,SCORE,SIXTEEN,SYMPTOM,T1C,T3B
946,CAF,DNMT1,GSTP1,H3K9ME3,HOMOLOGOUS,LNCAP,PCR,RESTORING,SEVENTY,STROMAL,TAKEN,TGBR2,TGF
160,169,199,399,800,FDA,INC,MEDIVATION,OVERALL,RES
169,504,CLINICALLY,CONCLUSION,HYPOXIA,IHC,LABEL,MEIER,METFORMIN,METHODS,OBJECTIVE,PET,PURPOSE,RADIATION,RESULTS,THREE
946,COLLEGE,MEDICAL,MOUNT,SCIENCE,SINAI,THESE,UNIVERSITY
169,947,956,COPYRIGHT,LNCAP,SAS,THESE
169,231,946,DUE,HB1,IFN,MCF,MDA,PCR,SCF
160,CTV,EIGHT,PTV,SIM,TCP
001,004,035,169,271,472,BLOOD,COPYRIGHT,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL,WHILE
169,BLOOD,COPYRIGHT,HOWEVER,RIA,STEROID
169,COPYRIGHT,HENCE,HPV,INC,INFECTION,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,ALP,CLEIA,COPYRIGHT,MMP,PSA,RESULTS
169,CHANGES,COPYRIGHT,LTD,TAKEN
001,113,168,169,170,177,185,194,CASES,CONCLUSION,CONCURRENT,COPYRIGHT,ESTIMATED,INC,LABEL,METHODS,OBJECTIVE,RARPS,RESULTS,THERE
001,160,169,AFRICAN,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,SERUM,THESE
024,169,177,450,ASSESSMENT,COMPOSITE,CONCLUSION,CONSORTIUM,COPYRIGHT,HRQOL,INC,INDEX,LABEL,METHODS,OBJECTIVE,QUALITY,RESULTS,TREATMENT
103,125,131,160,169,CARLO,COPYRIGHT,DOSIMETRIC,HOWEVER,INC,LABEL,MATERIALS,METHODS,MONTE,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,VOLUMETRIC
169,215,226,ARGON,CLINICALLY,COMPOSITE,CONCLUSION,COPYRIGHT,CUMULATIVE,GROUP,INC,INDEX,LABEL,MATERIALS,MEIER,MEN,METHODS,OBJECTIVE,PURPOSE,QOL,RADIATION,RESULTS,THERAPY,THERE
100,125,155,169,419,574,AUTOMATED,CONCLUSION,COPYRIGHT,D90,DOSIMETRIC,FIRST,GLEASON,GRADE,INC,LABEL,MATERIALS,METHODS,NUCLETRON,OBJECTIVE,PPB,PURPOSE,RESULTS,UNIVARIATE
019,049,169,AIM,APC,ARGON,BRITAIN,COLORECTAL,CONCLUSION,CONTROL,CRP,DISEASE,FOLLOWING,GREAT,IRELAND,LABEL,METHODS,OBJECTIVE,RESULTS,SIXTY
ADC,DWI,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS
ARRAY,BASED,DEFENSE,LNCAP,OXIDATIVE,PCR,PNT1A,SELOL,UNDER
248,488,507,ANOTHER,BACKGROUND,EASTERN,GROUP,III,LABEL,METHODS,RESULTS,SEVERAL,SPARC
169,177,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MOLDING,OBJECTIVE,PERCENT,PURPOSE,RESULTS,TEN,WILEY
10R,CCL16,CD4,CD8,CPG,INTRA
218,693,COX,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SCORE
051,132,163,177,210,598,AMICO,GLEASON,GROUP,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PSA,RESULTS,UNIVARIATE
HOWEVER,RADICAL,THERE
ASC,FACBC,FDG,LABEL,MET,METHODS,MLLB2,OBJECTIVE,PET,PROCEDURES,PURPOSE,RESULTS,USING
AFTER,BACKGROUND,CLINICIANS,CONCLUSION,LABEL,METHODS,PSA
104,547,634,654,768,781,APRIL,ASIAN,INDEX,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
ACCORDING,ALP,BMD,CLINICIANS,GLEASON,PLAIN
11C,169,18F,BACKGROUND,CONCLUSION,COPYRIGHT,FACBC,FURTHER,INC,LABEL,METHODS,PCA,PET,PSA,RESULTS,TBR
169,425,438,513,CONCLUSION,COPYRIGHT,INC,INCREASED,INSURANCE,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,SIR
169,COPYRIGHT,EDUCATION,EIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SPECIMENS,TESLA,UROLOGICAL
169,COPYRIGHT,INC
106,169,30D,AUTHORS,CLINICALLY,EMPLOYING,GLEASON,INC,LNCAP,NED,PC3,PCA,PCR,PUBLISHED
101,259,CUMULATIVE,FIRST,GRADE,INCIDENCES
HAFFNER,JCI,PROGNOSIS,THEIR
DESPITE,SIMILAR
100,169,AGE,COPYRIGHT,HOWEVER,SRC,THERE
CTC,INC,PUBLISHED,THERE
435,BASED,CNS,DUE,FURTHER,GHR,III,INC,INSTITUTE,MDA,MEL,NCI60,PRL,PUBLISHED,STAT5,STRIKINGLY,WHILE
169,COPYRIGHT,LTD,OVERALL,SSRIS,THEREFORE
169,ADT,LTD,THESE,WHILE,WILEY
CURRENTLY
019,169,620,JAPAN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
100,945,946,ACUTE,ADT,BACKGROUND,BORTOLO,CYBERKNIFE,GRADE,IRB,ITALY,LABEL,METHODS,PSA,RADIATION,RESULTS,ROBOTIC,SAN,VICENZA
ETS,III,PCR,PSA,TMPRSS2
169,COPYRIGHT,LTD,REUSE,SOMETIMES,WILEY
003,122,169,ADT,BACKGROUND,CONCLUSION,COX,IGF,IGFBP,INC,INSULIN,LABEL,METHODS,PSA,RESULTS,THERE,WILEY
169,826,BACKGROUND,CONVERSELY,INC,INPATIENT,LABEL,METHODS,NATIONWIDE,OVERALL,PCA,RESULTS,THERE,THESE,WILEY
131,177,FINALLY,FURTHER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIMILAR,USING,WHOLE
169,672,AUTHORS,BJU,LABEL,METHODS,OBJECTIVE,PCA,RESULTS
169,AUS,AUTHORS,BJU,CONTINENCE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,THERE
102,126,169,183,184,BACKGROUND,COPYRIGHT,LABEL,LTD,LUXEMBOURG,METHODS,RESULTS,THESE,UNION
649,964,CRC,FINLAND,FINNISH,IBD,INSURANCE,METHODS,OBJECTIVE,OVERALL,RESULTS,SIR
AAG,AKT,BIM,ERK,HSP90,PCA,USING
LAPC4,LNCAP
BACKGROUND,CASODEX,CONCLUSION,EGF,LABEL,METHODS,MMP,PRESENT,RESULTS,SRC,THEREFORE
945,946,CD4,DYNAMIC,EXOGENOUS,IGF,INTEGRINS
00001,135,226,241,385,ALPHA,AMACR,BACKGROUND,CAUCASIANS,COA,EXPRESSION,IHC,LABEL,METHODS,PCA,PCR,RESULTS,THERE
033,036,268,351,AFRICAN,AMERICANS,ASIAN,ASSESSMENT,FUNCTIONAL,GENERAL,LABEL,METHODS,OBJECTIVE,PURPOSE,QUALITY,RESULTS,THERE,TREATMENT,TRIAL
169,4VS,902,BACKGROUND,COX,ERG,GLEASON,HRQUARTILE,HRS,LABEL,METHODS,PARTIAL,PSA,RESULTS
215,COX,HOWEVER,RHO,TAKEN
CAP,CURRENT,LABEL,METFORMIN,MYC,PCA,PIN,REDUCED,SUMMARY,UNLABELLED
169,231,AFRICAN,CENTERS,CONTROL,COPYRIGHT,DISEASE,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,RRR,WILEY
001,031,235,250,CONCLUSION,CONVERSELY,INCLUSION,JANUARY,LABEL,METHODS,MRI,OBJECTIVE,PATIENT,PCA,PSA,PURPOSE,RESULTS,THERE
001,044,168,295,BACKGROUND,BETWEEN,GLEASON,LABEL,MATERIALS,MAY,MEN,METHODS,OVERALL,RESULTS,SEPTEMBER,THOSE
169,AMP,HOWEVER,INC,WILEY
ANY,FSH,SERTOLI,THERE
018,022,169,451,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,FIFTY,FURTHER,ID1,INC,LABEL,METHODS,MOLECULAR,RESULTS,SEVENTY
10X,250,HOPITAL,INTUITIVE,LUC,RADICAL,RARPS,ROBOTIC,SUNNYVALE,UNIVERSITY,USA,VINCI
100,145,ASTRO,BACKGROUND,D90,GLEASON,LABEL,MATERIALS,MAY,MEIER,METHODS,PATIENT,PHOENIX,PREPLANNED,PSA,RESULTS
00003,006,114,BACKGROUND,INCLUSION,LABEL,LDB,MATERIALS,METHODS,RESULTS,TAB,WITHOUT
0MM,169,176,1MM,2MM,3MM,4MM,5MM,8MM,931,963,BACKGROUND,COPYRIGHT,INCLUSION,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS
056,096,126,140,195,200,208,229,249,625,884,BACKGROUND,BMI,JANUARY,LABEL,METHODS,NINTH,REGARDLESS,RESULTS,THERE
428,500,PSA,SINCE
174,533,ACCURAY,CONCLUSION,IMAGE,INSTITUTES,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS,SUNNYVALE,THERE
169,297,400,473,AUTHORS,BJU,DRS,GLEASON,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,RESULTS,RTE
001,002,006,007,010,012,015,102,123,153,169,317,387,534,592,ADT,AUSTRALIA,AUTHORS,BJU,IRR,LABEL,METHODS,OBJECTIVE,PATIENT,PSM,RESULTS,RPS,THESE
100,137,150,169,200,400,700,750,ASPIRIN,AUTHORS,BETWEEN,BJU,CLAVIEN,III,LABEL,MAJOR,METHODS,OBJECTIVE,RARPS,RESULTS,RPS
169,174,AFTER,AUTHORS,BJU,CONCLUSION,FERTI,HOWEVER,INDEX,LABEL,LTD,MARCH,METHODS,OBJECTIVE,PVS,RESULTS,THERE,WILEY
HSP90,INHIBITING,NOVOBIOCIN,PRESTWICK,UTILIZING
100,945,BISPECIFIC,CD3,FAB
CONVERSELY,EPIGENETIC,FINALLY,H2A,H2AFZ,HISTONE,INDUCED,INHIBITION,REMARKABLY,SIRT1,TSS
001,015,021,024,026,044,169,217,335,509,549,AFTER,AMONG,BACKGROUND,BCR,COX,CURRENT,EQUAL,LABEL,MEIER,METHODS,RESULTS,SIMILAR,SOCIETY
169,BACKGROUND,C30,COX,EORTC,HRQOL,LABEL,METHODS,QLQ,QUALITY,RESULTS,SOCIETY,TREATMENT,WORLD
160,169,177,ACADEMY,ANDROLOGY,DESPITE,EJD,KNOWLEDGE,MAY,OVERALL,SOCIETY
174,III,MDV3100
956,BAP,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PLT,PSA,RESULTS,SCORE,STRONTIUM,USING
1154G,2578C,285,879,FINALLY,HOWEVER,THERE,THEREFORE
181,213,255,271,983,CONCLUSION,DEGRO,LABEL,METHODS,OBJECTIVE,OCTOBER,PERSONNEL,PURPOSE,QUIRO,RADIATION,RESULTS,SOCIETY,TIMES,TOTAL
137,258,BACKGROUND,GLEASON,LABEL,METHODS,MPMRI,PSA,RESULTS,SECONDARY,TPM
000,006,040,061,248,676,BACKGROUND,INDEX,LABEL,METHODS,PATIENT,PCI,RESULTS,SCALE,UTILITIES,UTILITY
AKT,BBN,BCA,CASODEX,EGF,EPIDERMAL
001,007,314,327,357,438,BACKGROUND,LABEL,METHODS,PRIMARY,PSA,RATES,REASONS,RESULTS,SECONDARY,TAX,TRIAL
APOPTOSIS,CELLS,CONTINUOUS,METHIONINE,THESE
169,320,BACKGROUND,CONCLUSION,COPYRIGHT,EASTERN,GROUP,INC,INVENTORY,LABEL,MDASI,METHODS,QOL,RESULTS,SOAPP,SYMPTOM
169,ADT,BACKGROUND,CONCLUSION,COPYRIGHT,COX,DPD,FAILURE,INC,LABEL,MARKERS,METHODS,PSA,RESULTS,SERUM,SRE
010,012,018,100,125,130,169,833,990,ADT,COPYRIGHT,D90,DFS,GLEASON,HOWEVER,INC,LABEL,LDR,MATERIALS,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,UNIVARIATE
177,25411,AAA,ALGORITHM,ANALYTICAL,ARIZONA,AXB,CONCLUSION,ECLIPSE,FINALLY,LABEL,MATERIALS,METHODS,OBJECTIVE,PLANS,PTV,PURPOSE,RESULTS
169,24H,AKT,APOPTOSIS,ATG,ATG12,AUTOPHAGY,AYURVEDIC,BAF,CHX,COPYRIGHT,HOWEVER,IRELAND,LC3,LTD,ROTTLERIN,WESTERN
874,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,UNIVERSITY,USING
169,AR3,BLACKWELL,EXPRESSION,FSH,OVERALL
HDR,HOWEVER,LDR,LOW,STUDIES
917,EMT,EPITHELIAL,ESRP1,MET,OVOL1,OVOL2,PROTEIN,REGULATORY,SEVERAL,TFS,USING
169
DU145,ECS,LNCAP,PC3
005,169,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,WILEY
169,627,BXS,COPYRIGHT,EMPIRICAL,ESTIMATION,GLEASON,HOPKINS,HOWEVER,JOHNS,LTD,UNIVERSITY,WHETHER,WILEY
169,ACCORDING,APOPTOSIS,MTT,PC3,SKNMC,THESE,VCH,WILEY
169,BACKGROUND,BORIS,DETECTION,GLEASON,INC,INCREASED,LABEL,METHODS,RESULTS,WILEY
001,006,007,026,030,222,AIM,CONCLUSION,DRE,GLEASON,ITALIAN,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SCORE
100,AIM,CONCLUSION,LABEL,METHODS,OBJECTIVE,PHASE,RESULTS
177,3DCRT,3DRCT,ACUTE,AFTER,BETWEEN,CONCLUSION,FORTY,GRADE,GROUP,LABEL,METHODS,OBJECTIVE,RADIATION,RESULTS,THERAPY,TREATMENT,V70GY,V95
241,AIM,CONCLUSION,DRE,LABEL,MATERIALS,METHODS,OBJECTIVE,PICOGREEN,PSA,RESULTS,SERUM
001,023,215,AGE,AIM,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,SIX
BACKGROUND,CD133,CONCLUSION,CSC,LABEL,LNCAP,LOW,MATERIALS,METHODS,RESULTS,ROS,THEREFORE
239,BACKGROUND,CONCLUSION,DU145,LABEL,LNCAP,MATERIALS,METHODS,PREVENTION,RESULTS
100,956,BACKGROUND,CONCLUSION,CONJUGATED,DU145,LABEL,LNCAP,MATERIALS,METHODS,MTT,PC3,PCR,RESULTS
500,CONCLUSION,DU145,ECTOPIC,ID1,ID2,ID3,ID4,INHIBITOR,LABEL,MATERIALS,METHODS,RESULTS,UNLABELLED,WESTERN
OPTIONS
169,BACKGROUND,DU145,HOWEVER,INC,LABEL,LAMP1,MDA,METHODS,PC3,PCA,RESULTS,SMALL,WESTERN,WILEY
ADT,ALBERTA,BACKGROUND,BRITISH,CONCLUSION,HOWEVER,LABEL,METHODS,ONTARIO,PHYSICIANS,PROVINCES,RESULTS,THERE
169,447,652,BACKGROUND,DOWNSTREAM,HRR,IRR,LABEL,METHODS,PSA,RESULTS,SOCIETY
150,303,352,374,398,412,CONCLUSION,EVALUATION,LABEL,LUT,MARCH,METHODS,NIGERIA,OBJECTIVE,PSA,PVR,RESULTS,SCORE,SEVENTY,SYMPTOM,THERE,WHILE
BIP,CREB3L4,DNAJC12,HSC70,HSP70,LNCAP,THESE
169,862,BACKGROUND,BRIGHAM,COX,EASTERN,GROUP,LABEL,LES,METHODS,PREDICTING,RESULTS,SOCIETY,WOMEN
169,HOWEVER,INC,NOD,THEIR,WILEY
169,BACKGROUND,CIS,LABEL,METHODS,RESULTS,SOCIETY,UPPER,WALKING
DPD,DU145,EVENTUALLY,PCR,TAKEN,WST
169,183,BARTH,CTLA4,GEORG,IPILIMUMAB,PARTIAL,REGRESSION,STUTTGART,THEREFORE
ARA70,FURTHER,HISTOLOGIC,HOWEVER,LNCAP,PCA,RESULTS
196,697,827,893,BECAUSE,CHINESE,DRE,PSA,SEVERAL
CHALLENGES,CURRENTLY,HOWEVER
LNCAP,SEVERAL,THROUGH,UDP,UGT,UGT2B,UGT2B15,UGT2B17
HOWEVER,WARBURG
169,HSP90,THESE,UBIQUITOUS
ABL,ATF,CCAAT,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,ROS,SRB,WESTERN
HAI,KNOCKDOWN,PCA,THESE
198,230,326,454,505,656,767,851,927,BACKGROUND,CIS,COOKING,DAILY,FRIED,ITALY,LABEL,METHODS,ORS,RESULTS,THESE,WESTERN
169,BACKGROUND,CONCLUSION,DCFDA,DHR,DU145,EXPRESSION,FURTHER,GENERAL,GSH,KNOCK,KNOCKDOWN,LABEL,MATERIALS,METHODS,PC3,PCR,RESULTS,ROS,THEIR
169,ANNEXIN,ANXA5
000,072,100,169,236,276,407,425,459,498,768,843,910,912,948,981,989,BACKGROUND,CONCLUSION,COPYRIGHT,COX,INC,INCIDENCE,INSURANCE,JANUARY,LABEL,METHODS,RESULTS,TAIWANESE,THERE,WHETHER
169,327,COPYRIGHT,COX,MEN,PUBLISHED,TAX,THESE
169,173,272,GLEASON,HOWEVER,LOW,PSA,VDR
169,177,BVZ,COX,HOWEVER,ONJ,OTHER
169,BACKGROUND,COPYRIGHT,DECREASES,DISCUSSION,INCIDENCE,INCREASING,INDIVIDUAL,LABEL,LTD,METHODS,RESULTS
169,194,864,COMPOSITE,CONCLUSION,COPYRIGHT,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,QOL,RESULTS
169,COPYRIGHT,INC,INCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,THESE
169,241,CHOLINE,COPYRIGHT,HOWEVER,PET,THEREFORE,ULTRASOUND
108,169,180,6MM,AFTER,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,SIS
169,COPYRIGHT,LTD,SEVERAL,TREATMENT
001,007,038,100,169,ADT,ASSESSMENT,BACKGROUND,CLINICALLY,COPYRIGHT,DISEASE,DURABILITY,FATIGUE,FUNCTIONAL,FURTHER,LABEL,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,QOL,RESULTS,SETTING,THERAPY,TRIAL
001,002,169,201,AMONG,AUTHORS,BJU,CONCURRENT,COX,LABEL,MEIER,METHODS,OBJECTIVE,RESULTS
169,904,AUTHORS,BCR,BJU,CONCLUSION,COX,LABEL,METHODS,OBJECTIVE,PSA,PSM,RESULTS,SMS
075,160,169,176,180,183,ADT,AGE,BACKGROUND,CON,INDICES,ISO,LABEL,LTD,MEN,METHODS,MHS,NUCLEAR,PCA,PHYSIOLOGY,PSA,PUBLISHED,RESULTS,SOCIETY,THESE,TOTAL,WBS,WILEY
076,169,296,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY
001,169,ADT,AGING,AUSTRALIAN,BACKGROUND,CHANGES,COLLEGE,CSA,HOUNSFIELD,LABEL,METHODS,PRE,RESULTS,ROYAL,THERE,THEREFORE,ZEALAND
001,169,859,ADT,AUSTRALIAN,BACKGROUND,COLLEGE,EIGHT,LABEL,METHODS,PROGRAMME,RESULTS,ROYAL,SUPPORT,ZEALAND
001,028,032,160,169,177,AMONG,B2M,FORTY,IHC,IMIDS,ISS,LTD,PUBLISHED,WILEY
169,LNCAP,MEK,NADPH,POSITIVITY,REDUCTION,THERE,THESE
169,213,ASSESSMENT,FUNCTIONAL,FURTHER,GENERAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,THERAPY,UROLOGICAL
001,169,176,215,SUCCESSFUL,UROLOGICAL
109,169,LABEL,LTD,METASTATIC,METHODS,OBJECTIVE,RESULTS,SUBMISSION,WILEY
102,160,169,177,252,ACADEMY,ANDROLOGY,MRI,SOCIETY,TYPICAL
335,454,COLORECTAL,FORCE,INSTITUTE,INSTITUTES,OVARIAN,PREVENTIVE,SCREENING,TRIAL
169,760,946,BACKGROUND,DRE,FOLLOWING,INC,LABEL,MALDI,METHODS,PCA,PRE,PSA,RESULTS,THESE,WILEY
169,190,196,330,BACKGROUND,CAP,DESPITE,ERG,ERP,INC,LABEL,METHODS,MONOAMINE,RESULTS,TMPRSS2,WILEY
141,169,221,26A,26B,BACKGROUND,ERG,INC,LABEL,METHODS,NETWORK,PCR,QUALITY,RESULTS,RIN,RRP,TMPRSS2,WILEY
169,945,BACKGROUND,FUNCTIONAL,HEALTHY,INC,LABEL,MET,METHODS,PSA,RESULTS,THESE,WILEY
001,002,031,134,169,177,280,546,BACKGROUND,INC,LABEL,METHODS,RESULTS,URINE,VOIDING,WILEY
169,BRITAIN,CASTRATION,COPYRIGHT,EFFECTS,GREAT,IRELAND,LTD,NGS,PC3,PCA,PUBLISHED,SCNAS,SOCIETY,WILEY,YWHAZ
198,SNP,THESE
960,EPIGENETIC,ETS,GSTP1,MYC,PIA,PIN,SUBSEQUENT,TMPRSS2
100,300,SINCE
169,BACKGROUND,EASTERN,FATIGUE,GROUP,LABEL,METHODS,RESULTS,SOCIETY,USING
946,947,AFTER,MEROPENEM,PSA,SUSPECTING
ADDITIONAL,MAY
021,027,036,038,342,65308,65309,GLEASON
AUA,FORCE,HOWEVER,INTERIM,ONGOING,SOCIETY,STUDIES,UROLOGICAL
BESIDES,BORTEZOMIB,ELASTIN,ELP,FDA,USING
169,COPYRIGHT,CPG,HOWEVER,INC,MOTIF,PATHOLOGY,PUBLISHED,SOCIETY,SP1
160,ANALYTICAL,PHI,PSA,ROC
169,945,AKT,ERK,EXCESSIVE,HIF,KNOCKDOWN,NADPH,PUBLISHED,ROS,THESE
10MIN,169,COPYRIGHT,INC,LPA,NADPH,NOX,OVERALL,PKC,PLC,ROS,USING
002,006,019,028,029,050,100,169,400,ACTRN,AUSTRALIA,BACKGROUND,BETWEEN,COPYRIGHT,GROUP,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RADAR,RADIATION,RANDOMISED,RESULTS,SECONDARY,SETTING,SUPERVISED,TRANS,TRIAL,ZEALAND
100,111,169,170,215,AFTER,APC,ARGON,COPYRIGHT,EFFECTS,INC,LABEL,MANAGEMENT,MATERIALS,METHODS,OBJECTIVE,PURPOSE,REDUCTIONS,RESULTS,SUBJECTIVE,THERE,TISSUES
001,005,034,039,099,169,257,491,748,763,ACUTE,COPYRIGHT,CRT,GROUP,INC,INTENSITY,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERAPY,THERE,TREATMENT,UNIVARIATE,V70
115,169,366,ADT,AUTHORS,BJU,LABEL,METHODS,OBJECTIVE,PHOENIX,RESULTS
169,AUTHORS,BJU,GLEASON,METASTASIS,PSA,TMN
001,004,005,078,122,169,383,AUTHORS,BCI,BCR,BGTIS,BJU,JANUARY,LABEL,MEIER,METHODS,NSS,OBJECTIVE,PSM,RESULTS,THERE
169,320,AUTHORS,BJU,COX,KRUSKAL,LABEL,MEIER,METHODS,OBJECTIVE,PATIENT,PREDICTORS,PRIAS,RECURRENCE,RESULTS,RFS,THERE,THESE
169,240,AUTHORS,BJU,FLEMISH,LABEL,METHODS,OBJECTIVE,PREDICTIVE,RESULTS,TOTAL
169,AFTER,AUTHORS,BJU,BT1,BT2,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,THEREFORE
TWITTER,USING
MEDICAL,TOOLKIT
184,EGF,EPCAM,EPITHELIAL,FET,PSA,SILICON,SINWS
103,CTV,LOCAL
AUC,RANKBOOST,ROC,SEVERAL
FINALLY
PET,RMS,SPECT
ACCORDING,AFTER,DCE,DIAGNOSIS,FITTING,HOWEVER,MRI,TOFTS
EVALUATION,SOLUBLE,WST
DNASE,ETS,GATA2,SNP,THESE,TMPRSS2
CAVERNOUS,CHOROIDAL,HOWEVER,IMAGING,MELANIN,NEOPLASMS,ORBITAL
169,BRITAIN,COPYRIGHT,ETS,GREAT,IRELAND,LTD,PCA,PUBLISHED,SOCIETY,TUMOURS,WILEY
169,753,AUC,BACKGROUND,FAS,GLEASON,INC,INCREASED,LABEL,METHODS,RESULTS,UPGRADING,WILEY
001,005,015,135,169,APART,BACKGROUND,BEP,CUMULATED,GCC,LABEL,METHODS,OCTOBER,RESULTS,SOCIETY,TREATMENT
000,100,243,CALIFORNIA,DURANGO,GEOGRAPHY,INSTITUTE,LABEL,METHODS,NAYARIT,NUEVO,OBJECTIVE,RATES,RAW,RECORDS,RESULTS,SINALOA,STATISTICS,SUR
169,P27,UPS,VARIOUS
000,BACKGROUND,GENERAL,LABEL,MEN,METHODS,NETWORK,OBJECTIVE,PRIMARY,PSA,RESULTS,RRS
100,181,BACKGROUND,BESIDES,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,PSA,TAPENTADOL,THERE
169,CASTRATION,IDIOPATHIC,OBESITY,UROLOGICAL
006,151,165,169,AUTHORS,BJU,GLEASON,IQR,LABEL,MEN,METHODS,OBJECTIVE,PNI,PSA,RESULTS,T2A
169,COPYRIGHT,INTENSE,SIMILAR,SNA,VCH,WILEY
CHECKPOINT,CHEK2,I157T,LOW,MEDICAL,MUTATIONS,STUDIES
000,150,AES,ALC,CONCLUSION,EVALUATION,METHODS,OVERALL,PBO,PERIPHERAL,RESULTS,SAG,SOLID,STUDIES
III,LARGE,MEDICAL,MEDLINE,METHODS,MPDL3280A,NON,NSCLC,RESULTS,SOCIETY,START,VALIDATING
029,100,125,130,145,173,175,305,D90,GRADE
002,006,145,169,946,BACKGROUND,GLO,INC,LABEL,LNCAP,MCF,METHODS,RESULTS,WILEY
169,BACKGROUND,BMS,BPH,EXPRESSION,INC,INCREASED,LABEL,METHODS,PCA,PCR,PRIMARY,PROSTATIC,RESULTS,SMO,THESE,WILEY
001,FURTHER,ICE,NRS
145,215,BACKGROUND,BASED,CONCLUSION,CONCURRENT,LABEL,METHODS,RESULTS,THESE,TREATMENT,TUNEL
001,002,005,008,031,113,169,480,BACKGROUND,CENTRAL,CONCLUSION,LABEL,LASER,METHODS,MOR,RESULTS,SOCIETY
177,307,929,994,ACE,COHEN,CONCLUSION,FCH,LABEL,LYMPH,MBQ,METHODS,OBJECTIVE,OVERALL,PET,PSA,PURPOSE,RESULTS
132,2D3,945,NRS,THESE
160,AFTER,AMONG,DU145,HOWEVER,LNCAP,THEIR,THESE
100,ADDITIONAL,CME,DELIVERED,EDUCATION,HODGKIN,INSTITUTE,IOM,KNOWLEDGE,PROGRAM,USA,WEBMD
BACKGROUND,CELLS,CONCLUSION,DU145,EPITHELIAL,EVS,GLEASON,IDS,INGENUITY,ISOLATION,LABEL,PATHWAY,PRECS,RESULTS,WESTERN
169,39852,AUSTRALIA,BACKGROUND,CCR,CENTRAL,COPYRIGHT,COX,HOWEVER,LABEL,LTD,METHODS,NSW,RESULTS,SOUTH,SUMMARY,WALES
169,946,BP2,COPYRIGHT,CR6,CRIF1,IRELAND,LTD,STAT3
005,100,177,320,956,ANALYTICAL,ASSAY,BACKGROUND,FPE,GENOMIC,GPS,LABEL,PCR,RESULTS,SCORE
169,266,AMONG,ANY,CLARITY,CONCLUSION,GLEASON,KEY,LABEL,LTD,NETWORK,OBJECTIVE,PATHOLOGY,RESULTS,SOCIETY,UROLOGICAL,WILEY
AGE,AGING,BECAUSE,THERAPIES

HOWEVER,LBD,PCA,TALEN,THESE
ROS,STAT3
001,ADJUSTING,CONCLUSION,III,LABEL,METHODS,OBJECTIVE,PSA,PTE,PURPOSE,RESULTS,SURROGACY
303,745,ADT,BETWEEN,CIMRT,CONCLUSION,HIMRT,LABEL,MAY,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
FINALLY,ROBOT
384,DECREASED,MTT,SNP,THESE,TRANSWELL,WESTERN
201,509,700,ARN,ODM,TAK
156,371,AFTER,BACKGROUND,BCR,COX,EQUAL,LABEL,METFORMIN,METHODS,RESULTS,UNADJUSTED,WHILE
BACKGROUND,CAUTION,LABEL,METHODS,PCA,RESULTS,THERE
200,205,BACKGROUND,FREQUENCY,GLEASON,HOPKINS,JHH,JOHNS,LABEL,METHODS,PLACEBO,PSA,PSADT,RCT,RESULTS,THESE
BPH,CDR,CW22R,DU145,FURTHER,HOWEVER,IHC,LNCAP,PC3,PCA,PCR,PSA
169,945,AMR,CLR,DU145,ERK,GLEASON,HISTOLOGIC,LABEL,LNCAP,MEK,METHODS,OBJECTIVE,PC3,PURPOSE,RAMP2,RAMP3,RES,RESULTS
945,AKT,FINALLY,FIRSTLY,HIF,HOWEVER,HYPOXIC,TAKEN,THESE
CURRENT,HOWEVER,MANAGEMENT
A2058,AMONG,CONSISTENT,JAK,JANUS,MCL,MLS,MYC,SRC,STAT3,TAKEN
29A,CONSIDERED,DU145,HOWEVER,LNCAP,LUCIFERASE,PC3,TARGETSCAN,TLR,TNF,TRAF4,UTR
000,300,TREATMENT,ZOLEDRONIC
ADP,LC3,LNCAP,LTD,NAC,PROPIDIUM,ROS,THEREFORE,VAD
108,169,183,215,956,ADT,BACKGROUND,COPYRIGHT,COX,HDR,IRELAND,LABEL,LTD,MEIER,METHODS,PSA,RESULTS,UNIVARIATE
BIPARTITE,DBD,NLS,THR877ALA
004,041,111,169,5GY,ADVERSE,AES,COPYRIGHT,COX,EARLY,INC,MEDICAL,PUBLISHED,STAGE,T1C,T3A
120,169,500,BACKGROUND,CONCLUSION,COPYRIGHT,EVALUATION,FORTY,GIVEN,GROUP,INC,LABEL,MEN,METHODS,OVERALL,PEMOX,PSA,RESULTS,SECONDARY,SIX,SOLID,WORKING
100,124,169,670,AEU,ANALYZE,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,THERE
155,169,331,398,478,503,506,5MG,797,853,859,863,BACKGROUND,COPYRIGHT,COX,ELDERLY,GRADE,INCIDENCES,LABEL,METASTATIC,METHODS,OBJECTIVE,OUTCOME,PRIMARY,PSA,PUBLISHED,RESULTS,SECONDARY,SETTING,TREATMENT,TRIAL
178,AUC,BACKGROUND,CONCLUSION,EIGHT,GRADE,INCREASES,LABEL,METHODS,MONITORING,MTD,PRIMARY,RESULTS,THERE,TRIAL
945,946,BEIGE,CELLS,DESPITE,HNSCC,HOWEVER
231,956,CD11B,CDK,HL60R,LNCAP,MDA,NBT,PIN,SEVERAL
DOCETAXEL,HOWEVER,OWING
000,254,726,AFTER,CHINESE,DEPRESSION,GDS,GERIATRIC,SCALE,SYMPTOM
19B,23B,26A,92A,AKT,BACKGROUND,HOWEVER,LABEL,PRINCIPAL,RESULTS,THESE,UNDER,UTR
AGE,ASR,BACKGROUND,HBV,HEPATITIS,HIV,HODGKIN,HOWEVER,HPV,INCIDENCE,LABEL,METHODS,NCR,NHL,RATES,RESULTS,SAHARAN,SIMILARLY
001,110,AMONG,ERG,ESPECIALLY,INTRA,MET,OVERALL,TMPRSS2
AKT,MECHANISMS,NLS,THESE
210,296,HOWEVER
169,954,BACKGROUND,BECAUSE,CELLS,CONCLUSION,GST,LABEL,METHODS,MONOCLONAL,RES,RESULTS,S4F,SEMAPHORIN,THESE,TRANSWELL
169,ACE,CONCLUSION,LABEL,LUCAP,MET,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,USING
LOCALLY,SIMILAR,THERE
BPH,GREENLIGHT,LABEL,METHODS,OBJECTIVE,PURPOSE,PVP,RESULTS,SIXTY
18F,INCIDENTAL,PET
945,954,LNCAP,PC3,PCA,TAKEN,ZNT
001,AFRICAN,CAP,WHILE
112,315,ABOUT,CASES,CONCLUSION,EPE,GLEASON,LABEL,METHODS,OBJECTIVE,PROSTATES,PSM,PURPOSE,RESULTS
176,197,COX,GLEASON,LABEL,MEIER,METHODS,MGS,OBJECTIVE,PATHOLOGY,PURPOSE,RESULTS,SGS,SOCIETY,T1C,UROLOGICAL
367,COLORECTAL,LABEL,METHODS,OBJECTIVE,OTHER,PURPOSE,RESULTS,SIR
000,100,169,BACKGROUND,BELARUS,BLM,BLOOM,BRCA2,HOWEVER,LABEL,METHODS,MUTATIONS,Q548X,RESULTS,UKRAINE
101,153,169,AFTER,CAPSURE,COPYRIGHT,COX,EDUCATION,FREQUENCY,INC,LABEL,LIFESTYLE,LIMITED,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T2C,UROLOGICAL
169,181,215,231,500,ASTERACEAE,BACKGROUND,BENTH,CONCLUSION,FURTHER,IRELAND,LABEL,LTD,MATERIALS,MCF,MDA,METHODS,MIA,RELEVANCE,RESULTS,WST
CURRENTLY,HIV,PUBLISHED,RESULTS,SAS,THEREFORE
100ML,169,221,COPYRIGHT,CZECH,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,OLOMOUC,PSA,RESULTS,SEVERAL,UNIVERSITY,UROLOGY
102,169,COMPLETELY,COMPOSITE,CONCLUSION,COPYRIGHT,INC,INDEX,LABEL,MEN,METHODS,MIXED,OBJECTIVE,RESULTS,URINARY
100,169,2MM,3MM,4MM,915,CARLO,COPYRIGHT,INITIALLY,IRELAND,LABEL,LTD,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,THROUGH
169,ACCORDING,BACKGROUND,BASED,COPYRIGHT,COX,CSM,GLEASON,HOWEVER,LABEL,LNI,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,THESE,TNM
421,BACKGROUND,EARLIER,FURTHER,LABEL,METHODS,RESULTS,TNM,UNIVERSITY
AIM,APRIL,CONCLUSION,LABEL,LIBRARY,METHODS,OBJECTIVE,PAT,PCA,RESULTS,SCIENCE,SIMILAR,THESE,XPC
BACKGROUND,DEPENDING,DIRECTIONS,LABEL,RADIATION,RESULTS
160,308,455,456,911,AUS,AUSTRALIA,AUSTRALIAN,BACHELORS,BACKGROUND,LABEL,MEN,METHODS,PATIENT,PSA,RESULTS,THERE,TRIAL,UNLABELLED
ADT,COLORECTAL,ERSPC,MAJOR,OVARIAN,PSA,RANDOMIZED,SCREENING,THESE
COX,HOWEVER,MEIER,NUCB2,PCA
167,956,ADVIA,ARCHITECT,CENTAUR,ELECSYS,FURTHER,G1200,HYBRITECH,LUMIPULSE,PASSING,PSA,WORLD
CHRONIC,CNS,HODGKIN,ICD,INCREASED,LABEL,METHODS,MORTALITY,OBJECTIVE,PCR,PURPOSE,RESULTS,SMR,SNC,SOUTH
APOPTOSIS,CONCLUSION,DU145,KNOCKDOWN,LABEL,METHODS,OBJECTIVE,PAI,PURPOSE,RESULTS,SFN,SIMILAR,TRANSWELL,WESTERN
NEWLY,PCA
EIGHT,IMAGE,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,TOF
115,124,386,COLORECTAL,COX,DIETARY,FURTHER,HOWEVER,OVARIAN,SCREENING,THESE,TRIAL
956,960,ABCC1,ABCC2,GST,III,INORGANIC,MMA,ODD,PRIOR,SOD,VARIOUS
EVS,LARGE
000,169,200,COPYRIGHT
ANN,ARBOR,BECAUSE,GLEASON,KARNOFSKY,ONKOPEDIA,TNM,WIKIPEDIA
JUN,PCA,RADIATION,THESE
169,736,754,ADT,AGE,COPYRIGHT,HIF1A,LTD,MOLECULAR,PCA,PCR,UNIVARIATE
AFTER,ATLASES,BACKGROUND,FINALLY,LABEL,METHODS,RESULTS,SIMILARITY,TEN
455,APRIL,BACKGROUND,GLEASON,LABEL,METHODS,MRI,PCA,PSA,RESULTS,SERUM
003,110,113,146,215,372,541,564,741,837,BLOCKED,CARLO,HIP,LABEL,METHODS,MONTE,OBJECTIVE,ORGAN,PURPOSE,RESULTS
AFTER,BACKGROUND,DESPITE,DIL,DU145,FURTHER,HOWEVER,INDIVIDUAL,LABEL,LNCAP,METHODS,RESULTS,SW620,USING,WASF3
000,100,124,133,149,169,259,392,542,746,759,ABC,AGE,BACKGROUND,COLORECTAL,CONCLUSION,COX,EFFECTIVE,LABEL,METHODS,NOMOGRAMS,OVARIAN,RESULTS,USING
024,125,169,1930S,211,372,636,987,ADJUSTMENT,ADULT,BACKGROUND,BIRTH,COPENHAGEN,COX,CSHRR,HOWEVER,HRS,LABEL,METHODS,RECORDS,RESULTS,THERE
AFTER,CHILE,INSTITUTE,NUTRITION,PREVENTION,THESE,WORLD
037,177,ACCORDING,BACKGROUND,GROUP,IFS,LABEL,METHODS,PCA,PRE,RALRP,RESULTS,THEREFORE
946,CD133,DUE,HOWEVER,LABEL,SIMILARLY,THESE,UNLABELLED,WNT
ACCURAY,BACKGROUND,D20,D50,DELIVERING,LABEL,MATERIALS,MEDICAL,METHODS,MULTIPLAN,RESULTS,SUNNYVALE
ASIAN,GNRHA
100,ATP,IKK,M659G,PKD,PP1,SAR
APO2L,BACKGROUND,DR4,DR5,JAK,LABEL,MCL,MONOCLONAL,PREVIOUSLY,PRINCIPAL,RESULTS,SOLUBLE,STAT3,TRA,TRAIL,TUNEL
916,CHROMATIN,EXPRESSION,FURTHER,GBM,GLI,GLI3R,THESE
33258,ANXA1,BACKGROUND,BAK,BAX,BCL,CONCLUSION,DU145,ERK,EXPRESSION,FURTHER,HOECHST,LABEL,METHODS,NAB,PC3,PCR,RESULTS
037,APC,BACKGROUND,BCR,CHINESE,CONCLUSION,CPG,ENGLISH,FURTHER,GST,GSTM1,GSTP1,LABEL,LANGUAGES,MATERIALS,MEDLINE,METHODS,RARBETA,RESULTS
AFRICAN,BPH,CAUCASIAN,GLEASON,REDUCTION
000,205,300,518,ADT,BACKGROUND,CONCLUSION,CUMULATIVE,HIP,LABEL,METHODS,PCA,RESULTS
120,945,946,CASTRATION,CD133,CELLS,CIC,CK5,ERG,HORMONE,INITIATING,PSA,RESISTANT,SSEA4,STAGE,TMPRSS2
100,181,BACKGROUND,CD133,CSC,LABEL,NOD,PCR,PRINCIPAL,RESULTS,SBT
NUCLEIC,SNP,SUFFICIENT,WHILE
001,AGREEMENT,BLAND,CONCLUSION,FIFTY,LABEL,METHODS,MRI,OBJECTIVE,PEARSON,PET,PURPOSE,RESULTS,SUVMEAN,VOI
002,005,007,023,030,041,049,085,1465C,196,197,199,202,261,300,357,625,648,667,776,815,835,CHINESE,LABEL,THESE,UNASSIGNED,UNLABELLED
ACTIVATED,AKT,CONVERSELY,FOXO3,GFP,NSC126188,TAKEN,THESE
119,203,233,506,697,DEPRESSION,DEPRESSIVE,ELECTRICIT,GAZ,GAZEL,HOWEVER,JANUARY,OVERALL,SCALE,STUDIES
946,AIF,ELLAGIC,FINALLY,HUR,LNCAP,ROS,SIRT1,TGF
MOLECULAR,PET
PCA
COLLEGE,PATIENT,SOCIETY
169,COPYRIGHT,INC,LCC,LNCAP,PCR,SNP
169,AMONG,LNCAP,PCR
019,114,166,169,177,326,BACKGROUND,CRPCS,ERG,LABEL,METHODS,RESULTS
002,012,023,044,087,089,094,111,312,341,434,458,488,530,551,573,610,656,668,865,918,964,CHECKLIST,GUIDELINES,HOWEVER,LABEL,LIBRARY,LOS,MATERIALS,METHODS,NETWORK,OBJECTIVE,OPERATING,REFERENCES,RESULTS,THERE
001,130,160,200,285,BACKGROUND,BPH,KAYSERI,LABEL,MATERIALS,METHODS,OUTPATIENT,PSA,RESULTS,THERE,UROLOGY,WBC
037,967,AFTER,AIM,LABEL,METHODS,OBJECTIVE,RATES,RESULTS,SIXTY
207,326,450,SEOUL
100,137,947,967,ANOVA,KRUSKAL,PERIPHERAL,WHITNEY
489,AFTER,PSA,THESE
169,191,22Q11,292,483,ELISA,GAG,HERVS,III,LABEL,METHODS,OBJECTIVE,PATIENT,PURPOSE,RES,RESULTS,SERUM,WHILE
120,215,ASSESSMENT,CONCLUSION,FEW,FUNCTIONAL,HFSSS,HOT,LABEL,METHODS,NEITHER,OBJECTIVE,PURPOSE,QOL,RESULTS,SOY,THERAPY
CYP24A1,LOCAL,REMARKABLY
102,301,352,398,775,797,843,ADVERSE,BACKGROUND,COU,CYP17,HRS,LABEL,METHODS,ORR,PSA,RESULTS,TREATMENT
109,ARM,BACKGROUND,BMD,LABEL,METHODS,QOL,RESULTS,SECONDARY,VITAMIN
169,945,954,COPYRIGHT,DU145,DUSP1,FEDERATION,JNK,OVERALL,PUBLISHED,SOCIETIES,THESE,TNF
EXPRESSION,FURTHER,INSULIN,THERE
169,CASPASE,CELLS,COPYRIGHT,GMP,IRELAND,JNK,LTD,NOS,PDT
160,169,574,COPYRIGHT,FOLLOWING,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,STUDIES,TREATMENT
169,171,808,CONCLUSION,COPYRIGHT,EVALUATING,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SINCE
169,177,956,CAFFEIC,COPYRIGHT,DHT,HOWEVER,LNCAP,LTD,PSA,SEVERAL
145,THESE,THR68,TYR15,WEE
000,100,200,THERE
018,117,BILATERAL,CONCLUSION,GLEASON,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,T1C
146,FINALLY,RESULTS
AFRICAN,COUNCIL,EVALUATING,INSTITUTE,SUGGESTED
100,BACKGROUND,CONCLUSION,JANUARY,LABEL,METHODS,MRI,OVERALL,PSA,REASONS,REGARDING,RESULTS
AMONG,CURRENTLY,DESPITE,HOWEVER,LABEL,MEDLINE,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS
005,008,019,153,232,247,265,312,99M,ACCORDING,CONCLUSION,EDTMP,LABEL,LBM,MDP,METHODS,OBJECTIVE,PATIENT,PLT,PURPOSE,RESULTS,ROC,USING,WBC

946,GLEASON,LNCAP,THERE,THESE
22RV1,945,946,ADIOL,AKT,DPN,GLEASON,KNOCKDOWN,LNCAP,PC3,VE2
LINC00913,SCHLAP1,SNF,SWI,THESE
169,177,201,AUC,COMPOSITE,COPYRIGHT,EDUCATION,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,4EBP1,AKT,CAP,CD326,CHEMO,COPYRIGHT,DU145,EPCAM,EXPRESSION,LNCAP,LTD,PCR,S6K,WESTERN
169,ASIC1,CANCEROUS,COPYRIGHT,FINALLY,IRELAND,KNOWLEDGE,LTD,NGF,TRPV1
003,005,109,169,183,542,546,APRIL,ASSESSMENT,BACKGROUND,BETWEEN,BPI,BRIEF,COPYRIGHT,FUNCTIONAL,HRQOL,INVENTORY,IQR,LABEL,LTD,METHODS,RESULTS,SHORT,THERAPY,THESE
001,10172,160,169,229,ACUTE,AMONG,BACKGROUND,COPYRIGHT,INC,INSTITUTES,ISP,LABEL,METHODS,NORSTROKE,NORWEGIAN,ORG,PUBLISHED,RESULTS,SCALE,TREATMENT,TRIAL
169,ARB,BACKGROUND,BBS,CCB,COPYRIGHT,COX,HOWEVER,LABEL,LTD,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,PROGRAM,PROVINCIAL,PUBLISHED,RESULTS,TDS,THERE
160,169,BOWEL,CONCLUSION,COPYRIGHT,INC,INCREASING,LABEL,METHODS,OBJECTIVE,RESULTS,SEVERAL,SIXTY,TREATMENT
160,169,179,516,ATYPS,BECAUSE,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
100,169,177,231,CONCLUSION,COPYRIGHT,DIR,DSC,HOUNSFIELD,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX,UNDER
169,330,346,655,CIEDS,COPYRIGHT,INC,LABEL,MARCH,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PBT,PURPOSE,RESULTS,SIX
169,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,DISCUSSION,EVADING,FDA,LABEL,LTD,METHODS,MODULATION,RESULTS
10878,169,70YEARS,85YEARS,AMONG,BACKGROUND,CONCLUSION,CONFIRMED,COPYRIGHT,CROWN,CYP17,LABEL,LTD,METHODS,OVERALL,PSA,PUBLISHED,RESULTS
163,169,256,280,954,AMONG,ERG,FURTHER,GLEASON,TMPRSS2
175,208,253,365,650,AFTER,APRIL,ASA,AVERAGE,BACKGROUND,BOARD,INDEX,INDICATION,LABEL,LONGEST,METHODS,MORBIDITY,OBJECTIVE,OCTOBER,PURPOSE,RADICAL,RESULTS,SEVEN,SOCIETY
161,223,277,946,III,KARAMOUZIS,MED,NONHORMONE,NOVEL,ONCOL,PAPATSORIS,PHASE,REGARDING,SOC
001,768,ANOVA,BACKGROUND,BLACK,GLEASON,LABEL,METHODS,PSA,RESULTS,WBC,WHITE
AFRICAN
169,BACKGROUND,LABEL,MATERIALS,METHODS,RESULTS,SPANISH,WEB
BACKGROUND,CXCR7,HS5,LABEL,METHODS,PC3,PCA,RESULTS,UTILISING
150,945,946,CAP,EXPRESSION,HOWEVER,PRY,SIMILARLY
HODGKIN,REPORTS,VARIOUS,WORLD
565,GLEASON,PCA,PSA,RAS,RASSF1A,STRATIFIED,THEREFORE,THESE
PARACRINE
200NM,22R,957,ADP,BAX,BCL,HOWEVER,PCA,THROUGH,TREATMENT
169,CD11B,GR1,MMP,PTHRP,SRC,TAKEN
100,222,532,649,745,767,984,BACKGROUND,EIGHT,INTER,IRELAND,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE,THESE
114,116,132,177,237,263,374,CONCLUSION,HOWEVER,LABEL,MBQ,METHODS,OBJECTIVE,PCS,PET,PSA,PURPOSE,RESULTS,THEREFORE
136,138,ERG,OVERALL,TMPRSS2
HOWEVER,TAM,THERE
ASSAY,BACKGROUND,BASED,CONTEXTUAL,EARLY,EGAPP,EVALUATION,GEN,GENOMIC,GROUP,LABEL,PREVENTION,PROBE,RATIONALE,RESULTS,SUMMARY,UTILITY,WORKING
34B,916,936,GSH,MYC,ROS,THROUGH,USP2A
00001,044,AGE,ANGLIAN,BACKGROUND,CONCLUSION,INCREASED,IRS,KINGDOM,LABEL,METHODS,NETWORK,PSA,RESULTS
159,169,205,500,AMONG,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PREDICTORS,PUBLISHED,PURPOSE,RESULTS,SWEDISH,T1C,UROLOGICAL
169,177,AFTER,AMONG,APRIL,COPYRIGHT,EDUCATION,HEMOSTATIC,HOWEVER,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
169,ACCURAY,COLLEGE,COPYRIGHT,CYBERKNIFE,ECLIPSE,GIVEN,HOWEVER,III,LABEL,LTD,MATERIALS,METHODS,OAR,OBJECTIVE,PTV,PUBLISHED,RESULTS,ROYAL,THERE,VSI
169,COPYRIGHT,FINALLY,HOOGSTEEN,INC,PC3,PPRHS,SP1,THESE
169,C842KSAKDR,COPYRIGHT,D847E,FURTHER,INC,K843M,K846M,LIPID,PTP,REDUCED,TAKEN,USING
COLLEGE,PATIENT,SOCIETY
13Q,13Q14,162,169,COPYRIGHT,GLEASON,HOWEVER,INC,OLFM4,PATHOLOGY,PUBLISHED,SOCIETY
003,005,008,012,047,064,143,179,213,283,293,343,416,457,505,859,898,983,ABSTRACTS,ASSESSMENT,BACKGROUND,BETWEEN,CENTRAL,CITATIONS,CONCLUSION,CONFERENCE,CONTROLLED,CURRENT,EED,EFFECTS,EVALUATION,FUNDING,GLEASON,HTA,INDEX,INDEXED,INSTITUTE,LABEL,MEDLINE,METHODS,MRI,NETWORK,NHS,NON,OBJECTIVE,OBJECTIVES,OTHER,OVERALL,PORTFOLIO,PROCESS,PROGRAMME,RESULTS,REVIEWS,SCC,SCIENCE,SERVICE,SEVENTEEN,SEVERAL,SOURCES,SYSTEMATIC,TECHNOLOGY,THERE,TYPES,UKCRN,WEB
ALP,BACKGROUND,BSP,CASTRATION,ET1,FINALLY,LABEL,METHODS,OPG,OPN,PC3,RESISTANT,RESULTS,RUNX2
ADDITIONAL,BACKGROUND,CIS,CONCLUSION,HOWEVER,LABEL,MEDLINE,METHODS,OVERALL,RESULTS,RRS,WESTERN
947,ATM,ATR,BRCA1,COMET,CONSISTENT,RICCARDIN
231,DEFICIENT,DKK,HOMOLOG,MDA,THESE,TREATMENT
001,008,398,ABOUT,LABEL,METHODS,OBJECTIVE,PATIENT,RADICAL,RESULTS,T3B
CAREFUL,SCORE,SUNITINIB,SYMPTOM
001,003,004,107,160,BACKGROUND,HOWEVER,LABEL,METHODS,RESULTS,SPINE
028,956,AKT,BIM,DISRUPTION,LNCAP,THESE,TRAMP
THEIR
908,946,BPH,FID,POWDERS,SAMPLES,SAW
945,DEPLETION,HIF
285,291,CONCLUSION,COX,LABEL,LINDA,MEDICAL,MEIER,PATHOLOGY,PCV,RESULTS,UNIVERSITY,UNLABELLED
HOWEVER,TGI,THEIR
FINALLY,GNR
954,AFRICAN,AMERICANS,CAUCASIAN,CHINESE,GLEASON,LNCAP,MET,NEUROPILIN,NRP,RANKL,THESE
COMMITTEE,ERG,GLEASON,JOINT,TMPRSS2
150,648,ADHERENCE,ATTRITION,AUTHORS,BACKGROUND,CENTRAL,COLLECTION,CONTROLLED,DESPITE,HENCE,HOWEVER,ISSUE,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PEDRO,PSYCLIT,RESULTS,SELECTION,SMD,THESE,WHICH
017,035,039,196,APRIL,BETWEEN,CONCLUSION,DFS,FACTORS,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE,TREATMENT
402,513,622,672,679,763,785,839,870,AUC,BPH,CONCLUSION,LABEL,METHODS,METHYLIGHT,OBJECTIVE,PCR,PSA,PURPOSE,RESULTS,SEARCHING,YAM
BACKGROUND,CONCLUSION,CRITICALLY,IMPERATIVE,LABEL,METHODS,RESULTS,UNMET
102,28A,400,DE3,ELISA,SDS,TAG,THESE,WESTERN
BMSCS,DU145,LNCAP,PC3,PCA,SILENCING,WNT5A
136,217,219,615,787,A1C,ABSENCE,BACKGROUND,EARLIER,FRAMINGHAM,HEART,HRS,IFG,INCREASED,LABEL,LIFESTYLE,METHODS,OBESITY,OFFSPRING,RESULTS,SASV9,SERUM
169,1RA,1RI,945,946,COPYRIGHT,COX,EXPRESSION,GLEASON,INCREASED,LTD,MEIER,PSA,REDUCED,REMARKABLY,TNF,TNFRI,TRAF2,TRAF6
169,215,AD5,BIOLOGY,CMV,COPYRIGHT,FEDERATION,IMPROVING,INC,LUC,MBS,PUBLISHED,ULTRASOUND,WORLD
169,BMI,CONCLUSION,COPYRIGHT,ESTIMATED,INC,LABEL,LRP,METHODS,OBJECTIVE,POTENTIAL,RESULTS,RETZIUS,VFA
169,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,FRANCIM,LABEL,LTD,METHODS,NET,RESULTS
169,CSC,HENCE,MYC,NOTABLY,SEVERAL,TREATMENT
135,613,751,761,BACKGROUND,GEO,H19,LABEL,METHODS,RESULTS,ROC,TNM,TOTAL
160,177,BPH,PSA,RESULTS
123,125,CARBOXY,CYS,GLU,IGLCE,LNCAP,RESULTS,THESE
CURRENTLY,HIV,NOTABLY,PROTEASES,THEREFORE,THESE
001,260,734,889,898,CONCLUSION,COX,END,HODGKIN,LABEL,MARRIED,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
287,377,664,774,863,ACTUARIAL,BCR,COX,GLEASON,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
044,069,079,1ST,250,265,277,2ND,3RD,500,517,641,688,689,730,750,BCRFS,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSM,RARPS,RESULTS,RRP
496,509,ASSOC,SINCE
100,160,FEW,LABEL,MEN,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SIX,TPB
013,065,256,477,58102,AFRICAN,AMERICANS,AMONG,ASSAY,ASSESSMENT,BACKGROUND,CAUCASIANS,COX,GENOTYPING,LABEL,MEN,METHODS,PROGRAM,PSA,RESULTS,SNP
741,BACKGROUND,COX,HRS,JANUARY,LABEL,METHODS,RESULTS,STATINS
FURTHER,MRI,OTHER,REPORTING,STANDARDS,START
FACTORS,HOWEVER,MRI
001,BACKGROUND,BPH,CONCLUSION,CRP,GLEASON,IIA,LABEL,LNCAP,MATERIALS,METHODS,PCA,PSA,RESULTS,SAA,SERUM,THESE
184,BACKGROUND,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,SMALLER,TCC,UROLOGISTS,WIDESPREAD
AFRICAN,ANTIGEN,ASIAN,BACKGROUND,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,PSA,RESULTS,SOUTH,STAGE,WHEREAS
169,COPYRIGHT,CROWN,DETECTION,POC,POINT,PUBLISHED
125,145,169,297,306,ABA,CAMV35S,COPYRIGHT,GFP,GUS,MIRABILIS,MUAS35SCP,NICOTIANA,PETUNIA,PROTEIN,UAS
025,037,169,275,668,AUC,COPYRIGHT,COX,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS,ROC,T1C,TREATMENT,UROLOGICAL
169,185,CCL,COPYRIGHT,DU145,HTB,LTD
001,002,005,024,10878,125,169,175GY,225,3MONTHS,5CC,5CM,BACKGROUND,COPYRIGHT,ENDPOINTS,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PRE,PURPOSE,RESULTS,SCORE,SYMPTOM,VPR
001,10877,10878,135,169,2NG,ADT,AUTHORS,CONCLUSION,COPYRIGHT,CYBERKNIFE,IRELAND,LABEL,LTD,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS
109,215,BACKGROUND,CONCLUSION,CONVERSION,LABEL,METHODS,PHAGE,RESULTS,SCREENING,SUCCESSFUL
094,283,287,340,376,400,471,472,477,497,519,542,608,677,AGREEMENT,CCC,CONCLUSION,FIFTY,IMAGING,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,REPORTING,RESULTS,THREE
006,025,072,183,357,383,500,569,617,655,691,714,734,743,ADC,ADVERSE,AUC,CONCLUSION,FIFTY,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PARAMETRIC,RESULTS,STUDENT,T2A
610,645,800,BASED,GSH
CD4,HOWEVER,LNCAP,PCR
945,954,HOWEVER,LNCAP,STZ,TNF
001,422,AFRICAN,BURKINA,MEN,PCA,SIX,SIXTY
ADRB2,AKT,BAD,CONCLUSION,ELISA,ERK,LABEL,METHODS,OBJECTIVE,PEARSON,PKA,PURPOSE,RESULTS,S112BAD,THESE,WESTERN,Y204ERK
181,CSS,FORTY,GLEASON,LABEL,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,TEN
169,945,947,CURRENT,STUDIES,THEIR,THEREFORE,THESE
26A,NOTABLY,THESE,ZCCHC11
000,149,AMONG,HODGKIN,INFECTIONS,POISSON,USA
MRI
HENCE,NEDD4,UAF,USP12,WDR20
022,163,257,272,290,777,870,877,957,ABOUT,AIM,BACKGROUND,CALLS,GPS,LABEL,MEN,METHODS,MIDLAND,NETWORK,PCA,PSA,RESULTS,SCREENING,ZEALAND
132,169,946,954,AKT,BAY,COPYRIGHT,EST,HSD,IGF,IRELAND,LTD,NBD,PCR,PI3,STS,TAKEN,WESTERN
108,137,169,COLLEGE,COPYRIGHT,FIFTY,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,UCL,UNIVERSITY
002,014,021,064,169,310,372,398,508,540,698,BCR,COPYRIGHT,GLEASON,INC,IQR,LABEL,LNS,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS
001,169,257,AUASS,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OBTAINING,PREVENTION,PSA,RESULTS,SIX,TRIAL,UROLOGICAL
169,AUTHORS,COPYRIGHT,INC,INCREASING,PUBLISHED,SILAC,USING
169,ADT,COPYRIGHT,LTD
001,169,215,COPYRIGHT,FORTY,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS
169,946,ADT,BACKGROUND,COPYRIGHT,FUNCTIONAL,LABEL,LNCAP,METHODS,OBJECTIVE,OUTCOME,PCA,PCR,PROOF,PUBLISHED,RESULTS,SETTING,UROLOGY,WNT
007,024,059,12Q,15Q,191,219,317,392,441,536,632,AMONG,ANTONIO,BIOMARKERS,CAUCASIAN,CAUCASIANS,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SAN,SOUTH,TEXAS
169,945,CACNA1D,CONSISTENT,COPYRIGHT,ERG,INC,TAKEN,THESE,TMPRSS2,WIDESPREAD
090,169,COMMITTEE,COMPETING,COPYRIGHT,CROWN,CSM,FUHRMAN,HOWEVER,III,INC,INCREASING,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OCM,POISSON,PUBLISHED,RCC,RESULTS,SIMILARLY
001,005,025,169,ADRB2,ADT,ASIC3,BACKGROUND,CFS,COMPARING,COPYRIGHT,CXCR4,DBI,HSPA2,LABEL,LTA,LTD,METHODS,NR3C1,P2RX7,P2RY1,PCF,PCR,PURINERGIC,RESULTS,THESE,TNF,VIPR2
169,AUTHORS,BJU,CURRENT,E2F,FURTHER,MDV3100,MYC,PERSISTENT
002,118,169,177,AUTHORS,BJU,EFD,INDEX,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PDE5I,PEARSON,RESULTS
169,ARDEN,AUTHORS,BJU,CLAVIEN,FOCAL,GALIL,GLEASON,HILLS,INC,INCLUSION,INDEX,JANUARY,LABEL,MARCH,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PRECISE,PSA,RESULTS,SCORE,SYMPTOM,T1C,T2A,THERE,URINARY,USA
001,169,268,443,AFTER,AMICO,AMONG,AUTHORS,BCR,BJU,CONCLUSION,COX,FAVOURABLE,GLEASON,INDEX,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,URINARY
001,002,003,005,169,227,AUTHORS,BETWEEN,BJU,C30,JANUARY,LABEL,METHODS,OBJECTIVE,ONB,QOL,RESULTS,TREATMENT
001,160,177,194,317,AFTER,BMI,SERUM,USING
153,169,174,307,634,AUTHORS,BETWEEN,BJU,GLEASON,JANUARY,LABEL,METHODS,OBJECTIVE,PER,PROCEDURES,PSA,RESULTS,THERE,TRB
BACKGROUND,DESPITE,EPS,LABEL,RESULTS,SH3,THESE,WHEREAS
120,169,345,661,AMONG,BJU,BLACK,CANCERS,COLORECTAL,CONCLUSION,GOVERNMENT,LABEL,METHODS,MORTALITY,OBJECTIVE,OVARIAN,PUBLISHED,RATES,RESULTS,SCREENING,USA
169,221,258,AUTHORS,BJU,CIS,CONCLUSION,DEFINITIVE,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,PSADT,RESULTS,THERE
003,009,028,169,ACCORDING,AUTHORS,BJU,BOO,BPE,EXCLUSION,INCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SCORE,SYMPTOM,URODYNAMIC
001,018,116,169,470,ACTUARIAL,AUTHORS,BCR,BCRFS,BJU,COX,CSS,GLEASON,LABEL,MEIER,METHODS,MFS,OBJECTIVE,PSA,RESULTS,THERE
003,016,169,211,280,484,663,AUTHORS,BCR,BJU,CONSIDERED,COX,ENE,IQR,LABEL,LNS,METHODS,OBJECTIVE,OVERALL,RESULTS
003,169,299,AUTHORS,BJU,LABEL,MAY,METHODS,OBJECTIVE,RADICAL,RESULTS,SEPTEMBER
169,184,AUTHORS,BJU,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SUCCESS,TECHNIQUE,THERE
127,169,AUTHORS,BJU,GLEASON,HITACHI,LABEL,METHODS,OBJECTIVE,PREIRUS,RESULTS,RTE,SIMILARLY,THREE
169,AUTHORS,BJU,CUMULATIVE,INDEX,LABEL,LIBRARY,LITERATURE,MEDLINE,METHODS,NURSING,OBJECTIVE,PCA,PSA,RESULTS,SIX,STUDIES
169,AUTHORS,BJU,PERFORMING
001,169,200,367,ADT,AUTHORS,BJU,BPH,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,RHAMM,THERE
169,173,272,AUTHORS,BJU,CONCLUSION,FGF23,LABEL,METHODS,OBJECTIVE,RESULTS,THREE
001,AUC,BACKGROUND,EORTC,LABEL,METHODS,MODEL,PURPOSE,RESULTS,SEVERAL,THEIR,V65
001,169,595,AFTER,AUTHORS,BCR,BJU,COX,GLEASON,HOWEVER,LABEL,MEIER,METHODS,OBJECTIVE,RESULTS,THEREFORE
207,COMPOSITE,HRQOL,INDEX,LABEL,METHODS,OBJECTIVE,RESULTS,URINARY
169,AUTHORS,BJU,EMT,JAK,JANUS,PI3,SERUM,VIA
001,136,142,169,263,298,AUTHORS,BJU,CONCLUSION,GLEASON,IMAGING,LABEL,METHODS,MRI,OBJECTIVE,PRIAS,PSA,RESULTS,T1C
033,125,169,ASTRO,AUTHORS,BJU,FURTHER,GLEASON,LABEL,LDR,METHODS,OBJECTIVE,PHOENIX,PSA,RESULTS,T2B
001,002,169,APRIL,AUTHORS,BJU,CONCLUSION,FORCE,HOWEVER,LABEL,MASTERFILE,MEDICAL,METHODS,OBJECTIVE,OVERALL,PHYSICIAN,PREVENTIVE,PSA,RESULTS,USA,WHILE
001,004,032,169,195,197,247,315,AUTHORS,BJU,END,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OPERATIVE,POPULATION,RESULTS,RPS,RRP,USA
002,018,107,169,ADDITIONAL,AUSTRALIA,AUTHORS,BJU,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SHORT,THERE,URINARY,WESTERN,WILEY
169,411BN,APRIL,AUTHORS,BIOLOGICAL,BJU,COMPOUNDS,CURRENTLY,GIVEN,III,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PHASE,RESULTS
160,BAX,BCL,MTT,PCR,THESE,USING,WESTERN
000,031,100,128,146,167,169,174,AGE,AUSTRALIA,AUSTRALIAN,AUTHORS,BJU,CONCLUSION,DESPITE,GLEASON,INSTITUTE,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PSA,RESULTS,SCREENING,THERE,VICTORIAN,WELFARE
098,155,235,4F2HC,571,962,987,ASCT1,ASCT2,BACKGROUND,BCH,CDC20,CONCLUSION,E2F,FINALLY,INHIBITION,LABEL,LAT,METHODS,RESULTS,UBE2C,WHITNEY
215,ADV,DESPITE,FIRST,MONTERREY,PSA,THERE
DIETARY,EXOGENOUS,HOWEVER,LNCAP,PIAS1,SMAD2,SMAD4
205,22RV1,691,945,BACKGROUND,CONCLUSION,CWR22,DLKPA,DU145,EL102,LABEL,METHODS,MULTIDRUG,RESULTS,TAXANES,TUBULIN
947,FGF
001,223,945,FDA,FURTHER,III,MAY,RACL2
103,186,ART,CUMULATIVE,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PROPENSITY,RESULTS,SRT,TEN,THESE
005,169,183,BACKGROUND,BAHNA,COPYRIGHT,DEFENSE,DEJORIA,DEPARTMENT,FOUNDATION,FUNDING,GREENBAUM,IQR,LABEL,LTD,MEN,METHODS,NCI,NIH,RESNICK,RESULTS,SAFEWAY
001,035,169,412,906,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,169,193,763,911,920,929,BETWEEN,COPYRIGHT,END,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,USING
CMP,SPR,SURFACE
AREAS,BACKGROUND,COVERED,LABEL,METHODS,OPINION,THEIR
ENGLISH,THERE,WHETHER
174,177,AMERICA,CONCLUSION,GAFCHROMIC,HITACHI,HOUSTON,ISP,KNOWLEDGE,LABEL,LTD,METHODS,OBJECTIVE,PHYSICS,RESULTS,RPC,TARRYTOWN,TEXAS,THERAPY,TPS,UNIVERSITY,WAYNE
118,499,ADULT,BMI,CIS,HOWEVER,LABEL,METHODS,OBJECTIVE,ORS,OVERWEIGHT,PURPOSE,RESULTS,USING
001,007,389,BCR,BCRFS,CONCLUSION,COX,FIFTY,GLEASON,JAPAN,LABEL,MATERIALS,METHODS,OBJECTIVE,PREDICTORS,PSA,PURPOSE,RESULTS
145,916,936,BAK,HISTONE,HRPCS,MCL,RPA32
169,ANTITUMOR,GRP78,HUMANIZED,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
BPH,CAVITATION,FOLLOWING,HENCE,THEREFORE
PSA
BPH,DUE,PSA,TDS,TRT
AGING,CURRENTLY,NIH,THERE,THESE
DRE,PSA,REFERENCES,TRT
110,DEFICIENCY
PSA,SINCE
145,H2O,INITIAL,LNCAP,METAL,MN8FE4O12,MRI,NMR,THESE,VBA
945,946,954,AKT,CULTURING,ECM,FAK,MMP,PKB,STUDIES
448,683,AMINO,ARG,PYA,TAK,TRP,TYR
280,FINALLY,SEVERAL
118,APOA4,ESI,FPA,PARTICULAR,STUDIES,THESE,WHEREAS
056,682,841,945,C111A,CHINA,FURTHER,HIF,HOWEVER,KNOWLEDGE,OVERALL,THEREFORE
BACKGROUND,BIO,CALIFORNIA,FINALLY,LABEL,MASON,METHODS,OVERALL,RESULTS,RUF,SEVERAL,UNIVERSITY,USC
BASED,DESPITE,INTERVIEWS,MODEL,MOTIVATION,PRISM,RELATIONAL,TEN
BACKGROUND,CONCLUSION,ENGLAND,EPS,LABEL,METHODS,RESULTS
001,160,169,AFRICAN,AFTER,ASIAN,BMI,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PVS,RESULTS,SCORE,SYMPTOM,THERE,USAGE
001,169,504,531,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,NMP22,OBJECTIVE,RESULTS
103,125,131,160,169,COPYRIGHT,D90,EXCELLENT,FURTHER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,AUTHORS,BACKGROUND,COPYRIGHT,DESPITE,IRELAND,LABEL,LTD,MEDLINE,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,QOL,RESULTS,STUDIES,SYSTEMATIC,THERE
003,104,169,177,916,COPYRIGHT,COV,CTV,D95,ERB,EUD,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEN,WHILE
CELLS,OVERALL,PC3,RELEASE,ROS,WHILE
LNCAP,MDV3100,SAR,STRUCTURE,THEREFORE
001,103,108,140,229,337,910,BCR,CONCLUSION,COX,HOWEVER,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PSM,RESULTS,ROBOT,UNIVERSITY
004,006,028,042,120,432,660,CONCLUSION,DENOSUMAB,ENROLLMENT,LABEL,METHODS,OBJECTIVE,PSA,PSADT,PURPOSE,RESULTS
160,FINALLY,TREFOIL
BINDING,CURRENTLY,PCR,PSA,THEREFORE
PRIMARY
008,029,178,280,ACCORDING,CHANGES,ESTIMATED,HOWEVER,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
945,ANTITUMOR,BACKGROUND,BIP,CCAAT,CDK,CELLS,EXPRESSION,GADD153,GRP78,IIA,LABEL,LNCAP,METHODS,RADIX,RESULTS,SALVIAE,TAN,TANSHINONE,THESE
106,188,BETWEEN,CONCLUSION,CURRENTLY,DESPITE,FURTHER,GERMANY,LABEL,MAY,METHODS,OBJECTIVE,OCTOBER,RESULTS,VCD
BMP,CAF,SEVERAL
100,116,160,169,COPYRIGHT,D10,HDR,INC,LABEL,LARGE,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,AKT,AML,COPYRIGHT,I3C,INC,OSU,ROS,THP
169,DOTAU,ELECTRONIC,KNL,NUCLEOSIDE
169,92A,CD133,CURRENT,CYP,DTX,HOWEVER,SEVERAL
BACKGROUND,CDS,CONCLUSION,DCE,DWI,FALSE,GLEASON,LABEL,METHODS,MRI,MVD,RESULTS,WHITNEY
001,176,FINALLY,LIGHT,MONOCLONAL,RLU,THERE,THESE
001,138,22RV1,CPG,DU145,EPH,EPHA1,GLEASON,INCREASED,LNCAP,PC3,PCR
112,22RV1,AKT,BAD,CDC42,DAILY,GTPASES,PAK,RAC,RHO,THESE
BAD,MCL,MYELOID,THESE,YET,ZSTK474
000,480,ATLAS,BESIDES,CHG,CPG,FASTDMA
571,580,588,A111E,CHAIN,FINALLY,GLYOXALASE,PCA,POLYMERASE
300,946,ADAPTOR,BCH,BMCC1,C9ORF65,COMPLEX,CONSISTENT,E1B,GST,GTP,INSTEAD,PRUNE,RAB,RELATED
149,190,GIVEN,HDLEC,IBC,REDUCTION,SUM
100,464,BASED,COLLECTION,ENGLISH,ICS,LABEL,METHODS,NLP,OBJECTIVE,OBJECTIVES,RESULTS,SENTIMENT,TOTAL,UNMET,WEB
169,179,682,AUC,BACKGROUND,FPSA2,GLEASON,HGPCA,HOWEVER,INC,LABEL,MEANWHILE,METHODS,PCA,PSA,PSAD2,PSADT,RESULTS,ROC,TPV,UNIVARIATE,WILEY
117,169,573,945,947,AMONG,BACKGROUND,COX,GLEASON,HOWEVER,INC,LABEL,METHODS,RESULTS,SEC14L2,SOD,WILEY
100,169,AZA,BACKGROUND,CONVERSELY,DNMT1,EVALUATION,GLEASON,HOWEVER,INC,LABEL,METHODS,PCA,RESULTS,THESE,TMA,TRAMP,TREATMENT,WILEY
000,169,200,480,945,BACKGROUND,CONCLUSION,CPG,FUNCTIONAL,INC,LABEL,LCM,METHODS,RESULTS,WILEY,XENOGRAFTS
169,182,780,946,BACKGROUND,HOWEVER,ICI,INC,LABEL,METHODS,PCA,PCR,RESULTS,USING,WILEY
001,169,175,922,ABOUT,AFRICAN,AMONG,BACKGROUND,CHINESE,CONCLUSION,CONSORTIUM,GLEASON,INC,LABEL,METHODS,ORS,PCA,RESULTS,SEVERAL,THESE,WILEY
001,015,415,430,ADHERENCE,BACKGROUND,CONCLUSION,ENDOCRINE,III,LABEL,METHODS,PHASE,RESULTS,THEIR,THESE,WHEREAS
002,169,548,726,735,834,AUC,DRE,PSA,SEVERAL,SNP
169,CURRENT,DHT,HOWEVER,INC,INHIBITION,PCA,WILEY
145,169,BACKGROUND,CONCLUSION,DESPITE,DU145,INC,LABEL,LNCAP,METHODS,P21,PC3,RESULTS,SERCA,THESE,THREE,WILEY
11P13,169,509,AFRICAN,AIM,AMERICANS,BACKGROUND,CAP,FEW,INC,LABEL,LOUISIANA,METHODS,NORTH,PROJECT,RESULTS,SNP,THESE,WILEY
169,215,667,ADDITIONAL,AUC,BACKGROUND,CHINA,CONCLUSION,HUASHAN,INC,LABEL,METHODS,PCA,RESULTS,SNP,UNDER,WILEY
169,232,239,BACKGROUND,BASED,CIS,INC,LABEL,METHODS,ORS,PCA,PSP94,RESULTS,SIMILAR,THESE,WILEY
946,HOWEVER,SMAD2,TARGETING,TGF,UTR
DISRUPTION,THERE,THESE,TRAIL
248,BETWEEN,CLAVIEN,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,OCTOBER,PATHOLOGY,PSA,PURPOSE,RESULTS,T3A,THERE
160,FIFTY,IHC,ISLET,NET,PAP,SINCE,THERE
046,145,ADVANTAGES,COMPARE,MDR,MECHANISM,NCI,OVERALL,SMAD4
BACKGROUND,CURRENTLY,LABEL,MATERIALS,METHODS,MORALES,MRI,OBJECTIVE,OBJECTIVES,RESULTS,SVI,T3B,THESE
001,002,007,413,485,734,BMI,CHINESE,ECE,FURTHER,GLEASON,HOWEVER,MRI,PATIENT,PCA,PEARSON,SAT,SVI,VAT
197,205,ALP,COX,GLEASON,MEIER,PCA,THESE
160,603,657,AFTER,APOC1,CIS,COX,CRP,GRS,HNF1A,HRS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
177,ALGORITHM,INTENSITY,SEQUENTIAL,VOLUMES
CYBERKNIFE,EIV,THERE,TODAY,TREATMENT,V75
PHASE,RPM
169,ACTIVATION,CONVERSELY,DU145,EGF,FINALLY,PCSCS
956,AFTER,DCM,JACARANDA,MCF,PC3
169,947,ATM,COPYRIGHT,EDUCATION,FEW,INC,INDUCTION,LABEL,MATERIALS,METHODS,NOTABLY,OBJECTIVE,PUBLISHED,PURPOSE,REGARDLESS,RESULTS,UROLOGICAL
169,465,BACKGROUND,CALIFORNIA,COPYRIGHT,DISEASE,FRANCISCO,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SAN,SETTING,UNIVERSITY
001,169,521,ANALYZE,BACKGROUND,COPYRIGHT,CSM,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PSM,PUBLISHED,RESULTS,SETTING,UROLOGY
169,COPYRIGHT,IRELAND,LTD
169,99M,ALA,ARG,ASN,CONH2,COPYRIGHT,DYNAMIC,ESI,GLN,GLY,GRP,H2O,LEU,LTD,MBN,MET,PC3,TECHNETIUM,TRP,VAL
169,COPYRIGHT,FINALLY,INC,MICRO
001,100,169,177,ATA,COMPOSITE,COPYRIGHT,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SYMPTOM
001,169,945,ADT,BIOLOGICAL,COPYRIGHT,CWR22,HK2,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,SIX
007,169,215,AKT,BP1,CONCLUSION,COPYRIGHT,ERG,EXPRESSION,INC,LABEL,METHODS,OBJECTIVE,RESULTS
002,004,140,143,169,177,AFTER,CONCLUSION,COPYRIGHT,GROUP,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE
001,143,169,177,196,ACCORDING,AMICO,BACKGROUND,CONCEPTION,CONCLUSION,COPYRIGHT,LABEL,MARSEILLES,OBJECTIVE,OBJECTIVES,RESULTS,SAS,SBR,THERE,UROLOGY
169,COPYRIGHT,LONGWOODS,ONTARIO,PUBLISHING,SINCE
169,233,241,243,COPYRIGHT,PUBLICADO,QUATERNARY,THROUGH
169,AFTER,CLUSTERING,ICP,INNER,LTD,PREDICTION
177,189,AVERAGE,BACKGROUND,BENEFIT,CALYPSO,D99,DMEAN,DOSIMETRIC,DVH,HOWEVER,INITIAL,IRB,LABEL,LARGEST,MATERIALS,MEDICAL,METHODS,MRI,OAR,OBI,OBJECTIVE,PER,PRECISE,PRIOR,PTV,PURPOSE,RESULTS,RIGID,T2C,UNIVERSITY,V50,VAN
169,946,AKT,CCL20,CXCL1,FURTHER,GSK3B,INSULIN,LTD,MEF,MELATONIN,OBESITY,PC3,PUBLISHED,WILEY
169,325,865,AUTHORS,BACKGROUND,BRITISH,DIETARY,DIETETICS,JOURNAL,LABEL,LTD,METHODS,NUTRITION,RESULTS,THREE,WALNUTS,WILEY
169,HCC,HNSCC,HOWEVER,THEREFORE
100,139,147,169,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,T1C,T2A,T2C,THERE,UROLOGICAL
916,946,H3K27,JAK,MTS,PRL,PROLACTIN,WESTERN
AREAS,BACKGROUND,COMPELLING,COVERED,LABEL,MDM2P,MECHANISMS,MELATONIN,METHODS,OPINION,SIRT1
008,048,109,131,171,177,BACKGROUND,BOOST,FURTHER,GRADE,LABEL,METHODS,RESULTS,SRT
AUC,INCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,PHS,POSTERIOR,PURPOSE,RESULTS,SEPTEMBER
11C,PET
945,946,AKT,BECAUSE,ERS
IGF,JANUS,LABEL,PCA,SOCS2,SRC,STAT5,SUMMARY,UNLABELLED
029,204,206,218,415,BMI,CHINA,HOWEVER,TAIXING,THESE
946,CRE,GHR,IGF,JANUS,LNCAP,PTP,SHP,STAT5
141,169,AUTHORITY,BASEL,COPYRIGHT,COW,DESPITE,DIRECTIVE,EARLY,THERE,UNMODIFIED
001,169,174,200,300,ADVERSE,AES,AUTHORS,BJU,EIGHT,LABEL,LDI,MEN,METHODS,MRI,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SOLUBLE,THERE,VTP
THESE
HSC,PC3,PCA,RAPAMYCIN,TAKEN
169,DNAPKCS,FINALLY,LABEL,SUBSEQUENT,THESE,UNLABELLED
169,FINALLY,LABEL,UNLABELLED,USING
169,189,463,740,ANXIETY,AUC,AUTHORS,BACKGROUND,BRIEF,BSI,COMPARISON,DEPRESSION,EVENT,HOWEVER,IES,INVENTORY,LABEL,LTD,METHODS,RESULTS,REVISED,SCALE,SYMPTOM,WILEY
FGFR1,GLEASON,PMP22,USING,VALIDATION
WORLDWIDE
120,167,DESPITE,HOWEVER,MEN,PCA
113,133,160,CRP,HOWEVER,HRV,NSCLC,PSA,THEREFORE
024,215,239,DOCETAXEL,PSA,THERE,TTN
001,174,956,ACE,BACKGROUND,LABEL,METHODS,PACLITAXEL,PC3,RESULTS
205,CNS,ESTIMATES,HODGKIN,LABEL,MEDLINE,METHODS,ORS,RESULTS
ART,BACKGROUND,LABEL,METHODS,TECHNIQUES
BACKGROUND,BPH,DUE,LABEL,METHODS,PCA,PSA,RESULTS,THEREFORE
169,DC1,OTHER,RECURRENCE
110,160,176,981,AFTER,DERENZO,DETECTION,FOV,OPENPET,PET,SEVERAL,THREE
946,ARD,CHRM1,INHIBITION,PCA,PNS,SCIENCE,SNS
DU145,INHIBITOR,LNCAP,MYC
COHEN,MYC,PROFESSOR,SET,SIR
593,603,833,971,BACKGROUND,COCHRAN,COMPARING,CONCLUSION,CONTROLLED,CURRENT,LABEL,METHODS,RESULTS,TRIAL
169,198,BCR,BPH,GLEASON,LABEL,LTD,METHODS,OBJECTIVE,PCA,RESULTS,THESE,WILEY
AREAS,BACKGROUND,COVERED,LABEL,METHODS,OPG,OPINION,RANKL
AREAS,BACKGROUND,COVERED,FURTHER,LABEL,METHODS,OPINION
216,259,945,950,ACETYLATED,ERK,HDAC6,HDACI,HISTONE,LNCAP,PCA,PP1,RAF
180,ANTIGEN,EUROPEANS,SNP,VENEZUELA
177,427,AFTER,AIM,BACKGROUND,CONCLUSION,DESPITE,LABEL,MARGINS,METHODS,NOVALIS,OBJECTIVE,RESULTS,SDS,SYSTEMATIC
169,BACKGROUND,BRONJ,CONCLUSION,FURTHER,HOWEVER,LABEL,METHODS,RESULTS,SEPARATION,SINCE
019,021,239,AIM,CAB,CONCLUSION,GLEASON,HORMONE,LABEL,METHODS,OBJECTIVE,PFS,RESULTS,THERE,ZOLEDRONIC
AFFAIRS,BACKGROUND,CONCLUSION,LABEL,MATERIALS,MEDICAL,METASTATIC,METHODS,NODAL,PCA,PSA,RESULTS,THESE,USING
169,177,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,MUL,OBJECTIVE,PRM,PURPOSE,RESULTS,WILEY
001,002,006,008,044,215,ADC,ANALYZING,GLEASON,LABEL,LOW,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THERE
BPH,HORMONE,SEX
215,586,CIS
100,273,ADENOVIRUS,BACKGROUND,CAR,CONCLUSION,COXSACKIE,EXPRESSION,HOWEVER,LABEL,METHODS,RESULTS,TMA
BACKGROUND,ERG,LABEL,METHODS,RESULTS,SCC,SMALL,WHILE
169,CONCLUSION,COPYRIGHT,CROWN,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROM,STUDIES
947,BACKGROUND,CBCTS,CONCLUSION,CTS,HOUNSFIELD,LABEL,METHODS,PDI,RESULTS
CELLSEARCH,FDA,METASTATIC,TAKEN
946,CARM1,GIVEN,HOWEVER,THEREFORE,TREATMENT
169,509,ARN,F876L
006,112,169,ANOVA,BACKGROUND,FAMOTIDINE,FURTHER,INC,LABEL,MAGNITUDE,METHODS,RESULTS,WILEY
BMD,ENDOCRINE,SECONDARY,SOCIETY
135,169,505,BACKGROUND,GLEASON,HOPKINS,INC,JOHNS,LABEL,MEIER,METHODS,PREDICTORS,PSA,RESULTS,WHILE,WILEY
015,954,ERC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,QUALITY,RESULTS,SNR
310,376
AKT,HENCE,LNCAP,MMP,OROSTACHYS,TAKEN,TER,TIGHT,TIMPS,TJS
HOWEVER,IDC,THEREFORE
001,106,177,200,AMONG,AUR,BACKGROUND,BPO,FOLLOWING,LABEL,METHODS,PFR,RESULTS
001,58102,AGENT,BACKGROUND,BCR,GLEASON,HOWEVER,LABEL,METHODS,NEITHER,RESULTS,TEQ
1980S,1990S,FINALLY,HDR
HOWEVER,MHC,NKG2D,TRAMP
169,174,20YEARS,DOXIL,INCREASED,PNM,SINCE
169,625,COMMITTEE,COPYRIGHT,CURRENT,EDUCATION,FUHRMAN,HOWEVER,INC,IQR,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SMOKING,TREATMENT,UROLOGICAL
041,169,403,591,COPYRIGHT,EDUCATION,HOWEVER,INC,JANUARY,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
AFTER,BACKGROUND,FURTHER,GLEASON,IBD,LABEL,METHODS,PSA,RESULTS,THERE
169,2GY,3GY,4N1M0,945,946,ACTUARIAL,BACKGROUND,CONCLUSION,COPYRIGHT,CTC,IRELAND,LABEL,LTD,MEIER,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,RILIT,THREE
041,100,10877,169,239,ACUTE,AFTER,COPYRIGHT,END,FORTY,INCIDENCE,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
COMPARISON,EXCLUSION,NUCLEIC,REMOVAL,SELECTIVE,SNARE
177,956,BACKGROUND,CONCLUSION,DORSTENIA,LABEL,METHODS,MTT,RESULTS,ROS
145,956,DOPPLER,OXI8006,OXI8007,SAR
945,946,947,LNCAP,POLYAMIDE,WHILE
169,COPYRIGHT,CYTOTOXIC,FEW,HENCE,SAS,SIRT1
160,169,674,CONVERSELY,COPYRIGHT,HOWEVER,INC,OVERALL,PATHOLOGY,PUBLISHED,SOCIETY
169,315,788,ATR,COPYRIGHT,EIF2AK1,GLYR1,HOWEVER,IRELAND,LNCAP,LTD,PSA,USING
169,177,COG,DESPITE,KEY,LABEL,METHODS,OBJECTIVE,RESULTS
169,342,COPYRIGHT,EDUCATION,INC,INDEX,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WHILE
169,AKT,CK2,COPYRIGHT,LTD,MMP
169,AUTHORS,COPYRIGHT,HOWEVER,IRELAND,LTD,MICROARRAY,NSCLC,PUBLISHED,WHILE
169,BECAUSE,COPYRIGHT,HOWEVER,PUBLISHED,SAS
169,BACKGROUND,CONTEXT,COPYRIGHT,CURRENT,DECADES,LABEL,MEDLINE,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,THESE,UROLOGY
1A1,CYTOSOLIC,SULT1A1,SULTS
169,252,AKT,BAX,BCL,CONCLUSION,ERK,FUNCTIONAL,LABEL,LTD,MATERIALS,MAY,METHODS,MTT,OBJECTIVE,OBJECTIVES,PCR,RESULTS,TAKEN,THESE,WILEY
480,FATIGUE,FEMALES,PREDICTORS
103,106,AMACR,BACKGROUND,FINALLY,FIRST,GLEASON,IMAGE,LABEL,METHODS,PROCRUSTES,RESULTS,THREE,TRF
ELASTICITY,FINALLY,FORCE,IMAGING,MODULATED,RADIATION,SMURF,SPATIALLY,SUPERSONIC,ULTRASOUND,WAVES

017,145,265,775,CONCLUSION,COX,GLEASON,HDAC1,HDAC2,HDACS,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,UNIVARIATE
150,258,ACCORDING,CONCLUSION,LABEL,METHODS,MUNICIPAL,OBJECTIVE,QINGDAO,RESULTS
HOWEVER,MDV3100,PCA,WESTERN
109,169,897,ADDITIONAL,AREVA,BACKGROUND,BASED,CONCLUSION,COX,HRS,INC,LABEL,METHODS,MORTALITY,NUCLEAR,RESULTS,WILEY
107,140,239,642,AGE,AMONG,ASIAN,CANCERS,COX,FURTHER,ICD,INCREASED,INSURANCE,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,USING
3E6,BACKGROUND,BPH,GLEASON,LABEL,METHODS,MONOCLONAL,OBJECTIVE,PR8,PSA,RESULTS
108,169,500,BASEL,BCR,COPYRIGHT,LABEL,METHODS,MINOR,OBJECTIVE,REGARDING,RESULTS,SRARP
237,239,ANY,BACKGROUND,CONCLUSION,DESPITE,GLEASON,LABEL,MAJOR,METHODS,OTHER,PRIMARY,PSA,QOL,RESULTS,SECONDARY
000,100,169,ALTERED,COPYRIGHT,CURRENT,DUE,ENT,JAPAN,PUBLISHED,SAS,UNTIL
169,BACKGROUND,BASED,BCR,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OUTCOME,PSA,PUBLISHED,RADICAL,RESULTS,SETTING,UROLOGY,USING
120,169,AFTER,ANGELES,ASSESSING,BACKGROUND,CALIFORNIA,COPYRIGHT,GLEASON,INDEX,LABEL,LOS,MEN,METHODS,OBJECTIVE,OUTCOME,OVERALL,PUBLISHED,RESULTS,SETTING,THERE,UNIVERSITY
AXIAL,BACKGROUND,CONCLUSION,CTV,LABEL,METHODS,RESULTS,THEREFORE
049,124,945,946,ADT,ARM,BACKGROUND,CRD,GRADE,LABEL,METHODS,QOL,RESULTS,THERE
17ALPHA,945,C21,CYP17
177,232,BECAUSE,EVALUATION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE,TRE
LABEL,METHODS,MLC,OBJECTIVE,PURPOSE,RESULTS,SIMULATED
ARGON,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
182,AUTOMATIC,BASED,FINALLY,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,326,541,883,ASIAN,AUTHORS,BJU,GLEASON,JANUARY,LABEL,LNI,LNS,METHODS,OBJECTIVE,PSA,RESULTS
004,016,110,169,AUTHORS,BJU,CONCLUSION,ERG,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PROTEIN,RESULTS,SVD
177,181,COA,DU145,HMG,RAS
001,003,169,229,392,431,597,672,677,753,BACKGROUND,COPYRIGHT,GLEASON,LABEL,METHODS,RESULTS,SOCIETY,VALIDATED
PC3,RESULTS
THESE
169,HHV,HOWEVER,MECHANISMS,STRIKINGLY,TAKEN
102,560,CAB,EMP,PSA
IMR,LNCAP,NAD,THESE
BACKGROUND,COMPLIANCE,GROWING,LABEL,METHODS,NORWEGIAN,PEARSON,PRIMARY,PSA,RESULTS,THERE
120HD,215,BACKGROUND,CARLO,CONCLUSION,DICOM,GHZ,INTEL,LABEL,METHODS,MILLENIUM,MLC,MONTE,PRIMO,RESULTS
769,786,ADDITIONAL,BACKGROUND,EPO,HOWEVER,LABEL,METHODS,RCC,RESULTS,RPTEC,TMA,USING
DENMARK,EMPLOYMENT,FINLAND,ICELAND,LABEL,METHODS,OBJECTIVE,RESULTS,TESTICULAR,VALID
001,240,AMICO,BETWEEN,CDS,CLAVIEN,DINDO,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,RESULTS,THERE
AMONG,DIVERSE,DU145,HAT,HDACI,HISTONE,LEADS,LNCAP,THESE
OTHER,THESE
160,215,420,CARLO,CCE,CLOUD,COMPUTE,EC2,ELASTIC,MONTE,STX,THREE,TVR,UNITS
954,ID1,IHC,JNK,JUN,KNOCKDOWN,PCR,PTPRK
120,240,300,480,509,945,ARN,CONCLUSION,LABEL,METHODS,OBJECTIVE,PRIMARY,PURPOSE,REDUCTION,RESULTS
001,002,004,007,101,114,CONCLUSION,ESTIMATES,HARRELL,KARNOFSKY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
BECAUSE,BENCHMARK,COMPARISON,REPORTS,STUDIES,TREATMENT
000,100,AFRICAN,ASHANTI,FEMALES,GHANA,KOMFO,SAHARAN,STEPS,THESE,USING
THESE,VARIOUS
121,239,AFTER,BMI,FIFTY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THESE
169,954,COPYRIGHT,DAD,INFUSIONS,LTD,PC3,TOTAL
169,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,REGARDLESS,RESULTS,THREE
000,115,169,171,240,498,541,692,736,941,AFTER,AMONG,ANY,APRIL,BIOBANK,COMMUNITY,CONCLUSION,COPYRIGHT,EDUCATION,ENGAGEMENT,FIFTY,FOUNDATION,INC,LABEL,MEDICAL,METHODS,MINNESOTA,OBJECTIVE,OLMSTED,PUBLISHED,RESULTS,ROCHESTER,SEVENTY
140,145,BACKGROUND,CONCLUSION,FUNDING,GLEASON,III,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SIX,THERE,TRIAL
000,001,008,149,232,239,300,AMONG,BACKGROUND,CLAVIEN,CONCLUSION,DAVINCI,DINDO,FINAL,FUNDING,LABEL,METHODS,OVERALL,RESULTS,ROBOT,TRIAL
AKT,BACKGROUND,CONVERSELY,DNMT1,DNMTS,LABEL,MG132,PCR,RASSF1A,RESULTS,TAKEN,THEREFORE,USING
11C,ADT,ASTRO,BETWEEN,CTCAE,GLEASON,PET,PHOENIX,PSA,SALVAGE,SEVEN
177,500,570,750,MODULATION,PC3,THERE,TREATMENTS,TUMOURS,XENOGRAFT
SET
169,UROLOGICAL
HENCE,KLK,PCA,PCR,PSA
262,559,682,728,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,PSA,RESULTS,UNTIL
169,COPYRIGHT,DRE,LTD,MRI,NEWER,PSA,RANDOMIZED,SCREENING,WILEY
174,BMETS,COMMERCIAL,CUMULATIVE,IVB,KEY,LABEL,MARKETSCAN,METHODS,OBJECTIVE,PURPOSE,RESULTS,USA
169,946,BACKGROUND,CPG,EPIGENETIC,FOCAL,GSTP1,HISTONE,INC,INCREASING,INSULIN,LABEL,LOI,METHODS,RAR,RASSF1A,RESULTS,SEVERAL,THESE,WILEY
169,BACKGROUND,BAX,CONCLUSION,GENISTEIN,HOWEVER,INC,JEVTANA,LABEL,METHODS,PC3,PCA,RESULTS,WILEY
FSH,PCA
107,160,169,183,184,CONCLUSION,GEORG,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,STATISTIC,STUTTGART,TESLA,THREE
177,58106,778,ACTUARIAL,BACKGROUND,BCR,LABEL,METHODS,OVERALL,RESULTS,UNI
001,163,267,58106,BACKGROUND,GLEASON,INCLUSION,INCREASING,LABEL,METHODS,PCA,PNI,PSA,RESULTS
LOW,OVERALL,SINCE,TREATMENT,TTH
169,231,ANIMALS,COPYRIGHT,MDA,PUBLISHED,THESE
CAREFUL,HOWEVER,OMEGA,PUFAS,ROS,THESE
013,015,046,049,100,150,169,AUTHORS,BPH,GENOTYPING,JOURNAL,NOS,PATHOLOGY,PCA,PSA,THERE
GLYCINE
BETWEEN,DEFINITIVE,LABEL,METHODS,OBJECTIVE,OCTOBER,RESULTS
BECAUSE,CHICAGO,FINALLY,PCB,PCB11,RESULTS,ROS
119,138,169,172,AGE,BACKGROUND,CONCLUSION,FIFTY,FURTHER,INC,LABEL,METHODS,MMT,MMT84,MMT95,OVERALL,PROCEDURE,RESULTS,RMS,WILEY
946,AXIN1,CONCLUSION,LABEL,METHODS,OBJECTIVE,PC3,PCR,RESULTS,SMAD3,TGF,WESTERN
100,169,251,779,961,AUC,BACKGROUND,CONCLUSION,EIS,INC,LABEL,METHODS,MHZ,RESULTS,ROC,SIMILARLY,WILEY
169,BACKGROUND,CYP17A1,DESPITE,FKBP5,HOWEVER,INC,LABEL,LNCAP,METHODS,PSA,RESULTS,THESE,TMPRSS2,WILEY
628,CALIFORNIA,DOING,INCLUDING,MEN,SYMPTOM,TECHNIQUE,WHILE
001,122,177,ADC,DIFFUSION,GLEASON,HOWEVER,KEY,LABEL,METHODS,MRI,NEITHER,OBJECTIVE,OBJECTIVES,PROSTATIC,REDUCED,RESULTS,SCORE
001,010,014,031,CONCLUSION,CSA,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,RESULTS
174,CONCLUSION,ECLIPSE,KNOWLEDGE,LABEL,MEDICAL,METHODS,MUS,OAR,OBJECTIVE,PTV,RESULTS,SYSTEMS,TREATMENT
169,1C3,200,CASTRATION,CELLS,CHROMATIN,GLEASON,LABEL,LNCAP,METHODS,NOVEL,OBJECTIVE,PURPOSE,RESULTS
13R,945,ADV,CEA,EPCAM,IGG,OVERALL,PAP2A,THEREFORE,USING,Z33
AMONG,INCLUSION,PCA,SAM68,SEVERAL,STRIKINGLY
946,AKT,HGPIN,HOWEVER,MUTATIONS,TGF
498,DOX,DOXOL,HCT,HEPG2,MCF,MTT,NCI,OVCAR,OVERALL,THEREFORE,WESTERN
144,192,244,65308,GLEASON,JANUARY,PSA,THESE
NANOLITER,PCR
10A,10F,169,945,946,947,COMPOUNDS,COPYRIGHT,DU145,FINALLY,LNCAP,PC3,SAS,STRUCTURE
601,DIAGNOSTIC,HGPCA,PCA,PREVENTION,TRIAL,WHILE
169,1B1,COPYRIGHT,HODGKIN,LTD,N3ADE,N7GUA,PAH,THEREFORE,THESE
169,350,386,BENCHMARK,CEN10,COPYRIGHT,ERG,ERG3P,ERG5P,HOWEVER,INC,MOLECULAR,PATHOLOGY,PUBLISHED,SOCIETY,THERE,THESE,ULTRA
031,169,185,200,947,954,ADDITIONAL,CAUCASIAN,COPYRIGHT,HOWEVER,INC,PUBLISHED,RIIIA,SOCIETY
145,169,956,COPYRIGHT,LTD,NCI,OXI8006
169,ACCORDING,COPYRIGHT,PUBLISHED,SAS
169,ATG,ATG12,AUTOPHAGY,BACKGROUND,COPYRIGHT,LABEL,METHODS,PDT,PHA,RESULTS,ROS,WESTERN
154,169,308,445,900,AFTER,COLORECTAL,COPYRIGHT,DIAGNOSTIC,IRELAND,LTD,METHODS,OVARIAN,SCREENING,TRIAL
169,916,ASSESSMENT,COPYRIGHT,GRAPE,HBV,HEPG2,LTD,PC3
169,ADT,COPYRIGHT,FURTHER,HOWEVER,LTD,PCA,TARGETING,THESE
169,COPYRIGHT,FINALLY,IRELAND,LTD
003,169,ADC,AIM,COLLEGE,CONCLUSION,COPYRIGHT,DCE,EVALUATION,INCLUDING,LABEL,LTD,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,ROYAL
111,169,177,COPYRIGHT,CZT,FURTHER,HYBRIDYNE,IMAGING,IMMEDIATE,INC,IRELAND,LABEL,LTD,METHODS,MOLECULAR,MRI,OBJECTIVE,PATHOLOGY,PROXISCAN,PURPOSE,RESULTS,SPECT,THERE
169,946,COPYRIGHT,DHT,FOLLOWING,HOWEVER,INC,N367T,WHEREAS
169,192,231,233,COPYRIGHT,HOWEVER,PUBLISHED,REGARDING,SAS
169,COPYRIGHT,FURTHER,INC,INSTITUTE,MEDLINE,NUTRITION,PHYSICIAN,QUERIES,THERE
110,160,169,240,376,538,581,AMONG,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MEDICAL,METHODS,OBJECTIVE,RESULTS,UNIVERSITY
001,169,357,531,726,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,LABEL,LTD,METHODS,NOTABLY,RESULTS
FLUOZIN
DERIVED,DESPITE,PCA,THEIR
161,CAP,CYP1B,THESE
48H,956,AIM,BAD,BAX,BCLXL,CONCLUSION,GLIDE,HESPERETIN,LABEL,METHODS,MTT,OBJECTIVE,RESULTS
100,THREE
BECAUSE,CHINESE,KNOWLEDGE,LABEL,MAY,METHODS,OBJECTIVE,RESULTS,SCIENCE,WEB
300,ABOUT,SCIENTIFIC
945,CURRENT,THESE
057,110,153,189,AMONG,ENRICHMENT,NPY,PSA,QUEST,QUICK,ROC,SMALL,TARGETS
11C,169,18F,IMAGING,UROLOGICAL,WESTERN
000,002,ADC,AIR,CONCLUSION,DIFFUSION,GLEASON,III,KRUSKAL,LABEL,MARCH,METHODS,OBJECTIVE,REGIONS,RESULTS,THERE,WHITNEY
MRI,RADIOLOGY,SOCIETY,UROGENITAL
177,954,AKT,ERK,EXPRESSION,GLEASON,LABEL,MEK,METHODS,OBJECTIVE,PSA,PURPOSE,RAF,RESULTS
CAP,DSB,LNCAP,MTT,RADIATION,THESE
945,HOWEVER,INDUCTION,INHIBITION,MCF,THERE
954,DOCETAXEL,DTX,DU145,EXPRESSION,FE3O4,LNCAP,MGNPS,THESE
100,108,322,430,GLEASON,GROUP,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,THERE,UNG,UNS,UPG
CONCLUSION,DEPRESSIVE,DISTANT,INSTITUTE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,WESTERN
COX,DYSURIA,HEMATURIA,LABEL,METHODS,NOMOGRAMS,OBJECTIVE,RESULTS,UNIVARIATE,URINARY
BACKGROUND,CCH,CD8,CONCLUSION,DCS,DELAYED,DTH,ELISPOT,EXPANSION,HOWEVER,LABEL,METHODS,PSA,RESULTS,SIX,TREATMENT
169,CURRENTLY,FINALLY,HOWEVER,LABEL,METASTATIC,UNLABELLED
003,160,476,BLOOD,GLEASON,MUFAS,PHYSICIANS,SFA
135,ADT,AHA,AMBULATORY,COLLEGE,CROSS,HEART,INSIGHT,KNOWLEDGE,LABEL,METHODS,NURSING,OBJECTIVE,OBJECTIVES,PURPOSE,RESULTS,SETTING,VARIABLES
AIM,BACKGROUND,CHRONIC,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,THERE
169,COPYRIGHT,END,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
013,021,169,247,405,AIM,BACKGROUND,FDR,GBC,GRS2978974,HOWEVER,LABEL,LINKAGE,METHODS,NORTH,OBJECTIVE,PCORR,RESULTS,THEREFORE,THESE,TRS2294008
113,121,134,148,200,209,306,354,731,BACKGROUND,COMMITTEE,ENDPOINTS,FINAL,GROUP,HOWEVER,INITIAL,LABEL,METHODS,OBJECTIVE,PIVOT,PURPOSE,RESULTS,THERE,THREE,TRIAL,USING
483,503,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PDE,POTENCY,PURPOSE,RESULTS
001,008,100,241,AMICO,AMONG,ASIAN,BCR,BETWEEN,GLEASON,LABEL,LRP,MEN,METHODS,OBJECTIVE,PSM,PURPOSE,RADICAL,RESULTS,T2C
100,169,177,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,SIX,TECHNICAL
018,022,035,169,199,223,300,CONCLUSION,COPYRIGHT,EPLND,HOPKINS,INC,JOHNS,LABEL,LNS,LPLND,MEN,METHODS,OBJECTIVE,RESULTS
169,BACKGROUND,BEAUCHAMP,CHILDRESS,FACULTY,LABEL,METHODS,PRESS,PUBLISHED,RESULTS,ULTIMATELY,UNIVERSITY
945,CRUCIALLY,EGF,EXPRESSION,HOWEVER,INHIBITION,NAV,NSCLC,TTX,VARIOUS
954,NADPH,NOX,PWR,ROS,TAKEN
ENDOCRINE,FURTHER,HOWEVER,PSA,RADICAL
HDL,LOW
181,AKT,COMPOUNDS,ERK,H1299,INHIBITORY,MTT,PFBR2,PFBR3,PFBR4
IFN,OVS,PC3,TPL,TRIPTOLIDE,TSA,VSV
031,095,954,POM,PRIMARY,PSA,SEVENTY,THERE,UROLITHIN,WONDERFUL
127,CONCLUSION,GLEASON,GROUP,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PREDICTIVE,PSA,RESULTS,SEMINAL
001,204,627,EXCEL,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,ROC,UNIVARIATE
INITIALLY,JANUARY,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,ONCOLOGIC,RESULTS
002,003,006,046,049,124,138,174,526,580,585,612,620,740,853,883,967,980,BASED,BEIJING,BMI,CHI,CHINESE,DENDROGRAM,GLEASON,LABEL,LMTK2,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERE
EIGHT,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,STUDIES
297,BACKGROUND,LABEL,MEDULLARY,METHODS,MTC,PATIENT,THEREFORE
ADT,ADVERSE,BACKGROUND,CASTRATION,EFFECTIVE,FINALLY,FOLLOWING,GLEASON,HOWEVER,HRPCA,LABEL,METHODS,RESULTS
AKT,CEN,ELEVATION,EVALUATION,FOLLOWING,HOWEVER,KRAFT,MAHAJAN,PIM,RES
947,BACKGROUND,CONCLUSION,LABEL,METHODS,ORGAN,RESULTS,SCANDIDOS,TRILOGY
108,ADT,AREAS,BACKGROUND,COVERED,DEGARELIX,DESPITE,LABEL,METHODS,OPINION,PCA
CONCLUSION,EXPRESSION,FINALLY,FUNCTIONAL,ITGA5,LABEL,METHODS,OBJECTIVE,OMNIBUS,RDX,RESULTS,RETRIEVAL
176,177,191,231,HOWEVER,LNCAP,MDA,THEREFORE,URSOLIC
ALS,ALZHEIMER,GLUTAMATE,INHIBITION,NDD,PARKINSON
001,AIM,BPH,CONCLUSION,EDUCATION,HOWEVER,IRANI,KAYSERI,LABEL,LABORATORY,METHODS,MPV,OBJECTIVE,PSA,RESULTS,TABLE
ADP,GLYCINE,GLYPHOSATE
169,4T1,947,A2A,AMP,CD4,CD8,FOXP3,IFN,LABEL,MCA,METHODS,MONOCLONAL,OBJECTIVE,OVA,PURPOSE,RESULTS,TAKEN
169,805,BACKGROUND,GLEASON,IGF,LABEL,LOW,METHODS,PHYSICIANS,PROTEIN,PSA,RESULTS
169,AUTHORS,EMT,HOWEVER,INCREASED,LTD,MOLECULAR,PCA,PUBLISHED,STAT3,WILEY
169,196,481,719,ADDITIONAL,AFTER,BONFERRONI,CHRONIC,CIS,NADPH,NAPDH,SCREENING,TRIAL,WHILE
172,346,CAG,CAUCASIANS,EGGER,HISPANICS,OCTOBER,STATA
CAS,IAS
169,EMT,F191G,FINALLY,HOXA9,LABEL,STRUCTURE,TARGETING,THEREFORE,THESE,TWIST,UNLABELLED
ACCORDING,DU145,EMT,ERK,FAK,FINALLY,FURTHER,HOWEVER,JNK,MMP,P53,SRC
100,169,956,AMONG,CHANGES,COPYRIGHT,ETOAC,GARCINA,HEX,HOESCHT,MMP,MTT,ROS,THERE,TREATMENT
138,140,169,278,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
AIM,CONCLUSION,CYC,DOCETAXEL,FINALLY,LABEL,MATERIALS,METHODS,METRONOMIC,OBJECTIVE,PC3,RESULTS,THESE
BASED,III,MEN,PHASE
163,300,ASSISTANT,BRITISH,CAMBRIDGE,FOUNDATION,GALUKANDE,JOURNAL,KIRBY,MEDAL,MEDICAL,MEN,NATASHA,PETER,ROGER,UNIVERSITY,UROLOGICAL,UROLOGY
100,120,135,168,169,170,200,250,406,575,956,AMICO,AUTHORS,BCR,BJU,COX,EERPE,GLEASON,IQR,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,PSM,RESULTS
001,002,006,009,030,043,048,064,411,541,584,599,771,898,946,AFTER,BNP,DIL,LABEL,METHODS,OBJECTIVE,PSM,PURPOSE,RESULTS,SIMILAR,THERE
945,C17,CYP17,FDA,III,ONGOING
BLADDER,DESPITE,USA
027,105,143,176,177,204,AUC,BISULPHITE,BNIP3,COBRA,CPG,D191V,EXPRESSION,GCPII,GLUTAMATE,GSTP1,H475Y,MDA,PCR,R190W,RASSF1A,ROC,SOD
515,810,CIS,CROHN,DENMARK,HODGKIN,IBD,JUTLAND,LABEL,METHODS,NORTH,OBJECTIVE,OBJECTIVES,POPULATION,RESULTS,SIR
174,ARRAY,CAUCASIAN,ECS,FURTHER,LDL,NDECS,PCR,TDECS,WILLEBRAND
169,COPYRIGHT,CTV,D95,ESTIMATION,INC,LABEL,LEVEL,MATERIALS,METHODS,NTCPS,OBJECTIVE,PURPOSE,RESULTS,TRUTH,USING,V70GY
169,HOWEVER,JNK,PREVIOUSLY,SP1,SP3,THESE,TMPRSS4
BACKGROUND,CIS,COX,DENMARK,DIAGNOSTIC,LABEL,MEN,METHODS,ORS,PSA,RESULTS
001,010,011,144,676,C30,CONCLUSION,EORTC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PURPOSE,QLQ,QOL,QUALITY,RESULTS,SHORT,TREATMENT
941,MECHANICAL,ROC
828,ANXIETY,APA,C30,CLUSTER,CROSS,DEPRESSION,EORTC,FATIGUE,INDEX,INVENTORY,LABEL,LOW,METHODS,NIGHT,OBJECTIVE,QUALITY,RESULTS,SCALE
ADT,CURRENT,PCA,THERE

174,223,945,ALPHARADIN,COPYRIGHT,III,PROUS,SCIENCE
945,FCF,GTP,HIF,MAMMALIAN,RAPID,SEPTINS
007,148,BACKGROUND,BCR,COX,GENERAL,GLEASON,INCREASED,LABEL,MEIER,METHODS,PSA,RESULTS,RRP
ADT,BACKGROUND,BRAIN,GIVEN,LABEL,MAPPING,METHODS,MRI,PARAMETRIC,RESULTS,VBM
BASED,COPII,COQ10,GOLGI,L02,PARKINSON,SCD,SINCE,T24,USING
ALU,AML,BACKGROUND,EXPRESSED,LABEL,MEASURING,RESULTS,THESE
LUC,PC3,TRAMP,WISP1
001,BACKGROUND,CIS,FURTHER,GSTM1,GSTP1,HOWEVER,ILE,ILE105VAL,LABEL,ORS,PRINCIPAL,RESULTS,VAL
CONVERSELY,HOWEVER,LNCAP,MSC,PC3,TAKEN,THESE,UTR
CD105,CHRONIC,THESE
000,200,585,838,LABEL,METHODS,OBJECTIVE,ONTARIO,OOP,OVERALL,PURPOSE,RADICAL,RESULTS,SURVIVORS
160,874,895,CONCLUSION,DISABLING,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS,SURVIVORS
000,003,004,005,020,021,037,041,045,048,049,081,091,141,165,184,339,717,741,946,CAUCASIANS,OVERALL,TGF
011,020,053,086,111,194,368,411,459,480,876,891,962,CHINA,DATABASES,EGGER,GPX,KNOWLEDGE,ORS,PCA
001,046,120,160,297,386,578,597,620,901,DENOSUMAB,III,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
CRPCA,PSA,SEVERAL
AIM,BACKGROUND,BMI,LABEL,OBJECTIVE,OVERWEIGHT,RCC,RESULTS
176,AUSTRALIA,BACKGROUND,CONCLUSION,EASTERN,LABEL,METHODS,OBJECTIVE,PURPOSE,QUEENSLAND,REGRESSION,RER,RESULTS,SOUTH,SUV,UVB,WALES
004,015,017,043,207,242,246,295,415,AEG,APC,ASTROCYTE,BACKGROUND,BASIC,CONCLUSION,COX,GLEASON,HOWEVER,IHC,LABEL,MATERIALS,METHODS,MMP,RESULTS
ETS,PSA,THEREFORE,TMPRSS2
211,236,308,353,FURTHER,LABEL,METHODS,MULTISTEP,OBJECTIVE,PURPOSE,RESULTS,SPECT,UPSTAGING,WBS
001,005,042,139,GLEASON
EARLY,HOWEVER,WHILE
33342,7A1,ALTOGETHER,HOECHST,IGF1R,MTT,PCR,REDUCED,TARGETSCAN,UTR,WESTERN
205,FAK,FUNCTIONAL,PCA,PCR,PSA,SRC,THROUGH,WESTERN
H3K4ME3,H3K9ME3,STUDIES,ZNF
EXPRESSION,IMPRINTED,INSULIN,PCR,PIE
169,ASP312ASN,CIS,HOWEVER,LYS751GLN,ORS,XPD
169,231,233,COPYRIGHT,PUBLISHED,SAS,SIMILARLY,STUDIES,THESE
169,231,233,5MM,8MM,COPYRIGHT,CTV,GTV,MRI,PTV,PUBLISHED,SAS
169,ASSESSMENT,BACKGROUND,COPYRIGHT,FUNCTIONAL,HRQOL,III,LABEL,LTD,METHODS,RESULTS,SIMILAR,THERAPY
169,728,ADJUSTMENT,COPYRIGHT,EXTENDING,LTD,SATSCAN,SIMILARLY,THESE
169,BNO,CIMICIFUGA,CONSISTENT,COPYRIGHT,ENT,SIMILAR,THESE
169,954,COPYRIGHT,CRT,DIFFERENT,DVH,III,INC,LABEL,MAJOR,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TREATMENT
169,325,CLINICALLY,COPYRIGHT,ECOLOGICAL,LABEL,LOWER,LTD,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SERUM,THERE
169,AMONG,BACKGROUND,BASED,CONTEXT,COPYRIGHT,DEPENDING,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SIMILARLY,SYNTHESIS,TEN,UROLOGY,WHETHER
169,945,946,COPYRIGHT,LARGE,PUBLISHED,SAS,WHILE,WITHOUT
157,160,169,BCR,CONCLUSION,COPYRIGHT,INC,LABEL,MEN,METHODS,OBJECTIVE,PATIENT,PSA,RESULTS,SRT,STEPHENSON,THREE
GTG,GTT,JNK,TAG
177,CONCLUSION,DCE,FORTY,GLEASON,KEP,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,THERE,TOFTS
087,BLAND,COMPARISON,CONCLUSION,EVALUATION,LABEL,MATERIALS,METHODS,OBJECTIVE,PERCENTAGE,RESULTS,SOLID
001,BACKGROUND,CDL,CONCLUSION,DESPITE,FEW,FURTHER,GAUTENG,HIV,LABEL,METHODS,NATIONWIDE,OBJECTIVE,PROVINCES,RESULTS,SCREENING,SOUTH,THERE,WESTERN
CHLAMYDIA,PSA
169,RSK
183,COMPOUNDS,GEORG,NMR,PANCRATIUM,STUTTGART
169,239,500,ALDEFLUOR,ALDH1A1,BPH,EPCAM,EXPRESSION,GLEASON,HOWEVER,LABEL,METHODS,NOTABLY,OBJECTIVE,PCR,PIN,PURPOSE,RESULTS,TROP2
358,CONGENITAL,HOWEVER,THERE
ATP,BACKGROUND,CLAUDIN,CONCLUSION,EMT,FURTHER,HOWEVER,KNOCKDOWN,LABEL,METHODS,P2Y,RESULTS,SNAIL,THEREBY
GPR,GPR54,KISSPEPTIN,METASTASIS,THESE
169,COPYRIGHT,HOWEVER,NSD,PUBLISHED,SAS,WHILE
169,COPYRIGHT,DEFORMABLE,DSC,GERMANY,NORMALIZED,PUBLISHED,THESE,THREE
125,169,177,BACKGROUND,BBN,CONCLUSION,GRP,LABEL,METHODS,PC3,PET,RESULTS,SFB,THREE,TYR
100NM,169,ABBOTT8,COPYRIGHT,CPC,FURTHER,HUVEC,IAP,LTD,PC3,SEVERAL
145,150,956,LNCAP,MTT,NPS,PCA,PCL,PEG,RSV
AIM,BACKGROUND,BELGIUM,CONCLUSION,GIVEN,LABEL,MEMBERS,METHODS,OBJECTIVE,QUALITY,RESULTS,THERE,THESE,WHITNEY
946,ACTRIIA,DOWNSTREAM,FURTHER,IIA,III,MORTALITY,PCA,SMAD1,TGF
947,ATPASES
ETK,HUVEC,MYC,SRC
169,AKT,AZD5363,HOWEVER,LNCAP,PSA,THEREFORE,THESE
215,HOLEP,HOLMIUM,LEIOMYOMA
169,945,946,RCC,STS
239,945,III,INHIBITION,SEPTEMBER,THESE,UNION
946,AKT,E2F,GSK,HOWEVER,THESE,UNDARIA,WAF,WNT
000,012,100,300,HOSPITALS,INPATIENT,LABEL,LOCAL,METHODS,OBJECTIVE,RESULTS,ROBOTIC,STATE,THERE
120,177,946,IMAGING,NIR,THESE
APART,CTV,DAILY,DVF,LABEL,METHODS,PCA,RESULTS,THERE,UNLABELLED
HOWEVER,IMAGE,OBI,OTHER,PTV,ROTATIONAL,THESE,TLD
INHIBITION
001,168,COMPLETED,FLORIDA,KNOWLEDGE,SEVEN,SEVENTY,SIXTY
169,956,ADP,AKT,BAD,BAX,BCL,COPYRIGHT,FADDR,FAS,IGF,IGF1R,LTD,NIMBOLIDE,WILEY
527,CATABOLIC,DU145,EBR,GENERALLY,HOWEVER,INDUCTION,INITIALLY,LNCAP,MDL,ODC,PAO,PNT1A,POLYAMINE,POLYAMINES,SMO
600,HOWEVER,PREFERE,PSA
A1C,BMI,COX,DISEASE,INSULIN,JANUARY,METFORMIN,THERE
169,867,BACKGROUND,BETWEEN,COPYRIGHT,COX,GREATER,HOWEVER,JANUARY,LABEL,MED,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,UROLOGY
POPULATION,PSA,RESULTS
COUNTRIES,SYSTEMS,TOTAL
160,177,183,956,LNCAP,MCF,SKBR3
120,169,710,800,AUSTRALIA,AUSTRALIAN,CONCLUSION,INDIGENOUS,INSTITUTE,LABEL,LTD,METHODS,OBJECTIVE,PTY,PUBLISHING,REGISTRIES,RESULTS,WELFARE,WILEY
129,ACCORDING,BACKGROUND,CHECK,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PROSTATIC,PSA,RESULTS,ROC,THERE
CLINICALLY,DU145,ELISA,GLUCOSE,LNCAP,PC3,PCA,PROTEIN,WESTERN
169,656,896,FFQ,MAJOR,TAC,TOTAL,USING
HUGGINS,III,NOVEL,THEIR
945,946,954,DCF,ELISA,JAK,MEK,TFA,THERE,TNF
003,EIGHT,LIVER,MEIER

145,3T3,956,AMONG,FRIEDEL,T24
006,177,CAUCASIAN,ELISA,IFI27,PERIPHERAL
169,BAK,BCL,CHANG,COPYRIGHT,DECREASED,EXPRESSION,HEP,HOWEVER,LTD,OVERALL,SKHEP,TUNEL
250,500,58102,BACKGROUND,CHANGES,COHORTS,DISULFIRAM,GIVEN,LABEL,METHODS,PCA,PSA,RESULTS,SECONDARY,THREE
003,133,206,58102,AFTER,BACKGROUND,BMI,CASES,FLORIDA,GLEASON,LABEL,METHODS,OBESE,PCA,PSA,RESULTS,ROCHESTER
105,152,754,BASED,CANDIDATE,ERBB3,EXPRESSION,LABEL,METHODS,MICRORNAS,OBJECTIVE,PCA,PREDICTED,PURPOSE,RESULTS
169,COPYRIGHT,HOWEVER,LTD,MCF
180,BACKGROUND,BCR,COX,GLEASON,HOWEVER,LABEL,MEIER,METHODS,NUCB2,PCA,PSA,RESULTS
169,CSF,THESE
001,169,223,301,6MONTHS,7MONTHS,9MONTHS,AUTHORS,COPYRIGHT,COU,HOWEVER,III,LTD,PHASE,PUBLISHED,WITHOUT
160,BECAUSE,BILATERAL,CALYPSO,CTV,D99,INC,INTENSITY,LABEL,MATERIALS,METHODS,OBJECTIVE,PBS,PUBLISHED,PURPOSE,RESULTS
217,BACKGROUND,CELSIUS,DUE,LABEL,METHODS,MUNICIPAL,RESULTS
169,223,ABSTRACTS,BACKGROUND,CONTEXT,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OTHER,PUBLISHED,RESULTS,SYNTHESIS,UNTIL,UROLOGY
169,BACKGROUND,BASED,CONTEXT,COPYRIGHT,FURTHER,IDEAL,ITEMS,LABEL,METHODS,MOLECULAR,OBJECTIVE,PREFERRED,PUBLISHED,REPORTING,RESULTS,REUTERS,REVIEWS,SCIENCE,SYNTHESIS,SYSTEMATIC,THOMSON,UROLOGY,WEB
002,007,036,047,120,169,ANGELES,BACKGROUND,BETWEEN,CALIFORNIA,COPYRIGHT,GLEASON,INDEX,LABEL,LIMITATION,LOS,MEN,METHODS,OBJECTIVE,OCTOBER,OUTCOME,PCI,PUBLISHED,REGRESSION,RESULTS,SEPTEMBER,SETTING,THESE,UFS,UNASSIGNED,UNIVERSITY,URINARY,UROLOGY
009,169,327,674,BACKGROUND,COPYRIGHT,COX,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,SINCE,TAX,UROLOGY,USING
BACKGROUND,BLADDER,CONCLUSION,FOLEY,LABEL,METHODS,TUR
389,946,CONCLUSION,LABEL,METHODS,MICROARRAY,OBJECTIVE,RESULTS,SAM,TGF,THESE
BACKGROUND,GAMMA,LABEL,MATERIALS,METHODS,RESULTS
001,100,130,945,BACKGROUND,C30,EFFECTS,EORTC,FURTHER,GISEQ,LABEL,METHODS,QLQ,RESULTS
AFTER,AMICO,BACKGROUND,CHANGES,CONCLUSION,DENMARK,GLEASON,HOWEVER,LABEL,METHODS,PCA,PSA,RESULTS,RPS,TESTS
DU145,HOWEVER,LITERATURE
169,AUTHORS,DRAWING,FOUNDATION,ILLNESS,LTD,RESULTS,SOCIOLOGY,WESTERN,WILEY
NGS
LABEL,MATERIALS,METHODS,OBJECTIVE,PLATO,PURPOSE,RESULTS
223,AMERICA,NORTH,THESE,USUALLY
GIVEN,MEDLINE,PROGNOSTIC,TOOLS,USING
001,007,123,AMONG,DISCOVERY,GLEASON,TAKEN
AIM,BACKGROUND,CONCLUSION,FURTHER,IRELAND,LABEL,LINCOLN,METHODS,NCR,OBJECTIVE,REGISTRIES,RESULTS
1075553,22RV1,BAY,CONCLUSION,LABEL,LNCAP,MBQ,METHODS,NON,OBJECTIVE,PET,PURPOSE,RESULTS
231,AFTER,ANIMALS,MDA,PLAIN
013,024,753,866,DTX,FORTY,PSA,QOL,SIXTY,THERE,WHETHER
063,105,146,160,172,193,276,571,LABEL,METHODS,OBJECTIVE,PILOT,PURPOSE,RESULTS,SELECTION,THERAPY,USA
145,169,COPYRIGHT,INHIBITION,IRELAND,LTD,NEITHER,PROMINENT,THESE
10775,10797,169,AUC,BILIVERDIN,BIOLOGICAL,BLVRB,BVR,IHC,IMAGING,LABEL,MALDI,PCA,PUBLISHED,ROC,TOF,UNASSIGNED,UNLABELLED
001,120,169,788,AUASS,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RADICAL,RESULTS,UROLOGICAL
169,AKT,COPYRIGHT,EDUCATION,EFFECTIVE,INC,INCREASED,LABEL,MATERIALS,METHODS,NVP,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WST
169,COLLEGE,CONCLUSION,COPYRIGHT,DMEAN,FIFTEEN,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PTV,PUBLISHED,RESULTS,ROYAL,SEQUENTIAL,V20,V30,V40
001,008,135,169,510,COPYRIGHT,INC,PROSTATIC,PSG,RETENTION,RPS
169,COPYRIGHT,KNOWLEDGE,PCA,SAS
038,169,752,ANALYTICAL,BACKGROUND,BIOMARKERS,CELLSEARCH,COPYRIGHT,CPE,CTC,FOXA1,GRHL2,LABEL,METHODS,OBJECTIVE,OUTCOME,PAXGENE,PCA,PCR,PUBLISHED,RESULTS,SETTING,TRANSCRIPT,UROLOGY
169,833,BACKGROUND,COPYRIGHT,CORRECTION,ERSPC,LABEL,LARGE,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RANDOMIZED,RESULTS,ROTTERDAM,RRS,SCREENING,SETTING,TRIAL,UROLOGY
169,BACKGROUND,COPYRIGHT,GLEASON,LABEL,LIMITED,METHODS,OBJECTIVE,OUTCOME,OVERALL,PATHOLOGIC,PUBLISHED,REASONS,RESULTS,SETTING
015,160,169,177,COPYRIGHT,DFS,HOWEVER,INC,LABEL,LDR,MATERIALS,MEIER,METHODS,OBJECTIVE,PHOENIX,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THESE,THREE
169,COPYRIGHT,DESPITE,IRELAND,LTD,RADICAL,THERE,TREATMENT
169,241,COPYRIGHT,DUE,FDG,HOWEVER,LABEL,METHODS,OBJECTIVE,PET,RESULTS
169,BACKGROUND,CONTEXT,COPYRIGHT,FORCE,HOWEVER,INC,JOURNAL,LABEL,METHODS,PREVENTIVE,PSA,PUBLISHED,RESULTS,SYNTHESIS
016,019,024,683,736,746,759,874,875,875GG,891,916,946,ADT,GLEASON,PCR,SMAD7,TGF
FOXO1,HOWEVER,PCR,TAKEN,UTR
178,916,936,COMPLEX,CSA,DU145,LNCAP
276,543,640,658,814,856,871,CIS,HOWEVER,LABEL,METHODS,OBJECTIVE,ORS,PUBLISHED,RESULTS
185,342,COA,HMGCR,INTRINSIC,SREBP,THESE
105,DU145,PC3
BACKGROUND,LABEL,PRINCIPAL,RESULTS,THEREFORE
001,283,BACKGROUND,CONCLUSION,DFS,FINALLY,FUNCTIONAL,LABEL,METHODS,ONCOLOGIC,PREDICTIVE,PSA,RESULTS,SCT,WHILE
ACTIVATION,ERLOTINIB,HRR,IGF1R,RAD51,REDUCED,THESE
COUNTER,FIRST,HOWEVER,NCI,OTHER,SNP,YET
001,237,ASSOCIATED,BACKGROUND,ILC,LABEL,NUCLEAR,PROTEIN,RESULTS,SINCE,YAP,YES
CEA,HOWEVER,PANCREATIC
100,IRE,METHODS
152,177,AGREEMENT,COHEN,FURTHER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RTT
CURRENTLY,FACBC,ISSUE,LABEL,METHODICAL,METHODS,MRI,OBJECTIVE,PET,PRACTICAL,RESULTS
946,BACKGROUND,CONCLUSION,DHT,ELISA,FINALLY,LABEL,LNCAP,METHODS,MTS,PAF,PCR,RESULTS,WNT
160,174,GLEASON,LOW,SOLUBLE,VTP,WST11
ACCORDING,AFTER,CONCLUSION,LABEL,LNCAP,METHODS,MTT,OBJECTIVE,PCR,RESULTS,THEREAFTER,TRANSWELL,WESTERN
152,169,CD147,DECREASED,DESPITE,ERG,GLEASON,PSA,REDUCED,RESULTS,THERE,TMPRSS2
00185,008,169,223,945,ASSESSMENT,COPYRIGHT,DENOSUMAB,EXCLUSION,INC,ISPOR,LABEL,METHODS,MPC,OBJECTIVE,PUBLISHED,RESULTS,SIMILAR,SOCIETY
111,151,160,190,245,490,AFRICAN,AMONG,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,RESULTS
GLEASON,PRIMARY,THESE
BACKGROUND,CONCLUSION,LABEL,METHODS,TAMOXIFEN
177,AIM,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
207,GLEASON,HOWEVER,PHYSICIANS,PSA
140,450,ADT,BACKGROUND,COX,LABEL,METHODS,MFS,RESULTS
000,179,185,230,IMAGING,THESE

BINDING,DOT1L,PCAT8,PHD
004,011,018,022,040,213,239,308,650,791,THESE
139,141,BACKGROUND,BRAIN,CONCLUSION,DISEASE,EPSCC,IRELAND,LABEL,MANAGEMENT,METHODS,PATIENT,PCI,RESULTS
AFTER,PATHOLOGY
108,146,2N0M0,3N0M0,65308,HOWEVER,MARCH,NHT,PSA,T1C
169,945,GLEASON,HOLMIUM,SERUM,UROLOGICAL
CAM,CONCLUSIVE,INITIAL,VITAMIN,ZYFLAMEND
001,286,333,880,989,AMONG,BACKGROUND,GLEASON,INDEX,INSTITUTE,LABEL,METHODS,OCTOBER,PREVENTION,RESULTS,TEN,TRIAL
095,241,BACKGROUND,CAUTION,CONVERSELY,GLEASON,HOWEVER,LABEL,MCL,METHODS,MPC,OBJECTIVE,OBJECTIVES,REGRESSION,RESULTS,UNIVARIATE,WHILE
001,147,ANALGESICS,BPI,BRIEF,CONCLUSION,CONSORTIUM,INVENTORY,LABEL,MATERIALS,METHODS,OBJECTIVE,PREVALENCE,PRO,PURPOSE,RESULTS,THESE
233,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,OPTIMAL,PURPOSE,QIS,RCC,RESULTS,THESE
001,610,AMONG,BLACK,CONCLUSION,END,FORTY,INEQUALITY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
BACKGROUND,LABEL,MEN,METHODS,NUTRITION,PSA,RESULTS,SHIFTWORK,USING
AFTER,CAH,ENDOCRINE,INADEQUATE
143,160,377,902,CONCLUSION,INPATIENT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPANISH,SRE
00001,108,169,228,457,487,546,AFTER,BACKGROUND,BETWEEN,CHT,COPYRIGHT,LABEL,METHODS,PFS,PSA,RESULTS,SEPTEMBER,SOCIETY,TAX
000,245,ANGELES,CALIFORNIA,COGNITIVE,CONCLUSION,EXACT,INDEX,INTRACLASS,LABEL,LOS,MEDICAL,METHODS,MOS,OBJECTIVE,PCI,PURPOSE,RESULTS,SEVENTY,SHORT,STRATEGIC,UNIVERSITY,WEB,WHITE
ADT,DESPITE,III,OTHER,PDGFR,VEGFR

100,174,241,386,AVERAGE,BACKGROUND,CALCULATED,ESPECIALLY,HOWEVER,LABEL,METHODS,MRI,RESULTS,V70,WITHOUT
GENOMIC,IDC,ILC,THBS4,THERE
GATEWAY,INSTITUTE,RADIATION,SOCIETY
HIV,LABEL,LIVER,MSM,OBJECTIVE,PLWHA,PURPOSE,RESULTS,SCREENING,SUMMARY,TRIAL
BACKGROUND,BASEL,FURTHER,HOWEVER,LABEL,MARCH,METHODS,OBESITY,PCA,RESULTS,THERE,THEREFORE
169,AZD1480,CWR22PC,FINALLY,LABEL,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS
178,GLEASON,S727A,SER,STAT3
152,169,COPYRIGHT,ERG,FEDERATION,FURTHER,GLEASON,INCREASED,PSA,PUBLISHED,SOCIETIES,THESE

946,AFTER,BACKGROUND,BCC,E12,HOWEVER,LABEL,METHODS
183,378,632,AGE,CONCLUSION,GLEASON,JANUARY,LABEL,MAY,METHODS,OBJECTIVE,PSA,RESULTS,UNIVERSITY,UPGRADE
BMI,HOWEVER,MRI,ROBOTIC,STAGE,THEREFORE,TME
13Q14,ADP,ALTOGETHER,ARL11,DELETIONS,MDR,PCA,REGULATION,T442C
003,007,016,100,ABNORMALLY,BACKGROUND,BMI,CHINESE,CVC,EASTERN,LABEL,PCA,PRINCIPAL,RESULTS,THESE
ANDROGENS,LUC,LUCIFERASE
954,B16,DU145,EXPRESSION,JAK,PDCD4,TAKEN
E2F,ERG,ETS,EWING,EWSR1,SUPPORTED,TMPRSS2,WHILE
124,169,177,CHO,COPYRIGHT,GLEASON,GPC,LTD,ROC,THERE,WILEY
169,945,954,AKT,CCL21,INC,KNOCK,PC3,STAT3,TRANSWELL,VEGFR,WILEY
169,956,ASSESSING,BECAUSE,LMP,TAMOXIFEN,TOREMIFENE,TREATMENT
10H,169,LNCAP,MDV3100,NOTABLY,THESE,VPC,YET
002,005,006,177,199,22RV1,268,300,383,742,956,CONCLUSION,LABEL,MEANWHILE,METHODS,OBJECTIVE,RESULTS,THERE,TUNEL
945,946,AE1,AE3,AMACR,CAREFUL,CEA,CK7,COA,CONCLUSION,E12,LABEL,METHODS,MME,OBJECTIVE,P504S,P63,PSA,RESULTS
001,005,031,074,170,283,58102,999,ADT,AFRICAN,BACKGROUND,LABEL,METHODS,PSA,RESULTS
169,COPYRIGHT,DU145,LC3,LNCAP,LTD,NOTABLY,PIPER,TAKEN
EVALUATION,MEMBERS,POLYMERASE
169,946,EMT,FINALLY,III,MZ7,SMAD2,SMAD3,SMAD7,TGF,V717M
160,215,BOARD,KIM,NAVOTEK,PCXMC,TREATMENT
510,BACKGROUND,BOARD,ENDOSCOPIC,ENDOSCOPY,FIFTY,GEORGETOWN,GRADE,IRB,LABEL,METHODS,QOL,RECTOSCOPY,RESULTS,SCORE,THERE,TRIAL,VRS
100,169,765,778,830,AUTHORS,BJU,COMPOSITE,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,VALIDATED
001,005,039,169,314,AUTHORS,BJU,CONCLUSION,COX,GLEASON,JANUARY,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,UNIVARIATE
001,087,169,499,AMONG,AUTHORS,BJU,CONCLUSION,CONVERSELY,COX,END,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SIMILAR,STRATIFIED,USING
169,391,AUTHORS,BJU,CIS,DIGOXIN,FURTHER,HRS,IRISH,LABEL,METHODS,OBJECTIVE,RESULTS,THESE
169,ACETATE,AUTHORS,BJU,DUE,IMAGING,ISI,PET,PSA,SCHOLAR,SCIENCE,STUDIES
169,AIM,GUM,JANUARY,LABEL,LTD,METHODS,OBJECTIVE,PATIENT,PTY,PUBLISHING,RESULTS,WILEY
169,AUTHORS,BJU,DROSPHILA,EN1,EN2,ENGRAILED,HOX,HOX13,PCA,STUDIES,URINARY
10Q,10Q11,10Q26,12Q24,169,174,17Q12,19Q13,707,AFRICAN,APPLIED,ASSESSMENT,AUTHORS,BIOSYSTEMS,BJU,CAUCASIAN,GENOTYPING,LABEL,METHODS,OBJECTIVE,PROGRAM,PSA,RESULTS,RS10788160,SNP,USA
169,AUTHORS,BJU,DCE,DWI,EVERY,HOWEVER,IMAGING,LABEL,METHODS,MRI,MRS,NPV,OBJECTIVE,OBJECTIVES,PPV,PSA,REPORTING,RESULTS,ROC,T2W,THERE,THESE
BPH,PCA,ULTIMATELY
029,248,25307,312,365,389,410,561,595,742,836,847,871,APRIL,HYPOTHESIS,JANUARY,LABEL,MEDLINE,METFORMIN,METHODS,OBJECTIVE,RANDOMIZED,RESULTS,THERE
CDC42,GTP,GTPASES,P21,PC3,RAC,RHO,S79
182,ATO,LC3,LNCAP,PC3,STUDIES,THESE
215,34A,60K,DU145,FUNCTIONAL,GENISTEIN,KNOCKDOWN,LABEL,LUCIFERASE,METHODS,MICROARRAY,OBJECTIVE,PC3,PCA,RESULTS,SUREPRINT,THESE
DHT,GLEASON,HOWEVER,LNCAP,NANOG
AGGRESSIVE,FURTHER,PSA,THESE
174,601,ANDALUSIA,ATM,BACKGROUND,BECAUSE,CATALONIA,CONCLUSION,COUNTRY,ERCC1,ERCC2,LABEL,METHODS,NON,OBJECTIVE,OPENARRAY,OUTCOME,P53,PRINCIPAL,RESULTS,SETTING,SNP,SNPATOR,SNPMATRIX,SPANISH,THESE,XRCC1,XSNPMATRIX
FIRST,USING,WHILE
141,210,365,375,945,HIF,MICRORNAS,PSA
181,AFTER,GDHSPFT,SHFSVGS,THESE,WHILE
BACKGROUND,BMI,COLORECTAL,EDITORS,INSTITUTES,LABEL,METHODS,MHT,NIH,OVARIAN,RESULTS,SCREENING,SUMMARY,THESE,TRIAL,USING,WHILE
169,ALA,BAY86,CONCLUSION,GLN,GLY,LABEL,LEU,METHODS,NH2,OBJECTIVE,PCA,PET,PHE,PURPOSE,RESULTS,STA,TRP,VAL
171,215,338,967,BONFERRONI,COLON,COLORECTAL,GECCO,LABEL,METHODS,OBJECTIVE,POPULATION,RESULTS,SEVERAL,SNP
169,778,BACKGROUND,FORCE,GIVEN,GREATER,HOWEVER,INC,LABEL,METHODS,PCA,PSA,RESULTS,ROC,WILEY
160,CNS,CROSS,FUNCTIONAL,MRI,THESE
949,APO,APOE2,FURTHER
160,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SFQ
505,916,BMS,CDC42,EX2,INHIBITION,LIM,LIMK1,LIMK2,LIMKS,MSC,NF2,PAK,RAC,SCHWANN,SCS,SIMILARLY
22RV1,945,CAVIN,HOWEVER,LNCAP,TAKEN,UTILIZING
946,947,BOOSTED,ELISPOT,IDO,IFN,LOCAL,LTB,LTI,REGULATORY,TGF,TREGS
178,INSTITUTES,OBESITY,THESE
001,100,125,158,285,305,560,AMICO,AUC,BETWEEN,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
169,241,ABOUT,BCR,CHOLINE,COPYRIGHT,CURRENT,FACBC,GLEASON,IMAGING,LOW,MRI,NUCLEAR,PCA,PET,PROSTATIC,PSA,RESONANCE,TODAY
005,006,160,169,389,ARTESUNATE,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METASTASIS,METHODS,MOLECULAR,MOSBY,OBJECTIVE,RESULTS,TGF,USING,WNT
169,215,BMP,CURRENTLY,GLEASON,INC,SNAIL,TWIST,USING
169,916,945,946,BPH,COPYRIGHT,DHT,LNCAP,RIS,SAS,STEROIDAL,THEREFORE
169,FK506,FKBPS,HSP90,THESE,TPR
001,169,BLOOD,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,PSA,RESULTS,TOTAL
143,145,169,HOWEVER,MIR,MKN45,RCK,THESE,THP
169,COPYRIGHT,ELECTRONIC,FEW,IRELAND,JANUARY,LTD
169,COPYRIGHT,FINALLY,INSULIN,ROS
169,APRIL,BACKGROUND,CONTEXT,COPYRIGHT,LABEL,LEVEL,MEDLINE,METHODS,OBJECTIVE,PARTICULAR,PATHOLOGY,PUBLISHED,RALRP,RESULTS,REVIEWS,SCIENCE,SOCIETY,STUDIES,SYNTHESIS,SYSTEMATIC,TECHNICAL,UROLOGICAL,UROLOGY,WEB
169,269,30891,492,493,769,985,ADT,AFTER,BACKGROUND,BASED,COPYRIGHT,EORTC,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,TREATMENT,UROLOGY
160,169,177,521,956,BIOLOGY,COPYRIGHT,FEDERATION,INC,NBS,PUBLISHED,SONOVUE,THEREFORE,ULTRASOUND,WORLD
001,169,227,C30,CONCLUSION,COPYRIGHT,EORTC,IRELAND,LABEL,LTD,METHODS,MIXED,OBJECTIVE,PURPOSE,QLQ,QOL,RESULTS
016,105,169,GLEASON,IDC,LABEL,LTD,METHODS,OBJECTIVE,PBX,PCA,RESULTS,SEMINAL,THREE,WILEY
ADT
001,197,307,ASSESSMENT,BACKGROUND,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,PSA,RESULTS,SECONDARY,WHEREAS
COUPLES
PROVIDING
COX,HODGKIN,HRS,MEIER,NHL,WHILE
169,945,AMACR,COA,COPYRIGHT,VCH,WILEY
169,183,CONTROLLED,DESPITE,GEORG,MAP,STUTTGART,TRANEXAMIC
169,183,GEORG,HOWEVER,LRP,RADICAL,RRP,STUTTGART
150,169,218,248,300,635,913,ALCOHOL,JAPAN,SMOKING
MSS31,THESE
001,153,160,514,791,967,AFTER,COMPASSION,CONVERGENT,EMOTIONAL,FURTHER,HOWEVER,INVENTORY,LABEL,METHODS,MEYER,OBJECTIVE,OLKIN,PTG,PURPOSE,RESULTS,SCALE
136,945,946,ACUTE,AFTER,CONCLUSION,CTV,GLEASON,INITIAL,LABEL,MAY,METHODS,OBJECTIVE,PSA,PTV,PURPOSE,RESULTS,SINCE,TOTAL
ADT,ASC,CASODEX,DESPITE,MDV3100,MECHANISM,PCA,PIAS3,STAT3,THESE,TRAMP,USING
20S,945,946,AKT,FURTHER,HOWEVER,MAR,PCA,PROTEASOME
113,114,239,BACKGROUND,CASTRATION,CONCLUSION,DES,LABEL,METHODS,PRE,PSA,RESULTS
169,ANOTHER,BACKGROUND,COPYRIGHT,DISCUSSION,ENGLISH,EXPERTS,FINALLY,FIRST,KLIBANSKI,LABEL,LITERATURE,MONITORING,PROLACTIN,PUBLISHED,RESULTS,SAS,SOMETIMES
169,AML,KEY,LABEL,METHODS,MINIMAL,OBJECTIVE,RESULTS,ROYAL,SOCIETY,USING
169,956,AMONG,ASP,BOC,LEU,LNCAP,SERCA
001,CURRENTLY,LABEL,METHODS,MHZ,OBJECTIVE,PURPOSE,RESULTS,THESE,ULTRASOUND
200,215,350,528,BREGMAN,GPU,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPLIT
3DCRT,CARLO,ECLIPSE,GAFCHROMIC,LABEL,METHODS,MIMIC,MONTE,OBJECTIVE,PURPOSE,RESULTS,THESE
HDR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
MICRORNAS
125,CONCLUSION,IHT,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SCORE
AFTER,ANNEXIN,AS2,CONCLUSION,INHIBITION,LABEL,METHODS,MTT,OBJECTIVE,P38,RESULTS,WESTERN
169,177
149,271,BACKGROUND,CLINICS,CONVERSELY,GLEASON,HOWEVER,JAMES,LABEL,METHODS,OBJECTIVE,PCA,PRIOR,PSA,RAPCS,RAPID,RESULTS,SEVEN,THESE,USING
169,CTC,DEP,LNCAP,VCH,WILEY
FGF10,HGF,HOWEVER,MTT,PC3,PCA,TARGETING,TGFB2,THESE
30846,30891,BACKGROUND,EORTC,GROUP,LABEL,MATERIALS,MEDLINE,METHODS,SOURCES,SYSTEMATIC,TREATMENT,UROLOGICAL
001,002,144,166,169,172,177,191,221,449,473,621,707,CONCLUSION,HISTOLOGIC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE,VARIABLES
AIM,BACKGROUND,GROUP,HYLAK,LABEL,MATERIALS,METHODS,OBJECTIVE,RADIATION,RESULTS
EMT,ENGLISH,ESPECIALLY,LABEL,METHODS,MICRORNAS,OBJECTIVE,RESULTS,SELECTION,SOURCES
100,169,AUTHORS,BJU,CONCLUSION,CT1,LABEL,METHODS,OBJECTIVE,PST,RESULTS
169,300,AUA,BJU,FURTHER,OTHER,PSA,UROLOGICAL
BACKGROUND,FACTORS,FEW,HISTORY,HRQOL,LABEL,MCS,METHODS,PCS,RESULTS
ADC,BACKGROUND,CDI,HENCE,LABEL,METHODS,RESULTS,ROC,THESE
205,954,CAF,CONCLUSION,EMT,HIF,INNOVATION,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,RESULTS
THESE
001,002,007,015,017,026,036,110,BACKGROUND,BPH,CONCLUSION,HOWEVER,LABEL,METHODS,RESULTS,SNAIL
026,215,400,AUC,BACKGROUND,FEULGEN,GLEASON,HGPIN,LABEL,METHODS,NUCLEAR,PCA,PHASE,RESULTS
169,945,BACKGROUND,CAP,DU145,GDI,GDP,HOWEVER,INC,INHIBITOR,LABEL,LNCAP,METHODS,PCR,RESULTS,RHO,TREATMENT,WESTERN,WILEY
145,COX,DISSECTION,GLUCOSE,GRP78,HOWEVER,SILENCING
34C,BACKGROUND,CONCLUSION,LABEL,MET,METHODS,PC3,PCA,RESULTS,THESE,UTR
145,916,968,BAX,BCL,HOWEVER,LNCAP,NAC,PC3,ROS,THESE
000,008,252,389,414,487,500,800,AMONG,FURTHER,PSA,RESULTS,SERUM,SEVERAL
468,AZA,CDK,EPIGENETIC,ETS,INHIBITION,MDA,MTT,NOTABLY,OTHER,USING
160,AKT,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
100,160,DOX,DU145,LABEL,METHODS,OBJECTIVE,PEI,PURPOSE,RESULTS,TPP
002,004,026,043,AVERAGE,BECAUSE,INCIDENCE,PDC,PIN,SFN,THERE,WDC
169,BASEL,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THEREFORE,THESE,WHOLE
169,945,946,COPYRIGHT,CXCR4,CXCR7,DU145,ECM,LNCAP,LTD,MMP,PC3,PCA,SDF,TAKEN
FAK,HSP90,METABOLIC,THESE,UNC,USING
GENOMIC,PROJECT,TAKEN,YET
BASED,CURRENTLY,GIVEN
500,AMONG,ANN,ARTIFICIAL,NEOPLASIA,REALIZING,THERE
169,COMPOUNDS,COPYRIGHT,LTD,PC3
001,169,954,ACM,ACTIVATED,ADT,CCL17,COPYRIGHT,COX,LSAMP,LTD,MEIER,MON1B,NUCLEAR,PSMD7
002,169,660,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS
169,945,AKT,ALPHA,APOPTOSIS,BAD,BCL,CONSISTENT,COPYRIGHT,RESULTS,THESE
169,BCL,DEFECTIVE,DU145,HSP70,LYSOSOMAL,NOTABLY,REMARKABLY,SU11652
169,COPYRIGHT,GLEASON,GLTSCR2,IRELAND,LTD,TAKEN
026,169,APRIL,BACKGROUND,BASEL,COPYRIGHT,GROUP,HBO,LABEL,MARCH,MATERIALS,METHODS,OVERALL,PSA,RADIATION,RESULTS,THERAPY
C81,CURRENT,LNCAP,RESISTANT,SXR,TERE1,THESE,VITAMIN
001,015,169,272,351,868,BASEL,CONCLUSION,COPYRIGHT,COX,HGPIN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,RFS
AUSTRALIA,FOLLOWING,LABEL,MELBOURNE,METHODS,OBJECTIVE,RESULTS,SF34R,WHILE
169,234,BIC,FOLLOWING,HOWEVER,INTENSIVE,LTD,LYMPHOMAS,MARSEILLE,PARIS,PWH,THERE,THREE,WILEY
149,160,169,177,ACCEPTANCE,AIM,BACKGROUND,BETWEEN,BRIEF,CONCLUSION,FEWER,INTERVIEWS,IRELAND,LABEL,LTD,MEN,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,WILEY
114,293,CONCLUSION,COX,DENMARK,DIAGNOSTIC,FINLAND,GERMANY,LABEL,METHODS,MICROARRAY,MOB3B,OBJECTIVE,PURPOSE,RESULTS
291,343,837,CONCLUSION,COX,CRUDE,CUMULATIVE,HRS,INCREASED,IQR,LABEL,METHODS,OBJECTIVE,ONTARIO,PURPOSE,RESULTS,THERE
169,215,AKT,CXCR4,ERG,ETS,IKK,LABEL,PREVIOUSLY,THESE,TMPRSS2,UNLABELLED,USING
118,126,169,BACKGROUND,CGH,COX,ERG,GLEASON,IHC,LABEL,METHODS,PSA,RESULTS,TMA,TMPRSS2
001,021,244,ACUTE,APRIL,ASIAN,BCR,CONCLUSION,COX,D90,DESPITE,GLEASON,LABEL,LDR,MATERIALS,METHODS,OBJECTIVE,PCA,PHOENIX,PSA,PURPOSE,RESULTS,T2C
001,116,724,890,AMONG,CONCLUSION,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
CRE,ETS,FUNCTIONAL,NOTABLY,PI3,RAS,THESE,USING
945,946,PSME1,THESE,WHEREAS
010,011,059,111,123,136,179,233,258,455,566,717,747,795,LIBRARY,MEDLINE,STATA,SUMMARY,THR241MET,XRCC3
DESPITE,HENCE,HOWEVER,PCA,PCIBP,THESE
FURTHER,MRI,QUALITY,SINCE,THEREFORE
22RV1,DU145,EIGHT,EXPRESSION,ITGB3,LNCAP,MTSS1,PCA,PCR,THERE,THESE
1940S,ANOTHER,ETS,FOXA1,PATHOLOGY,SIX
177,BACKGROUND,DUE,GLEASON,LABEL,METHODS,RESULTS,THESE
024,033,103,140,175,283,543,946,BACKGROUND,FEW,LABEL,METHODS,RESULTS
001,005,009,017,023,052,230,241,946,BACKGROUND,CHINESE,COX,EMT,FURTHER,GLEASON,IHC,LABEL,MEIER,METHODS,MTT,NOTABLY,PCA,PCR,RESULTS,TGF,THREE,USING
169,945,STEROID,T877A
169,INC,SIX,STEAP,THESE,USING
169,BACKGROUND,COPYRIGHT,LABEL,LNS,METHODS,MRI,OBJECTIVE,OUTCOME,PER,PUBLISHED,RESULTS,SETTING,TESLA,UROLOGY,USPIO
160,APO,APOA1,ASSESSMENT,BACKGROUND,CHRONIC,CONCLUSION,CONTEXT,FATIGUE,FUNCTIONAL,ILLNESS,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,THERAPY,THESE,TTR,WESTERN
169,COPYRIGHT,PUBLISHED,SIMILAR,THESE
162,169,336,CONCLUSION,COPYRIGHT,DRE,FALSE,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SIXTY,SONOVUE,THERE
169,BASED,COPYRIGHT,FEDERATION,LABEL,METASTASIS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETIES,SPARCL1
125,222,BACKGROUND,CONCLUSION,DOSIMETRY,FUNCTIONAL,LABEL,MARCH,MATERIALS,METHODS,MRI,PSA,RESULTS,RIS
COMMENTARY,GIVEN
160,729,ARRAY,BACKGROUND,FFF,GAFCHROMIC,HOWEVER,LABEL,METHODS,PANTHER,PHILIPS,PROWESS,PTW,RESULTS,RTP,SIEMENS,TPS
THERE,VESICLE,ZN2BDPA
001,066,177,180,216,280,31Y,496,75Y,AMICO,BACKGROUND,CHI,CONCLUSION,DEPENDENT,GLEASON,GRADING,HOWEVER,LABEL,METHODS,PSA,RADIATION,RESULTS,THESE,WHITNEY
100,169,174,APPLIED,BIOLOGISTS,BIOLOGY,HOWEVER,LTD,NANOBODIES,PSA,SOCIETY,THEREFORE,TSP,VHH,WILEY
169,946,ERG,ETS,IWP,OVERALL,STUDIES,TCF,TMPRSS2,WNT
169,ACC,BACKGROUND,CONCLUSION,COPYRIGHT,DESPITE,FGFR1,HPV,INC,LABEL,METHODS,RESULTS,SCC,SNUCS,WILEY
129,169,277,342,366,635,728,90401,ASI,BACKGROUND,CALGB,COPYRIGHT,GROUP,LABEL,METHODS,ORR,PFS,POISSON,PSA,RESULTS,SOCIETY,THERE
105,368,AFFAIRS,AMERICA,BACKGROUND,CENTRAL,COMMUTING,GOVERNMENT,LABEL,METHODS,PATIENT,RESULTS,RURAL,URBAN
145,945,IFN,IL6,INTERFERON,LNCAP,MDA,PC3,PCA,PCR,SILTUXIMAB,STAT1,THREE
169,356,708,AFTER,BACKGROUND,BLACK,COPYRIGHT,END,GEOGRAPHIC,GEORGIA,LABEL,MASTERFILE,MEDICAL,METHODS,OVERALL,PHYSICIAN,RESULTS,ROS,SOCIETY,WHICH
001,005,015,046,160,CK5,CK7,DONOR,HOWEVER,TTF
169,1A5,2C7,343,348,CDH11,EC3,HOWEVER,LABEL,MC3T3,PC3,THESE,UNLABELLED
901,AFTER,BLACK,INCLUSION
239,249,APRIL,BACKGROUND,CONCLUSION,GRADE,LABEL,METHODS,RESULTS,TREATMENT,ZOLEDRONIC
145,300
177,215,AFTER,BASED,NGO,PEG
HOWEVER,LABEL,OBJECTIVE,PURPOSE,RESULTS,STUDIES,SUMMARY
LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,VITAMIN,WHETHER
GLEASON,GROUP,III,INSTITUTE,LABEL,OBJECTIVE,PR7,PURPOSE,QUALITY,RESULTS,SOUTH,SUMMARY,THERE
001,208,509,743,823,912,AFTER,BETWEEN,BMI,FURTHER,MARCH,OBESE,PCA,PSA,THESE
DU145,HOWEVER,RACK1,THESE
AFTER,D95,DEA,PTV
100,600,650,BACKGROUND,CURRENT,INC,LABEL,MATERIALS,METHODS,MODEL,PUBLISHED,RESULTS,SOCIETY,SUO,UOS
004,112,169,221,COPYRIGHT,FORCE,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,OBJECTIVES,PREVENTIVE,PSA,RESULTS,SINCE,THERE
001,100,125,131,140,145,150,160,169,189,COPYRIGHT,D90,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,PVS,RESULTS,SMALL,SMALLER,SOCIETY
169,BACKGROUND,CONTEXT,COPYRIGHT,CURRENTLY,LABEL,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,TAXANES,THESE,UROLOGY
160,169,177,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,RESULTS,SIXTY,UNDER
001,160,169,711,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MASTERFILE,MEDICAL,METHODS,OBJECTIVE,PEARSON,RADIATION,RESULTS
160,169,AUS,CONCLUSION,COPYRIGHT,FORTY,INC,JANUARY,LABEL,METHODS,OBJECTIVE,RECORDS,RESULTS,STENT,THERE,UROLUME
169,BLADDER,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PROSTATIC,RESULTS,SCORE,UROLOGICAL
BASED,BAX,BCL,USING,WESTERN
CYP27B1,DBP,LNCAP,MEGALIN,PREVIOUSLY,TAKEN
100,EIGHT,HOWEVER,PSA
DIFFERENT,FURTHER,SEVERAL,TEA,THERE
DECREASED,FURTHER,HOWEVER,POPULATION
CONSISTENT,THESE,USING
001,100,169,750,ADC,CANCERS,CONCLUSION,COPYRIGHT,DIFFUSION,DWI,HOWEVER,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PARAMETERS,PURPOSE,RESULTS,TES,TESLA,WILEY
AFTER,GLEASON
CAUCASIAN,RCC,SUBSEQUENT
FOCUS,MCGUIRE,MODEL,RESULTS
140,630,BACKGROUND,BIOACTIVE,CIS,CONCLUSION,COX,HRS,LABEL,METHODS,RESULTS,USA,WASHINGTON
018,169,272,641,869,BMI,CIS,COLORECTAL,COX,OVARIAN,RRS,SCREENING,THEREFORE,THESE,TRIAL,TVU
960,BCL,GAL
172,174,186,947,BAX,LNCAP,RADIATION,THESE
398,BACKGROUND,COLORECTAL,CONCLUSION,GREATER,INSTITUTE,LABEL,METHODS,OVARIAN,RESULTS,SCREENING,SIMILARLY,SIX,THESE,TRIAL
800,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RAMAN,RESULTS,SVM,THERE,THESE
FINALLY,LABEL,MCS,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS,SHORT,THESE,TREATMENT
EASTERN,EPITHELIAL,WESTERN
100,395,400,500,800,CNR,DWI,FORTY,GLEASON,LABEL,MATERIALS,METHODS,NUMERICAL,OBJECTIVE,OBJECTIVES,REGIONS,RESULTS
100,105,124,169,ART,CONCLUSION,COPYRIGHT,D99,INC,LABEL,MATERIALS,METHODS,MLC,OBJECTIVE,PLN,PURPOSE,RESULTS
946,GB3,GSL,THESE
169,223,ALTOGETHER,COPYRIGHT,EGF,FER,FINALLY,IGF,IRELAND,LTD,PSA,SH2,SINCE,STAT3
289,954,CONCLUSION,DENMARK,EPE,EXACT,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,ROBOT,SMS,ST1,ST2,SVI,SWEDISH,UNIVERSITY
001,003,007,014,029,037,198,BCR,FURTHER,HOWEVER,LOG,SPECIALLY
ADM,BAX,BCL,CHINESE,DU145,FAS,HOWEVER,MDR,TAKEN,THEREFORE,TPL,TRIPTOLIDE
011,018,109,169,218,236,CHANGES,CONTINENCE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SOCIETY,TAMSULOSIN,UROLOGICAL
EXISTENCE,FINALLY,HOWEVER,THESE
169,177,233,HENRI,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESISTANCE,RESULTS,UROLOGICAL
145,169,61472,945,956,ADP,BAX,C17,COMPOUNDS,CYP17A1,CYP19,LNCAP,MCF,MOLECULAR,THESE,WESTERN,WILEY
169,COPYRIGHT,INC
169,BLADDER,COPYRIGHT,INC,SHORT
169,AUTHORS,BJU,CURRENTLY,FURTHER,GLEASON,THERE,THESE
055,135,172,186,244,530,585,754,BACKGROUND,COMMITTEE,CONCLUSION,FUNDING,GPS,LABEL,METHODS,PATIENT,RESULTS,TRIAL
GIVEN,LABEL,METHODS,UNLABELLED
001,116,120,131,BPH,BSP,ECLIA,ELISA,MEIER,NBM,PEARSON,PSA,PSADT,ROC,SERUM,VAS
178,AUTHORS,BACKGROUND,CENTRAL,COLLECTION,CONTROLLED,DECREASED,ELECTRONIC,HRQOL,ISSUE,LABEL,LIBRARY,MEDLINE,METHODS,NSCLC,OBJECTIVE,OBJECTIVES,PEDRO,RESULTS,SCIENTIFIC,SELECTION,SMD,THREE
169,CIT,COPYRIGHT,DUE,EARLIER,FURTHER,GLN,GLU,HOWEVER,JRESI,LTD,MAS,MRS,NUS,PCA,SPM,WILEY
169,ADT,COPYRIGHT,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,THESE,WILEY
029,035,049,177,280,299,309,ADT,BACKGROUND,BMD,HOWEVER,LABEL,METHODS,RESULTS,SERUM,UNLABELLED
BRONJ,CHIBA,COLLEGE,EVENTUALLY,SURGERY,THREE,TOKYO
100,GUIDELINES,MEDLINE,PET,THERE
AMONG,MEMBERS,PSA
AKT,BACKGROUND,CXCR4,DU145,LABEL,METHODS,PC3,RESULTS,SDF,THESE
HOWEVER,ROS,SMIP004,UPR
160,CMR,EARLY,WHILE
THESE
AFRICAN,AMERICANS
FINALLY,HOWEVER,MVD,NAFTOPIDIL,RCC,RENAL,STUDIES
CISPLATIN,HOWEVER,JNK,JUN,LNCAP,MTT,PCR,TPA
AFTER,BASED,LN3,LNCAP,MAO,TREATMENT
106,174,176,815,HOWEVER,ICG,PROLONGED
AFRICAN,AMERICANS,CAUCASIANS,GLEASON,MEDICAL,METASTASIS,NUCLEAR,PCA,UNIVERSITY
CTBP1,EPIGENETIC,FINALLY,FIRST,H3F3A,SMARCB1
000,024,065,10Q24,200,20Q11,20Q13,215,731,ACYP2,OBFC1,PXK,RTEL1
AGAINST,BACKGROUND,COLLEGE,CONTEXT,KINGDOM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,REPORTING,RESULTS,ROYAL
138,BACKGROUND,CONCLUSION,ENDPOINTS,GLEASON,LABEL,MEIER,METHODS,MRL,OUTCOME,PSA,RESULTS
NWFET,PSA,SINCE,TWEEN,WHILE
001,003,169,177,ANXIETY,AVERAGE,BACKGROUND,DESPITE,ICI,INDEX,INJECTION,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,RESULTS,SCALE,SOCIETY,THESE,WHILE
947,AIM,CONCLUSION,LABEL,MATERIALS,METHODS,MSNPS,OBJECTIVE,RESULTS
100,181,956,BAPTA,BHQ,CONVERSELY,GF109203X,HOWEVER,INHIBITION,PC3,THEREFORE,WST
001,AIM,BACKGROUND,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,TRAMP,ZOLEDRONIC
BACKGROUND,CONCLUSION,FBS,HMGA2,LABEL,MATERIALS,METHODS,RESULTS
169,CD49F,GPR48,LGR,LIN,MECHANISMS,NOTCH,PRESS,PSC,SONIC,TAKEN,TREATMENT,WNT
BACKGROUND,CROSS,ENGLISH,FLORIDA,HISPANICS,LABEL,METHODS,NOTABLE,POISSON,RESULTS,THERE,WHITE
138,BEDFORD,CONCLUSION,FIFTY,INCREASING,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PREBIOPSY,PROSTATIC,PSA,PURPOSE,RESULTS,THEREFORE
223,FURTHER,III
001,009,625,626,628,BACKGROUND,COHEN,DECISIONAL,IDENTIFIER,IMPORTANCE,LABEL,METHODS,OBJECTIVE,PCA,RELEVANCE,RESULTS,SCREENING,SETTING,TRIAL
001,035,046,149,290,58102,859,ABOUT,BACKGROUND,III,LABEL,METHODS,RESULTS,SUMMARY
485,577,58102,946,947,BACKGROUND,CONCLUSION,CPG,CXXC5,FOS,IFN,IL1,LABEL,LMX1B,METHODS,MYC,PATHWAY,PCA,RESULTS,THERE,TNF
001,004,967,ADT,AFRICAN,BACKGROUND,CAUCASIAN,CHINESE,COX,HAN,LABEL,MEIER,METHODS,OATPS,ORGANIC,RESULTS,SLCO1B3,SLCO2B1,SLCO3B1,SLCOS,THESE,TTP
CYP17,LNCAP,PSA
ATG16L1,BIOMARKERS,CONVERSELY,SINCE,TAKEN
169,ADT,COPYRIGHT,FOLLOWING,FURTHER,GLEASON,HOWEVER,INCLUSION,LTD,OTHER,PSA
117,169,ADT,ASSESSMENT,BFI,BRIEF,CONCLUSION,COPYRIGHT,EARLY,FATIGUE,III,INC,INVENTORY,LABEL,METHODS,OBJECTIVE,PROTECT,QOL,RESULTS,THERE,TREATMENT
169,AMONG,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
AIM,BACKGROUND,GLEASON,KAPPA,LABEL,METHODS,OBJECTIVE,RESULTS,THESE
KNOCKDOWN,LNCAP,THESE
000,266,401,667,AFRICAN,GENOMES,KLK,KLK15,PCR,THERE
26S,945,954,DU145,EXPRESSION,IKK,INHIBITION,PC3
100,732,739,829,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,ONTARIO,RADICAL,RESULTS
119,169,BACKGROUND,COPYRIGHT,DESPITE,END,HISPANICS,LABEL,METHODS,NONMARRIED,OVERALL,PSA,RESULTS,SOCIETY
169,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,MRI,NYQUIST,RESULTS,SIMULATION,WILEY
169,ADT,COPYRIGHT,FRAMEWORK,HOT,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,THERE,THESE,WILEY
HIPPO,KNOCKDOWN,LNCAP,PCA,PSA,SAFB1
ADT,PCA,USING
AFRICAN,CAUCASIAN,CURRENT,ERG,KEY
916,956,968,AIM,AKT,AUTOPHAGY,CONCLUSION,GFP,LABEL,LC3BI,LNCAP,LOBARIA,METHODS,MTT,OBJECTIVE,PC3,PCR,RAB,RESULTS,RETIGERIC,ROS,SIMILAR,WESTERN
101,945,946,947,948,956,A66,AIM,AKT,CAL,CCK,CONCLUSION,LABEL,METHODS,MYR,OBJECTIVE,PAN,PI3KS,RESULTS,SRB,WESTERN
ADC,AUC,BACKGROUND,CONCLUSION,DCE,DTI,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,REGIONS,RESULTS,ROC,THERE
HOWEVER
169,214,302,CAUCASIAN,CBM,DESPITE,FURTHER,LABEL,MEDLINE,PAT,THEREFORE,UNASSIGNED,UNLABELLED,XPC
169,ASPARTAME,CALIFORNIA,COPYRIGHT,DENMARK,HODGKIN,ITALIAN,JANUARY,LOW,LTD,NIH
169,270,ADT,COPYRIGHT,CROWN,INC,LHRHA,MEN,PCA,PRIMARY,PUBLISHED
028,169,172,860,BACKGROUND,COPYRIGHT,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,THERE,UROLOGY
169,99M,ACA,BACKGROUND,BBN,COPYRIGHT,EIGHT,HABBN,HYNIC,INC,LABEL,LOW,METHODS,RATIONALE,RESULTS,SPECT,TECHNETIUM,THERE,TPPTS
019,026,125,160,169,177,454,597,CONTROL,COPYRIGHT,DETERMINE,FAT,INC,LABEL,MATERIALS,METHODS,NEITHER,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY,T1C,T2A,THERE,UNIVARIATE
169,222,947,ATM,AUTHORS,COPYRIGHT,INC,MRN,PUBLISHED,THESE
169,COPYRIGHT,LTD,ONJ
111,411,416,COLORECTAL,COX,DIETARY,INC,LABEL,METHODS,OBJECTIVE,OVARIAN,PUBLISHED,PURPOSE,RESULTS,SCREENING,THESE,TOTAL,TRIAL
135,138,148,169,177,207,259,351,956,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
396,ASSAY,BACKGROUND,CPG,IMPRINTING,LABEL,LOI,METHODS,RESULTS,TFPI2,USING,WHILE,WT1
064,169,1ST,ABSTRACTS,ASSESSMENT,AUTHORS,BJU,CONTROLLED,CRI,CURRENT,EFFECTS,INDEX,JANUARY,LABEL,MEDLINE,MEN,METHODS,NIH,OBJECTIVE,OCTOBER,PROCESS,RCT,RESULTS,REVIEWS,ROBOTIC,SCIENCE,STUDIES,SURGEON,TECHNOLOGY,THERE
169,945,AUTHORS,BJU,CONCLUSION,DESPITE,DETECTION,LABEL,MEN,METHODS,OBJECTIVE,PSA,RESULTS,UTI
667,BACKGROUND,GLEASON,LABEL,METHODS,PCA,RESULTS,STUDENT
001,169,AUTHORS,BCR,BJU,CONCLUSION,COX,ESTIMATES,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OTHER,PSA,PSM,RESULTS
007,010,015,027,169,470,COX,EPE,EPSTEIN,FOCAL,LABEL,LTD,METHODS,OBJECTIVE,PATHOLOGY,PNI,RESULTS,SOCIETY,UROLOGICAL,WHEELER,WILEY
001,009,024,049,344,441,ADVERSE,BETWEEN,COPENHAGEN,DENMARK,FAVOURABLE,GLEASON,LABEL,METHODS,OBJECTIVE,PRIMARY,PSA,RESULTS
22RV1,946,APC,BACKGROUND,BECAUSE,CURRENT,DNMT1,DU145,GSTP1,HOWEVER,LABEL,LNCAP,METHODS,PCA,PCR,RAR,RESULTS,RG108
AFTER,ALONG,COMPLEXES,CRC,H2A,HISTONE,HMS,LYS27,PCA,PCG,REPRESSIVE,SIMILARLY,SINCE,TIC
AVAILABLE,CELLS,CONCLUSION,DISORDERS,LABEL,UNLABELLED,VITAMIN
002,160,169,183,CONCLUSION,DCE,GEORG,GLEASON,III,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,STUTTGART,THERE,USING
003,007,009,036,037,117,131,169,183,233,741,AMICO,BACKGROUND,CONCLUSION,GEORG,GERMANY,LABEL,MATCHED,METHODS,NADIR,NEITHER,PCA,PSA,RESULTS,STUTTGART,THERE,THESE
169,183,GEORG,IAD,III,STUTTGART,UNTIL,VARIOUS
494,971,AFRICAN,ASIAN,BACKGROUND,CIS,CYP17,EBSCO,LABEL,METHODS,MSPA1,OBJECTIVE,ORS,RESULTS,SCIENCE,THEREFORE,WEB
001,003,011,012,055,086,119,134,147,194,243,262,298,321,407,434,454,471,511,597,644,727,761,776,778,781,801,802,823,846,961,AFRICAN,ASIAN,BIOMEDICAL,CAUCASIAN,CHINESE,GSTM1,GSTT1,HOWEVER,KNOWLEDGE,LITERATURE,MEDLINE,OVERALL,PCA,SCIENCE,WEB,WHILE
169,INCREASED,INTERPLAY,MDSCS,OSTEOLYSIS,RES,THEREFORE,THESE
169,605,GONADAL,RES,THESE
CCAR1,DEPLETION,GATA2
339,CONCLUSION,CURRENTLY,DEFINIENS,GLEASON,LABEL,METHODS,OBJECTIVE,PROTEIN,PSA,PURPOSE,RESULTS,TMA,WHILE
145,900,ALTOGETHER,BAX,BESIDES,CCAAT,EBP,EGF,GLUCOSE,GRP78,INSTEAD,PDT,PHOTOFRIN,UPR,VAD
041,299,770,AMONG,BACKGROUND,CONCLUSION,LABEL,METHODS,ORS,PRESCRIBED,RESULTS,SWEDISH,TNM
001,152,945,ERG,GLEASON,INCREASED,KPNA2,RESULTS,TMPRSS2
AAH,ERG,FIFTY,TMPRSS2
002,087,180,AMICO,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SPECIMENS,TESLA
169,BASEL,COPYRIGHT,FURTHER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SPANNER,STENT
116,11R,169,549,945,947,956,COPYRIGHT,DIETHYL,DIVERSE,FEW,HCT,LTD,MICHAEL,MORPHOLINE,THP
946,CL2,PET
002,104,169,173,575,COPYRIGHT,COX,GLEASON,INC,INCREASING,LABEL,MATERIALS,MAXIMUM,MEIER,METHODS,MTD,OBJECTIVE,PSA,PURPOSE,RESULTS,SRT
001,137,2YL,BACKGROUND,LABEL,METHODS,MTT,OPTIMAL,RESULTS,TAKEN,TIM,WESTERN
CXCR4,HOWEVER,SRC,THEREFORE
AGE,BACKGROUND,DIFFERENCE,ESTIMATES,ISFAHAN,LABEL,MATERIALS,METHODS,RESULTS
626,BACKGROUND,HOWEVER,LABEL,MATERIALS,METHODS,NHL,RESULTS,THERE
497,BPH,LNCAP,MICRORNAS,RESULTS,TAKEN,UTR
MYCOPLASMA,THERE
152,309,956,AFTER,AMICO,LABEL,MEN,METHODS,OBJECTIVE,PSA,RADICAL,RESULTS
BACKGROUND,CONCLUSION,DEPTH,LABEL,RESULTS,THEREFORE
BACKGROUND,CTV,INCREASING,LABEL,METHODS,OAR,RESULTS,SIMILARITY,SMALL
001,005,007,101,158,259,BACKGROUND,CONCLUSION,COX,END,JANUARY,LABEL,METHODS,OLDER,PATIENT,RESULTS,THERE,WHETHER
945,CHROMATIN,H3K4ME3,H3K9ME1,H3K9ME2,H3K9ME3,HYPOXIA,JARID1B,JMJDS,JUMONJI,LNCAP,PSA,UNDER
ADS,EVENTUALLY,NOTABLY,PCSCS,STAGE,THESE,TRAMP
160,477,621,721,BEGINNING,JANUARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RELATIVELY,RESULTS
000,BACKGROUND,HOWEVER,INCREASED,ITALIAN,LABEL,METHODS,ORS,RESULTS,SWISS
175,600,COMBINING,DU145,HENCE,IC50S,LNCAP,MTS,PC3,PCR,THEREFORE,WHILE
ANTIGEN,EIS,IMPEDANCE,PSA
035,049,055,072,074,177,HCC,IHC,RCC,SIMILARLY,USING
146,278,AFTER,BACKGROUND,BMP,CONCLUSION,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,SUMMARY,THERE
FURTHER
169,961,FINALLY,PC3
148,500,INCLUSION,LABEL,MARCH,METHODS,MONITORING,OBJECTIVE,OCTOBER,QUALITY,RESULTS,SWEDISH
001,108,239,403,AFTER,COX,HENRI,LABEL,MEIER,METHODS,OBJECTIVE,PSA,PSM,RANDOMIZED,RESULTS,RFS
004,665,710,BACKGROUND,BIRC5,CHINESE,CIS,CONCLUSION,IAP,LABEL,METHODS,ORS,PCA,PSA,RESULTS,UTR
176,238,ADT,EVERY,HOWEVER,LABEL,MAY,METHODS,OBJECTIVE,OVERALL,RESULTS,SECONDARY,SEPTEMBER
160,BESIDES,CACCATGTT,CONSENSUS,DU145,LNCAP,LUCIFERASE,PCA,PCR,PREVIOUSLY,R1881,THESE,YIN,YY1
ACP,CENTRAL,ENGLISH,FLORIDA,KNOWLEDGE,LATINOS,SPANISH,USA,VENEZUELA
ADDRESSING,BONFERRONI,CORRECTION,CREIGHTON,HEREDITARY,PROTECTIVE,THEREFORE,UNIVERSITY
005,007,009,102,104,142,CONCLUSION,GLEASON,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,SVI,USING
177,AREAS,CONCLUSION,DWI,LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS
136,GAP,GLEASON,PKP,SH3,UNTIL
KNOWLEDGE,NON
145,375,AFA,ANNOTATION,FUNCTIONAL,HDACI,HDACS,HISTONE,MHC,PC3,THESE
ACTIVATION,HOWEVER,SEVERAL,THEREFORE
201,464,509,ALPHARADIN,ARN,AZD,BESIDES,CYP17,DENOSUMAB,EZN,GALETERONE,ODM,ORTERONEL,SINCE,SIPULEUCEL,UNDER
ACCORDING,CAP,CURRENTLY,EARLY,PSA
CONCLUSION,KNOCKDOWN,LABEL,LNCAP,METHODS,OBJECTIVE,PCA,PCR,RESISTANT,RESULTS,TCA
126,177,AFTER,BACKGROUND,FIFTY,FORTY,LABEL,METHODS,PSA,RADICAL,RESULTS,SIXTY,T1B,T3B,THERE
223,BACKGROUND,CLASS,INTUITIVE,LABEL,METHODS,REDUCTION,RESULTS,SCS,TARGETS,THEREFORE,THESE,UDP,UGT,UGT1A
CARCINOMA,HOWEVER,INSTEAD,LABEL,NMIBC,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE,THEREFORE
METASTATIC
177,FDG,HOWEVER,IMAGING,PET
169,APART,FAILURE,MDR
169,6MONTHS,CENTRAL,COPYRIGHT,DCR,GRADE,HOWEVER,III,IQR,LDM,LOW,LTD,MEDLINE,MTD,PFS,RDI,WHILE
169,370,8473T,94INS,COPYRIGHT,COX,INC,IRR,NFKB1,NSAID,PPARG
100NM,BACKGROUND,DU145,FINALLY,GHRELIN,LABEL,LNCAP,METHODS,PC1,PC2,PC3,PCR,RESULTS
001,007,169,263,AUSTRALIA,BJU,LABEL,LOCAL,METHODS,OBJECTIVE,OBJECTIVES,PATIENT,PRIMARY,RESULTS,RRP
169,AUTHORS,BJU,BMI,LABEL,METHODS,OBJECTIVE,RARPS,RESULTS,SEVEN,THERE
963,BACKGROUND,COM,COV,INTER,LABEL,METHODS,PROSTATES,REGARDING,RESULTS,RMS
002,106,178,946,967,AIM,CONCLUSION,HOWEVER,ITC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SEVENTY,TGF,WHILE
BACKGROUND,CONCLUSION,CTS,DEFORMABLE,DIR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,VMANUAL,VPROP
001,002,006,162,225,287,459,613,638,735,AGE,BETWEEN,INDEX,LABEL,METHODS,NVB,OBJECTIVE,PURPOSE,RESULTS,SHORT
101,108,477,674,AFTER,CROSS,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,OVERALL,RESULTS,SETTING,SOUTH,THERE,WALES
144,BACKGROUND,CONCLUSION,FOLLOWING,GLEASON,LABEL,MAY,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS
001,181,279,550,898,AGAINST,BACKGROUND,CIS,COX,III,LABEL,METHODS,PCA,RESULTS,TOENAIL,UNION
AMONG,APC,ASIAN,BACKGROUND,CHINESE,CIS,DECREASES,END,FILIPINAS,FILIPINOS,INCIDENCE,INDIANS,JOINPOINT,KAMPUCHEAN,KOREANS,LABEL,LAOTIAN,METHODS,PAKISTANI,PAKISTANIS,RATES,RESULTS,THESE,VIETNAMESE
001,004,027,100,156,215,ADC,AREAS,CONCLUSION,GLEASON,HIPAA,LABEL,LEAST,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,WHOLE
169,ASC,PIN,SNAIL,STAT3
169,APPROACHES,DESPITE,STUDIES
AURKA,DESPITE,HPN,NOVEL,PCA,PROMISING,SPARC,WESTERN,WNT5A,WT1
169,COPYRIGHT,ECTOPIC,HCC,HOWEVER,IGF,INC,PCR,RESULTS,SCREENING,THEREFORE,WILEY
011,147,178,180,306,548,993,COX,ECONOMICS,HRS,INITIATORS,JANUARY,LABEL,MEDICAL,METHODS,MORE2,NPH,OBJECTIVE,RESULTS,WHILE
097,174,5T4,PSA,THEREFORE
217,BACKGROUND,ENTRY,FIFTY,GRADE,LABEL,MARCH,MBQ,METASTRON,METHODS,NRS,REGARDING,RESULTS
954,968,AKT,COX,DU145,LIMITED,RG003,RG005,THERE
FDG,PET,PRIMARY,SCC,SERUM

730,946,I298T,P261L,T292A
160,LNCAP,MET
PTV,RTPSS
014,AFFYMETRIX,ANIMALS,BACKGROUND,IGF,LABEL,METHODS,OVERALL,PCA,PGE,PSA,RESULTS,SERUM,WESTERN
169,CASTRATION,COPYRIGHT,ELISA,ERK,FINALLY,LTD,PC3,PC3PR,RAC,THESE
160,169,COPYRIGHT,D90,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SDREF,SEVEN,SOCIETY
3T3,ROS,THESE
1980S,AFTER,FDA,HOWEVER,PSA
945,946,AMONG,AREAS,BACKGROUND,BESIDES,COVERED,DESPITE,DEVELOPING,LABEL,LXR,METHODS,OPINION,OXYSTEROLS,SLIMS
003,174,AQUILAB,DCE,DWI,GTV,KAPPA,LABEL,LESIONS,MASTERPLAN,METHODS,MRI,NET,OBJECTIVE,PURPOSE,RESULTS,SUBSEQUENT,T2W,TESLA,USING
HOWEVER
DESPITE,FIRST,HOWEVER,III,PHASE,PROMISING
SELECTION
COA,GOLGI,HBP,NAD,NADPH,PRINCIPAL,UDP
33258,BAX,BCL,FURTHER,HOECHST,HOWEVER,VITAMIN,VK4
JUN,LNCAP,THESE
182,ECTOPIC,MICRORNAS,NDRG1
946,BACKGROUND,CONCLUSION,HFE,INHIBITION,LABEL,RESULTS,SINCE,THEREFORE,USING
BACKGROUND,CHANGES,GEARRAYTM,LABEL,OBJECTIVE,PRINCIPAL,PSA,PURPOSE,RESULTS,THESE,TRIAL
157,APC,BACKGROUND,CHANGES,COMPARISON,GLEASON,GSTP1,ITALY,LABEL,MARKERS,METHODS,PCR,PREVALENCE,RESULTS,TURIN
19Q13,CFD,ENSEMBL,KLK,KLKB1,PSA,SEQUENCES
BASED,DESPITE
173,291,292,355,426,587,610,773,BACKGROUND,CRC,DELAYED,EHR,IDA,JANUARY,LABEL,MARCH,METHODS,OVERALL,PPV,PSA,RESULTS
160,METICULOUS
102,178,412,GLEASON,LABEL,MAB,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,PZB,RESULTS,THERE,TZB
GENERATION,HOWEVER
SEPTEMBER,THEREFORE

288,AIM,BPH,CONCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,REDUCTASE,RESULTS,SCORE,SYMPTOM
024,AIM,BETWEEN,CONCLUSION,DESPITE,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PPI,RESULTS,RRP,SHORT,THERE,URINARY
223,HOWEVER
AFTER,FINALLY,RRP,SHORT,WALSH
169,COPYRIGHT,IRELAND,LTD,PDT,ROS,THESE
169,ASIAN,COPYRIGHT,ISSUE,LTD,SPECIAL,WESTERN
001,037,150,169,200,CHAIN,CONCLUSION,DUE,GENOTYPES,HAPLOTYPE,INDIANS,LABEL,MATERIALS,METHODS,MMP,NORTH,OBJECTIVE,OVERALL,PCA,PCR,POLYMERASE,PURPOSE,RESULTS,VARIANT
160,169,22B,956,COPYRIGHT,DU145,GES,HEPG2,MCF,SAS,SORAFENIB
001,002,006,009,100,155,169,171,260,282,734,CAUSE,COPYRIGHT,EIGHT,HDR,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,T2B,THESE
004,125,160,169,423,AUSTRALIAN,COPYRIGHT,CROWN,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TCP,USING
169,72H,945,956,AKT,COPYRIGHT,DU145,FIRSTLY,LTD,THESE
169,183,278,294,486,492,496,498,APRIL,ATRASENTAN,AVENTIS,BACKGROUND,COPRIMARY,COPYRIGHT,INSTITUTE,LABEL,LTD,METHODS,PFS,RESULTS,THREE,UNASSIGNED
169,CALYPSO,COPYRIGHT,FEWER,INC,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEATTLE,WASHINGTON,WAVELET
169,200,956,CELLS,COPYRIGHT,HOWEVER,LNCAP,LTD,PCA
945,DU145,HEPG2,HIF,LTD,PEITC,PHENETHYL,PUBLISHED,SKBR3,TAKEN,U87
169,171,187,AEU,BACKGROUND,CONTEXT,COPYRIGHT,FOCAL,GLEASON,LABEL,METHODS,PUBLISHED,RADICAL,RESULTS,SYNTHESIS,TREATMENT
BACKGROUND,CERTAIN,DESPITE,KAPPA,LABEL,METHODS,OCTOBER,PCA,PURCHASING,RELATIVES,RESULTS
169,225,AUSTRALIAN,AUTHORS,BACKGROUND,BLAND,COLLEGE,FMS,IMAGING,JOURNAL,LABEL,LOA,MEDICAL,METHODS,RADIATION,RESULTS,ROYAL,RTS,SIX,SMALL,TREATMENT,ZEALAND
100,169,AUSTRALIAN,AUTHORS,BACKGROUND,BLADDER,COLLEGE,IMAGING,JOURNAL,LABEL,MEDICAL,METHODS,NON,OAR,OVERALL,RADIATION,RESULTS,ROYAL,SEVENTY,SUGGESTED,THERE,V40GY,V50GY,V60GY,V65GY,ZEALAND
163,300,700,APRIL,ASSESSMENT,BACKGROUND,BPS,BSC,CONCLUSION,CONFERENCE,DATABASES,DENOSUMAB,FUNDING,GENERALLY,INSTITUTE,ISSUE,LABEL,LIBRARY,MARCH,MAY,MEDLINE,METHODS,NMA,NSCLC,OBJECTIVE,OBJECTIVES,OWING,PAS,RESULTS,SCIENCE,SOURCES,SRE,STUDIES,SYSTEMATIC,TECHNOLOGY,WEB,WITHOUT
145,181,946,LCLET,THESE,TRITERPENE
123,33258,AIF,ANNEXIN,APOPTOSIS,BAX,BCL,CONCLUSION,HOECHST,LABEL,MCF,METHODS,MMP,MTT,OBJECTIVE,PCR,PHASE,RESULTS,THEREFORE,WESTERN
169,ACQUIRING,BACKGROUND,ELISA,HOWEVER,INC,LABEL,METHODS,RESULTS,WESTERN,WILEY
169,ADENOVIRUS,CAR,COXSACKIE,CRCAS,CTV,FEW,INC,PCS,PHASE,RECEPTORS,USING,WILEY
007,141,169,215,308,AMONG,APRIL,BACKGROUND,CHINA,CHINESE,CONCLUSION,HUASHAN,INC,LABEL,METHODS,PCA,PSA,RESULTS,THREE,WILEY
106,235,278,503,845,BACKGROUND,CONCLUSION,CONTROL,FURTHER,IRELAND,LABEL,MEN,METHODS,OBJECTIVE,PROGRAMME,PSA,RAPAC,RESULTS,SEVENTY,SIXTY,UNIVERSITY
004,007,009,135,168,215,AMONG,CPG
131,HOWEVER,LNCAP,NIS,SEVERAL
001,009,556,845,BACKGROUND,CONCLUSION,LABEL,METHODS,QRESEARCH,RESULTS,THERE
160,169,COPYRIGHT,FURTHER,INC,KNOCKDOWN,PATHOLOGY,PUBLISHED,RAMP1,SOCIETY,THESE
180,181,223,945,AFTER
28S,C2848,PHA,SIMILAR,U50
169,223,CBZ,COPYRIGHT,ENZ,IRELAND,LTD
AKT,CHRONIC,IL6,INCREASED,LABEL,LOF,MALIGNANT,MCR,OSM,PIN,STAT3,UNLABELLED
169,COPYRIGHT,LTD,OTF,SYNTHESIS,THEIR
169,174,AFTER,AGE,BACKGROUND,BLACK,CHI,COPYRIGHT,FORCE,GFK,INC,JOURNAL,KNOWLEDGE,LABEL,LLC,MARCH,METHODS,OBJECTIVE,OCTOBER,PANEL,PREVENTIVE,PSA,PUBLISHED,PURPOSE,RESULTS
016,021,027,111,117,133,ADT,HORMONALLY,ICD,LABEL,METHODS,OBJECTIVE,RESULTS,S72,TAMPERE,UNIVERSITY
220,400,CENTRAL,DALTEPARIN,INCREASED,LABEL,METHODS,OBJECTIVE,RESULTS,UNIVERSITY
945,946,947,ACTIVATION,ASC,BPH,CASP1,CLOSE,FURTHER,GIVEN,HOWEVER,IFN,LABEL,PC3,UNLABELLED
133,288,355,959,AFRICAN,AMERICANS,AMICO,BMI,CAPRA,CAUCASIAN,CONCLUSION,GEORGETOWN,GLEASON,GSU,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,UNIVERSITY,WASHINGTON,WHILE
946,EVALUATION,HOWEVER,HUR,IGF,INSULIN,PREVIOUSLY,SP1,UTR
002,137,177,600,BMD,HOWEVER,PSA,ZOLEDRONIC
166,464,500,644,856,AMONG,CASES,DISULFIRAM,SIMILARLY
AF1,FURTHER
SPECIAL
DUE,FINALLY,SMALL,THESE
027,327,849,863,971,998,LABEL,METHODS,OBJECTIVE,RESULTS
967,DRAGS,III,INDICATORS,PEARSON,PSA,THESE
001,181,BACKGROUND,BISPECIFIC,BOM,CARDIOCYTE,COMPLEXES,CONCLUSION,DISCUSSION,DOX,HOWEVER,LABEL,METHODS,OBJECTIVE,PC3,PDC,PGA,POLYMER,PURPOSE,RESULTS
001,002,223,233,314,528,809,921,BACKGROUND,BAYER,HEALTHCARE,LABEL,METHODS,RESULTS
BETWEEN,CYBERKNIFE,DISRUPTING,IRT,LARGE,LIVER,SERVICE,SPINE,TBF,TECHNICAL,TIMES,TREATMENT,WEIBULL
ADT,GETTING,MANEN,THESE,THREE
002,505,AFRICAN,CONCLUSION,LABEL,LOUISIANA,METHODS,NORTH,OBJECTIVE,PATIENT,PROJECT,RESULTS,SEPTEMBER
BESIDES,PSA

175,179,BASED,BESIDES,CBR,CONCLUSION,DCS,LABEL,MEDLINE,METHODS,OBJECTIVE,PSA,RESULTS,TEN
000,100,500,AKT,CONCLUSION,LABEL,METHODS,MTT,OBJECTIVE,PCR,RESULTS,WESTERN
017,075,100,250,274,425,500,AFTER,CONCLUSION,DU145,LABEL,METHODS,MTT,OBJECTIVE,PCR,RESULTS,TEA,WESTERN
AFTER,CONCLUSION,ELISA,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,STAT3,THEREFORE,TNF,WESTERN
002,004,13C,1B1,A119S,AFTER,BACKGROUND,FURTHER,L432V,LABEL,N453S,PCA,PRINCIPAL,RESULTS,STUDIES,THERE
001,247,300,417,673,ANTIGEN,AUC,DCA,DRE,FINALLY,INDEX,PCA,PHI,PSA,ROC,THESE
EGF,IGF,IGFBP,INCUBATION,LNCAP,SERUM
AZD3514,CONTINUED,DUNNING,HID28
604,ABC,ABCB1,ATP,DOCETAXEL,HOWEVER,KNOCKDOWN
169,432,475,516,AFFAIRS,AMICO,AMONG,BACKGROUND,COPYRIGHT,LABEL,MEN,METHODS,RESULTS,SOCIETY,USING
232,250,ADT,AKI,CASES,CIS,HOWEVER,IMPORTANCE,JANUARY,LABEL,MEN,METHODS,OBJECTIVE,ORS,OVERALL,RELEVANCE,RESULTS,SETTING,STATISTICS,THESE
404,809,AFTER,COMMUNITY,LABEL,METHODS,OBJECTIVE,PRIOR,PURPOSE,RESULTS,WHILE
ARTEMIS,COGNITIVE,MRI,ORGAN,THREE
158,160,222,404,705,802,COX,SERUM
CAP,THERE,THESE,WHILE
390,ANN,BASED,ETTEN,H2O,PAP,PHOSPHATE,RIA,SCHNEIDER,SCI,THEREFORE,THESE,VAN
177,899,BASED,DAILY,PTV
110,150,BACKGROUND,CONCLUSION,LABEL,METHODS,REGRESSION,RESULTS,THEREFORE,TREATMENT
017,2578A,634CC,634CG,BACKGROUND,BONFERRONI,CONCLUSION,CTX,FORTY,GEHAN,HARDY,LABEL,MEIER,METHODS,OVERALL,PCR,PFS,PRISM,PSA,RESULTS,SNP
863,ALPHA,BACKGROUND,CIS,CONCLUSION,COX,HRS,LABEL,MEN,METHODS,PREVENTION,RESULTS,SOLAR,TOCOPHEROL
001,054,114,120,169,180,205,280,310,833,BACKGROUND,BASEL,LABEL,LOCALIZED,MATERIALS,METHODS,ORP,OVERALL,RARPS,RESULTS
169,253,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,DVH,LABEL,LTD,METHODS,PTV,PUBLISHED,RESULTS
181,CHONDROSIA,FURTHER,HCA,HOWEVER,PC3,PRL,THESE
169,ADT,CHANGES,PCA,THERE,THESE
169,400,631,BETWEEN,COX,HOWEVER
152,160,169,193,563,987,BMI,CONCLUSION,COPYRIGHT,HOWEVER,III,INC,LABEL,MATERIALS,METHODS,OBESE,OBJECTIVE,PSM,RESULTS,WORLD
DESPITE,DU145,EMF,IODOPHENYL,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,WST
CYP11B1,CYP11B2,CYP17,CYP19,THESE,VIA
AKT,DIALLYL,PNT1A,THESE
100,125,500,ADHERENCE,AFRICAN,AMERICANS,CAUCASIAN,GLEASON,LOUISIANA,NORTH,PROJECT,RESULTS,TNM,TOTAL,WORLD
COMPOSITE,DU145
DESPITE,FINALLY,INCRNAS,PCA,THESE
001,185,AMONG,BACKGROUND,CONCLUSION,DRE,GLEASON,LABEL,METHODS,NON,OBJECTIVE,PSA,PURPOSE,RESULTS,THEREFORE,THESE,UNDER
595,COLLEGE,CONCLUSION,HOSPITALS,LABEL,LUPUS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SLE,THERE,UNIVERSITY,WHEREAS
159,BACKGROUND,BIOMARKER,DECREASED,HOWEVER,LABEL,MALDI,METHODS,PCI,RESULTS,SISCAPA,THESE
169,200,956,ISOLATION,PCR,VCH,WILEY
AFTER,HOWEVER,PARACRINE,TARGETING
HOWEVER,SEVERAL,THESE
FCH,GLEASON,PET,PSA,T3B
CHOLINE,FCH,PET
169,239,COPYRIGHT,E26,ERG,FUNCTIONAL,INC,TREFOIL
169,AKT,CONVERSELY,ECTOPIC,HOWEVER,RES,SH4
169,BACKGROUND,COPYRIGHT,EAU,LABEL,MEDLINE,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,REVIEWS,SYNTHESIS,UROLOGY
045,100,162,169,1ST,200,BACKGROUND,CLAVIEN,COMPARING,COPYRIGHT,DINDO,DOUGLAS,INDEX,JANUARY,LABEL,METHODS,OBJECTIVE,ONCOLOGIC,OUTCOME,POTENCY,PROCEDURE,PSM,PUBLISHED,RECURRENCE,RESULTS,RETZIUS,ROBOT,SETTING,THERE,UROLOGY
169,COPYRIGHT,DESPITE,IRELAND,LTD,WHILE
11KETODHT,11KETOT,11OHDHT,169,1NM,945,ADRENAL,C19,COPYRIGHT,DHT,IRELAND,LNCAP,LTD
002,005,ABERRATION,AFTER,BLOOD,LABEL,MATERIALS,METHODS,OBJECTIVE,PAINT,PURPOSE,RESULTS,THESE,WHOLE
107,500,ANALYSING,ASSESSMENT,BACKGROUND,DISCUSSION,DUE,GUIDELINE,HOSPITALS,HOWEVER,HTA,IMPROVING,ITALIAN,LABEL,LIBRARY,METHODS,NHS,OBJECTIVE,OBJECTIVES,OUTCOME,PROGRAMME,REGARDING,RESULTS,SINCE,STUDIES,SYSTEMATIC,TAX,TECHNOLOGY,THERE,WHERE
CLEAR,CONCERNING,DOSES,HOWEVER,LOOKING,OAR,PTV,SIMILAR
INSTEAD,OAR,PTV,SPS,V95
100,160,181,CELLS,CHINESE,CHO,CO2,OER,RAT,RBE
019,BACKGROUND,CONCLUSION,CURATED,EXPRESSION,FAIME,FUNCTIONAL,FURTHER,INDIVIDUAL,LABEL,MICROARRAY,MODULES,MOLECULAR,MOTIVATION,RESULTS,VIA

956,AFTER,HSP27,TUNEL,WHILE
178,215,956,ADC,FRA
EWING,FUNCTIONAL,GROSS,IMAGING,OWING,PCR,REVERSE
A11,E1A,E2F,FURTHER,INCREASED,SELECTIVE,THESE
119,315,530,BACKGROUND,LABEL,METFORMIN,METHODS,ONTARIO,RESULTS,THERE
001,879,BACKGROUND,DESPITE,LABEL,METHODS,OVERALL,PHYSICIAN,QUALITY,REPORTING,RESULTS,SINCE,SOCIETY,SWEDISH,THESE,UROLOGICAL
177,HDR,LDR,LITERATURE
ASIAN,CHINA,RAPIDLY,THESE,WESTERN
239,SINCE
BNNTS,BORON,LNCAP
ADT,AR3,ASF,HOWEVER,SF2,THESE,UNDER
DICER,DISRUPTING,III,INK4A,P16,P27,RNASE
ANG,CRITICALLY,HOWEVER,LABEL,RIBOSOMAL,UNLABELLED
169,4PG,956,ADT,COPYRIGHT,ESI,LTD,PATHWAY,SID,SRM
169,257,600,746,COPYRIGHT,HODGKIN,HOWEVER,INC,NADPH,PUBLISHED,USING
169,888,COPYRIGHT,EMBEDDING,GLEASON,GRAPH,HOWEVER,MACHINE,SUPPORT
169,946,CELASTROL,COPYRIGHT,DARBY,EMT,INC,MADIN,MIGRATION,SNAIL,TGF,THESE
169,COPYRIGHT,ERG,HOWEVER,INC,SMALL,THEREFORE,TMPRSS2,URINARY
169,BACKGROUND,CDSSS,COPYRIGHT,CORRECT,EMR,GPS,IRELAND,JANUARY,LABEL,LTD,METHODS,PROVIDING,PSA,RESULTS,THERE
169,BACKGROUND,COPYRIGHT,EVERY,GLEASON,HOWEVER,LABEL,METHODS,NODAL,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,UROLOGY,WHEREAS
169,213,442,AEU,COMPARING,COPYRIGHT,EPSTEIN,GLEASON,KLOTZ,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,T2A
169,COPYRIGHT,ERG,INC,PCA,TMPRSS2
020,150,169,315,568,BACKGROUND,CONCLUSION,COPYRIGHT,DUE,HOWEVER,LABEL,LTD,METHODS,NEPRO,RESULTS,THERE,TTP,WESTERN
169,CALYPSO,COPYRIGHT,FIRST,INC,LABEL,LILLIEFORS,MATERIALS,METHODS,OBJECTIVE,PEARSON,PURPOSE,RESULTS,THERE
000,014,100,169,COPYRIGHT,CTS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
004,100,164,169,192,208,COPYRIGHT,CROWN,CTV,D90,ESTIMATES,GLAND,HDR,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS
BRAZILIAN,COMPOSITE,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PORTUGUESE,RESULTS,VALIDATION
005,558,571,652,BRAZILIAN,DRE,GLEASON,ILLITERATE,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,T2A
023,047,100,111,123,946,INTEGRINS,LABEL,METHODS,PSA,RECURRENCE,RESULTS,THERE,UNLABELLED
143,266,CONCLUSION,GLEASON,INCREASING,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,THERE
001,003,023,064,135,AFRICAN,AFTER,BACKGROUND,CAUCASIANS,CONCLUSION,COX,EQUAL,LABEL,MATERIALS,METHODS,PSA,RESULTS,UNI,VAS,WHILE
169,BACKGROUND,COPYRIGHT,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PSA,PUBLISHED,RESULTS,SETTING,SEVEN,SMALL,UROLOGY
108,125,169,180,392,615,ADT,ASTRO,BACKGROUND,BETWEEN,CONCLUSION,COPYRIGHT,FORTY,GLEASON,GS7,IRELAND,KETTERING,LABEL,LTD,MATERIALS,METHODS,MSKCC,OBJECTIVE,OTHER,PHOENIX,POTENTIAL,PSA,PURPOSE,RESULTS,ROUTINE,SLOAN,T2B
100,169,704,COPYRIGHT,ESTIMATING,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,QOL,RESULTS
946,EMT,THESE
BRCA1,BRCA2
223
001,003,100,220,303CM,967,ASI,ASIAN,AVERAGE,BACKGROUND,CAU,CAUCASIAN,GLEASON,JAPAN,LABEL,METHODS,PCA,PROSTATES,RESULTS,RUSSIAN,THREE,TOKYO,WHITNEY
144,BETWEEN,CHANGES,CHASE,COX,FOX,GLEASON,HARRELL,HCI
HOWEVER,WHICH
238,709,715,790,HOWEVER,SCORE,SYMPTOM
145,167,169,945,946,AKT,BAX,BCL,BIOLOGY,CAFFEIC,DECREASED,DOC,ERK,LNCAP,MOLECULAR,PTX,SER,SUBSEQUENT,UNION
946,THESE
141,194,BACKGROUND,BCR,CONCLUSION,COX,GLEASON,LABEL,METHODS,MICRORNAS,MIR,PCR,RECURRENCE,RESULTS,THREE
100,169,ACTUARIAL,ADT,APRIL,CAD,COPYRIGHT,COX,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PURPOSE,RESULTS,RV100,TREATMENT,USING
169,294,ADDITIONAL,COPYRIGHT,GUIDELINE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHYSICIANS,PRINCIPLES,PSA,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,UROLOGICAL
169,945,946,948,BACKGROUND,CHEMOKINE,DU145,GENERAL,HOWEVER,LABEL,LNCAP,MCP,METHODS,PC3,PKC,RESULTS,SRC,TRANSWELL,TREATMENT
160,169,174,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MALAT,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TRANSWELL,UROLOGICAL
160,169,ADT,COPYRIGHT,INC
169,ALVAREZ,COPYRIGHT,INC,PAR,WOMEN
169,COPYRIGHT,CTC,EPITHELIAL,INC,USING
169,1C3,945,946,COPYRIGHT,CYP,DHT,HTS,INHIBITION,LTD
115,169,COPYRIGHT,INC,THESE
177,ECLIPSE,PTV,VARIOUS
169,177,348,360,451,AIM,AMONG,BACKGROUND,FURTHER,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PROPORTION,RESULTS,SOCIETY,SPAIN
169,BIOMETRIC,SOCIETY
946,CILIA,HOWEVER,INCREASED,NUCLEAR,PIN,PRIMARY,THEREFORE,THESE,WNT
BACKGROUND,H2S,LABEL,METHODS,NEITHER,PCA,PSA,RESULTS
WACHTEL
156,3PUFA,834,969,BACKGROUND,LABEL,METHODS,PREVENTION,RESULTS,STUDIES,TRIAL,VITAMIN
000,169,503,BACKGROUND,ERG,FURTHER,HOWEVER,INC,KAZAL,LABEL,METHODS,RESULTS,THESE,WILEY

227,945,AFRICAN,AMERICANS,CAUCASIANS,CIS,GSTP1,HOWEVER,ILE,ILE105VAL,ILE158VAL,MEDLINE,ORS,PCA,SCIENCE,VAL,WEB
169,850,BACKGROUND,END,FEWER,LABEL,METHODS,RATES,RECEIPT,RESULTS,SOCIETY
169,CASTRATION,CDK,F876L,FINALLY,FUNCTIONAL,LABEL,LNCAP,MDV3100,UNLABELLED
100,108,160,221,598,BACKGROUND,CONCLUSION,LABEL,MATERIALS,METHODS,RADIATION,RESULTS,SOCIETY,THERAPY
AD5,ONCOLYTIC,TRAMP
945,COMPLEX
667,BMJ,CLINICIANS,GENERAL,GROUP,IQR,LABEL,LIMITED,METHODS,OBJECTIVE,PMR,PUBLISHED,PUBLISHING,RESULTS,THERE
004,169,177,295,827,943,APRIL,COPYRIGHT,F20,F21,F23,F25,GENERALLY,ICD,INC,LABEL,MARCH,METHODS,OBJECTIVE,PHYSICIANS,PLACE,PRESS,RESULTS
IVGGWECEK,L132I,MRM,OTHER,PSA,SNP,SVILLGR
DUTCH,GIVEN,LRP,ROBOTIC,RRP
169,HOWEVER,ROBOT,THEREFORE,UROLOGICAL
001,100,160,169,AIM,BRITAIN,COLORECTAL,CONCLUSION,CROHN,DEFINITIVE,DISEASE,FEW,FIFTY,GREAT,IRELAND,LABEL,METHODS,OBJECTIVE,PERMANENT,PRIOR,RADIATION,RESULTS,SUCCESSFUL
AFTER,APC,BESIDES,C30,CD3,CD4,CD8,CHINA,CHINESE,CONCLUSION,DIAGNOSIS,GUIDELINES,LABEL,METHODS,OBJECTIVE,PSA,PSS,QLQ,QOL,RESULTS,TCELL,TOTALLY,TREATMENT,UROLOGICAL,WESTERN
AKT,DHA,DU145,FURTHER,NAC,PC3,RESULTS,ROS,SIMILARLY
BAX,BECAUSE,HOWEVER,LAPC4,LNCAP
946,BMP,MMP,TGF,THESE,TREATMENT
291,BACKGROUND,CELLSEARCH,CTC,EPCAM,EPITHELIAL,HOWEVER,LABEL,MCA,METHODS,NSCLC,RESULTS
174,AMONG,ARG,BACKGROUND,CRYAB,DISCUSSION,EXPRESSION,GIVEN,LABEL,METHODS,OVERALL,PCA,PCR,RESULTS,ROC,SEVERAL,SIMILARLY
169,956,COPYRIGHT,MHZ,RAMAN,SRL,SRS,USING,VCH,WILEY
169,ATTRITION,COPYRIGHT,LABEL,LOW,LTD,METHODS,OBJECTIVE,RESULTS,WILEY
177,ADHERENCE,AMONG,BACKGROUND,CONCLUSION,DAILY,IDENTIFIER,IMPORTANCE,LABEL,MAY,METHODS,OBJECTIVE,OVERALL,PSA,RANDOMIZED,RELEVANCE,RESULTS,SETTING,SOY,SUPPLEMENT,TRIAL
005,007,239,AFTER,BACKGROUND,CONCLUSION,FRANKEL,LABEL,METASTATIC,METHODS,OBJECTIVE,PATIENT,RESULTS,YOUNGER
945,946,EMT,HIF,PCA,SHRNA,SIMILAR,TAKEN
DNMTS,EOC,ETS,HDACS,MAGEA11,SP1,TSS
169,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,CXCR4,EFFECTS,FAK,GTPASES,LABEL,METHODS,PC3,RAB,SIGNALING,THESE
945,FGFR2,JUN,K14,MYC,NANOG,NANOGP8
002,005,END,HOWEVER,JAPAN,REGARDLESS,RESULTS,THESE,WESTERN,WORLDWIDE
2ML,ANY,BACKGROUND,LABEL,METHODS,RESULTS,THERE,TOPICAL
039,160,169,805,AUC,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,LNS,LTD,METHODS,PCA,RESULTS,ROC
169,177,BASEL,COMPARING,CONCLUSION,COPYRIGHT,LABEL,MATERIALS,METHODS,OBJECTIVE,PTE,RESULTS
165,169,508,527,947,CONCLUSION,COX,EGF,ERK,HOWEVER,INVERSELY,LABEL,MEK,METHODS,OBJECTIVE,PCR,PD98059,PURPOSE,RAF,RESULTS,RSK,THEREFORE,THESE,U0126,WESTERN
011,169,946,CLUSTERIN,EGR,IGF,KNOCKDOWN,LABEL,METHODS,MTT,OBJECTIVE,OGX,PCR,PURPOSE,RESULTS,UNTIL,WESTERN,WNT
149,177,178,185,239,AUR,BACKGROUND,D90,GRAYS,LABEL,METHODS,RESULTS
001,121,250,BACKGROUND,C30,COX,DEC,EORTC,EVERY,JAN,LABEL,METHODS,QLQ,QOL,RESULTS,SEVERAL
200,ASSISTANT,CHIEF,COUNCIL,ENDOCRINE,ESTONIA,FELLOWSHIP,GALUKANDE,GUEST,INSTITUTE,INTAS,LABORATORY,LEV,MEDICAL,METABOLISM,NATASHA,PETERSBURG,PHD,RUSSIAN,SOCIETY,TARTU,UNIVERSITY,USA
946,HIP1R,HPM,HUNTINGTIN,RTK,TEL,THESE
169,ACADEMY,ANDROLOGY,CANDIDATE,PAP,PSA,SOCIETY,ZAG
169,BACKGROUND,COPYRIGHT,DU145,DUPRO,INC,LABEL,LAPC4,LNCAP,MATERIALS,METHODS,PCR,RESULTS,THESE,TREATMENT,VEGFC,WILEY

169,BACKGROUND,BPH,CD49F,COPYRIGHT,INC,LABEL,METHODS,PCA,RESULTS,SUBSETS,USING,WESTERN,WILEY
CD4,CD8,COHORTS,CSF,OVERALL,PSA,THERE
160,177,ACROMEGALY,AGE,IGF,MALIGNANCY,RENAL,THEREFORE,THYROID
104,160,CONCLUSION,CT1,CT2,DISTANCES,IMAGING,INTENSITY,LABEL,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,TREATMENT,V50,V60,V70,V75
947,948,BECAUSE,GMP,NBP,PERIPHERAL
120,712,BACKGROUND,CENTERS,CONTROL,DISEASE,LABEL,METHODS,PREVENTION,PSA,RESULTS,WEB
118,AFTER,AUTHORS,CALIFORNIA,CONTROL,DISEASE,LABEL,METHODS,OBJECTIVE,PREVENTION,PSA,PURPOSE,RESULTS,WEB
427,ABSENCE,INTERVIEW,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SCREENING
160,PLANS,SIO,TPS
015,052,177,BACKGROUND,C4S,FORTY,GLEASON,LABEL,METHODS,PSA,RESULTS,TMA,TNM
BLAND,COHEN,LOA
100,D10,GRO,HDR,PTV,SWIFT
002,006,037,177,6GY,CONCURRENT,DOSES,OAR,PTV,RA1,RA2,SLIDING,TEN,V30,VOLUMETRIC
169,ADT,BMD,COPYRIGHT,FORTY,FURTHER,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS
6MV,CRT,REGARDING,RISPC,THERE,UNTIL,WHETHER
120,126,136,ACCORDING,ACUTE,ARC,BACKGROUND,CTCAE,EARLY,FFF,FLATTENING,GLEASON,INCLUSION,LABEL,METHODS,MODULATED,NEO,PSA,QUALITY,RESULTS,THERAPY,TOXICITIES,VOLUMETRIC
114,277,575,BACKGROUND,COX,HOWEVER,LABEL,MEIER,METHODS,PSA,PSADT,RESULTS,SRT,SUFFICIENT
001,002,009,035,100,150,200,BETWEEN,EBL,LABEL,METHODS,OBJECTIVE,PSM,PURPOSE,RESULTS
169,507,BECAUSE,DIFFERENT,LTD,WILEY
169,195,208,CHINA,CHINESE,ENGLISH,INCLUSION,JANUARY,LTD,MEDLINE,SCIENCE,WEB,WILEY
MICRORNAS
169,AXL,BCL,CONVERSELY,HOWEVER,MERTK,TAM,THESE,TYRO3
001,AGE,BACKGROUND,DISCUSSION,EFFORTS,GIVEN,INTERVIEW,LABEL,METHODS,PSA,RESULTS,SDM
152,215,444,776,BACKGROUND,BECAUSE,CAUCASIAN,CERTAIN,FDR,LABEL,METHODS,RESULTS,SNP,THESE,VDR,VITAMIN
010,019,060,130,155,270,496,819,ASP336ASN,BACKGROUND,BTNL2,CANDIDATE,GLY454CYS,HOWEVER,HPC,LABEL,METHODS,RESULTS,WES
AMONG,CHALLENGES,EPOTHILONE,PGP,VINCA
296,872,AGE,AMONG,FEW,LABEL,METHODS,MUL,NVB,OBJECTIVE,PURPOSE,RESULTS

APRIL,BERZOFSKY,BIOLOGY,BOONS,CCR,CHAIR,CHIEF,COMPLEX,DEPARTMENT,GEERT,GEORGIA,IMMUNOLOGY,INSTITUTE,JAN,JAY,JEFFREY,LABORATORY,NCI,PEPTIDE,ROSWELL,UNIVERSITY,VACCINE,WASHINGTON,WORLD
169,945,946,AHR,AUTHORS,COPYRIGHT,HIF,HYPOXIA,INC,LPA,PUBLISHED,SINCE,THESE
169,600,956,ADT,COPYRIGHT,DISCOMFORT,FIFTEEN,LTD,PSA,VACCINE
114,145,169,218,279,336,AUS,COPYRIGHT,EDUCATION,INC,JANUARY,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,BIOMARKERS,CHALLENGE,GENERALLY,ISSUE,MALDI,PROTEOMIC,SPECIAL
001,006,160,169,ADVANCE,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,XRT
154,160,169,178,ACCORDING,BCR,CONCLUSION,COPYRIGHT,FURTHER,III,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PATIENT,PHOENIX,PRIOR,PSA,RESULTS,STUTTGART,THREE,UNIVERSITY
169,CONVERSELY,COPYRIGHT,DTX,EPIGENETIC,FEDERATION,HDAC2,NR4A1,PCA,PUBLISHED,SOCIETIES,THESE
169,COLLEGE,COPYRIGHT,ESTIMATING,LABEL,LARGE,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROYAL
169,390,AFRICAN,AMERICANS,BACKGROUND,CAUCASIAN,CNS,CONCLUSION,COPYRIGHT,CTC,HOWEVER,INC,LABEL,METHODS,PFS,PI3,PSA,RESULTS,TORC1,TOXICITIES
160,169,590,BACKGROUND,CONCLUSION,COPYRIGHT,ECE,INC,LABEL,METHODS,MRI,RESULTS,ROC,SPS,TESLA
169,COPYRIGHT,DERIVED,GIVEN,HOWEVER,MOLECULAR,SNP
000,100,113,151,169,220,462,487PY,982PY,AMONG,BACKGROUND,COPYRIGHT,COX,HRS,LABEL,LTD,METHODS,NPC,RESULTS,USING
169,945,946,954,COPYRIGHT,INC,ITGA7,PATHOLOGY,PUBLISHED,SOCIETY,THESE,TIMP3
169,COPYRIGHT,CTC,EMT,IRELAND,LTD
001,006,169,177,ACT,COPYRIGHT,INC,INSURANCE,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,OCTOBER,PUBLISHED,RATIONALE,RESULTS,ROI,SNR,THEREFORE
120,160,169,177,AUR,BPH,COPYRIGHT,FIFTY,INC,LABEL,MATERIALS,METHODS,NIC,OBJECTIVE,OBJECTIVES,PCA,PUBLISHED,RATIONALE,RESULTS
100,169,191,3DCRT,649,810,ADT,COMPLIANCE,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,WHILE
160,169,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,METHODS,PDE5I,RESULTS,SAS,THERE,UNIMPAIRED
169,BACKGROUND,CONCLUSION,COPYRIGHT,JANUARY,LABEL,MEDLINE,METHODS,RELATIONS,RESULTS,SAS,THERE
002,11Q13,169,215,908,AMONG,BACKGROUND,COPYRIGHT,CORRELATED,FINNISH,GENOMES,HAPLOTYPES,LABEL,LTD,METHODS,PREVIOUSLY,PROJECT,RESULTS,THESE
001,169,177,AFTER,BACKGROUND,COPYRIGHT,D35,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
001,037,113,160,169,176,177,215,342,465,582,753,804,956,APRIL,BCR,CONCLUSION,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATHOLOGIC,PSA,RESULTS,SRM,T2A,T2B,T2C
BACKGROUND,FURTHER,III,LABEL,PC3,RESULTS,THESE
001,817,CONCLUSION,HOWEVER,LABEL,LOW,METHODS,OBJECTIVE,RESULTS,USING
169,COPYRIGHT,LTD,MRS,NMR,WILEY
158,160,174,BAP,BSI,COMPARISON,CONCLUSION,CTP,DUNNETT,EXINI,GROUP,HOWEVER,INDEX,JAPAN,LABEL,LTD,METHODS,OBJECTIVE,PSA,RESULTS,TOKYO,TRACP
170,231,956,AFRICAN,BLACK,HOWEVER,MCF,MDA,MTT,MURASHIGE,NEURO,SKOOG
290,956,DIFFERENT,FURTHER,MCF,SINCE,TALALAY,THESE,UNION
110,750,BARCELONA,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SEGURETAT,THERE,TREBALL,UROLOGY
DLBCL,HODGKIN,MRI,NHL,NON,PSA,SINCE
177,65309,BXO,EIGHT
001,169,17A,947,BLADDER,CD4,COPYRIGHT,FURTHER,INC,PBMCS,PUBLISHED,ROR,SOCIETY,THEREFORE,THESE
169,COLLEGE,COPYRIGHT,LTD,MRI,PUBLISHED,ROYAL
169,AUTHORS,BJU,PDE5I
015,016,017,105,130,169,180,500,AUTHORS,BJU,CATHETERS,CLAVIEN,INDEX,INTRA,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,STLRP
169,ADT,APRIL,BJU,ENGLISH,EXPLORE,HOWEVER,MEDICAL,PSA,PSADT,SUBJECT,THERE,USA,WHILE
AAA,LABEL,METHODS,NTCPAAA,NTCPPBC,OBJECTIVE,PBC,PURPOSE,RESULTS,STUDENT
169,BETWEEN,BJU,CONCLUSION,DVD,III,LABEL,MAY,METHODS,OBJECTIVE,PRIMARY,RESULTS,SABRE,SCREENING,THERE
001,002,038,158,169,247,366,464,489,549,600,733,961,AUC,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PHI,PRO,PROMETHEUS,PSA,RESULTS
004,169,BJU,FUNCTIONAL,GLEASON,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,PCA,PHOENIX,PSA,RESULTS,SFC,STC
246,BACKGROUND,GRADE,LABEL,MANAGER,MEDLINE,METHODS,NORRK,PSA,RANDOMIZED,RESULTS
HOWEVER,ILC,THESE
125,BACKGROUND,BIOMARKER,EIGHT,EXTENSIVE,GLEASON,LABEL,PCA,PRE,PRINCIPAL,RESTRICTED,RESULTS,SEMINAL,SUPPORT
213,545,639,CONCLUSION,EXPRESSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
008,051,284,848,AGE,AUC,BACKGROUND,BETWEEN,CHINA,CHINESE,CONCLUSION,DIGITAL,DRE,GLEASON,HOWEVER,HUASHAN,LABEL,MEN,METHODS,PCA,PSA,RESULTS,SCORE,SERUM,USA
155,211,215,22Q13,945,BACKGROUND,INDIVIDUAL,KARMA,LABEL,LIBRO,METHODS,RESULTS,SWEDISH
END,OTHER,RESULTS
169,945,956,GADD153,HNSCC,ISR,MCF,PC3,SALUBRINAL,SCC,SCC25,TAKEN
169,BECAUSE,COPYRIGHT,LTD,USING,WILEY
GENISTEIN
328,HOWEVER,LLL12,STAT3
169,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,MTT,PCR,PROTEIN,RESULTS,SARDH,WESTERN,WHILE,WILEY
169,178,331,AUROC,BACKGROUND,COPYRIGHT,CURRENT,GLEASON,INC,LABEL,METHODS,NAD,RESULTS,THESE,WILEY
001,085,169,527,558,AAS,AFRICAN,ALTOGETHER,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,HEAVY,INC,LABEL,METHODS,PCA,RESULTS,SMOKING,VALIDATED,WILEY
116,695,AUSTRALIA,BCR,GLEASON,LABEL,MARRIAGES,MEN,METHODS,OBJECTIVE,OBJECTIVES,POISSON,RADICAL,RESULTS,RPS,VICTORIAN
125,130,CONCLUSION,GRADE,LABEL,LOCAL,METHODS,OBJECTIVE,PDR,PET,PSA,PURPOSE,RESULTS,SALVAGE
169,AUC,BACKGROUND,COPYRIGHT,HOWEVER,IRELAND,LABEL,LNI,LTD,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,ROACH,THEREFORE
DWI,KNOWLEDGE,MOLECULAR,MRI,MRL,PET,THEREFORE,THESE
22RV1,AKT,CALORIE,EUTHANASIA,GANITUMAB,IGF,RESULTS
CURRENT,EVALUATION,HOWEVER,JANUARY,KNOWLEDGE,LABEL,LITERATURE,MARCH,METHODS,NURSING,OBJECTIVE,PROBLEM,SINCE
001,100,236,AFTER,GLEASON,LABEL,MEIER,METHODS,MFS,OBJECTIVE,OBJECTIVES,PSADT,RESULTS,SRT,THEREFORE
IQM,LABEL,METHODS,MLC,OBJECTIVE,PURPOSE,RESULTS
192,215,BRACHYVIEW,CARLO,HDR,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,SEVEN,SIMULATION
100,945,946,D95,D97,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,V95
BEAMS,EXAMPLE,FUSIONARC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,WHILE
100,LABEL,METHODS,MLC,OBJECTIVE,PURPOSE,RESULTS,THESE
177,244,376,817,BECAUSE,EPI,FMS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SINCE
AUSTRALIA,GROUP,LABEL,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,STRENGTHS,TRANS,TRIAL,ZEALAND
012,036,177,ESPECIALLY,EXCLUDING,FURTHER,IMRTCUT,LABEL,LARGE,METHODS,OAR,OBJECTIVE,PLANS,PTV,PURPOSE,RESULTS,V60
BMD
119,BACKGROUND,CONCLUSION,GOVERNMENT,HOPKINS,JOHNS,LABEL,LESIONS,METHODS,MRI,PCA,PUBLISHED,RESULTS,THESE,THREE,ULTRASOUND,USA
169,563,575,BACKGROUND,CONCLUSION,GLEASON,GP5,GRAYS,GS8,LABEL,METHODS,PRIMARY,RESULTS,SOCIETY,SRT
124,AMONG,BKV,BPH,FURTHER,JCV,PCA,PCR
160,DESPITE,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RES,RESULTS,SCHER,SECONDARY,TOXICITIES
CTR,EXPRESSION,HOWEVER,PCS
001,159,177,314,473,AIM,CONCLUSION,GROUP,LABEL,METHODS,OBJECTIVE,PEARSON,PSA,RESULTS,VAS,WHITNEY
174,BACKGROUND,DEPARTMENT,DRE,LABEL,METHODS,PBX,PCA,PSA,RESULTS,SEPTEMBER,THREE
117,147,650,AFTER,CRUDE,DRE,HGPIN,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,WIDESPREAD
121,174,647,ALEXA,DYNAMIC,FLUOR,MICROMIXER,MRI,SUCCESSFUL
102,108,125,437,521,589,623,848,AMONG,BACKGROUND,COLORECTAL,CONCLUSION,COX,INSTITUTES,LABEL,METHODS,OVARIAN,RESULTS,SCREENING,TRIAL,WHILE
001,169,184,186,211,592,609,639,663,940,BMI,CONFIDENCE,COPYRIGHT,HOWEVER,HTN,INC,LABEL,MARCH,MATERIALS,METABOLIC,METHODS,OBJECTIVE,OBJECTIVES,RATIO,RESULTS,THERE
169,COPYRIGHT,DESCRIBING,HISTORICAL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THEREFORE
001,009,169,276,COPYRIGHT,COX,EDUCATION,ENTRY,EXPECTANT,FURTHER,GLEASON,INC,LABEL,MANAGEMENT,MATERIALS,METHODS,NORTH,OBJECTIVE,OLDER,PUBLISHED,PURPOSE,REDUCTION,RESULTS,T1C,T2A,UROLOGICAL
001,018,169,338,595,COPYRIGHT,COX,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THOSE,UROLOGICAL
396,ANOVA,EORTC,FURTHER,HRQOL,ITEMS,KPS,LABEL,METASTASES,METHODS,OBJECTIVE,QLQ,QUALITY,RESULTS,THROUGH,TREATMENT
169,174,500,ADDITIONAL,AUTHORS,BJU,COMMITTEE,CONCLUSION,FURTHER,INDEX,LABEL,METHODS,MRI,NON,OBJECTIVE,RESULTS,SONABLATE
CTV,DESIRED,DVH,EUD,PTV,SIXTY,USING
100,819,AMICO,BETWEEN,BOUNDARIES,CONCLUSION,GLEASON,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RADICAL,RESULTS
ADC,CONCLUSION,DWI,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS

APRIL,ENDOCRINE,LUBIK,MOLECULAR,RELATED
EPIGENETIC
001,008,009,029,037,169,206,BACKGROUND,CRP,GLEASON,LABEL,METHODS,PSA,RESULTS,SOCIETY,THESE
926,CONCLUSION,GANODERMA,GE132,HOWEVER,LABEL,METHODS,MSC,NATURAL,OBJECTIVE,PC3,PURPOSE,RESULTS,ROYAL,SW480
945,HOWEVER,HSP70,HSP90,SMALL,STEROID,THERE
169,945,ATP,BACKGROUND,CHRONIC,COPYRIGHT,CYTOCHROME,GLUT1,GLYCOLYTIC,HOWEVER,INC,LABEL,LNCAP,METHODS,PGC,PRE,RESULTS,TNF,WARBURG,WILEY
172,175,177,AMONG,BACKGROUND,BCRFS,CONCLUSION,CSS,EIGHT,ENDPOINTS,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OVERALL,RECORDS,RESULTS,THESE
004,012,026,046,080,113,177,226,423,646,655,BSM,CASES,LABEL,METHODS,MRI,OBJECTIVE,PML,PROTRUSION,PURPOSE,RESULTS
160,212,331,603,660,738,ALTERED,CONCLUSION,EXPRESSION,HOWEVER,LABEL,LSCCS,METHODS,OBJECTIVE,PURPOSE,RESULTS
150,160,BACKGROUND,CAM,DISCUSSION,GCP,GERMANY,GUIDELINE,HODGKIN,LABEL,LOE,METHODS,OFTEN,PROGRAM,REGARDING,RESULTS,THERE
014,018,019,041,095,AFTER,DPD,FIFTY,GROUP,PSA,SOA,THERE,TTP
001,007,046,431,675,677,853,876,COCHRAN,GSTM1,GSTT1,MEDICAL,OVERALL,THERE,WANFANG
001,005,007,177,793,961,ANATOMICAL,CONCLUSION,DESPITE,DIXON,IMAGE,LABEL,MBQ,METHODS,OBJECTIVE,OVERALL,PET,PURPOSE,RESULTS,THERE,THESE
435,CH2,CL2,DU145,MCF,MDA,MTS,NMR,SEVERAL
146,327,BASED,BECAUSE,CHINA,TAX
223,LABEL,MET,OBJECTIVE,PURPOSE,RESULTS,SUMMARY

100,169,786,956,BASEL,COPYRIGHT,DU145,H2052,H2452,H28,HEPG2,HUH,LNCAP,MKN,NCI,SBC,T24,VHL
ERG,ETS,SIMILARLY,STUDIES
169,947,ARF,INK4A,LABEL,REG,UNLABELLED
000,301,398,797,BRIEF,CONCLUSION,COU,COX,EASTERN,GROUP,III,INVENTORY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SHORT,TREATMENT
AFTER,FCH,GLEASON,PET,PSA,SIX,STAGING
CHANGES,CTC,FDA,INC,NANOVELCRO,PUBLISHED,VALIDATED,WHILE
001,048,101,112,169,177,184,193,205,220,ALBUMIN,AT101,BACKGROUND,CONCLUSION,COPYRIGHT,COX,CRP,GLASGOW,INC,LABEL,METHODS,NLR,PROGNOSTIC,RESULTS,SCORE
001,BACKGROUND,C61,CONCLUSION,ENGLAND,ICD,III,IRELAND,IRISH,JANUARY,LABEL,LOS,METHODS,PATIENT,RADICAL,RESULTS,RPS,THESE,THOSE
169,COPYRIGHT,HOWEVER,IRELAND,LTD
145,169,AIB,COMBINING,COPYRIGHT,DOCKING,ETHYL,LTD,THEIR,TRP
AKT,BACKGROUND,COLON,CYQUANT,ERK,FINALLY,FURTHER,HOWEVER,INHIBITION,LABEL,MAP1D,MEK,METHODS,PDF,PROTEIN,RESULTS
A10,APT,EPI,EPIRUBICIN,LNCAP,PC3,PEG
169,183,208,564,802,CONCLUSION,DISCUSSION,FDA,FIXED,HEART,KNOWN,LABEL,LTD,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,RCT,RESULTS,WILEY
CONNECTION,LDL,PSA,THERE,TNF
172,313,ANN,ARTIFICIAL,BACKGROUND,FUZZY,GLEASON,INFERENCE,LABEL,METHODS,NEURO,PSA,RESULTS,SYSTEMS
091,177,220,304,411,ADVERSE,AKI,BPS,CONCLUSION,FDA,JANUARY,LABEL,LITERATURE,METHODS,OBJECTIVE,PURPOSE,REPORTING,RESULTS,ZOL
ADT,CASTRATION,CRPCS,PCA,WHILE
ERG,EST14,ETS,FINALLY,HERVK17,HMG,PCA,SLC45A3,TMPRSS2
490,980,DCE,GDC,GNE,MICRO,MRI,VSI
215,301,ADDITIONAL,BCA,BONFERRONI,COLORECTAL,HODGKIN,NHL,OVARIAN,SCREENING,TRIAL
BACKGROUND,LABEL,METHODS,RESULTS,SCIENCE,THERE,WEB
169,231,ADP,CONVERSELY,COPYRIGHT,ERK,IIA,KBM,LC3,LTD,MDA,NCI,OVERALL,PD98059,RAF,RSK,S6K,SALVIAE,TAN,WILEY
169,22RV1,945,BACKGROUND,CELLS,COPYRIGHT,DHT,DIFFERENT,DISRUPTION,H874Y,INC,LABEL,LAPC4,LNCAP,METHODS,MUTATIONS,REGARDLESS,RESULTS,T877A,THESE,WILEY
AWARENESS,BACKGROUND,FACTORS,LABEL,METHODS,NOW,PAP,POPULATION,PSA,RESULTS,SPAIN
001,842,986,BPH,PREVENTION,PSA,SCORE,SYMPTOM,TRIAL,USING
169,945,BACKGROUND,DHT,FACTORS,INC,LABEL,METHODS,PCR,RESULTS,WILEY
145,169,BACKGROUND,BPH,CONCLUSION,FINALLY,INC,LABEL,LNCAP,METHODS,PCA,PCR,PIM,PNT1A,RESULTS,SIRNA,WESTERN,WILEY
030,126,169,171,200,222,327,336,532,873,BBC,CONCLUSION,COPYRIGHT,GREENLIGHT,INC,IQR,LABEL,LASER,METHODS,OBJECTIVE,OCTOBER,PRIOR,PVP,PVR,QOL,RESULTS,SIMILARLY,SIX,THERE,URINARY,WILEY
13Q13,13Q14,169,174,AFFYMETRIX,BACKGROUND,CNA,GLEASON,INC,LABEL,METHODS,RESULTS,RGC32,SCORE,WILEY
132,145,169,APPROACHES,BACKGROUND,BCL,CASPASE,COMET,COPYRIGHT,GADD153,HDAC1,HISTONE,INC,LABEL,METHODS,PROTEIN,RESULTS,WESTERN,WILEY,WJ25591
ENGLISH,GENERAL,KNOWLEDGE,OVERALL,TESTICULAR,TOTAL
169,946,ALTOGETHER,CBF,COPYRIGHT,FB1,HOWEVER,INC,ROS,RUNX1,RUNX2,SINCE,WILEY
APR,MRI,PSA
956,BAX,BCL,CDK,MCF,NMR,P21,PC3,TREATMENT
954,KINASES,MECHANISMS,NUCLEAR,PPM1A
100,BACKGROUND,CONCLUSION,CURRENT,G3BP1,KLAKLAK,LABEL,LTVSPWY,MATERIALS,MDA,METHODS,RAS,RESULTS,THEREFORE,TOX
945,AKT,HIF,MMP,PC3,PI3KS,ZSTK474
BACKGROUND,DESPITE,LABEL,MEN,METHODS,RESULTS
BACKGROUND,EARLY,FOCAL,LABEL,METHODS,RESULTS
ADDITIONAL,BACKGROUND,CROSS,EVALUATION,IMAGING,LABEL,METHODS,MRI,NOVEL,PERTINENT,RESULTS

169,947,956,AFTER,CASPASE,COPYRIGHT,HOWEVER,JUN,LTD,MDA,MEKK1,OME,PHOSPHO,ROS,SOD,T24,UROLITHINS
PSA
048,169,176,215,427,520,871,906,BACKGROUND,BMI,GLEASON,GRS,LABEL,METABOCHIP,METHODS,RESULTS,SNP,WHR
100,169,183,300,400,ADP,ANTITUMOUR,BACKGROUND,BETWEEN,BRCA1,BRCA2,COPYRIGHT,DOHME,EASTERN,EIGHT,ETS,EVALUATION,FUNDING,GROUP,JAN,LABEL,LTD,MERCK,METHODS,NIRAPARIB,RESULTS,SHARP,SOLID,TOXIC,USA
169,COLLEGE,COPYRIGHT,LTD,PUBLISHED,ROYAL
169,COPYRIGHT,LTD,RESULTS
052,169,323,562,885,ACM,AFTER,AMONG,BCR,BESIDES,COPYRIGHT,COX,GLEASON,HOWEVER,HRS,INC,LABEL,MATERIALS,MEIER,METFORMIN,METHODS,OBJECTIVE,RESULTS
003,100,169,257,295,AIR,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PEARSON,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,STUDENT,UROLOGICAL,WATER
169,BACKGROUND,CONTEXT,COPYRIGHT,INC,LABEL,LOCOMOTION,LUC,LUCIFERASE,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS
169,344,AREAS,BACKGROUND,CONCLUSION,COPYRIGHT,ECE,GLEASON,INC,LABEL,LNI,MATERIALS,METHODS,PCA,RESULTS,SIX
169,177,231,233,6MONTHS,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,SEPTEMBER
169,CARLO,COPYRIGHT,DVH,LTD,MONTE,PLANS,PUBLISHED,TCP,TEN,THESE,TPS
001,169,177,600,ADC,CONCLUSION,COPYRIGHT,ERC,HIPAA,IRELAND,LABEL,LOWER,LTD,METHODS,MRI,OBJECTIVE,PAC,PURPOSE,RESULTS,ROI,SNR
169,814,CONCLUSION,COPYRIGHT,ICERTDT,ICLINDT,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SETTING,THERE
169,COPYRIGHT,HOWEVER,INC,SRS,THESE
169,177,6MM,717,COPYRIGHT,CROWN,CYBERKNIFE,D10,D80,D98,HDR,HOWEVER,INC,MEDICAL,OAR,PUBLISHED
215,BACKGROUND,E2F,KNOCKDOWN,LABEL,LIVER,LXR,METHODS,PCR,PUBLISHED,RESULTS,TAKEN
117,172,216,CONCLUSION,EBL,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
FE3O4,NCS,NPS,PAA
BACKGROUND,CONTEXT,E26,ETS,LABEL,LITERATURE,METHODS,OBJECTIVE,SEVERAL,SOURCES,UROVYSION
BACKGROUND,BASICALLY,DISCUSSION,DOF,LABEL,MANAGEMENT,MEDLINE,METHODS,MIS,RESULTS,STONE,THERE,TUMOURS,UROLOGY
000,100,1ST,309,628,JANUARY,LUXEMBOURG,MEIER,PSA,SINCE
ANTIGEN,ARTICLE,PSA,TRISOMY
MRI
006,007,136,140,227,248,BACKGROUND,BNS,GLEASON,LABEL,LOWER,LRP,METHODS,PCA,POTENCY,PSA,RESULTS
002,018,034,065,107,157,267,489,773,798,869,894,922,936,ACCORDING,CHINA,FURTHER,HOWEVER,KNOWLEDGE,MARCH,ORS,OVERALL,PCA,PUBLISHED,SCHOLAR,VDR
000,100,23ANDME,AUC,CONCLUSION,CROHN,LABEL,METHODS,NAVIGENICS,OBJECTIVE,PREDICTED,PREDICTIVE,PURPOSE,RESULTS
001,ADP,AIF,DIFFERENT,HENCE,INHIBITION,PROTEIN,THESE
CTC,DEP,LNCAP,PBMCS
100,169,COPYRIGHT,FITCS,FPANS,PSA,PUBLISHED,USING
BACKGROUND,BMI,CROSS,FIFTY,LABEL,MAXIMAL,METHODS,PHASE,RESULTS,THESE
MRI
0XS,169,946,COPYRIGHT,CURRENT,IRELAND,LTD,THESE,VARIOUS
169,AFTER,COPYRIGHT,DHEAS,DHT,IRELAND,LTD,STEROID,STS,THESE
169,COPYRIGHT,EFFORTS,EPIGENETIC,HDACS,INC
169,239,99M,COPYRIGHT,CTC,EFFECTIVE,FDA,GROUP,HOWEVER,III,INC,PATIENT,PCWG2,WORKING
169,COPYRIGHT,FDA,FIRST,INC,PUBLISHED
169,BENEFIT,COPYRIGHT,INC,WHERE
169,ADT,COPYRIGHT,DESPITE,INC,THESE
169,COPYRIGHT,HOWEVER,INC,PRIMARY,PSA,THERE,THESE,WESTERN
169,COPYRIGHT,HOWEVER,INC,INCREASED,THERE
169,COPYRIGHT,INC,PUBLISHED,THERE
169,COPYRIGHT,INC,LARGE,LRP,ORP,PUBLISHED
169,5ARIS,CONCLUSIVE,COPYRIGHT,FDA,INC
169,COPYRIGHT,INC,PAP,PCA,PSA,THERE
169,CLINICALLY,COPYRIGHT,HOWEVER,INC,OVERALL,PCA
160,BCR,CAPSURE,CONCLUSION,COX,CURRENTLY,DISEASE,DPC,EQUAL,HOPKINS,HOWEVER,INC,JHH,JOHNS,LABEL,METHODS,OBJECTIVE,PSA,PSADT,PUBLISHED,RESULTS,STRATEGIC
215
AFRICAN,GEORGETOWN,JACKSON,TWITTER
300MICROG,AFTER,BLACK,CONCLUSION,FCM,JNK,LABEL,METHODS,MTT,OBJECTIVE,RESULTS,THESE,WESTERN
140,169,204,DESIGNS,DTF,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,ARSENIC,BACKGROUND,CHRONIC,INC,INCREASED,LABEL,METHODS,PCR,RESULTS,THEREFORE,WESTERN,WILEY
181,183,COMPOUNDS,GEORG,SIX,STUTTGART,THEIR
GROUP,HODGKIN,NHL,THEREAFTER
003,215,451,694,696,935,AMONG,BPI,CIS,COLORECTAL,INHERITED,ITGB2,LBP,MYD88,ORS,OTHER,OVARIAN,SCREENING,SIXTEEN,TRIAL
AKT,BRADYKININ
SRE,THEREFORE,THESE
017,BMD,CURRENTLY,FEVER,HOWEVER,INDEX,ISI,LIBRARY,MANAGER,SCIENCE,SIMILAR,TEN,THERE,THESE,WMD
001,103,212,333,448,946,AIM,BACKGROUND,COX,EXPRESSION,GLEASON,LABEL,MATERIALS,MEIER,METHODS,MMP,OBJECTIVE,OVERALL,PSA,RESULTS
167,196,BACKGROUND,BPH,FURTHER,GP5,GP6,HPV,IRANIAN,LABEL,MATERIALS,METHODS,PCA,PCR,RESULTS
000,007,021,069,117,177,258,718,AMONG,BACKGROUND,CONCLUSION,GLEASON,HOWEVER,JANUARY,LABEL,MATERIALS,MAY,METHODS,NEWLY,NODAL,PATIENT,PSA,RESULTS,UROLOGY
105,BACKGROUND,BLADDER,BLOOD,CASES,LABEL,LEBANON,METHODS,PCR,RESULTS
ACCORDING,CHILE,HANGA,NUI,POLYNESIA,ROA
008,013,044,13Q22,266,288,BACKGROUND,BEIJING,C2ORF43,CHINESE,FOXP4,GLEASON,HOWEVER,LABEL,METHODS,OTHER,PCA,PCR,PSA,RESULTS,TIANJIN
190,595,621,785,AGA,BACKGROUND,BPH,COMMONEST,DEPARTMENT,GLEASON,KARACHI,LABEL,MATERIALS,METHODS,OVERALL,PATHOLOGIC,PATHOLOGY,RESULTS,SECTION,THESE,TMAJORITY,TUR,UNIVERSITY
HOWEVER,MMP,PLS,PLS10,THESE
001,120,COX,ESCCS,LABEL,LOW,METHODS,OBJECTIVE,PCR,PROTEIN,REPS2,RESULTS,TNM,WESTERN
100,452,4NG,521,BACKGROUND,DEPARTMENT,DIGITAL,DRE,EASTERN,GENERAL,HOSPITALS,INSTITUTE,KOIRALA,LABEL,MATERIALS,METHODS,NEPAL,OBJECTIVE,OUTPATIENT,PSA,RESULTS,SURGERY
018,029,169,CONTINENCE,GROUP,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE,UROLOGICAL
158,183,414,717,ANOVA,ARABIAN,FEW,MEN,PCA,PSA,SAUDI,SERUM,THEREFORE,UNIVERSITY,WESTERN
CPG,MAFUCCI,TET,THESE
CRITICALLY,THESE
221,HOWEVER,MCF,MIR,UTR
001,129,244,384,633,AMONG,CONCLUSION,END,GLEASON,IMPORTANCE,LABEL,METHODS,OBJECTIVE,RELEVANCE,RESULTS,SETTING,T2A,USING


181,CHEST,IGA,LABORATORY
169,386,932,956,ARIZONA,ARSENIC,BACKGROUND,HEART,HRS,INDIANS,INORGANIC,LABEL,LOW,METHODS,NORTH,RESULTS,SOUTH,THESE
ACCORDING,CONCLUSION,DEPARTMENT,GENERAL,INC,LABEL,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS,SPAIN,SURGERY,TEN,THERE,UNIVERSITY
169,215,AIM,CHERNOBYL,CONCLUSION,COPYRIGHT,FINLAND,FINNISH,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,THERE
439,BACKGROUND,CONCLUSION,JAPAN,LABEL,LIVER,METHODS,OSAKA,RESULTS,THESE
2000S,AFTER,AUSTRALIA,BACKGROUND,CONCLUSION,COUNTRIES,GEOGRAPHIC,ITALY,LABEL,METHODS,RESULTS,THESE,USA,WESTERN
303,LABEL,METHODS,OBJECTIVE,PSA,RATES,RESULTS,THERE,UNIVERSITY
361,515,BACKGROUND,BCR,CONCLUSION,EXPRESSION,FURTHER,HMGA1,LABEL,MICRORNAS,PCA,PCR,PRINCIPAL,RESULTS,VALIDATION,WHILE
105,160,CALYPSO
PCA,THESE
169,295,741,ADT,BACKGROUND,GLEASON,HOWEVER,LABEL,MEN,METHODS,RESULTS,SOCIETY
169,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,T2W,TSE,WILEY
008,108,169,206,AFTER,AMONG,AST,BACKGROUND,COX,DESPITE,ESTIMATES,INCREASING,LABEL,METHODS,OPTIMAL,PSA,RESULTS,SOCIETY
150,PC3,PET,THESE,VALIDATION
170,611,HOWEVER,ILLNESS,INSURANCE,INTENSE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
121,160,CAB,PSA,SHORTENING,UNIVARIATE,USING
476,945,AMACR,COA,ERG,FOAMY,GLEASON,LOW
000,001,169,317,CHOLINE,CIS,DMG,HOWEVER,JANUS,ORS,SERUM,USING
11C,177,708,752,BACKGROUND,CANCEROUS,CONCLUSION,DCE,LABEL,METHODS,MRI,OBJECTIVE,PET,PURPOSE,RESULTS,SUV,T2W
223,233,TARGETING
605,CONCLUSION,DUE,INCLUSION,LABEL,METHODS,OBJECTIVE,PITX2,PURPOSE,RESULTS,SIXTEEN
177,AMONG,CHOLINE,LABEL,METHODS,OBJECTIVE,PET,PSA,PSADT,PURPOSE,RESULTS
945,954,CBP,IKK,PCA
CDC42,FAK,HOWEVER,USING,WAVE1
10Q,169,COPYRIGHT,HOWEVER,IRELAND,LTD,MMP16
169,COPYRIGHT,INC,PUBLISHED,WEB
111,169,316,357,764,BACKGROUND,COLON,CONCLUSION,COPYRIGHT,FOLLOWING,INC,LABEL,LYNCH,MEIER,METHODS,MMR,PUBLISHED,RESULTS,SIR
ANDROGENIC,HOWEVER
001,015,032,154,169,194,222,250,383,580,860,941,961,993,ADD,BJU,COMPARING,DIAGNOSIS,KNOWN,LABEL,MBP,METHODS,OBJECTIVE,PROCEDURE,RESULTS,SUBJECT,UNLABELLED
169,177,679,AMONG,BJU,CONCLUSION,GREATER,LABEL,METHODS,MIXED,OBJECTIVE,RESULTS,THESE
169,470,AUSTRALIA,BJU,CONCLUSION,LABEL,METHODS,OBJECTIVE,RADIATION,RESULTS
066,169,181,183,BJU,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,TCR
001,093,169,188,391,827,ADJUSTING,BJU,CONCLUSION,COX,CRC,DESPITE,END,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RATES,RATIO,RCC,RESULTS,SIR,USING
001,006,216,835,CLIENTS,FILIPINOS,HAWAI,HAWAIIANS,RANDOMIZED
OMICS,THESE

AFTER,BACKGROUND,BOARD,CAB,COMMUNITY,LABEL,LEARNED,LESSONS,METHODS,OBJECTIVE,OBJECTIVES,PSA
413,BRCA1,BRCA2,ELISA,EN2,GLEASON,PSA,THERE,URINARY,URINE
324,BACKGROUND,LABEL,METHODS,OUTPATIENT,RESULTS
169,CAP,COPYRIGHT,ELISA,IHC,INC,LIN28,LNCAP,MYC,PATHOLOGY,PCR,PSA,PUBLISHED,SOCIETY,WESTERN
160,169,COPYRIGHT,PATHOLOGY,SAS,SOCIETY,UROLOGICAL
169,BLACKWELL,FURTHER,HOWEVER,THESE
AGE,BACKGROUND,CONFIDENCE,HODGKIN,HOWEVER,INCREASED,INTERVALS,ITALIAN,LABEL,METHODS,MORTALITY,OBJECTIVE,OBJECTIVES,PCB,PLANT,RESULTS,SMR,VITAL
CURRENTLY,TOF
BACKGROUND,BECAUSE,CONCLUSION,DEPARTMENT,EUCLIDEAN,GLIWICE,INSTITUTE,LABEL,METHODS,RESULTS
169,BRITAIN,COPYRIGHT,ECTOPIC,ERG,FOXP1,GLEASON,GREAT,IRELAND,LTD,PSA,PUBLISHED,SNP,SOCIETY,WILEY
169,BACKGROUND,COPYRIGHT,INC,LABEL,LNCAP,METHODS,MT1,MT2,MT3,MT4,NDRG1,RESULTS,WILEY
THERE
FURTHER
CSC,THESE
SEVERAL,TODAY
EVENTUALLY,SINCE,WILMS
BACKGROUND,GLEASON,HOWEVER,LABEL,METHODS,RESULTS,T1C
169,AUTHORS,COPYRIGHT,LTD,PUBLISHED,RESULTS
100,HPV,LPIN2,MBP,NF2,PGC1A,RWPE1,STRUCTURAL,THERE,TRPV6,UGT2B17
PKR,SMALL
CD133,CHEMOKINE,CXCR4,MECHANISM,PCA,THEREFORE,ZEB
AGING,ARS,LNCAP,MMP,PC3,PCA,THEREFORE,USING
100,137,169,7GY,8PTER,8QTER,947,BLOOD,COPYRIGHT,FURTHER,METAFER,METAPHASE,MYC,RINGS,ZEISS
100,114,115,169,177,649,COPYRIGHT,DETECTION,EDUCATION,HOWEVER,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WHOLE
001,003,169,563,599,697,698,734,750,922,COPYRIGHT,COX,EDUCATION,HARRELL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,UROLOGICAL
169,COPYRIGHT,IRELAND,LNCRNAS,LTD
169,182,183,AMONG,BLADDER,COPYRIGHT,FURTHER,MIR,THEREFORE
1000S,169,177,215,3000S,ADC,CONCLUSION,COPYRIGHT,DWI,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROC
002,169,177,250,500,62242,750,945,ANTITUMOR,BACKGROUND,COPYRIGHT,EMD,EMR,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SECONDARY,SETTING,TEAES,THERE,TREATMENT,TRIAL,UROLOGY
145,169,231,956,COPYRIGHT,JUGLONE,LLL12,LTD,MDA,MENADIONE,PD9,PLUMBAGIN,PUBLISHED,STAT3
169,1ST,33PCA,3RD,947,ARC,AUTHORS,BIOMARKER,COPYRIGHT,ETB,INTENSITY,IRELAND,LABEL,LTD,MATERIALS,METHODS,MODULATED,OBJECTIVE,PCA,PUBLISHED,PURPOSE,RADIATION,RESULTS,THERAPY,VOLUMETRIC
169,AFTER,BIOLOGY,COPYRIGHT,DESPITE,FEDERATION,INC,PUBLISHED,ULTRASOUND,WORLD
130,150,155,169,833,BACKGROUND,COPYRIGHT,DESPITE,DVH,GTV,IRELAND,LABEL,LTD,MATERIALS,METHODS,ONGOING,RESULTS,THERE
109,169,200,532,AFTER,APRIL,BETWEEN,BNC,CAD,CONCLUSION,COPYRIGHT,HOLAP,INC,INDEX,LABEL,MARCH,METHODS,OBJECTIVE,PROCEDURE,PVP,REGARDLESS,RESULTS,SCORE,SMALLER,SYMPTOM
087,169,181,592,896,AUSTRALIA,COLLEGE,COPYRIGHT,DEVON,ENGLAND,HAMLETS,LABEL,LTD,MALTHUS,MATERIALS,METHODS,OBJECTIVE,PCT,PRIMARY,PROGRAMME,PUBLISHED,RESULTS,ROYAL,SIMILAR,TOWER
169,215,CHRONIC,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RADIATION,RADICAL,RESULTS,SECONDARY
169,COPYRIGHT,LTD
169,COPYRIGHT,INC
169,946,BMDMS,CONCLUSION,DU145,IFN,LABEL,LTD,METHODS,MTT,OBJECTIVE,PC3,PCR,PROBLEM,RESULTS,THESE,TRAMP,TRMAP,WESTERN,WILEY
169,69A11,954,AKT,FINALLY,SAR,WILEY
001,002,008,032,125,223,467,739,BACKGROUND,CONCLUSION,DC1,GLEASON,HIPAA,IMAGING,LABEL,MATERIALS,MAXIMAL,METHODS,OBJECTIVE,PURPOSE,REPORTING,RESULTS,SEVENTY,THREE
169,1G7,AMD3100,CXCR4,DESPITE,DRD,DTX,DU145,LABEL,MYC,PC3,PC3DR,UNLABELLED
173,282,BLADDER,CIS,ORS,THERE,TOBACCO
001,169,315,582,BACKGROUND,CONVERSELY,COPYRIGHT,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,THERE
AFTER,BACKGROUND,CONTEXT,DESPITE,INFECTIOUS,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SYNTHESIS
169,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MEDLINE,METHODS,MRI,OBJECTIVE,RESULTS
169,200,215,COPYRIGHT,EXTENSIVE,GLEASON,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SIMILARLY,YET
100,106,169,519,643,ASSESSMENT,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,LTD,METABOLISM,METHODS,MINIGDS,MMMSE,MNA,NUTRITION,OBJECTIVE,ORA,OTHER,RESULTS,SOCIETY
011,AKT,BECAUSE,CLU,LNCAP,MDV3100,OGX,PSA,THESE
160,AKT,BACKGROUND,DECREASED,DU145,EXPRESSION,FINALLY,ID1,ID4,INHIBITOR,LABEL,LNCAP,METHODS,MYC,RESULTS
231,945,946,CONVERSELY,DU145,EED,EXCITINGLY,HDACI,MCF,MDA,TAM,THESE
300,500,BACKGROUND,CONCLUSION,DRE,ERSPC,FINNISH,LABEL,METHODS,PSA,RANDOMIZED,RESULTS,SCREENING,SHORT
233,CYTOTOXIC,NOVEL,SEVERAL
145,181,945,946,AKT,CHOLESTANE,FAK,KIP,LNCAP,MICRO,MYC,OXYSTEROLS,TREATMENT,TRIOL,TUNEL,WESTERN
001,002,006,010,053,095,177,AMONG,COMPARISON,CONCLUSION,COX,FDG,GLEASON,LABEL,MEIER,METHODS,PET,RESULTS,SUM,SUV,UNLABELLED
169,COPYRIGHT,COX,III,LTD,PROGNOSIS,WILEY
946,954,A375P,MALIGNANT,THERE
GLEASON,TNM
146,EFFECTS,STUDIES
119,182,CAUCASIAN,CHINESE,CONCLUSION,GRADE,HISTORICAL,INTENSITY,LABEL,MAY,METHODS,NETWORK,OBJECTIVE,OUTCOME,OVERALL,RESULTS,SETTING,THESE
160,945,FXR,THESE
023,105,168,423,BACKGROUND,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
AKT,BPH,DEPLETION,DU145,ILK,PCA,THESE,WESTERN

202,BACKGROUND,DISCUSSION,LABEL,MATERIALS,METHODS,PATIENT,RESULTS,SOCIETY,THERE
ADVANCE,BACKGROUND,CONCLUSION,LABEL,MATERIALS,MEDICAL,METHODS,MINNETONKA,OTHER,RESULTS,SIXTY,SYSTEMS,UNIVARIATE,USA
BACKGROUND,BFW,BWI,EBL,INDEXES,ISD,LABEL,MATERIALS,METHODS,MRI,PDI,RESULTS,RRP,RUC,SWI
139,141,21210,ACCORDING,BACKGROUND,ENDPOINTS,ERSPC,LABEL,MATERIALS,MEIER,METHODS,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING
BACKGROUND,BCR,LABEL,MATERIALS,METHODS,PSA,RADICAL,RESULTS,WHILE
BACKGROUND,LABEL,RESULTS,THEREFORE
160,169,ASSESSMENT,BACKGROUND,CONCLUSION,EIGHT,EVALUATION,GRADE,GRADING,JANUARY,LABEL,LTD,MEDLINE,METHODS,OBJECTIVE,RESULTS,SOURCES,WILEY
FINALLY,LIFESTYLE,SINCE
001,007,032,050,102,116,177,281,321,348,435,470,518,668,763,843,ABDOMINAL,AGE,CONCLUSION,INDEX,ITALIAN,LABEL,METHODS,NON,OBESE,OBJECTIVE,RESULTS
MRI
BACKGROUND,DISCUSSION,GPS,LABEL,OBJECTIVE
001,294,DRE,E26,ERG,ETS,PCA,PCR,PSA,SERUM,SINCE,TMPRSS2
III,PHASE,THESE,UNTIL,YET
177,CD133,CSC,DU145,FINDING,HOWEVER,LNCAP,PCA,SFM,THESE,UNDER
000,345,600,AMONG,BACKGROUND,CONCLUSION,GCMAF,HOWEVER,LABEL,MARCH,METHODS,MIRAI,RESULTS
BACKGROUND,CONCLUSION,EHRLICH,GCMAF,HELIX,LABEL,RESULTS
001,039,169,AFTER,LABEL,METHODS,OBJECTIVE,PURPOSE,QOL,RELEVANCE,STUDENT,WHITNEY
821,ADVERSE,ANY,AUTHORS,BACKGROUND,BLACK,CENTRAL,COLLECTION,CVD,DBP,DIASTOLIC,GREEN,LABEL,LDL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,RANDOMISED,RESULTS,REUTERS,SBP,SCIENCE,SELECTION,SEVEN,THERE,THOMSON,WEB
048,137,BETWEEN,GBM,NEUTROPHIL,NLR,THESE
001,112,115,177,247,864,910,ALU,AUC,BPH,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCR,PSA,RESULTS
169,509,ARN,DESPITE,F876L,LABEL,THESE,UNLABELLED
596,CAS,CURRENT,GIVEN,LABEL,MEN,THESE,UNLABELLED
048,181,302,374,520,746,894,AMONG,BACKGROUND,CONCLUSION,DEFENSE,DEPARTMENT,FOUNDATION,FUNDING,GLEASON,HORIZON,INSTITUTE,LABEL,LIMITATION,MEN,METHODS,OBJECTIVE,OUTCOME,POPULATION,PRIMARY,QUALITY,RESULTS,SOURCES,T2A,TREATMENT
017,023,110,153,177,235,243,253,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
001,006,025,038,100,BAZ2A,CONVERSELY,DU145,FGFR3,LABEL,METHODS,MICRORNAS,OBJECTIVE,PC3,PCR,RESULTS,SMARCA5,THAP2,THERE
001,017,036,100,218,253,315,649,CONCLUSION,LABEL,LAMB3,METHODS,MYC,OBJECTIVE,PCR,RAS,RESULTS,SMARCA5
001,133,412,671,735,945,ARI,GLEASON,LABEL,MEN,METHODS,NATIONWIDE,OBJECTIVE,OUTCOME,PATIENT,PRESCRIBED,RESULTS,SETTING
169,22RV1,COPYRIGHT,CPP,LTD,PLK,PSA
169,COPYRIGHT,LTD,QUANTUM,WHILE
956,ADR,AFTER,BACKGROUND,BAF,CHINESE,CONCLUSION,CONTEXT,DISCUSSION,EAF,FOUNDATION,HEMSL,LABEL,LAMIACEAE,MATERIALS,MCF,MDR,METHODS,MTT,OBJECTIVE,PCR,PEF,RESULTS,RH123,THESE
001,256,473,801,AFRICAN,ASSESSMENT,CAPRA,CONCLUSION,LABEL,METHODS,NETWORK,OBJECTIVE,PCA,PRESENTING,PURPOSE,RESULTS
CAP,CARCINOMA,CURRENTLY,DOWEX,FE2O3,LOD,THEREFORE
016,031,047,FUNCTIONAL,LABEL,METHODS,MRI,MUL,OBJECTIVE,OBJECTIVES,PAD,PCL,QOL,RESULTS,SURGERY,VISIBILITY
THESE
002,169,BACKGROUND,BP3,CHANGES,CONCLUSION,COPYRIGHT,ESTIMATING,IGF,IGFBP,INC,LABEL,MEN,METHODS,OBESE,OTHER,OVERWEIGHT,PCA,POTENTIAL,RESULTS,THERE,THESE,WILEY
169,239,946,BACKGROUND,CONVERSELY,COPYRIGHT,HOWEVER,INC,LABEL,LNCAP,METHODS,RESULTS,TAXANES,WESTERN,WILEY
169,ACTIVATION,AKT,BACKGROUND,COPYRIGHT,DIFFERENT,ERBB2,EXPRESSION,HOWEVER,INC,LABEL,LN3,LNCAP,METHODS,PC3,RESULTS,RTPCR,SOMATIC,THR1697ALA,WILEY
CK7,HMWKS,IHC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,WHITNEY
100,169,177,ADULT,BACKGROUND,BURNS,C57BL,COPYRIGHT,CYP17A1,INC,LABEL,METHODS,MOUSE,NOG,RESULTS,THESE,WILEY
169,AR9,BACKGROUND,BPH,COPYRIGHT,DHT,ENTOSIS,INC,KNOCK,LABEL,LNCAP,METHODS,PC3,PCA,RESULTS,RHO,THESE,WILEY
017,169,BACKGROUND,CONVERSELY,COPYRIGHT,DU145,GLEASON,HOWEVER,INC,LABEL,LIPOCALIN,LNCAP,METHODS,MTT,PC3,PCR,RESULTS,WESTERN,WILEY
784,AFTER,LABEL,MACRO,METHODS,OBJECTIVE,RESULTS,WITHOUT
AGE,ASSESSMENT,BONFERRONI,C30,EORTC,FURTHER,HRQOL,INCREASED,KARNOFSKY,KPS,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,QLQ,RESULTS,UNIVARIATE
879,892,946,ARF,DECREASED,FOXM1,HOWEVER,LOX,PCA,PLK,TRAMP,WITHOUT
125,174,787,AFP,CA125,CEA,CYFRA,G1200,LUMIPULSE,PASSING,PSA,SERUM
DESPITE,HOWEVER,MRI,ROBOTIC,THESE,USA
RADICAL,WHILE
CURRENT,PCA
169,239,250,332,BASEL,COPYRIGHT,HUASHAN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THESE
105,169,BACKGROUND,BASEL,CDC,COPYRIGHT,CRP,LABEL,LABORATORY,METHODS,ORP,POI,RESULTS,ROBOTIC,THERE,WBC
145,169,AKT,COPYRIGHT,FGF8B,FURTHER,IRELAND,LTD,P38
949,963,964,ETS,FINALLY,MMP,NON,NOTABLY,TAKEN
109,BECAUSE,ERG,EWING,GENERAL,HOWEVER,OTHER,PROX1,SMARCB1
GLEASON,OVERALL,PCA,PROSTATIC,USUAL
945,946,BPH,SERMS,THERE
169,174,500,BACKGROUND,BOWEL,COPYRIGHT,EARLY,FOCAL,GLEASON,INC,INDEX,LABEL,LARGE,METHODS,MRI,PRIMARY,PSA,PUBLISHED,QOL,RESULTS,SECONDARY,SONABLATE,T2CN0M0,TPM,TREATMENT,UNILATERAL,URINARY
169,ANGELES,BJU,CALIFORNIA,LABEL,LOS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,UNIVERSITY
160,169,ADDITIONAL,ADJUSTING,AGGREGATE,BACKGROUND,COPYRIGHT,CURRENT,END,ESTIMATES,INC,INSURANCE,LABEL,MATERIALS,METHODS,OVERALL,POPULATION,RESULTS,SMALL,THEREFORE,UNIVARIATE
169,COPYRIGHT,DIFFUSION,DTI,FSE,IMAGING,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESONANCE,RESULTS,THREE
160,945,946,947,BACKGROUND,CXCR4,CXCR5,FINALLY,FURTHER,HOWEVER,INHIBITION,LABEL,LNCAP,METHODS,PAR,PC3,PCA,RAC,RESULTS,THESE
169,BACKGROUND,COPYRIGHT,EAU,ESTRO,EXCLUSION,GEC,HDR,HDRBT,IRELAND,LABEL,LTD,METHODS,RESULTS
169,GCPII,GLUTAMATE,THERE,WHILE,WILEY
155,169,195,BJU,CAT,GLEASON,HOWEVER,LABEL,METHODS,MNSOD,MPO,OBJECTIVE,PSA,RESULTS,SIMILARLY,THERE,TURKISH
947,CD3,EBV,EXTRANODAL,LABEL,NKTCL,TCR,TIA,UNASSIGNED,UNLABELLED,VIRTUAL
001,150,169,200,220,ADT,AMONG,BED,BJU,EBT,FBF,FPF,GY2,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,USING
000,160,169,ACADEMY,AFTER,AUTHORS,CONSISTENT,EVALUATION,III,INC,IPILIMUMAB,THESE,WILEY
752,927,ABOVE,CONVERSELY,DISABILITY,KOREA,OFF,TRADE,VAS
121,177,926,BACKGROUND,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THEREFORE
100,110,129,945,946,BACKGROUND,BOARD,CONTEXT,CTV,FIFTY,IRB,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PTV,RESULTS,THERE
ACCORDING,AFRICAN,ASIAN,ASN,ASP312ASN,BACKGROUND,CAUCASIAN,CAUCASIANS,CONCLUSION,ERCC2,HOWEVER,LABEL,LYS751GLN,MATERIALS,METHODS,OBJECTIVE,RESULTS,STUDIES,THESE,XERODERMA,XPD
C2C12,CURRENT,PEARSON,USING,VALIDATION
215,GLEASON,IVD,TEN,THESE
DU145,GST,GSTM1,GSTP1,HOWEVER,LNCAP,MOLECULAR,PCR,THESE,ZEBULARINE
HOWEVER,RECURRENT,THESE
160,CARLO,CLASSIFIER,MONTE
001,002,003,COLORECTAL,ERSPC,OVARIAN,PSA,RANDOMIZED,SCREENING,SINCE
221,222,HORMONE,LNCAP,MIR,RAB1A
169,AIFM1,AMONG,BIK,CCND1,COPYRIGHT,DDIT3,FAS,HSPA5,INCREASED,LNCAP,LTD,PPP2R1A,PROTEOMIC,SFN
946,ALTERED,DHEAS,HSD,LTD,PUBLISHED,TGF,THESE,WHILE
001,002,003,169,174,BLACK,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RADICAL,RESULTS,UROLOGICAL
001,010,169,219,AUC,COPYRIGHT,EDUCATION,GIVEN,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,UROLOGICAL
169,181,250,256,308,780,945,AFTER,AUA,COPYRIGHT,EDUCATION,INC,LABEL,LOWER,MATERIALS,METHODS,OBJECTIVE,OLDER,PUBLISHED,PURPOSE,RESULTS,STORAGE,THESE,UROLOGICAL
169,COPYRIGHT,INC,LOW,PAR
107,169,945,946,AIM,AQUEOUS,BACKGROUND,COPYRIGHT,EL4,FPR,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,MTT,NADPH,OBJECTIVE,PCR,RELEVANCE,RESULTS,ROS,TNF,VIETNAM
116,169,177,181,945,956,COPYRIGHT,GANODERMA,KNOWN,UVB
100,169,239,BACKGROUND,CONTEXT,COPYRIGHT,DOPPLER,FOCAL,LABEL,MEDLINE,METHODS,OBJECTIVE,OCTOBER,RESULTS,SCIENCE,STUDIES,SYNTHESIS,UROLOGY,WEB
169,945,AKT,COPYRIGHT,DLD,EMT,INC,THESE
169,945,946,954,AKT,CONVERSELY,COPYRIGHT,EMT,EPITHELIAL,ERK,FINALLY,GSK,HOWEVER,METASTASIS,PC3,SNAIL,TAKEN,TNF
169,COPYRIGHT,GLEASON,SINCE,SSS
169,CONVERSELY,COPYRIGHT,INC,LABEL,LNS,MATERIALS,METHODS,OBJECTIVE,OVERALL,PET,PPV,RESULTS,THEREFORE
169,500,600,ADT,ANDROGENS,COPYRIGHT,INC,PERSISTENT,SERUM
169,495,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MORBIDITY,MOUNT,OBJECTIVE,OBJECTIVES,RESULTS,SINAI
169,949,COPYRIGHT,DET,FDA,LTD,PC3,PCL,PEG,RAP
169,ALZHEIMER,COPYRIGHT,HDL,HOWEVER,INCREASES,PUBLISHED,SEVERAL,THERE
077,169,223,438,BACKGROUND,COPYRIGHT,JANUARY,LABEL,METHODS,OBJECTIVE,OCTOBER,OUTCOME,OVERALL,PSA,PUBLISHED,RESULTS,SETTING,STRATIFIED,THERE,THESE,UROLOGY,USING
169,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
110,114,169,317,AEU,COPYRIGHT,HCT,HOWEVER,LABEL,MAY,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROBOTIC
177,AMINO,CBT1G,CBT2G,GPI,H2009,H2CBT1G,H2CBT2G,LNCAP,PC3,PET
497,ANTIGEN,BACKGROUND,CRP,GLASGOW,GLEASON,LABEL,METHODS,PROGNOSTIC,PSA,RESULTS,SCORE,SEVEN,THERE,THEREFORE
AKT,BACKGROUND,CLONOGENIC,LABEL,METHODS,MTT,NEITHER,NVP,RESULTS
946,BACKGROUND,BT474,CONCLUSION,FOCAL,IGF,IGF1R,INHIBITORS,INSULIN,KNOCKDOWN,LABEL,MAP,METHODS,RESULTS,WHOLE,WNT
191,BACKGROUND,EXPRESSION,HOWEVER,LABEL,METHODS,MMP,PSA,RESULTS,TOUCH
169,AKT,BACKGROUND,COPYRIGHT,ELISA,EXPRESSION,FOXO4,INC,INHIBITION,LABEL,METHODS,PKB,RESULTS,TRAMP,WILEY
169,978,BACKGROUND,CONCLUSION,EGF,ERLOTINIB,GEFITINIB,GOVERNMENT,INC,LABEL,METHODS,PHLORIZIN,PREVIOUSLY,RESULTS,SGLT1,THESE,USA,WILEY
169,946,AKT,BACKGROUND,BPH,DKK,ELISA,EXPRESSION,FIBROBLAST,INC,KNOCKDOWN,LABEL,LENTIVIRAL,METHODS,PCA,PRSCS,RESULTS,THEREFORE,WESTERN,WILEY,WNT
169,AMONG,BACKGROUND,CONSISTENT,COPYRIGHT,HOWEVER,INC,LABEL,METASTASIS,METHODS,PAX,PCR,RESULTS,WILEY
945,946,UDP
100,153,169,945,946,BACKGROUND,COPYRIGHT,EDTMP,LABEL,METHODS,RESULTS,SOCIETY
DIFFERENT,HOWEVER,MALDI,MELDI,SPE,TOF,TRACING
946,DKK,ENDOGENOUS,TGF,THESE,WNT
169,293,AFFYMETRIX,BACKGROUND,COPYRIGHT,FINALLY,HEK,INC,LABEL,LNCAP,MDV3100,METHODS,PSA,RESULTS,THESE,WILEY
169,982,AFRICAN,AMERICANS,BACKGROUND,BETWEEN,CERTAIN,COPYRIGHT,DEFINITIVE,GEOGRAPHIC,GLEASON,INDIANS,LABEL,LIMITED,METHODS,NATIVES,PSA,RESULTS,RURAL,SOCIETY,T1C,T2A,T2B,T2C,T2NOS,USING
169,946,CPO,INC,PSIDIUM,SHP,SRC,STAT3,WILEY
251,295,549,723,BCR,COX,GLEASON,KOREA,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SIMILAR,WESTERN
EVIDENTLY,JANUS,KALLIKREIN,KLK,REGARDING
OVERALL,STROMAL,STUMP
685,C685Y,CRADS,E1A,E1B,PCA
107,124,140,191,AMONG,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
GROUP,PSA
169,BETWEEN,COPYRIGHT,INC,JANUARY,PUBLISHED,SUBMISSION
000,100,112,160,169,178,197,269,288,423,494,734,922,981,ADVERSE,AGE,COPYRIGHT,DEPARTMENT,DUE,EDUCATION,EMERGENCY,INC,LABEL,MATERIALS,METHODS,NATIONWIDE,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL
000,139,289,372,717,797,AMONG,APPENZELL,BACKGROUND,FEDERAL,FSO,GRISONS,INCIDENCE,JOINPOINT,LABEL,METHODS,MODEL,POPULATION,PREVALENCE,RESULTS,SWISS,THERE
169,946,ARRBS,COPYRIGHT,INC,NOWHERE,STUDIES
169,COPYRIGHT,ETS,GATA3,INC,THESE
169,COPYRIGHT,INC,NETWORK
169,COPYRIGHT,INC,PUBLISHED,SEVERAL,SIMILARLY,SRT
169,BASED,COPYRIGHT,GLEASON,INC,PUBLISHED
169,CAREFUL,COPYRIGHT,ELDERLY,INC,MANAGEMENT,PUBLISHED
169,COPYRIGHT,INC
169,COPYRIGHT,INC,OVERALL
169,COPYRIGHT,INC,MEN,PUBLISHED,THERE
169,COPYRIGHT,GLEASON,INC
169,AVAILABLE,COPYRIGHT,HOWEVER,INC,PHYSICIAN,PUBLISHED
4T1,BACKGROUND,CONCLUSION,DU145,EFFECTS,HOWEVER,LABEL,METHODS,MSC,PCR,RESULTS,SIMILAR,THESE
100,HOWEVER,IGY14,LOQ,PRISM,PSA,SRM
FORCE,FURTHER,MAY,PREVENTIVE,PSA,THESE,UROLOGICAL
111,177,ALA,BB2,GLN,GLY,LEU,NH2,PET,PHE,SPECT,STA,TRP,VAL
000,100,162,182,410,AFTER,CZECH,ERSPC,GLEASON,GRAPH,PCA,PSA,THERE,TNM
100,171,180,712,931,ACCORDING,CONCLUSION,HOWEVER,IQR,LABEL,METHODS,NHA,OBJECTIVE,OBJECTIVES,PHOENIX,PSA,REGARDLESS,RESULTS,SEVENTY

CD4,EOSIN,HOWEVER,LYMPHOCYTE,PCA,TRICHROME
NUMERICAL,PEARSON
169,COPYRIGHT,HOWEVER,LTD,MRI,ROUTINE,THEREFORE,WILEY
BCL,BID,CONVERSELY,ERK,HOWEVER,MCF,MTT,PAR,RELATIVELY
BASED,CBI,HOWEVER,L1210,NOTABLY,PREVIOUSLY
024,036,139,APC,CONCLUSION,EERPE,LABEL,MEIER,METHODS,OBJECTIVE,PATHOLOGY,PPC,PSA,PSM,PURPOSE,RESULTS
001,163,194,290,591,GLEASON,HOWEVER,MAY,MEDICAL,MRI,PCA,RADBOUD,UNIVERSITY
155,169,186,337,492,916,BACKGROUND,BECAUSE,COPYRIGHT,COX,END,FOLLOWING,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PROPENSITY,PUBLISHED,RADICAL,RESULTS,SETTING,UROLOGY
169,AKT,BACKGROUND,CONTEXT,COPYRIGHT,ETS,LABEL,MAJOR,METHODS,MOLECULAR,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,THESE,UROLOGY
004,042,166,169,210,376,392,561,565,765,AFTER,BACKGROUND,COPYRIGHT,ERSPC,GIVEN,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,POISSON,PSA,PUBLISHED,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,SETTING,SYSTEMATIC,UROLOGY
169,COLLEGE,COPYRIGHT,FOCAL,LTD,PUBLISHED,ROYAL,THERE
021,105,ACUTE,AFTER,BACKGROUND,GRADE,LABEL,METHODS,PATIENT,PSA,RESULTS
169,BJU,EIGHT,JANUARY,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,TEN
185,270,560,AMONG,BACKGROUND,BRAGG,CALCEIN,DII,FIT,FNTDS,HDS,HOECHST,LABEL,METHODS,MEV,NEITHER,PC3,RESULTS,SMA,U87
103,50E,ARRAY,DENSITY,GLEASON,LOW,SUMMING,THESE
76A,AIN,LNCAP,SIMILARLY
MCF

ALGORITHMS,BACKGROUND,BECAUSE,HOWEVER,LABEL,NGS,RESULTS,USING
ALZHEIMER,BACKGROUND,BASED,DIFFUSION,FINALLY,LABEL,RESULTS
BACKGROUND,HOWEVER,LABEL,RESULTS,SEQ,SEQGSEA
160,ARCAP,EGF,EPIDERMAL,ERK,GLI,PCA,TRANSWELL
000,169,AUNRS,COPYRIGHT,CSC13,DU145,NIR,THEREFORE,VCH,WESTERN,WILEY
954,COHEN,CONCLUSION,DCE,DWI,HISTOLOGY,IMAGING,INTER,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,RADIOLOGY,REPORTING,RESULTS,SOCIETY,UROGENITAL,USING
000,001,024,062,067,180,500,CONCLUSION,DIFFUSION,DWI,FORTY,HOWEVER,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PPV,RESULTS
189,BACKGROUND,CONCLUSION,LABEL,METHODS,OVERALL,RESULTS
013,034,141,AFRICAN,AMONG,BCR,CCP,COX,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OUTCOME,PHOENIX,PUBLISHED,PURPOSE,RESULTS,THERE
13D,169,COPYRIGHT,DU145,HBA,LTD,PDGFR
NOVEL,TREATMENT
AKT,BACKGROUND,FURTHER,LABEL,PRINCIPAL,RESULTS,THERE
MAXIMUM,SINCE
946,CRE,TGF,THESE,WHILE
946,FURTHER,PKG,WDR77
155,183,189,370,387,405,594,659,727,750,BACKGROUND,BAD,BILATERAL,HOWEVER,KKP,LABEL,METHODS,RESULTS,RETENTION,WILDUNGEN
BACKGROUND,DENMARK,INVITATION,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS
169,203,571,COPYRIGHT,COX,CRP,FINLAND,FINNISH,HOWEVER,MEN
256,300,385,LABEL,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,TESLA
238,240,343,596,HOWEVER,LEP,PUBLISHED
169,AAS,AFRICAN,AMERICANS,CAS,CAUCASIANS,EMT,USING
169,AKT,EXPECTEDLY,RAC,REX,RHO,THESE

001,315,AMONG,CRUDE,EXPOSURES,IMPORTANCE,LABEL,METHODS,OBJECTIVE,RELEVANCE,REPLACING,RESULTS,SATURATED,SETTING
ANTISENSE,ETE,LOX,OXER1,SEVERAL,STUDIES
TREATMENT

945,AGGRESSIVE,DOX,THESE,VSV
230,AFTER,BACKGROUND,BMI,COX,LABEL,METHODS,PCA,PSA,RESULTS,WORLD
ADT,CYP17A1,EARLY,III,PCA,PHASE
946,DICKKOPFS,JUN,PCA,PTHRP,TCF,THESE,WNT
ADT,WESTERN
CONCLUSION,CPG,GUIDELINES,INSTITUTE,IOM,JANUARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TRUST
169,COPYRIGHT,EFFICIENT,FURTHER,HA2,IRELAND,LNCAP,LTD,THESE
001,169,220,945,AIM,ANOVA,BASEL,COPYRIGHT,EIGHT,GLEASON,LABEL,MATERIALS,MDA,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SERUM,THERE,UNIVARIATE
147,169,193,AUSTRALIA,AUSTRALIAN,BACKGROUND,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RTR,THERE
017,024,035,044,169,961,BACKGROUND,BLINDED,COPYRIGHT,DCE,DUE,GLEASON,KEP,KRUSKAL,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,P75,PCA,PUBLISHED,RESULTS,ROC,UROLOGY
169,EFFECTIVE,GENOMIC,JOURNAL
ADDITIONAL,CNS,GBM,OUTCOME,RESULTS,SEVERAL,THESE
945,AREAS,BACKGROUND,BPH,COVERED,LABEL,MEDICAL,MEDLINE,METHODS,OPINION
146AG,ASIAN,CHINESE,CIS,CRC,HCC,HOWEVER,INDIA,KOREA,MICRORNAS,NORTH,ORS,WHEREAS,WHILE
252,272,280,323,331,553,CD8,CTL,HLA,NCI,WHILE

177,180,945,946,99M,ARG,ASP,CHANGES,GLY,LINIFANIB,SPECT,U87MG
164,191,3TMRI,AIM,BASED,CONCLUSION,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PSA,RESULTS,THERE
945,946,ACUTE,AFTER,AIM,CONCLUSION,CRT,EQUIVALENT,FORTY,GRADE,GROUP,LABEL,METHODS,OBJECTIVE,RADIATION,RESULTS,SIB,THERAPY
004,024,1EC,247,BACKGROUND,CONCLUSION,GLEASON,IEC,IGF,IIB,III,LABEL,MATERIALS,METHODS,RESULTS
169,356,638,ANXIETY,ASSESSMENT,AUSTRALIA,CABRINI,COPYRIGHT,DEPRESSION,ENGLISH,FUNCTIONAL,GUIDELINES,HOSPITALS,INCLUSION,LABEL,LATROBE,LOWER,LTD,MEETING,METHODS,NPAGA,OBJECTIVE,PCA,QOL,RESULTS,SCALE,SECONDARY,THERAPY,THESE,WILEY
HOWEVER,TSP,VARIOUS
036,177,189,BEIJING,HOWEVER,MARCH,MEN,PEARSON,PSA
229,EXPRESSION,PAR
231,3ML,ACUTE,CATHEPSIN,INCREASES,KGP94,MDA,METASTASIS,NOVEL
100,11A,12A,13A,13I,145,169,176,COPYRIGHT,FURTHER,MTT,OXO,SAS
169,1C3,945,COMPOUNDS,COPYRIGHT,CSR,ISSUE,LTD,SELECTIVE,SPECIAL
169,200,COPYRIGHT,LTD,PERVASIVE,ROLES,THESE
ASHKENAZI,BRCA1,BRCA2,ICELANDIC,IGF,JAK,JANUS
169,COPYRIGHT,HENCE,RWPE1,TGF
169,AKT,COPYRIGHT,IGF,INC,NTG,RTK,TRAIL,WHILE
169,5MM,COPYRIGHT,CTV,INC,MFO,PUBLISHED,ROTATIONAL,TEN,V45,V70
000,002,024,102,125,145,169,369,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,169,947,956,COPYRIGHT,HOWEVER,INC,TAXOL,THESE,WST
100,169,344,CONCLUSION,COPYRIGHT,ERG,HGPIN,HOWEVER,IHC,INC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS
100,169,406,AES,CONCLUSION,COPYRIGHT,CURRENT,INC,LABEL,METHODS,MINNESOTA,OBJECTIVE,PROCEDURAL,RESULTS,THESE,UNIVERSITY
001,169,22034,57441,6H2,ABM,CAT,CONCERNING,COPYRIGHT,HOMOLOG,MICROARRAY,NB110,THERE,WESTERN
001,004,006,009,169,BJU,CALIFORNIA,FRANCISCO,GLEASON,HOPKINS,KETTERING,LABEL,MARSDEN,METHODS,OBJECTIVE,OBJECTIVES,RANDOMIZED,RESULTS,ROYAL,SAN,SLOAN,TORONTO,UNIVERSITY
092,169,293,BJU,COX,FINNISH,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,RESULTS,TAMPERE
169,524,BJU,GLEASON,HOPKINS,HOWEVER,LABEL,METHODS,OBJECTIVE,REGRESSION,RESULTS
100,169,640,BJU,CONCLUSION,GLEASON,HOPKINS,HOWEVER,IRS,JOHNS,LABEL,METHODS,OBJECTIVE,POISSON,PSA,RESULTS
231,CHINESE,MCF,MDA,THESE
144,AMONG,DWT,FUZZY,HOS,MACHINE,ORDER,SPECTRA,SUPPORT,THESE,THREE,TRANSFORM,ULTRASOUND,WAVELET
100,390,ADENINE,FAD,TRS
AFTER
003,011,210,300,CONCLUSION,CREATININE,DIGITAL,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
025,102,185,3N1,CONCLUSION,GLEASON,IMMEDIATE,LABEL,LRP,METHODS,OBJECTIVE,OCTOBER,PREDICTING,PSA,RAJAVITHI,RESULTS,STAGE,THREE,UNIVARIATE
215,ADT,AKT,ANOVA,ENDURANCE,GLUT4,INSULIN,PRIMARY
239,945,946,ENDOCRINE,ESTROGENS,RELATED,ZELLWEGER
003,051,169,288,381,874,906,ADDITIONAL,BACKGROUND,COPYRIGHT,END,INCIDENCE,LABEL,METHODS,MORTALITY,RESULTS,SIMILARLY,SOCIETY,STATISTICS,STUDIES,THESE,USING,VITAL
169,AML,CSC,INC,THESE,WILEY
169,BRITAIN,COPYRIGHT,GIVEN,GREAT,IRELAND,LTD,PUBLISHED,SOCIETY,WILEY
FURTHER,HOWEVER,NIGELLA,PLANT,USING

000,175,379,400,DETECTION,DRE,HGPIN,INCIDENCE,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RESULTS
103,141,169,29B,COPYRIGHT
169,COPYRIGHT,IAP,LTD,ML183,SAR,TRAIL
123,169,182,183,187,612,873,AUG,BACKGROUND,BETWEEN,COPYRIGHT,DOCETAXEL,EASTERN,FEB,FUNDING,GROUP,INC,IQR,LABEL,LTD,MEN,METHODS,REGENERON,TREATMENT
011,177,963,BACKGROUND,BRAGG,FURTHER,HEIDELBERG,HIT,HOUNSFIELD,ION,LABEL,PET,RESULTS,THERAPY,TOMOGRAPHY
169,267,465,732,AFRICAN,AIM,BACKGROUND,CAUCASIAN,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PRE,RESULTS,SOCIETY,VCS,XRT
169,ADT,BACKGROUND,BOWEL,COMPOSITE,DOMAINS,INDEX,LABEL,METHODS,MSM,OBJECTIVE,OUTCOME,PCA,QOL,RESULTS,SCALE,SEVEN,SOCIETY,THERE,URINARY,WHILE
BACKGROUND,GOLGI,HOWEVER,LABEL,METHODS,PCR,RESULTS,WESTERN
POTENTIAL,TRANSIENT,TRPV2
FATTY,HOWEVER,INHIBITORS,PET
775,ATLAS,DETECTION,EBV,EPSTEIN,HEPATITIS,HPV,SEQ,VIRAL,WHILE
215,AFTER,BACKGROUND,GLEASON,LABEL,LNCAP,METHODS,PATHOLOGIC,PSA,RESULTS,SIX,THESE
169,900,945,946,AKT,COPYRIGHT,DHT,HSP70,HSP90,KNOCKDOWN,PATHWAY,PCA,SOLID,TPR
136,147,169,174,27632,BACKGROUND,CELLS,COPYRIGHT,INC,LABEL,LUCAP,METHODS,MTS,PCR,R1881,RESULTS,RHO,STEMPRO,STR,WILEY,XENOGRAFTS
007,021,042,088,160,238,258,527,673,734,842,882,907,AMONG,ASIRS,CATALAN,CATALONIA,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPAIN,TARRAGONA,THESE
991,PATHOLOGIC,RADICAL
101,CD133,FINALLY,HOWEVER,LNCAP,MTT,PCSCS,SILENCE
145,181,BLOOD,CHOLINE,DECREASED,FOURIER,GNP,ICP,LABEL,METHODS,MTT,OBJECTIVE,PEI,PURPOSE,RESULTS,TEM,USING,XPS
169,200BP,COPYRIGHT,HOWEVER,INC,MLV,MOLONEY,PCR,RTS,VIRUS
169,177,916,956,968,ANNEXIN,APOPTOSIS,CASPASE,DAD,EPILOBIUM,KEY,LABEL,LNCAP,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROYAL,SOCIETY,USING
160,169,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,ROUTINE,WHOLE,WILEY
116,HCT,HOWEVER,MCF,NMR,SEVENTEEN
AFTER,AIM,COX,EARLY,ELISA,HDAC1,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,REGRESSION,RESULTS,ROC,SVM,THEREFORE
001,005,177,BACKGROUND,HPF,METHODS,MVD,OBJECTIVES,RESULTS
169,COPYRIGHT,COX,GLEASON,MEIER,PCA,UNIVARIATE
256,311,PSA,PVUII,SIMILARLY
CNS
160,AFRICAN,BASED,BLACK,DESPITE,EARLY,FIRST,HOWEVER,NON,WHITE
124,160,383,449,506,AFFAIRS,CONCLUSION,FURTHER,JANUARY,LABEL,MEDICAL,METHODS,MPM,OBJECTIVE,PURPOSE,RESULTS
945,AMP,LNCAP,PKA,PKARI,WESTERN
AFFYMETRIX,FORTY,FURTHER,SNP

ADDITIONAL,ASX,ASXL1,ASXL2,ASXL3,ASXM1,ASXM2,BOHRING,DROSOPHILA,KDM1A,MSI,NCOA1,NHR,OPITZ,PHD,PRC,TRUNCATION
15A,169,COPYRIGHT,LTD,PIM
160,OVERALL
169,272,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SET
169,BASED,CD4,CD8,COPYRIGHT,DAVID,EBV,EPSTEIN,ESPECIALLY,HBV,HCV,NOS,TIA,WHITNEY
169,BASEL,COPYRIGHT,ENGLISH,EXPERIENCE,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
135,169,333,408,702,BASEL,CONCLUSION,COPYRIGHT,GLEASON,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PCA,PSA,PSM,RESULTS,USING
169,COPYRIGHT,LTD,ONCOSTATIN,TGFBI,THESE,TREATMENT
13P,169,956,COPYRIGHT,DU145,PC3,PCDNA,SAR,SAS,STRUCTURE,THEIR
169,ADT,AGE,BACKGROUND,BECAUSE,CONTEXT,COPYRIGHT,CURRENT,INCREASING,LABEL,MEDLINE,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,THEREFORE,UROLOGY
145,485,945,BACKGROUND,CYTOTOXIC,LABEL,MONITORING,PCS,RESULTS
945,GIVEN,GPCRS,INCREASED,LIGANDS,RGS,RGS17
001,300,349,BACKGROUND,DISTANT,LABEL,METHODS,RESULTS,SIMILARLY
AGENT,CURRENT,EXPOSED,VIETNAM,WAR
MEP50,SMAD1,USING,WDR77,YEAST
157,176,177,550,99M,CIM,CONCLUSION,LABEL,LNCAP,METHODS,MIP,PC3,RESULTS,SPECT,THESE,TIM,UNLABELLED
169,BCC,COPYRIGHT,ICELAND,INCREASED
CYTOSTATIC,THEIR
109,169,AFRICAN,AMONG,BACKGROUND,COPYRIGHT,LABEL,LOWER,METHODS,RESULTS,SOCIETY,THESE
181,ACC,BCL,CDK,COA,DDP
ESTIMATES,FIRST,KNOWLEDGE,THIRD
143,DU145,FOLLOWING,MICRORN,MMP,THESE
160,THYROID,WORLD
AIM,BACKGROUND,BPH,CHILE,LABEL,METHODS,OBJECTIVE,RESULTS,SPECIMENS,THERE,THESE
105,422,608,BACKGROUND,INADEQUATE,INDEX,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,SWEDISH
169,175,ASSIA,COPYRIGHT,HRQOL,JANUARY,LABEL,LTD,MEDLINE,MEN,METHODS,OBJECTIVE,PERCEIVED,RESULTS,STUDIES
MRI
MRI
100,BACKGROUND,DISCUSSION,FURTHER,HOWEVER,IGF,LABEL,METHODS,MIF,SECONDARY,SEPARATING,TRIAL,VO2
000,127,169,257,AIM,AUSTRALIA,AUTHORS,DALYS,DUE,LABEL,METHODS,OBJECTIVE,RESULTS,USING
169,FURTHER,LTD,THESE,WILEY
145,946,A2780,ANNEXIN,H1299
160,954,BARRETT,CD4,DESPITE,IMPORTANT,JAK,THERE,WNT
169,353,ANXIETY,ASSESSMENT,CHINESE,DEPRESSION,FUNCTIONAL,FURTHER,GENERAL,HRQOL,LTD,PTY,PUBLISHING,THERAPY,WILEY,YOUNGER
956,BASED,DOT,FURTHER,SUSPENDED,USING
001,004,017,AGE,AMICO,CHANGES,GLEASON,JAPAN,LABEL,METHODS,OBJECTIVE,RESULTS,USA
151,CD4,CD8,GLEASON,MEIER,PCA,WHOLE
009,012,169,724,946,947,AKT,BRITAIN,CAV,CONVERSELY,COPYRIGHT,GLEASON,GREAT,IRELAND,LTD,PUBLISHED,SILENCING,SOCIETY,TGF,THESE,WILEY
169,947,COPYRIGHT,GLEASON,HYPOXIA,LNCAP,OTHER,PCS
223,CONFERENCE,JAMES,KANTOFF,RAPID
HOWEVER,LOW,MICROARRAY
BBN,LNCAP,PC3,RHD,THESE
526,BACKGROUND,CONCLUSION,CURRENT,LABEL,METHODS,PCA,RESULTS,THESE,TOTAL
169,200,BACKGROUND,CK5,CK8,CONCLUSION,INC,INDIVIDUAL,LABEL,LAPC4,LAPC9,LNCAP,METHODS,RESULTS,THESE,WILEY
BACKGROUND,DISCUSSION,ELECTRONIC,FURTHER,KINGDOM,LABEL,METHODS,OBJECTIVE,RESULTS,SCREENING
129,137,AFTER,RADICAL,SEVERAL
001,177,BLOOD,CD127,CD4,HOWEVER,PCA,THEIR,TREGS
AMONG,CONSISTENT,EGF,EMT,ERG,ETS,SRC,TMPRSS2
FINALLY,PCA,THESE
207,300,DESPITE,THROUGH
H19,MIA,NOTABLY
CONVERSELY,NOTABLY,TRP53
169,COLLEGE,COPYRIGHT,HDR,LDR,LTD,PUBLISHED,ROYAL,THERE
169,945,AMONG,ANXA1,AUTHORS,COPYRIGHT,DA3,EGF,INC,LNCAP,MOUSE,PUBLISHED,SUMOYLATED,THESE,Y21
001,073,169,449,744,COPYRIGHT,CUMULATIVE,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RANDOMIZED,RESULTS,THESE,UROLOGICAL
001,169,583,ASSESSING,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,UROLOGICAL
169,272,695,713,AGE,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PRIOR,PUBLISHED,PURPOSE,RESULTS,SINCE,SWEDISH,T1C,UROLOGICAL
169,259,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
001,014,018,115,169,177,188,319,COPYRIGHT,EDUCATION,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,333,898,AGE,COPYRIGHT,EDUCATION,HOWEVER,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PSS,PUBLISHED,PURPOSE,RESULTS,SCORE,SYMPTOM,UROLOGICAL,WHILE
169,COPYRIGHT,LBP,LNCAP,LTD
169,BAX,COPYRIGHT,IRELAND,LTD,SALMONELLA,THESE
169,CLOQUET,CONCLUSION,COPYRIGHT,INC,LABEL,LNS,METHODS,OBJECTIVE,PLNDS,PUBLISHED,RESULTS,RETRACTION
001,160,169,630,915,CONCLUSION,COPYRIGHT,EDV,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS
169,CONCISE,COPYRIGHT,EDUCATION,FOUNDATION,INC,MEDICAL,PHYSICIANS,PUBLISHED
169,174,176,2MM,4MM,6MM,7MM,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,TEN
001,169,192,867,AUC,COPYRIGHT,EXAMINING,FURTHER,HOWEVER,LTD,MALAT,PCA,PCR,ROC
002,004,042,169,22863,584,730,ADT,AFTER,BRITISH,CCI,COPYRIGHT,DISEASE,EARLY,EORTC,GLEASON,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,USAGE
AAP,COV,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,V70
011,169,657,COPYRIGHT,HEART,HOWEVER,HRV,LTD,PUBLISHED,THESE,WHILE
168,2013S,452,611,938,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,PSA,QALYS,QUALITY,RESULTS
160,2013S,299,594,655,736,AUSTRALIA,CONCLUSION,LABEL,MEN,METHODS,NETWORK,OBJECTIVE,OUTCOME,RESULTS,SETTING,THOSE,TREATMENT
FIRST
1ST,ASIAN,BACKGROUND,ENGLISH,INCLUSION,JANUARY,JAPAN,LABEL,LEVEL,MATERIALS,MEDLINE,METHODS,QOL,RESULTS,SCIENCE,WEB
371,850,BACKGROUND,INDIA,LABEL,LAR,LOCAL,MATERIALS,METHODS,NON,RESULTS,TMH,UNDER
008,018,100,132,BACKGROUND,ELISA,HODGKIN,LABEL,MATERIALS,METHODS,NSE,RESULTS
001,103,198,956,ANXIETY,APMRT,BACKGROUND,DEPRESSION,HOWEVER,KEBANGSAAN,LABEL,MATERIALS,MEDICAL,METHODS,RESULTS,THERE,UKMMC,UNIVERSITI,UNIVERSITY
HOWEVER,III,NPC,PHASE,PREVENTION,SURGERY,TRIAL,VITAMIN
35S,ACUTE,BPH,EPIDIDYMO,STI,UTI
ADT,DESPITE,EVENTUALLY,MEDICAL,THERE
ADDITIONAL,CURRENT,DEFECTS
002,1420C,2756A,B12,HOWEVER,MECHANISMS,MTHFR,MTR,SHMT1,THERE
ACHIEVING,HBP,HORMONE,IGF,INHIBITION,INSULIN
BACKGROUND,BV2,CONCLUSION,FINALLY,HOWEVER,LABEL,METHODS,RESULTS,SIMILARLY,VPP
945,946,AMONG,PEPTIDE
A588T,ASIAN,CAUCASIAN,HIF1A,LABEL,METHODS,NOV,OBJECTIVE,OVERALL,P582S,PURPOSE,RESULTS,STATA,STILL,THEREFORE
ASIAN,CAP,CAPSURE,FRANCISCO,INITIATIVE,JAPAN,JOINT,MEETING,SAN,SEVERAL,SINCE,SIXTH,USA
035,AFTER,AVERAGE,BACKGROUND,EASTERN,FACTORS,GRADE,GROUP,LABEL,MARCH,METHODS,PALLIATION,RESULTS,TREATMENT,UPDATED
169,800,ADC,ANOVA,AUC,CONCLUSION,COPYRIGHT,DFAST,DSLOW,DWI,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,ROC,WILEY
001,017,117,954,AUC,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,ORP,OVERALL,PSA,PURPOSE,RALRP,RESULTS
001,EPI,HORMONE,LBD,NTD,THESE
034,163,738,DM2,DMP,ENROLMENT,HYPOTHESIS,LABEL,METHODS,OBJECTIVE,PANCREATIC,POISSON,RESULTS,SIR,THERE
THEIR
215,SKENE
946,BACKGROUND,CONCLUSION,COX,CTX,LABEL,METHODS,OWING,PCA,RESULTS,SERUM
135,185,657DEL5,BACKGROUND,BRCA1,CHEK2,CONCLUSION,DRE,I157T,LABEL,METHODS,PSA,RESULTS,SNP,THESE,THREE
AFTER,AGE,BACKGROUND,CLINICALLY,CONCLUSION,GERIATRIC,LABEL,MEN,METHODS,RESULTS,THERE
169,924,ALONG,BACKGROUND,COPYRIGHT,INCOMPLETE,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,ONTARIO,PURPOSE,RESULTS,TREATMENT
164,279,362,COX,FLAVONOIDS,III
CURRENTLY,LTD,PUBLISHED,WESTERN
168,169,189,AMICO,BACKGROUND,CONTEXT,COPYRIGHT,FURTHER,GLEASON,INCIDENCE,LABEL,LND,MEDLINE,METHODS,OBJECTIVE,OCTOBER,OVERALL,PCA,PUBLISHED,RESULTS,SCIENCE,SHORT,STUDIES,SYNTHESIS,THREE,UROLOGY,WEB
169,BACKGROUND,CONTEXT,COPYRIGHT,DESPITE,DIFFERENT,ITEMS,LABEL,METHODS,OBJECTIVE,OPTIONS,PCA,PREFERRED,PSA,PUBLISHED,RADIATION,REPORTING,RESULTS,REVIEWS,STUDIES,SYNTHESIS,SYSTEMATIC,UROLOGY
000,169,173,246,371,423,BACKGROUND,COPYRIGHT,INCIDENCE,INSTEAD,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,SWEDISH,UROLOGY,WESTERN
169,216,CAREFUL,COPYRIGHT,LTD,MULTI,PUBLISHED
169,48692,COPYRIGHT,LTD
METASTASIS
169,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,METHODS,PCA,PSA,RESULTS,SAS
BACKGROUND,DESPITE,LABEL,METHODS,RESULTS
100,78000,945,AKT,ANTIBODIES,DESPITE,FINALLY,GRP78,LRP,RBD,SCATCHARD,THESE
169,191,199,229,237,268,276,947,CD8,CTL,GLQLGVQAV,HLA,HPN,IFN,LNCAP,LTD,PLTEYIQPV,SLLSGDWVL,THEREFORE,THESE,WILEY
AFTER,CURRENTLY,THEREFORE,WITHOUT
946,BPH,CONSISTENT,IGF,PCA,TGF,USING,WESTERN
169,DESPITE,SOCIETY,THERE,THESE
169,ADT,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,PET,RESULTS,SDC,WILEY
001,023,129,704,734,742,748,BCR,COX,GLEASON,INCREASING,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
946,GLEASON,HBP,METABOLIC,MICROARRAY,MYC,OGT,SUPPORTING
001,169,BACKGROUND,CALCULATOR,COPYRIGHT,LABEL,METHODS,PREVENTION,PSA,RESULTS,RISKS,SEPARATING,SOCIETY,TRIAL
169,410,434,552,622,ADT,BACKGROUND,COPYRIGHT,EASTERN,GLEASON,GROUP,LABEL,METHODS,RESULTS,SOCIETY,THERE
HOWEVER,MICRORNAS,MOUSE,TRAMP,TRANSGENIC
THEREFORE,THESE
108,11Q14,169,215,289,453,614,673,BACKGROUND,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SOMMERS,THESE,TREATMENT
276,65291,925,APRIL,DOCETAXEL,EIGHT,GLEASON,LUTENIZING,MARCH,PACLITAXEL,PSA,SIX,THREE
027,043,65291,65309,CHANGES,EGG,EHS,EIGHT,SIX
AFRICAN,AWARENESS,MEN,PROJECT
006,100,ADVERSE,BACKGROUND,BLOOD,CONFIDENCE,FURTHER,IL8,LABEL,LOW,METHODS,METRONOMIC,MOVIN,NSCLC,OBJECTIVE,PFS,PRIMARY,RESULTS,SEVENTY,TEK,TREATMENT,TRIAL,TTF
169,EGR,NOTABLY,REMARKABLY,WAALS
381,EIT,EXAMPLE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STUDENT,THESE
176,177,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
225,4GY,CTS,D99,DOSIMETRIC,LABEL,METHODS,MLC,OAR,OBJECTIVE,PURPOSE,RESULTS,SELECTIVE,SEVENTY,SIMILAR,USING,V56GY
001,181,AIM,CONCLUSION,COX,LABEL,MEIER,METHODS,OBJECTIVE,RESULTS,SARCOSINE,SERUM
AIM,CONCLUSION,FORTY,GLEASON,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,RIONERO,SEVENTEEN,UNIVERSITY,VULTURE
ITALIAN,THERE
ITALIAN,THERE
130,756,DISTANT,ML2,PC3,PCA,WESTERN
91K,94K,AWP,BACKGROUND,CEA,CONCLUSION,DOCETAXEL,EXCELLENCE,III,INCREASES,INSTITUTE,LABEL,METHODS,MODEL,NEWER,OBJECTIVE,RESULTS
152,231,29B,29C,946,ACTIVATION,DU145,MDA,RAR,TRAMP
LIMITLESS,STRIKINGLY,THESE,WHILE
001,105,169,454,946,AFRICAN,BACKGROUND,CAUCASIAN,COPYRIGHT,DELAY,END,INSTITUTE,LABEL,METHODS,RESULTS,SOCIETY,USING
169,350,CURRENTLY,ELISA,SINCE,VAP,VCH,WILEY
128,DESPITE,GLEASON,ITALIAN,LABEL,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,SCORE,THESE,THREE,TNM
HOWEVER,IMAGING
909,COX,EXPRESSION,HOWEVER,MMP,UUT,UUTUC
160,ABT,ASSAM,ATP,TAKEN,TFS,YBT
048,133,140,757,824,879,GLEASON,HOWEVER,PCA,PSA,THERE
160,945,EGR,INHIBITION,JNK,JUN,LNCAP,TNF,TPA
COMPONENTS,HOWEVER,MARIJUANA,STUDIES,THC,USA
213,752,966,BMI,CIS,COLORECTAL,CONCLUSION,HRS,LABEL,METHODS,OBESITY,OBJECTIVE,ORS,OVARIAN,PURPOSE,RESULTS,SCREENING,TRIAL,WHETHER
LXXLL,PELP1,THESE
048,169,177,CONCLUSION,EXPANSION,FORTY,IMAGING,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SITES,THOSE
091,092,106,114,169,270,315,AUR,BJU,COMPARING,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS
001,008,009,167,169,256,425,681,AMONG,BJU,DOPPLER,GLEASON,IMAGE,LABEL,METHODS,OBJECTIVE,RESULTS
ADT,LARGE
AMONG,III,PSA,RESULTS
223,427,FURTHER,III,O11,OGX,THERE
100,600,AMERICANS,DHA,EPA,OMEGA
GREEN,GTP,THERE
122,169,183,642,990,COPYRIGHT,EDUCATION,INC,INCLUSION,LABEL,MACCONKEY,MATERIALS,METHODS,OBJECTIVE,PROTECTION,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,946,AUTHORS,BEC,GLEASON,III,LEC,LTD,NIH,PATHOLOGY,PDGFR,PTY,PUBLISHING,SOCIETY,THESE,WILEY
AFRICAN,DIFFERENT,PROSTATIC,SINCE
946,956,ARD,ARS,USING
169,AKT,BACKGROUND,BEIGE,BRITISH,CHOLBUT,CONCLUSION,EFFECTS,KEY,LABEL,LUC,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS,SLN,SOCIETY,SOLID,THESE,WESTERN
169,207,239,ANXIETY,AUSTRALIA,COPYRIGHT,INTERVIEW,LABEL,LTD,MEN,METHODS,OBJECTIVE,REGRESSION,RESULTS,SCALE,TELEPHONE,WILEY
AFTER,BACKGROUND,ERT,FRANKEL,LABEL,METHODS,MRI,PATIENT,RESULTS,SIXTEEN
169,COPYRIGHT,LTD,MRI,WILEY
ERSPC,HOWEVER,PSA
BACKGROUND,COX,ENDORECTAL,LABEL,METHODS,PSA,RESULTS,T2W,TESLA,THERE,THESE,TRIAL
MRI,MRL,PET,PSA,SPECT
AUTOPSY,GLEASON,HOWEVER,PATHOLOGY,PSA,SERUM,SOCIETY,UROLOGICAL
HYPOXIA
IMPORTANCE,INFORMING,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OVERALL,RELEVANCE,RESPONSES,RESULTS,SETTING
169,954,COPYRIGHT,FURTHER,LCDAD,LTD,PC3
001,005,006,169,BACKGROUND,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PERINEURAL,PUBLISHED,RESULTS,SAS,SETTING,SIMILAR,SPECIMENS,SUBSEQUENT,UROLOGY,WHOLE
124,177,355,398,740,782,BPH,LABEL,M50,METHODS,OBJECTIVE,PVP,RESULTS
169,ABOLISHING,BMP,CAP,HOWEVER,LNCAP,MDV3100,SUBSEQUENT,TAKEN,TRAMP,USING

842,945,ACONM,HIF,HIF1A,HOWEVER,HYPOXIA,LNCAP,RESULTS,THESE
CONCLUSION,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
022,121,126,140,179,247,403,718,APRIL,ASIAN,CONCLUSION,GLEASON,LABEL,MATERIALS,MAY,MEN,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SMALLER
AFFYMETRIX,RMA,THESE,WHILE
956,APOPTOTIC,CHROMATIN,DIM,DR4,DR5,FAS,HOECHST,INTRA,LNCAP
177,945,946,ARG,ASP,BACKGROUND,BBN,CONCLUSION,GLY,LABEL,MATERIALS,METHODS,PC3,RADIATION,RESULTS,RGD
011,BETWEEN,CAA,FURTHER,ISR,JANUARY,ROBOTIC
160,954,EXPRESSION,GFP,INJECTION,KNOCKDOWN,OPG,PC3,PCR,PLAC8,RANKL,TOXICITIES
ERG,PCA,TMPRSS2,WESTERN
0332991,CDK,FINALLY,PCA,SUBSEQUENT
012,230,300,361,905,ADT,COX,PCA,SERUM
130,EQUAL,JANUARY,MARCH,OPERATIVE,PCA,THERE,THESE,USING
CONCLUSION,DFS,EXPRESSION,GLEASON,HOWEVER,HUNDRED,LABEL,METHODS,MMP,OBJECTIVE,PURPOSE,RESULTS,TIMPS
AAS,PET,SPECT
PCA,PSA,SINCE
ULTIMATELY,WHILE
169,187,473,AKT,COPYRIGHT,FURTHER,IAA,INC,THESE
169,176,180,200,270,COPYRIGHT,LTD,USING
120,169,946,BACKGROUND,BPH,COPYRIGHT,DESPITE,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SERUM
001,149,163,169,312,476,753,COPYRIGHT,EDUCATION,HGPIN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROSTATIC,PUBLISHED,PURPOSE,RECURRENCE,RESULTS,TEN,UNIVARIATE,UROLOGICAL
169,174,294,ADDITIONAL,ASTRO,AUA,COPYRIGHT,EDUCATION,GUIDELINE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHYSICIANS,PRINCIPLES,PUBLISHED,PURPOSE,RAP,RESULTS,UROLOGICAL
100MG,169,956,CCG,CLOGP,COPYRIGHT,LTD,RHO,SRF
100,169,200,COPYRIGHT,PC3,TAXANES,THESE
169,22043,30041,AFTER,BACKGROUND,COPYRIGHT,DUMMY,EARLY,EORTC,IRELAND,LABEL,LTD,MATERIALS,METHODS,OAR,OBJECTIVE,PURPOSE,RESULTS,RUN,SIX,VODCA
865,ALZHEIMER,AMONG,CUMULATIVE,HODGKIN,INDIANA,MORTALITY,PARKINSON,PCB,POISSON,PUBLISHED,THROUGH
001,100,160,169,857,BCR,BETWEEN,CONCLUSION,COPYRIGHT,EIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,OCTOBER,PSA,PSADT,RESULTS,SRT,THERE
169,ADT,ADVERSE,BACKGROUND,CONTEXT,COPYRIGHT,DENOSUMAB,LABEL,METHODS,OBJECTIVE,OSTEOCLAST,PCA,PREVENTION,PUBLISHED,RESULTS,SYNTHESIS,UROLOGY,ZOLEDRONIC
001,149,169,237,354,CONCLUSION,COPYRIGHT,END,INC,LABEL,METHODS,MORTALITY,OBJECTIVE,PROPENSITY,PSA,RESULTS,THROUGH
0GY,113,125,139,142,160,169,248,390,6GY,COPYRIGHT,CROWN,D90,DESPITE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS
160,169,AFFAIRS,AVERAGE,BETWEEN,CAPSURE,CONCLUSION,COPYRIGHT,DECREASED,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RESULTS,STRATEGIC,VETERAN
160,169,COPYRIGHT,INC
BACKGROUND,CONCLUSION,LABEL,LARGE,METHODS,RESULTS,THERE
250,BACKGROUND,BASAL,CONCLUSION,CTL,LABEL,METHODS,NATURAL,PCR,RESULTS,THESE
520,535,924,CCD,PSA,TESTING
ADT,HOWEVER,JQ1,MYC,USING
169,504,662,715,834,ASSOCIATED,BACKGROUND,GROUP,HBA1C,LABEL,METHODS,PRACTICAL,RESULTS,SNP,USING
169
BLOOD,SEANO
169,COPYRIGHT,LTD,MRI,WILEY
DESPITE,PET
BCL,DU145,EMT,EOTAXIN,MMP,MYC,NOTABLY,PCA,ZOL
945,946,954,B16,CD8,IAP,PC3,STAT3,SW620,THESE,TNF
154,160,270,517,816,CAUCASIAN,ERG,GLEASON,SEVENTY,SPANISH,THREE
137,145,BACKGROUND,BPH,CONCLUSION,DFS,FOLLOWING,GLEASON,LABEL,METHODS,PCA,PCR,PSA,RESULTS,RNU48,SNORD48,TOTAL,TUMOURS
001,012,022,044,061,064,160,293,946,ADDITIONAL,ADJUSTING,INCREASED,LABEL,METHODS,NUTRITION,OBJECTIVE,PSA,PURPOSE,RESULTS,SERUM,TOTAL,USING
112,160,499,DIETARY,GLEASON,LABEL,METHODS,OBJECTIVE,ORS,PURPOSE,RESULTS
000,100,160,985,991,DESPITE,END,INCIDENCE,IRR,LABEL,METHODS,OBJECTIVE,POISSON,PURPOSE,RESULTS
174,AFTER,AIM,ANALYZING,BACKGROUND,BETWEEN,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,STAGE
174,319,620,ELISA,NTX,OPG,PCR,ZOLEDRONIC
ANOTHER,EXCELLENT,LABEL,MINIMALLY,OBJECTIVE,PATIENT,PCA,PURPOSE,RADICAL,RESULTS,SUMMARY,SURGERY
API,GENOMIC,KIT,LUA,OPERATION,SQL,TFS
169,231,233,AFTER,AMONG,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PET,PSA,PUBLISHED,PURPOSE,RESULTS,SAS
144,169,550,AUNPS,BRUST,COPYRIGHT,FINALLY,LNCAP,PEG
129,169,AKT,ALA,ARG25,COPYRIGHT,ERK,INC,LNCAP,MEK,PCA,RAF,THESE,USING
169,COPYRIGHT,FINALLY,INC,METABOLIC
169,233,AUTHORS,JOURNAL,MAT,MICROSCOPY,POISSON,ROYAL,SOCIETY,STRAUSS
160,921,ADT,FDA,PSA
945,BCL,CDK,DU145,HOWEVER,LNCAP,ODC,PAO,PC3,POLYAMINES,PURVALANOL,SIMILARLY,SMO,TARGETING,THEREFORE,TRANSIENT
009,136,169,AIM,CLEAR,ERG,FEWER,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SEVEN,TMPRSS2,WILEY
C57BL,ELISA,ELISPOT,HOWEVER,HSP,HSP70,LUC
169,1C3,ALPHA,BCAR1,ERA,ERB,LABEL,LTD,METHODS,OBJECTIVE,PSA,RESULTS,SRC,THESE,WILEY
ATTENTION,CONCLUSION,LABEL,OBJECTIVE
145,INHIBITORS,SAR
COX,CURCUMA,DESPITE,OTHER,PCURC,TNF
2D3,AFTER,BASED,LOW,SEVERAL,TESTING,VITAMIN
HOWEVER,ULTRASOUND
167,265,413,511,673,815,901,988,ADPCA,AIPCA,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCA,PCR,RESULTS
CGA,CONCLUSION,HOWEVER,III,LABEL,LDL,LNCAP,METHODS,NSE,OBJECTIVE,PCR,RESULTS,SGIII,SREBP,TRANSIENT
231,BECAUSE,DU145,MDA,PEITC
FLAVONOIDS,PCA
III,PSA
954,LNCAP,PCR,RESISTANCE,THESE,WESTERN
001,010,045,AUSTRALIA,BACKGROUND,GOLDFIELDS,GREAT,LABEL,METHODS,MIXED,OBJECTIVE,OBJECTIVES,REGIONS,RESULTS,SIXTY,THERE,THESE,WESTERN
ANIMALS,PCA,THEREFORE,THESE
100,954,FURTHER,KNOCKDOWN,NEU,PCA
006,309,813,COLORECTAL,OVARIAN,SARCOSINE,SCREENING,TRIAL
DUE,PET
11C,ADT,AIM,CHOLINE,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,PSA,PSADT,RESULTS
003,17Q24,215,333,474,ADDITIONAL,AGA,CANDIDATE,COLORECTAL,INITIATIVE,NEIL3,OVARIAN,SCREENING,THEREFORE,THREE,WHI,WOMEN
000,163,ABSTRACTS,ASSESSMENT,BACKGROUND,BIOSCIENCE,CITATIONS,DATABASES,DCE,EFFECTS,ENGLISH,FEW,FUNDING,HOWEVER,INDEX,INDEXED,INSTITUTE,ISSUE,LABEL,LIBRARY,MARCH,MEDLINE,METHODS,MRI,MRS,NON,OBJECTIVE,OBJECTIVES,OTHER,PROCESS,PSA,REFERENCE,RESULTS,REVIEWS,SCI,SCIENCE,SERVICE,SOURCES,TECHNOLOGY,TESTS,TYPES,UNDER
CPG,EPIGENETIC,PEPID
MMP,OPG,RANKL,THEREFORE,THESE
CONVERSELY,GDP,NGF,RHO,TRK
167,216,327,ADIPOKINE,ADIPOKINES,BACKGROUND,BMI,CIS,COLORECTAL,CONCLUSION,LABEL,METHODS,MHT,ORS,OVARIAN,RESULTS,SCREENING,THESE,TRIAL
169,EPO,HOWEVER,INC,PCA,WILEY
000,115,169,300,480,ERG,GLEASON,GP3,GP4,GS6,GS7,LCM,NGS,TMPRSS2,WGA
ESPECIALLY
012,215,675,954,BACKGROUND,CONCLUSION,GLEASON,IHC,LABEL,METHODS,PSA,RESULTS
790,DRUGS,FIRST,HOWEVER,THEREFORE
PSA
169,COPYRIGHT,HRS,IMPORTANT,IRELAND,LTD,PARTICULAR
169,945,947,ACTIVATION,ATM,ATR,BRCA1,CDC25,COPYRIGHT,DDIT4,DR5,GADD45A,IRELAND,KNOCKDOWN,LTD,MEANWHILE,MICROARRAY,PCA,RETIGERIC
169,ATP,COPYRIGHT,DGC,GBM,GRK,GSC,LTD,PDGFR,PUBLISHED,USING
169,AMONG,COPYRIGHT,ISSUE,LTD,SPECIAL,SYNTHESIS
125,580,AHX,BPG,PSA
169,BLACKWELL,DEPRESSION,ENDOGENOUS,HEPG2,LNCAP,LTD,MCF,PUBLISHING,REGUCALCIN,RGN,SMP30
169,AUTHORS,BLOOD,BRITISH,DUE,NOVEL,PCA,SOCIETY
945,954,ALPINIA,BECAUSE,CARDAMONIN,ERK,FINALLY,RANKL,TNF
347,368,BAYES,FDR,JOURNAL,ODP,ROYAL,SOCIETY,UNDER
BACKGROUND,CONTEXT,LABEL,MEIER,METHODS,NR2F2,OBJECTIVE,OVARIAN,PCR,RAI14,RESULTS,SETTING,TARGETING,THESE
004,011,140,177,EARLY,GLEASON,PROTEIN,PSA,THERE,THEREFORE
PANCREATIC,SEVERAL,SPARC
100,AMONG,BECAUSE,BURKITT,EPR3864,ERG,ETS,EWING,EWSR1,PREVIOUSLY
457,557,CIS,CRT,END,GIVEN,IMPORTANCE,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,RELEVANCE,RESULTS,RRS,SETTING,THERE
AMONG,BACKGROUND,CONCLUSION,FUNDING,INSTITUTE,LABEL,LIMITATION,METHODS,OBJECTIVE,OLDER,PRIMARY,RESULTS,SETTING
000,169,199,795,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,MINIMALLY,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,124,169,945,COPYRIGHT,CYP17,ISSUE,LTD,REDUCTASE,SPECIAL,SYNTHESIS,TOK
100,125,144,169,256,ANEUPLOID,COPYRIGHT,CROWN,D90,DIPLOID,FEULGEN,FORTY,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,SEVENTY,TEN,THIONIN,USING
169,600,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
177,LNCAP,ULTIMATELY
FIRST,SOLID,THEREFORE
166,209,AMONG,BACKGROUND,CONCLUSION,HORMONE,LABEL,METHODS,RESULTS
20LYASE,945,C17,CYP17A1,CYTOCHROME,FDA,ONGOING,P450C17AND,P450SCCII,THEREFORE,THROUGH
169,946,954,ETS,SUPPORTING
174,946,956,ADT,ASC,CASODEX,DESPITE,MDV3100,MECHANISM,PCA,PSA,SMAD3,TGF,THESE,USING
ABCG2,AFTER,BACKGROUND,CAD,CSC,LABEL,MEC,MMP,MNU,NSC,OBJECTIVE,OCT,RESULTS,THESE,VIM,WNT,WPE
001,002,005,012,019,026,036,042,113,134,153,169,177,236,ACADEMY,ADT,AFTER,ANDROLOGY,BMD,DESPITE,HBA1C,OLDER,OVERALL,PREVALENCE,SOCIETY
169,AKT,ANNEXIN,BCL,BSN,COPYRIGHT,FINALLY,LNCAP,LTD,TAKEN,TUNEL,WILEY
404,498,AMONG,BPH,CAC,ERG,FOLLOWING,GLEASON,LABEL,METHODS,OBJECTIVE,OCC,PCA,PEARSON,PSA,PURPOSE,RESULTS,USING
947,948,ABS,B16,IFN,STRIKINGLY,TCR,TIL
049,169,269,506,543,824,AFFAIRS,ARB,COMPUTING,DEPARTMENT,GLEASON,THERE
169,COPYRIGHT,FINALLY,HIV,LTD,WILEY
ERK,GP130,JANUS,LIF,OSM,STATS
116,480,945,ANNEXIN,ATM,FIRST,GENISTEIN,HCT,HOWEVER,PCR,SOYBEAN,THESE
046,159,967,BACKGROUND,BCRFS,COX,ECE,GLEASON,LABEL,LNI,MATERIALS,MEIER,METHODS,PCA,PEARSON,RESULTS,THERE,WHITNEY
160,TCP
177,DUE,NOMINAL,SCANNED
160,DU145,HISTONE,MCL,PC3,SINCE,SP1,THESE
169,COPYRIGHT,CROWN,INC,PUBLISHED
11OHT,169,945,946,ATTENTION,CHINESE,COPYRIGHT,CYP11B1,CYP11B2,DOWNSTREAM,H295R,HSD,LNCAP,LTD
169,945,946,956,BPH,COMET,COPYRIGHT,FACSCAN,FURTHER,IGF,IRELAND,LTD,REDUCED
101,107,116,169,221,AGE,CCI,COPYRIGHT,COX,FURTHER,HTN,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
IRELAND,LTD,MOLECULAR,PSO,PUBLISHED
150,169,179,310,911,AGGRESSIVE,AIM,COPYRIGHT,EARLY,GLEASON,LABEL,LTD,METHODS,OBJECTIVE,PSA,RESULTS,TOTAL
010,1301G,AFTER,ARG399GLN,ASN118ASN,BACKGROUND,COX,ERCC1,INC,LABEL,METHODS,N118N,PFS,PUBLISHED,R399Q,RESULTS,SIMILARLY,XRCC1
169,ACUTE,BACKGROUND,CONCLUSION,COPYRIGHT,GRADE,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,ORS,PURPOSE,RESULTS,THESE,VARIATION
003,143,169,243,311,BACKGROUND,CONCLUSION,COPYRIGHT,COX,CTCAEV4,CUMULATIVE,DESPITE,DETAILS,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PATIENT,PHOENIX,PURPOSE,RESULTS,THERE
169,AUS,CONCLUSION,COPYRIGHT,HOLMIUM,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,USING,YAG
169,BALLISTIC,COPYRIGHT,PUBLISHED,SAS,TECHNIQUES
603,AMONG,CONCLUSION,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,MRI,OBJECTIVE,RESULTS,SYSTEMATIC,THREE
CONCLUSION,DESPITE,LABEL,MATERIALS,METHODS,RESULTS,UNLABELLED
108,168,174,AFTER,BPH,CD3,CD8,FIRST,IIC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCI,PIN,PSA,RESULTS,SERENOA,SPECIMENS
001,164,300,379,421,AFTER,AUC,CONVERSELY,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,TNM
110,135,169,261,334,392,5CM,AUC,BACKGROUND,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,SETTING,STEYERBERG,TREATMENT,UROLOGY,WHILE
AKT,CONCLUSION,FINALLY,INNOVATION,LABEL,METHODS,MM2,NADPH,OBJECTIVE,ONCOGENIC,PDCD4,RESULTS,ROS,THESE,USING
169,ACADEMY,HOWEVER,VDR
231,AFU,BRITISH,EAU,EXCELLENCE,INSTITUTE,NETWORK,SOCIETY,UROLOGICAL,UROLOGY
CSF,DOCETAXEL,THESE
CRT,NEWER
71000,AMICO,EARLY,RADICAL,REGARDING,THERE
LOCALIZED,PSA,SELECTION
DIFFERENT,FLA,PDT,PROSTATIC,THESE,THOSE
IMPROVING,MEANWHILE,MRI
DETECTION,MRI,PET,PSA
DRE,FORCE,HOWEVER,MEDIA,MRI,PREVENTIVE,PSA,SCREENING
003,169,ABILITY,AVERAGE,CEC,CONCLUSION,COPYRIGHT,IMAGE,INC,LABEL,MATERIALS,METHODS,MRI,NVB,OBJECTIVE,PEC,PURPOSE,RESULTS,SNR,WILEY
100,181,OPIOIDS
BIOMARKERS,MMP
169,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,MRS,OBJECTIVE,PURPOSE,READERS,RESULTS,WILEY
160,288,335,391,917,927,CIS,COX,HRS,INSTITUTES,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
177,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,PSA,RESULTS
150NG,169,945,946,COPYRIGHT,LTD,MCF,PROTEIN,USING
133,160,169,261,890,BASED,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
160,169,183,AMICO,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,TESLA,UNIVARIATE,UROLOGICAL
169,COPYRIGHT,INC,WIDESPREAD
169,COLLEGE,COPYRIGHT,CURRENT,HOWEVER,LTD,PUBLISHED,ROYAL
169,177,243,AGE,BECAUSE,CKD,GFR,GLEASON,HOWEVER,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,WILEY
ALZHEIMER,BACKGROUND,DIFFERENT,HOWEVER,LABEL,MEDEA,METHODS,RESULTS,SPANISH
005,100,177,823,832,AUC,BACKGROUND,BPH,CONCLUSION,DEPARTMENT,DRE,ELISA,EXPRESSION,FORMATION,INDIA,LABEL,LUCKNOW,METHODS,PCA,PSA,RESULTS,ROC,SEPTEMBER,THEREFORE,UROLOGY
001,003,011,017,020,GLEASON,NURR1,THESE
100,AMERICANS,ASIAN,LIVER,PHYSICIANS,PRIMARY
025,050,182,375,620,885,909,ALA,ALTERED,MNSOD
APOG2,APOPTOSIS,BACKGROUND,BESIDES,HUVEC,LABEL,METHODS,MTT,OBJECTIVE,RESULTS,THESE
APOPTOTIS,MTT,RES,THEREFORE
ASSESSMENT,BACKGROUND,FURTHER,HEART,LABEL,MATERIALS,METHODS,RESULTS,SEP,URBAN,VARIATION
AMONG,HOWEVER,THEREFORE
169,177,323,AIM,BACKGROUND,CAVERNOUS,GLEASON,LABEL,METHODS,NSS,OBJECTIVE,OUTCOME,PATIENT,PSA,RESULTS,SOCIETY,WHILE
B16,C57BL,GENISTEIN,NON
CHINA,EMT,PCA,WESTERN
016,109,318,400,546,578,923,COX,CUMULATIVE,DOCETAXEL,DSS,MEIER,THERE,THEREFORE,USING
630,BACKGROUND,LABEL,METHODS,NITRATE,RESULTS
ANTISENSE,LNCAP,THOSE,WHILE
022,946,CD4,HOWEVER,IIA,PBMCS,TCR
177,956,ARU,BACKGROUND,CONCLUSION,EVERY,LABEL,MATERIALS,METHODS,OVERALL,PSA,RESULTS,UNIVARIATE,UTI
201,AG490,FIRST,INHIBITION,JAK,JANUS,S3I,STAT3,WASF3
169,22RV1,ABNORMALLY,AGAIN,BASAL,COPYRIGHT,INDUCTION,SIMILAR,WHILE
924,946,BCL,E12,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEPTEMBER
ADT,DISCUSSION,LABEL,METHODS,NED,OBJECTIVE,PSA
100,300,966,CONCLUSION,GLEASON,III,LABEL,LFT,LRP,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGIC,PATIENT,PSA,PSM,RESULTS
190,ACCORDING,CONCLUSION,EPSTEIN,GLEASON,HOPKINS,JANUARY,JOHNS,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,TECHNICAL
100,177,282,CPC,DETECTION,DRE,HOWEVER,INCLUSION,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,P504S,PSA,RESULTS,SERUM,THERE
GIVEN
390,BACKGROUND,CONCLUSION,INCREASED,IPMNS,ITALIAN,ITALY,JANUARY,LABEL,METHODS,RESULTS
THESE,WHILE
ASIAN,BOTANICALS,CURIS,CURRENTLY,DUE,FDA,GENENTECH,GLI,SOUTHEAST,THESE
169,HODGKIN,LABEL,METHODS,MINNESOTA,NON,OBJECTIVE,OBJECTIVES,RESULTS,ROCHESTER,SEBACEOUS,SIX,SOCIETY,THEIR,THREE,TORRE,WHITE
947,ATP,GLEASON,MTT,THEREFORE,WESTERN
144,239,ADL,ADT,CWR22,FINALLY,HENCE
404,777,946,GLEASON,RAR,RASSF1A,THEREFORE,UNDER
125,135,945,946,ASN,BINDING,GPI,HAI,HGF,HOWEVER,LYS,MATRIPTASE,THESE
945,946,ALTOGETHER,ELEVATION,H3K27,HOMOLOG,LIVER,LXR,PCA,RECEPTORS,ZESTE
RADIATION
AAG,DESPITE,HSP90,SUPPORTING
169,BCL,KEAP1,NADPH,PGAM5,ROS,THESE,TRX
GIVEN,RALRP,RAPID,RESULTS,ROBOT,VINCI
177,185,CONCLUSION,FAB,HSG,LABEL,METHODS,OBJECTIVE,PC3,PET,PURPOSE,RESULTS
095,318,853,BACKGROUND,CIS,CONCLUSION,COX,HRS,JANUARY,JAPAN,LABEL,METHODS,RESULTS,THERE
BACKGROUND,CONCLUSION,GLEASON,HARMS,IMMEDIATE,LABEL,MEN,METHODS,RANDOMIZED,RESULTS,SCREENING

ADT,EORTC,GROUP,III,IMAGE,LABEL,OBJECTIVE,PCA,PURPOSE,RADIATION,RESULTS,SUMMARY,THERAPY,USA
100,AOM,COX,FRUIT,HOWEVER,MMP,THESE
64258,BAX,BCL,HOWEVER,LNCAP,QUERCETIN
BACKGROUND,HMW,LABEL,METHODS,MMP,RESULTS,THERE
006,048,AAG,BACKGROUND,III,LABEL,METHODS,NUTRITION,RESULTS,SERUM,THIRD
224,CAP,LUCIFERASE,NOTABLY,USING
945,ADT,DHT,HOWEVER,LNCAP,LUCAP35,REDUCTASE,THESE
223,MEETING,PRACTICES,TREATMENT
BASED,FEDERAL,GOVERNMENT,JPM,PROCESSING,PUBLISHED,SOCIETY,THESE,USA
141,169,287,BIOMARKERS,FOLLOWING,LABEL,METHODS,MRM,OBJECTIVE,PCA,PURPOSE,RELEVANCE,RESULTS,VCH,WILEY
036,ADT,BACKGROUND,BMD,END,KEY,LABEL,METHODS,OBJECTIVE,PCP,RATES,RESULTS,THERE
185,710,ADT,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PDR,PET,PSA,PURPOSE,RESULTS,TRIGGER
ADDRESSING,ALZHEIMER,PARKINSON,PREVENTION,ROS,SIMILARLY,THEREFORE,TRIAL,VITAMIN
946,ALTOGETHER,BACKGROUND,BLM,BRCA1,BRCA2,CCNB2,DHH,EMT,GADD153,GADD45A,H3F3B,IHH,LABEL,LNCAP,METHODS,PC3,PCA,PCR,PREVIOUSLY,RESULTS,SHH
169,459,896,AGENT,AOE,BACKGROUND,COPYRIGHT,GLEASON,HGPCA,HOWEVER,LABEL,LGPCA,METHODS,PCA,RESULTS,SOCIETY,THESE,VETERAN,VIETNAM
330,DU145,FINALLY,PC3,SP1,THESE
427,BCG,HSP,HSP27,OGX
FINALLY,OVERALL
BPH,INCREASED,INTRA
ADULT,ALREADY,ASSAY,BACKGROUND,CAUTION,EFFECTIVE,H295R,HORMONE,INHIBIN,KNOWN,LABEL,MATERIALS,METHODS,NCI,OBJECTIVE,REASONS,RESULTS,SERTOLI,SETTING,STUDIES,SUMMARY,TISSUES,WIDER
AKT,AZD5363,DU145,TAKEN
947,CK2,DU145,INCREASED,INHIBITION,LNCAP,RWPE1,THESE
466,AUSTRALIA,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
001,006,169,495,COPYRIGHT,COX,EDUCATION,ESTIMATES,EXCLUSION,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OVERALL,PEARSON,PUBLISHED,PURPOSE,RESULTS,THERE,URINARY,UROLOGICAL
000,117,169,373,425,442,485,857,COPYRIGHT,EDUCATION,END,INC,INCREASED,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL,WHILE
169,174,216,528,COPYRIGHT,EDUCATION,ERG,EXPRESSED,III,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SECRETION,TMPRSS2,UROLOGICAL
001,169,177,BACKGROUND,BMI,BPH,CAP,COPYRIGHT,INDIA,LABEL,LTD,METHODS,RESULTS,SIMILARLY,WHR
001,169,ADT,BACKGROUND,COPYRIGHT,INDEX,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PCA,PHOENIX,PRIMARY,PSA,PUBLISHED,RESULTS,SALVAGE,SECONDARY,SETTING,SIXTY,UROLOGY,WHOLE
014,125,150,160,169,916,AUR,CONCLUSION,COPYRIGHT,DELTA,EXPERIENCE,GRADE,GROUP,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,SCORE,SOCIETY,SYMPTOM,THERAPY,URINARY
00001,019,103,169,COPYRIGHT,D90,DOSIMETRIC,FIFTY,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PALLADIUM,PUBLISHED,PURPOSE,RESULTS,SOCIETY,VOLUMES
211,254,304,ACTUARIAL,BACKGROUND,BOWEL,COMPOSITE,CYBERKNIFE,FEWER,FIFTY,GRADE,GROUP,HDR,III,INDEX,LABEL,METHODS,PSA,QOL,RADIATION,RESULTS,THERAPY
160,169,4A4,640,ADDITIONAL,COA,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,WILEY
131,155,17Q21,182,215,221,22Q13,337,534,781,AFFYMETRIX,AFRICAN,AMERICANS,ARRAY,BACKGROUND,CONCLUSION,EUROPEANS,GENOTYPING,LABEL,LARGE,METHODS,QATAR,RESULTS,SAUDI,SNP,THREE,TUNISIANS,USING,WESTERN
330,KALLIKREIN,KLK,SNP

CYTOTOXIC,ELISA,LNCAP,PCR,PSA,R1881,SRB
169,176,CD133,CD44S,CONVERSELY,NOTABLY
BACKGROUND,CONCLUSION,CONTEXT,HOWEVER,LABEL,METHODS,OBJECTIVE,PCR,PRA,PRB,RECIPROCAL,RESULTS,SETTING,WESTERN
023,029,047,113,133,163,177,ADT,ASSESSMENT,FMD,GTN,LABEL,REDUCTION,THERE,UNASSIGNED
001,004,007,008,009,016,020,031,032,177,AMONG,GLEASON,PCA,PCR,PSA,QRT,SOCS2,SOCS6,SOCSS
137,EFFECTIVE,EIGHT,LABEL,METHODS,OBJECTIVE,PCN,PURPOSE,RENAL,RESULTS,THEREFORE
22RV1,945,CALPHOSTIN,CCK,DU145,HOWEVER,PC3,PCR,PKC,PMA,UNC5B,WESTERN
AUSTRALIA,BRAIN,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THREE

126,169,177,COPYRIGHT,HOWEVER,LOW
AGE,HOWEVER,STONE
169,945,COPYRIGHT,LNCAP,MTT,SAS
FINALLY,LABEL,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SUMMARY,THEREFORE
HENCE,LABEL,MANAGEMENT,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,WESTERN,WHILE
ADDITIONAL,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,VARIOUS
169,945,946,956,COPYRIGHT,DU145,LTD,LYSIMACHIA,NMR,PC3
ADI,ASS,AUTOPHAGY,HORMONE,USING,WHILE
169,303,COPYRIGHT,EDUCATION,ENGLISH,FDA,GIVEN,GUIDELINE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRINCIPLES,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL
001,169,286,561,674,806,952,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,SPON2,UROLOGICAL
169,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,RESULTS,THERE,THEREFORE
002,003,137,149,169,286,ABSENCE,BACKGROUND,COPYRIGHT,COX,GLEASON,IQR,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PATHOLOGIC,PREDICTORS,PSA,PUBLISHED,RESULTS,SETTING,UNASSIGNED,UROLOGY
00001,169,253,4GY,COPYRIGHT,GRADE,GROUP,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PDR,PHOENIX,PURPOSE,RESULTS,SOCIETY,STAGE,TREATMENT
100,125,135,160,162,169,191,194,ATV,COPYRIGHT,CROWN,D90,DESPITE,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TMS
169,COPYRIGHT,ERG,GLEASON,INC,TMPRSS2,UNTIL
169,BACKGROUND,CONCLUSION,COPYRIGHT,FINALLY,GAPDH,HACAT,IHC,INCREASED,IRELAND,LABEL,LTD,METHODS,NWASP,OBJECTIVE,OBJECTIVES,PCR,PUBLISHED,RESULTS,SOCIETY,THESE,WESTERN
169,946,CK7,COPYRIGHT,GATA3,INC,TUBULAR
169,BACKGROUND,CONTEXT,COPYRIGHT,DUE,INCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PUBLISHED,RESULTS,STUDIES,SYNTHESIS,UNDENIABLE,UROLOGY
009,055,110,169,175,958,ADT,COPYRIGHT,COX,GLEASON,IBF,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,SHORT
100,160,169,503,AGE,BACKGROUND,CONCLUSION,COPYRIGHT,COX,CPE,DVH,INC,LABEL,MATERIALS,METHODS,OVERALL,RESULTS,THERE
742,BACKGROUND,BASED,CLEARLY,DU145,HOWEVER,LABEL,LNCAP,MSY,RESULTS,SIMILARLY,SRY,TTCCA
251,2N0M0,3N0M0,465,748,GENERALLY,GLEASON,PCA,PSA,RPE
BACKGROUND,FAITH,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RADICAL,RESULTS,URINARY
CASTRATION,III,PHASE
ACT,CER,INSTITUTE,MAY
FINALLY,GEF,HOWEVER,PREVIOUSLY,SH3
169,208,BACKGROUND,ERG,EVALUATING,FATAL,HOWEVER,IHC,INC,LABEL,MEFPC,METHODS,MOLECULAR,NUCLEAR,PCR,PERMANENTE,PRIOR,RESULTS,TMPRSS2,WILEY
169,170,BACKGROUND,COPYRIGHT,EXPRESSION,FINALLY,GLUED,INC,LABEL,METHODS,PCA,RESULTS,TAXEL,WILEY
169,CBP,CONCLUSION,EXPRESSION,FUNCTIONAL,LABEL,LNCAP,METHODS,PCA,PEITC,RESULTS,SCOPE,USING,VCH,WILEY
DU145,ERBB4,EXPRESSION,HNF1B,HSPD1,IMPLICATED,LNCAP,NR4A1,OMNIBUS,PC3,PCR,RAP2A,SIX,TPD52
169,223,685,689,BRITAIN,CAUCASIAN,COPYRIGHT,EXOME,FOXA1,GENET,GREAT,IRELAND,LTD,MED12,OVERALL,PUBLISHED,SOCIETY,WILEY
232,245,BELLO,BETWEEN,BONES,CLINICO,CONCLUSION,DEPARTMENT,EDITION,EPI,GLEASON,HIV,JANUARY,LABEL,MATERIALS,METASTATIC,METHODS,NIGERIA,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THERE,UNIVERSITY,VERSION,VIRCHOW
DCS,HENCE,MHZ
1990S,BACKGROUND,CONCLUSION,LABEL,METHODS,MODEL,RESULTS,THESE
CONCURRENT,FORTY,SEPTEMBER
169,CLEARLY,COLLEGE,COPYRIGHT,III,LTD,MEDLINE,PHASE,PUBLISHED,ROYAL
BETWEEN,QOL,THERE,URINARY
AMERICA,NORTH,THROUGH,WHILE
160,169,BASED,COPYRIGHT,FUNCTIONAL,INC,NUCLEAR,PATHOLOGY,PCA,PUBLISHED,SOCIETY,STAT5
169,300,COPYRIGHT,EDUCATION,GUIDELINE,INC,LABEL,MATERIALS,METHODS,MODELED,OBJECTIVE,OUTSIDE,PANEL,PSA,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,COPYRIGHT,OVERALL,PC3,TREATMENT
169,ADVERSE,BACKGROUND,CONCLUSION,COPYRIGHT,CSF,CUP,DUTCH,FEBRILE,FIFTY,FORTY,GRADE,INC,INSTITUTE,IQR,LABEL,METHODS,OVERALL,PFS,PROGRAM,PSA,RESULTS,SERIOUS,TEAES
169,ACCORDING,AMICO,GLEASON,GUIDELINE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PREDICTIVE,PREDICTOR,RESULTS,UROLOGICAL,UROLOGY
130,150,160,210,946,956,COA,DU145,HMG,HYDROXY,LNCAP,TUNEL
954,AKT,HOWEVER,LNCAP,PCA,STUDIES,TAKEN
HOWEVER,LNCAP,PCA,PCR,SNAIL,THESE,WESTERN
34A,946,FACTORS,HYPOXIA,INDUCIBLE,LNCAP,NOS,PCA,SEQUENCING,SIRT1
152,946,AKT,CDE,CHR,IAP,IGF,MEK,NRP,SMADS,SURIVIN,TAKEN,TGF,USING
01910,370,60000,III,PC3,PHASE,XENOGRAFT
300,946,AFRICAN,CAUCASIAN,FURTHER,HOWEVER,PCA,PCR,TAKEN
169,BACKGROUND,CONCLUSION,COPYRIGHT,EXPRESSION,INC,INHIBITORS,LABEL,LNCAP,METHODS,MTS,PCR,RESULTS,SILENCING,WILEY,WNT
170,ACTIVATING,FGFR3,R3MAB,THEREFORE
169,350,ANOVA,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,STUDENT,THERE,WILEY
001,015,031,158,169,178,956,CONCLUSION,DIAGNOSTIC,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PCA,POTENTIAL,PSA,PURPOSE,RESULTS,WHITNEY
001,814,AFRICAN,AMERICANS,AMONG,HOWEVER,IRAK4,JAMAICANS,MDR,PCA,SEVEN,SNP,THEREFORE,TLR
351,ADVERSE,BACKGROUND,BETWEEN,CONSENSUS,GRADE,JANUARY,LABEL,MARCH,METHODS,PHOENIX,RESULTS
NGS,SNP
HOWEVER,INCREASING,MOUSE,TRAMP,TRANSGENIC,TREATMENT
019,425,813,974,AFTER,BACKGROUND,CONCLUSION,COX,DIAGNOSIS,JANUARY,LABEL,METHODS,PRIMARY,RESULTS
THESE,WARBURG,WHILE
AUSTRALIAN,HOWEVER,MEN
HOWEVER,M13,THESE,VII
126,AFRICAN,AMERICANS,BORDERLINE,NORTH,THERE,THESE,WHITE
114,AGE,BACKGROUND,LABEL,MEIER,METHODS,PSA,RESULTS,SECONDARY,THESE
160,207,239,AUSTRALIA,BACKGROUND,CONCLUSION,DESPITE,FIRST,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESPONSES,RESULTS
100,178,179,200,CONCLUSION,DICHLORIDE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEN,URINARY
CXCR4,CXCR6,HOWEVER,TUMOURS
116,AMERICA,CHINA,GPI,NORTH,PCR,THESE,WESTERN
015,169,AFTER,BACKGROUND,COPYRIGHT,ERG,GLEASON,INC,LABEL,METHODS,PI3,RESULTS,TMPRSS2,WILEY
005,015,104,145,BPH,CCK,GLEASON,LNCAP,MMP,PCA,PCR,SILENCING,TNM,WNT
102,135,BACKGROUND,COX,HRS,ICELANDIC,LABEL,METHODS,RESULTS,REYKJAVIK
100,284,945,946,CD40L,DASATINIB,DECREASES,PSA,SECONDARY,SRC,THERE
176,177,ACCORDING,CBCTS,CMD,CTS,CTV,D99,FORTY,ROT_C
192IR,CARLO,COMPTON,FMCWS,GROUP,ISA,MONTE,PHYSICISTS
049,CTV,DELIVERED,MCNEMAR,PTV,WHILE
018,028,AMONG,DOSIMETRIC,ECLIPSE,INTENSITY,MUS,OAR,OPTIMIZED,PLANS,PTV,SEVEN,TPS
100,135,169,177,186,400,671,711,DAO,HOWEVER,MACHINE,MUS,PANTHER,PARAMETER,TPS
D30,D50,D99,DOSIMETRY,KUTCHER,LYMAN,PTV,TCP,THEREFORE,V17GY,V35GY
CURRENTLY,FDA,SEVERAL,THESE,WORLDWIDE
160,169,ACM,ADT,AHR,COPYRIGHT,COX,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,T1C,T3B,TESTS
350,BACKGROUND,BETWEEN,CONCLUSION,FUNDING,LABEL,MEIER,METHODS,MORTALITY,OVERALL,RESULTS,TRIAL
169,CURRENTLY,IGF,INSULIN,IRS,PLX4032,RAF,SER,TREATMENT,V600E
169,495,510,CAUCASIAN,CONCLUSION,COPYRIGHT,CROSS,INC,LABEL,MEASURE,MEN,METHODS,OBJECTIVE,OUTCOME,OVERALL,PATIENT,PCA,PUBLISHED,RESULTS,SETTING,SOCIETY
BACKGROUND,CFS,CHANGES,DIRICHLET,HILIC,HOWEVER,LABEL,RESULTS
169,223,BJU,HOWEVER,III,INITIAL,MDV3100,PSA,RECURRENCE,USA
169,AKT,FKBP5,MMP10,NOTABLY,PTENCKO,RPS6KB1,SRC
DESPITE,GIVEN,WHETHER
169,AXL
ATLANTA,BACKGROUND,CENTERS,CONFERENCE,CONTROL,DISEASE,FEDERAL,GEORGIA,KEY,LABEL,METHODS,OBJECTIVE,PANELISTS,PREVENTION,RESULTS,SDM,SIXTEEN,THINKTANK,YET
169,APC,BACKGROUND,BETWEEN,BLACK,CONCLUSION,COPYRIGHT,FORCE,INC,INCIDENCE,JOINPOINT,LABEL,METHODS,PRIOR,PROGRAM,PSA,REGRESSION,RESULTS,WHITE,WILEY
IMAGING,MRI,PET
220,642,COX,CRP,LABEL,METHODS,MINIMAL,MORTALITY,OBJECTIVE,OBJECTIVES,PRE,RESULTS,SIMILAR,SWEDISH
113,120,169,CEA,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERUM,SEVENTY
001,016,023,58102,724,ASIAN,AUR,BACKGROUND,BETWEEN,BPH,CALIFORNIA,CURRENT,LABEL,METHODS,ORADJ,RESULTS,STATEWIDE
169,22863,COPYRIGHT,EORTC,FURTHER,GROUP,HDR,INSTITUTE,JAPAN,LTD,RADIATION,SEVERAL,THERAPY,TREATMENT
169,AUTHORS,COPYRIGHT,HOWEVER,IAS,INC,LUIGI,PROFESSOR,PUBLISHED,PWA,RICCIARDI,THESE
001,003,004,169,197,COPYRIGHT,COX,DIFFERENT,EDUCATION,FREEDOM,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,THESE,THOSE,UROLOGICAL
110,169,661,ASIAN,BACKGROUND,BEHAVIORAL,COPYRIGHT,CURRENT,DIGITAL,DRE,INC,LABEL,MATERIALS,MEN,METHODS,PSA,RESULTS
14C,169,177,184,196,230,738,956,ASCT2,BACKGROUND,COPYRIGHT,FACBC,INC,KINETIC,LABEL,METHODS,MICHAELIS,PET,RESULTS,SNAT2,TRANS,XENOPUS
012,025,164,169,266,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PRESCRIBED,RESULTS,THERE,TREATMENT
0MM,100,169,1MM,2MM,4MM,6MM,8MM,CBCTS,CONCLUSION,COPYRIGHT,CROWN,CTV,IGART,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS,ROS,RTT,USING
169,ADVERSE,BACKGROUND,BIOLOGICAL,COPYRIGHT,GROUP,IRELAND,LABEL,LTD,MATERIALS,MAY,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RADIATION,RESULTS,THERAPY
169,COPYRIGHT,HOWEVER,IMMEDIATE,LTD,PKP
946,DHT,EXPRESSION,HSD,MEMBERS,THESE
AFTER,PSA,TNM
23848,2ME,58125,AKT,AMP,CONCLUSION,COX,CPT,EP4,EPAC1,LABEL,METHODS,OBJECTIVE,RAS,RESULTS
945,FEW
007,BACKGROUND,BMP,BMP10,CONCLUSION,EXPRESSION,HOWEVER,LABEL,MATERIALS,METHODS,PCR,RESULTS,T24
004,177,AFRICAN,AIM,AMONG,CAUCASIAN,CONCLUSION,ELISA,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PC3,PCR,RESULTS,WESTERN
AIM,AIM1L,BACKGROUND,CONCLUSION,HLA,LABEL,MATERIALS,MESSENGER,METHODS,OBJECTIVE,RESULTS,RLRYT,SINCE,SYFPEITHI,TKLSA
160,778,APRIL,CONCLUSION,IMPORTANT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STUDIES,SURVIVORS
CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ULTRASOUND
004,007,045,125,826,AMP,FOLEY,JANUARY,JAPAN,SOCIETY
001,150,160
PCA,REMARKABLY,THEREFORE,USING
BAK,BAX,BLADDER,BRAZILIAN,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCR,PRIMA,RESULTS,RT4,T24
130,169,CHANGES,JMJD2,KDM4A,KDM4B,KDM4C,KDM4D,PHD,TUDOR,VARIOUS
SUZ12
CTBP1,HOWEVER,PSF
013,ACCORDING,AFTER,BACKGROUND,BETWEEN,CONCLUSION,HOWEVER,LABEL,MAY,METHODS,PSA,RESULTS
169,949,COPYRIGHT,HOWEVER,INHIBITION,IRELAND,LOX,LTD,OXER1,PKC,PLC
169,COPYRIGHT,INC,TRUNCATED
169,24H,33342,COPYRIGHT,CROWN,DHT,HOECHST,HOWEVER,JUGLANS,JUGLONE,LNCAP,LTD,MAXIM,MTT,OCCURRENCE,PSA,PUBLISHED,THEREFORE
027,169,193,COPYRIGHT,LABEL,LTD,MEN,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESPONSES,RESULTS
153,169,333,486,ADVERSE,AFTER,CANDIDATES,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,POISSON,PUBLISHED,PURPOSE,RESULTS,T1C,T2A,THESE,UROLOGICAL
001,032,169,496,735,COPYRIGHT,COX,EDUCATION,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PREDICTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,1GY,200,24H,53BP1,946,947,956,ATM,COPYRIGHT,DDR,DSB,PC3,PHOSPHO,PREVIOUSLY,PUBLISHED,ROS,SER1981,SMAD2,SMAD7,STUDIES,TGF,UNREPAIRED
169,AEU,COPYRIGHT,JANUARY,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SYNTHESIS,VALIDATION
169,BACKGROUND,CHALLENGES,COPYRIGHT,GROWING,LABEL,LTD,METHODS,RESULTS,THERE,WHILE
169,250,500,570,750,956,COMPARABLE,COPYRIGHT,HISTOLOGIC,INC,PUBLISHED
169,300,BIOLOGY,COMBINING,COPYRIGHT,FEDERATION,INC,MHZ,OPTICAL,PUBLISHED,ULTRASOUND,WHOLE,WORLD
169,COPYRIGHT,E26,ERG,GLEASON,INC,MOLECULAR,RESULTS,TMPRSS2
169,COPYRIGHT,GLEASON,INC
120,145,BACKGROUND,GLEASON,HOWEVER,LABEL,LNCAP,METHODS,PC3,RESULTS,SATB1,SPECIAL,THESE,WESTERN
NIR,WHILE
MRI
500,ANTIBIOTIC,CHRONIC,CONCLUSION,DRE,INDEX,INITIALLY,INSTITUTES,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,SCORE,SYMPTOM
648,711,AMONG,AUSTRALIA,BACKGROUND,CROSS,HRT,LABEL,METHODS,NSW,PSA,RESULTS,THESE,WHILE
RHODE
4FISH,MYC
169,ACC,ADP,AKT,AMP,COA,CONVERSELY,COPYRIGHT,JNK,JUN,LTD,OVERALL,ROS,S6K,WILEY
011,014,022,024,033,039,054,063,076,082,195,203,213,215,238,240,241,256,274,281,309,310,946,ADT,BIO,BMD,BTM,PCA,THERE,THESE
001,007,108,185,355,COX,CRC,HOWEVER,PCR
103,122,125,150,230,956,BED,CARLO,CONCLUSION,DVH,GBQ,LABEL,METHODS,MONTE,NOTABLY,OBJECTIVE,PURPOSE,RESULTS,SIMILARLY
000,CONCLUSION,FDA,III,LABEL,OBJECTIVE,PHASE,PUBLISHED,PURPOSE,SIPULEUCEL,SUMMARY
BASED,BECAUSE,CARLO,MONTE,THREE
169,COPYRIGHT,FIRSTLY,INC
169,ANNEXIN,ANXA7,CAP,COPYRIGHT,CRC,GBM,LOH,NPC
169,936,946,ATP,AUTHORS,COPYRIGHT,PUBLISHED,RAPAMYCIN,VARIOUS,WARBURG,WNT
044,158,169,393,452,616,642,658,802,823,897,936,967,AEU,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PASSING,PPV,PSA,PSACOMPLEX,PUBLISHED,RESULTS,ROC,THERE
ALTERED,CASODEX,EGF,FBS,LNCAP,PCA,SINCE,THESE,TREATMENTS
AXL,MER,PCA,THESE,TYRO3
ENGLISH
169,ASHKENAZI,BRCA1,ERG,INC,METASTATIC,PBRM1,SIXTY,TMPRSS2,WILEY
145,193,BCRFS,GLEASON,IHC,OCT4A,OCT4B,PCA,THEIR
169,946,947,B16,DCS,DU145,IFN,STAT1,VCH,VIRAL,WILEY
FINALLY,THESE

PSA,SOMATIC
210,ASSESSMENT,CHRONIC,CROSS,FUNCTIONAL,GENERAL,HEART,III,ILLNESS,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,THERAPY,THESE
169,HOWEVER,METASTATIC
169,2G7,DC101,DRUGS,FINALLY,INDIVIDUAL,PC3,THREE,VEGFA
ALPHA,EDUCATION,PSA
COXAL,GLEASON,HOWEVER,PAGET,PSA,SERUM
LABEL,MARKERS,METHODS,OBJECTIVE,PURPOSE,RADIOPAQUE,RESULTS,TLD
BIOLOGICAL,CARLO,EUD,FTP,HOWEVER,IFD,INCREASED,INVERSE,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RBE,RESULTS,STP,TCP
FLICE,FLIPS,HOWEVER,INHIBITORY,JNK,JUN,PROTEIN,SHORT,THESE,TRAIL
160,CYS49,FURTHER,GLY50,HOWEVER,NDRG1,PCR,PRECS,SDS,WESTERN
500,ABCG2,AFTER,DU145,NANOG,NANOGP8,THERE
945,956,AGP,BSA,ESI,EVALUATION
BASED,GIVEN,NAFLD,OBESE,SCREENING,THERE
239,IPILIMUMAB,TREATMENT
186,ASSESSMENT,HTA,TECHNOLOGY,WHILE
CONSISTENT,PCA,PIPOX,SARDH,TAKEN
153,CEA,EIGHT,HOWEVER,PSA,T3BN0M0
000,916,PSA,QALYS
969,AKT,BAD,DHA,PUFAS
169,633,BACKGROUND,FACTORS,LABEL,METHODS,PRIOR,RESULTS,SOCIETY,TOBACCO
001,123,151,169,289,BACKGROUND,COPYRIGHT,COX,INC,LABEL,METHODS,PCA,RESULTS,WASHINGTON,WILEY
160,OVERALL,PET,WHOLE
1990S,CURRENT,FURTHER,SINCE
243,246,332,350,874,985,AMONG,BACKGROUND,CONCLUSION,LABEL,METHODS,POPULATION,RESULTS,SWEDISH,SYMPTOM,TOTAL,UNIVERSITY
122,AFRICAN,BACKGROUND,KNOWLEDGE,LABEL,METHODS,NURSING,OBJECTIVE,PSA,RESULTS,SOUTH,THOSE,TSHWANE,WESTERN
000,001,169,BMI,CIS,COLORECTAL,CONCLUSION,COPYRIGHT,CVD,HRS,INC,LABEL,METHODS,OBESITY,OBJECTIVE,OVARIAN,OVERWEIGHT,RESULTS,SCREENING,TRIAL
001,119,130,136,169,172,311,385,550,64I,916,975,BPH,CHEMOKINES,COPYRIGHT,INC,PCA,PSA,PUBLISHED,REMARKABLY,SOCIETY
113,BACKGROUND,LABEL,METHODS,RADAR,RESULTS,SIMILAR,THERE
ADVANTAGES,BACKGROUND,CONCLUSION,CONTEXT,LABEL,MAKIN,METHADONE,METHODS,OBJECTIVE,OBJECTIVES
BACKGROUND,COURT,CURRENT,DEFENCE,DEVICES,EXPLOSIVE,HEADLEY,IMPROVISED,LABEL,MEDICAL,METHODS,RESULTS,ROYAL,THERE,THEREFORE
004,028,124,167,179,212,221,300,302,395,629,823,826,843,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCR,PTC,RESULTS,RUNX2,TSH
130,173,361,362,390,III,LABEL,METHODS,OBJECTIVE,PHASE,RESULTS
508,CAD,CONCLUSION,IAD,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEPTEMBER,THERE
012,169,ATHYMIC,BACKGROUND,COMBINING,COPYRIGHT,EXERCISING,INC,LABEL,LNCAP,METHODS,PCA,PRESENTLY,RESULTS,STD,SUSTAINED,WESTERN,WILEY
916,ACTIVITIES,K5A,L9G,MCF,MICROSCOPY,N39,PC3,R8G,W106F,W106G
100,400MG,CQA,DAILY,HOWEVER,THESE
160,177,CDF,DOT,PDT,THREE
215,278,292,967,BACKGROUND,D8S1734,D8S1742,LABEL,METHODS,MSS,RESULTS
11C,169,18F,637,BACKGROUND,CONTEXT,COPYRIGHT,DOR,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PET,PUBLISHED,REFERENCE,RESULTS,SCIENCE,SYNTHESIS,UROLOGY,WEB
108,169,ADT,BACKGROUND,CONTEXT,COPYRIGHT,IAD,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,OTHER,PCA,PSA,PUBLISHED,QOL,RESULTS,SYNTHESIS,UROLOGY
169,344,392,BACKGROUND,CAP,CAUCASOID,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,RESULTS,RUSSIAN,SNP,THERE,THREE
169,AUC,AUR,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,PUBLISHED,RATIONALE,RESULTS,SIMULATED,TAMOXIFEN
169,178,305,483,AUC,COPYRIGHT,CRT,DESPITE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TOTAL
169,502,AFTER,CONCLUSION,COPYRIGHT,DISEASE,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SAS,THESE,TNM
169,BLADDER,BOO,COPYRIGHT,MEDLINE,SAS
169,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,LABEL,METHODS,MRI,ONCOLOGIC,PSA,RESULTS,SAS,URINARY
420,ALIGNMENT,ANNOTATION,AUTOMATED,BACKGROUND,BASED,CD3,CD8,CONCLUSION,DIFFERENT,DONOR,EXACT,HOWEVER,LABEL,METHODS,RESULTS,TEN,TMA,TOTAL
184,BACKGROUND,CONCLUSION,CONTEXT,GLEASON,LABEL,LNS,METHODS,OBJECTIVE,RESULTS,THERE,THESE
158,183,CCP,GLEASON,LCMODEL,MAS,MRS,OVERALL,PLS,SEPARATING
000,100,181,231,320,BETWEEN,CTC,EPCAM,MDA,PC3,TEM,WHILE
169,AFTER,ANTIGEN,BLOOD,CHANGES,ELISPOT,FIFTY,MUC20,REGULATORY,TAA,TREGS
URINARY,VCF
E26,ETS,HOWEVER,SOMATIC
003,011,035,037,140,177,178,188,233,368,466,631,648,697,925,GLEASON,HOWEVER,MVD,PSA,THERE,THEREFORE
HOWEVER,PCA,PSA
ERG,ETS,SINCE,THESE,TMPRSS2,WESTERN
169,APOPTOSIS,BIOLOGY,COPYRIGHT,HOWEVER,INC,MOLECULAR,MSA,ORGANIC,UNION
100,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,THREE
160,283,792,952,COLORECTAL,COX,INSTITUTES,NIH,OVARIAN,SCREENING,SIMILAR,TRIAL,WOMEN
110,125,218,982,ADT,AMONG,CONCLUSION,D90,FURTHER,GLEASON,HDPPB,HIPCA,LABEL,MARCH,MEIER,METHODS,OBJECTIVE,PSA,RESULTS
169,COPYRIGHT,CRP,EAC,EMOTION,EMOTIONAL,FORTY,INC,LABEL,METHODS,OBJECTIVE,PROBING,RESULTS,RII,YET
106,140,155,169,997,COPYRIGHT,DISPERSIVE,UNDER
169,945,946,COPYRIGHT,EMT,FURTHER,HIF,IRELAND,LTD,SILENCING,STAT3,STRIKINGLY,TGF
169,24H,AKT,BAX,BCL,BOK,COPYRIGHT,CYR61,LTD,MCL,NAC,OVERALL,SILENCING
169,2YEAR,848,AUSTRALIAN,BACKGROUND,CONCLUSION,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,PSAVS,PURPOSE,RESULTS,SD1,SOUTH
100,169,583,ACCORDING,AMONG,BETWEEN,COPYRIGHT,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,RESULTS
132,169,COPYRIGHT,INC,INTENSITY,KNOWLEDGE,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,708,745,COPYRIGHT,INC,PLANS,PTV,PUBLISHED,TEN,THERE,V20,V40,V65
169,AFTER,COPYRIGHT,IMMEDIATE,INC,PUBLISHED
026,160,169,202,CELLSEARCH,CONCLUSION,COPYRIGHT,CTC,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,RESULTS,VARIABLES
001,111,169,215,5GY,COMPARING,COPYRIGHT,DIFFERENCE,HDR,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS,SOCIETY,VIRTUAL
169,COPYRIGHT,INC
169,COPYRIGHT,INC,RADIATION
169,COPYRIGHT,INC,PSA,PUBLISHED,SALVAGE,SIR,TECHNICAL
125,135,185,195,320,329,335,BACKGROUND,FALSE,HOWEVER,IFS,LABEL,METHODS,RESULTS,ROBOTIC,UNIVERSITY
007,017,073,207,261,327,402,439,593,608,ADC,BACKGROUND,DWI,FOCAL,GLEASON,LABEL,LARGE,METHODS,MRI,RESULTS,THEREFORE
CLU,FURTHER,GSTP1,HOWEVER,SINCE,WESTERN
100,425,AMONG,AVERAGE,BACKGROUND,LABEL,MATERIALS,METFORMIN,METHODS,MICRORNAS,OBJECTIVE,RESULTS
001,019,517,637,BACKGROUND,DFS,HOWEVER,KAYSERI,LABEL,MATERIALS,METHODS,RESULTS,TURKISH
010,029,128,BACKGROUND,CYP17,IRANIAN,LABEL,MATERIALS,METHODS,RESULTS,STUDIES,THEREFORE
100,ESPECIALLY,FET,MMP,SILICON,THEREFORE
120,FLT,HENCE,LDH,MTT,NPS,PC3
824NG,C57BL,CONVERSELY,CROSS,EIJ,FOXA2,HLLTJ,NOD,NZO,PHJ,PWK,THESE,TRAMP,WSB
ACTIVATION,CONSISTENT,CONVERSELY,DU145,EGF,ERK,INHIBITION,MEK,MODULATION,PCSCS,U0126,WHILE
001,006,023,038,150,169,174,BACKGROUND,COPYRIGHT,COX,HPRT1,INC,KLK15,LABEL,METHODS,PCR,RESULTS,ROC,SEVERAL,WILEY
161,413,DOPPLER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
008,169,184,242,426,BACKGROUND,BECAUSE,BPH,CHINESE,COPYRIGHT,HOWEVER,INC,ITGA6,LABEL,METHODS,PCA,PSA,RESULTS,SCORE,SYMPTOM,WILEY
22RV1,CMV,HSP70,HTERT,SHRNA
BACKGROUND,BECAUSE,CNS,FORTY,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RESULTS
104,169,177,AMONG,BACKGROUND,CAP,CCI,COPYRIGHT,COX,HRS,ILLNESS,INDEX,LABEL,METHODS,PREVIOUSLY,RESULTS,SOCIETY,THEREFORE,THESE,TOTAL
160,EPCAM,LABEL,METHODS,OBJECTIVE,PCA,PRIMARY,PURPOSE,RESULTS,USING
147,264,555,ELISA,FIBROBLAST,MOLECULAR,PCR
CONCERN,LABEL,MEN,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE,VARIATIONS
ADT,LABEL,MOLECULAR,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,SUMMARY
99M,GLEASON,LABEL,MRI,OBJECTIVE,PCA,PET,PURPOSE,RESULTS,SCORE,SUMMARY,THEREFORE
ART,COMPLIANCE,LABEL,OBJECTIVE,ONGOING,PURPOSE,RESULTS,SRT,SUMMARY,THREE
371,424,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RARLP,RESULTS
029,044,127,169,947,954,AFRICAN,CAUCASIAN,COPYRIGHT,ELISA,IIA,INC,PUBLISHED,RIIIA,SOCIETY,THESE
169,201,369,BACKGROUND,BCR,COPYRIGHT,COX,GLEASON,LABEL,LND,LNM,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,SEVENTY,SIXTY,UROLOGY
AKT,BAXM159,INCUBATION,MACROPHAGE,MIF,PC3,TREATMENT
160,215,CARLO,CONCERNING,DIRICHLET,DPGLM,EPIDS,GOLAY,MONTE,RMS,SIEMENS
169,COPYRIGHT,HDACS,HISTONE,INC,INCREASED,LIVER,LXR,PCA,RECEPTORS,TARGETING,THEREFORE
177,ADVERSE,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
110,144,169,AEU,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,PUBLISHED,RESULTS,T1C,T2A
169,802,AFTER,BETWEEN,COPYRIGHT,DPS,IRELAND,LABEL,LTD,METHODS,NAS,OBJECTIVE,PSA,PURPOSE,RESULTS
103,456,ARM,BACKGROUND,COX,III,INTENSITY,LABEL,METHODS,RESULTS,SUFFICIENT,THERE,UNIVARIATE
001,100,CONCLUSION,HOWEVER,METHODS,PC3,RADIATION,RESULTS
AFTER,CAREFUL,RADICAL
ADC,DCE,GTV,MRI,OAR,THERE,TPS,WHILE
HOWEVER,THEREFORE
COPYRIGHT,MILAN,PROUS,SCIENCE,UROLOGY
131,947,956,CLONOGENIC,CONCLUSION,DISULFIRAM,ESCALATING,LABEL,METHODS,NAT,RESULTS,THEREFORE,UNLABELLED,UVW
945,ACT,CANDIDA,COMPARISON,EPITOPE,HUACTN1,STI,THERE,THESE
ZOLEDRONIC
181,GROWING,PC3
ERG,MAST4,NDUFAF2,TMPRSS2,USING,VARIOUS
104,1990S,491,568,AFTER,BACKGROUND,LABEL,METHODS,MORTALITY,OCTOBER,OVERALL,POPULATION,RESULTS
CORYLOPSIS,DU145,FIFTEEN,LNCAP,NBT,UYEKI
008,426,ADDITIONAL,BECAUSE,BPH,CHINA,CHINESE,PCA,SNP,STRATIFIED
946,DEPLETION,EMT,IRS,REMARKABLY,ROS,TGF
101,215,ADC,AUC,DIAGNOSTIC,DIFFUSION,EXCEPTIONS,FIFTY,GLEASON,HOWEVER,III,LABEL,MATERIALS,METHODS,MIXED,OBJECTIVE,OBJECTIVES,RESULTS,VII
001,169,269,566,628,747,897,BASEL,CONCLUSION,COPYRIGHT,CRUDE,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,REGARDING,RESULTS
100,BIOSENSING,PEDOT
GROWING
133,214,ADJUSTING,AMONG,HRS,LABEL,MEN,METHODS,OBJECTIVE,ORS,RESULTS,REYKJAVIK
168,CAP,CONCLUSION,CUT,DETECTION,DRE,GLEASON,LABEL,MATERIALS,METHODS,NEITHER,OBJECTIVE,OVERALL,PSA,RESULTS,THERE,THEREFORE,TRU
ASO,CHANGES,MTT,PCR,TISSUES,TOTAL,TRANSWELL
302,552,575,984,BACKGROUND,CANCERS,CONCLUSION,ESTIMATES,HOWEVER,INCREASES,LABEL,METHODS,OBJECTIVE,PROGRAM,RESULTS,SEPTEMBER,SIR,TRADE,WORLD,WTC
494,538,692,AFTER,BACKGROUND,LABEL,METHODS,OBESITY,PIN,PSA,RESULTS
CONDUCTING,DUE,EVENTUALLY,GFF,INCUBATION,THESE
EARLY,HOWEVER,PSA,THERE
111,205,CONSISTENT,DECREASED,GLEASON,LNCAP,LOWER,MIR,PC3
ANGIOGENIC,HOWEVER,PCA,THEREFORE,THESE
HOWEVER,UTR
160,ATR,DU145,FINALLY,PCA,RCS,THESE
ENDOCRINE,RELATED
958,GENERAL,LABEL,METHODS,MIDLAND,NETWORK,OBJECTIVE,PSA,RESULTS,ZEALAND
ASIAN,BACKGROUND,BPH,CONCLUSION,INSURANCE,LABEL,MEDICAL,MEN,METHODS,RESULTS,WESTERN
001,014,240,BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS
125,169,ANY,COPYRIGHT,D90,GIVEN,INC,MEDICAL,MRI,PID,PUBLISHED
169,COPYRIGHT,CXC,DOPPLER,FINALLY,IL8,IRELAND,LTD,MGT
169,AEU,BACKGROUND,CONCLUSION,CONTEXT,COPYRIGHT,FOLLOWING,ISC,LABEL,METHODS,OBJECTIVE,PUBLISHED,SUMMARY,TUMOURS,UNASSIGNED
APPARENTLY,EPCAM,EPCAM16,STUDIES
439,CANCERS,CONSORTIUM,INSTITUTE,MOUSE,NCI,WHILE
001,777,CONCLUSION,GIVEN,HISPANICS,INTERVIEW,LABEL,METHODS,NON,OBJECTIVE,PURPOSE,RESULTS,SURVIVORS,THESE
125,169,215,333,405,AFFYMETRIX,BACKGROUND,COPYRIGHT,GENOMIC,GLEASON,LABEL,METHODS,MYC,PCA,RESULTS,SOCIETY,TARGETS,THESE,TPD52,USP10
239,AFTER,AMONG,BACKGROUND,CLASS,CONCLUSION,CSF,DP4,DR4,ELISPOT,ESO,GIVEN,GROUP,HLA,LABEL,METHODS,OWING,PSA,RESULTS,THREE
169,181,842,929,BCL,COPYRIGHT,DIETHYL,INSTITUTE,MTT,NCI,NMR,USA,USING,VCH,WILEY
CD133,IL1RA,KNOCKDOWN,MECHANISM,PCA,TR4
AFTER,BPH,DHT,LNCAP,MAZ,MYC,PCA,THESE
GLEASON,HOWEVER,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SCREENING,SUMMARY,THESE
169,226,235,436,437,COMPOSITE,COPYRIGHT,EDUCATION,INC,INDEX,INVENTORY,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PUBLISHED,PURPOSE,RESULTS,SUCCESSFUL,THREE,UIN,URINARY,UROLOGICAL
104,152,169,200,300,347,COPYRIGHT,DIAGNOSIS,EDUCATION,GLEASON,IMAGING,INC,LABEL,MATERIALS,METHODS,NETWORK,NONSEPTIC,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,REGARDING,RESULTS,SINCE,SYSTEMATIC,TESLA,UROLOGICAL
001,002,169,484,COPYRIGHT,EDUCATION,GENERAL,HOWEVER,INC,INCREASED,INDEX,JANUARY,KINGDOM,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TAYSIDE,THERE,UROLOGICAL
AAM,AFRICAN,DESPITE,EARLY,PCA
001,002,004,169,507,565,649,967,CONCLUSION,COPYRIGHT,GRIFFITHS,INC,LABEL,METHODS,OBJECTIVE,PEARSON,RESULTS,SCHAFER,SCORE,SYMPTOM,WHITNEY
169,220,257,CONCLUSION,COPYRIGHT,CROWN,DOSES,FEW,FURTHER,IMAGE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE
000,169,177,CONCLUSION,COPYRIGHT,DIFFERENT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEN
169,AEU,ANTIGEN,BPH,COPYRIGHT,CURRENTLY,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,SUMMARY,UNASSIGNED
169,COPYRIGHT
169,338,382,946,COPYRIGHT,CROWN,ELISA,FURTHER,HOWEVER,PUBLISHED,SEMEN,SIXTY,THESE
169,201,231,COPYRIGHT,DRE,MRI,PSA,PUBLISHED,SAS,ULTRASOUND
IMAGING
000,004,153,169,964,BACKGROUND,BEHAVIORAL,CCS,CHI,COPYRIGHT,HRQOL,LABEL,LTD,METHODS,OBJECTIVES,PCS,RESULTS,SHORT,USA,WILEY
169,COPYRIGHT,GIVEN,IMAGING,INC,RESON,WILEY
160,169,183,BIOLOGY,DIFFUSE,FEDERATION,GEORG,GUIDELINES,SOCIETIES,STUTTGART,ULTRASOUND
002,017,029,078,142,158,166,358,573,618,678,921,ABSTRACTS,BPS,FURTHER,LABEL,METHODS,OBJECTIVE,ONJ,OVERALL,RESULTS,SIMILAR
BBN,CONCLUSION,GRP,LABEL,METHODS,OBJECTIVE,PDT,PET,RESULTS
MRI
ADT,ALT,FEW,FORTY,GRADE,LABEL,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS
118,160,ACCURAY,ACTUARIAL,BETWEEN,CBK,CONCLUSION,CSS,CYBERKNIFE,EORTC,EVALUATION,FURTHER,GROUP,INC,INCLUSION,LABEL,MAY,METHODS,OBJECTIVE,PFS,PRIMARY,PURPOSE,RADIATION,RESULTS,SCALE,SOLID,SRT,SUNNYVALE,THERAPY,TREATMENT,USA
160,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,OTHER,PSA,PURPOSE,RESULTS,UNDER,VAS
160,ADVERSE,BETWEEN,CONCLUSION,CTCAE,EARLY,FURTHER,HDR,IHT,LABEL,METHODS,OBJECTIVE,RESULTS,SEPTEMBER
ALTERED,PCA,SRC,TAKEN,TARGETING
CHINA,CHINESE,MECHANISMS,PCA
169,176,AHGDM,BASED,BINDING,CONJUGATES,COPYRIGHT,DOC,DU145,FOLLOWING,GRP78,HSP,THESE
169,177,20GBQ,956,AE105,AE152,ALF,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,PET,RESULTS,UNLABELLED,UROKINASE
169,CLINICALLY,COPYRIGHT,DIAGNOSTIC,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,RATIO,RESULTS,SEVENTY
169,AMINOETHYL,APB,COPYRIGHT,IP3,LTD,SERCA,TRP,TRPV6,WHEREAS
100,183,496,500,CENTRAL,CONTROLLED,COX,MEDLINE,TRIAL
104,112,115,118,160,169,184,188,193,304,310,468,561,633,727,916,935,ADT,CONCLUSION,COPYRIGHT,FFS,INC,LABEL,MARKETSCAN,METHODS,OBJECTIVE,RESULTS,USING
169,ADULT,AFTER,AGE,CONCLUSION,COPYRIGHT,EARLY,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS
169,BASED,CARLO,COPYRIGHT,CTV,IRELAND,LABEL,LTD,MATERIALS,METHODS,MONTE,OBJECTIVE,PTV,PURPOSE,RESULTS
014,100,125,145GY,160,169,176,183,188GY,2GY,CONCLUSION,CONTINENCE,COPYRIGHT,D90,FOCAL,FURTHER,INC,INDEX,LABEL,MARCH,MATERIALS,METHODS,MRI,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,SCORE,SOCIETY,SYMPTOM
105,112,217,ARM,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,VARIABLES
169,231,233,COPYRIGHT,PUBLISHED,SAS
024,169,BPS,BRONJ,CLINICO,CONCLUSION,COPYRIGHT,FIFTY,INC,INFECTION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PAS,RESULTS
169,244,600,844,BCR,BJU,CONCLUSION,COX,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,OVERALL,PRIMARY,RESULTS,RRP,SRT
013,035,169,181,766,945,946,APOPTOSIS,COX,LABEL,METHODS,NAFTOPIDIL,OBJECTIVE,OBJECTIVES,RESULTS,SMAD2,UROLOGICAL
169,HOWEVER,UROLOGICAL
169,EOS,PCA,THEREBY,TREATMENT
AFTER,IGFBP,THESE
AUC,BAYES,CONCLUSION,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,ROC,SIX
ANTISENSE,ASONS,BFL,BPH,CONCLUSION,DU145,ISH,LABEL,LNCAP,METHODS,MTT,OBJECTIVE,PCR,RESULTS
INHIBITION,PCA
710,807,876,AIM,BACKGROUND,BARRETT,CAUCASIANS,CHI,CONCLUSION,EAC,END,HOWEVER,LABEL,METHODS,NIH,OBJECTIVE,OVERALL,RESULTS,THERE
CONVERSELY,E1A,ERK,INDIVIDUAL,MAP,MEK,STAT3
METASTATIC
946,948,ABCA1,ERK,EXPRESSION,HOWEVER,TGF
CELLS,PROPIDIUM,RESULTS,WHILE
001,945,946,947,AKT,BACKGROUND,CONCLUSION,FAK,IHC,LABEL,METHODS,PCA,PCR,PROTEIN,RESULTS,SIMILAR,THROUGH
169,945,BPH,COPYRIGHT,DHT,DLLME,ENZYMATIC,RIS,VARIABLES
129,169,ADVERSE,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERE,TREATMENT
18F,BCR,FACBC,IMAGING,PCA,PET,PSA,RESONANCE,TODAY
181,DU145,HOWEVER,JNK,MAP,NAC,ROS,SOD,THESE,U0126
001,350,AMICO,CAP,DEPARTMENT,FORTY,LABEL,METHODS,OBJECTIVE,PHOENIX,PSA,RECURRENCE,RESULTS,UNIVERSITY,UROLOGY
181,246,277,40S,50S,CAREFUL,CONCLUSION,GIVEN,LABEL,METASTASIS,METHODS,OBJECTIVE,OUTCOME,PREVENTIVE,PROJECT,PSA,RATES,RESULTS,SETTING,SWEDISH
111,DWI,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SPECT
BIOMARKERS,KNOWN,PAO,RADIATION
123,134,160,869,901,ACS,AOW,CIS,CONSORTIUM,FOUNDATION,HOWEVER,INADEQUATE,INSTITUTE,LABEL,METHODS,OBJECTIVE,OTHER,PURPOSE,RESULTS,SERVICE,SOCIETY,SURVIVORS,SUSAN,WOMEN
003,100,177,BPH,CONCLUSION,LABEL,METHODS,OBJECTIVE,PAI,PCA,PURPOSE,RESULTS,UROKINASE,USING
114,160,271,366,DEPENDING,NORWEGIAN,SIR,USING
945,ARTIFICIAL,DU145,HIF,LNCAP,MICRORNAS,PCA,UTR
945,946,949,BACKGROUND,BINDING,CD4,CD8,ELISA,FURTHER,IGE,LABEL,LOG,METHODS,PCA,PSA,RESULTS,THESE
169,288,330,BASEL,COPYRIGHT,HOWEVER,JAPAN,KYOTO,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SHEET
160,177,300,ARP,AUNPS,CARLO,MONTE,SER
169,BASED,FOLLOWING,LABEL,METHODS,OBJECTIVE,RESULTS,UROLOGICAL
AKT,BMX,TEC,TEL,USING
AFTER,DOCETAXEL,FIRST,HOWEVER,LOW,PRESCRIRE
945,946,954,DOCKING,FINALLY,HOWEVER,IKK,PAF,PMS1077,THESE,TNF,WESTERN
040,151,651,CGEMS,FORESTS,MARKERS,MMP16,MOFFITT,REGRESSION,ROBO1,SNP,SPLINES,THREE,TRM,USING
003,006,444,776,AFTER,AMONG,CIS,DISCOVERY,EHBP1,FALSE,ORS,SNP,UNCOVERING
001,119,215,93G,AIN,C57BL,FVB,MAXIMALLY,PCA,TRAMP
BIOLOGICAL
DENDRITIC,SINCE,WHILE
131,CEACAM6,ETS,FURTHER,MCF,OVERALL,THESE,U133A
BACKGROUND,BCR,CONCLUSION,CONSISTENT,DECIPHERTM,IRB,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THESE,TREATMENT,UROLOGISTS
100,160,500,956,BACKGROUND,CONCLUSION,DISEASE,FURTHER,GX301,IMIQUIMOD,ISA,LABEL,METHODS,MONTANIDE,OBJECTIVE,PROLONGED,RESULTS
CONCLUSION,FACBC,FURTHER,LABEL,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,TBR
CCND1,DU145,FINALLY,FIRST,HOWEVER,LNCAP,PC3,PREVIOUSLY,SUMOYLATED,TAKEN
100,177,BCI,BNC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,RRP,STUDENT,T2A,T2C
154,EMT,EPITHELIAL,HMGA2,HOWEVER,PCA,WESTERN
DESPITE,DU145,NUCLEAR,PC3,THESE
001,007,167,950,BACKGROUND,CONCLUSION,ECS,GLEASON,LABEL,METHODS,MVD,PCA,PSA,RESULTS,VASH1
111,111IN,176,177,ACA,AFTER,MULTIMERIC,NHS,PBS,PREVIOUSLY,RGD
BAY1075553,BECAUSE,DCFBC,PCA,PET,SEVERAL,THESE
PET
159,185,787,928,ACCORDING,AFRICAN,INSTITUTE,MIGRATION,NIGERIA,SIMILAR,STUDIES,WASHINGTON
CONCLUSION,LABEL,METHODS,OBJECTIVE,PLAIN,RESULTS,SPANISH,WORLDWIDE
ETS,THESE
176,200,BECAUSE,DEGARELIX,JAPAN,UNION
013,116,145,169,209,414,956,ANTITUMOR,B16,BCA,C38,C51,GXF,HCT,LABEL,LEWIS,METHODS,MIA,N87,NCI,OBJECTIVE,P02,P03,PURPOSE,RESULTS,SR475,TAXANES,THESE,TXT,XRP6258
001,124,160,224,945,ADDITIONAL,ASSESSMENT,BPI,BRIEF,COHEN,FUNCTIONAL,HOWEVER,INTENSITY,INVENTORY,LABEL,MCNEMAR,METHODS,OBJECTIVE,PEARSON,PPI,PRESENT,PURPOSE,RESULTS,THERAPY
MRG
22RV1,945,BPH,ECM,GLEASON,HOWEVER,K14,MFS,MMP,PC3,PCA,SMA,THEREFORE,TIMP1,TIMP2,TIMP3,TIMPS
945,BAX,BCL,CCK,ERP29,HIF,HOWEVER,INCREASED,MALDI,PROTEOMICS,ROS,THESE,THREE,TOF,WESTERN
001,208,295,468,584,588,645,AFFAIRS,AMONG,DESPITE,HOWEVER,IMPORTANCE,INDEX,LABEL,METHODS,OBJECTIVE,OUTCOME,PSA,RELEVANCE,RESULTS,SETTING
BACKGROUND,CONCLUSION,HOWEVER,LABEL,LND,LYMPH,METHODS,RESULTS
PTH,PTHRP,RANKL,THESE
041,945,DCE,GIVEN,GLEASON,HIF,HOWEVER,MRI,MVD,NUCLEAR,PRONOUNCED,THEREFORE
000,001,106,160,181,250,270,500,BRDICKA,FINALLY,MTT,SARCOSINE,THERE
BASED,DESPITE,SILYBUM
IMIQUIMOD,TRAMP,TREATMENT,TRMPA
947,MCL
002,007,169,426,706,ADT,AUA,BACKGROUND,COPYRIGHT,DAILY,FRACTURES,GROUP,INDEX,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PCA,PRS,PUBLISHED,RESULTS,SETTING,SYMPTOM,THESE,UROLOGICAL,UROLOGY
169,ASSESSMENT,BACKGROUND,CALIFORNIA,CAPRA,COPYRIGHT,EQUAL,FRANCISCO,HOWEVER,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PREDICTION,PUBLISHED,RESULTS,SAN,SETTING,STEPHENSON,UNIVERSITY,UROLOGY
169,COLLEGE,CONCLUSION,COPYRIGHT,DOCETAXEL,FURTHER,LABEL,LIBRARY,LTD,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PROMISING,PUBLISHED,RESULTS,ROYAL,SINCE,THESE
001,167,297,464,673,792,825,AMONG,COMPARISON,FURTHER,LABEL,METHODS,NNT,OBJECTIVE,OUTCOME,PLACEBO,REDUCTION,RESULTS,SCORE,SYMPTOM
115,432,490,922,BACKGROUND,CONCLUSION,COX,END,LABEL,MARITAL,MARRIED,MATERIALS,METHODS,RESULTS,UNMARRIED
147,529,BACKGROUND,EPSTEIN,GLEASON,LABEL,MATERIALS,METHODS,PSA,RESULTS,USING
186,BACKGROUND,LABEL,MATERIALS,METHODS,MRI,RESULTS,THERE
AFRICAN,AMERICA,AMERICANS,BACKGROUND,FURTHER,HISPANICS,INDEX,LABEL,METHODS,MORTALITY,PARADOX,RESULTS,TEXAS,USA,WELLBEING
AREAS,BACKGROUND,COMPOUNDS,COVERED,HOWEVER,LABEL,METASTATIC,METHODS,OPINION,OTHER
22RV1,ARF,CONVERSELY,LNCAP,MICRORNAS,PC3
262,324,356,ACTIVATED,ALZHEIMER,NOTABLY,PSK,SER,TAOKS
BACKGROUND,LABEL,METHODS,NORTH,OPTIMAL,PRIMARY,PSA,RESULTS,THREE
169,AKT,PIM,RTK
169,912,MVS,NSCLC,SDS,THESE,THREE,USING,VCH,WILEY
CCL,DIM,GIVEN,I3C,LNCAP,THESE,THP
ADT,ADVERSE,DENOSUMAB,MULTI,SRE
169,ANDROGENS,ARS,COPYRIGHT,CYTOMETRY,DESPITE,FQNLF,SOCIETY
166,458,AFRICAN,ASIAN,CAUCASIAN,CHINA,FURTHER,HOWEVER,JANUARY,SCIENCE,SEVENTEEN,WEB
FURTHER,THOUGHTFUL,TREATMENT
DEFINITIVE,SEVERAL
169,BASED,COPYRIGHT,HOWEVER,INC,RRP,URINARY
169,BCL,CHROMATIN,COPYRIGHT,FUNCTIONAL,LTD,THESE
169,295,AMBULATORY,ASSURANCE,COMMITTEE,COPYRIGHT,EDUCATION,FINALLY,HOPES,INC,LABEL,MATERIALS,MEDICAL,METHODS,NAMCS,OBJECTIVE,OFF,PUBLISHED,PURPOSE,QUALITY,RESULTS,SUCCESSFUL,UROLOGICAL,UROLOGY,WHILE
001,169,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SMALLER,THREE,UROLOGICAL,WHOLE
169,239,481,785,AFFYMETRIX,ALTERED,AMONG,COPYRIGHT,CPG,INC,METHYLATED,PATHOLOGY,PATHWAY,PUBLISHED,SNP,SOCIETY,THESE
169,173,COPYRIGHT,PUBLISHED,SAS
169,956,ANNEXIN,COPYRIGHT,DU145,HDACS,HISTONE,LNCAP,PC3,SAS,THESE,WESTERN
169,BACKGROUND,COPYRIGHT,FURTHER,GREEN,HOWEVER,LABEL,LTD,METABOLISM,METHODS,NUTRITION,OBJECTIVE,RELEVANCE,RESULTS,SOCIETY
169,200,300,456,462,918,AMONG,BACKGROUND,COPYRIGHT,CPA,FEW,IHT,LABEL,MAB,MEN,METHODS,OBJECTIVE,OUTCOME,PCA,PRIMARY,PSA,PUBLISHED,RESULTS,SECONDARY,SETTING,THERE,UROLOGY
228,CLINICALLY,DENMARK,RADICAL
169,AKT,BACKGROUND,BASEL,CD3,CD4,CD8,CHICAGO,CONFIRMED,COPYRIGHT,COX,EVEROLIMUS,HEMATOLOGY,LABEL,MEETING,MEIER,METHODS,OBJECTIVE,OCTOBER,OUTCOME,PFS,PSA,PUBLISHED,RESULTS,SEPTEMBER,SETTING,SEVERAL,SMALL,SOCIETIES,SOCIETY,SWISS,TREATMENT,TRIAL,UROLOGY,USA
169,945,BACKGROUND,COPYRIGHT,ESC,IPSCS,KRUPPEL,LABEL,METHODS,MYC,OBJECTIVE,OUTCOME,POU,PRIMARY,PRO,PUBLISHED,RESULTS,SETTING,SIMILARLY,SRY,SUCCESSFUL,THESE,UROLOGY
169,AVAILABLE,BACKGROUND,CONTEXT,COPYRIGHT,HOWEVER,JANUARY,LABEL,MEDLINE,METHODS,OBJECTIVE,OVERALL,PUBLISHED,RESULTS,SCIENCE,SYNTHESIS,UROLOGY,WEB
169,957,APT,BAX,CASPASE,COPYRIGHT,DOX,H40,LTD,P21,P27,PEG,PLA,THESE
169,600,AFTER,CONCLUSION,COPYRIGHT,ERB,INC,LABEL,LAT,MARGINS,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS
001,045,157,FURTHER,GLEASON,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PSA,PUBLISHED,PURPOSE,RESULTS,THERE,THREE
134,160,169,512,CONCLUSION,COPYRIGHT,COX,ESTIMATED,III,INC,LABEL,MEIER,METHODS,OBJECTIVE,PSA,RESULTS,THESE,TREATMENT
169,233,BACKGROUND,BCG,BLADDER,CONTEXT,COPYRIGHT,EAU,GROUP,GUIDELINES,LABEL,MEDICAL,MEDLINE,METASTATIC,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,RESULTS,SUBJECT,SYNTHESIS,UROLOGY
169,177,BACKGROUND,CONCLUSION,COPYRIGHT,EPLERENONE,LABEL,LTD,METHODS,PHASE,RESULTS
160,169,CENTRAL,COLLEGE,CONCLUSION,CONTROLLED,COPYRIGHT,ENROLMENT,III,LABEL,LTD,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,REGRESSION,RESULTS,ROYAL,SEPTEMBER,SRE
ANP,C57BL,PCA,THESE,YET
FDA,MONOCLONAL
AREAS,BACKGROUND,COVERED,DESPITE,LABEL,METHODS,OPINION,VARIATIONS
000,001,002,057,090,131,138,179,AUTHORITY,BRESCIA,CD4,HIV,HOWEVER,IRR,LHA,LOCAL,NADCS,POISSON,SIR
HOWEVER,USING
000,001,002,007,167,226,238,426,464,549,BACKGROUND,COMPARING,GLEASON,GROUP,HOWEVER,LABEL,METHODS,RESULTS
221,352,495,BACKGROUND,BMI,HBA1C,LABEL,METHODS,OBESE,OVERALL,RESULTS,THERE
ERG,FURTHER,MOUSE,PCA,SMAD4,TMPRSS2,TRANSGENIC
001,005,101,107,210,239,945,946,EPITHELIAL,PCS,SIMILAR,WHILE
169,174,AUTOMATION,CHROMEO,HOWEVER,LIF,NANOORANGE,PCA,PEAKS,PSA,VCH,WILEY
169,BAK,BCL,BH3,FINALLY,HRK,JNK,JUN,NH2
163,174,908,950,APPRAISAL,COMMITTEE,ERG,EXCELLENCE,GROUP,HOWEVER,III,INSTITUTE,JEVTANA,NHS,RELATED,SHEFFIELD,TAG,TECHNOLOGY,UNIVERSITY,UTILITY
169,COPYRIGHT,HIV,THERE
001,00499,DESPITE,DOI,ECTOPIC,F876L,MOLECULAR

18F,BASED,PET
ACCORDING,PET
CHOLINE,HOWEVER,PCA,PET,PSA,REGARDING,WHEREAS
001,945,946,DR7,SULT2B1,THESE,WHITNEY
PCA
608,AUSTRALIAN,BACKGROUND,CONCLUSION,COX,LABEL,METHODS,OVERALL,RESULTS,SIR,SMR,WESTERN
033,954,956,967,AMONG,CLINICALLY,COG,CONCLUSION,FUS,GLEASON,JANUARY,LABEL,MATERIALS,MAY,METHODS,NEITHER,OBJECTIVE,PCA,PREBIOPSY,PRIMARY,PURPOSE,RESULTS
169,231,233,AFTERWARDS,COPYRIGHT,FINALLY,III,PUBLISHED,SAS
169,COPYRIGHT,CROWN,MALIGNANT,PUBLISHED
145,177,230,288,945,AFTER,CONCLUSION,CSC,EMT,EVENTUALLY,FURTHER,HIF,LABEL,LNCAP,METHODS,MMP,MTT,NSP,OBJECTIVE,RESULTS,THROUGH,TRANSWELL,WESTERN
023,028,030,177,181,188,189,200,216,281,323,719,886,BPH,CONCLUSION,ELISA,GLEASON,HOWEVER,III,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,ROC,THERE,TSP
138,501,645,691,813,AUC,CHINESE,CONCLUSION,FUDAN,LABEL,METHODS,OBJECTIVE,RESULTS,SRE,THERE,UNIVERSITY
169,COPYRIGHT,INC,MEDICAL,MPD,PBS,PEARSON,PUBLISHED,STUDIES
169,AFFYMETRIX,BJU,ERG,ETS,LABEL,METHODS,OBJECTIVE,RESULTS,TMPRSS2
371,BACKGROUND,GLEASON,LABEL,METHODS,RESULTS
BACKGROUND,CONCLUSION,HODGKIN,LABEL,MATERIALS,METHODS,OBJECTIVE,POTENTIAL,PURPOSE,RESULTS
954,FURTHER,LNCAP,PC3,PTHRP,RANKL,THESE,WHILE
BACKGROUND,CONCLUSION,III,LABEL,MDV3100,METHODS,PFS,PSA,RESULTS,THREE
946,CAP,CHANGES,SERUM,SMALL,SRF,TAKEN
169,CBT,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,WILEY
CHOLINE,CONVERSELY,DUE,FURTHER,PET,PRIOR
211,ANTIGEN,BLACK,CAP,CARIBBEAN,DISPARITY,FLORIDA,HOWEVER,INVENTORY,MODEL,OVERALL,PSA,SOUTH,THEREFORE
003,121,169,464,717,CIS,COPYRIGHT,COX,HRS,MELBOURNE,PPL,SFA
169,DEVELOPING,ECTOPIC,HOWEVER,MDV3100,THESE
001,004,008,025,055,169,777,AFRICAN,AFTER,AMERICANS,BACKGROUND,CAUCASIAN,COPYRIGHT,EFFORTS,GLEASON,GREATER,HOWEVER,LABEL,METHODS,NETWORK,NORTH,RESULTS,SOCIETY
143,169,317,566,945,CONCLUSION,DISCOVERY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
948,955,LASSO,USING
126,141,205,MICRORNAS,PCA,PCR,PEARSON,PSA,WHILE
001,002,121,169,242,AMICO,COPYRIGHT,GENOMIC,GLEASON,INC,MYC,TNM
000,309,BACKGROUND,HOWEVER,INSURANCE,LABEL,METHODS,NHI,PHYSICIANS,RESULTS,TAIWANESE

226,825,BACKGROUND,COX,EXCLUDING,LABEL,MEIER,METHODS,RESULTS
336,500,819TT,942,ASIAN,CIS,HOWEVER,ORS,OVERALL
107,126,169,945,946,CONCLUSION,DESPITE,GLEASON,GROUP,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RADIATION,RESULTS,THERAPY,UROLOGICAL
GLEASON,IMAGING,MYCOSIS,PSA,SCC
ACTIVATED,BACKGROUND,HOWEVER,LABEL,MEANWHILE,METHODS,RESULTS,SRC,STAT3
GIVEN,HOWEVER,RMP,SCC,TMA,URI
002,11Q13,19Q13,251,979,ASHKENAZIC,AUC,BACKGROUND,CONCLUSION,LABEL,MEN,METHODS,ORS,POPULATION,RESULTS,THESE
174,CELGENE,III,USA
600,PREFERE
205,BACKGROUND,CONCLUSION,ELISA,ERK,LABEL,METHODS,PCA,PCR,RESULTS,RIP,TAKEN,UTR
19Q13,KLK,PSA
400,BACKGROUND,CHANGES,FIFTY,FIRST,LABEL,METHODS,PFS,PUBLISHED,RESULTS,SIMON,SORAFENIB,TREATMENT
169,ASC,BPH,COPYRIGHT,INC,PATHOLOGY,PUBLISHED,SOCIETY
245,ADT,DEGARELIX,USA,USING
000,ADT
100,239,BACKGROUND,EORTC,HDR,LABEL,METHODS,MRI,PSA,QOL,RESULTS,SCORE,THERE
015,021,169,BLACKWELL,GLEASON,KAROLINSKA,LABEL,LTD,METHODS,OBJECTIVE,OTHER,PUBLISHING,RESULTS,SEMINAL,SVI,THERE
00003,00005,003,005,009,015,019,940,BRCA1,BRCA2,CONCLUSION,COX,CSS,GLEASON,LABEL,MEIER,METHODS,MFS,MVA,OBJECTIVE,PCA,PURPOSE,RESULTS
052,277,280,283,524,528,963,CONCLUSION,DOCETAXEL,ENDOTHELIN,ENTHUSE,III,METHODS,PSA,PURPOSE,RESULTS,SECONDARY,THERE
181,946,AAE,ADP,APOPTOSIS,CAP,DELAYED,DU145,LNCAP,NUCLEAR,PIMENTA,POTENTIAL,RESONANCE,SILENCING,THESE,TREATMENT
CHINESE,ELIZABETH,JANUARY,OBJECTIVE,OUTCOME,QUEEN,RESULTS,SETTING
035,160,BASED,HOWEVER,MAJOR,PCA
000,FORCE,HOWEVER,PSA,USING
000,242,USA
001,138,CONCLUSION,INCREASING,METHODS,PRIMARY,RESULTS
AMONG,BACKGROUND,BMI,GLEASON,LABEL,MEN,METHODS,PSA,RESULTS,STATINS
ACP,AGREE,APPRAISAL,AUTHORS,COLLEGE,EVALUATION,FORCE,GUIDELINE,GUIDELINES,LABEL,METHODS,PHYSICIANS,PREVENTIVE,PSA,SOCIETY,STATEMENT,UNASSIGNED,UROLOGICAL
169,176,502,524,923,ABS,COPYRIGHT,PAP,PCA,PSA,TMS
169,COPYRIGHT,INC,MLR,NSCLC,PCA,PLSDA

169,BURKITT,COPYRIGHT,COX,EICOSANOID,EP1,FAS,HHV,INC,MOSBY,PEL,TNFRSF6
169,B12,COPYRIGHT,COQ10,DIETARY,EIGHT,IRELAND,LTD,PSA,RCT,THERE
169,AKT,COPYRIGHT,HOWEVER,INC,LNCAP,TAKEN,THESE
169,ATS,COPYRIGHT,ERS,HISTOLOGIC,IASLC,INC,TNM
169,945,946,COPYRIGHT,GIVEN,HOWEVER,PUBLISHED,SAS,SERMS,THESE
177,3DCRT,APRIL,BETWEEN,CTS,EORTC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SUBJECTIVE,VAS
ADP,AKT,BACKGROUND,BAD,BCL,ERK,JNK,LABEL,LNCAP,METHODS,RAC,RESULTS,RHO,THERAPY,VAV,XENOGRAFT
129,246,300,945,BACKGROUND,DHT,LABEL,NRS,PC3,RESULTS,SKI
007,011,064,141,143,147,159,217,230,628,676,677,954,961,AFTER,URINARY
100,104,177,200,400,956,FOURIER,HOECHST,PC3,PEG,TRANSFORM
956,BACKGROUND,CONCLUSION,GARCINA,HOWEVER,LABEL,MCF,METHODS,MIC,RESULTS,SRB,THP
ADT,CAP
2ND,CYP17A1,EFFORTS,HOWEVER,LBD,NTD,PCA,RATIONALLY,SEVERAL
1940S,ANDROGENS,HUGGINS,SINCE
200,945,BACKGROUND,BPH,GIANT,GPH,HOWEVER,LABEL,METHODS,PROSTATIC,TURPS
001,004,006,048,343,BACKGROUND,CHI,CONCLUSION,COX,DSS,LABEL,LOW,MEIER,METHODS,PFS,REDUCED,RESULTS
HOWEVER,PROSTATIC
946,967,ABSENCE,ADP,BRCA1,BRCA2,ERG,ETS,HOWEVER,III,INCREASED,LDR,LNCAP,PC3,PCA,RAD51,RUCAPARIB,THESE,TMPRSS2
HOWEVER,III,PIM,WHILE
144,AFTER,AIM,CONCLUSION,DELAYED,LABEL,METHODS,OBJECTIVE,RESULTS,TREATMENT
100,600,635,700,BACKGROUND,CLINICALLY,COMPARISON,CONCLUSION,FIRSTLY,LABEL,LIPOSOMAL,LNCAP,MATERIALS,METHODS,PC3,PDT,RESULTS,TOPICAL,WHEREAS
954,956,FN1,RESULTS,TREATMENT
256,956,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RESULTS,THREE
072,BCR,CONCLUSION,HOWEVER,LABEL,LNS,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS,THESE
100,125,156,160,585,ASSESSMENT,CONSENTING,FUNCTIONAL,HUI,INDEX,LABEL,METHODS,OBJECTIVE,ONTARIO,PATIENT,PCI,PURPOSE,QOL,REGRESSION,RESULTS,SCALE,THERAPY,THESE,UTILITIES,UTILITY
160,176,ACT,AFTER,BACKGROUND,BARIATRIC,BMI,CROHN,DVT,INSTITUTE,INSURANCE,LABEL,MARCH,METABOLIC,METHODS,RESULTS,SEPTEMBER,THERE
169,COPYRIGHT,COQ10,ECTOPIC,INC,RNS,ROS,SXR,TERE1,VITAMIN,WILEY
169,441,COPYRIGHT,DHH,LNCAP,NHT,PCA,PTCH1,SHH,SMO,SMOOTHENED,SONIC,TAK
160,FOLLOWING,HOWEVER,RRP,SINCE,WALSH
ANOTHER,AVAILABLE,CHINA,CHINESE,FINALLY,GWASS,PCA,WESTERN
001,261,ASIAN,HOWEVER,MEN,PCA,PSA,PVS,THERE,THEREFORE
000,258,890,DESPITE,HOWEVER,PCA,THESE
239,ADT,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,PURPOSE,RECURRENT,RESULTS,USING
001,006,ADT,AFTER,BACKGROUND,BMD,DECREASED,LABEL,MATCHED,MEN,METHODS,RESULTS,SUMMARY,VITAMIN
70S,BILATERAL
17908,17917,274,283,362,581,695,707,847,849,945,968,975,ATM,BROWN,INT,MESICEK,OLIVE,ONCOL,PKC,RES,SIX,STEEL,THERE,WOUTERS
116,DOC,DU145,HCT,LNCAP,PC3,TAXANES,THESE,WHILE
PBMCS,PCR
FINALLY,FINDR,FOURIER,RAMAN,SVM
946,TAU
169,COPYRIGHT,FDG,FINALLY,HOWEVER,ISSUE,KREBS,LIPID,METABOLISM,PCA,PET,SPECIAL
169,COPYRIGHT,LTD,METASTASIS,OVERALL,PRIMARY,SURGERY,WHILE
169,BPH,CHANGES,COPYRIGHT,CROWN,GLEASON,LTD,OVERALL,PATIENT,PUBLISHED,STROMAL
141,160,169,370,768,770,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS,STEYERBERG
015,018,026,100,169,292,AFTER,ASPIRIN,ASSESSMENT,BOWEL,COMPOSITE,CONCLUSION,COPYRIGHT,FINALLY,HOWEVER,HRQOL,INC,INDEX,INTENSITY,LABEL,MATERIALS,METHODS,OBJECTIVE,PROSTQA,PURPOSE,QUALITY,RESULTS,TREATMENT,V70
001,121,129,160,169,250,575,ADT,AFTER,CONCLUSION,COPYRIGHT,COX,IBF,INC,IQR,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,SRT,THERE
001,007,012,018,035,048,075,087,091,109,163,169,264,COPYRIGHT,GLEASON,INC,OVERALL
169,231,264,946,954,CHINESE,COPYRIGHT,LTD,MDA,PC3,RAW,SIX
109,125,169,269,BECAUSE,HOWEVER,JAPAN,PERMANENT
113,884,991,AIM,CONCLUSION,DWI,LABEL,METHODS,MRI,OBJECTIVE,RESULTS
001,138,168,177,185,250,314,ADT,CONCLUSION,FCH,IMAGING,LABEL,MBQ,METHODS,OVERALL,PET,PSA,RESULTS,TRIGGER,UNLABELLED,USING
001,006,156,164,169,AMONG,BACKGROUND,COPYRIGHT,END,ESTIMATES,HODGKIN,LABEL,MATCH,METHODS,RESULTS,SOCIETY,SOLID,SUBGROUPS,TRANSPLANT
169,AMONG,BACKGROUND,COLORECTAL,COPYRIGHT,LABEL,MEN,METHODS,NON,OVARIAN,PSA,RESULTS,SOCIETY
NCOA3,PCS,POZ,SRC,THESE
000,BACKGROUND,ERG,FOXP1,FOXP2,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,THESE
169,945,946,APART,COPYRIGHT,DUE,FIRST,INC,PC3,THIRD,WILEY
223,PHASE,SINCE,THESE,UNTIL
945,948,954,ADP,BCL,LNCAP,MCL,PC3,PKC,PTPL1
AFTER,BECAUSE,FGFR2,FGFR3,THROUGH
BACKGROUND,EGFL7,ELISA,HCC,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,SIMILARLY,TNM,WESTERN
FRESH,SVM,THESE
ERG,ETS,ONCOGENIC,TMPRSS2
006,169,21MHZ,AMONG,COPYRIGHT,DYNAMIC,FOLLOWING,INC,LABEL,MATERIALS,MCNEMAR,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,6MV,CARLO,COPYRIGHT,EBT,GAFCHROMIC,HOWEVER,INC,MEDICAL,MONTE,PUBLISHED,V95
160,ATM,CPT,HOWEVER,NEITHER,NK3,THEREFORE
000,240,CAP,CHANGES,CHEMOKINE,CHEMOKINES,CONTROL
ADDITIONAL,BACKGROUND,CD8,CSF,FDA,GEM,III,IPLIMUMAB,LABEL,METHODS,PHASE,PRO,RESULTS,THESE,TRAMP
000,200,215,264,376,630,FIRST,HOUGH,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
AFTER,CSI,HOWEVER,LABEL,METHODS,MIM,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,THREE,VARIOUS
177,BAT,CLARITY,ESPECIALLY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
215,BRACHYVIEW,DOSIMETRIC,INCORRECT,LABEL,METHODS,OBJECTIVE,PERSPEX,PURPOSE,RESULTS,THREE
931,956,963,CALYPSO,IRB,LABEL,MARGINS,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SETUP,THESE
D10,FOLLOWING,HDR,INVERSE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
A2780,HOWEVER,OVCAR,OVERALL,REMARKABLY,RESULTS
7OG,7OM,7OP,CLONOGENIC,DHS,DSS,FURTHER,HTB,ISOMERS,OVERALL,PC3,SILYBIN
961,BACKGROUND,CPG,ERG,GIVEN,LABEL,MEDIP,PCR,PRINCIPAL,RESULTS,SEQ,TDRD1,TMPRSS2,TUDOR
CURRENT,ORTHOTOPIC,PBS,THREE,UC1,UC3,ULTRASOUND,VSV,XENOGRAFT
032,191,215,376,545,984,AFRICAN,AMERICANS,ANXA4,CASP5,F13A1,GP6,HOWEVER,HUMANEXOME,INS,LDLRAD1,PSA,SLC16A6,SLC19A1,SNP,USING
10Q11,19Q13,946,FIRST,HOWEVER,MEN,PCA,REDUCTION
MCF2L,NTA,PCA,SEVERAL,THESE
ASM,BISULFITE,CGI,CRPCS,PCA,REDUCED,SEQUENCING,THESE
574,BCL,EP300,GENECODIS,GENISTEIN,GLEASON,JAK,LOW,LUCIFERASE,PCA,PCR,THESE,USING,UTR,WESTERN,WNT
BLARINA,C13,C27,SOR,SORICIDIN,TRPV6
CELASTROL,ERG,PCA,THEREFORE,TMPRSS2
100,169,AES,AMONG,BACKGROUND,CTC,III,LABEL,MET,METHODS,PRS,RESULTS,SDS,THESE
169,945,AFTER,ALANINE,COPYRIGHT,GTP,III,INC,LNCAP,PI3KS,PI3KSER83,PKA,REGULATORY,RHO,SER,SER83,SH3,THERE,WILEY
100,233,BLOOD,COMBINING,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SMOKING,TOBACCO
169,215,COPYRIGHT,LTD,WILEY
160,ABOUT,BACKGROUND,EUROPEANS,EUROPREVAL,JANUARY,LABEL,METHODS,RESULTS,SEVERAL
022,027,038,044,155,ADT,BETWEEN,CSS,GLEASON,LABEL,MARCH,METHODS,OBJECTIVE,PHOENIX,PRE,PRIMARY,PSA,PURPOSE,RESULTS
99M,OH2,SPECT
141,PSA
COX,FINALLY,HOWEVER,RCC,THERE
CTC,THEIR
215,POTENTIAL,PREVENTION,TRIAL,VITAMIN
169,200,205,BJU,COX,FACTORS,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SINCE
090,100,153,169,177,577,977,ART,BJU,END,LABEL,MEN,METHODS,OBJECTIVE,PROPENSITY,RESULTS
169,754,AUSTRALIA,AUSTRALIAN,AUTHORS,BACKGROUND,COLLEGE,CONCLUSION,GROUP,IMAGING,JOURNAL,LABEL,MEDICAL,METHODS,RADIATION,RANDOMISED,RESULTS,ROYAL,TRANS,TREATMENT,ZEALAND
169,810,947,AUSTRALIAN,AUTHORS,BACKGROUND,COLLEGE,CONCLUSION,IMAGING,JOURNAL,LABEL,MEDICAL,METHODS,PHOENIX,RADIATION,RESULTS,ROYAL,STUDIES,TCD50,ZEALAND
001,132,169,AIM,BACKGROUND,BTB,EFD,EFR,INDEX,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PDE5I,RESULTS,SOCIETY
169,183,946,ASSESSING,BACKGROUND,BLACKWELL,FREQUENCY,INDEXES,KEGEL,LABEL,LTD,MANAGEMENT,MEN,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHING,RELEVANCE,RESULTS,SYMPTOM
169,BLAND,GRAYSCALE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
169,AUTHORS,BLACKWELL,FOUNDATION,JOURNAL,LTD,MOLECULAR,PUBLISHED,PUBLISHING,TLR
150,169,178,236,ACUTE,BJU,COX,CTCAE,FORTY,INDEX,JANUARY,KETTERING,LABEL,MAY,MEIER,METHODS,NETWORK,OBJECTIVE,POTENCY,PSA,RESULTS,RFS,SLOAN,THERE
001,169,232,409,AUSTRALIA,AUSTRALIAN,BJU,CONVERSELY,GIVEN,GLEASON,HAEMATURIA,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SOCIETY,STRATIFIED,TPB,UROLOGICAL,USANZ,ZEALAND
100,116,145,169,BJU,CONFERENCE,CONSENSUS,JANUARY,LABEL,METHODS,MINIMISING,OBJECTIVE,RARPS,RESULTS,ROBOTIC,SECTION,THERE,UROLOGY
169,CONCLUSION,EGGER,LABEL,LTD,METHODS,OBJECTIVE,PTY,PUBLISHING,RESULTS,THERE,WILEY
001,003,765,770,BACKGROUND,CASTRATION,INSTITUTE,LABEL,MEN,METHODS,PSA,REPLACING,RESULTS,THERE
GPR54,KISSPEPTIN
169,CPG,DMR,ERG,FINALLY,GENOMIC,GLEASON,H3K4ME3,LABEL,METHODS,OBJECTIVE,PCG,PURPOSE,RESULTS,SUZ12
125,517,540,AUC,CALCULATOR,CONCLUSION,ERSPC,HOWEVER,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PREVENTION,PSA,PURPOSE,RANDOMIZED,RESULTS,ROC,SCREENING,THEREFORE,TRIAL,WESTERN
MRS,PCA
268,281,288,725,930,934,945,ALA,AMONG,BACKGROUND,CASES,CONCLUSION,COX,EPA,HRQUINTILE,LABEL,LINOLENIC,METHODS,NIH,PERSONS,RESULTS,RETIRED,SATURATED,TOTAL
HIF,NOTABLY,PC3,SILENCING,STAT1,VHL
001,547,946,990,AVAILABLE,BACKGROUND,CONCLUSION,HOWEVER,INDIRECTLY,LABEL,METHODS,MOM,RELEASE,RESULTS,SIR,THA,THESE
BACKGROUND,CENTRAL,CONCLUSION,LABEL,METASTATIC,METHODS,MRI,OBJECTIVE,PSA,RESULTS,SINCE
001,006,009,021,024,167,ASTRO,BACKGROUND,HORMONE,JANUARY,LABEL,METHODS,OBJECTIVE,PHOENIX,PRIOR,PSA,RESULTS,SECONDARY,TURIN,UNIVERSITY
ABOUT,EPSTEIN,GLEASON,LABEL,LOW,OBJECTIVE,PATIENT,PSA,PURPOSE,RESULTS,SUMMARY
169,8473T,BACKGROUND,BASEL,CAUCASIANS,CONCLUSION,COPYRIGHT,COX,EGGER,FINALLY,HARDY,LABEL,MEDLINE,METHODS,OVERALL,PCA,PTGS2,RESULTS,SCIENCE,UTR,WEB
034,169,588,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,GLEASON,LABEL,MATERIALS,METHODS,PSA,RESULTS,STATINS,USERS
169,264,BASEL,CHINESE,COPYRIGHT,DCA,ECP,LABEL,LNI,METHODS,OBJECTIVE,OVERALL,PTS,PURPOSE,RESULTS,SVI,THESE
169,177,ALLERGY,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,DEPARTMENT,DOPPLER,EARLIER,ELASTICITY,LABEL,LNS,METHODS,OBJECTIVE,PDS,RESULTS,UNIVERSITY
285,BASED,CAP,DESPITE,FOLKMAN,FORTY,JUDAH,MED
132,169,488,64257,99M,AGE,BACKGROUND,BASEL,CHINA,CHINESE,EARLY,FURTHER,GLEASON,LABEL,MATERIALS,METHODS,PCA,PSA,RESULTS,ROC,TNM,USING
HOWEVER,MRI,SDS,THERE
EPIRUBICIN,FE3O4,MAGNETITE,PVP,TEM,TGA,VIS
165,174,211,270,375,400,687,906,CHINESE,HAN,HOWEVER,III
WHILE
126,153,287,AFFAIRS,COX,LABEL,MEDICAL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
160,174,24H,24N,48H,48N,CMS,EPC,HOWEVER,HYPOXIA,PCA,THESE
000,184,503,ADT,ANDROGENS,CIS,CONCLUSION,COX,GENERAL,HRS,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SECONDARY,SIMILARLY
001,006,521,AMONG,BACKGROUND,FORTY,GLEASON,JANUARY,LABEL,METHODS,PSA,RESULTS,SEVEN
BACKGROUND,ERG,FIFTY,HOWEVER,IHC,LABEL,METHODS,RESULTS,THESE,USING
001,009,103,128,160,177,221,280,565,721,BNS,EHS,INDEX,JANUARY,ROBOTIC,RRP,SHORTER
250,945,946,947,DU145,KEV,LNCAP,PC3,SIEMENS,STABILIPAN
169,946,COPYRIGHT,EMT,IRELAND,LTD,TAKEN,TGF,WNT
169,174,556,AMONG,ASSESSMENT,COPYRIGHT,DIAGNOSTIC,EDUCATION,EVALUATION,GRADE,GRADING,INC,JANUARY,LABEL,MATERIALS,MAY,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QUALITY,RESULTS,STUDIES,UROLOGICAL
169,176,195,632,COPYRIGHT,DRE,EIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,RADICAL,RESULTS,SAS,T1C
125,300,652,939,946,BACKGROUND,CONTEXT,GENERALLY,HOWEVER,LABEL,METHODS,NUCLEIC,OBJECTIVE,RESULTS
EXCEL,OVERALL,THREE
PET,THERE
945,HOWEVER,MRI,SURGERY,TNF,VDA
005,031,11C,177,18F,AFTER,AMONG,BACKGROUND,COMBINING,CONCLUSION,LABEL,METHODS,NTD,OMS,PET,RESULTS
037,CONCLUSION,GLEASON,INITIAL,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SEVENTY
001,004,006,074,HAPLOTYPE,JAPAN,MULTI,PSA,THREE
200,945,946,BED,HDR,HOWEVER,INDICATION,T3A
150,169,177,C18,COPYRIGHT,RPR112698,RPR123142
128,169,259,324,ANY,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PREBIOPSY,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
FBL,HOWEVER,POL,PTB
169,945,956,AFP,COPYRIGHT,DETECTION,PSA,PZT
169,COPYRIGHT,DLT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PDGFR,PURPOSE,RESULTS,SEVENTEEN,SUNITINIB,USING,VEGFR,XRT
145,169,177,COPYRIGHT,HRM,INC,LNCAP,PAI,TREATMENT
100,102,169,3MM,CONCERNING,COPYRIGHT,D99,DIL,EXCEPTING,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,TREATMENT,V95
024,104,150GY,169,2CC,BACKGROUND,BETWEEN,BRT,COPYRIGHT,DVH,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,169,954,BCR,COPYRIGHT,COX,FURTHER,GLEASON,HARRELL,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,TMA
001,002,003,014,169,945,BACKGROUND,BMI,COPYRIGHT,LABEL,MEN,METHODS,OBESITY,OBJECTIVE,OUTCOME,PER,PERCENTAGE,REDUCTION,RESULTS,SETTING,UROLOGY
002,007,008,169,ADT,BACKGROUND,BETWEEN,COPYRIGHT,COX,GLEASON,LABEL,METHODS,NETWORK,OBJECTIVE,OUTCOME,PCA,PRIMARY,PSA,PUBLISHED,RESULTS,RFS,SETTING,SHORT,THESE,UIR,UNIVARIATE,UROLOGY
169,AUSTRALIA,BACKGROUND,COPYRIGHT,CRC,DISCUSSION,LABEL,LTD,METHODS,RESULTS,THESE
169,COPYRIGHT,EDUCATION,FOUNDATION,INC,MEDICAL,PUBLISHED
169,AMONG,CONCLUSION,COPYRIGHT,IMAGING,INC,LABEL,METHODS,MRI,OBJECTIVE,RANDOMIZED,REPORTING,RESULTS,TARGETING,UROSTATION
102,160,169,626,CONCLUSION,COPYRIGHT,GROUP,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,RADIATION,RESULTS,THERAPY,UNIVARIATE,USING
AREAS,BACKGROUND,COVERED,GIVEN,LABEL,METHODS,OPINION,PDGFR,PHASE
169,COPYRIGHT,INC
169,COPYRIGHT,INC,MAXIMUM,MCO,MEDICAL,PUBLISHED,RAYSTATION,TREATMENT,V50,V70
169,1CM,COPYRIGHT,INC,MEDICAL,PUBLISHED,SSD,TYPICALLY,WHETHER
BSMMU,COMFORT,DEPARTMENT,DHAKA,DRE,LTD,MEDICAL,MUJIB,NPV,NURSING,OCTOBER,PPV,PSA,PVT,ROC,THEREFORE,TRANS,UNIVERSITY,UROLOGY
169,CONCORDANT,EMT,FOXA1,TAKEN,USING
169,AKT,ERK,NOTABLY,WHEREAS
145,183,767,BACKGROUND,CONCLUSION,DKK,INITIALLY,LABEL,LNCAP,METHODS,MIR,PCR,RESULTS,SMAD4
169,258,BACKGROUND,COPYRIGHT,DIAGNOSTIC,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,REPORTING,RESULTS,SETTING,STANDARDS,STARD,START,STUDIES,THERE,UROLOGY
169,174,AMONG,COPYRIGHT,DESPITE,FDA,PUBLISHED,SAS,VANDETANIB
947,BACKGROUND,LABEL,LNCAP,MLV,RELATED,RESULTS,SIMILAR,SMC,SUBSEQUENT,THERE,VIRUS,XENOTROPIC
221,324,BACKGROUND,CONCLUSION,EDNRA,GREM1,HOWEVER,INTEGRATED,KPNA2,LABEL,LOX,METHODS,NOTICEABLY,PROTEIN,RESULTS,SCORE,SINCE,TNFAIP6
169,946,MECHANISM,MMP,TGF,THESE
22RV1,945,946,947,CONVERSELY,CXR,HOWEVER,HP1,LNCAP,SIMILARLY,TAKEN,THEREFORE
954,AKT,CCN,HOWEVER,NOV,OPG,PC3,RANKL,THESE,WESTERN
FOUNDATION,OCTOBER,PCF,RETREAT,SCIENTIFIC,SEVERAL
169,945,946,FINALLY
169,946,COX,CXCL6,DESPITE,FINALLY,GCP,GLEASON,PI3,PSA,PTGS2
001,105,160,169,269,292,996,ACADEMY,AFTER,ANDROLOGY,ANOTHER,SERUM,SOCIETY
169,COX,DU145,HENCE,OPPOSED,PGE,THEREFORE
177,215,AES,AMONG,BACKGROUND,III,LABEL,METHODS,PSA,RESULTS
011,024,273,368,398,641,947,AMONG,BALTIMORE,CALIFORNIA,CARET,FRANCISCO,GLEASON,HAVEN,HOWEVER,III,MPO,OVERALL,PUFAS,RETINOL,SAN,SEATTLE,TRIAL,WASHINGTON
134,301,320,MASSARRAY,PRACTICAL
074,155,211,215,272,CONSORTIUM,PRACTICAL,THESE
FOUNDATION,PHG

ERG,TMPRSS2,WHILE
160,HOWEVER,PSA
PSA
CLEARLY,COMMITTEE,FEDERAL,FORCE,KINGDOM,PREVENTIVE,PSA,RANDOMIZED,SCREENING,SIMILARLY,SWISS
169,BACKGROUND,CHANGES,COLORECTAL,COPYRIGHT,CRS,ITALIAN,ITALY,JOINPOINT,JOINPOINTS,LABEL,LTD,METHODS,PERCENT,PROGRAM,REGISTRIES,REGRESSION,RESULTS
001,169,177,AAA,AIR,BESIDES,CARLO,COPYRIGHT,ECLIPSE,INC,MAPES,MEDICAL,MGS,MONTE,PUBLISHED,XIO
169,174,954,ASA,BACKGROUND,BAX,CONCLUSION,COPYRIGHT,COX,DICLO,HOWEVER,IBEROGAST,LABEL,LDH,LPS,PMA,RESULTS,SEVERAL,STW,THESE,THP
001,009,011,012,013,017,474,BACKGROUND,HANDE,LABEL,METHODS,MVD,NUCLEAR,RESULTS,SAMPLES
725,AFTER,EIGHT,FURTHER,GEO
338,ASIAN,BACKGROUND,LABEL,MEDLINE,METHODS,NEWCASTLE,PRIOR,RESULTS,STATA
001,004,172,258,ASIAN,BACKGROUND,CAUCASIANS,CI1,CIS,GSTM1,LABEL,METHODS,ORS,RESULTS,SCIENCE,SIMILAR,WEB
006,012,018,033,040,055,063,097,105,161,170,178,184,194,308,459,519,796,910,925,965,BACKGROUND,CRP,FURTHER,LABEL,METHODS,OCTOBER,RESULTS
BACKGROUND,EQUOL,LABEL,MATERIALS,METHODS,PCA,RESULTS,STUDIES,WESTERN
001,110,159,165,206,230,254,267,328,ANALYZE,CONCLUSION,EIGHT,LABEL,MATERIALS,METHODS,OBJECTIVE,OPERATIVE,RESULTS,THOSE
408,CHINESE,DESPITE,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,STEPHENSON,USA
270,536,GLEASON,PCR,PSA
001,003,ADT,BACKGROUND,BMI,CHANGES,CONTEXT,IGF,IGFBP,LABEL,METHODS,OBJECTIVE,RESULTS,TREATMENT
169,900,EPS,EXPRESSED,PCA,THESE,TRANCHE,USING,VCH,WILEY
169,BACKGROUND,COPYRIGHT,INC,LABEL,LDH,MCT,METHODS,RESULTS,TSC,WILEY
169,946,AKT,BACKGROUND,COPYRIGHT,DU145,ELISA,HOWEVER,INC,INHIBITED,LABEL,LNCAP,METHODS,PCA,PCASC,PCR,REDUCED,RESULTS,SPARC,WILEY
169,374,439,502,COPYRIGHT,FIFTY,GLEASON,HGPIN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SEVEN,WILEY
169,AMONG,BACKGROUND,BECAUSE,COPYRIGHT,GENECHIPS,GLEASON,INC,LABEL,METHODS,NR6A1,PCA,RESULTS,WILEY
169,AFTER,AUTOPHAGIC,BACKGROUND,CONCLUSION,COPYRIGHT,FINALLY,GFP,HOWEVER,HRPCA,INC,INHIBITION,LABEL,LC3,LNCAP,METHODS,PCA,RESULTS,TAKEN,TREATMENT,WILEY
169,AFTER,BACKGROUND,COPYRIGHT,FATIGUE,INC,LABEL,MEN,METHODS,QOL,RESULTS,WILEY
10001,333,HOWEVER,MEANINGFUL,MECHANISMS,MEDICAL,PUBLISHERS,SEVENTH,USA
CONCLUSION,INSTITUTE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
174,JEVTANA,PSA,USA
014,100,150,160,BPH,HARDY,LOCUS,PCA,PCR,SERBIAN,SNP,THERE
OPTIMAL
001,100,BACKGROUND,CRC,LABEL,MATERIALS,METHODS,RESULTS,THESE
219,318,AFRICAN,AMERICANS,BACKGROUND,CAG,CYP3A43,EARLY,FRONTAL,GLEASON,LABEL,METHODS,RESULTS,STUDIES
711,AMONG,GISTS,SDH,THERE,THREE
803,969,CASES,ESTIMATES,LABEL,METHODS,NO2,OBJECTIVE,OBJECTIVES,RESULTS,THERE,THESE
034,153,169,BACKGROUND,COPYRIGHT,END,GLEASON,INC,LABEL,LHRHA,METHODS,PSA,RESULTS,ROC,SERUM,TTP,USING
GCDFP,LABEL,LESIONS,UNASSIGNED,UNDER,UNLABELLED,VIRTUAL,WHILE
549,NSCLC,OVERALL,PLK,REGARDING
145,COMBINING,THESE,ULTRASOUND
019,029,243,273,DIETARY,MARCH,MEN,STUDIES,THESE
013,014,215,BACKGROUND,HAPLOTYPE,IGF,LABEL,MEIER,METHODS,PCA,RESULTS
139,AMONG,CXCLS,DECREASED,FURTHER,HIF1A,IL6,IMPDH,ORIGINALLY,PAI,U87,USING
EPCAM,HOWEVER,PCA,POPULAR,PSA,THEREFORE,TRAMP,WITHOUT
127,198,CIS,CONCLUSION,CUMULATIVE,LABEL,LYNCH,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
169,COPYRIGHT,HRMAS,LTD,MRS,PCA,PSA,STUDIES,WILEY
169,ARCTURUSXT,COPYRIGHT,LCM,NANOVELCRO,NGS,VCH,WILEY
184,883,HOWEVER,LABEL,METHODS,MTB,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SIXTY,SWISS
005,008,167,229,312,708,AFFAIRS,CAP,DISEASE,FURTHER,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SIMILAR
BACKGROUND,DISCUSSION,LABEL,MEN,OBJECTIVE,THESE
DIAGNOSIS
001,028,127,269,3D26PBX,744,CANCERS,GLEASON,INITIAL,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TP14PBX,TR12PBX
CLINICIANS,SMN,USA
169,BECAUSE,BETWEEN,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SURGERY,URF
BECAUSE,CALIF,HOWEVER,INC,INTUITIVE,MINIMALLY,SUNNYVALE,VINCI
105,CTCAE,GRADE
046,128,138,177,181,193,200,994,ALP,ALT,AST,BACKGROUND,CONCLUSION,CZECH,GGT,INR,LABEL,LABORATORY,METHODS,QUICK
111,117,169,ADC,AIM,COLLEGE,CONCLUSION,COPYRIGHT,DCE,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,ROYAL
111,169,ANZ,AUTHORS,BACKGROUND,COLLEGE,DISCUSSION,JOURNAL,LABEL,METHODS,RESULTS,ROYAL,SURGERY,THERE
169,AIM,BACKGROUND,BLACKWELL,CONNECT,DISCUSSION,ETHICAL,FORTY,LABEL,LTD,METHODS,OBJECTIVE,OUTCOME,PUBLISHING,REASONS
7AU,7BB,H12,MOLECULAR,SAR
169,174,AMONG,CASODEX,INTESTINAL,KINETIC,LTD,PUBLISHED,SOCIETY,UDP,UGT,WHILE,WILEY
956,DOX,DU145,INCUBATION,MTS
CDX,CEA,CK7,PAS,PSA
153,MINIMAL
207,239,GROUP,INTERVIEW,LABEL,MEN,METHODS,OBJECTIVE,PSA,RESULTS,SEM,TELEPHONE
169,ADAMS,ELISA,MHC,NKG2D,STUDIES,THESE
169,ACTIVATED,FINALLY,HGF,IGF,MET,PC3,SRC
101,ABOUT,AGENT,CAT,CONCLUSION,KIM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PHU,PSA,RESULTS
169,954,AKT,COPYRIGHT,EXOGENOUS,LOX,USING
177,956,ADDITIONAL,BACKGROUND,CONCLUSION,FIFTY,GLEASON,LABEL,MAY,METHODS,PCA,PSA,RESULTS,SHEAR,SWI
COPENHAGEN,MRI,PC3,PCA,THESE
160,DU145,EUPHORBIA,JNK,MMP,PKC,WESTERN
ANOTHER,CONCLUSION,ICE,INITIAL,LABEL,MATERIALS,METHODS,OBJECTIVE,POTENTIAL,PURPOSE,RESULTS,TEN,THESE
00093,048,241,AGE,FURTHER,GRADE,GROUP,RADIATION,STUDENT,THERAPY,V20,V40,V60,V70
100,945,946,ADT,DHT,HSD,HSD17B6,THESE
001,160,ASIAN,BCR,BETWEEN,GLEASON,IQR,PSA
HOWEVER,PCA,PSA,SEVERAL,SINCE
CELLS,ELISA,THERE,THESE
169,COPYRIGHT,HDACI,LNCAP,LTD,THERE
169,946,A2780,CONSISTENT,COPYRIGHT,DHA,DU145,INC,NEITHER,WHILE,WNT
169,COPYRIGHT,IRELAND,LNCAP,LOX,LTD,PCA,TREATMENT
169,COPYRIGHT,IRELAND,LTD,NPS,TARGETING
169,239,COPYRIGHT,HOWEVER,IRELAND,JUN,LTD,MOLECULAR
105,169,ARTEMIS,BACKGROUND,COPYRIGHT,DETECTION,GLEASON,LABEL,MEN,METHODS,MRI,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,SEVENTY,SUSPICIOUS,UROLOGY
001,004,009,169,ADT,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRE,PSA,PURPOSE,RESULTS
169,945,ARI,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PREVENTION,RESTAGING,RESULTS,T1C,TRIAL
169,BCJ,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PBX,PCA,REDUCTION,RESULTS,THESE,THREE,USING
169,945,946,COPYRIGHT,GIVEN,INC,THERE
169,BCL,COPYRIGHT,GINKGETIN,LTD,OVERALL
138,160,274,431,503,934,BGM,CONCLUSION,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,ORP,OVERALL,PUBLISHED,RALRP,REGRESSION,RESULTS
110,116,153,169,177,99M,AFTERWARD,CONCLUSION,COPYRIGHT,EDTMP,INC,LABEL,METHODS,OVERALL,PET,RESULTS,UNLABELLED
169,192,193,262,307,385,954,AGREEMENT,ARO,AUO,BACKGROUND,COPYRIGHT,COX,EVENT,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PHASE,PSA,PUBLISHED,RESULTS,SETTING,SOCIETY,THERE,THESE,UROLOGY
169,218,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,USING
169,268,4GY,ADVERSE,BACKGROUND,CHANGES,COPYRIGHT,COX,CTCAE,FIFTY,KRUSKAL,LABEL,METHODS,OBJECTIVE,OUTCOME,OVERALL,PCA,PUBLISHED,QOL,RESULTS,SCORE,SETTING,SYMPTOM,TREATMENT,UNIVARIATE,UROLOGY,WHITNEY
160,169,BACKGROUND,BCL,CLONOGENIC,CONCLUSION,COPYRIGHT,HTB,INC,LABEL,MEL,METHODS,QUICK,RESULTS,RSV,THESE,TUNEL,XRT
001,160,169,177,BACKGROUND,COLLEGE,COPYRIGHT,HOWEVER,INC,JANUARY,LABEL,METHODS,NTC,PAPILLARY,PTC,PUBLISHED,RESULTS,SIXTY,THERE,THESE
146,321,562,947,BACKGROUND,COX,GIVEN,GLEASON,HGPIN,HP1,INCREASED,LABEL,METHODS,PCA,PEARSON,PSA,RESULTS,USING
160,169,ASSESSMENT,CLAVIEN,CONCLUSION,COPYRIGHT,DINDO,FUNCTIONAL,GLEASON,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SCORE,SYMPTOM,T1C,T2A,THERAPY,THREE,USING
169,945,946,954,ANATOMICAL,IKK,LPS,LTD,SOCIETY,TAKEN,THESE,WILEY
160,BACKGROUND,CISPLATIN,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,MTT,RESULTS
160,169,COPYRIGHT,LTD,M13,PROTEIN,PTD
169,177,AMONG,EXCLUSION,UNIVARIATE,UROLOGICAL
169,177,837,AIM,COX,EXCLUSION,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE,UROLOGICAL
ESPECIALLY,FURTHER,HSP,NOTEWORTHY,PCA,SINCE,THEREFORE
100,CONCLUSION,DCE,DWI,LABEL,MATERIALS,METHODS,MRI,MRS,OBJECTIVE,PSA,RESULTS,THREE
015,017,028,041,042,169,200,231,483,532,643,GLEASON,JANUARY,LABEL,LYMPHOCELE,METHODS,OBJECTIVE,OBJECTIVES,OPERATION,PROPENSITY,RESULTS,SEMINAL,THERE,UROLOGICAL
169,308,421,590,AFTER,BETWEEN,CONCLUSION,GLEASON,LABEL,LOWER,METHODS,OBJECTIVE,RESULTS,SCORE,SYMPTOM,UROLOGICAL
150,350,ALGORITHMS,CONCLUSION,DEPARTMENT,LABEL,MBQ,METHODS,OBJECTIVE,RADIATION,RESULTS,TRT,VARIOUS
100,125,255,CONCLUSION,DOSIMETRIC,HOWEVER,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,PID,RESULTS,SUBOPTIMAL
INCREASED,THROUGH
186,685,AFRICAN,AMERICANS,CAUCASIANS,JANUARY,REVMAN4,STATA,VDR,WANFANG
DESPITE
160,5ARIS,945,ADVERSE,BACKGROUND,BECAUSE,DUE,END,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PCA,PUBLISHED,PURPOSE,QUALITY,RESULTS,TREATMENT
100,571,856,956,BMI,CONCLUSION,COX,FURTHER,HOWEVER,HRS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
156,193,234,271,678,935,DIAGNOSIS,DIETARY,FEW,FEWER,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS
166,167,946,FAS,HEK293T,HOWEVER,K167R,LYS,MG132,PPC,ROS,SEVERAL,T166A,THR,TNF,TRAIL
246,A2780,CL2,CONCERNING,DICHROISM,HSA,L4AND,PC3,PF6,RU2,RUCL2,TSC,WHILE
945,ANOTHER,HOWEVER,III,INSTITUTE,LABEL,OBJECTIVE,PHASE,PURPOSE,RESULTS,SUMMARY,THESE
000,100,AMONG,AUTONOMOUS,HERTZEN,INSTITUTE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OKRUG,OVERALL,RESULTS
169,COPYRIGHT,DU145,EDMAN,LNCAP,MALDI,MEXICAN,MTT,PC3,PDT,PST,THESE,TOF,TPH
169,COPYRIGHT,CRPCS,INC,NCOR1,NOTABLY,SIAH2
154,381,763,788,818,CONCLUSION,HOWEVER,LABEL,METHODS,NURSE,OBJECTIVE,PATIENT,PHYSICIAN,PURPOSE,RESULTS,THERE,TREATMENT,ZOL
100,1000S,169,2000S,708,710,751,752,768,779,805,811,ADC,ADC1000,ADC2000,CONCLUSION,COPYRIGHT,DWI,GLEASON,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,ROC
005,009,CONCLUSION,D95,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TOMODIRECT,TREATMENT
011,ALPHARADIN,BECAUSE,HOWEVER,MDV3100,OGX,P17,SEVERAL,UNTIL
169,ADT,ADVERSE,GROUP,LTD,MEANING,SPOUSAL,WHETHER,WILEY
001,002,006,013,AFTER,ARF,CHANGES,MYC,P53,P53GENE,PCR,SIMILAR
DWI,MRI,PCI,RPE
100,ANOTHER,ASTRO,ATM,BACKGROUND,CYSTECTOMY,DAILY,HBO,HEMATURIA,HRC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
BACKGROUND,DISSONANCE,LABEL,METHODS,RESULTS,SURVEYING
000,100,4T1,CTC,EPCAM,MBS,THERE,USING
KIT,PCR,SATB1,SILENCING,SPECIAL,WESTERN
GBM,HPA,ORAI1,ORAI3,OVERALL,STIM1,USING,UTILIZING
169,PRL
001,005,169,387,BIOMARKER,ERG,GLEASON,LABEL,METHODS,OBJECTIVE,ORS,PURPOSE,RESULTS,TMPRSS2,URINE,USING
945,946,AH23848,AKT,COX,DU145,EP2,EP4,EXOGENOUS,L161982,LNCAP,PC3,RAPAMYCIN,TGF
132,270,369,517,639,AAM,AFRICAN,BACKGROUND,DESPITE,EAM,LABEL,LIMITED,METHODS,PCA,RESULTS
226,420,945,946,BACKGROUND,BCMO1,CONSORTIUM,DIETARY,INSTITUTE,LABEL,METHODS,NEITHER,RESULTS,SNP
AIM,CONCLUSION,FATIGUE,LABEL,METHODS,OBJECTIVE,PROTHER,RESULTS,TEXAS,UNIVERSITY
925,BACKGROUND,C30,CONCLUSION,CONTINENCE,EORTC,FUNCTIONAL,INTERVIEW,LABEL,MATERIALS,METHODS,QLQ,QOL,RADICAL,RESULTS,ROBOT
CONCLUSION,DU145,HENCE,LABEL,METHODS,MTT,NAC,OBJECTIVE,PC3,RESULTS
768,COX,GAZEL,HOSTILITY,HOWEVER,JANUARY,LABEL,LARGE,METHODS,OBJECTIVE,RESULTS,SEVERAL,THESE
209,410,BACKGROUND,COLORECTAL,LABEL,LEUKOCYTE,METHODS,ORS,OVARIAN,RCC,RESULTS,SCREENING,THERE,TRIAL
945,947,AKT,BINDING,MOLECULAR,VITAMIN
130,169,236,446,495,598,AMONG,BMI,CLEAR,COLORECTAL,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBESITY,OBJECTIVE,OVARIAN,RESULTS,SCREENING,SOCIETY,TRIAL
ERG,ETS,TMPRSS2
001,177,999,BRONJ,CONCLUSION,HOWEVER,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,WITHOUT
001,042,048,070,207,231,492,AMICO,EPLND,GLEASON,IQR,LABEL,METHODS,OBJECTIVE,PATIENT,PSA,PURPOSE,RALPS,RESULTS,ROBOTIC,SPLND,THERE
125,186,428,AUC,CONCLUSION,CONDUCTING,CYTOMETRIC,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SIMILARLY,WHILE
III,IMIDS,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
223,700,DENOSUMAB,DOCETAXEL,EARLY,FURTHER,III,LABEL,OBJECTIVE,OTHER,PURPOSE,RESULTS,SUMMARY,TAK
BACKGROUND,BECAUSE,CONCLUSION,DU145,LABEL,PC3,RESULTS,RGD,RGE
HOWEVER,MDP
000,007,040,150,169,894,946,AGE,BETWEEN,CONCLUSION,COPYRIGHT,DRE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,SERUM
169,250,956,BACKGROUND,COPYRIGHT,CSF,DCS,GRADE,INC,LABEL,METHODS,OVERALL,PRIOR,PSA,RESULTS,TH1
100,125,150,169,200,COPYRIGHT,D90,GREATER,INC,MEDICAL,PUBLISHED,USING,V20,V50
ADVERSE,C30,CONCLUSION,EORTC,HOWEVER,LABEL,METHODS,OBJECTIVE,PATIENT,PHYSICIANS,QLQ,QOL,RESULTS,THERE
132,180,BACKGROUND,CONTINENCE,INDEX,LABEL,LRP,METHODS,OBJECTIVE,PURPOSE,RESULTS,URINARY
398,BACKGROUND,CENTRAL,EARLY,HOWEVER,LABEL,MEDLINE,METHODS,RANDOMIZED,RESULTS,THERE
145,200,951,956,BOC,EMBRYONIC,ESI,HOWEVER,ICP,MALDI,MCF,NMR,TOF,UNDER
184,GAUCHER,GD1,HOWEVER,PATIENT,PMR
INTRINSIC,MTDNA,PCR,ROS
250,956,BCAS1,MYC,PCR,ROC,SEQUENCES,THESE,UCF
COI,FUNCTIONAL,THESE

001,BACKGROUND,BASED,CONCLUSION,LABEL,LNI,LNS,METHODS,OVERALL,PCA,RESULTS
794,BACKGROUND,HOWEVER,HRS,LABEL,METHODS,OVERALL,RESULTS,RFS
515,613,918,BACKGROUND,BMI,JANUARY,LABEL,MATERIALS,METHODS,PCA,RESULTS,SHR,SWEDISH
000,317,677CC,B12,BACKGROUND,CONCLUSION,JANUS,LABEL,METHODS,MMA,MTHFR,RESULTS,USING,VITAMIN
CURRENTLY,FINALLY,LNCAP,MARKERS,OR1D2,PSA
ADT,HOWEVER,III,STRATEGIES,THESE,ZOLEDRONIC
001,005,676,BACKGROUND,BARRETT,FURTHER,GOALS,LABEL,MALIGNANCY,METHODS,OBJECTIVE,RESULTS,SEVERAL
17AAG,946,AKT,CONSISTENT,GSK,HDAC6,HDACS,HOWEVER
103,169,AFTER,CONCLUSION,COPYRIGHT,DISCUSSION,FORUM,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,RCT,RESULTS,WEBCHOICE
103,169,239,6CC,AEU,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,PIN,PSA,PUBLISHED,RESULTS,RTU,T1A,THERE,THESE
000,169,200,203,216,450,494,ALZHEIMER,AMERICA,AMERICANS,BETWEEN,COPYRIGHT,INC,PUBLISHED,THESE,THROUGHOUT,TODAY,TOTAL
169,BACKGROUND,COPYRIGHT,DOCETAXEL,III,INC,LABEL,METHODS,PHASE,READY,RESULTS,SYNERGY
169,275,831,AFRICAN,AMONG,ANY,CHI,COLON,COPYRIGHT,CORPORATE,COX,HEALTHCARE,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,OVARIAN,PSA,REGULAR,RESULTS,SCREENING,SEPTEMBER,TRIAL,VHA,WAREHOUSE
169,COPYRIGHT,DESPITE,HOWEVER,KREBS,LTD,PUBLISHED,SLC30,SLC39
169,361,972,BACKGROUND,COPYRIGHT,COX,LABEL,LARGE,MEDICAL,METHODS,OBJECTIVE,OUTCOME,PCA,PCM,PUBLISHED,RESULTS,SETTING,THESE,TREATMENT,UNIVARIATE,UROLOGY,USING
169,336,BACKGROUND,BCR,COMPETING,COPYRIGHT,COX,CSM,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,OCM,OUTCOME,PUBLISHED,RESULTS,SETTING,SHORT,TEN,THESE,UROLOGY
141GG,141TT,156,198,APEX1,ASP148GLU,BACKGROUND,BER,CHINESE,HAN,HARDY,HOWEVER,LABEL,METHODS,PCA,PCR,RESULTS
000,169,185,AFP,CONTROL,COPYRIGHT,CRCAS,ELISA,MWCNT,PSA,THERE,VCH,WILEY
003,169,744,BACKGROUND,COPYRIGHT,CUMULATIVE,GLEASON,GROUP,LABEL,MEIER,METHODS,OTHER,PHOENIX,PSA,RADIATION,RESULTS,SHORT,SOCIETY,THERAPY,UNIVARIATE
250,BASED,METHODS,MOLECULAR,MRI,PET,SPECT
001,559,563,BACKGROUND,CHINA,LABEL,METHODS,PSA,PSM,RESULTS,RRP,THEREFORE
CONCLUSION,INITIAL,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
169,COPYRIGHT,FEW,INC,OTHER,SOCIETY
001,046,169,CIS,ENDOTHELIN,HOWEVER,HRS,PFS,TTP
FALSE,GLEASON,HOWEVER,PSA
CD146,CELLSEARCH,CSF,CSFMC,CTC,EPCAM,HMW,MAA,MRI,TUBES,VERIDEX
134,160,ASIAN,CULTURE,EASTERN,FURTHER,HOWEVER,PSA,SOUTH
COMPOUNDS
981,LABEL,METHODS,NYC,OBJECTIVE,PURPOSE,RESULTS,SES,STAGE,STATE,THERE
125,150,182,241,282,600,778,877,BCRFS,LABEL,METHODS,OBJECTIVE,OVERALL,POTENCY,PSA,PURPOSE,RESULTS
CHILD,ESOPHAGEAL,VATER
441,MULTIDRUG,PSA
100,25D,MIR,PRE,PROSTATIC,SIMILARLY,USING
DUE,OFTEN,PET
169,BASEL,COPYRIGHT,DESPITE,OLDER,RESULTS,TREATMENT,WHILE
160,AZA,CAP,DU145,NAB,PC3,PCR
99A,EXPRESSION,IGF1R,JMJD3,LINC00478,THESE
INCREASING,THEREFORE
169,CNS,COMPOUNDS,COPYRIGHT,SAS,SNB
169,945,946,AKT,COPYRIGHT,DOX,EFIPLADIB,ERK,LNCAP,SILENCING,THESE
169,AGILENT,CALIFORNIA,CLARA,COPYRIGHT,EDUCATION,GENOMIC,HOPKINS,IBARAKI,INC,JAPAN,JOHNS,KU7,KYOTO,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,RIKEN,SANTA,TOKYO,UNIVERSITY,UROLOGICAL,VANCOUVER
CHANCES,CONCLUSION,LABEL,LOW,METHODS,OBJECTIVE,RESULTS,UNLABELLED
169,COA,COPYRIGHT,ERK,INC,INSIG,OXYSTEROLS,PERHAPS,THEREFORE
169,215,330MG,96H,CDR,COPYRIGHT,FOLLOWING,INC,METAL,WESTERN
169,945,946,954,CAP,COPYRIGHT,INC,PTHRP,SINCE,TARGETING,THESE
001,014,020,025,036,169,190,B2M,BECAUSE,COLORECTAL,CONCLUSION,COPYRIGHT,CRC,DUKES,INC,KLK10,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCR,PSA,PUBLISHED,RESULTS,TNM,TOTAL,TUMOURS
169,COPYRIGHT,HOWEVER,LTD
000,169,BACKGROUND,CNS,COLORECTAL,COPYRIGHT,LABEL,LTD,METHODS,OVERALL,RATES,RESULTS,THERE
169,241,454,COPYRIGHT,EARLY,PET
000,150,163,169,200,329,708,894,BACKGROUND,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,QALYS,RESULTS,ROBOT,SERVICE,SETTING,UROLOGY
001,174,ADT,AMICO,AUA,BACKGROUND,CTCAE,CYBERKNIFE,GEORGETOWN,INVENTORY,LABEL,MAY,MEN,METHODS,PHOENIX,PSA,QUALITY,RESULTS,SCORE,SHORT,SYMPTOM,THERE,TOXICITIES,TREATMENT,UNIVERSITY,UROLOGICAL
AUC,BACKGROUND,HISTORICAL,LABEL,METHODS,RESULTS,TOC
FDA
00001,341,374,507,EPE,FURTHER,MANAGER,MEDLINE,PNI,SCIENCE,STUDIES,WEB
044,106,108,177,DISCOMFORT,LABEL,LEAKAGE,METHODS,OBJECTIVE,RESULTS
169,AUTHORS,CIL,CONTACT,JOURNAL,MICROSCOPY,ROYAL,SOCIETY
001,003,109,169,219,328,AALEN,BJU,COX,CUMULATIVE,DENMARK,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SIX
001,169,206,BCR,BJU,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,SRP,SVI,SVS
169,COPYRIGHT,VCH,WILEY
169,CONSENSUS,COPYRIGHT,DCE,LTD,MEETING,MRI,PSA,WILEY
012,177,309,CHRONIC,CONCLUSION,DISEASE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCORE
MRI,PET
00001,005,100,104,117,130,155,192,214,362,DETECTION,FAS,FIELD,GLEASON,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PRE,READERS,RESULTS,SSS
BASED,EARLY,FURTHER,IGF,PCA,WHILE
ESPECIALLY
508,555,613,651,670,681,705,712,736,779,794,818,883,913,933,941,977,982,AFRICAN,AMERICANS,CAUCASIANS,GSTP1,HENCE,HOWEVER,ILE,ILE105VAL,ILE158VAL,PCA,THERE,VAL
1990S,FUKUI,JAPAN,JOINPOINT,LABEL,MAJOR,METHODS,OBJECTIVE,RESULTS,STOMACH
CXR,DECREASED,EP2,EP3,EP4,FINALLY,L798106,LNCAP,TAKEN
169,945,BAF57,CONCLUSION,CRITICALLY,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNF,SWI,THESE
169,LNCAP,MDV3100,PSA,RESISTANCE,THESE
169,ADT,HOWEVER,LNCAP,MDV3100,METASTATIC,PPP2R1A,PPP2R2C,THESE
119,278,DWI,ENGLISH,HOWEVER,LABEL,MAY,METHODS,OBJECTIVE,PURPOSE,RESULTS,STATA,THERE
100,160,DELIVERIES,IPL,MLC
1017858,144,177,BAY,CONCLUSION,LABEL,MBQ,METHODS,PET,RESULTS,RM2,TREATMENT,UNLABELLED
SLN
945,ANDROGENS,DRUGS,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,TREATMENT
AKT,AMONG,BIM,CASEINE,CK2,PML,PROTEIN,SER,THR
169,427,EMT,HSP27,HSPB1,OGX,OVERALL,STAT3,TWIST
093,947,DELETIONS,ERG,FOXO1,FUNCTIONAL,PSA,SNP,USING
004,083,169,568,COPYRIGHT,COX,CSS,HARRELL,INC,JANUARY,LABEL,LND,MATERIALS,MEIER,METHODS,OBJECTIVE,RESULTS
169,946,967,BACKGROUND,BRESLOW,CDH11,COPYRIGHT,E26,ERG,INHBA,INITIAL,KRUSKAL,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PCA,PEARSON,PUBLISHED,RESULTS,SETTING,TMPRSS2,UROLOGY,WHITNEY
160,169,215,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SUSPICIOUS,TESLA,THEIR
169,411,ADT,CONCLUSION,COPYRIGHT,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THROUGH
013,018,023,040,162,169,230,253,433,CONCLUSION,COPYRIGHT,ECE,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PPM,PSA,RESULTS
100,109,169,215,800,BJU,DETECTION,INCREASING,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,USING
120,169,198,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,PRB,RADIATION,RESULTS,SRP
169,231,233,COPYRIGHT,PUBLISHED,SAS,TODAY
100,169,BCR,BJU,COLLEGE,FORTY,JANUARY,LABEL,MAJOR,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PSM,RESULTS,SOCIETY,THERE
169,200,400,699,734,956,BACKGROUND,CHANGES,CONCLUSION,CURRENT,HENCE,LABEL,LTD,METHODS,MIXED,PHASE,PTY,PUBLISHING,RESULTS,SERUM,THESE,UNIVERSITY,WILEY
214,BRAZILIAN,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
945,946,956,EPH,EPHA2,LCA,STRUCTURE,TRP
169,GTPASES,JOURNAL,MICROSCOPY,RHO,ROYAL,SOCIETY
ASIAN,GENISTEIN
945,946,EGL,EGLN1,HIF,THESE,UTR
ADVOCATES,DETECTION,EARLY,GUIDELINES,HOWEVER,PSA,SINCE
AMONG,PSA,THESE
100,11C,123,138,155,18F,783,818,869,946,AIM,CHOLINE,ENGLISH,KNOWLEDGE,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PCA,PET,PSA,RESULTS,REVIEWS,SCHOLAR,WEB
169,491,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,DEPRESSION,DEPRESSIVE,DSM,EMOTIONAL,EPISODE,HOWEVER,LABEL,MAJOR,METHODS,RESULTS,SCALE,SOMATIC,THEREFORE,VALID
169,174,1ST,317,438,4TH,754,967,ACCORDING,AMONG,BACKGROUND,BASEL,BETWEEN,COPYRIGHT,JANUARY,LABEL,METHODS,RESULTS,SOCIETY,VINCI,WHEREAS
169,174,550,BASED,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PLACEMENT,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
169,261,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,LYMPH,MATERIALS,METASTATIC,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL
160,169,COPYRIGHT,EIGHT,IA1,IA2,III,LTD,MALDI,MULTILOCUS,PHYLOGROUP,TOF
000,107,131,169,215,353,410,417,447,464,555,707,BACKGROUND,CONCLUSION,COPYRIGHT,ECO,EUCAN,LABEL,LTD,METHODS,NATIONS,RESULTS,THERE,THESE,UNION
012,046,169,AIM,COLLEGE,CONCLUSION,COPYRIGHT,FORTY,GLEASON,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PHOENIX,PSA,PUBLISHED,RESULTS,ROYAL,THEREFORE
169,177,COPYRIGHT,CRT,FURTHER,INSERTION,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,V70,V80,V90
169,ADT,COPYRIGHT,IRELAND,LTD,PCA
LTR,PSA,PSP
COMPARING
31P,AFTER,AMYLOID,CDC34,CDC53,EXPRESSION,HSP104P,HSP70,SDS,SEC27,USING
472,741,AFTER,INCREASING,NUTRITION,STUDIES,THEREFORE,THESE,THOSE
169,ADT,ANXIETY,ASSESSMENT,AUSTRALIA,COPYRIGHT,DEPRESSION,ENGLISH,FUNCTIONAL,GUIDELINES,LABEL,LTD,METHODS,NPAGA,OBJECTIVE,OBJECTIVES,PCA,QOL,RESULTS,SCALE,THERAPY,THESE,THOSE,WILEY
CURRENTLY,FIRST,HOWEVER,MRI
FURTHER,IMAGING,MRI,PET,REGARDING,WHILE
ADC,AUC,BPH,CONCLUSION,DWI,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
150,180,945,946,IPT,PROGNOSCAN,PSI,RECEPTEUR,RON,RTK,SIX
956,AFTER,AKT,THESE
QUI,WHETHER
686,CONCLUSION,END,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE
AIM,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,RESULTS,T1C,TESLA
008,ADT,AIM,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,TREATMENT
033,134,967,AIM,CONCLUSION,CONDIFENCE,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PSA,RESULTS,T29107A
000,945,946,AIM,ASTRO,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,RESULTS,THESE,THREE
946,A2780,CONSISTENT,ELEMENE,THESE
945,BACKGROUND,CONCLUSION,GF109203X,H2052,H2452,H28,LABEL,MATERIALS,METHODS,MTT,NAFTOPIDIL,NCI,PKC,RESULTS,TUNEL
PC3,ROS,SAG,SEVERAL
AIM,BACKGROUND,BIC,CONCLUSION,DHT,HOWEVER,LABEL,LNCAP,MATERIALS,METHODS,MTT,OBJECTIVE,PCR,POSTN,RESULTS,THROUGH,WHILE
083,116,446,523,630,854,935,971,BACKGROUND,CONCLUSION,COX,END,LABEL,METHODS,RESULTS,THERE
FURTHER,HOWEVER,SUBPATHWAY,VARIOUS
077,199,418,ALZHEIMER,APC,BESIDES,CONCLUSION,DECREASES,END,INCIDENCE,LABEL,METHODS,NLTCS,OBJECTIVE,OBJECTIVES,PARKINSON,RESULTS,USA
212,940,AM251,AM281,AM630,CB1,CB2,INC,PUBLISHED,WIN55
007,034,035,102,125,231,791,AIM,AMONG,ASIATIC,BACKGROUND,ENGLISH,EVERY,HDL,LABEL,LITERATURE,METABOLIC,METHODS,OBJECTIVE,RESULTS,SEPTEMBER
169,BOARD,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,MHZ,OBJECTIVE,RESULTS,TRANSVERSE
169,BKV,CK7,CK903,COPYRIGHT,GLEASON
169,COPYRIGHT,DESPITE,FEDERATION,GEM,PUBLISHED,SOCIETIES

014,215,954,ADC,AREAS,AUC,CONCLUSION,DCE,FIFTY,HIPAA,LABEL,MATERIALS,MEDIANS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
954,AGREEMENT,AMONG,BACKGROUND,CONSENTING,LABEL,METHODS,OBJECTIVE,ONCOLOGIC,PET,RESULTS

000,250,BACKGROUND,COLORECTAL,COMPETING,CURRENT,ERSPC,FORCE,LABEL,METHODS,OBJECTIVE,OVARIAN,POTENTIAL,PREVENTIVE,PSA,RANDOMIZED,RESULTS,SCREENING
145,169,AUTHORS,ECTOPIC,ERG,JOURNAL,MICRORNAS,TMPRSS2
CURRENTLY,THREE
3GALNAC,946,BECAUSE,GAL,TFD,THOMSEN
001,144,BACKGROUND,COX,ERSPC,FINNISH,HRS,LABEL,MEN,METHODS,PCS,PSA,RANDOMIZED,RESULTS,SCREENING,TRIAL
HOWEVER,LINAC,MLC,MUS
BPH,OVERALL
ERG,LABEL,OBJECTIVE,PIM,PURPOSE,RESULTS,SUMMARY,TMPRSS2
LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
125,169,231,233,COPYRIGHT,DIFFERENT,ESTRO,GEC,HOWEVER,MID,PUBLISHED,SAS
BASED,FINALLY,PIN,PROSTATIC,THERE
129,169,177,1NG,203,20MCI,223,239,241,99M,9IU,ALP,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,LABEL,MDP,METHODS,PSA,RESULTS,SERUM,SPECT,THERE,THREE
003,015,125,160,169,COM,COPYRIGHT,CRANIAL,FORTY,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE
100,103,105,125,160,169,200,COPYRIGHT,D90,GROUP,IMPLANT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSI,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,STM,THERAPY
169,ADVANCING,AMICO,BMI,CALIFORNIA,CONCLUSION,COPYRIGHT,COUNSELING,GLEASON,GREATER,IMPROVING,INC,LABEL,MATERIALS,METHODS,OBESE,OBJECTIVE,PSA,RESULTS,TREATMENT,UNIVERSITY
ADT,APA,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,RTH
116,165,207,217,226,228,367,APRIL,BACKGROUND,BETWEEN,CGE,CONCLUSION,EQUIVALENT,LABEL,METHODS,OCTOBER,RESULTS,THREE
171,BACKGROUND,CGE,CONCLUSION,CTCAE,LABEL,LOW,METHODS,MVA,RESULTS,SCORE,SEPTEMBER,SYMPTOM,THERE
125ML,130,ASA,BACKGROUND,BMI,CONCLUSION,FINAL,GFR,GLEASON,HEM,LABEL,MATERIALS,METHODS,MRI,POD,PSA,RENAL,RESULTS,T1C,T2BNX
100,BACKGROUND,CLAVIEN,HRQOL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RALPS,RESULTS,THERE
ADAPP,ANDROGENIC
101,102,103,107,109,112,123,132,133,138,146,152,156,157,167,179,BACKGROUND,CLU,FLICE,GRP78,HOWEVER,HSP27,LABEL,LNCAP,MATERIALS,METHODS,PCR,RESULTS,WESTERN
CD44S,HOWEVER,PC3,THESE
AFTER,AIM,AMACR,EXPRESSION,IHC,LABEL,METHODS,OBJECTIVE,PATCH,RESULTS,TMA
144,169,233,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,LASER,LCMODEL,METHODS,OBJECTIVE,PURPOSE,RAO,RESULTS,WILEY
169,946,ADP,CAP,EMT,INC,NAC,OXIDATIVE,PSO,ROS,THESE,WILEY
008,BUBR1,EGE,GLEASON,IHC,PHF,REDUCED,TAU,THERE,UNIVERSITY
889,920,APPLIED,ASHKENAZI,BIOSYSTEMS,SCREENING
160,BLOOD,CD105,EWING,INHIBITION,NOVEL
003,509,CAPACITOR,CAPACITORS,ERA,INHALATION,INTENSITY,JEM,PCB,USING
MRI
579,CRF,FORMULA,GIVEN,RADIATION
160,3DCRT,DSH,DVH,DVH10,DWH,INC,MRI,MSS,VODCA
001,004,016,024,035,1A1,411,CAUCASIANS,CHINA,CIS,CYTOCHROME,KNOWLEDGE,OVERALL,SCIENCE,SEPTEMBER,SIXTEEN,STRATIFIED,WEB
ABOUT,LABEL,LARGE,MEDLINE,METHODS,MTD,OBJECTIVE,OVERALL,PURPOSE,RESULTS,THESE
1940S
169,947,CD8,COPYRIGHT,CURRENT,DCS,FDA,IFN
169,4NG,5MG,945,946,ADT,ANOVA,BLOOD,COPYRIGHT,DHT,FIFTY,HOWEVER,LTD,PSA,STUDIES
ACUTE,ADVERSE,AFTER,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OVERALL,PHOENIX,PSA,PUBLISHED,PURPOSE,RESULTS,UNIVARIATE
002,169,468,ADT,COPYRIGHT,DSM,GROUP,INC,LABEL,MATERIALS,METHODS,MVA,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERAPY
104,105,106,169,ACHIEVING,COMPARISON,CONCLUSION,COPYRIGHT,D90,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,351,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRE,PUBLISHED,PURPOSE,RESULTS,THREE,UROLOGICAL
169,COPYRIGHT,HOWEVER,INC
169,471,BACKGROUND,COPYRIGHT,COX,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PPC,PREDICTORS,PSA,PUBLISHED,RESULTS,SETTING,THERE,TREATMENT,UROLOGY
001,169,969,ADD,AFTER,AHR,BJU,CONCLUSION,END,GLEASON,KNOWN,LABEL,MEN,METHODS,OBJECTIVE,PENDING,PIVOT,PSA,RESULTS,SUBJECT,T1C,TRIAL,UNLABELLED,WHETHER
945,946,AFM,COL,FURTHER,LNCAP,PC3,PCR,TAKEN,USING
27A,LOH,MCPH1,MUTATIONS,THREE,USING,UTR
ATG,DIFFERENT,ERG,ETS,READING,TMPRSS2,USAGE,UTR
CRE,EVEROLIMUS,FINALLY,TAMOXIFEN,USING
956,CGLIIQKNEC,CONCLUSION,CY5,GFP,KAREC,LABEL,MAESTRO,METHODS,MRI,OBJECTIVE,PC3,PURPOSE,RESULTS,SNR
102,107,CONCLUSION,COX,DESPITE,LABEL,MEIER,METHODS,PET,RESULTS,TREATMENT,UNLABELLED

169,945,C17,CYP17A1
015,177,233,AFTER,BECAUSE,FOURIER,IMPLANTED,POINCAR,THESE
169,299,BPH,COPYRIGHT,CURVE,HOWEVER,INC,NOTABLY,OPERATING,PCA,PCR,PSA,ROC,TMA
945,946,BASED,DESPITE,DVH,GTV,HOWEVER,RBE,VARIATIONS
BACKGROUND,INCIDENCE,LABEL,METHODS,MONITORING,MORTALITY,RESULTS,WHILE
146,169,BJU,COMPOSITE,EXCLUDING,INDEX,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,PSA,RESULTS,SCP

ADT,CAP,ISOLATION,SERUM,SRF,USING
002,004,006,007,008,009,010,012,015,016,020,021,022,027,029,033,039,044,045,125,6MG,AFTER,BMD,CHANGES,CONCLUSION,HCT,IBS,LABEL,MCH,MCV,METHODS,OBJECTIVE,PSA,RBC,RDW,RESULTS,SEPTEMBER,TOTALLY
001,009,132,169,BASED,BJU,COX,GLEASON,LABEL,LOW,MEIER,METHODS,OBJECTIVE,PHOENIX,PSA,RESULTS,THERE,UNLABELLED
178,4N0M0,BASED,CONCLUSION,GLEASON,GROUP,IAD,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SIX
107,128,365,542,725,CONCLUSION,DRE,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS,ROC

BELGIUM,DOCETAXEL,JEVTANA,THREE,UNTIL
ADP,HDACI,HISTONE,LNCAP,MMP,OVERALL,PC3,PNT1A,VAD
ALTOGETHER,PCA
946,ADRIAMYCIN,FINALLY,WHILE,WNT
945,946,CXCR4,DUE,GIVEN,NLS
005,133,967,AMICO,AMONG,ASSESSMENT,CAPRA,CONCLUSION,EPSTEIN,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PPV,PURPOSE,RESULTS
ADDITIONAL,BACKGROUND,CONCLUSION,DENOSUMAB,LABEL,METHODS,RESULTS,USA
100,125,144,169,ADVERSE,BACKGROUND,BASEL,COPYRIGHT,LABEL,METHODS,RESULTS
163,169,AKT,AVP,COPYRIGHT,FGF8B,FGFR3,FIBROBLAST,FUNCTIONAL,HSQAAVP,INC,LLAVPAA,P12
EGF,HOWEVER,LNCAP,OVERALL
169,412,COPYRIGHT,INC,METAL,MTS,PCR,SNP
125,169,1CM,961,COMPOSITE,COPYRIGHT,DOSES,EUS,INC,INDEX,IUS,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,URINARY,V35
002,037,043,116,169,211,AUC,CONVERSELY,COPYRIGHT,EDUCATION,INC,INCLUDING,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PHI,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,AZD3514,COPYRIGHT,LTD,PHASE,REMOVAL
019,026,169,COPYRIGHT,FORTY,IRELAND,LABEL,LTD,METHODS,MRI,OBJECTIVE,PURPOSE,PWI,RESULTS,THERE
004,100,104,111,121,138,168,169,183,956,AFTER,BACKGROUND,COPYRIGHT,FUNDING,IQR,LABEL,LHRHA,LTD,METHODS,MRC,OTHER,PARENTERAL,PATCH,RESULTS
127,169,BACKGROUND,BECAUSE,COMBINING,COPYRIGHT,LABEL,LNS,METHODS,MOLECULAR,NOTABLY,OBJECTIVE,OUTCOME,PCA,PCR,PSA,PUBLISHED,RESULTS,SETTING,THESE,TOPOGRAPHY,UROLOGY
169,272,347,BACKGROUND,COPYRIGHT,GROUP,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,STUDIES,SWEDISH,SYMPTOM,TRADE,UROLOGY,YET
044,169,171,AFTER,BJU,DECLINE,DUTCH,ERSPC,GPS,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PSA,RANDOMIZED,RESULTS,SCREENING
001,160,169,1990S,976,AST,CHANGES,CONCLUSION,COPYRIGHT,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,USING
169,BMI,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THOSE,USING
169,210,ANGELES,CALIFORNIA,CAP,CONCLUSION,COPYRIGHT,INC,INDEX,LABEL,LOS,LRP,METHODS,NERVE,OBJECTIVE,PCI,QOL,RESULTS,SHORT,THERE,UNIVERSITY
037,046,124,148,160,169,191,196,AFRICAN,AFTER,CALIFORNIA,CONCLUSION,COPYRIGHT,FRANCISCO,GLEASON,INC,LABEL,METHODS,NETWORK,OBJECTIVE,PCA,PSA,RESULTS,SAN,THESE,UNIVERSITY,WHITE
003,008,169,BJU,BRUEL,COPENHAGEN,DENMARK,DRE,G50,GERMANY,JANUARY,KJAER,LABEL,MEDICAL,METHODS,OBJECTIVE,PBX,PRIMA,RESULTS,SIEMENS
169,215,897,974,ADD,AMONG,BJU,CAP,CURRENTLY,EPSTEIN,INDEX,KNOWN,LABEL,LESIONS,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,SUBJECT,THESE,UNLABELLED
169,ADD,BJU,CALIFORNIA,COA,COX,HMG,HOWEVER,KNOWN,LABEL,METHODS,NEITHER,OBJECTIVE,PERMANENTE,PSA,RESULTS,STATINS,SUBJECT,THESE,UNLABELLED
001,169,849,865,ADD,ANY,BJU,DESPITE,INFECTIOUS,KNOWN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATIENT,PRE,RESULTS,SUBJECT,UNIVARIATE,UNLABELLED
001,169,ADD,BASED,BFS,BJU,GLEASON,HOPKINS,III,JOHNS,KNOWN,LABEL,METHODS,OBJECTIVE,PATHOLOGY,PSA,RADICAL,RESULTS,SOCIETY,SUBJECT,UNLABELLED,UROLOGICAL
BACKGROUND,CONCLUSION,LABEL,METHODS,PHYSICIANS
110,192,ACCORDING,CARLO,COMMISSION,FINALLY,GIVEN,HDR,HOWEVER,LABEL,METHODS,MONTE,OBJECTIVE,POINT,PROTECTION,PURPOSE,RESULTS,THESE
LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SPATIAL
100,CARLO,D10,D90,DVH,ISA,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS
CRT,DESPITE,HOWEVER,LABEL,METHODS,OBJECTIVE,POISSON,PURPOSE,RADIATION,RESULTS
BIOLOGICAL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESIDUALS,RESULTS
DESPITE,ECLIPSE,INC,LABEL,LAPLACIAN,MATHWORKS,MEDICAL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SYSTEMS
LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIMULATED,SIMULATION
LABEL,METHODS,MLC,OBJECTIVE,PTV,PURPOSE,RESULTS,THESE
169,198,303,568,AMICO,ANZ,AUTHORS,AVERAGE,BACKGROUND,COLLEGE,CONCLUSION,JOURNAL,LABEL,LIKELIHOOD,METHODS,MRI,RESULTS,ROYAL,SURGERY,THEREFORE
169,556,804,BACKGROUND,CONCLUSION,FOUNDATION,FOV,LABEL,LIMITED,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SIMILARLY
000,400,BACKGROUND,CONTEXT,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PTH,RESULTS,SETTING,THESE,TORONTO,VITAMIN
136,137,171,873,949,BACKGROUND,COX,FURTHER,GERMANY,HOWEVER,HRS,LABEL,LOW,METHODS,OVERALL,RESULTS,SEVERAL
169,COPYRIGHT,ECTOPIC,INC
18F,DWI,HOWEVER,IMAGE,LABEL,MARCH,MATERIALS,METHODS,MRI,OBJECTIVE,OCTOBER,PET,PURPOSE,RESULTS
169,AGING,COPYRIGHT,HOWEVER,INC,RUNNING,WESTERN
640,BACKGROUND,BPH,LABEL,MARKERS,MATERIALS,METHODS,PCA,PSA,RESULTS,SUB
129,452,ACADEMY,ERG,HGPIN,HOWEVER,MARCH,MEETING,PATHOLOGY,TMA,TMPRSS2
FPC,NORTH,REGISTRIES,SPC
001,002,015,034,160,169,ADT,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PURPOSE,RESULTS
169,AKT,CAFFEIC,COPYRIGHT,HOWEVER,LTD
169,CARCINOMAS,COPYRIGHT,EMT,EPITHELIAL,IRELAND,LTD,MALIGNANT,TRANSITION
169,232,775,AFTER,BIOPANNING,CAT12,COPYRIGHT,ELISA,FVPTC,IRELAND,LIGANDS,LTD,NPA,PTC,RAPID,SELECTIVE,THERE
167,AVAILABLE,BACKGROUND,CONCLUSION,DENMARK,FUNDING,GLEASON,HOWEVER,IMK,LABEL,METHODS,PSA,RESULTS,TEN,TRIAL
550,ASIAN,COX,STI,WESTERN
AFRICAN,BASED,CHRONIC,CURRENTLY,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SETTING,ULTIMATELY,WILEY
001,049,075,097,113,130,169,BETWEEN,BJU,BMI,HOWEVER,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,THERE

183,657,BACKGROUND,FORTY,GLEASON,HOWEVER,LABEL,MEDLINE,METHODS,MRI,PSA,RESULTS,THERE,THREE
485,559,793,CONCLUSION,FURTHER,GAD,HOWEVER,INSURANCE,LABEL,METHODS,OBJECTIVE,RESULTS,SIR
413,ASSESSMENT,CAPRA,CCP,COMBINING,CONCLUSION,COX,LABEL,METHODS,OBJECTIVE,PURPOSE,RECURRENCE,RESULTS
169,1BB,ODN
152,169,945,BACKGROUND,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,MICRORNAS,PCA,PCR,RESULTS,TGF,UTR,WESTERN,WILEY
045,174,273,818,DOCUMENTED,GERMANY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SIMILAR,SWITCHING,THESE,TREATMENT,TRENANTONE
160,CURRENT,FORCE,PREVENTIVE,PSA,USING
CTC
000,001,MEN,PSA
007,008,009,104,110,BACKGROUND,C677T,ECUADORIAN,GLEASON,LABEL,METHODS,MTHFR,MTR,REGARDING,RESULTS
ADDITIONAL,BACKGROUND,CHINESE,CIS,GLEASON,HOWEVER,LABEL,METHODS,ORS,PCA,PSA,RESULTS
100,121,BACKGROUND,COX,GLEASON,GLUCOSE,LABEL,METHODS,OBESITY,PCA,PSA,RECURRENCE,RESULTS,SERUM,SUM,THOSE
BACKGROUND,ERG,ETS,FURTHER,GLEASON,HOWEVER,LABEL,METHODS,PCA,RESULTS,TMPRSS2
EXTENSIVE,HOWEVER,THREE,USING
212,BACKGROUND,CONCLUSION,GLEASON,HOWEVER,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,RESULTS,SETTING
5MC,BCN,BRESLOW,CMD,DCN,SEVERAL,SSM
107,200,384,AUSTRALIAN,POPULATION
643,697,BPH,CAUCASIANS,GST,GSTM1,GSTT1
GST,INHIBITION,LNCAP,NB7,TRAIL,USING
104,335,DU145,GLEASON,HOWEVER,LNCAP,PC3,PCA,PCR,SCORE,TURNING
946
AKT,GIVEN
100,956,APOPTOSIS,CAT,GPX,HEK293T,HEPG2,MCF,RSV,SOD,TREATMENT,WESTERN
560,APRIL,BACKGROUND,BETWEEN,CONCLUSION,COX,DTX,INCIDENCES,JANUARY,LABEL,METHODS,PSA,RESULTS,THERE
177,945,956,BCL,CONCLUSION,DU145,EGF,EXPRESSION,FBS,LABEL,METHODS,MTT,NED,NSE,OBJECTIVE,PCR,RESULTS,TGF,WESTERN
CONCLUSION,CURRENT,EXTENDING,LABEL,MATERIALS,METHODS,OBJECTIVE,PROLONGED,REGARDING,RESULTS,T1A,TURBT
EWING
AIM,HELICAL
USING
BACKGROUND,FATIGUE,HOWEVER,ISI,JANUARY,KNOWLEDGE,LABEL,MEDLINE,METHODS,PSYCHINFO,RESULTS,SYSTEMATIC,WEB
LABEL,METHODS,OBJECTIVE,PM00104,PURPOSE,RESULTS,THREE
INCREASING,PCA
40S,CONSISTENT,CONVERSELY,COS,JUN,PTOV1,RACK1,THESE
169,COA,COPYRIGHT,FEDERATION,GIVEN,INSTEAD,LNCAP,PUBLISHED,SOCIETIES,SREBP
103,162,325,6EMEWZIWZ,BACKGROUND,FREQUENTLY,HOWEVER,LABEL,LCA,METHODS,OBJECTIVE,RCT,RESULTS,TRIAL,WEB,WEBCHOICE,WEBCITE
032,042,169,965,APMRT,CONCLUSION,COPYRIGHT,HOWEVER,INC,KEBANGSAAN,LABEL,MCS,MEDICAL,METHODS,OBJECTIVE,PCS,PURPOSE,QOL,RESULTS,SHORT,THERE,UKMMC,UNIVERSITI,UNIVERSITY
100,169,COPYRIGHT,INHIBITORS,SAS,STRUCTURE,THERE,VARIATIONS
169,177,222,947,956,BACKGROUND,COPYRIGHT,FDG,FFA,INC,LABEL,MBQ,METHODS,PC3,PCA,PET,RESULTS
169,BACKGROUND,CONCLUSION,COPYRIGHT,DENMARK,EARLY,LABEL,LTD,METHODS,RESULTS
169,945,946,COPYRIGHT,CURRENTLY,LTD,WESTERN
169,BACKGROUND,COPYRIGHT,COUNTRY,DENMARK,DISCUSSION,ICELAND,LABEL,LTD,METHODS,RESULTS
125,169,177,ADVERSE,COPYRIGHT,CROWN,GRADE,INC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PEG,PUBLISHED,PURPOSE,RESULTS,RV100,THERE,TOXICITIES
160,169,177,194,651,AFTER,ANY,COPYRIGHT,CTS,D90,FORTY,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,USING
001,006,011,015,045,100,169,193,901,COPYRIGHT,INC,INPATIENT,LABEL,MATERIALS,METHODS,NATIONWIDE,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,RPS
001,169,276,533,603,AFTER,BMI,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THESE
001,169,272,BASED,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS,SCALE,SEEMINGLY,VARIATIONS
008,169,A1C,ADT,AFFAIRS,BACKGROUND,COPYRIGHT,COX,DEPARTMENT,FEW,HBA1C,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,STUDENT
169,517,AMICO,BACKGROUND,BCR,CONTEXT,COPYRIGHT,DIAGNOSTIC,GLEASON,LABEL,LIMITED,METHODS,OBJECTIVE,PCA,PUBLISHED,REASONS,RESULTS,SEPTEMBER,SEVENTEEN,STUDIES,SYNTHESIS,TREATMENT,UROLOGY
HOWEVER,INC,PUBLISHED
169,BCL,COPYRIGHT,EXHIBIT,JACARIC,LNCAP,PLANT,PUBCHEM,THESE,THREE
107,160,169,280,ADT,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SECONDARY,TREATMENT,TTP
LABEL,METHODS,OBJECTIVE,OED,ORGAN,PURPOSE,RESULTS,RPLGD
169,194,451,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,PATIENT,PERCENT,RESULTS,SMALLER,THESE
001,006,008,169,617,ADD,BJU,KNOWN,LABEL,METHODS,OBJECTIVE,PCA,PREDICTIVE,PSA,REBIOPSIES,RESULTS,SUBJECT,UNLABELLED
112,169,177,200,233,400,BJU,COX,DESPITE,HOWEVER,LABEL,METHODS,OBJECTIVE,RECURRENCE,RESULTS,RRP,THERE,UNLABELLED
100,145,956,BAX,BCL,FOS,GAE,JUN,MMP,PNT1A
BACKGROUND,BRUNN,CONTEXT,GLANDULAR,LABEL,LIBRARY,MALIGNANT,METHODS,OBJECTIVE,SOURCES,WORLD
001,037,500,608,900,ASIAN,BACKGROUND,HOWEVER,LABEL,METHODS,RESULTS,THESE
B3GALT1,EMPLOYING,FURTHER,GOLGI,HOWEVER,LEWIS,LNCAP,PC3,TSA
114,947,CAF,CK8,EPCAM,GLEASON,HS5,NOD,NSG,USING
19A,27A,ABCA1,BASED,CPNE3,LNCAP,MICRORNAS,MODULATION,PCA,PDS5B,PTPRK,RAB13,SCORE,SINCE,SUZ12
169,CD133,CD49F,COPYRIGHT,CYTOMETRY,HOWEVER,SOCIETY
ADDITIONAL,ETS,GIVEN,SAM,SPDEF,TAKEN
ARF,CONVERSELY,ENDOGENOUS,PCA,PSA,TAKEN
946,BRCA1,BRCA2,KALLIKREIN,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE
12194,COSTS,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
ANALYZING,TLR
ASPIRIN,BACKGROUND,COLORECTAL,CONCLUSION,HNC,INSTITUTE,LABEL,METHODS,OVARIAN,REGULAR,RESULTS,SCREENING,TRIAL,USING
BACKGROUND,CONCLUSION,LABEL,LN3,LN4,LNCAP,METHODS,MIC,PC3,RESULTS,THESE
TREATMENT
133,196,1C4D4,AGS,APRIL,BACKGROUND,BETWEEN,EASTERN,GROUP,LABEL,MAY,METHODS,RESULTS
ANOVA,BACKGROUND,BAG,BCL,BIP,BONFERRONI,CELLS,COMPARISON,FUNCTIONAL,GRP78,HSP70,LABEL,METHODS,PCR,RESULTS,WHITNEY
954,APOPTOTIC
169,246,740,763,766,774,809,BJU,DRE,LABEL,METHODS,OBJECTIVE,PSA,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,THERE,WHETHER
208,340,792,800,AMONG,CONSORTIUM,PROJECT,SERVICE,THREE
PCA,THESE,WESTERN
HMGB1,NMR,USING
169,BRITAIN,COPYRIGHT,ERG,GREAT,HOWEVER,IRELAND,LTD,NUCLEOTIDE,PUBLISHED,SOCIETY,THESE,TMPRSS2,WILEY
169,COPYRIGHT,CTC,HOWEVER,PANCREATIC,THERE
169,231,956,COPYRIGHT,DNMT1,LNCAP,LTD,MCF,MDA,MOLECULAR,WILEY
241,270,AGE,AUC,ROC
CCK,CURRENT,GFP,LNCAP,METASTASIS,PGK,TRANSWELL
169,COPYRIGHT,PUBLISHED,SAS
169,238,CONCLUSION,COPYRIGHT,DWS,LABEL,METHODS,MRI,OBJECTIVE,PCA,RESULTS,SAS,SSECE,SSSVI,UNIVERSITY
169,BACKGROUND,CIS,CONCLUSION,COPYRIGHT,CPT,FORTUITOUS,LABEL,MATERIALS,METHODS,OVERALL,PCA,RESULTS,SAS
DOTANOC,NET,PET
100,130,190,620,BACKGROUND,DIGITAL,INDICATORS,LABEL,METHODS,RESULTS,RRP,SANTORINI
00002,005,104,152,169,AGE,BACKGROUND,CONCLUSION,EHS,GLS,IAI,INDEX,INDEXES,ISL,LABEL,METHODS,OBJECTIVE,OUTCOME,PCI,RESULTS,SCORE,SLS,SOCIETY,VAS,WOMEN
AFTER,BASED,CONCLUSION,ILK,LABEL,METHODS,MTT,OBJECTIVE,PCR,RESULTS,TRANSWELL,WESTERN
100,DEGARELIX,FIRST,FLUTAMIDE,OVERALL,PRESCRIRE,PSA,THERE
946,CONSISTENT,DKK,SILENCING,TGF,THESE,WNT
001,160,169,945,ACADEMY,ADT,ANDROLOGY,COX,DHT,FURTHER,GLEASON,GREAT,PSA,SOCIETY,THESE
345,CONCLUSION,IMAGE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PET,RESULTS
001,051,100,DAC,GLEASON,KAROLINSKA,PAC,UNIVERSITY
169,LBD,STRUCTURE
CONCLUSION,DISSECTION,GFP,LABEL,METHODS,OBJECTIVE,RESULTS
160,273,ALIGNMENT,CONCLUSION,DAILY,LABEL,MARGINS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,RSE
AFTER,BACKGROUND,CENTRAL,FACTORS,LABEL,METHODS,NORTH,NOS,OVERALL,REGISTRIES,RESULTS,STAGE,SUMMARY,USING,VARIABLES,VERSION
160,58T,AIF,BAX,BCL,HOWEVER,PLATYCODON,PRE,SPG,THESE
024,026,037,088,095,119,122,323,ADT,JANUARY,LABEL,MEIER,MEN,METHODS,OBJECTIVE,PCA,PRE,PSA,PURPOSE,RESULTS
ACAT1,AFTER,FURTHER,GLEASON,HMGCL,HOWEVER,LNCAP,LUCAP,OXCT1,PCR,TAKEN,UTILIZING,WESTERN
DESPITE,MAJOR,URINE
160,DESPITE,FDA,HOWEVER,IPILIMUMAB,KEY,RESULTS
190,AUSTRALIA,AUSTRALIAN,BACKGROUND,DISCUSSION,DISEASE,ENGAGEMENT,GROUP,LABEL,METHODS,PRIMARY,QOL,QUEENSLAND,SECONDARY,SOUTH,TRIAL,UROGENITAL,WALES,WESTERN,ZEALAND
AREAS,BACKGROUND,COVERED,FDA,III,LABEL,MEDLINE,METHODS,OPINION,OUTSIDE,PHASE,PREVAIL,SINCE
231,BAX,BCL,DU145,JQFFP,MDA,MMP,PNT1A
DIETARY,HOWEVER,TALALAY,THESE
172,200,CONCLUSION,DIGITAL,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS,SERUM,TAMSULOSIN,URINATION
CONCLUSION,LABEL,METHODS,MSP,OBJECTIVE,PCR,RAS,RESULTS
CONCLUSION,INHIBITION,LABEL,METHODS,MTT,OBJECTIVE,PC3,PCR,RESULTS,THREE,WESTERN
CONCLUSION,FOLLOWING,JAMAICA,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,WESTERN
947,ELISA,GCV,HOWEVER,HSV,IFN,RESULTS,THESE,TRAMP
123,BACKGROUND,BECAUSE,BRITISH,ECOLOGICAL,LABEL,MENDELIAN,METHODS,PROTECT,RESULTS,TESTING,TREATMENT,WHITE
106,341,342,ADVERSE,ANY,AUTHORS,BACKGROUND,CANCERLIT,CENTRAL,COLLECTION,COLORECTAL,CONTROLLED,DRE,EED,ERSPC,HARMS,LABEL,LOCALISED,MEDLINE,MEN,METHODS,NHS,OBJECTIVE,OBJECTIVES,OVARIAN,PSA,RANDOMIZED,RESULTS,SCREENING,SELECTION,TRIAL,UPDATED
PRIOR,THESE
169,945,946,CONSISTENT,EXOGENOUS,FGF,FGF19,FGF21,FGF23,KLB,THERE,THESE
169,296,METASTATIC,NUMBL
003,131,ADDITIONAL,APRIL,AUC,CONCLUSION,CONFIDENCE,DCE,HIPAA,JANUARY,LABEL,MATERIALS,MCNEMAR,METHODS,OBJECTIVE,PURPOSE,RESULTS,SVI
177,AVERAGE,CONCLUSION,GLEASON,HIPAA,IMMEDIATE,INVENTORY,LABEL,LESIONS,MATERIALS,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCORE,SYMPTOM,TREATMENT
000,100,226,334,490,AGE,ARACAJU,CONCLUSION,JOINPOINT,LABEL,METHODS,MORTALITY,OBJECTIVE,PROGRAM,PSA,RATES,REGRESSION,RESULTS,SERGIPE,THERE

140,164,169,BACKGROUND,BASED,CAUCASIAN,CAUCASIANS,COPYRIGHT,ELEMENT,EXPRESSION,GENOMIC,HEPATITIS,HOWEVER,IFN,INTERFERON,LABEL,METHODS,MXA,MYXOVIRUS,PGA,RESULTS,SNP,STIMULATED
002,036,146,169,183,CD138,ISS,LTD,NOTABLY,STAGING,WILEY
169,946,963,COPYRIGHT,INC,LEP,PANCREATIC,PATHOLOGY,PUBLISHED,S100P,SOCIETY,THESE
DIAGNOSIS,DIAGNOSTIC,DWI,MRI,PET,PSA,WHOLE
100,COLON,DLBCL,NERVOUS
945,954,AKT,ALPHA,BACKGROUND,BCL,CONCLUSION,CONSISTENT,HOWEVER,LABEL,NUCLEAR,PRINCIPAL,RESULTS,TNF
945,BACKGROUND,CASODEX,HOWEVER,LABEL,LNCAP,PRINCIPAL,RESULTS,SINCE
169,ATP,COPYRIGHT,NOTABLY,PC3,PIM,THESE,VCH,WILEY
169,945,956,AHR,COPYRIGHT,FRUPICA,INC,MCF,RESIDUE,SCALA,STEWARD,WILEY
169,956,ARS,COPYRIGHT,FURTHER,HOWEVER,MDV3100,T877A,UNRAVELING,VCH,W741C,WILEY
100,169,177,181,325,956,COPYRIGHT,EPILOBIUM,HOWEVER,LNCAP,LTD,PSA,RESULTS,UROLITHIN,WILEY
123,153,169,3DCRT,BACKGROUND,CHANGES,CLINICALLY,COPYRIGHT,LABEL,METHODS,PBT,QOL,RESULTS,SOCIETY
BAX,MTT,PCR,TUNEL
000,100,BACKGROUND,BARRETT,DISCUSSION,LABEL
213,229,500,524,LABEL,METHODS,OBJECTIVE,PFS,PHASE,PURPOSE,RESULTS,THERAPY,THERE
006,046,22RV1,895,AFTER,AMONG,DES,HSBP1,HSPB1,OAT,PCR
CONVERSELY,E74,ETS,EXOGENOUS,LNCAP,TAKEN
945,IGF,IGFBP,NLS,NUCLEAR,PSORT,TAKEN,THESE,VIA
169,COPYRIGHT,HPV,IRELAND,LTD,P53
001,KDM4B
INCREASED,LIVIN
945,946,ATP,DAUNOMYCIN,DUN,KNOCKDOWN,MULTIDRUG,OPN,RGD,THESE

946,AKT,CONCURRENT,ERK,OVERALL,RAS,SPRY2
116,169,AMONG,COPYRIGHT,SEQ,TNFSF10
169,2B4,945,947,ALLOFERON,COPYRIGHT,HOWEVER,IFN,TNF
012,169,863,BCR,CONCLUSION,COPYRIGHT,COX,GLEASON,GLS,INC,INCLUDING,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SMS,STAGE
169,823,956,BGC,COPYRIGHT,LTD,MCF,MTT,PC3,SAR
169,956,COPYRIGHT,LTD,MCF,SAR
169,945,946,COPYRIGHT,LTD,MCF,SIX,SRB,THEIR
144,160,169,268,827,AMERICA,AMONG,CONCLUSION,COPYRIGHT,DRE,HGPCA,HGPIN,INC,LABEL,LGPCA,MEN,METHODS,NORTH,OBJECTIVE,PBX,PCA,PSA,RESULTS,VARIABLES
127,148,160,169,772,828,856,AFTER,AUASS,BASED,BMI,CONCLUSION,COPYRIGHT,HOWEVER,INC,INCREASED,LABEL,METHODS,OBJECTIVE,RESULTS,SCORE,SYMPTOM,UROLOGICAL
169,178,946,ADV,BMA,CMV,COMBINING,COPYRIGHT,FURTHER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PR1,RESULTS,TSU
169,COPYRIGHT,III,INC,LABEL,MATERIALS,METASTATIC,METHODS,OBJECTIVE,OBJECTIVES,PHASE,RESULTS,SRE,THERE
169,5MG,5MO,BACKGROUND,COPYRIGHT,CTC,DOCETAXEL,ERCC1,GRADE,INC,LABEL,METHODS,RESULTS
169,ADA,COPYRIGHT,GLEASON,NPP,PCA,PLATELETS,SAS
D2B,DESPITE,DUE,EARLY,LTD,PUBLISHED
000,169,571,ADT,BACKGROUND,COPYRIGHT,COX,HRS,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,PUBLISHED,RESULTS,SETTING,UROLOGY
100,177,400,500,COCL2,CONCLUSION,CUSO4,HDR,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVEN,THREE
GPU,PUBLISHED
100,112,169,177,ADT,INDEX,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PCA,RADICAL,RESULTS,SOCIETY,THREE
100,BACKGROUND,DRE,LABEL,MATERIALS,METHODS,PREVENTION,PSA,RESULTS,TRIAL,USING
BACKGROUND,COLLECTED,INCIDENTAL,LABEL,MATERIALS,METHODS,RESULTS
BACKGROUND,CONCLUSION,EPS,ERG,FIRST,GAPDH,GIVEN,LABEL,MATERIALS,METHODS,PCR,PSA,RESULTS,REVERSE,TMPRSS2
BASED,POLYAMINES,UNDER
001,169,544,572,607,613,638,ASIAN,BJU,BMI,HOWEVER,JANUARY,LABEL,MAY,METHODS,OBJECTIVE,PSA,RESULTS,UNLABELLED
116,2ME,ABZ,AMONG,BACKGROUND,CONSISTENT,DU145,EXPLORING,FINALLY,HCT,LABEL,METHODS,RESULTS
100,183,945,LNCAP
FOLLOWING,GASTRIN,HOT,PEPTIDE,PET,RELEASING,SPECT,TOMOGRAPHY,USA
145,MCF,NMR
945,ALZHEIMER,DESPITE,DHT,DUE,THERE
APO2L,DR5,HOWEVER,SIMILARLY,THESE,TRAIL,USING
AFRICAN,BLACK,CERED,FLORIDA,IDM,TAMPA
DEGARELIX,FSH
BLE,CHV,FURTHER,PIPER,PLANT,THESE
CADMIUM,FURTHER,ROS,WHETHER,WHILE,XPA
CUMULATIVE,FDG,PET
177,932,CONCLUSION,IBD,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OLDER,PATIENT,POUCHITIS,RESULTS,THERE
169,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,DLS,LABEL,METHODS,MTD,PARTIAL,RESULTS,S60,S70,S80,V60,V80
13C,179,185,945,DHT,SRD5A,THESE
000,500,CALYPSO,IGRTS,RADIATION
169,177,700,COPYRIGHT,LTD,MRI,RESULTS,SDM,SEVERAL
000,116,169,310,420,579,932,CONCLUSION,COPYRIGHT,END,INC,LABEL,LIVER,METHODS,OBJECTIVE,RESULTS
154,169,BACKGROUND,CAP,CCK,CCND2,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED
AKT,CONVERSELY,GATA3,PIK3C2A,REMARKABLY
001,004,132,169,250,999,AEU,AMICO,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,SPANISH,THERE
001,169,183,842,ADT,AMONG,BACKGROUND,COPYRIGHT,COX,END,LABEL,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,UROLOGY
239,246,283,465,556,AMONG,BACKGROUND,CONCLUSION,LABEL,MAY,METHODS,PCA,RESULTS,THERE,TREATMENT
AFTER,CD8,DC6,DCS,DENDRITIC,ECD,FDA,HOWEVER,III,SIGNS,TAKEN,USING
147,616,AIM,LABEL,METHODS,MRI,OBJECTIVE,PCA,PPV,PRIAS,RESULTS
100,140,177,208,268,273,BACKGROUND,DIAGNOSTIC,JANUARY,LABEL,MARCH,METHODS,NPV,PCA,PPV,PSA,RESULTS,T1C
120,1ST,BACKGROUND,FINALLY,FOLLOWING,GLEASON,LABEL,METHODS,PCA,PSA,RESULTS,ROBOTIC,SINCE,SURGERY,THEREFORE,TURKISH,VINCI
FDG,GLEASON,PCA,PET,PSA
STEPHEN
002,100,125,139,149,177,205,215,239,300,500,515,526,800,ADC,CONCLUSION,KNOWLEDGE,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,T2W
946,OVERALL,WHILE
CASODEX,ETS,MOLECULAR
ERG,ETS,EXPRESSION,FINALLY,PCA,TMPRSS2
LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THEREFORE
267,885,ADDITIONAL,BELGIAN,COSTS,DISEASE,ICD,IMS,INCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RELATED,RESULTS,SRE,VERSION
001,144,202,332,375,797,803,AUC,BACKGROUND,COLORECTAL,COX,LABEL,M2012,METHODS,OVARIAN,RESULTS,SCREENING,TRIAL
BETULINIC,DUB,HOWEVER,INHIBITION,OVERALL,TRAMP,UPS
001,003,007,200,582,715,945,ARG,COX,DFS,HIF,HOWEVER,PDC,THESE
181,946,DU145,ELISA,HOWEVER,MMP,PD98059,THESE,WHEREAS
1NM,447,AMONG,BRIEFLY,DASATINIB,ESPECIALLY,EXPLOITING,FINALLY,PDB,UNIPROT
169,ARPCA,BRITAIN,CAM,COPYRIGHT,DHT,FGF,FGF8B,FIBROBLAST,GREAT,IRELAND,LNCAP,LTD,NH2,PUBLISHED,SOCIETY,THESE,TRAMP,WILEY
169,945,946,BACKGROUND,COPYRIGHT,DHT,INC,LABEL,LNCAP,MEC,METHODS,RESULTS,TCM,WILEY
ASAH1,FINALLY,THESE,USING
006,015,049,379,3N0,COX,HOWEVER,LABEL,MARTINGALE,METHODS,OBJECTIVE,RESULTS
PREDICTIVE,THESE
005,016,212,274,302,674,HOWEVER,PCR,VNTRS
EFFECTIVE,HOWEVER,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE
HOWEVER,LABEL,MRI,OBJECTIVE,PET,PURPOSE,RESULTS,SEVERAL,SIMILARLY,SUMMARY,THESE
ANTISENSE,BCL,CELLS,LNCAP
305,BACKGROUND,CONCLUSION,DESPITE,HOWEVER,LABEL,METHODS,PHYSICIANS,PSA,RESULTS,SWEDISH
169,947,CD11B,HLA,HOWEVER,INTERFERON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRE,RESULTS,UROLOGICAL,USA
169,945,ABOVE,BASED,COPYRIGHT,FIRST,FURTHER,GFP,LTD,PIGEONPEA,WESTERN,WILEY
169,185,215,ALTOGETHER,BCL,BRITAIN,COPYRIGHT,GREAT,IRELAND,LTD,MCL,PUBLISHED,SOCIETY,THESE,WILEY
160,169,177,178,183,CHI,CONCLUSION,DETECTION,DOPPLER,DWI,GEORG,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PATIENT,PSA,PURPOSE,RESULTS,STUTTGART,T2W
11C,125,18F,AVAILABLE,CEA,FDG,MRI,PET,PSA
101,169,AEU,AFTER,AMONG,BFS,COMMITTEE,CONCLUSION,COPYRIGHT,COX,DESPITE,ETHICAL,LABEL,MEIER,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS
169,530,CARCINOMAS,COPYRIGHT,GLEASON,PCA,TNM,USING
100,160,169,176,500,956,COPYRIGHT,FURTHER,LNCAP,LTD,PC3,PMNPS,R11,THESE
169,774,CALIFORNIA,COPYRIGHT,COX,IRELAND,LTD
001,130,136,150,169,200,311,346,500,AMICO,BJU,GLEASON,LABEL,LNI,LRP,METHODS,OBJECTIVE,PSA,RESULTS,THERE
CONCLUSION,DCE,ENDPOINTS,GOVERNMENT,LABEL,METHODS,MRI,OBJECTIVE,PFS,PUBLISHED,RESULTS,SIMON,SIX,USA
001,034,169,244,BETWEEN,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,UNIVARIATE,UROLOGICAL,USING
100,104,169,BACKGROUND,CONCLUSION,JANUARY,LABEL,METHODS,RESULTS,SHORT,UROLOGICAL
169,700,774,AIM,AUSTRALIA,AUSTRALIAN,HODGKIN,INSTITUTE,LABEL,LIMITED,LTD,METHODS,OBJECTIVE,PTY,PUBLISHING,RESULTS,WELFARE,WILEY
145,BAP31,CALPAIN,CENTRAL,EBENFURAN,FDR,III,INGENUITY,ONOBRYCHIS,PAR,PATHWAY,QQTOF,RAB,THESE,THROUGH,USING,WESTERN
169,BJU,CONTINUED,FSH,PCA
001,1990S,292,AGE,C61,DESPITE,FURTHER,GENERAL,GLEASON,GRO,ICD,INDEX,KINGDOM,REGISTRAR,RER,SOCIO
001,129,160,BASED,BICYCLE,BLOOD,CYCLING,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,UNIVARIATE
BACKGROUND,BAX,CLU,FINALLY,LABEL,LNCAP,METHODS,RAD17,RESULTS
CD11B,CSF1R,ITGAM,MDSCS,TAM,THESE,TIM
169,22RV1,ARS,BIOLOGY,CTE,EXPRESSION,FEDERATION,LNCAP,NON,PCR,PSA,Q640X
007,160,582,AFRICAN,ASIAN,CALIFORNIA,CVD,LABEL,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RESULTS,SURVIVORS
LIMITED
111,123,CUP,FDG,FDOPA,NET,PET,PREVIOUSLY,SPECT,UNION
169,2DE,BPH,HOWEVER,PCA,USING,VCH,WILEY
100,117,118,453,CALIFORNIA,EMR,LABEL,MATERIALS,MEDICAL,METHODS,NATURAL,NLP,OBJECTIVE,PERMANENTE,RESULTS
185,CAP,HOWEVER,LNCAP,TARGETS
BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THESE,UNIVERSITY,VINCENT
002,031,035,105,110,152,240,491,503,801,AFTER,CHINESE,CONCLUSION,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,PCA,RESULTS,THERE
004,006,007,010,177,722,723,741,753,956,GENISTEIN,LNCAP,SOY,WHILE
169,COPYRIGHT,IRELAND,LTD,RADICAL,TAKEN
ADT,AMONG,BCR,FDA,PSA
169,174,466,ASSAY,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,URINARY,UROLOGICAL,WHOLE
169,196,226,485,COPYRIGHT,EDUCATION,EPSTEIN,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,COPYRIGHT,HISTONE,INC
169,236,COPYRIGHT,EDUCATION,FINAL,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATHOLOGY,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,UROLOGICAL
138,169,302,ADVERSE,CHRONIC,COPYRIGHT,EDUCATION,INC,LABEL,LOCAL,MATERIALS,MAY,METHODS,NETWORK,OBJECTIVE,PHOENIX,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS,SOCIETY,UROLOGICAL
169,174,704,ABLATHERM,AMICO,COPYRIGHT,COX,EDUCATION,EVALUATION,GLEASON,HARLACHING,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PHOENIX,PSA,PUBLISHED,PURPOSE,RESULTS,THOSE,UROLOGICAL
001,153,169,208,254,361,ASSESSMENT,BACKGROUND,CAPRA,CONTINENCE,COPYRIGHT,COX,INDEX,LABEL,LOG,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,UROLOGY,YOUNGER
100,125,149GY,161GY,18G,20G,ACUTE,D90,DOSIMETRY,ENDPOINTS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,RV100,SCORE,SMALLER,SYMPTOM,THINSEEDS,URINARY
169,945,ANALOGS,CC214,COMPOUNDS,COPYRIGHT,LTD,PC3
002,11997,169,BACKGROUND,CONTEXT,COPYRIGHT,ELECTRONIC,EXPERTS,KNOWLEDGE,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SATURATION,STUDIES,SYNTHESIS,UROLOGY,WEB
169,COPYRIGHT,FIFTY,INC,INJECTION,INTENSITY,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,REDUCTIONS,RESULTS,THERE,V70
ASPEN,BEATSON,CHIEF,COMPARZ,FRANCESCA,GLASGOW,III,INSTITUTE,JONES,PHASE,PHD,PLUTO,STUDIES,UNIVERSITY
000,009,039,174,300,410,423,44K,739,783,814,875,972,979,ALEXA,AMONG,BACKGROUND,CLUSTER,CTC,DTC,EXPRESSION,FLUOR,LABEL,MICROARRAY,OVATION,PCA,PCR,PEARSON,RESULTS,TEN,USING,WHOLE
BACKGROUND,CONCLUSION,FILIP1L,LABEL,MATERIALS,METHODS,NON,RESULTS,THESE,TREATMENT
FURTHER,MEETING,SCIENTIFIC,SOCIETY
169,COPYRIGHT,FIRST,LTD,SIMULATION,WILEY
001,002,004,010,026,031,043,109,133,169,319,345,555,ACADEMY,AMONG,ANDROLOGY,CHANGES,COMPOSITE,HOWEVER,HRQOL,INDEX,PDE5I,SOCIETY
FURTHER,PXR,RXR
041,129,197,330,367,423,464,CD79A,GISTS,JAPAN,KIT
863,892,AMONG,CIS,GLEASON,LABEL,METHODS,OBJECTIVE,ORS,PCA,PURPOSE,RESULTS,TEA,USA,WASHINGTON
CURRENTLY,EMPIRICAL
INDIVIDUAL
AD5,ADP,HOWEVER,NIS,SPECT,THESE,VIRAL
142,151,152,AIM,BACKGROUND,HEART,HOWEVER,HTX,INCIDENCE,LABEL,METHODS,OBJECTIVE,REGULAR,RESULTS,TEN,WHILE
190,AFTER,EXTENSIVE,PHYSICIANS,PSA,SINCE
001,005,007,158,1990S,223,801,AMONG,DESPITE,HODGKIN,POISSON,THERAPY,USING
FURTHER,HEREDITARY
AMD,BACKGROUND,GIVEN,GROUP,LABEL,METHODS,PIVOT,RESULTS,TRIAL
169,ASN,BINDING,COPYRIGHT,HSA,LTD
GUIDELINES,HOWEVER
169,945,COPYRIGHT,LTD,PCR,TAKEN,TAP,TOCOPHEROL,TOS
169,200,223,322,899,BILATERAL,CAPSURE,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEN,METHODS,NERVE,OBJECTIVE,PCI,PUBLISHED,PURPOSE,RESULTS,STRATEGIC,URINARY,UROLOGICAL
000,169,COPYRIGHT,EARLY,ERG,ETS,INC,PCA,REMARKABLE,SRS,TMPRSS2,WHEREAS
169,193,CAP,COPYRIGHT,COX,INC,JANUARY,KAMAT,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PHOENIX,PSA,RADIATION,RESULTS,SOCIETY,VANCOUVER
169,945,CAP,CONCLUSION,CONVERSELY,COPYRIGHT,EXPRESSION,FORSKOLIN,GEO,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OMNIBUS,PC3,PKA,PRKAR2B,PSA,RESULTS
169,BAX,COPYRIGHT,DQA,FDA,LTD,MCL,MECHANISM,PEG
BESIDES,WESTERN
DSB,ERG,HOWEVER,TMPRSS2
WHILE
ARV,CANONICAL,HOWEVER,LBD,NH2,SINCE
CAP
100,HOWEVER,KENNARD,PCA,PLS,STONE,WHITNEY
106,174,200,283,287,302,363,454,477,481,962,ADDITIONAL,AZA,BACKGROUND,BECAUSE,EXPRESSION,GLEASON,LABEL,LNCAP,METHODS,NANOSTRING,PCR,R1881,RESULTS,THESE,UCR,USING
CTS,CTV,GYE,INTENSITY,LABEL,METHODS,RESULTS,SIB,SIMULATION,UNLABELLED
APOPTOSIS,BACKGROUND,BIRC6,CONCLUSION,GLEASON,IAP,INCREASED,INHIBITORS,LABEL,LNCAP,METHODS,PROTEIN,REDUCTION,RESULTS,WESTERN
104,ADT,LNCAP,MALDI,SWISS,TOF,UNIPROTKB
199,276,295,591,AFTER,BACKGROUND,CIS,CONCLUSION,CONTEXT,COX,HOWEVER,HRS,INSTITUTES,LABEL,METHODS,NIH,OBJECTIVE,OUTCOME,PERSONS,RESULTS,RETIRED,SETTING,YET
251,293,428,453,464,969,ALTERNATE,AMONG,BETWEEN,COX,FEW,HEALTHY,HEI,INDEX,INSTITUTES,NIH
100,169,177,300,956,ANOTHER,CONCLUSION,COPYRIGHT,ENDORECTAL,INC,LABEL,MATERIALS,METHODS,MRE,MRI,OBJECTIVE,PURPOSE,RESULTS,SHEAR,TESLA,WILEY
000,956,CONSISTENT,H3K4ME3,JARID1B,KDM5B,THEREFORE,THESE
169,338,445,BACKGROUND,BECAUSE,COD,COPYRIGHT,CSS,END,FAVORABLE,HOWEVER,LABEL,METHODS,RESULTS,SIX,SOCIETY
169,BASED,BASEL,COPYRIGHT,FURTHER,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,THESE
169,BASEL,CONCLUSION,COPYRIGHT,CYTOLOGIC,HISTOLOGIC,HOPKINS,JOHNS,LABEL,METHODS,OBJECTIVE,PDA,RESULTS,SINCE,THERE
108,112,160,169,215,COPYRIGHT,D90,EVALUATED,HGS,INC,LABEL,MASTERPLAN,MATERIALS,METHODS,NUCLETRON,OAR,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,VEENENDAAL
001,125,169,COPYRIGHT,DOSIMETRIC,INC,INDIVIDUAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE,USPRE
106,169,BACKGROUND,BASEL,COPYRIGHT,LABEL,MATERIALS,METHODS,PCA,PSA,RESULTS
547,BACKGROUND,CIS,FURTHER,GLEASON,HOWEVER,JANUARY,LABEL,MEDLINE,METHODS,RESULTS,RRS
000,048,100,1ST,287,377,384,504,505,JANUARY,THESE
107,841,ABIDJAN,ACCORDING,BURKITT,CANCERS,PATHOLOGY,THEREFORE,WORLD
945,C13,C15,C18,DU145,KEY,THESE,WADSWORTH
APRIL,BETWEEN,CONCLUSION,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,RESULTS
10Q11,22Q13,525,667,CHINESE,CONCLUSION,HAN,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SNP,WESTERN
ABCG2,BESIDES,CD133,CONCLUSION,CSC,DU145,EVENTUALLY,HOECHST,IA8,LABEL,LNCAP,METHODS,NANOG,NSP,OBJECTIVE,PCA,PRL,RESULTS,TSU
DHT,GLEASON
ACCORDING,BACKGROUND,CLOCK,CONCLUSION,GROUP,LABEL,METHODS,RESULTS
169,AIM,BACKGROUND,LABEL,MANNE,MEETING,METHODS,NORTHOUSE,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,VALIDATED
169,BACKGROUND,CONCLUSION,CURRENT,ENGLISH,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SOCIETY,THERE,WHILE
169,ADT,AIM,BACKGROUND,CURRENT,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,TREATMENT,WHERE
169,AIM,BACKGROUND,CONCLUSION,DESPITE,FEW,FOLLOWING,HOWEVER,LABEL,LITERATURE,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY
945,CWR22,DHT,EXPRESSION,LUCIFERASE,THESE,USING,UTR
ABL,ATP,BAX,BCL,CASPASE,CML,DASATINIB,DDP,HEP,MEASURING,MTT,SRC
160,169,183,CONCLUSION,FINALLY,GEORG,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,STRUCTURED,STUTTGART,USING
CONCLUSION,DIAGN,FIFTEEN,GISTS,KIT,LABEL,METHODS,MIETTINEN,NON,OBJECTIVE,PRESENTING,PRIMARY,PURPOSE,RESULTS,SEMIN,SEVEN,SUCCESSFUL
145,CSC,EMT,HOWEVER,MIR,MYC,PCA,THESE
BECAUSE,DUOX1,DUOX2,MAB,NADPH,ROS
FINALLY
255,AUSTRALIA,CONFIDENCE,THESE
169,AKT,COPYRIGHT,HYPOXIA,IMMUNOBLOT,INC,INGENUITY,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PATHWAY,RESULTS
001,030,041,042,169,COPYRIGHT,CROWN,GROUP,INC,INPATIENT,LABEL,LVT,MATERIALS,METHODS,NATIONWIDE,OBJECTIVE,OVERALL,PATIENT,PROJECT,PUBLISHED,RCS,RESULTS,THESE,THRESHOLD
169,COPYRIGHT,IRELAND,LARGE,LTD
DEPLETION,DROSOPHILA,FDA,HIPK2,MED19,USING
169,231,233,COPYRIGHT,PUBLISHED,SAS,TREATMENT
169,954,COPYRIGHT,DR5,HOWEVER,IRELAND,LNCAP,LTD,TRADD,TRAIL
000,100,140,296,314,489,576,737,747,BACKGROUND,BETWEEN,ESTIMATED,FAVOURABLE,LABEL,METHODS,PANCREATIC,POISSON,RESULTS,UNION,USING,WORLD
160,280,956,APIOS,COMPOUNDS,ESI,ISOFLAVONE,LNCAP,MEDIK,NMR,PSA,THEIR
250,400,956,BACKGROUND,CONCLUSION,CSF,LABEL,METHODS,PFS,PSA,RESULTS,TID,TREATMENT
BASED,HOWEVER
127,132,149,174,177,185,217,289,486,ADVERSE,PTV,TPS
CURRENT,IGS,PSA,THESE,WESTERN
095,322,366,661,BECAUSE,COLORECTAL,CONCLUSION,END,LABEL,METHODS,OBJECTIVE,PURPOSE,QUALITY,RESULTS,USING
047,143,164,169,307,AMONG,BACKGROUND,CAP,COPYRIGHT,CRUDE,HOWEVER,LABEL,MET,METHODS,RESULTS,SOCIETY,THERE,USING
122,125,128,153,177,BETWEEN,CONCLUSION,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,TUR
054,059,169,177,256,274,534,AFRICAN,AMERICANS,COPYRIGHT,DESPITE,HOWEVER,OVERALL,WHITE
169,AMONG,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,MEN,METHODS,RANDOMIZED,RESULTS,SOCIETY
001,302,307,911,AUSTRALIA,DIFFERENT,FURTHER,HOWEVER,IMPORTANCE,LABEL,METHODS,OBJECTIVE,OCTOBER,OUTCOME,PSA,RANDOMIZED,RELEVANCE,RESULTS,SECONDARY,SETTING,THOSE
169,945,946,COPYRIGHT,ECM,INC,LUMICAN,MMP,MT1,OVERALL,PCR
9FY,EPR,ERG,ETS,HGPIN,PCA,TAKEN,TMPRSS2,UNTIL
145,177,945,946,CURVE,DU145,FFF,FLATTENING,NYLON
459,541,560,ATP,BACKGROUND,COX,III,LABEL,METHODS,RESULTS,THERE
000,063,100,BACKGROUND,BEHAVIORAL,DRE,INDIVIDUAL,LABEL,MEN,METHODS,MSA,PCS,PSA,RESULTS
1990S,ANN,ARTIFICIAL
000
169,COINCIDENT,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,STATISTICS,UROLOGICAL,USING
155,169,184,COPYRIGHT,EDUCATION,FRACTURES,GOTHENBURG,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,AKT,COPYRIGHT,INC,LNCAP,PCA,THEREFORE,TMPRSS2,WESTERN
AFRICAN,AMERICANS,ASIAN,ETS,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THESE
001,011,018,025,033,17Q21,193,338,48ULTRA,800,945,BACKGROUND,CEP17,CONCERNING,DIEGO,GLEASON,IHC,LABEL,METHODS,PCA,PSA,RESULTS,SAN,TOP2A,USA
001,169,BACKGROUND,CENTRAL,CHINESE,CONCLUSION,CONTROLLED,COPYRIGHT,ELECTRONIC,ENGLISH,HOWEVER,JADAD,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,PERIODICAL,RESULTS,SERVICE,SOURCES,WANFANG
000,106,128,169,351,441,503,AGE,BACKGROUND,COPENHAGEN,COPYRIGHT,COX,DENMARK,HEART,LABEL,METHODS,NRI,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,THESE,UROLOGY
001,138,178,875,BACKGROUND,CONTENT,EFFECTS,EORTC,GROUP,HRQOL,INTER,LABEL,MANAGEMENT,METHODS,OBJECTIVE,OLAVS,RADIATION,RESULTS,SUBJECTIVE,THERAPY,TREATMENT
215,2NG,3N0M0,ARM,BACKGROUND,BCF,BCFFS,CGE,LABEL,METHODS,NADIR,RADIOLOGY,RESULTS,SOCIETY
169,AKT,AUTHORS,BACKGROUND,ECTOPIC,FAK,FOUNDATION,HOWEVER,INCREASED,JOURNAL,KNOCKDOWN,LABEL,MATERIALS,METHODS,PC3,POTENTIAL,PROTEIN,RESULTS,SOCIETY,SRC,STICHTING
BLADDER,CONCLUSION,GROUP,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SHORT,THERE,UISFS,URODYNAMIC
CONCLUSION,LABEL,LOCALIZED,METHODS,MIBCS,OBJECTIVE,PURPOSE,RESULTS,SNP
028,033,320,BACKGROUND,COX,GLEASON,HOWEVER,IGF1R,INSULIN,LABEL,METHODS,PSA,RESULTS
015,019,203,CASTRATION,CURRENT,GENOMIC,GLEASON,HCT,PCR,PSA
215,665,AFRICAN,AMERICANS,B13,BACKGROUND,LABEL,METHODS,RESULTS,TESTING
000,385,500,AGE,BACKGROUND,COLORECTAL,CONCLUSION,GIVEN,LABEL,METABOLITE,METHODS,OVARIAN,RESULTS,SCREENING,TAKEN,USING
913,945
189,349,397,956,AKT,ERK,LPA,PAK,RHO,RKI,ROCK1,ROCK2
169,COPYRIGHT,KINASES,WESTERN
169,COPYRIGHT,FURTHER,IRELAND,LTD,PRATT,SINCE,STEROID,THESE
002,004,007,103,169,213,261,302,COPYRIGHT,EDUCATION,HOWEVER,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
169,AGT,COPYRIGHT,DU145,LTD,STUDIES,THESE
169,COPYRIGHT,ENGRAILED,FEDERATION,PARKINSON,PUBLISHED,SOCIETIES
002,169,ACADEMY,AGA,ANY,BACKGROUND,COPYRIGHT,INC,LABEL,MEDLINE,METHODS,MOSBY,OBJECTIVE,PUBLISHED,RESULTS,THERE
011,160,169,329,ADT,APRIL,BETWEEN,COPYRIGHT,CSS,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEN,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE,XRT
001,006,007,132,169,334,693,COPYRIGHT,COX,ECE,LABEL,LTD,MEANWHILE,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PENDING,RESULTS
118,160,169,492,AFTER,CONCLUSION,COPYRIGHT,EPSTEIN,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIAS,RESULTS,USING
169,176,1MM,2MM,4MM,5MM,6MM,8MM,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,ESTIMATION,IRELAND,LABEL,LTD,MAP,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,POSTERIORI,PURPOSE,RESULTS,SHORT,STOCHASTIC
154,160,169,AMONG,CONCLUSION,COPYRIGHT,DWI,EST,GLEASON,INC,INCREASED,LABEL,METHODS,MRI,NST,OBJECTIVE,RESULTS,SST,TESLA,THESE,UNIVARIATE
174,97H,97L,BACKGROUND,CONCLUSION,HCC,HEPG2,L02,LABEL,LM3,LTQ,RESULTS,SIMILARLY,THESE
QOL,STUDIES,THEREFORE
100,AZA,BACKGROUND,LABEL,LID,LIM,MEC,METHODS,METHYLIGHT,RESULTS,TREATED,ZEB
BACKGROUND,CONCLUSION,EXPRESSION,HAI,HEPATOCYTE,IHC,LABEL,METHODS,PSA,RESULTS
AIM,BACKGROUND,COMBINING,CONCLUSION,DIEGO,DRE,GEN,LABEL,METHODS,OBJECTIVE,OPERATING,PCA,PROBE,PSA,RESULTS,ROC,SAN,USA
001,ABCC4,ATP,BACKGROUND,CONCLUSION,DOCETAXEL,FUNCTIONAL,LABEL,MATERIALS,MATLYLU,METHODS,MK571,MLL,PC3,R3327,RESULTS,SRB
002,AMERICA,AUSTRALIA,B13,CAUCASIANS,EASTERN,FINLAND,LATIN,NORTH,PCA,REDUCTION,SOUTH,WESTERN
056,116,374,522,865,BMI,COX,LABEL,METHODS,OBJECTIVE,RESULTS,SIMILARLY,THERE,THESE
159,830,CNS,END,MPNET,RESULTS,SUBSEQUENT,VARIATION
AAS,ARRIVAL,BACKGROUND,CONCLUSION,DEPARTMENT,III,JANUARY,LABEL,MEDICAL,METHODS,OCTOBER,RESULTS,STAGE,UNIVERSITY
004,008,104,177,961,ADC,AUC,CAD,CONCLUSION,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TOFTS
AKT,BIM,CRC,FIRST,HOWEVER,MODULATION,ROS,SW480,THESE
035,AMONG,AUDIT,BACKGROUND,CONCLUSION,DEVELOPING,DIAGNOSIS,LABEL,METHODS,PRIMARY,RESULTS
015,035,061,081,169,907,BACKGROUND,BASEL,COPYRIGHT,GLEASON,GS3,LABEL,METHODS,PCA,PSA,RESULTS
169,COPYRIGHT,HB1,IRELAND,LTD,MNP,THESE
169,COPYRIGHT,INHIBITORS,ISSUE,LTD,OCTOBER,SPECIAL,STS,SYNTHESIS
169,COPYRIGHT,FGF,INC,KLK15,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCR,PSA,PUBLISHED,RESULTS,SOCIETY,SUBSEQUENT,TOTAL,TRPM8,VARIATION
FIFTEEN,LOV,MED,SOS,TOF
231,300,945,946,ICP,MDA,MRI,OES
561,AZGP1,EIGHT,ERG,FIRST,FUNCTIONAL,NPY
CYTOTOXIC,III,INHIBITING
ATTENDEES,CORRECTING,ERSPC,LABEL,METHODS,OBJECTIVE,RESULTS,SETTING,THESE
141,578,ERSPC,FINLAND,ITALY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RANDOMIZED,RESULTS,SCREENING
169,BACKGROUND,C21,COPYRIGHT,GLEASON,INC,LABEL,METHODS,RESULTS,TREATMENT,WESTERN,WILEY
169,BACKGROUND,CCK,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,PC3,PCR,RESULTS,WESTERN,WILEY
GSEAROT,HOWEVER
169,BACKGROUND,CONCLUSION,COPYRIGHT,FURTHER,INC,JNK,LABEL,METHODS,MOLECULAR,NOVEL,PCR,RESISTANCE,RESULTS,RFS,TAKEN,WILEY
169,22RV1,BACKGROUND,COPYRIGHT,ECTOPIC,FOXO1,HOWEVER,INC,LABEL,METHODS,NH2,NTD,PCA,RESULTS,SRC,WILEY
169,ANIMALS,BACKGROUND,BPH,C57BL,CHRONIC,COPYRIGHT,IHC,INC,LABEL,MAJOR,METHODS,PA2,PROSTATIC,RESULTS,WILEY
HOWEVER,THESE
AFTER,CONCLUSION,DIFFERENT,GTV,LABEL,METHODS,OBJECTIVE,PET,PURPOSE,RESULTS,SHRINKAGE,SUV,THEREFORE
APOPTOSIS,BACKGROUND,BAK,BAX,BCL,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
177,AGE,BACKGROUND,LABEL,MEIER,METHODS,OBJECTIVE,RESULTS,ROC
120,BACKGROUND,FIFTY,GOLGI,GRADE,LABEL,METHODS,NON,OBJECTIVE,PSA,RESULTS,SIXTEEN
177,956,CTC,OEC,UNDER
ANXIETY,BACKGROUND,DIGITAL,DRE,HOWEVER,LABEL,MEN,METHODS,PRIMING,PSA,RESULTS
17B,37A,37B,AMONG,BACKGROUND,CONCLUSION,DU145,EARTH,HALOMONAS,LABEL,MCF,METHODS,OVERALL,RED,RESULTS,SEA,TOTAL
177,271,LABEL,METHODS,OBJECTIVE,PAA,PATIENT,PURPOSE,RESULTS,SHEAR,YOUNG
EXCISED,FURTHER,IMAGING,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
110,177,288,BLADDER,CBCTS,COMBINING,COMPARING,D98,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX,THESE,THREE,USING
119,177,ECLIPSE,GAMMA,IMNRT,INTENSITY,ION,LABEL,METHODS,MONITOR,NEUTRON,OBJECTIVE,PURPOSE,RBE,RESULTS,STATE,THERAPY,THESE,UNIVERSITY,VALIDATION,WAYNE,WHILE
001,120,130,160,177,ASCENSION,HDR,HOWEVER,LABEL,METHODS,MODEL,OBJECTIVE,PURPOSE,RESULTS,TECHNOLOGY
135,DVH,FIRST,KETTERING,LABEL,METHODS,MSKCC,OAR,OBJECTIVE,PCA,PURPOSE,RESULTS,SLOAN,THIRD,TPS
CTV,LABEL,METHODS,OAR,OBJECTIVE,PRV,PTV,PURPOSE,RBE,RESULTS,USING
177,INSIGHT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE,TOOLKIT
147,169,222,374,595,GLEASON,JANUARY,LABEL,LYMPH,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,T1C,T2A,UROLOGICAL
169,CYSTOGRAMS,GREENPLAST,HISTOACRYL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,UROLOGICAL
100,169,487,582,605,639,781,ANZ,AUSTRALIA,AUTHORS,BACKGROUND,BASED,COLLEGE,ESTIMATES,JOURNAL,LABEL,METHODS,QUEENSLAND,RALPS,RESULTS,ROBOT,ROYAL,RRP,SURGERY,THESE,TRANSITION,VINCI,WOMEN
185,460,562,786,956,ADR,EAR,HMR,MCF,NCI,OVCAR,PCO
169,FURTHER,TAKEN,WHILE,WNT7B
109,BACKGROUND,CONTEXT,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS
174,CONCLUSION,CPF,EXCEL,HEMATOLOGY,LABEL,METHODS,OBJECTIVE,RESULTS,STAGE
CYP17A1,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THERE,WHEREAS
LABEL,OBJECTIVE,PURPOSE,RESULTS,STUDIES,SUMMARY,THERE,THESE
ANTISENSE,DESPITE,HSP,HSP27,HSP90,III,LABEL,NEWER,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
DU145,H3K27,H4K20,HOWEVER,MAMMALIAN,USING,YY1
000,206,888,954,CA125,FORTY,LABEL,METHODS,MTD,OBJECTIVE,PSA,PURPOSE,RESULTS
107,108,126,129,162,196,ADULT,BETWEEN,CONCLUSION,EDITION,EPI,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,ONCOLOGIC,PATTERN,RESULTS,SIMILARLY,VERSION

THERE
177,CONCLUSION,CSR,LABEL,MATERIALS,METHODS,MRGBX,OBJECTIVE,OBJECTIVES,RESULTS,SUCCESS
132,160,169,420,AFTER,COMPANY,CONCLUSION,COPYRIGHT,III,JOURNAL,LABEL,LTD,MAINZ,METHODS,OBJECTIVE,PEDIATRIC,PUBLISHED,PURPOSE,RESULTS,RMS,URINARY,UROLOGY
002,160,169,177,215,216,AIM,ASSESSMENT,COLLEGE,COPYRIGHT,FUNCTIONAL,GENERAL,HDR,INDEX,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,QUALITY,RESULTS,ROYAL,THERAPY,THERE,TOI,TRIAL
169,C42,COPYRIGHT,FEDERATION,JMJD2,KDM1A,LNCAP,PC3,PSA,PUBLISHED,RECURRENT,SOCIETIES,TMPRSS2
169,233,AIM,BCG,COLLEGE,CONCLUSION,COPYRIGHT,DWI,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,POLYGONAL,PUBLISHED,RESULTS,ROYAL,TEN,THREE
001,031,032,038,100,100CC,126,148,169,182,205CC,741,935,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PHOENIX,PUBLISHED,PURPOSE,PV100,RADIATION,RESULTS,SCORE,SOCIETY,SYMPTOM,THERE,URINARY
144,174,BACKGROUND,BLADDER,CONCLUSION,LABEL,LITHOCLAST,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SLM,STONE,SWISS,UNDER,WESTERN
143,BACKGROUND,III,LABEL,LNCAP,METASTATIC,METHODS,MICRORNAS,MIR,PCR,RESULTS,THERE,THESE
182,AFTER,FOXF2,INITIALLY,KNOCK,MTSS1,UTR,WESTERN
125,ABC,ABCG2,ATP,EPITHELIAL,FUNCTIONAL,HOECHST
011,110,121,223,581,633,BACKGROUND,BRMET50,EXALT,LABEL,METHODS,RESULTS,USING,VALIDATION
ADP,ANDRO,DU145,SAC,TAXIFOLIN
AMONG,MIA,PEI,SEVEN
434,516,CONCLUSION,COX,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNP,THREE
013,044,086,169,199,502,577,644,678,700,COPYRIGHT,ERG,GLEASON,INDEX,MALDI,MSI,PSA,THESE,TMA,TMPRSS2
COMPOSITE,INDEX,PCI,QOL,QUALITY,THERE,USING
293,330,589,BACKGROUND,BASED,ENDOTHELIN,ENTHUSE,III,LABEL,METHODS,OWING,PFS,PSA,RESULTS,ZIBOTENTAN
001,002,007,AMICO,BACKGROUND,ERG,IHC,LABEL,METHODS,PCA,PSA,RESULTS,SIMILAR,TMPRSS2
001,004,020,1A1,350,992,CAUCASIANS,ILE,ILE462VAL,VAL,WANFANG
DEVELOPERS,PATIENT
181,BACKGROUND,CENTERS,CONCLUSION,CONTROL,DISEASE,FORCE,FUNDING,HORIZON,INSTITUTE,LABEL,LIMITATION,METHODS,OBJECTIVE,OUTCOME,POPULATION,PREVENTION,PREVENTIVE,PRIMARY,PSA,RESULTS,SOURCES,VARYING,WITHOUT
743,ASSESSMENT,EVALUATION,GRADING,LABEL,LIBRARY,METHODS,OBJECTIVE,OCTOBER,PSA,PURPOSE,QUALITY,RCT,RESULTS,SYSTEMATIC,WEB
HOWEVER,ILS,ITERATIVE,MLC,SINOGRAMS
169,COPYRIGHT,GFP,INC,MMP,PC3,PRMT6,TAKEN,TSP
145,169,945,946,948,949,ACTIVATION,COPYRIGHT,GNRHR,IRELAND,JNK,LNCAP,LTD,PKC,PMA,SUSTAINED
100,125,130GY,152,169,170GY,183,3NG,6GY,9GY,COPYRIGHT,D90,FUSED,HOWEVER,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,VOLUMES
100,148,169,4GY,5NG,ACCORDING,APRIL,BED,BETWEEN,COMMITTEE,COPYRIGHT,GLEASON,GROUP,GUIDELINES,HDR,IIB,INC,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PHOENIX,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY,TREATMENT
169,223,COPYRIGHT,HOWEVER,INC,PCA,TGF,THEREFORE
169,COPYRIGHT,HSP90,INC,LBD,LNCAP,MJC13,NTD,PCA,USING
001,011,028,045,169,177,200,AFTER,COX,END,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,UROLOGICAL
10A,145,A221A,BLM,CY5,HPV,MCF,SVR,THESE
169,ADD,BJU,CONCLUSION,FINALLY,HOWEVER,IMAGE,KNOWN,LABEL,METHODS,OBJECTIVE,RESULTS,SUBJECT,SYSTEMS,THEREFORE,UNLABELLED
169,846,ANTIGEN,BIOMETRIC,CARLO,COPYRIGHT,MONTE,PSA,SOCIETY
876,BASED,GLEASON,PRACTICAL,PSA
105,320,ACCORDING,PIN,PSA
CAVEATS
DENOSUMAB,GCT,GIANT,IMAGING,LOCAL,MEDICAL,METASTATIC,MONOSTOTIC,TYPICALLY
169,ACS,ACT,AFFORDABLE,COPYRIGHT,INC,INTERVIEW,PATIENT,PROTECTION,SOCIETY
000,AMERICANS,CALIFORNIA,CONCLUSION,DIEGO,ENERGETICS,HARVARD,HOWEVER,HUTCHINSON,INITIATIVE,INSTITUTE,LABEL,LOUIS,METHODS,NETWORK,NIH,OBJECTIVE,PURPOSE,RESULTS,SAN,SCIENCE,UNIVERSITY,WASHINGTON
001,ESPECIALLY,FAILURE,GLEASON,MYC,PCA,PSA,WESTERN
DIFFERENT,E2F1S,HOWEVER
145,COMPOUNDS,NDRG1,PCA,SCREENING
100,13R,17S,23S,24R,25S,49R,99M,CONCLUSION,FDG,LABEL,MDP,METHODS,MRI,NPV,NSCLC,OBJECTIVE,OBJECTIVES,PET,PPV,RESULTS,SEVENTY
000,001,177,392,539,AFRICAN,MEN,PCA
000,100,116,126,262,CONCLUSION,DCE,DIFFUSION,DW1,DW3,DWI,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,PSA,RESULTS
001,012,141,ALP,BPH,GLEASON,KENDALL,NON,PCA,PCR,PEARSON,PSA,SERUM,THERE,USING
HIP,HISTOLOGY,HOWEVER,INITIAL,MRI,PSA,THERE,THR,THREE,TOTAL
AFTER,BACKGROUND,GLEASON,LABEL,MATERIALS,METHODS,PROSTATES,REPORTS,RESULTS
945,DISCOVERY,FDA
002,003,018,052,BACKGROUND,CONSORTIUM,CYP24A1,DHCR7,INSTITUTE,LABEL,METHODS,NCI,RESULTS,SNP,STUDIES
945,GTP,PCA,RHO,RHOGTPASES,V14
169,215,723,945,AUA,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,MYO3B,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCORE,SEVERAL,SYMPTOM,THESE,UROLOGICAL
169,COPYRIGHT,ISSUE,SECRETOME,SPECIAL,THEREFORE,UPDATED
169,500,946,AFTER,AGA,AOM,APC,ATOH1,BACKGROUND,COLON,CONVERSELY,COPYRIGHT,CRC,DSS,ETS,EXPRESSION,INC,INSTITUTE,LABEL,METHODS,MIN,MYC,OBJECTIVE,PUBLISHED,RESULTS,SAM,SPDEF,SW480
116,145,169,231,956,ACETONE,ASTERACEAE,BACKGROUND,BENTH,COLON,CONCLUSION,COPYRIGHT,HCT,IRELAND,LABEL,LTD,MATERIALS,MCF,MDA,METHODS,MIA,NMR,OVARIAN,RELEVANCE,RESULTS,WST
169,947,COPYRIGHT,DEFECTS,HRS,IRELAND,LTD,MRE11,PERSISTENT,RAD51
169,COPYRIGHT,IRELAND,LTD
169,511,APC,CCND2,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,945,AMACR,COA,COPYRIGHT,COX,FXR,INHIBITORS,LTD,METHYLACYL,OTHER,P504S,PROTEIN,SAR
001,100,169,264,646,942,BACKGROUND,COPYRIGHT,INDEX,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PHI,PSA,PUBLISHED,RESULTS,SETTING,STRATEGIES,UROLOGY
169,628,812,CONCLUSION,COPYRIGHT,CROWN,DETAILS,INC,LABEL,MATERIALS,METHODS,NOMOGRAMS,OBJECTIVE,PUBLISHED,RESULTS,THESE
169,CHANGES,COPYRIGHT,DPPIV,FEDERATION,GLP,PUBLISHED,THEREFORE
100,125,169,225,945,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,LTURP,METHODS,PCA,PFR,PVR,QOL,RESULTS,SCORE,SYMPTOM
169,223,COPYRIGHT,III,INHIBITION,IRELAND,LTD,NOVEL
169,COPYRIGHT,INC
169,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,POK,POKEMON,RESULTS,THEREFORE,WESTERN
134,169,CLAVIEN,CONCLUSION,COPYRIGHT,DISSECTION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
169,AFTER,BECAUSE,COPYRIGHT,DEPENDING,INC,MRI,TESLA
CONCLUSION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,SIPULEUCEL,USING
001,003,005,008,016,024,036,169,329,343,409,945,946,ADT,AFTER,CONCLUSION,COPYRIGHT,IGF,INC,LABEL,LBM,MATERIALS,METHODS,OBJECTIVE,RESULTS,SEX
169,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THESE
008,131,169,ADVERSE,CONCLUSION,COPYRIGHT,GROUP,INC,INVENTORY,LABEL,MATERIALS,MEN,METHODS,MOUNT,OBJECTIVE,RADIATION,RESULTS,SCORE,SINAI,SYMPTOM,THERAPY
001,169,AFTER,CONCLUSION,COPYRIGHT,COX,INC,LABEL,MEIER,METHODS,OBJECTIVE,PNI,RESULTS
127,151,CLAVIEN,CONCLUSION,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SURGEON
001,108,169,200,CLAVIEN,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
100,102,104,169,CALIFORNIA,CONCLUSION,COPYRIGHT,COX,HISPANICS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PERMANENTE,RESULTS,THESE
169,ACR,COLLEGE,COPYRIGHT,IMAGING,INC,MRI,PUBLISHED,RADIOLOGY,THERE,ULTRASOUND
169,AUSTRALIAN,AUTHORS,BACKGROUND,COLLEGE,COMPOSITE,CONCLUSION,HRQOL,IMAGING,INDEX,INDIVIDUAL,JOURNAL,LABEL,MEDICAL,METHODS,PRESCRIBED,RADIATION,RESULTS,ROYAL,THERE,ZEALAND
169,AUSTRALIA,AUSTRALIAN,AUTHORS,BACKGROUND,COLLEGE,CONCLUSION,IMAGING,INDEX,JOURNAL,LABEL,MEDICAL,MEN,METHODS,RADIATION,REGULAR,RESULTS,ROYAL,STUDENT,THERE,WHITNEY,ZEALAND
153SM,154,177,MRI,THEREFORE,VAS
001,003,006,031,124,170,HOWEVER,INVENTORY,MEN,SHORT,SIXTY,URINARY,USING
HOWEVER,LNCAP,M12,PICOGREEN,SEEDING,THESE
999,DESPITE,GERMANY,ITALY,KEY,KINGDOM,LABEL,MAY,MEN,METHODS,OBJECTIVE,RESULTS,RHYME,SPAIN

145,33342,CONCLUSION,LABEL,MTT,OBJECTIVE,PCR,RESULTS,WESTERN
998,BACKGROUND,CONCLUSION,COX,FURTHER,INCLUDING,LABEL,METHODS,MORTALITY,RESULTS,SIMILAR
160,169,183,CONCLUSION,GEORG,HEALTHCARE,INGENIA,LABEL,MATERIALS,METHODS,OBJECTIVE,PHILIPS,PURPOSE,RESULTS,STUTTGART,TESLA,USA
001,067,169,309,544,ADC,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,WILEY
169,BACKGROUND,CONCLUSION,COPYRIGHT,DASATINIB,ELISA,HENCE,IGF,INC,LABEL,METHODS,RESULTS,SRC,WILEY,XENOGRAFT
700,945,ADRENAL,CYP17,III,ONGOING,PSA,TAK
120,177,198,AIM,BACKGROUND,CONCLUSION,GROUP,HOWEVER,INSTITUTES,LABEL,METHODS,NIH,OBJECTIVE,PCA,RESULTS
ERG,GLEASON,HOWEVER,MAPPING,THERE,TMPRSS2
PCA,PCSCS
034,074,181,522,PC3
239,510,BACKGROUND,BOARD,CYBERKNIFE,ECE,FORTY,GEORGETOWN,GRADE,IRB,LABEL,METHODS,PSA,QOL,RADIATION,RESULTS,TRIAL
100,169,AIM,AUTHORS,BACKGROUND,CURRENTLY,DIGESTIVE,ENDOSCOPY,HOWEVER,JAPAN,KOREA,LABEL,METHODS,OBJECTIVE,RESULTS,SOCIETY,STENT
BACKGROUND,LABEL,R1881,RESULTS,SIMILARLY,SP1,THREE
956,AKT,ERK,ITC,NEITHER,PC3
100,169,174,ACUTE,AFTER,BJU,CURRENT,CYBERKNIFE,DESPITE,FEW,GLEASON,III,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,SUNNYVALE,T2A,USA
158,15D,317,630,BACKGROUND,C30,EORTC,HRQOL,LABEL,MANAGEMENT,METASTATIC,METHODS,PALLIATIVE,PCA,QLQ,RESULTS,SEPTEMBER,UUSIMAA
FDA,UNTIL

100,HOWEVER,LOCALLY,PRESCRIRE,SHORTER,THREE,VARIOUS,WHICH
001,AFTER,ASSESSMENT,BLOOD,CONTROL,HDR,PCA,SIXTY,TBARS
006,034,393,459,934,BACKGROUND,BIOMEDICAL,CBM,CHINESE,COLLECTED,CONCLUSION,DATABASES,ELECTRONIC,FOLLOWING,GSTT1,LABEL,METHODS,ORS,OVERALL,RESULTS,SIMILAR,ULTIMATELY
954,ATM,BLADDER,CHINA,GENISTEIN
000,122,145,160,340,696,700,718,914,AFTER,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS
IFN,NKT,STILL
CONCLUSION,FIFTY,GROUP,LABEL,MATERIALS,METHODS,NHT,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,RRP,THERE
169,COPYRIGHT,LTD,WILEY
169,ATP,CD133,CD8,CEA,CERTAIN,COPYRIGHT,CRT,CTL,DOCETAXEL,HMGB1,HOWEVER,ICD,KILLING,MDR,MUC,PSA,THESE
169,COPYRIGHT,HIV,HODGKIN,INCIDENCE,NON,SAHARAN
100,169,DU145,EP1,EP2,EP3,EP4,EPR,HPV10,IHC,INCREASED,LNCAP,PC3,RUNX2,THESE,WESTERN
001,039,169,ACHIEVING,ACUTE,ASTRO,BACKGROUND,BASEL,COPYRIGHT,III,LABEL,METHODS,PHOENIX,PRIMARY,RESULTS,SALVAGE
OPINION
CASODEX,LNCAP,NOTABLY,TELOMERES
169,CD11B,CHEMOKINES,FOXP3,LABEL,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RESULTS,STAT3
169,ALCOHOL,BACKGROUND,BASEL,CAT,COPYRIGHT,GPX,HOWEVER,INCREASING,LABEL,METHODS,RESULTS,SEL15,THESE,THREE,ZEALAND
169,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,IMPROVING,LABEL,RESULTS,STRATIFIED,VARIOUS
160,176,177,952,ART,D95,EVALUATION,HOWEVER,THEREFORE
100,155,218,ADVERSE,BACKGROUND,INSTITUTE,LABEL,METHODS,RESULTS,SCORE,SYMPTOM
100,160,CURRENT,DVH,HDR
160,DMC,GENERALLY,GSI,PLANS,RBE,V95
001,006,019,027,046,266,277,486,521,AUSTRALIA,BACKGROUND,GEOMETRIC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SIXTY,TDI,THERE,THESE,WESTERN
491,BACKGROUND,FUNCTIONAL,HOWEVER,INSTITUTE,LABEL,METHODS,RESULTS,SIMILARLY
NMR
COLOADING,ENTRAPMENT,INSTEAD,SGM,SIM,SOLUBILITY
140,160,199,CASTRATION,CLINICALLY,COPYRIGHT,CURRENTLY,FDA,III,MDV,PREVAIL,PROUS,SCIENCE
141,169,BECAUSE,CONCLUSION,GLEASON,IGM,III,LABEL,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RES,RESULTS,THERE
AMONG,CD105,CELLS,CHRONIC,CWR22RH,FAP,HLA,THESE
169,945,946,COPYRIGHT,EGF,FGF,HOWEVER,INC,INCREASED,STATE,UNIVERSITY,WILEY
205,267,391,838,ALT,AST,ATP,BACKGROUND,BID,FORTY,KX2,LABEL,METHODS,MTD,PHASE,PSA,RESULTS,SRC
10216,630,DEFINIENS,ERG,FURTHER,GERMANY,HOWEVER,IHC,SEVERAL,SLC45A3,STAININGS,TMPRSS2
141,188,258,459,BACKGROUND,CONCLUSION,DCE,INCREASING,LABEL,MEN,METHODS,PREFERENCE,RESULTS,SCREENING,TRADE
001,002,004,035,037,103,125,169,200,218,772,ASIAN,BED,BJU,GLEASON,HAEMATURIA,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
100,382,ASSESSMENT,BACKGROUND,CONCLUSION,FLORIDA,FORTY,INSTITUTE,LABEL,METHODS,PER,RESULTS,THERAPY,THERE,THREE,UFPTI,UNIVARIATE,UNIVERSITY
THEREFORE
132,134,169,396,AMONG,GLEASON,JAPAN,LABEL,METHODS,OBJECTIVE,OCTOBER,RESULTS,TESLA,TOKYO,UROLOGICAL
HOWEVER,SEVERAL
004,169,178,954,ADD,BCR,BJU,COX,ELISA,GLEASON,GREATER,KNOWN,LABEL,MAIER,METHODS,NEITHER,OBJECTIVE,OPG,RANKL,RESULTS,SUBJECT,THERE,UNLABELLED,WHITNEY
945,PC3,TAKEN,USING
001,041,645,ADT,CAG,COX
946,954,956,BPH,GASTRIN,GRP,SHRINKAGE
945,946,FIRST,FUKUTIN,FUNCTIONAL,GTDC2,LARGE,MUTATIONS,PC3,POMGNT1,POMT1,POMT2,SEVERAL,THESE,WARBURG,WWS
169,660,ABL,BACKGROUND,CCG,CONCLUSION,COPYRIGHT,FOLLOWING,HOF,HOWEVER,INC,LABEL,LNCAP,METHODS,RESULTS,SRF,TFS,USING,WILEY
169,BACKGROUND,COPYRIGHT,COS,GOLGI,INC,LABEL,METHODS,PCR,RESULTS,WILEY
169,946,AKT,FAK,FURTHER,INC,LNCAP,LOW,PC3,SMAD2,SMAD3,SRC,TAKEN,TGF,THESE,WILEY
015,12P13,19Q13,464,584,642,BACKGROUND,K530R,LABEL,MATERIALS,METHODS,NEITHER,PERCENTAGE,PSA,REDUCTION,RESULTS,SNP,THESE
169,946,AIIB2,COPYRIGHT,FINALLY,IGF,INC,JUN,TRAMP,WILEY
003,011,013,140,177,1LI,GLEASON,MIB,PROTEIN,PSA,THERE
002,004,013,017,018,019,025,089,116,143,160,276,310,370,567,734,945,946,950,ACUTE,EORTC,LABEL,MATERIALS,METHODS,MINIMUM,OBJECTIVE,PURPOSE,RESULTS
BECAUSE,UPS
128,300,DESPITE,GLEASON,ITALIAN,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RADIATION,RESULTS,THESE,TNM
CONCLUSION,ENGLISH,GIVEN,LABEL,MANAGEMENT,MEDLINE,MEN,METHODS,MINIMALLY,OBJECTIVE,PSA,PURPOSE,RESULTS,SALVAGE,SEPTEMBER,SRP,URINARY
001,003,004,054,CELLSEARCH,CTC,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS
100,169,239,AURKA,CONCURRENT,ERG,HISTOLOGIC,PCA
169,25D,CK2,CYP24A1,FINALLY,INHIBITION,PC3,THESE,VITAMIN
CEACAM1,ECM,INHIBITION,SINCE
947,AKT,CAP,HSP90,MYC,PC3,TARGETING,THESE
153SM,AIM,CONCLUSION,EDTMP,FIFTY,FORTY,LABEL,METHODS,OBJECTIVE,REPORTS,RESULTS
200,945,956,FURTHER,HOWEVER,MCP,NPC,PREVENTION,TNF,TRIAL,VITAMIN
916,945,AD5,CRADS,E1A,E3B,METASTATIC,OPG,RGD,THESE
169,COPYRIGHT,ERG,ETS,HOWEVER,LTD,TMPRSS2
169,215,543,AFRICAN,CONCLUSION,COPYRIGHT,INTENTION,IRELAND,LABEL,LTD,MEN,METHODS,OBJECTIVE,RESULTS,SCREENING,THESE
006,009,029,044,047,065,070,072,103,169,177,ADJUSTMENT,ASSESSMENT,AUC,BACKGROUND,BETWEEN,CHECKLIST,COPYRIGHT,FACTORS,FUNCTIONAL,HRQOL,INFLUENCE,LABEL,MARCH,METHODS,OBJECTIVE,OUTCOME,PRIAS,PUBLISHED,QOL,RESULTS,SEPTEMBER,SETTING,SYMPTOM,THERAPY,UROLOGY
169,AKT,CONCURRENT,COPYRIGHT,GIVEN,OVERALL,PCA
169,538,ADD,BJU,FACTORS,GRADE,III,KNOWN,LABEL,METASTATIC,METHODS,OBJECTIVE,PCA,PHOENIX,PRESERVED,RESULTS,SEPTEMBER,SEVENTY,SUBJECT,THERE,UNLABELLED
002,169,215,639,706,785,894,ADD,BJU,COMMITTEE,EFS,KNOWN,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,SUBJECT,THERE,UNLABELLED
169,AUTHORS,BZT,JPP,KEY,LABEL,LNCAP,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROYAL,SOCIETY,THESE,XTT
126,132,169,199,331,ADD,BJU,KNOWN,LABEL,METHODS,NODAL,OBJECTIVE,RESULTS,RRP,SUBJECT,UNLABELLED
169,493,961,AUTHORS,BCR,BJU,COX,LABEL,METHODS,NETWORK,OBJECTIVE,ORP,OVERALL,PSA,RESULTS,USING
378,APRIL,AUC,BACKGROUND,COMPARING,DEVELOPED,EVALUATED,FLORIDA,HALEY,HGB,IDENTIFIED,III,JAMES,JANUARY,LABEL,METHODS,PBCDR,PPV,PSA,RBC,RESULTS,ROC,TAMPA,THESE,VETERAN
033,141,169,170,294,497,905,ADD,BJU,CONCLUSION,GLEASON,JANUARY,KNOWN,LABEL,LND,METHODS,OBJECTIVE,PROPENSITY,RESULTS,ROBOT,SUBJECT,UNLABELLED
105,169,743,913,AGE,BJU,GLEASON,HOPKINS,JOHNS,LABEL,LRP,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PSA,RADICAL,RALRP,RESULTS
BACKGROUND,BASED,COLORECTAL,CRC,FOCAL,HYPOTHESIS,LABEL,NOVEL,STAGE,UNASSIGNED
AFRICAN,CONSISTENT,HOWEVER
DESPITE,ENGLISH,IDEALLY,PCA,PSA,RESULTS,SEVERAL
DENOSUMAB,DUE,RANKL
169,BRITAIN,COPYRIGHT,EHMT1,GREAT,IRELAND,LOW,LTD,MTS,PUBLISHED,SOCIETY,WILEY
117,169,328,562,644,ADJUSTMENT,CHILDLESS,CIS,COPYRIGHT,ORS
169,182,203,COPYRIGHT,EMT,FINALLY,KNOCK,MET,MICRORNAS,MIR,PC3,SNAI2,STRIKINGLY
169,253,656,COPYRIGHT,GENERAL,HOWEVER,OUTCOME,PREVIOUSLY,STRONGEST,THESE
111,956,SARCOSINE,SINCE
028,033,040,041,044,320,AFTER,BACKGROUND,CCND1,CONCLUSION,COX,GLEASON,LABEL,MEIER,METHODS,PSA,RESULTS
228,AFTER,CD133,CSC,HES,MCF,MDA,NOTCH,ONS,SHH,SNALP,SW480,THESE
002,010,033,043,047,134,AFTER,AMERICANS,CONCLUSION,ESTRADIOL,III,LABEL,METHODS,MEXICAN,NUTRITION,OBJECTIVE,RESULTS,THIRD
DUE,NOS,PRESENTLY
001,064,335,536,BETWEEN,JANUARY,LABEL,METHODS,OBJECTIVE,PSM,RESULTS
DIFFUSE,FCH,FDG,PET,SIMILAR
AKT,MCL,MEK,MTT,OBESITY,OVCAR,USING
00001,258,AFRICAN,AMERICANS,FURTHER,MEN,PDE,THESE
014,045,221,222,COX,GLEASON
145,169,24H,AKT,BASED,CASPASE,COPYRIGHT,ERK,INC,JNK,MAP,ROS
000,169,500,COPYRIGHT,EPIGENETIC,INC,UROLOGICAL
100,169,COPYRIGHT,ERG,GEN,INC,PROBE,SINCE,SUCCESSFUL,TMPRSS2
169,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS,SAS,SCHWANN,SCHWANNOMA
169,535,636,ACCORDING,AMONG,COPYRIGHT,EGGER,ENGLISH,ISI,LABEL,LTD,MEDLINE,METFORMIN,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCIENCE,SRR,WEB
169,956,COPYRIGHT,INC,PP5,USING
183,500,621,969,BACKGROUND,BRITISH,COUNCIL,FOLIC,FOUNDATION,FUNDING,HEART,LABEL,MEDICAL,METHODS,RESULTS,STANDARDS,THERE
001,106,169,194,CONCLUSION,COPYRIGHT,FAS,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OVERALL,RESULTS
169,224,AFRICAN,APRIL,CARIBBEAN,CAUCASIAN,CONCLUSION,COPYRIGHT,COX,GUADELOUPE,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PITRE,PSA,PUBLISHED,RESULTS,SALVAGE,SAS,UNIVERSITY
169,5MM,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,LABEL,METHODS,MRI,NPV,PPV,PSA,RESULTS,SAS,SIXTY
169,ASSESSMENT,CONCLUSION,COPYRIGHT,HDL,LABEL,LDL,MATERIALS,METHODS,MODEL,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SAS
001,169,571,655,946,ASA,BACKGROUND,BLOCKER,COPYRIGHT,COX,EXCLUSION,GLEASON,LABEL,METHODS,NORWEGIAN,OBJECTIVE,OUTCOME,PCA,PEARSON,PUBLISHED,RESULTS,SETTING,STUDENT,UROLOGY,WHITNEY
231,BACKGROUND,CHANGES,CYTOSTATIC,LABEL,LNCAP,MDA,METHODS,RESULTS,U87MG
001,002,004,169,200,202,204,406,ADD,AMICO,BETWEEN,BJU,CLAVIEN,KNOWN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SUBJECT,THERE,UNLABELLED,UROLOGY,WHILE
170,241,740,COMPOUNDS,CURRENTLY,HERIN,HOWEVER
001,002,008,120,169,175,ADT,BJU,FEW,LABEL,METHODS,MODEL,OBJECTIVE,OBJECTIVES,RESULTS,THESE
169,ADD,ADT,BJU,CONCLUSION,DENOSUMAB,DESPITE,GABAPENTIN,GIVEN,KNOWN,LABEL,METFORMIN,METHODS,OBJECTIVE,PRESENT,RESULTS,SUBJECT,THERE,TOREMIFENE,UNLABELLED
160,169,AUTHORS,DECORIN,IGF,JOURNAL
169,174,ADD,BJU,DEFENSE,DEPARTMENT,GLEASON,KNOWN,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SUBJECT,THESE,UNLABELLED
131,946,BLM,QUALITY
001,012,169,812,APRIL,BJU,CONCLUSION,GLEASON,GS6,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,T1C
169,238,ADD,BJU,COX,GLEASON,KNOWN,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,SIMILARLY,SUBJECT,UNLABELLED
169,BLACKWELL,FOCUSED,LTD,PUBLISHING,THESE
180,620,CYTOTOXIC,EHRLICH,EUCALYPTUS,FURTHER,HEP,HOP,IMR,OVCAR,SARCOMA,SIX
BACKGROUND,CONTROL,LABEL,PAS,PEPTIDE,PRINCIPAL,RESULTS
946,CATENIN,CHROMATIN,CRPCA,LNCAP,PCA,PSA,THESE
001,947,AFTER,BECAUSE,BILATERAL,CASTRATION,DSB,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
ALTOGETHER,CCND2,PCA,THESE,TRAMP,USING,VPA
BASED,CONVERSELY
111,173,184,203,228,232,284,AUTOMATED,ERG,FURTHER
001,008,012,663,CENTERS,CONCLUSION,CROSS,DISCHARGE,INPATIENT,LABEL,METHODS,NATIONWIDE,OBJECTIVE,OBJECTIVES,RESULTS,SETTING,URINARY,UTI
946,ERBB2,FINALLY,MET,TAG,THESE
551,946,ADRB2,BAD,BEHAVIORAL,CONVERSELY,EFFECTS,MYC,PKA,PKI,THESE
BEHAVIORAL
945,946,ERBB2,JCI,MET,PCSCS,TARGETING,THERE,THESE
FIRST,HOWEVER,III
PATIENT
177,22RV1,479,AKT,AMG,CWR,GANITUMAB,IGF,THESE,WHILE
2GY,BEEKLEY,BRAGG,GRADE,HOWEVER,LABEL,METHODS,OBJECTIVE,PATIENT,RBE,RESULTS
100,169,259,670,685,CONCLUSION,GLEASON,GROUP,HOWEVER,IIA,IIB,III,IV1,IV2,JAPAN,LABEL,METHODS,OBJECTIVE,OVERALL,PROGNOSTIC,RESULTS,T2C,TNM,UROLOGICAL
169,ADVERSE,AIM,BACKGROUND,EARLY,LABEL,METHODS,OBJECTIVE,OUTCOME,PDE5I,RESULTS,SOCIETY,STUDIES,VED
169,ANZ,AUTHORS,BACKGROUND,COLLEGE,CONCLUSION,FORTY,ICU,INFECTIONS,JOURNAL,LABEL,METHODS,RATES,RESULTS,ROYAL,SURGERY,TREATMENT,UROSEPSIS
FAK,MMP,MT1,THESE
BPV,FOLEY,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PVR,QOL,RESULTS,SCORE,SYMPTOM,THESE
028,100,179,AFTER,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,REGARDING,RESULTS,RPE,RTE
GIVEN,REGIONS,THESE,WHEREAS
000,ENGLISH,HOWEVER,INVERSE,LABEL,MEDLINE,METHODS,OBJECTIVE,RESULTS,RRS,SEVENTEEN,TZD
CAP,DESPITE,FURTHER,INDUCTION,NDV,NEWCASTLE,ONCOLYTIC,OVERCOMING,PSA,R1881
946,948,956,ADT,AFTER,C17,THESE
ANNEXIN,MTT,THESE
000,400,ASSOCIATED,CARCINOMA,CURRENTLY,RANKL,TREATMENT,TREATMENTS
001,002,169,648,AFTER,BACKGROUND,BASEL,CAUCASIANS,COPYRIGHT,GSTT1,LABEL,METHODS,PCA,RESULTS,SCIENCE,WEB
108,168,180,AE1,AE3,DU145,MIB,NBF,PROLONGED,SHORT,SKOV3
AMONG,DOCETAXEL,PSA,THREE,TUR
GLEASON,THERE
AAT,BPH,ELISA
209,326,ACCORDING,BPH,FALSE,GROUP,PSA
ID1,ID2,ID3,ID4,PCA
C81,CONVERSELY,ID1,ID2,ID3,ID4,LNCAP,PCR
312,COX,MEIER,WNT5A
017,021,100,945,BACKGROUND,CRPCS,DESPITE,DU145,EXPRESSION,INCREASED,LABEL,LNCAP,MEIER,METHODS,MIGRATION,NOTABLY,PC3,RESULTS,TRANSWELL,UTR
000,946,AFFYMETRIX,ATLAS,COX,EGR,EVALUATION,IL1,MEMBERS,PREDICTIVE,PROTEIN,SIGNATURES,SPECS,STRATEGIC,THESE
ADAM9,MICROARRAY
001,005,053,116,164,366,412,489,579,616,631,795,937,ADDITIONAL,CHRONIC,CLL,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,THESE
BACKGROUND,BCR,DETECTION,ERG,FINDING,GENOMIC,LABEL,MOTIVATION,RESULTS,SNP,TMPRSS2
263,737,ABT,BCL,HSP70,MB231,MCL,MDA,MEMBERS,NAVITOCLAX,PC3,SILENCING,THESE,USING
MDV3100
001,002,169,253,963,AFTER,CONSORTIUM,COPYRIGHT,IGF,IGFBP,NCI,NORTH,PER,SEVERAL,SNP,SSTR5,TOTAL
CHINESE,CPG,CXCR7,FINALLY,LABEL,METHODS,MTT,NOTABLY,OBJECTIVE,PCR,PURPOSE,RESTORING,RESULTS,THESE,WESTERN,XENOGEN
148,169,177,263,421,700,963,BACKGROUND,COPYRIGHT,COX,GLEASON,LABEL,MARCH,METHODS,OBJECTIVE,OUTCOME,PCA,PHS,PHYSICIANS,PUBLISHED,RESULTS,SETTING,SEX,TNM,UNASSIGNED,UROLOGY,USING
200,239,600,BACKGROUND,CONCLUSION,CTC,GROUP,LABEL,METHODS,PFS,PSA,RESULTS,SECONDARY,WORKING
169,COPYRIGHT,IRELAND,LABEL,LTD,RESULTS
100,153,160,192,242,GADOLINIUM,GBQ,SCATTERED,TBQ
145,163,166,183,187,217,404,AFTER,BACKGROUND,BOARD,DESPITE,GLEASON,LABEL,METHODS,PATHOLOGY,RESULTS,THERE
169,2B4,946,AKT,FAK,INCREASED,KNOCKDOWN,LNCAP,MECHANISMS,PC3
900,AFRICAN,AFTER,CAUCASIAN,PSA,WHETHER
169,947,BRITAIN,COPYRIGHT,EWING,GPR64,GREAT,INHIBITION,IRELAND,LTD,METASTATIC,MICROARRAY,MMP,PGF,PUBLISHED,SLIT2,SOCIETY,TRAIL,WILEY
056,057,065,084,128,169,228,406,670,800,824,864,930,COPYRIGHT,HOWEVER,OVERALL,THERE
GLEASON,PSA
228,412,778,ACCORDING,BACKGROUND,CAM,GLEASON,LABEL,MEMBRANOUS,METHODS,PSA,RESULTS,TMA
246,267,798,AFRICAN,AMONG,BACKGROUND,CARIBBEAN,END,GLEASON,HOWEVER,JAMAICA,LABEL,METHODS,PSA,RESULTS,SAHARAN,SIMILAR
ANNEXIN,APOPTIN,E1A,MTT
109,240,267,C15,C30,CONCLUSION,EORTC,LABEL,METHODS,OBJECTIVE,PAL,PALLIATIVE,QLQ,QOL,QUALITY,RESULTS,SPECIAL,THREE,TREATMENT,UNIVARIATE
169,946,ADVERSELY,COPYRIGHT,FEDERATION,HOWEVER,KINDLIN,PUBLISHED,SMOOTHENED,SOCIETIES,TAKEN
1970S,945,BASED,DRUGS,III,MET,PCA,SINCE,THERE,THESE
EFFECTIVE,III,LOWER,MET,ONGOING,VEGFR
011,HOWEVER,III,IMPORTANT,OGX
153,223,945,946,III
223,ABOUT,BIOMARKERS,DIFFERENT,III,MET,SRC,TARGETING
945,946,DOCETAXEL,THERE,TUBULIN
ADDITIONAL,ANOTHER,III,PSA,SIPULEUCEL,THERE
509,ARN,PERSISTENT,THESE
001,700,APRIL,TAK,TOK
GIVEN,PREDICTIVE,THERE
DESPITE,FURTHER,SINCE
345,DISCUSSION,FOLLOWING,HCI,LABEL,MARCH,METHODS,OBJECTIVE,OCTOBER,OVERALL,PURPOSE,RESULTS,SEPTEMBER,SIXTY,THESE,TRICARE,USING
160,177,CARLO,CLEARLY,MODULATING,MONTE

105,169,528,658,736,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,POISSON,PSA,PURPOSE,RESULTS
001,160,169,AXIAL,BDI,BLAND,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MBI,MDI,METHODS,MRI,OBJECTIVE,RESULTS,THEREFORE,THREE
ACUTE,BACKGROUND,FURTHER,LABEL,METHODS,MRI,RADIATION,RESULTS,TRIAL
071,174,224,263,452,521,AIM,BACKGROUND,BMI,CONCLUSION,EARLY,FACTORS,LABEL,METHODS,OBJECTIVE,QRESEARCH,RESULTS,SETTING,THERE
100,176,231,99M,ANOVA,CONCLUSION,LABEL,MCF,MDA,METHODS,OBJECTIVE,PCR,PURPOSE,RATES,RESULTS
154,223,504,595,CONCLUSION,JANUARY,LABEL,METHODS,MPMNS,NEWLY,OBJECTIVE,PHYSICIANS,PURPOSE,RESULTS,THREE
169,ATLAS,COPYRIGHT,HOWEVER,INC,MOLECULAR,PROJECT,RAPID,SEVERAL,WILEY
169,223,945,BACKGROUND,COPYRIGHT,IGF,IGFBP,INC,LABEL,MAJOR,METHODS,MIB,PIN,PSA,PTH,RESULTS,TGF,TUNEL,WHETHER,WHILE,WILEY
000,100,152,169,173,215,290,350,580,660,900,CENTERS,CENTRAL,CONTROL,COPYRIGHT,DISEASE,FURTHER,HODGKIN,INC,INSTITUTE,NORTH,OVERALL,PREVENTION,REGISTRIES,SOCIETY,STATISTICS
169,492,549,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,PCA,POTENTIAL,REGULAR,RESULTS,THERE,WESTERN,WHETHER,WILEY
169,BACKGROUND,BPH,CONCLUSION,COPYRIGHT,CXCL1,CXCL8,CXCR2,DU145,INC,LABEL,METHODS,OTHER,PC3,PCA,RESULTS,TRAMP,WESTERN,WILEY
169,BACKGROUND,BMP,COPYRIGHT,DKK,HOWEVER,INC,LABEL,METHODS,MMP,OPG,PCA,PCR,RESULTS,SCLEROSTIN,SUBSTANCE,THREE,TRANSCRIPT,WILEY
169,315,945,ARI,BACKGROUND,COPYRIGHT,COX,GLEASON,HRS,INC,LABEL,METHODS,MORTALITY,PSA,RESULTS,TAMPERE,UNIVERSITY,WILEY
047,169,300,9FY,BACKGROUND,COPYRIGHT,EPR3864,ERG,ETS,INC,LABEL,MASON,MEIER,METHODS,NUCLEAR,PCA,RECURRENCE,RESULTS,SEATTLE,TMPRSS2,WHILE,WILEY
104,250,BACKGROUND,LABEL,METHODS,RESULTS,SEVERAL,WHERE
005,008,169,416,515,604,AMERICA,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,NORTH,RESULTS,WILEY
125,EPCAM
239,BECAUSE,CASTRATION,III,PHASE
ACCORDING,AMERICA,HOWEVER,PCA,PCAMR,PSA
FINALLY,PET
MRI,PET
177,EDTMP,III,KARNOFSKY,LABEL,MBQ,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTEEN
169,945,947,954,B16,BATF3,CD11C,CD8,CONVERTING,DCS,DCT,DTR,FLAGRP170,HYOU1,IFN
169,COPYRIGHT,FINALLY,GLYOXALASE,LNCAP,LTD,PC3
169,916,AURKA,COPYRIGHT,FEDERATION,HSC70,INHIBITION,MYB,PCA,PUBLISHED,SOCIETIES,SP1
169,25D,COPYRIGHT,D3VIA,GENOMIC,ISSUE,LTD,SPECIAL,VITAMIN
169,945,COPYRIGHT,EMPLOYING,HOWEVER,IFN,INC,INTERFERON,NOTABLY,NPS,STAT1,VSV
169,177,226,3MM,4MM,5MM,CONCLUSION,COPYRIGHT,DAILY,LABEL,METHODS,OBI,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,SAS
169,COPYRIGHT,FEDERATION,LACTATE,PNT1A,PUBLISHED,SOCIETIES
169,COPYRIGHT,MPT,STATINS,THESE
169,177,23B,99M,CIM,COPYRIGHT,DPA,GLU,HOWEVER,LNCAP,LTD,LYS,NMI,TIM
160,169,COPYRIGHT,PUBLISHED,SAS
169,187,208,679,COPYRIGHT,COSTS,EPI,EUROS,INCREASING,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,TOMOGRAPHY
100,169,1CM,2MM,3MM,4MM,6MM,BACKGROUND,COPYRIGHT,CT1,CT2,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,169,1CM,2CM,BACKGROUND,CHANGES,COPYRIGHT,CT1,CT2,CT3,CTS,HOWEVER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PDR,PTV,PURPOSE,RESULTS
169,CONCLUSION,COPYRIGHT,EORTC,GRADE,INTENSITY,IRELAND,LABEL,LTD,METHODS,MODULATED,MRI,OBJECTIVE,PURPOSE,RESULTS,SIX,SPACE,THESE
169,COMMUTING,CONCLUSION,COPYRIGHT,HORMONE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,QUALITY,REGISTRARS,RESULTS,RURAL,URBAN,USING
169,AFRICAN,CAUCASIAN,CONCLUSION,CONTENT,COPYRIGHT,HCP,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,REGARDLESS,RESULTS
169,COPYRIGHT,LTD,THESE
001,003,008,169,ACM,AHR,CAD,CHICAGO,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,PURPOSE,RESULTS,THESE
169,215,945,946,BASED,CIS,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,176,931,963,COPYRIGHT,DAILY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SVS,THEREFORE,USING
001,003,169,895,COLORECTAL,COPYRIGHT,HISPANICS,HODGKIN,HOWEVER,MATCH,NHL,SIR,SOCIETY,TRANSPLANT
169,BACKGROUND,BETWEEN,CONCLUSION,COPYRIGHT,ECE,GLEASON,LABEL,METHODS,MRI,OCD,OTHERWISE,PCA,PSA,PUBLISHED,RESULTS,SVI,THESE
001,169,75994,ADD,ADT,AMONG,BJU,COX,END,HOWEVER,KNOWN,LABEL,MEN,METHODS,OBJECTIVE,RECEIPT,RESULTS,SUBJECT,UNLABELLED
001,169,264,633,647,742,ADD,ASIAN,BJU,DRE,KNOWN,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SUBJECT,UNLABELLED,URINE,USING
015,019,021,169,192,BJU,COX,CSS,GLEASON,GROUP,LABEL,LNS,MAY,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PCA,RESULTS
001,169,ADD,BJU,BMI,INDEX,KNOWN,LABEL,MEIER,METHODS,OBJECTIVE,REGRESSION,RESULTS,SUBJECT,THESE,UNLABELLED,URINARY
160,169,CUTANEOUS,SOCIETY,TREATMENT
SNP,THEREAFTER
001,293,ABORIGINAL,ABOUT,APRIL,CONCLUSION,INDEX,INDIGENOUS,LABEL,MAY,METHODS,OBJECTIVE,OUTCOME,QUEENSLAND,RESULTS,SETTING,TERRITORY,WHILE
HOWEVER
252,BOZF1,BTB,POK,POZ,SP1
141,182,200,ECTOPIC,EXPRESSION,GNA12,GNA13,GPCRS,KNOCKDOWN,LNCAP,PC3,RHO,THESE,UTR
001,100,116,130,177,215,500,800,ADC,CONCLUSION,DIFFUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
169,183,AFTER,GEORG,STUTTGART
143,204,347,BACKGROUND,GLEASON,GROUP,INSTITUTE,LABEL,MATERIALS,METHODS,PSA,RESULTS,WORKING
002,008,293,967,BACKGROUND,CONCLUSION,COX,GLEASON,IHC,LABEL,METHODS,RESULTS
BCR,EBL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,POTENCY,RESULTS,ROBOTIC,SALVAGE
001,178,179,215,ADC,CSR,FIFTY,GLEASON,LABEL,LEVEL,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,WHITNEY
482,967,BACKGROUND,CONCLUSION,HAROW,HOWEVER,LABEL,MATERIALS,METHODS,REGARDING,RESULTS,SPECIAL,THEREFORE

100,169,BASEL,CD204,CD3,CD79ALPHA,COPYRIGHT,LABEL,MEDIATORS,METHODS,OBJECTIVE,RESULTS,THERE
STAGING
SEVERAL,THERE,WNT
002,273,691,APPEARANCE,ASSUMED,FINNISH,GLEASON,LABEL,LOCALIZED,METHODS,MRI,OBJECTIVE,PEARSON,PRIAS,PSA,RESULTS
BACKGROUND,GREENLIGHT,KTP,LABEL,MATERIALS,METHODS,OBJECTIVE,RECURRENCE,RESULTS,SEPTEMBER,THERE
AMS,CATHEPSIN,FURTHER,SELECTIVE
CD133,CWR,DESPITE,FIBROBLAST,GLEASON,MDV3100,RESISTANCE,SCORE,SRY,THESE
AFM,FORCE,LNCAP,MICROSCOPY,PCA,WESTERN
945,CARCINOMA,FUC,LNCAP,LYMPH,MGAT5,USING
KNOCKDOWN,THEREFORE,USING
007,105,126,169,183,231,386,GEORG,GSU,LESIONS,OVERALL,RTE,STUTTGART,SUSPICIOUS
169,183,APRIL,BASED,GEORG,PET,PSA,SEPTEMBER,STUTTGART,TREATMENT
001,128,379,ADT,AMONG,BACKGROUND,GHANA,GLEASON,LABEL,MEIER,METHODS,PSA,RESULTS,THERE
147,210,BACKGROUND,COLLEGE,CONCLUSION,DIAGNOSTIC,DSM,EDITION,LABEL,METHODS,OBJECTIVE,QOL,QUALITY,RESULTS,UNIVERSITY,WORLD
BACKGROUND,BUM,DISCOVERY,FALSE,FDR,INFERENCE,LABEL,METHODS,MICROARRAY,PREDICTION,REALITY,RESULTS,USING
001,110,215,300,700,ADC,AUC,CONCLUSION,DWI,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS
169,COPYRIGHT,HODGKIN,INC,SOCIETY
169,945,946,956,BT549,COPYRIGHT,DU145,EIGHT,HEXADECYL,HOWEVER,JIMT1,PC3,VCH,WILEY
111,267,278,ANPEP,APN,BACKGROUND,COMBINING,CONCLUSION,CSS,LABEL,METHODS,METHYLIGHT,NOVEL,RESULTS,RFS
PREDICTIVE,THESE
DESPITE,III,PREVIOUSLY
ARMED,BRADY,HOPKINS,INSTITUTE,JOHNS,RADICAL,UROLOGICAL,USING
KNOWLEDGE,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
DIETARY,LABEL,OBJECTIVE,PURPOSE,RADICAL,RESULTS,SUMMARY,THESE
169,289,COPYRIGHT,EDUCATION,GLEASON,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADICAL,RESULTS,UROLOGICAL
168,417,530,BACKGROUND,CAP,CONCLUSION,GLEASON,LABEL,METHODS,RESULTS,STUDIES,THESE,TMA
001,019,100,161,515,BACKGROUND,CDK,CONCLUSION,LABEL,LNCAP,METHODS,PSA,RESULTS
ADT,HOWEVER,PSA
169,947,BACKGROUND,COPYRIGHT,DESPITE,DU145,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS
169,BLACKWELL,DESPITE,GERMANY,HOWEVER,ITALIAN,ITALY,LTD,OVERALL,PUBLISHING,RESULTS,SPAIN,SPANISH
000,100,ASR,BACKGROUND,CENTRAL,CONCLUSION,DESPITE,FINALLY,INCREASING,LABEL,METHODS,RESULTS,SERBIAN,THESE,USING,VOJVODINA
169,AFTER,CWS,UROLOGICAL
001,144,169,285,345,356,616,6TH,7TH,980,ANESTHESIA,DIAGNOSIS,INDEX,PROCEDURE,UROLOGICAL
124,169,211,ADD,BJU,CLOSE,GLEASON,GROUP,KNOWN,LABEL,METHODS,MRI,OBJECTIVE,PRIAS,PSA,RESULTS,SUBJECT,UNLABELLED
001,169,219,388,727,955,963,AUC,BJU,CALIFORNIA,GLEASON,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PERMANENTE,PSA,RESULTS
145,169,386,471,573,965,BJU,COX,LABEL,MARSDEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROYAL,SNP,THERE
169,ADD,BASED,BJU,KNOWN,MRI,SUBJECT
160,169,AIM,AUTHORS,BRITAIN,COLORECTAL,CONCLUSION,DISEASE,EIGHT,GREAT,IRELAND,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,TRANS,TREATMENT
169,ALDEFLUOR,ALDH1,HEPATOCYTE,HGF,MET,PCR,TAKEN,WESTERN
305,364,BACKGROUND,CONCLUSION,FIRSTLY,GIVEN,LABEL,LNCAP,LXR,OVERALL,PRINCIPAL,RESULTS,SREBP,USING
169,947,AMONG,BRCA1,EXPRESSION,FOXP3,SOMATIC
LNCAP,POLYAMIDE,RNAP2
246,426,ACADEMY,JANUARY,LABEL,LEADING,MEMBERS,METHODS,NETWORK,OBJECTIVE,PHYSICIANS,PURPOSE,RESULTS
2D3,CRC,GIVEN,HOWEVER,THEREFORE,WNT
945,946,SEVERAL,THS,THYROID,TSH,YET
1C3,22RV1,AKR,CYP,HSD,IGF1R,INHIBITION,LNCAP,PSA,TREATMENT
116,169,3OMGA,947,CONCLUSION,DHPAA,HCT,LABEL,METHODS,RESULTS,SCOPE,SERUM,TEA,URINE,VCH,WILEY
169,500,946,CD127,CD4,COPYRIGHT,DUSP1,FOS,INCREASED,JUN,RESULTS,STUDIES,TGF,TREGS
128,169,COPYRIGHT,ERG,EXPRESSION,MOLECULAR,PCR,TDRD1,TMPRSS2,TUDOR
946,AIM,CONCLUSION,CRC,EST,HOWEVER,HSD,INITIALLY,LABEL,MEDLINE,METHODS,OBJECTIVE,RESULTS,STS
LOW,PIN
ADDITIONAL,BACKGROUND,CONCLUSION,CONTEXT,DENMARK,FOLLOWING,LABEL,METHODS,OBJECTIVE,OUTCOME,PRIMARY,RESULTS,SECONDARY,SETTING,SIMILARLY
024,045,AST,BACKGROUND,FIFTY,FOLLOWING,LABEL,METHODS,QLQ,RESULTS,THERE,TREATMENT
967,BACKGROUND,FIFTY,GLEASON,JANUARY,LABEL,METHODS,POTENTIAL,PSA,RESULTS
NOV,THEREFORE,THROUGH
250,AAA,AIR,DOSIMETRIC,GTV,HOUNSFIELD,PTV,RED,THERE,WHILE
021,177,421,798,DVH,EUD,NAGELKERKE,NTCPS,PC1,PC2,PCA,PRINCIPAL,TCP
131,EDEMA,EHL,TCP,THESE
CHANGES,HOWEVER,PSA,RAPID
5857G,BACKGROUND,BRCA1,BRCA2,DIAGNOSIS,DOPPLER,EARLY,ERG,GLEASON,GLU1953,LABEL,MANAGEMENT,METHODS,PSA,RADICAL,RESULTS
2NG,3MM,AMICO,BACKGROUND,COX,FORWARD,GLEASON,IRB,LABEL,MEIER,METHODS,MULTIFOCAL,OBJECTIVE,OBJECTIVES,OVERALL,PSA,RESULTS
223,AREAS,BACKGROUND,COVERED,III,LABEL,METHODS,OPINION,PHASE,UNTIL
APA,HOWEVER,KEY,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS,THESE
APA,DISCLOSURE,FIFTY,FRAMEWORK,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS
APA,ASPECTS,CMT,DECREASED,EAC,EMOTION,LABEL,LOW,METHODS,OBJECTIVE,RESULTS,SIXTY,WHETHER
467,BACKGROUND,LABEL,METHODS,RESULTS,TSP,UTR
169,ALA,HOWEVER,INC,MANGANESE,MNSOD,PCA,THEREFORE,TURKISH,VAL,WILEY
543,652,ELISA,FURTHER,GLEASON,HOWEVER,IGF,ORS,PREVENTION,RESULTS,THESE,TRIAL
002,010,119,146,157,205,227,438,665,776,884,ACUTE,ADVERSE,BETWEEN,CONCLUSION,D10,D90,GLEASON,GRADE,LABEL,METHODS,OBJECTIVE,RESULTS,UNIVARIATE
945,A2A,A2B,AMP,BAY60,CHX,DU145,LDH,LNCAP,PCR,TNF,WESTERN
22RV1,945,AKT,CXCR4,DESPITE,FURTHER,HOWEVER,ROS
128,BPH,KOREA,PSA
129,142,156,239,348,391,ATP,AUC,BAP,BECAUSE,CONCLUSION,CTC,CTX,KX2,LABEL,METHODS,OBJECTIVE,PFS,PSA,PURPOSE,RESULTS,SECONDARY,SRC
BACKGROUND,CONTROL,FINALLY,FURTHER,LABEL,METHODS,MULTI,PSA,QUALITY,RESULTS,TMC
125,945,AFP,BACKGROUND,CBS,CEA,LABEL,METHODS,PGD,RESULTS,THERE
CARCINOMAS,CELLSEARCH,DUE
169,C22,COPYRIGHT,INC,LNCAP,MYC,NADPH,S1P,SK1,SK2,SKI,THESE,WARBURG
169,BAYES,COPYRIGHT,LTD,POISSON,THROUGH
155NM,24H,250NM,956,BECAUSE,CACO2,DECREASED,DPI,DTI,DU145,INC,NADPH,PUBLISHED,ROS,THESE
916,CLAUDIN,NH2
100,169,768,ASSESSMENT,COLLEGE,CONCLUSION,COPYRIGHT,DCE,DIAGNOSTIC,JANUARY,LABEL,LTD,MATERIALS,MEDLINE,METHODS,MRI,OBJECTIVE,OCTOBER,PUBLISHED,QUALITY,RESULTS,ROYAL,SEVEN,STUDIES
169,COPYRIGHT,FINALLY,FOXP3,LTD,WHILE
111,169,ASSESSMENT,BACKGROUND,COPYRIGHT,FORTY,FUNCTIONAL,LABEL,LTD,METHODS,RESULTS,SURVEYS,THERAPY
094,169,232,519,571,958,AUASS,AUC,COPYRIGHT,DETECTION,EARLY,EDUCATION,EXCLUDING,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PREVENTION,PUBLISHED,PURPOSE,RESULTS,ROC,TRIAL,UROLOGICAL
000,169,174,213,276,300,426,APRIL,BASED,COPYRIGHT,EDUCATION,INC,INFECTION,INHIBIZONE,JANUARY,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL
169,339,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SECONDARY,UROLOGICAL
169,337,BETWEEN,C30,COPYRIGHT,EDUCATION,EORTC,GROUP,INC,INDEX,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PATIENT,PUBLISHED,PURPOSE,QLQ,RADIATION,RESULTS,SCORE,SYMPTOM,THERAPY,TREATMENT,UROLOGICAL
169,AFTER,CAP,COPYRIGHT,HOWEVER,INC,INCREASED,LUMINAL,PATHOLOGY,PUBLISHED,SMAD4,SOCIETY,TAKEN
168,169,621,BACKGROUND,COPYRIGHT,COX,FIFTY,INCREASED,LABEL,LOWER,MEN,METHODS,NEITHER,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,THESE,UROLOGICAL,UROLOGY
169,239,442,ALP,BACKGROUND,COPYRIGHT,COX,DUE,LABEL,LDH,METHODS,MVA,OBJECTIVE,OUTCOME,PREDICTED,PROGNOSTIC,PSA,PUBLISHED,RESULTS,SETTING,SMALETZ,UNASSIGNED,UROLOGY
160,169,177,304,318,485,556,700,ACCORDING,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,THESE,USING
086,160,169,CONCLUSION,COPYRIGHT,EINDHOVEN,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,SES,TREATMENT,YOUNGER
001,160,169,440,ANOVA,COLLEGE,CONCLUSION,COPYRIGHT,GENERAL,INSTITUTE,KRUSKAL,LABEL,LTD,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROYAL
107,169,3MM,8MM,BACKGROUND,CASES,COPYRIGHT,CROWN,IMAGE,KOLMOGOROV,LABEL,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,SMIRNOV,SYSTEMATIC
001,013,169,CLINICALLY,MEDLINE,UROLOGICAL
AUA,BACKGROUND,BASED,CONCLUSION,LABEL,METHODS,PRE,PSA,RESULTS,SUBJECTIVE,THESE
238,869,AOR,BACKGROUND,CIS,HODGKIN,LABEL,METHODS,OBJECTIVE,RESULTS,STRENGTHS,THERE
DISEASE,DU145,DUPRO,HPV,LNCAP,NUCLEAR,SATB1,SIMILARLY,SPECIAL
100,BACKGROUND,HOWEVER,LABEL,MRI,NPV,PPV,PRINCIPAL,RESULTS,SWI
AFRICAN,BACKGROUND,BPH,CAP,CAUCASIAN,CAUCASIANS,ELISA,FURTHER,LABEL,PRINCIPAL,PSA,RESULTS,TRAMP
AKT,DOC,DSB,HOWEVER,PCA,RADIATION,RAS,S6K,TAKEN
ADT,AMONG,PCA,THESE

100,215,956,AB2,CAPTURE,ECL,POTENTIAL,PSA,RUBPY
TOTAL
ADT,CASTRATION,HOWEVER,MDV3100,MEETING,RESISTANT
AMONG,ASIAN,CHILE,CHILEAN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIR,SWEDISH,T1C
CASITAS,CBL,DR4,DR5,TRAIL
169,183,192,193,ADT,AFTER,AMGEN,AVENTIS,BACKGROUND,BELGIUM,BETWEEN,COPYRIGHT,DEC,DOCETAXEL,EARLY,FUNDING,GLASS,IQR,KARNOFSKY,LABEL,LTD,METHODS,OCT,RESULTS
169,MEN,UROLOGICAL
AUSTRALIAN,BACKGROUND,CFS,GENOMIC,GLEASON,LABEL,METHODS,MLV,PCR,R462Q,RESULTS,RNASE,SAMPLES,USING,WHILE,XENOTROPIC
001,006,035,037,169,BJU,BMI,COX,EQUAL,LABEL,MEN,METHODS,OBJECTIVE,PCA,RESULTS,WHERE
169,174,260,ADD,BETWEEN,BJU,BOARI,CLAVIEN,DINDO,DUR,IVA,KNOWN,LABEL,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,RESULTS,ROBOT,SUBJECT,THERE,UNLABELLED
125,169,180,186,ADD,AFTER,APRIL,BJU,D90,HOWEVER,INDEX,KNOWN,LABEL,METHODS,MORBIDITY,OBJECTIVE,RESULTS,SCORE,SUBJECT,SYMPTOM,THERE,UNLABELLED,USING
AZIKIWE,BACKGROUND,CONCLUSION,LABEL,MALIGNANT,METHODS,OBJECTIVE,RENAL,RESULTS,THERE,UNIVERSITY
AZIKIWE,BACKGROUND,CONCLUSION,LABEL,MALIGNANT,METHODS,OBJECTIVE,RENAL,RESULTS,THERE,UNIVERSITY
BACKGROUND,INITIAL,LABEL,METHODS,NPS,RESULTS,USING,WEV
024,054,058,110,123,131,370,CONCLUSION,ESTIMATED,EXM,LABEL,MBQ,METHODS,MIP,RESULTS,SEVEN,SPECT,THESE,UNLABELLED,WHOLE
SINGAPORE
CONFERENCE,CONSENSUS
CXCR4,STAT3,THEREFORE,THESE
BACKGROUND,HODGKIN,HOWEVER,LABEL,METHODS,NEWER,PHYSICIANS,RESULTS,RIT,SEVERAL
BACKGROUND,DUE,INITIAL,LABEL,METHODS,MONOCLONAL,RESULTS,THERE,THEREFORE
BACKGROUND,COMBINING,DATABASES,FINALLY,LABEL,METHODS,RESULTS,SCHOLAR,THERE,THROUGH
BACKGROUND,III,LABEL,METHODS,PERIPHERAL,RESULTS,SIPULEUCEL,THERE
201,300,501,799,830,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS
163,177,242,967,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
AFRICAN,APRIL,BRAZILIAN,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,737,CENTRAL,CONCLUSION,LABEL,MATERIALS,MEDLINE,METHODS,NNT,OBJECTIVE,RATIO,RESULTS,SEVERAL,SIPULEUCEL,TTP
149,421,592,BACKGROUND,CONCLUSION,GLEASON,IPC,LABEL,MATERIALS,METHODS,RESULTS,THESE
946,AKT,CAV,DU145,GLUT3,HK2,IGF,LNCAP,MYC,OVERALL,THESE,WNT
169,945,AKT,AUTHORS,BLACKWELL,COMMONS,DU145,ERK,FOUNDATION,HOWEVER,LICENSE,LTD,MOLECULAR,PUBLISHED,PUBLISHING,USING
169,945,946,AKT,AUTHORS,BLACKWELL,COMMONS,CXC,CXCR4,EMT,FOUNDATION,HIF,IGF,KIT,LICENSE,LTD,MOLECULAR,NANOG,NOTCH,OCT,PUBLISHED,PUBLISHING,SCF,SOX,TGF,THESE
BF3,FLUTAMIDE,HOWEVER,LNCAP,MED,NILUTAMIDE
160,169,1ST,APPRAISAL,BACKGROUND,BLACKWELL,CONCLUSION,DIEKELMANN,KNOWLEDGE,LABEL,LTD,MEN,METHODS,NLN,NURSING,OBJECTIVE,OBJECTIVES,PRESS,PUBLISHING,RELEVANCE,RESULTS,STUDIES
BACKGROUND,CLEAR,CONCLUSION,LABEL,METHODS
CONCLUSION,DAB,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE,VORONOI
001,003,009,084,215,BACKGROUND,JAK,LABEL,PATHWAY,RESULTS
624,ALN,BACKGROUND,COX,FURTHER,INSURANCE,LABEL,METHODS,NHI,RESULTS
945,946,AKT,CAM,ERK,GELATIN,MMP,TAKEN,TNF,WESTERN
23B,27B,CONVERSELY,HOWEVER,INHIBITION,LNCAP,MICRORNAS,THESE
133,AKT,BACKGROUND,BMS,IGF,INSULIN,LABEL,MATERIALS,MDA,METHODS,PCA,RESULTS,SFK,SRC,THESE,TREATMENT
946,CATENIN,HOWEVER,MYC,THESE,WESTERN
AKT,DUB,K63
001,FATIGUE,FDA,III,MDV3100,MEDIVATION,PSA,SEPTEMBER
APC,COMBINING,PCA,POOLING,PSA
946,ACCORDING,CPG,DU145,FIRST,H3K9ME3,LNCAP,PC3,PCR,RAR,WESTERN,WHILE
177,202,212,ARSENIC,DESPITE,EPIDEMIOL,GIVEN,TAIWANESE,THERE
154,381,763,788,818,HOWEVER,LABEL,METHODS,NURSE,OBJECTIVE,PATIENT,PHYSICIAN,PHYSICIANS,PURPOSE,RESULTS,ZOL
130,177,181,200,246,257,2X2,400,427,547,581,AFRICAN,ALZHEIMER,AMERICANS,CERAD,CONCLUSION,CONSORTIUM,ESTABLISH,GROUP,LABEL,METHODS,MIS,OBJECTIVE,OBJECTIVES,PARTNERING,PREADVISE,RCT,RESULTS,SETTING,SEVERAL,SOUTHWEST,STAFF,WHILE
145,177,AES,BACKGROUND,CSS,DOC,HOWEVER,LABEL,LEUKOPENIA,METHODS,PSA,RESULTS,SERUM
169,AIM,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MEDLINE,METHODS,NEWCASTLE,OBJECTIVE,OCTOBER,PRIOR,RESULTS,RRS,SCALE,STATA
146,BACKGROUND,CHROMATIN,DU145,GLEASON,LABEL,LNCAP,PC3,PCA,RESULTS,THESE,TRANSWELL,USING,WT1
DESPITE,INITIAL,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THROUGH
916,LABEL,METHODS,OBJECTIVE,OVH,PTV,PURPOSE,RESULTS,TREATMENT,WHETHER
AAA,BOLTZMANN,CARLO,COMPARING,ECLIPSE,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RADIO,RESULTS,THESE,USING
945,946,HOWEVER,ISOEFFECT,LABEL,METHODS,OBJECTIVE,PURPOSE,RBE,RESULTS
DESPITE,EARLIER,RADICAL,TADALAFIL
063,138,375,380,518,900,991,CONCLUSION,GLEASON,HAN,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,UYGUR
AFTER,BAX,BCL,CONCLUSION,LABEL,METHODS,MTT,OBJECTIVE,PAR,PC3,RESULTS,WESTERN
146,169,AIM,BACKGROUND,COPYRIGHT,DEPARTMENT,LABEL,METHODS,OBJECTIVE,PARTNER,PUBLISHED,RESULTS,SOCIETY,URBAN
177,CTV,D90,HDRIB,INSTITUTE,PRE
200,CROHN,MSC,SLE,THESE
001,004,154,302,480,658,CHEK2,I157T,IVS2G,MUTATIONS,TRUNCATING
BLADDER,CERTAINLY,EAU,ENDOSCOPIC,HOWEVER,INFANTS,MRI,PAEDIATRIC,SOCIETY,THERE,UROLOGY,UTI,VUR
160,353,ACCOUNTING,AMONG,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STUDIES,SWEDISH
GLEASON,PSA,RADICAL
001,036,132,156,177,438,446,ADDICTION,AMONG,GLEASON,HOWEVER,OPIUM,PSA,SERUM,TOTAL
001,019,101,169,480,487,896,BACKGROUND,BASEL,BETWEEN,COPYRIGHT,COVARIATES,EUR,GLEASON,LABEL,LNI,METHODS,PCA,PSA,RESULTS,UNI
916,955
001,002,499,ATTITUDES,CONCLUSION,FORTY,LABEL,LOWER,METHODS,OBJECTIVE,PURPOSE,RESULTS,SES,STUDIES
467,CONCLUSION,HGPIN,III,LABEL,MEIER,MEN,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
100,AFTER,FORTY,INCIDENTAL,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,PROSTATIC,RESULTS,SCORE,SYMPTOM
BACKGROUND,CAR,GIVEN,HOWEVER,LABEL,METHODS,RESULTS,WESTERN
004,169,270,490,AGE,BASEL,COPYRIGHT,DRE,LABEL,METHODS,OBJECTIVE,PREDICTIVE,PSA,RESULTS
169,177,AUC,CAP,COD,COMPARING,COPYRIGHT,DSS,EMBEDDING,FIELD,GLEASON,GRAPH,MRI,MRS,MULTI,ROC,SUPERVISED,T2W
946,BPH,CELSIUS,CPG,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCA,PCR,RAR,RESULTS,UNLABELLED
002,014,169,170,176,177,183,184,BACKGROUND,COPYRIGHT,DOCETAXEL,ENROLMENT,FINLAND,FUNDING,GRADE,IRELAND,LABEL,LTD,MARCH,MAY,METHODS,RESULTS
115,161,169,174,177,200,ADD,BELGIUM,BJU,CONCLUSION,GERMANY,KNOWN,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEVEN,SIX,SPAIN,SUBJECT,TESTOPATCH,THESE,UNLABELLED,UROLOGY,USA
169,AGR,ANDROGENS,AUTHORS,DUCAP,FKBP5,JOURNAL,PCR,POL
300,ACCORDING,AVOIDANCE,BACKGROUND,DISCUSSION,FACED,FURTHER,IDENTIFIER,LABEL,METHODS,NCT,OTHER,RCT,TRIAL
AREAS,BACKGROUND,COVERED,CURRENTLY,IGF,LABEL,METHODS,OPINION,THESE
460,AFTER,DNMTS,DU145,G9A,THEIR,YFP
DENDRIMERS,GIVEN,THESE
188,DU145,HERCEPTIN,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RHENIUM,TREATMENTS
125,169,466,ACUTE,APRIL,D90,GRADE,GROUP,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RADIATION,RESULTS,SCORE,SYMPTOM,THERAPY,UROLOGICAL
001,005,006,169,CONCLUSION,COX,GLEASON,KYOTO,LABEL,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SALVAGE,UNIVERSITY,UROLOGICAL
001,162,169,ANGELES,CALIFORNIA,HOWEVER,INDEX,LABEL,LOS,METHODS,OBJECTIVE,RESULTS,THERE,UNIVERSITY,UROLOGICAL
BECAUSE,INCREASED,SBE
CPA
119,169,177,916,BECAUSE,CO2,CONCLUSION,COPYRIGHT,GH3,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PC3,PURPOSE,RESULTS,WILEY
169,341,AUC,CONCLUSION,COPYRIGHT,DWI,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,WILEY
126,141,142,177,244,289,409,830,834,881,93960,AWARENESS,EIGHT,MDACC
INC,KIT,MET,RANDOMIZED,XL184
THESE,WHILE
848,872,958,AFRICAN,AMERICANS,END,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PALLIATIVE,PCN,REASONS,RESULTS,RUS,SIXTEEN,THERE,USING
177,6TH,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,PVR,QOL,RESULTS,TAMSULOSIN,THERE,UFM
100,177,270,275,BACKGROUND,CLASICC,CRM,FIFTY,LABEL,METHODS,RESULTS,ROBOTIC,SCORE,SYMPTOM,TME
160,380,PC3,PCAG1,PCR,REVERSE,WHILE
GFM,HGPIN
118,130,AMONG,BASED,BLOOD,GLEASON,OVERALL,PCR,PSA
ADP,APOPTOSIS,BAX,BCL,CORDYCEPIN,CORDYCEPS,HOWEVER,IAP,MMP,ROS
100,120,126,130,156,164,172,194,210,220,245,290,313,BECAUSE,IMPLANT,JAPAN,PERMANENT
IGFBP,LNCAP
038,ADT,BACKGROUND,CONCLUSION,GLEASON,LABEL,MEN,METHODS,RESULTS,THEREFORE,WHILE
000,442,986,BACKGROUND,BPH,BRCA1,CONSORTIUM,COX,CRC,FINLAND,FINNISH,FINNS,GENOTYPING,ICPCG,LABEL,MASSARRAY,METHODS,PSA,RESULTS,THESE
223,535,AGE,CHINESE,DRE,NOMOGRAMS,PSA
AFTER,LABEL,LNCAP,METHODS,OBJECTIVE,PEG,PEI,PSMAE,RESULTS,THEIR,THESE
169,223,COPYRIGHT,III,LTD,PUBLISHED,TREATMENT
000,100,297,535,802,CHINA,CONCLUSION,LABEL,METHODS,MORTALITY,OBJECTIVE,PREVENTION,RESULTS,THIRD
002,005,007,026,036,169,COPYRIGHT,CT1,CT2,D10,D15,D20,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,V50,V60,V70,V80,V90
152,169,BASED,COPYRIGHT,DOX,HOWEVER,III,LTD,LYS,PITUITARY
15I,15J,15M,15N,169,COPYRIGHT,LTD,SAR
125,128,150,165,181,AFTER,CONCLUSION,LABEL,METHODS,NHT,OBJECTIVE,PSA,RESULTS,T1C,T3B,THEIR
956,BACKGROUND,CLONOGENIC,COX,LABEL,LNCAP,METHODS,NEO,PCR,RESULTS,THESE,TRAIL,TREATMENT
016,049,DESPITE,THREE
053,393,AFTER,AMONG,BACKGROUND,COX,FINALLY,ICD,LABEL,METHODS,POISSON,RESULTS,SNC,SWISS

ACTIVATION,EBP,ST3,STAT3,THESE,USING
197,BECAUSE,BIC,CYP46A1,CYTOCHROME,DUE
CARCINOMA,OTHER,THYROID
00032,012,027,031,11P15,12Q23,16Q,16Q22,D1S2137,FAL,FRACTIONAL,LOH,MSI,NIR,PCA
GIVEN,HOWEVER
200,AFRICAN,CONSTRUCT,HOWEVER
986,AFFYMETRIX,AGILENT,BLOOD,MICROARRAY,NATURAL,THESE,USING,WHETHER
000,100,106,126,253,269,439,748,778,850,928,AMONG,BACKGROUND,CASES,CONTEXT,COX,HODGKIN,LABEL,METHODS,OBJECTIVE,OUTCOME,RDS,RESULTS,SEPTEMBER,SETTING,SIR,STATE,THERE,TRADE,USING,WORLD
30962,ANOTHER,BCG,CIS,CUETO,CYSTOSCOPY,EORTC,IMMEDIATE,MMC,NMIBC,POSTPONING,RADICAL,SINCE,SYNERGO,TCC,TUR
AFTER,BESIDES
HODGE,PBX,PCA
ASIAN,DESPITE,FURTHER,HOWEVER,THROUGH
946,AKT,BACKGROUND,CONCLUSION,DU145,EFFECTIVE,ERK,LABEL,METHODS,NDRG1,PROTEIN,RAS,RESULTS,SILENCING,TGF
169,AFTER,COPYRIGHT,HOWEVER,PUBLISHED,SAS,SEVERAL,THEREFORE
001,004,008,119,157,162,169,BACKGROUND,COPYRIGHT,COX,FURTHER,GLEASON,LABEL,MEIER,METFORMIN,METHODS,OBJECTIVE,OUTCOME,PSA,PUBLISHED,RESULTS,RFS,SETTING,UNIVARIATE,UROLOGY
169,COPYRIGHT,DESPITE,HSP90
002,025,169,412,AFTER,C30,COPYRIGHT,LABEL,LRP,MARCH,METHODS,OBJECTIVE,PARTNER,QLQ,RESULTS,SAS,THERE
100,100NG,160,164,169,4NG,65YEARS,660NG,96YEARS,AFTER,CONCLUSION,COPYRIGHT,DIGITAL,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PULPECTOMY,RADICAL,RESULTS,SAS,SENEGAL,TREATMENT
160,169,223,CONCLUSION,COPYRIGHT,DENOSUMAB,III,LABEL,MDV,METHODS,OBJECTIVE,RESULTS,SAS,SIPULEUCEL,SOCIETY,UROLOGICAL,UROLOGY
LABEL,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SUMMARY
HOWEVER,MULTIMODAL,THERE
001,129,BACKGROUND,COMPOSITE,CONCLUSION,EXPRESSION,LABEL,METHODS,MYC,NOTABLY,RESULTS,SUBSEQUENT,THERE
000,011,047,100,109,203,250,258,341,355,406,430,459,492,543,572,590,604,605,680,709,719,742,750,794,844,875,912,921,946,958,BACKGROUND,BPH,COX,HOWEVER,INCIDENCES,INSURANCE,JANUARY,LABEL,METFORMIN,METHODS,RESULTS,TAIWANESE
PC3,ZKK
004,028,037,051,134,186,191,961,AFTER,ALA,BMI,DESPITE,HOWEVER,PROSTATIC,PSA,SERUM,SEVEN
HODGKIN,L1236,LNCAP,LOX,SMYD3,STAT6,TAKEN
AKT,BAD,BAX,BID,FAS,GTP,HOWEVER,JNK,LNCAP,LNCAPSHP53,THESE
00024,001,DTX,MHZ,MPA,PC3,THESE,ULTRASOUND,USMBS
128,448,928,966,AIM,ASSESSMENT,BIOMEDICAL,CHINESE,CONFIDENCE,EVALUATION,FURTHER,GRADING,INSULIN,LABEL,LIBRARY,LITERATURE,MARCH,MEDICAL,METHODS,OBJECTIVE,ORS,RESULTS,SCIENCE,WEB
3T3,BASED,CDC42,GM130,GOLGI,GTPASES,RAC,RHO,SIGNALING,SWISS
AKT,ANTIBODIES,BP1,DU145,HSP90,PROTEIN,S6K,THESE
120,160,171,177,AUR,GREENLIGHT,HPS,PCA,PSA,PVP,PVR,QOL,SCORE,SYMPTOM
001,008,404,495,BETWEEN,COCKCROFT,GAULT,GFR,LABEL,METHODS,OBJECTIVE,PERCENT,PSA,PURPOSE,RESULTS,SCREENING
001,016,160,631,BMI,CONVERSELY,HORMONE,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,TOTAL
PSMA1
BACKGROUND,CONCLUSION,DUE,EVALUATION,LABEL,METHODS,MRI,RESULTS,TCP
102,169,202,HOWEVER,INSURANCE,NHIRD,OVERALL,SIR,STUDIES
169,ADIPOSE,ADT,COPYRIGHT,CVD,INCREASES,LOW,LTD,OBESITY,THERE,TRT,WILEY
CDC37,DIMINISHED,DISRUPTION,GST,HSP90,TAKEN
CAUCASIANS,CBM,CONCLUSION,DATABASES,LABEL,MAY,METHODS,OBJECTIVE,RESULTS,STATA,TEN,TOTAL,VDR,VIP,WANFANG
169,CARCINOMA,COPYRIGHT,DU145,LNCAP,LTD,MRI,WILEY
138,169,188,214,402,489,ACAD8,ACADL,ACADM,ACADS,ACOXL,BIOLOGICAL,COA,FADS1,GWASS,INC,PDGFC,PYROXD2,SEVEN,SWEDISH,WILEY
169,COPYRIGHT,MANNICH,MICHAEL,NATURALLY,VCH,WILEY
100,129,169,3N0M0,AE1,AE3,AVAILABLE,COPYRIGHT,DETECTION,DTC,PCA,PRE,THEREBY
036,169,AMICO,AMONG,BACKGROUND,CONSENSUS,COPYRIGHT,EPE,FAILURE,GLEASON,INC,LABEL,METHODS,PATHOLOGIC,PCA,RESULTS,WILEY
169,BACKGROUND,COPYRIGHT,HPV,INC,LABEL,METHODS,RESULTS,WILEY
169,954,AS5,COPYRIGHT,INCREASED,INGENUITY,LNCAP,PATHWAY,TAKEN,TNFAIP8
169,945,946,CCN,COPYRIGHT,FAK,GDF,HUVEC,INC,THESE,WILEY,WILLEBRAND
104,169,875,BACKGROUND,BMI,CCB,CHI,COPYRIGHT,COX,DIAGNOSTIC,INC,INSTITUTE,LABEL,LOUISIANA,MEDICATION,METHODS,NORTH,PCA,PFS,PROJECT,PSA,RECURRENCE,RESULTS,ROSWELL,WILEY
001,169,961,CCS,COPYRIGHT,GLEASON,LCMODEL,LTD,MAS,MRS,THERE,WILEY
169,177,680,AF680,ALEXA,BACKGROUND,BBN,COPYRIGHT,FLUOR,INC,LABEL,LUC,METHODS,NH2,NIR,RESULTS,WILEY
169,ALDH1,BACKGROUND,COPYRIGHT,DESPITE,EMT,FOXP3,INC,INCREASED,LABEL,METHODS,PCR,RESULTS,TGFB3,THESE,WILEY,WNT5A
169,247,345,421,616,AML,COPYRIGHT,MDS,RECURRENT,SF3B1,SRSF2,U2AF1
043,169,348,ADT,BACKGROUND,COPYRIGHT,CSS,DFS,HOWEVER,LABEL,LDR,METHODS,NETWORK,OCTOBER,PHOENIX,RESULTS,SIXTY,SOCIETY,UNIVARIATE
100,177,CAD,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE
954,AIM,BACKGROUND,CAFFEIC,FURTHER,LABEL,OBJECTIVE,RESULTS
AFFYMETRIX,AIM,BACKGROUND,LABEL,MATERIALS,METHODS,OBJECTIVE,P53,RESULTS,SP1,SP3,TFS
169,BACKGROUND,BRAIN,COPYRIGHT,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
169,257,ANZ,AUTHORS,COLLEGE,COLORECTAL,JOURNAL,PERSISTING,ROYAL,SURGERY,ZEALAND
169,232,276,901,ADD,BJU,COSTS,HOWEVER,KNOWN,LABEL,METHODS,OBJECTIVE,RESULTS,SUBJECT,THERE,THESE,UNLABELLED,USA,UTILITIES
124,169,218,500,BETWEEN,COX,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,RESULTS,SIMILAR,T2A,THERE,UPSTAGING,UROLOGICAL,USING
142,155,169,244,419,861,ADDITIONAL,BACKGROUND,INDEX,LABEL,MEANWHILE,MEIER,METHODS,NETWORK,OVERALL,RESULTS,UROLOGICAL
GIVEN,HBS,PCA,THESE,VIRTUAL
169,946,APMIS,BDS,ELISA,LTD,NLR,NOD,PUBLISHED,WILEY
540,CONCLUSION,CONSISTED,CRC,FIRST,INITIATIVE,LABEL,METHODS,NOTABLE,OBJECTIVE,PURPOSE,RESULTS,THESE,THIRD,THREE
946,954,CONVERSELY,IL1,METFORMIN,SRC,STAT3,TAKEN
000,654,ADT,AMICO,BACKGROUND,CONCLUSION,DISCORDANT,END,GLEASON,HOWEVER,NETWORK,RESULTS
385,49A,49T,562,945,ADDITIONAL,CAUCASIANS,HOWEVER,JANUARY,STEROID
945,946,LXXLL,MIER1,THESE,WHILE
HOWEVER,JANUS,THESE
OBESITY
PCA,WESTERN
101,160,ESCRT,UEV
FURTHER,LZTS2,THESE,TREATMENT,USING
000,100,285,591,COSTS,DISEASE,GIVEN,HOWEVER,INTENSITY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,TREATMENT
100,169,AKT,ATP,CELLS,CG5,DAILY,ERMAS,LNCAP,MICROARRAY,OSU,SRC,THESE,TRAMP,WARBURG,WESTERN
125,CONCLUSION,FIFTY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
001,142,201,688,723,HOWEVER,THERE,THEREFORE
002,138,AFFAIRS,BACKGROUND,BONFERRONI,DESPITE,LABEL,METHODS,RATES,RESULTS
001,169,CONCLUSION,COPYRIGHT,COVARIATES,EDUCATION,FOUNDATION,INC,LABEL,MEDICAL,METHODS,NUTRITION,OBJECTIVE,PSA,PUBLISHED,RESULTS,SEDENTARY,SEPTEMBER
001,002,007,016,161,169,187,603,ADULT,CONCLUSION,COPYRIGHT,DRE,EDUCATION,HGPIN,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PANEL,PCA,PROGRAM,PSA,RESULTS,TREATMENT
169,BETWEEN,CONCERNING,COPYRIGHT,DEPENDING,GLEASON,IRELAND,LABEL,LTD,MAY,METHODS,MRI,MRT,OBJECTIVE,RESULTS,RTE,SCORE
169,COPYRIGHT,IRELAND,LTD,SELECTING
028,034,037,075,215,949,BCL,HOWEVER,PC3,PCA,PKC,PLUMBAGIN,PUBLISHED,RESULTS,STAT3,TAKEN,THESE,THREE
420,748,BACKGROUND,CONTEXT,DIAGNOSES,DIAGNOSTIC,GRADE,LABEL,METHODS,NEOPLASIA,OBJECTIVE,PROSTATIC,RESULTS,SMALL,SUSPICIOUS
000,001,008,BACKGROUND,COX,IRS,LABEL,MEIER,METHODS,MULTI,PCA,PEARSON,PERIOSTIN,POSTN,PSA,REGARDLESS,RESULTS,WHILE
003,169,946,AGE,BETWEEN,CALIFORNIA,CONCLUSION,COPYRIGHT,INC,LABEL,LEUPROLIDE,METHODS,OBJECTIVE,RESULTS,SHORT,STATE
004,016,169,213,225,510,948,ADT,COMPARE,COMPLAINTS,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHYSICIANS,RESULTS
001,169,177,760,770,BETWEEN,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS
223,MDV3100
EGFRS,FGFRS,SIGNALING
DESPITE,IR192,PA103,PSA
555,ABBOTTABAD,AMONG,ANOTHER,BACKGROUND,COMMONEST,CONCLUSION,DEPARTMENT,HARIPUR,HODGKIN,IEUKAEMIA,INCIDENCE,LABEL,LEUKAEMIAS,LYMPHOMAS,METHODS,RESULTS
CAT,HOWEVER,OXIDATIVE,ROS,THERE
200,209,367,409,775,AMONG,ENDOSCOPIC
001,007,491,594,BACKGROUND,BPH,CONCLUSION,FORTY,LABEL,METHODS,NIGERIA,RESULTS,SINCE,THERE,TRANSITION
ADENOSINE,AMP,ATP,BECAUSE,FURTHER,METFORMIN,THESE,TORC2,VIRTUALLY
AIM,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERE
347,BASED,CAP,GROUP,LABEL,METHODS,RESULTS,THERE,THESE,TNM,UNLABELLED
AUTOMATIC,FIRST,HOWEVER,LARGE,SDA,THIRD
EFFICIENT
ADDITIONAL,BACKGROUND,CONDITIONS,ELIXHAUSER,FLORIDA,INDEX,LABEL,METHODS,RESULTS,THERE
100,APPEARANCE,MUTATIONS,SEVERAL,TMPRSS2,VHL
945,AIF,BACKGROUND,GIVEN,LABEL,PARP1,PC3,PRINCIPAL,RESULTS,ROS,TOS,USING,VK3
945,ACTIVATED,AKT,BINDING,CONCLUSION,EMPLOYING,GRP78,LABEL,METHODS,OBJECTIVE,RESULTS,TETRAMERIC,TORC2,WESTERN
320,494,536,CLEVELAND,TAKEN
AKT,DU145,ERK,IGF,LNCAP,MIR,MM2,PDCD4,PI3,SHORT,SIMILAR,THESE,USING
1AR,ATM,ATR,ERG,HOWEVER,HPR,NOTABLY,TMPRSS2
200,500,550,555,600,620,630,655,680,900,930,RADICAL
BOWEL,FURTHER,HRQOL,QUALITY
117,450,AMONG,COX,DEFINITIVE,FURTHER,GLEASON,HOWEVER,KLOTZ,OVERALL,PSA,SINCE,TEN,WOLTERS
347,348,GROUP,HENCE,THESE,TRIAL
THERE
000,100,CENTERS,CONTROL,DISEASE,MEN,OLDER,OVERALL,PHYSICIANS,PREVENTION,QUALITY
FINALLY,THESE
CONSISTENT,DESPITE
STUDIES,TREATMENT
PRESENTING,PROTECT,THESE,TREATMENT
022,2NG,407,731,8NG,AFFAIRS,AFRICAN,COMPARISON,DEPARTMENT,GLEASON,HEALTHCARE,INSTITUTE,PIVOT,PROGRAM,PSA,QUALITY,RESULTS,STUDIES,TRIAL,USING
MEN
CONVERSELY,GLEASON,MEN,PREVIOUSLY,PSA
PSA,THESE,THROUGH
EFFORTS,GLEASON,PATHOLOGIC,PATHOLOGY,SOCIETY,YEARS
170,1980S,1990S,241,740,SCREENING,SOCIETY,TODAY
FACTORS,FINALLY,FIRST
400,488,ALEXA,CELLS,FLUOR,PHALLOIDIN
039,160,328,619,947,ALBERTA,ALCOHOL,CASES,CURRENT,GLEASON,III,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STAGE
ADT,AMONG,OTHER,PSA,THERE
169,177,658,840,956,COPYRIGHT,HOWEVER,ILE,ISOLEUCINE,PCR,REVERSE
FINALLY,NB2,PRL
150,665,956,SUBSEQUENT,THERE,THESE
169,400,436,945,946,947,948,EGF
000,HOWEVER,OVERALL,SPC
169,BECAUSE,CONSISTENT,COPYRIGHT,HBD,LNCAP,LTD,PSA,SRC,THESE,TMPRSS2,UGT2B17,USING
DU145,THESE
160,CAREGIVERS,CONTINUOUS,INTERVIEWS,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTPATIENT,PURPOSE,RESULTS,SETTING
1970S,FORUM,NURSING
AFTER,ALAS1,B2M,BASED,CELLS,EXPRESSION,GAPDH,HPRT1,NORMFINDER,SELECTION,TBP,UBC,YWHAZ
ALU,HOWEVER,PCR,THEREFORE
792,FUNCTIONAL,HENRI,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RALRP,RESULTS
10Q11,160,19Q13,215,496,999,CHINA,CHINESE,GUANGXI,PSA,SERUM,SLC45A3
016,025,047,179,193,223,231,BACKGROUND,FCR,HOWEVER,INVENTORY,LABEL,METHODS,RECURRENCE,RESULTS
169,1F5,FOXA1,HOWEVER,LNCAP
BACKGROUND,COLORECTAL,CONTROL,ERSPC,FORCE,LABEL,METHODS,OBJECTIVE,OVARIAN,PREVENTIVE,RANDOMIZED,RESULTS,SCREENING
169,BLADDER,DESPITE
169,4NG,593,AAM,AFRICAN,COPYRIGHT,HOWEVER,IRELAND,LTD,PIN,PSA
169,ACTIVATION,CALCIUM,COPYRIGHT,ISSUE,REDUCED,SPECIAL,SYMPOSIUM,WHILE
002,005,044,066,207,549,672,772,858,894,AMONG,AUC,BACKGROUND,CONCLUSION,DRE,EARLY,ERG,ETS,GLUTAHIONE,GSTP1,LABEL,MATERIALS,METHODS,MSP,PCR,PSA,RAS,RASSF1A,RESULTS,SEDIMENTED,TMPRSS2
ART,BT474,DU145,ERBB2,MYC,POTENTIAL,WNT
954,ASIAN,GENISTEIN,HOWEVER,SOY,WESTERN
117,FINALLY,GHRELIN,LNCAP,METABOLIC
117,328,332,AMERICANS,EUROPEANS,LABEL,METHODS,NON,NORTH,OBJECTIVE,OLDER,PCA,PSA,PURPOSE,RESULTS,SWEDISH,USING
169,CHANGES,COPYRIGHT,D191V,FOLH1,G206R,G245S,GCPII,H475Y,HAPLOTYPES,P160S,R190W,SIX,V108A,Y176H
169,COPYRIGHT,HOWEVER,PUBLISHED
011,ANTISENSE,CUSTIRSEN,HEMISPHERE,OGX,WESTERN
169,1B1,AHR,COPYRIGHT,IMMUNOBLOT,INC,LNCAP,PCR,THESE
160,169,293,COPYRIGHT,HCT,HEK,HOR,MCF,OCT,SAS,TRI
169,COPYRIGHT,IRELAND,LTD,METASTASIS,PCA
946,AMBULATORY,BACKGROUND,CIS,CROSS,GIVEN,HOWEVER,LABEL,MEDICAL,METHODS,RESULTS,THERE
173,215,278
001,003,157,169,523,614,814,BECAUSE,COPYRIGHT,COX,GLEASON,INC,MOLECULAR,PATHOLOGY,PCR,PITX2,PUBLISHED,SOCIETY
169,COPYRIGHT,INC,INCIDENCE,INNOVATIVE,LABEL,MARKERS,OBJECTIVE,PCA,PROTEOMICS,PSA,PUBLISHED,PURPOSE,RESULTS,SEVERAL,SOCIETY
103,169,6MM,COPYRIGHT,FOXP3,FURTHER,GLEASON,LTD,PSA,TREGS
169,BOWEL,COPYRIGHT,INC,MEDICAL,PUBLISHED,V50GY
169,551,553,BACKGROUND,CIS,COPYRIGHT,LABEL,LTD,METHODS,OVERALL,RESULTS,SIR
169,COPYRIGHT,DESPITE,III,INSTEAD,LTD,MAXILLO,PUBLISHED,RANKL,SINCE,SURGERY
000,100,169,ANTALYA,AVERAGE,BACKGROUND,COLORECTAL,COPYRIGHT,CROATIA,EASTERN,IZMIR,JOINPOINT,LABEL,LTD,MALTA,METHODS,NORTH,PERCENTAGE,RESULTS,ROMANIA,SOUTH
AREAS,BACKGROUND,COVERED,LABEL,MEDICAL,MEDLINE,METHODS,OPINION,PENDING
169,ACO,ACT,AFFORDABLE,COPYRIGHT,FEE,FFS,FINANCIAL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PBT,PURPOSE,RESULTS
169,177,ADT,BMD,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
015,169,718,CHF,COPYRIGHT,COX,EFFECTS,INC,INCREASING,INDEX,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PATIENT,PURPOSE,QUANTEC,RESULTS
169,300,956,COPYRIGHT,CROWN,HOWEVER,LTD,MTT,MYRICETIN,PUBLISHED
15D,169,539,549,756,763,775,777,831,852,866,872,889,892,BACKGROUND,COPYRIGHT,FINNISH,HRQOL,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,THESE,UROLOGY
169,BACKGROUND,CDC27,CNA,COPYRIGHT,EXOME,INTEGRATED,KDM6A,KIF5A,LABEL,METHODS,MULTILEVEL,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,THERE,UROLOGY
106,169,547,AFTER,AMICO,BACKGROUND,CLAVIEN,COPYRIGHT,DINDO,FOCAL,GLEASON,INDEX,IQR,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SCORE,SETTING,SYMPTOM,THERE,UROLOGY,VTP
ASIDE,DNAJC15,MCJ,TIM14,TIM23
001,002,003,187,452,495,887,COX,GLEASON,MEIER,PSA,T2A,UNILATERAL
BMS,PROGRAMMED
481,AFRICAN,ANTIGEN,INTRINSIC,MEN,SCREENING,TESTING
256,CTV,D95,PTV,SMALL
215,979,MEN,SMOC1
125,COLORECTAL,LABEL,LEVEL,METHODS,NPV,OBJECTIVE,OVARIAN,PPV,RESULTS,SCREENING,TRIAL
169,177,419,CB1,CB1IR,COPYRIGHT,FATTY,ISSUE,LIPID,METABOLISM,SPECIAL,USING,WILLEBRAND
FEATURE,NET,NUMERICAL
133,BECAUSE,EGR,FURTHER,INC,MG132,NAG,PROTEASOME,PUBLISHED,TRANSGENIC
169,215,COPYRIGHT,HOWEVER,INC,LNCAP,THESE,UNTREATED
047,169,200,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,FRONTLINE,INC,LABEL,LDK,LHRHA,LOW,MEDICAL,METHODS,P17,RESULTS,TTP
169,COPYRIGHT,FUNCTIONAL,INC
145,169,2C9,COMPOUNDS,COPYRIGHT,LNCAP,LTD,SILYBUM
169,997,BACKGROUND,BETWEEN,CONCLUSION,COPYRIGHT,INC,INTENSIVE,LABEL,METHODS,RESULTS,SIR
169,COPYRIGHT,LDL,LTD,PLA,SEVERAL
050,108,169,241,525,AEU,BACKGROUND,CHINESE,CONCLUSION,COPYRIGHT,DIEGO,GENOTYPING,HAN,INC,LABEL,MASSARRAY,METHODS,MPO,OBJECTIVE,OBJECTIVES,OTHER,PCA,PUBLISHED,RESULTS,SAN,SNP,TOTALLY,USA
HOWEVER,RAF,SGC7901,TAKEN,THESE,WOUND
003,004,031,12P70,945,946,BASED,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SERUM,SEVERAL
DIAGNOSIS,EARLY,PERHAPS

DEFINITIVE,MRI,PET,PROTONS
HOWEVER,SUI,URINARY
DENOSUMAB,RANKL,SOLID
HLA,III,PPV,RANDOMIZED
169,AKT,AZD5363,CONCLUSION,DU145,HOWEVER,LABEL,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS,S6K,TAKEN,THEREFORE,WHILE
160,169,ACADEMY,ADT,ANDROLOGY,CYP17A1,DHT,HENCE,SOCIETY,STS
946,AMONG,FINALLY,GTPASES,P21,PC3,RHO,TGF
FINALLY,PRSS3,SILENCING,USING
169,240,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,DEGARELIX,LABEL,METHODS,RESULTS,SCORE,SYMPTOM
000,100,169,185,APRIL,BACKGROUND,BASEL,COPYRIGHT,LABEL,METHODS,REGARDING,RESULTS
169,292,485,BACKGROUND,BASEL,CAUCASIANS,CONCLUSION,HOWEVER,LABEL,LIBRARY,MEDLINE,METHODS,PCA,RESULTS,STATA,VAL158MET
169,177,1ST,252,BACKGROUND,BASEL,BETWEEN,CONCERNING,COPYRIGHT,GERMANY,JANUARY,LABEL,LOWER,METHODS,NEITHER,RESULTS,TRACT,URINARY
D1B,FURTHER,NOTABLY,SNAI2,WHILE
160,169,177,240,244,ABOUT,COLLEGE,COPYRIGHT,GLEASON,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,QUALITY,RESULTS,ROYAL,SCORE,SYMPTOM,T2B,TNM
CONCLUSION,HODGKIN,LABEL,METHODS,NATIONWIDE,OBJECTIVE,OUTCOME,RESULTS,SETTING,SWEDISH
215,AIM,BACTERIAL,CD3,CD4,CD8,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,THEREFORE
237,305,660,PCA,PHYSICIANS,THESE
DIFFUSE,HASHIMOTO,NODULAR,THROUGH
KH7,LNCAP,PC3,RAF,UNTIL
169,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,LNCAP,METHODS,REGULATED,RESULTS,THESE,TRANSWELL,WESTERN,WILEY
169,458,500,782,BACKGROUND,CONSORTIUM,COPYRIGHT,GENOMES,IMPUTATION,INC,LABEL,MAF,METHODS,NCI,PROJECT,RESULTS,SNP,WILEY
169,VCH,WILEY
022,035,070,088,128,252,65309,6TH,905,AGAINST,BCR,FIFTY,HTX,III,JANUARY,PSA,SEPTEMBER,THERE,UNION,UNIVARIATE
160,CONVERSELY,ECM,ERBB2,HSP,HSP90,IGG,PSA,RIBOSOMAL,TREATMENT
160,960,BPH,DNMT1,GLEASON,GSTP1,LN4,PC3,PCA,PRIMARY,WHILE
183,ATTENTION,GEORG,STUTTGART
169,506,512,ADVERSE,CENTRAL,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,NCT,OBJECTIVE,PERIPHERAL,PUBLISHED,PURPOSE,RESULTS,SIPULEUCEL,TRIAL,UROLOGICAL
001,153,169,174,177,ADD,BJU,FIFTY,HOWEVER,INDEX,JANUARY,KNOWN,LABEL,METHODS,OBJECTIVE,RESULTS,RRP,SEPTEMBER,SUBJECT,THERE,UNLABELLED
001,169,413,424,837,AFTER,AHA,COPYRIGHT,EDUCATION,INC,INPATIENT,LABEL,MATERIALS,METHODS,NATIONWIDE,NIS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
945,CHIRALITY
AMONG
3BETA,CONCLUSION,DU145,ETOAC,LABEL,METHODS,MTT,NMR,OBJECTIVE,PC3,RESULTS
INHIBITION,INHIBITORS,TRPM8
954,AKT,BAK,BAX,BCL,BIM,CCL,CXC,CXCR4,ERK,MCL,MONITORING,PBMCS,RHO,TAKEN,WEV
BACKGROUND,CURRENT,DISULFIRAM,ERG,HOWEVER,LABEL,METHODS,RESULTS,SINCE,TAKEN,TMPRSS2
22RV1,22RV1RD,BACKGROUND,DOCETAXEL,DU145,DU145RD,HORMONE,LABEL,LNCAP,MDR,PRINCIPAL,RESULTS
HYPOTHESIS,IGF,INSULIN,IRS,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,SINCE,THESE
000,059,100,165,554,781,ADDITIONAL,ARB,CASES,CIS,GENERAL,KINGDOM,RRS
BIOLOGICAL,BIOPROP,DVH,III,LEVEL,NSCLC,TCP
174,CREMOPHOR,DOCETAXEL,DUE,FDA,PACLITAXEL,TAXOL,TAXUS,TODAY
160,AKT,ELISA,LNCAP,MAPKS,PC3,WESTERN
BACKGROUND,LABEL,MATERIALS,METHODS,RESULTS,THERE,UCP
ANDROGENS,FURTHER,HOWEVER,THESE
HOWEVER,OTHER
100,GLEASON,LABEL,METHODS,MTT,OBJECTIVE,PURPOSE,RESULTS,SIXTY,TURBOFLASH
270,342,BACKGROUND,FEW,GLEASON,JANUARY,LABEL,LRP,METHODS,NHT,PSA,RESULTS,SEPTEMBER,THERE
174
126,670,795,ARA,BACKGROUND,CONVERSELY,FURTHER,HOWEVER,LABEL,MAY,METHODS,RESULTS,STUDIES,THERE
125,CHINA,CHROMOSOME,CONSORTIUM,ESI,HPP,INDIA,MALDI,MRM,NAPPA,PROJECT,QTRAP,SPAIN,SRM
946,QUESTIONS,THESE
001,100,280,946,956,CARCINOMA,CONCLUSION,DOX,ETO,GSK,HOWEVER,LABEL,LNCAP,LYMPH,MATERIALS,METHODS,MTT,OBJECTIVE,RESULTS,SUBG1,THIAZOLYL,VIN
AMONG,BAYES,CA125,COLORECTAL,CONCLUSION,LABEL,METHODS,OBJECTIVE,OVARIAN,PEB,PURPOSE,RESULTS,SCREENING,TRIAL
169,ANECDOTAL,BP1,CONSISTENT,DU145,HGPIN,INHIBITION,LNCAP,NAD,PC3,RES,S6K,SIRT1,THEREFORE,THESE

255,CENTRAL,END,JANUARY,LABEL,MAJOR,MARCH,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,RESULTS,SAHARAN,SETTING
CURRENT,HOWEVER,MEN,TARGETING
COLORECTAL,FORCE,HOWEVER,INSTEAD,OVARIAN,PREVENTIVE,PSA,RANDOMISED,SCREENING,TRIAL
160,330,760,ESS,SIMILAR
15MIN,169,COPYRIGHT,LNCAP
169,COPYRIGHT,DR5,THEREFORE,TRAIL
ADS,DTSTA,PCA
DEPLETION,HSP70,KNOCKDOWN,PC3,TARGETING
169,ANTIGEN,APM,CD3,CD4,CD8,COPYRIGHT,FOXP3,HLA,INC,LENTIVIRUS,MACHINERY,PROCESSING,TAPASIN
133,140,169,219,254,COPYRIGHT,DU145,EP3,H89,L798106,LTD,NAF,PC3,PKA,SDF,SP1
169,499,795,797,804,806,COPYRIGHT,COX,EDUCATION,EXAMINING,HARRELL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PARTIAL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,964,CAUCASIAN,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL
500,954,956,BCL,BCLXL,INC,LYSATES,OVERALL,PUBLISHED,TMA,YIN,YY1
169,215,COPYRIGHT,ELISA,LTD,VEE,VENEZUELAN,VRP,WHILE
075,138,169,ABOUT,BACKGROUND,CONCLUSION,COPYRIGHT,INC,INPATIENT,LABEL,METHODS,NATIONWIDE,NINTH,PREVALENCE,PUBLISHED,RELATIVELY,RESULTS
169,AEU,BACKGROUND,COPYRIGHT,DENOSUMAB,LABEL,METHODS,PUBLISHED,RANKL,SUMMARY,ZOLEDRONIC
097,143,169,346,512,AEU,CONCLUSION,COPYRIGHT,GLEASON,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,THERE,VARIABLES,VERMEULEN
169,COPYRIGHT,CPG,EPIGENETIC,HOWEVER,INC,NOTABLY,THESE
001,030,045,100,169,396,BACKGROUND,COPYRIGHT,LABEL,LRP,MEIER,METHODS,OBJECTIVE,OUTCOME,PATIENT,PUBLISHED,RALPS,RESULTS,ROBOT,ROBOTIC,SETTING,SHORTER,UROLOGY
001,003,006,223,294,402,ADT,BACKGROUND,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,WHETHER
133,169,183,187,235,AFRICAN,AGE,ALZHEIMER,BACKGROUND,CAUSE,CODEM,COPYRIGHT,FACTORS,FOUNDATION,FUNDING,GATES,GBD,HIV,ISCHAEMIC,LABEL,LTD,MALARIA,MELINDA,METHODS,MODEL,POPULATION,RESULTS,SAHARAN,UIS
001,169,220,AVERAGE,CALYPSO,COLLEGE,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS,STUDENT,THESE,TREATMENT
169,COPYRIGHT,DISCERN,IHI,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PBT,PCA,PROVIDERS,PURPOSE,QUALITY,RESULTS,THERE,THESE
AUTOMATED,CONCLUSION,HOWEVER,LABEL,METHODS,MONITORING,PRE,RESULTS,UNLABELLED
143,186,945,ADT,CGE,CONCLUSION,DEFINITIVE,GRADE,LARGE,RESULTS
001,BACKGROUND,BASED,DISCUSSION,EORTC,FURTHER,LABEL,METHODS,OCTOBER,OVERALL,QLQ,RESULTS,SEPTEMBER,THESE,UNMET
THESE
CAMELUS,CH1,CURRENTLY,DIFFERENT,DUE,ELISA,GIVEN,HCABS,IGG,VHH
169,6TH,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PARIS,PUBLISHED,PURPOSE,RESULTS,TREATMENT,UROLOGICAL
169,366,CAPSURE,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCI,PHYSICIAN,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,UROLOGISTS
111,169,180,COPYRIGHT,EDUCATION,GRADE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OSTEOCLAST,PUBLISHED,PURPOSE,RANKL,RESULTS,UROLOGICAL
169,638,646,COPYRIGHT,EDUCATION,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OTHER,PUBLISHED,PURPOSE,RESULTS,SECONDARY,THERE,TOREMIFENE,UROLOGICAL
169,174,CONSISTENT,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
111,169,ANECDOTAL,COPYRIGHT,EDUCATION,ENGLISH,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PERTINENT,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WORRISOME
169,COPYRIGHT,DRE,EDUCATION,FIRST,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,THERE,THEREFORE,UROLOGICAL
002,007,169,262,ACTUARIAL,AGE,COPYRIGHT,COX,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T2A,UROLOGICAL
169,190,482,508,682,781,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,ONTARIO,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,CLASSIC,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBESITY,OBJECTIVE,PRIOR,PUBLISHED,PURPOSE,RESULTS,SINCE,UROLOGICAL
094,428,553,575,647,BACKGROUND,LABEL,METHODS,PRT,RESULTS,THERE
169,ANEUPLOIDY,CEP57,FGF,FGFR1,HOWEVER,MALIGNANT,RES,TAKEN
945,946,LNCAP,MEN,PCA,TAKEN

CAR,CCR,CURRENT,HOWEVER,USING
001,185,18FCH,224,233,APRIL,DISEASE,GLEASON,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,PET,PSA,PSADT,PURPOSE,RESULTS,SUBSEQUENT,THREE,TRIGGER
250,947,948,JAPAN

BACKGROUND,DETECTION,HOWEVER,LABEL,METHODS,PBL,PCA,PCR,PSA,RESULTS
169,GOLGI,LNCAP,PNTA1,THEIR,WILEY
009,169,337,617,AGREEMENT,AMONG,BLACKWELL,FIFTEEN,GLEASON,IMAGE,LABEL,LIMITED,METHODS,MINIMUM,NETWORK,OBJECTIVE,PATHOLOGY,PUBLISHING,RESULTS,SOCIETY,THERE,UROLOGICAL,WHILE
169,ANOTHER,BLACKWELL,COLLEGE,CONSENSUS,III,LIMITED,NHMRC,PUBLISHING,REPORTING,ROYAL,THERE
MEN
CHRONIC,CRP,IGG,RAT,SEVERAL,SPRAGUE
027,032,916,APC,CDC20,ECTOPIC,GLEASON,MITOTIC
EPIGENETIC,HENCE,INSTEAD
WITHOUT
000,132,BPH,COX,ITALIAN,JANUARY,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PCA,PROPENSITY,PURPOSE,RESULTS,THESE
169,AMONG,DIVERSE,INC,WILEY
956,BAK,BAX,BCL,BIM,CXCR3,CXCR4,CXCR5,CXCR6,FINALLY,LNCAP,MCL,MTT,PC3,PCA,USING,WEV
156,239,315,BIOLOGICS,BRITISH,CONCLUSION,ENGLAND,ENGLISH,HODGKIN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,POISSON,RESULTS,RISKS,SIR,SOCIETY,TNF
100,102,169,ADC,CONCLUSION,COPYRIGHT,DWI,ECE,FIFTY,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,WILEY
169,COPYRIGHT,GHR,GOLGI,INC,LNCAP,THESE,WILEY
231,HOWEVER,MATRIPTASE,MDA
015,024,AUSTRALIA,BACKGROUND,HODGKIN,HOWEVER,LABEL,METHODS,OUTCOME,RESULTS,TRANSPLANT,ZEALAND
169,954,956,AKT,COPYRIGHT,MYC,PACLITAXEL,PGP,TAX
ADT,HRQOL,INTENTION,PCA
169,COPYRIGHT,HODGKIN,LTD,NHL,THESE
002,169,ACUTE,ADVERSE,COPYRIGHT,CRT,DOSES,INC,MEDICAL,OAR,PUBLISHED,SALVAGE,THERE,THESE,THREE
103,150,BACKGROUND,CANCERS,CONFIDENCE,END,LABEL,METHODS,POISSON,RESULTS,SIR,THYROID
CURRENTLY,IMAGE
100,115,137,169,197,215,222,242,246,268,350,863,985,AMONG,COPYRIGHT,GY3,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PRESCRIBED,PROSTATIC,PURPOSE,RESULTS,SURVIVORS,UNIVERSITY
00005,00006,004,120,121,191,209,CTVPROS,CTVPVSAPCT,CTVPVSAPMR,CTVPVSSZCT,CTVPVSSZMR,EIGHT,HOWEVER,MRI,RATIO,STUDENT,VOLUMES
223,700,BASED,III,MDV3100,RESULTS,TAK
001,024,040,PRE
111,BPH,CHAIN,CONCLUSION,GENOTYPING,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,POLYMERASE,PSA,PURPOSE,RESULTS,SIMILARLY
177,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
000,160,177,190,AFTER,BPH,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,USING
100,107,BACKGROUND,HOWEVER,LABEL,METHODS,MYD88,MYELOID,OBJECTIVE,RESULTS,THERE
000,010,100,132,144,172,178,500,773,783,BACKGROUND,HOWEVER,ITALY,LABEL,METHODS,MORTALITY,OBJECTIVE,OTHER,REDUCED,RESULTS,WORLD
118,132,258,549,IHC,WESTERN
ADT,AFTER,BECAUSE,CEA,MRI,PSA
MRI,PSA,SIX
169,178,185,215,COPYRIGHT,CVS,DPV,ELISA,HRP,NTF,PSA,UNDER
132,148,169,210,227,ADT,BASEL,CHANGES,COPYRIGHT,HDL,LABEL,LDL,MAB,METHODS,OBJECTIVE,RESULTS,SERUM,THERE

ABCA1,AKT,GLEASON,LNCAP,REMARKABLY
FOXM1,NOTABLY,YET
177,237,946,956,ELISA,GELATIN,HOWEVER,MEANWHILE,MMP,PD98059,THESE,THROUGH,U87MG,WESTERN
CAT,GSH,SOD,THERE
200,FOUNDATION,MICROARRAY,NORTH,TMA
000,169,BACKGROUND,CHEMISTRY,DESPITE,LABEL,METHODS,MNAZYME,PCR,RESULTS
169,AUNPS,COPYRIGHT,CTT54,LNCAP,LTD
026,30D,DU145,LNCAP,MIR,MMP,PC3,PCA,SOCS1,STAT3,TAKEN,USING,UTR,WESTERN
BACKGROUND,FINALLY,FIRST,GAMMA,LABEL,LNCAP,METHODS,RESULTS,SILENCING
BRAIN,HOWEVER
945,946,ALDH1,ALDH2,ALDH3,ALDHS,GSH,HNE,MDA,METHIONAL,ROS
100,280,345,698,808,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OUTCOME,PBX,RAM,RESULTS
DICOM,DVH,DYK,LABEL,MELBOURNE,METHODS,NUCLEAR,OBJECTIVE,PEARSON,PERCENTAGE,PURPOSE,RESULTS,SUN,TPS,VAN
176,180,CHHIP,DIFFERENT,EUCLIDEAN,HOWEVER,LABEL,METHODS,OBJECTIVE,PLANS,PTV,PURPOSE,RESULTS,THESE
176,BACKGROUND,FURTHER,LABEL,METHODS,RESULTS,THESE,ULTIMATELY,USING
003,016,017,025,165,175,340,AFRICAN,BACKGROUND,CAUCASIAN,FORWARD,LABEL,METHODS,NCI,OBJECTIVE,PURPOSE,RESULTS,SERVICE,SURVIVORS,THERE
AFTER,POTENTIAL
169,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SIR,SWEDISH,UROLOGICAL
679,BACKGROUND,CONCLUSION,DESPITE,GUIDELINES,LABEL,MATERIALS,METHODS,RESULTS,TEN,THERE,UROLOGICAL,UROLOGISTS
079,124,139,208,258,377,470,499,514,852,BACKGROUND,COHEN,GLEASON,KAPPA,LABEL,MATERIALS,METHODS,PERINEURAL,PNI,RESULTS
136,290,516,806,BACKGROUND,CONCLUSION,DRE,LABEL,MATERIALS,METHODS,NPV,PNB,PPV,PSA,RESULTS,SERUM,THREE,WHILE
ADDITIONAL,BACKGROUND,LABEL,MATERIALS,METHODS,RESULTS
001,BACKGROUND,GRADE,JANSSEN,LABEL,METHODS,RESULTS
001,192,261,332,BACKGROUND,COX,DSS,GLEASON,HDR,LABEL,METHODS,PSA,RESULTS,THERE
BACKGROUND,DEPARTMENT,ENROLLMENT,LABEL,MEDICAL,METHODS,PILOT,RESULTS,SKCCC,TRIAL
FURTHER,HOWEVER,III
464,767,CONCLUSION,FEDERAL,LABEL,METHODS,NORTH,OBJECTIVE,RESULTS,SEVENTY,SOUTH,THERE,THESE,UNLABELLED
99M,GLEASON,HOWEVER,PET,PSA,THESE
100,1E8,2B4,AKT,PCR,SILENCING,WESTERN
AUNPS,FGFRS,FIBROBLAST,NOVEL,THESE
000,001,91263,BACKGROUND,CLPTM1L,FOLLOWING,LABEL,PRINCIPAL,RESULTS,THESE
ACTIVATION,DISRUPTION,PC3,PCA,PSA,SEVERAL,STAT3,STRIKINGLY,THESE
BECAUSE,DU145,FURIN,KIP,LNCAP,PACE4,PC7,PCS,USING,XTT
001,011,368,6TH,7TH,ASIAN,COMMITTEE,JOINT,LABEL,METHODS,OBJECTIVE,RESULTS,TNM
386,AMONG,BETWEEN,CONCLUSION,HOWEVER,KOREA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,011,177,BETWEEN,CONCLUSION,HOWEVER,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PCA,PURPOSE,RESULTS
973,AIM,EINDHOVEN,GLOBE,LABEL,METHODS,OBJECTIVE,QUESTIONS,RESULTS
674,AIM,AMONG,CONCLUSION,GLEASON,GS6,LABEL,LOW,METHODS,OBJECTIVE,PCA,PSA,RESULTS,STRATIFIED
BACKGROUND,BIC,CONCLUSION,EGF,LABEL,LNCAP,MATERIALS,METHODS,MYC,RESULTS,TAMOXIFEN
224,BACKGROUND,C32,CONCLUSION,GBM,HCT15,LABEL,MATERIALS,METHODS,RESULTS,U87,WHILE
946,AKT,DPI,FAS,INHIBITION,PC3,ROS
209,791,902,CAUCASIANS,HOWEVER,MEDLINE,OVERALL,SCIENCE,SIMILARLY,THEREFORE,WANFANG,WEB
160,GLY450VAL,PARK2,SER9THR
332,945,946,DESPITE,HOWEVER
007,311,413,GLEASON,LABEL,METHODS,OBESITY,OBJECTIVE,PROTECT,PSA,PURPOSE,RESULTS,THERE
494,692,AFTER,AMONG,DETROIT,DRE,FURTHER,HOWEVER,LABEL,METHODS,NSESI,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SES
CCD
160,IMAGING,ORBITAL,TREATMENT
102,127,CHINESE,CONCLUSION,CROSS,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SETTING,UROLOGY
111,945,946,FINALLY,GLEASON,GYLTL1B
BASED,SEMINAL
183,196,379,AMONG,HOWEVER,PCA,RADICAL,RRP,T1A,T2C,T3A
954,AGREEMENT,BACKGROUND,CENTERS,CONTROL,DISEASE,LABEL,METHODS,PREVENTION,PROGRAM,RESULTS
929,BACKGROUND,CANCORS,CRN,HMO,HOWEVER,III,LABEL,METHODS,NETWORK,OBJECTIVE,PPV,RESULTS,SECONDARY
100,CK903,ERG,HOWEVER,PIN,RADICAL
CTLA4,EMT,EPITHELIAL,KNOWLEDGE
SIPULEUCEL
ALIGNMENT,BAM,FASTQ,FURTHER,KNOWN,LNCAP,MAP,SAM,TARGETSCAN
CACO2,NOTABLY,ROS,TAKEN,WNT
001,514,BACKGROUND,BETWEEN,C30,EORTC,LABEL,METHODS,PCA,QLQ,QOL,RESULTS
169,BASEL,COPYRIGHT,ENCOUNTER,INDEX,LABEL,LIBRARY,MANAGER,METHODS,OBJECTIVE,PCA,PDE5I,PROFILE,QUESTIONS,RESULTS,SEP
021,042,135,169,352,556,946,BACKGROUND,BASEL,CD44S,COPYRIGHT,GLEASON,HGPIN,LABEL,MATERIALS,METHODS,PCA,RESULTS,TNM
169,COPYRIGHT,INC,PHYSICIANS,TIO
AFRICAN,CAUCASIAN,CAUCASIANS,ISSUE,LTD,PUBLISHED,SINCE,SPECIAL,THESE,VITAMIN
946,EGR,GSK,INC,LABORATORY,NAG,NSAID,PUBLISHED,STUDIES,TGF
169,ADJUSTMENT,ADT,ASSESSMENT,COPYRIGHT,COUPLES,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCALE,THERAPY,THOSE,WHILE
169,945,946,948,CAM,COPYRIGHT,CWR22RV,FEDERATION,HIF,PUBLISHED,SOCIETIES
001,002,013,10878,169,CDCA3,COPYRIGHT,GLEASON,HOX,HOXB3,IRELAND,LNCAP,LTD,MEIER,PSA,THEIR,THESE
169,COPYRIGHT,EARLIER,INC,OPG,PANCREATIC,RAS,SILENCING,THESE,TRAIL,WHILE
160,169,947,BECAUSE,BHPRE,COPYRIGHT,HINDGUT,INC,KSM,PATHOLOGY,PUBLISHED,SOCIETY,STROMAL,THESE,WHEREAS
001,009,169,313,328,422,COPYRIGHT,EDUCATION,INC,INCREASED,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PHYSICIANS,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
009,169,309,334,955,BOARD,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OLDER,PUBLISHED,PURPOSE,RESULTS,THERE,THESE,UROLOGICAL,UROLOGY
100,169,200,298,AFTER,COPYRIGHT,EDUCATION,ENCOUNTER,FOLLOWING,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIMARY,PROFILE,PUBLISHED,PURPOSE,RESULTS,SEP,UROLOGICAL
160,169,ADT,ASC,C81,COPYRIGHT,INC,LNCAP,PATHOLOGY,PCA,PUBLISHED,SOCIETY,THESE,TRAMP,USING
160,169,COPYRIGHT,FINALLY,FURTHER,IMAGING,INC,PATHOLOGY,PUBLISHED,SOCIETY
009,078,161,169,913,951,COPYRIGHT,GLEASON,INC,KRUPPEL,PATHOLOGY,PCA,PDCD4,PUBLISHED,SOCIETY
169,BACKGROUND,BMI,CONTEXT,COPYRIGHT,HOWEVER,INCREASING,LABEL,METHODS,OBESITY,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,THESE,UROLOGY,WESTERN,WHETHER
169,969,BACKGROUND,BECAUSE,CONTEXT,CONVERSELY,COPYRIGHT,CURRENT,DUE,LABEL,METHODS,OBJECTIVE,PCA,PRIMARY,PUBLISHED,RESULTS,SYNTHESIS,UROLOGY,WESTERN
169,501,AMONG,COLLEGE,COPYRIGHT,COX,HOWEVER,III,LABEL,LTD,MATERIALS,METHODS,NTX,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,THEREFORE,ZOL
104,114,169,BACKGROUND,CONTEXT,COPYRIGHT,GRADE,HOWEVER,INC,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,PATIENT,PURPOSE,RCC,RESULTS,SETTING,THERE
169,241,COPYRIGHT,PET,SMALL
169,241,BACKGROUND,CONCLUSION,COPYRIGHT,FDG,FIFTY,LABEL,METHODS,PET,RESULTS
169,COPYRIGHT,CURRENTLY,HOWEVER,LTD,STUDIES,WESTERN
169,COPYRIGHT,FEDERATION,FINALLY,PREVENTION,PUBLISHED,SOCIETIES,THESE,TOBACCO,WIDER
169,COPYRIGHT,INC,SEMINAR,SOCIETY,THERE
001,011,076,130,145,169,172,201,204,213,255,385,405,672,ACP,AMONG,BPH,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,OUTCOME,PROSTATIC,PSA,RESULTS,SERUM,SETTING,STUDENT,WHITNEY
CONCLUSION,LABEL,MARCH,METHODS,OBJECTIVE,PATIENT,PLACE,RESULTS,SEPTEMBER,SHAUKAT
032,035,169,300,332,413,640,739,823,AUC,COPYRIGHT,OPTIMIZING,PSA,PUBLISHED,ROC,THESE
100,AFTER,EMA,LABEL,PALLIATIVE,PROSTATIC,SLIDE,UNASSIGNED,UNLABELLED,VIRTUAL
160,169,177,AIM,AUTHORS,BRITAIN,CLOSURE,COLORECTAL,CONCLUSION,DISEASE,GREAT,IRELAND,LABEL,METHODS,OBJECTIVE,RESULTS,RUF,THERE
008,169,ANZ,AUSTRALIA,AUSTRALIAN,AUTHORS,BACKGROUND,BLADDER,CIS,COLLEGE,CONCLUSION,JOURNAL,LABEL,LARGE,METHODS,RCP,RESULTS,ROYAL,SOUTH,SURGERY,WALES
102,169,319,ASSESSMENT,GLEASON,HOWEVER,JAPAN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
169,207,257,259,453,946,FOLEY,JUDGING,UROLOGICAL
169,APMIS,CRC,LTD,OVERALL,PCA,PHE133LEU,POZ,PUBLISHED,SPECKLE,TSG,WILEY
DESPITE
800CW,EPCAM,FURTHER,IRDYE,MMC,MULTIMODAL,THREE,USING
100,140,258,266,364,482,528,CONCLUSION,DVC,GLEASON,LABEL,METHODS,NVB,OBJECTIVE,PSA,RESULTS,RRP,THERE,WALSH
001,029,150,AFTER,CCS,CONCLUSION,III,LABEL,METHODS,NBT,NIH,NINGBITAI,OBJECTIVE,PSA,RESULTS
022,035,100,153SM,99MTC,CONCLUSION,EDTMP,LABEL,MBQ,MDP,METHODS,OBJECTIVE,PCA,RESULTS
BMD,CONCLUSION,LABEL,MAB,METHODS,OBJECTIVE,PSA,RESULTS,THERE
008,169,BACKGROUND,BPH,CONCLUSION,FURTHER,LABEL,LINEA,NIGERIA,OBJECTIVE,RESULTS,SOCIETY
001,946,BACKGROUND,GLEASON,HOWEVER,LABEL,METHODS,MSP,PSA,REGARDLESS,RESULTS,WHETHER
784,CONCLUSION,ETHNICITY,IMD,INDEX,LABEL,METHODS,OBJECTIVE,PHASE,PURPOSE,RESULTS
018,169,215,668,694,956,ACCESS2,AUC,BACKGROUND,BECKMAN,CHEMISTRY,COULTER,GLEASON,LABEL,METHODS,PCA,PHI,PSA,RESULTS,ROC,SERUM,TOTAL
110,136,169,215,246,956,AUC,BACKGROUND,BECKMAN,CHEMISTRY,COULTER,DRE,E26,ERG,GEN,HOLOGIC,LABEL,METHODS,NEM,PCA,PHI,PROBE,PSA,RESULTS,ROC,SERUM,TMPRSS2
169,AMONG,COPYRIGHT,HCT,LNCAP,LTD,ROS,WILEY
169,BACKGROUND,BRITISH,CONCLUSION,COPYRIGHT,JOURNAL,LABEL,LTD,METHODS,PUBLISHED,RESULTS,SCREENING,SOCIETY,SURGERY,WILEY
100,120,177,300,BACKGROUND,CONTROL,LABEL,LNCAP,MATERIALS,METHODS,PC3,RESULTS,TEN
001,015,106,159,169,201,231,243,AMICO,CONCLUSION,COPYRIGHT,DOPPLER,DRE,ERA,LABEL,METHODS,OBJECTIVE,PDS,PSA,PUBLISHED,PURPOSE,RESULTS,SAS,SIXTY,VPN
100,945,COMMITTEE,EASTERN,EIGHT,GAL,GROUP,HAP,HYPERACUTE,IGG,JOINT,NEWLINK,PSA,RESULTS,SERUM,THESE,THREE
169,AUSTRALIAN,AUTHORS,BILATERAL,COLLEGE,HIP,IMAGING,INVERSE,JOURNAL,MEDICAL,RADIATION,ROYAL,ZEALAND
169,ACHIEVA,AUSTRALIAN,AUTHORS,COLLEGE,DWI,IMAGING,JOURNAL,LABEL,MEDICAL,METHODS,MRI,MRS,NPV,OBJECTIVE,PHILIPS,PPV,PSA,RADIATION,RESONANCE,RESULTS,ROYAL,TESLA,ZEALAND
ABDOMINAL,CONCLUSION,EMERGENCY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGY
460,ANTIGEN,DRE,LABEL,METHODS,NPV,OBJECTIVE,PPV,PREDICTIVE,PROSTATIC,PSA,RESULTS,TRANS,ULTRASOUND,VALUE
ADT,ANTIGEN,DEGARELIX,EAU,FSH,ITALY,PSA
ADI,AMONG,DHT,LNCAP
946,AKT,AMP,F12
105,309,947,DOSIMETRIC,HOWEVER,SEVERAL
120,160,177,418,CONCLUSION,EARLY,FACBC,LABEL,MBQ,METHODS,MRI,OBJECTIVE,PET,PURPOSE,RESULTS,SIX,SUV,THERE,URINE
AMP,COA
135,946,AKT,CDCP1,COMPLEXING,CUB,FAK,PI3,THEREFORE
DESCRIBED,TAMIS,TRANSANAL
169,BASEL,COPYRIGHT,CTC,PCR
ADENOVIRAL,AKT,ALTOGETHER,LNCAP,MACROPHAGE,MIF,NED,PCA,YET
169,186,210,255,ARIZONA,CLAVIEN,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MARCH,MATERIALS,MEDICAL,METHODS,OBJECTIVE,OCTOBER,RESULTS,T3A,UNIVERSITY
145,162,169,500,900,AMONG,AREAS,CONCLUSION,COPYRIGHT,COX,END,HOWEVER,HSA,INC,LABEL,MARKETS,METHODS,OBJECTIVE,POISSON,RESULTS,SERVICE,THESE
000,100,177,259,BACKGROUND,BETWEEN,HOWEVER,LABEL,METHODS,PCA,PSM,RESULTS,THEREFORE,THESE,UNIVERSITY
001,169,174,215,704,892,AUC,BECKMAN,COPYRIGHT,COULTER,EDUCATION,HYBRITECH,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
232,BACKGROUND,CONCLUSION,DIFFERING,DVH,LABEL,METHODS,OBJECTIVE,ORGAN,PURPOSE,RESULTS
169,AUTHORS,BJU,CONCLUSION,LABEL,METHODS,RESULTS
002,153,169,243,525,AMONGST,AUTHORS,BFR,BJU,GLEASON,INCLUSION,LABEL,METHODS,OBJECTIVE,PFP,PSA,RESULTS,T2B,THERE
004,043,169,AUTHORS,BJU,CONCLUSION,INVENTORY,LABEL,LRP,MEN,METHODS,OBJECTIVE,PSM,RESULTS,VINCI
001,169,249,AFTER,AUTHORS,BJU,COX,EPE,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SVI,TUMOURS
169,AUTHORS,BJU,FRYDENBERG
169,AUTHORS,BJU,CURRENTLY
169,AUTHORS,BJU,HGPIN
169,CHRONIC,COPYRIGHT,FATIGUE,MEETING,MICRO,RELATED,SINCE,STILL,TODAY,VIRUS,XENOTROPIC
001,206,AUC,CAD,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIX,STAND,WITHOUT
945,946
233,945,946,CLIC3,INCUBATING,WHILE
BASED,INSTEAD,LASSO
ERG,FURTHER,GLEASON,LOW,THESE,TMPRSS2,USING
954,GRP78,PAR
169,BACKGROUND,CHEMISTRY,CONTENT,LABEL,MAJOR,SUMMARY
140,177,340,410,DBR,LABEL,METHODS,OBJECTIVE,RADICAL,RESULTS
177,370,956,CONCLUSION,DCFBC,EXM,FDG,LABEL,MBQ,METHODS,PCA,PET,PREVIOUSLY,RADIATION,RESULTS,UNLABELLED
916,936,AKT,APOPTOSIS,BCL,BID,DIALLYL,DR4,DU145,ERK,FAS,HOWEVER,IAP,JNK,JUN,LY29004,MAPKS,MMP,PD98059,THESE
001,029,032,118,432,CAV,EBV,EPSTEIN,QDS,QUANTUM
946,CPT,HB1,IFN,KIT,LNCAP,SCF,THESE
AGAINST,COLLEGE,KINGDOM,REPORTING,ROYAL
DESPITE,SUI
LOW
178,DCE,DYNAMIC,EMPIRICAL,EU1,MRI,PUN,TOFTS
LABEL,MINIMALLY,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
946,HOWEVER,MUTATIONS,NR2F2,SMAD4,TGF,THESE
169,COPYRIGHT,IRELAND,LTD,THERE
169,223,954,BACKGROUND,CONTEXT,COPYRIGHT,DENOSUMAB,FURTHER,LABEL,MET,METHODS,OBJECTIVE,OPTIMAL,OSTEOCLAST,PCA,PUBLISHED,RESULTS,SRC,SYNTHESIS,UROLOGY,ZOLEDRONIC
001,002,023,169,196,443,497,799,833,842,AUC,BACKGROUND,COPYRIGHT,E26,ERG,ERSPC,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RANDOMISED,RESULTS,SCREENING,SETTING,TMPRSS2,UNIVARIATE,URINE,UROLOGY
169,BASED,COPYRIGHT,DUE,INC,NPS,PSA
169,33258,BAX,COPYRIGHT,GST,HOECHST,MTT,RESULTS,SAS,SW620
169,BACKGROUND,COPYRIGHT,GAP,LABEL,LNCAP,PC3,RESULTS,RHO,RHOGAPS,SEVERAL
169,945,946,COPYRIGHT,ESTROGENS,GIVEN,HOWEVER,INC,SERMS,THESE
081,169,177,ASSUMPTION,COPYRIGHT,CTS,CTV,D15,D25,D35,D50,D90,D98,EFFECTS,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,RMSPE
008,464,AFRICAN,LOWER,THEIR,THEREFORE
CD4,HANAHAN,HOWEVER,IC50S,IDO,METASTASIS,PCR,THESE,WHILE
169,174,180,24H,652,956,AMONG,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,LNCAP,METHODS,PDT,PEGYLATED,REGARDING,RESULTS,SEVERAL,USING
169,AGA,AVERAGE,BAY,COPYRIGHT,DEPARTMENT,GLEASON,HOWEVER,INC,JANUARY,KARACHI,PATHOLOGY,PERINEURAL,PSA,SECTION,UNIVERSITY
169,956,COLLEGE,COPYRIGHT,DAURICINE,LABEL,MEDICAL,METHODS,MTT,OBJECTIVE,PUBLISHED,RESULTS
169,CONCLUSION,COPYRIGHT,CTV,FIFTY,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRL,OBJECTIVE,PURPOSE,RESULTS
169,BACKGROUND,COPYRIGHT,EIGHT,GATHERING,INTENTION,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PERFORMING,PURPOSE,RADIATION,RESULTS,THERE
169,188,945,946,99M,BBN,COPYRIGHT,FURTHER,GAMMA,GLU,INC,MAG,RGD
169,COPYRIGHT,LNCAP,LTD
005,946,BME,CONCLUSION,DISCUSSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PC3,RESULTS
AREAS,BACKGROUND,COVERED,LABEL,METHODS,OPINION
500,PC3,PI3,SELECTIVE
1E8,390,DT390,EFFICACIES,INCREASED,MKN,PEPTIDE,TMTP1,TUNEL,USING
AVILA,BMX,IRM,MERCK,TEC,THEREFORE,THESE
AFTER,EIT,MREIT,MREPT

000,004,ERG,GLEASON,THERE
ADRENAL,CURRENT,DHT,DUCAP
169,183,BECAUSE,GEORG,STUTTGART,THESE
169,COPYRIGHT,IRELAND,LTD,SEQ
100,945,AE1,AE3,MFS,MIB,RIGHT,SMA
FUNCTIONAL,FURTHER,LBD,PCA,THEREFORE
003,017,450,962,END,HODGKIN,NHL,POISSON,PROGRAM,RESULTS,THERE
246,308,637,AMONG,BIRTH,BWS,CRUDE,THERE
BACKGROUND,BEOWULF,LABEL,UNLABELLED
001,065,458,526,782,ADCY5,CONSORTIUM,FTO,HNF1B,INSTITUTE,JAZF1,KCNQ1,PCA,T2D,TEN,THESE
169,BACKGROUND,BLINDED,CHEMISTRY,COLLECTION,CONTENT,DETECTION,EARLY,EVALUATION,INSTITUTE,LABEL,NETWORK,PROBE,REFERENCE,SINCE,SUMMARY
BACKGROUND,HOWEVER,LABEL,METHODS,NORWEGIAN,OBJECTIVE,PREDEFINED,RESULTS,THERE
15D,916,947,BECAUSE,CHROMATIN,HOWEVER,PGJ,TMPRSS2
169,916,936,BAPTA,BAX,COPYRIGHT,DPT,INC,MMP,NAC,ROS,USING,WILEY
169,AFTER,COPYRIGHT,DU145,HOWEVER,INC,PCA,SNAIL,THESE,TXR,WILEY
946,COX,EP2,PGE,POPULATION,PTGS2
005,018,039,041,042,122,DU145,IL6,LNCAP,PC3,SHP,SRC
AFTER,DUE,FINALLY,HOWEVER
169,ANNEXIN,BACKGROUND,COPYRIGHT,IGF,INC,INCREASED,LABEL,LNCAP,METHODS,PC3,PTHRP,PTPRF,RESULTS,SELECTIVE,SIMILAR,SRC,THESE,WILEY
169,349,946,AMACR,BACKGROUND,COA,COPYRIGHT,E12,GLEASON,INC,LABEL,METHODS,PIN,RESULTS,WILEY
169,ACTIVATION,COPYRIGHT,DOCETAXEL,INC,INCREASING,MSC,PC3,THESE,WILEY
000,100,151,169,AFFYMETRIX,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,COX,IGF,IGFBP,INC,LABEL,LNCAP,METHODS,RESULTS,SERUM,THREE,WESTERN,WILEY
105,150,225,300,600,900,945,ACT,AFTER,INSURANCE,INTRACLASS,KOHLRAUSCH,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
215,ACADEMY,EPA,LSS,PROTECTION,VII
HOWEVER
ATRTS,BACKGROUND,E2F,GIVEN,LABEL,METHODS,MICROARRAY,RESULTS,SMARCB1,USING,ZESTE
223,THESE
244,341,AFP,ANALYZE,CA125,CA153,CA199,CEA,CONCLUSION,ECLIA,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THESE
CLINICIANS,CONDUCT,ETHICAL,PRINCIPLES
22R,23R,DEPENDENCE,FBS,LNCAP,MCF,STUDIES
102,11313,12934,A131G,ACCORDING,BACKGROUND,CHINA,FIFTY,FURTHER,GSTM1,GSTP1,GSTT1,HOWEVER,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PUBLISHED,RESULTS,SCHOLAR
004,215,650,AGE,AUC,BACKGROUND,CHINA,CHINESE,DETECTION,DRE,HUASHAN,LABEL,METHODS,OBJECTIVE,OCTOBER,PCA,PREDICTIVE,PSA,RESULTS,SIMILAR,THESE
362,604,EGF,EMT,EPLIN,HOWEVER,PCA,USING
945,KNOCKDOWN,LIN,LNCAP,VDR
169,COPYRIGHT,INC,MRI,WILEY
320,946,PCA,THESE,TIC,WNT
703,HIV,HOWEVER,VIDEO
160,177,236,384,481,668,ADT,BACKGROUND,CLINICALLY,CURRENTLY,DESPITE,FOLLOWING,LABEL,OBJECTIVE,RESULTS,UNASSIGNED
CONVERSELY,DU145,LNCAP,MUTATIONS,THESE
167,169,AMONG,CES,COPYRIGHT,DELAYED,DEPRESSION,DEPRESSIVE,FCS,GMM,IL1R2,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESILIENT,RESULTS,STUDIES,VARIATION,VARIATIONS,WHILE
009,109,215,526,601,AFTER,CAUCASIAN,CAUCASIANS,CONCLUSION,COX,CYP17A1,CYP19A1,HSD17B2,HSD17B3,LABEL,MEIER,METHODS,OBJECTIVE,PURPOSE,REMARKABLY,RESULTS,SNP,TAIWANESE
100,169,435,956,COPYRIGHT,ETG,FINALLY,GMP,HL1,INC,MANNICH,MDA,NMR,SEVERAL
169,AGE,AUTHORS,BJU,CONCLUSION,GLEASON,HOWEVER,JANUARY,LABEL,LOCAL,METHODS,NORTH,OBJECTIVE,PSA,RESULTS,RRP,THERE,UNLABELLED
169,177,203,ACCORDING,ADD,AFTER,BJU,EFRPS,FACTORS,FURTHER,GROUP,INVENTORY,KNOWN,LABEL,MEN,METHODS,OBJECTIVE,PRP,RESULTS,SUBJECT,TREATMENT,UNLABELLED,USING,VED
169,UROLOGICAL
169,704,ANZ,AUTHORS,BACKGROUND,COLLEGE,CONCLUSION,FIFTY,JOURNAL,LABEL,METHODS,OUTCOME,OVERALL,RESULTS,ROYAL,SCORE,SHORT,SURGERY,SYMPTOM
169,CAUCASIAN,CAUCASIANS,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERWEIGHT,RESULTS,UROLOGICAL,USING,WORLD
106,169,ANZ,AUTHORS,BACKGROUND,COLLEGE,COLORECTAL,CONCLUSION,IQR,JOURNAL,LABEL,METHODS,PATIENT,RESULTS,ROYAL,SURGERY,THERE,WHITNEY,ZEALAND

695,ABOUT,AFTER,FURTHER,GLEASON,HORMONE,LOCALISED,PRESCRIRE,PSA,TRANSIENT,TREATMENT,WHICH,WITHOUT
945,954,CAP,CHRONIC,HIF,INHIBITION,STRIKINGLY
BACKGROUND,LABEL,PATHVISIO,PRINCIPAL,RESULTS,WORLDWIDE
CONVERSELY,ECRG4,ERG,ETS,EWING,EWSR1,KCNN2,LDOC1,NPT,NR0B1,PCA,USING
169,COPYRIGHT,CPLAS,VCH,WILEY
169,COPYRIGHT,IHC,PCA,SEM,VCH,WILEY
145,169,183,215,827,895,931,AUC,COPYRIGHT,DUTCH,PCR,SWEDISH,THEREFORE,TODAY
169,680,ALEXA,COPYRIGHT,FLUOR,LNCAP,MRI,OPTICAL,VCH,WILEY
169,182,183,205,221,222,34C,BACKGROUND,COPYRIGHT,EXPRESSION,GLEASON,GP4,GPS,HOWEVER,INC,LABEL,LCM,MEANWHILE,METHODS,PCR,RESULTS,VALIDATION,WILEY
169,16S,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,OVERALL,RADICAL,RESULTS,STS,THESE,WILEY
169,CALCIUM,COPYRIGHT,DESPITE,HOWEVER,PEG,PEGYLATED,VCH,WILEY
AFRICAN,AFTER,BALTIMORE,EXPLORING,INTEGRATED,SOUTHWEST,WHITE
005,011,CDR,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SINCE
002,005,007,126,130,280,300,362,385,470,754,786,799,874,BPH,GGC,PCA,TOTAL
145,205,MICROBIAL,MUCOR
100,129,170,18F,AIM,BASED,CHOLINE,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PSA,RESULTS
100
169,AIM,C30,COLLEGE,CONCLUSION,COPYRIGHT,EORTC,HDR,HOWEVER,INDEX,LABEL,LTD,MATERIALS,METHODS,MINIMALLY,OBJECTIVE,PUBLISHED,QLQ,RESULTS,ROYAL,SHORT,THERE,TREATMENT
169,AFP,COPYRIGHT,HCC,INC,PHA,THESE,USING
002,169,613,COPYRIGHT,GLEASON,INC,JANUARY,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PRIMARY,PURPOSE,RESULTS,USING
027,169,2CM,4FB,BLADDER,COPYRIGHT,CTV,HOWEVER,INITIALLY,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
169,COPYRIGHT,DSH,DVH,DWH,IRELAND,LTD,MRI,PUBLISHED
001,002,104,237,279,AGE,BARCELONA,DRE,LABEL,LOW,MAY,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SCREENING,VERMEULEN
002,003,967,CONCLUSION,GLEASON,LABEL,METHODS,NERVE,OBJECTIVE,PPB,PSA,PSM,RESULTS,SURGEON
001,003,169,950,964,ALPHA,CIS,COPYRIGHT,DBP,FINNISH,ORS,PREVENTION,SERUM,TOCOPHEROL
THERE
600,FINALLY,FURTHER,IRE,LNCAP
060,160,BACKGROUND,CLL,FIFTY,LABEL,METHODS,MOFFITT,OFTEN,RESULTS
100,123,124,131,158,160,224,99M,AHX,CONCLUSION,GLU,LABEL,LESIONS,LYS,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,SUVMEAN
111,145,160,177,99M,CONCLUSION,IGF,IGF1R,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TARGETING
HPE,METHODS,PRIMARY,RETROVIRUS,THESE
156,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PHOENIX,PSA,RESULTS,SALVAGE
160,690,692,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNP,WHILE
000,100,122,160,174,GEORGIA,GETIS,LABEL,LIMITED,METHODS,OBJECTIVE,ORD,POISSON,PURPOSE,RESULTS,SATSCAN,SIX,SOUTHWEST
142,147,150,160,BACKGROUND,CAUSE,CLOSE,CONCLUSION,LABEL,METHODS,PATIENT,RESULTS
APART,FIFTY,HISTOLOGY,KEY,LABEL,METHODS,MRGBS,MRI,OBJECTIVE,OBJECTIVES,RESULTS,USING
ELISA,HENCE,TCC
001,004,173,3A4,810,AFRICAN,ASIAN,CAUCASIAN,HOWEVER,RESULTS,SEVERAL
EXCELLENT,HDR,HOWEVER,III,LDR,LOW,PHASE
ARCAP,BESIDES,CAMALEXIN,EMT,INCREASED,LNCAP,NAC,NEO,ROS,SNAIL,WESTERN
169,ADJUDIN,ATP,CASPASE,COPYRIGHT,FURTHER,HOWEVER,INC,LND,TAKEN
169,COPYRIGHT,LNCAP,PC3,RETINOIDS,THEIR,THESE

169,BCA,COPYRIGHT,GADD45A,IRELAND,LTD,NAG,NSAID,ROS,TAKEN,THESE
160,169,1MM,4NG,63YEARS,CONCLUSION,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SAS,SIX
160,169,403,503,52YEARS,CHI,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SAS,STUDENT,T1C,T2A,T2B,T2C,THESE
169,200ML,AIM,BOO,BPH,CONCLUSION,CONTINENCE,COPYRIGHT,FREQUENCY,HOLMIUM,INITIAL,LABEL,MEDICAL,METHODS,OBJECTIVE,PSA,RESULTS,SAS,SERUM,SOCIETY,TREATMENT,UROLOGICAL
169,COPYRIGHT,PERMANENT,PSA,PUBLISHED,SAS,WHILE
014,021,114,131,169,ADT,CONCLUSION,COPYRIGHT,FOUNDATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,MOSBY,OBJECTIVE,PUBLISHED,RESULTS,THERE,VOICE
169,237,241,BACKGROUND,CONCLUSION,COPYRIGHT,DIAGNOSTIC,DUE,LABEL,METASTASES,METHODS,NEUROCIRUG,PUBLISHED,TORRE
169,241,COPYRIGHT,FCH,FDG,HOWEVER,PET
001,107,147,169,187,294,945,AES,BACKGROUND,COPYRIGHT,LABEL,MANAGEMENT,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RANDOMISED,RESULTS,SECONDARY,SETTING,TRIAL,UROLOGY
AFTER,BACKGROUND,CONCLUSION,DESPITE,LABEL,METHODS,THEREFORE

802,837,BACKGROUND,FINNISH,LABEL,METHODS,PCR,RESULTS
169,ATP,SOCIETY,TREATMENT
169,946,DU145,GIVEN,LNCAP,PC3,RADIATION,TGF
931,963,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SYSTEMATIC,THERE
CHANGES,CONCLUSION,INSTEAD,KNOWLEDGE,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,STUDENT,THERE
006,169,174,BISULFITE,COPYRIGHT,CPG,EDUCATION,FILIP1L,INC,ISOFORM,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SENESCENCE,UROLOGICAL
004,177,956,ANILINE,ANTICANCER,BHA,BUTYL,EXTENSIVE,FIC,HOWEVER,HYDROXY,LINDERA,MCF,NMR,WRL
ABOVE,AIM,CONCLUSION,DU145,GERMANY,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,ROSTOCK,THESE
125,162,BACKGROUND,D90,LABEL,LDR,LOW,METHODS,OAR,RAH,RESULTS,ROYAL,SIMILARLY,SMALL,STILL
169,COPYRIGHT,GIVEN,LTD,WILEY
ACTIVATION,AKT,BCL,HOWEVER,INHIBITION,LC3,PC3,RV1,SER2448,SER2481,THESE,UNC
169,20S,AMONG,APART,COLON,COPYRIGHT,FRESHWATER,LEISHMANIA,LTD,PLASMODIUM,SAR,THEREBY,THESE,WHILE,WILEY
005,169,COMBINING,CONCLUSION,COPYRIGHT,DCE,GEE,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PEARSON,PURPOSE,RESULTS,SEVENTY,T2W,WILEY
FRONTLINE,THESE
183,A11,AMP,FXXLF
001,412,919,962,BECAUSE,POISSON,THREE
024,048,233,512,CASES,CRP,MAX,MIN,SUPPL,THESE,VITAMINES
177,CHRONIC,CONSISTENT,EPIDEMIOL,GIVEN,JOURNAL,MAX,TOUVIER
AFRICAN,INSTITUTE,PHOTOVOICE,RESULTS,SOUTH
100,176,177,181,FINALLY,IRDYE800CW,MHZ,OPERATING,PET,SIEMENS,THREE
10Q23,AKT,ALTOGETHER,BACKGROUND,IHC,LABEL,MEIER,METHODS,NORTH,PCA,RESULTS,SEVERAL,USING
0000001,BACKGROUND,BPH,CTC,DETECTION,LABEL,METHODS,RAMAN,RESULTS
BEIJING,CHINA,CONTINENCE,CONVENTION,COPYRIGHT,FORBIDDEN,ICS,LOCATED,OLYMPIC,PROUS,SCIENCE,SOCIETY
145,BAX,BCL,CCK,LNCAP,SEPIA,SIO,SUB,THESE
945,AKT,III,INHIBITION,NAD,SIRT1,SIRTUIN,WHETHER
00006,328,AXIN2,FGF10,FGFR2,THERE,TOOTH
COMMISSION,NUCLEAR,RADIATION,RP162
292,355,779,ABDOMINAL,CONCLUSION,HOWEVER,JANUARY,LABEL,MATERIALS,METHODS,NOTABLY,OBJECTIVE,RESULTS,STAGING
202,287,299,721,AMONG,CONCLUSION,COSTS,END,HOSPICE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,100,CONCLUSION,LABEL,MET,METHODS,OBJECTIVE,PFS,PRIMARY,PURPOSE,RESULTS,SERUM,SEVENTY,THOSE,XL184
000,169,BACKGROUND,CHEMISTRY,LABEL,METHODS,PCA,PROTECT,PSA,RESULTS,SERUM,TESTING,THESE,TREATMENT
112,145,396,432,808,BACKGROUND,CONCLUSION,COX,LABEL,METHODS,RESULTS,SMOKING,UNTIL
001,BACKGROUND,CONCLUSION,CONVERSELY,DUSP1,ERK,GLEASON,LABEL,METHODS,PROFILING,RESULTS,SEF,THESE
BACKGROUND,CONCLUSION,LABEL,MEASURING,MEIER,METHODS,RESULTS
169,403,BACKGROUND,BETWEEN,COPYRIGHT,GLEASON,INC,LABEL,LATERALITY,LESIONS,METHODS,PCA,RESULTS,SPECIAL,TPMBS,TRUSB,WILEY
HOWEVER,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THEREFORE
HOWEVER,LABEL,OBJECTIVE,PPI,PURPOSE,RESULTS,SUMMARY
001,105,106,120,BACKGROUND,BPH,CAP,EXPRESSION,GLEASON,LABEL,METHODS,MMR,MUTATIONAL,OBJECTIVE,OBJECTIVES,PIN,PRO,RESULTS
ALTOGETHER,ATP,CHANGES,CONSISTENT,TRPM7
160,183,811,DIETS,DRC,MEDLINE,SEPTEMBER
CTC,PCR
100,956,CELECOXIB,COX,DU145,EARLIER,EXPRESSION,LNCAP,MTT,PC3,PCA,PCR,PHENOTYPIC,REDUCED
AMONG,CD168,METASTATIC,PCA,RHAMM,STUDIES
945,GEF,HOWEVER,PKA,SUBSEQUENT
945,FBXW7,HOWEVER,LUCIFERASE,UTR,WESTERN
391,METASTASIS,NETWORK,SBC,SECONDARY,THROUGH,TOWARDS,USING
200,400,FUNCTIONAL,PCA,SIXTEEN,THEIR
100,169,195,288,313,ADC,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE,WILEY
946,C2GNT,CORE2,HOWEVER,THESE,TRAIL
001,008,033,050,064,128,172,268,271,AIM,AMONG,BACKGROUND,BLOOD,BPH,CHRONIC,FEDERATION,HEART,INSTITUTE,LABEL,MAXIMUM,METHODS,PROSTATIC,RESULTS,SCORE,SYMPTOM
014,100,367,415,BACKGROUND,BPH,CPG,DNAME,GLEASON,HSP,HSPB1,LABEL,METHODS,PCA,RESULTS
BPH,DESPITE
EXPRESSION,GANODERMA,MRP,MTT,PACLITAXEL,PANAX,PREVIOUSLY,PRIMARY,WESTERN
CROOK,PSA
000,163,169,382,390,505,BASED,CLINICALLY,COPYRIGHT,EDUCATION,END,GLEASON,HOWEVER,INC,LABEL,LASER,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T1A,T1B,UROLOGICAL
035,169,781,CONVERSELY,COPYRIGHT,EDUCATION,END,GOING,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,REDUCTIONS,RESULTS,SECONDARY,SKILLED,UROLOGICAL
001,169,CHICAGO,CLEVELAND,COMMITTEE,COPYRIGHT,EDUCATION,INC,IQR,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RATES,RESULTS,UNIVERSITY,UROLOGICAL
169,344,770,861,886,AREAS,COPYRIGHT,COX,DESPITE,EDUCATION,END,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,POISSON,PUBLISHED,PURPOSE,RESULTS,SERVICE,STATE,UROLOGICAL,USING
001,169,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL
001,169,396,541,814,CON,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL,YES
001,100,169,AFTER,BETWEEN,COPYRIGHT,EDUCATION,HOWEVER,IMAGING,INC,JANUARY,LABEL,METHODS,OBJECTIVE,PERFUSION,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,300,COPYRIGHT,COX,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PREDICTION,PUBLISHED,PURPOSE,RESULTS,TOTAL,UROLOGICAL
134,169,904,COPYRIGHT,CUMULATIVE,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,UROLOGICAL
100GY,125,BACKGROUND,CHANGES,COMPARING,HIP,KARNOFSKY,KPS,LABEL,METHODS,MPD,RESULTS,ROUTINE,SCALE,SCORE,SIX,THERE,VAS
123,216,BACKGROUND,CHI,COMPOSITE,GEE,INDEX,LABEL,METHODS,OVERALL,QOL,RESULTS,SPANISH,THESE
169,EARLIER,HOWEVER,MANAGEMENT,UROLOGICAL
155,169,ADT,AIM,AUTHORS,BACKGROUND,BLACKWELL,CONCLUSION,ENGLISH,INDUSTRIAL,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHING,RESULTS
THERE
210,329,641,998,BACKGROUND,CONCLUSION,CONTEXT,DAILY,IDENTIFIER,LABEL,METHODS,OBJECTIVE,OUTCOME,PHYSICIANS,RESULTS,SETTING,THERE,TOTAL,TRIAL
125,168,AVIAN,E26,ERG
946,DIFFERENT,GLUCOSE,LIPID
160,177,ANY,BILATERAL,CSE,FOLEY,HDR,LABEL,METHODS,NPB,OBJECTIVE,PURPOSE,REGARDING,RESULTS,THERE,USING,VAS
ANTISENSE,IFN,LNCAP
700,DUE,MDV3100,TAK,TODAY
946,PCA,TGF
946,BASED,BPH,BPS,BRITISH,DUE,FURTHER,PCA,PSA,THERE
GAL
ALPHA,HOWEVER,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
169,COPYRIGHT,H3K27,H3K36,HISTONE,HMTASES,INC,MMSET
169,COPYRIGHT,HOWEVER,INC,SINCE,THESE,TRPM8
169,956,COPYRIGHT,INC,LNCAP,ROS
169,CONSISTENT,COPYRIGHT,INC,PIRH2,SILENCING
169,946,ACTIVIN,COPYRIGHT,DESPITE,EMT,FINALLY,INC,SNAIL,THERE
001,169,174,658,696,702,774,796,898,909,AUC,COMPARISON,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,REGRESSION,RESULTS,UNIVERSITY,UROLOGICAL,WASHINGTON,WISCONSIN
168,169,AFTER,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVERAL,THESE,UROLOGICAL,WHILE
169,COPYRIGHT,MRI,OVERLAP,PCA,PUBLISHED,UROLOGY
100,169,415,527,BACKGROUND,COMPLIANCE,COPYRIGHT,COX,DUTCH,GLEASON,LABEL,MEIER,METHODS,NTR1718,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,TRIAL,UROLOGY
001,006,160,169,725,782,802,842,957,COPYRIGHT,COX,EDUCATION,HOWEVER,INC,INCLUSION,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
CASES,GLEASON,HOWEVER,INC,PUBLISHED
120,169,332,947,CONCLUSION,COPYRIGHT,ENGLISH,LABEL,METHODS,OBJECTIVE,PANCREATIC,RESULTS,SAS
100,239,BACKGROUND,BCR,LABEL,METHODS,PSA,RESULTS,RETROPUBIC,RRP
123,ANNEXIN,BACKGROUND,BAD,BH3,BID,BIM,CONCLUSION,EXPRESSION,IHC,LABEL,METHODS,MTT,P53,RESULTS,RHODAMINE
106,169,171,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,LESIONS,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TESLA,UROLOGICAL,WORKING
169,945,AMACR,COA,COPYRIGHT,ERG,FINAL,HGPIN,IHC,INC,PCA,THREE,TMPRSS2
169,COPYRIGHT,INC
169,COPYRIGHT,CYP17,IRELAND,LTD,MEDLINE,MEETING,SOCIETY
169,177,438,BLOOD,CELLS,COPYRIGHT,CROWN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE
14S,18S,700,800CW,COMPOUNDS,CY5,CY7,ICG,IRDYE800CW,IRDYE800RS,NIR
MICRORNAS
142BR,956,C32,CLOSE,ITALY,LEBANON,LNCAP,MCF,NMR,NON,REMARKABLE,SPACH,SRB,TORMENTIC
ANDROGENS
HOWEVER,THESE
HEALTHY,MALDI,TOF,USING
945,946,AMONG,HOWEVER,THESE
CAG,CHLAMYDIA,CMV,ELAC2,HPV,HSV,NEISSERIA,THERE,TREPONEMA
00013,00406,388,BACKGROUND,CONCLUSION,KRUSKAL,LABEL,METHODS,OVARIAN,RESULTS,THESE,TYPICALLY
146AG,ASIAN,CIS,HCC,MICRORNAS,ORS,SIMILARLY
AFTER,BACKGROUND,CONCLUSION,HODGKIN,LABEL,METHODS,RESULTS,TREATMENT,USING
001,005,126,945,AIM,ANOVA,CONCLUSION,FSH,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PRL,PSA,RESULTS,THERE,UNIVARIATE
CONCLUSION,EPHA2,LABEL,METHODS,OBJECTIVE,PTX,PURPOSE,RESULTS,YNH,YSA
100,131,169,ELP,THESE
169,COPYRIGHT,PET,THESE,VCH,WILEY
160,PAT,SEVEN
170,227,264,364
107,204,491,AGE,CONCLUSION,DIGIT,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,VARIABLES,VERNIER
APRIL,CONCLUSION,FINALLY,JANUARY,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,OPTIMALLY,OTHER,PREDICTIVE,RESULTS,TOOLS,WHILE
035,120,702,811,BACKGROUND,CONCLUSION,CUMULATIVE,DENOSUMAB,FURTHER,INCIDENCE,LABEL,MEIER,METHODS,NSCLC,RANKL,RESULTS
AFTER,BACKGROUND,HENCE,INDIVIDUAL,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PCA,RESULTS
956,INDEX,PSA,PUBLISHED,SIMILAR,USING
FEW,FURTHER,WORKPLACE
169,COPYRIGHT,INC
001,018,169,ACCORDING,BETWEEN,CAP,CGA,COPYRIGHT,FURTHER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
BLENDED,SCIENCE,WORLD
169,COPYRIGHT,ELEMENT,GST,INC,LNCAP,NUCLEOTIDE,ORF,PSA,R1881,WIDESPREAD
176,AH2,FDU,JOURNAL,NETROPSIN,NMR,NOESY,PC3,PCA
105,141,390,BACKGROUND,HCA,LABEL,PCA,PRINCIPAL,RESULTS,THREE,USING
946,CD4,CD8,PAP,REGULATORY,TAKEN,TGF,THESE,TREGS,USING
100,956,HOWEVER,MACCONKEY,PRIOR,THERE,THEREFORE
BAK,BAX,BCL,BIM,LUCIFERASE,MCL,PCR,THESE
CATHEPSIN,IGF,TAKEN
194,301,398,797,BACKGROUND,BFI,BRIEF,COU,FATIGUE,III,INVENTORY,LABEL,METHODS,PATIENT,RESULTS
ABSTRACTS,AUTHORS,BACKGROUND,BRITISH,CENTRAL,COLLECTION,CONTROLLED,FINALLY,FURTHER,INDEX,ISSUE,JANUARY,LABEL,LIBRARY,MARCH,MEDLINE,METHODS,NURSING,OBJECTIVE,OBJECTIVES,RESULTS,SELECTION,SIGLE,SMD,WHERE
PRIMARY
22RV1,AAG,FURTHER,GANETESPIB,HOWEVER,HSP90,TARGETING

104,157,CHOLINE,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,PSA,PSADT,PURPOSE,RESULTS,THESE
001,007,116,134,165,184,ANY,BCF,C30,ELECTRONIC,EORTC,GLEASON,NHT,NON,OCTOBER,PRE,PSA,PSADT,QLQ,QOL,SRT,SVI
945,PREVENTION,THESE
169,183,215,267,268,956,AUSTRALIA,BACKGROUND,CALVARY,COPYRIGHT,COUNCIL,FUNDING,GLEASON,HOWEVER,INSTITUTE,LABEL,LTD,MATER,MEDICAL,METHODS,NEWCASTLE,OTHER,PRO,PSA,RADIATION,RESULTS,SOCIETY,T2A,T2B,THERE,TREATMENT,UNIVERSITY,ZEALAND
155,569,ADDITIONAL,AMERICANS,CADMIUM,COX,DESPITE,HOWEVER,III,NUTRITION,RDA,SIMILAR,THERE,THIRD
AST,BACKGROUND,CODED,CONTROLLED,CURRENT,LABEL,MEN,METHODS,RESULTS,STRATEGIES,TRIAL
169,BECAUSE,COPYRIGHT,CSC,DU145,EVOLUTION,LIGANDS,SELEX,SYSTEMATIC
HDR,LDR,LOW,PSA
115,160,174,BACKGROUND,LABEL,LNS,MATERIALS,METHODS,RESULTS
169,BACKGROUND,CHEMISTRY,CONTENT,LABEL,SUMMARY,VALIDATION
945,946,EXPRESSION,GTPASES,HOWEVER,RAC,THESE
169,945,COR,HDAC3,HDAC4,HIF,HOWEVER,III,RES,THROUGH
301,COU
004,008,228,383,657DEL5,BACKGROUND,BRCA1,CHEK2,CONCLUSION,I157T,LABEL,METHODS,MORTALITY,RESULTS,THESE,THREE
5HEAD,BDR,COMPARING,INITIALLY,MLC,WHILE
177,186,350,963,A12,ALGORITHM,ANALYTICAL,DOSES,EBT,GAFCHROMIC,INTENSITY,STORING
DOSIMETRIC,INCREASING,MAXIMUM,MUS,PLANS,PTV,SYNERGY,THESE
657,942,BACKGROUND,EARLIER,ENGLAND,III,LABEL,METHODS,RESULTS,STAGE,THERE
NETWORK,PRIMARY,THERE,UROLOGICAL
001,002,012,026,033,114,169,4RS,CONCLUSION,COPYRIGHT,EPR,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SIMILARLY
DU145,PARSIMONY
100,ANTONIO,BEATSON,FOUNDATION,FRANCESCA,GLASGOW,HUTCHINSON,INSTITUTE,MARSDEN,NHS,PHD,ROYAL,SAN,USA
128,AFTER,BACKGROUND,HOWEVER,LABEL,METHODS,OVERALL,PHYSICIANS,RESULTS,SDM,TRIAL
169,DISCOVERY,ERG,TMPRSS2
169,956,BASED,CONCLUSION,ENL,LABEL,LNCAP,METHODS,PCR,RESULTS,SCOPE,THERE,VCH,WILEY
34B,AKT,BIOLOGICAL,CONCLUSION,CPG,FINALLY,LABEL,METHODS,MIR,OBJECTIVE,PCR,PROFILING,PURPOSE,RESULTS,SNAIL,THESE,ZO1
718,AMONG,ASR,RIO,STATE,THESE
956
533,LABEL,LIMITED,METHODS,OBJECTIVE,ORS,RESULTS,THERE
001,110,115,ACCORDING,ALP,CHINESE,COX,MEIER,OSS,PSADT
AFRICAN,AMERICANS,BACKGROUND,CAUCASIAN,CAUCASIANS,CONCLUSION,GLEASON,LABEL,METHODS,RESULTS,THERE
003,005,010,019,028,105,313GG,ARGENTINE,BACKGROUND,COX,CURRENT,GST,GSTM1,GSTP1,GSTT1,ILE,LABEL,MEIER,METHODS,ORGAN,PCA,PCR,RESULTS,RRP,VAL
101,184,830,838,951,984,AMONG,BACKGROUND,COMMERCIAL,ENCOUNTERS,LABEL,MARKETSCAN,MEDSTAT,METHODS,RESULTS,SEPTEMBER,SRE,THOMSON
169,181,BACKGROUND,BASEL,COPYRIGHT,DOCETAXEL,LABEL,METHODS,PSA,RESULTS,TREATMENT
034,169,BACKGROUND,COPYRIGHT,INC,LABEL,METASTATIC,METHODS,NSE,PFS,RESULTS,SCC,SCCUT,SERUM,SMALL,THERE
169,CLAVIEN,COPYRIGHT,III,INC
169,COPYRIGHT,IRELAND,LTD
ASSESSMENT,DVC,SSL,TECHNIQUE
954,ALTOGETHER,DNMT1,MCF,RASSF1A,SP1,SSS,TSG
001,169,300,638,AUTHORS,BETWEEN,BJU,BMI,CONVERSELY,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,PCA,RESULTS,RRP,SIMILAR
THESE
CELLSEARCH,CTC,HOWEVER,LNCAP,MAGSWEEPER,SEQ,THESE
177,945,946,CD133,FURTHER,HOWEVER,LOW,PSA,TMPRSS2
416,527,HOWEVER,METASTATIC,SRC,TYR
286,CONSISTENT,EEF1A,HOWEVER,ROBO1,SEQ,SEVERAL,SLIT3,TAKEN,USH2A,USHER,USING
384,A2A,AMONG,GPCRS,H1975,L858R,NSCLC,T790M,THERE
115,157,215,726,967,BMI,WHILE
FOLEY,RECTO
827,889,BEDSIDE,BIOLOGY,DISCUSSION,ELIMINATE,GRAPHICAL,LABEL,MATERIALS,MEDICAL,METHODS,NLP,OBJECTIVE,OBJECTIVES,PROJECT,RESULTS,THESE,UNIFIED
177,CONCERNING
DORMANT,THESE
169,266,309,BACKGROUND,COPYRIGHT,COX,INC,LABEL,METHODS,PCA,RESULTS,SEP15,SEPP1,THESE,WHILE,WILEY
946,954,ALT,AST,CROHN,CURCUMA,EXTENSIVE,LOX,STAT3,VARIOUS
101,AGE,AIM,CARCINOMA,CIS,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
HERTZ,MECHANICAL,SNEDDON,THEREFORE,THESE
197,500,800,ADC,AUC,BACKGROUND,CONCLUSION,DC1,DCE,DETECTION,GLEASON,INCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROC,ROI
169,COPYRIGHT,GENERALLY,INC,MAD,METABOLIC,STEAM,STIMULATED
169,20S,231,26S,945,954,BAX,BORTEZOMIB,COPYRIGHT,DOCKING,HOWEVER,INC,MCF,MDA,UPS
100,125,150,168,187,190,223,CONCLUSION,D10,D30,D90,LABEL,MAY,METHODS,OBJECTIVE,PPB,PURPOSE,RESULTS
169,945,COPYRIGHT,CYP17A1,LTD
169,COPYRIGHT,EGF,ELISA,ETE,LNCAP,LYCOPODIUM,MTT,OXE,PC3,PCR
169,2D3,AMONG,COPYRIGHT,IRELAND,LTD,SINCE,THESE,VDR
169,COPYRIGHT,EWING,INC,MICROARRAY,STEAP,TAKEN
100,134,157,163,169,183,223,301,349,BACKGROUND,BRIEF,COPYRIGHT,COU,EASTERN,FUNDING,GROUP,INVENTORY,IQR,JANSSEN,LABEL,LTD,METHODS,PALLIATION,RESULTS,SHORT
169,COPYRIGHT,FEW,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SITES,SIXTEEN,STRATEGIES
169,AMONG,COPYRIGHT,ELAC2,INC,RNASE,SNP
169,177,956,BACKGROUND,CONCLUSION,COPYRIGHT,EOB,EOS,GBQ,INC,LABEL,METHODS,PET,RESULTS,SUFFICIENT,YM155
VARIOUS
CARIBBEAN,DISCOVERED,ERICIFOLIN,EUGENOL,JAMAICA,PIMENTA,SYSTEMATIC
IMR90,RRM2B
169,BACKGROUND,BASED,CD133,CHANGES,COPYRIGHT,FINALLY,INC,LABEL,MDV3100,METHODS,R1881,RATES,RESULTS,TREATMENT,WILEY
169,22RV1,945,BACKGROUND,COPYRIGHT,HUVEC,INC,LABEL,LNCAP,METHODS,NEP,NEUTRAL,PCR,RESULTS,WESTERN,WILEY
CWR22,ONCOLYTIC,THESE
160,945,946,ARG,ASP,GLY,NPS,PLL,SUCCESSFUL
100,177,600,ARTEMIS,CAP,EIGEN,GLEASON,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,SUPPORTIVE,THREE,UROSTATION,USA,WORKING
ADC,GLEASON,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS,SIMULATED,SIXTY,TRE,TUMOURS
ALPHARADIN,III
100,169,177,AMICO,BACKGROUND,BLADDER,CONCLUSION,COPYRIGHT,FIFTY,INC,LABEL,MEIER,METHODS,PCA,PSA,RESULTS,WATER
169,AFTER,AGE,AIM,BLACKWELL,CONCLUSION,GENERAL,HRS,LABEL,LTD,METHODS,OBJECTIVE,OHA,PUBLISHING,RESULTS
100,945,AMONG,COX,DENMARK,LABEL,METHODS,OBJECTIVE,RESULTS,TREATMENT
AGE,LABEL,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,SWEDISH,THESE,URINARY
1990S,AIS,AREAS,BACKGROUND,COVERED,FURTHER,LABEL,METHODS,OPINION,PGL2001,PHASE,SANFILIPPO,STEROID,STS,STX64
CAF,INHIBITION,NOTCH,XIX
ADDITIONAL,ENGLISH,EXTRACTION,JEVTANA,LABEL,LITERATURE,MEDLINE,METHODS,OBJECTIVE,OPTIONS,PHASE,REFERENCE,RESULTS,SELECTION,SIPULEUCEL,SOCIETY,SOURCES,SYNTHESIS,THREE
113,199,BACKGROUND,LABEL,METHODS,NETWORK,PSA,RESULTS,ROUTINE,SCREENING,THERE
FURTHER,LABEL,LIMITED,METHODS,OBJECTIVE,RESULTS

001,013,017,018,021,139,169,224,314,916,AFTER,BACKGROUND,CHEMISTRY,COX,LABEL,METHODS,PCR,RESULTS,TOTAL,UNIVARIATE
HGF,LABEL,MET,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOLUBLE,TOTAL,TREATMENT
179,181,183,185,22E,24R,COMPOUNDS,GEORG,NMR,ODYENDYEA,STUTTGART
INITIAL,NEWER,OPTIMAL,THROUGH,THROUGHOUT,USA
945,946,DHT,HAECS,LNCAP,PSA,THESE
001,006,023,035,049,268,342,BILATERAL,EBL,ERROR,GLEASON,INDEX,LABEL,METHODS,NVB,OBJECTIVE,OBJECTIVES,PARAMETER,PSM,RESULTS,THERE,WHILE
145,160,ADARB,DGCR8,EPIGENETIC,HILS1,LNCAP,OLIGO,PC3,PCA,TDRD1,THEREFORE,WHOLE
101,116,117,139,177,956,BPH,PIN,SERUM
041,962,BACKGROUND,BLOOD,CONCLUSION,FATTY,LABEL,METHODS,NUTRITION,OBJECTIVE,ORS,PATTERN,PUFAS,RESULTS,STUDIES,TREELET
246,817,AFTER,BACKGROUND,COX,DIETARY,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS
LIMNOTHRIX,LNCAP,ROS,SIMILARLY,SPIRULINA,TAKEN,THEREFORE,TPT
169,BLACKWELL,CEA,HPV,KINGDOM,LIMITED,MCCLUGGAGE,PRIMARY,PUBLISHING,SKENE,THERE,WHILE,WORLD
001,150,BACKGROUND,BPH,INDIA,JAK,LABEL,METHODS,RESULTS,STATS,THERE,THESE
THESE
HDR
248,384,492,GOLDENGATE,HEIDELBERG,INCREASED
240,282,473,AKT,BACKGROUND,GLEASON,HOWEVER,LABEL,PRINCIPAL,RESULTS,SER
158,186,578,FIRST,REGULATION,SER,THESE,THR
200,215,946,AFTER,CASTRATED,HSD,LNCAP,MOUSE,SCH,STX1383,STX2171
105,110,137,AAH,BACKGROUND,CONCLUSION,GLEASON,HGPIN,LABEL,METHODS,NEP,PCA,PTOV1,RESULTS,RPS,SPS
161,169,525,AMONG,BACKGROUND,COPYRIGHT,END,LABEL,METHODS,RESULTS,SOCIETY,SRS
169,CD151,HOWEVER,LIVER,MOUSE,TRAMP,TRANSGENIC,WESTERN
AKT,CELLS,JUN
002,005,010,021,126,166,282,2ND,350,408,420,445,4TH,544,610,770,847,AMONG,DESPITE,DRE,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS
174,3RD,AMICO,BACKGROUND,BRAZILIAN,CALIFORNIA,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OCTOBER,OPERATIVE,PSA,RESULTS,SHORT,TEN
HOWEVER,NEOBLADDER
100,BACKGROUND,DHT,GREB1,LABEL,LNCAP,METHODS,NDRG1,PC3,PCA,PCR,PSA,RESULTS,TMPRSS2
ANOTHER,CD4,CD8,DCS,DENDRITIC,FDA,FINALLY,HOWEVER
011,CLUSTERIN,III,OGX,PHASE,THESE
107,125,169,800,BJU,CLAIM,GLEASON,GOVERNMENT,LABEL,LESIONS,MARCH,METHODS,MRI,NETWORK,OBJECTIVE,RESULTS,TESLA,THERE,UNLABELLED,WORKS
000,153,169,179,280,385,508,556,9TH,AMONG,BJU,DISEASE,FOLEY,HOWEVER,LABEL,MARSHFIELD,MEIER,METHODS,OBJECTIVE,PATIENT,RESULTS,THERE,THESE,UNLABELLED,USING
001,096,140,604,717,857,AFRICAN,AMERICANS,AMONG,BACKGROUND,CDX,LABEL,LOW,METHODS,RESULTS,SNP,VDR,WHITE
021,169,400,429,559,580,971,AFRICAN,AMERICANS,BACKGROUND,CARIBBEAN,COPYRIGHT,CYP17,EIGHT,INC,LABEL,METHODS,OVERALL,PCA,PSA,RESULTS,USA,WILEY
071,169,352,382,BACKGROUND,COPYRIGHT,INC,LABEL,LOW,METHODS,PCA,PHS,PHYSICIANS,RESULTS,SEPP1,THESE,VARIATION,WILEY
169,ADT,BACKGROUND,CASTRATION,CGA,COPYRIGHT,EXPRESSION,III,INC,LABEL,MDK,METHODS,NED,RESULTS,T1B,TUBB3,WILEY
169,259,310,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,RESULTS,THERE,THESE,WESTERN,WILEY
169,COPYRIGHT,INC,PKA,PROTEIN,RD1,TAKEN,WILEY
169,26S,COPYRIGHT,FURTHER,INC,PIM,THR89,THROUGH,WILEY
169,COPYRIGHT,DISRUPTING,FURTHER,HOWEVER,JNK,JUN,ROS,SMALL,TAP
ART,BACKGROUND,CONCLUSION,GLEASON,III,LABEL,METHODS,PRESENTLY,PSA,PUBLISHED,RESULTS,SRT,THREE,WHERE
358,CONCLUSION,GIPC1,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PROTEIN,PURPOSE,RESULTS,STUDIES,UNI
001,005,169,AGE,AIM,ANOVA,BASEL,CONCLUSION,COPYRIGHT,ESR,FSH,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PRL,PSA,PTP,RESULTS,TRUSB
ANNEXIN,HGC,MICRORNAS,PCR
169,BASEL,BESIDES,COPYRIGHT
001,169,215,BACKGROUND,BETWEEN,CONCLUSION,COPYRIGHT,EORTC,HOWEVER,IRELAND,LABEL,LTD,METHODS,PREVALENCE,RADAR,RESULTS,THESE,USING
100,350,450,550,650,CBDCA,CBP,CHINESE,DCP,FIBONACCI,GRADE,HOWEVER,LABEL,METHODS,OBJECTIVE,PHASE,PURPOSE,RELEVANCE,RESULTS,THERE,UNLABELLED
BASED,CARLO,GTV,LABEL,LINAC,LOR,METHODS,MONTE,OBJECTIVE,PET,PURPOSE,RESULTS,VMC
160,CALYPSO,HEXAPOD,INC,LABEL,MEDICAL,METHODS,MLC,OBJECTIVE,PURPOSE,RESULTS,SIEMENS,THEREBY
177,CARLO,CHAIN,GEOMETRIC,LABEL,METHODS,MONTE,MRI,OBJECTIVE,POSTERIOR,PURPOSE,RESULTS,TESLA,USING
DU145,HOWEVER,LEU,LNCAP,MULTI,PACE4,PCS
169,945,946,947,ANTIGEN,AUTHORS,AUTOLOGOUS,BLACKWELL,CD40L,CTL,DC1,DCS,IFN,IMMUNOLOGY,JOURNAL,LTD,PGE,PUBLISHING,TNF,UVB
GIVEN,IGF,IGFBP
MRI
000,009,ADT,BETWEEN,CONCLUSION,FBG,HDL,JANUARY,LABEL,LDL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE
009,113,193,225,244,BACKGROUND,FURTHER,LABEL,METHODS,ORS,PCA,RESULTS,THERE
TRT,WHILE
223,ALPHARADIN,HORMONE,III,INTERIM,METASTASES,PSA,REFRACTORY
GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCR,RESULTS,WESTERN
009,054,118,264,637,710,719,727,767,789,790,811,812,825,846,857,890,925,963,CENTRAL,CONTROLLED,EGGER,HOWEVER,MAY,RRS,USING
APC,MUTATIONS,WHOLE
169,956,COPYRIGHT,DU145,MCF,MTT,SAS
HOWEVER
001,169,500,678,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,SURGEON,UROLOGICAL
945,946,FURTHER,HRFTESIMS,HUH,MCF,MYRICARIA,NMR
169,176,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,UROLOGICAL,USING
169,945,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,MYOBLASTS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL,WESTERN
169,946,COPYRIGHT,LTD,STRUCTURE
169,ANG,COPYRIGHT,IRBESARTAN,LTD,RHR,SHR,THEIR,THESE,VALSARTAN
006,169,ART,BACKGROUND,CONVERSELY,COPYRIGHT,COX,CSM,FINALLY,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,RESULTS,SETTING,THESE,UROLOGY
BERBAUM,DORFMAN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS
100,169,222,224,446,764,COMPOSITE,CONCLUSION,COPYRIGHT,CUTPOINTS,GLEASON,INC,INDEX,ISI,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SHORT,THESE,UIN,USING
110,16MIN,1NG,60G,956,AUC,BECAUSE,BRB,PCA,PUBLISHED
169,COPYRIGHT,DIFFUSION,DWI,INC,THERE
169,COPYRIGHT,DETECTION,INC,KNOWLEDGE
169,COPYRIGHT,INC,PSA
169,COPYRIGHT,INC,MRI,NEWER,THESE
169,COPYRIGHT,INC,SEQUENCES
169,COPYRIGHT,INC
003,015,038,169,AUTHORS,ERG,EXPRESSION,GLEASON,LTD,OVERALL,PATHOLOGY,PCA,PSA,PTY,PUBLISHING,SOCIETY,WESTERN,WILEY,YOUNGER
129,800,APRIL,BETWEEN,BMI,CVD,FOLEY,GLEASON,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,RRP,SUI
305,353,CONCLUSION,INDEX,LABEL,MATERIALS,METHODS,NHT,OBJECTIVE,PCI,POTENCY,PURPOSE,Q26,RESULTS,RRP,SEPTEMBER,THEIR
114,946,GLEASON,PCA,PIN,PSA,TZB
BACKGROUND,BASED,CONCLUSION,FORCE,GUATEMALA,GUATEMALAN,INTERNS,LABEL,METHODS,MOH,PREVENTIVE,RESULTS
122,735,CPG,FDR,PCA,SPON2
FCH,LABEL,METHODS,OBJECTIVE,PCA,PET,PROCEDURES,PURPOSE,RESULTS,SUV
001,FIFTY,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
006,402,945,946,ALPHA,BACKGROUND,LABEL,MEN,METHODS,PREVENTION,RESULTS,TBG,THYROID,TOCOPHEROL,TSH
AIF,APOPTOSIS,DU145,FINALLY,HOWEVER,LNCAP,OVERALL,PC3
FURTHER,HOWEVER,MDV3100,OVERALL,PERSISTENT
CANCEROUS,CIP2A,MYC
RADICAL,UROLOGIST
001,177,IGG,IGHG1,LNCAP,MTS,PC3
169,945,AHR,ARS,CAG,COPYRIGHT,INC,INCREASED,PNT1A
169,COPYRIGHT,GLEASON,LTD,THESE
111,160,169,177,5MG,970,BACKGROUND,CBZ,COPYRIGHT,GERMANY,GRADE,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PSA,PUBLISHED,RESULTS,SETTING,THREE,TREATMENT,UROLOGY
005,017,019,047,169,174,176,360,ARC,CONCLUSION,COPYRIGHT,DESPITE,FURTHER,LABEL,LTD,MATERIALS,MEDICAL,METHODS,MLC,MLCI2,MODULATED,OBJECTIVE,PHILIPS,PUBLISHED,PURPOSE,RESULTS,SYNERGY,SYSTEMS,THERAPY,TPS,VOLUMETRIC
001,114,169,197,212,324,432,BJU,BPH,CONCLUSION,DRE,GRADENIGO,ITALIAN,ITALY,JANUARY,LABEL,METHODS,OBJECTIVE,PIN,PSA,RESULTS,TURIN,UNLABELLED,WHILE
169,ASSESSMENT,AUSTRALIA,AUTHORS,BJU,COMMITTEE,LABEL,METHODS,NETWORK,OBJECTIVE,OUTCOME,PCR,RESULTS,SCORE,VICTORIAN
CHI,FIX,HARDY,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SCIENCE,THERE,VAL158MET
100,AFTER,BPH
125,ANDROLOGY,RETROPUBIC,RMAPE,UROLOGY
169,945,946,954,956,AP1,CSF,CURRENTLY,FURTHER,IGF,INC,OSCAR,PC3,PCA,PTHRP,RANKL,RESULTS,RUNX2,SILIBININ,TAC,TGF,TNF,WILEY
APPENDING,LEMUR,LMTK2
209,AMONG,BETWEEN,JANUARY,LABEL,METHODS,MRI,NPV,OBJECTIVE,OBJECTIVES,OVERSTAGED,PCA,PPV,RESULTS
ANOTHER,GIVEN,GOLGI
GEM,SINCE,THESE
031,554,946,AKT,CAV,DU145,FAK,IGG,OVERALL,PDGFR,SERUM,SRC,TREATMENT
16B,MALIGNANT,SUN,WNT
129,947,954,AFRICAN,CAUCASIAN,FCGAMMA,IGG,RIIIA,SINCE,THERE
001,177,ADDITIONAL,DCE,IMAGING,LABEL,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESONANCE,RESULTS
ARM,BACKGROUND,DISCUSSION,HELICAL,LABEL,METHODS,TRIAL,WHILE
169,AUTHORS,BACKGROUND,BRITISH,CONCLUSION,FUMONISIN,INHIBITION,JOURNAL,KEY,LABEL,LNCAP,METHODS,OBJECTIVE,PURPOSE,RESULTS,SK1,SKI,SOCIETY,THEREFORE,TREATMENT
169,174,804,822,BACKGROUND,CONCLUSION,DESPITE,HRQOL,INTERVIEW,LABEL,METHODS,RESULTS,SCALE,SURVIVORS,THESE
241,AIM,BRITISH,LABEL,METHODS,NETWORK,OBJECTIVE,RESPONSES,RESULTS,THERE,UROLOGICAL
HOWEVER,RUF,VARIOUS
BACKGROUND,GISTS,LABEL,RESULTS,UNASSIGNED,VIRTUAL
GPS,LABEL,METHODS,OBJECTIVE,RESIDENTS,RESULTS,THERE
214,AUTOMATED,BACKGROUND,CAS,GLEASON,LABEL,OSC,OVA,PIN,PPV,RESULTS
075,184,971,BPI,BRIEF,GROUP,INC,INVENTORY,LABEL,METHODS,OBJECTIVE,RESULTS,THESE,WHITE,WILEY
169,200,221,231,AUTHORS,BJU,DES,GROUP,LABEL,MARSDEN,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,ROYAL,TREATMENT,UNLABELLED,WORKING
169,COPYRIGHT,FORMS,SAS,THERE
169,BASED,COPYRIGHT,FEW,HOWEVER,SAS,THEREFORE,UROLOGISTS
169,COPYRIGHT,SAS
169,COPYRIGHT,HDL,LDL,SAS
169,BECAUSE,COPYRIGHT,SAS
169,174,ASSESSMENT,COPYRIGHT,HOWEVER,SAS
BPH,MIRABEGRON,OAB
DESPITE
ALPHA,ARI,AVODART,BPH,CURRENT,CURRENTLY,DRE,DRUGS,INITIAL,PDE,PROSCAR,PSA,RAPAFLO,SCORE,SYMPTOM
COPYRIGHT,HOWEVER,IDIOPATHIC,IPF,PROUS,SCIENCE
916,CRPCA,DUE,LBD,PCA
CAF,CHROMATIN,NOTABLY,TMA
825,CONCLUSION,GENERAL,KINGDOM,LABEL,METHODS,OBJECTIVE,OLDER,PURPOSE,RESULTS,WOMEN
001,169,177,946,ANXIETY,COPYRIGHT,DEPRESSION,DUTCH,LABEL,LTD,METHODS,OBJECTIVE,PROBLEM,RESULTS,SCALE,THESE,UNIVARIATE,WILEY
169,COPYRIGHT,DU145,IMPLANTED,INC,LIGHT,NCR,THESE,WILEY
279,290,336,669,AFTER,DIETARY,DUTCH,LABEL,METHODS,OBJECTIVE,PATHOLOGY,PURPOSE,REPORTS,RESULTS
050,133,178,423,482,677,845,888,929,THREE,XRCC7
440,956,CFPAC,CPFAC,LABEL,METHODS,MTT,NB142,NB165,OBJECTIVE,PKD,PROTEIN,PURPOSE,RAPID,RESULTS,THEREFORE
COPENHAGEN,DR1,FINALLY,HHDII,HLA,HOWEVER,LBD,TH1,THESE,USING
AFTER,GERMANY,PRIMARY,RESULTS,TECHNICAL,THERE
FRESH,HSP90
945,946,DAMPS,HMGB1,HOWEVER,TAKEN
DESPITE,GAL,GALECTINS,GIVEN,SILENCING
CALIFORNIA,COMPONENTS,CULTURALLY,FDMRS,INDIVIDUAL,LABEL,LATINOS,MEN,METHODS,OBJECTIVE,OBJECTIVES,PURPOSE,RESPECTFUL,RESULTS,SETTING
MPLUS,MULTILEVEL,SAS,SIMULATED
169,AFTER,COPYRIGHT,INC,INITIAL,LIVER,PRIMARY
000,006,021,022,169,177,495,656,668,721,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
011,169,CONCLUSION,COPYRIGHT,DESPITE,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SIXTY
043,169,807,810,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS
003,005,007,169,AFRICAN,AMICO,CONCLUSION,COPYRIGHT,INC,IQR,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,TTS,UNIVERSITY
169,945,ACT,COPYRIGHT,FET,PSA
169,223,945,AMERICA,COPYRIGHT,DEGARELIX,DENOSUMAB,III,LTD,MDV3100,SEVERAL,UNION,USA
169,197,946,947,AUTHORS,BJU,CONCLUSION,EMT,EXPRESSION,GLEASON,LABEL,METHODS,MMP,OBJECTIVE,RESULTS,SMS,SNAIL,SVI,THERE,TWIST,UNIVARIATE
169,304,CONCLUSION,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,NADIA,OBJECTIVE,PROSVUE,PSA,RESULTS
001,133,169,309,483,AFRICAN,AUTHORS,BCR,BJU,CARIBBEAN,CAUCASIAN,FURTHER,GLEASON,JAMAICA,LABEL,MATERIALS,MEDICAL,MEIER,MEN,METHODS,OBJECTIVE,PSA,RESULTS,UNIVERSITY,USA
100,176,190,252,300,305,500,BACKGROUND,BMI,CONCLUSION,FINAL,LABEL,METHODS,PARAMETERS,PSA,RESULTS,SEPTEMBER,THERE
001,002,023,106,638,ADAM9,BACKGROUND,CONCLUSION,COX,HOWEVER,LABEL,METHODS,PCR,RESULTS
203,525,608,615,649,726,735,758,788,808,820,875,877,AUC,BACKGROUND,CHINA,CHINESE,ECE,LABEL,LNI,MAY,METHODS,RESULTS,SVI,THERE,USING
169,AUTHORS,FINALLY,JOURNAL,NLS
169,ADD,AUTHORS,BJU,KNOWN,PSA,SUBJECT
945,COA,GLEASON,HOWEVER,RADICAL
945,946,AMONG,CYS86,FINALLY,ITG
169,BETWEEN,CURRENT,END,ENGLISH,HOWEVER,JANUARY,RISKS,ROBOT,UROLOGICAL
014,018,163,795,AES,BACKGROUND,CONCLUSION,CTX,GRADE,GREATER,LABEL,METHODS,NTX,PFS,PLACEBO,PSA,RESULTS
004,006,029,041,605,611,614,694,858,862,866,962,978,AUC,BACKGROUND,COLORECTAL,CONCLUSION,LABEL,METHODS,NEITHER,OVARIAN,PREDICTORS,RELAPSE,RESULTS,ROC,SCREENING,THESE,TRIAL
174,ASC,LEUCINE,PCA,TARGETING
215,795,ICELANDERS,SEVERAL,WESTERN
HAUSA,NIGERIA,OTHER,RENAL
116,120,160,169,947,COPYRIGHT,CTV,DIFFERENT,DIL,LTD,NTCPS,POISSON,PTV,PUBLISHED,TCP
125,169,239,313,546,COPYRIGHT,EDUCATION,INC,LABEL,LONGEST,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RECURRENCE,RESULTS,UROLOGICAL
001,169,198,822,AUC,AUR,CONCLUSION,COPYRIGHT,DOR,EGGER,INC,LABEL,LARGE,LIBRARY,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PCA,PUBLISHED,RATIONALE,RESULTS,SIXTEEN,VARIOUS
010,100,155,215,CONCLUSION,INC,LABEL,MEASURE,MEN,METHODS,OBJECTIVE,OUTCOME,PATIENT,PUBLISHED,RESULTS,SETTING,TMC
009,021,037,039,169,196,ADT,AFRICAN,COPYRIGHT,FFS,INC,LABEL,MATERIALS,MDV3100,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TDM,THESE
001,008,063,13G,14G,15G,169,35G,BACKGROUND,COMMITTEE,CONCLUSION,CONTEXT,COPYRIGHT,ENDOSCOPIC,GRADE,HEMOGLOBIN,HRP,INC,LABEL,METHODS,O3T,OBJECTIVE,OBJECTIVES,PERSISTENT,PUBLISHED,RESULTS
000,087,100,169,237,933,940,AEU,ANDALUS,ANDALUSIA,CATALONIA,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,PUBLISHED,REGIONS,RESULTS,SPAIN,SPANISH
169,AMONG,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,UNIVERSITY
001,065,080,105,169,CONCLUSION,COPYRIGHT,HOWEVER,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
169,177,1DAYS,332,843,880,8DAYS,ASA,BACKGROUND,BPE,BPH,CONCLUSION,COPYRIGHT,DEPARTMENT,LABEL,MEDICAL,METHODS,OBJECTIVE,PVP,RESULTS,SAS,TUR,TURIS
004,011,029,169,2NG,5NG,AFRICAN,AMICO,APRIL,CARIBBEAN,CONCLUSION,COPYRIGHT,EIGHT,FIFTY,GLEASON,JANUARY,LABEL,METHODS,NADIR,OBJECTIVE,PCA,PHOENIX,PSA,RESULTS,SAS,SIX
003,018,160,169,300,AFTER,CONCLUSION,COPYRIGHT,FIFTY,HOWEVER,LABEL,LRP,METHODS,OBJECTIVE,PURPOSE,RESULTS,SAS
102,160,169,174,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,MEDLINE,METHODS,MRI,RESULTS,SAS
169,COPYRIGHT,HORMONE,SAS,SCREENING,THESE
128,146,202,290,418,BACKGROUND,BASED,CONCLUSION,LABEL,RESULTS,TFBSS,THESE
113,AIM,ANTIGEN,CONCLUSION,DEPARTMENT,DIFFERENT,DRE,GERMANY,JANUARY,LABEL,MAY,METHODS,OVERALL,PCA,PLOVDIV,PSA,RESULTS,THEREFORE,UNIVERSITY,UNLABELLED,UROLOGY
BRCA2,SLE
177,215,485,800,849,948,GAMMA,MRI,PERLS,TESLA,U87,USING,USPIO
000,032,040,143,177,188,2ND,CONCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS
169,300,BACKGROUND,BECAUSE,CHEMISTRY,DPP,LABEL,LISAS,METHODS,MULTIPLEX,RESULTS,USING
037,082,762,BASED,SEVEN
145,169,231,956,COPYRIGHT,HEP,MCF,MDA,MEL,NMR,THEIR
169,2D3,945,CHROMATIN,COPYRIGHT,ISSUE,LTD,NCOR1,SPECIAL,SUBSEQUENT,VDR,VITAMIN
967,CHINESE,CP3,CURVE,DIFFERENT,DU145,LQL,NCI,OVERALL,PLQ,QUADRATIC,SRS,SRT,THEIR,U1690,UNIVERSAL,USC,USING
148,150,301,945,946,AAG,CIS,CNV,GENOMIC,LABEL,OBJECTIVE,ORS,RESULTS,UGT2B,UGT2B15,UGT2B17,URIDINE,WHILE
217,BACKGROUND,LABEL,METHODS,MMP,QSOX1,RESULTS
III,METASTATIC,PHASE,PRIOR
CTBP1,EXPRESSION,TAKEN,TRANSIENT
004,169,ADC,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SEVENTEEN,WILEY
BASIC,INITIALLY,PRIMARY,SINCE,THEREFORE,THESE
169,COPYRIGHT,FUNCTIONAL,INC,USING,WILEY
ODF
140,145,165,169,ACCORDING,ADT,BACKGROUND,COPYRIGHT,GLEASON,LABEL,METHODS,PSA,RANDOMIZED,RESULTS,SOCIETY
CONCLUSION,LABEL,OBJECTIVE,RALRP
CONCLUSION,DWI,LABEL,METHODS,MRI,NAF,OBJECTIVE,PET,RESULTS,WHOLE
100,177,350,614,618,708,769,BLOOD,CONCLUSION,EIGHT,LABEL,METHODS,MVD,OBJECTIVE,RESULTS
141,238,241,249,BMS,DEPARTMENT,MEDICAL
000,001,002,011,043,050,057,068,118,138,143,146,158,160,266,272,279,363,517,558,894,932,961,971,975,ASIAN,CAUCASIAN,HOWEVER,MET,SIX,STATA,SUMMARY,VAL,VAL158MET,VERSION
169,ANDROGENS,BACKGROUND,BASEL,C57BL,CHROMATIN,COPYRIGHT,DHT,LABEL,METHODS,OBJECTIVE,PCA,PCR,RAF,RESULTS,WESTERN,WHETHER
BACKGROUND,CBP,EXPRESSION,LABEL,METHODS,MTS,PCA,PCR,RESULTS,TARGETING,WESTERN,WHETHER
169,960,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,LABEL,METHODS,PROSTATIC,RESULTS,USING
100,147,370,617,CURRENTLY,EPE,METHODS,PARTIAL,PMS,RADICAL
224,AZA,FACTORS,HA22T,HCC,HEP3B,HEPG2,HOWEVER,RAF,SNAIL,VGH
963,FINALLY,INHIBITION,THESE
CTS,HOWEVER,PCA,WESTERN
370,BECAUSE,DIAGNOSIS,ECOLOGICAL,HODGKIN,HOWEVER,NHL,SEVERAL,STUDIES,UVA,UVB
CONVERSELY,OHD,VDR
AKT,CAM,QUERCETIN,RAT,WESTERN
BACKGROUND,CONCLUSION,IIB,III,LABEL,METHODS,PSA,RESULTS,THERE
CONCLUSION,INCREASED,LABEL,LNCAP,METHODS,PCA,RESULTS,UNLABELLED,VPA,WHILE
ENDPOINTS,ERSPC,GOTHENBURG,LABEL,METHODS,OBJECTIVE,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,THEREFORE
001,002,004,005,006,013,017,116,940,AVAILABLE,CIS,EVERY,LABEL,METABOLIC,METHODS,OBJECTIVE,OCTOBER,RESULTS
ADDITIONAL,ERG,ETS,THESE
AMONG,BELOW,ENGLISH,LIMITED,SIXTEEN
276,536,945,954,AKT,BACKGROUND,CONCLUSION,EXPRESSION,GLEASON,LABEL,LNCAP,METHODS,MMP,NLS,RESULTS,THESE
EARLY,EXPRESSION,PSA
169,CTC,PSA
169,ADT,CTC,DESPITE,INITIATION,LABEL,MEASURING,UNLABELLED
120,163,169,177,268,956,CONCLUSION,COPYRIGHT,EXCRETION,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,ORGAN,PURPOSE,RESULTS,SPRAGUE,THESE
169,ADT,COPYRIGHT,IRELAND,LTD,SINCE
169,BACKGROUND,CONTEXT,COPYRIGHT,ENGLISH,GLEASON,LABEL,MEDICAL,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,RESULTS,RPS,SINCE,SUBJECT,SYNTHESIS,UROLOGY,USING
001,019,024,044,089,145,169,171,172,192,344,457,462,482,514,AFTER,BACKGROUND,COPYRIGHT,FUNCTIONAL,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PROCEDURE,PUBLISHED,REGARDING,RESULTS,SETTING
AKT,BACKGROUND,CGA,COMET,DU145,ELISA,FINALLY,LABEL,LNCAP,METHODS,NED,RESULTS,THEREFORE,TREATMENT
126,172,A1C,AFTER,BMI,FURTHER,JAPAN,JDS,MULTI,PSA
AFRICAN,LABEL,METHODS,OBJECTIVE,RESULTS,TRUST
003,126,BACKGROUND,CAP,CONCLUSION,FATAL,LABEL,METABOLIC,METHODS,MORTALITY,OBJECTIVE,OVERALL,RESULTS,SEVENTY,TAB,THERAPY,URINARY
AGE,FINALLY
PDT,STUDIES
PDT
1H109,GLV,OVERALL
BACKGROUND,BPH,ELISA,EXOSOME,GLEASON,LABEL,METHODS,PCA,RESULTS,SMALL,THESE,WESTERN
ALTOGETHER,DLX,EMT,HOWEVER,TAKEN,TWIST
169,ANTITUMOR,III,OBJECTIVE,OTHER
004,118,177,251,308,346,806,AGE,CONCLUSION,COX,CRS,DUTCH,LABEL,LYNCH,MEIER,METHODS,MMR,OBJECTIVE,PURPOSE,RESULTS,SEVEN,SEX,SIR
001,169,289,866,961,BACKGROUND,BMI,COPYRIGHT,COX,LABEL,MEN,METABOLIC,METHODS,PROJECT,RESULTS,RRS,SOCIETY,THERE
004,139,177,BOHAN,CONCLUSION,ENHANCING,LABEL,METHODS,OBJECTIVE,PETER,RESULTS
DU145,GLUCOSE,GRP78,NPS,PC3,PNT1B,THEREFORE
160,216,ALS,END,FEW,INCREASING,INSTITUTE,LABEL,METHODS,OBJECTIVE,PARKINSON,PROGRAM,RESULTS,SMR,THERE,USING
DESPITE,PERHAPS,THESE
115,169,BCR,CAP,COPYRIGHT,DU145,ESPECIALLY,GLEASON,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCR,PIN,RESULTS,SENP1,THREE,TMA,WESTERN
169,956,ALTERATION,CCL20,COPYRIGHT,CXCL6,HCC,HCC24,HCC38,HOWEVER,IL6,IL8,MT3,QUINONE,SAS,WST
169,404,945,BACKGROUND,BPH,CONCLUSION,COPYRIGHT,FIFTY,HOWEVER,LABEL,LTD,METHODS,MYC,NANOG,OCT4A,PCA,PCR,RESULTS
110,ADT,BACKGROUND,BLACK,CAUCASIANS,LABEL,METHODS,PCA,QOL,RESULTS,THERE,THESE
169,CLAVIEN,COPYRIGHT,LRP,MINOR,PUBLISHED,THERE
127,169,185,205,227,330,528,AGA,BACKGROUND,COPYRIGHT,CRM,CYS,INC,INCREASED,INSTITUTE,KPT,LABEL,METHODS,MUTATIONS,OBJECTIVE,PAR,PUBLISHED,RESULTS,SELECTIVE,SINES
169,AREAS,AUSTRIA,BACKGROUND,BCA,BLADDER,CONTEXT,COPYRIGHT,LABEL,METHODS,OBJECTIVE,ONGOING,PATHOLOGY,PUBLISHED,RESULTS,SYNTHESIS,UROLOGY
169,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROBOTIC,SYSTEMATIC,UROLOGICAL,UROLOGISTS
100,169,ANOTHER,COPYRIGHT,EDUCATION,ERG,GLEASON,GRADE,HOWEVER,INC,LABEL,MATERIALS,METHODS,NEITHER,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TMPRSS2,UROLOGICAL
145,169,ANN,ARBOR,CHANGES,COPYRIGHT,EDUCATION,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PROTEIN,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,VORINOSTAT
169,LAPRA,REGARDING,UROLOGICAL
945,CPG,GADD45A,H3K9ME2,KMT,NCOR1,TAKEN,THESE,VDR
001,ERG,TMPRSS2,URINE
169,COPYRIGHT,INC,OVERALL,PCR,WILEY
124,155,163,165,18F,319,353,396,456,491,912,955,ACCORDING,CANCERS,CONTROL,FDG,HOWEVER,JAPAN,LABEL,METHODS,OBJECTIVE,PET,RESULTS,STAGE,UNION
ANGELES,BACKGROUND,CALIFORNIA,CONCLUSION,HOWEVER,INDEX,LABEL,LOS,LRP,METHODS,OBJECTIVE,ORP,PCI,QOL,QUALITY,RESULTS,UNIVERSITY
160,909,IGF,IGFBP,KINGDOM,LABEL,METHODS,OBJECTIVE,PSA,PSADT,PURPOSE,RESULTS,THERE
30D,DESPITE,GRP78
106,123,16511,193,380,905,908,ADULT,BACKGROUND,INCIDENCES,LABEL,LUT,MEIER,METHODS,NETWORK,ORGAN,PTM,RESULTS,SEPTEMBER,SHARING,SOT,TRANSPLANT
160,169,COPYRIGHT,JAPAN,PLM,PRECS,PUBLISHED,SOCIETY
169,5MG,AVODART,CONCLUSION,COPYRIGHT,DISCUSSION,FORTY,GSK,HISTOSCAN,INC,JANUARY,LABEL,MEN,METHODS,MRI,MULTI,OBJECTIVE,PLANNED,PRIMARY
001,004,148,169,300,AMICO,BACKGROUND,BCR,COPYRIGHT,GROUP,III,LABEL,LTD,METHODS,NVB,PSA,RESULTS,UNDERGOING
145,169,945,954,956,AFTER,COPYRIGHT,EDUCATION,INC,LABEL,LUCIFERASE,MATERIALS,METHODS,OBJECTIVE,PC3,PUBLISHED,PURPOSE,RESULTS,REVERSE,THESE,UROLOGICAL,WESTERN
032,155,169,261,655,700,COPYRIGHT,COX,EDUCATION,GLEASON,HARRELL,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
150,169,578,616,COPYRIGHT,EDUCATION,HOWEVER,INC,INPATIENT,LABEL,LOW,MATERIALS,METHODS,NATIONWIDE,NIS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL,USING,WHILE
169,5MM,AIM,COPYRIGHT,CROSS,FIFTY,LABEL,LTD,LYMPH,METHODS,MRI,NPV,OBJECTIVE,PPV,RESULTS,SEVENTY,USPIO
169,223,COPYRIGHT,III,INC,MDV,PHASE,PRACTICING,SINCE
169,COPYRIGHT,INC,THESE
169,COPYRIGHT,CURRENTLY,INC
169,COPYRIGHT,INC,SEVERAL,TARGETING,THESE
169,ADT,COPYRIGHT,INC
169,CLU,COPYRIGHT,HSP27,INC,WESTERN
169,CONVERSELY,COPYRIGHT,HRQOL,INC,THERE,TREATMENT
169,COPYRIGHT,INC
169,COPYRIGHT,INC,PUBLISHED,TARGETS,THESE
169,COPYRIGHT,III,INC,OTHER,PUBLISHED
169,COPYRIGHT,INC,PSA
169,COPYRIGHT,INC
001,169,183,198,232,233,311,502,503,945,956,BACKGROUND,CHARITABLE,COMIT,COPYRIGHT,EORTC,FUNDING,LABEL,LIGUE,LTD,METHODS,NATIONALE,RESULTS,TREATMENT,TRUST
001,135,169,183,270,BACKGROUND,BASED,COPYRIGHT,DWI,HOWEVER,IMAGING,LABEL,LIC,LNC,LSC,METHODS,NPV,OBJECTIVE,OUTCOME,PBX,PCA,PREDICTIVE,PUBLISHED,RESULTS,SETTING,UROLOGY
169,223,AFTER,BACKGROUND,BASED,CAUSE,COPYRIGHT,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING
169,AUSTRALIA,COPYRIGHT,INC
169,COPYRIGHT,MULTIPLEX,PSA
169,195,BETWEEN,COPYRIGHT,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MARCH,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,244,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROUTINE,TRANSITION,UROLOGICAL
011,021,026,031,039,042,169,BASED,COPYRIGHT,COX,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
092,135,169,233,242,322,334,656,956,BETWEEN,COPYRIGHT,COX,EDUCATION,FEW,GLEASON,INC,LABEL,LIMITED,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,THEREFORE,UROLOGICAL,WHILE
003,005,006,014,015,028,169,257,AGE,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THREE,UNIVARIATE,UROLOGICAL
169,270,513,AMERICANS,CLINICIANS,COPYRIGHT,EDUCATION,FEW,INC,KINCAID,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,READING,RESULTS,UROLOGICAL
169,AFFYMETRIX,ARRAY,COPYRIGHT,FINALLY,GLEASON,IHC,INC,MICROARRAY,PATHOLOGY,PCR,PUBLISHED,SEC14L1,SOCIETY,TCEB1
1034129,169,229,333,337,341,54239,872,BACKGROUND,COPYRIGHT,DETERMINE,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,STOCKHOLM,THERE,THESE,THROUGH,UROLOGY
001,169,177,289,435,BETWEEN,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,478,AMICO,ANATOMICAL,COPYRIGHT,EDUCATION,EXCELLENT,HOPKINS,INC,JOHNS,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PCW,PSA,PUBLISHED,PURPOSE,RADICAL,RESULTS,UROLOGICAL
169,703,953,COPYRIGHT,DECISIONAL,EDUCATION,INC,INVENTORY,IQR,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PHYSICIAN,PUBLISHED,PURPOSE,RESULTS,SCORE,SYMPTOM,THESE,UROLOGICAL,USING
ACCORDING,BACKGROUND,CONCLUSION,DDC,GREEN,HNSCC,LABEL,METHODS,PCR,RESULTS,TNM,TOTAL
001,157,BETWEEN,BMI,BPH,CHRONIC,GLEASON,IRANI,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,RPE,SCORE,SYMPTOM,THERE,TNM,TOTAL,TVE
AGE,BACKGROUND,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,NIGERIA,OBJECTIVE,PATHOLOGY,RESULTS,SOUTH,THESE,THOSE,THREE
189,AZIKIWE,BACKGROUND,CONCLUSION,LABEL,METHODS,NAUTH,NIGERIA,NNEWI,OBJECTIVE,RESULTS,THESE,THOSE,UNIVERSITY,USING
00003,00005,00006,00007,003,177,BACKGROUND,CONCLUSION,HEALTHY,INS,LABEL,METHODS,MM2,MRS,OBJECTIVE,PC3,PRESS,PURPOSE,RESULTS,SPRAGUE
ANORECTAL,BOWEL,COMPOSITE,EPICB,FECAL,INDEX,LABEL,METHODS,OBJECTIVE,PURPOSE,QOL,QUALITY,REGRESSION,RESULTS,SIXTY,THEREFORE
169,183,184,AGE,BACKGROUND,COLORECTAL,COPYRIGHT,COUNTRY,DALYS,DUTCH,ERASMUS,ESTIMATES,FUNDING,HDI,LABEL,LTD,METHODS,RESULTS,ROTTERDAM,SAHARAN,SCIENTIFIC,SOCIETY,THEREFORE,UNIVERSITY,WORLDWIDE
AMONG,BACKGROUND,CONCLUSION,LABEL,METHODS,PGR,RESULTS,TARGETING,THEREFORE,VEGFA
169,500,COPYRIGHT,HGPIN,IRELAND,LTD
169,657,COPYRIGHT,COX,FINLAND,FURTHER,LTD,NSAID
169,BRITISH,COLLEGE,COPYRIGHT,DESPITE,EXCELLENCE,GROUP,HOWEVER,INSTITUTE,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,RESULTS,ROYAL,SEPTEMBER,THERE,URO
160,169,321,664,BACKGROUND,COPYRIGHT,LABEL,METHODS,PSA,RESULTS,USING
ASSESSMENT,GLEASON,HOWEVER,INCIDENTAL,INCREASED,PCA,PSA,RCP,YET
157,169,430,DESPITE,FACTORS,JANUARY,LABEL,LEVEL,MARCHES,METHODS,OBJECTIVE,OBJECTIVES,REASONS,RESULTS,STUDENT,THERAPY,UNIVERSITY,UNLABELLED,UROLOGY
11Q13,612,SINCE,SNP
945,947,APOPTOSIS,BAX,BCLXL,FURTHER,HOWEVER,IFN,LNCAP,TNF,TNFSF12,TWEAK
037,120,177,184,AMONG,DRE,FDG,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PET,PSA,RESULTS,SECONDARY,THEREFORE
HOWEVER,THERE
160,949,AKT,HOWEVER,JNK,JUN,LOX,PKC,THESE,WDL
999,ABOUT,ARIZONA,DVT,THERE
130,AFTER,BACKGROUND,EORTC,FIRST,HBO,HDR,HYPERBARIC,LABEL,METHODS,PATIENT,RESULTS
160,200,ETS,FINALLY,LNCAP,MMP,TRANSGENIC,WHILE
108,549,BLK,DU145,HDF,HSP70,INITIALLY,LNCAP,NG108,PC3,SHOCK,TDF,YEARS
CONCLUSION,DOCETAXEL,LABEL,LNCAP,LUCIFERASE,METHODS,OBJECTIVE,PSA,RESULTS,WESTERN
EMT,EPITHELIAL,SNAIL
160,275,357,945,ADENOSINE,AMP,ATP,BML,HOWEVER,MIA,NAC,ROS,SMALL,THESE
AMONG,ATG12,AUTOPHAGIC,DU145,HOWEVER,LC3,LNCAP,THESE,VPA
10PBX,12PBX,169,253,923,AGE,BASEL,CDR,CHINESE,CONCLUSION,COPYRIGHT,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
ALA,ARG,ASN,FINALLY,ILE,LEU,MYTILUS,PHE,TFF
005,019,029,125,739,967,BACKGROUND,CHINESE,INCIDENCE,LABEL,METHODS,RESULTS,TOTAL,TOTALLY
169,215,698,ADVERSE,ATM,BACKGROUND,COPYRIGHT,CRT,ERCC2,FDR,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNP,THOSE,XRCC3
169,BASEL,BPH,CONCLUSION,COPYRIGHT,LABEL,MATERIALS,METHODS,NORMALIZED,OBJECTIVE,PCA,PCR,RESULTS

AIM,CONCLUSION,LABEL,LNCAP,MATERIALS,METHODS,NPS,OBJECTIVE,RESULTS
CURRENTLY,HOWEVER,THESE
169,UROLOGICAL
198,COMPARISON,TUR
206,619,80W,ASSESSMENT,GREEN,LASERSCOPE,LIGHT,OLYMPUS,PROSTATIC,QOL,RECURRENT
448,476,BACKGROUND,CASES,CUMULATIVE,HRS,LABEL,MELBOURNE,METHODS,RESULTS,VICTORIAN
23B,AKT,DEPLETION,EMT,INCREASED,SNAIL,SRC,THESE
169,COPYRIGHT,EXCLUSION,HOWEVER,LASER,LTD,MRS,TES,THEREFORE,THESE,WILEY
122,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RESULTS,SECONDARY,THERE
128,169,183,AFTER,BARTH,CONCLUSION,GEORG,LABEL,LOW,METHODS,OBJECTIVE,RESULTS,STIFFNESS,STUTTGART,THYROID,ULTRASOUND
000,012,016,024,026,029,038,043,088,125,169,177,215,250,3RD,495,500,505,DISSECTING,FORMULA,HOWEVER,LNCAP,THESE,TSU
174,1800795,1800796,236,357,572,613,636,941,992,ADDITIONAL,DUE,PCA,THERE
BACKGROUND,CONCLUSION,CURRENTLY,LABEL,METHODS,PCA,RESULTS,THERE
IMAGE,PSA
BACKGROUND,BCL,CONCLUSION,FOLLOWING,HYPOXIA,LABEL,LNCAP,METHODS,PCR,RESULTS,RUNX2
109,169,197,947,AFRICAN,AMERICANS,APOPTOSIS,CAUCASIAN,GLEASON,GLUTAMATE,HOWEVER,IHC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERUM,UNIVARIATE
NVB,THESE,WHILE
183,255,AFFYMETRIX,BLOOD,CONCLUSION,CURRENT,DIAGNOSIS,EXPRESSION,FOLLOWING,GLEASON,LABEL,MALAYSIAN,MATERIALS,METHODS,MICROARRAY,NORTH,OBJECTIVE,PCR,PSA,PURPOSE,RESULTS
412,946,CSN,ERMAS,SIRT1,SP1
001,BACKGROUND,CAUCASIANS,CIS,GSTM1,HOWEVER,LABEL,ORS,PCA,PRINCIPAL,RESULTS
177,AC133,CD133,CD49F,CFC
100,945,946,CRT,PC3,PKC,SER33,SER37,THEREFORE,WNT
281,294,655,661,679,689,749,AUC,HOWEVER,PSA
169,AMONG,ATP,EXPRESSION,ISOCITRATE,MYC,SDH,THESE,WARBURG
GLEASON,SERIOUS,T2A
001,005,256,487,503,BECAUSE,CONCLUSION,GIVEN,LABEL,METHODS,NETWORK,OBJECTIVE,PHC,PRIMARY,PURPOSE,RESULTS,USING
169,AFM,COPYRIGHT,EVALUATION,FINALLY,HERTZ,HOWEVER,INC,PC3,WILEY,YOUNG
946,HEIGHTENED,HOWEVER,THESE,TROP2
169,COPYRIGHT,IMAGING,INC,SOCIETY
300,65291,GLEASON,MAB,PSA
AKT,APOPTOSIS,BCL,CURRENT,DECADES,EMERGENCE,ISSUE,LATER,OTHER,SPECIAL
111,111IN,177,AIM,BESIDES,CONCLUSION,GASTRIN,LABEL,METHODS,NON,OBJECTIVE,PEPTIDE,RELEASING,RESULTS
ASSESSING,HOWEVER,PET,SPECT
002,016,11C,124,967,AGE,AIM,CBS,CENTRAL,CONCLUSION,DISEASE,DUTCH,LABEL,METHODS,OBJECTIVE,OVERALL,PET,PSA,PSADT,RECURRENT,RESULTS,SIXTY,STATISTIC,TEN,WHITNEY
11C,177,AIM,CHOLINE,CONCLUSION,LABEL,MEIER,METHODS,OBJECTIVE,PET,PSA,RESULTS,ROUGHLY,SRT
PET,RADIATION,SALVAGE
GTV,MRI,PET,PSA,RECURRENCE,SALVAGE,THERE,THESE
105,145,AMONG,BACKGROUND,BLACK,COX,GLEASON,INCLUSION,JANUARY,LABEL,METHODS,PSA,RESULTS,SEPTEMBER,THERE
124,CAP,UNTIL
169,CB1,CB2,COPYRIGHT,FURTHER,INC
169,198,AMONG,COPYRIGHT,CROWN,DU145,FURTHER,HAIRPIN,LIVIN,LTD,METASTATIC,PCR,PUBLISHED,TARGETSCAN,THEREFORE,UTR,WESTERN
001,009,169,429,586,AHA,COPYRIGHT,EDUCATION,INC,INPATIENT,LABEL,MATERIALS,METHODS,NATIONWIDE,NIS,OBJECTIVE,OWNERSHIP,PUBLISHED,PURPOSE,RADICAL,RESULTS,SEVERAL,UROLOGICAL
001,047,136,169,303,AUTOMATED,CAPISTRANO,COPYRIGHT,GLEASON,GROUP,IMAGE,INC,NEOPLASTIC,SAN,SIMILAR
127,169,208,290,ADT,AMICO,ANTIGEN,CONCLUSION,COPYRIGHT,FOCUSED,GLEASON,III,INTENSITY,IRELAND,LABEL,LOCAL,LTD,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SALVAGE,ULTRASOUND
169,AMONG,COPYRIGHT,HOWEVER,INC,PCR,RUNX2,SP3
HOWEVER
169,366,INCREASED,PRECISE,THESE,TODAY
141,469,498,BACKGROUND,CTD,ENRICHMENT,EXTENSIVE,GENERATION,HOMER,HOWEVER,INTEGRATED,JAN,KNOWLEDGE,LABEL,NCI,NGS,PATHGUIDE,PATHWAY,RESULTS,SEQUENCING,STUDIES,SYSTEMATIC,THERE
169,ADT,AUTHORS,BECAUSE,BJU,SINCE,TREATMENT
169,BJU,CYTOTOXIC
169,BJU,CTC,GUIDELINES,HOWEVER,OTHER,PSA,SEVERAL,THESE,UROLOGY,USA
162,169,388,693,BJU,COLORECTAL,ERSPC,OVARIAN,PSA,RANDOMIZED,SCREENING,TYROL,USA
169,223,COPYRIGHT,FDA,HOWEVER,INC,MDV3100,SINCE,THERE,THESE,UNTIL
CALABAR,EOSIN,GLEASON,HISTOLOGY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE,UNIVERSITY
AA861,AKT,COX,DHA,DU145,FATTY,KNOCKDOWN,LNCAP,LOX,PAN,PC3,PDK,SDC,THESE
536,AFRICAN,AFTER,AMERICANS,CARCINOGEN,INCREASED,PAH,WHITE
946,AKT,DU145,HOWEVER,LNCAP,MRAD9,PC3
169,176,196,238,713,CASES,COPYRIGHT,HOWEVER,ORS,VKA
169,347,367,CHINESE,CRICK,HAN,HOWEVER,HRM,INC,INTEGRINS,ITGAV,SNP,THESE,UTR,WILEY
121,215,463,PRACTICAL
119,125,132,147,169,344,CA125,COLORECTAL,COPYRIGHT,CURRENTLY,FORTY,HOWEVER,OVARIAN,RRS,SCREENING,STAGE,TRIAL,TVU,UKCTOCS,UPDATED
001,169,960,ADT,AFRICAN,AMERICANS,AMONG,BACKGROUND,COPYRIGHT,END,FEW,GUIDELINES,LABEL,MEN,METHODS,RESULTS,SOCIETY
1A1,2455A,3801T,640,645,801,959,ASIAN,CRUDE,HARDY,HOWEVER,HWE,ISI,MARCH,OVERALL,WEB
104,118,160,318,425,615,751,ACCORDING,ASIAN,CAUCASIAN,CIS,ETHNICITY,FURTHER,HOWEVER,JANUARY,ORS,SUMMARY
150,308,481,945,BPH,PCA,PCR,TNF
BPH
BACKGROUND,EARLIER,LABEL,METHODS,RESULTS
231,945,DISCOVERY,MDA,THESE,USING
000,100,102,108,24H,268,275,AUC,CONCLUSION,HBR,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS
112,137,194,215,382,443,CONSORTIUM,ICPCG,THESE,WHILE
160,282,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PIN,RESULTS,UROLOGISTS
ADT,E26,ETS,GLEASON,PCA,PSA,THERE,THESE
000,109,215,400,533,569,580,761,APRIL,BACKGROUND,CENTRAL,CFU,COMMITTEE,GLEASON,GROUP,HOWEVER,INSTITUTE,LABEL,METHODS,MONITORING,NCI,OBJECTIVE,PREVENTION,PURPOSE,RESULTS,SINCE,SITES,SOUTHWEST,TRANSITION,TRIAL,VITAMIN,WORKBENCH
000,141,160,224,22RV1,23A,296,320,375,376,BAX,LNCAP,MICRORNAS,PNT1A,USING,UTR,ZIP
005,046,125,ANTIGEN,CHI,CONCLUSION,CUT,DIGITAL,DRE,LABEL,MCNEMAR,METHODS,OBJECTIVE,OBJECTIVES,PEARSON,PSA,RESULTS,SEXTANT,TEN,THREE,TRU
DOCETAXEL,JAPAN,NOW,PSA
024,103,113,169,174,177,182,CLINICALLY,COLLEGE,COPYRIGHT,EDUCATION,FURTHER,GLEASON,INC,IQR,LABEL,MATERIALS,MCNEMAR,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,STRATEGIES,UNIVERSITY,UROLOGICAL
077,169,BOWEL,BRISTOL,COPYRIGHT,EDUCATION,INC,LABEL,LOWER,MATERIALS,MEN,METHODS,NUTRITION,OBJECTIVE,PUBLISHED,PURPOSE,REPORTING,RESULTS,SCALE,STOOL,THESE,UROLOGICAL
145,169,BAK,CLO,COPYRIGHT,HSA,III,INC,MCL,WHILE
169,50S,947,ALZHEIMER,AMONG,COPYRIGHT,HUNTINGTON,IDO,INC,INF,INHIBITION,PARKINSON,PCR
134,169,640,883,977,COPYRIGHT,EDUCATION,END,HOWEVER,ICD,INC,INITIAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
001,104,114,150,154,164,169,207,636,COPYRIGHT,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,BIC,COPYRIGHT,FOXA1,HOWEVER,IRELAND,LTD,MDV,MDV3100,SYNTHETIC,XENOPUS
169,BACKGROUND,COPYRIGHT,GLEASON,INC,INITIAL,LABEL,METHODS,MINEOLA,MORBIDITY,PRESALVAGE,PSA,RESULTS,SHORT,THERE,UNIVERSITY
001,010,049,169,313,709,BACKGROUND,COMPOSITE,CONCLUSION,COPYRIGHT,COX,INC,LABEL,METHODS,MFS,RESULTS
001,005,029,169,CELLSEARCH,CONCLUSION,COPYRIGHT,COX,CTC,GLEASON,INC,KENDALL,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PFS,RESULTS,THESE,TNM
001,103,124,125,160,169,180,304,COPYRIGHT,GLEASON,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,ANOTHER,COPYRIGHT,PUBLISHED,QUATERNARY,THESE
000PY,135,169,COPYRIGHT,HODGKIN,IRR,ITALIAN,ITALY,LTD,NHL,SEVEN,SIR,THREE
COMMITTEE,INC,JOINT,METASTASIS,NODES,PUBLISHED,TNM
169,CAP,COLLEGE,COMMISSION,COMMITTEE,CONTROL,COPYRIGHT,DIAGNOSTIC,FOLLOWING,INC,INSTITUTE,JOINT,PATHOLOGY,PROVIDING,STAGE,THESE,TNM,UNION
AREAS,BACKGROUND,BESIDES,CENTROSOME,COVERED,LABEL,METHODS,OPINION,STRATEGIES
207,213,220,233,BACKGROUND,INCLUSION,LABEL,METHODS,REOCS,RESULTS
AREAS,BACKGROUND,COVERED,DESPITE,HOWEVER,LABEL,METHODS,OPINION,PAR,THEREFORE
ADDITIONAL,HOWEVER,LYTIC,OPG,OSTEOLYSIS,PTHRP,RANKL,SEVERAL
000,001,173,200,500,600,BMI,CONCLUSION,ESTIMATED,GLEASON,HOWEVER,JANUARY,LABEL,LRP,METHODS,OBJECTIVE,PSA,RESULTS,RRP,THERE
NPS
004,215,AIM,AMIFOSTINE,CONCLUSION,GRADE,HYPOARC,LABEL,METHODS,OBJECTIVE,RESULTS
002,003,004,005,007,008,009,105,AGE,AIM,ANOVA,CONCLUSION,FSH,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PRL,PSA,RECORDS,RESULTS
ADC,AIM,AREAS,CONCLUSION,DWI,FORTY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
956,ATP,BACKGROUND,CONCLUSION,CSNK2A2,DRAK1,FLT,GAK,LABEL,MATERIALS,METHODS,RESULTS,SINCE,TILLANDSIA
946,950,BACKGROUND,CONCLUSION,DESPITE,DU145,EMT,FAK,LABEL,PC3,RESULTS,SRC,TAKEN,WHILE
169,946,BACKGROUND,CDKNI,COPYRIGHT,DU145,HOWEVER,ID1,ID3,ID4,INC,INHIBITOR,KNOCKDOWN,LABEL,METHODS,PC3,RESULTS,TGF,THESE,WILEY
14Q32,169,16Q23,AFRICAN,AMERICANS,ARRAY,BACKGROUND,CNV,COPYRIGHT,DESPITE,IGHG3,INC,LABEL,METHODS,RESULTS,TEN,THESE,THROUGH,WILEY
169,945,946,BACKGROUND,COPYRIGHT,DHT,FBS,HOWEVER,INC,LABEL,LNCAP,METHODS,PCR,RESULTS,THEREFORE,WESTERN,WILEY
947,ALK,ERG,ETS,NOTABLY,NTRK3,PTC,RECURRENT,RET,TMPRSS2
ANOTHER,MUCIN,PRIMARY,SECONDARY,THESE
FGF,FGFR2,FGFRS,GIVEN,LABEL,METHODS,OBJECTIVE,RESULTS
153,169,AKT,BACKGROUND,CDK,COPYRIGHT,FOXO1,FURTHER,INC,LABEL,LUCIFERASE,METHODS,MTT,PCR,RESULTS,TAKEN,UTR,WILEY
112,169,946,BACKGROUND,CCND1,COPYRIGHT,FORTY,FOS,INC,JUN,LABEL,METHODS,PHTPP,RESULTS,SUBSEQUENT,THESE,WILEY
169,272,309,BACKGROUND,CCL11,CCL17,COPYRIGHT,CXCL1,CXCL5,CXCL8,ELISA,EOTAXIN,FORCE,INC,LABEL,METHODS,MULTIPLEX,PCA,PREVENTIVE,PSA,RESULTS,SERUM,WILEY
169,2D3,CHANGES,CONCURRENT,COPYRIGHT,ISSUE,LNCAP,LTD,MYC,PPARA,SPECIAL,THESE,VDR,VITAMIN,WARBURG
140,168,169,183,BACKGROUND,COPYRIGHT,FUNDING,INSTITUTE,ITGAL,KETTERING,LABEL,LTD,MDX,METHODS,PCR,PERIPHERAL,RESULTS,SLOAN,TIMP1,USA
001,169,183,AFFYMETRIX,BACKGROUND,BEATSON,BIOMARKERS,CHARITY,COPYRIGHT,EXPRESSION,FOUNDATION,FUNDING,GLASGOW,KETTERING,LABEL,LPD,LTD,MARSDEN,METHODS,NHS,PAXGENE,PCR,RESULTS,ROYAL,SLOAN,THESE,TRUST,U133PLUS2,USA,WHOLE
169,241,AEU,BOTANICAL,BPH,COPYRIGHT,ENGLISH,EXCLUSION,HOWEVER,JANUARY,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,SPANISH,SYNTHESIS,SYSTEMATIC,THERE,UNASSIGNED
PROVIDING,TUR
169,436,559,945,AE1,AE3,CD117,COPYRIGHT,DISCOVERED,DOG,GAT,GTT,IMAGING,KIT,MITOTIC,SINCE
10Q23,169,CHINESE,GASTRIC,JAPAN,KOREA,MUCIN,PREVIOUSLY,SNP,WHILE
224,BACKGROUND,CFS,HIV,HPV,LABEL,LBC,PCR,RESULTS,THERE,USING
AMP,DIM,HOWEVER,LNCAP,THERE,THESE
947,AD5,CTL,DCS,IFN,MHC,TAP,THESE
22RV1,916,947,ADE1A1102,ADE1A1104,ADE1A1108,CBP,CR2,DU145,E1A,NEITHER,ONCOLYTIC,THESE,THROUGH,TRRAP,WHILE
ELEMENT,SEVERAL,STROMAL,TF1
THESE
181,ATM,BASED,HAT,TIP60
169,COMPOUNDS,COPYRIGHT,MCF,NOSCAPINE,PAPAVER,PC3,VCH,WILEY
540,ASIAN,CHINESE,VIETNAMESE,WOMEN
005,CONCLUSION,DISCUSSION,EPIDS,GLEASON,GREATER,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,TNM,TREATMENT,URINARY
CERTAIN
001,011,DIFFICULT,FIFTY,GROUP,ITD,LABEL,METHODS,OBJECTIVE,PDA,PURPOSE,RESULTS,RPP,THESE,WHILE
008,010,048,077,594,661,AGGRESSIVE,CONCLUSION,FURTHER,GLEASON,LABEL,METHODS,OBJECTIVE,PATHOLOGIC,PCA,PSA,RESULTS
821,CUMULATIVE,EIGHT,FDR,LYNCH,MANCHESTER,PSA,UPPER,UROLOGICAL
002,007,009,011,019,027,029,033,195,250,ADDITIONAL,DIPLOTYPES,METHYLENE,MTHFR,NAD,NORTH,NRH,PCA,PCR,QUINONE,SIMILARLY,VARIANT
012,035,149,152,CXCR4,HOWEVER,PCR,SDF,THERE,TURKISH
CIS,COX,HOWEVER,ORS,OVERALL,PCA
10A,231,MCF,MDA
DONOR
174,223,AFTER,ALPHARADIN,COMMISSION,CONCLUSION,LABEL,MBQ,METHODS,OBJECTIVE,PROTECTION,PURPOSE,RESULTS
100,FACTORS,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OVERALL,PATIENT,PSA,PSADT,PURPOSE,RESULTS
160,CONCLUSION,CRT,EIGHT,INDEX,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
160,162,AVPOSPR,CONCLUSION,CTV,LABEL,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,TEN,USING
160,ACUTE,CONCLUSION,CTV,EORTC,LABEL,LOW,MAY,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,SEPTEMBER,SIB,UNIVARIATE
160,ACUTE,BACKGROUND,CONCLUSION,LABEL,LNPPC,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TREATMENT
128,160,177,180,1980S,AFTER,BACKGROUND,CONCLUSION,ENDPOINTS,HAMBURG,LABEL,METHODS,RELATIVELY,RESULTS
000,001,AFTER,APRIL,BACKGROUND,GLEASON,LABEL,MAJOR,METHODS,NVB,RESULTS
AGE,BASED,COMPETING,CONSENSUS,ELDERLY,PCA,PSA,THERAPY
PCA,RPX
THEREFORE,WHILE
160,BALANCING,CHOICES,FURTHER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STRENGTHS
150,177,180,AFTER,ALERTNESS,ASSESSMENT,BACKGROUND,BLOOD,CO2,FORTY,LABEL,METHODS,OAA,PROLONGED,RESULTS,STATE
001,044,129,160,166,295,BETWEEN,INCIDENTAL
DISCUSSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,WISCONSIN
018,029,169,195,403,BACKGROUND,BASED,BASEL,COPYRIGHT,DIFFERENT,HOWEVER,LABEL,MATERIALS,METHODS,RESULTS,STATINS
GLEASON,PSA,SIX,T3AN1M0
186,298,BLUNT,BMI,EFFECTS,MARCH,MEIER,RRP,SAITAMA
002,HOWEVER,JANUARY,MARCH,MEYER,OVERALL,RRP,SIMILARLY,T1A
008,177,178,179,215,ADC,DIFFUSION,DWI,GLEASON,MRI
169,ERG,III,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TARGETING,TMPRSS2
FRESH,HSP90,INITIALLY
BACKGROUND,BASED,DUTCH,ENGLISH,FIFTEEN,GPS,ITALIAN,JANUARY,LABEL,MAY,MEDLINE,METHODS,PSA,PSYCHINFO,RESULTS,SPANISH,STUDIES,THREE
945,947,DY131,ERR,FEDERATION,GYNECOLOGY,HEC1A,HOWEVER,LABEL,METHODS,OBJECTIVE,OBSTETRICS,RESULTS
954,BCL,BECN1,BIRC2,BIRC3,CFLAR,JNK,KNOCKDOWN,MAPK8,RIPK1,THESE,TNFSF10,TRAF2,TRAIL
ERR,HOWEVER,RRR,VARIOUS
160,DIR,DVH,HENCE,LARGE,VARIATIONS
152,169,APRIL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,POTENTIAL,RESULTS,RETZIUS,SEPTEMBER,UROLOGICAL
945,CD133,CSC,EMT,HIF,HOWEVER,HYPOXIA,PDA,THESE,WHETHER,WHILE
GLV,MHCII,THEREFORE,THESE
DIS,NED,ORAI1,SEP,STIM1,TRPC1
001,BACKGROUND,CIS,CUMULATIVE,FURTHER,HOWEVER,LABEL,LAIRD,LITERATURE,METHODS,PCA,RESULTS,THERE
AMINO,BAG,BIP,GRP78,INHIBITION
954,AMONG,DENOSUMAB,III,PHASE

062,163,500,745,CLEARLY,CURRENT,ENGLAND,FOLLOWING,HOWEVER,OTHER,PSA,TGB,THESE,WALES
001,AIFM2,ARRAY,BACKGROUND,CONCLUSION,CRF,LABEL,METHODS,MIPEP,MSTO1,OBJECTIVE,PCR,RESULTS,SLC25A4,THESE
164,BACKGROUND,CD117,CD133,CD146,CONCLUSION,LABEL,METHODS,MVD,RESULTS
AIM,AMONG,BACKGROUND,KYOTO,LABEL,MATERIALS,METHODS,NOTCH,OBJECTIVE,PCA,PPI,RESULTS,TOTAL
16357,16S,177,339,473,500,945,956,BENZAMIDES,BLAST,DH5,KOCURIA,NMR,PC3
ROBOT
140,169,299,BJU,ERG,EXPRESSION,HGPIN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,RESULTS,UNLABELLED
001,003,169,AGAIN,AUTHORS,BJU,CLINICALLY,CYCLE,FIRSTLY,LABEL,METHODS,MOLECULAR,OBJECTIVE,OBJECTIVES,OVERALL,PCA,PCR,PREDICTION,RESULTS,SW480,UNLABELLED
103,125,169,BJU,CLINICIANS,COX,GROUP,LABEL,METHODS,MOUNT,OBJECTIVE,OBJECTIVES,RADIATION,RESULTS,SCORE,SEVERAL,SINAI,THERAPY,UNLABELLED,WHILE
CONCLUSION,LABEL,METHODS,OBJECTIVE,QOL,RESULTS,SEVENTY,TIP
BASED,CD4,CD8,GIVEN,HOWEVER,THESE
000,001,130,200,235,304,628,993,BACKGROUND,LABEL,METHODS,NAVIGATION,PATIENT,PROGRAM,RESULTS
665,703,BACKGROUND,CHINESE,CYR61,GLEASON,IGFBP10,LABEL,MEN,METHODS,PCA,PCR,PSA,RESULTS
169,BACKGROUND,BRM,CHEMISTRY,CURRENT,ERG,GLEASON,LABEL,METHODS,MFC,MICROFOCAL,PCR,RESULTS,THREE,TMPRSS2,URINE
169,752,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,QOL,QUALITY,QUESTIONS,RESULTS,THEREFORE,USING,WILEY
BESIDES,CSF,FURTHER,GRADE,MEIER,THREE,UNIVARIATE,UNIVERSITY
378,450,BACKGROUND,COLORECTAL,HOWEVER,LABEL,METHODS,NFKB1,OVARIAN,PUBLISHED,PULMONARY,RESULTS,SCREENING,SNP,SOCIETY,TRIAL
160,169,BASED,COPYRIGHT,FIFTY,HELICAL,IEC,LTD,PUBLISHED,THESE
169,COPYRIGHT,FURTHER,LTD,SAR,SENP1,SENTRIN,SPECS
169,946,956,COPYRIGHT,LTD,MAHKOSIDE,MAHKOTA
169,947,954,AUTHORS,BACKGROUND,BRITISH,JOURNAL,KEY,LABEL,LNCAP,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS,SOCIETY
001,169,376,BJU,CONVERSELY,DIAGNOSIS,ERSPC,GLEASON,LABEL,LEVEL,METHODS,OBJECTIVE,PPV,PSA,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,T2B,UNLABELLED
223,DOCETAXEL,WESTERN,WORLD
182,193,455,585,851,AFTER,AUSTRALIA,BACKGROUND,CONCLUSION,ESTIMATED,LABEL,METHODS,RESULTS,SOUTH,THESE,USING,WALES
169,LABEL,UNLABELLED,VISIBLE
160,662,716,945,CHINESE,GLEASON,HAN,HIF,HIF1A,HOWEVER,PCA,THESE
541,945,946,954,AMERICA,CXCL1,EFEMP,IKK,INHIBITION,SPARC,TREATMENT,WESTERN
160,DECREASED,EMERGENCE,LNCAP
261,474,CASES,CD4,HOWEVER
FURTHER,GFP,HENCE,INCREASED,LBD,MG132,NES,PC3,TREATMENT,USING,WESTERN
169,AMONG,COPYRIGHT,GTP,INC,PCA,SEVERAL
CAP,FINALLY,PN1,SHH,SONIC,USING,WHILE
005,212,22RV1,AMG,BAY2010112,CD3,CHINESE,DU145,LNCAP,MDA,NOD,PCA,RAPID
169,ACUTE,BACKGROUND,COPYRIGHT,GROUP,INC,LABEL,MATERIALS,METHODS,RADIATION,RADIOLOGY,RESULTS,SOCIETY,THERAPY
009,169,COPYRIGHT,ESTIMATES,FURTHER,LABEL,METHODS,OBJECTIVE,RCT,RESULTS,SAS,TZD
169,205,COPYRIGHT,DOCETAXEL,FUNCTIONAL,HOWEVER,INC,LOW,PATHOLOGY,PUBLISHED,SCREENING,SOCIETY,THEREFORE
TESTICULAR
015,021,038,045,100,118,169,AOR,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,TESLA,THREE
009,010,128,154,169,282,367,COPYRIGHT,CROWN,INC,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,URINARY
102,169,186,239,400,510,ADT,BACKGROUND,BMD,CHANGES,COPYRIGHT,LABEL,METHODS,NTX,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING
000,163,169,3DCRT,COLLEGE,CONCLUSION,COPYRIGHT,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OTHERWISE,PUBLISHED,RESULTS,ROYAL,SERVICE
006,169,AFP,CEA,COPYRIGHT,HOWEVER,IRELAND,LTD,PSA,THEREFORE
330,BESIDES,HOWEVER,ITERATIVE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESIDUE,RESULTS,SRC,THEREFORE
DIR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,RMM
CLINICALLY,DOSIMETRIC,GAMMA,LABEL,METHODS,MLC,OAR,OBJECTIVE,PTV,PURPOSE,RESULTS,ROTATIONAL,SLIDING,SYSTEMATIC,UNIFORMLY
931,963,FLORIDA,GAS,INSTITUTE,LABEL,METHODS,NGR,OBJECTIVE,POPULATION,PTV,PURPOSE,RESULTS,SIMILAR,THEIR,THERAPY,UNIVERSITY
001,044,109,169,COMPOSITE,CONTINENCE,FUNCTIONAL,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,REGARDING,RESULTS,SIMILARLY,UROLOGICAL
037,169,ADHERENCE,LABEL,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,UROLOGICAL,UROLOGY
AGE,AMERICA,AREAS,CENTRAL,CONCLUSION,FURTHER,HISPANICS,INSTITUTE,LABEL,METHODS,NHB,NHW,NON,OBJECTIVE,POISSON,RESULTS,SEP,USH
126,FINALLY
ASC,CD146,CFD,PRESENT,WHILE
169,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,RESULTS,THESE,VEGFR,WILEY
169,264,945,BACKGROUND,COPYRIGHT,ELISA,FINALLY,INC,LABEL,METHODS,PCR,RAW,RESULTS,THESE,TNF,USING,WESTERN,WILEY
169,BACKGROUND,CONCLUSION,COPYRIGHT,DU145,INC,JNK,LABEL,LNCAP,METHODS,PCA,PCR,RESULTS,SP1,THESE,WESTERN,WILEY
145,169,954,BACKGROUND,COPYRIGHT,DESPITE,ELISA,HOWEVER,INC,LABEL,METHODS,PCR,RESULTS,THESE,WILEY
169,ANCCA,ANIMALS,BACKGROUND,CHROMATIN,CONCLUSION,COPYRIGHT,E2F,EED,H3K4ME3,HOWEVER,IHC,INC,LABEL,LNCAP,METHODS,PCR,REGULATION,RESULTS,SUZ12,THEIR,UGS,WESTERN,WHILE,WILEY
000,046,150,160,169,215,AMONG,BACKGROUND,COPYRIGHT,IGF,IGFBP,INC,LABEL,METHODS,PCA,RESULTS,SERUM,WILEY
125,169,177,AIM,COPENHAGEN,COPYRIGHT,DESPITE,DUNNING,GRP,HENCE,LABEL,LTD,METHODS,OBJECTIVE,PET,RESULTS,TYR
131,AD5PB_RSV,NIS
145,177,270,AKT,BACKGROUND,CAP,CONCLUSION,EPHA2,FAK,GFP,LABEL,LNCAP,METHODS,PC3,RESULTS,SRC,WESTERN
410,800,AUC,AUSTRALIA,BACKGROUND,CAMBRIDGE,CONCLUSION,GLEASON,KINGDOM,LABEL,METHODS,PRIAS,PSA,RESULTS,TORONTO
169,174,175,226,301,948,COPYRIGHT,EDUCATION,INC,LABEL,MASSARRAY,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,549,956,BEL,COPYRIGHT,HCT,LTD,NMR,PDA,THEIR,TLC,VALERIANA
109,11C,169,18F,441,773,999,BACKGROUND,CHOLINE,CONTEXT,COPYRIGHT,ENGLISH,JANUARY,KNOWLEDGE,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PCA,PET,PUBLISHED,RESULTS,REVIEWS,SCHOLAR,STUDIES,SYNTHESIS,UROLOGY,WEB
134,LABEL,MATERIALS,METHODS,NNS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SEVENTY,SIMILARLY,SIXTY
169,AUTHORS,BJU,BRCA2,CONSORTIUM,CUNINGHAM,HGPIN,LABEL,LOH,METHODS,OBJECTIVE,OBJECTIVES,PCR,RESULTS,TEN,UNLABELLED
RADICAL
EUB,HITACHI,LABEL,METHODS,OBJECTIVE,RESULTS,RTE,SEPTEMBER,THREE
101,169,180,210,BJU,CLAIM,GOVERNMENT,JANUARY,LABEL,METHODS,MRI,OBJECTIVE,PINTO,PSA,RES,RESULTS,SCIARRA,UNLABELLED,WORKS
169,AUR,BJU,BPH,CIS,CONCLUSION,INSURANCE,LABEL,LEVEL,METHODS,OBJECTIVE,ORS,PROGNOSIS,RESULTS,STUDENT,THERE,UNIVARIATE,UNLABELLED,UTI
BESIDES,DGFIT,THERAPY
150,BALTIMORE,DAVINCI,FINALLY,FRIEDRICH,GERMANY,HALLE,HALSTED,HAMPTON,HOPKINS,JOHNS,ORIGINALLY,STEWART,TERENCE,THEODOR,THIERMANN,USA,WILLIAM,YOUNG
137,512,EQUIVOCAL,HODGKIN,NIGHT,RESULTS,THERE
176,751,759,EPIDEMIOL,JOURNAL,STUDIES,THESE
945,954,CANCERS,HIF,MYC,NOTABLY,RAS
BACKGROUND,DNASE,EPIGENETIC,LABEL,RESULTS,SP1,THESE
946,AKT,DU145,HOWEVER,LNCAP,MYC,REGULATION,TREATMENT
946,III,OXIDATIVE,TAKEN
AUTOCRINE,BACKGROUND,BAP,CONCLUSION,CONVERSELY,LABEL,METHODS,PSA,RESULTS,THESE
DEGARELIX,THERE,THESE
160,177,AVERAGE,DYNALOG,MACHINE,MCS,MLC,PLANNED,PPN,RMS
001,604,AFRICAN,BACKGROUND,DESPITE,FURTHER,GLEASON,LABEL,METHODS,OVERALL,PCA,PSA,RESULTS,THESE
132,331,BACKGROUND,FORTY,HOWEVER,LABEL,METHODS,RESULTS

INITIAL,METASTATIC
000,100,400,500,680,AGE,APC,BACKGROUND,CONVERSELY,EARLY,HOWEVER,INSTITUTE,ITALIAN,LABEL,METHODS,MORTALITY,OVERALL,RESULTS,STATISTICS,THESE,THROUGHOUT
498,696,AMONG,BACKGROUND,CHECKLIST,LABEL,METHODS,PROBLEM,RESOURCES,RESULTS,YOUNG,YOUNGER
BOWEN,EXTRA,PAGET,REASONS
169,401,515,882,916,ALLELIC,AML,APMIS,ARG,AUTHORS,SOMATIC
169,320,458,474,ADD,AUTHORS,BJU,GLASGOW,GPS,GREATER,KNOWN,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,OLDER,PSA,RESULTS,SUBJECT,UNLABELLED
169,177,300,APRIL,ARB,AUTHORS,BJU,CONCLUSION,FURTHER,INDEX,LABEL,LEVEL,METHODS,OBJECTIVE,POTENCY,REGULAR,RESULTS,RRP,SPL,STRETCHED,THERAPY,THERE,UNLABELLED,WHILE
100,174,AIM,CELLS,CHEMPRO,CONCLUSION,LABEL,LNCAP,MALIGNANT,MATERIALS,METHODS,OBJECTIVE,PROSTATIC,RESULTS
HOWEVER,MDV3100,MEN
169,APMIS,AUTHORS,GLEASON,HISTOLOGY,HOWEVER,INCLUSION,PCA,PSA,THERE,THREE
HOWEVER,JANUARY,UROLOGY
APTAMER,BACKGROUND,C14B1,CONCLUSION,HOWEVER,LABEL,PRINCIPAL,RESULTS,SELEX,STRUCTURAL,THEREFORE,THROUGH
ATO,BLI,DOPPLER,DYNAMIC,FLI,PC3,POWER,SIMILAR,SMALL,U87
370,CDK,DU145,ECTOPIC,FOXO1,LNCAP,MICRORNAS,TAKEN,THEREFORE
AMONG,BACKGROUND,CD8,EFFORTS,HLA,LABEL,LNCAP,PBMCS,PRINCIPAL,PSGR3,PSGR4,RESULTS,THESE
946,DIAGNOSTIC,GLEASON,PATHOLOGY,PSA,SIGNALS,URINE,USING
001,100,181,947,DHA,DU145,LNCAP,LOX,PC3,THESE
377,385,780,814,929,BACKGROUND,CIS,CONCLUSION,GIVEN,HOWEVER,LABEL,LIBRARY,MEDLINE,METHODS,RESULTS,REVIEWS,SCI,SEVENTEEN,SIMILARLY
256,324,CHI,CLASSIFIER,CLUSTER,GLEASON,MICROARRAY,SAM,THESE
CFS,CWR22,DESPITE,HOWEVER,MLV,NOTABLY,PCR,THESE
AUC,GIVEN,GLEASON,HOWEVER,PREDICTION,PSA,SP1,SP3
AFRICAN,ASIAN,ASN,ASN312ASP,ASP,BACKGROUND,CIS,CONCLUSION,FURTHER,GLN751LYS,LABEL,MEANWHILE,PCA,PRINCIPAL,RESULTS,SNP,STATA10,XPD
AMAZONIAN,DRS,PC3,THESE
22RV1,946,GLEASON,MYC,PC3,RUNX2,USING
AU565,BN999,FINALLY
BPH,E26,EMT,ERG,EXPRESSION,FUNCTIONAL,ILK,LEF,MICROARRAY,PCA,PNT1B,PRECS,QLT,SNAIL,THESE,TMPRSS2
945,954,ACTIVATED,AKT,CXCL1,DU145,GRO,HDAC1,HOWEVER,IKK,INDUCTION
169,COPYRIGHT,INC,OVERALL,WILEY
CD133,HOWEVER,USING
AKT,DISRUPTION,EXPRESSION,FAK,FYN,HOWEVER,KNOCKDOWN,PC3,PROTEIN,SRC,SW620,SYF,YES
945,CYP17A1,HOWEVER,III
ACCORDING,ATROPHY,NIH,NON,PIA,PIN,THESE
169,AMONG,COPYRIGHT,CPG,ICELAND,JAK,LTD,SEVERAL,STAT3
169,ACTIVATED,COPYRIGHT,LTD,PLATELETS,PMP
169,COPYRIGHT,GIVEN,GLEASON,INC,PROSTATIC,ROSETTE,SMALL,TTF
012,017,028,034,106,169,562,COPYRIGHT,COX,GLEASON,INC,PCA,THERE
231,555,E3S,FINALLY,KNOCKDOWN,MDA,PC3,THESE,USING
169,COPYRIGHT,DU145,HORMONE,INC,MET,SU11274
086,177,BACKGROUND,CONCLUSION,IDEALLY,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS
LNCAP,THESE
DU145,LYSOSOMAL,MALIGNANT
509,571,707,BACKGROUND,CIS,COX,HRS,LABEL,METHODS,RESIDENTS,RESULTS,THERE,THROUGH
EMT,MET,NANOG,PCA,THEREFORE,TSA
946,ACTIVIN,INHBA,INHBB,INHIBITION,LNCAP,LOCAL
004,169,700,ALCOHOL,BMI,CIS,COPYRIGHT,GLEASON,PROTECT,PSA,RGM,RRR
116,169,ALTOGETHER,COPYRIGHT,HCT,HDACI,HDACS,INHIBITION,MCF
AZA,CDR,CPG,DU145,DZNEP,LNCAP,PC3,SIMILARLY,TIMP3,TREATMENT,TSA,USING
ADDITIONAL,DESPITE,HOWEVER,MDV3100,PREVIOUSLY,THESE,USING
AR3,CONVERSELY,DESPITE,RHO,THESE
PSA
19Q13,215,484,934,AFRICAN,AMERICANS,CHINESE,HAN,THESE
133,22RV1,252,AIM,CONCLUSION,EIGHT,LABEL,LNCAP,LUCIFERASE,METHODS,MTT,OBJECTIVE,PCA,RESULTS,THESE,WESTERN,YEAST
114
ADDITIONAL,ADT,HEALTHCARE
001,463,945,ALPHA,CONCLUSION,D14,D21,D42,D72,ELISA,FATIGUE,INC,LABEL,METHODS,MICROARRAY,OBJECTIVE,PARKINSON,PUBLISHED,PURPOSE,RESULTS,SIXTEEN
BECAUSE,DIFFUSION,MRI
145,169,946,ABSIDIA,AMONG,COPYRIGHT,THESE
169,34A,504,945,AKT,AURKB,CCNB1,COPYRIGHT,DLBCL,EMT,FOX,FOXA1,FOXE1,FOXF1,FOXM1,FOXN5,FOXP1,FOXR1,GLI,IRELAND,LTD,MLL,MYC,PAFAH1B,SNP,UTR,WHOLE,YAP
169,956,ADP,COPYRIGHT,INC,ONCOSOMES,PATHOLOGY,PUBLISHED,SIMILAR,SOCIETY,STRUCTURES,THESE
001,169,233,AFTER,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL
026,169,381,645,ACUTE,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
169,751,COPYRIGHT,EDUCATION,FEW,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,REDUCTION,RESULTS,SECONDARY,UROLOGICAL
065,169,BACKGROUND,CAUSE,COPYRIGHT,COX,DVT,LABEL,METHODS,OBJECTIVE,OTHER,OUTCOME,PATIENT,PCA,PUBLISHED,RESULTS,SETTING,SURGERIES,TED,UROLOGY,USING
169,ADDITIONAL,BACKGROUND,BECAUSE,CONTEXT,COPYRIGHT,CURRENT,DRE,ENGLISH,HOWEVER,INDICATION,LABEL,MEDLINE,METHODS,OBJECTIVE,OPTIMISED,PCA,PSA,PUBLISHED,RESULTS,SEVERAL,SYNTHESIS,THESE,UROLOGY
102,103,128,132,169,215,940,AFFYMETRIX,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,NOTABLY,OBJECTIVE,PURPOSE,RESULTS,SNP,SOMMERS,THERE,THESE
169,COPYRIGHT,GLEASON,INC,PSA,USA
169,COPYRIGHT,DESPITE,INC,WHILE
169,176,CALYPSO,CONCLUSION,COPYRIGHT,CTV,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RIGID,ROTATIONAL,TREATMENT,TREATMENTS,USING
169,269,397,431,448,477,531,537,COPYRIGHT,INC,LABEL,LRT,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
017,056,169,223,258,476,877,AES,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,COX,ENDPOINTS,INC,LABEL,METHODS,RESULTS,THERE
448,BACKGROUND,ENGLISH,LABEL,LPC,MEN,METHODS,P3P,PATIENT,PROFILE,RESULTS,SPANISH,THERE,TRIAL,USING
001,169,357,694,AFTER,BMI,CAP,COPYRIGHT,GLEASON,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
010,127,169,177,945,AUC,AUTHORS,BJU,FURTHER,LABEL,METHODS,OBJECTIVE,PROTEOMICS,PSA,RESULTS,SINCE,UNLABELLED,URINE,USING,WESTERN,ZAG
169,HOWEVER,UROLOGICAL
HOWEVER,MDV3100
HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS
ACCOUNT,FIRST,HOWEVER,MOLECULAR,THROUGH
ANTIGEN,DIGITAL,DRE,FIRST,PSA,SCREENING
100,844,CALIFORNIA,CCB,CCR,DAVIS,LABEL,METHODS,OBJECTIVE,OVERALL,POPULATION,PURPOSE,RESULTS,UCD,UNIVERSITY
CAND1,SCF,THESE
947,HLA,IFN,PERIPHERAL,TCR,THESE
FOXA1,THESE,TREATMENT
160,194,AUSTRALIA,AUSTRALIAN,BACKGROUND,BUSSELTON,CANCERS,CONCLUSION,COX,LABEL,METHODS,RESULTS,THERE,USA,WESTERN,WORLD
169,526,ANHEDONIA,BECAUSE,CONCLUSION,COPYRIGHT,DEPRESSION,DEPRESSIVE,DSM,EPISODE,LABEL,LTD,MAJOR,METHODS,OBJECTIVE,PCA,RESULTS,SCALE,SDS,THESE,WILEY
007,215,AE1,AE3,BRE,GLEASON,INTER,TNM,USING,WHOLE
001,007,134,139,142,724,ERG,ETS,GLEASON,HOWEVER,PROSTATIC,THREE,TMA,TMPRSS2
169,CML,COPYRIGHT,INC,MOLECULAR,WILEY
ENGLISH,FATIGUE,MEDLINE,PORTUGUESE,SEX,SPANISH,URINARY
169,388,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,INTER,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T2A,THREE,UROLOGICAL
057,169,348,BLACK,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OLDER,PUBLISHED,PURPOSE,RESULTS,SOUTH,URINARY,UROLOGICAL,USING
169,174,BIOMARKER,COPYRIGHT,DETECTING,EDUCATION,ERG,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCIENCE,TMPRSS2,URINE,UROLOGICAL,WEB
035,119,169,COPYRIGHT,EDUCATION,FEW,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
001,016,027,169,208,237,713,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QUALITY,RESULTS,UROLOGICAL
169,ABOUT,ADT,AUSTRALIA,AUTHORS,BJU,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,PSA,QUEENSLAND,RESULTS,SHARP,THESE,TREATMENT,UNLABELLED,USA
002,169,AUTHORS,BASED,BJU,COCHRAN,CONCLUSION,HOWEVER,HRS,LABEL,MEDLINE,METHODS,OBJECTIVE,RESULTS,THERE,UNLABELLED
169,ADT,BJU,CONCLUSION,DLT,GLEASON,GRADE,HOWEVER,LABEL,LEVEL,METHODS,OBJECTIVE,PHASE,PRIOR,PSA,RESULTS,SUCCESSIVE,THERAPY,UNLABELLED
THEIR,THERE
000,300,340,390,ABOUT,BETWEEN,ERSPC,GOTHENBURG,HOWEVER,PRESCRIRE,PSA,THESE
FURTHER,HOWEVER,STUDIES,WORLDWIDE
ST131
111,BACKGROUND,FURTHER,GLU298ASP,LABEL,METHODS,PSA,RESULTS,THESE
169,CONCLUSION,DOWNSTREAM,DU145,HOWEVER,HVJ,JAPAN,KNOCKDOWN,LABEL,METHODS,NOD,OBJECTIVE,PC3,PURPOSE,RESULTS,RIG,TNF,TRAIL
169,836,CTC,EPCAM,INFLUENCE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
LABEL,MEETING,METHODS,OBJECTIVE,RESULTS
11C,18F,FACBC,FDG,FLT,INITIAL,PET,PSA
11C,18F,239,HOWEVER,OTHER,PCA,PET,PSA,SERUM,STUDIES
11C,18F,HGPIN,HOWEVER,MOLECULAR,MRI,PET,THEREFORE
INTENSE,JANUARY,LIBRARY,MEDLINE,MPMRI,MRI,PCA,PUBLISHED
DUE,EVERY,HOWEVER,PCA
124,BACKGROUND,DELAYED,DISCUSSION,HOWEVER,IMMEDIATE,LABEL,METHODS,THERE,TRIAL
AUSTRALIAN,BACKGROUND,COUNCIL,DISCUSSION,DVD,INTENTION,LABEL,METHODS,MINIMAL,SOUTH,THOSE,TRIAL,WALES,ZEALAND
AT1,PSA,RAS,THESE
001,047,061,306,572,BACKGROUND,CALIFORNIA,ESTIMATES,LABEL,MEN,METHODS,PERMANENTE,PSA,RESULTS
MECHANISM,PCA,TAKEN,TARGETING
169,COPYRIGHT,DUB,EPITOPE,VCH,WILEY
ANNEXIN,ANXA3
226,239,IGFBP,INSULIN,LOW,PCA,PSA,THERE,TNM
060,528,532,BACKGROUND,CONCLUSION,LABEL,METHODS,MONTEVIDEO,ORS,RESULTS,URUGUAY
160,AMONG,SUPPORTIVE,TIP
001,138,ANY,CONCLUSION,DCE,DWI,FORTY,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS,ROC,T2W
456,COX,FURTHER,HOWEVER,PRIME
100,169,ADT,ADVERSE,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,PCA,RESULTS,SECONDARY,TEN
169,174,COPYRIGHT,EDUCATION,INC,KNOWLEDGE,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,RIGHT,STATA,UROLOGICAL,WEB,WHILE
169,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SUCCESS,UROLOGICAL
BESIDES,BMC,HOWEVER,RIBEIRO,THEIR
BACKGROUND,CFH,CONVERSELY,FADS1,FREQUENTLY,INGENUITY,IPA,LABEL,LEP,METHODS,MIRLET7A2,OBESITY,PATHWAY,PCR,RESULTS
245,546,AFFAIRS,BACKGROUND,CHICAGO,DATES,DISCUSSION,GIVEN,INSTITUTE,LABEL,MEN,METHODS,NAVIGATION,PATIENT,PRIMARY,PROGRAM,SECONDARY,WHILE
169,APMIS,AUTHORS,CD3,ERG,PSA
ACCORDING,FGF,INHIBITION,NINTEDANIB,PDGFR,THERE,VEGFR
001,180,252,5XS,7XS,AFTER,AUTOMATIC,BETWEEN,CTV,DEVIATIONS,JANUARY,LAT,MARCH,OVERALL,PTV,PVS,SYSTEMATIC,THESE
470,769,963,CAPSURE,GLEASON,HOPKINS,JOHNS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,T2A
ADT,PRIMARY,THERE
LIFESTYLE,OTHER
100,215,AVERAGE,CYTOTOXIC,DISCOVERY,DU145,FALSE,LNCAP,MOLECULAR,PC3,RAPAMYCIN,RPM,URGCP,XTT
100,169,181,945,BASEL,COPYRIGHT,DU145,LNCAP,NAFTOPIDIL,T24
GLEASON,MICRORNAS,MIRNA,STUDIES
145,AMONG,MICRORNAS,RETROVIRAL
174,CPG,DACOGEN,DNMT1,DNMTI,GSTP1,HOWEVER,NSCLC,PCR,RASSF1A
174,348,COLORECTAL,INVERSE,OVARIAN,SCREENING,THESE,TRIAL
117,122,169,ADDITIONAL,AFTER,AIM,APC,AUTHORS,BRITAIN,CHRONIC,CHUTKAN,COLORECTAL,CONCLUSION,DISEASE,GREAT,IRELAND,LABEL,METHODS,OBJECTIVE,RESULTS
012,017,024,027,032,038,342,BACKGROUND,DFS,GLEASON,GOLGI,LABEL,METHODS,PSA,RESULTS,UNASSIGNED,VIRTUAL
169,BACKGROUND,BCR,LABEL,MATERIALS,MEDLINE,METHODS,RESULTS,THEREFORE,USING,WILEY
400,956,AREAS,ATP,BACKGROUND,COVERED,HOWEVER,LABEL,LYS67,METHODS,OPINION,PDB,PHE49
132,169,BLADDER,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
223,CLEARLY,III,SINCE,TAKEN,UNTIL
ADT,BECAUSE,PSA,SEVERAL
946,AKT,DISTURBED,EMPLOYING,MELATONIN
169,ADC,CHO,CIT,CONCLUSION,COPYRIGHT,DWI,FIFTY,HOWEVER,INC,LABEL,MATERIALS,METHODS,MMR,MRS,OBJECTIVE,PCA,PURPOSE,RESULTS,ROC,THERE,WEIGHTS,WILEY
006,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE
169,387,961,COPYRIGHT,JANUARY,NET,PERME,POHAR
947,PATIENT
003,169,370,493,BACKGROUND,COLORECTAL,HOWEVER,LABEL,LEUKOCYTE,METHODS,ORS,OVARIAN,REDUCED,RESULTS,SCREENING,SYSTEMATIC,TRIAL
100,177,500,AMONG,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PAC,RESULTS,WHEREAS
023,049,169,234,ADVANTAGES,AFTER,CLAVIEN,COPYRIGHT,EDUCATION,GLEASON,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SALVAGE,THERE,UNIVERSITY,UROLOGICAL,VANDERBILT
169,5RS,ATP,COPYRIGHT,INC,NULLOMERS,NULLOPS,ROS,RRRRRNWMWC,RRRRRWCMNW,RRRRRWFMHW,THESE
169,177,ADT,AFTER,BACKGROUND,BMD,BMI,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OVERALL,PCA,RESULTS,SFG,THESE,WHR
014,046,048,052,101,169,221,BACKGROUND,COPYRIGHT,COX,DOCETAXEL,INC,LABEL,MEIER,MEN,METHODS,RESULTS
343,350,693,BACKGROUND,COLORECTAL,CONCLUSION,END,GLEASON,LABEL,LTD,MEDICAL,MEIER,MEN,METHODS,OVARIAN,PUBLISHED,RESULTS,THERE
122,169,223,AES,BACKGROUND,COPYRIGHT,JONCKHEERE,LABEL,METHODS,OBJECTIVE,OUTCOME,POTENTIAL,PSA,PUBLISHED,RESULTS,SETTING,TRIAL,UROLOGY
169,498,APC,BELGIUM,CONCERN,COPYRIGHT,EDUCATION,GSTP1,INC,KINGDOM,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,AUTHORS,CONCURRENT,COPYRIGHT,INC,PUBLISHED,TIMP2,TIMP3,WHETHER
001,100,10A,169,205,COPYRIGHT,EDUCATION,ENDOGENOUS,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,RNU,THESE,UROLOGICAL
165,169,177,234,956,CELLS,COPYRIGHT,EGF,LNCAP,LTD,OVERALL,PCA
169,309,558,683,AMONG,CONCLUSION,COPYRIGHT,COX,END,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,POISSON,RESULTS,THESE,USING
169,AEU,BACKGROUND,CONTEXT,COPYRIGHT,GROUP,GUO,LABEL,METHODS,OBJECTIVE,ONCOLOGIST,ONCOLOY,PUBLISHED,RESULTS,SCIENTIFIC,SOGUG,SPANISH,SYNTHESIS,TUMOURS,URO,UROLOGIST,UROLOGY,WORKING
002,003,012,100,169,177,COPYRIGHT,ECLIPSE,EIGHT,INC,INJECTING,LABEL,MATERIALS,METHODS,OBJECTIVE,PLANS,PTV,PURPOSE,REGARDLESS,RESULTS
000,169,290,515,570,618,BACKGROUND,CONCLUSION,COPYRIGHT,GIVEN,INC,ISPOR,LABEL,METHODS,PUBLISHED,RESULTS,SOCIETY,STR,STUDIES,USING
169,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,LABEL,METHODS,PCA,PSA,RESULTS,SAS,THEIR
000,160,169,332,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,METHODS,PROSTATIC,RESULTS,SAS,TECHNIQUE,THERE
001,003,160,169,242,CIS,COPYRIGHT,DIFFERENT,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SAS,UCB
169,COPYRIGHT,MALIGNANT,POTENTIAL,PROSTATIC,SAS,STROMAL,STUMP,UNCERTAIN
160,169,BACKGROUND,CONCLUSION,COPYRIGHT,FURTHER,LABEL,MATERIALS,METHODS,RESULTS,SAS
169,COPYRIGHT,EDUCATION,GIVEN,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATHOLOGY,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THESE,UNDER,UROLOGICAL
001,005,169,203,237,264,272,276,311,945,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,SELECTIVE,UROLOGICAL
134,169,COPYRIGHT,COX,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,TEN,UROLOGICAL
001,006,009,023,067,146,169,276,596,791,985,BLADDER,CONTINENCE,COPYRIGHT,COX,EDUCATION,GLEASON,INC,INDEX,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,REGARDING,RESULTS,SEPTEMBER,T1C,UROLOGICAL,WHILE
089,169,222,249,300,413,802,889,913,962,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAMPLES,URINARY,UROLOGICAL
CTV,GTV,HOWEVER
AKT,DIETARY,ITC,THESE,THROUGH

EPIGENETIC,ERRB2,FOXP3,SATB1,SATB1IN,SPECIAL
001,003,005,011,048,169,210,376,420,AFTER,AMONG,AUTHORS,BJU,COX,CSS,ERSPC,GLEASON,HOWEVER,LABEL,LEVEL,MEN,METHODS,MFS,OBJECTIVE,PFS,PSA,RADICAL,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,THERAPY,UNLABELLED
169,AUTHORS,BACKGROUND,FOUNDATION,JOURNAL,LABEL,METHODS,RESULTS,SOCIETY,STICHTING
100,200,400,ADC,BPH,CONCLUSION,DECAY,DWI,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SDS,THERE,TRACE
001,016,CONCLUSION,FIFTY,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PPV,RESULTS,SIX
070,129,138,215,BASED,CONCLUSION,DWI,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS,ROC
CONCLUSION,CURRENTLY,LABEL,MRI,OBJECTIVE,OTHER
AFTER,CONCLUSION,FFP,III,LABEL,LABORATORY,NORMALIZED,OBJECTIVE,PCC,PURPOSE,RATIO,SUMMARY,TREATMENT
169,BACKGROUND,BPH,CAF,CATHD,CATHEPSIN,CD1,COPYRIGHT,INC,KNOCKDOWN,LABEL,METHODS,NPF,RESULTS,STROMAL,WESTERN,WILEY
169,BACKGROUND,BPH,CONCLUSION,COPYRIGHT,DCE,INC,LABEL,LARGE,METHODS,MRI,NTZ,PZT,RADICAL,RESULTS,SPECIMENS,TZT,WILEY
169,BACKGROUND,CONCLUSION,COPYRIGHT,ERK,GFP,H2B,INC,INTRA,LABEL,METHODS,MICROSCOPY,PLUMBAGIN,RESULTS,SYNGENEIC,VIEWING,VITAL,WHEREAS,WILEY
ADT,BACKGROUND,HORMONE,HOWEVER,LABEL,LITERATURE,METHODS,PSA,RESULTS,THEREFORE
169,BACKGROUND,COPYRIGHT,DOCETAXEL,DU145,HOWEVER,INC,KNOCKDOWN,LABEL,LNCAP,METHODS,PC3,RESULTS,THESE,WESTERN,WILEY
215,UROGENITAL
169,437,561,748,813,AMICO,BACKGROUND,BCR,COPYRIGHT,COX,ECE,EQUAL,GLEASON,INC,LABEL,METHODS,OVERALL,PSA,PSM,RESULTS,WILEY
169,946,BACKGROUND,COPYRIGHT,DU145,INC,INCREASED,LABEL,LNCAP,METHODS,PC3,RESULTS,SIMILAR,USING,WHEREAS,WILEY
215,ADC,AFTER,BACKGROUND,DIFFUSION,DISCUSSION,LABEL,METHODS,MRI,PEARSON,RESULTS,TSC
141,169,423,945,946,BAM,COPYRIGHT,DIAGNOSIS,INC,INTENSITY,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THREE
147,169,183,235,301,394,398,775,791,797,BACKGROUND,BETWEEN,BRIEF,COPYRIGHT,COU,EASTERN,GROUP,INVENTORY,IQR,LABEL,LTD,MAY,METHODS,PSA,RESULTS,SHORT
169,821,AMONG,BCR,CONCLUSION,COPYRIGHT,COX,GLEASON,INC,LABEL,METHODS,NETWORK,OBJECTIVE,PSA,RESULTS,T3A,USING
100,169,COPYRIGHT,GATA3,III,INC,S100P,UROTHELIAL
169,BESIDES,COPYRIGHT,IRELAND,LNCAP,LTD,NOS,TREATMENT
169,329,ACUTE,CTCAE,CYBERKNIFE,EIGHT,FURTHER,GRADE,LABEL,LTD,METHODS,OBJECTIVE,PSA,PTY,PUBLISHING,RESULTS,THERE,WILEY
CAV
100,CONCLUSION,LABEL,METHODS,MTT,OBJECTIVE,PCR,RESULTS,WESTERN
BPH,CONCLUSION,LABEL,LNCAP,MALDI,METHODS,OBJECTIVE,RESULTS,THERE,TOF
292,475,665,AUC,BETWEEN,CONCLUSION,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,PSA,RESULTS
ACCORDING,IP6,MOLECULAR,THERE
169,ADP,FINALLY,LABEL,THESE,UNLABELLED
946,BACKGROUND,CONCLUSION,LABEL,MATERIALS,METHODS,RESULTS
22RV1,ACTIVATION,CHO27,PCA
AIM,BACKGROUND,CONCLUSION,ERG,ETS,GDP,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,RESULTS,RHO,RHOGDIB,TMPRSS2,WNT
160,BAX,BCL,PCG,THESE,U87,USING
160,ADP,BIRC5,DAPK1,F10,LNCAP
ACTUARIAL,EVALUATION,GROUP,INCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PATTERN,PRIMARY,RADIATION,RESULTS,SCALE,SIXTY,SOLID,THERAPY,TREATMENT
018,071,116,393,956,ADR,CNS,HCT,HOP,INSTITUTE,NCI,RES,RXF,SNB,TGI
GLEASON,HOWEVER,LCM,MAPPING,PATTERN,SEQUENCING,WGA
169,1E8,ATP6V0C,BECEF,COPYRIGHT,HOWEVER,INC,LASS2,RESULTS,THEIR,THESE,TMSG1,WILEY
137,169,831,902,ADT,ANOVA,AUC,COPYRIGHT,DXA,MINERAL,MRI,ROC,SEVEN,SOCIETY,VERTEBRAL,VFA
169,183,AFTER,APART,GEORG,MRI,STUTTGART
PC3,PC3WT,SST,SSTR2,SSTR5
AUTOMATED,COMPOSITE,CONCLUSION,FORTY,INC,INDEX,LABEL,METHODS,OBJECTIVE,PUBLISHED,QOL,RESULTS
120,169,947,99M,CONCLUSION,COPYRIGHT,EVERY,INC,LABEL,LYMPHATIC,MARCH,METHODS,OBJECTIVE,OCTOBER,RESULTS,USING
ACTIVATION,CONVERSELY,DISEASE,EMT,ERK,HSP90,INITIATION,PCA
169,946,AKT,COPYRIGHT,INC,JNK,PC3,T24,TGF
169,241,AEU,BACKGROUND,BPO,CENTRAL,CONTEXT,CONTROLLED,COPYRIGHT,DEPENDING,EAU,GUIDELINES,LABEL,LASER,MEDICAL,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,RESULTS,REVIEWS,STRUCTURED,SUBJECT,SYNTHESIS,SYSTEMATIC,UROLOGY
169,AFFECTION,BACKGROUND,CLARK,DIMINISHED,LABEL,MARITAL,MASCULINE,METHODS,OBJECTIVE,OUTCOME,PCA,QUALITY,REGARDLESS,RELATED,RESULTS,SOCIETY
169,FINALLY,MIXED,UROLOGICAL,UROLOGISTS
176,MORBIDITY,OWING
169,205,211,4933940,CASES,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,SINCE,SPAIN,SPANISH,UNLABELLED
CMS,FIFTEEN,LABEL,MATERIALS,METHODS,MIM,OBJECTIVE,PURPOSE,RESULTS,THREE,VELOCITYAI
001,176,177,180,270,362,ADVERSE,GRADE,JAPAN,OSAKA,VERSION
004,009,235,AIM,BACKGROUND,CAREGIVERS,CLINICIAN,CLINICIANS,DYADS,GENERAL,LABEL,METHODS,MIXED,OBJECTIVE,RESULTS,SETTING,SUPPORT,THOSE,USING
124,199,206,212,222,325,376,468,479,527,599,609,638,855,882,CALIFORNIA,FRANCISCO,GLEASON,HOPKINS,HOWEVER,JOHNS,KETTERING,LABEL,MEDICAL,METHODS,MIAMI,OBJECTIVE,OVERALL,RESULTS,SAN,SLOAN,UNIVERSITY
169,AFRICAN,COPYRIGHT,LTD,SIMULATION,WILEY

112,169,200,310,800,AMONG,CENTERS,CENTRAL,CONTROL,COPYRIGHT,DISEASE,HISPANICS,HOWEVER,INC,INSTITUTE,LATINOS,NORTH,PREVENTION,REGISTRIES,SOCIETY,STATISTICS,STRATEGIES
169,337,463,761,AFTER,AMONG,ASIAN,BETWEEN,COPYRIGHT,PCM,PSA,TAIWANESE
BROAD,CHANGES,IRELAND,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
002,003,009,039,046,307,AIM,BETWEEN,CONCLUSION,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS
001,100,AFTER,DCE,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SEVERAL,USING
125,145,ASTRO,BETWEEN,BRT,GROUP,LABEL,LDR,MATERIALS,METHODS,NETWORK,OBJECTIVE,PURPOSE,RADIATION,RADIOLOGY,RESULTS,SOCIETY,THERAPY
103,10991,10996,DU145,INSTITUTE,LNCAP,SCI,SEVERAL,THESE,USA
945,AES,BACKGROUND,BPH,DESPITE,LABEL,LIBRARY,MEDLINE,METHODS,PRIMARY,QOL,RESULTS,SCORE,SILODOSIN,SYMPTOM
ADP,AKT,ANNEXIN,ASSAY,BACKGROUND,BCL,EFFECTIVE,ETHANOL,HOWEVER,LABEL,LNCAP,METHODS,MTT,PC3,PCA,RESULTS,ROS,TAKEN,THESE,TRAIL
145,945,946,ABSIDIA,AMONG,NMR,SEVEN
BASED,CURRENT,FINALLY,MYC,SIMILARLY,SIRT1,THESE
213,HOWEVER,IL6,LNCAP,PIM,PSA,S213A,THEREFORE
22RV1,AFTER,CASP7,DU145,FURTHER,LNCAP,USING
000,169,COPYRIGHT,INC,ROBOTIC,SEVERAL,SINCE
000,003,169,221,AIM,BASEL,COPYRIGHT,DRE,LABEL,METHODS,OBJECTIVE,POD,RESULTS,THERE
133,624,CURRENT,EPS,LTQ,MME,PARK7,SFN,SRM,THESE,TIMP1,WESTERN
169,279,COPYRIGHT,III,INC,LABEL,METHODS,OBJECTIVE,OBS,OXIDATIVE,PCA,PRO,PURPOSE,RESULTS,TOTAL
169,APRIL,ASSESSMENT,BACKGROUND,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,MEDLINE,METHODS,RESULTS,REVIEWS,SYSTEMATIC,TEA,THERE
169,CAP,CARLO,CHAIN,COPYRIGHT,HOWEVER,MAP,MONTE,MPM,MRF,MRI,MWMAP,MWMPM,SIMILARLY,TESLA
169,COPYRIGHT,INC,OLDER
169,668,956,COPYRIGHT,CUB,CUZD1,ELISA,III,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SERUM,SOCIETY
169,17Q12,215,ADD,AFTER,AUSTRALIAN,BJU,BONFERRONI,CONSORTIUM,CONTROL,HLA,HOWEVER,KNOWN,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PROXIES,RESULTS,SNP,STUDIES,SUBJECT,THERE,THESE,TRUST,UNLABELLED,WTCCC
169,ADT,BJU,CASTRATION,DESPITE,MDV3100
001,005,169,338,AFRICAN,APPRAISAL,ASSESSMENT,AUTHORS,BJU,COMMUNITY,EDUCATION,FOLKMAN,ILLNESS,LABEL,LAZARUS,LEVEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PROSTQA,QUALITY,RESULTS,SCALE,SERVICE,STUDIES,THERAPY,THERE,THESE,TREATMENT,UNLABELLED,YOUNGER
000,006,008,010,013,015,019,023,025,03774,04097,04395,044,045,04545,06278,06698,07211,07241,08377,095,09576,177,305,312,338,855,AMBULATORY,BOARD,EDUCATION,EXAMINING,LABEL,NETWORK,OBJECTIVE,OBJECTIVES,PCA,RESULTS,THREE,UNIVERSITY,UROLOGY
119,169,958,AGDAP,AGDAS,ANOGENITAL,BARCELONA,BJU,EISENBERG,ENVIRON,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PROGNOSIS,RESULTS,SPAIN,STUDIES,THERE,UNLABELLED
HAT,STRUCTURAL,THESE,TIP60
000,100,140,169,666,ACCOUNTING,AUTHORS,BJU,CONCLUSION,ERSPC,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,RANDOMIZED,RESULTS,SCREENING,SWEDISH,THERAPY,UNLABELLED
DKK,KLAKLAK,THESE,TMTP1
99M,CONCLUSION,FURTHER,LABEL,MDP,METHODS,OPTIMAL,PARTIAL,PSA,RESULTS,THERE,TKI,UNLABELLED
ASSAY,GLUCOSE,KIT
HOWEVER,INCREASING,M13,MOLECULAR,OWING,SPARC,UNTIL
192,232,632,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATIENT,RESULTS,STENT,THESE
53BP1,ADP,BRCA1,BRCA2,GIVEN,MRE11,MRN,OVERALL,PARPI,RAD50,RAD51,WHILE
GATA3,GLEASON,IHC,III,SCC,THROMBO,TMA,UCS
001,090,151,331,565,624,723,858,899,949,951,A1C,ADDITIONAL,CONCLUSION,CONVERSELY,COX,EXCLUDING,LABEL,METHODS,OBJECTIVE,OVERALL,PANCREATIC,RESULTS
169,946,BESIDES,COPYRIGHT,INC
127,131,133,169,174,391,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,RIGID,UROLOGICAL
169,COPYRIGHT,PCR,THESE,TOTAL
169,ANALYTICAL,COMPARISON,COPYRIGHT,LTQ,SRC
169,COPYRIGHT,INC,MANGANESE,MNSOD,THESE,ZNSOD
169,BACKGROUND,BCNAS,COPYRIGHT,FURTHER,IMAGING,INC,LABEL,METABOLISM,METHODS,PET,PRG,PRP,PUBLISHED,RESULTS,VZV
020,072,166,169,192,934,AIM,COLLEGE,CONCLUSION,COPYRIGHT,DCE,DWI,EXTENSIVE,FORTY,FURTHER,HOWEVER,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,THERE,THREE
001,002,003,004,011,032,128,157,169,176,219,297,347,357,360,380,424,435,516,598,685,710,739,819,841,921,ADT,AHR,COPYRIGHT,COX,DESPITE,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,NETWORK,OBJECTIVE,PSA,PURPOSE,RESULTS,RFS,SHORT,USING
169,182,945,ATM,BACKGROUND,BRCA2,COPYRIGHT,CRPCS,E26,ERG,HISEQ,LABEL,METHODS,MYC,NGS,OBJECTIVE,OTHER,OUTCOME,OVERALL,PCA,PUBLISHED,RESULTS,SETTING,THERE,TMPRSS2,UROLOGY
169,806,BACKGROUND,CONTEXT,COPYRIGHT,FEW,HOWEVER,ITEMS,LABEL,LIBRARY,LRP,MARCH,METHODS,MINIMALLY,OBJECTIVE,PCA,PREFERRED,PUBLISHED,REPORTING,RESULTS,REVIEWS,ROBOT,RPP,RRP,SCIENCE,SYNTHESIS,SYSTEMATIC,UROLOGY,WEB
169,946,947,AKT,COPYRIGHT,HTS,LTD,PC3,SAR,THESE
169,AKT,ANNEXIN,CARIBBEAN,CDK,CLUSIACEAE,COPYRIGHT,LNCAP,MAJOR,MTT,PKB,PSA,WESTERN
169,ACM,BACKGROUND,CAD,CHF,COPYRIGHT,COX,GLEASON,HOWEVER,LABEL,MEN,METHODS,NHT,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,T2A,THESE,UROLOGY,USING
002,162,169,246,439,968,BACKGROUND,COPYRIGHT,COX,FORTY,LABEL,MEIER,MEN,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,UROLOGY
031,115,178,BACKGROUND,CTV,FFF,FORTY,FURTHER,LABEL,METHODS,PCA,PHOENIX,PSA,RESULTS
100,ACCRUAL,AFTER,BACKGROUND,EVALUATION,FIRST,FURTHER,III,LABEL,METASTATIC,METHODS,OCTOBER,ORIGINALLY,RESULTS,STAGE,THERAPY,THESE,TRIAL
DENOSUMAB
169,212,250,400,ABOUT,EGF,EVALUATION,LABEL,METHODS,OBJECTIVE,PFS,PSA,PURPOSE,RESULTS,SEVEN,SWISS,TREATMENT
EPIGENETIC,USING
057,12P11,19P13,209,20Q11,215,519,663,745,869,902,946,AFRICAN,CONSORTIUM,NCI,SIMILARLY,SNP,TNBCC
247,256,4GLCNAC,945,946,GAL,GLYCOCONJ,KDN,TAKAHASHI,THESE
169,COPYRIGHT,LTD,WILEY
169,268,COPYRIGHT,INC,KEY,KIM,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEN,VARIOUS
001,052,103,130,169,180,ACP,ACUTE,AEP,COPYRIGHT,COX,EARLY,INC,LABEL,LCP,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TREATMENTS
ELONGATED,EVERY,IMPLANTING,WHILE
0CC,125,145,160,166,169,180,186,199,1CC,AUSTRALIA,COPYRIGHT,D10,D90,DOSIMETRIC,ESTRO,FTE,GEC,LDR,LOW,RAH,ROYAL,SEPTEMBER,THREE,URETHRA
160,169,AKT,BCL,COPYRIGHT,DOCETAXEL,FINALLY,HLA,HOWEVER,INC,NOTABLY,NOTCH,THESE,USING
169,90S,AMP,COPYRIGHT,INC,THEREFORE
001,169,BACKGROUND,CONCLUSION,COPYRIGHT,DENOSUMAB,DISEASE,END,LABEL,LTD,METHODS,PATIENT,RANKL,RESULTS,SRE
169,AIM,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,MTD,OBJECTIVE,PUBLISHED,RESULTS,SECONDARY
169,AUNPS,COPYRIGHT,NINPS,PBNPS,PSA
169,ADT,CONTENT,COPYRIGHT,EIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
001,145,169,AFRICAN,COPYRIGHT,EGF,FURTHER,GLEASON,INC,KAISO,NUCLEAR,PATHOLOGY,PUBLISHED,SOCIETY,THERE
110,169,220,250,300,346,387,AUTHORS,BJU,CHINESE,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,SETTING,TOTAL,UNLABELLED
169,AUTHORS,BJU,BRCA1,BRCA2,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNLABELLED
103,137,200,239,BACKGROUND,COX,FIFTY,LABEL,LDR,METHODS,MINIMAL,PSA,RESULTS
CURRENTLY,GEM,NON,THESE,WHILE
AKT,BACKGROUND,BAD,BCL,FAS,LABEL,MECHANISMS,METHODS,MOLECULAR,PC3,PROTEIN,RESULTS,TNF,TRAF1,TUNEL
001,002,015,023,169,173,503,ACT,BOARD,CHANGES,DIAGNOSIS,INSTITUTE,INSURANCE,INVENTORY,LABEL,LEVEL,MEN,METHODS,MRI,OBJECTIVE,PSA,RESULTS,SCORE,SYMPTOM,THERE,THESE,UNLABELLED,VARIOUS,WHOLE
001,077,BACKGROUND,CONCLUSION,COVARIATE,LABEL,METHODS,MIXED,PREVENTION,RESULTS,SHORT,TRIAL
AUROC,CONSORTIUM,DISCUSSION,FIRST,INTEGRATED,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
MHZ,OFFLINE,PZT,VDF,VERASONICS
CONCLUSION,DESPITE,FIFTEEN,LABEL,MEN,METHODS,OBJECTIVE,ONT,OUTCOME,PSA,RESULTS,SETTING,SEVENTY,WHETHER
003,023,396,GRADE,HDR,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
AD5PB_RSV,HOWEVER,LNCAP,NIS,PCR,USING
231,4T1,ANTONIO,BALBC,GFP,MDA,MUNDY,NEITHER,SAN,SEVERAL,WHILE
FURTHER,LNCAP,PCA,PCR,PSA
BASAL,LABEL,METHODS,OBJECTIVE,RESULTS
155,ASA,BMI,LABEL,LRP,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,POTENCY,RADICAL,RESULTS
014,027,031,ADIPOKINE,AIM,CONCLUSION,FIFTY,LABEL,METHODS,OBJECTIVE,RESULTS,SERUM,THERE,USING
012,178,263,281,345,368,591,CAP,GLEASON,HCT,HGB,PSA,SERUM,TRT
231,HOWEVER,MDA,THESE
156,BACKGROUND,CYP17,LABEL,METHODS,NLR,PFS,PSA,PSADT,RESULTS,SEVENTY,SIXTY
169,934,ERK,GFRA1,PDA,PERINEURAL,RET,TAKEN,THESE,VIDEO
127,CNA,CTC,CYP17,INHIBITION,INSTEAD,METASTATIC,PCA,PCR,THESE
169,AIM,APNEA,BACKGROUND,COMMITTEE,ENDOCRINE,LABEL,MEASURE,MEDICAL,MEN,METHODS,OBJECTIVE,OPERATING,OUTCOME,PROCEDURES,RESULTS,SLEEP,SOCIETY,STANDARDS,THERE,TTH,YOUNG
AMONG,ASSESSMENT,CONCLUSION,FIFTY,FUNCTIONAL,GENERAL,HOWEVER,ILLNESS,LABEL,METHODS,OBJECTIVE,PERCEPTION,QOL,RESULTS,SPOUSES,THERAPY
169,AIM,BACKGROUND,DAILY,EARLY,ERECTIONS,LABEL,MEASURE,MEDLINE,METHODS,NIGHTLY,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,THERAPY,VARDENAFIL
954,AKT,HES,HEY,LNCAP,MIGRATION,MOUSE,NOTCH,RBP,SFN,STRIKINGLY,THESE,TRANSGENIC
177,ASSESSMENT,GLEASON,KALLIKREIN,THREE
5AR,945,BPH,DHT,FURTHER,INHIBITION,SEVERAL,THERE,THESE
002,022,037,166,BPH,CAP,MEN,THESE
100,BACKGROUND,BASED,CLONOGENIC,DU145,HOWEVER,LABEL,LNCAP,METHODS,PC3,PDGFR,RESULTS,SUNITINIB,THEREFORE,VEGFR
231,ADP,AMP,ATP,BASAL,MDA,PC3,PURINERGIC
003,169,64257,COPYRIGHT,ECL,ITO,OWING,PSA,QDS,UNDER
120,169,174,203,215,24H,4T1,COPYRIGHT,DTX,PC3,PEGYLATED,THESE
GISTS,LABEL,METHODS,NON,OBJECTIVE,PCR,RESULTS,SEVEN
ADVERSE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,VAS
000,001,100,946,BACKGROUND,COMMISSION,GIVEN,HSCRC,LABEL,METHODS,OBJECTIVE,PURPOSE,RALRP,RESULTS,RRP,SERVICE,THERE,THEREFORE
001,155,200,AMICO,BACKGROUND,BCR,BETWEEN,COX,GROUP,LABEL,MEDIANS,MEIER,METHODS,REGARDLESS,RESULTS,THEREFORE,UNIVARIATE
005,BACKGROUND,CONCLUSION,GROUP,LABEL,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,ROI,TESLA,THESE
215,GLEASON
024,133,169,178,207,281,AUTHORS,BETWEEN,BJU,FORTY,HOWEVER,IHR,IHS,LABEL,METHODS,OBJECTIVE,OTHER,RESULTS,UNLABELLED
106,176,177,99M,BOC,DEMOMEDIN,GRP,HEK
945,946,BACKGROUND,HOWEVER,LABEL,PC3,RANKL,RESULTS,RUNX2,SIMILARLY,SMAD5,THESE
168,330,945,946,LABEL,METHODS,NEGLECTING,OBJECTIVE,PURPOSE,RESULTS,THESE,TREATMENT
106,150,153,180,375,900,AVERAGE,FOLEY,INVENTORY,LABEL,MARCH,MEN,METHODS,OBJECTIVE,POTENTIAL,PURPOSE,RESULTS,RSP,SCORE,SYMPTOM,THREE
BACKGROUND,CONCLUSION,FORTY,INSTITUTE,METHODS,RESULTS,SURVIVORS,YET
246,ACUTE,ALT,AML,APR,AST,CONCLUSION,HODGKIN,LABEL,METHODS,MTD,OBJECTIVE,PRIMA,PURPOSE,RESULTS
169,BACKGROUND,CETUXIMAB,COPYRIGHT,ELISA,IGG,INC,LABEL,METHODS,RESULTS,SEVERAL,WESTERN,WILEY,XTT
13910,169,630,873,COPYRIGHT,DAIRY,DENMARK,LACTASE,LCT,NUTRITION,ORS,THESE
177,CONCLUSION,DEFINITIVE,FSA,LABEL,MATERIALS,METHODS,OBJECTIVE,PROSTATIC,PURPOSE,RESULTS,SIX,THERE
ASSESSMENT,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,QUOTATIONS,RESULTS
156,BACKGROUND,BPH,CURRENT,DEVICES,FIRST,LABEL,MAY,MEDICAL,METHODS,RESULTS
001,002,009,012,029,169,236,377,495,583,621,AFRICAN,AMONG,BASEL,COPYRIGHT,GLEASON,LABEL,LOW,MEIER,METHODS,OBJECTIVE,PSA,RESULTS,T2A,THESE
169,COPYRIGHT,GLUT1,GLUT3,HENCE,HOWEVER,LDH,LNCAP,LTD,NMR,NUCLEAR,PC3,PCA,PCR,RESONANCE,WESTERN
945,ACCORDING,BACKGROUND,CEA,CRP,IVC,LABEL,METHODS,PSA,RESULTS,RIORDAN,SINCE,THERE,TNF,VITAMIN
169,CBCTS,MINIMAL,RADIOLOGY,ULTRASOUND,VETERINARY
AKT,BACKGROUND,CONCLUSION,DEPLETION,ERK,FURTHER,HOWEVER,LABEL,METHODS,MMP,PAR,PRINCIPAL,RESULTS,SUB,WITHAFERIN
DOPPLER,THEREAFTER,ULTRASOUND,UROLOGICAL

169,299,961,AFTER,PTPN6,ROS,SHP
169,COPYRIGHT,H1299,HOWEVER,INC,NSCLC,NUPR1,SILENCING,WILEY
265,986,COX,GLEASON,JANUARY,THERE,TNM
169,316,COPYRIGHT,FRANCIM,HAKULINEN,MEANWHILE,NET,PERME,POHAR,PPE,USING
169,ALGORITHM,ASIAN,COLORECTAL,COPYRIGHT,ENGLAND,NAMES,OVERALL,POISSON,POPULATION,SOUTH,STUDIES
160,950,A375P,ERBB2,PC3MLN4,SN12C,SN12PM6,TAKEN,THESE,USING
405,575,725,DU145
125,CHI,CONCLUSION,DRE,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PSA,RESULTS,SEXTANT
161,AMONG,BACKGROUND,BMI,BPH,CONCLUSION,CUT,DEVELOPING,FORTY,FURTHER,HDL,LABEL,LDL,MATERIALS,METHODS,PCA,PRIOR,PSA,RESULTS,ROC,TAS,THERE,VIT
160,169,BACKGROUND,COPYRIGHT,E2F3A,E2F3B,INC,LABEL,METHODS,OBJECTIVE,PCR,PUBLISHED,RESULTS,THEREFORE,WESTERN
641,CUP,GERMANY,HODGKIN,HOWEVER,RRS,SWEDISH
169,ATM,COPYRIGHT,FINALLY,IRELAND,LTD
169,216,276,579,617,902,930,AIM,COLLEGE,CONCLUSION,COPYRIGHT,INR,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,REGRESSION,RESULTS,ROYAL,THERE,THESE
169,BACKGROUND,CONCLUSION,COPYRIGHT,FEW,FOCAL,INDIVIDUAL,LABEL,MATERIALS,METHODS,ONCOLOGIC,PDT,RESULTS,SERIOUS
050,09443,169,ANOTHER,BACKGROUND,CAT,CHINESE,COPYRIGHT,DIEGO,GENOTYPING,HAN,INC,LABEL,MASSARRAY,METHODS,MPO,OXIDATIVE,PCA,RESULTS,SAN,SNP
001,10409,11932,169,424,837,AFTER,AHA,BACKGROUND,COPYRIGHT,DESPITE,HOWEVER,INPATIENT,LABEL,METHODS,NATIONWIDE,NIS,OBJECTIVE,ORP,OUTCOME,OVERALL,PUBLISHED,RESULTS,SETTING,UROLOGY,USING
169,ADDITIONAL,BACKGROUND,CALIFORNIA,CENTRAL,CIS,CONCLUSION,COPYRIGHT,HODGKIN,IDAHO,INDEX,LABEL,LTD,METHODS,NDI,OBJECTIVE,RESULTS,SINCE
169,24H,A2780,COPYRIGHT,LTD,PBS,PC3,RGD,ST7456CL1
169,229,549,AGE,BACKGROUND,CCI,COMPETING,CONVERSELY,COPYRIGHT,CSM,GLEASON,HOWEVER,INDEX,LABEL,METHODS,OBJECTIVE,OCM,OUTCOME,OVERALL,PCA,POISSON,PUBLISHED,RESULTS,SETTING,UROLOGY
160,169,COPYRIGHT,FAD,FMN,HUVEC,LNCAP,LTD,MRI,RCP,RIBOFLAVIN,SEM,TEM,THEIR,THEREFORE,USPIO
169,CONCLUSION,COPYRIGHT,CROATIA,GIVEN,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SES,SOCIO,UNION,VARIATION
CIN,CXCR4,CXCR6,MEIER,THESE
169,260,592,852,AUR,CANCERLIT,COPYRIGHT,DWI,FURTHER,INC,JANUARY,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS,SIX,SIXTEEN,TEN
169,BJU,COMPARABLE,THESE,TODAY
169,214,229,APMIS,AUTHORS,MIC,UME
169,34A,CDK,DU145,HOWEVER,MEF,THEREFORE,THESE,TSA
945,946,CARLO,HOWEVER,IMPLANTED,LABEL,METHODS,MONTE,OBJECTIVE,PURPOSE,RBE,RESULTS,TCP,THREE
100,CANCEROUS,EXPECTEDLY,LABEL,METHODS,MEV,OBJECTIVE,PURPOSE,RESULTS,THERE,THESE,ULTIMATELY
IMAGING,INSTEAD,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
005,113,157,232,366,AIM,APRIL,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,SUSPICIOUS
945,FOCAL,MGAT1,ONCOGENIC
LNCAP,MMP,PEG,R1881,RGD,SINCE,TAKEN,THEREFORE
488,AFTER,BACKGROUND,COX,INDEX,LABEL,METHODS,RESULTS,SCORE,SES,THERE
100,HOWEVER
ADT,DESPITE,MINIMIZING
GUIDELINES,PANEL,THESE
ABS,AGS,CD4,CSF,THESE,TREATMENT,USING
345,546,749,BACKGROUND,CONCLUSION,DOSES,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,ZOLEDRONIC
152,767,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RANDOMIZED,RESULTS,SCIENCE,STUDIES,TREATMENT,WEB
006,AGING,AMONG,ANXIETY,BACKGROUND,CONVERSELY,LABEL,METHODS,PERCEIVED,PROJECT,PSA,RESULTS
ENDORECTAL,ERB,FIFTEEN,GAS
177,AVERAGE,MACHINE,MLC,MUS,SIXTEEN,THERE,TPS
103,125,BED,CURRENTLY,EQUATIONS,THREE
119,ECLIPSE,PLANS,TREATMENT
490,CURRENT,PSA,THERE
AFRICAN,CHILEAN,CONTINENTS,HODGKIN,INCIDENCE,NAS,NORTH,SWEDISH,TURKISH,TURKS
945,949,954,PKC,PROTEIN,TNF
114,120,128,163,177,240,942,956,ACCORDING,AFTER,CONCLUSION,DU145,GFP,GSTP1,LABEL,METHODS,MTT,NEO,OBJECTIVE,RESULTS,TUNEL
ALTOGETHER,CLAUDIN,CONCLUSION,LABEL,LNCAP,METHODS,OBJECTIVE,RESULTS,SERUM,WESTERN
169,344,688,COPYRIGHT,CROWN,HDR,INC,INITIAL,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RATES,RESULTS,THREE
IMPROVING,INCREASING,LABEL,MATERIALS,METHODS,MODEL,OBJECTIVE,PRE,PSA,PURPOSE,RESULTS,SIMILAR,SRT,STRATEGIES,TCP
BECAUSE,HOWEVER,OATP1B3,OATP1BS,OATPS,THERE
SWEDISH,THEIR,THESE,USING,WESTERN
008,177,ANIMALS,CASTRATED,CWR22,DYNAMIC,MIB,PC3,PET
001,003,104,166,169,995,999,AFTER,AHR,AUTHORS,BJU,END,GLEASON,INCREASING,JANUARY,LABEL,LEVEL,METHODS,MRI,OBJECTIVE,PROGNOSIS,PSA,RESULTS,TECHNIQUES,THERE,THESE,UNLABELLED,USING
169,60MIN,COPYRIGHT,DIGESTION,HOWEVER,LNCAP,LTD
2ND,3RD,6TH,EUR,ISRAELI,NUTRITION,PARADOX,UNION

CONSISTENT,HOWEVER,MED50,PRMT5,PROTEIN,THESE,WDR77
CHRONIC,THEREFORE,THESE
254,450,520,566,956,ANTIGEN,BLOOD,CONCLUSION,DESPITE,GENERAL,INCIDENCE,IRR,LABEL,MAMMOGRAMS,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,OTHER,OUTCOME,POISSON,RESULTS,SETTING
CDF,CSC,EMT,HIF,HOWEVER,LNCAP,NANOG,PCA,TAKEN
AMD3100,CXCR4,PC3,SEVERAL,STROMAL,THEREFORE,THESE
169,183,956,CONCLUSION,DIAGNOSTIC,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,WHOLE,WRITTEN
005,271,627,679,695,879,896,BACKGROUND,CONCLUSION,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,THESE
AKT,DESPITE,DU145,FAK,OXIDATIVE,PC3,ROS,TRAMP,TRANSGENIC
128,169,179,183,231,233,241,545,818,847,997,CONCLUSION,COPYRIGHT,ECONOMICS,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS
41388,BACKGROUND,BLACK,BRAZILIAN,BROWN,LABEL,METHODS,OBJECTIVE,RESULTS,SETTING,WHITE
109,118,140,201,253,634,678,AUC,DIAGNOSTIC,DRE,HGPIN,JANUARY,LABEL,MAY,METHODS,NPV,OBJECTIVE,PCA,PPV,PSA,PURPOSE,RESULTS,ROC,T1C
169,AFRICAN,AMERICANS,CAP,CAUCASIAN,CONCLUSION,COPYRIGHT,ERG,ETS,GLEASON,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,ONCOGENIC,RESULTS,WESTERN
169,356,AMONG,CONCLUSION,COPYRIGHT,INC,LABEL,LYMPH,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,SIMILARLY,THEREFORE,THREE
169,CONCLUSION,COPYRIGHT,ESTERIFIED,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SEVEN,WESTERN
ALA,DU145,FUNCTIONAL,GLY,HOWEVER,INHIBITING,LEU,LNCAP,LYS,PCR,PEPT1,PEPT2,PEPTIDE,SAR,WESTERN
APRIL,AVENTIS,BBB,FDA,JEVTANA,MARCH
281,BACKGROUND,GLEASON,GS6,GS7,LABEL,LRM,METHODS,PCA,PSA,RATIO,RESULTS,USING
DUE
CAM,HOWEVER,OTHER,OVCAR
205,218,281,916,EMT,GLEASON,PCA,SIMILARLY,TAP63,THESE
107,306,331,474,504,842,BACKGROUND,BOARD,BRAIN,CENTRAL,ENGLAND,GENERATING,LABEL,LEUKAEMIA,METHODS,OBJECTIVE,OBS,OVERALL,RESULTS,SRR,WALES
169,ADT,BACKGROUND,COPYRIGHT,ERG,FINALLY,HGPIN,IDC,INC,LABEL,METHODS,PCA,RESULTS,TMPRSS2,WILEY
458,461,956,BAVARIA,CONCLUSION,CURRENT,LABEL,METHODS,OBJECTIVE,POISSON,RESULTS
THERE
SVC
143,145,CD133,CSC,MYC,PCA
169,AZGP1,BASEL,CONCLUSION,COPYRIGHT,DU145,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PCR,PSA,RESULTS,WESTERN
216,331,352,393,978,BPH,TEN
006,009,17Q21,18Q12,193,22Q11,395,541,651,876,916,FINNISH,HPC,HPCX1,LOD,OSA,USING
BACKGROUND,CONCLUSION,HOWEVER,LABEL,METHODS,RESULTS,THEREFORE,WEB
001,002,004,017,026,028,030,037,057,060,102,169,195,231,341,411,526,590,898,984,ASA,AUTHORS,BETWEEN,BFS,BJU,CONTINENCE,CSS,GLEASON,HOWEVER,ICS,ICSMALE,LABEL,LEVEL,MEIER,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,SOCIETY,THERAPY,THERE,UNLABELLED
000,275,AIM,BACKGROUND,DISCUSSION,GPS,HOWEVER,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,TEN,TESTING,WAIKATO,ZEALAND
169,2DE,954,DU145,THESE,VCH,WESTERN,WILEY
167,169,179,185,COPYRIGHT,FOLLOWING,LTD,MCF,MEK,MRS,PC3,U0126,WILEY
169,ATPASES,COPYRIGHT,GOLGI,INHIBITION,LNCAP,PCA,PSA,R1881,THESE,TREATMENT
005,144,AURKB,CCNB2,GLEASON,INCREASED,LNCAP,PC3,TOP2A,UBE2C
465,945,AMONGST,ENZYMATIC,FINALLY,SELECTIVE,THESE
001,110,181,256,371,736,946,CORTACTIN,COX,GLEASON,HDAC6,HDACS,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SIRT2
145,169,946,956,COPYRIGHT,GAL,GLC,HMBOA,LTD,M2BOA,SWEET
169,384,462,613,897,945,BIOMARKER,CALIPER,CHICAGO,CLOSE,COA,COPYRIGHT,E26,HOPKINTON,IBM,INC,METHYLACYL,STATISTICS,THREE
169,196,250,AMONG,BACKGROUND,COPYRIGHT,CYFRA,FDP,LABEL,METHODS,NMP22,RESULTS,ROC,UBC,URINARY
015,018,020,024,038,040,121,168,178,323,357,447,511,634,665,833,967,CONCLUSION,DOCETAXEL,JANUARY,LABEL,METHODS,OBJECTIVE,ORR,PSA,RESULTS,THERE
004,005,200,BACKGROUND,CONCLUSION,EARLY,INTERVALS,LABEL,METHODS,MRI,PSA,RAISING,RESULTS
DENOSUMAB,RANKL
DETECTION,NGS,SEQUENCING,SOLID,THESE
BACKGROUND,CLINICIANS,LABEL,METHODS,ONJ,RESULTS
002,003,201,247,331,COMPARING,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE
CD8,THERE,THESE,UNIVERSITY
100,AFTER,BASED,DKK,FIRST,HEP3B,HEPG2,LNCAP,MOI,PC3,PCR,REGARDING,THESE
160,267B1,APOPTOSIS,DIAMIDINO,KOREA,SACCHARINA
954,DU145,HIF,HYPOXIA
COMMUNITY,LABEL,MANEN,METHODS,OBJECTIVE,OBJECTIVES,PURPOSE,RESULTS,SETTING,SEVERAL,SYNTHESIS
169,AKT,COPYRIGHT,INC,LNCAP,M14,THESE,USING,WHEREAS
169,181,ADJUSTING,AFRICAN,CENTRAL,COMPOSITE,CONCLUSION,COPYRIGHT,HOWEVER,INDEX,IRELAND,LABEL,LTD,METHODS,NORTH,OBJECTIVE,PCA,QOL,RESULTS,TDM
169,CACO2,CALCITRIOL,COPYRIGHT,CYP24A1,DAC,HOWEVER,ISSUE,LTD,RXR,SINCE,SP1,SPECIAL,VDR,VITAMIN
169,ANDROGENS,CONVINCING,COPYRIGHT,IRELAND,LTD,PUBLISHED
169,COPYRIGHT,IRELAND,LTD,PXR
145,169,BRS,CHANGES,COPYRIGHT,FOLLOWING,LNCAP,LTD,TUNEL,WESTERN
169,946,CACO2,COPYRIGHT,CYP3A,IRELAND,LNCAP,LTD,VDR
169,954,AUTOCRINE,BACKGROUND,CHANGES,COPYRIGHT,CXCL8,CXCR1,CXCR2,ELISA,HIF,HYPOXIA,INCREASED,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PCR,PUBLISHED,RESULTS,SETTING,SMALL,TRANSIENT,UROLOGY
100,169,945,946,956,CONCLUSION,COPYRIGHT,DIFFERENT,GAS,LABEL,METHODS,NMR,OBJECTIVE,PINUS,PURPOSE,RESULTS
169,233,AUSTRIA,BACKGROUND,BCG,BLADDER,CIS,CONTEXT,COPYRIGHT,HOWEVER,LABEL,MARCH,METHODS,OBJECTIVE,PUBLISHED,RADICAL,RESULTS,STROMAL,SYNTHESIS,THESE,UROLOGY
CD133,EQUALLY,THESE,U87
945,AMP,C352G,C81,DU145,ECTOPIC,EGF,EXPRESSION,LNCAP,OXT,PC3,PERTUSSIS,PTX,RWPE1,THESE
ADAMS,FINALLY,INCREASED,JAGGED1,NOTCH,PC3,THESE,ZMP
10Q21,17P13,215,CROSS,D356N,DHT,FAM9B,REDUCTION,THESE
560,BACKGROUND,CONCLUSION,DOCETAXEL,GRADE,LABEL,MEDICAL,METHODS,RESULTS,UNIVERSITY
160,AFRICAN,BARBADIAN,BLACK,POPULATION
BCL,GLEASON,IGH
POWERPOINT
169,661,873,ADT,BPS,COPYRIGHT,MINERAL,OVERALL,SOCIETY
GLEASON,INCREASED,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,ZAG
945,JUK,PC3,PI3,WESTERN
ADDITIONAL,BASED
AKT,HSP90,THESE
145,169,COPYRIGHT,IRELAND,LNCAP,LTD,ROS
MPE
005,007,169,223,843,ADT,AUTHORS,BJU,COX,DESPITE,GLEASON,LABEL,LEVEL,LOCAL,MEIER,METHODS,OBJECTIVE,RESULTS,THERAPY,UNLABELLED,WHILE
ENRICHMENT
FURTHER,PSA
AFTER,CONCLUSION,EARLY,LABEL,METHODS,OBJECTIVE,RESULTS,SIX,THREE,VED
AFTER,CGA,CONCLUSION,LABEL,LACKING,METHODS,NSE,OBJECTIVE,RESULTS
001,002,008,013,024,120,BPH,CONCLUSION,III,LABEL,METHODS,OBJECTIVE,PSA,REGARDING,RESULTS
121,122,272,CONCLUSION,DU145,LABEL,METHODS,MTB,MTP,NOS,OBJECTIVE,PCR,RESULTS
2ND,4TH,CCK,CONCLUSION,LABEL,METHODS,MYC,OBJECTIVE,PC3,PPARGAMMA,RESULTS,THERE,USING
AFTER,CONCLUSION,KNOCKDOWN,LABEL,METHODS,MTT,OBJECTIVE,PCR,RESULTS,WESTERN
CHALLENGES,CHRONIC,CONDITIONS,DEPARTMENT,DOH,GCM,GENERIC,LABEL,METHODS,MODEL,OBJECTIVE,RESULTS,THERE,YORKSHIRE
111,316,357,764,BACKGROUND,COLON,CONCLUSION,FOLLOWING,LABEL,LYNCH,MEIER,METHODS,MMR,RESULTS,SIR
3DCRT,ADVANTAGES,BACKGROUND,BOWEL,COMPOSITE,CONCLUSION,INDEX,LABEL,METHODS,RESULTS,SIMILAR,THERE
215,243,LPP,MEDIKUS,PEROXIDASE,SPAIN,UNDER
180,215,25C,296,957,CDK,CONCLUSION,EFFECTS,KCL,LABEL,METHODS,MTT,OBJECTIVE,PBS,RESULTS,VALUE,WESTERN
DUOXS,NADPH,NEGATIVELY,NOX,ROS,THESE,WHILE
256,268,690,696,BACKGROUND,INSTITUTE,LABEL,METHODS,PSA,RESULTS,SECONDARY,SOCIETY,THERE
000,147,169,26A,ERG,LABEL,TMPRSS2,UNLABELLED,USING
946,KEY
000,018,146,169,172,256,COPYRIGHT,HOWEVER,HPV,INC,SIMILARLY,WHETHER,WILEY
125,150,HIV,JANUARY,TDM
141,169,226,351,718,ADVERSE,BETWEEN,BRT,CONCLUSION,COPYRIGHT,HDR,INC,IRT,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RESULTS,THREE
143,182,BACKGROUND,FPI,LABEL,RESULTS,SEVERAL
00001,100,179,215,228,286,963,DIAGNOSTIC,EIS
169,176,177,956,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
003,128,169,221,381,509,BJU,COMPETING,DISEASE,ERSPC,FAVOURABLE,GLEASON,HOWEVER,LABEL,LEVEL,LOW,MEIER,METHODS,OBJECTIVE,PCA,PRIAS,PSA,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,THERAPY,UNLABELLED
A36,AMI,PRMT1,PRMTS,PROTEIN
169,286,843,ANGELES,AUTHORS,BJU,CALIFORNIA,CAPSURE,DESPITE,INDEX,LABEL,LOS,METHODS,OBJECTIVE,PATIENT,RESULTS,UNIVERSITY
169,330,500,AUTHORS,BJU,CONCLUSION,DANUSERTIB,FURTHER,LABEL,METHODS,OBJECTIVE,PHA,PSA,RESULTS,SIXTY
032,169,191,ABLATHERM,AMICO,BJU,CONCLUSION,DURABLE,LABEL,LEVEL,MEIER,METHODS,OBJECTIVE,OCTOBER,PCA,PSA,RESULTS,STRATIFIED,STUTTGART,THERAPY,TMS,UNLABELLED
121,169,945,AKT,AUTHORS,BJU,CONCLUSION,DESPITE,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THERAPY,THERE,UNLABELLED
151,181,ARHGDIA,CASZ1,DU145,GENISTEIN,HOWEVER,INHIBITION,LUCIFERASE,MEIER,N4BP1,PC3,PCA,PCR,SOX17,TREATMENT,UTR
145,BACKGROUND,CONCLUSION,DOA,DOX,LABEL,LIPOSOMES,MCF,METHODS,MTT,PEG,RESULTS,SV119
176,1ST,2ND,FPD,MAY,TOMOGRAPHY
175,955,ACS,AFTER,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STRATEGIC
EVALUATION,NOW,SOLID
001,169,837,ACCORDING,BECAUSE,CONCLUSION,COX,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
HOWEVER,RAS,SPARC,SPARCL1
169,COMPLEX,COPYRIGHT,FINALLY,INC,LNCAP,OVERALL,WILEY
169,22RV1,B2M,BACKGROUND,COPYRIGHT,DU145,GSTP1,HIF1A,HKG,HYPOXIA,INC,LABEL,LNCAP,METHODS,NORMFINDER,PC3,PCR,PWR1E,RESULTS,RWPE1,UBC,WILEY
006,009,117,169,177,457,567,926,BACKGROUND,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,NUCLEOLAR,PCA,RESULTS,WILEY
1TH,3RD,6TH,QOL,RADICAL,THESE
433,FEW,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PROTECT,PSA,PURPOSE,RESULTS,TESTING,THERE,TREATMENT
169,BP1,COPYRIGHT,HOWEVER,INC,TREATMENT
169,174,500,BETWEEN,BJU,CALYPSO,CLAVIEN,CONCLUSION,LABEL,MEDICAL,METHODS,OBJECTIVE,OCTOBER,RESULTS,SEATTLE,UNLABELLED,USA,UTI
169,COPYRIGHT,HDR,PUBLISHED,SAS,WILLIAM
BACKGROUND,CENTRAL,FURTHER,LABEL,MEDLINE,METHODS,RESULTS,TAMOXIFEN
139,169,AMICO,CONCLUSION,COPYRIGHT,EPSTEIN,FURTHER,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS,THERE,THEREFORE
120,169,BOARD,CONCLUSION,COPYRIGHT,DOPPLER,ENDOSCOPE,FURTHER,INC,IQR,LABEL,METHODS,OBJECTIVE,RALPS,RESULTS,THERE,TILEPRO,VINCI
001,002,005,012,124,169,276,365,765,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
ADT,AFFAIRS,AMONG,BACKGROUND,DESPITE,LABEL,METHODS,RESULTS
177,945,949,HIF,HYPOXIA,MNP,PC3,PCL,PEG,PPEEA,THEREFORE
124,945,BESIDES,BINDING,CYP17,DOCKING,FIT,HANDRATTA,HORMONE,IFD,INDUCED,LBD,PCA,STEROID,STRUCTURE
AKT,LEHSSKLQL,PSA,THEREFORE
BACKGROUND,CONCLUSION,LABEL,METASTATIC,METHODS,PAGET
BASED,BECAUSE,CURRENT,FURTHER,III,INCREASED
174,BASED,CSF,FURTHER,III,IPILIMUMAB,LNCAP,PAP,PC3,PSA,USA,USING
027,068,169,177,215,ADC,AUC,CONCLUSION,CORRECTING,INTRA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,STAND,WHOLE
AUTOPHAGY,CELLS,CONVERSELY,INCREASED,LC3,LNCAP,MG132,PC3,TNF,TUNEL,WESTERN
DESPITE,DIAGNOSING,THEREFORE
033,042,043,057,169,215,386,583,854,894,BACKGROUND,CONCLUSION,EUROPEANS,HOWEVER,LABEL,LATINOS,MEC,METHODS,RESULTS,SNP,THERE
093,169,215,257,605,AAS,AFRICAN,AMERICANS,BACKGROUND,CHICAGO,CONCLUSION,LABEL,METHODS,RESULTS,SNP,WASHINGTON
000,001,003,100,105,125,ACHIEVING,BFS,BRT,DFS,DISEASE,LABEL,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
ERG,ETS,ETV,PC3,PCA,USING
169,183,3CLHAZA,956,COPYRIGHT,DMF,HOS,INC,LNCAP,MTT
174,HOWEVER,HPV,SIPULEUCEL
169,ALARA,COPYRIGHT,IMAGE,PUBLISHED,SAS,SEVERAL,THESE
001,006,007,043,ADJUSTING,BACKGROUND,BCR,BMI,EQUAL,HOWEVER,INCREASED,LABEL,METHODS,OBESE,OBESITY,OBJECTIVE,OUTCOME,PSA,PUBLISHED,RESULTS,SETTING
169,231,233,COPYRIGHT,INTENSITY,PUBLISHED,SAS
000,018,019,160,169,215,468,572,COPYRIGHT,HODGKIN,LTD,PERIPHERAL,PUBLISHED,VII
169,295,COPYRIGHT,LOD,PROSTATUS,PSA,TOTAL
169,COPYRIGHT,INC,LABEL,MAY,METASTATIC,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,PURPOSE,RESULTS
169,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,LOW,METHODS,OBJECTIVE,PARAMETERS,RESULTS,THESE
169,CHOLINE,COPYRIGHT,INC,PUBLISHED,SOCIETY,TARGETING
001,008,096,169,239,ADJUSTING,BLACK,COPYRIGHT,CURRENT,EDUCATION,HOWEVER,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,S8494,S8894,S9346,SUBGROUPS,UROLOGICAL
101,169,AFTER,BIOLOGY,COPYRIGHT,FEDERATION,INC,JANUARY,PUBLISHED,ULTRASOUND,WORLD
169,AIM,COPYRIGHT,LTD,TLD
169,ADDITIONAL,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS
101,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,STAGING,THREE
169,2000S,500,AREAS,CONCLUSION,COPYRIGHT,DWI,INC,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SEVENTY,THREE
169,COPYRIGHT,GOSERELINE,SAS
004,169,4MM,COPYRIGHT,GLEASON,LABEL,METHODS,MFC,MRI,OBJECTIVE,PSA,RESULTS,SAS,SEVENTY
169,AFTER,BACKGROUND,CONCLUSION,COPYRIGHT,DESPITE,FDA,LABEL,METHODS,RESULTS,SAS
169,COPYRIGHT,IMAGE,PUBLISHED,SAS
013,036,954,BLINDED,COX,CTS,INTER,KAPPA,KRUSKAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PCA,READERS,RESULTS
145,177,194,195,956,RED,SEQUENTIAL
COULD,ERG,PERHAPS,SIMILARLY,THESE
169,BACKGROUND,CLAVIEN,CONTEXT,COPYRIGHT,DELAY,FURTHER,LABEL,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SYNTHESIS,UROLOGICAL,UROLOGY
169,400,946,ANNEXIN,COPYRIGHT,CPT,CTP,DU145,HOWEVER,LNCAP,PROPIDIUM
169,COPYRIGHT,JMJD2,KDM4C,LTD,THEREFORE
100,OMICS,THESE
1H255,BACKGROUND,BVD,ECM,GLV,HOWEVER,LABEL,METHODS,MMP,ONCOLYTIC,PBS,RESULTS,TAKEN
004,105,BACKGROUND,LABEL,MEIER,OVERALL,PCA,PCR,PRINCIPAL,PSA,RESULTS,SERUM,UNIVARIATE
174,945,AKT,CARDURA,CLINICALLY,EPH,EPHA2,EPHA4,ERK,NMR,PI3,RAS,SIMILAR,THESE,THROUGH,TREATMENT
160,176,177,206,247,389,702,956,AFTER,BACKGROUND,BINDING,CONCLUSION,LABEL,METHODS,MRI,PTX,RESULTS,SIPPS,SPM
946,ASC,BPH,EARLY,EMT,MECHANISM,SILENCING,SNAIL,TGF,THESE,THP
160,177,SUBVOLUME,TCP
PC3,PDZ,RHO,THERE,THESE,TRUNCATION
946,EMT,HOWEVER,INITIALLY,INSTEAD,PRIMARY,STMN1,TGF,THESE
160,BACKGROUND,CONCLUSION,FATIGUE,LABEL,METHODS,NETWORK,RESULTS,WHILE
001,116,169,AZA,BPH,CDR,COPYRIGHT,DENSITY,GLEASON,HGPIN,LOW,NOTABLY,OVERALL,RELATED,SFRP1,SFRP2,SFRP4,SFRP5,SFRPS,USING,WNT
169,177,ADT,CELLS,COMBINING,COPYRIGHT,DSF,LNCAP,PCR,USING
069,204,327,BACKGROUND,BECAUSE,COX,FORTY,III,LABEL,MEN,METHODS,NUTRITION,RESULTS,THESE
169,AD5,AD6,ADENOVIRUS,E1A,ELEVATING,HOWEVER,KUPFFER,ONCOLYTIC,VIRTUALLY
AD5,FDA,III,OTHER,PHASE,SIPULEUCEL
145,1522B,53BP1,947,AG0,CELLS,FOLLOWING,MODULATED,THERE,THESE
169,945,946,954,FIRST,IKB,IL1,INC,LNCAP,LPS,PMA,PSA,ROS,TNF,WILEY
C57BL,CONCLUSION,FOLLOWING,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,STAT3,TDLNS
ATX,HOWEVER,HUVEC,LEDGF,LPA,ROS,THESE
000,068,12ADT,131,173,180,206,267,344,543,580,893,913,AMINO,BACKGROUND,FAP,LABEL,LNCAP,MCF,METHODS,MIXED,RESULTS
GAPDH
169,99M,BACKGROUND,COPYRIGHT,CTT,DPA,INC,LABEL,LNCAP,METHODS,PC3,PEG,RESULTS,SPECT,WILEY
169,946,947,APOPTOSIS,BACKGROUND,COPYRIGHT,HP1,INC,LABEL,LNCAP,LUCAP,METHODS,PHENOTYPIC,RESULTS,TUNEL,WILEY
169,BACKGROUND,BLOOD,CGA,COPYRIGHT,CTC,ELISA,FURTHER,INC,LABEL,METHODS,NSE,PCR,PSA,RESULTS,WILEY
208,231HM,MDA,PCR
221,C21,EVALUATING,P221A,POINT,PRO,PROTEASOME,REDUCED,TREATMENT,USING
GLEASON,MRI,REGARDING,THESE,TREATMENT
100,11600,169,AFTER,BACKGROUND,CASTRATION,COPYRIGHT,GENERAL,LABEL,LTD,METHODS,OVERALL,PSA,PUBLISHED,RESULTS,USING
169,AIM,BACKGROUND,CHANGES,CONCLUSION,DOPPLER,FIFTEEN,FLOWMETRY,HOWEVER,LABEL,LASER,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,TEN,THREE
252,40X,760,DISCUSSION,GLEASON,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,T2A,T2B,T2C,T3A
553,658,HOWEVER,INSTEAD,ITALY,STONE,TREATMENT,UROLOGICAL,WHILE
100,22RV1,DU145,GLEASON,HOWEVER,LNCAP,PC3,PCR,PROS1,PROTEIN,SIMILARLY,TAKEN,USING
182,331,642,DU145,FINALLY,PCR,TRANSIENT,USING,UTR
169,177,430,ANGELES,BACKGROUND,CALIFORNIA,COMPOSITE,COPYRIGHT,EXCLUDING,INDEX,LABEL,LOS,METHODS,PHOENIX,PSA,RESULTS,SOCIETY,STUTTGART,UNIVERSITY,URINARY,VALIDATED
888,954,956,AES,BACKGROUND,CONCLUSION,FORTY,LABEL,METHODS,PSA,RESULTS,SECONDARY,THERE
107,BACKGROUND,BCR,COMPONENTS,ELECTRONIC,GIVEN,LABEL,MEDICAL,METHODS,OBESITY,RESULTS,UNIVERSITY
001,019,028,036,250,300,314,AST,BACKGROUND,LABEL,METHODS,PHASE,PSA,RESULTS,THESE,WAIST
169,COPYRIGHT,DEVELOPING,HOWEVER,LNCAP,MECHANISMS,PPD,TARGETING
169,AIM,APRIL,CONFERENCE,COPYRIGHT,CROWN,DENOSUMAB,LABEL,LIBRARY,LTD,MARCH,MAY,MEDLINE,METHODS,NETWORK,OBJECTIVE,PUBLISHED,QOL,RESULTS,SCIENCE,SECONDARY,SOURCES,SRE,SYNTHESIS,WEB
001,169,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,174,ASC,COPYRIGHT,EDUCATION,GFP,INC,LABEL,LC3,LNCAP,MATERIALS,MECHANISM,METHODS,OBJECTIVE,PC3,PUBLISHED,PURPOSE,RESULTS,SIGMA,TARGETING,UROLOGICAL,USING,WESTERN
169,22RV1,COPYRIGHT,CPG,DU145,EDUCATION,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,AIM,COPYRIGHT,CRS,HODGKIN,ITALIAN,LABEL,LTD,METHODS,OBJECTIVE,REGISTRIES,RESOURCES,RESULTS,SEH,SERTS,SOCIO
169,COPYRIGHT,SEMINAL
169,192,ADVERSE,ASSESSMENT,FUNCTIONAL,INDEX,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,QUALITY,RESULTS,SCORE,SYMPTOM,T3AN0M0,THERAPY,UROLOGICAL
169,ENGLISH,OTHER,UROLOGICAL
001,169,177,205,361,410,AGE,AMONG,COX,HOWEVER,LABEL,MAY,MEDICAL,METHODS,OBJECTIVE,RESULTS,UROLOGICAL,UROLOGISTS

177,231,AML,BLOOD,DISRUPTION,HUVEC,KHT,MDA,PC3,RESULTS,S1P,THESE,USING
946,BCL,FURTHER,HOWEVER,MCL,MET,PCA,RESISTANCE,SABUTOCLAX
CACNA1D,CPG,DMB,ERG,ETS,GLYATL2,HLA,KCNH8,LNCAP,PCA,PDE3B,PLA1A,TDRD1,TMEM45B
COMPOUNDS,H3K27,HISTONE,HMT,SEVERAL
CD141,CD44S,CK5,CK7,PSA
169,950,LABEL,LNCAP,METHODS,OBJECTIVE,PCR,PSA,PURPOSE,RESULTS,USING,WESTERN
129,177,ADVERSE,BECAUSE,CONCLUSION,CTCAE,CURRENT,DUTCH,LABEL,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS
239,APRIL,BETWEEN,INDEX,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TPV,TZD
DU145,DUCAP,HOWEVER,IGF,IGF1R,INS,INSRA,LNCAP,PC3,THESE
EPC,EPHA2
107,137,165,177,696,CONCLUSION,FURTHER,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SERUM,YKL
169,737,ABT,COPYRIGHT,DU145,HOWEVER,LNCAP,LTD,PAB,WILEY
DESPITE,FOLLOWING,THERAPY
001,012,017,120,163,200,400,454,605,619,767,865,COX,PFS,PSA,PSADT
DU145,HOWEVER,LNCAP,MHC,NATURAL,THEREFORE,THESE,TRAIL
ASIAN,CAUCASIANS,CIS,ORS,PCA,T309G
132,169,COPYRIGHT,PCR,SAS,TELOMERASE,THESE,USING,WESTERN
000,169,711,835,AGA,BACKGROUND,COLORECTAL,COPYRIGHT,DETECTION,INC,INSTITUTE,LABEL,LOW,LOWER,METHODS,OBJECTIVE,OVARIAN,PUBLISHED,RESULTS
001,088,114,169,AFTER,BACKGROUND,BETWEEN,BMI,CCI,CONVERSELY,COPYRIGHT,ENOXAPARIN,LABEL,LTD,METHODS,RBC,RESULTS,SIMILARLY
HOWEVER,MANAGEMENT,THEREFORE
100,169,437,AMONG,BACKGROUND,CCI,COPYRIGHT,GLEASON,INDEX,LABEL,LIMITED,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,SETTING,TEN,UROLOGY
169,177,18F,282,BACKGROUND,COPYRIGHT,FEC,LABEL,LNM,METHODS,NPV,OBJECTIVE,OUTCOME,PCA,PET,PPV,PSA,PUBLISHED,RESULTS,UROLOGY
169,174,197,398,427,COPYRIGHT,EDUCATION,GLEASON,GUIDELINES,INC,INVENTORY,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEPARATED,SIMILARLY,UROLOGICAL
006,105,112,169,855,972,999,BLACK,COPYRIGHT,DATABASES,DIFFERENCE,EDUCATION,FLORIDA,HEALTHCARE,INC,INPATIENT,LABEL,MATERIALS,METHODS,OBJECTIVE,PROJECT,PUBLISHED,PURPOSE,RESULTS,STATE,UROLOGICAL,USING
001,067,075,102,169,194,197,218,224,233,242,260,280,281,310,705,711,889,972,988,991,BACKGROUND,BCR,COPYRIGHT,COX,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,SIXTY,SRT,TEN
001,002,111,123,132,141,169,199,277,289,440,791,805,BACKGROUND,COPYRIGHT,EARLY,INVENTORY,LABEL,LOWER,MEN,METHODS,OBJECTIVE,OCTOBER,OUTCOME,PUBLISHED,RESULTS,SCORE,SETTING,SYMPTOM,UNIVARIATE,UROLOGY
AIM,DISCUSSION,LABEL,OBJECTIVE,PAGET,PSA,UNASSIGNED,VIRTUAL
0000001,00001,001,003,135,169,237,401,627,633,685,949,AUC,COPYRIGHT,EDUCATION,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PUBLISHED,PURPOSE,RESULTS,ROC,SIMILAR,THERE,UROLOGICAL
001,169,215,280,729,AUC,BECKMAN,CALIFORNIA,COPYRIGHT,COULTER,EDUCATION,INC,INCLUDING,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PREDICTIVE,PUBLISHED,PURPOSE,REGRESSION,RESULTS,TOTAL,UROLOGICAL
105,169,177,ACCRUAL,COPYRIGHT,DISEASE,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
000,001,034,094,100,109,116,136,153,169,215,222,BECKMAN,COPYRIGHT,COULTER,EDUCATION,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SERUM,UROLOGICAL
167,169,189,215,ADDITIONAL,BECKMAN,COPYRIGHT,COULTER,COX,EDUCATION,GLEASON,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WHILE
008,169,318,COPYRIGHT,COX,EDUCATION,FURTHER,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,REQUIRING,RESULTS,UROLOGICAL,USING,WHILE
001,003,058,169,401,657,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,SERUM,UROLOGICAL
000,005,008,055,074,169,483,ANDOVER,COPYRIGHT,GENERATING,HEALTHCARE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHILIPS,PTV,PURPOSE,RESULTS,USING
125,160,956,ANIBA,ANIBAMINE,PUBLISHED,SAS
135,633,CHINESE,EORTC,HRQOL,LABEL,METHODS,OBJECTIVE,QLQ,RASCH,RESULTS,VERSION
BACKGROUND,DALYS,DISABILITY,HDI,INDIA,LABEL,METHODS,RESULTS,THESE,USING
001,122,169,176,ADD,BETWEEN,BJU,HOWEVER,ITE,ITR,KNOWN,LABEL,MAY,METHODS,NST,OBJECTIVE,OBJECTIVES,RESULTS,SUBJECT,THERE,THEREFORE,UNLABELLED
169,ANZ,AUTHORS,COLLEGE,CONCLUSION,CONSORT,DOCTORS,DRE,JOURNAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,POTENTIAL,PRACTICAL,PSA,RESULTS,ROYAL,SURGERY,THOSE
10Q22,118,200,223,445,945,TMA
OFTEN,THESE
DESPITE,HSP,HSP90
169,174,177,468,956,AFTER,CELLSEARCH,COPYRIGHT,CTC,CYTOMETRY,FCM,MDA,SOCIETY,TAKEN,VERIDEX
169,COPYRIGHT,EPSTEIN,LTD,MYC,NEWER,WILEY
GEORGIA,PROGRAM,SCREENING
103,178,190,480,E26,ERG,TMPRSS2
001,160,177,245,ADT,CHL,CRP,CVR,ELEVATION,FURTHER,HDL,LABEL,LDL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SFG,TAG
BPH,DU145,HOWEVER,MTT,PCR,REPRESSION,ZFX
956,APRIL,BETWEEN,CHINESE,CONCLUSION,GLEASON,JANUARY,LABEL,LYMPH,METHODS,OBJECTIVE,PSA,RESULTS,THESE
110,149,160,177,200,230,493,BETWEEN,CONCLUSION,CONTINENCE,GROUP,LABEL,LRP,MAY,METHODS,OBJECTIVE,PSM,RESULTS,T2A,T2B,T2C,T3A,T3B,THERE,THIRD,UNIVERSITY
001,096,177,201,216,338,352,400,443,624,933,956,971,CHINESE,CONCLUSION,DEC,DEPARTMENT,FIRST,GLEASON,JAN,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,ROC,UNIVERSITY,UROLOGY
169,COPYRIGHT,IMAGING,INC,NETWORK,STRATEGIES
169,COPYRIGHT,DCE,FSE,HOWEVER,INC,MRI,THERE,VFA
169,COPYRIGHT,INC,METABOLIC,METHODS,NOVEL
169,215,664,740,APRIL,BRF,CONCLUSION,COPYRIGHT,GYE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RBE,RESULTS
100,230,326,454,505,767,851,956,BACKGROUND,ITALY,LABEL,METHODS,ORS,RESULTS
169,487,503,ADVERSE,CONCLUDING,COPYRIGHT,GENERAL,INSIGHT,LTD,NETWORK,PRIMARY,USING
176,177,956,CTC,DU145,HOWEVER,LNCAP,PC3,SURFACE,THERE,THESE,WBC
169,BASED,TAKEN,UROLOGICAL
169,177,AAT,ADD,AUTOPHAGY,BJU,CONCLUSION,CONSISTENT,HENCE,HOWEVER,KNOWN,LABEL,LC3,LNCAP,MATERIALS,METHODS,OBJECTIVE,RESULTS,SUBJECT,UNLABELLED
169,177,181,2ND,ADVIA,AGREEMENT,AIA,AXSYM,BECKMAN,BJU,BLAND,BLOOD,CALIBRATED,CENTAUR,FOLLOWING,GENERATION,HOWEVER,HYBRITECH,IRELAND,IRISH,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,ROCHE,SIEMENS,TODAY,TOSOH,UNLABELLED
169,947,CD204,CD8,DCS,FURTHER,GIVEN,HOWEVER,IFN,RM1,SRA,THEREFORE,TRAMP,TREATMENT
946,CLU,EMT,HOWEVER,TAKEN,TGF
160,ABSTRACTS,AUTHORS,BACKGROUND,BECAUSE,CENTRAL,COLLECTION,CONTROLLED,EWB,FURTHER,HRQOL,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PEDRO,RESULTS,SCIENCE,SELECTION,SIGLE,SINCE,SMD,THERE,WEB,WHERE
956,CONVERSION,HOWEVER,PTGR1
010,019,094,COX,DU145,LNCAP,LOX,MDA,PCA,RELATIVELY
160,946,947,AMONG,CCAAT,CCND3,CEBPB,FLI,GADD45G,GSE2514,HOWEVER,KDR,LPL,NFKB1,PPARG,TGF
122,176,177,230,238,575,653,920,ADNEP,AKT,ATHYMIC,BAD,DU145,NEP,NEUTRAL
CYSTOSCOPY,III,MRI,PSA,TOTAL
021,100,208,65309,AMICO,GLEASON,MEIER,PSA,T2B,THEREFORE,USING
003,CHANGES,GLEASON,LDH,MCT,TAS,THESE,WARBURG
FURTHER,HLA,IGG,III,PPV,SINCE
AMONG,ARSER81,FOLLOWING,HORMONE,SINCE
AFTER,BACKGROUND,ERSPC,HOWEVER,LABEL,METHODS,PER,PSA,QALYS,RANDOMIZED,RESULTS,SCREENING,VARIOUS
001,160,399,520,800,BACKGROUND,EASTERN,GROUP,LABEL,MDV3100,MEDIVATION,METHODS,PSA,RATES,RESULTS
AFTER,LABEL,LIVER,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOS
BAO,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE,THREE
DVH,HOWEVER,LABEL,METHODS,OAR,OBJECTIVE,PURPOSE,RESULTS,SMALL
100,174,700,AFTER,AMERICA,AMS,CALYPSO,LABEL,METHODS,MODEL,MP35N,NORTH,OBJECTIVE,PHANTOM,PURPOSE,RESULTS
000,051,100,309,324,AGE,COMPETING,FDS,FREMANTLE,IRR,LABEL,METHODS,OBJECTIVE,PANCREATIC,RESULTS,THERE
120,121,241,AFTER,ANESTHESIA,CONCLUSION,CONTROL,EBL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
ESTIMATION,SINCE
100,FINALLY,GRAPH,LIVER,RESULTS
001,003,103,125,169,250,369,474,484,510,958,ADT,BACKGROUND,BETWEEN,COPYRIGHT,GLEASON,HRS,INCREASING,LABEL,MEIER,METHODS,RESULTS,SCHIFFLER,SOCIETY,UNIVERSITY
169,BACKGROUND,COLORECTAL,COPYRIGHT,GLEASON,HOWEVER,LABEL,METHODS,OVARIAN,PREVENTION,PROJECTING,REDUCTION,RESULTS,SOCIETY,TRIAL
427,ASO,HSP27,OGX,P53
005,007,009,011,018,028,037,045,108,148,160,192,300,BACKGROUND,GAL,GLEASON,LABEL,MATERIALS,METHODS,RESULTS,TISSUES
160,578,ALT,CREATININE,III,OTHER,POPULATION,PURPOSE,RESULTS,VERSION,YM155
002,005,982,DIMELQX,MELQX

180,SINCE,USING
155,181,223,250,BLOOD,CSF,EIGHT,GROUP,INCREASES,SERUM
108,AMONG,END,FACTORS,FIFTY,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SCORE
BACKGROUND,COLORECTAL,CONCLUSION,DIFFERENT,ENGLAND,INCREASING,KINGDOM,LABEL,METHODS,PLANS,RESULTS,THERE,USING
001,835,ADT,AMONG,BACKGROUND,CONCLUSION,LABEL,MATERIALS,METHODS,MORBIDITY,RADIATION,RESULTS,SCORING,UNIVARIATE
102,254,489,581,719,936,AUC,BACKGROUND,LABEL,MATERIALS,METHODS,OVERALL,PATHOLOGIC,PSA,RESULTS,ROUTINE,T1C
150,436,586,BACKGROUND,INACCURATE,INDEX,LABEL,MATERIALS,METHODS,ONCOLOGIC,RESULTS,SEPTEMBER

169,17571,AMONG,AUTHORS,BJU,BRAZILIAN,DRE,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,TUMOURS,UNLABELLED,USING
DESPITE,SUMOYLATED
145,DOXIL,FDA,LNCAP,LY3117273,SECRETORY,SSL,TREATMENT
169,CONVERSELY,COPYRIGHT,DRAWING,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,WILEY
125,142,280,AMICO,BACKGROUND,EMP,FURTHER,GLEASON,IQR,LABEL,MARCH,METHODS,PCA,PSA,RADICAL,RESULTS,SECONDARY,SEPTEMBER,SEVEN,SIX,T2C
005,010,014,023,114,825,BACKGROUND,BPH,CAP,GLEASON,HOWEVER,LABEL,METHODS,PCR,PSA,RESULTS,RUNX2
CASTRATION,HARNESSING,LNCAP,PCA
AKT,AXL,BCL,CURRENT,FAK,MER,NON,NSCLC,PROMISING,THESE
945,EXCELLENCE,FDA,HOWEVER,INSTITUTE,THESE,USING
169,270,765,ASIAN,ASN,ASP,ASP312ASN,BASEL,CAUCASIANS,COPYRIGHT,HOWEVER,LABEL,LYS751GLN,METHODS,OBJECTIVE,ORS,PCA,RESULTS,SER326CYS,XPD
PET
001,002,052,169,243,413,897,AMONG,BETWEEN,BJU,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,RADIATION,RESULTS,SMS,THERAPY,UNLABELLED,USING
169,BJU,CONCLUSION,DOCETAXEL,LABEL,LEVEL,MEIER,METHODS,OBJECTIVE,PFS,PSA,RESULTS,THERAPY,UNLABELLED
771,BACKGROUND,BLADDER,LABEL,MARGINS,MATERIALS,METHODS,RESULTS,SYSTEMATIC
514,764,BACKGROUND,CHI,CONCLUSION,LABEL,METHODS,MRI,RESULTS
169,ADT,BETWEEN,COPYRIGHT,INDEX,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,RTH,SIXTY,WILEY
113,169,215,871,ELISA,SAMPLES,THESE,VCH,WILEY
169,ASIDE,COPYRIGHT,DESPITE,FURTHER,LIVER,PATIENT,RECIPIENTS
169,268,323,519,946,INC,NCOA4,PSP94,SNP,TAKEN,THESE,WILEY
OPERATIVE,SEL
169,AKT,ANNEXIN,BACKGROUND,BCL,COPYRIGHT,EMBELIA,IAP,INC,LABEL,LNCAP,METHODS,RESULTS,WILEY
169,181,200,232,233,234,400,699,CONCLUSION,COPYRIGHT,COX,INC,LABEL,METHODS,OBJECTIVE,PHASE,PSA,PURPOSE,RESULTS,WILEY
141,169,375,378,409,APPLIED,BACKGROUND,BIOSYSTEMS,COPYRIGHT,INC,LABEL,METHODS,MIR,RESULTS,USING,WILEY
169,AMONG,BACKGROUND,BESIDES,BPH,COPYRIGHT,INC,LABEL,METHODS,PCA,PCR,PEPT1,PEPT2,RESULTS,THESE,WESTERN,WILEY
169,217,218,460,AUSTRALIAN,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,RESULTS,THERE,WESTERN,WILEY
169,261,AKT,COPYRIGHT,ERG,ETS,MOLECULAR,PREVALENCE,SER2448
169,COPYRIGHT,INC,POSITIONAL,POSITIONS,SYSTEMATIC,WILEY
CHANGES,FAS,FATTY,FDA,FURTHER,H1975,H3255,LABEL,METHODS,NMR,NSCLC,OBJECTIVE,PROCEDURES,PURPOSE,RESULTS,TCA,THESE
169,CD44S,DESPITE,DRG,INC,KAI,PIN,TEN,WILEY
BACKGROUND,HOWEVER,IMMEDIATE,INSTEAD,LABEL,METHODS,RESULTS,SEVERAL,THERE
001,002,004,009,029,045,155,499,INCREASING,JAPAN,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,UROLOGISTS
956,CELLS,CONCLUSION,DU145,EMT,ERK,FBS,FGF8B,GROUP,LABEL,METHODS,OBJECTIVE,PD98059,RESULTS,TRANSWELL
DETECTION,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SEVENTEEN
001,FIFTY,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,TRANSVERSE
169,213,COPYRIGHT,INC,PAGE4,PATHOLOGY,PCA,PUBLISHED,SOCIETY
145,169,956,ANG,ASSAY,AT1,AT2,AUTOMATED,CHAMBER,CHANGES,COPYRIGHT,COUNTER,HEALING,III,INC,LNCAP,MIGRATION,THESE,TRANSWELL,WESTERN,WOUND
169,COPYRIGHT,INC,MEDICAL,OAR,PTV,PUBLISHED,THEREFORE
169,25D,945,947,AF2,COPYRIGHT,CYP24A1,INC,RXR,VDR
006,058,160,169,932,COPYRIGHT,CSS,GLEASON,INC,LABEL,LDR,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE,TREATMENT
169,COPYRIGHT,ESPECIALLY,MRI,PUBLISHED
110,148,177,310,317,338,347,492,APRIL,BACKGROUND,BETWEEN,CONCLUSION,HOWEVER,LABEL,METHODS,OBS,RESULTS,THREE
000,177,499,684,GLEASON,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
001,088,189,280,420,956,AFTER,HEPG2,HOWEVER,IGG,IGM,INC,METHIONINE,NAB,PC3,PLP,PUBLISHED,RABBITS,THERE,ZEALAND
108,566,AMONG,CONCLUSION,GLEASON,III,JANUARY,LABEL,METHODS,OBJECTIVE,OCTOBER,PFS,PSA,RESULTS,SPECIAL
001,169,185,581,841,945,ADD,ADULT,BJU,BLOOD,CONCLUSION,DETECTION,EDUCATION,EVALUATION,GLEASON,III,KNOWN,LABEL,METABOLIC,METHODS,OBJECTIVE,PANEL,PROGRAM,PSA,RESULTS,SUBJECT,TREATMENT,UNLABELLED
001,169,240,ADD,AGE,AUTHORS,BJU,KNOWN,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PREDICTORS,RESULTS,SUBJECT,TREATMENT,UNLABELLED
001,169,693,ADD,BJU,CAPRA,KNOWN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,RRS,SEVEN,SUBJECT,UNLABELLED
169,BJU,FSS,LABEL,METHODS,OBJECTIVE,OCTOBER,RESULTS
145,169,APOPTOSIS,BJU,BPS,CALYCULIN,CONCLUSION,CURRENT,DETECTION,ELISA,KIT,LABEL,MATERIALS,METHODS,NOW,OBJECTIVE,OBJECTIVES,OKADAIC,PP1,RESULTS,THERAPIES,UNLABELLED,WESTERN,XTT,ZOLEDRONIC
111,169,181,214,945,BJU,BPH,CONCLUSION,HEIDELBERG,HOWEVER,LABEL,LEVEL,METHODS,MODIFIABLE,NUTRITION,OBJECTIVE,OXIDATIVE,PROGNOSIS,RESULTS,THESE,UNLABELLED
169,COPYRIGHT,LEUPROLIDE,WILEY
SINCE
HOWEVER,LNCAP,RED,THESE,WHILE
CD166,CD49F,LIN,LSC
AIM,BACKGROUND,CONCLUSION,DCN,DECORIN,E17,E19,EXPRESSION,LABEL,OBJECTIVE,P28,PRINCIPAL,RESULTS,SPARC
011,016,031,AKT,DEPLETION,FOXA1,GLEASON,HOWEVER,IGFBP,LNCAP,PSA,THESE
AKT,BIOLOGICAL,ERK,HORMONE,INCREASED,RECURRENT,RELEASING,THERAPIES
452,AMONG,BACKGROUND,CONCLUSION,FRESH,HYPOTHESIS,LABEL,METHODS,OBJECTIVE,RESULTS,START
069,BACKGROUND,LABEL,METHODS,RESULTS,STATINS,THERE
001,553,694,945,946,AMONG,BACKGROUND,DHT,GLEASON,LABEL,LOW,METHODS,NEITHER,PREVENTION,RESULTS,TRIAL
BLOOD,BPH,DESPITE,GLEASON,HYPOXIA,PSA,WHERE
CD4,CD8,CTLA4,PHENOTYPIC,TREATMENT
25C,ALA275PRO,BACKGROUND,CHINESE,DEPLETION,FURTHER,LABEL,LEWIS,METHODS,OBJECTIVE,OBJECTIVES,RATIONALE,RESULTS
169,CONFERENCE,COPYRIGHT,CURRENTLY,DENIS,IRELAND,JANUARY,KLOTZ,LTD,PCA,ROTTERDAM,SCIENTIFIC,STEYERBERG,TRACK
169,177,956,A2780,A2780CISR,ADP,ALBUMIN,ALTOGETHER,CISPT,COPYRIGHT,III,INC,PC3,PPH,RUTHENIUM
160,174,AMONG,HOWEVER,III,JEVTANA,MDR,STUDIES,TODAY,TREATMENT
169,COPYRIGHT,DESPITE,INC,REMARKABLY,TRIPARANOL
169,COPYRIGHT,CVD,INC
CRYSTAL,SAR,SMALL
KHABAROVSK,KOMSOMOLSK
181,AFTER,DR5,LABEL,METHODS,MTT,NUCLEAR,OBJECTIVE,PURPOSE,RESULTS
ABS,BASED,CD3,CD4,CD8,HOWEVER,THEIR
153,160,169,183,186,223,EDTMP,FURTHER,GEORG,III,RHENIUM,STRONTIUM,STUTTGART
167,169,183,408,AMICO,BACKGROUND,GEORG,III,LABEL,METHODS,PFS,RANDOMIZED,RESULTS,SALVAGE,STUTTGART
DENOSUMAB,OSTEOCLAST,SEVERAL
DSC
GIVEN,GSMTX,HOWEVER,LNCAP,MSCCA,TRPC1,TRPC3
AFTER,BACKGROUND,CLEVELAND,DOUGLAS,FLORIDA,LABEL,METHODS,OBJECTIVE,OPERATIVE,OUTCOME,RESULTS,SETTING
AFTER
DOC,GLEASON,HEMOGLOBIN,HOWEVER,THERE
124,150,160,22RV1,ANTIGEN,FURTHER,HOWEVER,KLK10,PC3,PCA
104,99MTC,BACKGROUND,CTS,CTV,FCH,LABEL,LNS,METHODS,PET,RESULTS,SNS,SPECT,THESE
001,153,800CW,AFTER,CONCLUSION,DSRED,EPCAM,FULLY,IRDYE,LABEL,LNS,METHODS,PC3,PET,RATES,RESULTS,SIMILARLY,UNLABELLED,USING
111,ADC,CONCLUSION,CONSISTENT,LABEL,LUCAP,METHODS,NONLINEAR,OVERALL,RESULTS,SIMILAR,SPECT,TENB2,UNLABELLED
4MM,8MM,GLEASON,MID
AFTER,MTT,PC3,PITUITARY,PTTG1,SIMILARLY
946,DU145,ELISA,FURTHER,GDF15,HPV,IL6,LNCAP,NDRG1,OTHER,PCR,RESULTS
LABEL,OBJECTIVE,ONGOING,PCA,PURPOSE,RESULTS,SUMMARY,THESE
LNCAP,SUSTAINED,THEREFORE
005,027,199,219,438,513,943,969,BACKGROUND,CONCLUSION,LABEL,MET,METHODS,OPN,PCA,PSA,RESULTS,ROC
143,154,160,233,DESPITE,GIVEN,INSTITUTE,LOIRE,RADIATION,SIXTY,USING
169,946,99M,ALA,BBN,COPYRIGHT,HYNIC,KIT,LTD,SEVERAL
036,058,127,144,164,181,241,277,741,963,968,CONCLUSION,DENOSUMAB,HOWEVER,III,LABEL,METHODS,OBJECTIVE,OVERALL,QALYS,RESULTS,SRE
GLY,SENP1,SENPS,SMALL,THESE,UBIQUITIN
CNS,GKSRS,THERE
CURRENTLY,HOWEVER,RADIATION
AMHR2,AMONG,BHR,CA125,CEA,GCT,HODGKIN,INCREASED,PROTEOMIC,THESE,VCP
115,131,AFFYMETRIX,BIOMARKERS,PAM,THESE
AKT,CAP,CD147,DTX,ERK,EXPRESSION,MTT,SELECTIVE,WESTERN
AKT,ECM,ERK,HOWEVER,IL6,INCREASES,LNCAP,MDA,PCA
169,183,GEORG,HOWEVER,III,PSA,STUTTGART
169,173,183,215,330,BACKGROUND,BETWEEN,CLAVIEN,CONCLUSION,DINDO,GEORG,JANUARY,LABEL,METHODS,RESULTS,SEPTEMBER,STUTTGART,VINCI
005,109,149,205,625,LOC642587,MIR,TRAP220
DETECTION,EARLY,FINALLY,HOWEVER,INSTITUTE,NETWORK
11248,160,946,ADVERSE,BCL,CONCLUSION,HOWEVER,LABEL,LNCAP,METHODS,OBJECTIVE,PDGFR,PURPOSE,RESULTS,SUNITINIB,VEGFR,VON,WESTERN,WILLEBRAND
169,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,CUSHING,LABEL,METHODS,THERE,TREATMENT
108,169,BASEL,COPYRIGHT,GLEASON,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,PCA,PSA,RESULTS,T1C
000,003,100,169,APHRODITE,ARP,BASEL,COPYRIGHT,FIFTY,IHC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
ADT,BACKGROUND,C30,CRPCA,EORTC,LABEL,LHRHA,METHODS,OVERALL,QLQ,QOL,RESULTS,THERE,WHETHER
068,090,169,296,354,420,522,581,726,730,BASEL,BLOOD,CAP,COPYRIGHT,HOWEVER,THEREFORE,THESE
010,047,169,400,588,650,819,961,AFTER,AMONG,COPYRIGHT,INC,ISPOR,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PEARSON,PUBLISHED,RESULTS,SELECTION,SOCIETY,THERAPY,WANTING,WTP
AFTER,CURRENTLY,EARLY,EPIGENETIC,FINALLY,HISTONE,KDM,KDM1A,KDM4C,PCA,SINCE,TIC,WHILE
079,956,COMPOUNDS,LNCAP,PC3,THESE
CHK,PC3,PCA,STUDIES
ASSAY,INHIBITION,SELECTIVE
945,946,CASTRATION,CATENIN,HIF,HOWEVER,HYPOXIA,LNCAP,THESE
00001,002,LABEL,LIBRARY,METHODS,OBJECTIVE,RESULTS,SEVEN
003,737,ANTIGEN,APC,CONCLUSION,CUMULATIVE,CYTOKINES,FDA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIPULEUCEL,THESE,TNC
160,293,298,AFTER,CHINESE,FEW,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SINGAPORE,TEA,THERE
218,233,451,BACKGROUND,CONCLUSION,LABEL,METHODS,PRIMARY,RESULTS
160,706,909,HOPKINS,JOHNS,MRE11,NBN,NBS,PROJECT,RAD50,S706X,SEQUENCING,UNIVERSITY
AGILENT,BLUNTED,CURRENT,EXPRESSION,INTRA,LRP,ORP,PCR,RALRP,RIN,VOLCANO
001,145,221,COX,EXPRESSION,GLEASON,HOWEVER,MEIER,MICRORNAS,PCR,PSA
176,CYBERKNIFE,GENERATED,NCP,OAR,PLANS,PTV,REDUCED
169,22RV1,COPYRIGHT,DHEAS,INC,KNOCKDOWN,LNCAP,OATP1A2,OATPS,SIMILAR,STX64
DIR,IGART,RANDO
16B,954,COMPONENTS,THESE,USING,WNT
BACKGROUND,CONTACT,LABEL,METAOMICS,MICROARRAY,SUMMARY
ONCOPHAGE,UNION
169,26RFA,AIM,CAP,CONCLUSION,COPYRIGHT,DU145,LABEL,LTD,METHODS,OBJECTIVE,RESULTS
215,300,400,498,744,BACKGROUND,BRM,LABEL,METASTASES,METHODS,PALLIATIVE,RADIATION,RESULTS,SPAIN,THESE
ANTIGEN,BACKGROUND,DEPOVAX,DPX,HLA,LABEL,METHODS,NATURALLY,RESULTS,TRIAL
BACKGROUND,BOXES,CONCLUSION,EXPERIENCE,FIFTEEN,FOLLOWING,HONEYCOMB,LABEL,METHODS,PROTOTYPES,RESULTS,SEVEN,THREE
181,521,BASED,COMPOSITE,GLEASON,INCREASING,LABEL,METHODS,OBJECTIVE,PCA,PSM,RESULTS,ULP
104,169,175,279,CONCLUSION,GLEASON,JANUARY,LABEL,MARCH,METHODS,MONTSOURIS,OBJECTIVE,OBJECTIVES,PATIENT,RESULTS,UROLOGICAL
ECM,PCA,SRC,WHILE
EPCAM,ERG,FINALLY,GENOMIC,PIN,PRIMARY,SCA,TAKEN,THESE,TMPRSS2
AZD8542,BASED,CONCLUSION,EXPRESSION,FURTHER,HPSCS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SMO,SMOOTHENED,SONIC,THESE
007,125,145,150,160,200,ADVERSE,APRIL,BETWEEN,GRADE,PATIENT,RD1,RV100,SEPTEMBER,T1C,USAGE
404,ASSESSMENT,BACKGROUND,CONCLUSION,FACTORS,LABEL,METHODS,PSA,RESULTS,SIMILAR,SMOKING,THESE
484,BACKGROUND,CONCLUSION,CRP,GSR,GSTP1,IL1RN,IL6,IL8,LABEL,METHODS,MPO,RESULTS,SNP,TNF,VARIATION
DHT,FURTHER,HNTEP,SAMPLES
652,CONFIDENCE,DRE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATIENT,REFUSAL,RESULTS
001,007,160,946,HOWEVER,MATRIPTASE,PC3,TTSPS
169,B16,COLON,COPYRIGHT,MXT,PREVIOUSLY,THESE,TREATMENT
VNP
169,CNH,COPYRIGHT,DOCETAXEL,LTD,PAMAM,PCA,RNASE,SYNTHETIC,USING
032,042,169,554,852,ADT,AES,BACKGROUND,CAD,COPYRIGHT,HOT,IAD,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,QOL,RESULTS,SETTING,TRIAL,UROLOGY,WHITNEY
169,177,AFTER,BMI,CALYPSO,CARTESIAN,COPYRIGHT,HISTOGRAMS,INC,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEATTLE,STRATIFIED,THERE
169,AIM,CONTOURING,COPYRIGHT,CTV,D90,ESTRO,GEC,GUIDELINES,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PROBATE,RESULTS,THREE,TSE
169,575,CAP,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PRE,RESULTS,SCREENING,UROLOGICAL
22RV1,BACKGROUND,DU145,EMT,EXPRESSION,KNOCKDOWN,LABEL,LNCAP,METHODS,OVERALL,PCR,RESULTS,SNAIL,THEREFORE
116,169,22RV1,945,954,LNCAP,MT1,NOTABLY,PKA,PKC,WILEY
DESPITE
169,994,AFTER,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,RESULTS,RIETE,WHILE
165,169,456,BACKGROUND,COPYRIGHT,GERMANY,LABEL,LTD,METHODS,RESULTS,WILEY
169,365,ANXIETY,BACKGROUND,CAUCASIAN,COMPOSITE,COPYRIGHT,CSA,FINALLY,INDEX,KENDALL,LABEL,LTD,MAX,MEN,METHODS,PCA,PSA,RESULTS,SCALE,SUM,WILEY
102,108,BACKGROUND,LABEL,MATERIALS,METHODS,RESPONSES,RESULTS,SPAIN,SPANISH
004,048,160,BACKGROUND,CONCLUSION,FURTHER,GRADE,GROUP,LABEL,MATERIALS,METHODS,RADIATION,RESULTS,THERAPY
ANTIGEN,CURRENT,ETS,HOWEVER,PCA,SINCE,TMPRSS2
001,145,177,APOPTOTIC,BACKGROUND,CONCLUSION,ELISA,INHIBITION,LABEL,METHODS,PCR,RESULTS,THEREFORE
ANXA2
177,956,ANS,CURRENT,SINCE,WGA,WHEAT
ANTIGEN,APART,DISCOVERY
187,205,222,DU145,EXPRESSION,PC3,PCA
001,137,169,318,692,AGE,ANY,BACKGROUND,BOOTSTRAP,COPYRIGHT,HGPCA,IBX,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,REGRESSION,RESULTS,SETTING,URINARY,UROLOGY
100,150,COMMISSION,PROTECTION,THROUGH,TREATMENT
049,169,ACADEMY,COPYRIGHT,DIETETICS,INC,NUTRITION,PUBLISHED,THESE
130,169,24H,AMICO,ANALYSING,COPYRIGHT,FURTHER,IMAGE,IRELAND,LABEL,LTD,MATERIALS,MEIER,METHODS,OBJECTIVE,PDR,PHOENIX,PSA,PURPOSE,RESULTS,SEVENTY,T1C,THERE
104,125,169,COMPOSITE,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,QUALITY,RESULTS,SCORE,SYMPTOM,THEIR,URINARY,UROLOGICAL
008,590,CSS,FFM,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,PCV,PPC,PSA,PURPOSE,RESULTS
169,AMONG,OTHER,QUITE,UROLOGICAL
177,BACKGROUND,CTV,LABEL,METHODS,PTV,RESULTS,STUDIES,SYSTEMATIC
CVD,HOWEVER,SINCE,THERE,THESE
001,701,CONCLUSION,CRUDE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,YET
026,BACKGROUND,BRIEF,CONCLUSION,DENOSUMAB,INVENTORY,LABEL,RESULTS,SRE
169,181,392,783,AFRICAN,AMERICANS,BACKGROUND,CALIFORNIA,COPYRIGHT,FURTHER,HAWAIIANS,HOWEVER,INC,LABEL,LATINOS,METHODS,RESULTS,WILEY
100,192,253,429,594,AFTER,AMONG,BACKGROUND,BETWEEN,DIAGNOSTIC,END,JANUARY,LABEL,METHODS,RESULTS
169,BACKGROUND,BECAUSE,COPYRIGHT,EBV,EPSTEIN,HPV,INC,LABEL,METHODS,PCR,RESULTS,THESE,WILEY
B16F0,B16F1,CONVERSELY,GRP78,HEP3B,HEPG2,PC3,THERE,THESE
946,ACT,BACKGROUND,ELISA,EPIGENETIC,LABEL,METHODS,PCA,PCR,RESULTS,SNP,TOTAL
001,003,004,011,094,132,444,946,ASIAN,BACKGROUND,BLAND,BMI,BSA,HCT,LABEL,METHODS,PSA,RESULTS,THERE
169,DRS,FRANK,MARCH,MEETING,PAOLO,PREVENTIVE,REBBECK,SAHARAN,SOCIETY,THERE,TIMOTHY,WASHINGTON
169,ABL,COPYRIGHT,DESPITE,DHA,EPA,HOWEVER,III,LTD,THESE
089,177,326,794,894,956,BACKGROUND,CADMIUM,CONCLUSION,LABEL,METHODS,RESULTS,SWEDISH
177,239,ACCORDING,BACKGROUND,CONCLUSION,LABEL,METHODS,PSA,RESULTS,SAGOPILONE,SIMON
169,CAF,CONVERSELY,EMT,GLUT1,HENCE,METABOLIC,SIRT3,WARBURG
ACC,AICAR,CBL,COA,CUR,DMC,HSP,HSP70,PC3,SHP
916,BECAUSE,BRITISH,CASODEX,GOVERNMENT,JOURNAL,PUBLISHED,THC,USA
111,160,162,311,418,945,AMONG,BACKGROUND,CONTEXT,E26,EPR3864,ERG,FUSIONS,LABEL,METHODS,OBJECTIVE,RESULTS
BACKGROUND,COUPLED,LABEL,RESULTS,SEQ,WHILE
22RV1,CWR,CWR22,OPN,TIMP2,WHILE
169,COPYRIGHT,LTD,WILEY
000,169,739,BACKGROUND,COPYRIGHT,END,LABEL,METHODS,PSA,RESULTS,SOCIETY
917,AUC,BMI,CAP,DRE,ITALIAN,ITALY,LABEL,MEN,METHODS,OBESE,OBESITY,OBJECTIVE,PSA,PURPOSE,RESULTS,ROC,THERE,UNIVERSITY
BACKGROUND,IMT,LABEL,METHODS
183,CENTRAL,GEORG,PSA,STUTTGART
169,COPYRIGHT,CUL4A,DAMAGED,HENCE,LNCAP,LTD,PC3,THEREBY
169,946,CD109,COPYRIGHT,INC,INSTEAD,PATHOLOGY,PUBLISHED,SMAD2,SOCIETY,STAT3,THESE
169,AFRICAN,COPYRIGHT,HOWEVER,INC,MEDICINAL,WORLD
BACKGROUND,BARCELONA,DP2,FIRST,HOUSING,LABEL,METHODS,POPULATION,RESULTS,SIXTEEN,SPANISH,THIRD
145,169,COPYRIGHT,INC,LNCAP,PCR,PWR,RYR,THREE,TOTAL
169,BASEL,CD103,COPYRIGHT,HAIRY,HCL,PET
169,COPYRIGHT,ISSUE,LOW,PROTEOMICS,PSA,SPECIAL,SRM,THESE
ADT,ANXIETY,BACKGROUND,COGNITIVE,CONTROL,DEPRESSION,DISCUSSION,GROUP,INVENTORY,LABEL,METHODS,ROSENBERG,SCALE,STATE,STUDIES,TRAIT,TRIAL
027,029,046,169,708,AMONG,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,UROLOGICAL
CANCERS,HOWEVER
100,181,ANNEXIN,BAPTA,BHQ,INCUBATION,INHIBITION,PC3
USA,WHILE

HOWEVER
223,CURRENTLY,FDA,MDV3100,PSA,THESE
AKT,CELLS,FURTHER,HOWEVER,PI3,PIN,THESE,TRANSGENIC
001,032,042,601,ACM,ADT,CASP3,COX,MARKERS,MEIER,PROGNOSTIC,SEVERAL,THREE
167,AMONG,FCS,GENERAL,GMM,IL6,KARNOFSKY,SCALE,SLEEP,VARIATION
1970S,BECAUSE,HOWEVER,NOVEL
100,174,BACKGROUND,CONCLUSION,FIRST,LABEL,METHODS,RATES,RESULTS,TREATMENT
001,025,945,947,APC,BACKGROUND,BPH,CONCLUSION,FXR,LABEL,LPC,LXR,METHODS,RAR,RESULTS,RXR,TMA,TNF
112,115,174,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MRI,NAVIGATION,OBJECTIVE,OBJECTIVES,PRIMARY,RESULTS,SUSPICIOUS,T2W,THERE,UROSTATION
300,956,BACKGROUND,CONCLUSION,HOWEVER,LABEL,METHODS,PSA,RESULTS,TRANSIENT
AIM,ASF,BACKGROUND,CONCLUSION,IGF,JANUARY,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,RESULTS
728,ADT,AIM,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,THEIR
169,961,ADC,CHO,CIT,CONCLUSION,FIFTY,LABEL,LRM,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
555,KOLMOGOROV,PATIENT,SINCE,SMIRNOV
CTV,D95,HOWEVER,INTENSITY,JAPAN,LOW,OCTOBER,PTV,REGULAR,THEREFORE,THESE,V95
946,DU145,EXOGENOUS,KNOCKDOWN,LNCAP,NODAL,PC3,REDUCED,RWPE1,SIMILAR,SKI,SMAD2,SMAD3,TGF,WPE
160,177,438,DRR,EUCLIDEAN,THERE
AMONG,BETWEEN,GLEASON,LYMPHATIC,MEANWHILE,PSA
000,113,130,192,201,240,337,3DCRT,529,586,663,816,939,FTE,GAMMA,JANUARY,JAPAN,KNIFE,LINAC,MARCH,PCS,RADIOLOGY,ROS,SOCIETY,THERE,THESE
INTRA,PAI
100,125,DIGITAL,FIRST,HOWEVER,THEREFORE,THIRD
ALTERED,DU145,LNCAP,THESE
145,611,945,946,ANEUGENIC,G21,GENISTEIN,GENOTOXIC
169,AKT,AMONG,COPYRIGHT,FISETIN,INC,USING
145,945,946,947,AMONG,FURTHER,GPCRS,LNCAP,MCR,MTT,PC3,SHU9119,THEIR
SIADH
ACUTE,BACKGROUND,BLADDER,COLORECTAL,CONCLUSION,DEC,ESOPHAGEAL,HODGKIN,INCIDENCE,INDIA,JAN,KASHMIR,LABEL,MATERIALS,METHODS,MYELOMA,NON,OVARY,PATTERN,RCC,RESULTS,STOMACH,URINARY
100,169,400,ALONG,AUC,COPYRIGHT,DIFFERENT,INTEGRATED,ISSUE,SEREX,SERPA,SPECIAL,TAA
169,ALZHEIMER,COPYRIGHT,INC,PARKINSON,PATHOLOGY,PUBLISHED,SOCIETY
169,945,946,CONSISTENT,COPYRIGHT,CXCR4,DU145,INC,LNCAP,PC3,PCA,THESE
169,791,ADDITIONAL,BACKGROUND,COPYRIGHT,DRE,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,SETTING,T2B,THESE,UROLOGY
169,B13,BACKGROUND,COPYRIGHT,HAPLOTYPE,LABEL,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,STOCKHOLM,SWEDISH,UROLOGY
169,241,AROMATASE,COPYRIGHT,EARLY
169,COPYRIGHT,INC,MEDLINE,TODAY
150,169,174,200,ANTIGEN,ATTENTION,BACKGROUND,BXT,CASES,CONCLUSION,COPYRIGHT,DOSIMETRY,GLEASON,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RADIATION,RESULTS,SCORE,SYMPTOM,THERE
169,22RV1,CONCLUSION,COPYRIGHT,DU145,GOLGI,GOLM1,HOWEVER,INC,LABEL,LNCAP,METHODS,OBJECTIVE,RESULTS,THERE,THESE,WESTERN
169,COPYRIGHT,FINALLY,FUNCTIONAL,HOWEVER,INC,PET,SENSITIVE,SPECT,THERE
020,042,044,120,169,967,AMONG,BACKGROUND,CONTINENCE,COPYRIGHT,FURTHER,JANUARY,LABEL,LRP,METHODS,OBJECTIVE,OUTCOME,PEARSON,PSA,PUBLISHED,RESULTS,SETTING,WHITNEY
001,003,012,100,112,169,183,203,212,290,328,396,AFTER,BACKGROUND,COPYRIGHT,DFS,DSS,FIFTY,FOCAL,LABEL,METHODS,OBJECTIVE,OCTOBER,OUTCOME,PSA,PUBLISHED,RESPECTIVE,RESULTS,SALVAGE,SETTING,SUFFICIENT,UROLOGY
ABERRATION,BACKGROUND,CCNE1,CNA,LABEL,MYC,OPERATING,RESULTS,SCA,SMART,SOMATIC,SUPPORTED,SYSTEMATIC,THREE
FINALLY,THESE
500,552,956,AFTER,LABEL,METHODS,MHZ,OBJECTIVE,OBJECTIVES,RESULTS,SIXTEEN,SONOGRAPHY
BACKGROUND,DWI,LABEL,MEDLINE,METHODS,MRI,MRS,RESULTS,SURFACE,SYSTEMATIC
169,183,CONCLUSION,GENERAL,GEORG,GPS,IDEALLY,IDM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,STUTTGART
945,947,948,ACTIVATION,HOWEVER,TMT,USING
000,200,500,BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS,WHETHER
025,062,160,169,177,236,300,COMPARISON,COPYRIGHT,DTA,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PTV,PURPOSE,RESULTS
005,169,188,218,274,326,ADT,BASED,COPYRIGHT,FAVORABLE,FFF,GLEASON,INC,LABEL,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RECURSIVE,RESULTS,T1C,T2A,T2B,T2C,THREE
169,COPYRIGHT,CROWN,EFFECTS,INC,LABEL,MANAGEMENT,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,STUDIES,SUBJECTIVE,THESE,TISSUES,TOTAL
169,241,CHOLINE,COPYRIGHT,MRI,PET,PSA
112,210,341,490,BACKGROUND,BECAUSE,END,LABEL,METHODS,PROGRAM,RESULTS,SWEDISH
001,016,144,183,327,AMICO,GLEASON,LABEL,LRP,METHODS,NRS,OBJECTIVE,RALRP,THERE,THEREFORE
001,118,18K,266,32K,34K,46K,473,666,AFTER,BACKGROUND,CHARGES,COLLEGE,CRS,INCREASING,INPATIENT,LABEL,LOS,MEN,METHODS,MIP,NATIONWIDE,NSQIP,OBJECTIVE,PROGRAM,PURPOSE,QUALITY,RESULTS,RRP,THC,ZIP
062,100,110,128,153,200,208,254,BACKGROUND,BETWEEN,JANUARY,LABEL,LRP,METHODS,OBJECTIVE,PSA,PURPOSE,RADICAL,RESULTS,THERE
169,629,702,853,917,BJU,BOOTSTRAP,EPE,GLEASON,HOPKINS,JANUARY,JOHNS,LABEL,MEN,METHODS,OBJECTIVE,PSA,RESULTS,T1C,T2B,T2C
ICP,III,NGF,PKH
177,178,179,946,AFTER,MBQ,PCA,SPECT,THESE,WBC
231,945,946,ATTACHMENT,ERK,MCF,MDA,MEK,MLC,RAF,RAS,SKOV3,TEM,THESE
103,169,GSTP1,INC,INDUCTION,LNCAP,ROS,RWPE1,SILENCING,THESE,WILEY
001,169,200,204,ASIAN,CHINESE,COPYRIGHT,EASTERN,ERG,ERK,GLEASON,INC,MEK,RAF,RAS,TMPRSS2,USING,V600E,WESTERN,WILEY
178,313,505,AAM,AFRICAN,LOUISIANA,NORTH,PATIENT,PROJECT,SINCE
AGGRESSIVE,FOXP3,HOWEVER
006,047,373,A28,AUSTRALIAN,HLA,IIM,SIR,SOUTH,THERE
949,99M,ACA,HOWEVER,HYNIC,SPECT
169,945,AKT,CK2,COPYRIGHT,IAP,LNCAP,LTD
CSF,PAP,SIP,SIPULEUCEL
169,ALTOGETHER,ATM,BASEL,BRCA1,COPYRIGHT,FINALLY,KU55933,PC3
EXTENSIVE
309,343,442,628,686,BACKGROUND,DIETARY,FFQ,HODGKIN,LABEL,METHODS,NHL,ORS,RESULTS
009,177,181,328,BACKGROUND,BPH,DIAGNOSIS,EXPRESSED,HOWEVER,LABEL,METHODS,PSA,RESULTS,SERUM
947,ADT,ASC,CASODEX,PCA,THEREFORE,USING
001,169,190GY,192,229,4GY,5GY,AMONG,BETWEEN,CONCLUSION,COPYRIGHT,GLEASON,GRADE,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SEVEN
AKT,PARTICULAR
169,ACADEMY,DENOSUMAB,RANKL
177,INCREASING,LABEL,METHODS,MHZ,MRI,OBJECTIVE,PURPOSE,RESULTS,TREATMENT,TREATMENTS
286,948,HDR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
125,218,265,BESIDES,D10,D90,ESTRO,GEC,LABEL,METHODS,NDR,OBJECTIVE,PATIENT,PID,PURPOSE,RESULTS
225,264,ACT,DSS,INSURANCE,IRB,KAPPA,LABEL,LEAVE,METHODS,MRI,OBJECTIVE,PURPOSE,RATER,RESULTS,SEGMENTED,SEVEN,SVM,THERE,THESE
ADVERSE,CEDIRANIB,STUDIES
946,CONSISTENT,TRAMP
946,ACUTE,BCL,CONSISTENT,GSK,HOWEVER,MCL,PPC,THESE,TRAIL
003,046,106,10Q21,129,12P12,15Q26,17P13,17Q21,215,791,LHCGR,NR2F2,PRMT6,SEX,SLCO1B1,T2D,TDGF3,THESE,UGT2B15,USING
390,524,CONSISTENT,GLY,KENNEDY,PRO,REMARKABLY,SIMILARLY
169,COPYRIGHT,VCH,WILEY
190,193,CONCLUSION,DLT,GRADE,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SILTUXIMAB,THESE,TOXICITIES
014,113,139,483,571,60S,897,AIM,AUD,AUD12,AUD17,AUD19,AUD32,COSTS,EUR,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
177,CHI,KAPPA,LABEL,METHODS,OBJECTIVE,PERFORMED,PURPOSE,RESULTS,RTE
169,946,COPYRIGHT,FOLLOWING,LTD,PEG
104,169,177,297,635,BACKGROUND,FURTHER,LABEL,METHODS,RESULTS
BACKGROUND,DESPITE,DISCUSSION,GERMANY,LABEL,METHODS,PROJECT,TRIAL
34A,COMPARISON,DU145,IPA,LNCAP,PC3,PCR
000,231,600,700,ACCORDING,ANGOLAN,BACKGROUND,CONCLUSION,ESPERAN,HOSPITALS,HOWEVER,IMPROVING,LABEL,MALARIA,METHODS,RESULTS,SAGRADA
FURTHER,GHRELIN
620,ABDOMINAL,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,THERE,WHITNEY
954,AREAS,COHEN,CONCLUSION,FIFTY,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS
CONCLUSION,LABEL,OBJECTIVE,PET
BACKGROUND,DENMARK,FRAILTY,LABEL,METHODS,RESULTS,STATISTICS
490,BACKGROUND,BLACK,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
169,AMONG,ARG,BSTU1,COPYRIGHT,HPV,INC,IRANIAN,PCR,PCRRFLP,PRO,WILEY
954,AKT,DU145,ERK,JNK,JUN,LNCAP,MAPKS,MMP,MTT,USING
1085949,121,ADULT,AFTER,BACKGROUND,CONCLUSION,HRS,LABEL,METHODS,RESULTS
650,BACKGROUND,CONTINUED,DIAGNOSIS,LABEL,METHODS,MORTALITY,NETWORK,NINTH,ORGAN,RESULTS,SEVERAL
AIM,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,SMALL,THERE
103,ACCORDING,HORMONE,LABEL,METHODS,OBJECTIVE,PURPOSE,RAD,RESULTS
000,200,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,TUSCANY
233,BCG,CSS,DESPITE,LABEL,MEDLINE,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,TUR
CURRENT,CYP17,FDA,III
954,CHI,GLEASON,HOWEVER,MMP,PHENOTYPIC,PSA
SH3
000,100,BACKGROUND,CENTERS,CONCLUSION,CONTROL,DISEASE,HOWEVER,INSTITUTE,LABEL,METHODS,RESULTS,THERE,USING
CAA,HGPIN,NEP,PCA,SSTRS,TAKEN
169,COPYRIGHT,LTD
388,496,BACKGROUND,CONCLUSION,LABEL,RESULTS
169,946,COPYRIGHT,INC,WESTERN
124,169,945,946,ACCEPTABLE,COPYRIGHT,CURRENT,ESI,PCA,PEI,PRECISION,PSA,SPE
001,169,358,406,COPYRIGHT,GENOTYPING,INC,PCR,SNP,THREE
001,020,036,100,120,137,169,301,309,369,430,561,760,AKT,AMICO,AMONG,AUTHORS,BJU,INVENTORY,IQR,JANUARY,LABEL,LNS,LNY,LOW,MAY,MEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE
CAUCASIANS,MED,MEDLINE,OVERALL,PUB,THEREFORE,V109G,WEB
OVERALL,THERE,TREATMENT,UNION
001,004,169,267,AFRICAN,AMERICANS,ANTONIO,BACKGROUND,COX,HISPANICS,LABEL,METHODS,PSA,RESULTS,SAN
008,013,023,026,035,717,CALIFORNIA,EPHX1,GSTM1,GSTP1,GSTT1,PCA,PTGS2,RED,SNP
400,792,954,CALIFORNIA,CONCLUSION,DISCUSSION,FAVORABLE,FURTHER,LABEL,MATERIALS,METHODS,OBJECTIVE,PERMANENTE,REPORTS,RESULTS,SAS,SCENT,TRAINED
169,AKT,BACKGROUND,COPYRIGHT,FOXO1,INC,LABEL,LNCAP,METHODS,RESULTS,TRANSITION,WILEY,WORTMANIN
032,122,169,212,263,303,448,655,776,946,ADT,BACKGROUND,COPYRIGHT,COX,GLEASON,HOWEVER,INC,LABEL,METHODS,NORWEGIAN,PCA,PSA,RESULTS,STATISTICS,WILEY
008,046,118,169,173,291,743,BACKGROUND,BETWEEN,COPYRIGHT,DETECTION,ERG,GLEASON,GRADE,INC,LABEL,METHODS,PCA,PSA,RESULTS,TMPRSS2,UNIVARIATE,WILEY
169,COPYRIGHT,ERG,ETS,PSA,RESULTANT,SIX,SLC45A3,TMPRSS2
001,100,169,215,BACKGROUND,BECKMAN,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,PCA,PSA,RESULTS,ROC,WILEY
002,155,169,282,829,AUC,COPYRIGHT,GLEASON,INC,LABEL,LNI,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,WILEY
100,169,174,228,CALGARY,COPYRIGHT,DIGITAL,EIGHT,FURTHER,INTERVIEW,LABEL,LTD,METHODS,OBJECTIVE,RECORDING,RESULTS,SIXTY,STRUCTURED,VANCOUVER,WILEY
004,005,006,150,169,568,CIS,COPYRIGHT,COX,HODGKIN,HRS,INVERSE,NHL,NORWEGIAN,TFA
001,003,231,552,569,735,BETWEEN,GLEASON,HOWEVER,LABEL,MEN,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
145,169,231,47D,946,COPYRIGHT,FINALLY,INC,MDA,SILIBININ,WNT,WNT3A
H3K9ME3,TESTING
169,CA2,CACCS,COPYRIGHT,GLEASON,IRELAND,LNCAP,LTD,PCR,THESE,TMEM16A,TNM,WESTERN,WST
169,COPYRIGHT,HOWEVER,LTD
169,ATP,CLQ,COPYRIGHT,INC,LNCAP,MODULATION,PCA,TAKEN
169,176,177,179,360,COPYRIGHT,CTV,D30,D99,INC,MEDICAL,PTV,PUBLISHED,RESULTS
100,169,185,190,196,204,220,COPYRIGHT,DWI,INC,PMB,TEN
169,239,252,COPYRIGHT,INC,LNCAP,NPS,PATHOLOGY,PCS,PUBLISHED,SIXTEEN,SOCIETY,SVS
169,250,AEU,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,METHODS,PUBLISHED,RESULTS,SEVEN,THERE
046,132,169,414,718,AFTER,COPYRIGHT,CURRENT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RADICAL,RESULTS,UROLOGICAL
169,209,379,419,ACTUARIAL,CLOSE,COPYRIGHT,EDUCATION,INC,IQR,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,STATISTICS,THESE,UROLOGICAL,VITAL
015,169,174,COPYRIGHT,COX,EDUCATION,FAILURE,INC,LABEL,MALIGNANT,MATERIALS,METHODS,NOTABLY,OBJECTIVE,PREDICTORS,PUBLISHED,PURPOSE,RESONANCE,RESULTS,STENT,THREE,UROLOGICAL
169,174,AVERAGE,COPYRIGHT,EDUCATION,EIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,REMOVAL,RESULTS,TEN,TREATMENT,UROLOGICAL,UROLUME
100,101,145,150,169,177,3CM,414,4CM,CENTRAL,COPYRIGHT,DOSIMETRIC,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCANS,SOCIETY,THERE,THESE
00001,129,169,967,BACKGROUND,COPYRIGHT,DIGITAL,IMAGING,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,PCA,PEARSON,PUBLISHED,RADIOLOGY,RESULTS,SETTING,SOCIETY,UROGENITAL,WHITNEY,YATES
036,042,169,180,360,807,BACKGROUND,COPYRIGHT,COX,INC,LABEL,METHODS,RESULTS,THERE
169,945,946,AKT,COPYRIGHT,HENCE,LIVER,LTD,LXR,OXYSTEROLS,RECEPTORS,THERE,THESE
001,169,177,800,ADC,CONCLUSION,COPYRIGHT,DIFFUSION,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,USING
169,215,346,500,AUC,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROC,UROLOGICAL
169,945,946,ARA70,COPYRIGHT,DU145,DUE,EDUCATION,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RC165,RESULTS,RU486,TREATMENT,UROLOGICAL,WESTERN
100,169,176,945,946,ANDROGENS,BPH,COPYRIGHT,CROWN,DHT,ETOAC,FMP,LOWER,PUBLISHED
169,CBCTS,COPYRIGHT,CTS,CTV,DOSES,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RED,RESULTS
125,169,179,185,COPYRIGHT,FORTY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE
1990S,22RV1,PUBLISHED,WHILE
169,BASED,COMMITTEE,COMPETENCE,COPYRIGHT,DUE,FEDERAL,FUNDS,GKV,HOWEVER,INSURANCE,IQWIG,JOINT,MDK,MDS,PSA,PUBLISHED,STATUTORY
124,169,COPYRIGHT,DEPENDING,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,876,CENTERS,COLLEGE,COMPLIANCE,COPYRIGHT,EDUCATION,EFFORTS,GIVEN,INC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL,USING
045,069,169,285,372,AFTER,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,ROUTINE,THERE,UROLOGICAL
009,169,437,446,AMICO,COPYRIGHT,COX,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,UNIVERSITY,UROLOGICAL
122,154,169,179,208,276,945,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,002,013,015,022,028,169,732,AMONG,ASIAN,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,MINIMALLY,OBJECTIVE,OBTAINING,PATIENT,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
174,327,AMONG,DOCETAXEL,HOWEVER,III,SINCE,TAX
123,169,916,99M,BACKGROUND,CONCLUSION,COPYRIGHT,CROWN,HOWEVER,INC,LABEL,METHODS,PAI,PEGYLATED,PEGYLATION,PUBLISHED,RESULTS,SPECT,THESE,WHOLE

007,022,029,046,150,239,BACKGROUND,G16129A,GLEASON,LABEL,PRINCIPAL,PSA,RESULTS,T16224C,T16311C,T16356C,THESE,USING
CNA,SOMATIC
003,022,027,666,708,AKT,BACKGROUND,CHINESE,CONCLUSION,GLEASON,LABEL,METHODS,PCA,PSA,RESULTS
CDC42,CONVERSELY,ELECTRICAL,MIMICKING,NIPP1,NOTABLY,PP1,REMARKABLY,TAKEN,THESE
169,AKT
169,205,217,29B,529,COPYRIGHT,DU145,HOWEVER,LNCAP,MOL,PCA,RES
301,COU,III,MDV3100,SIPULEUCEL
001,102,11C,124,185,354,400,542,721,730,AFTER,ASTRO,AUC,BCR,CHOLINE,DETECTION,LABEL,MBQ,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,ROC,SIEMENS,STATISTICS,TOTAL
BCG,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THEREFORE
001,100,133,139,161,BACKGROUND,CONCLUSION,LABEL,METHODS,OPHIOLITES,ORS,PPS,RESULTS,SAMPLES,SIVAS
ACTIN,CHINESE,DU145,LABEL,LNCAP,METHODS,MTS,OBJECTIVE,PC3,PCA,PURPOSE,RESULTS,WHILE
126,169,618,AIM,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,LABEL,METHODS,NNT,NNTBL,OBJECTIVE,PSA,RCT,RESULTS,THERE,WHILE
169,BACKGROUND,BASEL,COPYRIGHT,ELECTRONIC,ENGLISH,LABEL,MATERIALS,MEDLINE,METHODS,PBX,PCA,RESULTS,SATURATION
009,169,193,AGE,BACKGROUND,BASEL,COPYRIGHT,COX,CUMULATIVE,FACTORS,GLEASON,LABEL,MEIER,METHODS,RESULTS
100,155,169,177,333,438,493,ADVERSE,AFTER,AIM,AMERICA,ASSESSMENT,AUSTRALIA,BACKGROUND,BLOOD,CONCLUSION,IPASS,LABEL,LATIN,METHODS,MORBIDITY,OBJECTIVE,OUTCOME,PARAMETERS,PSA,RESTORING,RESULTS,SOCIETY
ACP,PAP
176,III,INNOVATIVE,MRI,PC3
ATTACHMENT,C3D,EIA,EVALUATION,IGG,IGM,THOMSEN
169,BACKGROUND,COPYRIGHT,DSI,LABEL,METHODS,OVERALL,PATIENT,RESULTS,SOCIETY,STANDARDS
541,636,820,AMONG,BACKGROUND,HBSAG,HCV,LABEL,METHODS,MONITORING,RESULTS,THERE
AIM,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
137,184,26B,34C,375,99A,ALTERED,HNSCC,HOWEVER,PCR
AFTER,COX,STUDIES,THEREFORE
AUTONOMIC,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,THEREFORE
160,438,ACCORDING,APC,GLEASON,GSTP1,HOWEVER,ITALIAN,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,RUNX3,SNP,THESE
160,614,616,CASES,CMV,IGG,LABEL,METHODS,OBJECTIVE,PCA,PREVENTION,PURPOSE,RESULTS,TRIAL
001,151,160,205,352,369,503,574,CONCLUSION,LABEL,LIKELIHOOD,METHODS,OBJECTIVE,PURPOSE,RESULTS,SECONDARY,THERE,TORONTO,TURKU,UUT
200,946,AKT,MET,PC3,SILENCING,TAKEN,VALIDATION
002,0MM,169,5MM,BACKGROUND,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PLANS,PTV,PURPOSE,RESULTS,SWIFTER,VRX
169,947,BACKGROUND,COPYRIGHT,DENSITY,DVH,HUS,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PHA,POP,PTV,PURPOSE,RESULTS,ROI,WAB
003,025,039,047,128,198,393,476,AMONG,HOWEVER,IMPORTANT,USING
GLEASON,PCA
000,100,1990S,AGE,BACKGROUND,CONCLUSION,DENMARK,LABEL,METHODS,POPULATION,PSA,RESULTS,WORLD
104,106,169,BACKGROUND,COX,EPP,FINNISH,LABEL,LTD,METHODS,OBJECTIVE,PATIENT,PSA,RESULTS,THESE,WILEY
171,183,364,367,731,ADVERSE,AFFAIRS,AMONG,BACKGROUND,DEPARTMENT,JANUARY,LABEL,METHODS,PIVOT,PROGRAM,PSA,RADICAL,RESULTS,STUDIES
169,COPYRIGHT,INC,NOVEL
RESULTS
946,CD49F,ESTROGENS,FINALLY,LIN,SUBSEQUENT,TROP2,VE2
22RV1,ADP,FINALLY,LNCAP,MAR,PC3,SATB1,THESE,VARIATIONS
946,947,950,963,DESPITE,EXPRESSION,PC3,RAC,WHILE
GASSIST,INCREASING,MICROARRAY
001,101,103,114,184,MEIER,NADIR,PSA,TTN
10S,12A,14B,169,4AS,6AR,6AS,6BR,8AR,945,946,956,APOPTOSIS,COPYRIGHT,CYANO,HEP,MIA,THESE,VCH,WILEY
169,181,786,945,ADR,BAUERENYL,CNS,COPYRIGHT,GOCHNATIA,LTD,MCF,NCI,OVCAR,RES,TGI,WILEY
001,169,177,956,COPYRIGHT,ESTIMATED,GLEASON,INC,TEN,WILEY
169,177,945,ACT,BACKGROUND,COMPLEX,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,PLA,PSA,RESULTS,THESE,WILEY
150,169,181,215,300,BACKGROUND,COPYRIGHT,INC,LABEL,LEAVING,METHODS,RADICAL,RESULTS,RIN,USING,WILEY
150,AFRICAN,SOUTH
023,069,239,399,537,645,703,761,804,823,945,BACKGROUND,LABEL,METHODS,POD,RESULTS,SCORE,SYMPTOM
29A,LUC,PCA,PCR,PGK,UTR,WESTERN
INDIA
954,963,BACKGROUND,CONCLUSION,DHMEQ,INDUCIBLE,LABEL,LNCAP,METHODS,RESULTS
005,284,300,400,BACKGROUND,CONCLUSION,DL0,DL1,DLT,LABEL,MAXIMUM,METHODS,MTD,REFRACTORY,RESULTS,SEVENTEEN,TEN
BACKGROUND,CONCLUSION,LABEL,MEN,METHODS,PSA,RESULTS,SCREENING,THESE,USING
008,044,AMONG,BACKGROUND,CONCLUSION,INCLUDING,LABEL,MARCH,MEIER,METHODS,PAGET,PDB,RESULTS,UNTIL
169,GROUP,HOWEVER,UROLOGICAL,WORKING
169,231,233,CELLULAIRE,COPYRIGHT,DESPITE,DUE,EWING,FRANCAISE,STEAP
169,683,ADVERSE,BRITISH,FURTHER,JOURNAL,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SOCIETY,TAK
285,371,ALLELIC,MTR,SHMT1,SIBERIA
AKT,M93,RED,RYR,THESE
198,946,AUNPS,LAMININ67R
ADVERSE,CONTEXT,HEALTHCARE,LABEL,MARCH,METHODS,OBJECTIVE,PCO,PSA,PURPOSE,QUALITY,RESULTS,SOCIETY
BACKGROUND,LABEL,METHODS,PSA,RESULTS,THESE,TREATMENT
000,145,HDAC3,HDAC4,LNCAP,MTT,OBVIOUSLY,PRESUMABLY,THEREFORE,WESTERN
FORCE,LABEL,METHODS,PREVENTIVE,PSA
LABEL,OBJECTIVE,OTHER,PURPOSE,RESULTS,SUMMARY,THESE
132,145,AIM,CELLS,CONCLUSION,EXPRESSION,HOWEVER,INCREASING,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,T286A,WESTERN
169,946,AMP,COPYRIGHT,HOWEVER,IMPORTANT,IRELAND,LTD,OBESITY
002,007,009,032,358,AFRICAN,AFTER,BACKGROUND,EIGHT,GIVEN,LABEL,METHODS,PCA,RESULTS,SNP,UNIVERSITY
615,7TH,DU145,PBS
1990S,PCA,PSA,SINCE
152,BACKGROUND,CHINA,CHINESE,COX,GLEASON,JANUARY,LABEL,MARCH,METHODS,PSM,RESULTS,TNM
DECREASES,DIM,HDAC1,HDAC2,HDAC3,HDAC4,HDAC6,HDAC8,HDACS,HISTONE,I3C,INC,INCREASED,LNCAP,PUBLISHED,TAKEN
BACKGROUND,DISABILITY,IDEALLY,INSTITUTE,LABEL,METHODS,NCI,RESULTS,THESE,YEARS,YLL
001,150,351,400,440,904,AFTER,BACKGROUND,BETWEEN,CLAVIEN,CONCLUSION,DINDO,III,LABEL,LND,METHODS,NODAL,OVERALL,RESULTS,UROLOGY,WHITNEY
945,AMACR,BACKGROUND,BLINDED,COA,LABEL,METHODS,RESULTS,SIXTY,THERE,UNASSIGNED,VIRTUAL
APPRAISAL,BLACK,CENTRAL,COGNITIVE,CONTROLLED,DOWNS,DVD,ENGLISH,IDM,KNOWLEDGE,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PCA,QOL,RESULTS,REVIEWS,SOURCES,SUBJECT,SYNTHESIS,SYSTEMATIC
121,883,KUB,LABEL,MARCH,MATERIALS,METHODS,MIGRATION,OBJECTIVE,PRE,PURPOSE,RESULTS
AT3,CONSISTENT,CWR22RV,DU145,FLEXX,HOWEVER,LNCAP,PPC,R3327,TAKEN,THROUGH
ADDITIONAL,AFTER,DEFINITIVE,HOWEVER,IMAGING,KEY,LABEL,MEDLINE,METHODS,MRI,NON,OBJECTIVE,OBJECTIVES,PCA,RESULTS,STS,THEREFORE
946,954,CONVERSELY,ENDOGENOUS,HDAC1,IKK,PAI,PKD,SILENCING,TAKEN,THESE

001,169,177,AFTER,BASEL,COMPARISON,COPYRIGHT,EARLY,HBO,JAPAN,LABEL,METHODS,OBJECTIVE,RESULTS
169,AIM,BACKGROUND,BASEL,COPYRIGHT,CURRENTLY,FOCUSED,HOWEVER,INTENSITY,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,RADIO,RECURRENT,RESULTS,SALVAGE,ULTRASOUND
FINALLY,TAKEN
AMONG,CHROMATIN,CONVERSELY,DEPLETION,DU145,EMT,EPIGENETIC,KNOCKDOWN,MMSET,MYELOMA,PCA,SET,WHSC1
001,043,169,594,AFTER,BACKGROUND,BASEL,COPYRIGHT,DIETARY,LABEL,MEN,METHODS,PSA,RESULTS,THERE
BENZO,CUMULATIVE,FFS,LABEL,METHODS,OBJECTIVE,PAH,RESULTS
169,945,946,ADT,BPH,COPYRIGHT,CYP11A1,CYP17A1,HSD17,IHC,INC,MALIGNANT,PATHOLOGY,PCA,PROTEIN,PUBLISHED,RECURRENT,SIX,SOCIETY
169,916,AKT,ATP,COPYRIGHT,INC,INHIBITION,KNOCKDOWN,NADPH,O3A,PC3,POTENTIAL,PRODH,PROLINE,TREATMENT
169,945,946,CNS,COPYRIGHT,ERE,LTD,MCF,TAKEN,THESE
169,BASED,CNR,COPYRIGHT,DCE,FLASH,GIVEN,HOWEVER,INC,MRI,SNR
169,COPYRIGHT,HOWEVER,INC,MRI,PET,THESE
001,003,004,008,033,169,317,427,587,ACTUARIAL,BETWEEN,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PURPOSE,RESULTS
120,169,176,180,240,AVERAGING,CALYPSO,COPYRIGHT,CORRECTION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
169,COPYRIGHT,EARLY,INC,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,RFS,SALVAGE,SRT,THERE
169,371,470,99M,AFTER,BACKGROUND,COPYRIGHT,IQR,LABEL,LND,LNS,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,SEVENTY,SNS,UROLOGY
001,026,050,169,280,300,563,621,778,COPYRIGHT,ESTIMATED,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PATIENT,PCA,PSA,RESULTS
169,CAP,COMPARISON,COPYRIGHT,DIFFERENT,FLA,INC,LABEL,LASER,MATERIALS,METHODS,OBJECTIVE,PDT,PROSTATIC,PURPOSE,RADIO,RESULTS,SEVERAL,THOSE
169,COPYRIGHT,DRE,HOWEVER,INC,PSA
169,COPYRIGHT,INC
003,169,AIM,ASSESSMENT,COLLEGE,CONCLUSION,COPYRIGHT,GREATER,HOWEVER,KARNOFSKY,KPS,LABEL,LTD,MANAGEMENT,MATERIALS,METHODS,OBJECTIVE,PROGRAM,PUBLISHED,RAPID,RESULTS,ROYAL,SYMPTOM
177,AUNPS,HRP,MWCNT,PSA,UNDER
001,003,317,337,967,ANOVA,BACKGROUND,COMPONENT,CONCLUSION,CURRENT,LABEL,MCS,METHODS,PCS,QOL,RESULTS,SUMMARY,WHILE
174,194,262,308,55208,700,814,BACKGROUND,CONCLUSION,ESI,FDA,LABEL,ORTERONEL,RESULTS,TAK
AGE,BPH,DIGITAL,DRE,MEN,PSA
HOWEVER,QOL
160AA,160CA,194,207,BACKGROUND,BECAUSE,EUROPEANS,HOWEVER,LABEL,MARCH,METHODS,NORTH,RESULTS,USING
680,824,945,947,BACKGROUND,CIS,COLORECTAL,LABEL,METHODS,OVARIAN,RESULTS,SCREENING,SERUM,TRIAL,VITAMIN
001,ADIPOKINE,FEW,GLEASON,PSA,SEVEN,SNP,THESE
120,916,BIOLOGICAL,ESTIMATED,EUD,KNOWLEDGE,LABEL,MAXIMUM,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SIB
000,218,945,ABOUT,ADT,MEANWHILE,POPULATION,PSA,TNF
946,CHANGES,EMT,FIBROBLAST,GLEASON,MMP,PROTEIN,RAF,RAS,TGF
174,DOX,DOXIL,MDR,NDC,NOTABLY,WHILE
PATIENT,USING
012,024,BACKGROUND,FIFTY,FURTHER,HOWEVER,LABEL,METHODS,PFS,RESULTS,THERE
BARRANDON,DU145,GREEN,LNCAP,PRIMARY,SCI,UNDER
WHILE
039,169,ADT,BACKGROUND,BECAUSE,CONVERSELY,COPYRIGHT,COX,CRT,END,INTENSITY,LABEL,METHODS,OBJECTIVE,OUTCOME,RESULTS,SETTING,UROLOGY
013,034,042,119,145,170,946,E12,ESOPHAGEAL,HOWEVER,THESE
AFTER,HEPATIC,MHV,RHV
HOWEVER,ROBOT
169,22R,956,957,COMPOUNDS,COPYRIGHT,OME,RESULTS,SAS
169,200,BESIDES,CONVERSELY,COPYRIGHT,GASTRIN,INC,MCF
001,169,182,229,640,COPYRIGHT,GEOGRAPHIC,HOWEVER,INC,INTEGRATED,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEXAS,WHITNEY
169,533,AFRICAN,CARIBBEAN,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,STRATIFIED,THOSE,TOBAGONIAN

22RV1,916,AD5,DU145,THESE
169,AUTHORS,BJU,DIFFERENT,INJECTION,LABEL,METHODS,OBJECTIVE,PROCEDURE,RESULTS,SPACING,THERE,THESE,UNLABELLED,V70
001,036,169,187,260,462,AUTHORS,BETWEEN,BJU,CONCLUSION,COX,DIAGNOSTIC,GLEASON,LABEL,LEVEL,METHODS,OBJECTIVE,PSA,PSM,RESULTS,UNLABELLED
169,621,660,AUTHORS,BASED,BJU,BSI,COX,FORTY,LABEL,MARCH,METHODS,OBJECTIVE,PSA,RESULTS,UNLABELLED
169,AUC,BJU,CONCLUSION,LABEL,LIBRARY,METHODS,OBJECTIVE,PCA,RESULTS,UNLABELLED
002,146,178,184,185,DVC,EBL,IMMEDIATE,LABEL,METHODS,OBJECTIVE,OPERATIVE,PURPOSE,RESULTS,THERE
169,LABEL,METHODS,NORMFINDER,OBJECTIVE,OBJECTIVES,REFERENCE,RESULTS,SERUM,SNORD43,SNORD44,SNORD48,UROLOGICAL
CCCTC,SLC45A3,USING,ZHANG
169,343,445,788,AFRICAN,BACKGROUND,CAUCASIAN,COPYRIGHT,GREATER,LABEL,METHODS,RESULTS,SOCIETY
169,240,295,299,594,ADVERSE,BACKGROUND,CARDIAC,COPYRIGHT,ENDOTHELIN,LABEL,METHODS,PERIPHERAL,RESULTS,SECONDARY,SOCIETY,ZIBOTENTAN
EMT,MMP,RAC1B
CENTROSOME,HOWEVER,RED,ROS
20A,945,MDA,PCA
169,177,30S,COPYRIGHT,FIRST,HOWEVER,SINCE
169,GLEASON,S1P,SPHK1,SPL,TMA
176,BACKGROUND,BALANCING,CONCLUSION,LABEL,MASTERPLAN,METHODS,NUCLETRON,PLANS,RESULTS,SINCE
103,104,105,BACKGROUND,LABEL,LABELLING,METHODS,MNCL2,MNCL2IN,MRI,NOD,RESULTS,SPIOS
COMPOUNDS,EFFECTIVE,SEVERAL,SH2,SRC
BACKGROUND,CPG,G2M,HP1,LABEL,LBR,LNCAP,MECP2,MUTATIONS,NIH,PROTEIN,RESULTS
169,HOWEVER,MIGRATION,NOD,PC3,PTN
ABI,III,NOVEL,PGP
169,17AAG,BLACKWELL,CONCLUSION,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHING,RESULTS
008,ANXIETY,EMOTIONAL,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS,SUPPORT,THREE,WAITING
AFTER,BACKGROUND,BIOSPEC,C57,CONCLUSION,III,LABEL,MATERIALS,METHODS,MNTNHEX,MRI,OBJECTIVE,OBSERVABLE,PARAVISION,PHANTOM,PURPOSE,PYP,RESULTS,THESE
052,071,127,131,142,169,626,722,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,METHODS,PSA,REGRESSION,RESULTS,STRATIFIED,TOTAL,TVS,WILEY
169,6331T,732,745,818,825,BACKGROUND,COPYRIGHT,DENSITY,FACTORS,INC,LABEL,LOW,MELBOURNE,METHODS,PCA,RESULTS,RFPCS,WHILE,WILEY
002,169,252,BACKGROUND,CONCLUSION,COPYRIGHT,INC,KLF,LABEL,LNCAP,METHODS,MOUSE,MSP,OVERALL,PCR,RESULTS,TRAMP,TRANSGENIC,TREATMENT,WILEY
021,700,BASED,CAUCASIANS,CIS,HOWEVER,ORS,PTGS2,SIMILARLY
160,DIFFERENT,WHILE
945,946,ACTIVATION,AKT,BACKGROUND,CHRONIC,CONCLUSION,HOWEVER,INHIBITORS,LABEL,METASTATIC,METHODS,PC3,PCR,RESULTS
001,007,157,569,726,CIS,FDA,III,INCIDENCE,OVERALL,PERTUZUMAB,PREVENTION,SCIENCE,SOCIETY,WEB
LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
473,AGC,AKT,ANTITUMOR,AT13148,ATP,BT474,CCT128930,INDUCTION,LABEL,MES,METHODS,OBJECTIVE,PC3,PIK3IP1,PKA,PURPOSE,RESULTS,RHO,SGK
215
214,525,ADDITIONAL,AMONG,C10,COX,DIETARY,SWEDISH
100,160,169,562,956,ADP,COPYRIGHT,HUVEC,LNCAP,LTD,THREE,VLAIP
177,954,DU145,LABEL,LNCAP,LOW,METHODS,OBJECTIVE,RESULTS,WESTERN
185,368,BETWEEN
BENEFITING,DESPITE,FDA
001,005,083,432,514,683,732,845,IHC,QDS,QUANTUM
MRI
PC3,RESULTS
AMP,CAM,CAMKI,CAMKS
945,ACCORDING,ACTIVATION,BASED,THESE
047,162,177,496,533,566,657,708,786,847,99M,AUC,CONCLUSION,DIAGNOSTIC,GLEASON,JANUARY,LABEL,MDP,METHODS,MRI,OBJECTIVE,PSA,RESULTS,SUR,WHOLE
BMI,CONVERSELY,IGF,INHIBITION,JUN
132,169,945,946,956,AFTER,COPYRIGHT,ELISA,HIF,JMR,MMP,PC3,SEVERAL,THESE,WESTERN
104,125,203,219,323,956,AUC,BACKGROUND,LABEL,MEN,METHODS,PSA,RESULTS,WBC,WHITE
000,100,118,142,300,600,700,800,BACKGROUND,BPH,GLEASON,ICERS,INITIATING,LABEL,METHODS,PATIENT,RESULTS
CTC,CURRENT,MRD
AREAS,BACKGROUND,COVERED,HOWEVER,LABEL,METHODS,ONGOING,OPINION,OVERALL,QUESTIONS
100,125,181,235,250,295,786,ADR,AMPHIBIAN,ANURA,BACKGROUND,BUFONIDAE,CONTEXT,HOWEVER,LABEL,MCF,MDR,METHODS,NCI,OBJECTIVE,OBJECTIVES,OVCAR,RESULTS,STEVAUX
100,164,181,407,500,AMONG,BACKGROUND,COMPOSITAE,CONCLUSION,CONTEXT,DISCUSSION,ISOLATION,LABEL,MATERIALS,METHODS,MTT,NMR,OBJECTIVE,RESULTS,TAGETES
DEP,HOWEVER,LNCAP,SEPARATION
169,ALZHEIMER,AUTHORS,BPH,FURTHER,III,JPP,KEY,LABEL,MEGESTROL,OBJECTIVE,OBJECTIVES,PHASE,RESULTS,ROYAL,SOCIETY,STUDIES,SUMMARY
169,945,954,ADP,AUTHORS,BCL,BRITISH,COMPLEMENT,DU145,IMMUNOLOGY,SOCIETY,TNF
100,107,CONCLUSION,LABEL,METHODS,MTT,OBJECTIVE,PCA,PR7,RESULTS,THERE,TRANSWELL
100,BPH,CONCLUSION,ELIVISION,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS
ACUTE,BACKGROUND,BOLOGNESE,COMPLIANCE,DERMA,FARMA,FURTHER,ITALY,JANUARY,LABEL,MATERIALS,METHODS,OCTOBER,RESULTS
415,AFTER,BACKGROUND,DEPRESSION,LABEL,METHODS,RESULTS,SCALE,STUDIES,WISCONSIN,WLS
AHX,AIM,BASED,BBN,CONCLUSION,CONJUGATES,DPHE6,LABEL,MATERIALS,MAXIMUM,METHODS,NH2,OBJECTIVE,RESULTS,TOMOGRAPHY
ANTIGEN,PAP,PROSTATIC,PSA
108,110,CAP,CIS,CONCLUSION,GLEASON,INCIDENTAL,LABEL,METHODS,OBJECTIVE,PIN,PRE,PROSTATIC,PURPOSE,RESULTS,TCC
343,ALZHEIMER,DISEASE,ENRICHMENT,FIRSTLY,HCM,HUNTINGTON,KNOWLEDGE,MEANWHILE,PARKINSON,SET,THIRDLY
739,764,AUC,BMI,BPH,CIH,INSTITUTE,MEDICAL,PREDICTIVE,PSA,TOKYO,TPV,UNIVERSITY
001,004,014,032,041,045,III,INCREASED,KPNA2,RECURRENT
101,177,212,216,315,392,612,676,677,718,824,830,956,ACCORDING,BACKGROUND,BPH,DRE,HOWEVER,LABEL,MATERIALS,METHODS,OCTOBER,PSA,QOL,RESULTS,SCORE,SUSPICION,SYMPTOM,THEREFORE,USG
100,154,181,CONCLUSION,ECE,EPC,GLEASON,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PATHOLOGY,PSA,RESULTS,RRP,SVI,TESLA
HOWEVER
MET,MOLECULAR,RET,SRC,UNTIL
THESE
GLEASON,SOCIETY,UROLOGICAL
176,408,DIFFERENT,MRI,REFERENCE,T1W,T2W,TFE,THEREFORE,WAC,WHILE
BACKGROUND,CONCLUSION,DOCETAXEL,GROUP,III,LABEL,METHODS,PSA,RESULTS,WORKING
ATAD2,MYC,USING
169,ADDITIONAL,ASSESSMENT,BACKGROUND,COMMITTEE,CONCLUSION,CONTEXT,COPYRIGHT,DESPITE,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RADIATION,RESULTS,SCALE,SYMPTOM
032,169,ADJ,BACKGROUND,COMMITTEE,CONCLUSION,CONTEXT,COPYRIGHT,EIGHT,FORTY,INC,LABEL,METHODS,MP3,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SYMPTOM
169,COPYRIGHT,FABRY,FPI,PEROT,PSA
169,231,945,946,COMPOUNDS,COPYRIGHT,JONES,MCF,MDA,MRC,OPPENAUER,REDUCTION,SAS,SEO
169,COPYRIGHT,IMAGING,INC,INSTITUTE,NETWORK,QIN
169,COMPLEX,COPYRIGHT,DYNAMIC,INC,MRI,SEVERAL,THESE
169,785,919,CLINICO,CONCLUSION,COPYRIGHT,DESPITE,GLEASON,INC,JANUARY,LABEL,METHODS,OBJECTIVE,PATHOLOGIC,PSA,RESULTS,T1C,THERE
001,002,133,169,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,THEREFORE
169,BACKGROUND,BPH,CONCLUSION,COPYRIGHT,GUANOSINE,LABEL,MATERIALS,MEDLINE,METHODS,OXIDE,PCA,PSA,RESULTS,RHO,SAS
177,BBN,FINALLY,PC3,PEG,PET
044,100,105,124,128,141,ADVERSE,BACKGROUND,CSS,GLEASON,HOWEVER,LABEL,METHODS,NETWORK,PHOENIX,PSA,RESULTS,SEVERAL,THERE,THESE
169,COPYRIGHT,INC,K68,K71,NLS,SIRT3
170,200,282,317,470,475,BACKGROUND,BMI,CLINICALLY,III,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERUM
00001,169,ADT,ARR,BCF,CANCERLIT,COPYRIGHT,DESPITE,INC,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
COLLOIDAL,DESPITE,FURTHER,THESE
ADT,AST,REGARDING,SINCE,THEREFORE
INTEGRATED,THESE,VALIDATION
ACC,ALTOGETHER,AMP,ATP,COA,DU145,HOWEVER,INHIBITION,LNCAP,NAD,NAMPT,PCA,SIRT1,SIRT3
141,191,19B,330,620,622,92A,92B,ABOUT,MPC,MPS,PPC,TGF,THESE,UTR
33342,34A,CYA,DU145,HOECHST,PC3,PTX,STUDIES,TREATMENT,TXR
181,ASTERACEAE,BR3,GNAPHALIUM,LNCAP,MCF,MIA,MTT,PC3,THESE
145,177,947,BACKGROUND,DROSOPHILA,LABEL,METHODS,MS0017509,MS0019266,RESULTS
THEIR
169,ANTIBODIES,CD105,CHINESE,CONCLUSION,FIFTY,LABEL,METHODS,MTD,OBJECTIVE,ONGOING,PURPOSE,RESULTS
PROSTATIC,STUMP
DIC,PSA,SEVERAL,THEREFORE
087,FURTHER,MAB,PSA
134,160,967,CASTRATION,ERG,SAMPLES,TMPRSS2
001,007,083,806,967,GLEASON,HOWEVER,STUDIES
609,945,946,ACTIVATION,AKT,AP7,BACKGROUND,CONCLUSION,HOWEVER,LABEL,METHODS,PC3,RESULTS,TRAMP,USING
100,300,400,600,ECLIPSE,MUS,THESE,TREATMENT
DEFORMABLE,DICOM,IGART,IRB,LINAC,THEREFORE,THESE,THREE,USING
CLARITY,DESPITE,MEDICAL,SEVENTEEN,SUBSEQUENT,ULTRASOUND,VARIATIONS
001,007,025,ADOBE,AGE,BIOIMAGENE,CS3,FREQUENCY,HOWEVER,MAGIC,PAX2P,PHOTOSHOP,PIXEL,SCOUT
ERG,ETS,EWING,EWSR1
22RV1,954,BCL,FOS,HOWEVER,JUN,PNT1A,SEVERAL,THEREFORE
AFTER,BCL,JNK,JUN,MTT,PCR
169,182,400,COPYRIGHT,FEDERATION,KI67LOW,PUBLISHED,SOCIETIES
125,169,946,COPYRIGHT,INC,LABEL,LNCAP,MCF,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,RM2,THEREFORE
180,4MG,4NG,5MG,60G,64Y,APPLIED,BPH,CONCLUSION,FOLEY,GEL,INDEX,JLS,LABEL,METHODS,OBJECTIVE,PATIENT,POINT,PSA,PURPOSE,RESULTS,USA
240,520,GLEASON,LABEL,MATERIALS,METHODS,NEITHER,OBJECTIVE,PSA,PURPOSE,RESULTS,SURGERY,T2C
177,GLEASON,III,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,PSA,PURPOSE,RESULTS,THERE
600,ASSESSMENT,CAYNE,LECHNER,MAY,MEN,NURSING,SOCIETY,THESE
AG494,AKT,ATP,DU145,ERK,F12,INHIBITION
COX,GLEASON,HOWEVER,PCR,PSA,SIMILAR,THERE,VASOACTIVE,VIP,VPAC1,VPAC2
016,018,027,028,038,043,047,049,137,160,193,956,CONVERSELY,GLEASON,LABEL,LOW,METHODS,NON,OBJECTIVE,PSA,PURPOSE,RESULTS,ROC,ULM,UNIVERSITY
000,001,032,160,177,873,AAS,AMERICANS,CAS,CAUCASIAN,ETHNICITY,FORMULA,PSA,THERE,WHILE
169,AVAILABLE,BACKGROUND,CALIFORNIA,CONTEXT,COPYRIGHT,FURTHER,ITEMS,KEY,LABEL,METHODS,OBJECTIVE,PCA,PREFERRED,PUBLISHED,RADICAL,REPORTING,RESULTS,REVIEWS,ROBOTIC,RRP,SECTION,SURGEON,SYNTHESIS,SYSTEMATIC,UROLOGY
169,BIOLOGY,COPYRIGHT,FEDERATION,INC,PUBLISHED,ULTRASONIX,ULTRASOUND,USA,WORLD
000,100,169,ATM,CLEARLY,COPYRIGHT,ERG,FEDERATION,PUBLISHED,SOCIETIES,THEREFORE,TMPRSS2
169,AKT,AUTHORS,BASIC,LNCAP,PC3,RAPAMYCIN,SOCIETY,TOXICOLOGY
116,169,CONCLUSION,INDICATION,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,OVERALL,RESULTS,ROUGHLY,TIS,UROLOGICAL
RAMAN,SHM,TRM
169,233,ADVERSE,CONCLUSION,EARLY,JANUARY,LABEL,METHODS,MINIMALLY,OBJECTIVE,OBJECTIVES,OCTOBER,OVERALL,PATHOLOGY,PSA,RESULTS,UROLOGICAL,UROLOGISTS
AREAS,ASH,BACKGROUND,COVERED,LABEL,METHODS,OPINION,SCLEROSTIN
231,BCR,CONCLUSION,COX,EXCLUDING,LABEL,MEIER,METHODS,OBJECTIVE,PCA,RESULTS,SUPPORTED,UNIVARIATE
945,BACKGROUND,E74,ETS,LABEL,RESULTS
295,BASED,ERG,LNCAP,PSA,TMED3
CELLS,EXOCYST,METASTASIS,REGULATION
100,181,ABCA1,CELLS,CHANGES,HMGCR,LDL,LNCAP,PCR,PWR,THESE,TREATMENT
650,673,BASED,CIT,CONSISTENT,GALK2,HOWEVER,ICK,KNOCKDOWN,LNCAP,MAP3K11,PSKH1,SER
7F5,BACKGROUND,CONCLUSION,FIRST,GOLDMAG,LABEL,METHODS,MRI,PCA,RESULTS,TAS
169,THESE
ETS,FURTHER,HOWEVER,LNCAP,LUC,MMP13,PC3,SAM,SPDEF,THESE,USING,UTILIZING
169,542,BACKGROUND,CONCLUSION,IGF,LABEL,METHODS,NUTRITION,ORS,RESULTS
ABROGATION,DUE,EXPRESSION,MYC,SIMILARLY,TRAMP
100,IAT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,WHILE
160,215,300,ACTIVATION,CONCLUSION,HOWEVER,INJECTION,LABEL,METHODS,OBJECTIVE,PNP,PURPOSE,RESULTS
169,ADIPOSE,BACKGROUND,BASEL,BPH,BPPAT,COPYRIGHT,HOWEVER,LABEL,LNCAP,METHODS,MMP,OBJECTIVE,PC3,PCA,PPATS,RESULTS,TPPAT,ZYMOGRAMS
000,001,100,169,519,BACKGROUND,CARSTAIRS,CONCLUSION,GLEASON,INCIDENCE,LABEL,MEN,METHODS,RESULTS,SOCIO
471,735,AMONG,ARTHRITIS,BPH,CONTROL,NSAID,PREVENTION,PSS,SCORE,SYMPTOM,TRIAL
128,177,FIRST
001,169,ADD,AUTHORS,BCR,BJU,CONCLUSION,COX,GLEASON,KNOWN,LABEL,MEIER,METHODS,NSM,OBJECTIVE,PSA,PSM,RESULTS,SUBJECT,UNLABELLED
169,670,674,708,728,763,784,817,ADD,AUC,AUTHORS,BGLAP,BJU,CURRENTLY,DESPITE,GLEASON,HOSPITALS,INTEGRATED,KNOWN,LABEL,METHODS,NET,OBJECTIVE,OBJECTIVES,PCA,RESULTS,SUBJECT,SULT1A1,UNIVARIATE,UNIVERSITY,UNLABELLED,VICKERS
100,169,174,215,BJU,DESPITE,FURTHER,INCREASED,INDEX,PSA,STUDIES,THERE
100,169,5FR,ALA,AUTHORS,BJU,FOLLOWING,LABEL,METHODS,OBJECTIVE,OLYMPUS,PDD,RESULTS,SIMILARLY,SINCE,STORZ,TCC,UNLABELLED,WHILE
956,FURTHER,PC3
001,003,169,984,ADD,AGE,BJU,CAD,KNOWN,LABEL,METHODS,NSS,OBJECTIVE,RESULTS,SUBJECT,UNLABELLED
100,169,380,ADD,BJU,CAUSE,CONCLUSION,COX,FOLLOWING,GLEASON,KNOWN,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PCA,PSA,RESULTS,SUBJECT,THERE,TREATMENT,UNLABELLED
001,006,027,104,166,169,685,ACM,BJU,CLINICALLY,COX,DRE,END,GLEASON,LABEL,LEVEL,METHODS,OBJECTIVE,PROGNOSIS,PSA,RESULTS,THERE,UNLABELLED,USING,WHITE
001,100,169,370,500,BCRFS,BJU,COX,GLEASON,HEILBRONN,LABEL,LRP,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
001,169,2N0M0,370,499,AUTHORS,BASED,BJU,CCL,CONCLUSION,CONFERENCE,CONSENSUS,GLEASON,ICS,LABEL,METHODS,OBJECTIVE,PATHOLOGY,PSA,RESULTS,SOCIETY,T2A,UNLABELLED,UROLOGICAL,UROLOGISTS
169,ADC,BJU,DIFFUSION,JANUARY,LABEL,MCNEMAR,METHODS,MRI,OBJECTIVE,RESULTS,TUR,UNLABELLED,USING
169,BECAUSE,HOWEVER,LABEL,METHODS,OBJECTIVE,PHYSICISTS,PURPOSE,RESULTS,THROUGH,TREATMENT
103,125,131,169,DUE,HOWEVER,LABEL,LOW,METHODS,OBJECTIVE,PALLADIUM,PHYSICISTS,PROWESS,PURPOSE,RESULTS
169,945,946,PHYSICISTS,SINCE
169,BOS,BRAGG,DET,LABEL,LSFUD,METHODS,OBJECTIVE,PHYSICISTS,PURPOSE,RESULTS,SPOTS
169,177,ARW,BASED,BLA,D95,DAILY,DVH,ERB,IMAGE,IRB,LABEL,METHODS,OBJECTIVE,PHYSICISTS,PTV,PURPOSE,RESULTS,T1CN0M0
169,947,LABEL,METHODS,OBJECTIVE,PHYSICISTS,PTV,PURPOSE,RESULTS,TPS
NH4,THEREFORE
567,658,715,793,978,988,COMFA,FIELD,INDICES,MOLECULAR,SIMILARITY,THESE
956,GFP,MTT
945,ADP,AMONG,BAX,BCL,BT474,GNM,MAA,OEC,OVCAR,TSCCA
ACTIVATING,BACKGROUND,CONCLUSION,LABEL,MATERIALS,METHODS,MTT,PC3,RESULTS
AKT,BACKGROUND,CHINESE,CONCLUSION,DME25,EXTRACT,FURTHER,LABEL,MATERIALS,METHODS,RESULTS,YANGZHENG
ANP,ERK,JUN,MAPK9,MAPKS,RAS,RAT,THEIR,THESE
DENOSUMAB,SRE
169,916,946,956,ABI,CYP17A1,DHT,FKBP5,HSD,LABEL,LAPC4,LNCAP,METHODS,OBJECTIVE,PURPOSE,RESISTANCE,RESULTS,TMPRSS2,TREATMENT
169,BACKGROUND,BASED,CHANGES,CONCLUSION,COPYRIGHT,CYP17,EXPRESSION,INC,LABEL,METHODS,RESULTS,THESE,WILEY
102,169,AGE,AMICO,BACKGROUND,COPYRIGHT,DESPITE,GLEASON,INC,LABEL,LOW,MATERIALS,MEDIANS,METHODS,PSA,RESULTS,SEVENTY,STUDIES,T1C,THREE,WILEY
169,AMERICA,CHINA,CLOSE,COPYRIGHT,EASTERN,NORTH,OCEANIA,SAHARAN,STOMACH,SUB,WESTERN
100,241,ADT,DFS,GRADE,GROUP,LABEL,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RADIATION,REGULARLY,RESULTS,THERAPY
BLADE,FURTHER,GLEASON,KEY,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS
000,160,AFTER,CYCLE,CYP17,ECG,LABEL,METHODS,OBJECTIVE,PURPOSE,QTC,RESULTS,THERE
001,043,174,185,235,BACKGROUND,CONCLUSION,FUNCTIONAL,INC,INDEX,INTUITIVE,ISR,LABEL,MARCH,METHODS,RESULTS,ROBOT,SCORE,SUNNYVALE,SYMPTOM,USA,VINCI
160,200,239,400,BID,CONCLUSION,DLT,FOLLOWING,HFS,HOWEVER,LABEL,MAXIMAL,METHODS,MTD,OBJECTIVE,PSA,PURPOSE,RESULTS,SIX,THREE
169,20A,946,CDODA,DU145,PC3,SP1,SP3,SP4,ZBTB4
EFFECTS,III,THESE
CONVERSELY,JNK,JUN,S120A,S120D,T148A,T148D,T183A,T183D
000,FINALLY,FIRST,GCPII,GLUTAMATE,HTS,TMR,USING
ADT,AES,DEGARELIX,III,PCA,PHASE,PSA,STRATEGIES

HDAC3,HOWEVER,INCREASED,KNOCKDOWN,PC3,PROTEIN,USING
ADDITIONAL,HOWEVER,PATENTING,PSA

177,185,200,CARLO,DYNAMIC,ECLIPSE,MONTE,PTV,THERE
00001,005,110,152,166,169,582,BACKGROUND,BLOOD,CONTEXT,COPYRIGHT,CUMULATIVE,JANUARY,LABEL,LRP,LYMPHOCELE,MANAGER,MEDLINE,METHODS,OBJECTIVE,OVERALL,PUBLISHED,RESULTS,RRP,SCIENCE,SYNTHESIS,WEB
006,100,169,AGE,BACKGROUND,CONTEXT,COPYRIGHT,CUMULATIVE,HOWEVER,JANUARY,LABEL,LRP,MANAGER,MEDLINE,METHODS,OBJECTIVE,POSTERIOR,PUBLISHED,RESULTS,REVIEWS,ROBOT,RRP,SCIENCE,SYNTHESIS,WEB
141,169,526,BACKGROUND,BCR,COLLEGE,CONTEXT,COPYRIGHT,DESPITE,FINALLY,JANUARY,LABEL,LRP,MANAGER,MEDLINE,METHODS,OBJECTIVE,PSM,PUBLISHED,RESULTS,RRP,SCIENCE,SEVERAL,STATA,STATACORP,STATION,SYNTHESIS,USA,WEB
002,100,169,AGE,AVAILABLE,BACKGROUND,COPYRIGHT,CUMULATIVE,LABEL,LRP,MANAGER,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,REVIEWS,RRP,SCIENCE,SYNTHESIS,WEB
000,001,002,005,006,008,028,050,062,169,210,AMONG,COPYRIGHT,LABEL,MCP,METHODS,OBJECTIVE,OBJECTIVES,OTHER,RESULTS,SAS,THERE,TOTAL
129,160,169,200,COPYRIGHT,FURTHER,HDR,INC,LABEL,MATERIALS,METHODS,MOSFETS,OBJECTIVE,PBC,PURPOSE,RESULTS,SIXTEEN,SPC,THERE
169,COMPOSITE,CONCLUSION,COPYRIGHT,III,INC,INDEX,INVENTORY,LABEL,MEN,METHODS,NOCTURNAL,OBJECTIVE,PHASE,RESULTS
169,AFTER,CONCLUSION,COPYRIGHT,DEPRESSION,INC,INVENTORY,KEGEL,LABEL,MAY,MEDICAL,METHODS,OBJECTIVE,RESULTS,THESE
169,1990S,BIG,COPYRIGHT,FLORIDA,LTD,PSA
169,CAR,CLASSICAL,COPYRIGHT,LIMBURG,LTD,POISSON
006,169,CONCLUSION,COPYRIGHT,DTI,EIGHT,INC,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,THERE,TRACT,VARIATION
160,169,240,CONCLUSION,COPYRIGHT,HOWEVER,III,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE,TREATMENT
001,008,133,142,169,177,339,396,APRIL,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OPIUM,PSA,RESULTS
108,120,147,169,AMONG,CHART,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,NETWORK,OBJECTIVE,PATIENT,RESULTS,SEVENTY
0NG,115GY,169,ACUTE,COPYRIGHT,FINAL,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SIX,SOCIETY,STAGING,T2A
145,169,956,COMPOUNDS,MCF,MTT,THESE,WILEY
CHALLENGES,MEN,WHILE
169,945,ADP,ATP,CL1,ROS,UDP,UTP
170,PCA
ANGELES,CALIFORNIA,DVD,HRQOL,INDEX,LABEL,LOS,MCS,METHODS,OBJECTIVE,OLAVS,PCI,PCS,RESULTS,SHORT,TRONDHEIM,UNIVERSITY
PRIMARY
174,998,CENTRAL,HEALTHCARE,KEY,KQ2,KQS,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,PANEL,QUALITY,QUESTIONS,RESULTS,REVIEWS,SNP,SOURCES,SYSTEMATIC,TECHNICAL,THREE
PC3,PCA,RM1,USING
99M,CXCR4,HBB,IGR,MMP,RUNX2,TECHNETIUM
APOPTOTIC,AUTOPHAGY,BACKGROUND,CCK,EXPRESSION,HOWEVER,HPC,LABEL,LC3,LNCAP,MDC,METHODS,ORI,P21,PROMOTING,RESULTS,TEM,WESTERN
SERCA
194,SOMATIC,TES
963,COMPLEX,FINALLY,HCC1954,SINCE
OVERALL,PCA,SNAIL
DESPITE
158,174,740,BSI,CONCLUSION,DWASS,EOD,LABEL,LTD,MATERIALS,MBQ,METHODS,OBJECTIVE,RESULTS,ROC,STEEL,THERE,THEREFORE
108,160,169,183,312,AFTER,CONCLUSION,DCE,DWI,FUNCTIONAL,GEORG,KAPPA,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,STUTTGART
181,231,ACCORDING,DPPIV,HOWEVER,LCK,MDA,PC3,TEBROPHEN,ZAP
BRITISH,INSTITUTE,INTEGRATED,MARCH,RADIOLOGY,SPECT,THERE
169,222,236,237,248,374,555,599,BACKGROUND,CONTEXT,COPYRIGHT,FIFTY,LABEL,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,SYNTHESIS,TECHNICAL,THERE,THOSE,UROLOGY,WHERE
AMONG,III,PFS,THESE
116,169,177,956,BESIDES,COPYRIGHT,ESI,HACAT,HCT,HUH,MCF,NMR,REAUMURIA,THREE
BACKGROUND,BRUNN,CONTEXT,ECTOPIC,LABEL,METHODS,OBJECTIVE,SOURCES,SPECIMENS
181,A2058,AMONG,DMF,DU145,MCF,RESULTS,TCT
124,138,BMI,CHINESE,CONCLUSION,GLEASON,HOWEVER,LABEL,MDR,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SLC22A3,THERE
CURRENTLY,PML
ANALYZING,ATTENTION,AUGMENTED,CENSORING,CONTROLLED,DEFICIT,HIV,INVERSE,METHODS,RANDOMIZED,SEQUENTIAL,SRCTS
169,AII,BPH,DIAGNOSIS,PCA,VCH,WILEY
169,MALDI,PROFILING,VCH,WILEY
00001,CAB,CALCULATED,CHINESE,CONCLUSION,ENGLISH,FINALLY,HOWEVER,IAB,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,QOL,RCT,RESULTS,THERE,USING,WMD
BACKGROUND,CLASS,HYPOTHESES,LABEL,METHODS,OBJECTIVE,RESULTS
BASED
946,ADT,AFRICAN,APC,CURRENT,DESPITE,HRQOL,MEASURE,MEDICAL,MOS,NON,PERCEIVED,REGRESSION,SCALE,SHORT,THESE,TREATMENT,WHITE
NCS
169,24H,956,AKT,BAD,BAX,BCL,CONCLUSION,COPYRIGHT,DIALLYL,DISCOVERY,DISULFIDE,EXCEL,FIT,FURTHER,IGF,INSULIN,LABEL,METHODS,MTT,OBJECTIVE,PACKAGE,PCR,PURPOSE,RESULTS,SINCE
169,COPYRIGHT,FINALLY,HOWEVER,IRELAND,LOW,LTD
169,946,COPYRIGHT,LNCAP,SAS
001,002,100,125,177,179,184,197,200,206,218,230,D90,SUFFICIENT,THERE,VR100
007,169,186,338,443,791,936,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,INS,LABEL,MATERIALS,METHODS,RALRP,RECURRENCE,RESULTS
169,250,309,425,890,BASEL,CLAVIEN,CONCLUSION,COPYRIGHT,CUT,LABEL,METHODS,OBJECTIVE,OVERALL,PBX,RESULTS,THREE,TRU
169,COPYRIGHT,JAPAN,PLM,PRECS,PUBLISHED,SOCIETY
125,144GY,160,169,ACUTE,COPYRIGHT,CROHN,CROWN,GRADE,GROUP,IBD,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,SEVEN,TEN,THERAPY,THERE
161,169,183,235,396,AIM,BACKGROUND,BNSRP,CONVERSELY,COX,HOWEVER,INDEX,LABEL,MEASURE,METHODS,OBJECTIVE,OUTCOME,OVERALL,RESULTS,SOCIETY,THEREFORE,THESE
169,BECAUSE,FINALLY,HOWEVER,MELATONIN,TNF,TRAIL,WILEY
AKT,INDUCTION,LNCAP
049,074,131,169,180,266,623,AMONG,BACKGROUND,COX,E26,ERG,LABEL,METHODS,PHYSICIANS,RESULTS,STUDIES,THESE,TMPRSS2,WHETHER
031,112,135,139,169,247,BACKGROUND,COPYRIGHT,COX,GLEASON,HOWEVER,LABEL,METHODS,NEITHER,OVERALL,PSA,RESULTS,SOCIETY,SRT,SUCCESS
329,386,715,954,APRIL,BACKGROUND,CENTRAL,COMMUNITY,CONCLUSION,CROSS,EIGHT,HOWEVER,INDEX,LABEL,METHODS,RESULTS,SEPTEMBER,TAYSIDE,THERE,TOPAS,VALIDATION
000,100,169,BACKGROUND,BECAUSE,COLORECTAL,COPYRIGHT,DIFFERENT,LABEL,METHODS,OVARIAN,REGRESSION,RESULTS,SCREENING,SOCIETY,TRIAL,USING
881,893,894,904,945,946,AKT,BACKGROUND,CHINESE,ELEMENE,HIF,KNOCKDOWN,LABEL,MOL,PHARM,PHARMACOL,RESULTS,ROS,SCI
CFS,ENV,GAG,HIV,HOWEVER,MLV,PBMCS,POL,RESULTS,THESE
AMACR,ANDROGENS,DUSP1,HOXC6,LNCAP,SAMPLES,SLC14A1,THESE
160,954,968,ANNEXIN,APOPTOSIS,ARTEPILLIN,BRAZILIAN,CASPASE,DEPSIPHER,DR4,DR5,ELISA,HOWEVER,LDH,LNCAP,MTT,NATURALLY,THESE,TRAIL,TRANSAM
177,400,AIM,AKI,CONCLUSION,COX,GFR,LABEL,METHODS,MONTHLY,OBJECTIVE,PHASE,RESULTS,SERUM,THERE
DESPITE
001,103,125,169,ADT,AUTHORS,BJU,CONCLUSION,COX,INCREASING,LABEL,LEVEL,METHODS,MOUNT,MSEFS,OBJECTIVE,OBJECTIVES,PREVIOUSLY,RESULTS,SCORE,SINAI,THERAPY,THERE,UNLABELLED
ANTIGEN,ERSPC,GIVEN,IRELAND,LABEL,LIFESTYLE,LTD,METHODS,NUTRITION,OBJECTIVE,OBJECTIVES,PRESS,PSA,RANDOMISED,RESULTS,ROYAL,SCREENING,SOCIETY,THERE
945,HOWEVER,PCA
001,110,201,207,514,529,COLORECTAL,CONCLUSION,FINALLY,LABEL,METHODS,OBJECTIVE,OVARIAN,PCA,PROPENSITY,PURPOSE,RESULTS,SCREENING,SURVIVORS,TRIAL,WEIGHTS
627,CANCERLIT,CONCLUSION,DWI,JANUARY,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OVERALL,RESULTS
169,210,750,COPYRIGHT,HPCX1,INC,SDS,SEVERAL,SPANX,TAR,WILEY
160,ADT,BACKGROUND,CONCLUSION,LABEL,MEDICINAL,METHODS,PFS,PSA,PSADT,RESULTS
001,023,120,177,956,BACKGROUND,BPO,LABEL,METHODS,PATIENT,PSA,PVR,QOL,RESULTS,THULIUM,YAG
100,109,115,BACKGROUND,CAD,EC507,IAD,III,LABEL,METHODS,OTT,PSA,RESULTS,SERUM,THERE
125,247,274,BACKGROUND,BPH,INCREASED,LABEL,METHODS,PCA,POTENTIAL,RESULTS,SERUM,SNP
AST
150,945,MODULATING,PIN,SENP1,SILENCING,WHEREAS
012,COX,DCDC2,DCX,EHF,ETS,LOGRANK,THESE
000,001,005,019,374,BACKGROUND,DISCUSSION,IFG,INSULIN,LABEL,METHODS,OBJECTIVE,RESULTS,SPAIN,THERE
154,AMONG,CUP,EVALUATION,HODGKIN,THERE,THESE,TTP
HOWEVER
CONCLUSION,CURRENTLY,GOING,LABEL,METHODS,OBJECTIVE,OBJECTIVES,THERE,VARIOUS
169,177,774,956,COPYRIGHT,PCR,PKC,PTK,REVERSE,THEREFORE
169,AFTER,COPYRIGHT,DETECTION,HOWEVER,INVADED,LIMITED,LYMPH,PSA,RMI,SAS,THEREFORE
101,169,ASIAN,BACKGROUND,BPH,CHINESE,COLO320,COPYRIGHT,EASTERN,GAT,GGT,GLEASON,LABEL,METHODS,PCA,PSA,RAS,RESULTS,WESTERN
125,169,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVENTY,SOCIETY
001,002,004,009,016,018,031,105,106,120,BPH,CAG,CAP,CYP19,PSA,SNP,USING,WHILE
947,AFTER,IFN,NGF,PRESENT,TUNEL
000,AFFAIRS,BLACK,CENTRAL,LABEL,METHODS,OBJECTIVE,RESULTS,VACCR,WHITE
110,666,BRITISH,COLORECTAL,OVERALL,THERE
HOWEVER,THESE
001,103,123,127,233,255,407,483,662,AFRICAN,AMERICANS,BECAUSE,HNF1B,NCOA4,PREVIOUSLY,SLC22A3,TAKEN
100,169,COPYRIGHT,GLEASON,HMB,INC,MALIGNANT,MELAN,SUBSEQUENT,URINE,WILEY
117,118,159,FOLLOWING,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THESE
309,GREEK,INDICATION,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEVEN,TEN
00248,CD4,CD8,DOM,HLA,PSA
121,BACKGROUND,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,QOL,RESULTS,THERE,YOUNGER
GROUP,HOWEVER,MONOGRAPHS,PROGRAMME,PUBLISHED,SINCE,WORKING
017,028,077,080,141,177,CONCLUSION,LABEL,MBQ,METHODS,NAF,PET,RESULTS,SIXTY,SUV,UNLABELLED
169,AH23848,BPH,CCAAT,CHROMATIN,COPYRIGHT,EP2,EP4,H89,HOWEVER,KNOCKDOWN,LTD,PROSTANOID
001,120,169,207,252,356,514,869,938,COPYRIGHT,HDR,INC,JANUARY,LABEL,LDR,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,AEU,COPYRIGHT,LABEL,LIBRARY,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,THERE,THEREFORE
111,169,177,215,5MM,AUC,BACKGROUND,COPYRIGHT,DYNAMIC,IRELAND,LABEL,LESIONS,LTD,METHODS,MRI,OBJECTIVE,PCA,RESULTS,ROC,STUDENT
001,116,117,125,150,160,169,200,526,901,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS,SOCIETY,STAGING,TREATMENT,TREATMENTS
100,125,144GY,169,COPYRIGHT,DOSIMETRIC,FOLEY,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
003,017,100,121,169,279,371,AFTER,COPYRIGHT,DISEASE,EXCELLENT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,T1A,T2C,UPGRADING
169,450,ASSURANCE,BRITISH,COPYRIGHT,CROWN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROGRAM,PROVINCIAL,PUBLISHED,PURPOSE,QUALITY,RESULTS,YUKON
169,178,COPYRIGHT,EORTC,IRELAND,LABEL,LTD,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
014,017,018,169,BACKGROUND,COPYRIGHT,ENDOSCOPY,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RECTOSCOPY,RESULTS,ROC,SCORE,SIMILAR,VRS
001,003,169,993,ADD,AUTHORS,BJU,COX,GLEASON,INDEX,KNOWN,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,SUBJECT,THEREFORE,UNLABELLED,URINARY,WHILE
169,233,COPYRIGHT,FDG,INC,PET
169,COPYRIGHT,DYNAMIC,INC,PCA,PERFUSION,PIXEL
001,014,025,029,046,054,081,084,116,126,146,169,171,220,261,338,440,464,538,729,958,969,981,ADD,BJU,CONCLUSION,CONTINUOUS,DESPITE,KNOWN,LABEL,METHODS,NPP,OBJECTIVE,PEARSON,PSA,RESULTS,SUB,SUBJECT,TRUSP,UNLABELLED,WHITNEY
052,169,405,AUTHORS,BJU,BMI,INDEX,LABEL,MET,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SYMPTOM,UROLOGICAL
005,008,017,129,169,281,312,626,BFS,BJU,COX,GLEASON,JANUARY,LABEL,MEIER,METHODS,OBJECTIVE,PREDICTIVE,PREDICTORS,PRIAS,PSA,RESULTS,T1C,THERE
169,293,COPYRIGHT,FURTHER,INC,PSEUDOGENE,SEQ,TAKEN
EPIGENETIC
169,APRIL,BLADDER,GLEASON,JANUARY,PATHOLOGY,URINARY,UROLOGICAL
946,DEPLETION,GEF,RAC,RHO
BCL,ERK,HOWEVER,MCL,MIAPACA,STAT3,THEREFORE,WESTERN,YM155
489,5ARIS,945,BACKGROUND,BPH,INSURANCE,LABEL,METHODS,NHIRD,REDUCTASE,RESULTS,TAIWANESE
172,CONCLUSION,DERIVED,GLEASON,HOX,HOXA9,LABEL,MEIS1,MEIS2,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
217,730,BECAUSE,EUKARYOTIC,GOLGI,IMPROVING
CLINICIANS,FURTHER,INITIATIVE,LABEL,METHODS,OBJECTIVE,PROMS,PURPOSE,RESULTS
147,ASXL1,CRPCS,ERG,ETS,FOXA1,HOWEVER,KDM6A,MLL,SIMILARLY,TMPRSS2,UTX
450,AFTER,BACKGROUND,COLORECTAL,CONCLUSION,DAILY,HRS,LABEL,MEN,METHODS,OVARIAN,RESULTS,SCREENING,TRIAL
169,COPYRIGHT,HOWEVER,PSA,SEVERAL
100,169,BACKGROUND,BECAUSE,BIO,BIOMARKER,COPYRIGHT,GLEASON,LABEL,METHODS,PANEL,PRO,RESULTS
223,ADT,CASTRATION,DEPENDING,DRE,GLEASON,PSA,SEVERAL
DENOSUMAB,FINALLY,III
169,CERTAIN,COPYRIGHT,GOLGI,LTD
122,169,177,180,BACKGROUND,CONCLUSION,COPYRIGHT,GENERALLY,LABEL,METHODS,PSA,PUBLISHED,RESULTS,SERUM,TAIWANESE
174,177,250,900,BACKGROUND,BLAND,CALYPSO,DAILY,DRR,LABEL,MEDICAL,METHODS,OBI,PEARSON,RESULTS
476,BACKGROUND,COMPARING,COX,HBA1C,HRS,LABEL,METHODS,RESULTS,SIMILARLY,SWEDISH
000,001,149,176,204,262,389,406,583,61777,784,805,AFTER,INSTITUTES,LABEL,METFORMIN,METHODS,OBJECTIVE,RESULTS,TAIWANESE,THOSE,USING
141,169,301,34A,452,945,946,CD133,PCR,TAKEN
CCCTC,LABEL,SLC45A3,UNLABELLED
174,BACKGROUND,BLOOD,IQR,LABEL,METHODS,PRIOR,PSA,RESULTS,THEREFORE
CAP,CD326,CURRENT,DESPITE,EPCAM,EPITHELIAL,FINALLY
169,174,BACKGROUND,BASED,CELLSEARCH,COPYRIGHT,EPCAM,FIBROBLAST,INC,LABEL,METASTATIC,METHODS,RESULTS,VERIDEX,WILEY
027,169,536,575,671,751,BACKGROUND,CAUCASIANS,CHINESE,CONSISTENT,CONSORTIUM,COPYRIGHT,G135E,HAPLOTYPE,HOWEVER,INC,LABEL,METHODS,PCA,RESULTS,WILEY
170,AIM,AMACR,BASED,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCA,PCR,PSA,RESULTS
BACKGROUND,C18,C19,C21,C33,C34,C50,C61,C66,C68,CRN,LABEL,METHODS,NORWEGIAN,NPR,PATIENT,REGULAR,RESULTS
169,BETWEEN,COPYRIGHT,ENDORECTAL,FURTHER,INC,LABEL,LOCAL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RECURRENCE,RESULTS
100,183,945,956,AKT,DU145,EGF,ERK,HIF,MMP,PD98059
119,130,169,309,872,CAUCASIANS,CRUDE,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,UROLOGICAL
ATS,BACKGROUND,LABEL,METHODS,PHANTOM,RESULTS,SPLITTING,THRESHOLD,TPS,TREATMENT
169,383,946,AFTER,APMIS,AUTHORS,FOS,JUN,SEVERAL,TGF,THERE
007,140,169,BMNCS,BPH,CD271,COPYRIGHT,DISCUSSION,ELISA,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OPG,RANKL,RESULTS,THESE,WILEY
001,160,176,236,268,368,504,HOWEVER,LYNCH,MEN,OVERALL,THESE
ABSTRACTS,DESPITE,ENGLISH,EXTRACTION,LABEL,LITERATURE,MEDLINE,METHODS,NETWORK,OBJECTIVE,PHASE,PSA,REFERENCES,RESULTS,SELECTION,SOURCES,STUDIES,SYNTHESIS,TREATMENT
169,ANALYSING,COPYRIGHT,HOWEVER,LTD,WHERE,WILEY
169,17Q21,268,928,930,BACKGROUND,LABEL,METHODS,NASHVILLE,RESULTS,UNIVERSITY,VANDERBILT
AFTER,BACKGROUND,CONCLUSION,COX,CYP17A1,HORMONE,LABEL,MEIER,METHODS,PCR,RESULTS
254,266,AKT,SUMO1
169,COPYRIGHT,GLEASON,HOWEVER,INC,MYC,PATHOLOGY,PUBLISHED,SOCIETY,THESE
ASSESSMENT,IN3,MTT,PCA,THEREFORE
BACKGROUND,CLINICALLY,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
719,OVCAR,TARGETING,THESE,TREATMENT
135,800,BACKGROUND,HOUNSFIELD,IMAGE,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SINCE
169,223,BJU,MDV3100
134,138,323,BACKGROUND,CONSORTIUM,CURRENT,ICPCG,LABEL,LOD,METHODS,PARAMETRIC,RESULTS
169,244,542,AMONG,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,ONJ,PURPOSE,RESULTS,WILEY
125,169,957,ADC,AMONG,CONCLUSION,COPYRIGHT,DCE,DTI,FORTY,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,ROC,THEREFORE,UNDER,WILEY
169,231,AIF,ANNEXIN,APOPTOSIS,DU145,EXPRESSION,FURTHER,INC,MCL,MDA,WESTERN,WILEY
101,169,177,182,BACKGROUND,BMI,CIGARETTE,COLORECTAL,COPYRIGHT,ESTIMATION,INC,LABEL,METHODS,OVARIAN,RESULTS,THESE,WILEY
TAKOTSUBO
BASED,DZNEP,PRE,USING
001,073,CLINICALLY,CONCLUSION,GLEASON,LABEL,MDA,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,RRP,THERE,TISSUES,TNM
234,600,634,945,JANUARY,LABEL,MEDLINE,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SAS,THERE,TURBT
167,816,983,AFRICAN,ASSESSMENT,BACKGROUND,LABEL,METHODS,RESULTS,STRATEGIC
106,362,832,945,CYP24A1,CYP27A1,CYP27B1,GLEASON,LABEL,METHODS,OBJECTIVE,PHS,PHYSICIANS,PURPOSE,RESULTS,RXR,SWEDISH,VARIATION,VDR,WAITING
012,022,160,196,1ST,2ND,353,3RD,4TH,731,AGE,BACKGROUND,BMI,CONCLUSION,COX,LABEL,METHODS,MORTALITY,PCA,RESULTS,SWEDISH
153,166,946,FAK,MAT,METASTATIC,SRC
474,BCL,DECREASED,DU145,FGC,FINALLY,H89,LNCAP,PKA,THEREFORE,THESE
946,ACTIVATION,HOWEVER,LEF,TCF,WNT
00185,223,552,695,875,ALPHARADIN,FURTHER,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
CONTINUED,CONVERSELY,CRPCS,EXPRESSION,LBD,MDV3100,UBE2C,WHILE
BAK,BAX,BCL,EXPRESSION,HOWEVER,MCL,PC3,SEVERAL,THEREFORE,THESE

169,23B,COPYRIGHT,CROWN,DU145,III,PCA,PRDX3,PUBLISHED
750,860,956,MIE,OPTICAL,RESULTS
DIAMOND,MDS,RIBOSOMAL,RIBOSOMES,RPS14,SHWACHMAN,THESE
169,729,ACADEMY,AMONG,BACKGROUND,BMI,COPYRIGHT,DIETETICS,ENHANCE,GREATER,INC,LABEL,METHODS,NUTRITION,OBJECTIVE,OBJECTIVES,OLDER,PRINCIPAL,PUBLISHED,REACH,RENEW,RESULTS,SURVIVORS,URBAN
169,947,APC,COPYRIGHT,CPG,CTL,MHC,ODN,SINCE,TLR,TRAMP
BACKGROUND,CONCLUSION,DISCUSSION,HIV,III,LABEL,NMR,RESULTS,ROD,VARIOUS
956,A2058,ACRONYCHIA,DU145,THREE
029,175,228,272,354,AFRICAN,AMERICANS,APA,CALIFORNIA,FACTORS,LABEL,LATINOS,METHODS,OBJECTIVE,PSA,RESULTS,TELEPHONE
169,BRMS1,COPYRIGHT,MECHANISMS,MODULATION,MOLECULAR,S1P,S1PR2,SK1,SPHINGOMAB,TRAMP
000,001,159,169,233,284,773,BACKGROUND,BETWEEN,COMMITTEE,COPYRIGHT,JOINT,LABEL,LOG,METHODS,NSCLC,PRS,REASONS,RESULTS,SOCIETY
AKT,CHINESE,DR5,HOWEVER,TAKEN,TRAIL,TRIPTOLIDE
946,AMONG,BMP,MAD,MH2,SMAD8,SMADS,TGF
160
048,106,160,246,25OHD,ALBUMIN,BMI,LABEL,METHODS,OBJECTIVE,PTH,RESULTS
CHOCHRANE,HOWEVER,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,OBJECTIVE,PURPOSE,RESULTS
005,BACKGROUND,CONCLUSION,COX,GLIOMAS,JANUARY,KETTERING,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,SDH,SIXTY,SLOAN,THERE
160,176,IMAGE,OUTCOME
AFTER,XELOX
PREVENTION,QOL,SINCE,SRE,THEREFORE
165,946,ACTIVATION,CONVERSELY,DU145,FLK,FLT,HYPOXIA,KDR,PC3,RWPE1,TGF,THESE,VEGFA,VEGFR,WHEREAS
004,169,177,980,COPYRIGHT,HAUSDORFF,HOWEVER,THEREFORE
169,BACKGROUND,CONCLUSION,COPYRIGHT,EDUCATION,FURTHER,HOWEVER,LABEL,LITHUANIA,LITHUANIAN,LOWER,LTD,METHODS,POISSON,RESULTS,STATISTICS,STRIKINGLY
023,169,3DCRT,402,621,768,COLLEGE,CONCLUSION,COPYRIGHT,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROYAL
169,COPYRIGHT,DESPITE,IRELAND,LTD,THERE
027,149,169,239,458,COPYRIGHT,ERG,GLEASON,INC,PATHOLOGY,PUBLISHED,SOCIETY
117,169,BACKGROUND,CONCLUSION,COPYRIGHT,I77,JANUARY,LABEL,LTD,MATERIALS,METHODS,NIGERIA,RESULTS,SAHARAN
169,521,702,ANTIBIOTIC,BACKGROUND,CAUSATIVE,COPYRIGHT,DESPITE,INFECTION,INFECTIONS,INFECTIVE,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PREVALENCE,PUBLISHED,RESULTS,SETTING,STUDENT,UROLOGY,UTI,WHITNEY
00001,169,777,ADT,ARR,CANCERLIT,COPYRIGHT,INC,LABEL,LIBRARY,MATERIALS,MEDLINE,METHODS,NNT,OBJECTIVE,PURPOSE,RESULTS,SIX,TMX
169,AIP,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS
169,28KDA,30KDA,41KDA,CATHEPSIN,COPYRIGHT,HOS,THESE
169,200,C57BL,COPYRIGHT,EDUCATION,HYPOXIA,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRIOR,PUBLISHED,PURPOSE,RESULTS,TRAMP,UROLOGICAL
169,945,946,947,COPYRIGHT,EDUCATION,EPITHELIAL,HOWEVER,INC,LABEL,MATERIALS,METHODS,MTT,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WESTERN
001,100,169,256,36270,40543,410,666,813,AALEN,AFTER,BACKGROUND,COPYRIGHT,ERSPC,HOWEVER,LABEL,METASTATIC,METHODS,OBJECTIVE,OUTCOME,PCA,POISSON,PSA,PUBLISHED,RANDOMIZED,REGULAR,RESULTS,SCREENING,SETTING,UROLOGY
PATHOLOGIC,PERITONEAL,PSA,RALRP,THERE
149,150,153,180,443,AFTER,BACKGROUND,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,PRIOR,PSA,RESULTS,THEIR
001,147,177,507,684,BACKGROUND,BETWEEN,CONCLUSION,DESPITE,JANUARY,LABEL,MATERIALS,METHODS,RESULTS
151,BACKGROUND,CONCLUSION,ECE,ESTIMATING,GLEASON,HOWEVER,LABEL,LOG,MATERIALS,METHODS,PNI,RESULTS,SCORE,WHILE
169,282,346,703,COPYRIGHT,CUMULATIVE,EDUCATION,FACTORS,INC,INCREASING,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,ONTARIO,PUBLISHED,PURPOSE,RESULTS,URINARY,UROLOGICAL
169,ADT,COPYRIGHT,LTD,PET,PSA,SPECT,THESE
100,169,956,ANP,AUTHORS,BACKGROUND,CONCLUSION,FLK,FOUNDATION,JOURNAL,KDR,LABEL,MATERIALS,METHODS,RESULTS,SOCIETY,STICHTING,THESE,WESTERN
BACKGROUND,CONSISTENT,GLEASON,LABEL,LNCAP,METHODS,PCA,PCR,POTENTIAL,PSA,QRT,RESULTS,SOX,SOX10
169,250,ADD,AUC,AUTHORS,BJU,CHANGES,GLEASON,HOWEVER,KNOWN,LABEL,METHODS,OBJECTIVE,PSA,PSADT,REGULAR,RESULTS,SUBJECT,T2A,UNLABELLED
027,105,142,169,247,567,AFTER,BJU,COX,LABEL,METHODS,OBJECTIVE,RECORDS,RESULTS,THERE,UNLABELLED
AREAS,BACKGROUND,COVERED,LABEL,MAO,METHODS,MONOAMINE,OPINION
004,345,457,992,CONCLUSION,INCREASED,INCREASES,LABEL,METHODS,OBJECTIVE,RESULTS
BACKGROUND,CONCLUSION,DESPITE,LABEL,METHODS,RESULTS,WESTERN
954,DENOSUMAB,HOWEVER,UNTIL,USA
264,956,CORPORA
AKT,AMONG,CONVERSELY,LNCAP
100,AMERICANS,END,INC,INSTITUTE,JANUARY,PUBLISHED,RESULTS,SOCIETY
000,001,040,139,177,230,GLEASON,HOWEVER,LABEL,LESIONS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ULTRASOUND
EGGER,PRO198LEU,STATA
116,540,746,946,AKT,LNCAP,PKA,SRC,USP10
169,200,239,442,BACKGROUND,BASEL,BETWEEN,BPS,COPYRIGHT,EAU,LABEL,MARCH,MATERIALS,METHODS,PCA,RESULTS
051,053,109,222,243,831,AMONG,BMI,COX,LABEL,METHODS,OBJECTIVE,PREVENTION,RESULTS,RRS
169,176,24H,COPYRIGHT,DYNAMIC,ETO,ETOPOSIDE,PBS,RUB,UNDER
169,177,956,CK2,COPYRIGHT,LNCAP,LTD,TBI
064,169,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,004,036,169,503,BACKGROUND,COPYRIGHT,LABEL,MCNEMAR,METHODS,OBJECTIVE,OUTCOME,PCA,PREDICTIVE,PUBLISHED,RESULTS,SETTING,UROLOGY
100,169,BACKGROUND,CONTEXT,COPYRIGHT,INCLUSION,LABEL,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,UROLOGY
169,199,217,259,CENTRAL,CONCLUSION,COPYRIGHT,GLEASON,GSU,INC,LABEL,METHODS,OBJECTIVE,RESULTS
169,BNC,CONCLUSION,COPYRIGHT,DESPITE,INC,JANUARY,LABEL,METHODS,OBJECTIVE,PVF,RESULTS
016,COX,FURTHER,GLEASON,HOWEVER,MEN,TEA,THREE
001,002,003,004,020,025,120,124,BACKGROUND,CONCERNING,GLEASON,LABEL,METHODS,PNI,PSM,RESULTS,SVI,UNASSIGNED,VIRTUAL
001,103,143,162,361,523,ERG,HGPIN,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SAMPLES,THERE
001,124,169,183,AMONG,BACKGROUND,BRITISH,CONCLUSION,COPYRIGHT,COX,ESTIMATED,FIFTY,JOURNAL,LABEL,LTD,METHODS,PUBLISHED,RESULTS,SOCIETY,SURGERY,THERE,WILEY
PSA
100,250,300,345,440,510,600,916,955,PAIRS
BECAUSE
12H,169,24H,60S,880,COPYRIGHT,LNCAP,MHZ
109,169,442,BACKGROUND,BASED,COPYRIGHT,EIGHT,EVALUATION,FEW,INC,LABEL,METHODS,RESULTS,SERUM,SOLID,TREATMENT
169,BACKGROUND,CITED,CONTEXT,COPYRIGHT,DESPITE,E26,ERG,HOWEVER,JANUARY,LABEL,MASSIVE,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,TMPRSS2,WESTERN
169,CAP,COPYRIGHT,CWR22,HOWEVER,INC,LNCAP,PRIMARY,PSA,SIMILAR,SRC,TIF
003,005,012,015,026,048,BACKGROUND,BLADDER,CONCLUSION,LABEL,METHODS,MMP,PCR,REGARDING,RESULTS
BACKGROUND,CONCLUSION,COX,GLEASON,HAZARDS,INDEX,LABEL,MEN,METHODS,PCS,RESULTS,THEREFORE
169,CAP,COPYRIGHT,EXPRESSION,IHC,INC,KNOCKDOWN,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCR,PSORIASIN,RESULTS
101,169,258,294,345,COPYRIGHT,COSTING,CROWN,EPI,KVI,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,TREATMENT
CALCIUM,LATER
000,152,431,CARLO,LABEL,MATERIALS,METHODS,MONTE,OBJECTIVE,OBJECTIVES,QALYS,RESULTS
001,131,3PB,AD5,ADP,LNCAP,NIS,PCA,SPECT,THESE
169,COPYRIGHT,LTD,THERE,VTE
169,AUTHORS,BJU,FINALLY,NOVEL,OTHER,UROLOGY
169,AUTHORS,BJU,FURTHER,HOWEVER,III,MDV3100,SIPULEUCEL,THESE
169,954,ADT,AUTHORS,BJU,DENOSUMAB,IAD,PSA,UROLOGY
169,ADT,APPROACHES,AUTHORS,BJU,HUGGINS,PSA,SINCE,WHILE
150,300,AMP,CXCR4,LNCAP
22RV1,5MG,CAUCASIAN,CDKIS,CONSISTENT,DGA,LNCAP,OVERALL,PCA,PSA,SYMPHYTUM
134,169,244,429,793,888,890,BACKGROUND,BPH,COPYRIGHT,GSTM1,GSTT1,INC,LABEL,METHODS,RESULTS,WILEY
001,160,174,5T4,945,CRP,IFN,III,MVA,RCC
235,AAT,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,RESULTS,RPE,THROUGH
160,236,241,GLEASON,HDL,HOWEVER,III,LABEL,LDL,METHODS,NEITHER,NUTRITION,OBJECTIVE,PREVENTION,PURPOSE,RESULTS,THESE
215,ERG,HGPIN,IDC,SINCE
GLEASON,THESE
HOWEVER,PCA
IGF,IGFBP,POPULATION
072,18F,FDG,LABEL,METHODS,NAF,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,STUDIES
AFRICAN,RESULTS
931,TRP,TRP_MIN,TST
001,003,177,403,AFTER,AMONG,APC,ARGON,BACKGROUND,BETWEEN,DEPENDING,FORTY,FREQUENCY,GRADE,HOWEVER,LABEL,METHODS,RADIATION,RBS,RESULTS,SCORE,THEIR
131,BLEOMYCIN,BLM,QUALITY,RESULTS,THEREFORE,XENOGRAPHY
215,253,302,945,BACKGROUND,CYP24A1,CYP27B1,DTC,FTC,LABEL,METHODS,PTC,RESULTS,THERE,THESE

CAREFUL,III,MEDICINES
DIFFERENT,DUE
PBMCS,PDCD4,PPP2R2A,SCC,USING
ALTERATION,BACKGROUND,BASED,CONTAINING,DISCOVERY,DISSECT,EVENT,LABEL,MOTIVATION,RESULTS,SEQ,STRUCTURAL
945,946,AUTOCRINE,JNK,NH2,PDGFD,PDGFR,TAKEN,USING
001,100,104,554,BACKGROUND,DECLINING,GLEASON,ITT,LABEL,METHODS,OVERALL,PSA,PSADT,RESULTS
ATP,CDC42,E329K,HEPATOCYTE,HGF,LIM,LIMK1,MET
BIP,CLU,EXPRESSION,GRP78,MG132,TAKEN
001,177,237,274,632,723,ASSESSMENT,CASES,GLEASON,LOW,MEIER,PSA,PTI,THESE
280,AMONG,BACKGROUND,FIFTEEN,FORTY,LABEL,METHODS,PSA,RESULTS,SEVENTY
169,22E,945,946,956,BAX,BCL,COMMIPHORA,COPYRIGHT,DU145,FURTHER,LTD,MCF,NMR,NOESY,PC3,THEIR
169,304,ANALYTICAL,COPYRIGHT,FURTHER,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PROSVUE,PSA,PUBLISHED,RESULTS,SOCIETY,THESE,USING
169,183,340,AMONG,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,UROLOGICAL
169,AMERICA,BACKGROUND,CAP,CHILEAN,COPYRIGHT,DRE,HOWEVER,INC,LABEL,LATIN,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,ROC,SIXTY,USING
BACKGROUND,CBT,DISCUSSION,LABEL,METHODS,NETWORK,PRIOR,RCT,SEVENTY,TRIAL,UKCRN10904
169,AMPRENAVIR,BAX,COPYRIGHT,HIV,MLV,PREXMRV,XENOTROPIC
169,AUTHORS,COLLEGE,JOURNAL
945,946,ARG,ASP,CONVERSELY,ECM,GLY,PRO,RGD,SER,SINCE
THERE
150,945,946,EFFECTS,HOWEVER,LABEL,OBJECTIVE,PROTECTION,PURPOSE,RESULTS
945,AAA,CD151,ERK,GFP,MTT,PC3,TAKEN,WESTERN
4TH,CELLS,HOWEVER,ID1,PC3,PTHRP,THESE
AKT,CELLS,DU145,DUERR,EGF,HOWEVER,PC3,PCA,PCR
001,107,319,BCR,COX,INTENSIVE,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
954,FURTHER,MEK,RAF,TAKEN
HOWEVER
125,272,320,945,CHANGES,LOWER,QOL,TAMSULOSIN,THESE
451,CASES,GLEASON,MEN,RECURRENCE
EGF,ERK,FOS,NUCLEAR,WHILE
160,CARLO,FINALLY,FIRST,IBA,MONTE,PBS,TPS,XIO
169,513,572,APOPTOSIS,COPYRIGHT,HOWEVER,INC,INHIBITOR,PATHOLOGY,PROTEIN,PUBLISHED,SOCIETY,THESE,THROUGH
001,169,ANONYMOUS,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,RESULTS
169,COA,COLLEGE,COPYRIGHT,ERG,LTD,PUBLISHED,ROYAL,TMPRSS2
141,169,276,ADT,AGE,BACKGROUND,COPYRIGHT,FREEDOM,GROUP,HOWEVER,ICORG,IRELAND,IRISH,LABEL,LTD,MATERIALS,METHODS,NAD,NEO,OBJECTIVE,PURPOSE,RESULTS
004,026,169,202,221,CHINESE,COPYRIGHT,GENOTYPING,HAN,INC,LYS939GLN,PAT,PCA,PCR,XPC
169,206,232,300,469,BACKGROUND,COLLEGE,COPYRIGHT,DRE,EDINBURGH,IRELAND,IVU,LABEL,LTD,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,ROYAL,SUBSEQUENT
009,017,169,ADDITIONAL,BACKGROUND,COPYRIGHT,CTC,III,LABEL,LAHNC,LTD,MATERIALS,METHODS,NED,OBJECTIVE,PARTIAL,PURPOSE,RESULTS,THESE
149,301,BACKGROUND,DRE,LABEL,METHODS,PCS,PSA,RESULTS
215,EARLY,HENCE,PSA,QCM,SPR
169,COPYRIGHT,CROWN,FDG,INC,PET,PSA,PUBLISHED
177,ACUTE,BACKGROUND,HRQOL,INDEX,LABEL,LOW,METHODS,MRI,NETWORK,PCA,PSA,QUALITY,RESULTS,SINCE
145,AT1,AT2,BACKGROUND,FINALLY,LABEL,LIMITED,LNCAP,MATERIALS,METHODS,MTT,RESULTS,THESE,USING
169,BACKGROUND,COPYRIGHT,DOF,LABEL,LTD,METHODS,MRI,RESULTS,STD,SUPER,WILEY
176,177,4MM,5MM,8MM,DOF,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
946,AKT,BASED,NON,PC3,PI3,SMAD3,TGF
ASSESSMENT
AMONG
101,945,954,BACKGROUND,CONCLUSION,FURTHER,LABEL,METHODS,RESULTS,THESE,TNF
169,BACKGROUND,BASEL,COPYRIGHT,FUNCTIONAL,LABEL,METHODS,MRI,PCA,PSA,RESULTS
10Q11,128,169,946,BASED,CELLS,COPYRIGHT,THESE
001,169,BACKGROUND,COPYRIGHT,INC,LABEL,LHRHA,METHODS,NEITHER,PHOENIX,PSA,RESULTS,SIXTY,THERE
160,169,BATHO,BEAMNRC,CARLO,COPYRIGHT,DOSXYZNRC,DVH,ECLIPSE,LAW,LTD,MONTE,PBC,POWER,PUBLISHED,TPS,WHEREAS
169,414,985,COPYRIGHT,EXAMINING,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
113,169,COPYRIGHT,DEVIATION,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RADIATION,RESULTS,THERAPY,THREE,TREATMENT
002,005,009,032,169,177,AFTER,COMMISSION,CONCLUSION,CONVERSELY,COPYRIGHT,D50,D98,DSC,INC,LABEL,MATERIALS,METHODS,OAR,OBJECTIVE,PLANS,PURPOSE,RADIATION,RESULTS,UNITS,V20,V50,V60,V70,V75
160,169,COPYRIGHT,CTV,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,THEIR,WITHOUT
946,ADDITIONAL,ANALOGS,LNCAP,LTD,PUBLISHED
169,291,301,945,BACKGROUND,CASTRATION,CONCLUSION,COPYRIGHT,III,LABEL,LTD,METHODS,PSA,RESISTANT,RESULTS,THERE,TTP
001,169,832,AFTER,BCR,CONCLUSION,COPYRIGHT,EDUCATION,FOUNDATION,GLEASON,INC,JANUARY,LABEL,MEDICAL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,THESE
427,HOWEVER,HSP27,OGX,THESE
451,SUBMISSION,THERE,THREE
BCR,MRI,ORGAN,PET,PSA,REGARDLESS,SALVAGE
001,035,169,AKT,BACKGROUND,COPYRIGHT,ERG,FIFTY,GLEASON,LABEL,METHODS,MYC,PFS,PSA,RESULTS,SOCIETY,TAX2501,UNIVARIATE
100,131,169,177,209,721,884,COPYRIGHT,HOWEVER,LTD,MRI,WILEY
138,169,613,BACKGROUND,COPYRIGHT,DETECTION,LABEL,METHODS,PCA,RESULTS,SOCIETY
DUE,FDG,MRI,PET,SUBSEQUENT,WHILE
089,523,AFRICAN,AMERICANS,CAUCASIAN,CAUCASIANS,CERTAIN,CIS,COX,HRS,LABEL,LIFESTYLE,METHODS,MINIMIZING,MULTILEVEL,NIH,OBJECTIVE,OBJECTIVES,RESULTS
605,697,ASIAN,CONCLUSION,LABEL,METHODS,NUTRITION,OBJECTIVE,PURPOSE,RESULTS,RRS,THERE
145,169,916,936,AIF,AKT,BACKGROUND,BCL,COPYRIGHT,HRPCS,IAP,INC,INCREASING,LABEL,METHODS,PROTEIN,RESULTS,ROS,THEREFORE,WESTERN,WILEY
169,225,618,BACKGROUND,CALIFORNIA,COPYRIGHT,COX,FRANCISCO,GLEASON,LABEL,METHODS,RESULTS,ROC,SAN,SOCIETY,UNIVERSITY,USING
169,BACKGROUND,BPH,COPYRIGHT,ERG,INC,LABEL,METHODS,PCA,RESULTS,THERE,TMPRSS2,WILEY
169,239,723,BACKGROUND,COPYRIGHT,ENDOCRINE,ERG,FORTY,FRESHLY,GOSERELIN,INC,LABEL,LNCAP,METHODS,RESULTS,TMPRSS2,WILEY
183,200,946,954,CERTAIN,CLEVENGER,COX,FORTUNELLA,FRESH,FURTHER,GEORG,KUMQUAT,LNCAP,NMR,RTX,SIL,STUTTGART,WAX
169,3DCRT,COPYRIGHT,CROWN,GIVEN,INTENSITY,LTD,PUBLISHED,THERE,THREE
169,177,BACKGROUND,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE,VOLUNTARY
024,169,509,ACUTE,BACKGROUND,COPYRIGHT,DVH,GRADE,GROUP,IRELAND,KUTCHER,LABEL,LKB,LTD,LYMAN,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERAPY,THESE,VARIATIONS
169,3MM,5MM,9NG,COPYRIGHT,EPE,GLEASON,INC,INCREASING,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY,T1C,T2A,T2B,T2C,THESE
169,COPYRIGHT,INC
172,188,755,783,BACKGROUND,BASED,INCIDENCE,LABEL,METHODS,POISSON,RESULTS,SINGAPORE
169,956,AMONG,COPYRIGHT,DMC,LNCAP,LTD
169,CEA,CK903,COPYRIGHT,INC,NAS,NUCLEAR,PSA
100,103,125,132,144,169,ADVERSE,ASTRO,COPYRIGHT,FOCAL,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,MRS,OBJECTIVE,PFS,PHOENIX,PPI,PSA,PURPOSE,RADIATION,RESULTS,SOCIETY,TREATMENT
169,212,966,AIM,BACKGROUND,DIAGNOSIS,DRE,INITIATING,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,RESTANDOL,RESULTS,SOCIETY,TRT
001,153,169,576,AIM,BACKGROUND,END,LABEL,METHODS,NORTH,OBJECTIVE,OUTCOME,OVERALL,PCA,RESULTS,SOCIETY,TREATMENT
001,002,169,AMICO,AUTHORS,BCR,BECAUSE,BJU,COX,GLEASON,LABEL,LEVEL,LRP,MATERIALS,MEIER,METHODS,OBJECTIVE,ORGAN,RESULTS,THERAPY,THERE,THESE,UNLABELLED,URINARY
001,011,101,168,169,348,361,373,BCR,BJU,COX,DU145,GLEASON,HMGB1,HOWEVER,LABEL,LNCAP,MEIER,METHODS,OBJECTIVE,RESULTS,THERE,UNLABELLED
956,APC,BACKGROUND,BIOMARKERS,EPIGENETIC,GSTP1,INCREASING,LABEL,MSP,PCR,PSA,RESULTS
169,BJU,ENGLISH,GLEASON,HOWEVER,JANUARY,LABEL,MATERIALS,MEDLINE,METHODS,NOVEL,OBJECTIVE,OBJECTIVES,PSA,RECTO,RESULTS,TREATMENT,UNLABELLED
169,771,AES,AUTHORS,BJU,BRIEF,COMPOSITE,EDMED,FIFTY,INDEX,INVENTORY,IRRITATIVE,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,PCA,QOL,RAD,RESULTS
ACC,COA,HOWEVER,LNCAP,PC3,USING,WESTERN
384,393,CAUCASIAN,COMPELLING,RUSSIAN,SIBERIA
169,99MTC,BACKGROUND,CTT,INC,LABEL,LNCAP,METHODS,PERCENT,RESULTS,SPECT,WHILE,WILEY
100,HOWEVER,VIRTUALLY
AFRICAN,BARBADIAN,KEY
174,177,AUTOMATIC,BACKGROUND,CBCTS,CONCLUSION,CTS,DSC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
JAK,OBESITY,PI3,PROMINENT,PSA,THESE
125,945,946,956,ACTIVATED,AIM,B16,CONCLUSION,F10,HCS,HEPARIN,LABEL,METHODS,MTS,OBJECTIVE,PCR,RESULTS,TGF,WESTERN
CLAUDIN,EMA,GCT,HOWEVER,PNI,SCHWANN,THESE,THREE
169,17A,18A,18I,18J,18L,956,CLAISEN,COPYRIGHT,LTD,NCI,NMR,SCHMIDT,THREE
111,206,ACE,BACKGROUND,CONCLUSION,LABEL,MATERIALS,METHODS,PSA,RESULTS
TEA,WESTERN
171,187,EYE,HOWEVER,UNKNOWN
945,954,BCL,C57BL,DU145,HOWEVER,LPS,PC3,PCA,PREVIOUSLY,THEREFORE
449,BACKGROUND,HOWEVER,IBC,LABEL,MYC,PRINCIPAL,REPLICATED,RESULTS
CELASTROL,CHINESE,GOD,JUN,LEI,LNCAP,MEANWHILE,PCA,SENP1,TAKEN,THUNDER,TRIPTOLIDE,UNBALANCE
FOLLOWING
MRI,SVM
ACTIVATING
130,17Q24,FOXA1,PCA,SNP
223,240,BACKGROUND,GLEASON,HPN,LABEL,METHODS,RESULTS
1E8,2B4,DU145,GDP,GTP,HOWEVER,PAG,RAS,TAKEN
169,177,836,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,RESULTS,THEREFORE
169,220,300,AFTER,COPYRIGHT,GLEASON,INC,LABEL,LYMPH,METHODS,OBJECTIVE,PCA,PROCEDURES,PURPOSE,RESULTS
AGE,BESIDES,CANCERS,INUIT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,POPULATION,RESULTS
174,HDT,HORMONE,PRC,ZYFLAMEND
100,200,231,400,956,BBI,LNCAP,MDA,PIC,THESE
40PATIENTS,GALAL,HOSPITALS,HUSSEIN,SAYED,TRANS,ULTRASOUND,UNIVERSITY
169,215,483,686,ASIAN,BACKGROUND,C2ORF43,CHINESE,EASTERN,FOXP4,FURTHER,HAN,LABEL,METHODS,PHASE,RESULTS,RS9600079
236,ALU,MSP,NCOA4,PCA,UTR
945,BGP,LNCAP,MCF,VDR
CONTINENTS,EASTERN,INCIDENCE,ISLANDS,LARGE,PACIFIC,SOUTH,THEREFORE
108,160,DCE,DIAGNOSTIC,ECE,ENDORECTAL,ERC,IRB,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS,T2W
135,AUC,BACKGROUND,CONCLUSION,GRADE,LABEL,METHODS,RESULTS,TTP
AMONG,CLINICALLY,EPHA2,IIB,REDUCTION,WESTERN,YET
CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,STROMAL,TREATMENT
BACKGROUND,CONCERN,CONTEXT,DHT,LABEL,METHODS,MHC,OBJECTIVE,OUTCOME,RESULTS,SERUM,SETTING
169,947,956,COPYRIGHT,DU145,INC,MCF,ROS,SUPEROXIDE,THEIR
111,123,169,AMERICA,CAP,COPYRIGHT,DESPITE,GIVEN,INC,MIP,NORTH,PET,SPECT,WHILE
169,211,293,666,959,COPYRIGHT,DESPITE,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGY,PSA,RESULTS,SOCIETY,THERE,UROLOGICAL
006,169,831,ANDROGENS,BACKGROUND,COPYRIGHT,DHT,GLEASON,GOV,IDENTIFIER,KEY,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PER,PSA,REDUCTION,RESULTS,SETTING,UROLOGY
169,183,184,BACKGROUND,CONTINENTS,COPYRIGHT,FUNDING,HDI,INCIDENCE,INDEX,LABEL,LTD,METHODS,RESULTS
102,169,CONCLUSION,COPYRIGHT,COX,EARLY,GROUP,INC,IRISH,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OS1,OS2,PSA,PURPOSE,RESULTS
001,005,010,10780,169,322,509,800,946,AFTER,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADICAL,RESULTS,TGF,THESE
001,002,014,169,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,NTCPS,OBJECTIVE,PET,PURPOSE,RESULTS,SUV,TCP,THERE,THREE
006,236,296,ADVERSE,AMONG,BACKGROUND,BMS,BRISTOL,CUMULATIVE,GRADE,LABEL,METHODS,MYERS,RESPONSES,RESULTS
LNCAP,LXR,OVERALL,SREBP,THERE,USING,WHEREAS
169,206,232,233,234,CONCLUSION,COPYRIGHT,GEORGES,LABEL,METHODS,OBJECTIVE,PARIS,PCA,RCC,RCP,RESULTS,SAS,THESE,THREE
169,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,LABEL,METHODS,MULTIFOCAL,PUBLISHED,REGARDING,RESULTS,SAS
169,AFTER,COPYRIGHT,GIVEN,GROSS,INC,METASTATIC,PSA
169,CONCLUSION,COPYRIGHT,CURRENTLY,INC,LABEL,METHODS,OBJECTIVE,RESULTS,VINCI
025,087,099,106,110,119,169,213,606,735,836,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,OBESITY,OBJECTIVE,PCA,PSA,RESULTS
119,139,169,200,205,207,286,291,316,574,954,COHEN,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,MRI,OBJECTIVE,PBX,RESULTS,THERE,THESE,UNILATERAL
223,ALPHARADIN,AMONG
137,FINDING,MIDAS,THEREFORE
CONVERSELY,KNOCKDOWN,LNCAP,PCA,TRAMP
ACTIVATING,DIFFERENT,FURTHER,LBD,PCA
169,BACKGROUND,COPYRIGHT,GLYOXALASE,INC,LABEL,LNCAP,METHODS,PC3,RESULTS,WESTERN,WILEY
169,948,954,BACKGROUND,BRADYKININ,COPYRIGHT,INC,LABEL,METHODS,MMP,PKC,PP2,RESULTS,SRC,TRANSWELL,WESTERN,WILEY
000,001,AGE,DRE,HOWEVER,PSA,SERUM,SYRIA,THESE
408,483,BPH,CAG,GGC,HOWEVER,PCR,PSA,TURKISH
038,043,251,273,CHINESE,FURTHER,GENOTYPES,PCR,SNP
ERK,ETS,MEK,RAF,RAS
169,COPYRIGHT,HOWEVER,INC,PCR
024,105,366,553,576,707,980,ALTOGETHER,BACKGROUND,FINNISH,LABEL,METHODS,RESULTS
169,COPYRIGHT,HOWEVER,LTD
001,002,169,215,AMONG,AUC,BACKGROUND,COPYRIGHT,DCA,GLEASON,LABEL,METHODS,NET,NRI,OBJECTIVE,OUTCOME,PCA,PREDICTIVE,PUBLISHED,REDUCTION,RESULTS,SETTING,SEVERAL,SIMILAR,UROLOGY
001,037,049,169,210,502,ADT,AGAIN,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PSAHT,PURPOSE,RESULTS,SEVENTY
101,102,105,107,108,109,115,118,156,169,177,208,COPYRIGHT,CTV,CUMULATIVE,D90,DOSIMETRIC,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,URETHRA,V90
008,052,160,169,172,328,465,529,967,974,BETWEEN,COPYRIGHT,FURTHER,GLEASON,IBF,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PURPOSE,RESULTS,UNIVARIATE
160,169,808,945,946,CIS,COPYRIGHT,DETAILS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,STUDIES
169,192,CHANGES,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MIGRATION,OBJECTIVE,PATIENT,PURPOSE,REALEYE,RESULTS,SCORE,SYMPTOM
169,COPYRIGHT,LTD,TELOMERES
169,COPYRIGHT,LTD,STAT3,THERE,THEREFORE,THESE
126,BACKGROUND,CONCLUSION,GLEASON,HOWEVER,LABEL,RESULTS,URINARY
452,BMI,COMPOSITE,GLEASON,INDEX,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,URINARY,YOUNGER
194,385,579,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
126,GLEASON,GPC,JANUARY,PCA,PPV,PREDICTIVE,PSA,SIXTY,T1C,TPC,VALUE
144,COLOR,CONCLUSION,DOPPLER,DRE,GROUP,JANUARY,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,ULTRASOUND
001,002,123,306,CGA,COMPARISON,CONCLUSION,KRUSKAL,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PATIENT,PSA,RESULTS,STAGE,STUDIES,WHITNEY
132,150,176,180,200,BLADDER,FOLLOWING,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,THREE,URINARY
001,035,120,127,132,168,205,248,252,ADT,CONCLUSION,LABEL,LBM,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,LTD,MICROSCOPY,NMR,QUANTUM,SQUID,TEM,WILEY
100,169,BASED,BECAUSE,CONCLUSION,COPYRIGHT,HGPIN,INC,LABEL,MATERIALS,METHODS,MRI,NPV,OBJECTIVE,PSA,PURPOSE,RESULTS,TESLA,WILEY
169,AKT,COPYRIGHT,FINALLY,HOWEVER,MOLECULAR,REDUCTION,SPRY2
ADP,AKT,BAX,BCL,LPS,PI3,THEREFORE
000,146,169,945,946,BPH,COMMITTEE,COPYRIGHT,DECREASED,DGS,HGPIN,IGF,INC,LABEL,LAM,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SAMPLES,SIXTY,STATE,UNICAMP,UNIVERSITY,WESTERN,WILEY
170,254,956,BACKGROUND,CONCLUSION,CONTINUOUS,INSTITUTE,LABEL,METHODS,OBJECTIVE,PROJECT,RESULTS,SEPTEMBER,SEVERAL,THREE,WORLD
FOURIER,PHANTOM,PSF,SNR
000,GERMANY,MRI,PCA
004,019,143,145,169,30A,34A,AVAILABLE,BACKGROUND,BLOOD,CONCLUSION,COPYRIGHT,EXPRESSION,INC,LABEL,METHODS,MICRORNAS,MIR,OBJECTIVE,PCR,RESULTS,WILEY
229,239,BACKGROUND,CONCLUSION,KARNOFSKY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SUMMARY,THREE,UME,UNIVERSITY
AKT,BAX,BCL,CONVERSELY,DU145,HSP27,LEDGF,LNCAP,PCS,SILENCING,THESE
946,BKV,CD103,CD127,CD3,CD4,EPSTEIN,FOXP3,IGG,PCA,TAG
945,EXPRESSION,HENCE,HIF,HYPOXIA,MUTATED,THEREFORE,THESE
AMONG,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
001,101,152,169,564,COPYRIGHT,DOPPLER,IRELAND,LABEL,LTD,METHODS,MFI,NPV,OBJECTIVE,OBJECTIVES,PPV,PSA,RESULTS
COMPELLING,III
137,151,ABOUT,HOWEVER,LABEL,LOCAL,METHODS,NETWORK,OBJECTIVE,RESULTS,SWEDISH,THERE,UROLOGY
159,179,423,600,763,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,T1C
AFP,BACKGROUND,CASES,CONCLUSION,DISCUSSION,LABEL,METHODS,RESULTS
AREAS,BACKGROUND,BETWEEN,COVERED,HOWEVER,LABEL,MEDLINE,METHODS,OPINION
946,MMP,PCA,TGF,THESE
BACKGROUND,CAM,CEA,CK7,CONTEXT,IMP,LABEL,METHODS,MOC31,OBJECTIVE,RESULTS,S100P,SMAD4
014,337,343,538,604,763,AGE,BETWEEN,EAC,END,ESOPHAGEAL,RESULTS,SEER9,SIR,THERE
200,400,558,625,COMMENCING,MEROPENEM,OFLOXACIN,OVERALL,REGIMEN,THERE,TRUSGBP,TRUSGPB
CREB1,FFL,LITERATURE,MYC,NETWORK,TFS
945,954,ANCCA,ATAD2,BCL,HOWEVER,MMSET,THESE,TNF,VEGFA,WHSC1
99M,CONCLUSION,ICG,LABEL,LNS,METHODS,RESULTS,SNS,SPECT,THESE,UNLABELLED
169,177,AVERAGE,CONCLUSION,COPYRIGHT,DEFORMABLE,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,WILEY
257,375,451,956,ASP312ASN,GROUP,HOWEVER,LABEL,LYS751GLN,METHODS,OBJECTIVE,PURPOSE,RESULTS,XERODERMA,XPD
169,ANG,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PC3,PRE,RESULTS,THESE,WILEY
169,ANG,BACKGROUND,COPYRIGHT,FURTHER,INC,LABEL,LNCAP,MAP,METHODS,RESULTS,WILEY
945,MEL,MKN45,THEREFORE,WON
001,058,426,488,914,946,BACKGROUND,BMI,CONCLUSION,LABEL,MEN,METHODS,RESULTS
946,950,953,BACKGROUND,HOWEVER,HYDROPATHY,LABEL,METHODS,PCR,PKC,PRC,PREVIOUSLY,PRKCZ,RESULTS,THEREFORE
DUE,ENDOGENOUS,GREEN,METHODS,MICRORNAS,PCR,REVERSE,RNU44,RNU48,RNU6B,TOTAL,UNIVERSAL,WIDESPREAD
401,632,967,BETWEEN,EGGER,FIXED,LABEL,MATERIALS,MEDLINE,METFORMIN,METHODS,OBJECTIVE,RESULTS,SEVENTEEN,THERE
946,HOWEVER,NODAL,STRIZZI
ASODN,QRS
025,145,BACKGROUND,LABEL,MATERIALS,METHODS,MMP,PCA,PCR,PROGNOSIS,PSA,RESULTS
001,169,178,955,BASED,COPYRIGHT,ERG,FURTHER,HOWEVER,INC,ISH,MOLECULAR,PATHOLOGY,PCA,PEARSON,PUBLISHED,SOCIETY,TMPRSS2
AMERICA,BACKGROUND,DELAYED,DEPARTMENT,HISPANICS,INDEX,LABEL,METHODS,RESULTS,STATE,TEXAS,TOBIT,USA,WELLBEING
EARLY
DU145,SEM
105,125,169,AIM,BACKGROUND,LABEL,METHODS,MRI,OBJECTIVE,OUTCOME,RESULTS,SOCIETY
009,213,945,AIM,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,ORTHOTOPIC,PC3,RESULTS
123,128,351,378,474,COMPARING,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,THERE
101,CONCLUSION,GLEASON,INTER,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREAFTER
755,AES,BECAUSE,III
CURRENT,INTENSE,PSA,SEVERAL
309,734,ADT,BACKGROUND,BMD,DENOSUMAB,LABEL,LOWER,MEN,METHODS,RESULTS

FDA,SIPULEUCEL,WESTERN
124,239,AUC,BASED,BAYES,MRI,ROC,SVM,USING
014,169,COPYRIGHT,DOCETAXEL,ENGINEERED,HOWEVER,INC,THERE
AMONG,TRP,TRPC1,TRPC3,TRPC6,TRPM7,TRPM8,TRPV6
169,ATP,COPYRIGHT,HOWEVER,INHIBITION,PROTEIN,ROS,SFN
169,BPC,BPS,COPYRIGHT,EXPRESSION,HOWEVER,INC,PATHOLOGY,PATHWAY,PCA,PCR,PUBLISHED,SOCIETY,THESE
001,003,134,169,ADDITIONAL,AFTER,AUA,AUTHORS,BJU,INDEX,LABEL,METHODS,OBJECTIVE,PCA,QOL,RESULTS,SYMPTOM,THERE,UROLOGICAL
AKT,BACKGROUND,BECAUSE,BMS,DU145,HGF,LABEL,MET,METHODS,MTT,PCR,RESULTS,SRC,THESE,WESTERN
SRM,THREE
169,183,945,EFFECTIVE,GEORG,SERMS,STUTTGART
930,ADT,BACKGROUND,END,INDICATION,LABEL,METHODS,RESULTS
BEL7404,E1B,TRAIL
215,HOWEVER
MCF,PC3,ROS,SEVERAL,WRL
MEDLINE
169,ATP,COPYRIGHT,FINGOLIMOD,LNCAP,LTD,S1P,SKI,THEREFORE
BACKGROUND,CONCLUSION,COUNTRY,LABEL,METHODS,NAVARRA,POISSON,PSA,RESULTS,SPAIN,SPANISH
169,COPYRIGHT,IRELAND,LTD
169,CONCLUSION,COPYRIGHT,ESTIMATES,INC,LABEL,METHODS,NAMBOUR,OBJECTIVE,PERSONS,PUBLISHED,RESULTS,SUN,WEARING
169,178,946,AKT,AMP,CAMKK,COPYRIGHT,CSA,EGF,HOWEVER,INC,PIP,THESE
001,130,169,C30,COPYRIGHT,EFFECTS,EORTC,FFQ,FREQUENCY,GISEQ,HRQOL,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,QLQ,RESULTS,THERE
169,225,390,500,890,BACKGROUND,BCR,COPYRIGHT,COX,HOWEVER,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,OVERALL,PCA,PROPENSITY,PSA,PUBLISHED,RESULTS,SETTING,SIMILAR,THEREFORE,THESE,UROLOGY,USING
169,COPYRIGHT,HIV,INC,SMI,THESE
160,169,COPYRIGHT,IMAGE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
051,084,169,ASTRO,CONCLUSION,COPYRIGHT,CRT,GROUP,III,INC,LABEL,MATERIALS,METHODS,NHT,OBJECTIVE,PHASE,PHOENIX,PURPOSE,RADIATION,RESULTS,SOCIETY,THERAPY
169,COPYRIGHT,FGF,MEDICAL,OTHER,SAS,SEPTEMBER,SOCIETY,STOCKHOLM,TARGETING
169,944,BACKGROUND,BCR,COPYRIGHT,COX,FURTHER,GLEASON,JANUARY,KAROLINSKA,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PCA,PSA,PUBLISHED,RESULTS,ROBOT,SETTING,STOCKHOLM,UNIVERSITY,UROLOGY
169,202,434,643,BACKGROUND,BDP,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OUTCOME,PSA,PUBLISHED,RESULTS,SETTING,SRE,UROLOGY,ZOL,ZOLEDRONIC
169,BACKGROUND,BPH,COPYRIGHT,EIGHT,GIVEN,IRELAND,LABEL,LIBRARY,LTD,MEDLINE,METHODS,PSA,RESULTS
117,169,967,COPYRIGHT,GLEASON,LVI,MEIER,PSA,PUBLISHED,THEREFORE
188,ASSAY,IFAST,PSA,USING
200,400,AUSTRALIA,BACKGROUND,DISCUSSION,HOWEVER,LABEL,METHODS,NON,QOL,ROBOTIC,TRIAL,WESTERN,WHILE
169,BLACKWELL,GROUP,LTD,MALIGNANCY,PUBLISHING,THROUGH,ULTIMATELY
7F5,BACKGROUND,CONCLUSION,FIRST,GOLDMAG,IGG,LABEL,MATERIALS,METHODS,MRI,RESULTS
004,DEP,FURTHER
477,GIVEN,HEPATOCYTE,HGF,MET,TAKEN,TIUL1
CFS,LNCAP,MLV,PBMCS,PCR,STATE,USING,WHILE
PSE,RUBIN,ZHANG
145,956,AMONG,BACCAUREA,DCM,DIFFERENT,GAE,MCF,MTS,TOTAL,TPC

001,169,BACKGROUND,BIGH3,BPH,CARCINOMA,CD147,CONCLUSION,COPYRIGHT,ECM,ELISA,HOC,LABEL,METHODS,MOLECULAR,PCR,RESULTS,ROC,SERUM,STMN1,TCC,UROTHELIAL
001,169,237,687,739,768,784,837,AUC,BASEL,CALCULATOR,CANCEROLOG,COPYRIGHT,GLEASON,HGPCA,INSTITUTO,LABEL,METHODS,MEXICAN,NET,OBJECTIVE,OBJECTIVES,PCA,PREVENTION,RATES,RESULTS,TRIAL
150,169,220,ABLATHERM,CLAVIEN,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE,TMS
153,169,BASED,COPYRIGHT,GADD153,GREEN,IRELAND,JAPAN,LTD,TRAIL
169,ANALYZING,COPYRIGHT,HOWEVER,INC,S1PR1,STAT3,TARGETING
400,800,BASED,CDS,ECL,MWNTS,NPS,NTS,PSA,TIO
LHERMITTE,PROTEUS,RILEY,RUVALCABA,SINCE,SOMATIC
001,22RV1,946,CONCLUSION,CONVERSELY,FAS,FLICE,HDACI,HOWEVER,LABEL,LNCAP,MAXIMAL,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,177,BACKGROUND,COLORECTAL,CONCLUSION,DBP,FURTHER,LABEL,METHODS,ORS,OVARIAN,RESULTS,SCREENING,THESE,THREE
CONCLUSION,DCE,LABEL,MRI,OBJECTIVE,PERFORMING
169,AT713,EXPRESSION,IQCAT,QCONCAT,VCH,WILEY
169,189,22RV1,254,DOCETAXEL,DU145,RESISTANCE,THESE,VCH,WHILE,WILEY
BASED,BLADDER,GOALS,HOWEVER,NMIBC,POSTULATED
109,250NG,AFRICAN,BACKGROUND,DRE,GLEASON,HOWEVER,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,SOUTH,STATA,STUDIES,THERE,TNM,V10
123,169,3NG,AIM,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OVERALL,PET,PSA,RESULTS,VALIDATION
130,138,169,389,768,ABUJA,ASR,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,DESPITE,LABEL,LTD,MATERIALS,METHODS,NIGERIA,POPULATION,RESULTS,SAHARAN,SSA
169,COPYRIGHT,FINALLY,HIV,MULTIFOCAL,SAS
003,100,BACKGROUND,CONCLUSION,CTCAE,CTV,D75,ERB,INFIELD,LABEL,MAXIMUM,METHODS,RESULTS,SCALE,SYMPTOM,V20,V30,V40
33342,956,ADT,AHS,AUC,BACKGROUND,CWR22,DCE,EXTRACTED,HOECHST,LABEL,METHODS,MRI,RESULTS,USING
CTLA4,III,MDV3100,MET,METASTATIC,NOVEL,OPTIMAL,SRC
DUE,HOWEVER,PSA
3PUFA,969,ALA,FAO,HOWEVER,OMS,RCT,THERE
100,145,176,177,300,CONCLUSION,DOX,INCUBATION,LABEL,LIPOSOMES,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
ACPPS,CPP,DOX,ENZYMATIC,MCF,MMP,THESE
150,174,177,500,947,ANTIGEN,ARTIFICIAL,ASSAY,BURLINGAME,CTL,CYTOTOX,DCS,ELISPOT,FITCHBURG,NON,NPS,PROMEGA,THESE
946,ADDITIONAL,ANTONIO,E7389,ENGLISH,EXTRACTION,HALAVEN,LABEL,METHODS,OBJECTIVE,PHASE,RESULTS,SAN,SCHOLAR,SOCIETY,SOURCES,SYNTHESIS
215,219,BASED,EPIGENETIC,THESE
120,183,779,CCI,HOWEVER,KU0063794,LNCAP,PHOSPHO,THR
30G,530,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
097,177,317,695,AFRICAN,BASAL,BMI,COX,FASTING,LABEL,METHODS,NORTH,OBJECTIVE,RESULTS,TOTAL
169,747,AFRICAN,COMPARISON,COPYRIGHT,EUR,HOWEVER,INCIDENCE,SAHARAN
110,169,BACKGROUND,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,OVERALL,PHOENIX,PSA,RESULTS,ROC,THESE,UNIVERSITY,VARIOUS,WILEY
CAM,PCA
245,366,CONTINUED,HEPATITIS,HOWEVER,HPV,IMPORTANT,LABEL,METHODS,OBJECTIVE,OTHER,PACIFIC,PURPOSE,RESULTS,ZEALAND
CBCTS,HOWEVER,RESULTS,THESE
100,AIM,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,RRP
CURRENTLY

001,006,046,093,169,291,COPYRIGHT,COX,GLEASON,HOWEVER,INC,MEIER,THERE,THESE
C11,F18,FDG,LABEL,MOLECULAR,OBJECTIVE,PET,PURPOSE,RESULTS,SEVERAL,SUMMARY,THERE
CURRENT,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THESE
AMONG,GLEASON,HOWEVER,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SCREENING,SUMMARY
CURRENTLY,HOWEVER,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
141,169,525,737,BJU,DIAGNOSTIC,DOR,HOWEVER,HSROC,QUALITY,THERE,USING
001,169,244,285,ANGELES,BACKGROUND,CALIFORNIA,CHANGES,FIFTY,GENERAL,HOWEVER,HSD,INDEX,LABEL,LOS,LSD,MEASURE,METHODS,OBJECTIVE,OUTCOME,PCI,QOL,RESULTS,SHORT,SOCIETY,THERE,UNIVERSITY
BACKGROUND,FEW,LABEL,MEDLINE,METHODS,RESULTS,SECONDARY,SIXTEEN,THERE
150,290,309,32G,399,403,528,660,739,887,BACKGROUND,CAUCASIANS,EX5,HOWEVER,LABEL,OVERALL,PRINCIPAL,RESULTS,THROUGH,WHILE
22RV1,BACKGROUND,DERSE,INFECTIOUS,LABEL,OVERALL,RESULTS,SINCE,XENOTROPIC
BACKGROUND,CHINESE,CONCLUSION,ELISA,GLEASON,LABEL,PCA,PRINCIPAL,PSA,RESULTS,ROC,SPON2,USING
BACKGROUND,CFS,HOWEVER,LABEL,METHODS,PCR,RESULTS
22RV1,CWR22,MLV,PCR,THESE,WHILE,XMRV1
23B,916,BURKITT,FURTHER,GLS,GLUTAMINE,MIR,MYC,P5C,PC3,POX,PRODH,PROLINE,USING
BECAUSE,END,GENOMES,KYOTO,PATHWAY,RESULTS
945,ERG,EWS,MYC,PML,RAR
119,159,173,CONCLUSION,LABEL,METHODS,OBJECTIVE,ONTARIO,RESULTS,VARIATIONS,WITHOUT
12Q24,169,AFRICAN,AMERICANS,BACKGROUND,COPYRIGHT,INC,LABEL,LOUISIANA,METHODS,RESULTS,SNP,THESE,WILEY
001,150,641,BETWEEN,BMI,CONCLUSION,ENHANCE,KINGDOM,LABEL,MAY,METHODS,OBJECTIVE,OLDER,OVERALL,PURPOSE,REACH,RENEW,RESULTS,SHORT,THESE
181,946,OVCAR
246,908,BASED,MED,PCA,TCP
786,946,AKT,HOWEVER,LIPUS,LM8,LOW,MC3T3,METASTATIC,SAOS2
11C,PET
160,AKT,PSA,TAKEN
001,005,BACKGROUND,BCL,COMBINING,FOLLOWING,LABEL,LNCAP,METFORMIN,METHODS,MICROMOLAR,OBESITY,PC3,RESULTS,USING,WESTERN
3DCRT,BACKGROUND,COMPARISON,CONCLUSION,KAS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TREATMENT
BMM,COX
DESPITE,EMT,FINALLY
169,BACKGROUND,BASEL,CELLS,CONCLUSION,COPYRIGHT,GTPASES,INCREASED,LABEL,MB231,MDA,METHODS,RAB11,RAB25,RESULTS,TAKEN
MICRORNAS
233,AKT,BCG,CURRENTLY,MCF,MYCOPLASMA,THESE
169,AUTHORS,BLK,DU145,GRP78,HSP70,JOURNAL,LNCAP,NG108,ORF,PC3,TDF,THEREFORE,THESE
116,169,BACKGROUND,BANKS,BLOOD,CONCLUSION,GLEASON,HOWEVER,ICS,LABEL,METHODS,PAD,RESULTS,THERE,VARIABLES
169,AUTHORS,BJU,FURTHER,MICRORNAS,THESE
001,002,004,005,010,022,028,030,039,152,156,64I,64V,916,GENOTYPING,HOWEVER,MCP,PCR,TURKISH
293,HEK,HOWEVER,LNCAP,PSMAE,RESULTS,THESE
135,CENTERS,COMMITTEE,CONTROL,DISEASE,FORCE,LIPID,MEN,PRACTICES,PREVENTION,PREVENTIVE,SCREENING,THERE,ULTRASOUND
CONCLUSION,IDEAL,ITALIAN,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,UNIVARIATE,VARIOUS
APOPTOTIC,CONCLUSION,FIFTY,GLEASON,HISTOLOGIC,LABEL,METHODS,MIB,OBJECTIVE,PEARSON,RESULTS,SEVENTY,STUDENT,THERE
407,457,950,AMONG,APRIL,DEPARTMENT,INDIA,JANUARY,KASHMIR,MEDICAL,MRD,RECORDS,SKIMS,STOMACH
174,945,AFTER,AIM,BOTULINUM,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,RESULTS,SV2
000,10Q23,112,250,ETS,FOXA1,MED12,RECURRENT
002,021,497,760,765,936,CALIFORNIA,CONTROL,COOKING,EPHX1,GSTT1,HOWEVER,LEU432VAL,PCA,PTGS2,THESE,THREE,TYR113HIS
DISCUSSION,JAPAN,LABEL,METHODS,OBJECTIVE,RESULTS,THESE,WHILE
169,COPYRIGHT,DIVERSILAB,LTD,PCR,SUBTYPING,TC12S
051,169,AUSTRALIA,BRIEF,COMPOSITE,COPYRIGHT,CROWN,HOWEVER,INDEX,KEY,LABEL,LOW,LTD,METHODS,MULTI,NURSE,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SCALE,THERE
169,363,411,422,865,872,BEGINNING,BLACK,COPYRIGHT,DESPITE,DREICER,FERRARI,FIRST,IMMUNOL,KANTOFF,LTD,MANDL,MED,NAT,REDFERN,REV,SHORE,SIPULEUCEL,SMALL
005,169,812,ADDITIONAL,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,ITALIAN,LABEL,METHODS,OBJECTIVE,PCA,RESULTS,THESE
169,174,ADENOSINE,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SIGMA,UROLOGICAL,WESTERN
001,003,008,169,172,344,946,C825T,COPYRIGHT,DUE,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
169,174,22RV1,ALDEFLUOR,ALDH1,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,NOD,OBJECTIVE,PROM1,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,494,CONCLUSION,COPYRIGHT,DECISIONAL,IRELAND,LABEL,LPC,LTD,METHODS,OBJECTIVE,P3P,PATIENT,PHYSICIAN,PRIOR,PROFILE,RESULTS,WHILE
169,CAP,CONCLUSION,COPYRIGHT,DOCETAXEL,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PC3,PC3WT,PRESENT,RESULTS,RET,VEGFA,VEGFR,XENOGRAFT
595,AFRICAN,AMERICANS,ANOVA,BECAUSE,BOWEL,COMPOSITE,COUNSELING,DESPITE,DISEASE,ESTIMATES,HRQOL,INC,INDEX,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PUBLISHED,RADICAL,RESULTS,SHORT,STUDENT
169,640,BASED,COPYRIGHT,GRI,LTD,NCI,PUBLISHED,RGD,THESE
169,775,AMONG,BACKGROUND,BECAUSE,CONFIDENCE,COPYRIGHT,DESPITE,EARLY,END,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,UROLOGY
169,COPYRIGHT,INC,THALIDMIDE,THESE
169,COPYRIGHT,CTT54,CY5,LTD,PEG
170,400,EIGHT,FRANKEL,LABEL,METHODS,MINIMALLY,OBJECTIVE,RESULTS,TEN,THESE
223,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,POD,RESULTS
AGILENT,CONTROL,CROHN,FOLH1,IBD,SET,THESE,WHOLE
AKT,BACKGROUND,BCL,EGF,HOWEVER,JNK,LABEL,LC3,LNCAP,NAC,NRG,PREVIOUSLY,PRINCIPAL,RESULTS,ROS,S6K,THESE
169,1990S,BACKGROUND,CAPSURE,CHANGES,COPYRIGHT,END,LABEL,METHODS,PRIMARY,RESULTS,SOCIETY,STRATEGIC,THESE
169,924,COPYRIGHT,CYTOMETRY,DIGITAL,FEULGEN,HOWEVER,SOCIETY
KALLIKREIN,KLKP1,LNCAP,LTR,THEREFORE,THESE,THREE
916,956,BACKGROUND,CONCLUSION,FAK,FIRST,LABEL,METHODS,MRI,NON,PC3,REPORTING,RESULTS,SRC,THERE,TREATMENT
BACKGROUND,BISULPHITE,CONCLUSION,GIVEN,LABEL,METHODS,METHYLIGHT,PCA,RESULTS,TSA
HSV,HSV1716,IMMEDIATE,PCR,SCC,USING
DOPPLER,ESPECIALLY,GLEASON,HOWEVER,LABEL,MRI,OBJECTIVE,PCA,PRESENT,PURPOSE,RESULTS,SHEAR,SUMMARY,TECHNICAL,THREE,VARDENAFIL
169,COPYRIGHT,INC
CEA,INC,MUC,PSA,PUBLISHED
169,COPYRIGHT,III,INC,SIPULEUCEL
169,BACKGROUND,COPYRIGHT,LABEL,METHODS,PDT,PINUS,RESULTS,TREATMENT
169,954,BAX,BCL,CADMIUM,CDS,COPYRIGHT,CROWN,HOWEVER,LNCAP,LTD,NAC,PROTECTION,PUBLISHED,QDS,RESULTS,ROS
145,169,181,22RV1,916,AUTHORS,BACKGROUND,BDS,BRITISH,CBD,JOURNAL,KEY,LABEL,LNCAP,METHODS,MTT,OBJECTIVE,OTHER,PCC,PURPOSE,RESULTS,SEVERAL,SOCIETY,THC,THESE,TRPM8,TUNEL
001,AFTER,APRIL,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,NVB,ORGAN,RESULTS
001,118,147,AFTER,APRIL,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,ORGAN,PSA,PSM,RESULTS
001,AFTER,APRIL,BACKGROUND,CONCLUSION,GLEASON,LABEL,MAJOR,METHODS,NVB,ORGAN,RESULTS
001,114,162,169,220,AFTER,APRIL,BACKGROUND,CONCLUSION,GLEASON,LABEL,METHODS,NVB,ORGAN,PSA,RESULTS
BACKGROUND,CELLS,CONCLUSION,CYTOCHROME,GSH,INCREASED,LABEL,LNCAP,MATERIALS,METHODS,NAC,RESULTS,ROS
145,AFTER,BACKGROUND,CONCLUSION,LABEL,LNCAP,MATERIALS,METHODS,RESULTS
100,956,CAM,CTC,ECM,EMBRYOS,GFP,IMAGING
ACTIN,AFTER,BACKGROUND,CONCLUSION,DIFFERENT,FUNCTIONS,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,RESULTS,SEVERAL
946,CHROMATIN,COX,DU145,PCA,TGF,THESE
13Q,169,COPYRIGHT,DIAPHANOUS,ERK,MEK,MOLECULAR,RB1,SILENCING,THERAPIES,THESE,WHILE
169,1INTEGRIN,945,946,BPH,CD133,COPYRIGHT,PRESS,PROSTATIC,SINCE,THESE
119,160,169,204,297,680,ALPHA,AMACR,BACKGROUND,COA,COPYRIGHT,HGPIN,HOWEVER,INC,LABEL,METHODS,RESULTS,SIXTY,THREE,WESTERN,WILEY
169,BACKGROUND,CELLTITER,COPYRIGHT,DCFDA,EXPRESSION,INC,LABEL,METHODS,NATURAL,PIPER,RESULTS,ROS,WILEY
005,100,150,956,AFTER,GSH,IMPEDANCE,MT1,MT2,MTT,OXIDATIVE,PC3,PNT1A
003,806,CONFERENCE,CONSENSUS,GLEASON,PATHOLOGY,SOCIETY,THESE,UROLOGICAL
355,386,ADHERENCE,BACKGROUND,CONCLUSION,COX,INSTITUTE,LABEL,METHODS,NUTRITION,OBJECTIVE,RESULTS,WORLD
008,036,169,366,936,ABU,AMONG,ANNUALIZED,ARTIFICIAL,BOARD,CHI,COPYRIGHT,EDUCATION,ENDOSCOPIC,FURTHER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVERAL,UROLOGICAL,UROLOGY
011,169,427,BACKGROUND,COPYRIGHT,DRE,GROUP,HOWEVER,INC,JANUARY,LABEL,METHODS,PSA,RESULTS,THERE
169,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OXIDATIVE,RESULTS
001,169,503,BACKGROUND,BCR,COPYRIGHT,COX,HARRELL,INC,LABEL,MATERIALS,METHODS,PREDICTIVE,RESULTS,TNM
BACKGROUND,CHESS,FOCUS,INC,LABEL,METHODS,PUBLISHED,RESULTS,SUPPORT
069,169,BACKGROUND,BCR,COPYRIGHT,EPPENDORF,HAMBURG,JANUARY,LABEL,MEDICAL,MEIER,METHODS,NEUROSAFE,NSM,OBJECTIVE,OUTCOME,PROCEDURE,PSM,PUBLISHED,RESULTS,RPS,SECONDARY,SETTING,SMS,SYSTEMATIC,UNIVERSITY,UROLOGY
169,177,207,258,BACKGROUND,COPYRIGHT,DUOROTATE,GERMANY,JANUARY,KEYPORT,LABEL,LYMPH,MAJOR,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,OUTCOME,PROCEDURE,PUBLISHED,RESULTS,RICHARD,SETTING,UROLOGY
200,231,468,ARRAY,BACKGROUND,BLOOD,CTC,EMT,EPCAM,EPITHELIAL,FURTHER,KPL,LABEL,MDA,METHODS,PCR,PHENOTYPIC,RESULTS,THESE,TRANSITION,TWIST
001,AZ10397767,BACKGROUND,BCL,CAP,CONSISTENT,CXCL8,CXCR1,CXCR2,ELISA,LABEL,METHODS,PC3,PCR,PEMETREXED,RESULTS,SUBSEQUENT,TOMUDEX
000,160,LNCAP,PSA,T877A
123,169,198,238,495,946,AFTER,CRIP1,GROUP,GSTP1,HIF3A,LABEL,METHODS,MICROARRAY,OBJECTIVE,PURPOSE,RAR,RASGRF2,RESULTS,RUNX3,TNFRSF10D,UNIVARIATE,VALIDATION
169,292,ADT,BIOMARKERS,EXTRACTED,FASTING,LABEL,MARKERS,METHODS,NOTABLE,OBJECTIVE,PURPOSE,RESULTS,STEROID
001,006,155,169,251,318,724,946,LABEL,LOW,METHODS,NETWORK,OBJECTIVE,PURPOSE,RESTRICTED,RESULTS,SERUM,THESE
169,CCL,PRIMING,SHORTLY,THESE,USING
169,252,CHIMICA,COPYRIGHT,HELVETICA,HOWEVER
150,180,230,298,800,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SIXTEEN
6TH,LABORATORY,TLS
106,BACKGROUND,BPH,CROSS,EASTERN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SERUM,SETTING
CARLO,LOW,MONTE,THERE,THREE,TRACE
009,017,019,022,023,034,039,177,259,299,ADT,BACKGROUND,BMD,FRACTURES,LABEL,METHODS,RESULTS,SUMMARY
RMS,SIMILARLY
228,252,AFTER,BACKGROUND,BESIDES,DISCUSSION,EFFICIENCY,INSTITUTE,IQWIG,LABEL,METHODS,QUALITY,RESULTS
129,169,804,809,838,889,ASIAN,ASSESSMENT,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,T1C,T3A,THESE,UROLOGICAL,WESTERN
169,916,947,EX3
GTPASES,HOWEVER,RAL
END,PSA,RESULTS
240,4Z1,GLEASON,STMN1
169,34B,LABEL,MYC,THESE,TRANSGENIC,UBIQUITIN,UNLABELLED,USP2A
169,MYC,UBIQUITIN
138,241,280,575,610,694,ADDITIONAL,AGE,AUC,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNP,USEFULNESS
162,167,169,456,500,512,552,605,726,772,959,AUC,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PSA,RESULTS,WILEY
016,098,107,169,465,642,931,BACKGROUND,COPYRIGHT,HOWEVER,INC,JANUARY,LABEL,MAY,METHODS,PCA,PSA,RESULTS,SCORE,SYMPTOM,WILEY
113,188,205,211,BNM,BNS,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PAE,PSA,PURPOSE,RESULTS,RRP,SIXTEEN,THERE,TNM
BACKGROUND,CONCLUSION,FDA,III,LABEL,METHODS,MONITORING,OCTOBER,ONGOING,RESULTS
125,169,945,BASEL,CLINICALLY,COPYRIGHT,HERCEPTIN,THESE
177,181,APATONE,BRQ,GSH,HOWEVER,VK3
213,850,PIM,REGULATION,SER,THR
BECAUSE,C81,DU145,LNCAP,MODULATING,PACLITAXEL,PGP,THESE
D95,DAILY,PTV
176,177,CORRECTION,FORTY,LIMITED,NOVALIS
176,177,920,923,952,992,BECAUSE,CARLO,CURRENTLY,HOWEVER,MCNP5,MONTE,PHYSICISTS
106,CTV,D98,EUD,HOWEVER,MEANWHILE,PBS
945,946,CISPLATIN,INTEGRINS,NPS,PEG,RGD,RGDFK
137,169,AGE,AGING,AMICO,ANDROLOGY,BJU,CONCLUSION,GLEASON,LABEL,LOW,METHODS,OBJECTIVE,OBJECTIVES,PCA,PSA,RESULTS,SOCIETY,THESE,UNLABELLED,UROLOGY,VERMEULEN
001,022,169,194,AGC,ASIAN,BJU,CTA,CTC,LABEL,METHODS,OBJECTIVE,RESULTS,SNP,THREE,UNLABELLED
006,027,125,169,176,181,AUTHORS,BJU,DENMARK,ELISA,EN2,EPSTEIN,GIVEN,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRE,PROJECT,PSA,RESULTS,THERE,UNLABELLED,URINARY
169,AUTHORS,BJU,DESPITE,OCCURRENCE
155,169,350,577,COPYRIGHT,EDUCATION,ENDOTHELIN,ENTHUSE,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OPTIMAL,PUBLISHED,PURPOSE,RESULTS,SCREENING,UROLOGICAL
22RV1,A10,BACKGROUND,CONSISTENT,DISCUSSION,LABEL,LNCAP,MATERIALS,METHODS,RESULTS,THESE
103,109,154,169,193,205,425,COPYRIGHT,FCA,HCA,INC,IRELAND,ISPOR,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,REDUCED,RESULTS,SOCIETY
AGN,ASIAN,BESIDES,CHINA,DOH,KOREA,NAKAI
110,169,APMIS,ASSESSMENT,AUTHORS
ADT,AREAS,BACKGROUND,COVERED,LABEL,MDV3100,METHODS,NOVEL,OPINION,SEPARATELY
ANOTHER,HOWEVER,STUDIES,SUSPICIOUS
859,883,885,888,976,AIM,BACKGROUND,BASED,CONCLUSION,COX,FCD2010,FDR,LABEL,METHODS,OBJECTIVE,RESULTS,SPECIFIED,SWEDISH
169,200,CYP1A,FOLLOWING,GSTP1,HGPIN,PIN,SIMILAR,THESE
169,177,ADC,CHO,CIT,CONCLUSION,COPYRIGHT,DWI,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,WILEY
EXTENSIBLE,THESE,VARIATIONS
484,668,945,AGS,FSH,III,LOH,SNU,TAKEN,THESE,TREATMENT,UTR
000,177,ADC,DIFFUSION,DWI,FORTY,HISTOLOGY,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROI,TESLA
653,ALIGNRT,COMPARING,CRT,DPI,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SETUP
PERSISTENT,SALMONELLA,THEREFORE
183,AKT,EP2,EP4,GTP,HK2,INCIDENCE,RAL,SN12C
954,BCL,MICROARRAY,PCA,STAT3
169,CONFORMAL,COPYRIGHT,EASTERN,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,SCALE,THERAPY,TREATMENT
169,COPYRIGHT,HOWEVER,INC,MENTHOL,SUBSEQUENT
169,3AO,COPYRIGHT,IRELAND,LTD,NOTABLY,PHASE
001,113,124,169,177,237,345,946,COPYRIGHT,CTX,INC,PAGET,SCLEROSTIN,SERUM,THESE
169,946,COPYRIGHT,CROWN,FINALLY,HOWEVER,LTD,OPG,PIVONKA,PTH,PTHRP,PUBLISHED,RANKL,SEVERAL,WNT
001,004,005,006,012,024,027,116,169,264,2PG,300,302,316,328,329,333,344,388,3NMOL,408,519,597,6MONTHS,956,9NMOL,ADT,AFTER,BAP,BMD,COPYRIGHT,COUPLED,DELTA,DPD,IGF,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SERUM,THESE
169,COPYRIGHT,INC,P501S,THESE
169,647,COPYRIGHT,COX,FURTHER,ICD,INC,INSURANCE,LABEL,METHODS,OBJECTIVE,PHYSICIANS,PRESS,RESULTS,TAIWANESE
169,946,ACTIVIN,ADT,COPYRIGHT,FSH,LTD,PCA,PSA,TGF,THEREFORE,TREATMENT
001,041,051,169,185,295,297,300,412,519,730,831,942,972,973,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THEREFORE
001,169,694,COMPETING,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,100,169,195,644,894,COPYRIGHT,CUMULATIVE,CURRENT,EDUCATION,FURTHER,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,173,177,550,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OVERALL,PREDICTORS,PUBLISHED,PURPOSE,RESULTS,THOSE,UROLOGICAL
169,COPYRIGHT,EDUCATION,FOCAL,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SALVAGE,THESE,UROLOGICAL
169,174,COPYRIGHT,CTC,EDUCATION,FINALLY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCIENCE,TECHNICAL,UROLOGICAL,WEB
169,916,964,COPYRIGHT,DCE,DYNAMIC,EES,INC,MODEL,MRI,SINCE,USING
097,099,119,120,150,169,398,605,ASSESSMENT,BACKGROUND,BMI,CKD,COPYRIGHT,COX,EPI,ESTIMATED,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,PSA,RESULTS,THEREFORE,WHILE
169,ALTOGETHER,AUR,AUTOMATED,COPYRIGHT,FIRST,INC,LABEL,MATERIALS,METHODS,NUMBERS,OBJECTIVE,OBJECTIVES,PUBLISHED,RATIONALE,RESULTS,SPATIAL,THREE
169,BIOMETRIC,CVPOL,EPOCE,PROGNOSTIC,SOCIETY,THESE
169,AUTHORS,BJU,DES,LOW,PSA,THESE
001,008,009,011,019,030,037,039,044,111,169,181,254,471,611,795,AMONG,AUTHORS,BJU,CONCLUSION,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,ONJ,RESULTS,SEPTEMBER,TAX,TOOTH,UNLABELLED,USING,WBC
181,COMPOUNDS,HALICLONA,HCT,INDONESIAN,LNCAP,MCF
108,152,APART,AREAS,BACKGROUND,COVERED,EARLY,III,LABEL,LYS,METHODS,ONGOING,OPINION,PHASE,RECEPTORS,RESULTS
CPU,GHZ,INTEL
AFTER,FIFTY,SIMILARLY,TREATMENT
001,327,469,ANXIETY,AUSTRALIAN,DEPRESSION,FURTHER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCALE
145,169,BACKGROUND,BAX,BCL,CONCLUSION,COPYRIGHT,INC,LABEL,LNCAP,METHODS,NIS,NON,PCR,RESULTS,WILEY
001,160,313,632,670,761,859,AUC,BMS,EAU,GLEASON,LABEL,MDP,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,UROLOGY
001,002,003,004,010,031,845,BCR,COX,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,PREDICTORS,PSA,PSM,PURPOSE,RESULTS
800,945,ACUTE,CRP,FURTHER,PCA,PSA,THESE,UNIVERSITY
CD8,CERTAIN,CMV,HLA,MOUSE,PSA,TRAMP,TRANSGENIC
222,AMONG,DEPLETION,LABEL,TAKEN,TARGETING,UNLABELLED,USING
DESPITE,FINALLY,LABEL,PSA,THEREFORE,UNLABELLED
222,NADPH,ROS,USING
HOWEVER,PSA,SERUM
COLORECTAL,GWA,OVARIAN,SCREENING,TRIAL
001,100,169,AMONG,BACKGROUND,CASES,COPYRIGHT,CROWN,CRUDE,LABEL,METHODS,NOVEL,OBJECTIVE,OUTCOME,PNB,PUBLISHED,RESULTS,SETTING,UTI
169,BACKGROUND,CONTEXT,CONVERSELY,COPYRIGHT,DESPITE,ENGLISH,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SYNTHESIS,UROLOGY
169,BACKGROUND,CONTEXT,COPYRIGHT,ENGLISH,LABEL,METHODS,OBJECTIVE,PATIENT,PCA,PUBLISHED,RESULTS,SYNTHESIS,THEREFORE,UROLOGY
169,177,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,RPM,TPS
169,317,431,881,COPYRIGHT,END,GIVEN,INC,LABEL,MATERIALS,MEN,METASTATIC,METHODS,OBJECTIVE,OBJECTIVES,PROPENSITY,PUBLISHED,RESULTS,SALVAGE,WHILE
001,004,012,169,200,275,CAB,CAP,CIS,COPYRIGHT,DIAGNOSIS,END,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,WHILE
FET,OPN,THESE
106,146,169,202,251,AUTHORS,BPH,BRITISH,GENERAL,IRS,JOURNAL,LABEL,METHODS,OBJECTIVE,RESULTS,RISKS,SOCIETY,THERE
001,169,665,COMPETING,CONVERSELY,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PROPENSITY,RATES,RESULTS,UROLOGICAL
169,505,GENERAL,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RECURRENCE,RESULTS,RULES,STUDIES,UROLOGICAL
169,690,BLACKWELL,LTD,MEN,PUBLISHING,SINCE
CHINA,CONCLUSION,LABEL,METHODS,OBJECTIVE,REJECTION,RESULTS
100,200,22RV1,400,CONCLUSION,LABEL,METHODS,MTT,OBJECTIVE,RAPAMYCIN,RESULTS
BPH,CONCLUSION,GLEASON,III,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PIM,PSA,RESULTS
001,012,116,136,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERE
170,AUC,CHINESE,CONCLUSION,DRE,LABEL,METHODS,OBJECTIVE,PIN,PSA,RESULTS,ROC
110,BACKGROUND,BETWEEN,BNS,BPH,BPV,LABEL,MATERIALS,MAY,METHODS,QOL,RESULTS,SCORE,SECONDARY,SYMPTOM
100,750,ABOUT,BACKGROUND,DEPENDING,DETECTION,DISCUSSION,GLEASON,LABEL,MARCH,METHODS,OBJECTIVE,OCTOBER,PSA,RATIONALE,REGARDING,RESULTS,T3B,TUR
169,2B4,COPYRIGHT,INC,LASS2,MMP,PCR,RFQ,THERE,TMSG1,WESTERN,WILEY
169,COPYRIGHT,EPIGENETIC,ETS,HOWEVER,INCREASING,LXN,RARRES1,SNP
169,500,AAG,HSP70,HSP90,LABEL,LNCAP,METHODS,NVP,OBJECTIVE,PURPOSE,RESULTS,TARGETING
100,EFFECTS,ERK,EXTENSIVE,FGFRS,FINALLY,LABEL,METHODS,OBJECTIVE,PNT1A,PURPOSE,RESULTS,TARGETING,TREATMENT
BRAGG,HOWEVER,JAPAN,THESE
169,COPYRIGHT,LNCAP,LTD,THESE,VIS
160,169,174,176,200,215,360,600,CONCLUSION,COPYRIGHT,FFF,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRESCRIBED,PTV,PURPOSE,RESULTS,THERE,USING,VOLUMETRIC,X10,X6FFF
100,169,209,228,CONCLUSION,COPYRIGHT,III,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PHASE,PRE,PURPOSE,RESULTS,STUDENT
110,141,160,169,182,402,ACUTE,BETWEEN,COPYRIGHT,GRADE,HORMONE,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRE,PSA,PURPOSE,RESULTS,THERE
169,945,956,APOPTOSIS,CASPASE,COPYRIGHT,ELISA,LNCAP,TREATMENT
011,169,427,ASO,ATP,CLU,COPYRIGHT,HSP27,ISSUE,LTD,OGX,SMALL
015,021,036,169,177,BJU,BPH,COX,DDC,DFS,GLEASON,GREEN,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PSA,RESULTS,TOTAL,UNLABELLED
169,208,300,352,560,AUTHORS,BJU,GLEASON,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,PROGNOSIS,PSA,RESULTS,T1B,T1C,T2A,T2B,T2C,THERE,THESE,UNLABELLED
169,ANZ,AUSTRALIA,AUTHORS,BACKGROUND,BETWEEN,COLLEGE,CONCLUSION,JANUARY,JOURNAL,LABEL,METHODS,RESULTS,ROYAL,SURGERY,WELLINGTON,ZEALAND
946,ADJUSTMENT,ANXIETY,BEHAVIORAL,DEPRESSION,DIAGNOSTIC,FINALLY,FRAGILITY,HRQOL,MANAGEMENT,PESSIMISM,PSYCH,TENSION,THESE,WHITE
169,946,AUTHORS,CDS,JPP,KEY,LABEL,METHODS,MOLECULAR,NEITHER,NMR,OBJECTIVE,OBJECTIVES,OVERHAUSER,PC3,REGARDLESS,RESULTS,ROYAL,SOCIETY
169,267,727,CANDIDATE,COPYRIGHT,EMR,LABEL,LTD,METHODS,NINTH,OBJECTIVE,PPV,PURPOSE,RESULTS,WHILE,WILEY
202,638,CA125,COLORECTAL,KINGDOM,OVARIAN,SCREENING,THERE,TRIAL
COLORECTAL,EOC,OVARIAN,SCREENING,TARGETING
001,029,945,ALTERED,BECAUSE,GPC,HOWEVER,MCF,MEIER,METASTASIS,OVERALL,PKC,SILENCING
100,177,956,AOC,BBN,CONCLUSION,GBQ,GRPRS,LABEL,METHODS,PET,RESULTS,SMALL,UNLABELLED
017,030,033,036,062,079,082,105,229,246,CONCLUSION,FCH,LABEL,MBQ,METHODS,PET,RADIATION,RESULTS,UNIVERSITY,UNLABELLED
005,009,036,047,052,100,105,109,123,130,161,169,969,ADJUSTMENT,ANOVA,ANXIETY,CONCLUSION,COPYRIGHT,DCS,DECISIONAL,DEPRESSION,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SCALE,SECONDARY,THERE,WILEY
169,BACKGROUND,BECAUSE,COPYRIGHT,END,HOWEVER,LABEL,METHODS,NOMOGRAMS,POPULATION,PROGRAM,QUERY,RESULTS,SOCIETY,WEB
ABS,CAR,CAUCASIAN,ERG,OCT,PVEPS,RPE,THESE
BASIC,CELLSEARCH,DESPITE,FDA,FURTHER,PSA,THOSE,VERIDEX
169,COPYRIGHT,ELK,ERG,ETS,ETV,HOWEVER,INC,SEVERAL,USING
001,003,015,041,104,169,241,AFFYMETRIX,CNV,COPYRIGHT,INC,PATHOLOGY,PSA,PSADT,PUBLISHED,SNP,SOCIETY
946,HENCE,HOWEVER,TAKEN
34BETAE12,CEA,CK7,CONCERNING,CONCLUSION,LABEL,METHODS,OBJECTIVE,P504S,PAP,PROSTATIC,PSA,RESULTS
CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS
AFTER,CDM,CONCLUSION,EGF,LABEL,METHODS,MTT,OBJECTIVE,RESULTS
BASIC,CHANG,CMV,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,S2PRO
PARTICULAR,TREATMENT
100,267,AIM,ATM,CRPCS,HOWEVER,NOTABLY,TYR
169,231,468,COPYRIGHT,DOX,FURTHER,HOWEVER,INC,LNCAP,MDA,NPS,PF127,PLURONICS,PVA,RELEASE,THESE,WILEY
169,933,954,AKT,BCL,FAS,NUCLEAR,RXR,THESE,TRAIL,WNT
169,COPYRIGHT,INC,MRI,THERE,WILEY
BRAIN,FDG,FEW,FIFTY,HCC,JANUARY,LIMITED,MEDLINE,PET
120,BACKGROUND,C75,CONCLUSION,FATTY,HOWEVER,INHIBITION,LABEL,LNCAP,METHODS,RESULTS
CTC,HOWEVER,PC3
BACKGROUND,CONCLUSION,HEALTHCARE,LABEL,METHODS,OBJECTIVE,RESULTS,SPOUSES,THERE,THOSE,WHEREAS
169,DISRUPTION
169,BASED,COPYRIGHT,DU145,E2A,GIVEN,ID1,ID3,INC,MYC,PC3,SILENCING,THESE
001,169,180,726,763,825,857,899,924,BJU,CONCLUSION,HOWEVER,LABEL,LEVEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS,UNLABELLED
100,161,169,ADD,AUTHORS,BJU,CONCLUSION,COX,FURTHER,GLEASON,HARRELL,HOWEVER,KNOWN,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SUBJECT,THESE,THREE,UNLABELLED
001,169,221,252,AHR,AUTHORS,BJU,CAB,CONCLUSION,COX,FACTORS,GLEASON,INCREASING,LABEL,LEVEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,THERAPY,THESE,UNLABELLED
169,BJU,CYP,FURTHER,HOWEVER,METASTATIC,THERE
001,048,11752,169,BJU,BRITISH,EARLY,INTERIM,LABEL,METHODS,NEITHER,OBJECTIVE,OBJECTIVES,PSA,RESULTS,UNLABELLED,VARIOUS,YOUNGER
204,215,360,DESPITE,DIETARY,DIMEIQX,GSTM1,GSTT1,HCA,HEIDELBERG,MEIQX,MNSOD,NUTRITION,PCA
049,083,AAS,AFRICAN,CAP,CAS,CAUCASIAN,DIETARY,HISTORY,LOUISIANA,NCI,NORTH,PROJECT,RESULTS
133,ASSESSING,CLAVIEN,LABEL,METHODS,OBJECTIVE,RESULTS
177,179,210,BACKGROUND,BOO,CHINA,FORTY,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,PVP,PVR,QOL,RESULTS,SCORE,SYMPTOM,THERE
129S4,AKT,CAP,CRE,EMT,FURTHER,FVB,HOWEVER,LSL,MMS,PIN,R270H,R273H,THESE,TRP53
169,22RV1,945,AFTER,AKT,ERK,FIFTY,HOWEVER,IGF,TEN,TNF,WHEREAS
000,001,067,100,597,894,BACKGROUND,LABEL,METHODS,PSA,RESULTS
109,150,160,297,406,ADHERENCE,AGE,AMONG,CUMULATIVE,FACTORS,FIRST,LABEL,MEN,METHODS,OBJECTIVE,OFF,PATIENT,PRESCRIBED,PURPOSE,RESULTS,SIXTY,SWEDISH
145,954,AKT,CAFFEIC,LNCAP,MYC,PCR,USING,WESTERN
169,177,956,CHINA,COMPARISON,COPYRIGHT,DU145,HOWEVER,LNCAP,PC3,SEA,THEIR,TYDEMANIA
495,831,852,CHINESE,ERSPC,GLEASON,HOWEVER,JANUARY,MARCH,OVERALL,PREVENTION,PSA,RANDOMIZED,SCREENING,SEVERAL,THEREFORE,TRIAL,WESTERN
GLEASON,OTHER,PCA,PSA,SINCE,SOUTH,SWEDISH
DESPITE,PSA
169,CONVERSELY,COPYRIGHT,DESPITE,EXPRESSION,FURTHER,INC,INCREASED,PCA,ROS,STEROID,THESE,W134F
169,1B1,947,CANCERS,COPYRIGHT,CYTOCHROME,GIVEN,HOWEVER,IRELAND,LTD,STUDIES
000,190,BACKGROUND,CENTERS,COLORECTAL,INC,INDEX,LABEL,LSS,METHODS,OVARIAN,PUBLISHED,RESULTS,SCREENING,TELEPHONE,TEN,TRIAL
169,AALEN,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,POTENTIAL,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE,THREE,WILLIAM
102,129,134,169,219,CONSISTENT,COPYRIGHT,FAS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,BACKGROUND,BRIER,CONVERSELY,COPYRIGHT,GALLINA,LABEL,METHODS,NORTH,OBJECTIVE,OBJECTIVES,OUTCOME,PRIMARY,PUBLISHED,RESULTS,ROBOT,ROC,SOCIETY,SVI,THREE,UROLOGICAL,UROLOGY,USING
041,077,134,144,169,17Q,289,412,ASIAN,CAP,CAUCASIANS,CHINESE,COPYRIGHT,GLEASON,INC,INDIANS,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
169,COPYRIGHT,GLEASON,PCA,SAS,THESE
100,125,145,169,185,186,CONSISTENT,COPYRIGHT,D90,INC,PUBLISHED
169,945,946,ALTOGETHER,COPYRIGHT,INC,PCA,PSA
007,021,168,169,1A1,COPYRIGHT,INC,MACEDONIAN,URIDINE
176,177,246,765,780,810,ICG,PC3,PIN,SUCCESSFUL
ANOTHER,LABEL,MAGIC,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,TPS
176,177,956,ANIMALS,DOX,FINALLY,FIRST,FUS,INCREASED,INSIGHTEC,LABEL,LNCAP,METHODS,MHZ,OBJECTIVE,OPTIMAL,PARAMETRIC,PURPOSE,RESULTS,THERE,THIRD
956,CUSUM,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
103,EDITING,LABEL,METHODS,OBJECTIVE,PURPOSE,RBF,RESULTS,STRUCTURES,STUDIES,SURFACE,THESE
BACKGROUND,HOWEVER,INDUCTION,LABEL,LNCAP,LNSHH,MC3T3,RESULTS,SHH,SONIC,THEREFORE
100,757,911,AUC,BACKGROUND,CONCLUSION,CURRENT,DIAGNOSTIC,GLEASON,LABEL,MEIER,METHODS,PCA,PCR,PSA,RESULTS,ROC,SINCE,THEREFORE,USING
AFTER,FOLLOWING,THOSE
066,AMONG,BACKGROUND,COX,DESPITE,INSURANCE,LABEL,METHODS,NHI,RESULTS,TAIWANESE
271,641,895,927,954,AP1,ASSESSING,CAUCASIANS,SNP285G,SNP309G,SNP309T,SNP344A,SNP344T,SP1,WHILE
174,400,CELLSEARCH,ERG,HOWEVER,ISOLATION,MOLECULAR,T868A,THESE,TMPRSS2
LOUISIANA,USA
FORCE,OCTOBER,PREVENTIVE,PSA,THESE
205,332,916,945,946,HENCE,PCA,THEREFORE
PIONEER
105,ATLAS,CONSORTIUM,PATHOLOGY,PROGRAM
129,160,175,185,360,CONCLUSION,COX,DIFFUSE,GROUP,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,T1C
021,048,BPH,CONCLUSION,GLEASON,LABEL,MATERIALS,METHODS,MMP,MT1,OBJECTIVE,PCA,PCR,PSA,RESULTS
001,082,BETWEEN,BRAZILIAN,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PAULO,PSA,RESULTS,SAO,SECTION,SEPTEMBER,SOCIETY,STATE,UROLOGY
001,177,BPH,CONCLUSION,DOPPLER,DRE,LABEL,MATERIALS,METHODS,OBJECTIVE,POWER,PSA,PUD,RESISTIVE,RESULTS,SCORE,THERE,ULTRASOUND
169,COPYRIGHT,D95,DAILY,INC,INTENSITY,LABEL,LARGE,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,THESE,V79
169,428,COPYRIGHT,END,EXPRESSION,GLEASON,INC,PERCENTAGE
AKT,BACKGROUND,IDR,INTRATUMOR,LABEL,METHODS,RESULTS,SRC,THESE,VEGFR
169,III,LABEL,METHODS,OBJECTIVE,PEC,PURPOSE,RATES,RESULTS,SEMINAL,THREE
169,350,492,956,ACTIVATION,GLEASON,IGF,III,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SIXTEEN,THESE
AGS,BACKGROUND,IIA,LABEL,METHODS,PKS,PRIMARY,RESULTS
169,BRITAIN,COPYRIGHT,FINALLY,GREAT,HOWEVER,IRELAND,LTD,MPS,PUBLISHED,SOCIETY,WILEY
FURTHER,HOWEVER,INCREASING
160
160,231,CONCLUSION,DER,ICG,LABEL,MDA,MET,METHODS,OBJECTIVE,OPTICAL,PC3,PURPOSE,RESULTS
160,PATHOLOGY,SOCIETY,UROLOGICAL
181,BAX,GTP,HDAC1,HDACS,HISTONE,LNCAP,LYS,TREATMENT

001,300,370,401,AHR,AMONG,COLORECTAL,DIETARY,EPHX1,GSTM3,MEIQX,OVARIAN,SCREENING,TRIAL,UGT1A,USING,XME
100,793,798,BACKGROUND,GROUP,LABEL,METHODS,PSA,RESULTS,SERUM,THERE,THREE
CONCLUSION,FGF23,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TIO
001,002,177,181,EAU,FINALLY,GLEASON,GUIDELINES,PCA,PEARSON,PROMISING,PSA,RRP,STUDENT,THEREFORE,THESE
CUR,DMC,HOWEVER,MMP,MTT,THEREFORE,THESE
708,CLINICALLY,CONVERSELY,FUNCTIONAL
BPS,REMARKABLY,TOP,TORIN
101,169,220,AFTER,COPYRIGHT,COX,CYP17,GIVEN,HRS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,ORR,OVERALL,PFS,PSA,RESULTS,SIMILAR
021,169,AFRICAN,CALCULATOR,CAP,CAUCASIAN,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,PREVENTION,RESULTS,RISKS,TRIAL,USA
329,AGE,EORTC,INDEX,INSTEAD,QLQ,REGARDLESS,THESE
117,169,956,COMPOUNDS,COPYRIGHT,E10,F10,FN1,FN2,INHIBITORY,MTT,SAS,SIXTY
169,947,BACKGROUND,COPYRIGHT,DSB,DU145,HOMOLOGOUS,IGF,IRELAND,LABEL,LNCAP,LTD,METHODS,OBJECTIVE,PC3,PURPOSE,RADIATION,RESULTS,THESE
016,069,116,220,AIM,ASTRO,GLEASON,LABEL,LOW,METHODS,OBJECTIVE,PHOENIX,PSA,RESULTS
145,215,946,BLI,INCUBATION,RFC,RIIFC,SMAD2,SMAD3,TAD,TGF,THESE
001,004,010,023,169,177,ADC,CONCLUSION,FORTY,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PARAMETRIC,PURPOSE,RESULTS,SEVENTY
AFRICAN
169,ADT,BACKGROUND,CONVERSION,COPYRIGHT,DHT,FINALLY,GFP,HOWEVER,INC,INDUCTION,LABEL,LNCAP,METHODS,PCA,RESULTS,WILEY
001,060,087,169,19Q13,536,AFRICAN,BACKGROUND,CAP,COPYRIGHT,HOWEVER,INC,LABEL,LOUISIANA,METHODS,NORTH,PROJECT,PSA,RESULTS,SNP,TESTS,WILEY
169,CHARLES,COPYRIGHT,GOODWIN,HUGGINS,INC,NOBEL,PRIZE,WILEY,WILLARD
CONCLUSION,FCH,LABEL,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,THESE
006,008,042,106,169,344,368,372,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,LTD,METHODS,OUTCOME,PHASE,RESULTS,SEVEN,WESTERN,WILEY,YOUNGER
169,266,304,ADDITIONAL,BACKGROUND,COPYRIGHT,CYP19A1,INC,LABEL,MATERIALS,METHODS,PCA,RESULTS,THERE,THROUGH,WILEY
100,956,BACKGROUND,ELISA,IGG,IL8,LABEL,LNCAP,METHODS,RESULTS
HOWEVER
PCA,PDT,PPP
HOWEVER,SPANISH
945,ANDROGENS,CONSISTENT,CONVERSELY,DHT,FURTHER,HOWEVER,KLK,KLK14,LG4
AFTER,NAVIGATION,SPECT
DETERMINED,HOWEVER,SIX
ALABAMA,BLACK,GEORGIA,LABEL,LOUISIANA,METHODS,NORTH,OBJECTIVE,PCA,PURPOSE,RESULTS,SOUTH,WASHINGTON
BACKGROUND,FDFT1,FINALLY,LABEL,METHODS,RESULTS,RS2645429
006653848,100,AES,BACKGROUND,GLEASON,GROUP,HOWEVER,LABEL,METHODS,NTC,OTHER,OTHERWISE,PSA,RADICAL,RESULTS
145,185,225,AG0,RAD,THESE,UNIFORM
000,011,111,172,175,488,688,BACKGROUND,CGEMS,FOLLOWING,GLEASON,HOWEVER,III,LABEL,MARKERS,MDR,METHODS,MOLECULAR,NCI,PCA,PRIOR,PRKCQ,RESULTS,SEN,SNP,YET
169,CONCLUSION,COPYRIGHT,DISCHARGE,INC,LABEL,MARCH,METHODS,OBJECTIVE,RESULTS
001,007,008,103,119,123,125,169,242,CONCLUSION,COPYRIGHT,COX,GLEASON,GROUP,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PHOENIX,RADIATION,RESULTS,THERAPY,TREATMENT
169,700,CAM,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SELECTION,THERAPY
145,ASS,BACKGROUND,BP1,CONCLUSION,DECREASED,INHIBITION,LABEL,LNCAP,OCT,PCR,RESULTS
103,177,206,945,ADT,ANDROGENS,BETWEEN,EGF,FIFTY,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
000,100,200,233,325,911,BACKGROUND,FDR,HOWEVER,HPEAK,KBP,LABEL,METHODS,POLII,RESULTS
CAM,HSA,MMP,MT1,PECAM,THESE
AFTER,HOWEVER,KLF,MTM,SDK,SP1,SP3,SP4,TAKEN,TFS
006,007,009,169,177,BACKGROUND,COMMITTEE,CONVERSELY,COPYRIGHT,CPE,HOWEVER,JOINT,LABEL,MEIER,METHODS,NETWORK,RESULTS,SOCIETY,STAGING,THERE
169,445,AFTER,BACKGROUND,COPYRIGHT,END,FEW,HOWEVER,HRQOL,LABEL,MEDICAL,METHODS,RESULTS,SHORT,SOCIETY
169,543,BACKGROUND,BECAUSE,CHANGES,COPYRIGHT,FINALLY,FRESH,LABEL,LTD,METHODS,RESULTS,START,WILEY
AFRICAN,AMERICANS,CONCEPTUAL,DIVERGENT,FERRELL,INSTITUTE,MODEL,QUALITY,THESE
169,AFTER,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,RESULTS,THESE,WILEY
233,326,652,LABEL,METHODS,OBJECTIVE,RESULTS
WHETHER
169,179,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,XVI
AFTER,CONCLUSION,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,VC1,WESTERN
001,009,100,125,169,200,299,300,399,400,495,499,967,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THERE
169,251,ADT,COPYRIGHT,DUE,GLEASON,INC,INJECTING,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SALVAGE,SOCIETY,T3A
187,ANDROGENS,BACKGROUND,CYP17A1,HSD17B3,HSD17B4,LABEL,LTD,METHODS,NCOA4,PUBLISHED,RESULTS,SNP,STAT3,SULT2A1,THESE
032,110,169,916,963,AUNPS,COPYRIGHT,ELISA,LOD,PSA,RLS,UNDER
000,169,ANALYTICAL,BACKGROUND,COPYRIGHT,EP5,HYBRITECH,LABEL,LOB,LOD,LOQ,METHODS,PSA,RESULTS,THERE,TOTAL
001,169,251,BECKMAN,COPYRIGHT,DRE,HGPIN,INDICATION,PCA,PHI,PSA,ROC
946,CFC,CRYPTIC,EGF,EMT,EPITHELIAL,FRL,INC,NODAL,PUBLISHED,SNAIL,TGF,THEREFORE
169,AFTER,ASC,BACKGROUND,CONCLUSION,COPYRIGHT,FDG,FMA,INC,INHIBITION,LABEL,METHODS,PET,POTENTIAL,RESULTS,THREE
169,COPYRIGHT,INC,MRI,RADICAL
160,169,187,ADT,COPYRIGHT,DXA,INC,INITIAL,PUBLISHED,SIXTEEN,SOCIETY
169,177,281,ADT,CONCLUSION,COPYRIGHT,FMS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THREE
160,169,177,947,963,CALYPSO,COPYRIGHT,CRT,HEXAPOD,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,WITHOUT
169,695,BACKGROUND,COMPETING,CONVERSELY,COPYRIGHT,GLEASON,GROUP,LABEL,METHODS,OBJECTIVE,OUTCOME,PUBLISHED,RESULTS,SETTING,UROLOGY
169,COPYRIGHT,INC,PUBLISHED,SOCIETY,THERE
MV4,THESE
001,169,285,372,AST,BJU,CENTURY,CHICAGO,CMT,COMMISSION,CONCLUSION,FACTORS,GLEASON,INITIAL,JANUARY,JOINT,LABEL,MEN,METHODS,OBJECTIVE,OCTOBER,OPTIONS,PSA,RCT,RESULTS,T1C,T2B,THERE,THESE,TREATMENT,UNIVERSITY,UNLABELLED,WHILE
000,001,169,633,AUTHORS,BETWEEN,BJU,CONCLUSION,GOTHENBURG,LABEL,MEN,METHODS,OBJECTIVE,ORS,PSA,RANDOMIZED,RESULTS,SCREENING,T2B,THERE,TRIAL,UNLABELLED
169,BECKMAN,INHIBITION,INSTITUTE,JOURNAL,NELFINAVIR,S1P,S2P,SREBP,THESE,WESTERN
001,169,257,274,694,AUTHORS,BJU,HOWEVER,INDEX,LABEL,LEVEL,LRP,METHODS,OBJECTIVE,RESULTS,RRP,THERAPY,UNLABELLED
200,215,946,956,EM011,FOURIER,HOWEVER,NMR,NOS,OCH,PHASE
FURTHER,HOWEVER,OVERALL
002,044,048,169,201,505,ACCORDING,AUTHORS,BJU,CONCLUSION,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PREVIOUSLY,PSA,RESULTS,UNLABELLED
EMA,FDA,ZOLEDRONIC
447,532,FURTHER,INTER,POTENTIAL,THESE,WBV
169,366,BASED,CNR,COPYRIGHT,FIFTY,LTD,MRI,NMR,OVERLAP,SNR,TSE,ULTRASMALL,USPIO,WILEY
169,177,800CW,BIOLOGICAL,COPYRIGHT,IRDYE,LTD,NHS,NIR,PRIOR,WILEY
III,LABEL,OPINION,STATEMENT,THESE,UNASSIGNED
169,224,BACKGROUND,BASP1,COPYRIGHT,DNMT1,ERMAS,GADD45A,GADD45B,GSTP1,INC,LABEL,LAMB3,LNCAP,METHODS,MICROARRAY,PCR,RESULTS,SIRNA,SP1,TACSTD2,TARGETING,THESE,WESTERN,WILEY
169,22RV1,945,946,ACUTE,AKT,CHIR99021,COPYRIGHT,FINALLY,GLEASON,GSK,GSK3A,GSK3B,MDV3100
001,169,450,917,934,CIS,COPYRIGHT,COX,ESTIMATED,HODGKIN,HRS,INSTITUTES,MAPPING,NIH,OZONE,RESTRICTED,TOTAL,UVR
BACKGROUND,CLINICIANS,CRITICALLY,LABEL,MEDLINE,METHODS,NNT,RESULTS,SRE
100,169,185,COPYRIGHT,CURRENT,DSM,HRS
106,169,185,ADT,AHR,AMONG,BACKGROUND,COPYRIGHT,COX,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,RISKS,SETTING,STRATEGIES,UROLOGY
000,001,181,385,AGE,CONCLUSION,ELECTRONIC,LABEL,MARSHFIELD,METHODS,OBJECTIVE,PSA,RESULTS,SETTING,THERE,WISCONSIN
169,CLINICALLY,COPYRIGHT,HOWEVER,INC,METASTASIS,PUBLISHED,SOCIETY,SURGERY
168,169,945,946,AMONG,CONCLUSION,COPYRIGHT,FREEDOM,GLEASON,HOWEVER,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,945,CCK,CELLS,COPYRIGHT,DU145,HIF,HOWEVER,IGF,INC,KIT,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PC3,POTENTIAL,RESULTS,WESTERN,ZNSO4
169,961,AUTHORS,CONCLUSION,COPYRIGHT,IGF,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SETTING
169,THERE,WILEY

ANTIGEN,INCREASED,PIN,THESE,YIN,YY1
BACKGROUND,CONCLUSION,EVALUATION,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,OVERALL,PURPOSE,RESULTS,T1A,T1B,T2B,T2W,T3A,TNM,TSE
169,BOARD,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,WILEY
169,COPYRIGHT,INC,SOCIETY,THERE,WHILE
000,001,100,119,180,185,296,497,ASIAN,BETWEEN,INSURANCE,VTE
142,176,800,AMONG,COX,DUTCH,IMS
367,BETWEEN,MAY,MEN
169,COPYRIGHT,CROWN,DCA,HYBRIDARC,INC,MUS,PLANS,PUBLISHED
001,002,169,177,COPYRIGHT,D35,D95,ECLIPSE,FURTHER,INC,MEDICAL,PTV8100,PUBLISHED,THERE,THREE,V95
169,176,993,COPYRIGHT,COUCH,EXACT,GERMANY,INC,MEDICAL,NOVALIS,OVERALL,PUBLISHED,ROBOTIC,ROTATIONAL
001,003,162,169,794,BCR,COPYRIGHT,COVARIATES,COX,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PSA,PSM,RESULTS,RPP
945,946,COPOLYMERS,EDA,FLUTAMIDE,LNCAP,PEG
BACKGROUND,FEDERAL,LABEL,METHODS,NOTABLY,RESULTS,THESE,WHILE
ATP,BAF,BIOGRID,GENEMANIA,GILFORD,HUTCHINSON,INDEX,LAMIN,SNF,SWI,THESE
945,DESPITE,EXPRESSION,FAS,GSTP1,PC3,SIMILARLY,THESE,TNF,TRAIL
001,100,135,270,525,630,690,967,AFFYMETRIX,BACKGROUND,CONCLUSION,CRC,FURTHER,GENOTYPING,INDIVIDUAL,LABEL,METHODS,PCA,PLINK,PREVIOUSLY,RESULTS,SEVEN,SNP
701,APPLIED,BACKGROUND,BASED,CEP,FINDING,LABEL,PKC,PRINCIPAL,RESULTS,USING
169,AKT,GDC,GSK690693,HOWEVER
169,945,DESPITE,FURTHER,GRO,MMP,PKD,PROTEIN,THESE,USING
945,BMP,EGF,FGF,FUNCTIONAL,IIB,LNCAP,MC3T3,SHH,SMAD1,SONIC,TAKEN
946,DESPITE,HOWEVER,HSP90,NLS,PCA,SYNTHESIS,THEREFORE,WHEREAS
945,ASIAN,DESPITE,HOWEVER,THESE
CURRENT,DESPITE,EIT,TREIT,ULTRASOUND,WHILE
945,946,AKT,MAMMALIAN,PC3,PI3,PKC,PROTEIN
181,AIM,CONCLUSION,FURTHER,LABEL,MCP,METHODS,OBJECTIVE,PROSTACAID,RESULTS,SECRETION,WESTERN
203,377,649,ACE,BMI,COX,EFFECTS,GENERAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,POISSON,RESULTS,SETTING,THERE
ERG,HDAC1,HDAC2,HDAC3,HDACS,HOWEVER,SEQ,TAKEN,USING
169,260,BACKGROUND,COPYRIGHT,EAU,GERMANY,LABEL,LNI,LTD,METHODS,OVERALL,PLNDS,RESULTS,UROLOGY
169,ADDITIONAL,COPYRIGHT,FURTHER,LTD,PC3,TAKEN,ZKSCAN3
800,ADVANTAGE,BACKGROUND,END,ENROLLEES,LABEL,MEDICAL,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SMALL,VDW,VIRTUAL,WAREHOUSE
169,BRE,CRC,FACTORS,GLEASON,III,METASTASIS,PROGNOSTIC,REGARDLESS,TNM,UNION
012,122,177,956,BACKGROUND,BMS,CAP,CONCLUSION,LABEL,LIPOPHILIC,METHODS,RESULTS,STATINS
169,CFS,COPYRIGHT,HOWEVER,PCA,SEVERAL,SINCE
000,123,GLEASON,HOWEVER,LNS,PATHOLOGY,SOCIETY,UROLOGICAL
BACKGROUND,COVERED,DESPITE,HGF,LABEL,MET,METHODS,OPINION,PHASE,UNDER
GDI,GDP,HOWEVER,PROTEIN,RHO,SINCE,TMA
169,945,946,COPYRIGHT,EPH,EPHA2,PC3,SURFACE,THESE,VCH,WILEY
169,BACKGROUND,COPYRIGHT,CXR,H89,HOWEVER,HPR50,INC,LABEL,LNCAP,METHODS,OXIDATIVE,PDE4B,PKA,RESULTS,WESTERN,WILEY
161,175,181,191,195,205,351,365,947,BACKGROUND,CD4,CD8,DR1,ELISPOT,HLA,IFN,INC,LABEL,METHODS,MHC,PAP,PROSTATIC,PUBLISHED,RESULTS,WILEY
AAS,AFRICAN,BASED,COMMUNITY,SOUTH,VESEY
690,SEX,WOMEN
FIFTY,RESULTING,SEVEN,THESE
016,182,198,319,413,457,474,611,793,804,818,FEULGEN,JANUARY,LABEL,METHODS,OBJECTIVE,OCTOBER,PURPOSE,RESULTS,TOTAL,URINE
043,085,562,CIS,FIFTEEN,INSULIN,JANUARY,RRS,SUMMARY,THESE,USA
153,223,DECISIONS,EDTMP,GIVEN,LABEL,MET,OPINION,SRC,STATEMENT,UNASSIGNED
197,256,945,CAUCASIAN,CYP17,CYTOCHROME,PCR,PSA
945,946,CCK,CD133,NANOG,PC3,WESTERN
100,200,AFTER,MTT,P20,TRAIL,WESTERN
BASIC,CONFERENCE,CURRENT,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,STRATEGIES,SUCCESSFUL,SURVIVORS,THERE
PSA,THEREFORE
512,AFRICAN,AUC,CALCULATOR,CLEVELAND,GLEASON,GRADE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PREVENTION,RESULTS,TRIAL
061,086,160,177,240,CONCLUSION,DEGARELIX,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THREE
CONCLUSION,LABEL,METHODS,THESE
001,177,800,961,ADC,ANOVA,DIFFERENT,FORTY,GLEASON,KEY,LABEL,METHODS,MINIMUM,MRI,OBJECTIVE,OBJECTIVES,PCA,RESULTS,SUBJECTIVE
METASTASES
160,268,347,CONCLUSION,DAILY,DIETARY,HRS,LABEL,METHODS,MIDLIFE,OBJECTIVE,ORS,PCA,RESULTS,REYKJAVIK,THROUGH
160,798,BACKGROUND,IGF,IGFBP,LABEL,METHODS,RESULTS,THERE
114,121,160,230,514,620,COX,DIETARY,HRS,LABEL,MELBOURNE,METHODS,OBJECTIVE,PURPOSE,RESULTS
160,588,814,BASED,FURTHER,LABEL,METHODS,OBJECTIVE,POISSON,PURPOSE,RESULTS,SMALL
100,BECAUSE,C2ORF40,ECRG4,HEK,PC3,WHEREAS
947,950,CAR,CD3,ERBB2,LABEL,METHODS,NOTABLY,OBJECTIVE,PURPOSE,RESULTS,SFG,THESE
946,E26,MVS,PCA,THERE
BAK,BAX,BCL,BETULINIC,FURTHER,HOWEVER,NPC,THESE
218,436,BACKGROUND,BECAUSE,EIGHT,FACTORS,LABEL,METHODS,RESULTS,TOTAL
1980S,ANATOMICAL,CURRENTLY,HOWEVER,THESE,WALSH
DESPITE,GLEASON,HOWEVER,PSA
THERE
HOWEVER,REPORTS
025,046,1304G,1304T,160,222,244,441,452,647,670,948,993,CONCLUSION,ELISA,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,SNP
032,160,AGE,AVERAGE,LABEL,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,TOKUHASHI
001,003,100,102,639,AUSTRALIA,CRC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SIR,SIX,THERE,USA,ZEALAND
OVERALL,PSA
116,145,169,350,COPYRIGHT,GOLGI,HCT,HOWEVER,PDT,PEG
169,COPYRIGHT,OTHER,PRO197LEU,SNP,SOD
139,177,278,286,BACKGROUND,CONCLUSION,FAILURE,LABEL,LRP,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
001,215,BACKGROUND,CONCLUSION,HOWEVER,IRRADIATED,LABEL,METHODS,NON,PC3,RESULTS
946,MODULATION,OVERALL,PROTEIN,THEREFORE
744,ARG,ASN,ASP,BACKGROUND,CONCLUSION,CURRENT,GLY,LABEL,METHODS,NGR,RGD,THESE,TUMORHOPE
946,LNCAP,SRY,THESE
388,CONTIGUOUS,DPC,EPE,GLEASON,NPC,PNI,PSA,SVI
006,040,045,065,151,448,643,BACKGROUND,LABEL,METHODS,PTH,RESULTS,SECONDARY,SERUM
10Q26,800,945,946,FGFR2,MMP,NOS2A,RESULTS,TGF,TNF
000,100,AFFAIRS,AGE,AIM,AVERAGE,CONCLUSION,CROATIA,DEPARTMENT,INCIDENCE,JOINPOINT,LABEL,METHODS,MORTALITY,NATIONS,OBJECTIVE,POPULATION,RESULTS,TREND,WORLD
CONCERNING,FINALLY
BRCA1,BRCA2
BPH,PCA,ROS
797,824,APRIL,AUC,BACKGROUND,DCE,ECE,FIRST,HISTOLOGIC,IMAGING,LABEL,MATERIALS,MAY,METHODS,MRI,NPV,PCA,PPV,RADICAL,RESONANCE,RESULTS,SVI,THEREFORE
EWING,OVERALL,STEAP,STILL
HOWEVER,PSA,ZEALAND
169,241,COPYRIGHT,LABEL,MCC,METHODS,OBJECTIVE,OBJECTIVES,ORA,PUBLISHED,RESULTS,SPAIN,THESE
153,169,281,290,AEU,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESPONSES,RESULTS,SPAIN,SPANISH,THESE,TREATMENT
169,176,1MM,5MM,AFTER,BACKGROUND,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEN,THERE
002,003,004,006,016,037,074,169,718,ACTUARIAL,AMONG,CONVERSELY,COPYRIGHT,DIFFERENT,IRELAND,LABEL,LTD,METHODS,MVA,OBJECTIVE,PURPOSE,RESULTS,UNIVARIATE,UVA,V75
107,160,169,215,BACKGROUND,CONCLUSION,COPYRIGHT,DEFAULT,EUD,FINALLY,FWS,HENCE,LABEL,LTD,METHODS,MFS,OBJECTIVE,PFS,PUBLISHED,PURPOSE,RESULTS,TEN,THERE,TREATMENT
169,BILATERAL,COPYRIGHT,MEDICAL,PSA,PUBLISHED,RAP,ROBOTIC,TEN,UROLOGY
153,169,186,223,COPYRIGHT,IRELAND,LTD
169,ATP,COPYRIGHT,COX,DU145,P2Y,PKC,PLA,PREVIOUSLY,SAS,SRC
169,177,CONCLUSION,COPYRIGHT,INC,LABEL,MAY,METHODS,OBJECTIVE,OVERALL,PATIENT,RESULTS,STRICTURE,TREATMENT
169,201,231,ABSCESSES,CHRONIC,COPYRIGHT,DOPPLER,ENDORECTAL,MRI,PUBLISHED,SAS
001,134,169,200,210,ACCEPTABLE,AFTER,AUTHORS,BJU,DIAGNOSTIC,DUE,FCH,HOWEVER,JANUARY,LABEL,LEVEL,LND,LNE,LNS,METHODS,MRI,NPV,OBJECTIVE,OBJECTIVES,OTHER,PET,PPV,RESULTS,SEVERAL,STAGING,THEREFORE,UNLABELLED
002,101,169,205,220,603,623,BCL,BECAUSE,BJU,COX,CURRENT,GIVEN,LABEL,METHODS,OBJECTIVE,OVERALL,PFS,RESULTS,SERUM,UNLABELLED
169,220,530,ASSESSMENT,BCR,BJU,CAPRA,DESPITE,DIFFERENT,GRAPHICAL,HOWEVER,INCREASING,LABEL,LEVEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PROGNOSIS,RESULTS,SCORE,THEREFORE,UNLABELLED,USA
169,AUC,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRL,OBJECTIVE,PSA,PURPOSE,RESULTS,ROC,SIXTY,STEPHENSON
169,388,COPYRIGHT,DSH,DVH,HOWEVER,IRELAND,LABEL,LKB,LTD,MATERIALS,METHODS,OBJECTIVE,OUTCOME,PURPOSE,RESULTS,SUBJECTIVE
169,AHMED,AUTHORS,BJU,GIVEN,LABEL,MATERIALS,MEDLINE,METHODS,OBJECTIVE,OCTOBER,RESULTS,THERE,THREE
001,004,042,047,053,169,329,354,676,AFRICAN,AMERICANS,AMONG,BJU,CLINICIANS,COMPOSITE,CONVERSELY,INDEX,LABEL,LEVEL,METHODS,NOTABLY,OBJECTIVE,OBJECTIVES,PDE5I,PSA,RESULTS,THERAPY,THERE,THOSE,UNLABELLED,VED
169,AEU,BCG,CARCINOMA,COPYRIGHT,LABEL,METHODS,NMIBC,OBJECTIVE,OBJECTIVES,PROSTATIC,PUBLISHED,RESULTS,STROMAL,UROTHELIAL
169,AEU,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,METHODS,OBJECTIVE,PUBLISHED,SUMMARY
169,AEU,ASTRO,AUA,COPYRIGHT,DISSECTION,EAU,END,ESTRO,FORUM,LABEL,METHODS,OBJECTIVE,PCA,PIVOT,PSA,PUBLISHED,RESULTS
110,956,AAP,DAP,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,THREE
031,034,060,185,230,294,326,390,468,505,607,767,852,ITALY
ADC,DIFFUSION,INITIAL
ASPIRIN,BACKGROUND,LABEL,METHODS,REGULAR,RESULTS,SEPTEMBER
141,169,BACKGROUND,BIVARIATE,BLACK,COPYRIGHT,LABEL,METHODS,PROVIDERS,PSA,RESULTS,SOCIETY
ANTIGEN,OWING
120,178,185,215,406,BASED,IMAGING,MINIMUM,T1C,TAILORING
001,027,055,079,208,230,956,BEIJING,CONCLUSION,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SERUM
160,200,MLC,THREE
460,913,BACKGROUND,BRCA1,CONCLUSION,LABEL,METHODS,MULTIPLEX,RESULTS,THERE,USING
169,361,959,ADDITIONAL,AFTER,BASEL,CAUCASIANS,COPYRIGHT,LABEL,LIBRARY,METHODS,OBJECTIVE,PCA,RESULTS,STATA
001,003,004,040,150,169,487,CAP,COPYRIGHT,COX,INC,LABEL,LNS,LOG,MATERIALS,MEIER,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PSA,RESULTS,TOTAL
GLEASON,MODALITIES,THREE
CASTRATION,FDA,III,NEOPLASIC,SIPULEUCEL,THESE
DOCETAXEL,OTHER,PREDICTIVE,UNTIL
223,III,MDV3100,OTHER
169,676,783,AUC,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,RADICAL,RESULTS,ROC,STAGE,T1C
945,AXL,DU145,HIF,KNOCKDOWN,LNCAP,PC3,SNAIL
169,174,208,215,243,452,AIM,BACKGROUND,BECKMAN,CONCLUSION,COPYRIGHT,COULTER,EARLY,INDEX,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SAS,SERUM,WHETHER
003,009,036,169,177,377,AFTER,AMICO,CHI,CONCLUSION,COPYRIGHT,GLEASON,GROUP,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,SAS
169,177,1ST,CONCLUSION,COPYRIGHT,COTONOU,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,SAS
DU145,THEREFORE,THESE
169,HOWEVER,UROLOGICAL,UROTHELIAL
BACKGROUND,CURRENT,LABEL,METHODS,RESULTS,THERE,USING
100,945,AKT,DU145,FURTHER,HIF,HUVEC,OVERALL,PCA,RESULTS,THESE,THISTLE,THREE
ANTIGENIC,BACKGROUND,CD49F,EPCAM,EPITHELIAL,EVALUATION,FURTHER,LABEL,LCS,NON,PCR,PCS,PRINCIPLE,PSA,RESULTS,SCS
FINALLY,GAP,LNCAP,VITAMIN
FIRST,IGF,MEN,METABOLIC,PCA,WHILE
001,003,024,025,033,169,AKT,BACKGROUND,COPYRIGHT,DIETARY,HCD,HFD,HOWEVER,INC,LABEL,LNCAP,MCP,METHODS,PCA,RESULTS,WILEY
169,600,BRCA1,BRCA2,BRITAIN,COMPARISON,COPYRIGHT,GREAT,IRELAND,LTD,PUBLISHED,RECURRENT,SOCIETY,SOMATIC,THESE,TSHZ3,UTILIZING,WILEY
152,169,BACKGROUND,BCR,CIS,COPYRIGHT,COX,INC,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,RRS,SRT,THESE,WILEY
169,BACKGROUND,COPYRIGHT,CSC,DESPITE,INC,LABEL,METHODS,RESULTS,THESE,WILEY
CARLO,GENERAL,MGH,MONTE,PBS
144
169,COPYRIGHT,FSH,INC,WHILE
169,215,BRITISH,COPYRIGHT,ETL,FOV,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVERAL,SOCIETY
169,8MM,COPYRIGHT,FACTORS,FIRST,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THREE
169,CONCLUSION,COPYRIGHT,CTL,DNASE,EXPRESSING,HLA,INC,LABEL,METHODS,OBJECTIVE,RESULTS
BIPOLAR,ELECTRODE,OLYMPUS,TURBT,USA
246,293,BACKGROUND,DUE,LABEL,MATERIALS,METHODS,RESULTS,REVENUE,SEVENTY,USING
100MG,169,946,COPYRIGHT,LTD,PUBLISHED,SAR,SUBSEQUENT
003,026,041,042,045,060,113,169,183,257,454,644,655,AFTER,ASSESSMENT,BACKGROUND,COMPOSITE,COPYRIGHT,COUNCIL,FOCAL,FOUNDATION,FUNCTIONAL,FUNDING,GENERAL,GLEASON,INDEX,IQR,LABEL,LTD,MEDICAL,MEN,METHODS,MRI,PELICAN,PRIMARY,PSA,RADICAL,RESULTS,SCORE,SYMPTOM,THERAPY,THERE,TRIAL,TRUST,URINARY
947,CD8,HLA,IFN,LOCAL
381,AMONG,IMMIGRANT,INSURED,PAP
197,946,ABC,GOLGI,PROTEIN,S37,T41,TGN,THESE,WHEREAS,WHILE,WNT
487,501,AGC,FINALLY,GTPASES,HOWEVER,PROTEIN,RHO
100,976,AMONG,BACKGROUND,CONTEXT,END,INTENSITY,LABEL,METHODS,OBJECTIVE,OUTCOME,POPULATION,RATES,RESULTS,SETTING,THERE
001,100,149,942,954,983,APC,BPH,GSTP1,PCA,PSA,ROC
FINALLY,HOWEVER,III,PSA
CGA
ANATOMICAL,AUTOMATIC,FIRST,REGIONS,THIRD
HOPKINS,JOHNS,PATHOLOGY,RECURRENT,THREE,TYPICALLY
001,002,003,133,945,CHOCC,FOLLOWING,FRESH,GLEASON,INTEGRITY,LABEL,LOW,MAS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SAMPLES,VII
169,175,288,440,AMICO,ANZ,AUSTRALIA,AUTHORS,BACKGROUND,COLLEGE,CONCLUSION,CONTINENCE,FELLOWSHIP,FORTY,JOURNAL,LABEL,LRP,METHODS,OCTOBER,PATIENT,RESULTS,ROYAL,SEPTEMBER,SURGERY,THERE,USING
A300E,CD3,USING
101,BINDING,CAV,CSD,ELISA,FURTHER,GSH,GST,N32,POTENCY
BIOACTIVE,CERTAIN,LNCAP,THESE
22RV1,916,CL1,CTGVT,D55,DD3,DU145,E1A,E1B,PCA,TARGETING,THERAPY,THEREFORE,TUNEL,WESTERN
AKT,INHIBITION,LNCAP,PSMC1,THERE,TTK
E2F,HDAC3,HOWEVER,PCA
002,023,026,123,670,CONCLUSION,LABEL,METHODS,OBJECTIVE,OTHER,PROVIDERS,PURPOSE,RESULTS,THERE,THESE
001,290,578,611,647,722,CONCLUSION,IBF,LABEL,METHODS,OBJECTIVE,PCM,PURPOSE,RESULTS,SEVENTEEN,THERE
916,CHROMATIN,DHS,DNASE,THESE,WHILE
839,ADVERSE,AFFAIRS,BACKGROUND,CHARLESTON,CONCLUSION,CONTEXT,FIFTY,GLEASON,HOWEVER,JOHNSON,LABEL,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,OTHER,OUTCOME,PSA,RALPH,RESULTS,SETTING,SOUTH,UNIVERSITY
000,104,AFRICAN,AVERAGE
169,COPYRIGHT,CTC,DTC,FURTHER,GFP,HOWEVER,INC,WILEY
169,183,945,956,ADENIJI,AKR1C,COPYRIGHT,INHIBITION,LTD,MED
365,CARLO,CHAIN,EARLY,HOWEVER,MONTE
100,123,140,169,190,200,390,470,956,BACKGROUND,COPYRIGHT,DU145,F11,GENERAL,GREEN,HOWEVER,LABEL,LNCAP,METHODS,RESULTS,ROS,SINGLET,TOXIC,U87,UNDER
244,300,III,OVERALL,SIMILARLY
169,AUTOPHAGIC,AUTOPHAGY,BECAUSE,INC,NVP,PDT,SOCIETY,WILEY
169,COMPOUNDS,ESIMS,KUNTH,PC3,ROS,SOCIETY
169,1C3,946,956,AKR,AKR1C,BRAZILIAN,MOLECULAR,PC3,SOCIETY
169,ADDITIONAL,CSC,EHF,EMT,ETS,LOW
101,EPIGENETIC,EXPRESSION,K27,RAF,SUZ12,THESE,USING
27A,ANDROGENS,HOWEVER,INCREASING,MICRORNAS,PHB,PROHIBITIN
GIVEN,GLEASON,KALLIKREIN,KLK,KLK14,USING
143,331,DECREASED,EIGHT,KALLIKREIN,KLK,KLK10,PCA,PCR,THESE
EPIGENETIC,KLK,REPORTS
KLK
CONVERSELY,EMT,MALIGNANT,SNAI1,TIC
AKT,ARF,EPIGENETIC,INK4A,PCA
145,169,945,BINDING,BPH,COPYRIGHT,DESPITE,FUNCTIONAL,HIF,HYPOXIA
2C4,ERB,ERBB2,HERCEPTIN
003,014,016,022,117,158,169,179,COPYRIGHT,ERG,INC,PCA,PCR,TMPRSS2,WILEY
169,956,COPYRIGHT,INC,USING,WILEY
181,EGC,HAT,THESE
FOURIER
1B1,4326C,4326G,CIS,ORS,PCA
PCA,THESE
ETS
HOWEVER,PSA
100,103,115,ALP,COX,GLEASON,MEIER,PCA,THESE
AAD,ANNEXIN,APOPTOSIS,BAX,BCL,CASPASE,GAPDH,HMGN5,INFECTION,LNCAP,PCR,TUNEL,WESTERN

000,AUTOPSY,DIAGNOSES,HOWEVER
149,178,FURTHER,HOWEVER,INFECTION,MAY,PSA,SEPTEMBER,THERE
169,188,AMP,CONSISTENT,CONVERSELY,COPYRIGHT,INC,LNCAP,PKA,RHO,SER188ALA,THESE
120,169,CONCLUSION,COPYRIGHT,FDG,LABEL,LTD,METHODS,OBJECTIVE,PERHAPS,PET,RESULTS,SUV
169,CONCORDANT,COPYRIGHT,HENCE,INC,THESE
169,375,400,BAX,CAP,CONCLUSION,COPYRIGHT,EXISULIND,GLEASON,INC,LABEL,MEN,METHODS,OBJECTIVE,PUBLISHED,RESULTS,THERE
169,COPYRIGHT,DESPITE,INC,MINOR
001,053,169,215,318,410,564,622,642,650,756,765,801,960,AVERAGE,CAP,COMPARISON,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PEARSON,PSA,RESULTS,RRP,UNIVERSITY
167,169,546,603,838,APRIL,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,MEIER,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
169,COPYRIGHT,HOWEVER,LTD,OVERALL,PSA,THEREFORE,ULTIMATELY
169,174,250,C30,COPYRIGHT,EDUCATION,EULEXIN,FLUTAMIDE,INC,LABEL,MATERIALS,METHODS,MONITORING,OBJECTIVE,ONPHASE,PUBLISHED,PURPOSE,QLQ,RESULTS,THERAPY,UROLOGICAL
169,AUTHORS,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,PET,PSA,RESULTS
169,BACKGROUND,CNA,COPYRIGHT,HOWEVER,LABEL,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SNV,SWE,TEN,UROLOGY
018,130,133,169,264,750,ADT,ASTRO,BACKGROUND,COPYRIGHT,COX,FLUTAMIDE,LABEL,MARCH,MEIER,METHODS,OBJECTIVE,OUTCOME,OVERALL,PFS,PHOENIX,PUBLISHED,RADIOLOGY,RESULTS,SECONDARY,SETTING,SOCIETY,UROLOGY
042,169,173,383,ADT,AUTHORS,BJU,C30,LABEL,LEVEL,METHODS,OBJECTIVE,PCA,PSA,QLQ,RCT,RESULTS,SECONDARY,THERAPY,UNLABELLED
001,169,AFTER,BACKGROUND,BES,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,NEITHER,OPTIMAL,PERSISTING,PSA,RESULTS,TAM,TAMOXIFEN
100,169,ACUTE,BJU,BONFERRONI,CUMULATIVE,INDICES,LABEL,LEVEL,METHODS,OBJECTIVE,OVERALL,PATIENT,QOL,RESULTS,SYMPTOM,THERAPY,THESE,UNLABELLED,URINARY
169,ABSTRACTS,ADDITIONAL,AUTHORS,BJU,EFFECTS,JANUARY,KNOWLEDGE,LABEL,LVI,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,REVIEWS,SCHOLAR,SYSTEMATIC,WEB
001,169,366,373,AFRICAN,BECKMAN,BJU,CAUCASIAN,CONCLUSION,COULTER,DEFENSE,DEPARTMENT,DIAGNOSTIC,HYBRITECH,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,UNLABELLED,USING
FURTHER,GERMANY,MEANWHILE,SRE,THESE,WHILE,ZOLEDRONIC
169,175,177,182,240,ADT,BJU,DECREASES,DEGARELIX,INDEX,KEY,LABEL,LEVEL,MEDICAL,METHODS,OBJECTIVE,PCA,PSA,QOL,RCT,RESULTS,SCORE,SYMPTOM,THERAPY,TPV,UNLABELLED,WHILE
169,AFRICAN,BLACKWELL,DIGITAL,FVIII,LTD,PSA,PUBLISHING
AFTER,BLP,EGF,III,PHASE
HOWEVER,MEN
223,AREAS,AUA,BACKGROUND,COVERED,HOWEVER,III,LABEL,METHODS,OPINION,PHASE,THEREFORE
946,ACTIVATION,ADRENERGIC,ARRESTIN2,ARS,THESE
AFP,GOLGI,HCC,HOWEVER
008,114,BACKGROUND,CONCLUSION,CYP24A1,CYP27A1,CYP27B1,LABEL,MARCH,MEN,METHODS,PATHWAY,RESULTS,SNP,TESTS,VDR
101,169,ACTIVATED,AMONG,BACKGROUND,COPYRIGHT,ESI,HOWEVER,IONIZATION,LABEL,LTD,METHODS,PSA,RATIONALE,RESULTS,SURFACE,THEREFORE,WILEY
169,COLLEGE,COPYRIGHT,DWI,LTD,MRI,PUBLISHED,ROYAL,THERE
100,ASM,ROUSSON
945,BACKGROUND,CONCLUSION,HIF,HYPOXIA,INCREASED,LABEL,METHODS,MYC,NSC,ORTHOTOPIC,RESULTS,TREATMENT
117,131,169,186,206,248,274,280,298,392,554,852,BETWEEN,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
169,308,374,413,709,961,BOARD,COPYRIGHT,EDUCATION,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THESE,TOTAL,UROLOGICAL,UROLOGY,WHILE
001,169,212,255,298,414,687,COPYRIGHT,EDUCATION,GLEASON,GRADING,INC,KAPPA,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UPGRADING,UROLOGICAL
169,427,642,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
137,169,257,265,775,COPYRIGHT,EDUCATION,INC,LABEL,LOWER,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,017,123,169,211,251,365,739,COPYRIGHT,COX,EDUCATION,EQUAL,GLEASON,INC,LABEL,MATERIALS,MEIER,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THEREFORE,UROLOGICAL
015,169,177,245,331,COPYRIGHT,EDUCATION,HOWEVER,INC,INCREASING,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,002,045,049,169,204,ADULT,COPYRIGHT,COX,EDUCATION,EVALUATION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T2BN0M0,UROLOGICAL
027,160,169,175,178,353,COPYRIGHT,EDUCATION,IMAGING,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,SIX,SUSPICIOUS,UROLOGICAL
132,169,606,AMICO,COPYRIGHT,EDUCATION,END,EXCLUSION,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,THERE,THOSE,UROLOGICAL
01876,169,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
101,169,AUSTRALIAN,AUTHORS,BACKGROUND,BETWEEN,COLLEGE,HDR,IMAGING,JOURNAL,LABEL,MEDICAL,METHODS,POTENCY,RADIATION,RESULTS,ROYAL,SIXTY,ZEALAND
169,AUSTRALIAN,AUTHORS,COLLEGE,IMAGING,JOURNAL,LABEL,MATERIALS,MEDICAL,METHODS,OAR,OBJECTIVE,PLANS,PURPOSE,RADIATION,RESULTS,ROYAL,THERE,ZEALAND
169,COPYRIGHT,INC,RELATED,THROUGH,UNDER
RBI1033,REMOVAL
145,169,945,954,BMS345541,COPYRIGHT,FINALLY,HOWEVER,IKK,INC,NEOPLASIA,PC3,PCA,PRESS,SIMILAR,TAKEN
006,026,12Q21,15Q21,215,800,903,945,946,ANTIGEN,BECAUSE,CAUCASIAN,CHROMOSOME,PSA,SCREENING,THESE,TYROL
008,100,250,398,AFFAIRS,AFTER,BACKGROUND,CONTEXT,COX,HOWEVER,JANUARY,LABEL,LARGE,LOW,MEASURE,METHODS,NORTHWEST,OBJECTIVE,OUTCOME,RESULTS,SETTING,THESE,TOTAL
169,ARS,CURRENT,FKBP5,MEL,PSA,T877A,W741C
946,APC,BINDING,GSK,HOWEVER,SMAD7,TGF
102,169,183,191,297,AZA,EPIGENETIC,FUNCTIONAL,GEORG,IGF,M12,P69,PITX2,STUTTGART
169,BACKGROUND,COPYRIGHT,INC,INHIBITION,LABEL,METHODS,MMP,OPN,PCA,PCR,RESULTS,THESE,WILEY
169,181,BASED,COPYRIGHT,HOWEVER,III,INC,LNCAP,NAD,WILEY
004,037,052,101,325,ADDITIONAL,ASSESSMENT,BACKGROUND,CONCLUSION,GROUP,LABEL,METHODS,OBJECTIVE,RESULTS,SCALE,SYMPTOM,THERE,WEB,WEBCHOICE
244,248,AFRICAN,AMERICANS,BACKGROUND,CONCLUSION,FACTORS,KEY,LABEL,MEASURING,METHODS,MHQOL,OBJECTIVE,OTHER,PHQOL,QOL,RESULTS,TELEPHONE
100,177,181,183,CANDIDA,GEORG,H37RV,MCF,MIC,PLA,POLYGONUM,STUTTGART,THP,VRE
100,945,AMACR,BESIDES,KIT,KSP,NAS,OTHER
166,TMEM166,VARYING
EARLY,MINIMALLY,NOTES,WHILE
HODGKIN,MORTALITY,THERE

001,215,65285,65308,65309,951,ADC,DIFFUSION,DWI,MRI
000,241,956,AMONG,ARCAP,BACKGROUND,CONCLUSION,CPG,EMT,GENISTEIN,LABEL,METHODS,RESULTS,TNF,USING,WNT
169,ASA,COPYRIGHT,GLUCOSE,LTD,PC3,SKBR3
009,100,103,110,125,145,169,185,204,239,COPYRIGHT,D90,GLEASON,INC,LABEL,MATERIALS,MEDICAL,METHODS,NETWORK,OBJECTIVE,PNI,PSA,PURPOSE,RECORDS,RESULTS,TAHOE,TREATMENT,VARIABLES
002,003,005,169,179,238,COPYRIGHT,EXPRESSION,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RESULTS
221,946,PCL,PEG,PSMAA10,TGX,THESE
22RV1,946,ELISA,PTPRF,THESE
945,AFP,CDS,CEA,ECL,ITO,PSA,RET,USB
CONTROL,DTX
465,788,795,885,DESORPTION,PCA,THESE
239,BACKGROUND,CD4,CD8,DBY,FINALLY,FURTHER,LABEL,MHC,PRINCIPAL,RESULTS,TRAMP
19A,727,BACKGROUND,LABEL,MEANS,PCR,PRINCIPAL,RESULTS,SAMPLES,TRANSCRIPT
552,946,CHROMATIN,DU145,HOWEVER,SER,STAT3,WNT
001,002,100,ADT,AFTER,BMD,CONCLUSION,DXA,FIFTY,FRACTURES,IAD,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,SUBSEQUENT
104,BACKGROUND,CONCLUSION,LABEL,METHODS,POTENTIAL,RESULTS
003,007,008,AIM,BECAUSE,CONCLUSION,EMPIRICAL,FSH,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PRL,PSA,RESULTS,TRUSB
BACKGROUND,CONCLUSION,EXPRESSION,FURTHER,HTR1A,HTR1B,HTR2B,LABEL,MATERIALS,METHODS,RESULTS
BRCA1,FINALLY,LIMK2
000
FEDERAL,THESE
HOWEVER,SIMILARLY
173,598,627,THESE
FORTY,SIX
169,BACKGROUND,COPYRIGHT,LABEL,LTD,METHODS,MRI,RESULTS,SNR,WILEY
FINALLY,THESE
017,035,044,BACKGROUND,FORTY,INITIAL,LABEL,MAB,METHODS,PSA,RESULTS,THERE,TTP,WHITNEY,ZOL
100,FINALLY,NPS,TNP
000,169,AKT,ATG12,BECLIN1,HOWEVER,LC3,THESE,THROUGH
248,361,576,995,ENGLAND,EQUIVALENT,INCIDENCE,JOINT,LABEL,LINKAGE,METHODS,NHS,NJR,OBJECTIVE,OUTCOME,RESULTS,SETTING,SIMILARLY,THESE,WALES
169,947,948,ATM,BAD,BAX,COPYRIGHT,H2A,HRPCS,INC,PKC,ROTTLERIN,SER1981,USING
945,947,948,HOWEVER,PREVENTION,TRIAL,VITAMIN
177,207,369,400,419,737,ABT,APOPTOSIS,BAX,BCL,DOCETAXEL,LABEL,MCL,METHODS,MTT,OBJECTIVE,RESULTS,WESTERN
002,012,023,029,068,149,177,181,200,205,380,707,749,766,AFTER,AUC,CHINESE,LABEL,LOW,METHODS,OBJECTIVE,PSA,RESULTS
100,945,CONCLUSION,GRADE,LABEL,METHODS,OBJECTIVE,RESULTS,SMA
100,141,181,BETWEEN,CONCLUSION,JANUARY,LABEL,METHODS,MRDWI,OBJECTIVE,PSA,RESULTS
001,144,174,177,217,333,357,616,636,CLAVIEN,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,OPERATIVE,PURPOSE,RESULTS,RRP,SOCIETY
APY,EPH,EPHA4,ISOTHERMAL,KYL,NMR,VTM
CAP,SCANO
125,168,312,DAR,DIGITAL,FDG,HENCE,LNCAP,PCA,PSA,PSA30
AIM,CONCLUSION,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS
ADDITIONAL
169,945,946,957,AAZTA,BECAUSE,COPYRIGHT,MOLECULAR,MRI,PET,RGD,THESE,VCH,WILEY
169,AFTER,COMPARING,COPYRIGHT,INC,LABEL,METHODS,NON,OBJECTIVE,RESULTS,RRP,SIXTY,UPP,WILEY
169,COPYRIGHT,DCE,HOWEVER,INC,MRI,THERE,THESE,WILEY
015,047,169,CONCLUSION,COPYRIGHT,DOA,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,RRP,SIXTY,THEREFORE,URA,WILEY
160,COLORECTAL,LABEL,METHODS,OBJECTIVE,OVARIAN,PURPOSE,RESULTS,SIMULATED,UNDER,WHILE
CHINESE,LABEL,METHODS,MODEL,OBJECTIVE,PCA,RESULTS
021,255,945,946,ABHD4,AFTER,FAK,HOWEVER,INDUCTION,SRC
AFTER,CHANGES,COX,LABEL,MEIER,METHODS,MULTI,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
169,BACKGROUND,COPYRIGHT,CTT,DECREASING,INC,LABEL,LNCAP,METHODS,PCTCS,PEG,RESULTS,WILEY
152,AIM,CD117,CONCLUSION,EARLY,GISTS,JANUARY,KIT,LABEL,METHODS,OBJECTIVE,PRE,RESULTS,SURGERY,THESE
120,182,226,356,ABLATHERM,ACTUARIAL,AMICO,BACKGROUND,CENTRES,DISEASE,LABEL,METHODS,PHOENIX,PSA,RESULTS,TMS,WHOLE
GREATER,HOWEVER,QOL,THESE
130,169,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RADICAL,RESULTS,T3A,T3B,UROLOGICAL
001,004,010,049,169,286,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SHORTER,STRATIFIED,UROLOGICAL
001,012,119,124,150,169,226,238,275,281,330,580,ACCORDING,ADD,APRIL,AUTHORS,BCR,BJU,CONCLUSION,COX,CSS,GLEASON,HOWEVER,KNOWN,LABEL,LNS,MEIER,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PSA,RESULTS,SIMILARLY,SUBJECT,UNLABELLED
169,185,A11,BLACKWELL,BW4,HLA,KIR,LTD,NATURAL,PCR,PUBLISHING,SSP
SECONDARY,THESE,TREATMENT
144,18F,241,532,AMONG,BACKGROUND,BNC,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,THEIR,VAN,VELTHOVEN,VVT
003,008,015,215,ASIAN,BACKGROUND,BMAL1,DIAGRAM,DISRUPTION,KINGDOM,LABEL,NEITHER,PRINCIPAL,PUNJABI,RESULTS,SAT2D,SNP,SOUTH
100,177,376,CRANIAL,CTV,D90,HDR,HOWEVER,USING
BAX,BCL,DU145,ETHANOL,EUR,LNCAP,RCM,RUBUS
4T1,945,946,954,AKT,CHEMOKINES,IKB,LUC,MCP,OVERALL,TGF
FURTHER,HOWEVER,MYC
ATM,ATR,HOWEVER,NKG2D
169,946,COPYRIGHT,PCR,POTENTIAL,SEVERAL
COMPETING,DIC,GIBBS,VARIOUS
169,COPYRIGHT,CSC,FURTHER,GENISTEIN,IRELAND,LTD,PCA,TCS,THEREFORE
16Q23,HOWEVER,THESE
947,BPH,CURRENTLY,DU145,LNCAP,OLEUROPEIN,OXIDATIVE
100,169,192,207,332,449,497,995,AMONG,COPYRIGHT,CSS,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
169,177,486,AFTER,COPYRIGHT,CTV,DOSIMETRIC,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNS
169,ANORECTUM,BLADDER,COLON,CONSENSUS,COPYRIGHT,FEMUR_L,FEMUR_R,GROUP,IMAGE,INC,LABEL,MATERIALS,MESORECTUM,METHODS,NOS,OBJECTIVE,PENILEBULB,PURPOSE,RADIATION,RESULTS,SMALLBOWEL,THERAPY,THESE,WEB
169,241,AEG,COPYRIGHT,DIAGNOSIS,FEW
169,BECAUSE,COPYRIGHT,LTD
004,169,215,25067,AEU,AGE,COPYRIGHT,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,SCORE,T1C,THESE
048,160,166,169,200,250,335,555,562,738,811,956,ACE,BACKGROUND,CONCLUSION,COPYRIGHT,CWR22,DM738,INC,LABEL,METHODS,RESULTS,SERUM,TREATED,WESTERN,WHITNEY
FIRST,HENCE,LABEL,LSSMS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,SOI,SSM
125,177,508,774,ARLINGTON,AUTOMATED,CNR,HEALTHCARE,HEIGHTS,IMAGE,INC,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ULTRASOUND
176,177,AFTER,CONCLUSION,FIRST,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,PVC,RESULTS
300,ANOTHER,HOWEVER,LABEL,LARGE,METHODS,OBJECTIVE,PROMISING,PURPOSE,RESULTS,SINCE,SNU
CONVERSELY,HOWEVER,ION,LABEL,METHODS,MLC,OBJECTIVE,OFFSETS,PTV,PURPOSE,RESULTS,SYSTEMATIC,TEN
001,100,125,145,150,200,LABEL,LDR,METHODS,OBJECTIVE,PARAMETERS,PURPOSE,REDUCTION,RESULTS
ANOVA,EFFECTS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
AIM,APOPTOSIS,CONCLUSION,LABEL,LNCAP,METHODS,OBJECTIVE,PCR,RESULTS,TFDP3,WESTERN
200,945,947,PARTIAL,PC3,THERE,TLC,TNF,TOF
TREATMENT
101,ACCORDING,AGE,CONCLUSION,LABEL,LRP,MARCH,METHODS,OBJECTIVE,OBJECTIVES,ORP,RESULTS,THESE,THREE
123,158,746,CIS,CONCLUSION,EUROPEANS,LABEL,METHODS,OBJECTIVE,ORS,PURPOSE,RESULTS,SIMILAR,THESE,UNASSIGNED
177,956
169,COPYRIGHT,OPERATIVE,OTHER,PUBLISHED,ROBOT,ROBOTIC,SAS
160,169,ASP,COPYRIGHT,GLP,GLY,III,LNCAP,LYS,MAC,MCF,PRO,SAS,SER,THEIR,THESE,TRP
293,CHO,ENV,HIV,HOWEVER,MOMLV,NOTICEABLY,XENOTROPIC
EXPRESSION,LABEL,LENTIVIRAL,LIN28,METHODS,OBJECTIVE,PCA,PCR,PURPOSE,RESULTS,THESE
001,002,106,AAS,ACCURATELY,AFRICAN,ASIAN,BACKGROUND,BLACK,CAJUN,CAP,CAUCASIAN,INDIVIDUAL,LABEL,LOUISIANA,METHODS,NORTH,PRINCIPAL,PROJECT,RESULTS,THESE,WHITE
174,AVENTIS,COMMISSION,JEVTANA,MARCH,MEDICINES,PARIS,UNION,WEB
PSA,THEREFORE
ALP,C30,CONCLUSION,EORTC,LABEL,MATERIALS,MBQ,METHODS,OBJECTIVE,PSA,PURPOSE,QLQ,QOL,RESULTS,VAS
151,BETWEEN,CONCLUSION,HOWEVER,JANUARY,LABEL,MATERIALS,MAY,METHODS,MRI,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SEVERAL,TESLA,THERE
001,280,CONCLUSION,GLEASON,GROUP,HOWEVER,KOREA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,WESTERN
ADT,THERE,THESE
CHOLINE,DESPITE,PET,SENSITIVE
AFTER,BACKGROUND,LABEL,LESIONS,METHODS,MRI,RESULTS
240,40S,50S,720,890,BACKGROUND,CONCLUSION,END,INSTITUTE,LABEL,MAJOR,METHODS,OUTCOME,PROGRAM,PSA,RESULTS,SINCE,SOCIETY,WHILE
99M,BECAUSE,EXTENSIVE,FDG,LIVER,PET
141,152,183,192,22RV1,425,CURCUMA,DDX39,DUE,FKBP4,FURTHER,HMGB1,MALDI,PPP2R1A,RBM17,TAKEN,TOF
169,174,308,511,ADT,BACKGROUND,COPYRIGHT,FATIGUE,IL6,INC,LABEL,METHODS,RESULTS,THESE
154,169,BECAUSE,COPYRIGHT,FINALLY,KENNARD,LARGE,PCA,STONE
027,175,327,573,CMTM5,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
184,189,292,CONCLUSION,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,POSTBIOPSY,PPV,PURPOSE,READERS,RESULTS
BOARD,CONCLUSION,LABEL,MATERIALS,MEANS,METHODS,OBJECTIVE,ONTARIO,PURPOSE,RESULTS,RIGID,UNIVERSITY,WESTERN
1990S,HOWEVER,SNP,THEIR
947,CD122,CD4,CD8,COMBINING,FINDING,HOWEVER,IFN,TRAMP

117,161,340,435,945,946,AJS,BINDING,GAP,GTP,GTPASES,MALIGNANT,RHO,THEIR,THESE
000,169,BACKGROUND,COPYRIGHT,FURTHER,INC,LABEL,METHODS,NRBP1,RESULTS,TMA,TSC,WILEY
169,945,BACKGROUND,BCL,CONCLUSION,COPYRIGHT,EXPRESSION,HIF,HOWEVER,IHC,INC,LABEL,LNCAP,MATRIGELS,METHODS,PARP1,PCR,RESULTS,THESE,VETSPON,WILEY
169,203,BACKGROUND,CELLS,COPYRIGHT,DBD,EFFECTS,EMT,HOWEVER,INC,LABEL,LAPC4,LNCAP,METHODS,PCR,PSA,RESULTS,THESE,WILEY
169,572,AMINE,BACKGROUND,CAUCASIAN,COPYRIGHT,INC,LABEL,METHODS,PCA,RESULTS,WILEY
169,945,BACKGROUND,CALCIUM,CALPAIN,COPYRIGHT,FAK,FOCAL,GAP,INC,IONOMYCIN,LABEL,LPA,METHODS,NCK,PKC,RAS,RAT,RESULTS,WILEY
099,160,169,183,AUSTRIA,CONCLUSION,GEORG,GERMANY,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,QALYS,RESULTS,STUTTGART
145,169,200,945,946,AKT,COPYRIGHT,FINALLY,INC,LNCAP,MOLECULAR,MTT,NOD,VPA,WILEY
169,BACKGROUND,COPYRIGHT,HMW,INC,LABEL,METHODS,NRS,NUCLEAR,RESULTS,STRIKINGLY,VDR,VITAMIN,WILEY
ARI,LABEL,OBJECTIVE,PCA,PURPOSE,RESULTS,SUMMARY,THESE
BECAUSE,LABEL,OBJECTIVE,PURPOSE,RESULTS,SCREENING,SUMMARY
LABEL,NOVEL,OBJECTIVE,PURPOSE,RESULTS,SIMILARLY,SUMMARY
III,LABEL,MDV3100,NOVEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
946,CARDIOL,HIC,HOWEVER,KIM,MOL
ARSENIC,BACKGROUND,CSC,INORGANIC,LABEL,MALIGNANT,MEC,METHODS,MMP,NONCONTACT,NSC,OBJECTIVE,RESULTS,TRANSWELL,WESTERN,WPE
169,COPYRIGHT,CROWN,EIT,EPITHELIAL,HOWEVER,PUBLISHED,THERE,TRANSITION
177,641,ART,BACKGROUND,INTENSITY,LABEL,METHODS,RADIATION,RESULTS,SYSTEMATIC,THERAPY
240,BACKGROUND,DISCUSSION,HIT,LABEL,METHODS,PET,TOMOGRAPHY,TRIAL
155,293,5TH,695,AUSTRALIAN,CHINA,CONCORD,DRE,IRELAND,ITALY,JANUARY,KINGDOM,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,PROJECT,PSA,RESULTS,SERUM,SETTING
BACKGROUND,INDEX,LABEL,METHODS,OBJECTIVE,POPULATION,RESULTS,SOUND
DEPARTMENT,THERE
100,DESPITE,HPV16,SERUM,THEREFORE
946,ABR,C57BL,CD11B,DELAYED,EL4,PCR,TGF,TRAMP
945,BACKGROUND,BIP,CDK,GADD153,GRP78,JNK,LABEL,LNCAP,METHODS,NOD,PRINCIPAL,RESULTS,SEVERAL
946,956,HEP,HOWEVER,SIMILAR
169,CCD,CONCLUSION,COPYRIGHT,ENEIN,GHONEIM,HOWEVER,ILEAL,INC,LABEL,METHODS,MONTI,OBJECTIVE,RESULTS,WALLACE
001,003,169,621,699,APV,CONCLUSION,COPYRIGHT,FIRST,FLORIDA,INC,LABEL,METHODS,OBJECTIVE,RESULTS
169,COPYRIGHT,FLORIDA,LTD,NORTH,ZIP
169,174,ACR,COLLEGE,COPYRIGHT,GUIDELINES,IMAGE,INC,PUBLISHED,RADIOLOGY
ADIPOCYTE,BACKGROUND,CONVERSELY,LABEL,LNCAP,METHODS,OBESITY,RESULTS,SVF,VIS
169,BLACKWELL,GIVEN,LTD,PSA,PUBLISHING,TFNAB,THERE,THESE
169,945,AKT,BLACKWELL,CHANGES,CONVERSELY,DU145,EXPRESSION,LABEL,LTD,MATERIALS,METHODS,MTT,OBJECTIVE,OBJECTIVES,PCR,PUBLISHING,RESULTS,TGF
169,239,289,AUSTRALIA,AUTHORS,BJU,CROSS,DRE,LABEL,MEN,METHODS,OBJECTIVE,PSA,QUEENSLAND,RESULTS,THERE
165,169,236,AUTHORS,BJU,BLAND,CALCULATED,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
169,AUTHORS,BJU,LABEL,MEN,METHODS,OBJECTIVE,PATIENT,PSA,RESULTS
169,200,AUSTRALIAN,AUTHORS,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,OVERALL,PPC,PSA,RESULTS,TREND
154,169,ACTUARIAL,AUSTRALIAN,AUTHORS,BJU,CONCLUSION,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,PSA,RESULTS,WHILE
169,945,AMACR,AUTHORS,BJU,HGPIN,PIN
001,982,AUC,BACKGROUND,GLEASON,LABEL,LNI,LOW,LYMPH,MATERIALS,METHODS,PCA,PSA,RESULTS
118,11Q13,122,166,642,644,690,755,765,BACKGROUND,GENOMES,INCREASING,LABEL,METHODS,OCTOBER,PILOT,RESULTS,SNP,YRI
231,CDC42,ERM,EZRIN,GEF,MDA,PC3,RAC,RADIXIN,SIMILAR,VAV
147,160,324,756,DIAGNOSIS,LABEL,METHODS,OBESITY,OBJECTIVE,RESULTS
946,947,AKT,CHINESE,DU145,ERK,FURTHER,GAL,HAN,INK4A,KNOCKDOWN,LNCAP,PC3,PCA,SENESCENT
169,800,946,GLEASON,TGF
662,680,685,689,719,725,732,859,887,954,ADC,DIAGNOSTIC,DWI,FIFTY,GLEASON,KEY,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS
BISCHIP,CPG,NOTABLY
AMAZINGLY,BECAUSE,EXPRESSION,PCA,PTF,T164A,TFS,THESE
004,019,043,142,169,247,GLEASON,HYPOXIA,LABEL,METHODS,OBJECTIVE,PROSTRATE,PURPOSE,RESULTS
145,169,COPYRIGHT,DSC,INC
169,201,231,ANTIGEN,COPYRIGHT,MRI,PROSTATIC,PSA,PUBLISHED,SAS,USING
169,201,231,COPYRIGHT,MRI,PUBLISHED,SAS
001,002,003,004,100,142,145,169,177,233,251,253,275,316,425,452,613,630,641,701,710,763,956,AQUEOUS,ASTERACEAE,BACKGROUND,BENTH,CONCLUSION,COPYRIGHT,DOCETAXEL,IRELAND,LABEL,LTD,MATERIALS,METHODS,PACLITAXEL,RELEVANCE,RESULTS,WST
169,945,ADT,ARI,BPH,CASTRATION,COPYRIGHT,CTP17A1,DHT,EVERY,HOWEVER,IAD,INCREASING,IRELAND,LTD,MAB,MDV3100,PSA,PUBLISHED,REDUCTASE,THERE
169,201,231,COPYRIGHT,PUBLISHED,SAS,URO
169,201,231,2NG,COPYRIGHT,MRI,PSA,PUBLISHED,SAS,SINCE,THERE
128GY,169,4GY,6GY,945,946,9GY,COPYRIGHT,GLEASON,GRADE,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PHOENIX,PSA,PUBLISHED,PURPOSE,RADIOLOGY,RESULTS,SOCIETY,T2B,THERE,TREATMENT
072,100,169,COPYRIGHT,FORTY,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,MRI,NPV,OBJECTIVE,PPV,PSA,RESULTS,THERE,THESE
169,231,AEU,COPYRIGHT,D541E,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,PUBLISHED,R462Q,RESULTS
101,109,150,169,241,561,750,937,945,AEU,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,SOCIO,SPANISH,TNM,VALIDATION
940,AMONG,FFQ,INDIVIDUAL,LABEL,METHODS,NNR,NUTRITION,OBJECTIVE,POPULATION,RESULTS,SETTING,SWEDISH,USING
100,132,169,483,BLACKWELL,ERG,ETS,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHING,RESULTS,TMPRSS2
256,464,AMONGST,LABEL,METHODS,OBJECTIVE,RESULTS,TOTAL
22RV1,ASSAY,BACKGROUND,DBD,EFFECTS,EOS,GENERATION,INHIBITION,LABEL,LNCAP,METHODS,MODULATION,MTT,PCA,RESULTS,WNT
169,AMERICA,AUTHORS,BJU,CONSENSUS,CURRENTLY,DOPPLER,FOCAL,HOWEVER,NEWER,NORTH,SYSTEMATIC,UROLOGICAL
ABL,BACKGROUND,BCR,COLON,CRK,JNK,LABEL,LNCAP,METHODS,MTT,PC3,PROTEIN,RESULTS,SW480,THROUGH,TNF,TRAIL,WESTERN
000,001,100,195,390,AGE,ASIAN,BACKGROUND,CONCLUSION,FARMERS,INMOL,INSTITUTE,LABEL,LEVEL,METHODS,NUCLEAR,OCTOBER,PAKISTANI,READING,RED,RESULTS,SHAUKAT
AGING,CONGRES,COPYRIGHT,EAU,PARIS,PROUS,SCIENCE,UROLOGY
HOWEVER,PSA,SINCE,YET
DU145,EXPRESSION,HOWEVER,PC3,TAKEN,THESE
AKT,EGF,ERBB2,LNCAP,OTHER,THESE,UNDER
CRR,DISEASE,GRM,HOPKINS,INSTITUTE,JOHNS,MARKERS,THESE
150,187,ERG,THERE
574,CLINICIANS,HGPIN,PSA
007,USING
150,169,1990S,ACS,BACKGROUND,CDC,CENTERS,CENTRAL,CONTROL,COPYRIGHT,DISEASE,INCIDENCE,INSTITUTE,LABEL,METHODS,NCI,NORTH,PREVENTION,REGISTRIES,RESULTS,SOCIETY,STATISTICS
945,947,ACTIVATION,EFFECTS,PC3,TG2,THESE
159,AFTER,AMONG,CONCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SALVAGE,SRT,UNIVARIATE
170,BACKGROUND,GIVEN,LABEL,METHODS,PSA,RESULTS,THERAPY,THESE
001,169,AFTER,BACKGROUND,BPH,COPYRIGHT,COX,DESPITE,HRS,LABEL,METHODS,OBJECTIVE,OUTCOME,PREVENTION,PUBLISHED,RESULTS,SCORE,SETTING,SYMPTOM,THESE,TRIAL,UROLOGY
169,ADDITIONAL,BACKGROUND,CANDIDA,CAP,COPYRIGHT,DESPITE,EPSTEIN,INC,LABEL,MATERIALS,MEDLINE,METHODS,RESULTS
125,169,185,187,947,99M,CONCLUSION,COPYRIGHT,CYS,GLY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEIR,TYR
CTC,THEREFORE
003,005,006,008,043,11Q13,478,AFTER,CONSORTIUM,CTBP2,IGF,IGFBP,SNP,THERE,USING
125,132,169,961,BETWEEN,C30,CES,CONCLUSION,COPYRIGHT,CURRENT,DEPRESSION,EORTC,HRQOL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,QLQ,RESULTS,SCALE,SHORT,SOCIETY,STUDIES,TREATMENT,UTRECHT
143,745,BACKGROUND,CIS,COX,CUTANEOUS,HODGKIN,LABEL,METHODS,MRR,NHL,OVERALL,RESULTS,SCC,USING
169,AIM,BACKGROUND,JANUARY,LABEL,MEASURE,MEDLINE,METHODS,OBJECTIVE,OUTCOME,PSYCHINFO,RESULTS,SEPTEMBER,SOCIETY,THERE
BACKGROUND,CONTEXT,GLEASON,HISTOLOGIC,LABEL,METHODS,OBJECTIVE,PATHOLOGY,SOCIETY,SOURCES,SUBSEQUENT,UROLOGICAL
BACKGROUND,CONTEXT,HOWEVER,IDC,LABEL,METHODS,OBJECTIVE,SOURCES
BACKGROUND,CONTEXT,LABEL,LIBRARY,METHODS,MOLECULAR,OBJECTIVE,SOURCES
BACKGROUND,CAREFUL,CONTEXT,LABEL,METHODS,OBJECTIVE,OBJECTIVES,SEVERAL,SOURCES
BACKGROUND,DISCUSSION,HOWEVER,LABEL,METHODS,STUDIES,TRIAL
149,169,177,AIM,BACKGROUND,BETWEEN,BLACKWELL,CONCLUSION,HOWEVER,LABEL,LTD,MEN,METHODS,OBJECTIVE,PUBLISHING,RESULTS,SEPTEMBER,TREATMENT
207,495,GLEASON,PSA,Q22FS,SINCE
266,AMONG,CD151,CONCERNING,CUB,FURTHER,HOWEVER,RAB,SEVERAL,USING
032,100,102,106,189,378,AMONG,GLEASON,LABEL,METHODS,OBJECTIVE,RADICAL,RESULTS
160,240,273,AFTER,DEGARELIX,III,LABEL,METHODS,OBJECTIVE,PHASE,RESULTS
800,CONCLUSION,DWI,LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS
CONCLUSION,KEEPING,LABEL,METHODS,OBJECTIVE,RESULTS
100,169,916,COPYRIGHT,FXL,FXR,INC,MRI,PARAMETER,PARAMETRIC,PATHOLOGY,WILEY
169,BACKGROUND,COPYRIGHT,GDC,INC,LABEL,MDA,METHODS,PCA,PTCH1,REDUCTION,RESULTS,SMOOTHENED,SONIC,WILEY
169,ATHYMIC,BACKGROUND,BAX,BCL,CHANGES,COPYRIGHT,COX,IGFBP,INC,INCREASES,LABEL,METHODS,PCA,RESULTS,SINCE,SOY,TRPV6,WILEY
900,AMONG,AUS,FIFTY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIGMOID,THERE,THOSE,USC
042,135,175,186,404,533,930,AMONG,COX,LABEL,METFORMIN,METHODS,OBJECTIVE,PCA,RESULTS,VETERAN
APOPTOSIS,LABVIEW,PC3,RELATED,TNF,TRAIL
DESPITE,NOTABLY,TACC2,TAKEN,USING
MAL,PCA,RHO,SILENCING,SRF,TAKEN
945,FK506,FKBPS,RAPAMYCIN
MALDI,PSA,TAKEN,TOF
001,005,050,181,CONCLUSION,DESPITE,EASTERN,GRADE,GROUP,LABEL,METHODS,OBJECTIVE,PFS,PURPOSE,RESULTS
001,AMONG,COX,END,MEIER,OVERALL,RESULTS,SIC,SMALL
ALZHEIMER,BACKGROUND,CONDITIONS,INCHIANTI,LABEL,METHODS,RESULTS,STUDIES,SUCCESSFUL
160,169,183,GEORG,STUDIES,STUTTGART
141,CROSS,EFFECTS,PFE,RESULTS
AFTER,FULLY,SIPULEUCEL
025,945,956,BECAUSE,CALCITRIOL,CYP27B1,DIETARY,MCF,THESE
001,230,CIN,HEPARANASE,HPSE2,IMAGE,LAB,LABEL,MATERIALS,METHODS,OBJECTIVE,THERE
945,954,AKT,APOPTOSIS,BAX,BCL,DU145,FURTHER,IAP,IKK,TUNEL
117,450,AMONG,DEFINITIVE,FURTHER,GLEASON,HOWEVER,LABEL,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,SINCE,SUMMARY,TEN
223RADIUM,LABEL,OBJECTIVE,PURPOSE,RADIATION,RANDOMIZED,RESULTS,SUMMARY
100,INCLUSION,LABEL,OBJECTIVE,PRIAS,PURPOSE,RESULTS,SUMMARY,WEB
169,COPYRIGHT,INHIBITING,IRELAND,LTD
169,176,AUTHORS,BLACKWELL,FDA,FOUNDATION,GENISTEIN,JOURNAL,LNCAP,LTD,MOLECULAR,MTT,PUBLISHING,ROS,TOPOTECAN,TREATMENTS
003,005,015,169,219,967,COX,CYP26A1,ERG,GLEASON,HOXD3,III,LABEL,METHODS,METHYLIGHT,OBJECTIVE,PSA,PURPOSE,RESULTS,TBX15,TMPRSS2
123,169,183,209,291,305,400,584,ACCRUAL,AVENTIS,BACKGROUND,CELECOXIB,CONTROLLED,COPYRIGHT,COUNCIL,CURRENT,FFS,FUNDING,HORMONE,JAN,LABEL,LTD,MEDICAL,METHODS,OCT,PSA,RESULTS,THERE
0063794,354,BMP,BMPRI,ID1,LDN,LNCAP,PC3,SMAD1,SMAD8,SMADS,SMALL,TAKEN,WYE
INCUBATION,LNCAP,QUERCETIN
295,ADDITIONAL,AFTER,COX,GLEASON,LABEL,MEN,METHODS,OBJECTIVE,RESULTS
169,CYP17,III,MDV3100,THESE,TREATMENT
LABEL,METHODS,OBJECTIVE,OPERATIVE,PURPOSE,RESULTS,THERE,THREE,TREATMENT
956,CBDIV17,EMBELIN,LABEL,LNCAP,METHODS,OBJECTIVE,PEG,PURPOSE,RESULTS,SER,THEREFORE,THESE
GROUP,JAPAN,KENICHI,LABOR,NOW,UNIVERSITY,YOSHIYUKI
145,946,BACKGROUND,HOWEVER,LABEL,LNCAP,METHODS,RESULTS
ADDITIONAL,AGGRESSIVE,LABEL,OBJECTIVE,PURPOSE,RESULTS,SCREENING,SUMMARY
169,COPYRIGHT,EXPRESSION,INC,PATHOLOGY,PIAS1,PROTEIN,PUBLISHED,SOCIETY,TAKEN
105,140,169,BACKGROUND,CASODEX,COPYRIGHT,DEPENDING,DHT,FLU,LABEL,LNCAP,LTD,MATERIALS,MDV3100,METHODS,PSA,R1881,RESULTS,THESE,WHILE
001,002,004,005,169,859,ACM,BJU,COX,END,LABEL,LEVEL,MARRIED,MATERIALS,METHODS,NEVER,OBJECTIVE,OBJECTIVES,PROGNOSIS,RESULTS,SDW,SEPARATED,UNLABELLED
007,100,198,AFTER,AGE,BOUNCES,CONCLUSION,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS
063,169,782,BEHAVIORAL,BJU,BRFSS,CONCLUSION,FORCE,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PREVENTIVE,PSA,RESULTS,USA
22RV1,CADMIUM,CELLS,CWR,DU145,LNCAP
100,215,ADC,AIM,BASED,CANDIDATES,CONCLUSION,DWI,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,PCA,PSA,RESULTS
234,611,747,911,APRIL,CED,CENTERS,CONCLUSION,FDG,LABEL,METHODS,ONCOLOGIC,PET,RESULTS,SINCE,THERE,THESE,UNLABELLED
471,511,945,ARIOL,AUTOMATED,BACKGROUND,CONCLUSION,CRI,DESPITE,LABEL,METHODS,OVERALL,RESULTS,THESE,TMA
209,33342,800,APOPTOSIS,HOECHST,MEV,UVC
PLK
IMPLANTED,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,947,COPYRIGHT,INHIBITION
ASIAN,CAUCASIANS,FIRST,FURTHER,HOWEVER,JAPAN
161,AIM,AMONG,BACKGROUND,EXPOSED,LABEL,METHODS,OBJECTIVE,RESULTS,ROC,THERE
100,120,121,156,AIM,BACKGROUND,CHILE,COMMISSION,INTENSITY,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,STAGING,THEIR,URINARY
177,956,AADAC,CES,FLU,FLUTAMIDE,HOWEVER,THESE,USING
169,287,CONCLUSION,COPYRIGHT,FURTHER,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PSA,PSADT,RESULTS,SRT,THERE
169,945,COPYRIGHT,INC,SEVERAL
215,945,CONCLUSION,DU145,EF1,GFP,HEK,LABEL,METHODS,OBJECTIVE,RESULTS,WESTERN
001,100,169,BACKGROUND,CLOSE,COPYRIGHT,DOPPLER,EVOLUTION,GLEASON,LABEL,MARCH,MATCHED,METHODS,OBJECTIVE,OUTCOME,PRIMARY,PSA,PUBLISHED,RESULTS,SEPTEMBER,SETTING,UROLOGY
169,391,BACKGROUND,CALIFORNIA,COPYRIGHT,EPSTEIN,FRANCISCO,GLEASON,KETTERING,LABEL,METHODS,MIAMI,OBJECTIVE,OUTCOME,PRIAS,PUBLISHED,RADICAL,RESULTS,SAN,SLOAN,THESE,UNIVERSITY,UROLOGY
169,COPYRIGHT,GIVEN,HOWEVER,INC
001,169,AFTER,CONCLUSION,COPYRIGHT,CRT,CTV,DESPITE,DVH,EFFECTS,FACULTY,GROUP,INC,LABEL,LOCAL,MATERIALS,METHODS,OAR,OBJECTIVE,PURPOSE,QUANTEC,RADIATION,RESULTS,SURGERY,THERAPY,TREATMENT,URINARY,USING
BACKGROUND,LABEL,METHODS,MRI,OBJECTIVE,RESULTS
COLLECTION,GAS,LABORATORY,LOUIS,MINUTES,POSTMORTEM,SAINT,SPECIMENS,THESE,TOXICOLOGY,UNIVERSITY
AMONG,BIO,BOULDER,DIM,GLEASON,PCA,THESE,UTR,ZESTE
FOLLOWING,INSTITUTE,KABAT,LABEL,METHODS,MOFFITT,OBJECTIVE,PURPOSE,QOL,RESULTS,SIMILAR,WEEKS
ATLAS,CEACAM5,PAP,PROTEIN,PSA,SLC45A3,UPK3A
BACKGROUND,END,HOWEVER,LABEL,RCC,RESULTS,SOLID
002,006,160,177,731,862,APRIL,CONCLUSION,DVC,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS
001,160,605,946,BCR,BMI,CONVERSELY,COX,CURRENT,EARLY,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SEX
169,825,ASP299GLY,CIS,COPYRIGHT,FURTHER,HOWEVER,ORS,THR399ILE
AUTOPHAGY,BECAUSE,FINALLY,HS27A,HS5,LC3,NED,PCA,STAT3
169,503,673,ASSESSMENT,BASEL,BCR,CAPRA,CAPSURE,COPYRIGHT,COX,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,STRATEGIC,WESTERN
028,036,042,112,121,160,169,194,281,511,967,BACKGROUND,BETWEEN,CONCLUSION,COPYRIGHT,FORTY,GENERAL,GLEASON,HOWEVER,LABEL,MARCH,METHODS,PUBLISHED,RESULTS,SEPTEMBER,TAIWANESE
BACKGROUND,CONCLUSION,LABEL,PSA,RESULTS,THESE
125,340,BACKGROUND,CAB,DISCUSSION,GLEASON,III,LABEL,METHODS,PCA,PRIOR,PSA,RCT,SECONDARY,SEPTEMBER,THESE,THOSE,TRIAL
AREAS,HOWEVER,IHC,MOLECULAR
BACKGROUND,BLOOD,CFS,DISCUSSION,DU145,E1245,LABEL,LNCAP,MDM,METHODS,MICRORNAS,PBL,PERIPHERAL,RESULTS,TOTAL,WHILE
945,947,DISEASE,KENNEDY,NRS,NUCLEAR,PTM
001,005,106,492,GLEASON,JANUARY,LABEL,MEDICAL,METHODS,OBJECTIVE,RESULTS,T1C,T2A,T2B,T3A,TNM
169,1A1,ADAPTATION,CARNS,CASTRATION,COPYRIGHT,HOWEVER,NANOG,NK3,PRESS,THESE
169,231,COPYRIGHT,DU145,EOH,ETOAC,LTD,MCI,MDA,OVERALL,SRC,STAT3,SUDACHITIN,WILEY
BASED,CXC,HOWEVER
ATLAS,BACKGROUND,DARTMOUTH,DISCUSSION,END,III,LABEL,METHODS,OBJECTIVE,RESULTS
DU145,MENTHOL,MTT,TRPA1,TRPM8
CAD,IRELAND,LTD,PUBLISHED
100,109,160,169,BETWEEN,CANCEROUS,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TEFRT
ACTIVITIES,ADT,ASSESSMENT,BACKGROUND,BALANCE,BATTERY,CHRONIC,CONFIDENCE,CONTROL,DISCUSSION,FATIGUE,FUNCTIONAL,GROUP,HOWEVER,ILLNESS,LABEL,MEDICAL,METHODS,SCALE,SHORT,SIX,SIXTY,THERAPY,TRIAL,VERSION
103,110,120,125,137,145,169,1CM,50D,BED,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,PLANS,PUBLISHED,PURPOSE,RESULTS,SOCIETY,TEN
169,178,185,5MM,8MM,COPYRIGHT,FURTHER,HOWEVER,INC,INSTITUTE,JAMES,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
0NG,100,121,169,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PERMANENT,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,AFM,BASED,COPYRIGHT,CURRENT,HOWEVER,LTD,THEIR,THERE,THESE,YOUNG
AFRICAN,AMERICANS,LABEL,METHODS,OBJECTIVE,RESULTS,SEVENTY
11356,11641,202,BACKGROUND,BASED,CAUCASIANS,CIS,CONCLUSION,COX,HOWEVER,LABEL,METHODS,ORS,PCA,RESULTS,STATA
169,1990S,QUALITY,UROLOGICAL
169,BACKGROUND,LABEL,METHODS,PREBIOPSY,REFERENCES,RESULTS,THERE,UROLOGICAL
104,177,946,956,SEVERAL,SULT1A1,SULT1E1,SULTS,TAM,THERE,THESE,TOR,TOREMIFENE
11R,169,177,754,99M,CGRRAGGSC,COPYRIGHT,LTD,WILEY
HOWEVER
RADIOGRAPH,THERE,THESE
036,067,075,177,269,908,916,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEIR,TME
040,169,177,323,AMONG,BASEL,COPYRIGHT,GENOTYPING,JAPAN,LABEL,METHODS,MULTI,OBJECTIVE,OBJECTIVES,PCR,PREVENTIVE,PSA,RESULTS
001,169,194,424,669,998,BACKGROUND,CONCLUSION,COPYRIGHT,COSTS,COX,INC,ISPOR,LABEL,LOWER,METHODS,PUBLISHED,RESULTS,RRP,SIMILAR,SOCIETY
000,159,259,892,BASED,BAVARIA,CHANGES,GERMANY,POPULATION,SIR,SPC,UTILIZING
100,169,BIACORE,COPYRIGHT,ELISA,IMPROVING,INC,INDIVIDUAL,PSA
945,946,BACKGROUND,CELLS,ECM,LABEL,METHODS,RESULTS,USING
ACTIVATED,CLCA2,HOWEVER,THROUGH
ALTOGETHER,BAX,BCL,DU145,IMMUNOBLOT,LNCAP,MYB,NOTABLY,PC3,RWPE1,RWPE2,USING
150,169,200,916,936,956,AIF,ATF,BAX,BCL,CELLS,CHINESE,COMET,COPYRIGHT,GADD153,GRP78,INC,QUERCETIN,THESE,WESTERN,WILEY
CLINICIANS,SECONDARY,TUR
128,169,BRITAIN,COPYRIGHT,ENDOCRINE,ERG,FRESHLY,GREAT,IRELAND,LTD,PUBLISHED,SOCIETY,TMPRSS2,WILEY
170,HBA1C,HOWEVER,UNTIL
CYP,CYP17A1,HOWEVER,III,UNTIL
005,169,290,312,535,668,AUC,BACKGROUND,COPYRIGHT,DRE,INC,LABEL,METHODS,NEM,PCA,PSA,RESULTS,ROC,SARCOSINE,WILEY
169,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,PSA,RESULTS,USING,WILEY
169,946,ARB,BACKGROUND,CONCLUSION,COPYRIGHT,FURTHER,INC,LABEL,LNCAP,METHODS,PSA,RESULTS,THESE,TRANSGENIC,WILEY
001,169,947,954,APOPTOSIS,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,IGG,INC,LABEL,LOCALLY,METHODS,MTS,PCA,PCR,RESULTS,WESTERN,WILEY
BCR,HOWEVER,PCA,PSA,RADIATION,RECURRENCE
169,COPYRIGHT,GENERAL,GTPASES,INC,RHO,ROCK1,TARGETING,TIAM1
AMONG,BRCA1,BRCA2,MRI,THESE
169,AFRICAN,AMERICANS,ANGELES,AUA,BETWEEN,BJU,CALIFORNIA,CAUCASIAN,CAUCASIANS,CONCLUSION,INDEX,LABEL,LOS,METHODS,OBJECTIVE,OCTOBER,PCI,RESULTS,SCORE,SYMPTOM,THERE,UNIVERSITY,UNLABELLED,URINARY,UROLOGICAL
126,169,189,ADDITIONAL,AUTHORS,BJU,BRITISH,FEW,GROUP,III,LABEL,MATERIALS,MDV3100,METHODS,OBJECTIVE,OBJECTIVES,RESPONDERS,RESULTS,SEPTEMBER,TREATMENT,UNLABELLED,URO
043,169,AUTHORS,BJU,BPH,COLORECTAL,CONCLUSION,DRE,GENERALLY,LABEL,LEVEL,MEN,METHODS,NSAID,OBJECTIVE,OLMSTED,OVARIAN,PSA,RESULTS,SCREENING,THERAPY,THEREFORE,TRIAL,UNLABELLED,URINARY
169,946,CALLICARPA,COMPOUNDS,PC3,SOCIETY
169,DU145,III,INC,MTT,SOCIETY,TAM,WILEY

PROTEASOME,TPR,UBIQUITIN,UPS
169,COMPETING,MEIER
214,441,ACCORDING,BACKGROUND,BETWEEN,DRE,EAU,LABEL,LOW,MARCH,METHODS,PCA,PSA,RESULTS
145,954,LIVIN,PCA,THESE
BASAL,CD104,CD49F,CD9,SINCE,THEIR,THESE,VARIOUS
ADP,DR5,TAKEN,TRAIL
000,BASED,CHIBA,HEAVY,HIMAC,ION,JAPAN,MAY,MEDICAL,SINCE,THESE
125,945,954,956,AFTER,AIM,AKT,CONCLUSION,LABEL,METHODS,OBJECTIVE,PC3,PCR,RESULTS,SNAIL,TNF,WESTERN
169,954,COPYRIGHT,DESPITE,INC,LNCAP,NADPH,ROS,TAKEN,THESE
169,200,956,COPYRIGHT,HOWEVER,RG3
060,158,2976392,746,824,BACKGROUND,CAUCASIANS,CIS,EXTENSIVE,LABEL,METHODS,ORS,RESULTS
169,22RV1,COPYRIGHT,DELETED,INC,LNCAP,PCA,RHOGTPASE,SP1,THESE,TREATMENT,TSA
169,COMPLEX,COPYRIGHT,ETS,EWING,MODULATION
001,007,009,021,061,169,250,300,400,BACKGROUND,COMPOSITE,COPYRIGHT,GREATER,HOWEVER,INDEX,LABEL,METHODS,OBJECTIVE,OUTCOME,PROCEDURE,PUBLISHED,RARPS,RESULTS,SETTING,UROLOGY,WHILE
169,200,COPYRIGHT
001,002,003,004,005,169,279,BETWEEN,COPYRIGHT,ECE,ENDORECTAL,GLEASON,IMAGE,IMAGING,INC,LABEL,MATERIALS,METHODS,MRI,NETWORK,OBJECTIVE,PSA,PURPOSE,RESULTS
111,140,169,174,177,207,CLAVIEN,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MAY,MEDICAL,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,VINCI,WIDESPREAD
001,169,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEDICALLY,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SERUM,UROLOGICAL,USING
100,169,237,329,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METASTASIS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,USING
000,100,101,169,BASED,COPYRIGHT,EDUCATION,EXACT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESECTION,RESULTS,THESE,UROLOGICAL
169,249,272,BLACK,CHANGES,COPYRIGHT,COX,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,T2A,UNIVARIATE,UROLOGICAL
000,169,560,AFTER,COPYRIGHT,DESPITE,EDUCATION,FEWER,GLEASON,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,TREATMENT,UROLOGICAL
109,169,177,329,386,804,965,COPYRIGHT,EDUCATION,INC,JANUARY,KINGDOM,LABEL,MALIGNANT,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RECURRENT,RESULTS,SEPTEMBER,THERE,THEREFORE,UROLOGICAL,VISIBLE
169,AMONG,COPYRIGHT,PET,PUBLISHED,SAS
125,169,COPYRIGHT,EDUCATION,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
169,AMERICA,BACKGROUND,CARIBBEAN,CONTEXT,CONTINENTS,COPYRIGHT,ESTIMATED,INCIDENCE,INCREASING,LABEL,METHODS,MORTALITY,NORTH,OBJECTIVE,OCEANIA,PCA,PUBLISHED,RESULTS,SAHARAN,SOUTH,SYNTHESIS,UROLOGY,WORLD
CONCEPT,DU145,ERG,FCA,FUNCTIONAL,LNCAP,PCA,PRDX3,PRDX4,REVERSE,TMPRSS2
000,100,151,169,946,AGE,AMONGST,BACKGROUND,CENTRAL,HODGKIN,LABEL,LTD,METHODS,MSYAMBOZA,NATIONWIDE,OCTOBER,RESULTS,SEPTEMBER,WHILE
HOWEVER,NOTCH,SEVERAL
169,USING
169,COPYRIGHT,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,QOL,RESULTS,USA,WILEY
001,002,011,26S,AMONG,ICP,THESE
169,COPYRIGHT,III,LTD,WILEY
CUL4A,ECTOPIC,ERK,FINALLY,NOTABLY
AKT,ENDMT,HOWEVER
100MG,STAGE
169,COPYRIGHT,ERG,INC,TMPRSS2,ULTIMATELY
169,BACKGROUND,CONTEXT,COPYRIGHT,ELECTRONIC,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SEPTEMBER,SYNTHESIS,UROLOGY,WHILE
169,ADDITIONAL,BACKGROUND,BECAUSE,CONTEXT,COPYRIGHT,ENGLISH,LABEL,MEDLINE,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SCA,SYNTHESIS,UROLOGY
169,BACKGROUND,COPYRIGHT,COX,CUMULATIVE,INDEX,JANUARY,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,PCA,PUBLISHED,RESULTS,SETTING,SIMILARLY,UROLOGY
023,177,945,946,997,AFTER,BMI,COX,DISEASE,FINNISH,HEART,ISCHAEMIC,RESULTS,RRS,SERUM,TOCOPHEROL
169,769,956,AUTHORS,DESPITE,DYNAMIC,H3K4ME2,H3K4ME3,HDM,HOWEVER,INHIBITION,JARID1B,JHDMS,JOURNAL,K4ME3,KDM4A,KDM4C,KDM5B,MICHAELIS,PHD,SEVERAL,STRUCTURE
005,008,010,017,018,028,035,036,050,052,1997A,BACKGROUND,BPH,HEKAL,HIGHEST,LABEL,PCA,PSA,RESULTS,UNIVARIATE
005,ADC,CONCLUSION,FIFTY,GLEASON,LABEL,METHODS,MRI,PET,RESULTS,UNLABELLED,VOLUMES
131,258,BACKGROUND,FURTHER,INFECTING,JANUARY,LABEL,METHODS,MOLECULAR,PATIENT,RESULTS,ST131
640,AFRICAN,AMERICANS,GLEASON,HISPANICS,HOUSTON,HOWEVER,MEDICAL,PCA,TEXAS,THREE
AFTER,APRIL,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SINCE
6C4,945,DIAGNOSES,GLEASON,MALIGNANT,TEN,WHILE
001,002,132,151,169,738,CONCLUSION,COPYRIGHT,GROUP,INC,LABEL,LNS,MATERIALS,METHODS,MRL,OBJECTIVE,PCA,PET,PURPOSE,RADIATION,RESULTS,THERAPY,THEREFORE
169,BACKGROUND,CASES,COPYRIGHT,LABEL,LTD,METHODS,PCA,RESULTS
000,CURRENTLY,MICRORNAS,PCA,THEREFORE,THESE,UTR
001,003,160,162,182,388,AFTER,BACKGROUND,CONTROLLED,CURRENT,LABEL,MEN,METHODS,PSA,RANDOMIZED,RESULTS,SCREENING,SEVERAL,THERE
169,602,HRQOL,LABEL,METHODS,MID,OBJECTIVE,RESULTS,SETTING,TRUST
169,AKT,FAS,H2A,INCREASED,PCA,RADIATION,RSV,THESE,TOXICITIES,TRAILR1,XRT
009,049,149,177,956,ADULT,ATP,EDUCATION,FEDERATION,IDF,III,PANEL,PROGRAM,SERUM,TREATMENT
026,119,169,347,402,479,749,BJU,CONCLUSION,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,UNLABELLED
169,OTHER,THERE,UROLOGICAL
169,BLACKWELL,FIFTEEN,FRAMEWORK,LTD,NVIVO,PUBLISHING,THESE
001,169,789,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,UROLOGICAL
035,100,215,324,393,642,652,SNP
009,169,207,BACKGROUND,COPYRIGHT,GROUP,HOWEVER,INC,LABEL,METHODS,OTHER,RESULTS,SEVEN,THESE,WILEY
169,231,COPYRIGHT,FOLLOWING,IAP,INC,MDA,ROS,THEREFORE,THESE,WILEY
169,AUC,BACKGROUND,CONSORTIUM,COPYRIGHT,ECE,GLEASON,IGF,INC,IRISH,LABEL,METHODS,PCA,RESULTS,WILEY
169,BASED,COPYRIGHT,GIVEN,INC,JANUARY,LABEL,MAY,MEDLINE,METHODS,OBJECTIVE,RESULTS,WILEY,YES
169,GRANADA,LABEL,METHODS,OBJECTIVE,RESULTS,SPAIN,THESE
108,110,156,CONCLUSION,GLEASON,INITIAL,LABEL,METHODS,OBJECTIVE,PET,PSA,PURPOSE,QUESTIONS,RESULTS
006,009,018,035,145,169,22RV1,ABSENCE,BACKGROUND,BPH,COPYRIGHT,INC,LABEL,LNCAP,METHODS,PCA,PCR,POTENTIAL,RAS,RASSF,RASSF10,RESULTS,WILEY
169,945,ANDROGENS,BACKGROUND,COPYRIGHT,DHT,ERG,ETS,FINALLY,INC,LABEL,METHODS,PREVIOUSLY,PSA,RESULTS,TMPRSS2,WILEY
001,009,040,048,051,059,169,BACKGROUND,BCR,BLACK,CAP,COPYRIGHT,COX,CRUDE,EQUAL,GLEASON,HOSPITALS,LABEL,LOW,METHODS,PSM,RESULTS,SES,SOCIETY,ZIP
169,5E1,926,FURTHER,GDC,GLI,IPI,SMO
169,AQUAPORIN,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,HOWEVER,LABEL,METHODS,OBJECTIVE,PKC,RESULTS,THESE
169,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,ELISA,HOWEVER,LABEL,METHODS,NOTABLY,OBJECTIVE,PC3,PCA,PRIMARY,RESULTS,SVF
945,AMACR,CK7,COA,HOWEVER,NAS,SOLID
EPIGENETIC,HOWEVER,THERE
CURRENTLY,DESPITE,LABEL,MED,METHODS,OBJECTIVE,PUB,RESULTS,UUTTS
182,262,BACKGROUND,GLEASON,LABEL,METHODS,RESULTS,ROBOTIC,RRP,T2C,UNASSIGNED,VIRTUAL
131,945,946,AMONG,BACKGROUND,BED,DOSES,GY2,LABEL,LOCAL,METHODS,OVERALL,RESULTS,THERE
COA,HMG,RANDOMIZED,WHILE
AREAS,BACKGROUND,COVERED,III,LABEL,METHODS,OPINION,PHASE,THESE,WHILE
113,BACKGROUND,GLEASON,H4K20,HOWEVER,LABEL,METHODS,PCA,PSA,RESULTS,SIMILAR
AREAS,BACKGROUND,COVERED,III,LABEL,METHODS,OPINION,PHASE,PSA
001,002,186,239,894,926,FURTHER,PSA,REGARDING
BECAUSE,HES
004,016,147,279,BACKGROUND,COX,LABEL,LRC,PRINCIPAL,RESULTS,THESE
92A,AKT,DIM,EMT,HOWEVER,PCA,PSA,RANKL,RUNX2,THEREFORE
AD5,ONCOLYTIC,SPECT
169,CYP17A1,MDV3100,THEREFORE
169,654,ANXIETY,BACKGROUND,COPYRIGHT,DEPRESSION,FINANCIAL,IRELAND,LABEL,LTD,METHODS,RESULTS,SIMILAR,WILEY
169,BACKGROUND,COPYRIGHT,LABEL,METHODS,PCA,RESULTS,SEVERAL,SOCIETY,STI,THEREFORE,THESE
945,954,AKT,AXL,HOWEVER,IKK,TAKEN
169,COPYRIGHT,HOWEVER,IRELAND,LTD,MEDLINE
ATC,HOWEVER,III,LABEL,MOLECULAR,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,TARGETING,THEIR
FINALLY,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
169,BIGINELLI,COPYRIGHT,LTD,RNS,ROS,THESE
169,COPYRIGHT,FURTHER,HOWEVER,INC,THERE,WESTERN
CRP,IEF,PSA
CTC,PSA
5T4,III,MVA,PHASE,STUDIES
169,BACKGROUND,III,LABEL,METHODS,OBJECTIVE,OBJECTIVES,SECONDARY,SOCIETY,THERE,THESE,THREE,THROMBOSIS,VTE
956,ELISA,EPH,EPHA2,FINALLY,FUNCTIONAL
405,513,557,915,931,CONCLUSION,COSTS,DENOSUMAB,LABEL,METHODS,MORTALITY,NSCLC,OBJECTIVE,PHASE,QALYS,RESULTS,SRE
032,035,114,160,BACKGROUND,BPS,FURTHER,GLEASON,INCREASED,IRS,LABEL,METHODS,REMMELE,RESULTS,STEGNER
133,AFTER,DU145,ECTOPIC,PC3,PCR,THESE
ADDITIONAL,MCT,SLC16
DFS,GLEASON,MMP,PCA,PSA,PSADT,RESULTS,UNIVARIATE
956,DHT,LNCAP,LUC,LUCIFERASE,PC3,SINCE,TAKEN,THEREFORE
169,629,634,650,COPYRIGHT,IRELAND,LTD,PUBLISHED
145,169,946,954,COPYRIGHT,HOWEVER,HRM,IRELAND,LNCAP,LTD,SEQUENCING,SP1
155,177,332,COLLEGE,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,ROYAL
COLLEGE,CONCLUSION,INTENSITY,LABEL,METHODS,OBJECTIVE,RESULTS,ROYAL,SEVENTEEN
001,002,005,154,169,536,954,COPYRIGHT,DESPITE,INC,NEITHER,NUCLEAR,THESE
169,AKT,BPH,CONSISTENT,DU145,GLEASON,HOWEVER,LNCAP,PC3,PCS,PIN,TAKEN,THEREFORE,WHILE
169,320,AUC,BACKGROUND,CALCULATOR,COPYRIGHT,DESPITE,DRE,DUTCH,ERSPC,GLEASON,LABEL,LTD,METHODS,OBJECTIVE,PCA,PREDICTION,PSA,RANDOMISED,RESULTS,SCREENING,UNDER
001,002,003,015,169,APRIL,COPYRIGHT,CURRENT,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SEVERAL,SMOKERS,SOCIETY,THERE
169,BIOLOGICAL,COPYRIGHT,HOWEVER,LTD,PUBLISHED,RESULTS
169,ASTRO,CNS,COPYRIGHT,CURRENT,FORCE,IRELAND,LTD,PBT,RADIATION,SOCIETY
007,018,118,132,169,22863,AIM,COPYRIGHT,CROWN,EORTC,GLEASON,IDC,III,LABEL,LTD,MEIER,METHODS,OBJECTIVE,PUBLISHED,RESULTS
169,COPYRIGHT,GTP,INC,LAPC4,THERE
167,169,184,286,303,389,400,876,AFTER,BACKGROUND,CONTEXT,COPYRIGHT,LABEL,LRP,METHODS,OBJECTIVE,ORP,PSM,PUBLISHED,RADICAL,RATES,RESULTS,SECONDARY,SUMMARY,SYNTHESIS,TOTAL,UROLOGY
ANOVA,ASSAY,BACKGROUND,CONCLUSION,CURRENTLY,GLEASON,GRADE,HOWEVER,IGG,LABEL,METHODS,MOLECULAR,RESULTS,SCORE,STUDENT,WHITNEY
BACKGROUND,ERBB2,LABEL,MET,PDZRHOGEF,RAC,RESULTS,SOMATIC
169,BJU,ITALY,LABEL,LEVEL,MARCH,MATERIALS,METHODS,MILAN,NAZIONALE,OBJECTIVE,OBJECTIVES,PROGRAMME,RESULTS,THERAPY,UNLABELLED
954,BACKGROUND,CONCLUSION,HOWEVER,LABEL,LNCAP,PC3,PCA,PRINCIPAL,PSA,RESULTS
DESPITE,GLEASON,MUTATIONS,THEREFORE
916,FIRST,INSTEAD,PML,ROS,WHILE
100,120,177,202,273,300,328,501,BMI,MEN,OPTIMAL,SERUM
946,FORMATION,KNOCKDOWN,OVERALL,PCA,PELP1,THESE
11C,509,739,ACCORDING,AIM,CONCLUSION,FORTY,LABEL,METHODS,OBJECTIVE,PET,PSA,RESULTS,STUDENT,SUV
ANTICANCER,DOX,LNCAP,THESE
176,177,FURTHER,MLC,VOLUMETRIC
HOWEVER,III,PATIENT,SIPULEUCEL,VITAL
DESPITE,PCA,WESTERN,WHILE
CSC,PCA
941,963,AFRICAN,BACKGROUND,BLACK,JANUARY,LABEL,METHODS,ORS,POPULATION,RESULTS,SIMILARLY,THESE,TRAINED
169,29B,BETWEEN,EARLY,EPITHELIAL,LNCAP,PC3,SNAIL,THEREFORE,TWIST
169,COPYRIGHT,CURRENTLY,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS
169,176,BECAUSE,CONCLUSION,COPYRIGHT,DAVID,INC,KRESS,LABEL,MATERIALS,METHODS,OBJECTIVE,PROJECTION,PURPOSE,RESULTS,SCANS,USING
169,947,CONCLUSION,COPYRIGHT,DYNAMIC,HOWEVER,IMAGE,INC,INTENSITY,LABEL,METHODS,MLC,OBJECTIVE,PURPOSE,RESULTS
000,013,048,169,191,ADT,COPYRIGHT,GLEASON,HOWEVER,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,UNIVERSITY
013,059,169,ADDITIONAL,AVERAGE,COPYRIGHT,DUE,EXCLUDING,FIFTEEN,INC,INSTITUTES,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,VODCA
002,169,CONCLUSION,COPYRIGHT,ENGAGEMENT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SEEKING,USING
111,169,ASSESSING,BACKGROUND,CGA,CONCLUSION,COPYRIGHT,FORTY,FURTHER,HAZELWOOD,INC,LABEL,METHODS,NED,OCTREOSCAN,PHE,RESULTS,SSTR2
AE1,KIT,LCNEC,TTF
AIM,BACKGROUND,CONCLUSION,DUE,EIGHT,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS,SUSPICIOUS,TESLA
BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS
194,206,207,506,ATLAS,BACKGROUND,CONCLUSION,GBM,KLK,LABEL,MATERIALS,METHODS,OVERALL,RESULTS,THERE
012,109,158,176,360,487,567,956,BACKGROUND,CONCLUSION,DOCETAXEL,HOWEVER,LABEL,MARCH,MAY,METHODS,PSA,RESULTS,SERIOUS,THEREFORE,TTF,ULTIMATELY
AIM,BACKGROUND,CONCLUSION,GADD45A,JNK,JUN,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,RESULTS,THESE
VITAMIN
ANP,BACKGROUND,CONCLUSION,JUN,LABEL,MATERIALS,METHODS,RESULTS,THESE
MRI
PCA,UNTIL
492,AFRICAN,BLACK,BLOOD,CHICAGO,VITAMIN
103,142,169,295,956,BACKGROUND,BASED,BASEL,CONCLUSION,COPYRIGHT,LABEL,METHODS,RESULTS
PSA
111,139,169,739,BACKGROUND,BASEL,COPYRIGHT,LABEL,LND,MEIER,METHODS,PRIMARY,PSA,RESULTS
105,125,144,150,169,184,289,601,890,ADDITIONAL,AIM,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,UTRECHT
001,006,085,169,945,AEU,BMI,COPYRIGHT,EXCLUSION,FORTY,LABEL,METHODS,MEXICAN,OBJECTIVE,OVERWEIGHT,PCA,PSA,PUBLISHED,REDUCTASE,RESULTS
033,160,183,BCL,CLL,FURTHER,GENISTEIN,GLEASON,LUMINAL,NK3,NORWEGIAN,PCA,PCR,THERE
BACKGROUND,HDR,LABEL
HOWEVER,REASONS
HTS,PERUVOSIDE,THESE
AFRICAN,BACKGROUND,END,GREATER,HISPANICS,HODGKIN,LABEL,METHODS,NHL,RESULTS
169,BAT,COPYRIGHT,CRPCS,INC,ORS,THESE,WILEY
169,BACKGROUND,CIC,CONCLUSION,COPYRIGHT,F12,GFD,INC,LABEL,METHODS,RESULTS,WILEY
CONCURRENT,FDA,III
014,015,025,169,BJU,COVARIATES,DIAGNOSTIC,GLEASON,LABEL,LEVEL,MEN,METHODS,OBJECTIVE,PSA,PSADT,RESULTS,UNLABELLED
001,026,120,169,215,945,981,AGAIN,BJU,CHC,HOWEVER,KRUSKAL,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THERE,UNLABELLED,VEH,WESTERN
107,149,169,500,665,AUC,AUTHORS,BJU,CONCLUSION,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,TPM,UNLABELLED
NMR
176,AMONG,EARLIER
BAK,BCL,BIK,BORTEZOMIB,DILTIAZEM,DU145,GRP78,HOWEVER,LNCAP,PRESUMABLY,VELCADE
ARS,CK5,CK8,EARLY,THESE,USING
169,AUTOLOGOUS,COHORTS,CTC,LABEL,METHODS,NONTAXANE,OBJECTIVE,PSA,PURPOSE,RESULTS,TREATMENT
001,169,BACKGROUND,COPYRIGHT,INDEX,INPATIENT,LABEL,LOS,LVT,METHODS,NATIONWIDE,NIS,OVERALL,PROJECT,RESULTS,RPS,SOCIETY
169,ACCORDING,INC,NETWORK,OVERALL,SOCIETY,THREE
USING
300,946,ALTERED,BMI,CONCLUSION,DMR,ELISA,H19,INSULIN,LABEL,LOWER,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,UCB
11C,170,177,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PET,PSA,PSADT,PURPOSE,RESULTS
ACTUARIAL,BACKGROUND,GROUP,LABEL,METHODS,MIU,PSA,RADIATION,RESULTS,SEVEN,THERAPY,THERE,VACCINE
000,203,205,ARGONAUTE,LNCAP,PCA,USING
5MC,945,ASSOCIATED,TET
AFTER,HOWEVER,SEVERAL,UROGENITAL,WEGENER
169,COPYRIGHT,LRP,LTD,PEARSON
AKT,ANOTHER,CTD,HOWEVER,PC3
169,COPYRIGHT,EPIGENOME,HOWEVER,IRELAND,LTD
169,200,CAD,HESSIAN,INSTITUTE,PHYSICS
169,44B,COMPOUNDS,COPYRIGHT,LNCAP,LTD,SIMILARLY,THESE
169,ADT,PCA,SINCE
169,INSTITUTE,PHYSICS,RBF
945,946,DHA,EMT,PC3,SMA,TGF,THESE
001,362,749,799,893,BACKGROUND,BECAUSE,CLAVIEN,CONCLUSION,III,LABEL,METHODS,OBJECTIVE,PSM,PURPOSE,RESULTS,RRP
800,945,956,BACKGROUND,CDCP1,CUB,GFP,HIF,HOWEVER,HYPOXIA,LABEL,METHODS,PC3,PROTEIN,RESULTS,SRC,TEM,THESE,TM4SF,VHL
AKT,GAP,GGAP2,GTP,INCREASED,MUTATIONS,OVERALL,RAS,SIMILAR,WESTERN
BECAUSE,DESPITE,MCF10AT,THESE,USING
946,ALTOGETHER,CD9
CXCR2,IL8,P53,SMALL,THEREFORE,WHILE
169,CHROMATIN,COPYRIGHT,G9A,GST,INC,MMP13,PIP,RUNX2,RX2,SINCE,TRANSIENT,USING,WHEREAS,WILEY
000,378,508,553,810,ASSESSMENT,BACKGROUND,BEP,BREAK,DIAGNOSIS,DRG,GROUP,HEATH,HTA,ITALIAN,LABEL,MATERIALS,METHODS,POINT,RELATED,RESULTS,ROBOTIC,TECHNOLOGY,UNIVERSITY,VINCI
169,COPYRIGHT,HISTONE,HOWEVER,INC,JUMONJI,LNCAP,THR34,TSA,WILEY
EVALUATING,LABEL,OBJECTIVE,PHYSICIAN,PURPOSE,RESULTS,SUMMARY
CURRENT,HENCE,LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
LABEL,MRI,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SUMMARY,THERE
185,956,CHANGES,DU145,FOLLOWING,INK4A,THESE,VACCINIUM,WCE
169,BPH,CONVERSELY,COPYRIGHT,ECM,IRELAND,LNCAP,LTD,PCA,THESE,USING
132,169,177,48H,956,ANNEXIN,BCL,CCK,CHINESE,COPYRIGHT,DU145,HOWEVER,JIN,LTD,NAC,PAB,ROS,TAKEN,WESTERN
035,215,323,ABO,JAPAN,THROUGH
000,100,685,AGE,CUP,HOWEVER,INCREASING,LIVER,MALIGNANT,OVERALL,SWEDISH
169,194,BACKGROUND,CONCLUSION,COPYRIGHT,DOCETAXEL,HOWEVER,INC,LABEL,METHODS,MTS,PC3,PROTEIN,RESULTS,THERE
169,956,ABNORMALLY,BACKGROUND,CK2,COPYRIGHT,GENERAL,INCUBATION,LABEL,LNCAP,METHODS,RESULTS,THEREFORE,WESTERN
169,BACKGROUND,BECAUSE,CONTEXT,COPYRIGHT,EVALUATION,HOWEVER,LABEL,MEDLINE,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,REVIEWS,SCIENCE,SYNTHESIS,SYSTEMATIC,WEB
169,776,790,ANOTHER,CD4,CD8,COPYRIGHT,HOWEVER,INTERIM,KEY,LTD,MHC,PEPTIDE
000,100,128,135,144,158,169,567,COLLECTION,COPYRIGHT,HEIDELBERG,INC,INSTITUTE,LABEL,MATERIALS,METHODS,MORAL,OBJECTIVE,OBJECTIVES,PATHOLOGY,PROGRAM,REGARDING,RESULTS,SINCE,THEIR,TNM,WHEREAS
001,150,169,194,231,250,CONCLUSION,CONTINENCE,COPYRIGHT,ENDOPELVIC,FUNCTIONAL,GLEASON,INC,INCLUSION,JANUARY,LABEL,METHODS,OBJECTIVE,OIF,PATHOLOGIC,PRESERVING,PSA,RESULTS,THERE
169,194,CAP,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,MINNESOTA,MIXED,OBJECTIVE,OLMSTED,PSA,RESULTS,THESE
169,194,CONCLUSION,COPYRIGHT,FORTY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,SEVERAL
169,194,ADT,AMONG,CASES,COPYRIGHT,FIFTY,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PFS,RESULTS,SIXTY
001,133,169,194,CONCLUSION,COPYRIGHT,INC,IQR,JANUARY,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,SUBJECTIVE
169,186,194,210,BASED,CIS,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THREE
169,173,194,CAGIANNOS,CONCLUSION,COPYRIGHT,EPLND,INC,LABEL,LNI,METHODS,OBJECTIVE,RESULTS
169,600,BACKGROUND,CONCLUSION,CONFIDENCE,COPYRIGHT,EFFECTS,LABEL,LTD,MEN,METHODS,OLDER,RESULTS,SIR,SWEDISH
169,241,5MG,AEU,AFTER,APRIL,BACKGROUND,COPYRIGHT,DOCETAXEL,LABEL,MAY,METHODS,PSA,PUBLISHED,RESULTS
160,169,194,COPYRIGHT,PIM,SAS
109,124,169,BMS,CONCLUSION,COPYRIGHT,EVALUATION,GRADE,GROUP,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SECONDARY,SOLID,TAX,TCX,UNLABELLED,WORKING
169,COPYRIGHT,LTD,PAGET,SINCE
009,169,930,AMONG,BACKGROUND,CIS,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OUTCOME,POISSON,PUBLISHED,RESULTS,SETTING,SIR,STUDIES,THESE,UROLOGY
001,002,008,169,304,680,746,ADT,CONCLUSION,COPYRIGHT,EDUCATION,FALSE,FDR,FOUNDATION,INC,LABEL,MEDICAL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SNP
169,194,AGENT,CAP,COPYRIGHT,INC,SEVERAL,THESE
169,413,946,BACKGROUND,CODOMINANT,COPYRIGHT,CRT,IRELAND,LABEL,LTD,MATERIALS,METHODS,NEITHER,OBJECTIVE,PURPOSE,RESULTS,TGF
100,473,954,CD133,EGF,MIC,PCS,SER,THESE
956,AKT,APOPTOSIS,MCL,SORAFENIB
FOXA1,FURTHER,INHIBITION,LNCAP,OVERALL
001,145,ANOVA,DU145,LABEL,MATERIALS,METHODS,MHC,OBJECTIVE,PC3,PDE,PDE11,RESULTS,THESE,TREATMENT,WHITNEY
160,302,LABEL,METHODS,NSCLC,OBJECTIVE,PURPOSE,RESULTS,SEVEN,THESE
064,107,144,AFTER,AUSTRALIA,IQR,LABEL,MEN,METHODS,OBJECTIVE,OUTCOME,QUEENSLAND,RESULTS,TREATMENT
091,AMONGST,BMI,CONCLUSION,FEW,HOWEVER,LABEL,METHODS,OBJECTIVE,PROTECT,PSA,PURPOSE,RESULTS
HCT,PTA,VARIOUS
DG8S737,MYC,PCA
169,BASED,COPYRIGHT,CTV,INC,INTER,LABEL,MARGINS,MATERIALS,METHODS,OBJECTIVE,PBM,PTV,PURPOSE,RESULTS
169,COPYRIGHT,FORTY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PBT,PCA,PURPOSE,RCT,RESULTS,SEVENTEEN,WTP
169,231,99M,AMONG,ASP,COPYRIGHT,GRP,INC,LABEL,MAG,MCF,MDA,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SEVERAL,T47
169,AGE,COPYRIGHT,DETECTION,EARLY,EPCDP,FURTHER,LITHUANIA,LITHUANIAN,LTD,POPULATION,PROGRAMME,PSA,PUBLISHED,ROYAL,SOCIETY,THERE
169,382,BACKGROUND,BASED,BCA,COPYRIGHT,DFS,DSS,JANUARY,LABEL,METHODS,OBJECTIVE,PATHOLOGIC,PRIMARY,PUBLISHED,RESULTS,RFS,SETTING,UROLOGY
169,364,BRCA1,COPYRIGHT,LTD
169,231,233,CONCLUSION,COPYRIGHT,DISCUSSION,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS
FDA,FINALLY
801,ADVERSE,AMONG,BACKGROUND,DESPITE,GERMANY,ITALY,LABEL,METHODS,OBJECTIVE,RESULTS,SIGNS,SPAIN,TDS,TREATMENT
ARTIFACTS,CALYPSO,CRAWLEY,KINGDOM,LABEL,MEDICAL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEATTLE,SYNERGY,THESE,XVI
100,BASED,CALYPSO,DIL,GAMMA,LABEL,MEDICAL,METHODS,OBJECTIVE,PLANS,PTV,PURPOSE,RESULTS,SEATTLE,USA
CARLO,LABEL,LARGE,LDR,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS,THERE,THEREFORE,THREE
120,931,963,BECAUSE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SDS,SGT,WITHOUT
916,963,BEAMS,LABEL,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,THREE,TPS
949,BLANK,GOS,GOSERELIN,LNCAP,PCL,PEG,SERUM
001,020,036,038,233,408,760,BACKGROUND,CASES,CIS,CONCLUSION,LABEL,METHODS,MIN,OBJECTIVE,ORS,PUFAS,RESULTS,SUPPL,THESE,VITAMINES
AMONG,ANALYZING,ETS,HOWEVER,PC3,SIMILAR,TET,THESE,USING
169,AUC,CARLO,ELTEREN,MONTE,ROC,STRATUM,VCH,WILEY
CTLA4,CYTOTOXIC
169,945,946,COPYRIGHT,EPCAM,FAK,HOWEVER,IGF,INC,RACK1,SRC,THESE,USING,WILEY
169,COPYRIGHT,LBD,LTD
001,169,200,FCH,GSTP1,INC,LABEL,METHODS,OBJECTIVE,PCR,PET,PURPOSE,RARB2,RESULTS,THESE,WILEY
169,945,ATHYMIC,DIGOXIN,HIF,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,WESTERN,WILEY
169,945,946,HOWEVER,UROLOGICAL
LATER,RECURRENCE
001,007,013,015,029,048,049,053,092,128,19E,218514200,220,251,318,486,491,534,653,965,C30,EORTC,LABEL,LITHUANIA,METHODS,OBJECTIVE,ORS,QLQ,QOL,QUALITY,RESULTS
946,AMONG,INCREASED
PCA,WESTERN
011,015,018,1306C,1306T,169,190,200,303,418,735,BACKGROUND,COPYRIGHT,GENOTYPING,HAPLOTYPE,HOWEVER,INC,INDIA,LABEL,METHODS,NORTH,OBJECTIVE,PCA,PCR,PUBLISHED,RESULTS,THESE,TIMP2,TIMPS
IMAGE,MRI,PET,THESE
223,945,CYP17,DENOSUMAB,MDV3100,OVERALL
000,100,101,139,283,398,565,703,717,APART,BACKGROUND,CONCLUSION,ESTIMATING,LABEL,MATERIALS,METHODS,POISSON,RESULTS,UNION,USING,WORLD,YOUNGER
BACKGROUND,CELLSEARCH,COMPARISON,GENOMIC,HOWEVER,LABEL,METHODS,RESULTS,WGA
001,015,169,656,842,AMONG,AUTHORS,BFS,BJU,BOARD,CSS,GLEASON,LABEL,MEIER,MEN,METHODS,MFS,OBJECTIVE,PSA,RESULTS,T2B,THERE,UNLABELLED
169,BLACKWELL,CASES,DESPITE,GLEASON,LABEL,LNS,LTD,METHODS,OBJECTIVE,PCA,PSA,PUBLISHING,RESULTS,SEVEN
169,218,434,931,ADIPOSE,AUC,BJU,CONCLUSION,GLEASON,INCREASING,LABEL,LEVEL,METHODS,OBJECTIVE,PPF,PROGNOSIS,RESULTS,UNLABELLED
169,ASIAN,CALIFORNIA,CHANGES,NORTH
174
169,177,183,219,402,447,AMICO,BCF,BJU,HORWITZ,LABEL,MAY,METHODS,NORTH,OBJECTIVE,OVERALL,PRE,PRIMARY,PSA,RESULTS,STUTTGART,UNLABELLED
033,169,323,341,731,857,877,889,896,937,ADC,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,TESLA,WILEY
001,133,148,157,182,201,460,731,BACKGROUND,INCREASED,LABEL,METHODS,RESULTS,THROMBOSIS
447,AEROMONAS,BETWEEN,DESPITE,EARLY,JANUARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEPTEMBER,SIX,UROSEPSIS
DRUGS,OPTICAL,OTHER
001,169,736,AFTER,BACKGROUND,COPYRIGHT,EFFORTS,END,FRAGMENTED,HERFINDAHL,HIRSCHMAN,INDEX,LABEL,METHODS,PSA,RESULTS,SOCIETY,USING
BACKGROUND,FEE,FEW,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,WHILE
946,GDF,HOWEVER,PCA,TGF
016,033,BACKGROUND,C677T,CIS,LABEL,METHODS,MTHFR,NEITHER,ORS,OVERALL,RESULTS
ADT,BPS,DENOSUMAB,IGG,OSTEOPENIA,RANKL
200,946,DEPLETION,EMT,EPITHELIAL,MIR,VARIOUS
169,ADULT,COPYRIGHT,LTD,SMOKERS
ADVERSE,SERIOUS,SIPULEUCEL,TREATMENT
HOWEVER,SIPULEUCEL
HOWEVER,HU1,TRT,USP2A
AKT,DIMINISHED,DL100,HIV,HOWEVER,LNCAP,SAQ,SAQUINAVIR,TNF,TRAIL,TREATMENT
129SV,169,COPYRIGHT,ELISA,ENDOCAN,HOWEVER,MOUSE,PUBLISHED,THESE
THEREFORE
169,195,B16,COPYRIGHT,ESI,INC,NMR,PC3,TAKEN
169,AHX,GLU,III,LNCAP,LYS,PET,SOCIETY
APA,CONGRUENCE,FIFTY,THOSE,USING
169,AUSTRALIAN,BLACKWELL,III,LTD,PTY,PUBLISHING,SINCE
100,140,169,280,AUTHORS,BJU,CAB,CONCLUSION,CSS,FIFTY,GLEASON,LABEL,METHODS,OBJECTIVE,PFS,PSA,RESULTS,THERE,UNLABELLED
169,AMONG,DIGOXIN,ERS,HOWEVER,OTHER,THESE,WOMEN
169,176,COPYRIGHT,INC,TECHNIQUE,USING,WILEY
CAD,CONCLUSION,COUNT,INTENSITY,LABEL,MET,METHODS,OBJECTIVE,RESULTS,USING
008,125,155,BETWEEN,CHI,CONTINUOUS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,VAN,VELTHOVEN
ATP,HOWEVER,USING
000,101,172,176,325,500,964,BOOLEAN,CGEMS,HOPKINS,HOWEVER,INSTITUTE,JHH,JOHNS,MARKERS,OPERATION,PCA,SCREENING,SIXTEEN,SNP,TESTING
160,ACUTE,ADVERSE,CONCLUSION,CTCAE,DVH,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIB,V65,V70,V75
005,268,ADDITIONAL,GLEASON,ILL,PATHOLOGY,SOCIETY,THESE,THREE,UROLOGICAL
ADT,BASED,COLLEGE,CROSS,DESPITE,PCA,STUDIES
AKT,EPIGENETIC,INSTEAD,WHEREAS
DUE,GREATER,HOWEVER
HSC,PCA
ETS
003,10Q26,11Q12,141,215,557,804,FAM111A,FAM111B
169,CARLO,COPYRIGHT,DRE,INC,MONTE,ORS,PSA,USING
169,AFM,BACKGROUND,COPYRIGHT,DESPITE,GENERAL,LABEL,LNCAP,MAJOR,METHODS,SCOPE,THESE
946,AKT,GTPASES,RHO,UROKINASE
143,169,ANALYZE,BACKGROUND,CLAVIEN,CLOQUET,COPYRIGHT,LABEL,LIMITED,LYMPH,METHODS,OBJECTIVE,PLA,PROCEDURE,PSA,PUBLISHED,RESULTS,ROBOTIC,SEPTEMBER,SETTING,UNDER,UROLOGY
100,169,177,99M,AUC,BACKGROUND,BASED,BVC,COPYRIGHT,HOWEVER,LABEL,METHODS,MRI,OBJECTIVE,PCA,PUBLISHED,RESULTS,SETTING,TECHNETIUM,TXR,UROLOGY,WBMRI
169,COPYRIGHT,HOWEVER,IRELAND,JEGHERS,LTD,PEUTZ
169,COPYRIGHT,IMAGING,INC,MEDICAL,PUBLISHED,STRUCTSURE,THEREFORE,THESE
169,177,198,BLADDER,CONCLUSION,COPYRIGHT,DAILY,ISOTROPIC,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SAS,SEVENTEEN,SIX
169,194,945,COPYRIGHT,HYDROXY,LTD,SEEBACH,USING,VOLTAGE
169,194,CONCLUSION,COPYRIGHT,LABEL,METHODS,MRI,OBJECTIVE,POSTERIOR,PTV,PURPOSE,RESULTS,SAS,TDM,TEN
169,BMP,EC109,HOWEVER,INSTEAD,KNOCKDOWN
108,144,ANOTHER,BETWEEN,COX,CSS,GLEASON,IQR,JANUARY,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PSA,RESULTS
154,260,ACCRUAL,BACKGROUND,LABEL,METHODS,RESULTS,TRIAL
AKT,ATO,LNCAP,ROS,THESE
101,115,134,155,174,ARGONAUTE,CPG,H3K9ME2,HEPARANASE,HPA,INSTEAD,PCR,SP1,TFIIB,TGS,THESE,TSS
108,239,EXPRESSION,GLEASON,KNOCKDOWN
22RV1,234,CFS,MLV,THESE,URISMAN,XENOTROPIC
HOWEVER,RAR,SAMD3
CONCLUSION,HSP,HSP27,LABEL,LNCAP,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,TREATMENT,WESTERN
916,ACTIVATION,LABEL,LBD,METHODS,OBJECTIVE,PCA,PURPOSE,Q640X,RESULTS,THESE
169,CHEMISTRY,PSA,ROYAL,SOCIETY
000,100,102,115,119,152,996,AFTER,BACKGROUND,COMPARISON,DESPITE,LABEL,METHODS,PCR,PSA,RESULTS,SERUM,THERE,TOTAL
017,215,349,BACKGROUND,CCP,CONCLUSION,GLEASON,LABEL,METHODS,PSA,RESULTS,TOTAL
100,169,AFTER,COMPARISON,COPYRIGHT,EARLY,GROUP,INC,LABEL,MATERIALS,MEIER,METHODS,MUCOSAL,OBJECTIVE,PURPOSE,RADIATION,RECTOSCOPY,RESULTS,SCORE,THERAPY,TREATMENT,VRS
169,194,197,945,AFRICAN,ATTENDING,CONCLUSION,COPYRIGHT,FURTHER,HIV,INC,INDEX,LABEL,METHODS,OBJECTIVE,QUALITY,RASCH,RESULTS,SETTING,SOUTH,SPIRITUAL,SWB,TRANSLATED,UGANDAN,VITAS
169,300,316,660,685,ACCORDING,LNCAP,MG132,NH1,THESE
100,11P13,12P12,169,945,AFTER,ARRAY,AUTHORS,BLACKWELL,CGH,LTD,MIB,PATHOLOGY,PSA,PTY,PUBLISHING,SMA,SOCIETY,WT1
169,AUTHORS,BLACKWELL,DEPARTMENT,DESPITE,GENERAL,GLEASON,HGPIN,LTD,PATHOLOGIC,PATHOLOGY,PTY,PUBLISHING,SOCIETY,TAIWANESE,THERE,WESTERN
AMD3100,CD133,CXCL4,CXCR4,HOWEVER
PANDA,THZ
169,AIC,BIC,COPYRIGHT,CRITERION,LTD,WILEY
160,177,181,264,324,HEPG2,MTT,PC3,RAW,WRL
BESIDES,PET
APART,PET
100,165,252,AFTER,AIM,BACKGROUND,C30,CONCLUSION,CONCORDANT,EORTC,GIVEN,LABEL,METHODS,OBJECTIVE,PF2,QLQ,QOL,RADICAL,RESULTS,SCALE
125,177,CONCLUSION,DCE,EIGHT,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,RESULTS
100,130,215,300,500,800,992,ADC,CONCLUSION,DWI,LABEL,MATERIALS,METHODS,MRI,NPV,OBJECTIVE,PPV,RESULTS,ROI,SIXTEEN
163,169,600,CONCLUSION,HIPAA,LABEL,MATERIALS,METHODS,NAA,OBJECTIVE,PURPOSE,RESULTS,SIMILAR
127,169,795,BETWEEN,CONCLUSION,DIAGNOSTIC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS
169,170,177,211,ADC,CANCERS,CONCLUSION,GLEASON,HIPAA,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,WHOLE
NAMED,SUBSEQUENT
CHINA,JAPAN,JOINPOINT,KOREA,SINGAPORE,THERE,THEREFORE,THESE
100,125,18F,BACKGROUND,FIFTY,LABEL,LIMITED,METHODS,MTD,PDS,RESULTS,SEVENTEEN,THREE,TIW
FIRST,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,SUPPORTIVE
004,006,009,380,636,874,ADT,BACKGROUND,CONCLUSION,COX,FFS,FORTY,GLEASON,LABEL,MEIER,METHODS,RECURSIVE,RESULTS
110,140,281,282,292,318,LABEL,METHODS,NPV,OBJECTIVE,PATHOLOGIC,PCS,PPV,PURPOSE,RESULTS,SHEAR,SIX,SWE,YOUNG
956,CASPASE,DU145,LNCAP,PC3,THESE
105,107,139,204,410,462,HBV,HIV,SPAIN,THERE
AREAS,BACKGROUND,COVERED,DESPITE,FDA,III,LABEL,METHODS,OPINION,PHASE,SERMS,TOREMIFENE
013,PREFERENCE,SES
169,ADDITIONAL,APRIL,AUTHORS,BJU,CONFERENCE,MAY,THESE,ULTIMATELY,UNTIL,WESTERN
169,AUTHORS,BJU,CONFERENCE,DIAGNOSIS,HOWEVER,THESE
945,954,ADCK2,AMONG,HIF,HYPOXIA,IKK,JNK,PRKAR2B,TAKEN,THESE,TNF,TRIB2,TRPM7
001,122,BPH,MAPPING,OVERALL,WHITNEY
145,BPH,GLEASON,HOWEVER,LNCAP,PSA,SERUM,TAKEN
ADJUSTMENT,GROUP,LABEL,LOCKE,MARITAL,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERAPY,THERE,TREATMENT
169,177,181,183,946,AMONG,BENTH,GEORG,NFF,NMR,PC3,STUTTGART
32D,950,CD3,ERBB1,ERBB2,OWING,T1E,T1E28,USING
ACA,BBN
BACKGROUND,CCI,COLORECTAL,CONCLUSION,COX,ELDERLY,JANUARY,LABEL,METHODS,POPULATION,PREVALENCE,RESULTS
280,BACKGROUND,DTX,EMP,LABEL,METHODS,PSA,RESULTS,THERE,TTP
006,158,174,181,COMPOSITE,CONCLUSION,INDEX,LABEL,METHODS,OBJECTIVE,PAINFUL,RESULTS,SEVEN,SWEDISH
948,C1B,DBL,GLU,PKC,THR,TYR,VAV
AFTER,AUSTRALIAN,BACKGROUND,CONCLUSION,CRC,HOWEVER,LABEL,METHODS,NSCLC,OLDER,RESULTS
BACKGROUND,CONCLUSION,EXTRACTION,FUNDING,GLEASON,HEALTHCARE,LABEL,MEDLINE,METHODS,OBJECTIVE,PREDICTORS,PRIMARY,PSA,PUBLISHED,PURPOSE,QUALITY,RESULTS,SELECTION,SIXTEEN,SOURCES,SYNTHESIS
DESPITE
000,132,240,302,311,503,542,814,BACKGROUND,CFS,GERMANY,HIV,HOWEVER,HVS,LABEL,METHODS,PCR,RESULTS,XENOTROPIC
HMW,LABEL,LMW,METHODS,OBJECTIVE,PACLITAXEL,POLYMER,PTX,PURPOSE,RESULTS
372,500,CAGCT,CGGCT,CGTCG,MYC
001,002,208,946,AMACR,E12,LABEL,METHODS,MIB,OBJECTIVE,PURPOSE,REFERRING,RESULTS,THESE
100,169,AKT,EMT,HOWEVER,MAP,MEK,RAS
160,ARD6562,ARD6563,BACKGROUND,LABEL,METHODS,RESULTS,THERE,THEREFORE
644,BACKGROUND,BEDOK,CONCLUSION,HOWEVER,LABEL,LUTSS,METHODS,NORTH,QOL,RESULTS,SCORE,SINGAPORE,SYMPTOM,THERE
125,144,AFRICAN,AGE,BACKGROUND,CASES,CAUCASIAN,COMMISSION,END,IRS,JOINT,LABEL,METHODS,PSA,RESULTS,THERE,THESE
IMAGING,ISSUE,LABEL,METHODICAL,METHODS,MONITORING,MRI,OBJECTIVE,PRACTICAL,PSA,RADIATION
246,431,CCAAT,E2F,FINALLY,INCREASING,LNCAP,NUSAP,PC3,TRANSIENT
001,002,125,144,148,160,170,252,667,919,CONCLUSION,GLEASON,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,UTRECHT
HOWEVER
CONVERSELY,STUDIES,THROUGH
160,287,574,BACKGROUND,CONCLUSION,DAH,DOSES,EBT,LABEL,METHODS,PTV,RESULTS
636,655,704,714,718,ANN,AUC,DVH,EUD,FOLLOWING,THESE
CHINESE,ERG,FURTHER,KHDRBS3,NOTABLY,THERE,THREE,TMPRSS2,USP9Y
169,246,COLLECTION,COPYRIGHT,LTD,THERE,THEREFORE
136,169,194,COPYRIGHT,CTV,DAILY,IMAGE,INC,INTER,LABEL,MATERIALS,METHODS,MVISION,OBJECTIVE,PTV,PURPOSE,RESULTS,SIEMENS,SYNERGY
11195,ANT,CONTROL,HENCE,PBR,SEVERAL
AFTER,DRR,HDR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THEREFORE,THREE
947,ANNEXIN,BACKGROUND,BLOOD,H2A,HENCE,LABEL,MATERIALS,METHODS,RESULTS,THERE
169,499,ALLELIC,BIALLELIC,BLACKWELL,KEAP1,LABEL,LTD,METHODS,NAD,OBJECTIVE,PUBLISHING,RESULTS,SOMATIC
169,GENERAL,JOURNAL,MICROSCOPY,NMF,ROYAL,SOCIETY
179,239,BACKGROUND,BASED,DETECTION,HCV,HIV,HOWEVER,LABEL,PBMCS,PCR,PRINCIPAL,RESULTS,WESTERN,XENOTROPIC

945,946,AKT,BCL,CAFFEIC,MICROARRAY,MYC
SIX
945,946,954,CPG,DU145,HOWEVER,LNCAP,PC3,ST3GALS,THEREFORE
22RV1,AUSTRALIA,DU145,EXPRESSION,HOWEVER,LNCAP,MEN,PCA,PSA,SP1,THESE,TMPRSS2
AKT,IHC,TFA,TFS
945,946,AUTOMATED,DESPITE,ESTROGENS,EXOGENOUS,USING
AMONG,FDA,FDR,THESE
945,946,954,AKT,CCN,FINALLY,ILK,NOV,TAKEN
169,COPYRIGHT,INHIBITED,VCH,WILEY
169,252,956,CHIMICA,COMPOUNDS,COPYRIGHT,HELVETICA,THEIR
183,GEORG,STUTTGART
160,AFFYMETRIX,CNA,DFS,IHC,LNM,PCR,PRIMARY,THROUGH
CCCTC,FOXA1,H3K4ME2,HOWEVER,UNDER
704,BACKGROUND,CTC,LABEL,METHODS,RESULTS,SAMPLES
CONCLUSION,LABEL,OBJECTIVE,PURPOSE,SUMMARY
422,897,BACKGROUND,GLASGOW,GLEASON,LABEL,METHODS,NLR,OUTCOME,PROGNOSTIC,RER,RESULTS,SCORE,THERE
152,946,BACKGROUND,COLORECTAL,ERSPC,FACTORS,FIFTY,FORCE,LABEL,MEDICAL,METHODS,OVARIAN,PSA,RANDOMISED,RESULTS,SCREENING
110,803,AUC,BACKGROUND,CAP,FURTHER,GLEASON,LABEL,METHODS,PCR,RESULTS,SPARC,THEREFORE,VALIDATION
204,BACKGROUND,CONCLUSION,HOWEVER,LABEL,MCC,MCV,METHODS,PCR,RESULTS,SAMPLES
169,BASEL,COPYRIGHT,PSA,USA
001,177,CONCLUSION,LABEL,METHODS,MRI,PCA,PET,RESULTS,UNLABELLED,WHOLE
1990S,ADT,CRITICALLY,DESPITE,OVERALL,PSA
ADT,INSULIN,PCA
HOWEVER,PSA
1980S,BECAUSE,HOWEVER,PSA
CONSIDERED,CYR61,FURTHER,PCA
001,100,169,COPYRIGHT,INC,PCR,PLA,PSA,SENSITIVE,USING
161,177,908,HOWEVER
134,143,167,169,189,BACKGROUND,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,PATHOLOGY,PCA,PRIAS,PSA,PUBLISHED,RESULTS,SETTING,UROLOGY
169,916,945,AF4,COLLECTED,COPYRIGHT,IEF,WHILE
169,COPYRIGHT,LTD
11C,169,AFTER,COPYRIGHT,IMAGE,IRELAND,LABEL,LTD,METHODS,MRI,OBJECTIVE,OBJECTIVES,PET,RESULTS
125,169,714,715,ACUTE,AUR,COMPARISON,CONCLUSION,COPYRIGHT,INC,JANUARY,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,PREDICTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,STILL,THEREFORE,TORONTO,UNIVERSITY,UTRECHT
169,553,643,COPYRIGHT,GLEASON,LTD,PSA,THESE
077,169,COPYRIGHT,COX,DOSES,FIRST,GRADE,GROUP,INC,INSTEAD,KUTCHER,LABEL,LKB,LYMAN,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERAPY,THERE,THIRD,V75,VDOSE
169,COMPLIANCE,COPYRIGHT,INC,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SECONDARY,TREATMENT
002,008,035,100,169,223,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,VAS
169,194,COPYRIGHT,COX,DU145,EDUCATION,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
108,110,169,218,ADT,BACKGROUND,BTB,COPYRIGHT,GLEASON,HDR,III,INCIDENCE,IRELAND,LABEL,LTD,METHODS,PSA,RESULTS,RFS,SECONDARY
014,169,COPYRIGHT,DOCETAXEL,ENGINEERED,HOWEVER,IRELAND,LTD,THERE
169,194,946,COPYRIGHT,INC,SMAD4,TGF
100,104,150,169,208,462,ACCORDING,ADT,BACKGROUND,BASED,CAP,COPYRIGHT,GEE,INC,LABEL,METHODS,PBS,PCI,RAD,RESULTS
157,169,AUR,AXIAL,COPYRIGHT,DWI,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OTHER,PUBLISHED,RATIONALE,RESULTS
001,004,008,169,194,258,COPYRIGHT,CURRENTLY,EDUCATION,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PCI,PUBLISHED,PURPOSE,RESULTS,THESE,UROLOGICAL,USING
169,194,947,COMPARING,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PERIPHERAL,PUBLISHED,PURPOSE,REGULATORY,RESULTS,SINCE,UROLOGICAL
169,194,196,AFTER,COPYRIGHT,EDUCATION,GANGNAM,HEALTHCARE,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCORE,SEOUL,SYMPTOM,UNIVERSITY,UROLOGICAL,USING
116,169,243,264,447,470,977,AMONG,BACKGROUND,CANCERS,COLORECTAL,COPYRIGHT,DIAGNOSIS,ENDOSCOPY,FSG,INC,LABEL,METHODS,MOSBY,OBJECTIVE,OUTCOME,OVARIAN,PREVALENT,PUBLISHED,RESULTS,SCREENING,SETTING,SOCIETY,THESE,TRIAL
169,AKT,AUTHORS,JOURNAL,ORIGINALLY,PHLPP
004,115,169,250,400,CETUXIMAB,CMP,COPYRIGHT,INC,KEY,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RADIOLOGIC,RESULTS,THERAPY,TTP
110,169,AUTHORS,FORWARD,HIV,HOWEVER,JOURNAL,MOLONEY,MOMLV,RTS
169,BJU,HOWEVER
120,150,LOD,M13,PBF,PEDOT
ACL,ATP,COA,THEREFORE
ATLAS,BPH,DRE,EPS,FINALLY,PCA,PROTEIN,TECHNOLOGY,URINARY,WESTERN
169,BASEL,CAM,COPYRIGHT,MAXIMUM,SYSTEMS
931,963,DESPITE,LABEL,METHODS,OBJECTIVE,POPULATION,PTV,RESULTS,SYSTEMATIC,TCP,TREATMENT
110,169,CAP,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OPERATING,PURPOSE,QDA,QISES,QUADRATIC,RESULTS,ROI,T2W,TESLA,WILEY
PATHOLOGIC,RANKL,THERE,WHILE
916,945,ACADEMY,CHANG,DHT
COMMENTARY,DUE,GIVEN,HOWEVER,SIPULEUCEL,TODAY
HOWEVER
169,177,ADT,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,LOW,LTD,METHODS,NETWORK,PSA,RESULTS
169,1990S,COPYRIGHT,FORCE,PREVENTIVE,PSA,SAS,SCREENING,YET
169,BACKGROUND,COPYRIGHT,DESPITE,GLEASON,LABEL,METHODS,OBJECTIVE,PRIOR,PUBLISHED,RESULTS,SETTING,STUDENT,UROLOGY
169,182,757,ADDITIONAL,ADT,BACKGROUND,COPYRIGHT,COX,HOWEVER,LABEL,METHODS,OBJECTIVE,PAD,PCA,PUBLISHED,RESULTS,UROLOGY
000,100,150,169,194,200,CARLO,COPYRIGHT,EDUCATION,HOWEVER,INC,INCREASED,LABEL,MATERIALS,METHODS,MONTE,OBJECTIVE,OLDER,PATIENT,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
016,169,194,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
001,041,169,194,264,429,485,680,AFTER,COPYRIGHT,EDUCATION,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PROPENSITY,PUBLISHED,PURPOSE,RADICAL,RESULTS,THESE,UROLOGICAL,USING
169,194,290,ASIAN,COPYRIGHT,EDUCATION,END,GLEASON,INC,INTENSITY,LABEL,MATERIALS,METHODS,OBJECTIVE,PATIENT,PUBLISHED,PURPOSE,RESULTS,THREE,UROLOGICAL
169,194,820,COPYRIGHT,CURRENT,EDUCATION,GIVEN,INC,LABEL,MATERIALS,METHODS,NUTRITION,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL
001,169,194,795,AUC,BLACK,COPYRIGHT,EDUCATION,FURTHER,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OLDER,PUBLISHED,PURPOSE,RESULTS,ROC,UROLOGICAL
BMI,OBESITY
CURRENTLY,INTENSITY,TOWARDS
BACKGROUND,COVERED,DUE,LABEL,LEUPROLIDE,METHODS,OPINION
000,100,169,AUTHORS,BJU,GROUP,PSA,RESULTS,TECHNICAL
169,AUTHORS,BJU,LOW,WHOLE
120,ADDITIONAL,FEW,LABEL,METHODS,OBJECTIVE,OUTPATIENT,PHYSICIANS,PROVIDERS,PURPOSE,RATES,RESULTS
089,BACKGROUND,COLORECTAL,FACTORS,FIRST,III,JANUARY,LABEL,METHODS,OVERALL,RESULTS,USING,VTE
10Q23,169,16Q22,16Q23,21Q22,AFFYMETRIX,COPYRIGHT,HGPIN,IDENTICAL,INC,MICROARRAY,THESE,USING,WILEY
029,159,169,605,AIS,CAP,INC,SOCIETY,VARIATION,WILEY
MICRORNAS
945,BPH,CURRENTLY,NEITHER,THREE
120,ADT,BASED,DENOSUMAB,RANKL,SRE
169,177,200,BACKGROUND,COPYRIGHT,DEFORMABLE,DISCUSSION,ENDORECTAL,GHZ,INTEL,IRELAND,LABEL,LTD,METHODS,MRI,RAM,REFINEMENT,RESULTS,TPS,USING
002,169,AFTER,ANGELES,AUTHORS,BFB,BJU,BLADDER,CALIFORNIA,INDEX,KEGEL,LABEL,LEVEL,LOS,METHODS,OAB,OBJECTIVE,OVERACTIVE,OVERALL,PCI,QOL,QUALITY,RCT,RESULTS,SCORE,SYMPTOM,THERAPY,UNIVERSITY,UNLABELLED,URINARY
001,116,BACKGROUND,BETWEEN,COMPOSITE,INDEX,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,RRP
100,125,169,175,177,183,216,AUTHORS,BJU,D90,GROUP,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PATIENT,PERSISTENT,PSA,RADIATION,RESULTS,SCORE,SYMPTOM,THERAPY,THERE
041,070,ADH1B,ALCOHOL,COLORECTAL,OVARIAN,SCREENING,THREE,TRIAL
DUE,FURTHER,TRP,TRPV6
228,252,CONCLUSION,FEBRILE,FIRST,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,TECHNISCHE,UNIVERSIT
ERG,ONCOGENIC,WESTERN
FDA,YET
124,169,194,COMMITTEE,COPYRIGHT,HIPAA,INC,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RECURRENT,RESULTS
169,194,918,BETWEEN,COPYRIGHT,INC,INTENSITY,LABEL,MATERIALS,METHODS,MINIMALLY,OBJECTIVE,PURPOSE,RESULTS,THERE
108,125,131,169,194,ASTRO,CONCLUSION,CONSENSUS,COPYRIGHT,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PHOENIX,PURPOSE,RADIATION,RADIOLOGY,RESULTS,SOCIETY,THERAPY,THERE,TREATMENT
160,169,186,190,BETWEEN,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCORE,SYMPTOM,THESE
169,177,CHI,COPYRIGHT,CROWN,DRR,DSC,HOUNSFIELD,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SCANS,WHOLE
169,797,COMPETING,CONVERSELY,COPYRIGHT,CSM,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PCA,PROPENSITY,PURPOSE,RESULTS,THESE
169,652,CALYPSO,CHASE,CONCLUSION,CONFORMAL,COPYRIGHT,FIFTEEN,FOX,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SET
122,132,134,169,375,BAP,COPYRIGHT,INC,LABEL,MARCH,METHODS,NTX,OBJECTIVE,ONJ,OVERALL,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,SIMILARLY,USING
DEPLETION,EPIGENETIC,H3K27,HMT,SET,SUV39H1,UHRF1
169,ABS,COMPLIANCE,CONCLUSION,COPYRIGHT,INC,LABEL,LDR,MATERIALS,METHODS,MOUNT,NUCLEAR,OBJECTIVE,PUBLISHED,PURPOSE,RADIO,RESPONSES,RESULTS,SIXTY,SOCIETY,THERE,USA
169,194,BASIC,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY
100,113,115,125,150,169,245,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
EPHA2,HENCE
169,DU145,NMR,SOCIETY,STRUCTURES
946,CSC,DU145,HOWEVER,THESE
185,230,326,367,492,505,767,852,BACKGROUND,CONCLUSION,ITALY,LABEL,METHODS,RESULTS
DR5,DU145,HOWEVER,PC3,ROS,THESE,TRAIL
001,008,100,169,195,BACKGROUND,CONCLUSION,COPYRIGHT,DESPITE,FURTHER,GLEASON,INC,INDIVIDUAL,LABEL,METHODS,RESULTS,THERE,WILEY
169,183,AKT,BAX,GEORG,IGF1R,LNCAP,MCF,STUTTGART,TRIFOLIUM
169,COPYRIGHT,ELECTRODES,VCH,WILEY
CLINICALLY,CTC,HOWEVER,LABEL,OBJECTIVE,OVERALL,PURPOSE,RESULTS,SUMMARY
III,IPILIMUMAB,LABEL,NOVEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THESE
AFTER,APRIL,BETWEEN,COUCH,CTV,LABEL,MATERIALS,METHODS,OBJECTIVE,ORGAN,PTV,PURPOSE,RESULTS,SYSTEMATIC
ADT,LABEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
945,CYP17,FDA,LABEL,MDV3100,NOVEL,OBJECTIVE,PURPOSE,RESULTS,SUMMARY,THESE
004,1B1,221,447,668,CYTOCHROME,HOWEVER,ISI,LEU,LEU432VAL,OVERALL,SNP,STATA,TEN,VAL
169,215,BACKGROUND,COPYRIGHT,FUNDING,GRADE,INSTITUTES,IPILIMUMAB,LABEL,LTD,METHODS,PSA,RANDOMISED,RESULTS
169,183,215,AMSTERDAM,BACKGROUND,COPYRIGHT,DUE,DUTCH,FOUNDATION,FUNDING,FURTHER,GENESYS,INC,KWF,LABEL,LTD,MEDICAL,METHODS,RESULTS,SOCIETY,STICHTING,UNIVERSITY
102,169,283,286,CONCLUSION,COPYRIGHT,EMOTIONAL,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SEQUENCES
169,COPYRIGHT,PCR,SAS
037,125,140,150,169,362,439,791,7TH,ADT,BACKGROUND,BETWEEN,BRITISH,COPYRIGHT,D90,ESTIMATED,GENERALLY,GLEASON,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RESULTS,THERE
10A,145,169,956,COPYRIGHT,LNCAP,LTD,MCF,MTT,SIX,SULFIDE,THESE
169,194,CAR,COPYRIGHT,FURTHER,HOWEVER,INC,MDR,NR1I2,NR1I3,NUCLEAR,PXR
108,117,169,265,438,844,AMICO,BACKGROUND,CLINICALLY,COPYRIGHT,DETERMINE,EPSTEIN,EXCLUSION,GLEASON,LABEL,MARCH,METHODS,MRI,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SETTING,UROLOGY
169,CGD,CHRONIC,COPYRIGHT,INC
169,945,ANOTHER,COA,COPYRIGHT,INC
11A,12A,CNS,HUVEC,OVERALL
169,20S,AKT,BAD,CENTRAL,LABEL,LNCAP,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,UROLOGICAL
ADIPOSE,INCREASING
KNOCKDOWN,THESE,THROUGH,VDR
001,005,280,560,ARMSTRONG,BETWEEN,EMP,MARCH,PSA,PSADT,RATES,TREATMENT
946,ADDITIONAL,ADT,DOCETAXEL,FDA,RANKL,SEVERAL,SRC,VACCINE
111,130,140,145,177,342,AFTER,CONCLUSION,ESI,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SINCE,SPR
100,160,ASP,BLOCK,CONCLUSION,DOX,DU145,IONIC,LABEL,METHODS,OBJECTIVE,PC3,PEG,POLYMER,PURPOSE,RESULTS
160,CROSS,LNCAP,PCR,PSM,THESE,THREE,TRANSWELL,WESTERN
169,COPYRIGHT,S1P,THESE,THROUGH
073,130,135,260,268,520,55M,ASIAN,CAUCASIAN,CIS,HDL,HOWEVER,ORS,Q192R,SIMILARLY
177,212PB,BUN,THESE,TREATMENT
KEY,LABEL,MRI,RADIOLOGY,SOCIETY,UNLABELLED,UROGENITAL
160,169,180,188,CHROMOSOME,COPYRIGHT,EXPRESSION,KRC,PCR,RCC,SAS
169,946,COPYRIGHT,FEDERATION,PUBLISHED,SMAD2,SMAD4,SMADS,SOCIETIES,TGF
001,007,019,169,225,391,941,BASED,BJU,HOWEVER,INPATIENT,LABEL,LOS,METHODS,NATIONWIDE,OBJECTIVE,OVERALL,PROPENSITY,RCC,RESULTS,UNLABELLED
076,140,169,176,MONOCLONAL,SNO,SOCIETY,TIN
169,ACADEMY,ANDROLOGY,ASA,AUTHORS,BPH,ELISA,HSE,IBT,JOURNAL,LIS,PSA,SIT,TAT,THERE,YLP
605,CONCLUSION,GLEASON,LABEL,MEIER,METHODS,NON,OBJECTIVE,PSA,PSM,RESULTS,RRP,UNIVARIATE
169,175,APRIL,BETWEEN,CHIBA,HEAVY,INSTITUTE,ION,LABOR,MARCH,MEDICAL,OCTOBER,SINCE,TECHNOLOGY,UROLOGICAL,WELFARE
177,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,WITHOUT
CTV,LABEL,METHODS,OAR,OBJECTIVE,PHYSICIAN,PLANS,PTP,PTV,PURPOSE,RESULTS
177,CTV,INTENSITY,LABEL,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS
103,176,COMMISSION,LABEL,METHODS,OBJECTIVE,PROTECTION,PURPOSE,RANDO,RESULTS,ROTATIONAL,SIEMENS,TLD
CONCERN,HDR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
100,137,176,177,CLINICALLY,D30,D90,HOWEVER,INSTEAD,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEVEN,THESE,USING
181,PC3,PCM
169,183,ACCORDING,BMD,DVO,GEORG,HISTORY,SECONDARY,STUTTGART,THEREFORE
091,103,384,AFTER,CONCLUSION,DIAGNOSIS,EPSTEIN,GLEASON,KOREANS,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
001,002,004,006,031,169,177,340,ASP,CAP,COPYRIGHT,G894T,GENOTYPING,INC,NEITHER,NOS,PCR,SEVERAL,STUDIES
021,036,114,BACKGROUND,CONCLUSION,EWING,LABEL,MEMBRANOUS,METHODS,RESULTS
425,633,BACKGROUND,DVC,ENDOSCOPIC,GLEASON,HOWEVER,LABEL,MATERIALS,MEIER,METHODS,OCTOBER,OPERATIVE,PSA,RALRP,RECURRENCE,RESULTS
OCCURRENCE,PATHOLOGY,THREE
945,AREAS,BACKGROUND,BPH,COVERED,DHT,LABEL,METHODS,OPINION
200,BACKGROUND,BAGGING,COMPONENT,EMBEDDING,GRAPH,HOWEVER,LABEL,LOCALLY,MRI,PRINCIPAL,RESULTS
BECAUSE,CASODEX,DEPLETION,DISRUPTION,GIVEN,NOTABLY,PCA,R1881
169,229,918,BACKGROUND,CIS,COX,HRS,LABEL,MEN,METHODS,RESULTS,WHETHER
007,169,547,729,AMONG,BACKGROUND,CAD,LABEL,MEN,METHODS,OVERALL,PCA,PSA,RESULTS,WHETHER
ABL,HSP70,HSP90,KNOCKDOWN,THESE,WASF3
001,037,116,200,646,ADJUNCTIVE,CONCLUSION,COX,ECE,LABEL,LOWER,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PATIENT,PCA,PSA,RESULTS
GROUP,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
110,177,ANOVA,BACKGROUND,BPH,CONCLUSION,CURRENT,LABEL,METHODS,PCA,PSA,RESULTS,S1P,SPHK1
AMICO,HOWEVER,LEVEL,PCA
141,169,BACKGROUND,COPYRIGHT,INC,LABEL,LNCAP,METHODS,PCA,PHENETHYL,RESULTS,SHP,WILEY
169,BACKGROUND,COPYRIGHT,INC,LABEL,LIN28,METHODS,NANOG,RESULTS,THEIR,WILEY
111,AOC,BBN,LABEL,METASTATIC,METHODS,MICRO,MICROCT,MICROSPECT,OBJECTIVE,PROCEDURES,PURPOSE,RESULTS,SPECT
100,BACKGROUND,BRCA1,BRCA2,CNV,LABEL,METHODS,RESULTS,SEVERAL,USING
169,578,BJU,EXCLUSION,FINAL,GLEASON,JANUARY,LABEL,MARCH,METHODS,NPV,OBJECTIVE,PPV,RESULTS,RRP,STUDIES,UNLABELLED
169,181,200,220,413,AE1,AE3,AUTHORS,BJU,CURRENT,DEPENDING,GLEASON,HOWEVER,KNOWLEDGE,LABEL,LNS,METASTATIC,METHODS,OBJECTIVE,PSA,RESULTS,THREE,UNLABELLED
169,338,995,AUTHORS,BCR,BJU,COX,GLEASON,INSTEAD,LABEL,LEVEL,MEIER,METHODS,OBJECTIVE,OLDER,PROGNOSIS,PSA,RADICAL,RESULTS,UNLABELLED
169,AUTHORS,BJU,LABEL,METHODS,OBJECTIVE,PATIENT,RESULTS,THESE
169,689,729,773,872,AFTER,AIKAIKE,AUC,BJU,GREENES,LABEL,METHODS,OBJECTIVE,OLMSTED,PCA,PSA,RESULTS
047,169,BJU,BLOOD,CYTARABINE,ERG,GRADE,KAZAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SPINK,TEN,THERE,TMPRSS2,UNLABELLED
100,169,BJU,CONCLUSION,DEBULKING,EXCELLENT,FINALLY,LABEL,METHODS,OBJECTIVE,PCA,PSA,RADICAL,RESULTS,SALVAGE,SURGERY,THERE,UNLABELLED
001,002,042,169,233,341,704,AUTHORS,BCG,BJU,BNI,CENTRAL,DYSURIA,FINALLY,HOWEVER,MEDLINE,MMC,NMIBC,SCIENCE,SIX,THREE,WEB
001,016,023,086,169,571,699,943,ASC,AUTHORS,BETWEEN,BJU,CCI,CONVERSELY,COVARIATES,FINALLY,FLORIDA,INDEX,LABEL,METHODS,MORTALITY,OBJECTIVE,RESULTS,RPS,SEVERAL,UNLABELLED,VTE
169,BIOMETRIC,CARLO,HOWEVER,MONTE,SOCIETY
183,COMPLEXES,COMPOUNDS,COX,DU145,MCF,MEOSALH,STRUCTURES
1BB,945,947,CTL,IFN,THESE,TNF
120,174,AMONG,CLOSE,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SBX,SEVENTY,TBX,THERE
002,100,166,179,238,378,616,CHINESE,LABEL,METHODS,OBJECTIVE,OVERALL,PCA,PSA,PURPOSE,RESULTS,ROC,TZI,USING
040,1377C,174,195,196,250,DEL,FUNCTIONAL,HOWEVER,INS,NORTH,PCA,SNP,VARIANT
169,946,947,CBS,CONCLUSION,COPYRIGHT,CSE,ENDOGENOUS,INC,LABEL,LNCAP,METHODS,OBJECTIVE,RESULTS,WESTERN
001,003,015,040,119,169,966,ABT,AHC,CENTERS,CONCLUSION,CONVERSELY,COPYRIGHT,HBT,INC,INDEX,INPATIENT,IOBCT,LABEL,METHODS,NATIONWIDE,OBJECTIVE,ORP,OVERALL,RESULTS
005,045NG,169,177,194,945,947,AXYSM,CAD,COPYRIGHT,DESPITE,FURTHER,GCPII,GENOTYPING,GLUTAMATE,H475Y,HOWEVER,NAALADASE,PCR,PYMOL
108,169,177,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,LABEL,LOW,METHODS,METRONOMIC,RESULTS
132,18B,34B,542,650,AFTER,AZA,CPG,EXPRESSION,GLEASON,PC3,PCA,PCR,SILENCING
LTD,MDV3100,PUBLISHED
PSA
169,COPYRIGHT,DUE,LOD,PSA,QDS,SIO
169,802,ADDITIONAL,BASEL,COMPETING,CONCLUSION,COPYRIGHT,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,THESE
169,947,ALZHEIMER,COPYRIGHT,LTD,MUTATIONS,NOTCH,SEVERAL
100,169,AUTHORS,HOWEVER,JPP,KEY,L1210,LABEL,LEWIS,METHODS,OBJECTIVE,OBJECTIVES,PEG,PEGYLATED,RESULTS,ROYAL,SOCIETY,TOPOTECAN,TYPICALLY
169,HOWEVER,JOURNAL,LARGE,THEIR,THERE
169,181,BIO,COPYRIGHT,INC,PHENETHYL,WILEY
169,190,692,CAUSE,COPYRIGHT,DISCHARGE,HDR,NEITHER,SIMILARLY,SWEDISH
KIT,OTHER
132,AKT,ERK,JMR,MEK,NOVEL,PCR,RAF,SV1,WESTERN
169,945,AKT,COPYRIGHT,DU145,LNCAP,PCK,XSC
100,182,INCREASED,LABEL,MARCH,MDC,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,RESULTS,SIMILAR,UROLOGISTS,WILLIAM
EPSTEIN,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SIXTY,TEN
032,051,120,169,24C,956,ABCC2,AUC,ENZYMES,INHIBITION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SEVERAL,SORAFENIB,TOTAL,UGT
145,DBD,ETS,HOWEVER,III,LNCAP,PC3,PCA,PCR,THEREFORE,USING,VII
177,178,185,239,442,515,CTC,EXTENSIVE,HOWEVER,III,NSCLC
AFTER,ASIAN,BPH,PCA,PSA,THROUGH,WESTERN,WESTERNERS
APPROACHES,HOWEVER,SINCE
945,947,TAKEN,TH1,TH2
CTC
CTC,LNCAP
CELLS,CTC,NUCLEAR,VTE
100,169,384,702,727,754,768,794,795,825,837,860,881,961,AUTOMATED,BACKGROUND,BSI,COPYRIGHT,DEVELOP,GLEASON,INDEX,LABEL,METHODS,OBJECTIVE,PCA,PEARSON,PREDICTIVE,PUBLISHED,RESULTS,SETTING,THERE,UROLOGY
001,169,237,766,779,785,823,826,AUC,CALCULATOR,CANCEROLOG,CAP,CONTINUED,COPYRIGHT,DRE,GLEASON,HGCAP,INC,INSTITUTO,JANUARY,LABEL,MATERIALS,METHODS,MEXICAN,OBJECTIVE,OBJECTIVES,PREVENTION,PSA,RATES,RESULTS,TRIAL
000,169,COPYRIGHT,FDA,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PRODUCTION,RESULTS,THERE
169,177,COPYRIGHT,ELECTRONIC,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,TUR
001,013,044,169,2NG,526,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,SVB,T2B,T3B,THREE
BACKGROUND,COMPONENT,HOWEVER,ICA,LABEL,PCA,PRINCIPAL,RESULTS
123,124,125,127,131,169,SULF1,WILEY
1A1,450,624,CYP,CYTOCHROME,GLEASON,PCA
001,039,105,140,500,576,AAS,AFRICAN,ANGELES,BACKGROUND,CALIFORNIA,CONCLUSION,FURTHER,INDEX,LABEL,LOS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIMILAR,SIMILARLY,UNIVERSITY
174,CELLSEARCH,CTC

ALZHEIMER,GLIPTINES,PREVENTIVE,PSA
929,946,BACKGROUND,CONCLUSION,DEPRESSIVE,DIVERSE,INCREASES,LABEL,METHODS,RESULTS
181,BACKGROUND,CAP,ENTINOSTAT,FOXP3,HISTONE,INOCULATED,LABEL,LOW,METHODS,MYC,PCR,RENCA,RESULTS,STAT3,SURVAXM,TEFFS,THESE,TREGS,WESTERN
945,CAP,HOWEVER,SMA
169,259,386,452,520,BACKGROUND,BMI,BRITISH,CONCLUSION,COPYRIGHT,JOURNAL,LABEL,LTD,METHODS,OBESE,PSA,PUBLISHED,RESULTS,SERUM,SOCIETY,SURGERY,THERE,WILEY
PSA,QALYS,USING
500,7TH,CONCLUSION,CRP,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,URINALYSIS,WBC
239,945,946,ADT,AMONG,BACKGROUND,DISCUSSION,LABEL,MATERIALS,METHODS,PSA,RESULTS,SAMPLES,SDF,THESE,TNF
001,002,111IN,177,185,99MTC,AFTER,BISPECIFIC,BOM,BOMANTI,CONCLUSION,EXQUISITE,FAB,LABEL,LABELED,MBQ,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPECT
169,205,395,491,BACKGROUND,BASEL,COMPARISON,COPYRIGHT,GROUP,LABEL,METHODS,MRI,PBX,PCA,RESULTS
174,BACKGROUND,BLOOD,CELLSEARCH,CTC,HOWEVER,LABEL,MATERIALS,METHODS,PCA,PSA,RESULTS,SAMPLES
AKT,DU145,FURTHER,GLEASON,LAMIN,LNCAP,PC3,WESTERN
INCLUDING,RADIATION
013,025,046,169,300,CAP,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS,T1C,THESE
169,5MM,BACKGROUND,COMPOSITE,COPYRIGHT,FIFTY,FOLEY,INDEX,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PLACEMENT,PPB,PURPOSE,RESULTS
169,194,293,312,BACKGROUND,CONCLUSION,COPYRIGHT,COX,ERG,ETS,GLEASON,HOWEVER,LABEL,LOW,LTD,MEN,METHODS,OVERALL,PCA,RESULTS
001,160,169,194,229,424,457,AHR,AST,COMPETING,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,T2C
100,169,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIMILARLY,SIX,TEN
160,169,205,285,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SALVAGE,SEVEN,SRT,THERE
157,169,371,BECAUSE,COPYRIGHT,END,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
100,125,129,145,169,194,COPYRIGHT,D10,D20,D33,D50,D75,D90,DECLINE,ERECTIONS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,VARIABLES
105,135,169,AGE,BJU,COX,FURTHER,HOWEVER,INSULIN,LABEL,METHODS,OBJECTIVE,RESULTS,UNLABELLED
954,AMONG,BESIDES,CXC,CXCR4,DU145,HOWEVER,OVERALL
BACKGROUND,BASED,DATABASES,DESPITE,LABEL,LOCALLY,MEDLINE,METHODS,OCTOBER,RESULTS,THERE
001,BACKGROUND,IPS,LABEL,PRINCIPAL,RESULTS
056,946,CATENIN,CONCLUSION,CRPCS,FINALLY,LABEL,MDA,METHODS,OBJECTIVE,PURPOSE,RESULTS,TEN,THESE,TOP,WNT
073,223,443,447,AMONG,BACKGROUND,COLORECTAL,DIAGNOSTIC,FSG,LABEL,METHODS,OVARIAN,RESULTS,SCREENING,TRIAL
BECAUSE,FOCAL
215,955,OCH,PSA,THESE
002,011,023,039,047,145,169,20A,221,595,623,801,824,AMICO,AUC,BACKGROUND,CAPRA,COPYRIGHT,EXPRESSION,FURTHER,INC,LABEL,METHODS,PCA,PCR,RESULTS,THESE,WILEY
169,860,924,AFTER,AUC,BACKGROUND,BPH,CAP,CHINESE,COPYRIGHT,INC,LABEL,METHODS,PCR,PSA,RESULTS,ROC,WILEY
125,1GB,CARLO,CORE2,D10,D90,DUO,GHZ,INDUSTRIES,INTEL,LDR,MONTE,RAM,V90
252,CRF,EMOTIONAL,FATIGUE,OVERALL,PIPER,REVISED,SCALE,USING
RETURNING
111,CONJUGATES,HOWEVER,PROTEIN
001,031,169,214,625,725,AFTER,AUTHORS,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,ROC,SUSTAINED
137,169,BACKGROUND,CONCLUSION,DISCUSSION,HEURISTIC,LABEL,LTD,MEN,METHODS,MODEL,OBJECTIVE,PCA,PROCESSES,RESULTS,SYSTEMATIC,WILEY
1980S,758,945,ADT,EFFECTIVE,GTX,HOWEVER
169,182,18F,946,956,AKT,AZD5363,CHRONIC,FDG,RAS,THERE,U87
945,AIM,AMACR,BACKGROUND,CONCLUSION,CRUSH,LABEL,METHODS,OBJECTIVE,RESULTS
169,AUTOPHAGY,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,LAPC4,LDS,LNCAP,METHODS,OIL,PCA,RED,RESULTS,WILEY
169,COPYRIGHT,CORRECTING,DESPITE,INC,PATTERN,WILEY
100,132,150,169,177,948,956,COPYRIGHT,INC,MRI,NMR,THESE,WILEY
169,BRITAIN,COPYRIGHT,DESPITE,GREAT,IRELAND,LTD,MYC,OVERALL,PUBLISHED,REMARKABLY,SOCIETY,WILEY
169,186,419,533,ADDITIONAL,AGE,ATLANTA,BACKGROUND,COPYRIGHT,DISTRICTS,GEORGIA,LABEL,LARGE,METHODS,RECORDS,RESULTS,SOCIETY,VITAL
001,100,177,200,234,378,400,749,ALT,AST,NR2F2,PCR,PROSTACAID
DESPITE,GLEASON,PSA,THERE
246,ADULT,HSP,SCH,THEREFORE,THESE
002,177,215,ADC,ANTIGEN,BACKGROUND,DIFFUSION,DWI,GLEASON,LABEL,MATERIALS,METHODS,PSA,RESULTS,WHITNEY,WHOLE
000,102,144,249,550,571,578,876,903,912,967,99MTC,ABOUT,CONCLUSION,LABEL,MATERIALS,METASTATIC,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
000,014,019,020,025,110,145,177,197,BACKGROUND,CONCLUSION,CTC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THESE
CURRENT,SIMILARLY
CYP17,MEDICAL
945,ACE,AMONG,CONVERSELY,DESPITE,LNCAP,NLS,PCR,PTHLH,PTHRP,REDUCTION,TNF
946,CXCL1,CXCL5,RII,TGF,THESE
169,291,AUSTRALIA,BACKGROUND,CLEAR,COPYRIGHT,HIV,LABEL,LIMITED,LTD,METHODS,RESULTS,SCREENING,THOSE,WILEY
169,302,484,BACKGROUND,COPYRIGHT,EFFECTS,FEW,FOCUS,LABEL,LTD,MANCOVA,METHODS,PATIENT,PROGRAM,QOL,RESULTS,WILEY
169,COPYRIGHT,DU145,EGF,ELISA,ERBB2,INC,JDF12,LABEL,LNCAP,METHODS,MTZ,OBJECTIVE,PCA,PURPOSE,RESULTS,SRB,UNDER,WILEY
169,BACKGROUND,COPYRIGHT,ECTOPIC,EFFECTS,GPNMB,HPV,INC,LABEL,LNCAP,METHODS,NDRG1,PCR,PSA,R1881,RESULTS,WILEY
169,945,946,BACKGROUND,CHICAGO,CK2,COPYRIGHT,FURTHER,INC,LABEL,LUCIFERASE,METHODS,PCR,RESULTS,WILEY
169,22RV1,ADP,ATM,BACKGROUND,COPYRIGHT,INC,KU55933,LABEL,LNCAP,METHODS,RESULTS,SUSTAINED,WILEY
BACKGROUND,LABEL,LOW,METHODS,PCA,PSA,RESULTS,STUDIES,USING
228,322,ADT,AFRICAN,ASIAN,BACKGROUND,COMPOSITE,CONCLUSION,HISPANICS,HRQOL,INDEX,LABEL,MEDICAL,MEN,METHODS,OTHER,RESULTS,SHORT
178,2GY,BACKGROUND,GTV,HOWEVER,LABEL,METHODS,PET,PTV,QOL,QUALITY,RESULTS,SIB,SUV,TREATMENT,WHOLE
169,587,945,ARI,AVODART,BECAUSE,BJU,CAREFUL,CHI,CONCLUSION,LABEL,MEN,METHODS,OBJECTIVE,PROSCAR,PSA,RESULTS,TREATMENT,UNLABELLED
169,ADT,COPYRIGHT,INC,RESULTS
009,033,102,169,381,BASED,BJU,INCREASED,LABEL,LEVEL,MEN,METHODS,OBJECTIVE,PROGNOSIS,RANDOMIZED,RESULTS,SCREENING,THESE,TREATMENT,UNLABELLED
001,006,007,845,LABEL,OBJECTIVE,RESULTS,THESE
239,327,BACKGROUND,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,TAX,TFI,THERE,TOT,TREATMENT
946
001,189,669,DEVELOPING,END,FORCE,LABEL,PREVENTIVE,RESULTS,UNLABELLED,USING
156,BETWEEN,CONCLUSION,DECISIONAL,LABEL,METHODS,OBJECTIVE,OUTCOME,PURPOSE,RESULTS,SCALE
169,COPYRIGHT,INC,RMS,WILEY
169,ABR,ANIMALS,BACKGROUND,COPYRIGHT,CXCR4,FURTHER,INC,LABEL,LOX,METHODS,RESULTS,SDF,THEREFORE,WILEY
001,002,149,169,221,975,AMONG,COPYRIGHT,FINLAND,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE,USING,WILEY
169,189,COPYRIGHT,ELISA,FORUM,INC,JAPAN,JOURNAL,WILEY,ZUMAN
ADT,WHILE
001,177,BMS,KHT,MET,WHILE
001,002,003,006,018,022,169,954,BACKGROUND,BASEL,CONCLUSION,COPYRIGHT,DECREASED,GLEASON,LABEL,LOW,METHODS,PCS,PSA,RESULTS
105,112,ASIAN,BASED,BRIER,EASTERN,GROUP,ISHII,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,BASEL,COPYRIGHT,DESPITE,HOWEVER
005,169,260,BACKGROUND,BASEL,BETWEEN,COPYRIGHT,GLEASON,LABEL,METHODS,PATIENT,PHOENIX,PSA,RESULTS,THERE
169,COPYRIGHT,GROUP,HOWEVER,IRELAND,LTD,SOGUG,SPANISH
169,176,365,CONVERSELY,COPYRIGHT,DAILY,FAVORABLE,GROUP,INC,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RADIATION,RESULTS,THERAPY,V10,V15,V45,WITHOUT
169,173,176,COPYRIGHT,EXPANDING,FALSE,FPS,IMAGE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROBUSTNESS,TOTAL,VARIATIONS
160,169,AGO1522,CARLO,COPYRIGHT,DU145,INC,LABEL,MATERIALS,METHODS,MONTE,OBJECTIVE,PURPOSE,RESULTS
100,169,239,264,AFTER,BETWEEN,COPYRIGHT,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RADIATION,RESULTS,SEVEN,SOCIETY,TOXICITIES,TREATMENT
169,194,BACKGROUND,BPO,CENTRAL,CONTEXT,CONTROLLED,COPYRIGHT,DEPENDING,EAU,GUIDELINES,LABEL,LASER,MEDICAL,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,RESULTS,REVIEWS,STRUCTURED,SUBJECT,SYNTHESIS,SYSTEMATIC,UROLOGY
169,ADT,CAP,CONCLUSION,COPYRIGHT,CROWN,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SEVENTY,THERE
000,169,203,334,CANDIDA,COPYRIGHT,CULTURE,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,THERE,UTI
169,176,177,COPYRIGHT,FORTY,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PET,PURPOSE,RESULTS,SUV,T2W
121,147,169,AFTER,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SAS,SEMINAL
076,542,BACKGROUND,FEW,LABEL,METHODS,OVERALL,RESULTS,SEVERAL,THREE
007,013,014,100,169,200,3DCRT,ADT,AFTER,BETWEEN,COPYRIGHT,CTV,GLEASON,GRADE,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PRIOR,PURPOSE,RESULTS,T2C,TREATMENT
145,169,246,COPYRIGHT,FORTY,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PCL,PREDICTION,PURPOSE,RESULTS,SITES
169,945,AFTER,AMONG,BACKGROUND,BECAUSE,BILATERAL,COPYRIGHT,CURRENTLY,HIF,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
154,169,598,AGE,ALZHEIMER,AUTHORS,CONCLUSION,COPYRIGHT,END,FILES,GERIATRICS,INDIVIDUAL,JOURNAL,LABEL,METHODS,NLTCS,OBJECTIVE,OBJECTIVES,PARKINSON,RESULTS,SERVICE,SETTING,SOCIETY
498,BACKGROUND,BLADELESS,CONCLUSION,FASCIAL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROUTINELY,SEVERAL,SPLITTING
220,AMONG,BPH,CONCLUSION,INDEX,LABEL,LOWER,METHODS,OAB,OBJECTIVE,RESULTS,SCORE,SYMPTOM,TRACT,URINARY
HOWEVER,PTP1B,PTPN1
169,COMPETING,GROUP,LABEL,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,THERAPY
169,BACKGROUND,COPYRIGHT,FORTY,GLEASON,GRADE,LABEL,METHODS,MRI,PSA,RESULTS,SOCIETY,TREATMENT
BACKGROUND,CONCLUSION,CROSS,HOWEVER,INTER,JACCARD,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
005,10Q,126,169,COPYRIGHT,DESPITE,GLEASON,MYC,PGA,PSA,SOCIETY
CASODEX,CONCLUSION,IIA,LABEL,LNCAP,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
169,AUTOPHAGY,BECN1,COPYRIGHT,LTD,RAS
160,169,176,COPYRIGHT,INTENSITY,LTD,MLC,MODULATED,PUBLISHED,QCS,RADIATION,TEN,THERAPY,THEREFORE
183,403,MCF,THERE
100,169,BACKGROUND,CLAVIEN,CONTEXT,COPYRIGHT,CSS,ENGLISH,GLEASON,ITEMS,JANUARY,LABEL,MAJOR,MEDLINE,METHODS,OBJECTIVE,OCD,PCA,PRE,PREFERRED,PUBLISHED,REPORTING,RESULTS,REVIEWS,SALVAGE,SCIENCE,SRP,SYNTHESIS,SYSTEMATIC,URINARY,UROLOGY,WEB
169,AFTER,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PATIENT,PHASE,PSA,PURPOSE,RESULTS,SEPTEMBER
945,946,COMPOUNDS,DHT,LBD,LBP,PCA,PROLONGED,THESE
945,946,AKT,BESIDES,CPO,GHF,OVERALL
178,179,326,CYS,FURTHER,HOGG1,HOWEVER,SER,SEVERAL
025,ADT,HOWEVER,LNCAP,PCA,SINCE,USING
ACP10,CASTRATION,REGIONS,SNP,THESE
22RV1,AKT,BAD,BCL,BIM,ERK,MCL,MEK,NOTABLY,PC3,SORAFENIB,SRC,STAT3
ACCORDING,BACKGROUND,BECAUSE,CONCLUSION,LABEL,METHODS,RESULTS,SCIENTIFIC
000,345,ASSESSING,BACKGROUND,C30,EORTC,HOWEVER,LABEL,MATERIALS,METHODS,PHYSICIANS,PSA,QLQ,QOL,RESULTS,SCHLESWIG,VERSION
CIS,DAYTIME,ESPECIALLY,PATIENT,STROMAL,THEREFORE
HOWEVER
169,863,945,BACKGROUND,C30,COMMITTEE,CONCLUSION,CONTEXT,COPYRIGHT,EORTC,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,QLQ,QOL,QUALITY,RESULTS,THESE,TREATMENT
252,CONSISTENT,CTBP1,CTBPS,HDACS,SUBSEQUENT
009,144,145,169,183,194,289,302,945,AMERICA,AUG,BACKGROUND,BETWEEN,COPYRIGHT,EIGHT,FUNDING,GLEASON,INCIDENCE,LABEL,LTD,MARCH,METHODS,NORTH,RESULTS
006,145,956,ABZ,ADDITIONAL,CMC,MAA,OVCAR,PEGMEMA,THREE,WHILE
001,169,305,333,411,BLACKWELL,DRS,JANUARY,LABEL,LTD,METHODS,OBJECTIVE,PIS,PUBLISHING,RESULTS,SRS,TBSRS,TNM
945,946,ABL,BACKGROUND,HIF,HOWEVER,HRE,LABEL,MCL,PCA,PDGFR,PRINCIPAL,RESULTS,USING

235,985,HIV,IHC,LEDGF,OXIDATIVE,PANEL,PCR,PROTEIN,THESE,TISSUESCAN,TRANSCRIPT
ACT,BACKGROUND,HOWEVER,LABEL,METHODS,RESULTS,SURVIVORS
CR1,DFS70,HIV,HSP27,HSP27PR,LEDGF,MECP2,PC3,THESE
001,116,GLEASON,LABEL,LOH,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,STIM2,THESE
CONVERSELY,FINALLY,PCA,PSA,SER,THESE,TMPRSS2,W741C
ACTIVATING,ALZHEIMER,AMP,FURTHER,JUN,MKFKLHV,NES,THESE
003,120,128,157,169,344,452,COPYRIGHT,FDR,HOWEVER,HYPOTHESIS,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OTOLOGICAL,PTC,RESULTS,SNP,SOCIETY
038,169,ADM,COPYRIGHT,E231G,ID4,LNCAP,MUTATIONS,NR2F1,PTGDS,T857A,T877A,THREE
001,115,160,169,183,BASED,CONCLUSION,DRE,FALSE,GEORG,IMAGING,LABEL,MATERIALS,METHODS,MRI,NPV,OBJECTIVE,PCA,PPV,PSA,PURPOSE,RESULTS,ROC,STUTTGART,T1W,T2W
104,169,AFTER,APRIL,CONCLUSION,CONTINUOUS,HIPAA,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PURPOSE,RESULTS,SEVEN
945,DU145,PAI,PC3,PCR,PTPL1,PTTG1,THESE
169,194,AML,COPYRIGHT,GFP,INC,THERE,THESE,UNTIL
106,357,839,ADT,BACKGROUND,CONCLUSION,CONTROLLED,DCE,LABEL,LPC,MEN,METHODS,RESULTS,THESE,URINARY
IMAGING,LABEL,OBJECTIVE,PURPOSE,RAMAN,RESULTS,SUMMARY
BOARD,FOCAL,HOWEVER,LABEL,METICULOUS,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
CONSISTENT,DCF,DU145,JANUS,NOBILETIN,OVERALL,SRC,STAT3
169,ALONE,DESPITE,JOURNAL,THERE
ECM,H3K27,MMP,THESE,TIMP2,TIMP3,TIMPS
142,337,916,BACKGROUND,CAP,CONCLUSION,CONTINUED,CWR,DHT,EXPRESSION,FINDING,LABEL,PRINCIPAL,RESULTS,TARGETING,THERE
109,169,263,ALZHEIMER,COPYRIGHT,CORRECTION,LTD,WILEY,WTP
169,945,954,CHINA,COPYRIGHT,CXCR4,HOWEVER,IAP,INC,LIVIN,LNCAP,PCA,WESTERN,WILEY
010,012,078,597,686,734,815,995,ASHKENAZI,COMPARING,E1B1B1C,FINNS,N1C,POPULATION
115,160,ADT,AFTER,BCR,BETWEEN,COX,GLEASON,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,RRP
169,745,CONCLUSION,COPYRIGHT,END,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
100,125,145,169,176,CONCLUSION,COPYRIGHT,FIRST,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBL,PAI,PNT,PROSTATES,PURPOSE,RADIOLOGY,RESULTS,SOCIETY
169,COPYRIGHT,CTV,CURRENT,GROSS,INADEQUATE,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THREE,XRT
012,017,105,141,142,152,169,172,381,ACS,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,STATINS,UNIVARIATE
RADICAL
169,ASPIRIN,HOWEVER,LIMITED,MACMILLAN,PUBLISHERS
169,ADT,COPYRIGHT,DHT,III,LOW,LTD,NOTABLY,PCA,SEVERAL
134,144,169,287,BASEL,COPYRIGHT,KLEBSIELLA,LABEL,METHODS,OBJECTIVE,RESULTS,TRUSB
169,241,278,416,427,544,862,939,AEU,COPYRIGHT,DATES,ERSPC,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RANDOMIZED,RESULTS,SCREENING,SPANISH,THESE
AFTER,BACKGROUND,CLINICALLY,CONCLUSION,ERK,FURTHER,LABEL,MEK,METHODS,RAF,SINCE,THEREFORE,TUR
169,194,946,ADT,COPYRIGHT,IRELAND,LTD,MECHANISMS,RII,SINCE,TGF,THERAPY
169,950,956,M13,NIR,SOCIETY,SWNTS
160,169,ACADEMY,THREE
169,APRIL,BJU,CONFERENCE,MAY
169,APRIL,AUTHORS,BJU,CONFERENCE,DOCETAXEL,HUNGARY,MAY,PARTICULAR,PROGNOSTIC,PSA,RESULTS,THESE,USA
003,100,177,197,198,CONCLUSION,COPENHAGEN,DYNAMIC,LABEL,MAT,MATERIALS,METHODS,MRI,OBJECTIVE,RESULTS
028,120,147,432,ADT,AFTER,DENOSUMAB,III,MICHAELSON,PSA,RESTAGING,UNTIL
100,192,THESE
2ND,3RD,LABEL,METASTATIC,METHODS,OBJECTIVE,PURPOSE,RESONANCE,RESULTS
AVAILABLE,BACKGROUND,LABEL,MATERIALS,MET,METHODS,RESULTS,SRC
CA2,MENTHOL,MMP,PCR,SCC,SEVERAL,THESE,TRP,TRPM8
169,BASED,CONCLUSION,COPYRIGHT,DYNAMIC,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,SUPPORT,WILEY
001,176,202,946,CYP17A1,CYTOCHROME,NOTABLY,P450C17,TOK,WHEREAS
100,150,160,945,946,CONSISTENT,LNCAP,PECAM,PEITC,PHENETHYL
22RV1,ADT,AR3,CRPCA,CWR,LUCAP,PCA,PCR,SIMILARLY
221,590,99A,99B,BPH,CRPCS,EXPRESSION,FINALLY,LNCAP,PIK3IP1,SEVEN,UTR
112,350,392,408,COX,JANUARY,LABEL,METFORMIN,METHODS,MORTALITY,OBJECTIVE,RESULTS
286,945,946,AKT,GSK,IMMUNOBLOT,SER21
169,194,COPYRIGHT,KUJ,LTD,MMP,MOMORDICA,MT1,PC3
169,945,COPYRIGHT,DHT,HIF,HYPOXIA,INC,LNCAP,THESE
169,AEU,BLADDER,BOARI,COPYRIGHT,LABEL,METHODS,OBJECTIVE,OVERALL,PROLONGED,PUBLISHED,RESULTS,SINCE
100,509,ARN,CONTINUED,MAXIMAL,MDV3100,WHILE
169,194,COPYRIGHT,INC,PSA,UNDER
169,COPYRIGHT,IRELAND,LOW,LTD,RAP,RAP1GAP,RCC,RESCUED,SN12C,THESE
053,066,100,169,177,COPYRIGHT,IMAGING,INC,LABEL,MATERIALS,METHODS,NORFOLK,OBJECTIVE,PUBLISHED,PURPOSE,REFERENCE,RESULTS,SYSTEMS,THREE,TRANCHE,UROSTATION
169,916,945,946,COPYRIGHT,HOWEVER,LNCAP,LTD,PCA,TREATMENT
169,BACKGROUND,BASED,COPYRIGHT,DCE,DIFFERENT,DWI,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PROLONGED,PURPOSE,RESULTS,USING
000,169,1990S,385,458,556,BACKGROUND,CONTROLLED,COPYRIGHT,FINNISH,HOWEVER,III,LABEL,METHODS,NUMBERS,OBJECTIVE,PARAMETERS,PCA,POPULATION,PSA,PUBLISHED,RANDOMISED,REDUCTION,RESULTS,SETTING,THOSE,TRIAL,UROLOGY
169,AFTER,BPH,CAP,CCK,COPYRIGHT,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PC3,PCR,PLNCRNA,PWR,RESULTS,SILENCING,TUNEL,WESTERN
169,587,600,634,967,AUC,BETWEEN,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,MEMBRANOUS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
004,169,617,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
112,122,152,177,BACKGROUND,C30,CMF,EORTC,FEC,GOSERELIN,INCREASED,INSURANCE,LABEL,MEIER,METHODS,NHI,QAS,QLQ,QUALITY,RESULTS,TEC,TOTAL,TREATMENT
1C3,945,946,COX,LNCAP,SAR,SELECTIVE,STRUCTURE,THESE,USING
177,409,421,435,956,ABC,ASSESSMENT,GLC14,MDA
169,AFTER,CD4,CD8,COPYRIGHT,CUREVAC,IIA,LTD,NSCLC,PCA,PHASE,THEREFORE,THESE,WILEY
085,145,946,CONCLUSION,LABEL,LNCAP,LUCAP,METHODS,OBJECTIVE,PCR,PHA,PHASEOLUS,PURPOSE,RESULTS
150,176,180,AFTER,INFECTIOUS,MAY
169,947,ATM,COPYRIGHT,H2A,IRELAND,LTD,PIM
169,194,946,947,948,CATENIN,COPYRIGHT,HOWEVER,LEF,MMP,TAKEN
169,AOC,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,RESULTS,SCN,THESE
ALA,BBN,CONCLUSION,GLN,GLY,INC,LABEL,LEU,METHODS,MICRO,OBJECTIVE,OBJECTIVES,PET,PHE,PUBLISHED,RESULTS,TRP,VAL
001,169,664,785,AUC,EXPRESSION,IHC,JAK,LABEL,LTD,METHODS,OBJECTIVE,PCA,RESULTS,ROC,STAT3
100,101,200,201,300,AGE,APRIL,BACKGROUND,CDS,CLAVIEN,CONCLUSION,DINDO,III,JANUARY,LABEL,LRP,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY,THERE,THREE,USING
001,002,005,169,BLACKWELL,CONCLUSION,ERG,ETS,HOWEVER,KAZAL,LABEL,LTD,METHODS,OBJECTIVE,PCA,PUBLISHING,RESULTS
119,2ND,650,926,BACKGROUND,COX,GLEASON,HAZARDS,LABEL,MEN,METHODS,MIDSPAN,RATIO,RESULTS
200,PEG,PEGYLATED,PEGYLATION,THREE,WHILE
016,047,169,ANGELES,BJU,CALIFORNIA,CONCLUSION,INDEX,LABEL,LOS,METHODS,OBJECTIVE,OTHER,RESULTS,SEVERAL,THERE,UNIVERSITY,UNLABELLED,URINARY
145,956,AMYRISINS,POLYGAMAIN,THREE
169,ANXIETY,AUTHORS,BJU,DEPRESSION,INVENTORY,LABEL,LEVEL,MEN,METHODS,OBJECTIVE,PCA,RANDOMIZED,RESULTS,SCREENING,SHORT,STATE,STUDIES,THESE,TRAIT,UNLABELLED
BELFAST,FURTHER
BEHAVIORAL,BRFSS,CONDITION,COVERED,ISLANDS,LABEL,LIMITED,METHODS,OBJECTIVE,OVERALL,PAP,PROBLEM,REPORTING,RESULTS,USING
BIOLOGICAL,CBP,FOXA1,GATA2,HISTONE,NUCLEAR,THESE
AKT,CHANGES,COA,ERK,HYPOXIA,RAS,REDUCTION,THEREFORE
ARG,CDR,DESPITE,FAB,FAB25,ISOTHERMAL,LYS,THEREFORE
007,013,018,036,177,231,346,384,BMI,EAU,GUIDELINES,ISA,ISSAM,PREVALENCE,SEPTEMBER,TDS,VARIABLES
108,169,194,5NG,AEU,AFTER,BACKGROUND,CHRONIC,COPYRIGHT,INDEX,INSTITUTES,LABEL,METHODS,NIH,PSA,PUBLISHED,RESULTS,SCORE,SYMPTOM
169,COPYRIGHT,IRELAND,LTD
BACKGROUND,LABEL,PC3,REDUCTION,REF52,RESULTS,THESE
000,008,014,016,017,030,033,039,044,052,074,081,135,272,402,946,974,995,998,999,BACKGROUND,BIA,BMI,FFM,GLEASON,HOWEVER,LABEL,MEN,METHODS,RESULTS,SEVERAL
169,630,690,745,777,950,981,BJU,HGPIN,LABEL,MEN,METHODS,OBJECTIVE,OTHER,PATIENT,PCA,PSA,RESULTS,SEPTEMBER,UNLABELLED
001,151,165,169,276,370,477,761,BJU,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PSM,RESULTS,SUFFICIENT,UNLABELLED
234,BAKER,CONCLUSION,GRADE,HAEMATURIA,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS
100,954,CONCLUSION,DCE,LABEL,METHODS,MRI,OBJECTIVE,PSA,RESULTS,ROC,THERE,THREE
005,139,169,606,AFTER,BACKGROUND,ESTIMATES,HRS,LABEL,METHODS,NUTRITION,RESULTS,THERE
001,038,169,215,331,501,882,ADA,BACKGROUND,COLORECTAL,LABEL,LOW,METHODS,OVARIAN,PRODUCT,RESULTS,SCREENING,SEVERAL,SNP,TRIAL,TRUNCATED
945,AMONG,COMPARISON,ECM,HOWEVER,MMP,SEVERAL
001,008,169,BACKGROUND,BCR,BETWEEN,COPYRIGHT,COX,INC,LABEL,MEIER,METHODS,PREDICTORS,PSA,RESULTS,THERE,THEREFORE,WILEY
012,015,017,169,262,BACKGROUND,BETWEEN,COMPOSITE,COPYRIGHT,INDEX,JANUARY,LABEL,METHODS,POTENCY,RESULTS,SOCIETY,YOUNG
ARF,CDKN2,DECREASED
171,187,PCA,PSA
ABCG2,CD117,CSF,DU145,NANOG,NANOGP8,PCR,SCF
000,169,542,715,ABOUT,AFRICAN,COPYRIGHT,SAHARAN,SOCIETY,SUB
400,543,FEW,FRESH,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,START,WHILE
AKT,DESPITE,GRP78,QDOTS,QDS,QUANTUM
DIGITAL,LABEL,MOLECULAR,MRI,OBJECTIVE,PURPOSE,RESULTS,SUMMARY
190,215,AFTER,CLAVIEN,CONCLUSION,GRADE,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
294,385,AMICO,ECE,LABEL,METHODS,MRI,NVB,OBJECTIVE,OVERALL,PCA,PURPOSE,RESULTS,STAGING
CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE
145,22RV1,BACKGROUND,CONCLUSION,LABEL,LOWER,METHODS,NADPH,NORMALITY,NOX,OXIDATIVE,RESULTS,SHAPIRO
EGF,EMT,FINALLY,HPV,SIRT1
169,LIMITED,MACMILLAN,MRI,PUBLISHERS,T2W,VALIDATION
169,ABOVE,COPYRIGHT,DESPITE,EXTENSIVE,INC,THEREFORE
169,235,733,COPYRIGHT,EDUCATION,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,POTENTIAL,PUBLISHED,PURPOSE,RESULTS,THERE,UROGENITAL,UROLOGICAL
169,215,531,720,CENTRAL,COPYRIGHT,DECREASING,EDUCATION,INC,LABEL,MATERIALS,METHODS,NORTH,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
176,LOW,PTX
169,ADT,AIM,BACKGROUND,HOWEVER,LABEL,MEASURE,MEDLINE,METHODS,OBJECTIVE,OUTCOME,PHYSICIANS,RESULTS,SEPTEMBER,SOCIETY,THERE
BACKGROUND,BAX,CLONING,HOWEVER,INSTEAD,LABEL,LIC,LNCAP,PCR,RESULTS,UTILIZING
169,THERE,THESE,UROLOGICAL
125,169,2012THE,AUTHORS,BJU,FEWER,HOWEVER,PSA,RAPID,SALVAGE,SPAIN
005,049,100,143,153,169,AUTHORS,BJU,SCORE,SEATTLE,SYMPTOM,THERE
BACKGROUND,CXCL9,ELISA,IHC,LABEL,METHODS,RESULTS,SEVEN,SIXTEEN
001,169,558,890,ADC,AMONG,CDR,CONCLUSION,COPYRIGHT,ESPECIALLY,GLEASON,GROUP,INC,LABEL,MATERIALS,METHODS,NPV,OBJECTIVE,PPV,PSA,PURPOSE,RESULTS,WILEY
000,038,100,169,769,BACKGROUND,COPYRIGHT,END,LABEL,METHODS,OVERALL,RESULTS,SOCIETY,USING
169,226,AFTER,BACKGROUND,BCR,BPH,CONCLUSION,CPG,EXPRESSION,FOLLOWING,FURTHER,LABEL,LNCAP,METHODS,PC3,RESULTS
005,101,126,177,478,BPH,CONVERSELY,HOWEVER,LATIN,NAT,NAT2A803G,NAT2G857A,NAT2T481C,PCA
AKT,CORDYCEPIN,CORDYCEPS,LNCAP,MMP,TER,THESE,TJS
603,PC3,RSK
ABOUT,BACKGROUND,INSTITUTE,LABEL,MANAGEMENT,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,ROM,TAILORING
169,BECAUSE,COPYRIGHT,CRPCS,FURTHER,IRELAND,KNOWN,LTD,PCS,THEREFORE
169,194,COPYRIGHT,CXCR4,GPCRS,IRELAND,LTD,MOLECULES,PSA,SRC,TAKEN,THESE
001,005,007,012,017,169,171,AFTER,COPYRIGHT,EDUCATION,GLEASON,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL
130,169,174,180,COPYRIGHT,EDUCATION,ERG,ETS,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SERUM,TMPRSS2,UROLOGICAL,WIDESPREAD
001,169,177,448,516,AFRICAN,CAUCASIAN,CHANGES,COPYRIGHT,DESPITE,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,THERE,UROLOGICAL,USING,WHETHER
001,169,194,AFFAIRS,AMONG,CENTRAL,COPYRIGHT,END,FACILITIES,INC,LABEL,METHODS,OBJECTIVE,RESULTS,VHA
001,169,194,AMICO,BCR,BCRFS,CONCLUSION,COPYRIGHT,COX,INC,LABEL,LOCAL,MEIER,METHODS,OBJECTIVE,PCA,PSA,RESULTS,RRP
169,194,COPYRIGHT,DIGITAL,INC,SPHENOIDAL
002,008,012,019,022,023,055,078,123,138,159,169,173,296,ADT,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PPC,PURPOSE,RESULTS,T2B,UNIVARIATE
169,194,CONCLUSION,COPYRIGHT,GROUP,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RADIATION,RESULTS,THERAPY
169,CONCLUSION,COPYRIGHT,CURRENT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPECTRA,TESLA
169,194,956,COMPOUNDS,COPYRIGHT,DIGITALIS,ESI,MCF,NMR,THEIR
145,169,194,462,AFTERWARD,ANOVA,COPYRIGHT,DIFFERENT,DOTAP,PIT,SAS,SLN
125,169,COPYRIGHT,GROUP,IIB,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PUBLISHED,PURPOSE,RESULTS,SOCIETY,STAGE,TREATMENT
169,BCR,COPYRIGHT,ENGLISH,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSM,RESULTS,THEREFORE
001,025,169,395,434,468,810,AVERAGE,BACKGROUND,COMMITTEE,COPYRIGHT,ETHICAL,KNOWLEDGE,LABEL,LITERATURE,METHODS,MULTITRAIT,OBJECTIVE,PCA,PREDICTORS,PSA,PUBLISHED,RESULTS,SETTING,TRENT,UROLOGY
169,392,474,BACKGROUND,BEGINNING,CONSISTENT,COPYRIGHT,EXAMINE,FEBRILE,FEVER,LABEL,METHODS,OBJECTIVE,PNB,PUBLISHED,RANDOMIZED,RESULTS,ROTTERDAM,SCREENING,SETTING,STUDIES,UROLOGY
100,169,AUTHORS,BLACKWELL,GLEASON,HISTONE,LNCAP,LTD,PATHOLOGY,PC3,PTY,PUBLISHING,SILENCING,SOCIETY,THESE
CLI,CONCLUSION,FDG,FLT,LABEL,METHODS,MODERATELY,PC3,PET,RESULTS,UNLABELLED
169,737,ABT,ASSESSMENT,BH3,COPYRIGHT,GIVEN,HCQ,INC,INDUCTION,LABEL,LNCAP,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROS,TARGETING,THESE,WILEY
001,004,121,169,1C3,200,AMONG,BACKGROUND,BCAR1,BECAUSE,COPYRIGHT,INC,LABEL,METHODS,RESULTS,SINCE,WILEY
945,AMACR,COA,LNCAP
BMP,HPC,HSC,LNCAP,PC3,THESE
107,141,375,574,742,BACKGROUND,CONCLUSION,LABEL,METHODS,RESULTS,THESE
123,137,169,200,397,AMONGST,CONCLUSION,DEPARTMENT,KINGDOM,LABEL,METHODS,OBJECTIVE,RESULTS,THERE
169,194,COPYRIGHT,ERG,MAJOR,NGS,THESE,TMPRSS2
001,105,169,293,AIM,BACKGROUND,BNSRP,CCI,COX,FINALLY,INDEX,LABEL,MEASURE,MEIER,METHODS,OBJECTIVE,OUTCOME,OVERALL,RESULTS,SEVERAL,SIMILARLY,SOCIETY,THEREFORE
108,161,237,AFFAIRS,CALCIUM,CIS,CONCLUSION,GLEASON,HARVARD,LABEL,MEDICAL,METHODS,OBJECTIVE,ORS,RESULTS,TOTAL
AKT,AREAS,BACKGROUND,COVERED,LABEL,METHODS,NSCLC,OPINION,SMALL,TARGETABLE
169,354,BACKGROUND,BANKS,BLOOD,CONCLUSION,HOWEVER,INFECTION,LABEL,METHODS,MLV,RESULTS,SEVERAL,TAHOE,WESTERN,XENOTROPIC
CLASSIC,INTRAGENIC,MICRORNAS
945,946,FER,GLYCANS,HOWEVER,LAMININ,STAT3,THESE
119,200,CONSISTENT,FOLLOWING,GIVEN,SEQUENCING,SIMILARLY,THESE
BACKGROUND,LABEL,PROCESSING,UNITS,UNLABELLED,URL
945,LABEL,METHODS,NEITHER,OBJECTIVE,OBJECTIVES,PIN,PRIMARY,PSA,RESULTS
009,169,509,642,652,679,BACKGROUND,CONSORTIUM,INSTITUTE,LABEL,METHODS,RESULTS
257,HOWEVER,SIMILARLY,THEREFORE,THESE
22RV1,ABCG2,BMI,CSC,DU145,LABEL,LNCAP,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS
DEPENDING,HOWEVER
001,169,307,AGE,CONCLUSION,COPYRIGHT,EDUCATION,FOUNDATION,INC,JANUARY,LABEL,MAY,MEDICAL,MEIER,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROCHESTER,SIR,THERE
145,946,956,BACKGROUND,CARCINOMA,CONCLUSION,CXCL4,CXCR3,INSTEAD,LABEL,LNCAP,PF4,PLC,RESULTS,THESE,WHILE
BECAUSE,CONCLUSION,FALSE,GLEASON,LABEL,METHODS,OBJECTIVE,OVERALL,PROGNOSIS,RESULTS,SINCE,UNLABELLED
17Q21,200,BACKGROUND,INSTITUTES,LABEL,LINKAGE,METHODS,RESULTS
001,005,169,177,227,277,352,413,BACKGROUND,BLACKWELL,INFERENCES,KEY,LABEL,LTD,METHODS,PUBLISHING,RESULTS,SENSORY,SIXTEEN
7TH,HEY,MTT,NMR,STRUCTURAL,STRUCTURES
169,945,CHOLINE,CONCLUSION,IMAGING,LABEL,METHODS,OBJECTIVE,OXIDATION,PC3,PET,PURPOSE,RAPID,RESULTS
169,308,380,469,886,AFRICAN,AMERICANS,BACKGROUND,CAP,CARIBBEAN,COPYRIGHT,HOWEVER,INC,JAMAICA,LABEL,LEONE,METHODS,NIGERIA,RESULTS,SNP,TEN,WILEY
169,AMERICA,COPYRIGHT,GOVERNMENT,INC,PUBLISHED,WILEY
169,CHEMISTRY,DESPITE,FURTHER,ROYAL,SOCIETY
169,194,945,COPYRIGHT,IRELAND,LTD
169,AUTHORS,BJU,HOWEVER,PATIENT,SEVERAL,THERE,THEREFORE,THESE,TREATMENT
ADT,AKT,CURRENT,E26,ETS,GLEASON,INCREASED,PROTEIN,THESE
107,ABL,PSA,TYR
000,001,111,119,124,148,172,213,227,271,297,352,356,429,550,605,642,646,653,851,951,958,964,967,976,977,981,984,985,BETWEEN,CONCLUSION,CONTROLLED,CURRENT,EFFECTS,FEWER,GRADE,KENDALL,LABEL,MAY,METHODS,OBJECTIVE,OBJECTIVES,OUTCOME,PROBE,PROTECT,PSA,PURPOSE,RESULTS,TESTING,THESE,TREATMENT,TRIAL
277,423,BACKGROUND,COLORECTAL,COX,ESTROGENS,HRS,LABEL,METHODS,OVARIAN,RESULTS,SCREENING,TRIAL
APRIL,BECAUSE,HOWEVER,PAP,PATIENT,PREVIOUSLY,SIPULEUCEL
OPTIONS,PSA,THESE
954,DENOSUMAB,III,RANKL,SUBSEQUENT
001,81G,AFRICAN,ASIAN,CAUCASIAN,CONSISTENT,HAPLOTYPES,SLC22A3,STUDIES
ADT,AWARENESS,HOWEVER,QOL,WHILE
ANDROGENS,NEWER
ADT,PROVIDING
ADT,FIFTY,FURTHER,NOW,PCA,QOL,THERE
HOWEVER,PCA
169,CWR22,HOWEVER,LIMITED,MACMILLAN,PUBLISHERS,THESE
001,002,012,013,226,298,368,BSI,CONCLUSION,CRMPC,LABEL,LOG,METHODS,OBJECTIVE,PRIOR,PSA,PURPOSE,RESULTS,THERE,THESE
284,684,688,741,917,999,BACKGROUND,CONCLUSION,ITALY,LABEL,METHODS,ORS,RESULTS,THESE
CONCLUSION,DETECTION,LABEL,METHODS,OBJECTIVE,PET,PSA,PSADT,PSAVE,PURPOSE,RESULTS
001,108,133,140,165,169,194,266,BACKGROUND,BECAUSE,COPYRIGHT,LABEL,METHODS,NSS,OBJECTIVE,OVERALL,PROCEDURE,PSM,PUBLISHED,RESULTS,SETTING,UROLOGY
169,CLEAR,COPYRIGHT,DES,EPR,EXHAUSTIVE,NMR,THESE
AREAS,BACKGROUND,COVERED,LABEL,MDV3100,METHODS,OPINION
CD3,EPCAM,EPCAMXCD3,ESA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,TRAIL

001,009,033,080,130,790,BACKGROUND,BMI,LABEL,MATERIALS,MEDLINE,METHODS,OCTOBER,PCA,RESULTS,THEREFORE
001,002,003,004,169,177,324,945,946,COPYRIGHT,GENOTYPES,INC,IRANIAN,PCA,PCR,PVULL,SERUM,THERE,WILEY
169,174,613,620,740,752,830,837,860,911,923,AUC,BACKGROUND,COPYRIGHT,CTC,INC,LABEL,METHODS,NINTY,PCR,PSA,PSM,PSMAR,RESULTS,RFS,ROC,WILEY
000,108,340,345,685,AFTER,BACKGROUND,CIS,COLORECTAL,CUMULATIVE,DRE,LABEL,METHODS,MORTALITY,OCTOBER,OVARIAN,POISSON,PSA,RESULTS,RRS,SCREENING,TRIAL
169,318,AFRICAN,AMERICANS,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,METHODS,RESULTS,SIXTY,USING,WILEY
169,954,ACTIVATION,BACKGROUND,CONCLUSION,COPYRIGHT,COX,DAP,DU145,ELISA,INC,LABEL,MDP,METHODS,PC3,PCR,PIN,RESULTS,THESE,TLR,TRAMP,TRI,WILEY
169,946,ALK,BACKGROUND,CDK,COPYRIGHT,INC,INCREASED,INK4B,KIP,LABEL,LNCAP,METHODS,RESULTS,SMAD2,SMAD3,TGF,THEREFORE,WESTERN,WILEY
GIVEN,HODGKIN,LABEL,LUPUS,NHL,OBJECTIVE,PURPOSE,RESULTS,SLE,SUMMARY
008,118,134,163,233,407,FAS,KEY,LABEL,METHODS,MRI,OBJECTIVE,RESULTS,USING
169,194,COPYRIGHT,EUPATORIN,FINALLY,INC,SAC
001,169,194,916,COPYRIGHT,INC,KFM,KISS1,PATHOLOGY,PCA,PUBLISHED,SOCIETY
138,169,194,AKT,ANGII,ARB,CAP,COPYRIGHT,GLEASON,INC,LNCAP,MCP,PATHOLOGY,PSA,PUBLISHED,SOCIETY,SPECIMENS
169,177,265,COLLEGE,COPYRIGHT,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RESULTS,ROYAL,THERE
169,AKT,CAP,CHRONIC,COPYRIGHT,HIF,INC,JAK,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,WESTERN
169,CCKRA,COPYRIGHT,LORGLUMIDE,MRI,PC3,WHILE
169,330,9TH,BLACKWELL,END,HOWEVER,LTD,OVERALL,PROGRAM,PUBLISHING,RESULTS
ANNEXIN,BACKGROUND,GCV,HSV,LABEL,METHODS,MTT,PAMAM,PCR,RESULTS,WESTERN
945,946,AHX,ALA,ARG,ASP,BACKGROUND,BASED,BBN,GLN,GLU,GLY,INC,LABEL,LEU,MET,METHODS,MICRO,PET,PUBLISHED,RESULTS,RGD,TRP,VAL
001,133,169,195,266,BACKGROUND,CNS,COPYRIGHT,JANUARY,LABEL,METHODS,OBJECTIVE,PROCEDURE,PUBLISHED,RESULTS,SETTING,UROLOGY
169,945,AKT,ATM,COPYRIGHT,HISTONE,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS,S6K,THESE,UNTREATED
AKT,AXIIR,FINALLY,HSC,OCL,PCA,THESE
BIP,BORTEZOMIB,DU145,ERS,GADD153,HSPA5,LNCAP,OVERALL,PC3,PCA,USING
169,183,BRUCHOVSKY,CAB,GEORG,HOWEVER,IAB,III,STUTTGART
169,ADT,ASA,COPYRIGHT,INC,METABOLISM,NSAID,TAKEN
AIS,ALONE,AROMATASE,CYP17A1,SINCE,TAMOXIFEN
001,419,444,967,DISORDERS,DSM,INTERVIEW,LTD,MAJOR,MIXED,PUBLISHED,REGARDLESS,STRUCTURED,WOMEN
041,169,357,669,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,RRP,SHORT,UTILIZING
100,130,151,169,408,477,COPYRIGHT,FOAMY,GLEASON,INC,LIMITED,THERE
160,169,AFTER,AUC,BJU,DIAGNOSTIC,DRE,GLEASON,LABEL,LEVEL,METHODS,OBJECTIVE,PROBE,RESULTS,THERE,THESE,UNLABELLED
169,BACKGROUND,BIO,COPYRIGHT,D10,D90,HDR,LABEL,LTD,MATERIALS,METHODS,OAR,OBJECTIVE,PTV,PUBLISHED,PURPOSE,RESULTS,TREATMENT
169,UROLOGICAL
003,100,101,102,103,104,105,169,183,BLACKWELL,CONCLUSION,LABEL,LTD,METHODS,OBJECTIVE,PUBLISHING,RESULTS
215,ADDITIONAL,HOPKINS,JOHNS,MARKERS,MYEOV,PCA,SYK,THOSE
AES,ATTENTION,RESULTS
BIU87,E1A,HOWEVER,HUC,LUC,PSCAE,R1881,T24
ANIMALS,DOCETAXEL,INSIGHTEC,LNCAP,MRI,RESULTS
5TH,ASIAN,CAP,CAPSURE,CHINA,FIFTH,INDONESIA,INITIATIVE,JAPAN,JOINT,KOREA,MEETING,SINCE,TOKYO,USA
1PTER,890,CHROMOSOME,DELETIONS,RECOGNIZED
189,220,406,522,593,607,685,797,COMPLETED,CONCLUSION,LABEL,METHODS,OBJECTIVE,OVERALL,PURPOSE,RESULTS,RISKS,ROBOTIC
954,HOWEVER,NAVIGENICS,OVERALL,PGS,SCREENING,SNP,THERE
555,652,AMONG,ELISA,INOSINE,PCA,SIXTY,THESE
INDIA,MARCH,OVERALL
BACKGROUND,CERTAIN,FURTHER,KEY,LABEL,METHODS,OBJECTIVE,RESULTS,SECONDARY,THERE,USING,WHILE,WISCONSIN
001,145,BASED,BCL,DOX,LNCAP,PCA,TREATMENT
169,AFTER,APT,NPS,PCA,SOCIETY,USING
001,002,003,004,006,009,036,169,205,305,335,343,349,351,380,384,ADT,AFTER,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,RESULTS,SEVENTY,WILEY
169,ABCC2,ABCG2,AKT,BCL,CCA,CONCLUSION,COPYRIGHT,HOWEVER,LABEL,LIVER,ROS,UNLABELLED
169,283,384,667,708,AUC,BACKGROUND,COPYRIGHT,CRC,DRE,HOWEVER,INC,JANUARY,LABEL,METHODS,PCA,PRI,PSA,RESULTS,SEVERAL,WILEY
169,BACKGROUND,COPYRIGHT,DU145,EXPRESSION,HMGA1,INC,LABEL,LNCAP,METHODS,PCA,RESULTS,THESE,WESTERN,WILEY
169,AZD2171,BACKGROUND,CEDIRANIB,CONCLUSION,COPYRIGHT,DU145,INC,LABEL,METHODS,PCA,PDGFR,RESULTS,THESE,VEGFR,WILEY
169,218,802,BACKGROUND,COPYRIGHT,HOWEVER,INC,LABEL,LNCAP,METHODS,RESULTS,WILEY
169,954,AKT,BACKGROUND,CIS,COPYRIGHT,INC,LABEL,LNCAP,METHODS,NED,RESULTS,S17,SH2,SOCS1,SOCS6,SOCS7,STAT3,USING,WILEY
00269,031,126,131,169,ADT,ALLELIC,BACKGROUND,COPYRIGHT,GLEASON,HSD17B2,INC,LABEL,METHODS,RESULTS,WILEY
169,ASO,BACKGROUND,COPYRIGHT,FINALLY,INC,LABEL,LNCAP,METHODS,RESULTS,THESE,TREATMENT,WILEY
045,139,169,374,410,514,BMI,CIS,COPYRIGHT,COX,FEW,HRS,MELBOURNE,USING
169,ABD,ANTIGEN,BACKGROUND,CALBIOCHEM,COPYRIGHT,FITZGERALD,INC,LABEL,METHODS,PSA,RESULTS,SEROTEC,THESE,WILEY
100,169,BACKGROUND,CASTRATION,CELLS,CHROMATIN,COPYRIGHT,CRPCS,DHT,INC,K14,LABEL,LNCAP,METHODS,PCR,POL,PSA,RESULTS,THESE,TMPRSS2,WILEY
ANXIETY,CONFUSION,DEPRESSION,IMPOTENCE,VARIOUS
CONCURRENT,CONVERGENT,DIVERGENT,FURTHER,LABEL,METHODS,NEEDS,OBJECTIVE,PRINCIPAL,PURPOSE,RESULTS,SHORT,SUPPORTIVE
169,AMERICA,AMONG,BACKGROUND,BCA,JOURNAL,LABEL,METHODS,NORTH,PCA,PSA,RESULTS,ULTIMATELY
169,LABORATORY,UROLOGICAL
UTR
150,206,675,PSA,SECONDARY
733,AUC,CALCULATOR,ERSPC,GOETEBORG,KINGDOM,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PREVENTION,PSA,RESULTS,ROUND,SABOR,THERE,TRIAL,TYROL
CYBERKNIFE,HOWEVER,IMAGE
11A,11L,169,956,ANNEXIN,COPYRIGHT,HOECHST,LTD,MTT,NMR,PBD,SUBG1,THESE
169,194,946,AKT,AMONG,COPYRIGHT,INC,PATHOLOGY,PDGFR,PUBLISHED,SIMILAR,SOCIETY,TAKEN
169,2CC,2GY,2ML,4GY,5GY,945,946,CONCLUSION,COPYRIGHT,HGI,INC,LABEL,MATERIALS,METHODS,PUBLISHED,PURPOSE,RESULTS,SOCIETY,UNLABELLED
100,169,223,BACKGROUND,CONTEXT,COPYRIGHT,LABEL,MDV,MDV3100,MEDICAL,MEDLINE,MET,METHODS,MOLECULAR,OBJECTIVE,OCTOBER,PUBLISHED,RESULTS,SOCIETY,SRC,SYNTHESIS,UROLOGICAL,UROLOGY
00002,00005,003,004,020,025,036,169,213,526,AFTER,BACKGROUND,BCR,CAUCASIAN,CAUCASIANS,COPYRIGHT,COX,DETERMINE,HSD17B1,HSD17B2,HSD17B3,HSD17B4,HSD17B5,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SETTING,THESE,UROLOGY
169,176,177,833,ADDRESSING,CONCLUSION,COPYRIGHT,IMPLANTED,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
001,002,005,009,030,100,169,194,594,638,BACKGROUND,CONVERSELY,COPYRIGHT,DECREASED,LABEL,METHODS,OBJECTIVE,RESULTS,RRP,SETTING,UROLOGY
169,194,COPYRIGHT,FURTHER,GLEASON,GRADE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PURPOSE,RESULTS,T1C,T2B
001,169,400,562,962,BETWEEN,COPYRIGHT,CSA,ELECTRONIC,INC,LABEL,MATERIALS,MAXIMUM,METHODS,NETWORK,OBJECTIVE,PATIENT,PTV,PURPOSE,RESPECTIVE,RESULTS,SVP
PAMAM,SUCCESSFUL,TEA
784,838,946,AHR,AMONG,ASSOCIATED,BACKGROUND,BECAUSE,COLORECTAL,CONCLUSION,CONFIDENCE,DEFINITIVE,ENROLLMENT,INCIDENCE,LABEL,LIKELIHOOD,LOWER,METHODS,RATIO,RECEIVE,RESULTS,TREATMENT
160,CELLSEARCH,CSS,DETECTION,FDA
160,CADMIUM,CHANGES,ROS
ADDRESSING,CER,DEPARTING,USA,USING,WITHOUT
HOWEVER,LNCAP,THESE,TRAMP
001,040,096,140,160,717,CALIFORNIA,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,STUDIES
945,946,DPN,EPI,LTD,METABOLISM,PPT,PSA,PUBLISHED,R1881,STROMAL,STUDIES,TGF,USING
169,602,610,656,662,675,679,AUC,BAYES,BNS,BRITISH,COMPARING,CONCLUSION,COPYRIGHT,FINALLY,HEURISTIC,HOWEVER,INFIRMARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PREDICTION,RESULTS,ROC,ROYAL,SUBSETS,UROLOGICAL,USING
169,COPYRIGHT,INC,INHIBITION,PSS,THESE,TIC,USING
169,COPYRIGHT,LABORATORY,LTD
169,194,462,889,BACKGROUND,COPYRIGHT,INPATIENT,LABEL,LRP,METHODS,NATIONWIDE,OBJECTIVE,OCTOBER,ORP,PRIOR,PUBLISHED,RARPS,RELYING,RESULTS,RPS,SETTING,UROLOGY
169,COPYRIGHT,DESPITE,INC,PUBLISHED
169,COPYRIGHT,ETS,INC,PC3,PC3PR,TAKEN
145,169,COPYRIGHT,DR4,DR5,EXPRESSION,HMGB1,HOWEVER,INC,LNCAP,PSA,THEREFORE
169,463,493,543,836,AFTER,CAP,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OLDER,PSA,RESULTS,UPGRADING
149,246,437,ANOTHER,ANTIBODIES,HBV,HCV,HIV,OVERALL,PBMCS,SPAIN
306,AGE,COX,HRS,LABEL,MEIER,METHODS,OBJECTIVE,PURPOSE,RESULTS
500,800,BACKGROUND,BECAUSE,CONCLUSION,LABEL,METHODS,RESULTS,TEN
ASCORBATE,ATP,HOWEVER,LAPC4,TAKEN,THROUGH,WHEREAS
ENDOTHELIN,UNTIL,WESTERN
300,AUC,DRE,ERSPC,LABEL,METHODS,MISSING,OBJECTIVE,OBJECTIVES,PSA,RANDOMIZED,RESULTS,RISKS,SCREENING
AFTER,IFM
946,BPH,EMT,EPITHELIAL,EXPRESSION,FOXA1,HOWEVER,SNAIL,TGF
AOS,ATM
160,400,GLEASON,HOWEVER,INCLUDING,OVERALL,THERE
AKT,AMONG,HOWEVER
945,ERK,FURTHER,HOWEVER,MEK,MMP,PCA,PD98059,TGF,THESE
DEPLETION,FINALLY,FIRST,HOWEVER,KDM6A,NUCLEIC,RAD51,TAKEN
CURRENTLY,GIVEN,PET
10Q11,11Q13,160,17Q12,17Q24,730,979,CONSORTIUM,HOWEVER,HPC,PCA
LABEL,METHODS,MPH,NERVE,OBJECTIVE,PURPOSE,RESULTS,THESE
LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SEPTEMBER,THERE
169,COPYRIGHT,HOWEVER,IRELAND,LTD
BECAUSE,PSA
946,BECAUSE,PROMISE,WNT
169,COPYRIGHT,CYP17,III,LTD,PHASE
003,169,BMD,CANDIDATE,COPYRIGHT,INC,RDX,RFD
169,BACKGROUND,COPYRIGHT,EVALUATION,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,LTD,REFINEMENT
100,169,173,215,5TH,ADVERSE,COMMITTEE,COPYRIGHT,FAVORABLE,FOLEY,GLEASON,GRADE,HDR,HOWEVER,INC,INSTITUTE,IRB,JOINT,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,STAGE,T2B,ULTRASOUND
169,215,AFTER,COPYRIGHT,CTV,GTV,INC,LABEL,MATERIALS,METHODS,MODEL,OBJECTIVE,PURPOSE,RESULTS
169,177,1ML,2ML,9ML,COPYRIGHT,HOWEVER,JACCARD,LABEL,LOCAL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SOCIETY
169,174,945,956,COPYRIGHT,INC,LNCAP,PEG,THESE
001,014,056,159,169,184,673,917,COPYRIGHT,FINALLY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PSA,RESULTS
139,169,177,194,426,471,495,945,CONCLUSION,COPYRIGHT,HIF,INC,LABEL,METHODS,OBJECTIVE,PC3,RESULTS,SILENCING,WESTERN
002,004,169,707,COMPOSITE,CONCLUSION,COPYRIGHT,INC,INDEX,LABEL,METHODS,OBJECTIVE,PREDICTORS,PSA,PUBLISHED,RESULTS,RRP,THERE
103,115,125,169,247,994,BETWEEN,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS
158,197,AFTER,AMONG,BACKGROUND,DETECTION,LABEL,METHODS,PAC,RESULTS,THESE
007,CLINICALLY,NOTABLY,SRC,STAT1,STAT3
945,ADDITIONAL,HISTONE,MRS
216,243,459,DUTCH,GEP,NET,POISSON
NOD,THESE
023,043,050,160,601,ADT,GLEASON,HOWEVER,LABEL,METHODS,MOLECULAR,OBJECTIVE,PURPOSE,RESULTS,TRU9I,VDR
00001,ACCORDING,AUC,DRE,ECE,LABEL,MATERIALS,METHODS,MRI,NPV,OBJECTIVE,OBJECTIVES,OVERALL,PCA,PPV,PRE,PSA,RESULTS,ROC,T3A,T3B
AFTER,C4A,HSA,IGG,MALDI,PSA,REVERSE,SELECTIVE,THREE
169,ASSAY,AUTHORS,BJU,DUE,ENGLISH,HOWEVER,MRI,OPTIMISING,SCORE,STRATEGIES
104,169,215,345,AUTHORS,BJU,CANCERS,CASES,CONCLUSION,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,UNLABELLED
001,007,100,169,629,887,928,943,ADT,AUTHORS,BJU,BLACK,CONVERSELY,DESPITE,END,FINALLY,LABEL,MEN,METHODS,OBJECTIVE,RESULTS,UNLABELLED,USA
046,100GY,103,110GY,125,129,169,199,259,4GY,BETWEEN,CONCLUSION,COPYRIGHT,CTCAE,GRADE,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,OVERALL,PUBLISHED,PURPOSE,RESULTS,SCORE,SOCIETY,THERE,TOXICITIES
125,169,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,SUBSEQUENT,T1C
954,DENOSUMAB,RANKL
DESPITE,URINARY
130,560,AFRICAN,AMERICANS,BACKGROUND,BMI,FINALLY,GLEASON,IQR,LABEL,METHODS,OBJECTIVE,OVERALL,PERIPHERAL,PSA,PSM,PURPOSE,RECORDS,RESULTS,THESE,WHILE

169,AFTER,COPYRIGHT,INC,LC3,ORI,PCR,SEM,TEM,UNDER,WESTERN,WILEY
001,006,012,022,100,120,169,183,AMONG,BACKGROUND,BRITISH,CONCLUSION,COPYRIGHT,JOURNAL,LABEL,LTD,METHODS,OPERATIONS,OUTCOME,PUBLISHED,RESULTS,RRP,SIXTY,SOCIETY,SURGERY,WILEY
123,268,371,894,DAILY,ICELAND,THESE,THROUGH
BPH,CRP,GLEASON,IIA,PCA,PSA
169,215,27632,CONTINUED,COPYRIGHT,CRC,HOWEVER,INC,PATHOLOGY,PRIMARY,PUBLISHED,RHO,SOCIETY
115,136,147,169,184,193,435,AIM,BACKGROUND,BNSRP,CCI,CONCLUSION,CONVERSELY,INDEX,LABEL,MEASURE,MEIER,METHODS,OBJECTIVE,OUTCOME,RESULTS,SIMILARLY,SOCIETY
169,C12,COPYRIGHT,CRD,FINALLY,GAL,LTD
169,177,AFTER,COPYRIGHT,CTV,FSV,HOWEVER,INC,MEDICAL,MINIMUM,PSV,PTV,PUBLISHED,SVS
014,029,047,091,169,333,343,676,AFTER,AIM,BACKGROUND,BCR,COX,CRUDE,LABEL,MEIER,METHODS,OBJECTIVE,OUTCOME,RESULTS,SOCIETY,THESE
BAK,BCL,BH3,DU145,III,MCL,PCS,THESE,ULTIMATELY
103,122,169,ANGELES,CALIFORNIA,CONCLUSION,COPYRIGHT,HOMME,INC,INDEX,LABEL,LOS,MARCH,METHODS,MINIMALLY,MODULAR,OBJECTIVE,PATIENT,PHASE,RESULTS,TREATMENT,UNIVERSITY,WOUND
169,AEU,BACKGROUND,CONTEXT,COPYRIGHT,HOWEVER,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SYNTHESIS
134,138,169,AEU,BETWEEN,COPYRIGHT,DIAGNOSTIC,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS
001,100,169,ACCORDING,AEU,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PIN,PUBLISHED,RESULTS,THESE,WINDOWS
DETECTION,PSA
169,BLACKWELL,EINDHOVEN,ELDERLY,LTD,PUBLISHING
169,1940S,HOWEVER,JAPAN,UROLOGICAL,USA
222,268,359,BRCA1,BRCA2,THERE
ETS,PCA,R2ORS,RUNX2,SDS,TFS,USING
169,194,945,946,AML,ATP,CK2,CML,COPYRIGHT,INC,PML,SER,SEVERAL,THR
169,200,280,COPYRIGHT,HOWEVER,INTERFRIN,PEG,PEGYLATED,PEGYLATION,PLL
145,231,956,III,MDA,MEL,OVCAR,RESULTS
440,555,965,BLOOD,CONCLUSION,CYP17,ERG,LABEL,MARCH,MAXIMAL,METHODS,OBJECTIVE,OCTOBER,PERSISTENT,POTENTIAL,PURPOSE,RESULTS,TMPRSS2
131,945,954,CASPASE,D131A,MCF,PAR
AFTER,ATP,BACKGROUND,BPH,HPECS,LABEL,METHODS,RESULTS
BACKGROUND,BMI,BPH,FURTHER,HOWEVER,LABEL,METHODS,RESULTS
ACTIVATED,THESE
001,396,BACKGROUND,CONTEXT,GLEASON,IGF,IGFBP,LABEL,LARGE,METHODS,OBJECTIVE,OUTCOME,RESULTS,SETTING,THERE
169,194,CA125,COLORECTAL,COPYRIGHT,LTD,OVARIAN,SCREENING,TRIAL
100,169,BJU,ENGLISH,LABEL,MATERIALS,MEDLINE,MEN,METHODS,OBJECTIVE,RESULTS
169,FURTHER,HOWEVER,THERE
BACKGROUND,BEHAVIORAL,DESPITE,LABEL,METHODS,RESULTS,SMOKERS,STUDIES,THESE,WHILE
000,039,042,046,120,169,ADDITIONAL,BACKGROUND,COPYRIGHT,ESTIMATED,LABEL,METHODS,RESULTS,SOCIETY,THESE
101,169,1NG,215,250,ASSESSMENT,BACKGROUND,BECAUSE,COPYRIGHT,FUNCTIONAL,FURTHER,INDEX,LABEL,METHODS,OUTCOME,PERIPHERAL,PSA,RESULTS,SOCIETY,THERAPY,THERE,TREATMENT
104,123,223,262,622,AMONG,BACKGROUND,KEY,LABEL,MEDICAL,MEN,METHODS,OBJECTIVE,PRACTICES,PRIMARY,PSA,RESULTS,SOUTH,VAS
169,380,387,553,718,AFTER,BACKGROUND,CASES,COPYRIGHT,HOWEVER,LABEL,MEDICATION,METHODS,RESULTS,SOCIETY,STATINS,THERE
001,169,ADULT,AFTER,AMONG,BACKGROUND,BIVARIATE,COMPONENT,COPYRIGHT,GENERAL,HRQOL,LABEL,LOUISIANA,MCS,METHODS,NORTH,PCS,PROJECT,RAPID,REALM,RESULTS,SHORT,SOCIETY,SUMMARY,THESE,YET
H3K4ME3,THROUGH
FURTHER,HOWEVER,PCS,PHB,PSA,USING
135,948,AKT,CDCP1,CUB,PARP1,PKC,PREVENTING,SRC
AMONG,CGH,EXPRESSION,LAPC4,OPCN2,TAKEN,TOWARDS
112,136,231,737,ABT,ANNEXIN,BAD,BAX,BCL,DU145,HOWEVER,MCL,MDA
200,215,GLEASON,OVERALL,THEREFORE
169,HOWEVER,RAD51
AKT,CONVERSELY,ERK,FAS,HSP27,LNCAP,PEA,THESE
AKT,ELK,ERK,IGF,MTT,PC3,PCR,WESTERN
EERPE,ENDOSCOPIC
124,133,160,CPS,LABEL,METHODS,OBJECTIVE,PCA,PSA,RESULTS,RTE
100,160,AMONG,BAX,BCL,HEPG2,NSAID,THEREFORE,THESE
169,BACKGROUND,COPYRIGHT,GENERAL,ISSUE,LABEL,MAJOR,METHODS,NON,SCOPE,SPECIAL,THEREFORE
127,129,169,177,194,212,339,636,AEU,BETWEEN,COPYRIGHT,HDL,LABEL,LDL,METHODS,OBJECTIVE,PUBLISHED,RESULTS
169,AEU,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,LIBRARY,MEDLINE,METHODS,PUBLISHED,RESULTS,SCIENCE,SPT,STP,THERE
169,AKT,COPYRIGHT,INHIBITION,LC3,PC3,SEVERAL,TAKEN
169,180,AVAILABLE,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,TDM
100,169,257,429,ACCORDING,BETWEEN,BILATERAL,BJU,CLAVIEN,GRADE,LABEL,LNS,METHODS,NVB,OBJECTIVE,PATIENT,RESULTS,STUDIES
169,174,512,AFTER,APRIL,AUTHORS,BJU,CENTERS,CONCLUSION,CYP17A1,LABEL,MEDICAL,METHODS,OBJECTIVE,PAP,PSA,REFERENCE,RESULTS,SEATTLE,SINCE,SIPULEUCEL,SOCIETY,UNLABELLED,USA
169,293,339,AUTHORS,BETWEEN,BJU,CLASS,CLAVIEN,FOLEY,FUNCTIONAL,INITIAL,IQR,JANUARY,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,PST,RESULTS,SPLINTING,THERAPY,UNLABELLED,URINARY
169,22RV1,COPYRIGHT,DCFDA,EDUCATION,HNE,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UROLOGICAL,WESTERN
169,611,752,AGE,COPYRIGHT,COX,EDUCATION,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PROSTATIC,PUBLISHED,PURPOSE,RESULTS,SCORE,UNIVARIATE,URINARY,UROLOGICAL
169,295,398,582,COPYRIGHT,EDUCATION,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,ORS,PUBLISHED,PURPOSE,RESULTS,SEVERAL,T1C,UROLOGICAL
169,BACKGROUND,BLACKWELL,CONCLUSION,KAOHSIUNG,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHING,QUALITY,RELEVANCE,RESULTS,SEVENTY,SIXTY,UROLOGICAL
ARS,CLINICALLY,EXPRESSION,IIA,LNCAP,SYNTHESES
001,4EBP1,CYP17,HOWEVER,LNCAP,R1881,TOK,W741C,W741L
CBP,CHROMATIN,LYS,PSA,TBP,TMPRSS2
945,946,CONSISTENT
169,178,183,242,253,BESIDES,CONCLUSION,FURTHER,GSE,ILLNESS,LABEL,METHODS,NON,OBJECTIVE,PURPOSE,RESULTS,STUTTGART,SUFFERING,THEREFORE,TPF
169,231,COPYRIGHT,ERK,INC,JNK,MAP,MAPKS,MDA,OVERALL,PC3,USING,WILEY
169,183,COMPOUNDS,GEORG,KNOWN,PC3,STUTTGART,THEIR,VITRO
169,AUSTRALIA,COPYRIGHT,FURTHER,GIVEN,HODGKIN,NSW,SOUTH,WALES
169,308,609,AKT,BAD,CAM,COPYRIGHT,INC,LNCAP,STO,TAKEN,WILEY
169,2ME,473,4EBP1,945,AKT,COPYRIGHT,CPT,EPAC1,GRP78,INC,PDE3B,PDE4D,PKA,SER,SILENCING,THESE,WILEY
169,COPYRIGHT,GASTWIRTH,LTD,WILEY
100,169,194,CONCLUSION,COPYRIGHT,CRYOPROBE,INC,IPP,LABEL,METHODS,OBJECTIVE,OCTOBER,RESULTS
169,CASES,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THESE
169,194,946,COPYRIGHT,HISTOLOGIC,INC,LY2109761,MDA,MRI,PCA,PMO,SMAD2,TGF
004,030,037,169,310,413,897,AMONG,BETWEEN,COPYRIGHT,END,INC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SMS,USING
008,009,169,225,ADT,AFTER,ART,BETWEEN,COPYRIGHT,GLEASON,GRADE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SVI
169,196,946,AKT,COPYRIGHT,LTD
100,169,956,COPYRIGHT,GSTP1,PCR
169,946,BECAUSE,CURRENTLY,DU145,HYPOXIA,LABEL,LNCAP,NED,NOTCH,RESULTS,UNLABELLED
611,EFFECTS,ERR,FOUNDATION,LSS,POISSON,RADIATION,THERE
001,024,103,170,191,225,276,281,BLOOD,BMI,GLEASON,HOWEVER,LABEL,LND,MARCH,METHODS,OBJECTIVE,OTHERWISE,OWING,RESULTS,ROBOTIC,THERE,WHEREAS
167,215,FUNCTIONAL,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE
233,244,ANDROGENS,BACKGROUND,BRITISH,CONTEXT,FINALLY,GLEASON,HOWEVER,LABEL,LAVAL,METHODS,OBJECTIVE,OUTCOME,PCR,RESULTS,SETTING,UGT,UGT2B15,UGT2B17,UNIVERSITY,VANCOUVER
945,BACKGROUND,CONCLUSION,CONTEXT,CYP17A1,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,TREATMENT,URINARY
169,AUA,BACKGROUND,BOWEL,COMPOSITE,COPYRIGHT,CYBERKNIFE,INDEX,INVENTORY,LABEL,MEN,METHODS,NETWORK,PSA,RESULTS,SOCIETY,THERE,UROLOGICAL
169,COPYRIGHT,GNR,INC,PAE,SUB,WILEY
169,COPYRIGHT,ERGONOMICS,LTD,RESULTS,SOCIETY
169,194,BACKGROUND,CONTEXT,CONTINUED,COPYRIGHT,CRITICALLY,LABEL,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,QOL,RESULTS,SYNTHESIS,THESE,UROLOGY,WEB,WHILE
956,BAPTA,CELECOXIB,CONVERSELY,GF109203X,INHIBITION,PC3,PMA,THESE
954,PC3,THESE
000,1970S,1990S,AMONG,BACKGROUND,CONCLUSION,INDEX,INEQUALITY,KNOWLEDGE,LABEL,METHODS,NORWEGIAN,RESULTS
071,1154G,693,CAUCASIANS,PUBLISHED
DUE,GCE,HRP,NANOPOROUS,NPG,PSA
169,194,231,252,ADP,APPPI,ATP,COPYRIGHT,EXPRESSION,INC,IPP,KLF,LNCAP,MCF,MDA,MICROARRAY,PC3,PERMANENT,PUBLISHED,THESE,WESTERN
072,AMONG,BACKGROUND,CIS,COLORECTAL,CONCLUSION,GRILLED,LABEL,METHODS,ORS,OVARIAN,RESULTS,SCREENING,TOTAL,TRIAL
169,LIPID,NONWETTING,PRINT,SOCIETY,TEMPLATES
BACKGROUND,CONTEXT,LABEL,MDV,METHODS,NEWER,PATIENT,T1C
160,169,215,956,ADC,COPYRIGHT,EPITHELIUM,GLEASON,INC,SIMILAR,STROMAL,WILEY
169,200,BACKGROUND,COMPARING,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,PSA,RADICAL,RESULTS,STAGE,TRANSIENT,WILEY
003,005,015,169,204,528,945,ARI,BACKGROUND,COPYRIGHT,COX,GLEASON,HOWEVER,INC,LABEL,METHODS,PCA,RESULTS,WILEY
004,129,169,179,431,BACKGROUND,BETWEEN,COPYRIGHT,GLEASON,INC,LABEL,METHODS,PBX,PCA,PSA,RESULTS,SIXTY,SPECIMENS,UNILATERAL,WILEY
169,BACKGROUND,CASTRATION,COPYRIGHT,EFFECTS,ERK,FUNCTIONAL,GIVEN,INC,LABEL,METHODS,MTT,PCR,RESULTS,WILEY
169,BACKGROUND,COPYRIGHT,DETECTION,EPIGENETIC,GSTP1,INC,LABEL,METHODS,PSA,RESULTS,THEREFORE,THESE,WHILE,WILEY
169,COPYRIGHT,GCV,HSV,INC,LNCAP,PAMAM,PSMAE,WILEY
169,BACKGROUND,COPYRIGHT,IAP,INC,LABEL,LNCAP,METHODS,PCR,PEITC,RESULTS,TRANSWELL,WESTERN,WILEY
10A,169,22RV1,COPYRIGHT,EPHB4,HOWEVER,MCF,THESE
169,826,COPYRIGHT,COX,GENERAL,HOWEVER,HRS,OVERALL
000,100,125,150,200,240,280,350,471,500,600,711,900,DEPARTMENT,GGT,THERE
001,171,333,350,490,ASC,BETWEEN,CCI,COVARIATES,FIRST,FLORIDA,IHP,INDEX,LABEL,LOS,METHODS,MORTALITY,OBJECTIVE,PURPOSE,RESULTS,RPS
109,300,CGS,DUTCH,ERSPC,GPS,HENCE,JANUARY,KNOWLEDGE,PCA,PSA,RANDOMIZED,REMARKABLY,SCREENING
160,956,EFFECTS,TREATMENT
205,4F2HC,CONCLUSION,EXPRESSION,LABEL,LAT,MET,METHODS,OBJECTIVE,PC3,PCR,PET,PURPOSE,RESULTS
045,174,947,CD4,CD8,COMBINING,FOXP3,HOWEVER,IFN,NOVEL,PSK,TRAMP,YAC
ANNEXIN,BASED,BAX,BCL,CHINESE,CURRENT,MATRINE,SOPHORA,THERE
004,028,160,CAV,CRO,CURRENT,FRK,GSH,HOWEVER,THESE,TNM
100,22RV1,410,945,ATHYMIC,FURTHER,PCA,THERE,THROUGH,USING
DESPITE,DIETARY,KNOCKDOWN,MG132,OMEGA
169,495,CPG,HSD17B2,RB1
945,946,FAK,RUNX1,RUNX2,RUNX3,TGF,TNF,WNT
APPRAISAL,BACKGROUND,EIGHT,EVALUATION,FRAMEWORK,GUIDELINES,LABEL,METHODS,RESULTS
946,CUB,LNCAP,PCA,PDGFR,RANKL,TAKEN
DEPLETION,E2F,E2F3A,E2F3B,HELLS,STRIKINGLY,USING
100,177,193,871,FINALLY,FIRST
BACKGROUND,DISCUSSION,EVALUATING,LABEL,METABOLITE,METHODS,OBJECTIVE,RESULTS
CCND1,CONCLUSION,CPG,LABEL,LCNEC,METHODS,OBJECTIVE,PURPOSE,RB1,RESULTS,SMALL,UBE2C
169,CHROMATIN,COPYRIGHT,H2B,IRELAND,LNCAP,LTD,PSA,RNF20,RNF40,SINCE
169,210,AKT,COPYRIGHT,DU145,EGF,ERK,EXPRESSION,HN1,IRELAND,KNOCKDOWN,LNCAP,LTD,PD98059,R1881,THEREFORE
001,015,111,166,16792,169,835,BESIDES,CHINESE,COPYRIGHT,CROWN,EASTERN,HCC,KOREANS,MAY,MEDLINE,PCC,PUBLISHED,THROUGH
169,945,954,COPYRIGHT,DIM,HIF,HOWEVER,I3C,INCREASED,IRELAND,LTD,PCA,PHASE,PSA,THESE
109,123,169,197,215,AGE,ANGELES,BACKGROUND,BNVBP,CALIFORNIA,COPYRIGHT,DETERMINE,GLEASON,HAR,INDEX,LABEL,LOS,METHODS,OBJECTIVE,PDE5I,PUBLISHED,RESULTS,SETTING,UNIVERSITY,UROLOGY
001,003,005,017,169,215,ADC,COPYRIGHT,DWI,EIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PRETX,PSA,PURPOSE,RESULTS,SERUM
169,COPYRIGHT,IRELAND,LTD,SELECTING
169,945,956,CHINESE,COPYRIGHT,CTS,DHT,IRELAND,LNCAP,LTD,PCA,PSA,TMPRSS2
169,BACKGROUND,CONTEXT,COPYRIGHT,ENGLISH,LABEL,MARCH,MEDLINE,METHODS,OBJECTIVE,PERFORM,PUBLISHED,RESULTS,SCIENCE,SCP,SYNTHESIS,THESE,TITLE,TNM,UROLOGY,WEB
001,169,200,505,BACKGROUND,BCR,COPYRIGHT,CSS,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,OVERALL,PCA,PREDICTION,PSA,PUBLISHED,RESULTS,ROUGHLY,SETTING,THESE,UROLOGY
169,228,266,494,ADDITIONAL,BORDERLINE,CAP,CONCLUSION,COPYRIGHT,INC,LABEL,MEN,METHODS,OBJECTIVE,P3P,PATIENT,PROFILE,RESULTS
169,BLACKWELL,LTD,NORTH,NRW,PUBLISHING,RHINE,SIR,WESTPHALIA
169,945,946,BASED,CURRENT,H874Y,HOWEVER,IKK,LBD,T877A,W741C,WILEY
169,BIOMETRIC,EXTENDING,SOCIETY,THESE
DAN,DESPITE,LABEL,MEIER,METHODS,OBJECTIVE,PARAMETERS,PROSTATIC,PSS,RESULTS,SCORE,SEVENTY,SYMPTOM
007,100,116,500,BACKGROUND,CLAVIEN,JANUARY,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS
BRAWLEY,COKKINIDES,CONCLUSION,EXPERIMENT,LABEL,METHODS,OBJECTIVE,RESULTS,SMITH,STATEMENT
GLEASON,H3K27,PCA
087,088,107,108,150,956,ACTIVATOR,INHIBITORS,MCL,MYC,SH2,STAT1,STAT3,STAT5,TRANSDUCER
AF1,ASSAY,BIOLOGICAL,CLICK,LNCAP,MICHAEL,NMR,NTD,PC3,SAR
169,COPYRIGHT,LTD,METABOLISM,MOUSE
169,AUC,BACKGROUND,BPH,BRIEFLY,CALD1,COMBINING,CONCLUSION,COPYRIGHT,CY3,LABEL,LEDGF,METHODS,PARK7,PSA,PSIP1,RESULTS,SERUM,USING
169,194,COPYRIGHT,FINALLY,OTHER,RECURRENCE,SEVERAL
005,025,169,ASSESSMENT,BLACKWELL,GPS,HOWEVER,LAP,LEICESTER,LTD,PACKAGE,PUBLISHING,SIX,THERE,THESE,THREE
001,169,742,AUA,AUASS,BCR,BETWEEN,BJU,BLOOD,DELTA,HCT,INDEX,INTRA,LABEL,LEVEL,LOS,METHODS,OBJECTIVE,QOL,RESULTS,SCORE,SYMPTOM,UNLABELLED,URINARY,VALIDATED
176,956,COMET,HOWEVER,LNCAP,MMS,OVERALL,P53,THEREFORE,UVA,UVC
169,945,BJU,CERTAIN,ILLNESS,INDEX,LABEL,MEANING,MEN,METHODS,OBJECTIVE,PEARSON,PRIMARY,RESULTS,SCALE,UNLABELLED
AGC,AKT,PHLPP,PKC,PRECISE,SER,THR
007,032,169,655,AKT,ARR,CAV,HGPIN,MYC,OVERALL,PIN,PREVIOUSLY
169,183,ABOVE,BACKGROUND,CONCLUSION,DRE,ESPECIALLY,GEORG,JANUARY,LABEL,MARCH,MEDLINE,METHODS,OVERALL,RESULTS,SIX,STUTTGART,UAP,WITHOUT
169,BACKGROUND,CONCLUSION,COPYRIGHT,LABEL,LTD,METHODS,PEERS,RESULTS,TEN,WILEY
TRAIL
EPCAM
33342,956,BAX,BCL,HOECHST,MEANWHILE,TYPICAL
370,387,425,BACKGROUND,FURTHER,GLEASON,LABEL,METHODS,PSA,RESULTS,THERE,THOSE
210,849,AUC,BACKGROUND,BETWEEN,DRE,GUNMA,INDICATOR,LABEL,METHODS,PSA,RESULTS,UNIVERSITY
132,160,269,AMICO,AMONG,BECAUSE,GLEASON,JANUARY,LABEL,METHODS,MRI,OBJECTIVE,OVERALL,PSM,PURPOSE,RESULTS
FOLEY
171,AUC,BACKGROUND,CONCLUSION,ELASTICITY,GLEASON,III,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPS
160,ADC,AMICO,DWI,GLEASON,MRI,THREE
100,160,CGLIIQKNEC,CNR,CONCLUSION,CY5,KAREC,LABEL,METHODS,MRI,OBJECTIVE,ORTHOTOPIC,PURPOSE,RESULTS
244,ANALYZING,EFFORTS,INDICATING,PCA
145,169,ADC,REPRIMO
038,ADT,DIETARY,FIFTY,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,SIXTY,TOTAL
169,ARS,COPYRIGHT,FINALLY,FOXA1,GLEASON,HOWEVER,INC,PATHOLOGY,PSA,PUBLISHED,SOCIETY,THESE
000,100,362,605,AMONG,BACKGROUND,DALYS,ENGLAND,HIGHEST,LABEL,METHODS,MORTALITY,RESULTS,THERE,WALES,WORLD
169,192,215,256,275,ADT,AFTER,BETWEEN,BFS,CONCLUSION,COPYRIGHT,CSS,DESPITE,DFS,GLEASON,GRADE,GROUP,HDR,INC,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RADIATION,RESULTS,THERAPY
169,COPYRIGHT,CRMP5,CV2,ENGLISH,IGG,NMO
160,169,92A,COPYRIGHT,CSC,LTD,TARGETING
100,102,125,133,169,965,COPYRIGHT,COX,DESPITE,DISCUSSION,GROUP,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS
169,COPYRIGHT,CURRENT,MRI,PRIOR,PUBLISHED,THESE,UROLOGY
169,200,293,514,ACT,AFTER,CLINICIANS,COPYRIGHT,HRQOL,INC,INSURANCE,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,945,947,956,ABCA1,ATP,COPYRIGHT,CROWN,DU145,HOWEVER,INC,LIVER,LNCAP,LXR,PUBLISHED,THESE
169,COPYRIGHT,EXPERIMENT,INC,SEO,TAKEN
001,169,180,181,360,887,COPYRIGHT,ESTIMATED,GLEASON,INC,LABEL,MARCH,MATERIALS,METASTASES,METHODS,MOUNT,OBJECTIVE,PSA,PURPOSE,RESULTS,SINAI,UNIVARIATE
169,AWALL,BASED,COPYRIGHT,EAS,FINALLY,IAS,INC,LABEL,LAM,MATERIALS,METHODS,OBJECTIVE,PRM,PURPOSE,RESULTS,RWALL,SEVERAL
169,BACKGROUND,COPYRIGHT,INC,LABEL,METHODS,MICHAELIS,PET,RESULTS,TEN,THEREFORE
AMONG,AXL,MERTK,PSMA1,TAM,TYRO3
181,625,945,946,ASSAY,BACKGROUND,CONCLUSION,CONTEXT,DON,DUNAL,INHIBITORY,LABEL,METHODS,MIC,MINIMUM,NON,OBJECTIVE,RESULTS,SOLANACEAE,SOLANUM,TITRE
NSUN2,PROTEIN
DAPK1,GLEASON,SCORE,SFRP2
001,007,169,215,285,561,786,879,ADT,AFTER,ANTIGEN,AREAS,COPYRIGHT,IAUGC,IMAGING,INC,MRI,PSA,THESE,WILEY
169,COPYRIGHT,DESPITE,HOWEVER,LTD,MDA,MRI,PCA,SU10944,WILEY
AFTER,CEA,HENCE,M30,THESE
177,AMONG,APRIL,CTX,LABEL,METHODS,OBJECTIVE,PROSTATIC,PURPOSE,RESULTS,THESE
181,22RV1,AKT,BCL,BELINOSTAT,HDACI,HISTONE,PC3,THESE
003,007,100,168,199,960,APRIL,CAUSE,COX,CSS,GLEASON,HOWEVER,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,194,AFTER,BACKGROUND,CONTEXT,COPYRIGHT,ESPECIALLY,FURTHER,HOWEVER,LABEL,MEDLINE,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SYNTHESIS,THEREFORE,UROLOGY,WIDESPREAD
002,160,169,176,ARW,BILATERAL,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PLANS,PURPOSE,RESULTS,TEN,THESE,THREE
945,FAB,KINETIC
100,130,150,177,203,214,266,BACKGROUND,BLADDER,CTV,HOWEVER,LABEL,METHODS,PTV,RESULTS,THERE,TREATMENT
169,COPYRIGHT,INC,PROTEIN,THESE,WILEY
169,ARM,COPYRIGHT,DHH,DHT,GLI,IHH,LNCAP,PCA,SHH
145,AKT,DASATINIB,FAK,INHIBITION,LNCAP,SRC,STAT3,THEREFORE,WESTERN
549,GRP78,HDF,HSP70,TDF,THESE,WESTERN
008,100,120,160,177,200,956,AFTER,ANATOMICAL,CALCULATED,ESPECIALLY,INDIVIDUAL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SPECIMENS
027,029,041,095,168,169,807,882,AST,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SEPTEMBER,T2BNXM0,TREATMENT
169,22RV1,945,AEROBIC,BACKGROUND,CAP,CONCLUSION,COPYRIGHT,DU145,HIF,INC,LABEL,METHODS,OBJECTIVE,RESULTS,THESE
169,ADT,BJU,CONCLUSION,CRPCA,IAD,INSTEAD,LABEL,MEDLINE,METHODS,OBJECTIVE,PCA,RESULTS
945,946,HOWEVER,TRP,TRPM8
491,526,AAF,AFA,AFRICAN,AMERICANS,FURTHER,HBB,HOWEVER,IAF,LATINOS,SEVERAL,THERE,UYGHURS,WORLD
169,215,BACKGROUND,COPYRIGHT,EGR,FAS,FIELD,HOWEVER,INC,LABEL,METHODS,RESULTS,SIMILARLY,WILEY
009,130,169,503,642,686,706,BECAUSE,COPYRIGHT,GLEASON,INC,KIT,P504S,PCR,PSA,SCNEC,TTF,WILEY
169,945,AUC,BACKGROUND,BORTEZOMIB,CONCLUSION,COPYRIGHT,EGF,GLEASON,HEREGULIN,IIA,INC,LABEL,LAPATINIB,METHODS,REGULATION,RESULTS,ROC,WESTERN,WILEY
169,COPYRIGHT,DCI,DIAGNOSTIC,DRE,DWI,IMAGING,INC,MRI,PSA,WESTERN,WILEY
169,BIOMARKER,COPYRIGHT,COX,GLEASON,INC,KIF1A,LABEL,LOG,METHODS,OBJECTIVE,OLDER,PCR,PSA,PURPOSE,RESULTS,THESE,USING,WILEY
15A,169,203,221,222,239,23B,27B,BACKGROUND,COMPARISON,COPYRIGHT,FUNCTIONAL,HOWEVER,INC,LABEL,LNCAP,METHODS,RESULTS,WILEY
169,174,945,946,BACKGROUND,CAM,COPYRIGHT,FUNCTIONAL,INC,LABEL,LNCAP,METHODS,PCA,RESULTS,VOLTAGE,VSSCS,WILEY
049,050,062,067,072,083,094,099,169,215,241,283,292,337,361,371,407,415,ADC,ANISOTROPY,BLAND,CONCLUSION,COPYRIGHT,DTI,INC,INTRA,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBTURATOR,PURPOSE,RESULTS,WILEY
169,956,ALTOGETHER,BECAUSE,COPYRIGHT,INC,MRI,WILEY
10P14,COLORECTAL,CRC,MYC,SNP,THEREFORE
169,231,468,945,946,GRO,HMVEC,MDA,THEREFORE
120,130,215,981,CIVCO,CNR,ESE,IBA
169,239,AIM,HOWEVER,SEQUENTIAL,UROLOGICAL,ZOLEDRONIC
243,258,440,448,753,764,BRADLEY,CHARLES,ENDOCRINOL,FELDMAN,HUGGINS,MDV3100,METAB,MOSTAGHEL,NAT,ONCOL,PHARMACOL,PRACT,RES,REV,SAWYERS,SCHER
500,650,AAG,DOCETAXEL,FORTY,LABEL,METHODS,MINOR,MTD,OBJECTIVE,PURPOSE,RESULTS,SERUM
APART,BACKGROUND,CONTACT,FINDING,HOWEVER,LABEL,PATHVAR,SINCE,SUMMARY
945,UNTIL
169,ADVERSE,APC,COPYRIGHT,CSF,LTD,PAP,PHASE,SERIOUS,SIPULEUCEL,TREATMENT
012,149,518,903,GLEASON,LABEL,METHODS,MRI,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
293,478,BECAUSE,HOWEVER,PEBBLES,THESE
169,BECAUSE,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,SEVEN,UROLOGICAL
THEREFORE
194,OVERALL,POPULATION,REGISTRIES,SIR,SWEDISH,WHETHER
615,GLEASON,JARID1B,KDM3A,KDM3B,KDM4A,PHD,PLANT
946,ANEUPLOIDY,RAB21,SPATIAL,THEREFORE,THESE
032,794,AMONG,HYPOTHESIS,LABEL,METHODS,OBJECTIVE,POISSON,RESULTS
111,151,169,276,438,929,ALPHA,COPYRIGHT,FINNISH,PREVENTION,SINCE,TOCOPHEROL
180MV,500,956,AFTER,CELLS,CYS,GLEASON,GSH,INC,KNOCKDOWN,MMP,MODULATION,NADPH,PC3,PRECS,PUBLISHED
160,177,956,ALA,ASA,CARDIAC,CHANGES,CONTROL,FURTHER,LABEL,MAP,METHODS,OBJECTIVE,PURPOSE,RESULTS,RRP,TEN
101,169,233,583,905,ANOVA,ARRANGING,COPYRIGHT,HSD,PC3,SAS,SQL,TUKEY
150,151,169,301,COPYRIGHT,HOWEVER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SALVAGE,SRT
165,169,5MM,BETWEEN,COPYRIGHT,CTC,CTV,GRADE,IRELAND,LTD,PHOENIX,PTV
169,388,BACKGROUND,BOOTSTRAP,COPYRIGHT,GRADE,IRELAND,KUTCHER,LABEL,LKB,LTD,LYMAN,MATERIALS,METHODS,MRC,OBJECTIVE,PARAMETER,PURPOSE,RESULTS,THEREFORE
169,BECAUSE,COPYRIGHT,DESPITE,INC,OWING
140,169,438,472,666,BACKGROUND,CONCLUSION,CONFIDENCE,COPYRIGHT,ERE,LABEL,LTD,METHODS,OR1,OR2,RATIO,RESULTS,SNP285C,SNP285G,SNP309G,SNP309T,SP1
169,ADDITIONAL,BACKGROUND,BPH,CENTRAL,COMPARISON,CONTEXT,COPYRIGHT,FURTHER,LABEL,METABOLIC,METHODS,OBJECTIVE,OUTCOME,PATIENT,PCA,RESULTS,SEPTEMBER,SYNTHESIS,UROLOGY
169,COPYRIGHT,INC,SOCIETY,STATE,UROLOGY,WASHINGTON
AGE,CUMULATIVE,FINALLY,HRS,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OBVIOUSLY,OTHER,RESULTS,SWEDISH
001,332,443,AMONG,BETWEEN,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PFS,PURPOSE,RESULTS
000,COLON,DEFINITIVE,ERSPC,LABEL,MEDLINE,METHODS,OBJECTIVE,OBJECTIVES,OVARIAN,PCA,PSA,RANDOMIZED,RESULTS,SCREENING,TRIAL
150,751,BLOOD,GLN,HYPER,INDIA,LYS,NORTH,XERODERMA,XPD
034,085,ACEIS,ARB,CONCLUSION,LABEL,MEDLINE,METHODS,OBJECTIVE,PFS,PSA,RESULTS,SCIENCE,TEN,THERE,USING,WEB
BETWEEN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
BAYES,SEVERAL
945,HIF,IMMUNOBLOT,KNOCKDOWN,LNCAP,NDRG1
169,AKT,COPYRIGHT,EARLY,EGR,ERK,IGF,IRELAND,LTD,RESULTS,TAKEN
008,061,CONCLUSION,ERB,IMS,INC,KOLMOGOROV,LABEL,LARGE,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SMIRNOV
169,BOUND,COPYRIGHT,CTC,INC,THERE
169,COPYRIGHT,DESPITE,GLEASON,INC,PATHOLOGIC,RECEIPT,SEMINAL,THERE,TOTAL
945,FOXA1,GIVEN
169,559,619,622,BJU,CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS,THREE,UNIVERSITY,UNLABELLED
125,169,747,AMONG,ASTRO,AUTHORS,BJU,D90,GLEASON,LABEL,LEVEL,MEIER,METHODS,NEITHER,NOMOGRAMS,OBJECTIVE,PHOENIX,PREDICTIVE,PROGNOSTIC,PSA,RADIATION,RESULTS,SOCIETY,THEIR,UNLABELLED
308,473,945,954,956,ADP,AIM,AKT,CONCLUSION,FMK,INNOVATION,LABEL,METHODS,OBJECTIVE,PCA,REDOX,RESULTS,SER,THR,TREATMENT,VAD
169,22RV1,BRCA1,CLONOGENIC,DECREASED,DU145,H1299,LABEL,METHODS,MRE11,OBJECTIVE,PARPI,PC3,PRIMARY,PURPOSE,RAD51,RESULTS,SIMILAR,THESE
13Q22,215,CHINESE,CONSORTIUM,GLEASON,HOWEVER,THESE
956,BAX,GREEN,GTP,HDACS,LNCAP,MG132,THESE
946,AGE,AIC,BACKGROUND,CONCLUSION,GIVEN,GLEASON,LABEL,MATERIALS,METHODS,PCR,PSA,RESULTS,SINCE,TGF
001,700,ALTOGETHER,FURTHER,III,INHIBITORS,MDV3100,TAK,TOK
000,EVERY,GERMANY,INCREASING,PSA
100,150,160,200,AFTER,RM1,RM1CELL,THESE
101,ADP,BACKGROUND,BCL,GRADE,LABEL,MEN,METHODS,RESULTS,SECONDARY
017,169,183,734,AFTER,BACKGROUND,COPYRIGHT,DEC,EARLY,FEB,FUNDING,LABEL,LTD,MEN,METHODS,PSA,RESULTS,THEREFORE,USA
APC,BACKGROUND,BEHAVIORAL,DECREASING,END,GRADE,INFLATION,LABEL,LTD,METHODS,PROGRAM,PUBLISHED,REGISTRIES,RESULTS,SIMILAR,THERE
169,385,500,554,AIM,BACKGROUND,BMI,COLORECTAL,COPYRIGHT,FSG,INADEQUATE,LABEL,LTD,METHODS,OBESITY,OBJECTIVE,OVARIAN,RESULTS,SCREENING,TRIAL
001,169,185,240,AFTER,ANOTHER,BJU,DUTCH,EIGHT,GLEASON,INCLUSION,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,PROGNOSIS,PSA,RANDOMIZED,RESULTS,SCREENING,T2A,THESE,THOSE,UNLABELLED
169,JOURNAL,RELEASE,THESE
BEE,SEVERAL

000,CURRENTLY,PREVALENCE,TREATMENT
EMT,EPITHELIAL,HOWEVER,LUCAP35
169,946,AFFYMETRIX,COPYRIGHT,IRELAND,LTD,PCR,SINCE,USING
000,001,110,AFTER,IGF,IGFBP,OVERALL,PSA
145,169,181,COPYRIGHT,INSTITUTE,NCI,THREE,VCH,WILEY
AFRICAN,BAY,FLORIDA,FORUM,LATER,MEN,TAMPA
133,177,BACKGROUND,JANUARY,LABEL,MEDICAL,METHODS,OCTOBER,PHASE,PSA,RESULTS,UNIVERSITY,VANDERBILT,VARIOUS
ART,CBP,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SRC,TIF,TIP60
104,169,170,BACKGROUND,COPENHAGEN,COPYRIGHT,DETERMINE,EQUALLY,HEART,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SETTING,UROLOGY
169,322,547,885,AREAS,AUC,BACKGROUND,COPYRIGHT,DEVELOP,DRE,ERSPC,FURTHER,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PREDICTIVE,PREVENTION,PSA,PUBLISHED,RANDOMIZED,RCS,REPLACING,RESULTS,ROTTERDAM,SCREENING,SETTING,SIMILAR,T2B,TRIAL,UROLOGY
125,159,160,169,612,ALTOGETHER,BACKGROUND,COPYRIGHT,GLEASON,GROUP,INC,LABEL,METHODS,OVERALL,RESULTS,SCORE,T2A
001,003,110,169,193,ACUTE,CD4,COPYRIGHT,GLEASON,HIV,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PRE,PURPOSE,RESULTS
169,172,AFTER,COPYRIGHT,D9602,GIRLS,GROUP,IIA,III,INC,INTERGROUP,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,RMS,THREE
169,215,COPYRIGHT,MULLERIAN
169,241,AMONG,COPYRIGHT,IBD,INFLIXIMAB
001,002,169,APRIL,EIGHT,EXCLUDING,MEDLINE,SCIENCE,SCREENING,UROLOGICAL,WEB
105,129,169,968,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL
135,169,184,211,CAPILLARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UROLOGICAL,WHEREAS
946,954,AKT,LNCAP,PSA,WESTERN
215,324,776,ERCC1,FDR,GIVEN,MEN,NER,WHILE
CCS,DRE,LIBRARY,PCA,PSA,THERE
AFTER,ALPHARADIN,APART,DOCETAXEL,III,MDV3100
HOWEVER,MEN,NEITHER,PSA,YET
160,BPH,GIVEN,KOREA,PANAX,RG3,SINCE
02E,09E,148,177,17E,251,73E,74E,951,BACKGROUND,HGPIN,HOWEVER,IHC,INC,LABEL,METHODS,PSA,PUBLISHED,RESULTS,THERE,TMA
169,194,CMV,COPYRIGHT,COX,ERK,GIVEN,IE1,INC,MEC,POSTULATES,PUBLISHED
169,COPYRIGHT,DETERMINE,EXERCISING,EXPLORE,INC,PCS
113,169,216,BETWEEN,CONCLUSION,COPYRIGHT,INC,JANUARY,LABEL,METHODS,OBJECTIVE,RESULTS,SCREENING
001,169,246,943,BACKGROUND,BLOOD,COCHRAN,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,SETTING,SEVEN,UROLOGY,WORLD
001,004,146,169,233,BACKGROUND,BCA,BCG,CIS,CONNAUGHT,COPYRIGHT,COX,HRS,LABEL,METHODS,NMIBC,OBJECTIVE,PUBLISHED,RESULTS,SETTING,SIXTY,TUR
169,17AAG,1MM,231,24H,2DG,500NM,ALLYLAMINO,BSO,COPYRIGHT,GSH,INC,INCREASES,INHIBITORS,MDA,NAC,THESE,TRX
001,169,400,442,883,ADD,AHC,COPYRIGHT,DISCHARGE,INC,INPATIENT,LABEL,LOS,METHODS,NATIONWIDE,OBJECTIVE,OVERALL,RESULTS,RPS,SIMILARLY
169,911,AES,BACKGROUND,BETWEEN,BMI,CONCLUSION,COPYRIGHT,GRADE,INC,JANUARY,LABEL,METHODS,RADICAL,RESULTS,THESE
169,879,CHINA,CHINESE,COPYRIGHT,COX,DEBULKING,III,IRELAND,LABEL,LTD,MEIER,METHODS,OBJECTIVE,PCA,PROGNOSTIC,PSA,RESULTS,SEVEN
169,223,BACKGROUND,CONTEXT,COPYRIGHT,GIVEN,LABEL,MDV3100,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SEPTEMBER,SYNTHESIS,UROLOGY
169,BACKGROUND,COPYRIGHT,LABEL,LNI,METHODS,NETWORK,OBJECTIVE,OVERALL,PCA,PUBLISHED,RESULTS,SETTING,SIMILARLY,THEREFORE,UROLOGY
169,BACKGROUND,CONCLUSION,COPYRIGHT,DESPITE,INTERVIEW,JANUARY,LABEL,LTD,MAY,METHODS,RESULTS,RRS,USING
056,169,BETWEEN,COMBINING,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PNI,PPC,PURPOSE,RESULTS,STAGE,T1C,WILLIAM
169,500,CONCERNING,COPYRIGHT,DEPARTMENT,INC,LABEL,MAGNESIUM,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SECONDARY
150,169,207,567,576,600,AFTER,COPYRIGHT,CTV,ERB,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,THESE
141,169,221,362,BFF,COPYRIGHT,GLEASON,GRADE,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RADIATION,RADIOLOGY,RESULTS,SOCIETY,THERAPY,THESE
001,040,046,103,125,169,291,521,812,967,AFTER,APRIL,COPYRIGHT,CRT,GRADE,GROUP,INC,LABEL,MARCH,MATERIALS,METHODS,MORBIDITY,OBJECTIVE,PEARSON,PURPOSE,QOL,RADIATION,RESULTS,SCORE,SCORING,SYMPTOM,THERAPY,TREATMENT,URINARY
111,115,169,311,336,541,ACCORDING,BASED,COPYRIGHT,HOWEVER,INC,LABEL,LNI,MATERIALS,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,ROACH
100,169,177,192,339,960,COPYRIGHT,HWL,IRELAND,LABEL,LTD,METHODS,NUCLETRON,OBJECTIVE,OBJECTIVES,PTV,RESULTS,SCATTER,TPS,USING
169,COPYRIGHT,FIRSTLY,LTD,THESE
ANALYTE,ELISA,IEF,IGG,PCA,PROTEIN,PSA,QQQ,SRM
DU145,PCA,RSV,THESE,TYPICALLY,WESTERN,XRT
001,169,207,271,AFRICAN,AMERICANS,BACKGROUND,COPYRIGHT,FIFTY,GUIDELINES,LABEL,LTD,METHODS,PCA,REASONS,RESULTS,WILEY
169,COPYRIGHT,DMA,KC2,LNCAP,LNP,PSA,SILENCING
169,BACKGROUND,COPYRIGHT,EMT,ENDOCRINE,EXPRESSION,GTPASES,INC,LABEL,METHODS,RESULTS,RHO,TREATMENT,WILEY
169,946,BACKGROUND,CONCLUSION,COPYRIGHT,HEXIM,HOWEVER,INC,LABEL,METHODS,RESULTS,TGF,TRAMP,WILEY
169,945,946,COPYRIGHT,HOWEVER,INC,TAKEN,WILEY
899,ENGLISH
DESPITE,THESE,TPS,VITAMIN
114,115,169,194,BACKGROUND,CONCLUSION,COPYRIGHT,COX,GLEASON,LABEL,LTD,METHODS,PSA,RESULTS
027,063,119,169,287,403,ADT,AMONG,BJU,BMI,FINALLY,LABEL,LEVEL,MEN,METHODS,OBESE,OBJECTIVE,PROGNOSIS,PROGNOSTIC,RESULTS,THESE,UNLABELLED,USA
162,169,AFTER,AUTHORS,BJU,HISTOLOGY,HOWEVER,LABEL,METHODS,NOVEL,OBJECTIVE,PATIENT,PHS,RESULTS,THREE,UNLABELLED
001,169,ADT,BJU,CONCLUSION,DOPPLER,GLEASON,INDEX,LABEL,LEVEL,MEDICAL,METHODS,OBJECTIVE,PSA,RESULTS,THERAPY,UNLABELLED
114,141,169,176,AUTHORS,BJU,FSH,LABEL,LEVEL,METHODS,OBJECTIVE,PSA,RESULTS,THERAPY,TREATMENT,UNLABELLED
007,169,283,BJU,EPSTEIN,ERSPC,HOWEVER,LABEL,LEVEL,LOW,METHODS,OBJECTIVE,PCA,PSA,RANDOMIZED,RESULTS,SCREENING,THERAPY,THESE,UNLABELLED
167,169,303,AFRICAN,BCR,BJU,COX,GLEASON,LABEL,LEVEL,MEIER,MEN,METHODS,OBJECTIVE,PSA,RESULTS,THERAPY,UNLABELLED
001,131,169,287,AGING,AUTHORS,BALTIMORE,BJU,CLINICIANS,HOPKINS,JOHNS,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,PROGNOSTIC,PROGRAM,PSA,PSAYV,RESULTS,THERE,THESE,UNLABELLED
028,032,120,169,183,319,716,956,AMGEN,BACKGROUND,COPYRIGHT,DENOSUMAB,FUNDING,INC,LABEL,LTD,METHODS,OVERALL,PSA,RANKL,RATES,RESULTS
169,405,547,585,599,631,641,689,701,730,755,775,AUC,BJU,ECE,IBX,LABEL,METHODS,OBJECTIVE,RESULTS,SVI
001,102,164,169,565,638,AUTHORS,BJU,CONCLUSION,LABEL,MEANWHILE,METHODS,OBJECTIVE,PREDICTIVE,PSA,RESULTS,UNLABELLED
002,047,056,169,200,321,BJU,FOCAL,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PREDICTIVE,PSA,RESULTS,THESE,UNLABELLED
169,229,AUTHORS,BJU,GLEASON,LABEL,METHODS,NORWEGIAN,OBJECTIVE,PSA,RESULTS,SEVERAL,UNLABELLED
169,659,BLACKWELL,COMPLETED,DESPITE,DISCHARGE,HOWEVER,LTD,PUBLISHING,SURVIVORS
169,END,LABEL,METHODS,OBJECTIVE,PRINCIPAL,RESULTS,SIMILARLY,SUBGROUPS,THERE,TRUST,USING
945,954,AYURVEDIC,CHITRAK,EXTENSIVE,OVERALL,PLUMBAGIN,RANKL
946,AMP,CFS,MCF,SEVERAL,WHILE,XENOTROPIC

160,MALIGNANT,MARIE
DIFFERENT,PCR,TG2
4TH,5TH,SCLEROTIC
ECTOPIC,EXPRESSION,FINALLY,HOWEVER,MICRORNAS,PCR
001,083,088,169,177,231,233,272,278,339,343,355,361,471,694,943,AFTER,CONCLUSION,COPYRIGHT,COX,FEW,INSURANCE,LABEL,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SAS
169,COPYRIGHT,INC
100,99M,CONCLUSION,DETECTION,GAMMA,IHC,LABEL,LIMITED,LYMPH,MBQ,METASTATIC,METHODS,OBJECTIVE,PURPOSE,RESULTS,SLN,SUP
071,818,AUC,CONCLUSION,LABEL,METHODS,OBJECTIVE,PET,PSA,PURPOSE,RESULTS,ROC
954,ADT,AFTER,CRPCA,DESPITE,FINALLY,HOWEVER,PCA
AFRICAN,AMERICANS,ASIAN,CAUCASIANS,GSTP1,HOWEVER,OTHER,PSA,SEVERAL,SOMATIC,SOY,WESTERN
169,25D,BECAUSE,CONSISTENT,CONVERSELY,COPYRIGHT,CYP27B1,INC,VDR
169,461,ADT,AFRICAN,AUTHORS,BJU,END,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,THERAPY,TREATMENT,TREATMENTS,UNLABELLED
019,022,038,048,124,169,237,410,795,AMONG,AOR,BJU,COMPARE,LABEL,LEVEL,MEN,METHODS,OBJECTIVE,RESULTS,THERAPY,THESE,TREATMENT,UNLABELLED,WHITE
001,002,169,435,669,AUC,BJU,DIAGNOSTIC,DUE,GIVEN,GLEASON,HOWEVER,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,ROC,THERE,UNLABELLED
665,715,CHINESE,FURTHER,PCA,PSA,UTR,VHL,VON
945,AKT,BACKGROUND,BP1,CCK,CYTOTOXIC,GIVEN,HIF,HYPOXIA,LABEL,LUCIFERASE,METHODS,PCR,RESULTS,UNDER
100,231,967,ABI,AMERICANS,ASHKENAZI,BACKGROUND,CARLO,CAUCASIANS,COMMITTEE,D541E,GLEASON,LABEL,METHODS,MONTE,PRISM,PSA,R461Q,R462Q,RESULTS
120,392,AMONG,BACKGROUND,CAUSE,END,FOLLOWING,GLEASON,LABEL,METHODS,RESULTS,STAGE
CVD,LDL,LIMITED,TAG
001,003,031,064,169,476,597,622,661,844,954,ANXIETY,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,THERE,WILEY
169,COPYRIGHT,PDA,VCH,WILEY
001,007,015,169,200,BESIDES,COPYRIGHT,ERG,ETS,INC,MYC,OUTLIER,PCA,PCR,SLC45A3,TLDAS,WILEY
HOWEVER,LNCAP,PCA,SINCE
001,003,011,021,024,284,481,E26,ERG,ETS,EXPRESSION,GLEASON,INCREASING,PSA,RANDOMIZED,SCREENING,SINCE,STUDIES,THERE,TMPRSS2
169,ADDITIONAL,COMPOSITE,COPYRIGHT,DAILY,GLEASON,HOWEVER,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PUBLISHED,PURPOSE,QOL,QUALITY,RESULTS,STAGE
169,383,AFTER,CONCLUSION,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PHS,PHYSICIANS,PURPOSE,RESULTS
169,636,AFTER,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
001,002,005,033,060,100,10Y,125,169,176,ACTUARIAL,CONCLUSION,COPYRIGHT,COX,CROWN,INC,INDEX,LABEL,MATERIALS,MEIER,METHODS,NETWORK,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,UNIVARIATE
169,184,339,897,CONCLUSION,COPYRIGHT,DETROIT,END,INC,JANUARY,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
001,006,169,385,588,AUC,BACKGROUND,BASED,BECAUSE,COPYRIGHT,FEW,GLEASON,LABEL,LNI,METHODS,MVA,OBJECTIVE,OCTOBER,PCA,PUBLISHED,RESULTS,SEPTEMBER,SETTING,UROLOGY,USING,UVA
001,169,350,BACKGROUND,CONVERSELY,COPYRIGHT,CURRENTLY,GLEASON,INDEX,LABEL,METHODS,OBJECTIVE,PCA,PHI,PSA,PUBLISHED,RESULTS,SETTING,UROLOGY
169,257,AML,APRIL,BACKGROUND,CML,COPYRIGHT,CROSS,HODGKIN,IRELAND,LABEL,LTD,MEDLINE,METHODS,NHL,RESULTS
000,169,200,443,BECKMAN,BJU,CONCLUSION,COULTER,DIAGNOSTIC,FEE,INDEX,LABEL,METHODS,OBJECTIVE,PHI,PSA,RESULTS,USA
001,004,11Q13,169,17Q24,263,BJU,CAP,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,T1C
169,275,700,AMERICA,AUTHORS,BJU,BRITAIN,BRITISH,ECE,ENGLAND,EXCELLENCE,GLEASON,INSTITUTE,LABEL,LEVEL,METHODS,NORTH,OBJECTIVE,PSA,RESULTS,SVI,THERAPY,THERE,UNLABELLED
169,APC,AUTHORS,BJU,COMBINING,DIAGNOSTIC,GSTP1,LABEL,LEVEL,METHODS,NPV,OBJECTIVE,RESULTS,UNLABELLED
169,BJU,DIAGNOSTIC,HOWEVER,LABEL,LEVEL,METHODS,OBJECTIVE,PATHOLOGY,PSA,RESULTS,SIXTEEN,THERE,UNLABELLED
001,169,988,BASED,CONTINUOUS,COX,GENERAL,HRS,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,WILEY
263,EPS,EXPRESSED,PC3,PCA,SILAP
001,006,008,009,013,015,020,024,036,169,232,BJU,CONCLUSION,DISEASE,GLEASON,INSULIN,IQR,LABEL,LEVEL,METHODS,OBJECTIVE,PROGNOSIS,PSA,RESULTS,SIMILARLY,UNLABELLED
169,AMERICA,AUTHORS,BJU,BREAK,CONCLUSION,CONSENSUS,EARLY,FOCAL,GROUP,LABEL,METHODS,NORTH,OBJECTIVE,PRECISE,RESULTS,THERE,THESE,UNLABELLED
BMP,EXPRESSION,FURTHER,GPI,ID1,KNOCKDOWN,PCR,REPULSIVE,RGM,WESTERN
181,22RV1,DU145,HPV,LNCAP,SIMILAR,SOLANUM,VIRALLY
006,019,041,056,074,CD105,CD144,CD146,COMPARING,EXPRESSION,GLEASON,HOWEVER,MVD,SOLID,THERE
177,956,EGF,LDH,MICROSCOPY,MTT,WESTERN
169,AFRICAN,AMERICANS,BACKGROUND,BINDING,CONCLUSION,COPYRIGHT,GLEASON,GPX,INC,LABEL,METHODS,PROTEIN,RESULTS,THESE,WESTERN,WILEY
169,AFTER,BACKGROUND,CARBIDOPA,COPYRIGHT,INC,LABEL,LNCAP,METHODS,PSA,RESULTS,SERUM,WILEY
154,169,466,611,950,ADT,BACKGROUND,COPYRIGHT,END,LABEL,MEDICAL,MEN,METHODS,RESULTS,SOCIETY,TES
100,119,120,177,189,1ST,862,AUC,CEA,CONCLUSION,DLT,HODGKIN,KOS,LABEL,METHODS,OBJECTIVE,PBMCS,PURPOSE,RESULTS
169,947,ATM,BACKGROUND,COPYRIGHT,DDR,DISCUSSION,HSVEC,INC,LABEL,METHODS,PREVIOUSLY,RESULTS,WEE1A,WILEY
100,169,181,ADDITIONAL,BACKGROUND,COPYRIGHT,ELISA,IGG2A,INC,LABEL,METHODS,MONOCLONAL,RESULTS,WESTERN,WILEY
169,946,ADDITIONAL,BRITAIN,CD280,COPYRIGHT,DU145,ENDO180,GREAT,IRELAND,LTD,PC3,PUBLISHED,RECIPROCAL,SOCIETY,TGF,THESE,WILEY
169,300,900,AMONG,BACKGROUND,BECAUSE,COPYRIGHT,LABEL,METHODS,MICROARRAY,PBMCS,PERIPHERAL,RESULTS,SOCIETY,THERE,THESE
001,169,500,AFTER,ASTRO,BACKGROUND,CLAVIEN,COPYRIGHT,GLEASON,INDEX,LABEL,METHODS,PHOENIX,PSA,RESULTS,SALVAGE,SCORE,SOCIETY,SONABLATE,WHOLE
169,APRIL,CALIFORNIA,FRANCISCO,GLEASON,HOPKINS,HOWEVER,JOHNS,MEDICAL,MEN,SAN,SEPTEMBER,TORONTO,UNIVERSITY,UROLOGICAL
100,215,AMONG,CLEVELAND,FDG,GLEASON,HEALTHCARE,KRUSKAL,LABEL,MET,METHODS,OBJECTIVE,PET,PHILIPS,RESULTS,ROC,TUKEY
016,169,400,700,ACT,ADC,AREAS,AUC,BOARD,CONCLUSION,COPYRIGHT,HIPAA,INC,INSURANCE,LABEL,MATERIALS,MAY,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,WILEY
960,AFTER,COMPLEXES,DENSITY,DEPENDENT,DFT,FUNCTIONAL,PALLADIUM,PC3,VIS,XPY
CULTURING,TIC
BACKGROUND,DU145,LABEL,METHODS,MOLECULAR,PC3,PCA,PNP,RESULTS,SILENCING,THEREFORE
206,BPH,LABEL,METHODS,OBJECTIVE,PREDICTIVE,PSA,PURPOSE,RESULTS
117,118,151,293,370,515,566,867,903,ADT,BACKGROUND,CONCLUSION,DOC,EFFECTIVE,GLEASON,GRADE,LABEL,METHODS,PSA,RESULTS,SECONDARY,TREATMENT
078,080,160,211,235,351,436,695,732,951,BACKGROUND,BEHAVIORAL,LABEL,LEAST,METHODS,MIE,RESULTS,USING
160,183,BBP,CDK,LNCAP,MDA,PCA,TREATMENT
150,ASSESSING,BACKGROUND,LABEL,METHODS,OBJECTIVE,RESULTS,TDM
314,AMONG,EWING,HOWEVER,KAPOSIFORM,PROX1,THERE
169,557,AUTHORS,COPYRIGHT,END,ESOPHAGUS,INC,JOURNAL,PROGRAM,RESULTS,SIR,SOCIETY,THESE,WILEY
101,294,AMONG,BACKGROUND,LABEL,METHODS,NPV,PPV,RESULTS,THERE
916,945,CYP17A1,DHT,EVENTUALLY,FURTHER
169,194,ATP,CLINICALLY,COPYRIGHT,FDA,HSP90,ISSUE,PROTEIN,SEVERAL,SHOCK,SPECIAL,THERE,ULTIMATELY
956,ACE,MIXED,PDT,UNTREATED,WHILE
160,AIM,BACKGROUND,CONCLUSION,IRELAND,IRISH,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,TREATMENT
007,008,022,403,967,AUSTRALIA,BACKGROUND,CAM,LABEL,METHODS,PEARSON,RESULTS
001,169,267,506,AMICO,CAP,COCHRAN,CONCLUSION,COPYRIGHT,GERMANY,HOWEVER,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,RESULTS
019,032,037,169,613,AMONG,ANALYSING,CONTINUOUS,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,PRIMARY,PUBLISHED,RESULTS
001,003,005,008,020,165,169,192,245,AVERAGE,BACKGROUND,BLADDER,CIS,COPYRIGHT,COX,CSS,DESPITE,INC,IQR,LABEL,LVI,MATERIALS,METHODS,PROGNOSIS,RESULTS,SEVENTEEN,UCB
014,169,599,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PCV,PURPOSE,RESULTS
150,169,300,450,600,750,900,ADC,COPYRIGHT,EIGHT,EPI,FOURIER,HASTE,INC,SIEMENS
169,COPYRIGHT,H2A,IRELAND,LNCAP,LTD,MYC,PSA,TREATMENT,WHILE
169,194,240,241,99M,CONCLUSION,COPYRIGHT,LABEL,LYMPHATIC,MBQ,METHODS,OBJECTIVE,PURPOSE,RESULTS,SLN,SPECT,THREE

169,AMONG,COPYRIGHT,IMMIGRANTS,SWEDISH
141,169,298,346,375,COPYRIGHT,MOUSE,THREE,TRAMP,TRANSGENIC
169,COPYRIGHT,HISTONE,THESE
000,100,109,128,169,774,COPYRIGHT,FINNISH,NSO,PCA
BAX,BCL,KIT,SAC,WESTERN
561,956,CAM,III,PSA,SUBSEQUENT
001,160,946,CONFIDENCE,CONTROL,MASCULINE,WORRY
169,COPYRIGHT,PSA
945,954,CK2,IRELAND,LTD,NUCLEAR,PUBLISHED,SER,TBG,THR
005,015,126,323,330,BACKGROUND,GLEASON,INDIVIDUAL,JANUARY,LABEL,LNI,LNY,LRP,METHODS,OBJECTIVE,ORP,PSA,PUBLISHED,PURPOSE,RATES,RESULTS,SEPTEMBER,THERE,VARIATION
007,046,106,169,CYP,STAINED,SXR,TOTAL,WESTERN
169,AUTHORS,B7H,BACKGROUND,BRITISH,CHOLBUT,CONCLUSION,ERK,EXPRESSION,HUVEC,JOURNAL,KEY,MIGRATION,PCR,PURPOSE,RESULTS,SLN,SOCIETY,THESE,WESTERN
231,946,956,AHR,AMP,BBP,CREB1,DBP,HDAC6,MDA,MYC,PKA,WHILE
AMONG,BACKGROUND,CASTRATION,HOWEVER,LABEL,METHODS,RESULTS
100GY,169,194,1GY,3GY,ADAPTED,BACKGROUND,CARLO,CONCLUSION,COPYRIGHT,EBT,FUNCTIONAL,GAFCHROMIC,LABEL,MATERIALS,METHODS,MONTE,NUMBERS,PET,PUBLISHED,RESULTS,TCP,USING
EARLY
100,10Q23,125,132,169,182,311,330,414,940,AKT,COPYRIGHT,FAS,INC,WILEY
169,800,COMPELLING,FOLLOWING,GLEASON,POLYPHENON
100,169,AMONG,BRCA1,BRCA2,COLOMBIAN,CONCLUSION,COPYRIGHT,FIFTEEN,INC,LABEL,METHODS,MUTATIONS,OBJECTIVE,RESULTS
169,AUTHORS,BJU,CLINICIANS,CONCLUSION,DEPENDING,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,SEVERAL,UNLABELLED
169,680,AUTHORS,BJU,GIVEN,LABEL,METHODS,OBJECTIVE,PATIENT,PSA,RESULTS,UNLABELLED
010,105,121,124,142,154,169,583,AUTHORS,BJU,FINNISH,GENERAL,INDEX,LABEL,LEVEL,METHODS,OBJECTIVE,PEARSON,PRIAS,PSA,RESULTS,SCORE,SYMPTOM,THERAPY,UNLABELLED
001,003,177,498,ANXIETY,CONCLUSION,INVENTORY,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCALE,SIXTY,STATE,TRAIT
490,796,AVOIDANCE,BACKGROUND,DENMARK,FINLAND,ICELAND,LABEL,METHODS,RESULTS,WORKING
103,AUC,BACKGROUND,DRE,LABEL,MEN,METHODS,PSA,RESULTS
169,COPYRIGHT,NOVEL,SIMILARLY,SOCIETY
ANTISENSE,CELLS,LNCAP
444,CHINESE,COMPROMISE,CONNECTIVE,CYCLE,DISORDERS,IPA,METABOLISM,MYC,NETWORK,NUCLEIC,PCR,REGULATION,THESE
160,BUNGE,HOWEVER,IIA,MTT,STUDIES,TANSHINONE
AKT,DU145,IMMUNOBLOT,LNCAP,MYC,PC3,TLR

ELF,ERG,ETS,ETV,FEV,PCA,THESE,TMPRSS2
169,22911,ARO,BACKGROUND,BCR,CONTEXT,COPYRIGHT,EORTC,GIVEN,GROUP,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SOCIETY,SOUTHWEST,SYNTHESIS,THERE,THREE,TREATMENT,UROLOGY
169,194,700,APC,BACKGROUND,CONTEXT,COPYRIGHT,CRITICALLY,CSF,FURTHER,LABEL,MDV3100,MEDLINE,METHODS,OBJECTIVE,PUBLISHED,RESULTS,SIPULEUCEL,SYNTHESIS,TAK,UROLOGY
169,500,BACKGROUND,COPYRIGHT,IMA,JANUARY,LABEL,LND,METHODS,OBJECTIVE,PROCEDURE,PUBLISHED,RESULTS,SEPTEMBER,SETTING,SOCIETY
169,18F,COLLEGE,COPYRIGHT,FURTHER,LTD,MEDLINE,MRI,PUBLISHED,ROYAL,THERE
101,169,334,860,ADVERSE,AUSTRALIA,AUTHORS,BJU,CONCLUSION,CTCAE,DOSES,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,SCORE,SYMPTOM,THERAPY,THERE,UNLABELLED
162,169,AFTER,BJU,CIS,CONCLUSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNLABELLED
169,AUTHORS,BJU,DOCETAXEL,III,MDV3100,PROMISING,PSA
164,169,567,ASTRO,AUTHORS,BJU,FOCAL,LABEL,LEVEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PROLONGED,RESULTS,SELECTIVE,THERAPY,UNLABELLED,URINARY
169,COPYRIGHT,HOWEVER,INC,MRAD9,THESE,WHICH,WILEY
153,169,447,449,469,CIS,COPYRIGHT,FRACTIONAL,GLEASON,ORS,PROTECT,THERE
101,125,174,BACKGROUND,CLAVIEN,DINDO,FOCUS,IRELAND,LABEL,MATERIALS,METHODS,RALRP,RESULTS,VINCI
160,223,920,AFTER,AMACR,CONCLUSION,E12,GLEASON,HGPIN,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
169,215,COPYRIGHT,DISCARDING,GWA,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,SWEDISH,THREE,YET
169,BCL,COPYRIGHT,IRELAND,LTD,MCL,PROTOPINE
169,COPYRIGHT,HOWEVER,IRELAND,LTD
CONSISTENT,EXPRESSION,GOLGI,POLYMERASE,TAKEN
145,243,946,BONFERRONI,CHANGES,DOCETAXEL,FURTHER,HOWEVER,IFIH1,INGENUITY,PCR,RESULTS,TGF,TGFB1,THESE,WHOLE
169,AKT,ATP,COPYRIGHT,DU145,ERK,HOWEVER,INHIBITORS,LNCAP,OVERALL,PC3,PCA,PKC,ROS,RWPE1,ZNSO4
169,536,AMONG,BACKGROUND,CAG,CAUCASIAN,COPYRIGHT,GGN,INC,LABEL,METHODS,OBESITY,RESULTS,THEREFORE,WILEY
031,116,140,169,177,BACKGROUND,COPYRIGHT,CYR61,ELISA,INC,LABEL,METHODS,PCA,PKA,PREVIOUSLY,RESULTS,SERUM,THERE,THESE,WILEY
169,916,CHIPS,COPYRIGHT,CYP17A1,CYP19A1,FINALLY,GLI,HOWEVER,INC,PCR,PRSCS,PTCH1,SAG,WILEY
169,BACKGROUND,CASTRATION,CLASS,COPYRIGHT,HDL,INC,LABEL,LNCAP,METHODS,PSA,RESULTS,SCAVENGER,SILENCING,WILEY
001,002,145,169,BACKGROUND,BASED,BPH,COPYRIGHT,FUNCTIONAL,INC,LABEL,LNCAP,METHODS,MMP,RESULTS,WESTERN,WILEY
169,BACKGROUND,BPH,COPYRIGHT,CYTOGLOBIN,HGPIN,IHC,INC,LABEL,METHODS,MICROARRAY,PIA,PIN,PROSTATIC,RESULTS,SEVERAL,WILEY
169,BRITAIN,BRU,CAP,COPYRIGHT,DHT,GLEASON,GREAT,IIO,IRELAND,LDMDS,LNCAP,LTD,PCR,POL,PUBLISHED,SOCIETY,THESE,WILEY
151,ADVERSE,AES,BACKGROUND,INJECTION,LABEL,LEUPROLIDE,METHODS,PSA,RESULTS,THERE
169,692,919,991,BACKGROUND,COPYRIGHT,END,FIRST,LABEL,METHODS,MRP,NORTHEAST,ORP,RESULTS,SOCIETY,TOTAL
169,239,261,BACKGROUND,BCL,CANCERS,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,METHODS,RESULTS,TMA,WILEY
169,80KDA,BPH,COPYRIGHT,EGF,ERK,IGG,INC,PRE,THESE
169,330,369,647,AFTER,COPYRIGHT,GRADE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
100,169,311,642,BACKGROUND,BANKS,BASED,BLOOD,CMIAS,IDR,INSPECTION,LABEL,METHODS,RESULTS,WESTERN,XENOTROPIC
001,169,518,AFRICAN,BACKGROUND,CAUCASIAN,COPYRIGHT,GLEASON,INCLUSION,LABEL,MEDICAL,METHODS,PCA,PSA,RESULTS,SOCIETY
187,BPH,GLEASON,HOWEVER,NH2,PC3,PCA,SINCE,WESTERN
215,BECAUSE,CD4,CD8,DIETARY,FIFTEEN,SEO,TAKEN
AKT,CELLS,JNK,LABEL,METHODS,OBJECTIVE,PREVIOUSLY,PURPOSE,RESULTS,ROS
160,AFTER,SONOVUE,ULTRASOUND
AP1,BTG,ERK,INK4A,JMJD3,KDM6B
160,1C4D4,ADVERSE,AGS,CHINESE,CHO,CONCLUSION,DESPITE,DISEASE,HOWEVER,LABEL,METHODS,OBJECTIVE,PHASE,PRIMARY,PSA,PURPOSE,RESULTS,SECONDARY,SIMILAR,SIX
001,006,017,028,031,169,195,212,250,BER,COPYRIGHT,HAPLOTYPE,HOWEVER,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PCA,PCR,PURPOSE,RESULTS,SIMILARLY,VARIANT,VARIATIONS,XRCC1
001,108,169,177,931,956,963,CONCLUSION,COPYRIGHT,FORTY,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
160,169,ADENOVIRAL,COPYRIGHT,INC,LABEL,LM3,LNM35,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RADIATION,RESULTS,TREATMENT
169,BORIS,BROTHER,CCCTC,COPYRIGHT,CTCFL,LOWER,LTD
169,194,2000S,218,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,INTENTION,LABEL,LTD,METHODS,PSA,RESULTS,SFA
003,100,118,169,174,354,AUTHORS,BJU,CAP,CSS,GLEASON,LABEL,LEVEL,MEIER,METHODS,MFS,OBJECTIVE,PFS,PSA,RESULTS,THERAPY,UNLABELLED
169,239,946,AKT,COPYRIGHT,CURRENT,LNCAP,NED,TRAMP
169,AUTOMATIC,BLAND,CIGARETTE,CONCLUSION,COPYRIGHT,FURTHER,GFM,HOWEVER,INC,IPL,LABEL,MATERIALS,METHODS,OBJECTIVE,PEARSON,PURPOSE,RESULTS,XVI
CAP,FDA,HOWEVER,INC,PUBLISHED,WHILE
EXCRETION,PHASE,TOTAL,ZIBOTENTAN
000,169,408,AUC,BACKGROUND,CONCLUSION,COPYRIGHT,DAVID,FUNCTIONAL,INC,LABEL,METHODS,PSA,RESULTS,ROC,SERUM,WILEY
FURTHER,ROS,TYR
100,175,176,189,190,233,355,362,364,365,366,368,375,383,388,ADS,BACKGROUND,CFT,CLEAR,COLLEGE,CONCLUSION,EMERGENCY,LABEL,METHODS,RESULTS
103,166,COMMISSION,CONCLUSION,LABEL,METHODS,NTCPS,OBJECTIVE,ORGAN,PROTECTION,RESULTS,THERE
169,257,ADT,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,DEPRESSION,GDS,GERIATRIC,LABEL,METHODS,RESULTS,SCALE,SOCIETY,THREE
001,167,169,215,312,759,BACKGROUND,COPYRIGHT,INPATIENT,INSURANCE,LABEL,METHODS,NATIONWIDE,NIS,OVERALL,PRIVATE,PROJECT,RESULTS,RPS,SIMILARLY,SOCIETY
149,169,177,710,ADT,AFTER,BACKGROUND,BECAUSE,COPYRIGHT,CSS,FURTHER,HOWEVER,LABEL,METHODS,PHOENIX,RESULTS,SOCIETY,THERE,UNIVERSITY
BACKGROUND,ETS,LABEL,MECHANISMS,METHODS,RESULTS,SEMINAL
160,486,956,BCL,DR5,LOW,RU486,TAKEN,TRAIL
160,198,ADT,AFTER,ANXIETY,BACKGROUND,BRIEF,CRF,DEPRESSION,EIGHT,FATIGUE,INVENTORY,LABEL,MANAGEMENT,METHODS,QUALITY,RESULTS,SCALE,SCORE,SYMPTOM,THERE,TREATMENT
169,181,22RV1,COPYRIGHT,HDAC1,HDAC3,HDACS,INC,STUDIES,TREATMENT,WILEY
945,946,BASED,CARLO,CATCHESIDE,HENCE,LEA,MINERBO,MONTE,POISSON,POISSONIAN,SEVERAL,TCP,THERE,THESE,TYPICALLY
001,169,188,635,AGE,AUC,BACKGROUND,COPYRIGHT,DETECTION,DRE,EARLY,INSTITUTE,LABEL,LIMITED,METHODS,MODEL,NETWORK,PREVENTION,PSA,RESULTS,SOCIETY,TRIAL,UNDER
133,BACKGROUND,FIBROBLAST,GLEASON,LABEL,LNCAP,METHODS,MTT,RESULTS,THESE,TISSUES
800,BACKGROUND,BECAUSE,IAS,LABEL,MEN,METHODS,PSA,RESULTS
169,464,918,AWARENESS,BACKGROUND,COPYRIGHT,END,LABEL,METHODS,RECORDS,RESULTS,SOCIETY
015,169,174,AN3CA,COPYRIGHT,FURTHER,INC,KLE,LABEL,METHODS,NANOSTRING,OBJECTIVE,OBJECTIVES,PCR,RESULTS
169,1960S,947,COPYRIGHT,INC,NIGELLA,ROS,STAT3
169,BIOMETRIC,SOCIETY
136,169,945,AUTHORS,BLACKWELL,FOUNDATION,HIF,JOURNAL,LNCAP,LTD,MOLECULAR,MST,PUBLISHING,STAT3,THESE
145,AICAR,AMP,HENCE,INCUBATION,INHIBITION,JNK,JUN,NADPH,ROS,VAS2870
032,125,169,239,512,737,APRIL,BACKGROUND,CONTEXT,COPYRIGHT,D9901,EVALUATION,HEADING,JANUARY,LABEL,MEDICAL,METHODS,NOTABLY,OBJECTIVE,OCTOBER,OTHER,PCA,PSA,PUBLISHED,RESULTS,SUBJECT,SYNTHESIS,THREE,TREATMENT,UROLOGY
169,BACKGROUND,CONTEXT,COPYRIGHT,CURRENT,DIAGNOSIS,DIFFUSION,LABEL,MEDLINE,METHODS,MRI,OBJECTIVE,PUBLISHED,RESULTS,SYNTHESIS,UROLOGY
169,194,BACKGROUND,CONCLUSION,COPYRIGHT,FINNISH,HOWEVER,LABEL,LTD,METHODS,RESULTS
001,169,200,701,954,AUTHORS,BJU,LABEL,LEVEL,METHODS,MPP,OBJECTIVE,PSA,RCT,REDUCTION,RESULTS,TPB,UNLABELLED,VAS
169,246,ANGELES,AUTHORS,BJU,CALIFORNIA,DISEASE,INDEX,LABEL,LEVEL,LOS,METHODS,OBJECTIVE,PCI,RESULTS,THERAPY,UNIVERSITY,UNLABELLED
169,453,ANOTHER,ASSESSMENT,AUTHORS,BJU,COMPOSITE,CONCLUSION,HOWEVER,INDEX,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,THERAPY,UNLABELLED
169,CONVERSELY,COPYRIGHT,HOWEVER,IIA,LNCAP,LTD,PSA,SER,TAKEN,TANSHINONE,WILEY
946,BMP,FINALLY,GST,HIC,ID1,LIM,MH2,MYC,PC3,SMAD1,SMADS
946,LMTK2,SMAD2,TGF
945,ACINI,KI16425,LPA,LPAR1,RHO,ROCK1,S1P
156,169,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PBT,PUBLISHED,PURPOSE,QOL,RESULTS,SCORE,SOCIETY,SYMPTOM,VAS
CONCLUSION,LABEL,METHODS,OBJECTIVE,RESULTS
HOWEVER,MRI,PRE
001,169,AUTHORS,BJU,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,SEPTEMBER,THERAPY,UNLABELLED,WITHOUT
001,003,009,169,285,940,BJU,CONCLUSION,GLEASON,HENCE,LABEL,LEVEL,METHODS,NHMRC,OBJECTIVE,PATHOLOGY,PROGNOSIS,PSM,RESULTS,SOCIETY,UNLABELLED,UROLOGICAL,VARIOUS
00024,001,100,169,ACCUPSA,AUTHORS,BCR,BJU,COX,DIAGNOSTIC,HOPKINS,JOHNS,LANGONE,LEVEL,MEDICAL,MEIER,METHODS,NADIR,OBJECTIVES,OVERALL,PSA,RESULTS,SPECIMENS,THOSE,UNIVERSITY,USING
001,057,058,100,117,160,169,177,ADT,AUTHORS,BETWEEN,BJU,CONTROL,GLEASON,LABEL,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,OVERALL,PSA,RESULTS,SEPTEMBER,SERUM,TREATMENT
001,003,049,169,ASIAN,AUTHORS,BJU,BMI,CONCLUSION,GROUP,LABEL,METHODS,OBJECTIVE,OPERATING,RESULTS,RETRO,UNLABELLED
133,169,183,AUTHORS,BJU,GLEASON,HOWEVER,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THEREFORE,UNLABELLED
169,COGNITIVE,COPYRIGHT,INTERVIEWS,LABEL,LTD,METHODS,OBJECTIVE,PCA,RESULTS,THERAPY,WILEY
BLM,CENTRAL,NOW
10A,11A,12A,13A,13B,14A,14B,169,181,BASED,CNS,CONVERSELY,COPYRIGHT,EIGHT,FURTHER,MICHAEL,VCH,WILEY
BACKGROUND,BASED,CURRENT,DISCUSSION,LABEL,METHODS,RESULTS,STUDIES,URINARY
169,COPYRIGHT,IRELAND,LTD
100,440,ACCORDING,ALP,BACKGROUND,BETWEEN,COX,DRE,EOD,GLEASON,LABEL,METHODS,PSA,RESULTS,T1C,VARIOUS
159,BACKGROUND,JANUARY,LABEL,METHODS,MORTALITY,MULTILEVEL,RESULTS
MAK,TAKEN,TDY
169,201,343,395,441,472,507,567,601,619,693,BACKGROUND,BPH,CONCLUSION,COPYRIGHT,HP1,LABEL,METHODS,OVERALL,OXIDATIVE,PCA,PSA,RESULTS,SERUM
169,CASTRATION,COPYRIGHT,CYP17,CYTOCHROME,DESPITE,HSP,III,IRELAND,LTD,MDV3100,SEVERAL
015,043,046,169,516,ASTRO,COPYRIGHT,COX,EPPENDORF,HYPOXIA,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PHOENIX,PURPOSE,RADIATION,RESULTS,SOCIETY
103,125,126,169,177,775,779,840,ABSENCE,AMONG,BECAUSE,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,T2A,T2B
008,169,197,550,586,COPYRIGHT,C_INC,GRADE,INC,ITALIAN,LABEL,MATERIALS,METHODS,M_INC,NOMOGRAMS,OBJECTIVE,PURPOSE,P_INC,RADIATION,RESULTS
113,134,146,393,ADVERSE,AGREEMENT,CONCLUSION,CTCAE,GYN,INTRACLASS,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
160,516,BACKGROUND,ENGLISH,GREATER,HISPANICS,LABEL,LATINOS,METHODS,NEEDS,OVERALL,RESULTS,SHORT,SPANISH,SUPPORTIVE,SURVIVORS,THERE,THESE
169,COPYRIGHT,DORMANT,LTD,ONGOING
001,169,C57BL,CAP,COPYRIGHT,CPG,CTL,FDA,HCIRNKSVI,INC,INDUCTION,LABEL,MATERIALS,METHODS,NOVEL,OBJECTIVE,ODN,PSA,PUBLISHED,RESULTS,SIPULEUCEL,THEREFORE,TREATMENT
033,148,169,178,208,214,AMONG,BACKGROUND,BOARD,COPYRIGHT,COX,ELBOW,INC,JOURNAL,LABEL,MATERIALS,METHODS,MOSBY,PATHOLOGIC,PUBLISHED,RESULTS,SURGERY
004,100,169,177,313,ADVERSE,APRIL,AUTHORS,BJU,CONCLUSION,COX,EVENT,GLEASON,GRADE,HDR,LABEL,LEVEL,METHODS,OBJECTIVE,PSA,RESULTS,THERAPY,UNLABELLED
BACKGROUND,HOWEVER,LABEL,RESULTS
333,448,640,CONCLUSION,EPI,KVI,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE
100,BACTERIAL,CPE,EXPRESSION,MCF,SKMEL
160,2GLCN,956,CONCLUSION,GLUCOSE,LABEL,METHODS,OBJECTIVE,PC3,PROCEDURES,PURPOSE,RESULTS,SIMILARLY
000,173,177,239,256,270,338,500,736,ADC,CNR,CONCLUSION,DWI,FORTY,IMAGING,KEY,LABEL,METHODS,MRI,OBJECTIVE,RESONANCE,RESULTS
003,103,160,210,EXPRESSION,GLEASON,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THERE,THYMIDINE,XPA
001,169,APOPTOSIS,BACKGROUND,BAD,COPYRIGHT,DU145,INC,LABEL,LNCAP,METHODS,PC3,RESULTS,WESTERN,WILEY
100,177,AHT,BACKGROUND,CRT,FIFTY,JANUARY,LABEL,METHODS,PHOENIX,PSA,RESULTS,SEVENTY,SHT,T1C,WESTERN
169,221,410,AUTHORS,BACKGROUND,BJD,BRITISH,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,REGARDING,RESULTS
BACKGROUND,CONCLUSION,END,INCIDENCE,LABEL,METHODS,MORTALITY,OVERALL,PSA,RESULTS,TEN,USA,USING
169,334,349,503,820,BACKGROUND,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,MATERIALS,METHODS,OVERALL,PCA,PSA,RESULTS,THREE,WILEY
BACKGROUND,BECAUSE,FORTY,HIV,LABEL,METHODS,MLV,RESULTS,THESE,XENOTROPIC
CONSEQUENT,H1299,XXIII
100,169,194,ANTIGEN,BPH,COPYRIGHT,GLEASON,INC,OPN,PCA,PCR,PROSTATIC,PSA,ROC,SCORE
100,102,177,BACKGROUND,CONCLUSION,DOSIMETRIC,HOWEVER,INTENSITY,LABEL,METHODS,PTV,REPORTS,RESULTS,SEPTEMBER,SEVENTY,V40,V60,V70
169,171,177,956,AUC,CAP,COPYRIGHT,EIGEN,GABOR,HOWEVER,IMAGING,LTD,MAWERIC,MRI,MRS,RESONANCE,RESULTS,WILEY
146,224,AFTER,ATN,BACKGROUND,COX,HOWEVER,LABEL,MEIER,METHODS,MFS,PSA,PSADT,RESULTS,SEVERAL
BECAUSE,CFS,HOWEVER,QN10S,XENOTROPIC,XMRVS
169,194,AEU,CANCERLIT,COPYRIGHT,FACTORS,FURTHER,INDEX,LABEL,LITERATURE,MEDLINE,METHODS,OBJECTIVE,PREVENTION,PRIMARY,PUBLISHED,RESULTS,SCIENCE,WESTERN
169,236,342,AUTHORS,HENCE,INFECTION,INFECTIOUS,SOCIETY
145,A2780,MTX
LABEL,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS
053,169,261,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,METHODS,PSA,RESULTS,TMA,WILEY
169,AKT,BACKGROUND,COPYRIGHT,INC,LABEL,LNCAP,METHODS,PCR,PSA,R1881,RESULTS,SILENCING,SIMILAR,SRC,WILEY
169,264,945,947,954,AUTHORS,BACKGROUND,BRITISH,IKK,INHIBITION,JOURNAL,KEY,LABEL,METHODS,OBJECTIVE,PURPOSE,RANKL,RAW,RESULTS,SOCIETY
095,169,COPYRIGHT,CURRENT,LTD,PHASE,THESE,THREE,WILEY
001,034,115,169,177,ADJUSTMENT,AFTER,BACKGROUND,BRIEF,COPYRIGHT,COUPLES,INDEX,INVENTORY,LABEL,METHODS,NEITHER,RESULTS,SCALE,SOCIETY,SYMPTOM
169,946,BASED,COPYRIGHT,COULD,DICKKOPF1,HOWEVER,WNT
001,012,016,116,169,303,482,761,ADT,AIP,COPYRIGHT,COX,GLEASON,MEIER,PCA,PCR
007,025,033,169,389,AUTHORS,BJU,C30,CHANGES,CONTINENCE,LABEL,LEVEL,LOOKING,METHODS,OAB,OBJECTIVE,PERSISTENT,QLQ,RESULTS,SOCIETY,THERAPY,TREATMENT,UNLABELLED,WHEREAS
169,ADT,AUTHORS,BJU,CRUCIALLY,HOWEVER,PUBLISHED,THERE
169,BLACKWELL,LTD,PUBLISHING
BACKGROUND,JAPAN,LABEL,METHODS,PREVENTIVE,PSA,RESULTS
160,496,885,CAUCASIAN,HOWEVER,INCREASED,MAY,OVERALL,STRATIFIED
022,160,AFTER,GLEASON,GSTP1,HOWEVER,LABEL,METHODS,MSP,OBJECTIVE,PCA,PCR,PSA,RESULTS,THESE
BACKGROUND,CONCLUSION,EARLY,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,SYSTEMATIC
007,102,167,227,BACKGROUND,CONCLUSION,GENERAL,HRQOL,LABEL,METHODS,NHS,OBJECTIVE,RESULTS,SHORT,STUDIES
102,169,194,432,526,642,BACKGROUND,BETWEEN,COPYRIGHT,COX,CROWN,DISCHARGE,LABEL,MEN,METHODS,OBJECTIVE,PCA,PUBLISHED,RESULTS,SETTING,TED
169,203,CONCLUSION,COPYRIGHT,GIVEN,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PHYSICIANS,RESULTS,THEREFORE,THEREIN
001,010,012,169,CONCLUSION,COPYRIGHT,GLEASON,LABEL,LTD,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SCORE,SRT,STUDIES,UNIVARIATE
169,223,239,COPYRIGHT,III,LTD,PHASE,PUBLISHED,SINCE
100,140,169,177,57S,600,BRITISH,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
001,003,169,330,AFRICAN,AOR,BETWEEN,CONCLUSION,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PCA,PENDING,PSA,PURPOSE,RESULTS
10000,129,169,194,2171287,745,BACKGROUND,COPYRIGHT,CPA,JANUARY,LABEL,LTD,METHODS,NETWORK,ORS,RESULTS,THERE,WHILE
013,029,169,AFTER,BACKGROUND,FEW,LABEL,LSCCS,METHODS,RESULTS,THERE,WILEY
001,BACKGROUND,CONCLUSION,FIFTY,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PURPOSE,RESULTS,WHILE
BECAUSE,CAG
127,169,174,AFTER,ASAPS,AUC,AUTHORS,BJU,DIAGNOSIS,DRE,FINALLY,HGPIN,HOWEVER,LABEL,LEVEL,METHODS,NPV,OBJECTIVE,PAB,PCA,PPV,PSA,RESULTS,TOTAL,UNLABELLED,WHILE
001,002,031,150,169,383,AUTHORS,BJU,DIAGNOSTIC,DOPPLER,GLEASON,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNLABELLED
001,120,169,257,715,AUTHORS,BETWEEN,BJU,CANCERS,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS
169,18F,CAP,COPYRIGHT,GLUT1,GLUTS,HGPIN,HOWEVER,INC,LOW,WILEY
100,101,104,125,160,169,5GY,BLADDER,COPYRIGHT,FIFTEEN,GROUP,INC,LABEL,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RADIATION,RESULTS,SOCIETY,SRP,THERAPY,UDS
100,121,169,258,945,COPYRIGHT,HOWEVER,INC,LABEL,LTURP,MATERIALS,METHODS,OBJECTIVE,PCA,PLANNED,PUBLISHED,PURPOSE,RESULTS,SCORE,SOCIETY,SYMPTOM
126,127,150,169,194,492,COPYRIGHT,DOSIMETRIC,INC,INTERPLANT,MEDICAL,PUBLISHED
169,COPYRIGHT,ERG,GLEASON,HOWEVER,INC,TMPRSS2,USING
169,954,BCL,BECAUSE,COPYRIGHT,COX,CXCR4,IAP,MMP,OVERALL,WESTERN,WHETHER,ZYFLAMEND
031,ADVANCING,AFFAIRS,ANGELES,BACKGROUND,BEACH,CENTERS,CONCLUSION,GREATER,LABEL,LOS,MEDICAL,MEN,METHODS,OBJECTIVE,RESULTS
160,175,665,BMI,CONVERSELY,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,PSM,PURPOSE,RESULTS,RRP,SERUM
231,474,956,ACTIVATION,ANNEXIN,APOPTOSIS,BAX,BCL,DM102,MCF,MDA,NOE,ROS,THESE
239,271,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PANCREATIC,RECORDS,RESULTS
161,165,589,872,AGE,LABEL,METHODS,MINNESOTA,OBJECTIVE,OLMSTED,OPTIMAL,OUTCOME,PSA,QALYS,RESULTS,SOURCES
001,169,325,712,931,AIM,BACKGROUND,BECAUSE,BETWEEN,CONCLUSION,INDEX,LABEL,MARCH,METHODS,OBJECTIVE,OUTCOME,PEARSON,RESULTS,SOCIETY,THERE
169,181,786,AUTHORS,BASED,BJU,GLEASON,INT,LABEL,LEVEL,METHODS,MRI,NOMOGRAMS,OBJECTIVE,OBJECTIVES,PCA,PREDICTION,PROGNOSIS,PSA,RESULTS,T1C,T2A,THERE,UNLABELLED
001,169,174,257,269,368,443,ANXIETY,AUTHORS,BETWEEN,BJU,CALCULATOR,COMPLIERS,DECISIONAL,DIAGNOSTIC,DUTCH,ERSPC,INVENTORY,LABEL,LEVEL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RANDOMIZED,RESULTS,SCALE,SCREENING,SHORT,STATE,TRAIT,UNLABELLED,UROLOGISTS
001,002,006,108,148,151,169,189,AUTHORS,BJU,CONCLUSION,COX,FURTHER,GLEASON,LABEL,LEVEL,MEIER,METHODS,OBJECTIVE,PROGNOSIS,RESULTS,TGG,UNIVARIATE,UNLABELLED
169,AUTHORS,BJU,CONCLUSION,KEY,LABEL,METHODS,OBJECTIVE,RESULTS,THESE,TREATMENTS,UNLABELLED
001,169,ADT,AFTER,AUTHORS,BJU,FURTHER,LABEL,LEVEL,MEN,METHODS,OBJECTIVE,RCT,RESULTS,THERAPY,UNLABELLED
005,007,025,169,174,175,AUTHORS,BJU,COMPOSITE,HRQOL,INDEX,LABEL,LRP,METHODS,OBJECTIVE,RESULTS,SCORE,SUBSCALES,SUMMARY,THERE,URINARY,USING
0GY,169,177,AUTHORS,BJU,CONCLUSION,HDR,HORMONE,JANUARY,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEVEN,T1C,TEN
001,003,078,100,105,169,373,AUTHORS,BJU,LABEL,LEVEL,METHODS,OBJECTIVE,RESULTS,THERAPY,UNLABELLED
169,181,916,945,ADT,BACKGROUND,COPYRIGHT,DHT,DU145,INC,LABEL,LNCAP,METHODS,MTT,PCA,PCR,PSA,PTS33,RESULTS,TMPRSS2,WESTERN,WILEY
169,AKT,BACKGROUND,CLONING,CONCLUSION,COPYRIGHT,DU145,INC,LABEL,LNCAP,METHODS,PCR,RESULTS,WILEY
001,024,068,169,212,499,661,BACKGROUND,CONTROL,COPYRIGHT,CYTOKINES,DBC,DOCETAXEL,FURTHER,INC,LABEL,METHODS,MST,PPV,RESULTS,WILEY
169,26S,BACKGROUND,CLONOGENIC,COPYRIGHT,DU145,INC,LABEL,METHODS,PROTEASOME,RESULTS,WHILE,WILEY
169,BACKGROUND,COPYRIGHT,DOWNSTREAM,HOWEVER,INC,LABEL,METHODS,MMP,MTT,PCR,RESULTS,SEVERAL,THEREFORE,WESTERN,WILEY,XENOTROPIC
002,169,764,775,COPYRIGHT,IGF,ORS,SERUM
169,257,946,AFTER,COPYRIGHT,HOWEVER,LABEL,LTD,MEN,METHODS,OBJECTIVE,RESULTS,WILEY
AFTER,GRA,GRB,LABEL,MAB,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,QOL,RESULTS,TESTS,TIP,TOP,TREATMENT
AMONG,BACKGROUND,FURTHER,LABEL,METHODS,PSA,RESULTS,TTP
ASPIRATION,DIAGNOSES,FRESH,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SUTURELESS,THREE
BPH,CHANGES,PCA,SEVERAL
125,169,427,COMMISSION,COPYRIGHT,EARLY,HOWEVER,INC,JAPAN,LABEL,MATERIALS,METHODS,OBJECTIVE,PROTECTION,PUBLISHED,PURPOSE,RESULTS,SEPTEMBER,SOCIETY
001,103,125,125GY,140GY,144GY,169,192,715,COPYRIGHT,COX,GLEASON,INC,IRIDIUM,LABEL,MATERIALS,METHODS,OBJECTIVE,PALLADIUM,PSA,PUBLISHED,PURPOSE,RESULTS,RFS,SOCIETY
001,003,026,033,102,110,136,169,246,BETWEEN,BMI,CAP,COPYRIGHT,CRUDE,DRE,GLEASON,INC,ITALY,LABEL,MATERIALS,MEN,METHODS,OBESITY,OBJECTIVE,PSA,RESULTS,SIX
169,194,COPYRIGHT,DOSIMETRIC,HOWEVER,INC,MEDICAL,PTV,PUBLISHED,SEVEN,V20,V70
169,COPYRIGHT,III,IRELAND,LTD,THEREFORE,TREATMENT
169,COPYRIGHT,FUS,LTD,MRI
155,156,169,273,CONCLUSION,COPYRIGHT,DRE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,UNIVARIATE
001,002,169,COPYRIGHT,CROWN,DISCUSSION,EBR,HDR,LABEL,LTD,METHODS,OBJECTIVE,ONTARIO,PUBLISHED,PURPOSE,QOL,RESULTS,THEREFORE
169,BACKGROUND,COPYRIGHT,ERAL1,GENERAL,ISSUE,LABEL,MAJOR,MAMMALIAN,METHODS,SCOPE,SPECIAL
GCS,IMPORTANT,THESE
169,329,BACKGROUND,CASTRATION,CGH,COPYRIGHT,CRPCS,ECTOPIC,FAM110B,INC,LABEL,LAS1L,METHODS,MYC,RESULTS,SIX,WILEY,YIPF6
169,APOPTOSIS,BACKGROUND,COPYRIGHT,GRB,INC,INHIBITION,LABEL,LNCAP,METHODS,RESULTS,THESE,WILEY
169,BACKGROUND,BINDING,BPH,CONCLUSION,COPYRIGHT,GHRELIN,GHS,IMAGING,INC,LABEL,LNCAP,METHODS,PCA,PIN,RESULTS,WILEY
169,AFTER,AREAS,AUC,BACKGROUND,BTA,CEA,COPYRIGHT,EGF,FORWARD,LABEL,METHODS,NMP22,PPP,RESULTS,ROC,SOCIETY
AAV,BAC,EBNA1,EPSTEIN,GIVEN,ITR,T2HEA,THESE
050,100,169,194,ACUTE,ADVERSE,APRIL,BETWEEN,COPYRIGHT,EVENT,GRADE,HDR,INC,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,VERSION
169,194,COPYRIGHT,EDC,ENDOCRINE,ERS,FURTHER,IRELAND,LTD,SINCE,THESE
APRIL,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,REGARDING,RESULTS
042,048,178,500,ADC,AUC,DIFFUSION,DWI,GLEASON,KEY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PEARSON,RESULTS,ROC
945,946,DECREASED,DGS,FGF,GLEASON,IGF,MMP
950,ACCRA,AFRICAN,AMERICANS,BACKGROUND,BPH,DRE,FURTHER,GHANA,HOWEVER,LABEL,METHODS,PSA,RESULTS,SCORE,SYMPTOM,WESTERN
ADT,COUPLES,THESE
OVERALL,PREVIOUSLY,RETRACTION,THESE
BACKGROUND,FIFTY,GLEASON,HENCE,HOWEVER,LABEL,MEDICAL,METHODS,OBJECTIVE,OVERALL,PSA,RADICAL,RESULTS,SIXTY,STAGE
215,AT6,AZI,LN4,ODC,PCR,THESE
100,ARBSS,CRPCS,FINALLY,LNCAP,SNAI2,ZWINT
947,948,ACT,HOWEVER,OEC,TCR,THESE
112,169,179,192,697,CONCLUSION,COPYRIGHT,CROWN,ENGLAND,LABEL,LTD,METHODS,OBJECTIVE,OVERALL,PUBLISHED,PURPOSE,RESULTS
004,134,169,397,467,967,COPYRIGHT,CSM,CUMULATIVE,DESPITE,END,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,USING
106,169,BACKGROUND,CAP,COPYRIGHT,DCE,DIAGNOSTIC,DYNAMIC,FLASH,GERMANY,GLEASON,IMAGING,INC,LABEL,MEN,METHODS,MRI,OVERALL,PITTSBURG,PSA,RESULTS,SIEMENS,THREE,TIM
169,CAP,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,RESULTS,ROBOT
000,026,200,703,858,AGE,GLEASON,HENCE,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEK,SWEDISH,USING
169,257,330,BACKGROUND,COPYRIGHT,HOWEVER,LABEL,LTD,MATCHED,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,STRATEGIES,THERE,WILEY
169,AFRICAN,BACKGROUND,BLACK,CARIBBEAN,CONCLUSION,COPYRIGHT,ENGLISH,FURTHER,LABEL,LTD,METHODS,NON,RESULTS,USA,WHITE,WILEY
169,193,COPYRIGHT,IRELAND,IRISH,LTD,PARTICULAR,SCREENING,WILEY
DISCUSSION,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PAGET,RESULTS
001,004,009,016,037,177,199,299,311,349,508,OPG,SERUM
ENHANCING,FINALLY,PCA,TAKEN
105,108,BACKGROUND,CONCLUSION,E7389,GRADE,LABEL,MEN,METHODS,PSA,RESULTS,TREATMENT
169,CONCLUSION,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PHYSICIANS,REQUESTING,RESULTS
001,007,148,169,AFRICAN,AFTER,AMERICANS,BACKGROUND,BETWEEN,CAUCASIAN,CAUCASIANS,COPYRIGHT,HEALTHCARE,INDEX,INPATIENT,LABEL,METHODS,MIRPS,NATIONWIDE,NIS,ORP,PROJECT,RESULTS,SOCIETY
BKPYV
001,007,115,169,554,ADVERSE,AHC,AUTHORS,BJU,INPATIENT,LABEL,LEVEL,METHODS,NATIONWIDE,OBJECTIVE,ORP,PROJECT,RESULTS,SIMILARLY,THERAPY,UNLABELLED,USA
169,AUTHORS,BJU,HBO,LABEL,METHODS,OBJECTIVE,RESULTS
001,005,017,027,029,048,169,201,262,298,684,AUTHORS,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,SIMILARLY,SURROGATE,TUMOURS,UNDER
001,012,013,031,041,108,115,147,154,169,262,AUTHORS,BJU,DIAGNOSTIC,HGPIN,LABEL,LEVEL,METHODS,OBJECTIVE,OVERALL,PBX,PCA,PIN,PLURIFOCAL,PSA,RESULTS,UNLABELLED
169,418,AUTHORS,BJU,CIS,CONFIDENCE,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,PARTNERED,RESULTS
169,AUS,AUTHORS,BETWEEN,BJU,LABEL,METHODS,OBJECTIVE,OCTOBER,QOL,RESULTS,WHETHER
111,169,233,5531DELTT,BRCA1,BRCA2,COSTA,JOS,MUTATIONS,OTHER,RICAN,SAN,THESE,WILEY
AFFAIRS,ATLANTA,BACKGROUND,GLEASON,JANUARY,LABEL,MEDICAL,MEN,METHODS,ORS,PSA,RESULTS,SEVERAL
00001,005,177,ADT,BMD,CANCERLIT,MEDLINE,NNT,NTT,SOCIETY,TREATMENT,ZOLEDRONIC
BINDING,HOMOLOG,KLF,KRUPPEL,ZESTE
169,1CM,364,5MM,6MM,8MM,COPYRIGHT,IRELAND,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,SEVENTEEN,THREE,V65
169,603,COPYRIGHT,DTX,INC,LABEL,NPS,PCL,PEO,UNASSIGNED,UNLABELLED
169,194,COPYRIGHT,INC,MEDICAL,PHILIPS,PINNACLE3,PUBLISHED,RESULTS
169,177,4NG,954,AIM,BPH,CONCLUSION,COPYRIGHT,DIFFERENT,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SAS,SERUM
100,169,200,956,COPYRIGHT,HOWEVER,INC,TAKEN,THESE,WILEY
000,012,169,191,239,241,278,323,AUTHORS,BJU,COX,END,LABEL,MEIER,METHODS,OBJECTIVE,RESULTS,SCC,USING
169,693,BJU,CLAIM,COMPARING,DESPITE,END,GLEASON,GOVERNMENT,LABEL,MEN,METHODS,OBJECTIVE,PCA,RESULTS,WORKS
169,ADT,AUTHORS,BJU,CONTROL,CPS,DECISIONAL,DRS,ENGLISH,HOT,LABEL,LEVEL,METHODS,NEEDS,OBJECTIVE,RESULTS,SCALE,SEVERAL,SWD,THERE,THREE,TREATMENT,UNLABELLED
169,365,ADT,AFTER,AUTHORS,BJU,CHINESE,CONCLUSION,COX,INSURANCE,LABEL,METHODS,OBJECTIVE,RESULTS,THERE,THESE
116,128,169,515,AUTHORS,BJU,BPH,CONCLUSION,HOWEVER,INDEX,LABEL,LEVEL,LOWER,METHODS,OAB,OBJECTIVE,QOL,RESULTS,SCORE,SYMPTOM,THERAPY,TRACT,UNLABELLED,URINARY
000,163,169,AUTHORS,BJU,CONCLUSION,COSTS,DEGARELIX,EXCELLENCE,INSTITUTE,LABEL,METHODS,OBJECTIVE,OUTCOME,QALYS,RESULTS
106,169,AUTHORS,BJU,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SCORE,SYMPTOM,THERE
169,176,AUTHORS,BJU,CAP,CASPASE,LABEL,LNCAP,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,VITAMIN
169,174,175,348,AUTHORS,BJU,EPSTEIN,FIRST,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,T1C,T2A,T2C,T3A,T3B,TREATMENT
142,155,169,914,AUTHORS,BJU,INDEX,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
169,APRIL,AUTHORS,BETWEEN,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEPTEMBER,THERE
001,169,444,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,METHODS,RESULTS,WILEY
105,109,122,169,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,MEIER,METHODS,RESULTS,SAMPLES,THERE,WILEY
ID4,LABEL,METHODS,OBJECTIVE,PCR,PURPOSE,RESULTS
100,143,145,15A,169,191,206,218,916,ABI,BACKGROUND,CAP,CONCLUSION,COPYRIGHT,HGPIN,INC,ISOLATION,LABEL,METHODS,MICRO,MIX,PCR,RESULTS,REVERSE,RNU43,SIXTY,THROUGH,UNIVERSAL
169,877,AUTHORS,BJU,CONVERSELY,END,FINALLY,HOWEVER,LABEL,LNI,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,OVERALL,PLNDS,RESULTS
004,169,173,494,598,667,717,764,AMICO,AUTHORS,BFS,BJU,BOARD,CPE,CSS,EARLY,EPE,ERA,GLEASON,LABEL,METHODS,MFS,OBJECTIVE,PSA,RADICAL,RESULTS,T2B
169,BLACKWELL,HOWEVER,LTD,PUBLISHING
001,169,601,ACM,ADT,ALPK1,BACKGROUND,BASED,CONCLUSION,COX,ERE,JOURNAL,LABEL,MEIER,METHODS,RESULTS,TACC2,THEREFORE,THESE
197,298,AUTHORS,BACKGROUND,GUIDELINES,III,LABEL,LEVEL,METHODS,OBJECTIVE,PATHOLOGIC,PRIMARY,QUESTIONS,RESULTS,TREATMENT
169,ADDITIONAL,COMPOUNDS,COPYRIGHT,FDA,HOWEVER,IRELAND,LBD,LTD,NRS,NUCLEAR,SEVERAL,STRUCTURAL,THEIR
169,194,ASSOCIATED,COPYRIGHT,FRESH,HSP90,ISSUE,PROTEIN,SHOCK,SPECIAL
001,008,012,037,098,160,205,AGE,DRE,LABEL,METHODS,OBJECTIVE,PCA,PIN,PREDICTIVE,PSA,PURPOSE,RESULTS,THEREFORE
BPS,LATER,ZOL
169,COLLEGE,COPYRIGHT,LTD,PUBLISHED,RADIOLOGY
CORRECTED,END,PROGRAM,RESULTS,THESE
001,014,037,169,180,189,194,214,272,290,304,421,513,515,547,711,965,CHINA,GLEASON,HAN,PSA,STRATIFIED,THEREFORE
CD8,CTL,HLA,PAP,PSA,THESE
110,194,252,324,650,770,938,AMICO,CAP,COX,DISEASE,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS,THERE
169,178,1MM,5MN,AMICO,COPYRIGHT,ECE,HISTOLOGY,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PCA,PURPOSE,RESULTS,SPACE,SVI,T2W
169,177,487,AUTHORS,BJU,CONCLUSION,HOWEVER,LABEL,METHODS,OBJECTIVE,RESULTS,VAS
CASODEX,HOWEVER,LNCAP,NAKAI,OVERALL,PCA,PSA,TARGETING
001,100,110,131,169,177,4MM,COPYRIGHT,FIFTEEN,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,POSTERIOR,PUBLISHED,PURPOSE,RESULTS,SOCIETY
169,BCG,CAP,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,NMIBC,OBJECTIVE,OBJECTIVES,RESULTS,THOSE
111,169,189,370,463,500,569,702,730,854,CAP,CHINESE,COPYRIGHT,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,ROC,THOSE,USING
169,CELASTROL,COPYRIGHT,FURTHER,HSP90,INC,LC3,LC3II,MEK,WILEY
169,642,896,ACRYLAMIDE,COPYRIGHT,COX,PSA,RESULTS,THERE
946,ALZHEIMER,INCREASING,SINCE
NOTABLY,THESE
ANTICANCER,HOWEVER,ZOL,ZOLEDRONIC
JNK,LABEL,LIP,METHODS,OBJECTIVE,PURPOSE,RESULTS,ROS,THESE
AWARENESS
DEFICIENCY,ERK,MYC,PIM,THESE
236,306,BACKGROUND,BOARD,DRE,LABEL,METHODS,RESULTS
168,BACKGROUND,BASED,LABEL,METHODS,PFS,PSA,RESULTS,YM155
ESTROGENS,NOVEL,PHASE,STS,THESE
169,947,CD4,COPYRIGHT,ELISPOT,HLA,IFN,THEREFORE
STEROID,STRIKINGLY
HOWEVER,OTHER,RNS,ROS,STUDIES
169,172,177,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,RESULTS,T2W
169,5CM,ADDITIONAL,COLLEGE,COPYRIGHT,CURRENT,FURTHER,LARGE,LTD,MEDLINE,PUBLISHED,ROYAL,STUDIES,SUGGESTED,THERE
101,169,AUTHORS,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,THERE
003,169,174,226,APRIL,AUTHORS,BJU,BXT,C30,CONCLUSION,INDEX,LABEL,LDR,MARCH,METHODS,OBJECTIVE,QLQ,QOL,RESULTS,SCORE,SYMPTOM,THERE,TREATMENT,URINARY
169,391,BACKGROUND,BANKS,BLOOD,CFS,CHINA,CHINESE,CONCLUSION,HOWEVER,LABEL,LNCAP,METHODS,PCR,RESULTS,SUBSEQUENT,XENOTROPIC
169,201,204,232,405,899,ACP,AUTHORS,BJU,BPH,COMPARING,LABEL,METHODS,OBJECTIVE,PROSTATIC,PSA,RESULTS,SEPTEMBER,STUDENT,TYGERBERG,UTI,WHITNEY
169,AUTHORS,BJU,BPH,CONCLUSION,EXPRESSION,GLEASON,INCREASED,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,T21,TAKEN,TMA
001,169,170,220,276,678,692,AUTHORS,BASED,BJU,INDEX,KETTERING,LABEL,METHODS,MSKCC,OBJECTIVE,RESULTS,SLOAN
001,152,169,184,198,224,273,301,408,708,AGE,AUTHORS,BETWEEN,BJU,BNS,JANUARY,LABEL,MEN,METHODS,OBJECTIVE,POTENCY,RESULTS
120,169,AUTHORS,AVERAGE,BJU,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS
169,227,AUTHORS,BJU,CONCLUSION,GLEASON,LABEL,LOW,METHODS,OBJECTIVE,PRIMARY,PSA,RESULTS,RRP,TOTAL
001,169,185,199,310,ADT,AFTER,AUTHORS,BETWEEN,BJU,EXCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,SVI,THEREFORE
100,160,REMARKABLY
169,BLACKWELL,FOUNDATION,HOWEVER,ILLNESS,LTD,PSA,PUBLISHING,SOCIOLOGY
169,BLACKWELL,BRITISH,LTD,PUBLISHING,THOSE
247,AIM,GLEASON,INDICATION,LABEL,METHODS,OBJECTIVE,PGU,PPB,PRIMARY,RESULTS,SIX
107,160,323,395,592,697,862,892,AMICO,BCR,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE,WHILE
ALTERED,BACKGROUND,DEGRADO,FCH,GLEASON,JANUARY,LABEL,METHODS,PCA,PET,POTENTIAL,PSA,RESULTS,STUDIES
HOWEVER,LRP,ROBOT
RADIATION,WHILE
100,169,APRIL,BACKGROUND,BLACKWELL,FINNISH,LABEL,LTD,METHODS,OBJECTIVE,OBJECTIVES,OCTOBER,PERSONS,PUBLISHING,RELEVANCE,RESPONSES,RESULTS,SUPPORT
100,177,582,CONCLUSION,DEPARTMENT,GLEASON,LABEL,LRP,METHODS,OBJECTIVE,PFS,PSA,PSM,RESULTS,THESE,UNIVERSITY,UROLOGY
603,BECAUSE,DU145,FOXO3,PC3,PROTEASOME,SCF,SIRT1,SIRT2,SIRTUIN,TAKEN
169,AMONG,COPYRIGHT,FURTHER,INC,OCCURRENCE
169,BACKGROUND,CHROMATIN,CONCLUSION,COPYRIGHT,E2F,E2F3A,EXPRESSION,INC,LABEL,METHODS,PCR,RESULTS,THESE,WESTERN,WILEY
169,BACKGROUND,BASED,COPYRIGHT,III,INC,LABEL,METHODS,PHASE,RESULTS,SINCE,WILEY
169,172,251,602,ASIAN,AUC,BACKGROUND,CALCULATOR,COPYRIGHT,DUTCH,ERSPC,INC,KPCRC,LABEL,METHODS,PCA,PRC,PSA,RANDOMIZED,RESULTS,SCREENING,WILEY
169,COPYRIGHT,HEPG2,I3C,INC,NAD,NQO,TRAMP,TREATMENTS,WESTERN,WILEY
169,AFTER,AUTOMATED,BACKGROUND,COPYRIGHT,DEFENSE,DEPARTMENT,DOD,LABEL,METHODS,RESULTS,SOCIETY
147,169,COPYRIGHT,COX,DEPRESSION,END,LABEL,LTD,METHODS,NINTH,OBJECTIVE,POISSON,RESULTS,THESE,WILEY
000,004,160,167,169,177,235,270,437,449,557,AGE,AIM,BACKGROUND,BMI,DRE,INDICATION,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SEPTEMBER,SERUM
160,COMPOUNDS,CURRENT,CURRENTLY,LABEL,LBD,METHODS,NTD,OBJECTIVE,OBJECTIVES,RESULTS,SMALL,THESE
APC,GLEASON,GSTP1,HOWEVER,III,MEDICAL,PCA,THESE,UNIVERSITY
004,016,169,309,321,630,BACKGROUND,COPYRIGHT,COX,HEAVY,INC,LABEL,METHODS,PATHOLOGIC,PSA,RESULTS,SMOKING,THERE,UNIVARIATE
500,ADENOVIRAL,E1A,LNCAP,MTS,OFF,PPT,PRIMARY
003,134,169,171,560,COPYRIGHT,MEN,STRATEGIC,THEREFORE
000,001,030,169,183,BACKGROUND,COPYRIGHT,END,IMAGING,LABEL,METHODS,RESULTS,SOCIETY
001,009,102,126,292,457,502,738,916,COX,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,UNIVARIATE
231,954,CONVERSELY,CSF,CXCL1,ECM,IL8,KNOCKDOWN,LNCAP,MDA,PRSS3
18S,28S,45S,BISULFITE,CPG,FURTHER,HOWEVER,MYC
AMONG,BACKGROUND,CONCLUSION,FORTY,LABEL,METHODS,PSA,RESULTS
542,AFTER,HYPOTHESES,INCREASING,LABEL,MEN,METHODS,OBJECTIVE,OVERALL,RESULTS,STRATEGIES
10MIN,169,194,2CC,945,946,BACKGROUND,CONCLUSION,COPYRIGHT,GRADE,GYE,INC,LABEL,LQ2,MATERIALS,METHODS,PUBLISHED,RESULTS,SOCIETY
169,COPYRIGHT,INC,MRI
001,014,160,169,177,5MG,AFTER,COPYRIGHT,GLEASON,GREATER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PPB,PUBLISHED,PURPOSE,RESULTS,SOCIETY,UNIVARIATE
001,169,COPYRIGHT,GLEASON,INC,STUDIES,TOTAL
104,169,343,815,967,985,AFTER,COPYRIGHT,COX,INC,INSURANCE,STUDIES,TAIWANESE,THERE,WESTERN
169,COPYRIGHT,IRELAND,LTD,PUBLISHED,REGULATION
012,177,183,250,393,567,641,681,778,842,899,BACKGROUND,BCR,CONCLUSION,GLEASON,LABEL,METHODS,PSA,PTV,RESULTS,SERUM
006,032,150,169,224,239,300,ATN,COPYRIGHT,ENDPOINTS,HOWEVER,INC,LABEL,LOW,METHODS,OBJECTIVE,PRE,PSA,PSADT,RESULTS,SERUM
169,567,AVERAGE,CAP,COPYRIGHT,FIFTY,GLEASON,IMMEDIATE,INC,LABEL,METHODS,NOTABLY,OBJECTIVE,PSA,PUBLISHED,RESULTS
001,002,039,150,169,185,528,905,AUTHORS,BJU,BMI,GLEASON,LABEL,METHODS,OBJECTIVE,PEARSON,PSA,RESULTS,USING
169,BLACKWELL,FOUNDATION,ILLNESS,INCIDENCE,LTD,PSA,PUBLISHING,SOCIOLOGY
016,250,AMONG,ASIAN,INDIANS,INITIATIVE,SATHI,SOUTH,TOTAL
169,786,COPYRIGHT,LUC,MANAGEMENT,MB231,MDA,PC3,RCC,SOCIETY,THESE
169,239,ADT,ANG,BACKGROUND,COPYRIGHT,ELISA,INC,LABEL,METHODS,MVD,RESULTS,STILL,THREE,WILEY
169,BACKGROUND,CONCLUSION,COPYRIGHT,DU145,H6D,IGF,INC,LABEL,METHODS,NAG,NON,RESULTS,SERUM,WILEY
104,150,169,254,ADT,BACKGROUND,CHANGES,COPYRIGHT,ESTIMATING,GEE,INC,LABEL,METHODS,PBS,PCI,RESULTS,WILEY
169,AMONG,BACKGROUND,COPYRIGHT,DUNNING,GST,INC,LABEL,LNCAP,METHODS,PC3,PCR,PRO,RESULTS,SER,TFG,THESE,THR,TOF,TRK,WILEY
169,BCA,CHROMATIN,COPYRIGHT,DHT,FKBP5,HOWEVER,INC,INDUCED,PCA,PIP,PROLACTIN,PROTEIN,PSA,RUNX2,USING,WILEY
319,401,481,542,576,735,FEW,FIFTY,FORTY,MEN,PCA,SEVENTY
749,BACKGROUND,COX,GLEASON,LABEL,MEIER,METHODS,PSM,RESULTS,RRP,THESE
001,174,177,ADT,ASSESSMENT,BOARD,CONCLUSION,FOUNDATION,LABEL,METHODS,NETWORK,OBJECTIVE,PURPOSE,RESULTS,THERE,WORLD
DHPEA,LABEL,LNCAP,MCF,MDA,METHODS,MTT,OBJECTIVE,PC3,PURPOSE,RESULTS,SEVERAL,SW480
356,671,CAF,CFH,COMPARISON,DCN,EMT,FBLN1,MESENCHYME,OGN,PARVA,SPARC,TAG
169,COPYRIGHT,COX,GLEASON,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,UNIVARIATE
169,500,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RESULTS
169,22RV1,BPH,CONCLUSION,COPYRIGHT,DU145,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,PCR,RESULTS
100,136,150,169,175,200,202,ACTUARIAL,AMICO,APRIL,BETWEEN,CAP,COPYRIGHT,EBL,FUNCTIONAL,GLEASON,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,ROBOTIC,THERE
169,BACKGROUND,CASES,COPYRIGHT,ERG,INC,LABEL,METHODS,OBJECTIVE,PCR,PITX2,PSA,RESULTS
001,002,103,169,ADT,ANXIETY,ASSESSMENT,COPYRIGHT,DEPRESSION,FUNCTIONAL,GLEASON,GROUP,IMAGE,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PITTSBURGH,QUALITY,RESULTS,SCALE,SLEEP,THERAPY
169,916,936,954,BIOCHANIN,COPYRIGHT,DR5,DU145,INC,INDUCTION,LNCAP,SOLUBLE,TRAIL
003,008,169,230,950,BACKGROUND,BMI,COPYRIGHT,GLEASON,JANUARY,LABEL,METHODS,OBESE,OBJECTIVE,PSA,PUBLISHED,RESULTS,SETTING,T1C,UROLOGY
169,COPYRIGHT,PEG,PLNPS,RAK
169,BASAL,COPYRIGHT,CSC,IRELAND,LTD
169,CHANGES,COPYRIGHT,EXPRESSION,GLEASON,INC,PERCENTAGE
169,ANXIETY,AUSTRALIAN,COMPOSITE,CONSISTENT,COPYRIGHT,DEPRESSION,INDEX,LABEL,LTD,METHODS,NEEDS,OBJECTIVE,RESULTS,SCALE,SUPPORTIVE,THREE,WILEY
105,123,169,BACKGROUND,COPYRIGHT,COX,DISCHARGE,EARLIER,HRS,LABEL,METHODS,RESULTS,SOCIETY,SWEDISH,THERE,TNM
145,DU145,HOWEVER,LNCAP,NEITHER,ODC,THESE
004,160,955,AFRICAN,AFTER,AMERICANS,CRC,INSTEAD,NORTH,OBESE,PSA
169,183,ACUTE,BLACKWELL,DECREASED,FASTING,FOLLOWING,GROUP,LABEL,LTD,METHODS,OBJECTIVE,PLACEBO,PUBLISHING,RESULTS
169,1C1,BACKGROUND,COPYRIGHT,FURTHER,INC,LABEL,LNCAP,METHODS,NAD,RESULTS,ROS,SINCE,THEREFORE,WILEY
169,ALB,BACKGROUND,COPYRIGHT,CYTOGLOBIN,INC,IPCEF,LABEL,LEDGF,METHODS,PCA,PRDX6,PRDXS,RESULTS,TPO,VALIDATION,WILEY
108,169,215,525,604,617,631,AUC,BACKGROUND,CHINESE,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,ORS,PCA,RESULTS,ROC,WILEY
169,COPYRIGHT,ETS,INC,WILEY
169,945,946,947,BACKGROUND,CD4,COPYRIGHT,DENDRITIC,DPI,HOWEVER,IFN,INC,LABEL,LNCAP,METHODS,NADPH,RESULTS,SOD,TH1,TNF,WILEY
138,145,169,BACKGROUND,CETRORELIX,COPYRIGHT,INC,LABEL,MDA,METHODS,PCA,RESULTS,WESTERN,WILEY
448,AMONG,BACKGROUND,CONCLUSION,LABEL,METASTASES,METHODS,NBG,NEITHER,OBJECTIVE,PREDICTIVE,RESULTS,SUMMARY,T12,T15,THERE,TOKUHASHI,UNIVERSITY
169,2N0M0,370,869,CES,COPYRIGHT,DEPRESSION,DEPRESSIVE,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,QOL,RESULTS,SAQ,SCALE,STUDIES,UROLOGICAL
169,945,BFA,COPYRIGHT,DHT,EFFECTS,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THEREFORE,UNDER
001,143,159,169,352,477,AFTER,BILATERAL,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SEVENTEEN,T2A
008,021,105,169,494,599,BETWEEN,CONCLUSION,COPYRIGHT,FIFTY,INC,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,PERINEURAL,PNI,PSA,RESULTS,STAGE
169,COPYRIGHT,EGF,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PC3,PC3WT,RESULTS,VEGFR
169,ADDITIONAL,COPYRIGHT,DES,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SECONDARY,TTP
169,945,INC,THESE,WILEY
169,AMONG,COPYRIGHT,HODGKIN,INCIDENCE,OPTIMAL,STATISTICS
169,853,BACKGROUND,COPYRIGHT,HEALTHCARE,LABEL,LOS,METHODS,QUALITY,REPORTING,RESULTS,SOCIETY,STATE,WASHINGTON
ENGLISH,PSA
ACCORDING,CANINES,THERE
H2A,HISTONE,NOTABLY,TSS,USING
016,115,169,893,987,BACKGROUND,BCC,COPYRIGHT,LABEL,LTD,METHODS,ORS,RESULTS,SWEDISH
169,946,COPYRIGHT,IRELAND,LTD,TGF,THERE
003,023,050,055,239,BASED,COX,GLEASON,HOWEVER,PCA,PSA,SEVERAL
239,400,GRADE,LABEL,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SORAFENIB,STRATEGIES
169,289,ADDITIONAL,COMPARISON,COPYRIGHT,END,INC,INSTITUTE,LABEL,LOWER,MATERIALS,METHODS,OBJECTIVE,OLDER,RESULTS,SIR,WHITE
006,169,500,ACTIVATION,ADDITIONAL,CONCLUSION,COPYRIGHT,FORTY,INC,LABEL,LAPATINIB,METHODS,OBJECTIVE,OUTCOME,PFS,PRIMARY,PSA,PSADT,PURPOSE,Q787Q,RESULTS
100,121,169,194,AFTER,AMONG,CONCLUSION,COPYRIGHT,GRADE,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,THESE
169,CAP,CONCLUSION,COPYRIGHT,IIB,IMAGE,INC,ITALIAN,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
169,COPYRIGHT,IRELAND,LTD,SINCE
137,143,169,193,205,257,APRIL,COPYRIGHT,INC,LABEL,MARCH,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,ONCOLOGIC,PSA,RESULTS
169,COPYRIGHT,IRELAND,LTD,PUBLISHED
169,956,COPYRIGHT,ETS,IMMUNOBLOT,LNCAP,NDRG1,PSA,RESULTS,THESE,TRANSIENT
001,019,020,021,563,579,640,717,773,828,883,AUC,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS
BACKGROUND,BASED,CONCLUSION,FIFTY,LABEL,METHODS,PATIENT,RESULTS
001,169,327,AUTHORS,BJU,BMI,CONCLUSION,GLEASON,LABEL,METHODS,OBJECTIVE,RESULTS,TVS
001,101,169,555,599,687,728,791,819,857,895,954,999,AUC,CAP,CONCLUSION,COPYRIGHT,DRE,GLEASON,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,OVERALL,PSA,RESULTS
169,902,ATTITUDES,CLEAR,COPYRIGHT,DETECTION,EARLY,HOWEVER,INC,INSTITUTE,KNOWLEDGE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PRIMARY,PROVIDERS,RESULTS,SCREENING
169,ADDITIONAL,COPYRIGHT,GLEASON,INC,MEDLINE,PSA,SURGERY,WHILE
BCL,DOCETAXEL,DU145,FIRSTLY,HDACI,LNCAP,MCL,NAPHTHALEN,PC3,THESE
100,169,AUTHORS,BJU,CELLS,CONCLUSION,DU145,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THESE
169,AUTHORS,BJU,BRITISH,COMPLEX,GLEASON,IMPROVING,JANUARY,LABEL,MATERIALS,METHODS,OBJECTIVE,OPERATIONS,PATIENT,PSA,PSM,RESULTS,SECTION,SEPTEMBER,TNM,UROLOGICAL
001,002,004,005,038,169,381,774,AFRICAN,BACKGROUND,BETWEEN,BIOMARKER,BMI,CAUCASIAN,COPYRIGHT,EVALUATION,FREQUENCY,INDIANA,LABEL,METHODS,PSA,RESULTS,SOCIETY,THESE,UNIVERSITY
102,BESIDES,CURRENT,PCA,PCR,WESTERN
ECTOPIC,GEF,INCREASED,RHO,THESE
015,027,030,036,100,100CC,150,150CC,169,ACUTE,COPYRIGHT,COX,CROWN,GROUP,INC,INCREASED,LABEL,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,RADIATION,RESULTS,THERAPY,UNIVARIATE
007,011,033,035,041,116,169,177,194,226,ADT,CONCLUSION,COPYRIGHT,COX,GLEASON,HOWEVER,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PCA,PURPOSE,RADIATION,RESULTS,THERE
ADDITIONAL,CLA,DHA,EPA
169,AMONG,BACKGROUND,CONCLUSION,COPYRIGHT,III,INC,LABEL,METHODS,NIH,PCA,PSA,RESULTS,WHETHER,WILEY
BACKGROUND,BETWEEN,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SEXUALITY,THERE
158,169,AMONG,ASHKENAZI,AUTHORS,BJU,BRCA1,BRCA2,CONCLUSION,INITIAL,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS
001,HOWEVER,LASS2,PCR
011,035,053,169,AFRICAN,ASSESSMENT,BACKGROUND,CHASE,COPYRIGHT,CRC,DESPITE,FOX,LABEL,METHODS,PREDICTORS,PROGRAM,RESULTS,SCREENING,SOCIETY
001,010,157,169,259,312,493,536,648,655,696,744,774,955,BACKGROUND,CASES,COPYRIGHT,FAILURE,HARRELL,INCLUSION,INSTITUTE,LABEL,MEDICAL,METHODS,PSA,RESULTS,SEATTLE,SOCIETY,UNIVERSITY,UTRECHT
001,169,893,AUC,BACKGROUND,BERGH,COPYRIGHT,GLEASON,LABEL,METHODS,PCA,RESULTS,SOCIETY
001,009,169,BACKGROUND,COPYRIGHT,EGF,ERBB3,GLEASON,HRG,INC,LABEL,METHODS,MIF,PNI,RESULTS,THESE,TISSUES,TMA,WILEY
169,945,946,957,BACKGROUND,COPYRIGHT,HOWEVER,INC,LABEL,LNCAP,MESSENGER,METHODS,NTRS1,NTSR1,RESULTS,WILEY
169,BACKGROUND,CHANGES,COPYRIGHT,DISEASE,ESTIMATES,INC,LABEL,METHODS,REGRESSION,RESULTS,THESE,TREATMENT,WILEY
15Q11,169,17Q21,22Q12,233,762,BACKGROUND,CONSORTIUM,COPYRIGHT,ICPCG,INC,LABEL,LOD,METHODS,MYC,RESULTS,SNP,THESE,WILEY
169,223,700,ADDITIONAL,BACKGROUND,COPYRIGHT,III,INC,LABEL,MDV3100,METHODS,RESULTS,SRC,TAK,VARIOUS,WILEY
INHIBITORY,LNCAP,MMP,QUINOLINES
001,002,037,916,BACKGROUND,III,LABEL,METHODS,NHS,PRIVATE,RESULTS,SERVICE
155,APPROACHES,FOXP3,SATB1,UTR

169,AEU,COPYRIGHT,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PUBLISHED,RESULTS
000,018,153,169,199,300,309,844,886,AUSTRALIA,AUSTRALIAN,CONSORTIUM,COPYRIGHT,GENOTYPING,INC,KALLIKREIN,KINGDOM,KLK12,KLK13,PRACTICAL,SNP
AMONG,FDA,HSV,SIPULEUCEL
169,BACKGROUND,BPH,CHRONIC,COPYRIGHT,INC,LABEL,METHODS,MPO,RESULTS,SEVERAL,WILEY
169,530,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,METHODS,MEYER,PSA,RESULTS,THESE,WILEY
151,312,7TH,9TH,BACKGROUND,CONCLUSION,FURTHER,GLEASON,LABEL,MATERIALS,METHODS,NOTES,OVERALL,POTENTIAL,PSA,RESULTS
100,125,160,169,2MM,5CM,5MM,CARLO,COPYRIGHT,DOSXYZNRC,EBT,INC,INCREASING,KODAK,LABEL,MATERIALS,METHODS,MONTE,OBJECTIVE,OTHER,PUBLISHED,PURPOSE,RESULTS,SIMILAR,SOCIETY,XV2
145,169,CLU,COPYRIGHT,INC,INFECTION,MDA,SIMILARLY,WILEY
169,300,480,956,COPYRIGHT,ETS,LNCAP,MTD,PIM,REMARKABLY
169,263,301,319,637,647,814,942,AUC,BACKGROUND,CAPITANIO,COPYRIGHT,DCA,GLEASON,LABEL,METHODS,PREDICTIVE,RESULTS,ROC,SEVERAL,SOCIETY
967,ELISA,FATTY,III,INCREASED,KRUSKAL,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERUM,THERE
007,100,145,169,341,6NG,8CC,9GY,ABOUT,BCF,BECAUSE,COPYRIGHT,COX,GLEASON,INC,LABEL,MEIER,METHODS,NETWORK,OBJECTIVE,PHOENIX,PUBLISHED,PURPOSE,RESULTS,SOCIETY,T1C,USING
160,183,ALCOHOL,AMONG,BACKGROUND,LABEL,METHODS,NSCLC,OPTIMAL,REGARDING,RESULTS,STAGE,SURVIVORS
169,COPYRIGHT,INC
ASSAY,BASED,DRE,LABEL,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,SCORE,T1C,THESE,USING
210,520,BPH,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,URINARY,UROLOGICAL,UTI
570,BACKGROUND,CONGRUENT,COX,DFS,GLEASON,LABEL,MEIER,METHODS,PSA,RESULTS,SCORE,SURVIVORS,USA,WHITE
001,002,021,026,035,050,169,404,BCR,COPYRIGHT,GLEASON,INC,JYR,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PERCENT,PSA,PTV,RECURRENCE,RESULTS
166,169,184,COPYRIGHT,EERPE,EORTC,INC,LABEL,METHODS,OBJECTIVE,QLQ,RESULTS,THREE,URINARY
169,500,AGE,CONCLUSION,COPYRIGHT,HOWEVER,ICS,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,PREDICTIVE,PSA,RALRP,RESULTS
021,114,169,177,BACKGROUND,BECAUSE,COPYRIGHT,DESPITE,LABEL,METHODS,OVERALL,RESULTS,ROBOTIC,SOCIETY,WISCONSIN
101,166,169,205,220,327,332,BACKGROUND,COPYRIGHT,LABEL,MEN,METHODS,OBJECTIVE,PSA,PUBLISHED,RESULTS,SETTING,SIX,TAX,UROLOGY
003,169,920,945,AMACR,BACKGROUND,COA,COPYRIGHT,COX,GLEASON,INC,LABEL,LOW,METHODS,METHYLACYL,PHYSICIANS,RESULTS,WILEY
177,CONCLUSION,CRAWLEY,FITCHBURG,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PHILIPS,RESULTING,RESULTS,VOLUMETRIC
112,213,229,269,CANCERS,CONCLUSION,DOPPLER,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PDS,PSA,RESULTS
006,028,147,169,175,289,354,880,945,AUTHORS,BJU,ECE,LABEL,METHODS,NSS,OBJECTIVE,OVERALL,PSA,PSM,RESULTS,THERE
107,132,464,673,C30,COX,EORTC,III,JANUARY,LABEL,METHODS,OBJECTIVE,PATIENT,PURPOSE,QLQ,QOL,RESULTS,THESE,UNIVARIATE,WHILE
012,019,075,160,169,194,378,594,ACM,ADT,AHR,AMONG,CHF,COPYRIGHT,COX,III,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PURPOSE,RESULTS,T3AN0M0
039,177,943,DSC,ERROR,HAUSDORFF,IMAGING,LABEL,LOW,METHODS,MRI,NMI,NORMALIZED,OBJECTIVE,PURPOSE,RESONANCE,RESULTS,SIMILARITY,STUDENT,TRE,ULTRASOUND
303,750,CURRENT,GLEASON,JAN,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SEVEN
040,319,337,AMMAN,BACKGROUND,DUE,HUSSEIN,LABEL,MARCH,METHODS,RECORDS,RESULTS,THERE
007,036,560,ABCB1,AUC,CONCLUSION,DEC,DOCETAXEL,LABEL,LDH,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SERUM,SNP,TREATMENT
CLEC14A,FINALLY,FUNCTIONAL,TEM
169,177,194,687,786,COPYRIGHT
001,004,169,385,476,CHICAGO,COPYRIGHT,GLEASON,HGPIN,INC,LABEL,LGPIN,MATERIALS,MEIER,METHODS,OBJECTIVE,RESULTS
002,003,015,163,169,594,757,BACKGROUND,COPYRIGHT,GLEASON,LABEL,METHODS,OBJECTIVE,PCA,PSA,PUBLISHED,RESULTS,SETTING,THESE,UROLOGY
169,ANDROGENS,COPYRIGHT,HOWEVER,IRELAND,LTD
049,125,169,1KG,5NG,BMI,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THESE,UNIVARIATE
169,191,209,AUTHORS,BJU,CONCLUSION,GLEASON,LABEL,MEN,METHODS,NETWORK,OBJECTIVE,OBJECTIVES,PSA,REDUCTION,RESULTS,USING
001,003,011,014,038,232,405,LABEL,LRP,METHODS,NSM,OBJECTIVE,OVERALL,PSM,PURPOSE,RESULTS,THESE,THREE
160,18G,CONCLUSION,DOF,FREEDOM,IMAGING,LABEL,METHODS,MRI,OBJECTIVE,PHANTOM,PURPOSE,RESONANCE,RESULTS,STD,THESE
177,880,LNCAP,THESE
169,BACKGROUND,COPYRIGHT,CROATIA,EASTERN,LABEL,LTD,METHODS,OUTCOME,RESULTS,SOUTH
169,BETWEEN,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,RESULTS,THERE,WILEY
ADT,GLEASON,HOWEVER,SCORE,T2C
001,002,006,AFRICAN,DESPITE,GLEASON,LABEL,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,REGARDLESS,RESULTS,SIMILAR,THREE,WHITE
169,ARS,COPYRIGHT,IRELAND,LTD,REGARDLESS
114,129,169,200,215,400,ADRENAL,BACKGROUND,COMPOUNDS,COPYRIGHT,CYP,FACTORS,INC,LABEL,METHODS,PRIOR,PSA,PSADT,RESULTS,SIXTY,WILEY
169,22RV1,945,ALA,ANNEXIN,ARG,BACKGROUND,COPYRIGHT,CPD,FAR,INC,LABEL,LNCAP,MDA,METHODS,MTS,PCA,PRL,REGULATION,RESULTS,WILEY
MYC,USING
146,ESTIMATES,IDM,LABEL,METHODS,OBJECTIVE,PHYSICIANS,PURPOSE,RESULTS
100,169,194,AFTER,CONCLUSION,COPYRIGHT,D90,INC,LABEL,MATERIALS,METHODS,NEEDLES,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY
153,169,186,189,ACCORDING,COPYRIGHT,JADAD,KEY,LARGE,LTD,REPORTING,SCIENCE,SEPTEMBER,THERE,WEB
169,22RV1,BACKGROUND,COPYRIGHT,ERK,FINALLY,INC,INCREMENTS,LABEL,LNCAP,METHODS,RESULTS,RUNX2,THESE,TRAMP,WILEY
169,945,BACKGROUND,CAP,COPYRIGHT,EXPRESSION,GDI,HOWEVER,IL6,INC,LABEL,LNCAP,MALDI,METHODS,PMF,RESULTS,THESE,TREATMENT,WILEY
169,177,215,336,AAS,AFRICAN,AMERICANS,ANC,BACKGROUND,BEN,CBC,COPYRIGHT,COX,FURTHER,GLEASON,INC,LABEL,MEIER,METHODS,PCA,RESULTS,SINCE,WILEY
169,BACKGROUND,COPYRIGHT,EXPRESSION,INC,KATANIN,LABEL,METHODS,RESULTS,STRIKINGLY,WILEY
169,215,411,ANTIGEN,ASIAN,CAUCASIANS,COPYRIGHT,HAPLOTYPE,MET1THR,NUTRITION,SIX,SNP,THESE
AUSTRIA,HOWEVER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PCA,POISSON,PSA,RESULTS,TYROL
189,828,AFRICAN,ASIAN,RESULTS,THESE
CURRENT,HOWEVER
169,194,COPYRIGHT,CTC,CURRENTLY,DISSECTING,DTC,GLEASON,HOWEVER,INITIALLY,IRELAND,LTD,PCA,PCR,PSA
169,268,471,525,913,AMONG,BRIEF,COPYRIGHT,GENERAL,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,RESULTS
160,169,194,197,COPYRIGHT,GRADE,INC,INCIDENCE,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SCORE,SYMPTOM,THERE
008,237,372,609,APRIL,BACKGROUND,BCR,BETWEEN,CONCLUSION,DESPITE,GLEASON,INSIGCA,LABEL,MAY,METHODS,PSA,RESULTS,SIXTY,UNIVERSITY
117,126,169,BACKGROUND,CONCLUSION,COPYRIGHT,DEPARTMENT,DESPITE,DISCUSSION,GERMANY,LABEL,LTD,MAXILLO,METHODS,ONJ,PUBLISHED,RESULTS,SURGERY,UNIVERSITY
124,169,AUTHORS,INFECTION,INFECTIOUS,PCR,SOCIETY,THESE,USING
ADIPOSE,ASC,CXCR4,EXPRESSION,MDA,PC3,RAS,THESE,TRAMP
169,447,ANDROGENS,BACKGROUND,CGEMS,COPYRIGHT,DESPITE,HOPKINS,HOWEVER,INC,JOHNS,LABEL,MARKERS,PCA,PRINCIPAL,RESULTS,THESE,WILEY
031,032,033,1104HIS,150,ARG309GLN,ASP,BPH,GLN,THERE,XPG,XRCC1
039,076,508,681,AFTER,CAG,EGGER,HOWEVER,TAKEN,THERE,USA
169,309,COMPARING,COPYRIGHT,ECE,ENDORECTAL,GLEASON,INC,LABEL,LAD,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,RESULTS,RRP,SVI
001,106,169,177,CASES,CGA,COPYRIGHT,GLEASON,IAD,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SCORE
006,160,169,194,585,ADT,CLEVELAND,COMPARING,CONCLUSION,COPYRIGHT,FHR,GLEASON,INC,LABEL,MATERIALS,METHODS,NETWORK,OBJECTIVE,PSA,PURPOSE,RESULTS,UHR
169,739,902,905,AF2,COPYRIGHT,FUNCTIONAL,FXXLF,H874Y,IRELAND,LBD,LTD,LXXLL,LYS,Q902A,Q902K,Q902R,STRUCTURAL,TYR
001,102,157,169,174,394,515,552,779,BACKGROUND,BFS,COPYRIGHT,CSS,GLEASON,INC,LABEL,MATERIALS,MEIER,METHODS,PNI,PSA,RESULTS,THEIR
169,COPYRIGHT,EXPRESSION,IRELAND,LNCAP,LTD,MDA,PCA,RESULTS,SEVERAL,STAT3
001,160,169,193,194,274,678,ADT,CONCLUSION,COPYRIGHT,DESPITE,GLEASON,GRADE,INC,JANUARY,LABEL,MATERIALS,MAXIMUM,METHODS,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,V20,V65
001,169,289,658,670,840,893,901,ALONG,APRIL,CAUSE,COPYRIGHT,COX,CSS,EXCELLENT,GLEASON,INC,LABEL,MATERIALS,METHODS,MFS,NETWORK,OBJECTIVE,PURPOSE,RESULTS,SUBGROUPS,THESE,XRT
003,006,011,012,013,016,039,048,169,228,284,512,AUC,COMPARABLE,COPYRIGHT,DUTCH,INC,INCLUDING,KUTCHER,LABEL,LKB,LYMAN,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,SERIALITY
LABEL,LNCAP,METHODS,OBJECTIVE,PC3,PURPOSE,RESULTS
983,ART,BACKGROUND,GROUP,LABEL,METHODS,PRIMARY,PSA,RESULTS,SOUTHWEST
169,ADT,COPYRIGHT,IGF,INC,TARGETING,USING
001,002,009,169,406,658,668,ACCORDING,AMONG,BCR,COPYRIGHT,ECE,GLEASON,HOWEVER,INC,LABEL,MEANWHILE,METHODS,NSM,OBJECTIVE,PSM,RESULTS
169,AUTHORS,BACKGROUND,BRITISH,CAM,GST,HUVEC,JOURNAL,KEY,LABEL,MEK,METHODS,OBJECTIVE,PLUMBAGIN,PURPOSE,RAC,RAS,RESULTS,SOCIETY,VEGFR,WESTERN
001,003,229,239,BACKGROUND,KARNOFSKY,KPS,LABEL,METHODS,MORTALITY,OBJECTIVE,PURPOSE,RESULTS,UME,UNIVERSITY
145,169,33258,916,936,ADENOSINE,APOPTOSIS,BACKGROUND,BAX,BCL,CONCLUSION,COPYRIGHT,FGC10,HOECHST,INC,LABEL,LNCAP,METHODS,MMP,MRS1220,MTT,PC3,RESULTS,ROS,THESE,WILEY
169,22RV1,BACKGROUND,CLDN3,CLDN4,CONCLUSION,COPYRIGHT,CPE,CYTOTOXIC,DU145,INC,LABEL,METHODS,PC3,PRECS,REDUCED,RESULTS,THESE,WILEY
169,22RV1,BACKGROUND,BCL,BCLXL,CAP,COPYRIGHT,DHT,ELISA,INC,LABEL,LNCAP,METHODS,PCR,POTENTIAL,PSA,RESULTS,THESE,WESTERN,WILEY,ZYF,ZYFLAMEND
169,368,372,451,711,CHINA,CHINESE,CLEARLY,COPYRIGHT,FGFR4,HBV,HCC,HOWEVER,INC,SNP,WILEY
ARG,ARG462GLN,ASP,ASP541GLU,CAUCASIAN,CAUCASIANS,CIS,GLN,GLU,HOWEVER,ORS,OVERALL,PCA
001,601,ACM,ACTIVATED,ADT,AFTER,BACKGROUND,CONCLUSION,COX,LABEL,MEIER,METHODS,RESULTS,SKAP1
100,169,967,ADDITIONAL,ASSESSMENT,COLLEGE,CONCLUSION,COPYRIGHT,DESPITE,FIFTY,HOWEVER,JANUARY,LABEL,LTD,MATERIALS,METHODS,OBJECTIVE,OCTOBER,ORDINAL,PEARSON,PRIMARY,PROGRAM,PUBLISHED,RAPID,RESULTS,ROYAL,SYMPTOM
100,169,ADP,ARFGAP3,COPYRIGHT,DHT,GOLGI,LNCAP,PSA,SMALL
AFTER,CAM,FOLLOWING,TTF
169,194,BASIL,COPYRIGHT,HILARIS,INC,LABEL,LITERATURE,MATERIALS,METHODS,OBJECTIVE,PUBLISHED,PURPOSE,RESULTS,SOCIETY,THEIR,UROLOGISTS
169,3E6,CAP,CLONE,COPYRIGHT,FOCAL,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
125,169,414,468,576,597,BCR,COPYRIGHT,COX,D90,GLEASON,INC,JANUARY,LABEL,MATERIALS,MEIER,METHODS,NETWORK,OBJECTIVE,PHOENIX,PPB,PSA,PURPOSE,RESULTS,THEREFORE
169,BETWEEN,CONCLUSION,COPYRIGHT,FIRST,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,THESE,USING
169,194,718,COPYRIGHT,DOSES,INC,LABEL,MATERIALS,METHODS,NOMOGRAMS,OBJECTIVE,PREDICTION,PURPOSE,RESULTS,THREE,V75GY
007,009,160,169,194,CONCLUSION,COPYRIGHT,CTV,GROUP,INC,LABEL,MATERIALS,METHODS,MRL,OBJECTIVE,PSA,PURPOSE,RADIATION,RESULTS,SEVENTY,TEN,THERAPY,THERE
160,169,194,945,COPYRIGHT,FORTY,FURTHER,INC,LABEL,LIF,MATERIALS,METHODS,MIP,OBJECTIVE,PURPOSE,REGARDING,RESULTS,TNF
003,105,125,169,177,194,ARLINGTON,COPYRIGHT,D90,HEIGHTS,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PROSTATES,PURPOSE,RAPID,RESULTS,SEPTEMBER
003,078,169,177,287,653,CENTRAL,COPYRIGHT,DAILY,HOWEVER,IMAGE,INC,IPC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
001,002,240,GLEASON,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PERSISTENT,PSA,RESULTS
233,244,984,AMONG,FACTORS,LABEL,METHODS,OBJECTIVE,OVERALL,RESULTS,THESE
169,COPYRIGHT,IRELAND,LTD,SERTOLI,TESTICULAR
169,COPYRIGHT,HOWEVER,IRELAND,LTD
002,112,150,169,ADT,COPYRIGHT,HOT,LTD,QOL,TEN,THERE,TREATMENT,WILEY
169,ANDROGENIC,ANDROGENS,BACKGROUND,COPYRIGHT,E1A,HOWEVER,INC,LABEL,LNCAP,METHODS,PCA,RESULTS,THESE,USING,WESTERN,WILEY
143,169,BACKGROUND,BCR,COPYRIGHT,GLEASON,HOWEVER,INC,LABEL,METHODS,NOMOGRAMS,PSA,PSADT,RESULTS,SEMINAL,SINCE,WILEY
001,016,106,109,169,177,305,BACKGROUND,COPYRIGHT,EARLY,ELISA,HAZARDS,INC,LABEL,METHODS,PCA,RATIO,RESULTS,SERUM,WILEY
154,169,266,ADDITIONAL,BACKGROUND,CONCLUSION,COPYRIGHT,ELISA,GLEASON,III,INC,LABEL,METHODS,PCA,REGARDLESS,RESULTS,UNIVARIATE,WILEY
169,945,946,CAC,CN2,COPYRIGHT,FUNCTIONAL,NCC,PCR
ESSENTIAL,SECONDARY
126,CAP,CONCLUSION,DRE,GROUP,HOWEVER,III,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THREE,VAS
019,027,032,062,LABEL,MEN,METHODS,OBJECTIVE,PURPOSE,RESULTS
109,ASSOCIATED,PFE,RESULTS
169,COPYRIGHT,INC,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,OID,PATIENT,QOL,RESULTS,SYMPTOM,THESE
169,194,ARC,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,STOCKHOLM,WHEREAS,XIO
169,196,215,216,BED,COPYRIGHT,GRADE,HDR,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS,UNIVARIATE
001,123,160,169,184,945,ACADEMY,BACKGROUND,CONCLUSION,COPYRIGHT,DIFFERENT,INC,JORGE,LABEL,METHODS,MOSBY,MSH,NODULAR,NPY,OBJECTIVE,PUBLISHED,RESULTS,SAN,SPAIN
043,061,084,116,117,154,169,209,284,300,308,360,374,730,732,761,762,824,953,969,COPYRIGHT,DESPITE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PSA,RADICAL,RESULTS,RRP,WHILE
001,650,ACM,ADT,COX,GLEASON,LABEL,MEIER,METHODS,OBJECTIVE,PCA,PSA,RESULTS,SCORE
498,BACKGROUND,GLEASON,LABEL,METHODS,PSA,RESULTS,SEVEN
169,ADVANTAGES,COPYRIGHT,DESPITE,IRELAND,LTD,PSA,TREATMENT
142,169,BACKGROUND,CLINICIANS,CONCLUSION,COPYRIGHT,DESPITE,LABEL,LTD,MAXILLO,METHODS,PUBLISHED,RESULTS,SURGERY

001,169,218,591,926,ANALYZABLE,APF,COPYRIGHT,DESPITE,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PREDICTED,PSA,PURPOSE,RESULTS,WEB
169,COPYRIGHT,DESPITE,INC,LAPATINIB,NK1,NOW,SUBSTANCE,THESE,WILEY
001,169,AUC,COMBINING,COPYRIGHT,DRE,ERG,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCR,PSA,RESULTS,SERUM,TMPRSS2
120,169,COPYRIGHT,DD3,EXPRESSION,GLEASON,INC,LABEL,LNS,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCR,PSA,RESULTS,UNIVARIATE
001,004,013,027,035,042,169,AUTHORS,BAP,BJU,CONCLUSION,LABEL,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,SERUM,SRE
000,559,ABSTRACTS,ASSESSMENT,EFFECTS,EURONHEED,EVALUATION,FURTHER,LABEL,LITERATURE,MARCH,METHODS,NHS,OBJECTIVE,RESULTS,REVIEWS,STATE,TECHNOLOGY,UNIVERSITY
BACKGROUND,END,EXCEPTIONS,FURTHER,GERMANY,HODGKIN,LABEL,METHODS,RESULTS,UNTIL,USA
329,425,642,AAC,AFRICAN,CBPPS,COUNCIL,FOLLOWING,FURTHER,INSTITUTE,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SOCIETY
026,BACKGROUND,BMI,LABEL,METHODS,PSA,RESULTS
947,ANTISENSE,EMPLOYING,EXPRESSION,HLA,IFN,LNCAP,PAP,PCR,PSA,THESE,WHILE
169,176,356,BIOLOGICAL,COPYRIGHT,DIS,DVH,FIFTEEN,INC,LABEL,MATERIALS,METHODS,MONITOR,OBJECTIVE,PURPOSE,RESULTS,THREE
150,153,169,171,340,348,353,357,369,375,BETWEEN,CONFORMAL,COPYRIGHT,FLORIDA,INC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,OCTOBER,PURPOSE,RESULTS,THERAPY,THESE,THREE,UNIVERSITY
169,BAX,BCL,BH3,CC2,CLU,CLUSTERIN,COPYRIGHT,INC,THESE,WILEY
169,183,248,267,286,306,BACKGROUND,COPYRIGHT,COX,GLEASON,INC,LABEL,METHODS,PHYSICIANS,RESULTS,WILEY
001,032,047,100,169,215,BACKGROUND,CONCLUSION,COPYRIGHT,EXPRESSION,FES,GLEASON,HOWEVER,INC,IRS,KIMAP,LABEL,METHODS,PIN,PTK,RESULTS,WILEY
002,003,034,077,138,169,BACKGROUND,CONVERSELY,COPYRIGHT,FURTHER,HOWEVER,INC,LABEL,LOW,METHODS,RESULTS,SERUM,UNIVARIATE,WILEY
001,006,169,173,193,500,ADT,AFTER,CAD,COPYRIGHT,IAD,III,INC,LABEL,LOW,MATERIALS,MEIER,METASTATIC,METHODS,OBJECTIVE,OBJECTIVES,PSA,QOL,RESULTS,THEREFORE,UNIVARIATE,WITHOUT
153,177,647,EDTMP,LABEL,METHODS,OBJECTIVE,PSA,RESULTS
156,169,BIOMEDICAL,COPYRIGHT,LABEL,LTD,MEDICAL,METHODS,OBJECTIVE,PROCESS,RESULTS,WILEY
005,009,223,240,463,CHRONIC,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,SNP,UTR
169,194,CONCLUSION,COPYRIGHT,ENDOCRINE,EVENTUALLY,INITIALLY,LABEL,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,YET
001,007,169,177,194,COMPARING,COPYRIGHT,D90,DOSIMETRY,FACTORS,GIVEN,INC,INTER,LABEL,MATERIALS,METHODS,OBJECTIVE,PID,PURPOSE,RESULTS
169,194,ACUTE,ADVERSE,AMONG,BETWEEN,COMPOSITE,COPYRIGHT,CROWN,FURTHER,GLEASON,GROUP,HDR,INC,INDEX,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PSA,PUBLISHED,PURPOSE,RADIATION,RATES,RESULTS,T2B,T2C,THERAPY,THERE,THREE,TREATMENT
001,046,169,441,630,ADT,COPYRIGHT,COX,GLEASON,INC,LABEL,LOW,MATERIALS,METHODS,OBJECTIVE,PFS,PSA,PURPOSE,RESULTS
000,169,COPYRIGHT,CSC,ISOLATION,WHILE
442,628,686,BACKGROUND,DIETARY,HODGKIN,LABEL,METHODS,NHL,ORS,RESULTS
169,AMONG,BECAUSE,COMPANY,COPYRIGHT,ENDOSCOPIC,EUS,FNA,INC,MESOTHELIN,S100P,SIXTY,USING,WILEY
169,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OVERALL,PCA,PSA,RESULTS,WILEY
169,BACKGROUND,CONCLUSION,COPYRIGHT,END,INC,LABEL,METHODS,RAIRS,RESULTS,WILEY
030,169,997,AFRICAN,BACKGROUND,CAUCASIAN,CHINESE,COPYRIGHT,INC,LABEL,METHODS,PSA,RESULTS,THESE,WILEY
169,ALTERNARIA,AMP,BACKGROUND,BCL,COPYRIGHT,INC,INHIBITION,LABEL,LC3II,METHODS,MTT,PROTEIN,RESULTS,THESE,WESTERN,WILEY
000,10Q11,10Q26,11Q13,163,169,17Q12,17Q24,190,19Q13,215,713,754,BACKGROUND,BASED,CAUCASIAN,CGEMS,COPYRIGHT,INC,LABEL,MARKERS,METHODS,NOTABLY,PCA,PROJECT,RESULTS,THESE,WILEY
169,181,800CW,BACKGROUND,CONCLUSION,COPYRIGHT,DSRED,FURTHER,INC,IRDYE,LABEL,LNS,METASTASIS,METHODS,NIR,PC3,PCA,PET,RESULTS,THESE,WILEY
169,AMICO,ASO,BACKGROUND,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,LNCAP,METHODS,PIN,RESULTS,THERE,TREATMENT,WHEREAS,WILEY
001,003,006,013,ADT,AEROBIC,CHANGES,CONCLUSION,DXA,LABEL,METHODS,OBJECTIVE,PURPOSE,RESISTANCE,RESPONSES,RESULTS,THERE
100,179,397,ASSESSMENT,BACKGROUND,CONCLUSION,FATIGUE,JANUARY,KARNOFSKY,KPS,LABEL,MATERIALS,METHODS,OCTOBER,ORDINAL,PROGRAM,RAPID,RESULTS,SIMILAR,SINCE,SYMPTOM
169,177,194,961,BLADDER,COPYRIGHT,CTV,INC,INCLUSION,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS
160,169,CHANGES,CONCLUSION,COPYRIGHT,KEY,LABEL,LTD,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,TURKISH,WEB
023,177,CONCLUSION,FIFTY,GROUP,LABEL,METHODS,OBJECTIVE,PATIENT,PSA,RESULTS,THEREFORE,VUA,WHITNEY
BLADDER,COMPOSITE,EARLY,INDEX,INVENTORY,LABEL,MEN,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SHORT
169,181,BASED,COPYRIGHT,DIM,HOWEVER,I3C,INC,THESE,WILEY
CHI,EUB,HITACHI,JAPAN,LABEL,MEDICAL,METHODS,OBJECTIVE,PURPOSE,RESULTS,RTE,SYSTEMATIC,SYSTEMS,TOKIO
016,025,165,BMI,GLEASON,HOWEVER,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
005,017,045,266,326,BACKGROUND,CAP,CYS,GLEASON,LABEL,METHODS,PCR,RESULTS,SER,THESE
169,194,COPYRIGHT,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,USING
169,194,AFTER,COPYRIGHT,DESPITE,FIFTY,HOWEVER,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,PSA,PURPOSE,RESECTION,RESULTS,SEMINAL,SRT
001,002,004,009,102,169,BACKGROUND,BCR,CONCLUSION,COPYRIGHT,EPCAM,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SEVERAL,UNIVARIATE
169,194,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,THREE
100,183,LABEL,METHODS,MRI,OBJECTIVE,PCA,PSA,PURPOSE,RESULTS,TESLA
000,169,202,215,323,617,AFTER,AUTHORS,BJU,FINNISH,GLEASON,HOWEVER,LABEL,METHODS,OBJECTIVE,PCA,PIRKANMAA,PSA,RESULTS
169,AKT,COPYRIGHT,DCB,ENHANCING,HOWEVER,INC,NAC,POLYPLOIDY,ROS,TREATMENT,WILEY
169,945,COPYRIGHT,DU145,GLUT1,HIF,PAIII,TREATMENT
169,AZA,CAO,COPYRIGHT,CPG,GPCRS,PCR,RGS,TARGETING
106,169,AFTER,ASA,COMPARING,CONCERNING,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,OVERALL,RESULTS,SOCIETY,THERE
169,COPYRIGHT,DU145,EGF,INC,MAT,MLL,PC3,RHEUM,STAT3,THESE,TRAMP
005,008,095,102,169,ACCORDING,AMICO,CAP,COPYRIGHT,FIFTY,GROUP,HOWEVER,INC,LABEL,METHODS,OBJECTIVE,RESULTS,SBX,SEVEN,THERE,TURBP,UTI
169,IRELAND,LTD
114,140,ANONYMIZED,ASSESSMENT,AVERAGE,HOWEVER,LABEL,MEDICATION,METHODS,OBJECTIVE,PURPOSE,RESULTS,SYMPTOM
221,CAP,CCK,LNCAP,MIR,NSE,PC3,PCR,WESTERN
ALCOHOL,KRUSKAL,PSA,SERUM
169,COPYRIGHT,EIGHT,FORTY,INC,LABEL,MATERIALS,MEIER,METHODS,MRI,OBJECTIVE,OVERALL,PET,PSA,RESULTS,SEVENTY,SRS
169,177,239,BACKGROUND,BASED,CONCLUSION,COPYRIGHT,CSF,DLT,DOCETAXEL,INC,LABEL,METHODS,RESULTS
160,216,CONCLUSION,HAROW,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,THEREFORE
160,246,738,CONCLUSION,LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,USING
169,202,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS
169,176,194,360,COPYRIGHT,DAVIS,DTS,FDK,INC,KRESS,LABEL,MATERIALS,METHODS,OBJECTIVE,PURPOSE,RESULTS
169,194,BACKGROUND,CONCLUSION,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MRI,RESULTS,THESE
114,160,169,945,946,COPYRIGHT,DISCUSSION,INC,LABEL,MATERIALS,METHODS,NOW,OBJECTIVE,PURPOSE,RESULTS
169,COPYRIGHT,LTD,RESULTS,SINCE
169,174,194,AFTER,COPYRIGHT,DOSIMETRY,IBA,ICA,INC,LABEL,MATERIALS,MATRIXX,METHODS,OBJECTIVE,PURPOSE,RESULTS,THREE
100,169,174,194,ADDITIONAL,CALYPSO,CHANGES,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,TREATMENT
169,200,33342,956,BHM,COPYRIGHT,HOECHST,MRI,PC3,TREATMENT,USPIO
169,946,AKT,COPYRIGHT,DESPITE,DHT,IGF,INC,PREVIOUSLY,R1881,SINCE,WILEY
001,112,169,194,BECAUSE,COPYRIGHT,CROWN,INC,PLANS,PROTOCOLS,PUBLISHED
169,COPYRIGHT,DLT,GRADE,INC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,PATHOLOGIC,RESULTS,SIB
001,002,169,177,354,367,370,691,956,ADT,ASSESSMENT,BACKGROUND,COPYRIGHT,DESPITE,GLEASON,GNRHA,IGF,INC,INSULIN,LABEL,METHODS,PSA,RESULTS,SEVENTY
169,599,BECAUSE,CONCLUSION,COPYRIGHT,FIFTY,FORTY,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,T1C,T2A,THERE
133,169,577,BMI,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBESITY,OBJECTIVE,OVERALL,PERCENTAGE,PSA,PSM,RECORDS,RESULTS,THERE
169,956,AMONG,AUTHORS,BECAUSE,BLACKWELL,FOUNDATION,INITIAL,JOURNAL,LTD,MCF,MOLECULAR,PRE,PUBLISHING,SIX,STATINS,STRE1,STRE6
009,024,132,169,199,615,COPYRIGHT,FINALLY,GLEASON,PRIMARY,PSA,REDUCED
002,003,005,017,038,169,601,ACM,ADT,COPYRIGHT,COX,MEIER
FURTHER,GLEASON,PCA,THEREFORE
049,169,170,ACCRA,AGE,CONCLUSION,COPYRIGHT,GHANA,GLEASON,INC,KNOWN,KORLE,LABEL,METHODS,OBJECTIVE,PSA,RESULTS,SCREENING,THERE,THESE,VARIOUS
135,446,AMICO,COMPARISON,END,GLEASON,LABEL,MEN,METHODS,NODAL,OBJECTIVE,OBJECTIVES,PATHOLOGIC,PROGRAM,REPLACING,RESULTS,ROACH,THREE
169,CAP,COPYRIGHT,GPI,INC,LABEL,MATERIALS,METHODS,MTT,OBJECTIVE,OBJECTIVES,PCR,RESULTS,SILENCING,WESTERN
001,013,015,028,177,190,576,BRONJ,COX,INCREASED,INSTITUTE,JANUARY,LABEL,MASONIC,METHODS,MINNESOTA,OBJECTIVE,RESULTS,TEN,UNIVERSITY
PSA
169,COPYRIGHT,CTV,INC,LABEL,MATERIALS,METHODS,MINIMAL,MRI,OBJECTIVE,PURPOSE,RESULTS,TREATMENT
169,194,COPYRIGHT,GLEASON,HOWEVER,INC
001,002,013,169,3W6,947,969,C20,CONCLUSION,COPYRIGHT,FRESH,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,RESULTS,THESE
169,CD4,CD8,CHP,COPYRIGHT,CT7,EIGHT,ELISA,ESO,EXPRESSION,HORMAD1,WESTERN
169,946,947,AKT,BLACKWELL,CONCLUSION,DISCUSSION,HOWEVER,INHIBITION,KNOWN,LABEL,LNCAP,LTD,METHODS,MTT,OBJECTIVE,PUBLISHING,RESULTS,WESTERN
143,145,169,375,810,COPYRIGHT,MICRORNAS,MIRNA,PCR
169,947,COPYRIGHT,LNCAP,THESE
002,1263A,165,169,19G,205,652,CAP,CONCLUSION,COPYRIGHT,D302H,DESPITE,INC,INDIA,INSTITUTE,IVS12,LABEL,MATERIALS,MEDICAL,METHODS,NORTH,OBJECTIVE,RESULTS,SCIENCE,THESE,USING
005,169,960,BCS,CONCLUSION,COPYRIGHT,GSTP1,INC,LABEL,METHODS,MIR,OBJECTIVE,PCR,RESULTS,WESTERN,XTT
169,CAP,COPYRIGHT,DCEMR,INC,LABEL,MATERIALS,METHODS,MRI,OBJECTIVE,PSA,PURPOSE,RESULTS,SERUM,THERE
169,177,COPYRIGHT,GROUP,INC,LABEL,LIDOCAINE,MATERIALS,METHODS,MPP,OBJECTIVE,OBJECTIVES,PSA,RESULTS,THESE,THREE,TPB,VAS
169,500,COPYRIGHT,EPIDERMAL,INC,LABEL,LAPATINIB,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,SEVEN,TREATMENT
003,016,021,122,143,169,987,BMI,CALCULATED,CONCLUSION,COPYRIGHT,DIFFERENCE,GLEASON,INC,LABEL,METHODS,MEYER,MRI,OBESE,OBJECTIVE,RESULTS,RRP,THESE
169,490,510,ALA7VAL,ASP302HIS,ATM,BACKGROUND,BID,CASP8,COPYRIGHT,EIGHT,GERMANY,GLEASON,HIS64,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SER133ALA,SNP,THESE,VAL410ILE
169,228,258,AFP,AMONG,COPYRIGHT,INC,LABEL,LYMPH,METHODS,OBJECTIVE,PAFPS,PSA,RESULTS,SINCE,THERE
003,140,169,ASPIRIN,AUTHORS,BACKGROUND,COLLEGE,CURRENT,JOURNAL,LABEL,METHODS,PCA,PHYSICIANS,PSA,RESULTS,ROYAL,THESE
109,169,174,819,COPYRIGHT,LABEL,LTD,METHODS,OBJECTIVE,PATIENT,RESULTS,THERE,THOSE,WILEY
LABEL,METHODS,OBJECTIVE,PURPOSE,RESULTS,THERE,TRAIT
169,177,ASI,AUC,CONCLUSION,COPYRIGHT,GLEASON,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,PCA,PSI,RESULTS,ROI,SRA,SRB,THERE
169,COPYRIGHT,ESPECIALLY,HGPIN,INC,PET,PRIMARY,PROMISING,PSA
012,102,169,COPYRIGHT,GLEASON,LNCAP,OCTAMER,POU,THESE
014,051,168,169,883,COPYRIGHT,COX,HOWEVER,IHD,REGARDLESS
CONCLUSION,DOSIMETRIC,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS
148,169,BPH,CAP,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,MMP,OBJECTIVE,OBJECTIVES,RESULTS,SDF,UNIVARIATE
169,946,947,APART,APP,COPYRIGHT,HOWEVER,NEP
LABEL,LRP,MEDLINE,METHODS,NEITHER,NON,OBJECTIVE,OBJECTIVES,RESULTS,RRP,UNTIL,WHILE
169,347,COPYRIGHT,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS,RMS
169,954,BACKGROUND,COHEN,COPYRIGHT,EVALUATION,IRELAND,LABEL,LTD,METHODS,MRI,RESULTS,T3B,THESE,WHILE
169,COPYRIGHT,INC,PCR,TELOMERASE
169,COPYRIGHT,DOC,LNCAP,SPECIMENS
169,946,BBN,CONVERSELY,COPYRIGHT,EMT,FINALLY,ILK,MMP,TMA
169,AUC,CANCEROUS,CONCLUSION,COPYRIGHT,CPEAK,DCE,DESPITE,FIFTY,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,PURPOSE,RESULTS,ROC,TTP
169,BCL,CELECOXIB,COPYRIGHT,COX,HOWEVER,INDUCTION,IRELAND,LTD,MCL
169,969,BRAFO,COMMISSION,COPYRIGHT,FRAMEWORK,LTD,PUBLISHED,SIXTH,SOY,THERE,THESE
HOWEVER,MOLECULAR
ACUTE,FORTY,LABEL,MATERIALS,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PROLONGED,RESULTS,ROACH,TREATMENT
100,169,2MM,2NG,4MM,562,6MM,833,837,971,AREAS,AUC,CONCLUSION,COPYRIGHT,CSI,DCE,DCEMR,GRE,GROUP,IRELAND,LABEL,LTD,MATERIALS,METHODS,MRI,OBJECTIVE,OBJECTIVES,PET,PPV,PSA,RESULTS,ROC,RRP,TSE
169,240,CD147,COPYRIGHT,COX,GLEASON,INCREASED,MEIER,NOVEL,PCA,PSA
160,167,169,ADDITIONAL,ANXIETY,COPYRIGHT,FCS,GMM,INVENTORY,LABEL,LOW,LTD,METHODS,OBJECTIVE,PURPOSE,RESULTS,STATE,SUBGROUPS,USING,YOUNGER
001,003,169,331,ACCORDING,CONCLUSION,COPYRIGHT,COX,GLEASON,INC,LABEL,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,TGC
013,021,038,100,155,169,CONCLUSION,CONFORMITY,COPYRIGHT,CTV,INC,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,PTV,PURPOSE,RESULTS
169,394,404,452,507,C30,CHANGES,CONCLUSION,COPYRIGHT,EORTC,LABEL,LTD,METHODS,OBJECTIVE,QLQ,RESULTS,WILEY
100,186,357,633,672,CONCLUSION,GLEASON,JANUARY,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS,STAGING,UROLOGY
022,169,215,CONCLUSION,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,PURPOSE,RESULTS,ROACH,T1C
125,169,975,ADDITIONAL,COPYRIGHT,COX,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,PHOENIX,PSA,PURPOSE,RESULTS,STAGE,TEN
001,007,102,169,177,CONCLUSION,COPYRIGHT,CYBERKNIFE,DYSURIA,GRADE,GROUP,INC,LABEL,LOW,MATERIALS,MEIER,METHODS,OBJECTIVE,PATIENT,PERSISTENT,PSA,PURPOSE,QOD,RADIATION,RESULTS,THERAPY,THERE,TREATMENT,URINARY
ADT,HOWEVER
177,314,ASTRO,LABEL,MARCH,METHODS,OBJECTIVE,OBJECTIVES,PHOENIX,RADIATION,RESULTS,SOCIETY,WHILE
169,BACKGROUND,COPYRIGHT,GLEASON,INC,LABEL,METHODS,OBJECTIVE,PSA,RECURRENCE,RESULTS,THOSE
013,169,BCR,CAP,COPYRIGHT,FAILURE,GLEASON,INC,LABEL,MAB,MATERIALS,METHODS,OBJECTIVE,PRE,PSA,RESULTS,SALVAGE,SRT,SUCCESS
BACKGROUND,DIFFERENT,DISCUSSION,LABEL,ONCOLOGIC,ROBOT
169,ACCURAY,ACUTE,BETWEEN,CBK,COPYRIGHT,CYBERKNIFE,DISEASE,FURTHER,GRADE,INC,LABEL,MATERIALS,MAY,METHODS,OBJECTIVE,PURPOSE,RESULTS,SRT,SUNNYVALE
956,LNCAP,PC3
009,160,249,258,395,BCR,CONCLUSION,GLEASON,INCREASING,LABEL,METHODS,OBJECTIVE,PSA,PSM,PURPOSE,RESULTS
169,ADDITIONAL,ADVERSE,COPYRIGHT,GLEASON,GRADE,GROUP,IMAGE,INC,INSTITUTE,LABEL,MATERIALS,METHODS,OBJECTIVE,PHASE,PHOENIX,PURPOSE,RADIATION,RESULTS,STAGE,THERAPY
169,654,AFTER,BACKGROUND,COPYRIGHT,EMMPRIN,IRELAND,LABEL,LITERATURE,LTD,MATERIALS,METHODS,RCC,RESULTS
100,169,194,COPYRIGHT,RMS,USING
131,146,169,185,772,791,APRIL,BASED,COPYRIGHT,GLEASON,IRELAND,LABEL,LTD,METHODS,MRS,OBJECTIVE,RESULTS,ROC
150,COX,INSURANCE,SLE,TAIWANESE
001,056,438,AUC,BILATERAL,COX,LABEL,MEIER,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,ROC,USING
354,856,954,DFS,GLEASON,KAPPA,LABEL,METHODS,OBJECTIVE,PATHOLOGY,PSA,PURPOSE,RESULTS,SOCIETY,UROLOGICAL
223,945,BPH,DHT,EGF,FAS,FIN,IGF,MODULATION,OHT,ORM,SERMS,TAM,TAMOXIFEN,TGF,USING
169,22RV1,945,946,BASAL,CONCLUSION,COPYRIGHT,DU145,FURTHER,HIF1A,HOWEVER,HYPOXIA,HYPOXIC,III,INC,LABEL,METHODS,OBJECTIVE,PC3,RESULTS,THESE,TUBB3
160,231,A21,CVA21,DAF,MDA,OVERALL,THROUGH
100,169,194,COPYRIGHT,DOD,INTRA,LABEL,LARGE,MAX,METHODS,OBJECTIVE,PHASE,PURPOSE,RESULTS,SEEDS,STD,TECHNICAL
169,COPYRIGHT,CTX,DISRUPTED,INC,LABEL,LATER,LOW,METHODS,NTX,OBJECTIVE,OBJECTIVES,PSA,PUBLISHED,RESULTS,SEVERAL
EVALUATION,THERE,TRT
169,COPYRIGHT,GLEASON,III,IRELAND,LTD,PHASE
BACKGROUND,DISCUSSION,LABEL,METASTATIC,METHODS,TMD,TMJ
37LRP,CPP,HOWEVER,PENTS,R11,R13
FURTHER,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,SALVAGE,SRALP
169,AIM,BACKGROUND,CONCLUSION,CURRENTLY,LABEL,OBJECTIVE,RESULTS,SOCIETY,THERE,VED
169,COPYRIGHT,IRELAND,LABEL,LTD,METHODS,OBJECTIVE,ORM,PRO,QOL,RESULTS,WEB
000,148,945,946,BACKGROUND,CEC,CTC,GLEASON,INTEGRINS,LABEL,LOW,METHODS,PRIMARY,PSA,RESULTS,SECONDARY,THERE,TREATMENT,TTP
HISTONE,K382R,RKO,TAKEN,THEREFORE
NUMERICAL,ROC
169,198,651,ACUTE,AMONG,AUR,BPH,CAP,COPYRIGHT,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,OTHER,OVERALL,PSA,RESULTS
001,022,120,159,169,442,601,ALP,COPYRIGHT,COX,GIVEN,INC,LABEL,LIKELIHOOD,MATERIALS,MEIER,METHODS,OBJECTIVE,OBJECTIVES,PSA,REDUCTION,RESULTS,SURROGACY
108,132,169,207,495,CONCLUSION,COPYRIGHT,GLEASON,GROUP,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OVERALL,PSA,RESULTS,T1C,T2A,T2B,THEREFORE
169,687,COPYRIGHT,DCA,EPE,FINALLY,INC,LABEL,LNI,METHODS,OBJECTIVE,OVERALL,RESULTS,SVI
169,COPYRIGHT,INC,KNOWLEDGE
046,162,169,ACCRUAL,AFTER,BACKGROUND,CHANGES,COPYRIGHT,IGF,IGFBP,INC,INSULIN,LABEL,METHODS,OCTREOTIDE,PSA,RESULTS,WHILE
CASES,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,PUBLISHED,RESULTS,SERUM,SKENE
169,16S,215,220,230,BCA,CAP,CONCLUSION,COPYRIGHT,INC,LABEL,METHODS,NEITHER,OBJECTIVE,PCR,RCC,RESULTS,SERUM
001,002,006,009,012,031,169,356,AGE,COPYRIGHT,ESPECIALLY,INC,JANUARY,LABEL,METHODS,OBJECTIVE,OBJECTIVES,RESULTS,THERE
169,1990S,ACCORDING,COPYRIGHT,GIVEN,INC,SINCE,WHILE
103,115,169,285,673,COMPARING,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,RESULTS,SINCE
169,BACKGROUND,CD133,CONCLUSION,COPYRIGHT,HOWEVER,INC,LABEL,METHODS,PC3,RESISTANCE,RESULTS,SUSPENSION,THESE
169,ANOTHER,CONCLUSION,COPYRIGHT,ECD,GLEASON,INC,ISH,LABEL,LVD,MER,METHODS,MMP,OBJECTIVE,RESULTS,THEREFORE
005,169,945,ARI,BPR,CAP,COPYRIGHT,GLEASON,INC,IQR,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,PSADT,RESULTS,TUPSA
018,024,041,169,192,224,309GG,A670G,CAP,CCND1,CCND1AA,CONCLUSION,COPYRIGHT,FAS,G309T,G670A,G870A,INC,INDIA,LABEL,METHODS,OBJECTIVE,PCR,RESULTS,THEREFORE,WHEREAS
169,764,990,ASSESSMENT,CALIFORNIA,CAPRA,CAPSURE,COPYRIGHT,FRANCISCO,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PFS,RESULTS,RRP,SAN,UNIVERSITY
001,003,017,020,044,169,457,831,AFTER,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,MEN,METHODS,OBJECTIVE,ORP,RESULTS,SIMILARLY
169,ANNEXIN,APOPTOSIS,BAX,BCL,COPYRIGHT,INC,LABEL,LNCAP,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PCR,RESULTS,THERE,ZNT
100,261,956,ABCB1,COMBINING,EXCELLENT,HUVEC,LNCAP,NCI60,PC3,SCREENING,SW620
169,INC,METASTATIC,WILEY
169,BRCA1,INC,WILEY
945,946,IIA,PHASE
169,194,AFRICAN,CONFIDENCE,COPYRIGHT,EIGHT,FORCE,GIVEN,INC,LABEL,METHODS,OBJECTIVE,PHYSICIAN,PSA,RESULTS
001,169,194,ANTIGEN,COPYRIGHT,ENTRY,GLEASON,GROUP,INC,IRB,LABEL,METHODS,OBJECTIVE,PRE,PSA,PSADT,RESULTS,THESE,WORKING
00001,001,009,150,169,235,264,376,405,426,477,AIX75,BACKGROUND,CONCLUSION,LABEL,METHODS,POTENTIAL,PSA,RESULTS,SOCIETY
100,200,BACKGROUND,CRM,DLT,LABEL,METHODS,NSCLC,OTHER,RESULTS,SINCE,VORINOSTAT
AFTER
174,BACKGROUND,CASES,DISCUSSION,LABEL,METHODS
GOD,SIXTY,SPANISH,UTILIZING
169,COPYRIGHT,INC,UPS
100,900,AUC,CAP,DIAGNOSIS,GABOR,GLEASON,REGIONS
169,COPYRIGHT,IRELAND,LTD
169,BLACKWELL,GIVEN,LTD,PSA,PUBLISHING,WHILE
145,169,215,ANIMALS,AUTOPSY,COPYRIGHT,HOWEVER,INC,LABEL,MATERIALS,METHODS,MN1,OBJECTIVE,OBJECTIVES,ORTHOTOPIC,RESULTS,ULTRASOUND
001,007,015,107,146,169,194,AGE,CAB,CHINESE,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,MEDICAL,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
000,002,101,169,177,CONCLUSION,COPYRIGHT,DAKAR,GLEASON,JANUARY,LABEL,METASTASIS,METHODS,OBJECTIVE,PSA,PURPOSE,RESULTS,SAS,THREE
169,ARCANGELI,CLEVELAND,COPYRIGHT,SAS
119,169,194,204,228,233,ANN,APRIL,AUC,BACKGROUND,BECKMAN,CAP,COPYRIGHT,DEPARTMENT,DIAGNOSTIC,DRE,INC,INSTITUTE,LABEL,MATERIALS,MAY,MEDICAL,METHODS,OVERALL,PSA,RESULTS,ROC,TOTAL,UNIVERSIT,UROLOGY
169,194,COPYRIGHT,END,INC,RESULTS
001,100,105,125,169,180,AVAILABLE,COPYRIGHT,DOSIMETRY,INC,IOP,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,PSA,RESULTS
111,169,194,627,754,947,CAP,COPYRIGHT,GLEASON,INC,LABEL,MATERIALS,METHODS,OBJECTIVE,OBJECTIVES,REGRESSION,RESULTS,SPECT,SVI,T1C
